PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Fellmeth, AX				Fellmeth, AX			The challenge to patent law of pure chemical protein synthesis	NATURE BIOTECHNOLOGY			English	Editorial Material								The emergence of pure chemical protein synthesis as a commercially viable method of drug design and production will create serious problems in the patent system.	Arizona State Univ, Coll Law, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	Fellmeth, AX (corresponding author), Arizona State Univ, Coll Law, POB 877906, Tempe, AZ 85287 USA.	aaron.fellmeth@asu.edu						[Anonymous], 1999, U.S. Patent, Patent No. [5,880,263, 5880263]; [Anonymous], 2000, U.S. Patent, Patent No. [6,057,434, 6057434]; BLANK G, 2004, Patent No. 6797814; BURNHAM NL, 1994, AM J HOSP PHARM, V51, P210, DOI 10.1093/ajhp/51.2.210; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; Demaine LT, 2002, STANFORD LAW REV, V55, P303, DOI 10.2307/1229595; HANCOCK WS, 1972, J BIOL CHEM, V247, P6224; Hudecz F, 2001, SELF-ASSEMBLING PEPTIDE SYSTEMS IN BIOLOGY, MEDICINE AND ENGINEERING, P139; Kochendoerfer GG, 2003, SCIENCE, V299, P884, DOI 10.1126/science.1079085; Warren JD, 2004, J AM CHEM SOC, V126, P6576, DOI 10.1021/ja0491836; 2002, Patent No. 6476190; 2004, Patent No. 6794500; 2004, Patent No. 6800473; 2004, Patent No. 6806065	14	1	1	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2005	23	5					547	549		10.1038/nbt0505-547	http://dx.doi.org/10.1038/nbt0505-547			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	923XS	15877067				2022-12-25	WOS:000228943500018
J	Forest, T; Barnard, S; Baines, JD				Forest, T; Barnard, S; Baines, JD			Active intranuclear movement of herpesvirus capsids	NATURE CELL BIOLOGY			English	Article							2,3-BUTANEDIONE MONOXIME; DIFFUSION; CHROMATIN; PROTEINS; DYNAMICS; MYOSIN	Although small molecules diffuse rapidly through the interphase nucleus(1,2), recent reports indicate that nuclear diffusion is limited for particles that are larger than 100 nm in diameter(3). Given the apparent size limits to nuclear diffusion, there is some debate as to whether the movement of large particles should be attributed to diffusion or to active transport(4-6). Here, we show that 125 nm-diameter herpes simplex virus 1 (HSV-1) capsids are actively transported within infected nuclei. Movement is directed, temperature- and energy-dependent, sensitive to the putative myosin inhibitor 2,3-butanedione monoxime (BDM)(7,8) and to actin depolymerization with latrunculin-A, but insensitive to actin depolymerization with cytochalasin-D.	Cornell Univ, Vet Educ Ctr C5132, Dept Microbiol & Immunol, Ithaca, NY 14853 USA; Univ Sydney, Fac Vet Sci, Sydney, NSW 2006, Australia	Cornell University; University of Sydney	Baines, JD (corresponding author), Cornell Univ, Vet Educ Ctr C5132, Dept Microbiol & Immunol, Ithaca, NY 14853 USA.	jdb11@cornell.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T35AI007227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050740] Funding Source: NIH RePORTER; NIAID NIH HHS [T35 AI07227-19] Funding Source: Medline; NIGMS NIH HHS [R01 GM50740] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bettinger BT, 2004, NAT REV MOL CELL BIO, V5, P410, DOI 10.1038/nrm1370; Dasgupta A, 1999, J VIROL, V73, P2006, DOI 10.1128/JVI.73.3.2006-2015.1999; Desai P, 1998, J VIROL, V72, P7563, DOI 10.1128/JVI.72.9.7563-7568.1998; Gorisch SM, 2004, P NATL ACAD SCI USA, V101, P13221, DOI 10.1073/pnas.0402958101; HERRMANN C, 1992, BIOCHEMISTRY-US, V31, P12227, DOI 10.1021/bi00163a036; Ostap EM, 2002, J MUSCLE RES CELL M, V23, P305, DOI 10.1023/A:1022047102064; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Platani M, 2002, NAT CELL BIOL, V4, P502, DOI 10.1038/ncb809; Politz JCR, 2003, MOL BIOL CELL, V14, P4805, DOI 10.1091/mbc.E03-06-0395; SAXTON MJ, 1994, BIOPHYS J, V66, P394, DOI 10.1016/S0006-3495(94)80789-1; Seksek O, 1997, J CELL BIOL, V138, P131, DOI 10.1083/jcb.138.1.131; Shav-Tal Y, 2004, SCIENCE, V304, P1797, DOI 10.1126/science.1099754; Smith GA, 2001, P NATL ACAD SCI USA, V98, P3466, DOI 10.1073/pnas.061029798; Tseng Y, 2004, J CELL SCI, V117, P2159, DOI 10.1242/jcs.01073; Ward PL, 1996, J VIROL, V70, P4623, DOI 10.1128/JVI.70.7.4623-4631.1996	15	96	99	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2005	7	4					429	U54		10.1038/ncb1243	http://dx.doi.org/10.1038/ncb1243			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	912KA	15803134				2022-12-25	WOS:000228075500021
J	Martin, MJ; Muotri, A; Gage, F; Varki, A				Martin, MJ; Muotri, A; Gage, F; Varki, A			Human embryonic stem cells express an immunogenic nonhuman sialic acid	NATURE MEDICINE			English	Article							PROLONGED UNDIFFERENTIATED GROWTH; HUMAN FEEDERS; DIFFERENTIATION; CULTURE; SERUM; LINES; DERIVATION	Human embryonic stem cells (HESC) can potentially generate every body cell type, making them excellent candidates for cell- and tissue-replacement therapies. HESC are typically cultured with animal-derived 'serum replacements' on mouse feeder layers. Both of these are sources of the nonhuman sialic acid Neu5Gc, against which many humans have circulating antibodies. Both HESC and derived embryoid bodies metabolically incorporate substantial amounts of Neu5Gc under standard conditions. Exposure to human sera with antibodies specific for Neu5Gc resulted in binding of immunoglobulin and deposition of complement, which would lead to cell killing in vivo. Levels of Neu5Gc on HESC and embryoid bodies dropped after culture in heat-inactivated anti-Neu5Gc antibody-negative human serum, reducing binding of antibodies and complement from high-titer sera, while allowing maintenance of the undifferentiated state. Complete elimination of Neu5Gc would be likely to require using human serum with human feeder layers, ideally starting with fresh HESC that have never been exposed to animal products.	Univ Calif San Diego, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Salk Institute	Varki, A (corresponding author), Univ Calif San Diego, Glycobiol Res & Training Ctr, 9500 Gilman Dr,Mailcode 0687, La Jolla, CA 92093 USA.	varkiadmin@ucsd.edu						Amit M, 2000, DEV BIOL, V227, P271, DOI 10.1006/dbio.2000.9912; Amit M, 2004, BIOL REPROD, V70, P837, DOI 10.1095/biolreprod.103.021147; Badcock G, 1999, CANCER RES, V59, P4715; BARDOR M, 2004, J BIOL CHEM     1129; Bradley JA, 2002, NAT REV IMMUNOL, V2, P859, DOI 10.1038/nri934; Carpenter MK, 2003, CLONING STEM CELLS, V5, P79, DOI 10.1089/153623003321512193; Cheng LZ, 2003, STEM CELLS, V21, P131, DOI 10.1634/stemcells.21-2-131; Chou HH, 1998, P NATL ACAD SCI USA, V95, P11751, DOI 10.1073/pnas.95.20.11751; Conley BJ, 2004, INT J BIOCHEM CELL B, V36, P555, DOI 10.1016/j.biocel.2003.07.003; Cowan CA, 2004, NEW ENGL J MED, V350, P1353, DOI 10.1056/NEJMsr040330; D'Amour K, 2000, NAT BIOTECHNOL, V18, P381, DOI 10.1038/74429; Draper JS, 2004, STEM CELLS DEV, V13, P325, DOI 10.1089/1547328041797525; Draper JS, 2004, NAT BIOTECHNOL, V22, P53, DOI 10.1038/nbt922; DUBOIS C, 1990, J BIOL CHEM, V265, P2797; Gearhart J, 2004, NEW ENGL J MED, V350, P1275, DOI 10.1056/NEJMp048045; Hovatta O, 2003, HUM REPROD, V18, P1404, DOI 10.1093/humrep/deg290; Itskovitz-Eldor J, 2000, MOL MED, V6, P88, DOI 10.1007/BF03401776; Keller G, 1999, NAT MED, V5, P151, DOI 10.1038/5512; Koivisto H, 2004, REPROD BIOMED ONLINE, V9, P330, DOI 10.1016/S1472-6483(10)62150-5; Miyamoto K, 2004, STEM CELLS, V22, P433, DOI 10.1634/stemcells.22-4-433; Nakashima K, 2004, NAT MED, V10, P23, DOI 10.1038/nm0104-23; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Richards M, 2002, NAT BIOTECHNOL, V20, P933, DOI 10.1038/nbt726; Richards M, 2003, STEM CELLS, V21, P546, DOI 10.1634/stemcells.21-5-546; Rosler ES, 2004, DEV DYNAM, V229, P259, DOI 10.1002/dvdy.10430; Tangvoranuntakul P, 2003, P NATL ACAD SCI USA, V100, P12045, DOI 10.1073/pnas.2131556100; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Varki A, 2001, YEARB PHYS ANTHROPOL, V44, P54, DOI 10.1002/ajpa.10018; Yamaguchi M, 2002, TRANSFUSION, V42, P921, DOI 10.1046/j.1537-2995.2002.00149.x; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	31	711	800	1	60	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					228	232		10.1038/nm1181	http://dx.doi.org/10.1038/nm1181			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15685172				2022-12-25	WOS:000226797300032
J	Uchida, T; Nakamura, T; Hashimoto, N; Matsuda, T; Kotani, K; Sakaue, H; Kido, Y; Hayashi, Y; Nakayama, KI; White, MF; Kasuga, M				Uchida, T; Nakamura, T; Hashimoto, N; Matsuda, T; Kotani, K; Sakaue, H; Kido, Y; Hayashi, Y; Nakayama, KI; White, MF; Kasuga, M			Deletion of Cdkn1b ameliorates hyperglycemia by maintaining compensatory hyperinsulinemia in diabetic mice	NATURE MEDICINE			English	Article							FORKHEAD TRANSCRIPTION FACTOR; CELL-CYCLE PROGRESSION; KINASE INHIBITOR P27(KIP1); LEPTIN RECEPTOR GENE; CYTOPLASMIC LOCALIZATION; PROTEIN-KINASE; DEPENDENT PHOSPHORYLATION; INSULIN-RECEPTOR; FACTOR FOXO1; EXPRESSION	The protein p27(Kip1) regulates cell cycle progression in mammals by inhibiting the activity of cyclin-dependent kinases (CDKs). Here we show that p27(Kip1) progressively accumulates in the nucleus of pancreatic beta cells in mice that lack either insulin receptor substrate 2 (Irs2(-/-)) or the long form of the leptin receptor (Lepr(-/-) or db/db). Deletion of the gene encoding p27(Kip1) (Cdkn1b) ameliorated hyperglycemia in these animal models of type 2 diabetes mellitus by increasing islet mass and maintaining compensatory hyperinsulinemia, effects that were attributable predominantly to stimulation of pancreatic beta-cell proliferation. Thus, p27(Kip1) contributes to beta-cell failure during the development of type 2 diabetes in Irs2(-/-) and Lepr(-/-) mice and represents a potential new target for the treatment of this condition.	Kobe Univ, Grad Sch Med, Div Diabet & Digest & Kidney Dis, Dept Clin Mol Med,Chuo Ku, Kobe, Hyogo 6500017, Japan; Kobe Univ, Grad Sch Med, Div Mol Med & Med Genet, Int Ctr Med Res, Kobe, Hyogo 6500017, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 8128582, Japan; Harvard Univ, Sch Med, Howard Hughes Med Inst, Joslin Diabet Ctr, Boston, MA 02215 USA	Kobe University; Kobe University; Kyushu University; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Howard Hughes Medical Institute	Kasuga, M (corresponding author), Kobe Univ, Grad Sch Med, Div Diabet & Digest & Kidney Dis, Dept Clin Mol Med,Chuo Ku, 7-5-1 Kusunokicho, Kobe, Hyogo 6500017, Japan.	kasuga@med.kobe-u.ac.jp	Sakaue, Hiroshi/ABE-2337-2021	Sakaue, Hiroshi/0000-0002-2468-2363				Bernal-Mizrachi E, 2001, J CLIN INVEST, V108, P1631, DOI 10.1172/JCI13785; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CLARK A, 1988, DIABETES RES CLIN EX, V9, P151; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Cunningham MA, 2004, MOL ENDOCRINOL, V18, P1756, DOI 10.1210/me.2004-0071; Deng SP, 2004, DIABETES, V53, P624, DOI 10.2337/diabetes.53.3.624; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Fujita N, 2003, J BIOL CHEM, V278, P49254, DOI 10.1074/jbc.M306614200; Garofalo RS, 2003, J CLIN INVEST, V112, P197, DOI 10.1172/JCI200316885; HELLERSTROM C, 1976, ACTA ENDOCRINOL-COP, V83, P145; Herrera PL, 2000, DEVELOPMENT, V127, P2317; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Kulkarni RN, 2002, NAT GENET, V31, P111, DOI 10.1038/ng872; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Matsumoto M, 2003, J CLIN INVEST, V112, P935, DOI 10.1172/JCI200318816; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Sakuraba H, 2002, DIABETOLOGIA, V45, P85, DOI 10.1007/s125-002-8248-z; Schreyer SA, 1998, J CLIN INVEST, V102, P402, DOI 10.1172/JCI2849; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Tanabe K, 1997, BIOCHEM BIOPH RES CO, V241, P765, DOI 10.1006/bbrc.1997.7894; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; Uchida T, 2000, MOL CELL BIOL, V20, P126, DOI 10.1128/MCB.20.1.126-138.2000; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Wolf G, 2001, J MOL MED, V79, P382, DOI 10.1007/s001090100241; Wolf G, 1998, KIDNEY INT, V53, P869, DOI 10.1046/j.1523-1755.1998.00829.x; Xuan SH, 2002, J CLIN INVEST, V110, P1011, DOI 10.1172/JCI200215276; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	45	170	177	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					175	182		10.1038/nm1187	http://dx.doi.org/10.1038/nm1187			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15685168				2022-12-25	WOS:000226797300025
J	Gohla, A; Birkenfeld, J; Bokoch, GM				Gohla, A; Birkenfeld, J; Bokoch, GM			Chronophin, a novel HAD-type serine protein phosphatase, regulates cofilin-dependent actin dynamics	NATURE CELL BIOLOGY			English	Article							LIM-KINASE; FILAMENT TURNOVER; BINDING PROTEIN; EYES ABSENT; PHOSPHORYLATION; ADF/COFILIN; ACTIVATION; SLINGSHOT; REORGANIZATION; CYTOKINESIS	Cofilin is a key regulator of actin cytoskeletal dynamics whose activity is controlled by phosphorylation of a single serine residue. We report the biochemical isolation of chronophin (CIN), a unique cofilin-activating phosphatase of the haloacid dehalogenase ( HAD) superfamily. CIN directly dephosphorylates cofilin with high specificity and colocalizes with cofilin in motile and dividing cells. Loss of CIN activity blocks phosphocycling of cofilin, stabilizes F-actin structures and causes massive cell division defects. Our findings identify a physiological phospho-serine protein substrate for a mammalian HAD-type phosphatase and demonstrate that CIN is an important novel regulator of cofilin-mediated actin reorganization.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Bokoch, GM (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	bokoch@scripps.edu		Gohla, Antje/0000-0002-7442-1487	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434, R01GM044428] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39434, GM44428] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano T, 2002, J BIOL CHEM, V277, P22093, DOI 10.1074/jbc.M201444200; Ambach A, 2000, EUR J IMMUNOL, V30, P3422, DOI 10.1002/1521-4141(2000012)30:12<3422::AID-IMMU3422>3.0.CO;2-J; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bamburg JR, 2002, TRENDS CELL BIOL, V12, P598, DOI 10.1016/S0962-8924(02)02404-2; Birkenfeld J, 2003, BIOCHEM BIOPH RES CO, V302, P526, DOI 10.1016/S0006-291X(03)00182-7; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Collet JF, 1999, J BIOL CHEM, V274, P33985, DOI 10.1074/jbc.274.48.33985; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; Cramer LP, 2002, CELL MOTIL CYTOSKEL, V51, P27, DOI 10.1002/cm.10013; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Gohla A, 2002, CURR BIOL, V12, P1704, DOI 10.1016/S0960-9822(02)01184-3; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; HITTMAIR A, 1995, LAB INVEST, V72, P70; Ichetovkin I, 2002, CURR BIOL, V12, P79, DOI 10.1016/S0960-9822(01)00629-7; Jang YM, 2003, J BIOL CHEM, V278, P50040, DOI 10.1074/jbc.M309619200; Kaji N, 2003, J BIOL CHEM, V278, P33450, DOI 10.1074/jbc.M305802200; Lappalainen P, 1997, NATURE, V388, P78, DOI 10.1038/40418; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; NAGAOKA R, 1995, CELL MOTIL CYTOSKEL, V30, P1, DOI 10.1002/cm.970300102; Nagata-Ohashi K, 2004, J CELL BIOL, V165, P465, DOI 10.1083/jcb.200401136; Nishita M, 2004, J BIOL CHEM, V279, P7193, DOI 10.1074/jbc.M312591200; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Rayapureddi JP, 2003, NATURE, V426, P295, DOI 10.1038/nature02093; Rogers SL, 2003, J CELL BIOL, V162, P1079, DOI 10.1083/jcb.200303023; Selengut JD, 2001, BIOCHEMISTRY-US, V40, P12704, DOI 10.1021/bi011405e; Tootle TL, 2003, NATURE, V426, P299, DOI 10.1038/nature02097; Toshima J, 2001, MOL BIOL CELL, V12, P1131, DOI 10.1091/mbc.12.4.1131; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Zhan Q, 2003, CELL MOTIL CYTOSKEL, V54, P1, DOI 10.1002/cm.10079	35	245	257	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2005	7	1					21	+		10.1038/ncb1201	http://dx.doi.org/10.1038/ncb1201			14	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	884UZ	15580268				2022-12-25	WOS:000226113500011
J	Maiato, H; Khodjakov, A; Rieder, CL				Maiato, H; Khodjakov, A; Rieder, CL			Drosophila CLASP is required for the incorporation of microtubule subunits into fluxing kinetochore fibres	NATURE CELL BIOLOGY			English	Article							CRANE-FLY SPERMATOCYTES; MITOTIC SPINDLE; MOTOR PROTEINS; ANAPHASE-A; DYNAMICS; CHROMOSOME; MITOSIS; METAPHASE; COMPONENT; EMBRYOS	The motion of a chromosome during mitosis is mediated by a bundle of microtubules, termed a kinetochore fibre (K-fibre), which connects the kinetochore of the chromosome to a spindle pole. Once formed, mature K-fibres maintain a steady state length because the continuous addition of microtubule subunits onto microtubule plus ends at the kinetochore is balanced by their removal at their minus ends within the pole. This condition is known as 'microtubule poleward flux'(1). Chromosome motion and changes in position are then driven by changes in K-fibre length, which in turn are controlled by changes in the rates at which microtubule subunits are added at the kinetochore and/or removed from the pole(2). A key to understanding the role of flux in mitosis is to identify the molecular factors that drive it. Here we use Drosophila melanogaster S2 cells expressing alpha-tubulin tagged with green fluorescent protein, RNA interference, laser microsurgery and photobleaching to show that the kinetochore protein MAST/Orbit - the single CLASP orthologue in Drosophila - is an essential component for microtubule subunit incorporation into fluxing K-fibres.	New York State Dept Hlth, Wadsworth Ctr Labs & Res, Lab Cell Regulat, Albany, NY 12201 USA; SUNY Albany, Dept Biomed Sci, Albany, NY 12222 USA; Marine Biol Lab, Woods Hole, MA 02543 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Marine Biological Laboratory - Woods Hole	Rieder, CL (corresponding author), New York State Dept Hlth, Wadsworth Ctr Labs & Res, Lab Cell Regulat, Empire State Plaza, Albany, NY 12201 USA.	rieder@wadsworth.org	Maiato, Helder/J-9466-2013	Maiato, Helder/0000-0002-6200-9997	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM040198, R01GM059363, R01GM040198] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM040198, GMS59363, R37 GM040198-22, R01 GM059363, GMS40198, R37 GM040198-21, R01 GM059363-06] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brust-Mascher I, 2002, MOL BIOL CELL, V13, P3967, DOI 10.1091/mbc.02-05-0069; Carvalho P, 2003, TRENDS CELL BIOL, V13, P229, DOI 10.1016/S0962-8924(03)00074-6; Chen W, 2004, NAT CELL BIOL, V6, P227, DOI 10.1038/ncb1104; CZABAN BB, 1993, J CELL SCI, V105, P571; Desai A, 2003, GENE DEV, V17, P2421, DOI 10.1101/gad.1126303; Forer A, 1997, PROTOPLASMA, V197, P230, DOI 10.1007/BF01288032; Ganem NJ, 2004, J CELL BIOL, V166, P473, DOI 10.1083/jcb.200404012; GORDON GW, 1980, THESIS U PENNSYLVANI; Goshima G, 2003, J CELL BIOL, V162, P1003, DOI 10.1083/jcb.200303022; Hoffman DB, 2001, MOL BIOL CELL, V12, P1995, DOI 10.1091/mbc.12.7.1995; Khodjakov A, 1996, J CELL BIOL, V135, P315, DOI 10.1083/jcb.135.2.315; LaFountain JR, 2004, MOL BIOL CELL, V15, P5724, DOI 10.1091/mbc.E04-08-0750; Lawrence CJ, 2004, J CELL BIOL, V167, P19, DOI 10.1083/jcb.200408113; Lemos CL, 2000, EMBO J, V19, P3668, DOI 10.1093/emboj/19.14.3668; Maddox P, 2002, CURR BIOL, V12, P1670, DOI 10.1016/S0960-9822(02)01183-1; Maiato H, 2003, CELL, V113, P891, DOI 10.1016/S0092-8674(03)00465-3; Maiato H, 2002, J CELL BIOL, V157, P749, DOI 10.1083/jcb.200201101; MAIATO H, J CELL BIOL; Maiato Helder, 2003, Biological Procedures Online, V5, P153, DOI 10.1251/bpo57; MITCHISON TJ, 1992, J CELL BIOL, V119, P569, DOI 10.1083/jcb.119.3.569; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; Rogers GC, 2004, NATURE, V427, P364, DOI 10.1038/nature02256; Rogers SL, 2002, J CELL BIOL, V158, P873, DOI 10.1083/jcb.200202032; Sharp DJ, 2002, CURR BIOL, V12, pR585, DOI 10.1016/S0960-9822(02)01098-9; SKIBBENS RV, 1993, J CELL BIOL, V122, P859, DOI 10.1083/jcb.122.4.859; Tirnauer JS, 2002, MOL BIOL CELL, V13, P4308, DOI 10.1091/mbc.e02-04-0236; Wadsworth P, 2004, TRENDS CELL BIOL, V14, P413, DOI 10.1016/j.tcb.2004.07.004; Waters JC, 1996, MOL BIOL CELL, V7, P1547, DOI 10.1091/mbc.7.10.1547; Yin HW, 2002, MOL BIOL CELL, V13, P1881, DOI 10.1091/mbc.01-09-0458	29	145	149	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2005	7	1					42	+		10.1038/ncb1207	http://dx.doi.org/10.1038/ncb1207			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	884UZ	15592460	Green Accepted, Green Submitted			2022-12-25	WOS:000226113500013
J	Hu, J; McCall, CM; Ohta, T; Xiong, Y				Hu, J; McCall, CM; Ohta, T; Xiong, Y			Targeted ubiquitination of CDT1 by the DDB1-CUL4A-ROC1 ligase in response to DNA damage	NATURE CELL BIOLOGY			English	Article							SOCS-BOX MOTIF; BINDING-PROTEIN; COMPLEX INTERACTS; V-PROTEIN; CULLIN 4A; F-BOX; SCF; DEGRADATION; UBIQUITYLATION; PROTEOLYSIS	Cullins assemble a potentially large number of ubiquitin ligases by binding to the RING protein ROC1 to catalyse polyubiquitination, as well as binding to various specificity factors to recruit substrates(1-4). The Cul4A gene is amplified in human breast and liver cancers, and loss-of-function of Cul4 results in the accumulation of the replication licensing factor CDT1 in Caenorhabditis elegans embryos and ultraviolet ( UV)-irradiated human cells. Here, we report that human UV-damaged DNA-binding protein DDB1 associates stoichiometrically with CUL4A in vivo, and binds to an amino-terminal region in CUL4A in a manner analogous to SKP1, SOCS and BTB binding to CUL1, CUL2 and CUL3, respectively. As with SKP1-CUL1, the DDB1-CUL4A association is negatively regulated by the cullin-associated and neddylation-dissociated protein, CAND1. Recombinant DDB1 and CDT1 bind directly to each other in vitro, and ectopically expressed DDB1 bridges CDT1 to CUL4A in vivo. Silencing DDB1 prevented UV-induced rapid CDT1 degradation in vivo and CUL4A-mediated CDT1 ubiquitination in vitro. We suggest that DDB1 targets CDT1 for ubiquitination by a CUL4A-dependent ubiquitin ligase, CDL4A(DDB1), in response to UV irradiation.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Xiong, Y (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	yxiong@mail.unc.edu	高, 雨莉/HGU-8187-2022; , Proteomics Core UNC/AFQ-7201-2022	McCall, Chad/0000-0003-3542-9053; Ohta, Tomohiko/0000-0002-9700-7342	NIGMS NIH HHS [GM067113] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067113] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrejeva J, 2002, J VIROL, V76, P11379, DOI 10.1128/JVI.76.22.11379-11386.2002; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Chen LC, 1998, CANCER RES, V58, P3677; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Furukawa M, 2002, J BIOL CHEM, V277, P15758, DOI 10.1074/jbc.M108565200; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Higa LAA, 2003, NAT CELL BIOL, V5, P1008, DOI 10.1038/ncb1061; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kamura T, 2001, J BIOL CHEM, V276, P29748, DOI 10.1074/jbc.M103093200; KEENEY S, 1993, J BIOL CHEM, V268, P21293; Li BH, 2002, MOL CELL BIOL, V22, P4997, DOI 10.1128/MCB.22.14.4997-5005.2002; Li XH, 2003, J BIOL CHEM, V278, P30854, DOI 10.1074/jbc.C300251200; Lin GY, 1998, VIROLOGY, V249, P189, DOI 10.1006/viro.1998.9317; Liu JD, 2002, MOL CELL, V10, P1511, DOI 10.1016/S1097-2765(02)00783-9; Nag A, 2001, MOL CELL BIOL, V21, P6738, DOI 10.1128/MCB.21.20.6738-6747.2001; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Osaka F, 2000, EMBO J, V19, P3475, DOI 10.1093/emboj/19.13.3475; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Shiyanov P, 1999, J BIOL CHEM, V274, P35309, DOI 10.1074/jbc.274.50.35309; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Ulane CM, 2003, J VIROL, V77, P6385, DOI 10.1128/JVI.77.11.6385-6393.2003; Ulane CM, 2002, VIROLOGY, V304, P160, DOI 10.1006/viro.2002.1773; Wertz IE, 2004, SCIENCE, V303, P1371, DOI 10.1126/science.1093549; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Yasui K, 2002, HEPATOLOGY, V35, P1476, DOI 10.1053/jhep.2002.33683; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zhang Y, 2003, EMBO J, V22, P6057, DOI 10.1093/emboj/cdg577; Zheng JY, 2002, MOL CELL, V10, P1519, DOI 10.1016/S1097-2765(02)00784-0; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhong WW, 2003, NATURE, V423, P885, DOI 10.1038/nature01747	37	283	299	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2004	6	10					1003	+		10.1038/ncb1172	http://dx.doi.org/10.1038/ncb1172			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	859FY	15448697				2022-12-25	WOS:000224250000016
J	Segal, E; Friedman, N; Koller, D; Regev, A				Segal, E; Friedman, N; Koller, D; Regev, A			A module map showing conditional activity of expression modules in cancer	NATURE GENETICS			English	Article							GENE-EXPRESSION; HEPATOCELLULAR-CARCINOMA; DOWN-REGULATION; MICROARRAY DATA; METASTASIS; KINASE; TUMOR; BONE; ORGANIZATION; PROGRESSION	DNA microarrays are widely used to study changes in gene expression in tumors, but such studies are typically system-specific and do not address the commonalities and variations between different types of tumor. Here we present an integrated analysis of 1,975 published microarrays spanning 22 tumor types. We describe expression profiles in different tumors in terms of the behavior of modules, sets of genes that act in concert to carry out a specific function. Using a simple unified analysis, we extract modules and characterize gene-expression profiles in tumors as a combination of activated and deactivated modules. Activation of some modules is specific to particular types of tumor; for example, a growth-inhibitory module is specifically repressed in acute lymphoblastic leukemias and may underlie the deregulated proliferation in these cancers. Other modules are shared across a diverse set of clinical conditions, suggestive of common tumor progression mechanisms. For example, the bone osteoblastic module spans a variety of tumor types and includes both secreted growth factors and their receptors. Our findings suggest that there is a single mechanism for both primary tumor proliferation and metastasis to bone. Our analysis presents multiple research directions for diagnostic, prognostic and therapeutic studies.	Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA; Hebrew Univ Jerusalem, Sch Comp Sci & Engn, IL-91904 Jerusalem, Israel; Harvard Univ, Bauer Ctr Genom Res, Cambridge, MA 02138 USA	Stanford University; Hebrew University of Jerusalem; Harvard University	Koller, D (corresponding author), Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA.	koller@cs.stanford.edu; aregev@agr.harvard.edu	Segal, Eran/AAF-4855-2019; Friedman, Nir/H-9692-2012	Friedman, Nir/0000-0002-9678-3550; Segal, Eran/0000-0002-6859-1164				Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Boot AM, 1999, EUR J CANCER, V35, P1693, DOI 10.1016/S0959-8049(99)00143-4; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ferrari N, 2003, J LEUKOCYTE BIOL, V74, P302, DOI 10.1189/jlb.1102581; Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5; Ge BX, 2003, J BIOL CHEM, V278, P2286, DOI 10.1074/jbc.M210918200; Granata OM, 2002, MOL CELL ENDOCRINOL, V193, P51, DOI 10.1016/S0303-7207(02)00095-3; Hynes RO, 2003, CELL, V113, P821, DOI 10.1016/S0092-8674(03)00468-9; Iguchi H, 2002, J EXP CLIN CANC RES, V21, P309; Ihmels J, 2002, NAT GENET, V31, P370, DOI 10.1038/ng941; Kanehisa M, 2002, NUCLEIC ACIDS RES, V30, P42, DOI 10.1093/nar/30.1.42; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kim SC, 1999, BLOOD, V93, P3893, DOI 10.1182/blood.V93.11.3893.407k14_3893_3899; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Lione AM, 2000, J NEUROCHEM, V75, P934, DOI 10.1046/j.1471-4159.2000.0750934.x; Mita H, 2002, MOL CELL BIOL, V22, P4544, DOI 10.1128/MCB.22.13.4544-4555.2002; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Reinholz MM, 2002, BREAST CANCER RES TR, V74, P255, DOI 10.1023/A:1016339120506; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Segal E, 2003, NAT GENET, V34, P166, DOI 10.1038/ng1165; Shi CS, 2001, J BIOL CHEM, V276, P24293, DOI 10.1074/jbc.M100089200; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Tanay A, 2004, P NATL ACAD SCI USA, V101, P2981, DOI 10.1073/pnas.0308661100; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739	30	533	571	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2004	36	10					1090	1098		10.1038/ng1434	http://dx.doi.org/10.1038/ng1434			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	857YN	15448693	Green Accepted, Bronze			2022-12-25	WOS:000224156500018
J	Bradley, J; Baltus, A; Skaletsky, H; Royce-Tolland, M; Dewar, K; Page, DC				Bradley, J; Baltus, A; Skaletsky, H; Royce-Tolland, M; Dewar, K; Page, DC			An X-to-autosome retrogene is required for spermatogenesis in mice	NATURE GENETICS			English	Article							SPERMATOGONIAL DEPLETION JSD; PROCESSED PSEUDOGENES; GENE; RETROPOSON; TESTIS; MOUSE; IDENTIFICATION; EXPRESSION; PROTEIN; PROLIFERATION	We identified the gene carrying the juvenile spermatogonial depletion mutation (jsd), a recessive spermatogenic defect mapped to mouse chromosome 1 (refs. 1,2). We localized jsd to a 272-kb region and resequenced this area to identify the underlying mutation: a frameshift that severely truncates the predicted protein product of a 2.3-kb genomic open reading frame. This gene, Utp14b, evidently arose through reverse transcription of an mRNA from an X-linked gene and integration of the resulting cDNA into an intron of an autosomal gene, whose promoter and 5' untranslated exons are shared with Utp14b. To our knowledge, Utp14b is the first protein-coding retrogene to be linked to a recessive mammalian phenotype. The X-linked progenitor of Utp14b is the mammalian ortholog of yeast Utp14, which encodes a protein required for processing of pre-rRNA(3) and hence for ribosome assembly. Our findings substantiate the hypothesis(4) that mammalian spermatogenesis is supported by autosomal retrogenes that evolved from X-linked housekeeping genes to compensate for silencing of the X chromosome during male meiosis(5-7). We find that Utp14b-like retrogenes arose independently and were conserved during evolution in at least four mammalian lineages. This recurrence implies a strong selective pressure, perhaps to enable ribosome assembly in male meiotic cells.	MIT, Howard Hughes Med Inst, Whitehead Inst, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; MIT, Whitehead Inst, Ctr Genome Res, Cambridge, MA 02142 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute	Page, DC (corresponding author), MIT, Howard Hughes Med Inst, Whitehead Inst, Cambridge, MA 02142 USA.							ASHWORTH A, 1990, EMBO J, V9, P1529, DOI 10.1002/j.1460-2075.1990.tb08271.x; Banks KG, 2003, GENOMICS, V82, P254, DOI 10.1016/S0888-7543(03)00155-1; BEAMER WG, 1988, BIOL REPROD, V38, P899, DOI 10.1095/biolreprod38.4.899; BOER PH, 1987, MOL CELL BIOL, V7, P3107, DOI 10.1128/MCB.7.9.3107; Boettger-Tong HL, 2000, BIOL REPROD, V63, P1185, DOI 10.1095/biolreprod63.4.1185; Boettger-Tong HL, 2001, BIOCHEM BIOPH RES CO, V288, P1129, DOI 10.1006/bbrc.2001.5899; Chen HH, 2002, GENOMICS, V80, P140, DOI 10.1006/geno.2002.6808; Cremers Frans P. M., 1992, Human Molecular Genetics, V1, P71, DOI 10.1093/hmg/1.2.71; DAHL HHM, 1990, GENOMICS, V8, P225, DOI 10.1016/0888-7543(90)90275-Y; Dass B, 2001, J BIOL CHEM, V276, P8044, DOI 10.1074/jbc.M009091200; Dragon F, 2002, NATURE, V417, P967, DOI 10.1038/nature00769; Elliott DJ, 2000, HUM MOL GENET, V9, P2117, DOI 10.1093/hmg/9.14.2117; Halford S, 2001, GENOMICS, V72, P203, DOI 10.1006/geno.2001.6469; HANDEL MA, 1994, CYTOGENET CELL GENET, V66, P83, DOI 10.1159/000133672; Hendriksen PJM, 1997, GENOMICS, V41, P350, DOI 10.1006/geno.1997.4673; Kojima Y, 1997, Int J Urol, V4, P500, DOI 10.1111/j.1442-2042.1997.tb00293.x; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; MARDON G, 1990, MOL CELL BIOL, V10, P681, DOI 10.1128/MCB.10.2.681; MCCARREY JR, 1987, NATURE, V326, P501, DOI 10.1038/326501a0; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nagase T., 1996, DNA RES, V3; Ohta H, 2001, INT J ANDROL, V24, P15, DOI 10.1046/j.1365-2605.2001.00257.x; RICHLER C, 1994, MOL BIOL CELL, V5, P1341, DOI 10.1091/mbc.5.12.1341; SARGENT CA, 1994, HUM MOL GENET, V3, P1317, DOI 10.1093/hmg/3.8.1317; Scanlan M J, 2001, Cancer Immun, V1, P4; Sedlacek Z, 1999, GENOMICS, V61, P125, DOI 10.1006/geno.1999.5931; SOLARI AJ, 1974, INT REV CYTOL, V38, P273, DOI 10.1016/S0074-7696(08)60928-6; Tohda A, 2001, BIOL REPROD, V65, P532, DOI 10.1095/biolreprod65.2.532; Uechi T, 2002, NUCLEIC ACIDS RES, V30, P5369, DOI 10.1093/nar/gkf696; VANIN EF, 1984, BIOCHIM BIOPHYS ACTA, V782, P231, DOI 10.1016/0167-4781(84)90057-5; Zhang ZL, 2003, GENOME RES, V13, P2541, DOI 10.1101/gr.1429003	31	86	90	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2004	36	8					872	876		10.1038/ng1390	http://dx.doi.org/10.1038/ng1390			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	842AG	15258580				2022-12-25	WOS:000222974000021
J	Francino, MP				Francino, MP			An adaptive radiation model for the origin of new gene functions	NATURE GENETICS			English	Article							OLFACTORY RECEPTOR GENES; AMPLIFICATION-MUTAGENESIS; TRANSFERRED GENES; NATURAL-SELECTION; GENOME EVOLUTION; FAMILY; DUPLICATION; BACTERIAL; MUTATION; GROWTH	Current models for the evolution of new gene functions after gene duplication presume that the duplication events themselves have no effect on fitness. But those duplications that result in new gene functions are likely to be positively selected from their inception. The evolution of new function may start with the amplification of an existing gene with some level of preadaptation for that function, followed by a period of competitive evolution among the gene copies, resulting in the preservation of the most effective variant and the 'pseudogenization' and eventual loss of the rest.	Lawrence Berkeley Natl Lab, DOE Joint Genome Inst, Evolutionary Genom Dept, Walnut Creek, CA 94598 USA; Lawrence Berkeley Natl Lab, Genom Div, Walnut Creek, CA USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Francino, MP (corresponding author), Lawrence Berkeley Natl Lab, DOE Joint Genome Inst, Evolutionary Genom Dept, 2800 Mitchell Dr, Walnut Creek, CA 94598 USA.	mpfrancino@lbl.gov	Francino, M.Pilar/H-9090-2015	Francino, M.Pilar/0000-0002-4510-5653				Aharoni A, 2005, NAT GENET, V37, P73, DOI 10.1038/ng1482; CAIRNS J, 1991, GENETICS, V128, P695; Chan KMA, 2002, SYST BIOL, V51, P855, DOI 10.1080/10635150290155836; Clark AG, 2003, SCIENCE, V302, P1960, DOI 10.1126/science.1088821; Dujon B, 2004, NATURE, V430, P35, DOI 10.1038/nature02579; Dunham MJ, 2002, P NATL ACAD SCI USA, V99, P16144, DOI 10.1073/pnas.242624799; Eldredge N., 1972, P82; Force A, 1999, GENETICS, V151, P1531; Fortna A, 2004, PLOS BIOL, V2, P937, DOI 10.1371/journal.pbio.0020207; Gevers D, 2004, TRENDS MICROBIOL, V12, P148, DOI 10.1016/j.tim.2004.02.007; Gilad Y, 2000, NAT GENET, V26, P221, DOI 10.1038/79957; Gilad Y, 2003, AM J HUM GENET, V73, P489, DOI 10.1086/378132; Gilad Y, 2003, MOL BIOL EVOL, V20, P307, DOI 10.1093/molbev/msg013; GINGERICH PD, 1983, SCIENCE, V222, P159, DOI 10.1126/science.222.4620.159; Guillemaud T, 1999, HEREDITY, V83, P87, DOI 10.1038/sj.hdy.6885370; Hall BG, 2003, GENETICA, V118, P143, DOI 10.1023/A:1024149508376; Harrison PM, 2002, J MOL BIOL, V318, P1155, DOI 10.1016/S0022-2836(02)00109-2; Hendrickson H, 2002, P NATL ACAD SCI USA, V99, P2164, DOI 10.1073/pnas.032680899; Holloway AK, 2004, MOL BIOL EVOL, V21, P1625, DOI 10.1093/molbev/msh195; Hooper SD, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-8-r48; Hooper SD, 2003, MOL BIOL EVOL, V20, P945, DOI 10.1093/molbev/msg101; Hughes AL, 1999, CELL MOL LIFE SCI, V56, P94, DOI 10.1007/s000180050010; HUGHES AL, 1994, P ROY SOC B-BIOL SCI, V256, P119, DOI 10.1098/rspb.1994.0058; Huynen MA, 1998, MOL BIOL EVOL, V15, P583, DOI 10.1093/oxfordjournals.molbev.a025959; Jablonski David, 1996, P256; Johnson ME, 2001, NATURE, V413, P514, DOI 10.1038/35097067; Jordan IK, 2001, GENOME RES, V11, P555, DOI 10.1101/gr.GR-1660R; Karev GP, 2002, BMC EVOL BIOL, V2, DOI 10.1186/1471-2148-2-18; Karev GP, 2003, BIOINFORMATICS, V19, P1889, DOI 10.1093/bioinformatics/btg351; Kim SJ, 1999, BIOTECHNOL BIOENG, V64, P741, DOI 10.1002/(SICI)1097-0290(19990920)64:6<741::AID-BIT14>3.0.CO;2-X; Kondrashov FA, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-2-research0008; LANDE R, 1976, EVOLUTION, V30, P314, DOI 10.1111/j.1558-5646.1976.tb00911.x; Lespinet O, 2002, GENOME RES, V12, P1048, DOI 10.1101/gr.174302; Liu Y, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r64; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; LYNCH M, 1990, AM NAT, V136, P727, DOI 10.1086/285128; Mefford HC, 2001, HUM MOL GENET, V10, P2363, DOI 10.1093/hmg/10.21.2363; Mira A, 2001, TRENDS GENET, V17, P589, DOI 10.1016/S0168-9525(01)02447-7; Moore RC, 2003, P NATL ACAD SCI USA, V100, P15682, DOI 10.1073/pnas.2535513100; Newman T, 2003, GENOME RES, V13, P781, DOI 10.1101/gr.769003; Ohno S., 1970, EVOLUTION GENE DUPLI; Qian J, 2001, J MOL BIOL, V313, P673, DOI 10.1006/jmbi.2001.5079; Reams AB, 2003, MOL MICROBIOL, V47, P1291, DOI 10.1046/j.1365-2958.2003.03342.x; Riehle MM, 2001, P NATL ACAD SCI USA, V98, P525, DOI 10.1073/pnas.021448998; Romero D, 1997, ANNU REV GENET, V31, P91, DOI 10.1146/annurev.genet.31.1.91; Roth JR, 2004, J BACTERIOL, V186, P4855, DOI 10.1128/JB.186.15.4855-4860.2004; Roth JR, 2004, RES MICROBIOL, V155, P342, DOI 10.1016/j.resmic.2004.01.016; Schluter D., 2000, ECOLOGY ADAPTIVE RAD; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Simpson G. G., 1953, MAJOR FEATURES EVOLU, DOI DOI 10.7312/SIMP93764; Simpson G.G., 1944, TEMPO MODE EVOLUTION, DOI DOI 10.1073/pnas.1821292116; Stanley S. M., 1979, MACROEVOLUTION PATTE; Trask BJ, 1998, HUM MOL GENET, V7, P2007, DOI 10.1093/hmg/7.13.2007; TURELLI M, 1988, EVOLUTION, V42, P1085, DOI [10.2307/2408923, 10.1111/j.1558-5646.1988.tb02526.x]; Wagner A, 2002, GENOME BIOL, V3; Wagner PJ, 1996, EVOLUTION, V50, P990, DOI 10.1111/j.1558-5646.1996.tb02341.x; Young JM, 2002, HUM MOL GENET, V11, P1153, DOI 10.1093/hmg/11.10.1153; Zhang JZ, 1998, P NATL ACAD SCI USA, V95, P3708, DOI 10.1073/pnas.95.7.3708; Zhong SB, 2004, P NATL ACAD SCI USA, V101, P11719, DOI 10.1073/pnas.0404397101	59	141	145	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2005	37	6					573	577		10.1038/ng1579	http://dx.doi.org/10.1038/ng1579			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	931OT	15920518	Green Submitted			2022-12-25	WOS:000229495300007
J	Sakuntabhai, A; Turbpaiboon, C; Casademont, I; Chuansumrit, A; Lowhnoo, T; Kajaste-Rudnitski, A; Kalayanarooj, SM; Tangnararatchakit, K; Tangthawornchaikul, N; Vasanawathana, S; Chaiyaratana, W; Yenchitsomanus, PT; Suriyaphol, P; Avirutnan, P; Chokephaibulkit, K; Matsuda, F; Yoksan, S; Jacob, Y; Lathrop, GM; Malasit, P; Despres, P; Julier, C				Sakuntabhai, A; Turbpaiboon, C; Casademont, I; Chuansumrit, A; Lowhnoo, T; Kajaste-Rudnitski, A; Kalayanarooj, SM; Tangnararatchakit, K; Tangthawornchaikul, N; Vasanawathana, S; Chaiyaratana, W; Yenchitsomanus, PT; Suriyaphol, P; Avirutnan, P; Chokephaibulkit, K; Matsuda, F; Yoksan, S; Jacob, Y; Lathrop, GM; Malasit, P; Despres, P; Julier, C			A variant in the CD209 promoter is associated with severity of dengue disease	NATURE GENETICS			English	Article							SP1 BINDING-SITE; DC-SIGN; HEMORRHAGIC-FEVER; MYCOBACTERIUM-TUBERCULOSIS; INCREASED RISK; BONE-DENSITY; INFECTIONS; POLYMORPHISMS; PATHOGENESIS; CORRELATE	Dengue fever and dengue hemorrhagic fever are mosquito-borne viral diseases. Dendritic cell - specific ICAM-3 grabbing nonintegrin (DC-SIGN1, encoded by CD209), an attachment receptor of dengue virus, is essential for productive infection of dendritic cells(1,2). Here, we report strong association between a promoter variant of CD209, DCSIGN1-336, and risk of dengue fever compared with dengue hemorrhagic fever or population controls. The G allele of the variant DCSIGN1-336 was associated with strong protection against dengue fever in three independent cohorts from Thailand, with a carrier frequency of 4.7% in individuals with dengue fever compared with 22.4% in individuals with dengue hemorrhagic fever ( odds ratio for risk of dengue hemorrhagic fever versus dengue fever: 5.84, P = 1.4 x 10(-7)) and 19.5% in controls ( odds ratio for protection: 4.90, P = 2 x 10(-6)). This variant affects an Sp1-like binding site and transcriptional activity in vitro. These results indicate that CD209 has a crucial role in dengue pathogenesis, which discriminates between severe dengue fever and dengue hemorrhagic fever. This may have consequences for therapeutic and preventive strategies.	Inst Pasteur, INSERM E102, F-75724 Paris, France; Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Pediat, Bangkok 10400, Thailand; Mahidol Univ, Fac Sci, Dept Biochem, Bangkok 10400, Thailand; Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Pediat, Bangkok 10400, Thailand; Ctr Natl Genotypage, F-91057 Evry, France; Mahidol Univ, Ramathibodi Hosp, Fac Med, Res Ctr, Bangkok 10400, Thailand; Inst Pasteur, F-75724 Paris, France; Mahidol Univ, Med Mol Biol Unit, Fac Med, Siriraj Hosp, Bangkok 10700, Thailand; Natl Sci & Technol Dev Agcy NSTDA, Med Biotechnol Unit, Natl Ctr Genet Engn & Biotechnol BIOTEC, Pathum Thani 12120, Thailand; Khon Kaen Univ, Minist Publ Hlth, Dept Pediat, Khon Kaen 40000, Thailand; Mahidol Univ, Siriraj Hosp, Dept Pediat, Fac Med, Bangkok 10700, Thailand; Mahidol Univ, Ctr Vaccine Dev, Inst Sci & Technol Res & Dev, Nakhon Pathom 73170, Thailand; Inst Pasteur, Genet Papillomavirus & Canc Humain, F-75724 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Mahidol University; Mahidol University; Mahidol University; CEA; UDICE-French Research Universities; Universite Paris Saclay; Mahidol University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Mahidol University; National Science & Technology Development Agency - Thailand; National Center Genetic Engineering & Biotechnology (BIOTEC); Khon Kaen University; Ministry of Public Health - Thailand; Mahidol University; Mahidol University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Julier, C (corresponding author), Inst Pasteur, INSERM E102, 28 Rue Docteur Roux, F-75724 Paris, France.	cjulier@pasteur.fr	JULIER, Cécile/M-9824-2017; Matsuda, Fumihiko/B-9893-2009	JULIER, Cécile/0000-0002-1538-0240; Kalayanarooj, Siripen/0000-0002-3568-0929; Kajaste-Rudnitski, Anna/0000-0003-1549-2426; Jacob, Yves/0000-0001-9125-2374				Abecasis GR, 2000, BIOINFORMATICS, V16, P182, DOI 10.1093/bioinformatics/16.2.182; BURKE DS, 1988, AM J TROP MED HYG, V38, P172, DOI 10.4269/ajtmh.1988.38.172; CHIEWSILP P, 1981, AM J TROP MED HYG, V30, P1100, DOI 10.4269/ajtmh.1981.30.1100; Fernandez-Mestre MT, 2004, TISSUE ANTIGENS, V64, P469, DOI 10.1111/j.1399-0039.2004.00304.x; Grant SFA, 1996, NAT GENET, V14, P203, DOI 10.1038/ng1096-203; Halary F, 2002, IMMUNITY, V17, P653, DOI 10.1016/S1074-7613(02)00447-8; HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268; Harendza S, 2003, J BIOL CHEM, V278, P20490, DOI 10.1074/jbc.M211536200; INNIS BL, 1989, AM J TROP MED HYG, V40, P418, DOI 10.4269/ajtmh.1989.40.418; Klimstra WB, 2003, J VIROL, V77, P12022, DOI 10.1128/JVI.77.22.12022-12032.2003; Liu HB, 2003, GENE, V313, P149, DOI 10.1016/S0378-1119(03)00674-7; Liu WL, 2004, J BIOL CHEM, V279, P18748, DOI 10.1074/jbc.M311227200; Loke H, 2002, AM J TROP MED HYG, V67, P102, DOI 10.4269/ajtmh.2002.67.102; Loke H, 2001, J INFECT DIS, V184, P1369, DOI 10.1086/324320; Mann V, 2001, J CLIN INVEST, V107, P899, DOI 10.1172/JCI10347; Martin MP, 2004, J VIROL, V78, P14053, DOI 10.1128/JVI.78.24.14053-14056.2004; Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887; Mummidi S, 2001, J BIOL CHEM, V276, P33196, DOI 10.1074/jbc.M009807200; Navarro-Sanchez E, 2003, EMBO REP, V4, P723, DOI 10.1038/sj.embor.embor866; PEREZ MLP, 1987, HAEMATOLOGIA, V20, P83; Rothman AL, 2003, ADV VIRUS RES, V60, P397, DOI 10.1016/S0065-3527(03)60010-2; Sibley K, 2003, CANCER RES, V63, P4327; Stephens HAF, 2002, TISSUE ANTIGENS, V60, P309, DOI 10.1034/j.1399-0039.2002.600405.x; Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468; Takahashi Masazumi, 2003, J Bioinform Comput Biol, V1, P253, DOI 10.1142/S021972000300006X; Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840; van Kooyk Y, 2003, TRENDS MOL MED, V9, P153, DOI 10.1016/S1471-4914(03)00027-3; Vaughn DW, 2000, J INFECT DIS, V181, P2, DOI 10.1086/315215; WHO, 1997, DENG HAEM FEV DIAGN; Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004	30	226	248	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2005	37	5					507	513		10.1038/ng1550	http://dx.doi.org/10.1038/ng1550			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	922TU	15838506	Bronze, Green Published			2022-12-25	WOS:000228862300020
J	Wang, X; Weisleder, N; Collet, C; Zhou, JS; Chu, Y; Hirata, Y; Zhao, XL; Pan, Z; Brotto, M; Cheng, HP; Ma, JJ				Wang, X; Weisleder, N; Collet, C; Zhou, JS; Chu, Y; Hirata, Y; Zhao, XL; Pan, Z; Brotto, M; Cheng, HP; Ma, JJ			Uncontrolled calcium sparks act as a dystrophic signal for mammalian skeletal muscle	NATURE CELL BIOLOGY			English	Article							CA2+ SPARKS; MDX MOUSE; ELEMENTARY EVENTS; HEART-MUSCLE; 2 MECHANISMS; RELEASE; CONTRACTION; FIBERS; CELLS; MICE	Most excitable cells maintain tight control of intracellular Ca2+ through coordinated interaction between plasma membrane and endoplasmic or sarcoplasmic reticulum. Quiescent sarcoplasmic reticulum Ca2+ release machinery is essential for the survival and normal function of skeletal muscle(1-3). Here we show that subtle membrane deformations induce Ca2+ sparks in intact mammalian skeletal muscle. Spontaneous Ca2+ sparks can be reversibly induced by osmotic shock, and participate in a normal physiological response to exercise. In dystrophic muscle with fragile membrane integrity, stress-induced Ca2+ sparks are essentially irreversible. Moreover, moderate exercise in mdx muscle alters the Ca2+ spark response. Thus, membrane-deformation- induced Ca2+ sparks have an important role in physiological and pathophysiological regulation of Ca2+ signalling, and uncontrolled Ca2+ spark activity in connection with chronic activation of store-operated Ca2+ entry may function as a dystrophic signal in mammalian skeletal muscle.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Rush Univ, Sch Med, Dept Mol Physiol & Biophys, Chicago, IL 60612 USA; Peking Univ, Inst Mol Med, Beijing 100871, Peoples R China	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rush University; Peking University	Ma, JJ (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Lane, Piscataway, NJ 08854 USA.	maj2@umdnj.edu	Heping, Cheng/AAE-2680-2019; Weisleder, Noah L/A-7098-2013; cheng, heping/A-7299-2011	Heping, Cheng/0000-0002-9604-6702; Weisleder, Noah L/0000-0002-2619-8022; Weisleder, Noah/0000-0003-2710-3088; Pan, Zui/0000-0003-4105-901X	NCI NIH HHS [R01-CA95739] Funding Source: Medline; NHLBI NIH HHS [R01-HL69000] Funding Source: Medline; NIA NIH HHS [R01-AG15556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095739] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allamand V, 2000, HUM MOL GENET, V9, P2459, DOI 10.1093/hmg/9.16.2459; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Chawla S, 2001, J PHYSIOL-LONDON, V536, P351, DOI 10.1111/j.1469-7793.2001.0351c.xd; Cheng H, 1999, BIOPHYS J, V76, P606, DOI 10.1016/S0006-3495(99)77229-2; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; Collet C, 2004, BIOPHYS J, V87, P268, DOI 10.1529/biophysj.103.039305; Conklin MW, 1999, BIOPHYS J, V77, P1394, DOI 10.1016/S0006-3495(99)76988-2; Crawford GE, 2001, HUM MOL GENET, V10, P2745, DOI 10.1093/hmg/10.24.2745; FONG P, 1990, SCIENCE, V250, P673, DOI 10.1126/science.2173137; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; Gomez AM, 1997, SCIENCE, V276, P800, DOI 10.1126/science.276.5313.800; Ito K, 2001, J CELL BIOL, V154, P1059, DOI 10.1083/jcb.200105040; Kirsch WG, 2001, J PHYSIOL-LONDON, V537, P379, DOI 10.1111/j.1469-7793.2001.00379.x; Klein MG, 1996, NATURE, V379, P455, DOI 10.1038/379455a0; Kumar A, 2004, FASEB J, V18, P102, DOI 10.1096/fj.03-0453com; Lacampagne A, 2000, P NATL ACAD SCI USA, V97, P7823, DOI 10.1073/pnas.97.14.7823; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; Lee EH, 2004, AM J PHYSIOL-CELL PH, V286, pC179, DOI 10.1152/ajpcell.00176.2003; Leijendekker WJ, 1996, BRIT J PHARMACOL, V118, P611, DOI 10.1111/j.1476-5381.1996.tb15445.x; Lynch GS, 2000, AM J PHYSIOL-CELL PH, V279, pC1290, DOI 10.1152/ajpcell.2000.279.4.C1290; Mallouk N, 2000, P NATL ACAD SCI USA, V97, P4950, DOI 10.1073/pnas.97.9.4950; Pan Z, 2002, NAT CELL BIOL, V4, P379, DOI 10.1038/ncb788; Paschen W, 2001, CELL CALCIUM, V29, P1, DOI 10.1054/ceca.2000.0162; Porter JD, 1998, J CELL SCI, V111, P1801; Shirokova N, 1998, J PHYSIOL-LONDON, V512, P377, DOI 10.1111/j.1469-7793.1998.377be.x; TAKAGI A, 1992, J NEUROL SCI, V110, P160, DOI 10.1016/0022-510X(92)90023-E; TSUGORKA A, 1995, SCIENCE, V269, P1723, DOI 10.1126/science.7569901; Wier WG, 1999, CIRC RES, V85, P770, DOI 10.1161/01.RES.85.9.770; Zhou J, 2003, J GEN PHYSIOL, V122, P95, DOI 10.1085/jgp.200308796	29	128	134	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2005	7	5					525	530		10.1038/ncb1254	http://dx.doi.org/10.1038/ncb1254			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	926LA	15834406				2022-12-25	WOS:000229123500020
J	Saito, T; Iwata, N; Tsubuki, S; Takaki, Y; Takano, J; Huang, SM; Suemoto, T; Higuchi, M; Saido, TC				Saito, T; Iwata, N; Tsubuki, S; Takaki, Y; Takano, J; Huang, SM; Suemoto, T; Higuchi, M; Saido, TC			Somatostatin regulates brain amyloid beta peptide A beta(42) through modulation of proteolytic degradation	NATURE MEDICINE			English	Article							ALZHEIMERS-DISEASE; MOUSE HIPPOCAMPUS; PRIMARY NEURONS; A-BETA; NEPRILYSIN; EXPRESSION; CLEARANCE; IMMUNOREACTIVITY; ENDOPEPTIDASE; LOCALIZATION	Expression of somatostatin in the brain declines during aging in various mammals including apes and humans(1,2). A prominent decrease in this neuropeptide also represents a pathological characteristic of Alzheimer disease(3,4). Using in vitro and in vivo paradigms, we show that somatostatin regulates the metabolism of amyloid beta peptide (A beta), the primary pathogenic agent of Alzheimer disease, in the brain through modulating proteolytic degradation catalyzed by neprilysin. Among various effector candidates, only somatostatin upregulated neprilysin activity in primary cortical neurons. A genetic deficiency of somatostatin altered hippocampal neprilysin activity and localization, and increased the quantity of a hydrophobic 42-mer form of A beta, A beta(42), in a manner similar to presenilin gene mutations that cause familial Alzheimer disease. These results indicate that the aging-induced downregulation of somatostatin expression may be a trigger for A beta accumulation leading to late-onset sporadic Alzheimer disease, and suggest that somatostatin receptors may be pharmacological-target candidates for prevention and treatment of Alzheimer disease.	RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, Wako, Saitama 3510198, Japan	RIKEN	Iwata, N (corresponding author), RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	iwatan@brain.riken.go.jp; saido@brain.riken.go.jp	Sado, Takaomi/AAN-2759-2021; Saito, Takashi/G-2563-2015; Saido, Takaomi C/N-5472-2015	Sado, Takaomi/0000-0003-1970-6903; Saito, Takashi/0000-0002-9659-9251; Saido, Takaomi C/0000-0003-1970-6903				BACK SA, 1989, J NEUROSCI, V9, P4439; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; DAVIES P, 1980, NATURE, V288, P279, DOI 10.1038/288279a0; Doggrell SA, 2004, EXPERT OPIN INV DRUG, V13, P69, DOI 10.1517/13543784.13.1.69; GARCIAJIMENEZ A, 2002, BRAIN AGING, V2, P7; Hama E, 2001, J BIOCHEM-TOKYO, V130, P721, DOI 10.1093/oxfordjournals.jbchem.a003040; Hama E, 2004, J BIOL CHEM, V279, P30259, DOI 10.1074/jbc.M401891200; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hayashi M, 1997, BRAIN RES, V749, P283, DOI 10.1016/S0006-8993(96)01317-0; Iwata N, 2004, J NEUROSCI, V24, P991, DOI 10.1523/JNEUROSCI.4792-03.2004; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Iwata N, 2002, J NEUROSCI RES, V70, P493, DOI 10.1002/jnr.10390; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Jinno S, 2003, J COMP NEUROL, V461, P333, DOI 10.1002/cne.10700; Joshi DD, 2001, BLOOD, V98, P2697, DOI 10.1182/blood.V98.9.2697; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Moller LN, 2003, BBA-BIOMEMBRANES, V1616, P1, DOI 10.1016/S0005-2736(03)00235-9; Shimon I, 1997, J CLIN INVEST, V99, P789, DOI 10.1172/JCI119225; Shirotani K, 2001, J BIOL CHEM, V276, P21895, DOI 10.1074/jbc.M008511200; Takano J, 2000, J BIOCHEM, V128, P83, DOI 10.1093/oxfordjournals.jbchem.a022733; Turner A.J., 2004, ABETA METABOLISM ALZ, P419; van de Nes JAP, 2002, ACTA NEUROPATHOL, V104, P351, DOI 10.1007/s00401-002-0551-7; Wang GJ, 1999, METHODS, V18, P459, DOI 10.1006/meth.1999.0813; Wang TL, 1998, CARDIOVASC RES, V40, P557, DOI 10.1016/S0008-6363(98)00192-8; Wolfe M., 2003, ABETA METABOLISM ALZ, P33; Yasojima K, 2001, NEUROSCI LETT, V297, P97, DOI 10.1016/S0304-3940(00)01675-X; Zeyda T, 2001, BRAIN RES, V906, P107, DOI 10.1016/S0006-8993(01)02563-X	29	277	291	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2005	11	4					434	439		10.1038/nm1206	http://dx.doi.org/10.1038/nm1206			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15778722				2022-12-25	WOS:000228180500036
J	Wada, T; Nakashima, T; Oliveira-dos-Santos, AJ; Gasser, J; Hara, H; Schett, G; Penninger, JM				Wada, T; Nakashima, T; Oliveira-dos-Santos, AJ; Gasser, J; Hara, H; Schett, G; Penninger, JM			The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis	NATURE MEDICINE			English	Article							BONE-RESORPTION; DOCKING PROTEIN; GROWTH-FACTOR; RECEPTOR; DIFFERENTIATION; ACTIVATION; MICE; OSTEOPETROSIS; TRANSDUCTION; MECHANISMS	Morphogenesis and remodeling of bone involve synthesis of bone matrix by osteoblasts and coordinate resorption of bone by osteoclasts. Defective bone remodeling caused by altered osteoclast activity underlies a multitude of osteopenic disorders. Receptor activator of NF-kappa B (RANK) and its ligand RANKL have been identified as essential factors involved in osteoclast development and bone remodeling, but their mechanism and interacting factors have not been fully characterized. Here we report that the molecular adapter Grb-2-associated binder-2 (Gab2) associates with RANK and mediates RANK-induced activation of NF-kappa B, Akt and Jnk. Inactivation of the gene encoding Gab2 in mice results in osteopetrosis and decreased bone resorption as a result of defective osteoclast differentiation. We also show that Gab2 has a crucial role in the differentiation of human progenitor cells into osteoclasts. We have thus identified a new, key regulatory scaffold molecule, Gab2, that controls select RANK signaling pathways and is essential for osteoclastogenesis and bone homeostasis.	Austrian Acad Sci, Inst Mol Biotechnol, A-1030 Vienna, Austria; Univ Toronto, Dept Immunol, Univ Hlth Network, Toronto, ON M5G 2C1, Canada; Arthrit & Bone Metab Dept, CH-4002 Basel, Switzerland; Univ Vienna, Dept Internal Med 3, Div Rheumatol, A-1090 Vienna, Austria	Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Vienna	Wada, T (corresponding author), Austrian Acad Sci, Inst Mol Biotechnol, Dr Bohrgasse 3-5, A-1030 Vienna, Austria.	teiji.wada@imba.oeaw.ac.at; josef.penninger@imba.oeaw.ac.at	Gasser, Juerg Andreas/AAT-5389-2020; Penninger, Josef M/I-6860-2013	Gasser, Juerg Andreas/0000-0002-0106-364X; Penninger, Josef M/0000-0002-8194-3777				Baron R, 1996, REV RHUM, V63, P633; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082; Gonzalez-Espinosa C, 2003, J EXP MED, V197, P1453, DOI 10.1084/jem.20021806; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Gu HH, 2003, J CELL BIOL, V161, P1151, DOI 10.1083/jcb.200212158; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Hibi M, 2000, LEUKEMIA LYMPHOMA, V37, P299, DOI 10.3109/10428190009089430; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Liu Y, 2002, FEBS LETT, V515, P1, DOI 10.1016/S0014-5793(02)02425-0; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Matsuzaki K, 1998, BIOCHEM BIOPH RES CO, V246, P199, DOI 10.1006/bbrc.1998.8586; NAKAMURA I, 1995, FEBS LETT, V361, P79, DOI 10.1016/0014-5793(95)00153-Z; Nishida K, 2002, BLOOD, V99, P1866, DOI 10.1182/blood.V99.5.1866; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Seiffert M, 2003, MOL CELL BIOL, V23, P2415, DOI 10.1128/MCB.23.7.2415-2424.2003; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753; Yamasaki S, 2001, J BIOL CHEM, V276, P45175, DOI 10.1074/jbc.M105384200	28	143	158	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2005	11	4					394	399		10.1038/nm1203	http://dx.doi.org/10.1038/nm1203			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15750601				2022-12-25	WOS:000228180500030
J	Aligianis, IA; Johnson, CA; Gissen, P; Chen, DR; Hampshire, D; Hoffmann, K; Maina, EN; Morgan, NV; Tee, L; Morton, J; Ainsworth, JR; Horn, D; Rosser, E; Cole, TRP; Stolte-Dijkstra, I; Fieggen, K; Clayton-Smith, J; Megarbane, A; Shield, JP; Newbury-Ecob, R; Dobyns, WB; Graham, JM; Kjaer, KW; Warburg, M; Bond, J; Trembath, RC; Harris, LW; Takai, Y; Mundlos, S; Tannahill, D; Woods, CG; Maher, ER				Aligianis, IA; Johnson, CA; Gissen, P; Chen, DR; Hampshire, D; Hoffmann, K; Maina, EN; Morgan, NV; Tee, L; Morton, J; Ainsworth, JR; Horn, D; Rosser, E; Cole, TRP; Stolte-Dijkstra, I; Fieggen, K; Clayton-Smith, J; Megarbane, A; Shield, JP; Newbury-Ecob, R; Dobyns, WB; Graham, JM; Kjaer, KW; Warburg, M; Bond, J; Trembath, RC; Harris, LW; Takai, Y; Mundlos, S; Tannahill, D; Woods, CG; Maher, ER			Mutations of the catalytic subunit of RAB3GAP cause Warburg Micro syndrome	NATURE GENETICS			English	Article							GTPASE-ACTIVATING PROTEIN; CONGENITAL CATARACT; OPTIC ATROPHY; RETARDATION; SUBFAMILY	Warburg Micro syndrome (WARBM1) is a severe autosomal recessive disorder characterized by developmental abnormalities of the eye and central nervous system and by microgenitalia. We identified homozygous inactivating mutations in RAB3GAP, encoding RAB3 GTPase activating protein, a key regulator of the Rab3 pathway implicated in exocytic release of neurotransmitters and hormones, in 12 families with Micro syndrome. We hypothesize that the underlying pathogenesis of Micro syndrome is a failure of exocytic release of ocular and neurodevelopmental trophic factors.	Univ Birmingham, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Birmingham Womens Hosp, W Midlands Reg Genet Serv, Birmingham B15 2TG, W Midlands, England; Wellcome Trust Sanger Inst, Embryo Gene Express Patterns, Cambridge CB10 1SA, England; St James Univ Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England; Humboldt Univ, Charite Univ Hosp, Inst Med Genet, D-13353 Berlin, Germany; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Birmingham Midlands Eye Hosp, Birmingham, W Midlands, England; Birmingham Childrens Hosp, Birmingham, W Midlands, England; Great Ormond St Hosp Sick Children, NE Thames Reg Genet Serv, London WC1N 1EH, England; Univ Groningen Hosp, Dept Clin Genet, NL-9700 RB Groningen, Netherlands; Univ Cape Town, Div Human Genet, ZA-7925 Cape Town, South Africa; St Marys Hosp, Acad Dept Med Genet, Manchester M13 0JH, Lancs, England; St Joseph Univ, Fac Med, Med Genet Unit, Beirut, Lebanon; Univ Bristol, Bristol, Avon, England; St Michaels Hosp, Dept Clin Genet, Bristol BS2 8EG, Avon, England; Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; Univ Calif Los Angeles, Cedars Sinai Med Ctr, David Geffen Sch Med,Med Genet Inst, Steven Spielberg Pediat Res Ctr,SHARES Child Disa, Los Angeles, CA 90048 USA; Univ Copenhagen, Gentofte Hosp, Wilhelm Johannsen Ctr Funct Genome Res, DK-1168 Copenhagen, Denmark; Univ Copenhagen, Gentofte Hosp, Div Pediat Ophthalmol & Handicaps, DK-1168 Copenhagen, Denmark; Univ Leicester, Div Med Genet, Dept Med, Leicester LE1 7RH, Leics, England; Univ Leicester, Div Med Genet, Dept Genet, Leicester LE1 7RH, Leics, England; Osaka Univ, Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	University of Birmingham; Birmingham Women's Hospital; Wellcome Trust Sanger Institute; Saint James's University Hospital; University of Leeds; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Max Planck Society; University of Birmingham; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Groningen; University of Cape Town; University of Manchester; University of Bristol; University of Chicago; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Herlev & Gentofte Hospital; University of Leicester; University of Leicester; Osaka University	Maher, ER (corresponding author), Univ Birmingham, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.	e.r.maher@bham.ac.uk	Gissen, Paul/A-4352-2010; Shield, Julian PH/D-6297-2014; Mundlos, Stefan/ABH-9585-2020; Morgan, Neil V/A-5475-2009; Dobyns, William/AAI-2768-2020; MAHER, EAMONN R/A-9507-2008; woods, christopher g/A-1361-2010; Dobyns, William Brian/ABC-6525-2021; Graham, John M./J-1429-2019; Megarbane, Andre/ABD-5574-2021; Hampshire, Daniel/Q-3540-2019	Gissen, Paul/0000-0002-9712-6122; Shield, Julian PH/0000-0003-2601-7575; Morgan, Neil V/0000-0001-6433-5692; Dobyns, William/0000-0002-7681-2844; MAHER, EAMONN R/0000-0002-6226-6918; Harris, Laura/0000-0003-4312-7223; Mundlos, Stefan/0000-0002-9788-3166; Tannahill, David/0000-0002-3811-6864; Johnson, Colin/0000-0002-2979-8234; fieggen, karen/0000-0002-2910-6306; Trembath, Richard/0000-0003-0550-3400				Ainsworth JR, 2001, OPHTHALMOLOGY, V108, P491, DOI 10.1016/S0161-6420(00)00540-6; DI GG, 2004, BRAIN RES DEV BRAIN, V150, P17; Fukui K, 1997, J BIOL CHEM, V272, P4655, DOI 10.1074/jbc.272.8.4655; Graham JM, 2004, AM J MED GENET A, V128A, P235, DOI 10.1002/ajmg.a.30060; Hiesinger PR, 1999, J NEUROSCI, V19, P7548, DOI 10.1523/JNEUROSCI.19-17-07548.1999; Jelitai M, 2004, J NEUROSCI RES, V76, P801, DOI 10.1002/jnr.20106; Li L, 2003, CELL MOL LIFE SCI, V60, P942, DOI 10.1007/s00018-003-2240-7; Megarbane A, 1999, J MED GENET, V36, P637; Nagano F, 1998, J BIOL CHEM, V273, P24781, DOI 10.1074/jbc.273.38.24781; Owens DF, 2002, NAT REV NEUROSCI, V3, P715, DOI 10.1038/nrn919; Schluter OM, 2002, J BIOL CHEM, V277, P40919, DOI 10.1074/jbc.M203704200; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; WARBURG M, 1993, AM J DIS CHILD, V147, P1309, DOI 10.1001/archpedi.1993.02160360051017; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	15	159	164	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2005	37	3					221	223		10.1038/ng1517	http://dx.doi.org/10.1038/ng1517			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	901QU	15696165				2022-12-25	WOS:000227297800012
J	Johnson, TM; Hammond, EM; Giaccia, A; Attardi, LD				Johnson, TM; Hammond, EM; Giaccia, A; Attardi, LD			The p53(QS) transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality	NATURE GENETICS			English	Article							CELL-CYCLE ARREST; P53 TUMOR-SUPPRESSOR; WILD-TYPE P53; P53-DEPENDENT APOPTOSIS; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; MICE; HYPOXIA; TARGET; PERP	The role of transcriptional activation in p53 function is highly controversial. To define this role in vivo, we generated a Trp53 knock-in construct encoding a protein carrying mutations of two residues that are crucial for transactivation (L25Q, W26S). Here we show that these mutations have selective effects on the biological functions of p53. Although its ability to activate various p53 target genes is largely compromised, the p53(QS) protein retains the ability to transactivate the gene Bax. The ability of the p53(QS) mutant protein to elicit a DNA damage-induced G1 cell cycle-arrest response is also partially impaired. p53(QS) has selective defects in its ability to induce apoptosis: it is completely unable to activate apoptosis in response to DNA damage, is partially unable to do so when subjected to serum deprivation and retains substantial apoptotic activity upon exposure to hypoxia. These findings suggest that p53 acts through distinct, stimulus-specific pathways to induce apoptosis. The importance of the biological activity of p53(QS) in vivo is underscored by our finding that expression of p53(QS), which cannot bind mdm2, induces embryonic lethality. Taken together, these results suggest that p53 has different mechanisms of action depending on specific contextual cues, which may help to clarify the function of p53 in preventing cancer.	Stanford Univ, Sch Med, Dept Radiat Oncol, Div Radiat & Canc Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA	Stanford University; Stanford University	Attardi, LD (corresponding author), Stanford Univ, Sch Med, Dept Radiat Oncol, Div Radiat & Canc Biol, Stanford, CA 94305 USA.	attardi@stanford.edu		Hammond, Ester/0000-0002-2335-3146	NIAMS NIH HHS [R01 AR065403] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR065403] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adelman DM, 2000, GENE DEV, V14, P3191, DOI 10.1101/gad.853700; Adimoolam S, 2002, P NATL ACAD SCI USA, V99, P12985, DOI 10.1073/pnas.202485699; AKAZAWA S, 1994, METABOLISM, V43, P830, DOI 10.1016/0026-0495(94)90262-3; Attardi LD, 2000, GENE DEV, V14, P704; Attardi LD, 2004, ONCOGENE, V23, P973, DOI 10.1038/sj.onc.1207026; ATTARDI LD, 1996, EMBO J, V15, P3702; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chavez-Reyes A, 2003, CANCER RES, V63, P8664; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISCHER B, 1993, J REPROD FERTIL, V99, P673, DOI 10.1530/jrf.0.0990673; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hemann MT, 2004, P NATL ACAD SCI USA, V101, P9333, DOI 10.1073/pnas.0403286101; Ihrie RA, 2003, CURR BIOL, V13, P1985, DOI 10.1016/j.cub.2003.10.055; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; LUNA RMD, 1995, NATURE, V378, P203; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Reczek EE, 2003, MOL CANCER RES, V1, P1048; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Uesugi M, 1999, P NATL ACAD SCI USA, V96, P14801, DOI 10.1073/pnas.96.26.14801; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	47	115	116	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2005	37	2					145	152		10.1038/ng1498	http://dx.doi.org/10.1038/ng1498			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	893AB	15654339				2022-12-25	WOS:000226690100020
J	Horike, S; Cai, ST; Miyano, M; Cheng, JF; Kohwi-Shigematsu, T				Horike, S; Cai, ST; Miyano, M; Cheng, JF; Kohwi-Shigematsu, T			Loss of silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome	NATURE GENETICS			English	Article							CPG-BINDING PROTEIN; DNA METHYLATION; MONOCHROMOSOMAL HYBRIDS; HISTONE METHYLATION; IN-VIVO; MECP2; GENE; BRAIN; IDENTIFICATION; EXPRESSION	Mutations in MECP2 are associated with Rett syndrome, an X-linked neurodevelopmental disorder. To identify genes targeted by Mecp2, we sequenced 100 in vivo Mecp2-binding sites in mouse brain. Several sequences mapped to an imprinted gene cluster on chromosome 6, including Dlx5 and Dlx6, whose transcription was roughly two times greater in brains of Mecp2-null mice compared with those of wild-type mice. The maternally expressed gene DLX5 showed a loss of imprinting in lymphoblastoid cells from individuals with Rett syndrome. Because Dlx5 regulates production of enzymes that synthesize gamma-aminobutyric acid (GABA), loss of imprinting of Dlx5 may alter GABAergic neuron activity in individuals with Rett syndrome. In mouse brain, Dlx5 imprinting was relaxed, yet Mecp2-mediated silent-chromatin structure existed at the Dlx5-Dlx6 locus in brains of wild-type, but not Mecp2-null, mice. Mecp2 targeted histone deacetylase 1 to a sharply defined, similar to1-kb region at the Dlx5-Dlx6 locus and promoted repressive histone methylation at Lys9 at this site. Chromatin immunoprecipitation-combined loop assays showed that Mecp2 mediated the silent chromatin-derived 11-kb chromatin loop at the Dlx5-Dlx6 locus. This loop was absent in chromatin of brains of Mecp2-null mice, and Dlx5-Dlx6 interacted with far distant sequences, forming distinct active chromatin-associated loops. These results show that formation of a silent-chromatin loop is a new mechanism underlying gene regulation by Mecp2.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Kohwi-Shigematsu, T (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, 1 Cyclotron Rd,Mail Stop 84-171, Berkeley, CA 94720 USA.	terumiks@lbl.gov	MIYANO, MASARU/I-1353-2015; Horike, Shin-ichi/C-4319-2015	Horike, Shin-ichi/0000-0002-4256-9129; Cheng, Jan-Fang/0000-0001-7315-7613				Alvarez JD, 2000, GENE DEV, V14, P521; Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Balmer D, 2002, HUM GENET, V110, P545, DOI 10.1007/s00439-002-0724-4; Budden SS, 2001, BRAIN DEV-JPN, V23, pS133, DOI 10.1016/S0387-7604(01)00338-2; Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; Chen RZ, 2001, NAT GENET, V27, P327, DOI 10.1038/85906; Chen WG, 2003, SCIENCE, V302, P885, DOI 10.1126/science.1086446; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; Dragich J, 2000, HUM MOL GENET, V9, P2365, DOI 10.1093/hmg/9.16.2365; Drewell RA, 2002, NUCLEIC ACIDS RES, V30, P1139, DOI 10.1093/nar/30.5.1139; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; Hoshiya H, 2003, J HUM GENET, V48, P208, DOI 10.1007/s10038-003-0006-6; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones BE, 1998, EXTREMOPHILES, V2, P191, DOI 10.1007/s007920050060; Kimura H, 2003, J BIOL CHEM, V278, P4806, DOI 10.1074/jbc.M209923200; Kimura MI, 2004, J HUM GENET, V49, P273, DOI 10.1007/s10038-004-0139-2; Kohwi-Shigematsu T, 1998, METHOD CELL BIOL, V53, P323; Kriaucionis S, 2003, HUM MOL GENET, V12, pR221, DOI 10.1093/hmg/ddg286; Lalande M, 1999, Adv Neurol, V79, P421; Lalande M, 1996, ANNU REV GENET, V30, P173, DOI 10.1146/annurev.genet.30.1.173; Lee MP, 1999, P NATL ACAD SCI USA, V96, P5203, DOI 10.1073/pnas.96.9.5203; Lewis A, 2004, NAT GENET, V36, P1291, DOI 10.1038/ng1468; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Mager J, 2003, NAT GENET, V33, P502, DOI 10.1038/ng1125; Martinowich K, 2003, SCIENCE, V302, P890, DOI 10.1126/science.1090842; Mitsuya K, 1999, HUM MOL GENET, V8, P1209, DOI 10.1093/hmg/8.7.1209; Mizuno Y, 2002, BIOCHEM BIOPH RES CO, V290, P1499, DOI 10.1006/bbrc.2002.6370; Murrell A, 2004, NAT GENET, V36, P889, DOI 10.1038/ng1402; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Okita C, 2003, GENOMICS, V81, P556, DOI 10.1016/S0888-7543(03)00052-1; Ono R, 2003, GENOME RES, V13, P1696, DOI 10.1101/gr.906803; Palferman S, 2001, AM J HUM GENET, V69, P570; Panganiban G, 2002, DEVELOPMENT, V129, P4371; Piras G, 2000, MOL CELL BIOL, V20, P3308, DOI 10.1128/MCB.20.9.3308-3315.2000; Shahbazian MD, 2002, AM J HUM GENET, V71, P1259, DOI 10.1086/345360; Shahbazian MD, 2002, NEURON, V35, P243, DOI 10.1016/S0896-6273(02)00768-7; Shahbazian MD, 2002, HUM MOL GENET, V11, P115, DOI 10.1093/hmg/11.2.115; Spilianakis CG, 2004, NAT IMMUNOL, V5, P1017, DOI 10.1038/ni1115; Stuhmer T, 2002, DEVELOPMENT, V129, P245; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; Traynor Jeff, 2002, BMC Med Genet, V3, P12, DOI 10.1186/1471-2350-3-12; Tudor M, 2002, P NATL ACAD SCI USA, V99, P15536, DOI 10.1073/pnas.242566899; Weitzel JM, 1997, MOL CELL BIOL, V17, P5656, DOI 10.1128/MCB.17.9.5656; Yamada Y, 2004, GENOME RES, V14, P247, DOI 10.1101/gr.1351604; Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084	50	432	459	1	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2005	37	1					31	40		10.1038/ng1491	http://dx.doi.org/10.1038/ng1491			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	883FX	15608638				2022-12-25	WOS:000225997500018
J	Meetei, AR; Levitus, M; Xue, YT; Medhurst, AL; Zwaan, M; Ling, C; Rooimans, MA; Bier, P; Hoatlin, M; Pals, G; de Winter, JP; Wang, WD; Joenje, H				Meetei, AR; Levitus, M; Xue, YT; Medhurst, AL; Zwaan, M; Ling, C; Rooimans, MA; Bier, P; Hoatlin, M; Pals, G; de Winter, JP; Wang, WD; Joenje, H			X-linked inheritance of Fanconi anemia complementation group B	NATURE GENETICS			English	Article							NUCLEAR-COMPLEX; CHROMOSOME; INACTIVATION; MOUSE; FEMALE; COMMON; BRCA2	Fanconi anemia is an autosomal recessive syndrome characterized by diverse clinical symptoms, hypersensitivity to DNA crosslinking agents, chromosomal instability and susceptibility to cancer(1,2). Fanconi anemia has at least 11 complementation groups (A, B, C, D1, D2, E, F, G, I, J, L)(3,4); the genes mutated in 8 of these have been identified. The gene BRCA2 was suggested to underlie complementation group B, but the evidence is inconclusive(5). Here we show that the protein defective in individuals with Fanconi anemia belonging to complementation group B is an essential component of the nuclear protein 'core complex' responsible for monoubiquitination of FANCD2, a key event in the DNA-damage response pathway associated with Fanconi anemia and BRCA(3,6,7). Unexpectedly, the gene encoding this protein, FANCB, is localized at Xp22.31 and subject to X-chromosome inactivation. X-linked inheritance has important consequences for genetic counseling of families with Fanconi anemia belonging to complementation group B. Its presence as a single active copy and essentiality for a functional Fanconi anemia-BRCA pathway make FANCB a potentially vulnerable component of the cellular machinery that maintains genomic integrity.	NIA, Genet Lab, NIH, Baltimore, MD 21224 USA; Vrije Univ Amsterdam, Med Ctr, Dept Clin Genet, NL-1081 BT Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Pediat & Hematol Oncol, NL-1007 MB Amsterdam, Netherlands; Oregon Hlth & Sci Univ, Div Mol Med & Mol Med Genet, Portland, OR 97239 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Oregon Health & Science University	Wang, WD (corresponding author), NIA, Genet Lab, NIH, 333 Cassell Dr,TRIAD Ctr Room 3000, Baltimore, MD 21224 USA.	wangw@grc.nia.nih.gov; joenje@vumc.nl	Wang, Weidong/AAV-2446-2021; Pals, Gerard/A-5198-2011	Pals, Gerard/0000-0003-4091-7115; Wang, Weidong/0000-0002-0658-7928	NATIONAL INSTITUTE ON AGING [ZIAAG000688, Z01AG000688] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLEN RC, 1992, AM J HUM GENET, V51, P1229; Andreu N, 2003, BLOOD CELL MOL DIS, V31, P332, DOI 10.1016/S1079-9796(03)00168-2; Apostolou S, 1996, NAT GENET, V14, P324, DOI 10.1038/ng1196-324; Brown CJ, 2003, TRENDS GENET, V19, P432, DOI 10.1016/S0168-9525(03)00177-X; Bruun D, 2003, DNA REPAIR, V2, P1007, DOI 10.1016/S1568-7864(03)00112-5; Carrel L, 1999, P NATL ACAD SCI USA, V96, P14440, DOI 10.1073/pnas.96.25.14440; Cumming RC, 2001, NAT MED, V7, P814, DOI 10.1038/89937; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; de Winter JP, 2000, HUM MOL GENET, V9, P2665, DOI 10.1093/hmg/9.18.2665; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Heine-Suner D, 2003, AM J MED GENET A, V122A, P108, DOI 10.1002/ajmg.a.20160; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Jegalian K, 1998, NATURE, V394, P776, DOI 10.1038/29522; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Lee JT, 2003, CURR BIOL, V13, pR242, DOI 10.1016/S0960-9822(03)00162-3; Levitus M, 2004, BLOOD, V103, P2498, DOI 10.1182/blood-2003-08-2915; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Meetei AR, 2003, MOL CELL BIOL, V23, P3417, DOI 10.1128/MCB.23.10.3417-3426.2003; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; MONK M, 1979, NATURE, V281, P311, DOI 10.1038/281311a0; RUSSELL LB, 1961, SCIENCE, V133, P1795, DOI 10.1126/science.133.3467.1795; STRATHDEE CA, 1992, NAT GENET, V1, P196, DOI 10.1038/ng0692-196; Tanaka M, 2003, AM J PATHOL, V163, P295, DOI 10.1016/S0002-9440(10)63653-X; Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852; Tischkowitz M, 2003, BRIT J HAEMATOL, V123, P469, DOI 10.1046/j.1365-2141.2003.04640.x	25	226	244	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2004	36	11					1219	1224		10.1038/ng1458	http://dx.doi.org/10.1038/ng1458			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	867HI	15502827	Bronze			2022-12-25	WOS:000224832800027
J	Blower, SM; Chou, T				Blower, SM; Chou, T			Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance	NATURE MEDICINE			English	Article							INTRINSIC TRANSMISSION DYNAMICS; MDR-TB; SENSITIVITY; UNCERTAINTY; EPIDEMICS; THERAPY; COMPLEX; EXAMPLE; IMPACT; TREAT	`Hot zones' are areas that have >5% prevalence (or incidence) of multidrug-resistant tuberculosis (MDRTB). We present a new mathematical model (the amplifier model) that tracks the emergence and evolution of multiple (pre-MDR, MDR and post-MDR) strains of drug-resistant Mycobacterium tuberculosis. We reconstruct possible evolutionary trajectories that generated hot zones over the past three decades, and identify the key causal factors. Results are consistent with recently reported World Health Organization (WHO) data. Our analyses yield three important insights. First, paradoxically we found that areas with programs that successfully reduced wild-type pansensitive strains often evolved into hot zones. Second, some hot zones emerged even when MDR strains were substantially less fit (and thus less transmissible) than wild-type pansensitive strains. Third, levels of MDR are driven by case-finding rates, cure rates and amplification probabilities. To effectively control MDRTB in the hot zones, it is essential that the WHO specify a goal for minimizing the amplification probability.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, David Geffen Sch Med, UCLA AIDS Inst, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Blower, SM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, 1100 Glendon Ave,Penthouse 2, Los Angeles, CA 90024 USA.	sblower@mednet.ucla.edu			NIAID NIH HHS [R01 AI041935] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041935] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], [No title captured]; Bankes SC, 2002, P NATL ACAD SCI USA, V99, P7263, DOI 10.1073/pnas.092081399; Blower S, 1999, NAT MED, V5, P358, DOI 10.1038/7328; BLOWER SM, 1995, NAT MED, V1, P815, DOI 10.1038/nm0895-815; Blower SM, 1998, J MOL MED, V76, P624, DOI 10.1007/s001090050260; BLOWER SM, 1994, INT STAT REV, V62, P229, DOI 10.2307/1403510; Blower SM, 1998, NAT MED, V4, P673, DOI 10.1038/nm0698-673; Blower SM, 2002, LANCET INFECT DIS, V2, P374, DOI 10.1016/S1473-3099(02)00292-X; Blower SM, 1996, SCIENCE, V273, P497, DOI 10.1126/science.273.5274.497; CastilloChavez C, 1997, J MATH BIOL, V35, P629, DOI 10.1007/s002850050069; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P661; Cohen T, 2003, LANCET INFECT DIS, V3, P13, DOI 10.1016/S1473-3099(03)00483-3; Dye C, 2000, P NATL ACAD SCI USA, V97, P8180, DOI 10.1073/pnas.140102797; Dye C, 2002, J INFECT DIS, V185, P1197, DOI 10.1086/339818; Elzinga G, 2004, LANCET, V363, P814, DOI 10.1016/S0140-6736(04)15698-5; Espinal MA, 2001, NEW ENGL J MED, V344, P1294, DOI 10.1056/NEJM200104263441706; Espinal MA, 2003, INT J TUBERC LUNG D, V7, P607; ESPINAL MA, 2003, 2 WHO; Farmer P, 1998, INT J TUBERC LUNG D, V2, P869; FARMER P, 1999, GLOBAL IMPACT DRUG R; Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4; Hopewell PC, 2002, B WORLD HEALTH ORGAN, V80, P427; ISEMAN MD, 1994, P NATL ACAD SCI USA, V91, P2428, DOI 10.1073/pnas.91.7.2428; Iseman MD, 2002, EUR RESPIR J, V20, p87S, DOI 10.1183/09031936.02.00309102; Lietman T, 2000, CLIN INFECT DIS, V30, pS316, DOI 10.1086/313881; Migliori GB, 2002, INT J TUBERC LUNG D, V6, P858; Mitnick C, 2003, NEW ENGL J MED, V348, P119, DOI 10.1056/NEJMoa022928; Mukherjee JS, 2004, LANCET, V363, P474, DOI 10.1016/S0140-6736(04)15496-2; PABLOSMENDEZ A, 2000, 1 WHO; Porco TC, 1998, THEOR POPUL BIOL, V54, P117, DOI 10.1006/tpbi.1998.1366; Porco TC, 2001, J ACQ IMMUN DEF SYND, V28, P437, DOI 10.1097/00042560-200112150-00005; Reichman L. B., 2002, TIMEBOMB GLOBAL EPID; Sanchez MA, 1997, AM J EPIDEMIOL, V145, P1127; Sterling TR, 2003, BMJ-BRIT MED J, V326, P574, DOI 10.1136/bmj.326.7389.574; Suarez PG, 2002, LANCET, V359, P1980, DOI 10.1016/S0140-6736(02)08830-X; Ziv E, 2001, AM J EPIDEMIOL, V153, P381, DOI 10.1093/aje/153.4.381	36	163	173	0	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2004	10	10					1111	1116		10.1038/nm1102	http://dx.doi.org/10.1038/nm1102			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15378053				2022-12-25	WOS:000224245800042
J	Schubert, C				Schubert, C			Mitochondria's secret weapon	NATURE MEDICINE			English	News Item																			0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2004	10	10					1051	1051						1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15459706				2022-12-25	WOS:000224245800028
J	Guo, DH; Li, MY; Zhang, Y; Yang, P; Eckenrode, S; Hopkins, D; Zheng, WP; Purohit, S; Podolsky, RH; Muir, A; Wang, JZ; Dong, Z; Brusko, T; Atkinson, M; Pozzilli, P; Zeidler, A; Raffel, LJ; Jacob, CO; Park, Y; Serrano-Rios, M; Larrad, MTM; Zhang, ZX; Garchon, HJ; Bach, JF; Rotter, JI; She, JX; Wang, CY				Guo, DH; Li, MY; Zhang, Y; Yang, P; Eckenrode, S; Hopkins, D; Zheng, WP; Purohit, S; Podolsky, RH; Muir, A; Wang, JZ; Dong, Z; Brusko, T; Atkinson, M; Pozzilli, P; Zeidler, A; Raffel, LJ; Jacob, CO; Park, Y; Serrano-Rios, M; Larrad, MTM; Zhang, ZX; Garchon, HJ; Bach, JF; Rotter, JI; She, JX; Wang, CY			A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes	NATURE GENETICS			English	Article							CHROMOSOME 11Q13; LINKAGE-DISEQUILIBRIUM; SUSCEPTIBILITY LOCUS; SIGNAL-TRANSDUCTION; ACTIVATION; GENES; MELLITUS; IDDM4; TAB2; RECEPTOR	Previous studies have suggested more than 20 genetic intervals that are associated with susceptibility to type 1 diabetes (T1D)(1,2), but identification of specific genes has been challenging and largely limited to known candidate genes. Here, we report evidence for an association between T1D and multiple single-nucleotide polymorphisms in 197 kb of genomic DNA in the IDDM5 interval. We cloned a new gene (SUMO4), encoding small ubiquitin-like modifier 4 protein, in the interval. A substitution (M55V) at an evolutionarily conserved residue of the crucial CUE domain of SUMO4 was strongly associated with T1D (P = 1.9 x 10(-7)). SUMO4 conjugates to IkappaBalpha and negatively regulates NFkappaB transcriptional activity. The M55V substitution resulted in 5.5 times greater NFkappaB transcriptional activity and similar to2 times greater expression of IL12B, an NFkappaB-dependent gene. These findings suggest a new pathway that may be implicated in the pathogenesis of T1D.	Med Coll Georgia, Ctr Biotechnol & Gen Med, Augusta, GA 30912 USA; Med Coll Georgia, Off Biostat & Bioinformat, Augusta, GA 30912 USA; Med Coll Georgia, Childrens Med Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA; Univ Florida, Coll Med, Dept Pathol, Gainesville, FL 32610 USA; Univ Roma La Sapienza, Ist Clin Med 2, Rome, Italy; Univ So Calif, Sch Med, Dept Med, Los Angeles, CA 90033 USA; Hanyang Univ Hosp, Seoul, South Korea; Univ Complutense, Fac Med, E-28040 Madrid, Spain; Beijing Red Cross Blood Ctr, HLA Lab, Beijing, Peoples R China; INSERM, Unite Rech, U580, Ctr Assoc Claude Bernard, Paris, France	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; State University System of Florida; University of Florida; Sapienza University Rome; University of Southern California; Hanyang University; Hanyang University Hospital; Complutense University of Madrid; Institut National de la Sante et de la Recherche Medicale (Inserm)	She, JX (corresponding author), Med Coll Georgia, Ctr Biotechnol & Gen Med, 1120 15th St,CA4098, Augusta, GA 30912 USA.	jshe@mail.mcg.edu; cwang@mail.mcg.edu	Podolsky, Robert/GRY-0740-2022; Pozzilli, Paolo/A-5235-2010; zhang, yan/AAG-7349-2019; Purohit, Sharad/ABA-8054-2021	zhang, yan/0000-0003-0906-9410; Wang, Cong-Yi/0000-0001-7914-168X; Brusko, Todd/0000-0003-2878-9296; Purohit, Sharad/0000-0003-0385-3829				Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Best JL, 2002, MOL CELL, V10, P843, DOI 10.1016/S1097-2765(02)00699-8; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; Delepine M, 1997, AM J HUM GENET, V60, P174; DENG GY, 1995, AM J HUM GENET, V56, P528; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Eckenrode S, 2000, HUM GENET, V106, P14, DOI 10.1007/s004399900186; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Joseph J, 2002, J CELL BIOL, V156, P595, DOI 10.1083/jcb.200110109; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; LUO DF, 1995, AM J HUM GENET, V57, P911; Luo DF, 1996, HUM MOL GENET, V5, P693, DOI 10.1093/hmg/5.5.693; Matsuda A, 2003, ONCOGENE, V22, P3307, DOI 10.1038/sj.onc.1206406; Matunis MJ, 2002, MOL CELL, V10, P441, DOI 10.1016/S1097-2765(02)00653-6; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Melchior F, 2002, CELL CYCLE, V1, P243, DOI 10.4161/cc.1.4.131; Nakagawa Y, 1998, AM J HUM GENET, V63, P547, DOI 10.1086/301974; Onengut-Gumuscu S, 2002, IMMUNOL REV, V190, P182, DOI 10.1034/j.1600-065X.2002.19014.x; Owerbach D, 2000, DIABETES, V49, P508, DOI 10.2337/diabetes.49.3.508; Pociot F, 2002, GENES IMMUN, V3, P235, DOI 10.1038/sj.gene.6363875; Qian YC, 2001, J BIOL CHEM, V276, P41661, DOI 10.1074/jbc.M102262200; Rogers RS, 2003, J BIOL CHEM, V278, P30091, DOI 10.1074/jbc.M301344200; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Tian S, 2002, BIOCHEM J, V367, P907, DOI 10.1042/BJ20021085; Twells RCJ, 2003, HUM GENET, V113, P99, DOI 10.1007/s00439-003-0940-6; Twells RCJ, 2001, GENOMICS, V72, P231, DOI 10.1006/geno.2000.6492; Wang CY, 2003, GENE, V306, P37, DOI 10.1016/S0378-1119(02)01210-6	30	315	352	2	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2004	36	8					837	841		10.1038/ng1391	http://dx.doi.org/10.1038/ng1391			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	842AG	15247916				2022-12-25	WOS:000222974000015
J	Roh, TY; Ngau, WC; Cui, KR; Landsman, D; Zhao, KJ				Roh, TY; Ngau, WC; Cui, KR; Landsman, D; Zhao, KJ			High-resolution genome-wide mapping of histone modifications	NATURE BIOTECHNOLOGY			English	Article							YEAST HETEROCHROMATIN; ACETYLATION; H4; TRANSCRIPTOME; DEACETYLATION; NUCLEOSOME; TELOMERES; PROMOTER; GCN5P	The expression patterns of eukaryotic genomes are controlled by their chromatin structure, consisting of nucleosome subunits in which DNA of approximately 146 bp is wrapped around a core of 8 histone molecules(1). Post-translational histone modifications play an essential role in modifying chromatin structure(.)(2) Here we apply a combination of SAGE 3 and chromatin immunoprecipitation (ChIP) protocols to determine the distribution of hyperacetylated histones H3 and H4 in the Saccharomyces cerevisiae genome. We call this approach genome-wide mapping technique (GMAT). Using GMAT, we find that the highest acetylation levels are detected in the 5 end of a gene's coding region, but not in the promoter. Furthermore, we show that the histone acetyltransferase, GCN5p, regulates H3 acetylation in the promoter and 5 end of the coding regions. These findings indicate that GMAT should find valuable applications in mapping target sites of chromatin-modifying enzymes.	NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA; Natl Biotechnol Ctr, Computat Biol Branch, Natl Lib Med, NIH, Bethesda, MD 20894 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Zhao, KJ (corresponding author), NHLBI, Lab Mol Immunol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	zhaok@nhlbi.nih.gov	Landsman, David/C-5923-2009; Landsman, David/GZK-5496-2022	Landsman, David/0000-0002-9819-6675; Roh, Tae-Young/0000-0001-5833-0844	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005801, ZIAHL005801] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Boeger H, 2003, MOL CELL, V11, P1587, DOI 10.1016/S1097-2765(03)00231-4; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; CHAN CSM, 1983, CELL, V33, P563, DOI 10.1016/0092-8674(83)90437-3; DAVIE JR, 1981, NUCLEIC ACIDS RES, V9, P3205, DOI 10.1093/nar/9.13.3205; DuBois ML, 2000, COLD SPRING HARB SYM, V65, P281, DOI 10.1101/sqb.2000.65.281; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Horak CE, 2002, METHOD ENZYMOL, V350, P469, DOI 10.1016/S0076-6879(02)50979-4; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Pryde FE, 1999, EMBO J, V18, P2538, DOI 10.1093/emboj/18.9.2538; Reinke H, 2003, MOL CELL, V11, P1599, DOI 10.1016/S1097-2765(03)00186-2; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Saha S, 2002, NAT BIOTECHNOL, V20, P508, DOI 10.1038/nbt0502-508; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wan MM, 2001, HUM MOL GENET, V10, P1085, DOI 10.1093/hmg/10.10.1085	22	156	173	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2004	22	8					1013	1016		10.1038/nbt990	http://dx.doi.org/10.1038/nbt990			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	842YB	15235610				2022-12-25	WOS:000223039500031
J	Jones, SM; Feldmann, H; Stroher, U; Geisbert, JB; Fernando, L; Grolla, A; Klenk, HD; Sullivan, NJ; Volchkov, VE; Fritz, EA; Daddario, KM; Hensley, LE; Jahrling, PB; Geisbert, TW				Jones, SM; Feldmann, H; Stroher, U; Geisbert, JB; Fernando, L; Grolla, A; Klenk, HD; Sullivan, NJ; Volchkov, VE; Fritz, EA; Daddario, KM; Hensley, LE; Jahrling, PB; Geisbert, TW			Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses	NATURE MEDICINE			English	Article							VESICULAR STOMATITIS VIRUSES; HEMORRHAGIC-FEVER; GLYCOPROTEINS; CHILDREN; DISEASE	Vaccines and therapies are urgently needed to address public health needs stemming from emerging pathogens and biological threat agents such as the filoviruses Ebola virus (EBOV) and Marburg virus (MARV). Here, we developed replication-competent vaccines against EBOV and MARV based on attenuated recombinant vesicular stomatitis virus vectors expressing either the EBOV glycoprotein or MARV glycoprotein. A single intramuscular injection of the EBOV or MARV vaccine elicited completely protective immune responses in nonhuman primates against lethal EBOV or MARV challenges. Notably, vaccine vector shedding was not detectable in the monkeys and none of the animals developed fever or other symptoms of illness associated with vaccination. The EBOV vaccine induced humoral and apparent cellular immune responses in all vaccinated monkeys, whereas the MARV vaccine induced a stronger humoral than cellular immune response. No evidence of EBOV or MARV replication was detected in any of the protected animals after challenge. Our data suggest that these vaccine candidates are safe and highly efficacious in a relevant animal model.	Publ Hlth Agcy Canada, Special Pathogens Program, Natl Microbiol Lab, Winnipeg, MB R3E 3R2, Canada; Univ Manitoba, Dept Immunol, Winnipeg, MB R3E 3R2, Canada; Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R3E 3R2, Canada; USA, Med Res Inst Infect Dis, Ft Detrick, MD 21702 USA; Univ Marburg, Inst Virol, D-35037 Marburg, Germany; NIAID, Vaccine Res Ctr, NIH, Bethesda, MD USA; Univ Lyon 1, INSERM, U412, Filovirus Lab, F-69007 Lyon, France; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA	Public Health Agency of Canada; University of Manitoba; University of Manitoba; Philipps University Marburg; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Uniformed Services University of the Health Sciences - USA	Feldmann, H (corresponding author), Publ Hlth Agcy Canada, Special Pathogens Program, Natl Microbiol Lab, 1015 Arlington St, Winnipeg, MB R3E 3R2, Canada.	Heinz_Feldmann@hc-sc.gc.ca	Volchkov, Viktor/M-7846-2014	Volchkov, Viktor/0000-0001-7896-8706; Hensley, Lisa/0000-0003-1188-4342	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI005082, ZIAAI005082, Z01AI005081, Z01AI005079, ZIAAI005079, ZIAAI005081, Z01AI005080, ZIAAI005080] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Borio L, 2002, JAMA-J AM MED ASSOC, V287, P2391, DOI 10.1001/jama.287.18.2391; BRANDT CD, 1969, AM J EPIDEMIOL, V90, P484, DOI 10.1093/oxfordjournals.aje.a121094; BUKREYEV AA, 1995, ARCH VIROL, V140, P1589, DOI 10.1007/BF01322532; Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P308; Feldmann H, 2003, NAT REV IMMUNOL, V3, P677, DOI 10.1038/nri1154; Garbutt M, 2004, J VIROL, V78, P5458, DOI 10.1128/JVI.78.10.5458-5465.2004; Geisbert Thomas W, 2003, Expert Rev Vaccines, V2, P777, DOI 10.1586/14760584.2.6.777; Geisbert TW, 2004, NAT MED, V10, pS110, DOI 10.1038/nm1142; Geisbert TW, 2002, EMERG INFECT DIS, V8, P503; Hevey M, 1998, VIROLOGY, V251, P28, DOI 10.1006/viro.1998.9367; Ignatyev GM, 1996, J BIOTECHNOL, V44, P111, DOI 10.1016/0168-1656(95)00104-2; Jahrling PB, 1999, J INFECT DIS, V179, pS224, DOI 10.1086/514310; JAHRLING PB, 1999, MANUAL CLIN MICROBIO, P1125; Piedra PA, 1998, PEDIATRICS, V101, P1013, DOI 10.1542/peds.101.6.1013; Roberts A, 1998, J VIROL, V72, P4704, DOI 10.1128/JVI.72.6.4704-4711.1998; Roberts A, 1999, J VIROL, V73, P3723, DOI 10.1128/JVI.73.5.3723-3732.1999; Rose NF, 2001, CELL, V106, P539, DOI 10.1016/S0092-8674(01)00482-2; Sanchez A, 2004, J VIROL, V78, P10370, DOI 10.1128/JVI.78.19.10370-10377.2004; Sanchez A, 1996, P NATL ACAD SCI USA, V93, P3602, DOI 10.1073/pnas.93.8.3602; Sanchez A, 2001, FIELDS VIROLOGY, P1279; Schlereth B, 2000, J VIROL, V74, P4652, DOI 10.1128/JVI.74.10.4652-4657.2000; Schnell MJ, 1996, P NATL ACAD SCI USA, V93, P11359, DOI 10.1073/pnas.93.21.11359; Schulick AH, 1997, J CLIN INVEST, V99, P209, DOI 10.1172/JCI119149; SMITH DH, 1982, LANCET, V1, P816; Sullivan NJ, 2000, NATURE, V408, P605, DOI 10.1038/35046108; Sullivan NJ, 2003, NATURE, V424, P681, DOI 10.1038/nature01876; WAGNER RR, 1996, FIELDS VIROLOGY, V1	27	477	532	1	107	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2005	11	7					786	790		10.1038/nm1258	http://dx.doi.org/10.1038/nm1258			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	942TB	15937495	Bronze			2022-12-25	WOS:000230304200036
J	Le Blanc, I; Luyet, PP; Pons, V; Ferguson, C; Emans, N; Petiot, A; Mayran, N; Demaurex, N; Faure, J; Sadoul, R; Parton, RG; Gruenberg, J				Le Blanc, I; Luyet, PP; Pons, V; Ferguson, C; Emans, N; Petiot, A; Mayran, N; Demaurex, N; Faure, J; Sadoul, R; Parton, RG; Gruenberg, J			Endosome-to-cytosol transport of viral nucleocapsids	NATURE CELL BIOLOGY			English	Article							VESICULAR STOMATITIS-VIRUS; MEMBRANE; RECEPTOR; PROTEIN; BINDING; VESICLES; DOMAINS; PATHWAY; CELLS; LOCALIZATION	During viral infection, fusion of the viral envelope with endosomal membranes and nucleocapsid release were thought to be concomitant events. We show here that for the vesicular stomatitis virus they occur sequentially, at two successive steps of the endocytic pathway. Fusion already occurs in transport intermediates between early and late endosomes, presumably releasing the nucleocapsid within the lumen of intra- endosomal vesicles, where it remains hidden. Transport to late endosomes is then required for the nucleocapsid to be delivered to the cytoplasm. This last step, which initiates infection, depends on the late endosomal lipid lysobisphosphatidic acid ( LBPA) and its putative effector Alix/ AIP1, and is regulated by phosphatidylinositol- 3-phosphate ( PtdIns( 3) P) signalling via the PtdIns( 3) P- binding protein Snx16. We conclude that the nucleocapsid is exported into the cytoplasm after the back- fusion of internal vesicles with the limiting membrane of late endosomes, and that this process is controlled by the phospholipids LBPA and PtdIns( 3) P and their effectors.	Univ Geneva, Dept Biochem, CH-1211 Geneva, Switzerland; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Queensland, Ctr Microscopy & Microanal, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia; Inst Pasteur, Seoul 136791, South Korea; INSERM, U504, F-94807 Villejuif, France; Inst Expt Pathol, CH-1011 Lausanne, Switzerland; Ctr Med Univ Geneva, Dept Physiol, CH-1211 Geneva, Switzerland; Univ Grenoble 1, Hop A Michallon, INSERM, F-38043 Grenoble, France	University of Geneva; University of California System; University of California Berkeley; University of Queensland; University of Queensland; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Geneva; CHU Grenoble Alpes; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Gruenberg, J (corresponding author), Univ Geneva, Dept Biochem, 30 Quai E Ansermet, CH-1211 Geneva, Switzerland.	jean.gruenberg@biochem.unige.ch	Emans, Neil/H-4299-2011; Fauré, julien/AAJ-1845-2020; Parton, Robert G/C-5673-2009	Fauré, julien/0000-0002-3660-9809; Parton, Robert G/0000-0002-7494-5248; SADOUL, Remy/0000-0002-4763-0320; PETIOT, Anne/0000-0001-8038-470X; PONS, Veronique/0000-0001-5821-8481; Demaurex, Nicolas/0000-0002-9933-6772				Abrami L, 2004, J CELL BIOL, V166, P645, DOI 10.1083/jcb.200312072; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Carlton J, 2005, TRAFFIC, V6, P75, DOI 10.1111/j.1600-0854.2005.00260.x; Choi JH, 2004, J CELL SCI, V117, P4209, DOI 10.1242/jcs.01233; Chow A, 2002, NATURE, V418, P988, DOI 10.1038/nature01006; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121; Fernandez-Borja M, 1999, CURR BIOL, V9, P55, DOI 10.1016/S0960-9822(99)80048-7; Futter CE, 2001, J CELL BIOL, V155, P1251, DOI 10.1083/jcb.200108152; Galve-de Rochemonteix B, 2000, ARTERIOSCL THROM VAS, V20, P563; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GRUENBERG J, 1985, EUR J CELL BIOL, V38, P312; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360; Habermann B, 2004, EMBO REP, V5, P250, DOI 10.1038/sj.embor.7400105; Hanson BJ, 2003, J BIOL CHEM, V278, P34617, DOI 10.1074/jbc.M300143200; Huber LA, 2000, TRAFFIC, V1, P494, DOI 10.1034/j.1600-0854.2000.010607.x; Incardona JP, 2002, CURR BIOL, V12, P983, DOI 10.1016/S0960-9822(02)00895-3; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Khor R, 2003, TRAFFIC, V4, P857, DOI 10.1046/j.1398-9219.2003.0140.x; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Kobayashi T, 1998, SEMIN CELL DEV BIOL, V9, P517, DOI 10.1006/scdb.1998.0257; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Kobayashi T, 2002, J BIOL CHEM, V277, P32157, DOI 10.1074/jbc.M202838200; Lakadamyali M, 2003, P NATL ACAD SCI USA, V100, P9280, DOI 10.1073/pnas.0832269100; Lebrand C, 2002, EMBO J, V21, P1289, DOI 10.1093/emboj/21.6.1289; Lloyd TE, 2002, CELL, V108, P261, DOI 10.1016/S0092-8674(02)00611-6; Marsh M, 1997, J CELL SCI, V110, P95; MARSH M, 1983, CELL, V32, P931, DOI 10.1016/0092-8674(83)90078-8; Matsuo H, 2004, SCIENCE, V303, P531, DOI 10.1126/science.1092425; Murk JL, 2002, SEMIN CELL DEV BIOL, V13, P303, DOI 10.1016/S1084952102000605; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Odorizzi G, 2003, J CELL SCI, V116, P1893, DOI 10.1242/jcs.00395; Pak CC, 1997, BIOCHEMISTRY-US, V36, P8890, DOI 10.1021/bi9702851; PARTON RG, 1992, J CELL SCI, V103, P335; PESONEN M, 1983, J CELL BIOL, V97, P638, DOI 10.1083/jcb.97.3.638; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; Petiot A, 2003, J CELL BIOL, V162, P971, DOI 10.1083/jcb.200303018; Piguet V, 1999, CELL, V97, P63, DOI 10.1016/S0092-8674(00)80715-1; Reaves BJ, 1996, J CELL SCI, V109, P749; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Sbrissa D, 2002, J BIOL CHEM, V277, P6073, DOI 10.1074/jbc.M110194200; Sinclair AM, 1997, GENE THER, V4, P918, DOI 10.1038/sj.gt.3300479; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; THOMAS D, 1985, J VIROL, V54, P598, DOI 10.1128/JVI.54.2.598-607.1985; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; WHITNEY JA, 1995, CELL, V83, P703	54	235	241	3	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2005	7	7					653	U25		10.1038/ncb1269	http://dx.doi.org/10.1038/ncb1269			18	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	941BX	15951806	Green Accepted, Green Submitted			2022-12-25	WOS:000230190800009
J	Cao, H; Weller, S; Orth, JD; Chen, J; Huang, B; Chen, JL; Stamnes, M; McNiven, MA				Cao, H; Weller, S; Orth, JD; Chen, J; Huang, B; Chen, JL; Stamnes, M; McNiven, MA			Actin and Arf1-dependent recruitment of a cortactin-dynamin complex to the Golgi regulates post-Golgi transport	NATURE CELL BIOLOGY			English	Article							ENDOPLASMIC-RETICULUM; NETWORK; PROTEIN; CDC42; CYTOSKELETON; INHIBITION; ASSEMBLES; COMPONENT; RECEPTOR	Cortactin is an actin-binding protein that has recently been implicated in endocytosis. It binds directly to dynamin-2 (Dyn2), a large GTPase that mediates the formation of vesicles from the plasma membrane and the Golgi. Here we show that cortactin associates with the Golgi to regulate the actin- and Dyn2-dependent transport of cargo. Cortactin antibodies stain the Golgi apparatus, labelling peripheral buds and vesicles that are associated with the cisternae. Notably, in vitro or intact-cell experiments show that activation of Arf1 mediates the recruitment of actin, cortactin and Dyn2 to Golgi membranes. Furthermore, selective disruption of the cortactin - Dyn2 interaction significantly reduces the levels of Dyn2 at the Golgi and blocks the transit of nascent proteins from the trans-Golgi network, resulting in swollen and distended cisternae. These findings support the idea of an Arf1-activated recruitment of an actin, cortactin and Dyn2 complex that is essential for Golgi function.	Mayo Clin, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA; Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	Mayo Clinic; Mayo Clinic; University of Iowa	McNiven, MA (corresponding author), Mayo Clin, Ctr Basic Res Digest Dis, 1642D Guggenheim Bldg,200 1st St SW, Rochester, MN 55905 USA.	mcniven.mark@mayo.edu	Orth, James/Q-4905-2019; Chen, Ji-Long/AAJ-2134-2021	Chen, Ji-Long/0000-0002-4274-0563; ORTH, JAMES/0000-0002-8559-6186; Stamnes, Mark/0000-0002-5869-7985	NIDDK NIH HHS [DK56647] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056647] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allan VJ, 2002, NAT CELL BIOL, V4, pE236, DOI 10.1038/ncb1002-e236; ANDERSON KL, 1995, EUR J CELL BIOL, V66, P25; Benmerah A, 1999, J CELL SCI, V112, P1303; BROWN WJ, 1986, J CELL BIOL, V103, P1235, DOI 10.1083/jcb.103.4.1235; Cao H, 2000, J CELL SCI, V113, P1993; Cao H, 2003, MOL CELL BIOL, V23, P2162, DOI 10.1128/MCB.23.6.2162-2170.2003; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DE M, 2000, J CELL SCI, V113, P2331; De Matteis MA, 1998, CURR OPIN CELL BIOL, V10, P542, DOI 10.1016/S0955-0674(98)80071-9; di Campli A, 1999, CELL MOTIL CYTOSKEL, V43, P334, DOI 10.1002/(SICI)1097-0169(1999)43:4<334::AID-CM6>3.0.CO;2-3; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; Fucini RV, 2002, MOL BIOL CELL, V13, P621, DOI 10.1091/mbc.01-11-0547; Fucini RV, 2000, J BIOL CHEM, V275, P18824, DOI 10.1074/jbc.M000024200; Henley JR, 1996, J CELL BIOL, V133, P761, DOI 10.1083/jcb.133.4.761; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; Krueger EW, 2003, MOL BIOL CELL, V14, P1085, DOI 10.1091/mbc.E02-08-0466; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; Lippincott-Schwartz J, 1998, CURR OPIN CELL BIOL, V10, P52, DOI 10.1016/S0955-0674(98)80086-0; Luna A, 2002, MOL BIOL CELL, V13, P866, DOI 10.1091/mbc.01-12-0579; Maier O, 1996, BIOCHEM BIOPH RES CO, V223, P229, DOI 10.1006/bbrc.1996.0876; MATOVCIK LM, 1990, EUR J CELL BIOL, V53, P203; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; McNiven MA, 1998, CELL, V94, P151, DOI 10.1016/S0092-8674(00)81414-2; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Musch A, 2001, EMBO J, V20, P2171, DOI 10.1093/emboj/20.9.2171; Nishimura N, 2002, P NATL ACAD SCI USA, V99, P6755, DOI 10.1073/pnas.092150699; Orth JD, 2003, CURR OPIN CELL BIOL, V15, P31, DOI 10.1016/S0955-0674(02)00010-8; Orth JD, 2002, P NATL ACAD SCI USA, V99, P167, DOI 10.1073/pnas.012607899; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Schafer DA, 2002, CURR OPIN CELL BIOL, V14, P76, DOI 10.1016/S0955-0674(01)00297-6; SCHWANINGER R, 1992, METHOD ENZYMOL, V219, P110; Stamnes M, 2002, CURR OPIN CELL BIOL, V14, P428, DOI 10.1016/S0955-0674(02)00349-6; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Toomre D, 1999, J CELL SCI, V112, P21; Valderrama F, 1998, EUR J CELL BIOL, V76, P9, DOI 10.1016/S0171-9335(98)80012-5; Weaver AM, 2002, CURR BIOL, V12, P1270, DOI 10.1016/S0960-9822(02)01035-7; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Weed SA, 1998, J CELL SCI, V111, P2433	42	138	143	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2005	7	5					483	U45		10.1038/ncb1246	http://dx.doi.org/10.1038/ncb1246			14	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	926LA	15821732				2022-12-25	WOS:000229123500015
J	Hintersteiner, M; Enz, A; Frey, P; Jaton, AL; Kinzy, W; Kneuer, R; Neumann, U; Rudin, M; Staufenbiel, M; Stoeckli, M; Wiederhold, KH; Gremlich, HU				Hintersteiner, M; Enz, A; Frey, P; Jaton, AL; Kinzy, W; Kneuer, R; Neumann, U; Rudin, M; Staufenbiel, M; Stoeckli, M; Wiederhold, KH; Gremlich, HU			In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe	NATURE BIOTECHNOLOGY			English	Article							ALZHEIMERS-DISEASE; TRANSGENIC MICE; NEUROFIBRILLARY TANGLES; MOUSE MODELS; CONGO RED; PLAQUES; BRAIN; BINDING; PROTEIN; MICROSCOPY	As Alzheimer's disease pathogenesis is associated with the formation of insoluble aggregates of amyloid beta-peptide, approaches allowing the direct, noninvasive visualization of plaque growth in vivo would be beneficial for biomedical research. Here we describe the synthesis and characterization of the near-infrared fluorescence oxazine dye AOI987, which readily penetrates the intact blood-brain barrier and binds to amyloid plaques. Using near-infrared fluorescence imaging, we demonstrated specific interaction of AOI987 with amyloid plaques in APP23 transgenic mice in vivo, as confirmed by postmortem analysis of brain slices. Quantitative analysis revealed increasing fluorescence signal intensity with increasing plaque load of the animals, and significant binding of AOI987 was observed for APP23 transgenic mice aged 9 months and older. Thus, AOI987 is an attractive probe to noninvasively monitor disease progression in animal models of Alzheimer disease and to evaluate effects of potential Alzheimer disease drugs on the plaque load.	Novartis Inst Biomed Res, Discovery Technol, CH-4002 Basel, Switzerland; Novartis Inst Biomed Res, Nervous Syst Dept, CH-4002 Basel, Switzerland	Novartis; Novartis	Gremlich, HU (corresponding author), Novartis Inst Biomed Res, Discovery Technol, CH-4002 Basel, Switzerland.	hansulrich.gremlich@novartis.com	Rudin, Markus/F-2417-2010					Agdeppa ED, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-24-j0004.2001; Agdeppa Eric D, 2003, Mol Imaging Biol, V5, P404, DOI 10.1016/j.mibio.2003.09.010; Backskai BJ, 2001, NAT MED, V7, P369, DOI 10.1038/85525; Bacskai BJ, 2003, P NATL ACAD SCI USA, V100, P12462, DOI 10.1073/pnas.2034101100; Bacskai BJ, 2002, J CEREBR BLOOD F MET, V22, P1035, DOI 10.1097/00004647-200209000-00001; Benveniste H, 1999, P NATL ACAD SCI USA, V96, P14079, DOI 10.1073/pnas.96.24.14079; Bremer C, 2001, NAT MED, V7, P743, DOI 10.1038/89126; Funovics M, 2003, ANAL BIOANAL CHEM, V377, P956, DOI 10.1007/s00216-003-2199-0; Graves EE, 2003, MED PHYS, V30, P901, DOI 10.1118/1.1568977; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Klunk WE, 2002, J NEUROPATH EXP NEUR, V61, P797, DOI 10.1093/jnen/61.9.797; KLUNK WE, 1994, NEUROBIOL AGING, V15, P691, DOI 10.1016/0197-4580(94)90050-7; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; Klunk WE, 2001, LIFE SCI, V69, P1471, DOI 10.1016/S0024-3205(01)01232-2; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Mathis CA, 2003, J MED CHEM, V46, P2740, DOI 10.1021/jm030026b; Mathis CA, 2004, CURR PHARM DESIGN, V10, P1469, DOI 10.2174/1381612043384772; Mathis CA, 2002, BIOORG MED CHEM LETT, V12, P295, DOI 10.1016/S0960-894X(01)00734-X; MCMURTRE.KD, 1970, J ORG CHEM, V35, P4252, DOI 10.1021/jo00837a632; Meyer-Luehmann M, 2003, NAT NEUROSCI, V6, P370, DOI 10.1038/nn1022; Neuweiler H, 2002, ANGEW CHEM INT EDIT, V41, P4769, DOI 10.1002/anie.200290044; Ntziachristos V, 2003, EUR RADIOL, V13, P195, DOI 10.1007/s00330-002-1524-x; Nussbaum RL, 2003, NEW ENGL J MED, V348, P1356, DOI 10.1056/NEJM2003ra020003; Okamura N, 2004, J NEUROSCI, V24, P2535, DOI 10.1523/JNEUROSCI.4456-03.2004; Ono M, 2003, NUCL MED BIOL, V30, P565, DOI 10.1016/S0969-8051(03)00049-0; Poduslo JF, 2004, BIOCHEMISTRY-US, V43, P6064, DOI 10.1021/bi0359574; Poduslo JF, 2002, NEUROBIOL DIS, V11, P315, DOI 10.1006/nbdi.2002.0550; Rudin M, 2003, NAT REV DRUG DISCOV, V2, P123, DOI 10.1038/nrd1007; Shoghi-Jadid K, 2002, AM J GERIAT PSYCHIAT, V10, P24, DOI 10.1176/appi.ajgp.10.1.24; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Styren SC, 2000, J HISTOCHEM CYTOCHEM, V48, P1223, DOI 10.1177/002215540004800906; Suemoto T, 2004, NEUROSCI RES, V48, P65, DOI 10.1016/j.neures.2003.09.005; Wadghiri YZ, 2003, MAGN RESON MED, V50, P293, DOI 10.1002/mrm.10529; Weissleder R, 2003, NAT MED, V9, P123, DOI 10.1038/nm0103-123; Wunder A, 2004, ARTHRITIS RHEUM-US, V50, P2459, DOI 10.1002/art.20379; Zamrini E, 2004, NEUROBIOL AGING, V25, P685, DOI 10.1016/j.neurobiolaging.2004.02.009; Zhang J, 2004, MAGN RESON MED, V51, P452, DOI 10.1002/mrm.10730	37	270	284	1	82	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2005	23	5					577	583		10.1038/nbt1085	http://dx.doi.org/10.1038/nbt1085			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	923XS	15834405				2022-12-25	WOS:000228943500030
J	Snoeck, HW				Snoeck, HW			Serum of youth?	NATURE BIOTECHNOLOGY			English	Editorial Material							CELLS	Injured tissues in aged animals are regenerated by exposure to young serum.	CUNY Mt Sinai Sch Med, Dept Gene & Cell Med, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Snoeck, HW (corresponding author), CUNY Mt Sinai Sch Med, Dept Gene & Cell Med, 1 Gustave L Levy Pl,Box 1496, New York, NY 10029 USA.	hans.snoeck@mssm.edu						Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Conboy IM, 2002, DEV CELL, V3, P397, DOI 10.1016/S1534-5807(02)00254-X; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Conboy IM, 2003, SCIENCE, V302, P1575, DOI 10.1126/science.1087573; Finch CE, 2004, SCIENCE, V305, P1736, DOI 10.1126/science.1092556; Geiger H, 2002, NAT IMMUNOL, V3, P329, DOI 10.1038/ni0402-329; Henckaerts E, 2004, BLOOD, V104, P374, DOI 10.1182/blood-2003-12-4304; Hepple Russell T, 2003, Sci Aging Knowledge Environ, V2003, ppe31; Labrie JE, 2004, J EXP MED, V200, P411, DOI 10.1084/jem.20040845; Morrison SJ, 1996, NAT MED, V2, P1011, DOI 10.1038/nm0996-1011; Partridge TA, 2002, GENE THER, V9, P752, DOI 10.1038/sj.gt.3301764; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447	12	5	5	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2005	23	4					434	435		10.1038/nbt0405-434	http://dx.doi.org/10.1038/nbt0405-434			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	914AR	15815669				2022-12-25	WOS:000228197300020
J	Yu, L; Liu, CH; Vandeusen, J; Becknell, B; Dai, ZY; Wu, YZ; Raval, A; Liu, TH; Ding, W; Mao, C; Liu, SJ; Smith, LT; Lee, S; Rassenti, L; Marcucci, G; Byrd, J; Caligiuri, MA; Plass, C				Yu, L; Liu, CH; Vandeusen, J; Becknell, B; Dai, ZY; Wu, YZ; Raval, A; Liu, TH; Ding, W; Mao, C; Liu, SJ; Smith, LT; Lee, S; Rassenti, L; Marcucci, G; Byrd, J; Caligiuri, MA; Plass, C			Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia	NATURE GENETICS			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; EPIGENETIC ALTERATIONS; TRANSGENIC MICE; LIVER-TUMORS; CPG ISLANDS; SLIT2 GENE; EXPRESSION; CELLS; APOPTOSIS; PROTEINS	DNA methylation is associated with malignant transformation, but limitations imposed by genetic variability, tumor heterogeneity, availability of paired normal tissues and methodologies for global assessment of DNA methylation have limited progress in understanding the extent of epigenetic events in the initiation and progression of human cancer and in identifying genes that undergo methylation during cancer. We developed a mouse model of T/natural killer acute lymphoblastic leukemia that is always preceded by polyclonal lymphocyte expansion to determine how aberrant promoter DNA methylation and consequent gene silencing might be contributing to leukemic transformation. We used restriction landmark genomic scanning with this mouse model of preleukemia reproducibly progressing to leukemia to show that specific genomic methylation is associated with only the leukemic phase and is not random. We also identified Idb4 as a putative tumor-suppressor gene that is methylated in most mouse and human leukemias but in only a minority of other human cancers.	Ohio State Univ, Div Human Canc Genet, Tzagournis Med Res Facil 464A, Columbus, OH 43210 USA; Ohio State Univ, Div Hematol Oncol, Columbus, OH 43210 USA; Gen Hosp PLA 301, Dept Hematol, Beijing, Peoples R China; Univ Calif San Diego, Dept Med, Div Hematol Oncol, San Diego, CA 92103 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Canc Leukemia Grp B, Chicago, IL USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of California System; University of California San Diego; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Plass, C (corresponding author), Ohio State Univ, Div Human Canc Genet, Tzagournis Med Res Facil 464A, 420 W 12th Ave, Columbus, OH 43210 USA.	plass-1@medctr.osu.edu	Reever, Larson/H-9685-2019; Plass, Christoph/H-7192-2014; Xiao, Yang/B-5668-2012	Reever, Larson/0000-0002-5692-4793; Yu, Li/0000-0001-6872-2665				Akama TO, 1997, CANCER RES, V57, P3294; Andres-Barquin PJ, 1999, EXP CELL RES, V247, P347, DOI 10.1006/excr.1998.4360; Beger C, 2001, P NATL ACAD SCI USA, V98, P130, DOI 10.1073/pnas.98.1.130; Bellido M, 2003, HAEMATOLOGICA, V88, P994; BENEZRA R, 1994, CELL, V79, P1057, DOI 10.1016/0092-8674(94)90036-1; Bounpheng MA, 1999, FASEB J, V13, P2257, DOI 10.1096/fasebj.13.15.2257; Chan ASW, 2003, ONCOGENE, V22, P6946, DOI 10.1038/sj.onc.1206799; Cheson BD, 1996, BLOOD, V87, P4990, DOI 10.1182/blood.V87.12.4990.bloodjournal87124990; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Costello JF, 2002, METHODS, V27, P144, DOI 10.1016/S1046-2023(02)00067-1; Dai ZY, 2002, GENOME RES, V12, P1591, DOI 10.1101/gr.197402; Dai ZY, 2001, NEOPLASIA, V3, P314, DOI 10.1038/sj.neo.7900162; Dallol A, 2003, ONCOGENE, V22, P4611, DOI 10.1038/sj.onc.1206687; Dallol A, 2003, CANCER RES, V63, P1054; Dallol A, 2002, CANCER RES, V62, P5874; Davuluri RV, 2001, NAT GENET, V29, P412, DOI 10.1038/ng780; Fehniger TA, 2001, J EXP MED, V193, P219, DOI 10.1084/jem.193.2.219; Filmus J, 2001, GLYCOBIOLOGY, V11, p19R, DOI 10.1093/glycob/11.3.19R; FREUND RJ, 1997, STAT METHODS; Gilliland DG, 2002, CANCER CELL, V1, P417, DOI 10.1016/S1535-6108(02)00081-8; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Jen Y, 1996, DEV DYNAM, V207, P235; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Jen Y, 1997, DEV DYNAM, V208, P92, DOI 10.1002/(SICI)1097-0177(199701)208:1<92::AID-AJA9>3.0.CO;2-X; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kee Y, 2001, MECH DEVELOP, V109, P341, DOI 10.1016/S0925-4773(01)00576-7; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Paine-Saunders S, 1999, GENOMICS, V57, P455, DOI 10.1006/geno.1999.5793; Rush LJ, 2004, CANCER RES, V64, P2424, DOI 10.1158/0008-5472.CAN-03-2870; Rush LJ, 2001, BLOOD, V97, P3226, DOI 10.1182/blood.V97.10.3226; SHOJI W, 1994, J BIOL CHEM, V269, P5078; Smiraglia DJ, 1999, GENOMICS, V58, P254, DOI 10.1006/geno.1999.5840; Tateno M, 2001, CANCER RES, V61, P1144; Wang B, 2003, CANCER CELL, V4, P19, DOI 10.1016/S1535-6108(03)00164-8; Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799; WENDELHANSEN V, 1994, LEUKEMIA, V8, P476; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Youn HD, 2000, EMBO J, V19, P4323, DOI 10.1093/emboj/19.16.4323; Yu L, 2004, GENOMICS, V84, P647, DOI 10.1016/j.ygeno.2004.06.010; Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970; Zhu WG, 2001, CANCER RES, V61, P1327	45	147	188	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2005	37	3					265	274		10.1038/ng1521	http://dx.doi.org/10.1038/ng1521			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	901QU	15723065				2022-12-25	WOS:000227297800017
J	Kondo, S; Murakami, T; Tatsumi, K; Ogata, M; Kanemoto, S; Otori, K; Iseki, K; Wanaka, A; Imaizumi, K				Kondo, S; Murakami, T; Tatsumi, K; Ogata, M; Kanemoto, S; Otori, K; Iseki, K; Wanaka, A; Imaizumi, K			OASIS, a CREB/ATF-family member, modulates UPR signalling in astrocytes	NATURE CELL BIOLOGY			English	Article							ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; TRANSCRIPTION FACTOR; ER STRESS; MESSENGER-RNA; GRP78; IDENTIFICATION; EXPRESSION; APOPTOSIS; ELEMENT	Endoplasmic reticulum (ER) stress transducers IRE1, PERK and ATF6 are well known to transduce signals from the ER to the cytoplasm and nucleus when unfolded proteins are accumulated in the ER. Here, we identified OASIS as a novel ER stress transducer. OASIS is a basic leucine zipper ( bZIP) transcription factor of the CREB/ATF family with a transmembrane domain that allows it to associate with the ER. The molecule is cleaved at the membrane in response to ER stress, and its cleaved amino-terminal cytoplasmic domain, which contains the bZIP domain, translocates into the nucleus where it activates the transcription of target genes that are mediated by ER stress-responsive and cyclic AMP-responsive elements. Intriguingly, OASIS was induced at the transcriptional level during ER stress in astrocytes of the central nervous system, but not in other cell types examined. Furthermore, overexpression of OASIS resulted in induction of BiP and suppression of ER-stress-induced cell death, whereas knockdown partially reduced BiP levels and led to ER stress in susceptible astrocytes. Our results reveal pivotal roles for OASIS in modulating the unfolded protein response in astrocytes, and the possibility that cell type-specific UPR signalling also exists in other cells.	Miyazaki Univ, Fac Med, Dept Anat, Miyazaki 8891692, Japan; Nara Inst Sci & Technol NAIST, Div Struct Cellular Biol, Nara 6300101, Japan; Nara Med Univ, Dept Anat, Nara 6348522, Japan; Yamagata Univ, Sch Med, Dept Emergency Med, Yamagata 9909585, Japan	University of Miyazaki; Nara Institute of Science & Technology; Nara Medical University; Yamagata University	Imaizumi, K (corresponding author), Miyazaki Univ, Fac Med, Dept Anat, Kihara 5200, Miyazaki 8891692, Japan.	imaizumi@med.miyazaki-u.ac.jp	Wanaka, Akio/GPW-8926-2022; Wanaka, Akio/AAC-9754-2019; Wanaka, Akio/ABE-4671-2020; Longo, Kenneth A/A-5631-2010	Wanaka, Akio/0000-0001-9951-9862; 				Bruce AJ, 1996, P NATL ACAD SCI USA, V93, P2312, DOI 10.1073/pnas.93.6.2312; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; ERICKSON AH, 1979, J BIOL CHEM, V254, P1771; Espenshade PJ, 1999, J BIOL CHEM, V274, P22795, DOI 10.1074/jbc.274.32.22795; Honma Y, 1999, MOL BRAIN RES, V69, P93, DOI 10.1016/S0169-328X(99)00102-3; Imaizumi K, 1997, J BIOL CHEM, V272, P18842, DOI 10.1074/jbc.272.30.18842; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Luo SZ, 2003, J BIOL CHEM, V278, P37375, DOI 10.1074/jbc.M303619200; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nikaido T, 2002, MOL BRAIN RES, V108, P129, DOI 10.1016/S0169-328X(02)00521-1; Nikaido T, 2001, HISTOCHEM CELL BIOL, V116, P141; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Omori Y, 2002, BIOCHEM BIOPH RES CO, V293, P470, DOI 10.1016/S0006-291X(02)00253-X; Omori Y, 2001, NUCLEIC ACIDS RES, V29, P2154, DOI 10.1093/nar/29.10.2154; PECHAN PA, 1992, NEUROREPORT, V3, P469, DOI 10.1097/00001756-199206000-00003; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002	29	228	240	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2005	7	2					186	U112		10.1038/ncb1213	http://dx.doi.org/10.1038/ncb1213			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	893LC	15665855				2022-12-25	WOS:000226719500016
J	Ueda, HR; Hayashi, S; Chen, WB; Sano, M; Machida, M; Shigeyoshi, Y; Iino, M; Hashimoto, S				Ueda, HR; Hayashi, S; Chen, WB; Sano, M; Machida, M; Shigeyoshi, Y; Iino, M; Hashimoto, S			System-level identification of transcriptional circuits underlying mammalian circadian clocks	NATURE GENETICS			English	Article							PERIOD HOMOLOGS; EXPRESSION; PROTEIN; OSCILLATION; COMPONENT; CLONING; MOUSE; LIMB; PAR	Mammalian circadian clocks consist of complexly integrated regulatory loops(1-5), making it difficult to elucidate them without both the accurate measurement of system dynamics and the comprehensive identification of network circuits(6). Toward a system-level understanding of this transcriptional circuitry, we identified clock-controlled elements on 16 clock and clock-controlled genes in a comprehensive surveillance of evolutionarily conserved cis elements and measurement of their transcriptional dynamics. Here we report the roles of E/E' boxes, DBP/E4BP4 binding elements(7) and RevErbA/ROR binding elements(8) in nine, seven and six genes, respectively. Our results indicate that circadian transcriptional circuits are governed by two design principles: regulation of E/E boxes and RevErbA/ROR binding elements follows a repressor-precedes-activator pattern, resulting in delayed transcriptional activity, whereas regulation of DBP/E4BP4 binding elements follows a repressor-antiphasic-to-activator mechanism, which generates high-amplitude transcriptional activity. Our analysis further suggests that regulation of E/E boxes is a topological vulnerability in mammalian circadian clocks, a concept that has been functionally verified using in vitro phenotype assay systems.	Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Mol Med Labs, Tsukuba, Ibaraki 3058585, Japan; RIKEN, Ctr Dev Biol, Lab Syst Biol, Chuo Ku, Kobe, Hyogo 6500047, Japan; Univ Tokyo, Grad Sch Med, Dept Pharmacol, Tokyo 1130033, Japan; Natl Inst Adv Ind Sci & technol, Res Ctr Glycosci, Tsukuba, Ibaraki 3058566, Japan; Kinki Univ, Sch Med, Dept Anat & Neurobiol, Osakasayama, Osaka 5898511, Japan	Astellas Pharmaceuticals; RIKEN; University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST); Kindai University (Kinki University)	Ueda, HR (corresponding author), Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Mol Med Labs, 21 Miyukigaoka, Tsukuba, Ibaraki 3058585, Japan.	uedah-tky@umin.ac.jp	Ueda, Hiroki R/C-5037-2014	Ueda, Hiroki R/0000-0001-8342-9176				Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; Bae K, 2001, NEURON, V30, P525, DOI 10.1016/S0896-6273(01)00302-6; Bunger MK, 2000, CELL, V103, P1009, DOI 10.1016/S0092-8674(00)00205-1; Falvey E, 1996, BIOL CHEM, V377, P797; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; Honma S, 2002, NATURE, V419, P841, DOI 10.1038/nature01123; Honma S, 1998, BIOCHEM BIOPH RES CO, V250, P83, DOI 10.1006/bbrc.1998.9275; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Kitano H, 2002, SCIENCE, V295, P1662, DOI 10.1126/science.1069492; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824; Mitsui S, 2001, GENE DEV, V15, P995, DOI 10.1101/gad.873501; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Panda S, 2002, NATURE, V417, P329, DOI 10.1038/417329a; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Reick M, 2001, SCIENCE, V293, P506, DOI 10.1126/science.1060699; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Sato TK, 2004, NEURON, V43, P527, DOI 10.1016/j.neuron.2004.07.018; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Ueda HR, 2002, NATURE, V418, P534, DOI 10.1038/nature00906; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; Zheng BH, 2001, CELL, V105, P683, DOI 10.1016/S0092-8674(01)00380-4; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	30	603	619	1	49	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2005	37	2					187	192		10.1038/ng1504	http://dx.doi.org/10.1038/ng1504			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	893AB	15665827				2022-12-25	WOS:000226690100027
J	Cabantous, S; Terwilliger, TC; Waldo, GS				Cabantous, S; Terwilliger, TC; Waldo, GS			Protein tagging and detection with engineered self-assembling fragments of green fluorescent protein	NATURE BIOTECHNOLOGY			English	Article							ESCHERICHIA-COLI; IN-VIVO; STRUCTURAL GENOMICS; MOLECULAR EVOLUTION; MAMMALIAN-CELLS; FUSION PROTEINS; EXPRESSION; COMPLEMENTATION; PEPTIDE; SOLUBILITY	Existing protein tagging and detection methods are powerful but have drawbacks. Split protein tags can perturb protein solubility(1-4) or may not work in living cells(5-7). Green fluorescent protein (GFP) fusions can misfold(8) or exhibit altered processing(9). Fluorogenic biarsenical FLaSH or ReASH(10) substrates overcome many of these limitations but require a polycysteine tag motif, a reducing environment and cell transfection or permeabilization(10). An ideal protein tag would be genetically encoded, would work both in vivo and in vitro, would provide a sensitive analytical signal and would not require external chemical reagents or substrates. One way to accomplish this might be with a split GFP(11), but the GFP fragments reported thus far are large and fold poorly(11,12), require chemical ligation(13) or fused interacting partners to force their association(11-14), or require coexpression or co-refolding to produce detectable folded and fluorescent GFP(11,12). We have engineered soluble, self-associating fragments of GFP that can be used to tag and detect either soluble or insoluble proteins in living cells or cell lysates. The split GFP system is simple and does not change fusion protein solubility.	Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87545 USA	United States Department of Energy (DOE); Los Alamos National Laboratory	Waldo, GS (corresponding author), Los Alamos Natl Lab, Biosci Div, MS-M888,POB 1663, Los Alamos, NM 87545 USA.	waldo@lanl.gov	Cabantous, Stephanie/AAB-5113-2020; Terwilliger, Thomas/AEF-4827-2022; Cabantous, Stephanie/M-3282-2014; Terwilliger, Thomas/AAM-4079-2020; Terwilliger, Thomas C/K-4109-2012	Cabantous, Stephanie/0000-0002-8406-9421; Cabantous, Stephanie/0000-0002-8406-9421; Terwilliger, Thomas/0000-0001-6384-0320; Terwilliger, Thomas C/0000-0001-6384-0320				Adams SR, 2002, J AM CHEM SOC, V124, P6063, DOI 10.1021/ja017687n; Armstrong N, 1999, PROTEIN SCI, V8, P1475, DOI 10.1110/ps.8.7.1475; Baird GS, 1999, P NATL ACAD SCI USA, V96, P11241, DOI 10.1073/pnas.96.20.11241; Baneyx F, 1999, CURR OPIN BIOTECH, V10, P411, DOI 10.1016/S0958-1669(99)00003-8; Bertens P, 2003, ARCH VIROL, V148, P265, DOI 10.1007/s00705-002-0918-z; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; Fahnert B, 2004, ADV BIOCHEM ENG BIOT, V89, P93; FitzGibbon S, 1997, EXTREMOPHILES, V1, P36, DOI 10.1007/s007920050013; Fox JD, 2001, PROTEIN SCI, V10, P622, DOI 10.1110/ps.45201; Gerstein M, 2003, SCIENCE, V299, P1663; Ghosh I, 2000, J AM CHEM SOC, V122, P5658, DOI 10.1021/ja994421w; Goh CS, 2004, J MOL BIOL, V336, P115, DOI 10.1016/j.jmb.2003.11.053; Hu CD, 2003, NAT BIOTECHNOL, V21, P539, DOI 10.1038/nbt816; Kelemen BR, 1999, NUCLEIC ACIDS RES, V27, P3696, DOI 10.1093/nar/27.18.3696; KIM JS, 1993, PROTEIN SCI, V2, P348; Knaust RKC, 2001, ANAL BIOCHEM, V297, P79, DOI 10.1006/abio.2001.5331; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; Makrides SC, 1996, MICROBIOL REV, V60, P512, DOI 10.1128/MMBR.60.3.512-538.1996; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Nixon AE, 2000, PROTEIN ENG, V13, P323, DOI 10.1093/protein/13.5.323; Ozawa T, 2003, NAT BIOTECHNOL, V21, P287, DOI 10.1038/nbt791; Ozawa T, 2001, ANAL CHEM, V73, P5866, DOI 10.1021/ac010717k; Ozawa T, 2001, CURR OPIN CHEM BIOL, V5, P578, DOI 10.1016/S1367-5931(00)00244-1; Patterson GH, 1997, BIOPHYS J, V73, P2782, DOI 10.1016/S0006-3495(97)78307-3; Pelletier JN, 1999, NAT BIOTECHNOL, V17, P683, DOI 10.1038/10897; Pelletier JN, 1998, P NATL ACAD SCI USA, V95, P12141, DOI 10.1073/pnas.95.21.12141; RICHARDS FM, 1959, J BIOL CHEM, V234, P1459; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAL M, 1985, J BIOL CHEM, V260, P9976; Terwilliger TC, 2004, NAT STRUCT MOL BIOL, V11, P296, DOI 10.1038/nsmb0404-296; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; ULLMANN A, 1967, J MOL BIOL, V24, P339, DOI 10.1016/0022-2836(67)90341-5; Waldo GS, 2003, CURR OPIN CHEM BIOL, V7, P33, DOI 10.1016/S1367-5931(02)00017-0; Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904; Wehrman T, 2002, P NATL ACAD SCI USA, V99, P3469, DOI 10.1073/pnas.062043699; Wigley WC, 2001, NAT BIOTECHNOL, V19, P131, DOI 10.1038/84389; Yokoyama S, 2003, CURR OPIN CHEM BIOL, V7, P39, DOI 10.1016/S1367-5931(02)00019-4; Zhang SF, 2004, CELL, V119, P137, DOI 10.1016/j.cell.2004.09.012	39	564	596	10	204	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2005	23	1					102	107		10.1038/nbt1044	http://dx.doi.org/10.1038/nbt1044			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	885ZK	15580262				2022-12-25	WOS:000226195700036
J	Tompa, M; Li, N; Bailey, TL; Church, GM; De Moor, B; Eskin, E; Favorov, AV; Frith, MC; Fu, YT; Kent, WJ; Makeev, VJ; Mironov, AA; Noble, WS; Pavesi, G; Pesole, G; Regnier, M; Simonis, N; Sinha, S; Thijs, G; van Helden, J; Vandenbogaert, M; Weng, ZP; Workman, C; Ye, C; Zhu, Z				Tompa, M; Li, N; Bailey, TL; Church, GM; De Moor, B; Eskin, E; Favorov, AV; Frith, MC; Fu, YT; Kent, WJ; Makeev, VJ; Mironov, AA; Noble, WS; Pavesi, G; Pesole, G; Regnier, M; Simonis, N; Sinha, S; Thijs, G; van Helden, J; Vandenbogaert, M; Weng, ZP; Workman, C; Ye, C; Zhu, Z			Assessing computational tools for the discovery of transcription factor binding sites	NATURE BIOTECHNOLOGY			English	Article							GENOME ANNOTATION ASSESSMENT; REGULATORY ELEMENTS; PREDICTION; SEQUENCES; GENES; DNA	The prediction of regulatory elements is a problem where computational methods offer great hope. Over the past few years, numerous tools have become available for this task. The purpose of the current assessment is twofold: to provide some guidance to users regarding the accuracy of currently available tools in various settings, and to provide a benchmark of data sets for assessing future tools.	Univ Washington, Dept Comp Sci & Engn, Seattle, WA 98195 USA; Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Lipper Ctr Computat Genet, Boston, MA 02115 USA; Katholieke Univ Leuven, ESAT SCD, B-3001 Louvain, Belgium; Univ Calif San Diego, Dept Comp Sci & Engn, La Jolla, CA 92093 USA; State Sci Ctr GosNIIGenet, Moscow 117545, Russia; Russian Acad Sci, VA Engelhardt Mol Biol Inst, Moscow 119991, Russia; Boston Univ, Bioinformat Program, Boston, MA 02215 USA; Univ Calif Santa Cruz, Ctr Biomol Sci & Engn, Santa Cruz, CA 95064 USA; Moscow MV Lomonosov State Univ, Dept Bioengn & Bioinformat, Moscow 119992, Russia; Univ Milan, Dept Comp Sci & Commun DICo, Milan, Italy; Univ Milan, Dept Biomol Sci & Biotechnol, Milan, Italy; INRIA Rocquencourt, F-78153 Le Chesnay, France; Free Univ Brussels, SCMB, B-1050 Brussels, Belgium; Rockefeller Univ, Ctr Studies Phys & Biol, New York, NY 10021 USA; Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; Univ Calif San Diego, Bioinformat Program, La Jolla, CA 92093 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Queensland; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; KU Leuven; University of California System; University of California San Diego; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Boston University; University of California System; University of California Santa Cruz; Lomonosov Moscow State University; University of Milan; University of Milan; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Rockefeller University; University of California System; University of California San Diego; University of California System; University of California San Diego	Tompa, M (corresponding author), Univ Washington, Dept Comp Sci & Engn, Box 352350, Seattle, WA 98195 USA.	tompa@cs.washington.edu	Pavesi, Giulio/AAB-3230-2022; Ye, Chun/AAK-4868-2021; Makeev, Vsevolod/E-8015-2013; Workman, Christopher T/K-1066-2015; Eskin, Eleazar/J-9187-2012; Sinha, Saurabh/A-3058-2008; Pesole, Graziano/K-5283-2019; Pesole, Graziano/C-1408-2009; Pesole, Graziano/E-9051-2014; Mironov, Andrey/C-8024-2012; Favorov, Alexander V/K-2699-2018; van Helden, Jacques/D-8590-2013; Simonis, Nicolas/E-5124-2010	Ye, Chun/0000-0001-6560-3783; Makeev, Vsevolod/0000-0001-9405-9748; Workman, Christopher T/0000-0002-2210-3743; Eskin, Eleazar/0000-0003-1149-4758; Pesole, Graziano/0000-0003-3663-0859; Pesole, Graziano/0000-0003-3663-0859; Favorov, Alexander V/0000-0003-2595-1091; van Helden, Jacques/0000-0002-8799-8584; church, george/0000-0001-6232-9969; Frith, Martin/0000-0003-0998-2859; Vandenbogaert, Mathias/0000-0002-3073-9688	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG003110, R01HG002602] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01 HG02602, 1R01HG03110] Funding Source: Medline; Telethon [GP0101Y01] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); Telethon(Fondazione Telethon)		Ao W, 2004, SCIENCE, V305, P1743, DOI 10.1126/science.1102216; Ashburner M, 2000, GENOME RES, V10, P391, DOI 10.1101/gr.10.4.391; BAILEY TL, 1995, P 3 INT C INT SYST M, P21; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Burset M, 1996, GENOMICS, V34, P353, DOI 10.1006/geno.1996.0298; Eskin Eleazar, 2002, Bioinformatics, V18 Suppl 1, pS354; FAVOROV AV, 2004, P BGRS 2004 BGRS NOV; Frith MC, 2004, NUCLEIC ACIDS RES, V32, P189, DOI 10.1093/nar/gkh169; Hertz GZ, 1999, BIOINFORMATICS, V15, P563, DOI 10.1093/bioinformatics/15.7.563; Hughes JD, 2000, J MOL BIOL, V296, P1205, DOI 10.1006/jmbi.2000.3519; Moult J, 2003, PROTEINS, V53, P334, DOI 10.1002/prot.10556; Pavesi G, 2004, NUCLEIC ACIDS RES, V32, pW199, DOI 10.1093/nar/gkh465; Pevzner P A, 2000, Proc Int Conf Intell Syst Mol Biol, V8, P269; Reese MG, 2000, GENOME RES, V10, P483, DOI 10.1101/gr.10.4.483; Regnier M, 2004, DISCRETE MATH THEOR, V6, P191; Sinha S, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-170; Sinha S, 2003, THIRD IEEE SYMPOSIUM ON BIOINFORMATICS AND BIOENGINEERING - BIBE 2003, PROCEEDINGS, P214, DOI 10.1109/BIBE.2003.1188949; Sinha S, 2003, NUCLEIC ACIDS RES, V31, P3586, DOI 10.1093/nar/gkg618; Thijs G, 2001, BIOINFORMATICS, V17, P1113, DOI 10.1093/bioinformatics/17.12.1113; van Heiden J, 2000, NUCLEIC ACIDS RES, V28, P1808, DOI 10.1093/nar/28.8.1808; van Helden J, 1998, J MOL BIOL, V281, P827, DOI 10.1006/jmbi.1998.1947; Wingender E, 1996, NUCLEIC ACIDS RES, V24, P238, DOI 10.1093/nar/24.1.238; Workman C T, 2000, Pac Symp Biocomput, P467	23	876	925	1	63	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2005	23	1					137	144		10.1038/nbt1053	http://dx.doi.org/10.1038/nbt1053			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	885ZK	15637633	Green Published			2022-12-25	WOS:000226195700043
J	Weiss, RA; McMichael, AJ				Weiss, RA; McMichael, AJ			Social and environmental risk factors in the emergence of infectious diseases	NATURE MEDICINE			English	Article							WEST-NILE-VIRUS; HIV-INFECTION; TRANSMISSION; AIDS; MORTALITY; INFLUENZA; ENCEPHALITIS; TRANSFUSION; RETROVIRUS; COUNTRIES	Fifty years ago, the age-old scourge of infectious disease was receding in the developed world in response to improved public health measures, while the advent of antibiotics, better vaccines, insecticides and improved surveillance held the promise of eradicating residual problems. By the late twentieth century, however, an increase in the emergence and reemergence of infectious diseases was evident in many parts of the world. This upturn looms as the fourth major transition in human-microbe relationships since the advent of agriculture around 10,000 years ago. About 30 new diseases have been identified, including Legionnaires' disease, human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), hepatitis C, bovine spongiform encephalopathy (BSE)/variant Creutzfeldt-Jakob disease (vCJD), Nipah virus, several viral hemorrhagic fevers and, most recently, severe acute respiratory syndrome (SARS) and avian influenza. The emergence of these diseases, and resurgence of old ones like tuberculosis and cholera, reflects various changes in human ecology: rural-to-urban migration resulting in high-density peri-urban slums; increasing long-distance mobility and trade; the social disruption of war and conflict; changes in personal behavior; and, increasingly, human-induced global changes, including widespread forest clearance and climate change. Political ignorance, denial and obduracy (as with HIV/AIDS) further compound the risks. The use and misuse of medical technology also pose risks, such as drug-resistant microbes and contaminated equipment or biological medicines. A better understanding of the evolving social dynamics of emerging infectious diseases ought to help us to anticipate and hopefully ameliorate current and future risks.	UCL, Wohl Vir Ctr, Div Infect & Immun, London W1T 4JF, England; Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0200, Australia	University of London; University College London; Australian National University	Weiss, RA (corresponding author), UCL, Wohl Vir Ctr, Div Infect & Immun, London W1T 4JF, England.	r.weiss@ucl.ac.uk; tony.mcmichael@anu.edu.au						ANDERSON R M, 1991; Auvert B, 2001, AIDS, V15, pS15, DOI 10.1097/00002030-200108004-00003; Bell D, 2004, PHILOS T R SOC B, V359, P1107, DOI 10.1098/rstb.2004.1492; Blower SM, 2004, NAT MED, V10, P1111, DOI 10.1038/nm1102; BROCKMANN D, 2005, SARS CASE STUDY EMER; Burnet FM, 1972, NATURAL HIST INFECT; Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; Butler C, 2000, LANCET, V356, P1445, DOI 10.1016/S0140-6736(05)74091-5; Caldwell JC, 2000, POPUL DEV REV, V26, P117, DOI 10.1111/j.1728-4457.2000.00117.x; Chua KB, 1999, LANCET, V354, P1257, DOI 10.1016/S0140-6736(99)04299-3; COHEN A, 2003, INT J ENVIRON HEAL R, V13, pS29; DARBY SC, 1995, NATURE, V377, P79, DOI 10.1038/377079a0; De Clercq E, 2004, NAT REV MICROBIOL, V2, P704, DOI 10.1038/nrmicro975; Di Giulio DB, 2004, LANCET INFECT DIS, V4, P15, DOI 10.1016/S1473-3099(03)00856-9; Diamond J., 1997, GUNS GERMS STEEL SHO; Drancourt M, 2004, EMERG INFECT DIS, V10, P1585, DOI 10.3201/eid1009.030933; Drucker E, 2001, LANCET, V358, P1989, DOI 10.1016/S0140-6736(01)06967-7; DUFFY JOHN, 1951, BULL HIST MED, V25, P324; Engelthaler DM, 1999, EMERG INFECT DIS, V5, P87, DOI 10.3201/eid0501.990110; Frenzen PD, 2004, EMERG INFECT DIS, V10, P1536, DOI 10.3201/eid1009.030403; Garrett L., 2000, BETRAYAL TRUST COLLA; Hahn BH, 2000, SCIENCE, V287, P607, DOI 10.1126/science.287.5453.607; Hale P, 2001, NATURE, V412, P271, DOI 10.1038/35085650; Halpin K, 1999, VET MICROBIOL, V68, P83, DOI 10.1016/S0378-1135(99)00063-2; Iwamoto M, 2003, NEW ENGL J MED, V348, P2196, DOI 10.1056/NEJMoa022987; Johnson AM, 2001, LANCET, V358, P1835, DOI 10.1016/S0140-6736(01)06883-0; Johnson NPAS, 2002, B HIST MED, V76, P105, DOI 10.1353/bhm.2002.0022; Koopmans M, 2004, LANCET, V363, P587, DOI 10.1016/S0140-6736(04)15589-X; Lee HC, 1996, BIOL SIGNAL, V5, P101; Levy SB, 2004, NAT MED, V10, pS122, DOI 10.1038/nm1145; Mackenzie JS, 2004, NAT MED, V10, pS98, DOI 10.1038/nm1144; Magre S, 2004, J VIROL, V78, P5812, DOI 10.1128/JVI.78.11.5812-5819.2004; Mahy BWJ, 1998, DEV BIOL STAND, V93, P31; McMichael AJ, 2004, PHILOS T ROY SOC B, V359, P1049, DOI 10.1098/rstb.2004.1480; McMichael AJ, 2004, LANCET, V363, P1155, DOI 10.1016/S0140-6736(04)15902-3; McMichael AJ, 2001, HUMAN FRONTIERS ENV, DOI [10.1017/CBO9781139106924, DOI 10.1017/CBO9781139106924]; McNeill W.H., 1976, PLAGUES PEOPLES, V1st ed.; Morens DM, 2004, NATURE, V430, P242, DOI 10.1038/nature02759; MORSE SS, 1995, EMERG INFECT DIS, V1, P7, DOI 10.3201/eid0101.950102; Palese P, 2004, NAT MED, V10, pS82, DOI 10.1038/nm1141; PARMENTER RR, 1993, SEVILLETA LTER PUBLI, V41, P1; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; Patz JA, 2004, ENVIRON HEALTH PERSP, V112, P1092, DOI 10.1289/ehp.6877; Pealer LN, 2003, NEW ENGL J MED, V349, P1236, DOI 10.1056/NEJMoa030969; Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143; Perel P, 2004, BMJ-BRIT MED J, V328, P895, DOI 10.1136/bmj.328.7444.895; Raoult D, 1997, EMERG INFECT DIS, V3, P357, DOI 10.3201/eid0303.970313; Schwartz M., 2003, COWS TURNED MAD; Speck Reinhard S., 1993, P642, DOI 10.1017/CHOL9780521332866.089; Taylor LH, 2001, PHILOS T R SOC B, V356, P983, DOI 10.1098/rstb.2001.0888; Tiemersma EW, 2004, EMERG INFECT DIS, V10, P1627, DOI 10.3201/eid1009.040069; Webby R, 2004, NAT MED, V10, pS77, DOI 10.1038/nm1151; Weiss RA, 2004, PHILOS T R SOC B, V359, P1137, DOI 10.1098/rstb.2004.1487; Weiss RA, 1998, NATURE, V391, P327, DOI 10.1038/34772; Weiss RA, 2002, TRENDS MICROBIOL, V10, P314, DOI 10.1016/S0966-842X(02)02391-0; Weiss RA, 2001, NATURE, V410, P963, DOI 10.1038/35073632; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Wilson K, 2004, LANCET, V364, P477, DOI 10.1016/S0140-6736(04)16820-7; Wolfe ND, 2004, LANCET, V363, P932, DOI 10.1016/S0140-6736(04)15787-5; zur Hansen H, 2003, INT J CANCER, V107, P687, DOI 10.1002/ijc.11517	60	352	383	2	225	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2004	10	12		S			S70	S76		10.1038/nm1150	http://dx.doi.org/10.1038/nm1150			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	879RC	15577934	Green Published			2022-12-25	WOS:000225733900002
J	Zimmerman, S; Daga, RR; Chang, F				Zimmerman, S; Daga, RR; Chang, F			Intra-nuclear microtubules and a mitotic spindle orientation checkpoint	NATURE CELL BIOLOGY			English	Article							FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; ASTRAL MICROTUBULES; BIPOLAR SPINDLE; POLE BODY; MECHANISM; ENVELOPE; ALIGNMENT; MOVEMENT; DYNAMICS	Cells of the fission yeast Schizosaccharomyces pombe have a checkpoint mechanism that reportedly monitors the orientation of the mitotic spindle. Astral microtubules in pre-anaphase spindles are thought to contact the contractile actin ring at the plasma membrane in order to rotate the spindle and to sense spindle orientation. Here, we show that these microtubules are actually inside the nuclear envelope.	Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA	Columbia University	Chang, F (corresponding author), Columbia Univ Coll Phys & Surg, Dept Microbiol, 701 W 168th St, New York, NY 10032 USA.	fc99@columbia.edu	Daga, Rafael/P-8340-2014	Daga, Rafael/0000-0001-5726-761X				Chang F, 2004, MOL BIOL CELL, V15, P1793, DOI 10.1091/mbc.E03-09-0691; Ding DQ, 1998, J CELL SCI, V111, P701; Ding R, 1997, MOL BIOL CELL, V8, P1461, DOI 10.1091/mbc.8.8.1461; Gachet Y, 2004, EMBO J, V23, P1289, DOI 10.1038/sj.emboj.7600156; Gachet Y, 2001, NATURE, V412, P352, DOI 10.1038/35085604; Garcia MA, 2001, EMBO J, V20, P3389, DOI 10.1093/emboj/20.13.3389; Nabeshima K, 1998, MOL BIOL CELL, V9, P3211, DOI 10.1091/mbc.9.11.3211; Oliferenko S, 2003, NAT CELL BIOL, V5, P766, DOI 10.1038/ncb0903-766; Oliferenko S, 2002, NAT CELL BIOL, V4, P816, DOI 10.1038/ncb861; Rajagopalan S, 2004, CURR BIOL, V14, P69, DOI 10.1016/j.cub.2003.12.027; Rosenblatt J, 2004, CELL, V117, P361, DOI 10.1016/S0092-8674(04)00341-1; Sagolla MJ, 2003, J CELL SCI, V116, P4891, DOI 10.1242/jcs.00796; Sato M, 2003, NAT CELL BIOL, V5, P764, DOI 10.1038/ncb0903-764; Tournier S, 2004, MOL BIOL CELL, V15, P3345, DOI 10.1091/mbc.E04-03-0256; Tran PT, 2001, J CELL BIOL, V153, P397, DOI 10.1083/jcb.153.2.397; Venkatram S, 2004, MOL BIOL CELL, V15, P2287, DOI 10.1091/mbc.E03-10-0728; West RR, 1998, MOL BIOL CELL, V9, P2839, DOI 10.1091/mbc.9.10.2839; Yoshida M, 2004, METHODS, V33, P226, DOI 10.1016/j.ymeth.2003.11.018	18	30	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2004	6	12					1245	1246		10.1038/ncb1200	http://dx.doi.org/10.1038/ncb1200			2	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	875WQ	15573098				2022-12-25	WOS:000225453300018
J	Rabut, G; Doye, V; Ellenberg, J				Rabut, G; Doye, V; Ellenberg, J			Mapping the dynamic organization of the nuclear pore complex inside single living cells	NATURE CELL BIOLOGY			English	Article							MOBILE NUCLEOPORIN; NUP107-160 COMPLEX; PROTEIN; NUP98; KINETOCHORES; SUBCOMPLEX; NUP153; NUP2P	Most cellular activities are executed by multi-protein complexes that form the basic functional modules of their molecular machinery(1). Proteomic approaches can provide an evermore detailed picture of their composition, but do not reveal how these machines are organized dynamically to accomplish their biological function. Here, we present a method to determine the dissociation rates of protein subunits from complexes that have a traceable localization inside single living cells. As a case study, we systematically analysed the dynamic organization of vertebrate nuclear pore complexes (NPCs), large supramolecular complexes of about 30 different polypeptides(2). NPC components exhibited a wide range of residence times covering five orders of magnitude from seconds to days. We found the central parts of the NPC to be very stable, consistent with a function as a structural scaffold, whereas more peripheral components exhibited more dynamic behaviour, suggesting adaptor as well as regulatory functions. The presented strategy can be applied to many multi-protein complexes and will help to characterize the dynamic behaviour of complex networks of proteins in live cells.	European Mol Biol Lab, Gene Express Programme, D-69117 Heidelberg, Germany; European Mol Biol Lab, Cell Biol & Biophys Programme, D-69117 Heidelberg, Germany; Inst Curie, CNRS, UMR 144, F-75248 Paris 05, France	European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Ellenberg, J (corresponding author), European Mol Biol Lab, Gene Express Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.	jan.ellenberg@embl.de	Ellenberg, Jan/I-4688-2014; Rabut, Gwenaël/E-7257-2011	Ellenberg, Jan/0000-0001-5909-701X; Rabut, Gwenaël/0000-0003-2658-2769				Belgareh N, 2001, J CELL BIOL, V154, P1147, DOI 10.1083/jcb.200101081; Bodoor K, 1999, J CELL SCI, V112, P2253; Carrero G, 2003, METHODS, V29, P14, DOI 10.1016/S1046-2023(02)00288-8; Charpilienne A, 2001, J BIOL CHEM, V276, P29361, DOI 10.1074/jbc.M101935200; Cronshaw JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/jcb.200206106; Cronshaw JM, 2003, P NATL ACAD SCI USA, V100, P5823, DOI 10.1073/pnas.1031047100; Daigle N, 2001, J CELL BIOL, V154, P71, DOI 10.1083/jcb.200101089; Denning D, 2001, J CELL BIOL, V154, P937, DOI 10.1083/jcb.200101007; Dilworth DJ, 2001, J CELL BIOL, V153, P1465, DOI 10.1083/jcb.153.7.1465; Drummond SP, 2002, J CELL BIOL, V158, P53, DOI 10.1083/jcb.200108145; Dundr M, 2002, J STRUCT BIOL, V140, P92, DOI 10.1016/S1047-8477(02)00521-X; Dundr M, 2002, SCIENCE, V298, P1623, DOI 10.1126/science.1076164; Enninga J, 2003, MOL CELL BIOL, V23, P7271, DOI 10.1128/MCB.23.20.7271-7284.2003; Galy V, 2003, MOL BIOL CELL, V14, P5104, DOI 10.1091/mbc.E03-04-0237; Griffis ER, 2004, MOL BIOL CELL, V15, P1991, DOI 10.1091/mbc.e03-10-0743; Griffis ER, 2002, MOL BIOL CELL, V13, P1282, DOI 10.1091/mbc.01-11-0538; Guan TL, 2000, MOL CELL BIOL, V20, P5619, DOI 10.1128/MCB.20.15.5619-5630.2000; Harel A, 2003, MOL CELL, V11, P853, DOI 10.1016/S1097-2765(03)00116-3; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Janin J, 2000, PROTEIN PROTEIN RECO, P1; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; Lindsay ME, 2002, CELL, V110, P349, DOI 10.1016/S0092-8674(02)00836-X; Loiodice I, 2004, MOL BIOL CELL, V15, P3333, DOI 10.1091/mbc.E03-12-0878; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Olsson M, 2004, EXP CELL RES, V292, P359, DOI 10.1016/j.yexcr.2003.09.014; Rabut G, 2004, J MICROSC-OXFORD, V216, P131, DOI 10.1111/j.0022-2720.2004.01404.x; Ribbeck K, 2001, EMBO J, V20, P1320, DOI 10.1093/emboj/20.6.1320; Smith AE, 2002, SCIENCE, V295, P488, DOI 10.1126/science.1064732; Suntharalingam M, 2003, DEV CELL, V4, P775, DOI 10.1016/S1534-5807(03)00162-X; Walther TC, 2003, CELL, V113, P195, DOI 10.1016/S0092-8674(03)00235-6; Walther TC, 2002, J CELL BIOL, V158, P63, DOI 10.1083/jcb.200202088; Zolotukhin AS, 1999, J VIROL, V73, P120, DOI 10.1128/JVI.73.1.120-127.1999	33	343	346	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2004	6	11					1114	U27		10.1038/ncb1184	http://dx.doi.org/10.1038/ncb1184			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	867BI	15502822				2022-12-25	WOS:000224816700017
J	Royal, CDM; Dunston, GM				Royal, CDM; Dunston, GM			Changing the paradigm from 'race' to human genome variation	NATURE GENETICS			English	Article							HUMAN GENETIC DIVERSITY	Knowledge from the Human Genome Project and research on human genome variation increasingly challenges the applicability of the term 'race' to human population groups, raising questions about the validity of inferences made about 'race' in the biomedical and scientific literature. Despite the acknowledged contradictions in contemporary science, population-based genetic variation is continually used to explain differences in health between 'racial' and 'ethnic' groups. In this commentary we posit that resolution of apparent paradoxes in relating biology to 'race' and genetics requires thinking 'outside of the box'.	Howard Univ, Natl Human Genome Ctr, Coll Med, Washington, DC 20059 USA	Howard University	Royal, CDM (corresponding author), Howard Univ, Natl Human Genome Ctr, Coll Med, 2216 6th St NW,Suite 207, Washington, DC 20059 USA.	croyal@howard.edu						Bamshad M, 2004, NAT REV GENET, V5, P598, DOI 10.1038/nrg1401; Bamshad MJ, 2003, AM J HUM GENET, V72, P578, DOI 10.1086/368061; Barbujani G, 1997, P NATL ACAD SCI USA, V94, P4516, DOI 10.1073/pnas.94.9.4516; BRACE CL, 1964, CURR ANTHROPOL, V5, P313, DOI 10.1086/200502; BURCHARD EG, 2003, NEW ENGL J MED, V248, P117; CITRIN T, 2003, GENOMICS POPULATION; COOPER R, 1984, AM HEART J, V108, P715, DOI 10.1016/0002-8703(84)90662-8; Cooper RS, 2003, NEW ENGL J MED, V348, P1166, DOI 10.1056/NEJMsb022863; DOBZHANSKY T, 1963, CURR ANTHROPOL, V4, P360, DOI 10.1086/200401; DUNSTON GM, 2004, PRAEGER HDB BLACK AM, P757; Duster Troy, 2003, BACKDOOR EUGENICS; EDMONSON MS, 1965, CURR ANTHROPOL, V6, P167, DOI 10.1086/200579; ELLISON GTH, 2002, CRITICAL PUBLIC HLTH, V12, P265; Foster MW, 2002, GENOME RES, V12, P844, DOI 10.1101/gr.99202; Frank R, 2001, DEMOGRAPHY, V38, P563, DOI 10.2307/3088319; GATES RR, 1963, CURR ANTHROPOL, V4, P208, DOI 10.1086/200362; Goodman AH, 2000, AM J PUBLIC HEALTH, V90, P1699, DOI 10.2105/AJPH.90.11.1699; Jorde LB, 2000, AM J HUM GENET, V66, P979, DOI 10.1086/302825; Kittles RA, 2003, ANNU REV GENOM HUM G, V4, P33, DOI 10.1146/annurev.genom.4.070802.110356; Kuhn T. S., 1962, STRUCTURE SCI REVOLU; Lee S S, 2001, Yale J Health Policy Law Ethics, V1, P33; LIVINGSTONE FB, 1958, CURR ANTHROPOL, V3, P279; NASH M, 1962, CURR ANTHROPOL, V3, P285, DOI 10.1086/200294; NEWMAN MT, 1963, CURR ANTHROPOL, V4, P189, DOI 10.1086/200360; Phimister EG, 2003, NEW ENGL J MED, V348, P1081, DOI 10.1056/NEJMp030028; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; Smedley A, 1999, RACE N AM ORIGIN EVO; Tishkoff SA, 2002, NAT REV GENET, V3, P611, DOI 10.1038/nrg865; Tishkoff SA, 2003, ANNU REV GENOM HUM G, V4, P293, DOI 10.1146/annurev.genom.4.070802.110226; WIERCINSKI A, 1962, CURR ANTHROPOL, V3, P2, DOI 10.1086/200244	30	70	73	0	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2004	36	11		S			S5	S7		10.1038/ng1454	http://dx.doi.org/10.1038/ng1454			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	867PH	15508004	Bronze			2022-12-25	WOS:000224854000003
J	Kramer, A; Mailand, N; Lukas, C; Syljuasen, RG; Wilkinson, CJ; Nigg, EA; Bartek, J; Lukas, J				Kramer, A; Mailand, N; Lukas, C; Syljuasen, RG; Wilkinson, CJ; Nigg, EA; Bartek, J; Lukas, J			Centrosome-associated Chk1 prevents premature activation of cyclin-B-Cdk1 kinase	NATURE CELL BIOLOGY			English	Article							CELL-FREE-EXTRACTS; PROTEIN-KINASE; DNA-DAMAGE; SPINDLE FORMATION; AURORA-A; PHOSPHORYLATION; CHECKPOINT; CYCLE; MITOSIS; ACCUMULATION	Entry into mitosis occurs after activation of Cdk1, resulting in chromosome condensation in the nucleus and centrosome separation, as well as increased microtubule nucleation activity in the cytoplasm. The active cyclin-B1-Cdk1 complex first appears at the centrosome, suggesting that the centrosome may facilitate the activation of mitotic regulators required for the commitment of cells to mitosis. However, the signalling pathways involved in controlling the initial activation of Cdk1 at the centrosome remain largely unknown. Here, we show that human Chk1 kinase localizes to interphase, but not mitotic, centrosomes. Chemical inhibition of Chk1 resulted in premature centrosome separation and activation of centrosome-associated Cdk1. Forced immobilization of kinase-inactive Chk1 to centrosomes also resulted in premature Cdk1 activation. Conversely, under such conditions wild-type Chk1 impaired activation of centrosome-associated Cdk1, thereby resulting in DNA endoreplication and centrosome amplification. Activation of centrosomal Cdk1 in late prophase seemed to be mediated by cytoplasmic Cdc25B, whose activity is controlled by centrosome-associated Chk1. These results suggest that centrosome-associated Chk1 shields centrosomal Cdk1 from unscheduled activation by cytoplasmic Cdc25B, thereby contributing to proper timing of the initial steps of cell division, including mitotic spindle formation.	Danish Canc Soc, Inst Canc Biol, Dept Cell Cycle & Canc, DK-2100 Copenhagen O, Denmark; Heidelberg Univ, Med Klin & Poliklin 5, D-69115 Heidelberg, Germany; Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany	Danish Cancer Society; Ruprecht Karls University Heidelberg; Max Planck Society	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Dept Cell Cycle & Canc, Strandblvd 49, DK-2100 Copenhagen O, Denmark.	bartek@biobase.dk	Bartek, Jiri/G-5870-2014	Wilkinson, Christopher/0000-0002-7448-0938; Lukas, Jiri/0000-0001-9087-506X; Lukas, Claudia/0000-0001-7169-6883; nigg, erich/0000-0003-4835-5719				Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; BAILLY E, 1992, J CELL SCI, V101, P529; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Blomberg-Wirschell M, 1998, METHOD ENZYMOL, V298, P228, DOI 10.1016/S0076-6879(98)98022-3; De Souza CPC, 2000, EXP CELL RES, V257, P11, DOI 10.1006/excr.2000.4872; Dutertre S, 2004, J CELL SCI, V117, P2523, DOI 10.1242/jcs.01108; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Gillingham AK, 2000, EMBO REP, V1, P524; Hinchcliffe EH, 2001, SCIENCE, V291, P1547, DOI 10.1126/science.1056866; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hu BC, 2001, J BIOL CHEM, V276, P17693, DOI 10.1074/jbc.M009340200; Hut HMJ, 2003, MOL BIOL CELL, V14, P1993, DOI 10.1091/mbc.E02-08-0510; Itzhaki JE, 1997, NAT GENET, V15, P258, DOI 10.1038/ng0397-258; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Khodjakov A, 2000, CURR BIOL, V10, P59, DOI 10.1016/S0960-9822(99)00276-6; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; Laronne A, 2003, MOL BIOL CELL, V14, P3730, DOI 10.1091/mbc.E02-12-0850; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Liu QH, 2000, GENE DEV, V14, P1448; Lukas C, 2001, CANCER RES, V61, P4990; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHTA K, 1993, J CELL SCI, V104, P125; Pines J, 2001, NAT CELL BIOL, V3, pE3, DOI 10.1038/35050676; Rieder CL, 1998, J CELL BIOL, V142, P1013, DOI 10.1083/jcb.142.4.1013; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sibon OCM, 2000, NAT CELL BIOL, V2, P90, DOI 10.1038/35000041; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Takada S, 2003, CELL, V113, P87, DOI 10.1016/S0092-8674(03)00202-2; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0	34	264	271	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2004	6	9					884	U71		10.1038/ncb1165	http://dx.doi.org/10.1038/ncb1165			15	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	852IZ	15311285				2022-12-25	WOS:000223750300018
J	Phillips, N; Hayward, RD; Koronakis, V				Phillips, N; Hayward, RD; Koronakis, V			Phosphorylation of the enteropathogenic E-coli receptor by the Src-family kinase c-Fyn triggers actin pedestal formation	NATURE CELL BIOLOGY			English	Article							PROTEIN-TYROSINE KINASES; HOST-CELL CYTOSKELETON; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; EPITHELIAL-CELLS; TIR RECEPTOR; EPEC; ACTIVATION; NCK; REARRANGEMENT	Enteropathogenic Escherichia coli (EPEC) causes diarrhoeal disease worldwide(1). Pathogen adherence to host cells induces reorganization of the actin cytoskeleton into 'pedestal-like' pseudopods beneath the extracellular bacteria(2). This requires two bacterial virulence factors that mimic a ligand-receptor interaction. EPEC delivers its own receptor, the translocated intimin receptor (Tir), into the target cell plasma membrane, which is phosphorylated on interaction with the bacterial surface protein intimin(3). Tir phosphorylated on Tyr 474 (ref. 4) binds the cellular adaptor Nck(5,6), triggering actin polymerization(7). Nevertheless, despite its critical role, the mechanism of Tir Tyr 474 phosphorylation remains unknown. Here, by artificially uncoupling Tir delivery and activity, we show that Tir phosphorylation and Nck-dependent pedestal formation require the Src-family kinase (SFK) c-Fyn. SFK inhibitors prevent Tyr 474 phosphorylation, and cells lacking c-fyn are resistant to pedestal formation. c-Fyn exclusively phosphorylates clustered Tir in vitro, and kinase knockdown suppresses Tir phosphorylation and pedestal formation in cultured cells. These results identify the transient interaction with host c-Fyn as a pivotal link between bacterial Tir and the cellular Nck-WASP-Arp2/3 cascade, illuminating a tractable experimental system in which to dissect tyrosine kinase signalling.	Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England	University of Cambridge	Koronakis, V (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.	vk103@mole.bio.cam.ac.uk		Koronakis, Vassilis/0000-0002-1353-1092; Hayward, Richard David/0000-0002-1710-2172				Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Campellone KG, 2004, J CELL BIOL, V164, P407, DOI 10.1083/jcb.200306032; Campellone KG, 2002, MOL MICROBIOL, V43, P1227, DOI 10.1046/j.1365-2958.2002.02817.x; Celli J, 2000, CELL MICROBIOL, V2, P1, DOI 10.1046/j.1462-5822.2000.00033.x; CUDMORE S, 1995, NATURE, V378, P636, DOI 10.1038/378636a0; Foger N, 2001, J CELL SCI, V114, P1169; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; Goosney DL, 2001, INFECT IMMUN, V69, P3315, DOI 10.1128/IAI.69.5.3315-3322.2001; Gruenheid S, 2001, NAT CELL BIOL, V3, P856, DOI 10.1038/ncb0901-856; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hayward RD, 2002, TRENDS CELL BIOL, V12, P15, DOI 10.1016/S0962-8924(01)02183-3; Ilangumaran S, 1999, MOL BIOL CELL, V10, P891, DOI 10.1091/mbc.10.4.891; Kalman D, 1999, NAT CELL BIOL, V1, P389, DOI 10.1038/14087; Kenny B, 1999, MOL MICROBIOL, V31, P1229, DOI 10.1046/j.1365-2958.1999.01265.x; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Liu H, 1999, MOL MICROBIOL, V34, P67, DOI 10.1046/j.1365-2958.1999.01574.x; Nataro JP, 1998, CLIN MICROBIOL REV, V11, P403; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; ROSENSHINE I, 1992, EMBO J, V11, P3551, DOI 10.1002/j.1460-2075.1992.tb05438.x; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; Selbach M, 2002, J BIOL CHEM, V277, P6775, DOI 10.1074/jbc.C100754200; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Touze T, 2004, MOL MICROBIOL, V51, P73, DOI 10.1046/j.1365-2958.2003.03830.x; Zobiack N, 2002, J CELL SCI, V115, P91	28	104	106	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2004	6	7					618	625		10.1038/ncb1148	http://dx.doi.org/10.1038/ncb1148			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	834TX	15220932				2022-12-25	WOS:000222434900016
J	Ranish, JA; Hahn, S; Lu, Y; Yi, EC; Li, XJ; Eng, J; Aebersold, R				Ranish, JA; Hahn, S; Lu, Y; Yi, EC; Li, XJ; Eng, J; Aebersold, R			Identification of TFB5, a new component of general transcription and DNA repair factor IIH	NATURE GENETICS			English	Article							FACTOR TFIIA; YEAST; SUBUNITS; COMPLEX; RECONSTITUTION; HOLOENZYME; KINASE; TAGS; CDK7	We previously described the use of quantitative proteomics to study macromolecular complexes(1). Applying the method to analyze a yeast RNA polymerase II preinitiation complex, we identified a new 8-kDa protein, encoded by the uncharacterized open reading frame YDR079c-a, as a potential new component of the preinitiation complex. Here we show that YDR079c-a is a bona fide component of polymerase II preinitiation complexes and investigate its role in transcription. YDR079c-a is recruited to promoters both in vivo and in vitro and is required for efficient transcription in vitro and for normal induction of GAL genes. In addition, YDR079c-a is a core component of general transcription and DNA repair factor IIH and is required for efficient recruitment of TFIIH to a promoter. Yeast lacking YDR079c-a grow slowly, and, like strains carrying mutations in core TFIIH subunits, are sensitive to ultraviolet radiation. YDR079c-a is conserved throughout evolution, and mutations in the human ortholog account for a DNA repair deficient form of the tricothiodystrophy disorder called TTD-A(2). The identification of a new, evolutionarily conserved, core TFIIH subunit is essential for our understanding of TFIIH function in transcription, DNA repair and human disease.	Inst Syst Biol, Seattle, WA 98103 USA; Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA	Institute for Systems Biology (ISB); Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Ranish, JA (corresponding author), Inst Syst Biol, 1441 N 34th St, Seattle, WA 98103 USA.	jranish@systemsbiology.org	Eng, Jimmy K/I-4202-2012	Eng, Jimmy K/0000-0001-6352-6737				Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; AUSUBEL FM, 2002, CURRENT PROTOCOLS MO; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Feaver WJ, 1997, J BIOL CHEM, V272, P19319, DOI 10.1074/jbc.272.31.19319; Gelbart ME, 2001, MOL CELL BIOL, V21, P2098, DOI 10.1128/MCB.21.6.2098-2106.2001; GIGLIAMARI G, 2004, NAT GENET       0627; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Han DK, 2001, NAT BIOTECHNOL, V19, P946, DOI 10.1038/nbt1001-946; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; Ideker T, 2000, J COMPUT BIOL, V7, P805, DOI 10.1089/10665270050514945; Iyer V, 1996, P NATL ACAD SCI USA, V93, P5208, DOI 10.1073/pnas.93.11.5208; KANG JJ, 1995, MOL CELL BIOL, V15, P1234; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Li XJ, 2003, ANAL CHEM, V75, P6648, DOI 10.1021/ac034633i; LI XJ, 2003, NAT BIOTECHNOL, V75, P6648; MATSUI P, 1995, NUCLEIC ACIDS RES, V23, P767, DOI 10.1093/nar/23.5.767; Ranish JA, 2003, NAT GENET, V33, P349, DOI 10.1038/ng1101; RANISH JA, 1991, J BIOL CHEM, V266, P19320; Ranish JA, 1999, GENE DEV, V13, P49, DOI 10.1101/gad.13.1.49; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; Sung P, 1996, J BIOL CHEM, V271, P10821, DOI 10.1074/jbc.271.18.10821; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; Taylor J.R., 1997, INTRO ERROR ANAL STU, P181; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; Vermeulen W, 2000, NAT GENET, V26, P307, DOI 10.1038/81603	27	120	122	0	5	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2004	36	7					707	713		10.1038/ng1385	http://dx.doi.org/10.1038/ng1385			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	833QT	15220919	Bronze			2022-12-25	WOS:000222354100020
J	Sen, GL; Blau, HM				Sen, GL; Blau, HM			Argonaute 2/RISC resides in sites of mammalian mRNA decay known as cytoplasmic bodies	NATURE CELL BIOLOGY			English	Article							INTERFERENCE; MICRORNA; CLEAVAGE	RNA interference (RNAi) is an important means of eliminating mRNAs, but the intracellular location of RNA-induced silencing complex (RISC) remains unknown. We show here that Argonaute 2, a key component of RISC, is not randomly distributed but concentrates in mRNA decay centres that are known as cytoplasmic bodies. The localization of Argonaute 2 in decay centres is not altered by the presence or absence of small interfering RNAs or their targeted mRNAs. However, RNA is required for the integrity of cytoplasmic bodies because RNase eliminates Argonaute 2 localization. In addition, Argonaute 1, another Argonaute family member, is concentrated in cytoplasmic bodies. These results provide new insight into the mechanism of RNAi function.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Baxter Lab Genet Pharmacol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Blau, HM (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, 269 Campus Dr,CCSR 4225A, Stanford, CA 94305 USA.	hblau@stanford.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018179] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020961, R37AG009521, R01AG009521] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL65572] Funding Source: Medline; NIA NIH HHS [AG09521, AG20961] Funding Source: Medline; NICHD NIH HHS [HD18179] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bashkirov VI, 1997, J CELL BIOL, V136, P761, DOI 10.1083/jcb.136.4.761; Cougot N, 2004, J CELL BIOL, V165, P31, DOI 10.1083/jcb.200309008; Eystathioy T, 2003, RNA, V9, P1171, DOI 10.1261/rna.5810203; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gazzani S, 2004, SCIENCE, V306, P1046, DOI 10.1126/science.1101092; Gu S, 2005, RNA, V11, P38, DOI 10.1261/rna.7158605; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Jing Q, 2005, CELL, V120, P623, DOI 10.1016/j.cell.2004.12.038; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Orban TI, 2005, RNA, V11, P459, DOI 10.1261/rna.7231505; Pham JW, 2004, CELL, V117, P83, DOI 10.1016/S0092-8674(04)00258-2; Sen G, 2004, NAT GENET, V36, P183, DOI 10.1038/ng1288; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; Souret FF, 2004, MOL CELL, V15, P173, DOI 10.1016/j.molcel.2004.06.006; Teixeira D, 2005, RNA, V11, P371, DOI 10.1261/rna.7258505; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434	18	471	502	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2005	7	6					633	U28		10.1038/ncb1265	http://dx.doi.org/10.1038/ncb1265			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	932OD	15908945				2022-12-25	WOS:000229562100018
J	Yu, P; Liu, B; Kodadek, T				Yu, P; Liu, B; Kodadek, T			A high-throughput assay for assessing the cell permeability of combinatorial libraries	NATURE BIOTECHNOLOGY			English	Article							CHROMATOGRAPHY/TANDEM MASS-SPECTROMETRY; SOLID-PHASE SYNTHESIS; HEAT-SHOCK-PROTEIN; SMALL-MOLECULE; GLUCOCORTICOID-RECEPTOR; SYSTEM; LIGANDS; DERIVATIVES; ABSORPTION; PEPTIDES	There is great interest in the identification of synthetic molecules that are capable of manipulating protein-protein interactions in living cells. Peptides, unlike other classes of small molecules, have binding properties appropriate for this application, but most are poorly cell permeable and sensitive to proteases. Therefore, considerable effort has been expended in the development of libraries of oligomeric peptide-like molecules(1-4). However, there are no clear-cut rules to guide the design of libraries rich in cell permeable compounds. Furthermore, currently available empirical methods to assess permeability may not accurately reflect true permeability and/or are capable of only modest throughput(5-12). We describe here an assay for assessing the relative cell permeability of synthetic molecules in the context of steroid fusions that is capable of high throughput and can be used in any transfectable cell line.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Biomed Invent, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kodadek, T (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	thomas.kodadek@utsouthwestern.edu		Kodadek, Thomas/0000-0003-1930-4795	NIDDK NIH HHS [P01 DK 58398] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK058398] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alluri PG, 2003, J AM CHEM SOC, V125, P13995, DOI 10.1021/ja036417x; APELLA DH, 1997, NATURE, V387, P381; ARTURSSON P, 1991, BIOCHEM BIOPH RES CO, V175, P880, DOI 10.1016/0006-291X(91)91647-U; Belitsky JM, 2002, BIOORGAN MED CHEM, V10, P3313, DOI 10.1016/S0968-0896(02)00204-3; Bertorelli G, 1998, PULM PHARMACOL THER, V11, P7, DOI 10.1006/pupt.1998.0119; BRASELMANN S, 1993, P NATL ACAD SCI USA, V90, P1657, DOI 10.1073/pnas.90.5.1657; Brocard J, 1998, NUCLEIC ACIDS RES, V26, P4086, DOI 10.1093/nar/26.17.4086; Burton PS, 1996, J PHARM SCI, V85, P1336, DOI 10.1021/js960067d; Chen SB, 2004, J AM CHEM SOC, V126, P410, DOI 10.1021/ja037390k; Ding S, 2003, P NATL ACAD SCI USA, V100, P7632, DOI 10.1073/pnas.0732087100; Fung EN, 2003, RAPID COMMUN MASS SP, V17, P2147, DOI 10.1002/rcm.1165; Goodwin JT, 1999, J PEPT RES, V53, P355, DOI 10.1034/j.1399-3011.1999.00072.x; Goodwin JT, 2001, J MED CHEM, V44, P3721, DOI 10.1021/jm010253i; Kodadek T, 2002, TRENDS BIOCHEM SCI, V27, P295, DOI 10.1016/S0968-0004(02)02105-9; Licitra EJ, 1996, P NATL ACAD SCI USA, V93, P12817, DOI 10.1073/pnas.93.23.12817; Lundberg M, 2001, NAT BIOTECHNOL, V19, P713, DOI 10.1038/90741; MANZ B, 1982, J STEROID BIOCHEM, V17, P335, DOI 10.1016/0022-4731(82)90208-4; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Olivos HJ, 2002, ORG LETT, V4, P4057, DOI 10.1021/ol0267578; Peterson RT, 2000, P NATL ACAD SCI USA, V97, P12965, DOI 10.1073/pnas.97.24.12965; Phillips ST, 2002, J AM CHEM SOC, V124, P58, DOI 10.1021/ja0168460; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; ROUSSEAU GG, 1979, NATURE, V279, P158, DOI 10.1038/279158a0; Seebach D, 2003, ANGEW CHEM INT EDIT, V42, P776, DOI 10.1002/anie.200390205; Taylor EW, 1997, PHARMACEUT RES, V14, P572, DOI 10.1023/A:1012140709158; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; Wang Z, 2000, J MASS SPECTROM, V35, P71, DOI 10.1002/(SICI)1096-9888(200001)35:1<71::AID-JMS915>3.0.CO;2-5; ZUCKERMANN RN, 1994, J MED CHEM, V37, P2678, DOI 10.1021/jm00043a007; ZUCKERMANN RN, 1992, J AM CHEM SOC, V114, P10646, DOI 10.1021/ja00052a076	30	82	85	2	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2005	23	6					746	751		10.1038/nbt1099	http://dx.doi.org/10.1038/nbt1099			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	933LA	15908941				2022-12-25	WOS:000229628700037
J	Fraser, HB				Fraser, HB			Modularity and evolutionary constraint on proteins	NATURE GENETICS			English	Article							COEVOLUTION; EXPRESSION	Modularity, which has been found in the functional and physical protein interaction networks of many organisms, has been postulated to affect both the mode and tempo of evolution. Here I show that in the yeast Saccharomyces cerevisiae, protein interaction hubs situated in single modules are highly constrained, whereas those connecting different modules are more plastic. This pattern of change could reflect a tendency for evolutionary innovations to occur by altering the proteins and interactions between rather than within modules, in a manner somewhat similar to the evolution of new proteins through the shuffling of conserved protein domains.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Fraser, HB (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	hunter@ocf.berkeley.edu						DOOLITTLE RF, 1995, ANNU REV BIOCHEM, V64, P287, DOI 10.1146/annurev.bi.64.070195.001443; Fisher R.A., 1930, GENETICAL THEORY NAT; Fraser HB, 2002, SCIENCE, V296, P750, DOI 10.1126/science.1068696; Fraser HB, 2004, P NATL ACAD SCI USA, V101, P9033, DOI 10.1073/pnas.0402591101; Gerhart J, 1997, CELLS EMBRYOS EVOLUT; Han JDJ, 2004, NATURE, V430, P88, DOI 10.1038/nature02555; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Hirsh AE, 2005, MOL BIOL EVOL, V22, P174, DOI 10.1093/molbev/msh265; Jordan IK, 2004, MOL BIOL EVOL, V21, P2058, DOI 10.1093/molbev/msh222; Krylov DM, 2003, GENOME RES, V13, P2229, DOI 10.1101/gr.1589103; Needham J, 1933, BIOL REV BIOL P CAMB, V8, P180, DOI 10.1111/j.1469-185X.1933.tb01153.x; Schlosser G, 2002, THEOR BIOSCI, V121, P1, DOI 10.1078/1431-7613-00049; Schlosser G., 2004, MODULARITY DEV EVOLU; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; Waxman D, 1998, SCIENCE, V279, P1210, DOI 10.1126/science.279.5354.1210	15	130	136	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2005	37	4					351	352		10.1038/ng1530	http://dx.doi.org/10.1038/ng1530			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	911XL	15750592				2022-12-25	WOS:000228040000016
J	Genove, G; DeMarco, U; Xu, HY; Goins, WF; Ahrens, ET				Genove, G; DeMarco, U; Xu, HY; Goins, WF; Ahrens, ET			A new transgene reporter for in vivo magnetic resonance imaging	NATURE MEDICINE			English	Article							FERRITIN H-CHAIN; GENE-EXPRESSION; IRON-UPTAKE; CELLS; OVEREXPRESSION; RELAXATION	We report a new platform technology for visualizing transgene expression in living subjects using magnetic resonance imaging (MRI). Using a vector, we introduced an MRI reporter, a metalloprotein from the ferritin family, into specific host tissues. The reporter is made superparamagnetic as the cell sequesters endogenous iron from the organism. In this new approach, the cells construct the MRI contrast agent in situ using genetic instructions introduced by the vector. No exogenous metal-complexed contrast agent is required, thereby simplifying intracellular delivery. We used a replication-defective adenovirus vector to deliver the ferritin transgenes. Following focal inoculation of the vector into the mouse brain, we monitored the reporter activity using in vivo time-lapse MRI. We observed robust contrast in virus-transduced neurons and glia for several weeks. This technology is adaptable to monitor transgene expression in vivo in many tissue types and has numerous biomedical applications, such as visualizing preclinical therapeutic gene delivery.	Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Pittsburgh NMR Ctr Biomed Res, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA	Carnegie Mellon University; Carnegie Mellon University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Ahrens, ET (corresponding author), Carnegie Mellon Univ, Dept Biol Sci, 4400 5th Ave, Pittsburgh, PA 15213 USA.	eta@andrew.cmu.edu	Goins, William/GLT-6681-2022; Genove, Guillem/F-1158-2011	Goins, William/0000-0001-7744-9891; Genove, Guillem/0000-0002-8558-3107	NIAMS NIH HHS [P50-AR049617] Funding Source: Medline; NIBIB NIH HHS [P41-EB001977, R01-EB003453] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB001977, R01EB003453] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Ahrens ET, 2003, MAGN RESON MED, V49, P1006, DOI 10.1002/mrm.10465; Bulte JWM, 2004, METHOD ENZYMOL, V386, P275; BULTE JWM, 1994, J MAGN RESON IMAGING, V4, P497, DOI 10.1002/jmri.1880040343; Contag CH, 2002, ANNU REV BIOMED ENG, V4, P235, DOI 10.1146/annurev.bioeng.4.111901.093336; Corsi B, 1998, BIOCHEM J, V330, P315, DOI 10.1042/bj3300315; Cozzi A, 2000, J BIOL CHEM, V275, P25122, DOI 10.1074/jbc.M003797200; Dhenain M, 1997, NEUROBIOL AGING, V18, P517, DOI 10.1016/S0197-4580(97)00105-X; Epsztejn S, 1999, BLOOD, V94, P3593, DOI 10.1182/blood.V94.10.3593.422k26_3593_3603; Gambhir SS, 1999, P NATL ACAD SCI USA, V96, P2333, DOI 10.1073/pnas.96.5.2333; Gottesfeld Z, 1996, MAGN RESON MED, V35, P514, DOI 10.1002/mrm.1910350410; Kircher MF, 2003, CANCER RES, V63, P6838; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; KORETSKY AP, 1990, P NATL ACAD SCI USA, V87, P3112, DOI 10.1073/pnas.87.8.3112; LEVI S, 1992, BIOCHEM J, V288, P591, DOI 10.1042/bj2880591; Louie AY, 2000, NAT BIOTECHNOL, V18, P321, DOI 10.1038/73780; OKON E, 1994, LAB INVEST, V71, P895; SANTAMBROGIO P, 1993, J BIOL CHEM, V268, P12744; STOLZ JF, 1986, NATURE, V321, P849, DOI 10.1038/321849a0; Vymazal J, 1996, MAGN RESON MED, V36, P61, DOI 10.1002/mrm.1910360111; Vymazal J, 1996, MAGN RESON MED, V35, P56, DOI 10.1002/mrm.1910350108; Vymazal J, 1998, J INORG BIOCHEM, V71, P153, DOI 10.1016/S0162-0134(98)10047-8; Walter G, 2000, P NATL ACAD SCI USA, V97, P5151, DOI 10.1073/pnas.97.10.5151; Weissleder Ralph, 2000, Nature Medicine, V6, P351, DOI 10.1038/73219; WELCH S, 1992, TRANSFERRIN IRON CAR; YEH TC, 1993, MAGN RESON MED, V30, P617, DOI 10.1002/mrm.1910300513	25	331	358	1	42	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2005	11	4					450	454		10.1038/nm1208	http://dx.doi.org/10.1038/nm1208			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15778721				2022-12-25	WOS:000228180500039
J	Ito, H; Koefoed, M; Tiyapatanaputi, P; Gromov, K; Goater, JJ; Carmouche, J; Zhang, XP; Rubery, PT; Rabinowitz, J; Samulski, RJ; Nakamura, T; Soballe, K; O'Keefe, RJ; Boyce, BF; Schwarz, EM				Ito, H; Koefoed, M; Tiyapatanaputi, P; Gromov, K; Goater, JJ; Carmouche, J; Zhang, XP; Rubery, PT; Rabinowitz, J; Samulski, RJ; Nakamura, T; Soballe, K; O'Keefe, RJ; Boyce, BF; Schwarz, EM			Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy	NATURE MEDICINE			English	Article							DEBRIS-INDUCED OSTEOLYSIS; IN-VIVO; OSTEOCLAST DIFFERENTIATION; OSTEOPROTEGERIN LIGAND; RECEPTOR ACTIVATOR; REPAIR; BIOLOGY; CELL; REGENERATION; CARTILAGE	Structural allograft healing is limited because of a lack of vascularization and remodeling. To study this we developed a mouse model that recapitulates the clinical aspects of live autograft and processed allograft healing. Gene expression analyses showed that there is a substantial decrease in the genes encoding RANKL and VEGF during allograft healing. Loss-of-function studies showed that both factors are required for autograft healing. To determine whether addition of these signals could stimulate allograft vascularization and remodeling, we developed a new approach in which rAAV can be freeze-dried onto the cortical surface without losing infectivity. We show that combination rAAV-RANKL- and rAAV-VEGF-coated allografts show marked remodeling and vascularization, which leads to a new bone collar around the graft. In conclusion, we find that RANKL and VEGF are necessary and sufficient for efficient autograft remodeling and can be transferred using rAAV to revitalize structural allografts.	Univ Rochester, Ctr Musculoskeletal Res, Rochester, NY 14642 USA; Kyoto Univ, Grad Sch Med, Dept Orthopaed Surg, Kyoto 6068507, Japan; Aarhus Univ Hosp, Dept Orthoped, DK-8000 Aarhus, Denmark; Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of Rochester; Kyoto University; Aarhus University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Schwarz, EM (corresponding author), Univ Rochester, Ctr Musculoskeletal Res, 601 Elmwood Ave,Box 665, Rochester, NY 14642 USA.	edward_schwarz@urmc.rochester.edu	Gromov, Kirill/AAP-3737-2020; Gromov, Kirill/AAM-2270-2020	Gromov, Kirill/0000-0002-8114-5193; Soballe, Kjeld/0000-0001-8872-9856	NHLBI NIH HHS [P01 HL066973, P01 HL051818, HL066973] Funding Source: Medline; NIAMS NIH HHS [R01 AR048681, R01 AR051469-01, R01 AR048149, AR43510, R01 AR043510, AR48149, AR48681, AR51469, R01 AR051469] Funding Source: Medline; NIEHS NIH HHS [P01 ES011854, ES011854] Funding Source: Medline; NIGMS NIH HHS [P01 GM059299] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066973, P01HL051818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051469, R01AR043510, R01AR048681, R01AR048149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM059299] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baltzer AWA, 2004, GENE THER, V11, P344, DOI 10.1038/sj.gt.3302195; BERREY BH, 1990, J BONE JOINT SURG AM, V72A, P825, DOI 10.2106/00004623-199072060-00005; Boden SD, 2002, SPINE, V27, P2662, DOI 10.1097/00007632-200212010-00005; Bonadio J, 1999, NAT MED, V5, P753, DOI 10.1038/10473; BOS GD, 1983, J BONE JOINT SURG AM, V65, P89, DOI 10.2106/00004623-198365010-00012; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; BURCHARDT H, 1987, ORTHOP CLIN N AM, V18, P187; Childs LM, 2002, J BONE MINER RES, V17, P192, DOI 10.1359/jbmr.2002.17.2.192; Childs LM, 2001, J BONE JOINT SURG AM, V83A, P1789, DOI 10.2106/00004623-200112000-00004; Colnot C, 2003, DEVELOPMENT, V130, P4123, DOI 10.1242/dev.00559; Deckers M, 2001, LAB INVEST, V81, P5, DOI 10.1038/labinvest.3780207; Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7; Enneking WE, 2001, J BONE JOINT SURG AM, V83A, P971, DOI 10.2106/00004623-200107000-00001; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Friedlaender GE, 2001, J BONE JOINT SURG AM, V83A, pS160; Gamradt SC, 2004, ANN BIOMED ENG, V32, P136, DOI 10.1023/B:ABME.0000007798.78548.b8; Garbuz DS, 1998, ORTHOP CLIN N AM, V29, P199, DOI 10.1016/S0030-5898(05)70318-7; Goater J, 2000, J RHEUMATOL, V27, P983; Goldberg V M, 1993, Semin Arthroplasty, V4, P58; Gould SE, 2000, J ORTHOP RES, V18, P920, DOI 10.1002/jor.1100180611; Hadjiargyrou M, 2002, J BIOL CHEM, V277, P30177, DOI 10.1074/jbc.M203171200; Hidaka C, 2003, J ORTHOPAED RES, V21, P573, DOI 10.1016/S0736-0266(02)00264-4; Kon T, 2001, J BONE MINER RES, V16, P1004, DOI 10.1359/jbmr.2001.16.6.1004; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lieberman JR, 2002, MOL THER, V6, P141, DOI 10.1006/mthe.2000.0663; LORD CF, 1988, J BONE JOINT SURG AM, V70A, P369, DOI 10.2106/00004623-198870030-00008; Musatov S, 2004, P NATL ACAD SCI USA, V101, P3627, DOI 10.1073/pnas.0308289101; Musgrave DS, 2000, CLIN ORTHOP RELAT R, P290; Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153; Rabinowitz JE, 2000, VIROLOGY, V278, P301, DOI 10.1006/viro.2000.0707; Sandhu HS, 2003, SPINE, V28, pS85, DOI 10.1097/00007632-200308011-00014; Schwarz EM, 2000, CLIN ORTHOP RELAT R, pS31, DOI 10.1097/00003086-200010001-00005; Stevenson S, 1997, J BONE JOINT SURG AM, V79A, P1; Tiyapatanaputi P, 2004, J ORTHOP RES, V22, P1254, DOI 10.1016/j.orthres.2004.03.017; Ulrich-Vinther M, 2002, J BONE JOINT SURG AM, V84A, P1405, DOI 10.2106/00004623-200208000-00017; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; Wu D, 2003, J CELL BIOCHEM, V88, P467, DOI 10.1002/jcb.10332; Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224-2232.1998; Zhang R, 2003, J BIOL CHEM, V278, P51267, DOI 10.1074/jbc.M310678200; Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681	40	218	226	0	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					291	297		10.1038/nm1190	http://dx.doi.org/10.1038/nm1190			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15711561	Green Accepted, Green Submitted			2022-12-25	WOS:000227541300024
J	Entesarian, M; Matsson, H; Klar, J; Bergendal, B; Olson, L; Arakaki, R; Hayashi, Y; Ohuchi, H; Falahat, B; Bolstad, AI; Jonsson, R; Wahren-Herlenius, M; Dahl, N				Entesarian, M; Matsson, H; Klar, J; Bergendal, B; Olson, L; Arakaki, R; Hayashi, Y; Ohuchi, H; Falahat, B; Bolstad, AI; Jonsson, R; Wahren-Herlenius, M; Dahl, N			Mutations in the gene encoding fibroblast growth factor 10 are associated with aplasia of lacrimal and salivary glands	NATURE GENETICS			English	Article							FIBROBLAST GROWTH FACTOR-10; SJOGRENS-SYNDROME; MAJOR SALIVARY; FGF10; CLASSIFICATION; CRITERIA; IIIB; LIMB	Autosomal dominant aplasia of lacrimal and salivary glands (ALSG; OMIM 180920 and OMIM 103420) is a rare condition characterized by irritable eyes and dryness of the mouth. We mapped ALSG to 5p13. 2- 5q13. 1, which coincides with the gene fibroblast growth factor 10 (FGF10). In two extended pedigrees, we identified heterozygous mutations in FGF10 in all individuals with ALSG. Fgf10(+/-) mice have a phenotype similar to ALSG, providing a model for this disorder. We suggest that haploinsufficiency for FGF10 during a crucial stage of development results in ALSG.	Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, SE-75185 Uppsala, Sweden; Inst Postgrad Dent Educ, Natl Oral Disabil Ctr, SE-55111 Jonkoping, Sweden; Inst Postgrad Dent Educ, Dept Pediat Dent, SE-55111 Jonkoping, Sweden; Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Oral Mol Pathol, Tokushima 7708506, Japan; Univ Tokushima, Fac Engn, Dept Biol Sci & Technol, Tokushima 7708506, Japan; Inst Postgrad Dent Educ, Dept Maxillofacial Radiol, SE-55111 Jonkoping, Sweden; Univ Bergen, Fac Dent, Dept Odontol Periodont, N-5009 Bergen, Norway; Univ Bergen, Gade Inst, N-5021 Bergen, Norway; Karolinska Inst, Dept Med, SE-17176 Stockholm, Sweden	Uppsala University; Jonkoping University; Jonkoping University; Tokushima University; Tokushima University; Jonkoping University; University of Bergen; University of Bergen; Karolinska Institutet	Dahl, N (corresponding author), Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, SE-75185 Uppsala, Sweden.	niklas.dahl@genpat.uu.se	Klar, Joakim/H-2900-2019; Matsson, Hans/A-2502-2013; Matsson, Hans/A-5787-2019; Wahren-Herlenius, Marie/AAN-6942-2021	Klar, Joakim/0000-0003-4185-7409; Matsson, Hans/0000-0002-8193-4029; Matsson, Hans/0000-0001-6161-1559; Wahren-Herlenius, Marie/0000-0002-0915-7245				Bagai S, 2002, J BIOL CHEM, V277, P23828, DOI 10.1074/jbc.M201658200; Bolstad AI, 2002, ARTHRITIS RES, V4, P353, DOI 10.1186/ar599; De Moerlooze L, 2000, DEVELOPMENT, V127, P483; Emoto H, 1997, J BIOL CHEM, V272, P23191, DOI 10.1074/jbc.272.37.23191; Ferreira APS, 2000, AM J MED GENET, V94, P32, DOI 10.1002/1096-8628(20000904)94:1<32::AID-AJMG7>3.0.CO;2-F; Makarenkova HP, 2000, DEVELOPMENT, V127, P2563; MILUNSKY JM, 1990, AM J MED GENET, V37, P371, DOI 10.1002/ajmg.1320370316; Min HS, 1998, GENE DEV, V12, P3156, DOI 10.1101/gad.12.20.3156; Ohuchi H, 2000, BIOCHEM BIOPH RES CO, V277, P643, DOI 10.1006/bbrc.2000.3721; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; VITALI C, 1993, ARTHRITIS RHEUM, V36, P340, DOI 10.1002/art.1780360309; Vitali C, 2002, ANN RHEUM DIS, V61, P554, DOI 10.1136/ard.61.6.554; Wiedemann HR, 1997, AM J MED GENET, V68, P222, DOI 10.1002/(SICI)1096-8628(19970120)68:2<222::AID-AJMG20>3.0.CO;2-V; Yeh BK, 2003, P NATL ACAD SCI USA, V100, P2266, DOI 10.1073/pnas.0436500100; Young W, 2001, ORAL SURG ORAL MED O, V92, P38, DOI 10.1067/moe.2001.113549	15	117	121	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2005	37	2					125	127		10.1038/ng1507	http://dx.doi.org/10.1038/ng1507			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	893AB	15654336				2022-12-25	WOS:000226690100017
J	Maroto, R; Raso, A; Wood, TG; Kurosky, A; Martinac, B; Hamill, OP				Maroto, R; Raso, A; Wood, TG; Kurosky, A; Martinac, B; Hamill, OP			TRPC1 forms the stretch-activated cation channel in vertebrate cells	NATURE CELL BIOLOGY			English	Article							XENOPUS-LAEVIS OOCYTES; MECHANOSENSITIVE CHANNELS; FUNCTIONAL EXPRESSION; HUMAN HOMOLOG; ION CHANNELS; LIVING CELLS; CALCIUM; MEMBRANE; PROTEINS; CLONING	The mechanosensitive cation channel (MscCa) transduces membrane stretch into cation (Na+, K+, Ca2+ and Mg2+) flux across the cell membrane, and is implicated in cell-volume regulation(1), cell locomotion(2), muscle dystrophy(3) and cardiac arrhythmias(4). However, the membrane protein(s) that form the MscCa in vertebrates remain unknown. Here, we use an identification strategy that is based on detergent solubilization of frog oocyte membrane proteins, followed by liposome reconstitution and evaluation by patch-clamp(5). The oocyte was chosen because it expresses the prototypical MscCa (greater than or equal to 10(7) MscCa/oocyte)(6) that is preserved in cytoskeleton-deficient membrane vesicles(7). We identified a membrane-protein fraction that reconstituted high MscCa activity and showed an abundance of a protein that had a relative molecular mass of 80,000 (M-r 80K). This protein was identified, by immunological techniques, as the canonical transient receptor potential channel 1 (TRPC1)(8-10). Heterologous expression of the human TRPC1 resulted in a > 1,000% increase in MscCa patch density, whereas injection of a TRPC1-specific antisense RNA abolished endogenous MscCa activity. Transfection of human TRPC1 into CHO-K1 cells also significantly increased MscCa expression. These observations indicate that TRPC1 is a component of the vertebrate MscCa, which is gated by tension developed in the lipid bilayer, as is the case in various prokaryotic mechanosensitive (Ms) channels(11).	Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA; Univ Western Australia, Sch Med & Pharmacol, Crawley, WA 6009, Australia; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Western Australia; University of Texas System; University of Texas Medical Branch Galveston	Hamill, OP (corresponding author), Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA.	ohamill@utmb.edu	Wood, Thomas/B-6172-2012; Wood, Thomas/GWZ-2481-2022; Martinac, Boris/A-7178-2018	Wood, Thomas/0000-0001-8962-8571; Martinac, Boris/0000-0001-8422-7082				Bobanovic LK, 1999, BIOCHEM J, V340, P593, DOI 10.1042/0264-6021:3400593; Bode F, 2001, NATURE, V409, P35, DOI 10.1038/35051165; Brereton HM, 2000, MOL CELL BIOCHEM, V214, P63, DOI 10.1023/A:1007193720930; Brereton HM, 2001, BBA-MOL CELL RES, V1540, P107, DOI 10.1016/S0167-4889(01)00124-0; CHRISTENSEN O, 1987, NATURE, V330, P66, DOI 10.1038/330066a0; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Jespersen T, 2002, BIOTECHNIQUES, V32, P536, DOI 10.2144/02323st05; Lee J, 1999, NATURE, V400, P382, DOI 10.1038/22578; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Martinac B, 2003, PROG BIOPHYS MOL BIO, V82, P11, DOI 10.1016/S0079-6107(03)00002-6; MCBRIDE DW, 1992, PFLUG ARCH EUR J PHY, V421, P606, DOI 10.1007/BF00375058; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; OBREGONFRANCO A, 2002, J PHYSL, V539, P391; Riccio A, 2002, MOL BRAIN RES, V109, P95, DOI 10.1016/S0169-328X(02)00527-2; Sinkins WG, 1998, BIOCHEM J, V331, P331, DOI 10.1042/bj3310331; SUKHAREV SI, 1993, BIOPHYS J, V65, P177, DOI 10.1016/S0006-3495(93)81044-0; TAGLIETTI V, 1988, J PHYSIOL-LONDON, V407, P311, DOI 10.1113/jphysiol.1988.sp017417; Tsiokas L, 1999, P NATL ACAD SCI USA, V96, P3934, DOI 10.1073/pnas.96.7.3934; Vandebrouck C, 2002, J CELL BIOL, V158, P1089, DOI 10.1083/jcb.200203091; WALL DA, 1989, J MEMBRANE BIOL, V107, P189, DOI 10.1007/BF01871724; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; Wilkinson NC, 1998, J MEMBRANE BIOL, V165, P161, DOI 10.1007/s002329900430; Wu G, 1998, PFLUG ARCH EUR J PHY, V435, P572, DOI 10.1007/s004240050554; YANG XC, 1990, J PHYSIOL-LONDON, V431, P103, DOI 10.1113/jphysiol.1990.sp018322; Zhang Y, 2000, J PHYSIOL-LONDON, V523, P117, DOI 10.1111/j.1469-7793.2000.t01-1-00117.x; Zhang Y, 2000, J PHYSIOL-LONDON, V523, P83, DOI 10.1111/j.1469-7793.2000.t01-2-00083.x; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2	30	475	520	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2005	7	2					179	U99		10.1038/ncb1218	http://dx.doi.org/10.1038/ncb1218			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	893LC	15665854				2022-12-25	WOS:000226719500015
J	Cantor, CR; Nelson, MR				Cantor, CR; Nelson, MR			Haplotyping in biomedicine - practical challenges	NATURE BIOTECHNOLOGY			English	Editorial Material							GENETIC ASSOCIATION; SUSCEPTIBILITY; DISEASE		Sequenom Inc, San Diego, CA 92121 USA; Inst Hautes Etud Sci, F-91440 Bures Sur Yvette, France	Sequenom; UDICE-French Research Universities; Universite Paris Saclay	Cantor, CR (corresponding author), Sequenom Inc, 3595 John Hopkins Court, San Diego, CA 92121 USA.	ccantor@sequenom.com						Ardlie KG, 2002, NAT REV GENET, V3, P299, DOI 10.1038/nrg777; Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; Kammerer S, 2003, P NATL ACAD SCI USA, V100, P4066, DOI 10.1073/pnas.2628028100; Lai E, 2002, NAT GENET, V32, P353, DOI 10.1038/ng1102-353; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047; Patil N, 2001, SCIENCE, V294, P1719, DOI 10.1126/science.1065573; Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718; Silander K, 2004, DIABETES, V53, P1141, DOI 10.2337/diabetes.53.4.1141; Sing CF, 2003, ARTERIOSCL THROM VAS, V23, P1190, DOI 10.1161/01.ATV.0000075081.51227.86; Zondervan KT, 2004, NAT REV GENET, V5, P89, DOI 10.1038/nrg1270	13	5	5	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2005	23	1					21	22		10.1038/nbt0105-21	http://dx.doi.org/10.1038/nbt0105-21			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	885ZK	15637611				2022-12-25	WOS:000226195700015
J	Mattila, E; Pellinen, T; Nevo, J; Vuoriluoto, K; Arjonen, A; Ivaska, J				Mattila, E; Pellinen, T; Nevo, J; Vuoriluoto, K; Arjonen, A; Ivaska, J			Negative regulation of EGFR signalling through integrin-alpha(1)beta(1)-mediated activation of protein tyrosine phosphatase TCPTP	NATURE CELL BIOLOGY			English	Article							GROWTH-FACTOR RECEPTOR; PKC-EPSILON; PHOSPHORYLATION; INTEGRINS; EXPRESSION; MUTANT	Integrin-mediated cell adhesion regulates a multitude of cellular responses, including proliferation, survival and crosstalk between different cellular signalling pathways(1). So far, integrins have been mainly shown to convey permissive signals enabling anchorage-dependent receptor tyrosine kinase signalling(2-4). Here we show that a collagen-binding integrin alpha(1)beta(1) functions as a negative regulator of epidermal growth factor receptor (EGFR) signalling through the activation of a protein tyrosine phosphatase. The cytoplasmic tail of a 1 integrin selectively interacts with a ubiquitously expressed protein tyrosine phosphatase TCPTP (T-cell protein tyrosine phosphatase) and activates it after cell adhesion to collagen. The activation results in reduced EGFR phosphorylation after EGF stimulation. Introduction of the a 1 cytoplasmic domain peptide into cells induces phosphatase activation and inhibits EGF-induced cell proliferation and anchorage-independent growth of malignant cells. These data are the first demonstration of the regulation of TCPTP activity in vivo and represent a new molecular paradigm of integrin-mediated negative regulation of receptor tyrosine kinase signalling.	VTT Tech Res Ctr Finland, FIN-20520 Turku, Finland; Univ Turku, Ctr Biotechnol, FIN-20520 Turku, Finland	VTT Technical Research Center Finland; University of Turku	Ivaska, J (corresponding author), VTT Tech Res Ctr Finland, FIN-20520 Turku, Finland.	johanna.ivaska@vtt.fi		Ivaska, Johanna/0000-0002-6295-6556				Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; COOL DE, 1992, P NATL ACAD SCI USA, V89, P5422, DOI 10.1073/pnas.89.12.5422; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Galic S, 2003, MOL CELL BIOL, V23, P2096, DOI 10.1128/MCB.23.6.2096-2108.2003; Gardner H, 1996, DEV BIOL, V175, P301, DOI 10.1006/dbio.1996.0116; Gardner H, 1999, J CELL SCI, V112, P263; Hao LN, 1997, J BIOL CHEM, V272, P29322, DOI 10.1074/jbc.272.46.29322; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ivaska J, 2003, NAT CELL BIOL, V5, P363, DOI 10.1038/ncb957; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Ivaska J, 1999, J CELL BIOL, V147, P401, DOI 10.1083/jcb.147.2.401; Ivaska J, 2002, EMBO J, V21, P3608, DOI 10.1093/emboj/cdf371; Kim TY, 2003, J BIOL CHEM, V278, P15272, DOI 10.1074/jbc.M205792200; Klingler-Hoffmann M, 2001, J BIOL CHEM, V276, P46313, DOI 10.1074/jbc.M106571200; Liu SC, 2000, J CELL SCI, V113, P3563; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; Pan Y, 2001, GENE CHROMOSOME CANC, V30, P187, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1075>3.3.CO;2-8; Pankov R, 2003, J BIOL CHEM, V278, P18671, DOI 10.1074/jbc.M300879200; Persson C, 2004, MOL CELL BIOL, V24, P2190, DOI 10.1128/MCB.24.5.2190-2201.2004; Pozzi M, 1998, J CELL BIOL, V142, P587; Simoncic PD, 2002, CURR BIOL, V12, P446, DOI 10.1016/S0960-9822(02)00697-8; Su AI, 2001, CANCER RES, V61, P7388; Tiganis T, 1999, J BIOL CHEM, V274, P27768, DOI 10.1074/jbc.274.39.27768; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; Zienolddiny S, 2001, BRIT J CANCER, V84, P226, DOI 10.1054/bjoc.2000.1528	30	148	156	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2005	7	1					78	+		10.1038/ncb1209	http://dx.doi.org/10.1038/ncb1209			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	884UZ	15592458				2022-12-25	WOS:000226113500018
J	Roca, AL; Georgiadis, N; O'Brien, SJ				Roca, AL; Georgiadis, N; O'Brien, SJ			Cytonuclear genomic dissociation in African elephant species	NATURE GENETICS			English	Article							MITOCHONDRIAL; NUCLEAR	African forest and savanna elephants are distinct species separated by a hybrid zone(1-4). Because hybridization can affect the systematic and conservation status of populations, we examined gene flow between forest and savanna elephants at 21 African locations. We detected cytonuclear dissociation, indicative of different evolutionary histories for nuclear and mitochondrial genomes. Both paternally (n = 205 males) and biparentally (n = 2, 123 X-chromosome segments) inherited gene sequences indicated that there was deep genetic separation between forest and savanna elephants. Yet in some savanna locales distant from present-day forest habitats, many individuals with savanna-specific nuclear genotypes carried maternally transmitted forest elephant mitochondrial DNA. This extreme cytonuclear dissociation implies that there were ancient episodes of hybridization between forest females and savanna males, which are larger and reproductively dominant to forest or hybrid males(1,2,5-7). Recurrent backcrossing of female hybrids to savanna bulls replaced the forest nuclear genome. The persistence of residual forest elephant mitochondria in savanna elephant herds renders evolutionary interpretations based on mitochondrial DNA alone misleading and preserves a genomic record of ancient habitat changes.	SAIC Frederick, Basic Res Program, Lab Genom Divers, Frederick, MD 21702 USA; Mpala Res Ctr, Nanyuki, Kenya; NCI, Lab Genom Divers, Frederick, MD 21702 USA	Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	O'Brien, SJ (corresponding author), SAIC Frederick, Basic Res Program, Lab Genom Divers, Frederick, MD 21702 USA.	obrien@ncifcrf.gov	OBRIEN, STEPHEN/ABD-1346-2020	Roca, Alfred/0000-0001-9217-5593; OBRIEN, STEPHEN/0000-0001-7857-0757	NATIONAL CANCER INSTITUTE [ZIABC005367, Z01BC005367] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barriel V, 1999, CR ACAD SCI III-VIE, V322, P447, DOI 10.1016/S0764-4469(99)80093-6; Blanc J.J., 2003, AFRICAN ELEPHANT STA; Blaxter M, 2003, NATURE, V421, P122, DOI 10.1038/421122a; Comstock KE, 2002, MOL ECOL, V11, P2489, DOI 10.1046/j.1365-294X.2002.01615.x; Coyne JA, 2004, SPECIATION; Debruyne R, 2004, CLADISTICS, V20, P80; Eggert LS, 2002, P ROY SOC B-BIOL SCI, V269, P1993, DOI 10.1098/rspb.2002.2070; GACKHAUS D, 1958, SAUGETIERK MITT, V6, P166; GEORGIADIS N, 1994, J HERED, V85, P100, DOI 10.1093/oxfordjournals.jhered.a111405; Groves Colin P., 2000, Elephant, V2, P4; Grubb Peter, 2000, Elephant, V2, P1; Hebert PDN, 2003, P ROY SOC B-BIOL SCI, V270, pS96, DOI 10.1098/rsbl.2003.0025; Maglio V.J., 1973, Transactions Am phil Soc, V63, P1, DOI 10.2307/1006229; Maley J, 1998, REV PALAEOBOT PALYNO, V99, P157, DOI 10.1016/S0034-6667(97)00047-X; Murphy WJ, 1999, GENOME RES, V9, P1223, DOI 10.1101/gr.9.12.1223; Nagao Y, 1998, GENES GENET SYST, V73, P21, DOI 10.1266/ggs.73.21; Nyakaana S, 1999, MOL ECOL, V8, P1105, DOI 10.1046/j.1365-294x.1999.00661.x; Nyakaana S, 2002, HEREDITY, V89, P90, DOI 10.1038/sj.hdy.6800110; Nyakaana S, 2001, ANIM CONSERV, V4, P231, DOI 10.1017/S1367943001001275; Poole JH, 1999, ANIM BEHAV, V58, P185, DOI 10.1006/anbe.1999.1117; Roca A. L., 2002, PACHYDERM, V33, P93; Roca AL, 2001, SCIENCE, V293, P1473, DOI 10.1126/science.1059936; Rohwer S, 2001, EVOLUTION, V55, P405; Shaw PA, 1997, S AFR J SCI, V93, P273; Silver Lee M., 1995; Slotow R, 2000, NATURE, V408, P425, DOI 10.1038/35044191; Sukumar R., 2003, LIVING ELEPHANTS EVO; Thompson L. G., 2002, Science, V298, P589, DOI 10.1126/science.1073198; Vignaud P, 2002, NATURE, V418, P152, DOI 10.1038/nature00880; White F., 1983, VEGETATION AFRICA DE, P356	30	170	177	1	43	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2005	37	1					96	100		10.1038/ng1485	http://dx.doi.org/10.1038/ng1485			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	883FX	15592471				2022-12-25	WOS:000225997500027
J	Churchill, G; Airey, DC; Allayee, H; Angel, JM; Attie, AD; Beatty, J; Beavis, WD; Belknap, JK; Bennett, B; Berrettini, W; Bleich, A; Bogue, M; Broman, KW; Buck, KJ; Buckler, E; Burmeister, M; Chesler, EJ; Cheverud, JM; Clapcote, S; Cook, MN; Cox, RD; Crabbe, JC; Crusio, WE; Darvasi, A; Deschnepper, CF; Doerge, RW; Farber, CR; Forejt, J; Gaile, D; Garlow, SJ; Geiger, H; Gershenfeld, H; Gordon, T; Gu, J; Gu, WK; de Haan, G; Hayes, NL; Heller, C; Himmelbauer, H; Hitzemann, R; Hunter, K; Hsu, HC; Iraqi, FA; Ivandic, B; Jacob, HJ; Jansen, RC; Jjepsen, KJ; Johnson, DK; Johnson, TE; Kempermann, G; Kendziorski, C; Kotb, M; Kooy, RF; Llamas, B; Lammert, F; Lassalle, JM; Lowenstein, PR; Lu, L; Lusiss, A; Manly, KF; Marcucio, R; Matthews, D; Medrano, JF; Miller, DR; Mittleman, G; Mock, BA; Mogil, JS; Montagutelli, X; Morahan, G; Morris, DG; Mott, R; Nadeau, JH; Nagase, H; Nowakowski, RS; O'Hara, BF; Osadchuk, AV; Page, GP; Paigen, B; Paigen, K; Palmer, AA; Pan, HJ; Peltonen-Palotie, L; Peirce, J; Pomp, D; Pravenec, M; Prows, DR; Qi, ZH; Reeves, RH; Roder, J; Rosen, GD; Schadt, EE; Schalkwyk, LC; Seltzer, Z; Shimomura, K; Shou, SM; Sillanpaa, MJ; Siracusa, LD; Snoeck, HW; Spearow, JL; Svenson, K; Tarantino, LM; Threadgill, D; Toth, LA; Valdar, W; de Villena, FPM; Warden, C; Whatley, S; Williams, RW; Wiltshire, T; Yi, NJ; Zhang, DB; Zhang, M; Zou, F				Churchill, G; Airey, DC; Allayee, H; Angel, JM; Attie, AD; Beatty, J; Beavis, WD; Belknap, JK; Bennett, B; Berrettini, W; Bleich, A; Bogue, M; Broman, KW; Buck, KJ; Buckler, E; Burmeister, M; Chesler, EJ; Cheverud, JM; Clapcote, S; Cook, MN; Cox, RD; Crabbe, JC; Crusio, WE; Darvasi, A; Deschnepper, CF; Doerge, RW; Farber, CR; Forejt, J; Gaile, D; Garlow, SJ; Geiger, H; Gershenfeld, H; Gordon, T; Gu, J; Gu, WK; de Haan, G; Hayes, NL; Heller, C; Himmelbauer, H; Hitzemann, R; Hunter, K; Hsu, HC; Iraqi, FA; Ivandic, B; Jacob, HJ; Jansen, RC; Jjepsen, KJ; Johnson, DK; Johnson, TE; Kempermann, G; Kendziorski, C; Kotb, M; Kooy, RF; Llamas, B; Lammert, F; Lassalle, JM; Lowenstein, PR; Lu, L; Lusiss, A; Manly, KF; Marcucio, R; Matthews, D; Medrano, JF; Miller, DR; Mittleman, G; Mock, BA; Mogil, JS; Montagutelli, X; Morahan, G; Morris, DG; Mott, R; Nadeau, JH; Nagase, H; Nowakowski, RS; O'Hara, BF; Osadchuk, AV; Page, GP; Paigen, B; Paigen, K; Palmer, AA; Pan, HJ; Peltonen-Palotie, L; Peirce, J; Pomp, D; Pravenec, M; Prows, DR; Qi, ZH; Reeves, RH; Roder, J; Rosen, GD; Schadt, EE; Schalkwyk, LC; Seltzer, Z; Shimomura, K; Shou, SM; Sillanpaa, MJ; Siracusa, LD; Snoeck, HW; Spearow, JL; Svenson, K; Tarantino, LM; Threadgill, D; Toth, LA; Valdar, W; de Villena, FPM; Warden, C; Whatley, S; Williams, RW; Wiltshire, T; Yi, NJ; Zhang, DB; Zhang, M; Zou, F		Complex Trait Consortium	The Collaborative Cross, a community resource for the genetic analysis of complex traits	NATURE GENETICS			English	Article							ENVIRONMENT; STRAINS; MICE	The goal of the Complex Trait Consortium is to promote the development of resources that can be used to understand, treat and ultimately prevent pervasive human diseases. Existing and proposed mouse resources that are optimized to study the actions of isolated genetic loci on a fixed background are less effective for studying intact polygenic networks and interactions among genes, environments, pathogens and other factors. The Collaborative Cross will provide a common reference panel specifically designed for the integrative analysis of complex systems and will change the way we approach human health and disease.	Jackson Lab, Bar Harbor, ME 04609 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN USA; Univ So Calif, Keck Sch Med, Los Angeles, CA USA; Univ Texas, MD Anderson Canc Ctr, Sci Pk Res Div, Smithville, TX USA; Univ Wisconsin, Dept Biochem, Madison, WI 53705 USA; Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA; Natl Ctr Genome Resources, Santa Fe, NM USA; Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Portland, OR 97201 USA; Univ Colorado, Inst Behav Genet, Boulder, CO 80309 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Hannover Med Sch, Inst Lab Anim Sci & Cent Anim Facil, D-3000 Hannover, Germany; Johns Hopkins Univ, Dept Biostat, Baltimore, MD 21205 USA; Vet Affairs Med Ctr, Dept Behav Neurosci, Portland, OR USA; Cornell Univ, Inst Genom Divers, Ithaca, NY USA; Univ Michigan, Mental Hlth Res Inst, Ann Arbor, MI USA; Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, Memphis, TN 38163 USA; Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; Univ Memphis, Dept Psychol, Memphis, TN 38152 USA; QTL & Modifier Loci Grp, MRC Mammalian Genet Unit, Harwell, Oxon, England; Univ Massachusetts, Sch Med, Brudnick Neuropsychiat Res Inst, Worcester, MA USA; Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Evolut Systemat & Ecol, IL-91905 Jerusalem, Israel; Inst Rech Clin Montreal, Montreal, PQ H2W 1R7, Canada; Purdue Univ, Dept Stat, W Lafayette, IN 47907 USA; Univ Calif Davis, Dept Anim Sci, Davis, CA 95616 USA; ASCR, Inst Genet Mol, Videnska, Czech Republic; SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Biostat, Buffalo, NY 14260 USA; Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA; Univ Cincinnati, Med Ctr, Div Expt Hematol, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45267 USA; Univ Texas SW, Dallas, TX USA; NYU, Sch Med, Dept Environm Med, Tuxedo Pk, NY USA; Univ Tennessee, Ctr Hlth Sci, Dept Orthopaed Surg Campbell Clin, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Ctr Genom & Bioinformat, Dept Pathol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Ctr Dis Connect Tissues, Memphis, TN 38163 USA; Univ Groningen, Dept Stem Cell Biol, NL-9700 AB Groningen, Netherlands; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA; Stanford Univ, Stanford, CA 94305 USA; Max Planck Inst Mol Genet, Berlin, Germany; NIH, Bethesda, MD 20892 USA; Univ Alabama Birmingham, Clin Immunol & Rheumatol, Birmingham, AL USA; Int Livestock Res Inst, Nairobi, Kenya; Heidelberg Univ, Dept Med 3, Heidelberg, Germany; Med Coll Wisconsin, Dept Physiol, Milwaukee, WI 53226 USA; Groningen Bioinformat Ctr, Inst Math & Comp Sci, Groningen, Netherlands; Mt Sinai Sch Med, Dept Orthopaed, New York, NY USA; Oak Ridge Natl Lab, Div Life Sci, Mammalian Genet Grp, Oak Ridge, TN USA; Charite Univ Med Berlin, Max Delbruck Ctr Mol Med, Dept Expt Neurol, Berlin, Germany; Univ Wisconsin, Med Sci Ctr, Dept Biostat & Med Informat, Madison, WI USA; Univ Tennessee, Ctr Hlth Sci, Dept Surg, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA; Univ Antwerp, Dept Med Genet, B-2020 Antwerp, Belgium; Univ Aachen, Univ Hosp Aachen, Dept Med 3, Aachen, Germany; Univ Toulouse 3, Ctr Rech Cognit Anim, F-31062 Toulouse, France; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90024 USA; Cedars Sinai Med Ctr, Gene Therapeut Res Inst, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Ctr Hlth Sci, Dept Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Ctr Hlth Sci, Dept MIMG, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Ctr Hlth Sci, Dept Human Genet, Los Angeles, CA 90024 USA; Univ Calif San Francisco, San Francisco Gen Hosp, Dept Orthopaed Surg, San Francisco, CA USA; NCI, CCR, NIH, Bethesda, MD 20892 USA; McGill Univ, Dept Psychol, Montreal, PQ, Canada; McGill Univ, Ctr Res Pain, Montreal, PQ, Canada; Inst Pasteur, Unite Genet Mammiferes, Paris, France; Western Australian Inst Med Res, Ctr Diabet Res, Perth, WA, Australia; Yale Univ, Sch Med Pulm & Crit Care Med, New Haven, CT USA; Wellcome Trust Ctr Human Genet, Oxford, England; Case Western Reserve Univ, Cleveland, OH 44106 USA; Roswell Pk Canc Inst, Buffalo, NY 14263 USA; Univ Kentucky, Lexington, KY USA; Russian Acad Sci, Inst Cytol & Genet, Novosibirsk 630090, Russia; Univ Alabama Birmingham, Dept Biostat, Sect Stat Genet, Birmingham, AL 35294 USA; Columbia Genome Ctr, New York, NY USA; Univ Helsinki, Dept Med Genet, Natl Publ Hlth Inst, Biomedicum Helsinki,Dept Mol Med, FIN-00014 Helsinki, Finland; Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA; Univ Nebraska, Dept Anim Sci, Lincoln, NE USA; Acad Sci Czech Republ, Inst Physiol, Prague, Czech Republic; Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH USA; Univ Cincinnati, Coll Med, Cincinnati, OH USA; Vanderbilt Univ, Med Ctr, Div Nephrol, Nashville, TN USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; McKusick Nathans Inst Genet Med, Baltimore, MD USA; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON, Canada; Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA; Rosetta Inpharmat LLC Merck & Co, Res Genet, Seattle, WA USA; Inst Psychiat, SGDP Ctr, London, England; Univ Toronto, Ctr Study Pain, Pain Genet & Phenom Res Unit, Toronto, ON, Canada; Program Neurosci, Toronto, ON, Canada; Northwestern Univ, Ctr Funct Genom, Evanston, IL USA; Shriners Hosp Crippled Children, Res Ctr, Portland, OR USA; Univ Helsinki, Rolf Nevanlinna Inst, Dept Math & Stat, FIN-00014 Helsinki, Finland; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Mt Sinai Sch Med, Dept Cell & Gene Med, New York, NY USA; Univ Calif Davis, Dept Environm Toxicol, Davis, CA 95616 USA; Novartis Res Fdn, Genom Inst, San Diego, CA USA; Univ N Carolina, Dept Genet, Chapel Hill, NC USA; So Illinois Univ, Sch Med, Springfield, IL USA; KCL Inst Psychiat, Dept Neurosci, London, England; Univ Rochester, Med Ctr, Rochester, NY 14642 USA; Cornell Univ, Dept Biol Stat & Computat Biol, Ithaca, NY USA; Univ N Carolina, Sch Publ Hlth, Dept Biostat, Chapel Hill, NC USA	Jackson Laboratory; Vanderbilt University; University of Southern California; University of Texas System; UTMD Anderson Cancer Center; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Los Angeles; National Center for Genome Resources (NCGR); Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Boulder; University of Pennsylvania; Hannover Medical School; Johns Hopkins University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cornell University; University of Michigan System; University of Michigan; University of Tennessee System; University of Tennessee Health Science Center; Washington University (WUSTL); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Memphis; MRC Harwell; University of Massachusetts System; University of Massachusetts Worcester; Hebrew University of Jerusalem; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of California System; University of California Davis; Czech Academy of Sciences; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Emory University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of Texas System; University of Texas Southwestern Medical Center Dallas; New York University; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Groningen; Rutgers State University New Brunswick; Rutgers State University Medical Center; Stanford University; Max Planck Society; National Institutes of Health (NIH) - USA; University of Alabama System; University of Alabama Birmingham; CGIAR; International Livestock Research Institute (ILRI); Ruprecht Karls University Heidelberg; Medical College of Wisconsin; University of Groningen; Icahn School of Medicine at Mount Sinai; United States Department of Energy (DOE); Oak Ridge National Laboratory; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Wisconsin System; University of Wisconsin Madison; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Antwerp; RWTH Aachen University; RWTH Aachen University Hospital; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); McGill University; McGill University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Western Australia; Yale University; University of Oxford; Wellcome Centre for Human Genetics; Case Western Reserve University; Roswell Park Cancer Institute; University of Kentucky; Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS; University of Alabama System; University of Alabama Birmingham; Columbia University; Finland National Institute for Health & Welfare; University of Helsinki; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Nebraska System; University of Nebraska Lincoln; Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Vanderbilt University; Johns Hopkins University; University of Toronto; Harvard University; Beth Israel Deaconess Medical Center; Merck & Company; University of London; King's College London; University of Toronto; Northwestern University; University of Helsinki; Jefferson University; Icahn School of Medicine at Mount Sinai; University of California System; University of California Davis; Novartis; University of North Carolina; University of North Carolina Chapel Hill; Southern Illinois University System; Southern Illinois University; University of London; King's College London; University of Rochester; Cornell University; University of North Carolina; University of North Carolina Chapel Hill	Churchill, G (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.	garyc@jax.org	Roder, John/G-6468-2013; Mock, Beverly A/B-3110-2015; Chesler, Elissa/K-4641-2019; de Haan, Gerald/D-2081-2015; de Haan, Gerald/AAF-8963-2019; Morahan, Grant/T-7501-2019; Pravenec, Michal/B-1666-2012; Jansen, Ritsert C/C-1160-2013; Crusio, Wim/ABE-1287-2021; Forejt, Jiri/AAF-5276-2019; Crusio, Wim/ABD-5214-2021; Llamas, Bastien/AAK-1693-2021; Llamas, Bastien/Y-2781-2018; Nowakowski, Richard/C-3217-2016; Matthews, Douglas/F-6867-2012; Gershenfeld, Howard K/HGF-0536-2022; Palmer, Abraham/L-2158-2014; Kooy, Frank/F-5276-2014; Buckler, Edward/GPS-4932-2022; Spearow, Jimmy/AAL-2798-2020; Schalkwyk, Leonard C/A-2150-2010; Churchill, Gary/AAY-7496-2020; Kempermann, Gerd/F-5416-2010; Buckler, Edward/L-7651-2019; Forejt, Jiri/G-7719-2012; Burmeister, Margit/A-3157-2013; Crusio, Wim/A-7070-2008; Threadgill, David W/N-4425-2013; Valdar, William/AAE-4354-2019; Mogil, Jeffrey/AAA-9611-2019; Williams, Robert W./H-8789-2016; Deschepper, Christian/J-4783-2015	Mock, Beverly A/0000-0003-2479-4549; Chesler, Elissa/0000-0002-5642-5062; de Haan, Gerald/0000-0001-9706-0138; de Haan, Gerald/0000-0001-9706-0138; Pravenec, Michal/0000-0001-9197-5871; Jansen, Ritsert C/0000-0003-2977-9110; Forejt, Jiri/0000-0002-2793-3623; Crusio, Wim/0000-0001-6638-202X; Llamas, Bastien/0000-0002-5550-9176; Llamas, Bastien/0000-0002-5550-9176; Palmer, Abraham/0000-0003-3634-0747; Kooy, Frank/0000-0003-2024-0485; Schalkwyk, Leonard C/0000-0001-7030-5756; Churchill, Gary/0000-0001-9190-9284; Kempermann, Gerd/0000-0002-5304-4061; Buckler, Edward/0000-0002-3100-371X; Forejt, Jiri/0000-0002-2793-3623; Burmeister, Margit/0000-0002-1914-2434; Crusio, Wim/0000-0001-6638-202X; Threadgill, David W/0000-0003-3538-1635; Mogil, Jeffrey/0000-0003-1359-5720; Himmelbauer, Heinz/0000-0001-8897-2928; Gershenfeld, Howard/0000-0002-4107-1513; Marcucio, Ralph/0000-0002-0537-818X; Nowakowski, Richard/0000-0002-5006-3670; Farber, Charles/0000-0002-6748-4711; Sillanpaa, Mikko J./0000-0003-2808-2768; Rosen, Glenn/0000-0001-8281-5446; Page, Grier/0000-0003-2582-3786; Williams, Robert W./0000-0001-8924-4447; Cox, Roger/0000-0001-7170-5014; Deschepper, Christian/0000-0001-6234-4667; /0000-0001-7147-8237; Broman, Karl/0000-0002-4914-6671; Mott, Richard/0000-0002-1022-9330	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073760] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P60AA010760] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL073760] Funding Source: Medline; NIAAA NIH HHS [P60 AA010760] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Belknap JK, 1998, BEHAV GENET, V28, P29, DOI 10.1023/A:1021404714631; Carlborg O, 2004, NAT REV GENET, V5, P618, DOI 10.1038/nrg1407; Chesler EJ, 2003, NEUROINFORMATICS, V1, P343, DOI 10.1385/NI:1:4:343; CLARK AG, 1999, LIMITS KNOWLEDGE EVO; Gibson G, 2002, GENET RES, V80, P1, DOI 10.1017/S0016672302005839; Hartwell L, 2004, SCIENCE, V303, P774, DOI 10.1126/science.1094731; Jansen RC, 2003, NAT REV GENET, V4, P145, DOI 10.1038/nrg996; JANSEN RC, 1995, THEOR APPL GENET, V91, P33, DOI 10.1007/BF00220855; JIN C, IN PRESS GENETICS; Nadeau JH, 2003, GENOME RES, V13, P2082, DOI 10.1101/gr.1186603; Reifsnyder PC, 2000, GENOME RES, V10, P1568, DOI 10.1101/gr.147000; Shimomura K, 2001, GENOME RES, V11, P959, DOI 10.1101/gr.171601; SILLANPAA MJ, IN PRESS ANN HUM GEN; Threadgill DW, 2002, MAMM GENOME, V13, P175, DOI 10.1007/s00335-001-4001-Y; Williams SM, 2004, BIOESSAYS, V26, P170, DOI 10.1002/bies.10401; Zerhouni E, 2003, SCIENCE, V302, P63, DOI 10.1126/science.1091867	16	736	755	1	82	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2004	36	11					1133	1137		10.1038/ng1104-1133	http://dx.doi.org/10.1038/ng1104-1133			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	867HI	15514660	Bronze			2022-12-25	WOS:000224832800005
J	Noma, K; Sugiyama, T; Cam, H; Verdel, A; Zofall, M; Jia, ST; Moazed, D; Grewal, SIS				Noma, K; Sugiyama, T; Cam, H; Verdel, A; Zofall, M; Jia, ST; Moazed, D; Grewal, SIS			RITS acts in cis to promote RNA interference-mediated transcriptional and post-transcriptional silencing	NATURE GENETICS			English	Article							FISSION YEAST CENTROMERES; HISTONE H3 METHYLATION; EPIGENETIC CONTROL; HETEROCHROMATIN DOMAIN; LYSINE-9 METHYLATION; DROSOPHILA; DNA; PLANTS; RECOGNITION; PATHWAYS	RNA interference is a conserved mechanism by which double-stranded RNA is processed into short interfering RNAs (siRNAs) that can trigger both post-transcriptional and transcriptional gene silencing. In fission yeast, the RNA-induced initiation of transcriptional gene silencing (RITS) complex contains Dicer-generated siRNAs and is required for heterochromatic silencing. Here we show that BITS components, including Argonaute protein, bind to all known heterochromatic loci. At the mating-type region, BITS is recruited to the centromere-homologous repeat cenH in a Dicer-dependent manner, whereas the spreading of BITS across the entire 20-kb silenced domain, as well as its subsequent maintenance, requires heterochromatin machinery including Swi6 and occurs even in the absence of Dicer. Furthermore, our analyses suggest that RNA interference machinery operates in cis as a stable component of heterochromatic domains with BITS tethered to silenced loci by methylation of histone H3 at Lys9. This tethering promotes the processing of transcripts and generation of additional siRNAs for heterochromatin maintenance.	NCI, Mol Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard Medical School	Grewal, SIS (corresponding author), NCI, Mol Cell Biol Lab, NIH, Bethesda, MD 20892 USA.	grewals@mail.nih.gov	Verdel, André/M-5201-2013	VERDEL, Andre/0000-0001-6048-3794; Sugiyama, Tomoyasu/0000-0001-5704-6606	NATIONAL CANCER INSTITUTE [ZIABC010523, Z01BC010523] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aravin AA, 2003, DEV CELL, V5, P337, DOI 10.1016/S1534-5807(03)00228-4; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Grewal SIS, 1997, GENETICS, V146, P1221; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Hall Ira M., 2003, P205; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hsieh J, 2000, ANNU REV GENET, V34, P187, DOI 10.1146/annurev.genet.34.1.187; Hutvagner G, 2002, CURR OPIN GENET DEV, V12, P225, DOI 10.1016/S0959-437X(02)00290-3; Jia ST, 2004, SCIENCE, V304, P1971, DOI 10.1126/science.1099035; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Llave C, 2002, PLANT CELL, V14, P1605, DOI 10.1105/tpc.003210; Matzke M, 2001, SCIENCE, V293, P1080, DOI 10.1126/science.1063051; Mochizuki K, 2002, CELL, V110, P689, DOI 10.1016/S0092-8674(02)00909-1; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nakayama J, 2001, EMBO J, V20, P2857, DOI 10.1093/emboj/20.11.2857; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Pal-Bhadra M, 2004, SCIENCE, V303, P669, DOI 10.1126/science.1092653; Pal-Bhadra M, 2002, MOL CELL, V9, P315, DOI 10.1016/S1097-2765(02)00440-9; Partridge JF, 2002, CURR BIOL, V12, P1652, DOI 10.1016/S0960-9822(02)01177-6; Pham JW, 2004, CELL, V117, P83, DOI 10.1016/S0092-8674(04)00258-2; Provost P, 2002, P NATL ACAD SCI USA, V99, P16648, DOI 10.1073/pnas.212633199; Reinhart BJ, 2002, SCIENCE, V297, P1831, DOI 10.1126/science.1077183; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Schotta G, 2002, EMBO J, V21, P1121, DOI 10.1093/emboj/21.5.1121; Schramke V, 2003, SCIENCE, V301, P1069, DOI 10.1126/science.1086870; Selker EU, 2003, NATURE, V422, P893, DOI 10.1038/nature01564; STEINER NC, 1994, CELL, V79, P865, DOI 10.1016/0092-8674(94)90075-2; Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Xie ZX, 2004, PLOS BIOL, V2, P642, DOI 10.1371/journal.pbio.0020104; Zilberman D, 2003, SCIENCE, V299, P716, DOI 10.1126/science.1079695	35	305	319	0	8	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2004	36	11					1174	1180		10.1038/ng1452	http://dx.doi.org/10.1038/ng1452			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	867HI	15475954	Bronze			2022-12-25	WOS:000224832800020
J	Xu, WM; Liu, LZ; Charles, IG; Moncada, S				Xu, WM; Liu, LZ; Charles, IG; Moncada, S			Nitric oxide induces coupling of mitochondrial signalling with the endoplasmic reticulum stress response	NATURE CELL BIOLOGY			English	Article							UNFOLDED PROTEIN RESPONSE; ER STRESS; CELLS; ATF6; CALCIUM; INHIBITION; APOPTOSIS; CLEAVAGE; LOCALIZATION; THAPSIGARGIN	Nitric oxide ( NO) is a pleiotropic signalling molecule that binds to cytochrome c oxidase (complex IV) reversibly and in competition with oxygen(1-3). This action of NO has both physiological and pathophysiological consequences. Here we report that endogenously generated NO, which disrupts the respiratory chain, may cause changes in mitochondrial calcium flux. This induces cleavage of the endoplasmic reticulum ( ER) stress-regulated transcription factor p90 ATF6 into an active p50 form. Cleavage depends on a calcium-dependent serine protease through a regulated intramembrane proteolysis (RIP) process(4,5). p50 ATF6 then translocates to the nucleus to upregulate expression of the ER-resident molecular chaperone, glucose-regulated protein 78 (Grp78)(4). The increase in Grp78 provides significant cytoprotection(6) against toxic agents, including thapsigargin, a selective ER calcium-ATPase inhibitor(7). Cytoprotection is abolished after treatment with cyclosporin A (CsA), which disrupts mitochondrial calcium signalling(8), or with the calcium chelator BAPTA-AM(9). The NO-mediated ER stress response is diminished in rho(0) cells devoid of mitochondrial DNA(10), consistent with our evidence that NO-dependent mitochondrial disruption is coupled to the ER stress response.	UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England	University of London; University College London	Moncada, S (corresponding author), UCL, Wolfson Inst Biomed Res, Cruciform Bldg,Gower St, London WC1E 6BT, England.	s.moncada@ucl.ac.uk	Xu, Weiming/A-6274-2008	Xu, Weiming/0000-0002-7085-7814				Beltran B, 2002, P NATL ACAD SCI USA, V99, P8892, DOI 10.1073/pnas.092259799; Brown GC, 2001, BBA-BIOENERGETICS, V1504, P46, DOI 10.1016/S0005-2728(00)00238-3; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Chen LY, 2000, J CELL BIOCHEM, V78, P404, DOI 10.1002/1097-4644(20000901)78:3<404::AID-JCB6>3.0.CO;2-8; Chen X, 2002, J BIOL CHEM, V277, P13045, DOI 10.1074/jbc.M110636200; Cooper CE, 2002, TRENDS BIOCHEM SCI, V27, P33, DOI 10.1016/S0968-0004(01)02035-7; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; DRUMMOND IAS, 1987, J BIOL CHEM, V262, P12801; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gotoh T, 2002, J BIOL CHEM, V277, P12343, DOI 10.1074/jbc.M107988200; Horn TFW, 2002, FASEB J, V16, P1611, DOI 10.1096/fj.02-0126com; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Lenz O, 2001, P NATL ACAD SCI USA, V98, P12701, DOI 10.1073/pnas.221447598; Mateo J, 2003, BIOCHEM J, V376, P537, DOI 10.1042/BJ20031155; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; Nowicky AV, 1998, J PHYSIOL-LONDON, V507, P131, DOI 10.1111/j.1469-7793.1998.131bu.x; PACKER MA, 1994, FEBS LETT, V345, P237, DOI 10.1016/0014-5793(94)00461-7; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Schweizer M, 1996, BIOCHEMISTRY-US, V35, P4524, DOI 10.1021/bi952708+; Seidah NG, 1999, P NATL ACAD SCI USA, V96, P1321, DOI 10.1073/pnas.96.4.1321; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Toure BB, 2000, J BIOL CHEM, V275, P2349, DOI 10.1074/jbc.275.4.2349; Xu WM, 2001, FASEB J, V15, P213, DOI 10.1096/fj.01-0590fje; Xu WM, 2000, NAT CELL BIOL, V2, P339, DOI 10.1038/35014028; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2001, MOL CELL BIOL, V21, P1239, DOI 10.1128/MCB.21.4.1239-1248.2001	30	144	150	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2004	6	11					1129	U32		10.1038/ncb1188	http://dx.doi.org/10.1038/ncb1188			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	867BI	15502820				2022-12-25	WOS:000224816700019
J	Kehat, I; Khimovich, L; Caspi, O; Gepstein, A; Shofti, R; Arbel, G; Huber, I; Satin, J; Itskovitz-Eldor, J; Gepstein, L				Kehat, I; Khimovich, L; Caspi, O; Gepstein, A; Shofti, R; Arbel, G; Huber, I; Satin, J; Itskovitz-Eldor, J; Gepstein, L			Electromechanical integration of cardiomyocytes derived from human embryonic stem cells	NATURE BIOTECHNOLOGY			English	Article							SKELETAL MYOBLAST TRANSPLANTATION; INFARCTED MYOCARDIUM; HEART-FAILURE; BIOLOGICAL PACEMAKER; RAT CARDIOMYOCYTES; HUMAN BLASTOCYSTS; IN-VITRO; DIFFERENTIATION; REPAIR; TISSUE	Cell therapy is emerging as a promising strategy for myocardial repair. This approach is hampered, however, by the lack of sources for human cardiac tissue and by the absence of direct evidence for functional integration of donor cells into host tissues. Here we investigate whether cells derived from human embryonic stem (hES) cells can restore myocardial electromechanical properties. Cardiomyocyte cell grafts were generated from hES cells in vitro using the embryoid body differentiating system. This tissue formed structural and electromechanical connections with cultured rat cardiomyocytes. In vivo integration was shown in a large-animal model of slow heart rate. The transplanted hES cell-derived cardiomyocytes paced the hearts of swine with complete atrioventricular block, as assessed by detailed three-dimensional electrophysiological mapping and histopathological examination. These results demonstrate the potential of hES-cell cardiomyocytes to act as a rate-responsive biological pacemaker and for future myocardial regeneration strategies.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Physiol & Biophys, Sohnis Family Res Lab Regenerat Funct Myocardium, IL-31096 Haifa, Israel; Rambam Med Ctr, Dept Obstet & Gynecol, IL-31096 Haifa, Israel; Rambam Med Ctr, Dept Cardiol, IL-31096 Haifa, Israel; Rambam Med Ctr, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel; Univ Kentucky, Coll Med, Dept Physiol, Lexington, KY 40536 USA	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Rambam Health Care Campus; Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of Kentucky	Gepstein, L (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Physiol & Biophys, Sohnis Family Res Lab Regenerat Funct Myocardium, POB 9649, IL-31096 Haifa, Israel.	mdlior@tx.technion.ac.il	Gepstein, Lior/H-9458-2012	kehat, izhak/0000-0002-4388-1579				Alcolea S, 1999, CIRC RES, V84, P1365; Amit M, 2000, DEV BIOL, V227, P271, DOI 10.1006/dbio.2000.9912; BenHaim SA, 1996, NAT MED, V2, P1393, DOI 10.1038/nm1296-1393; Cohn JN, 1997, CIRCULATION, V95, P766; Edelberg JM, 1998, J CLIN INVEST, V101, P337, DOI 10.1172/JCI1330; Etzion S, 2001, J MOL CELL CARDIOL, V33, P1321, DOI 10.1006/jmcc.2000.1391; Feld Y, 2002, CIRCULATION, V105, P522, DOI 10.1161/hc0402.102661; Gepstein L, 2002, CIRC RES, V91, P866, DOI 10.1161/01.RES.0000041435.95082.84; Gepstein L, 1997, CIRCULATION, V95, P1611; Itskovitz-Eldor J, 2000, MOL MED, V6, P88, DOI 10.1007/BF03401776; Kehat I, 2002, CIRC RES, V91, P659, DOI 10.1161/01.RES.0000039084.30342.9B; Kehat I, 2001, J CLIN INVEST, V108, P407, DOI 10.1172/JCI12131; Klug MG, 1996, J CLIN INVEST, V98, P216, DOI 10.1172/JCI118769; Kusumoto FM, 1996, NEW ENGL J MED, V334, P89, DOI 10.1056/NEJM199601113340206; Leor J, 1996, CIRCULATION, V94, P332; Li RK, 1997, CIRCULATION, V96, P179; Menasche P, 2003, J AM COLL CARDIOL, V41, P1078, DOI 10.1016/S0735-1097(03)00092-5; Menasche P, 2001, LANCET, V357, P279, DOI 10.1016/S0140-6736(00)03617-5; Miake J, 2002, NATURE, V419, P132, DOI 10.1038/419132b; Muller-Ehmsen J, 2002, CIRCULATION, V105, P1720, DOI 10.1161/01.CIR.0000013782.76324.92; Mummery C, 2003, CIRCULATION, V107, P2733, DOI 10.1161/01.CIR.0000068356.38592.68; Murry CE, 1996, J CLIN INVEST, V98, P2512, DOI 10.1172/JCI119070; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Pasumarthi KBS, 2002, CIRC RES, V90, P1044, DOI 10.1161/01.RES.0000020201.44772.67; Potapova I, 2004, CIRC RES, V94, P952, DOI 10.1161/01.RES.0000123827.60210.72; Qu JH, 2003, CIRCULATION, V107, P1106, DOI 10.1161/01.CIR.0000059939.97249.2C; Reinecke H, 1999, CIRCULATION, V100, P193, DOI 10.1161/01.CIR.100.2.193; Reinecke H, 2000, J CELL BIOL, V149, P731, DOI 10.1083/jcb.149.3.731; Reinlib L, 2000, CIRCULATION, V101, pE182; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; Rubart M, 2003, CIRC RES, V92, P1217, DOI 10.1161/01.RES.0000075089.39335.8C; SATIN J, 2004, J PHYSL; Scorsin M, 1997, CIRCULATION, V96, P188; SOONPAA MH, 1994, SCIENCE, V264, P98, DOI 10.1126/science.8140423; Taylor DA, 1998, NAT MED, V4, P929, DOI 10.1038/nm0898-929; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442; Xu CH, 2002, CIRC RES, V91, P501, DOI 10.1161/01.RES.0000035254.80718.91	38	642	710	1	67	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2004	22	10					1282	1289		10.1038/nbt1014	http://dx.doi.org/10.1038/nbt1014			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	860EU	15448703				2022-12-25	WOS:000224326100030
J	Shechter, D; Costanzo, V; Gautier, J				Shechter, D; Costanzo, V; Gautier, J			ATR and ATM regulate the timing of DNA replication origin firing	NATURE CELL BIOLOGY			English	Article							XENOPUS EARLY EMBRYOS; LAEVIS EGG EXTRACTS; DAMAGE CHECKPOINT; S-CHECKPOINT; INITIATION; COMPLEX; KINASE; DISRUPTION; CDC45; RPA	Timing of DNA replication initiation is dependent on S-phase-promoting kinase (SPK) activity at discrete origins and the simultaneous function of many replicons(1,2). DNA damage prevents origin firing through the ATM- and ATR-dependent inhibition of Cdk2 and Cdc7 SPKs(3,4). Here, we establish that modulation of ATM- and ATR-signalling pathways controls origin firing in the absence of DNA damage. Inhibition of ATM and ATR with caffeine or specific neutralizing antibodies, or upregulation of Cdk2 or Cdc7, promoted rapid and synchronous origin firing; conversely, inhibition of Cdc25A slowed DNA replication. Cdk2 was in equilibrium between active and inactive states, and the concentration of replication protein A (RPA)-bound single-stranded DNA (ssDNA) correlated with Chk1 activation and inhibition of origin firing. Furthermore, ATM was transiently activated during ongoing replication. We propose that ATR and ATM regulate SPK activity through a feedback mechanism originating at active replicons. Our observations establish that ATM- and ATR-signalling pathways operate during an unperturbed cell cycle to regulate initiation and progression of DNA synthesis, and are therefore poised to halt replication in the presence of DNA damage.	Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Integrated Program Cellular Mol & Biophys Studies, New York, NY 10032 USA	Columbia University; Columbia University	Gautier, J (corresponding author), Columbia Univ Coll Phys & Surg, Dept Genet & Dev, Hammer Hlth Sci Ctr Room 1620,701 W 168th St, New York, NY 10032 USA.	jg130@columbia.edu	Shechter, David/B-4660-2008; Gautier, jean/A-2774-2008	Shechter, David/0000-0001-9388-6004; Costanzo, Vincenzo/0000-0002-2920-9508	NATIONAL CANCER INSTITUTE [R01CA092245] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA92245] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Blow JJ, 2001, J CELL BIOL, V152, P15, DOI 10.1083/jcb.152.1.15; Brown EJ, 2000, GENE DEV, V14, P397; Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398; Costanzo V, 2000, MOL CELL, V6, P649, DOI 10.1016/S1097-2765(00)00063-0; Costanzo V, 2004, PLOS BIOL, V2, P600, DOI 10.1371/journal.pbio.0020110; Costanzo V, 2001, MOL CELL, V8, P137, DOI 10.1016/S1097-2765(01)00294-5; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; GABRIELLI BG, 1992, J BIOL CHEM, V267, P1969; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Herrick J, 2000, J MOL BIOL, V300, P1133, DOI 10.1006/jmbi.2000.3930; Hyrien O, 2003, BIOESSAYS, V25, P116, DOI 10.1002/bies.10208; HYRIEN O, 1993, EMBO J, V12, P4511, DOI 10.1002/j.1460-2075.1993.tb06140.x; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Liu QH, 2000, GENE DEV, V14, P1448; Lucas I, 2000, J MOL BIOL, V296, P769, DOI 10.1006/jmbi.2000.3500; Marheineke K, 2001, J BIOL CHEM, V276, P17092, DOI 10.1074/jbc.M100271200; MARHEINEKE K, 2004, J BIOL CHEM; Miao H, 2003, J BIOL CHEM, V278, P4295, DOI 10.1074/jbc.M204264200; Mimura S, 2000, GENES CELLS, V5, P439, DOI 10.1046/j.1365-2443.2000.00340.x; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; PAINTER RB, 1981, MUTAT RES, V84, P183, DOI 10.1016/0027-5107(81)90061-0; Pu LX, 2002, J BIOL CHEM, V277, P46877, DOI 10.1074/jbc.M207902200; Robertson K, 1999, ONCOGENE, V18, P7070, DOI 10.1038/sj.onc.1203194; Shechter D, 2004, DNA REPAIR, V3, P901, DOI 10.1016/j.dnarep.2004.03.020; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; Vuillard L, 1998, EUR J BIOCHEM, V256, P128, DOI 10.1046/j.1432-1327.1998.2560128.x; Waiter J, 1997, SCIENCE, V275, P993, DOI 10.1126/science.275.5302.993; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	35	289	304	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2004	6	7					648	655		10.1038/ncb1145	http://dx.doi.org/10.1038/ncb1145			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	834TX	15220931				2022-12-25	WOS:000222434900020
J	Vogt, G; Chapgier, A; Yang, K; Chuzhanova, N; Feinberg, J; Fieschi, C; Boisson-Dupuis, S; Alcais, A; Filipe-Santos, O; Bustamante, J; de Beaucoudrey, L; Al-Mohsen, I; Al-Hajjar, S; Al-Ghonaium, A; Adimi, P; Mirsaeidi, M; Khalilzadeh, S; Rosenzweig, S; Martin, OD; Bauer, TR; Puck, JM; Ochs, HD; Furthner, D; Engelhorn, C; Mansouri, D; Holland, SM; Schreiber, RD; Abel, L; Cooper, DN; Soudais, C; Casanova, JL				Vogt, G; Chapgier, A; Yang, K; Chuzhanova, N; Feinberg, J; Fieschi, C; Boisson-Dupuis, S; Alcais, A; Filipe-Santos, O; Bustamante, J; de Beaucoudrey, L; Al-Mohsen, I; Al-Hajjar, S; Al-Ghonaium, A; Adimi, P; Mirsaeidi, M; Khalilzadeh, S; Rosenzweig, S; Martin, OD; Bauer, TR; Puck, JM; Ochs, HD; Furthner, D; Engelhorn, C; Mansouri, D; Holland, SM; Schreiber, RD; Abel, L; Cooper, DN; Soudais, C; Casanova, JL			Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations	NATURE GENETICS			English	Article							INTERFERON-GAMMA-RECEPTOR; BACILLE CALMETTE-GUERIN; EXTRA N-GLYCOSYLATION; FUNCTIONAL-CHARACTERIZATION; 1 DEFICIENCY; CD40 LIGAND; IFN-GAMMA; MYCOBACTERIAL; SUBSTITUTION; DYSFIBRINOGEN	Mutations involving gains of glycosylation have been considered rare, and the pathogenic role of the new carbohydrate chains has never been formally established. We identified three children with mendelian susceptibility to mycobacterial disease who were homozygous with respect to a missense mutation in IFNGR2 creating a new N- glycosylation site in the IFN gamma R2 chain. The resulting additional carbohydrate moiety was both necessary and sufficient to abolish the cellular response to IFN gamma. We then searched the Human Gene Mutation Database for potential gain- of- N- glycosylation missense mutations; of 10,047 mutations in 577 genes encoding proteins trafficked through the secretory pathway, we identified 142 candidate mutations ( similar to 1.4%) in 77 genes ( similar to 13.3%). Six mutant proteins bore new N- linked carbohydrate moieties. Thus, an unexpectedly high proportion of mutations that cause human genetic disease might lead to the creation of new N- glycosylation sites. Their pathogenic effects may be a direct consequence of the addition of N- linked carbohydrate.	Univ Paris 05, Necker Med Sch, INSERM, U550,Lab Human Genet Infect Dis, F-75015 Paris, France; Shanghai Med Univ 2, Ruijin Hosp, French Chinese Lab Genom & Life Sci, Shanghai, Peoples R China; Cardiff Univ, Biostat & Bioinformat Unit, Cardiff CF14 4XN, Wales; Cardiff Univ, Inst Med Genet, Cardiff CF14 4XN, Wales; Hop St Louis, Dept Immunopathol, F-75010 Paris, France; King Faisal Specialist Hosp & Res Ctr, Dept Pediat, Pediat Infect Dis Unit, Riyadh 11211, Saudi Arabia; King Faisal Specialist Hosp & Res Ctr, Dept Pediat, Immunol Unit, Riyadh 11211, Saudi Arabia; Shaheed Beheshti Univ Med Sci, Natl Res Inst TB & Lung Dis, Tehran 19556, Iran; NIH, Lab Clin Infect Dis, Bethesda, MD 20892 USA; Hosp Santa Creu & Sant Pau, Serv Immunol, Barcelona, Spain; NCI, NIH, Bethesda, MD 20892 USA; NHGRI, NIH, Bethesda, MD 20892 USA; Univ Washington, Dept Pediat, Seattle, WA 98109 USA; Klinikum Wels, Dept Pediat, A-4600 Wels, Austria; Hosp Sick Children, Dept Pediat, D-80337 Munich, Germany; Washington Univ, Dept Pathol & Immunol, St Louis, MO 63110 USA; Hop Necker Enfants Malad, Pediat Immunol & Hematol Unit, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Shanghai Jiao Tong University; Cardiff University; Cardiff University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; Shahid Beheshti University Medical Sciences; National Institutes of Health (NIH) - USA; Hospital of Santa Creu i Sant Pau; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Washington; University of Washington Seattle; Washington University (WUSTL); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Casanova, JL (corresponding author), Univ Paris 05, Necker Med Sch, INSERM, U550,Lab Human Genet Infect Dis, 156 Rue Vaugirard, F-75015 Paris, France.	casanova@necker.fr	Mirsaeidi, Mehdi/A-6448-2008; Schreiber, Robert D/A-1276-2013; Casanova, Jean-Laurent/I-3418-2017; Cooper, David N/H-4384-2011; Schreiber, Robert/Q-7550-2019; adimi-naghan, parisa/G-5849-2017; de la Calle-Martin, Oscar/Q-3353-2016; Mirsaeidi, Mehdi/D-8164-2011; Boisson-Dupuis, Stéphanie/I-2040-2017; Boisson-Dupuis, Stephanie/AAF-5066-2021; Alcais, Alexandre/J-5882-2017; adimi, Parisa/AAN-1103-2020; Abel, Laurent/H-8888-2017; Bustamante, Jacinta/H-7877-2017; mansouri, davood/G-6471-2017; Vogt, Guillaume/L-6046-2015; soudais, claire/F-9756-2016	Schreiber, Robert D/0000-0001-6311-0432; Cooper, David N/0000-0002-8943-8484; adimi-naghan, parisa/0000-0002-4201-2822; de la Calle-Martin, Oscar/0000-0001-9717-053X; Boisson-Dupuis, Stéphanie/0000-0002-7115-116X; Alcais, Alexandre/0000-0002-1012-2226; Abel, Laurent/0000-0001-7016-6493; Bustamante, Jacinta/0000-0002-3439-2482; mansouri, davood/0000-0002-0564-8282; Vogt, Guillaume/0000-0001-8192-1247; soudais, claire/0000-0002-4387-6649; Chuzhanova, Nadia/0000-0002-4655-3618; Casanova, Jean-Laurent/0000-0002-7782-4169; Chapgier, Ariane/0000-0002-1734-0744; khalilzadeh, soheila/0000-0002-3365-2449; Schreiber, Robert/0000-0003-1590-2341; Mirsaeidi, Mehdi/0000-0001-5298-8442	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000116] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000647, ZIAAI000647] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alder NN, 2004, J BIOL CHEM, V279, P22787, DOI 10.1074/jbc.R400002200; ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; Altare F, 1998, J CLIN INVEST, V102, P2035, DOI 10.1172/JCI4950; Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432; ALY AM, 1992, P NATL ACAD SCI USA, V89, P4933, DOI 10.1073/pnas.89.11.4933; Asano N, 2003, GLYCOBIOLOGY, V13, p93R, DOI 10.1093/glycob/cwg090; BACK AL, 1993, BIOCHEM BIOPH RES CO, V193, P912, DOI 10.1006/bbrc.1993.1712; Bajorath J, 1996, PROTEIN SCI, V5, P531; Becchis M, 1999, BREAST CANCER RES TR, V54, P101, DOI 10.1023/A:1006100929670; Casanova JL, 2004, NAT REV IMMUNOL, V4, P55, DOI 10.1038/nri1264; Casanova JL, 2002, ANNU REV IMMUNOL, V20, P581, DOI 10.1146/annurev.immunol.20.081501.125851; Clementi R, 2001, J MED GENET, V38, P643, DOI 10.1136/jmg.38.9.643; de Jong R, 1998, SCIENCE, V280, P1435; de la Calle-Martin O, 2001, J CLIN INVEST, V108, P117, DOI 10.1172/JCI10993; Doffinger R, 2000, J INFECT DIS, V181, P379, DOI 10.1086/315197; Dorman SE, 2004, LANCET, V364, P2113, DOI 10.1016/S0140-6736(04)17552-1; Dorman SE, 1998, J CLIN INVEST, V101, P2364, DOI 10.1172/JCI2901; Dupuis S, 2003, NAT GENET, V33, P388, DOI 10.1038/ng1097; Dupuis S, 2001, SCIENCE, V293, P300, DOI 10.1126/science.1061154; Egan ME, 2004, SCIENCE, V304, P600, DOI 10.1126/science.1093941; Feinberg J, 2004, EUR J IMMUNOL, V34, P3276, DOI 10.1002/eji.200425221; Fieschi C, 2004, BLOOD, V104, P2095, DOI 10.1182/blood-2004-02-0584; Fitches AC, 2001, THROMB HAEMOSTASIS, V86, P1023; Hamano A, 2004, BLOOD, V103, P3045, DOI 10.1182/blood-2003-07-2569; Hammerle MM, 2000, GLYCOCONJUGATE J, V17, P807, DOI 10.1023/A:1010992827511; Jouanguy E, 2000, J CLIN INVEST, V105, P1429, DOI 10.1172/JCI9166; Jouanguy E, 1997, J CLIN INVEST, V100, P2658, DOI 10.1172/JCI119810; Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604; Jouanguy E, 1999, NAT GENET, V21, P370, DOI 10.1038/7701; Kall L, 2004, J MOL BIOL, V338, P1027, DOI 10.1016/j.jmb.2004.03.016; KAUDEWITZ H, 1986, FIBRINOGEN FIBRIN FO, V4, P91; Lonnqvist L, 1996, GENOMICS, V36, P468, DOI 10.1006/geno.1996.0492; Lowe JB, 2003, ANNU REV BIOCHEM, V72, P643, DOI 10.1146/annurev.biochem.72.121801.161809; Lu Y, 1998, J BIOL CHEM, V273, P568, DOI 10.1074/jbc.273.1.568; MAEKAWA H, 1991, J BIOL CHEM, V266, P11575; MAEKAWA H, 1992, J CLIN INVEST, V90, P67, DOI 10.1172/JCI115857; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Manna PR, 2002, HUM MOL GENET, V11, P301, DOI 10.1093/hmg/11.3.301; Molday Robert S, 2004, Novartis Found Symp, V255, P95; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; PARAD RB, 1990, P NATL ACAD SCI USA, V87, P6786, DOI 10.1073/pnas.87.17.6786; Pariyarath R, 1996, FEBS LETT, V397, P79, DOI 10.1016/S0014-5793(96)01134-9; Puck JM, 1997, BLOOD, V89, P1968; Ridgway HJ, 1997, BRIT J HAEMATOL, V99, P562; Rosenzweig SD, 2004, J IMMUNOL, V173, P4000, DOI 10.4049/jimmunol.173.6.4000; Steen M, 2004, BLOOD, V103, P3381, DOI 10.1182/blood-2003-06-2092; Stenson PD, 2003, HUM MUTAT, V21, P577, DOI 10.1002/humu.10212; Sugo T, 1999, BLOOD, V94, P3806, DOI 10.1182/blood.V94.11.3806.423a17_3806_3813; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; YAMAZUMI K, 1989, J CLIN INVEST, V83, P1590, DOI 10.1172/JCI114056	50	162	167	1	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2005	37	7					692	700		10.1038/ng1581	http://dx.doi.org/10.1038/ng1581			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	941EA	15924140				2022-12-25	WOS:000230196400015
J	Desrosiers, MP; Kielczewska, A; Loredo-Osti, JC; Adam, SG; Makrigiannis, AP; Lemieux, S; Pham, T; Lodoen, MB; Morgan, K; Lanier, LL; Vidal, SM				Desrosiers, MP; Kielczewska, A; Loredo-Osti, JC; Adam, SG; Makrigiannis, AP; Lemieux, S; Pham, T; Lodoen, MB; Morgan, K; Lanier, LL; Vidal, SM			Epistasis between mouse Klra and major histocompatibility complex class I loci is associated with a new mechanism of natural killer cell-mediated innate resistance to cytomegalovirus infection	NATURE GENETICS			English	Article							GENE-COMPLEX; VIRAL-INFECTIONS; BAC CONTIG; RECEPTOR; LY49; MAP; RECOGNITION; MICE; HLA; LIGAND	Experimental infection with mouse cytomegalovirus ( MCMV) has been used to elucidate the intricate host-pathogen mechanisms that determine innate resistance to infection. Linkage analyses in F-2 progeny from MCMV-resistant MA/My (H2(k)) and MCMV-susceptible BALB/c (H2(d)) and BALB. K ( H2k) mouse strains indicated that only the combination of alleles encoded by a gene in the Klra ( also called Ly49) cluster on chromosome 6, and one in the major histocompatibility complex (H2) on chromosome 17, is associated with virus resistance. We found that natural killer cell - activating receptor Ly49P specifically recognized MCMV-infected cells, dependent on the presence of the H2k haplotype. This binding was blocked using antibodies to H-2D(k) but not antibodies to H-2K(k). These results are suggestive of a new natural killer cell mechanism implicated in MCMV resistance, which depends on the functional interaction of the Ly49P receptor and the major histocompatibility complex class I molecule H-2D(k) on MCMV-infected cells.	McGill Univ, Dept Human Genet, Montreal, PQ H3A 1B1, Canada; McGill Univ, McGill Ctr Study Host Resistance, Montreal, PQ H3G 1A4, Canada; Inst Rech Clin Montreal, Montreal, PQ H2W 1R7, Canada; Univ Quebec, INRS, Laval, PQ H7V 1B7, Canada; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Biomed Sci Grad Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; McGill Univ, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada	McGill University; McGill University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Quebec; Institut national de la recherche scientifique (INRS); University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; McGill University; McGill University	Vidal, SM (corresponding author), McGill Univ, Dept Human Genet, Montreal, PQ H3A 1B1, Canada.	silvia.vidal@mcgill.ca	Lanier, Lewis L/E-2139-2014	Lanier, Lewis L/0000-0003-1308-3952; Makrigiannis, Andrew/0000-0002-7258-9411; Pham, Trung/0000-0003-2724-2547	NCI NIH HHS [R01 CA089294] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089294] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arase H, 2004, REV MED VIROL, V14, P83, DOI 10.1002/rmv.422; Arase H, 2002, SCIENCE, V296, P1323, DOI 10.1126/science.1070884; Belkin D, 2003, J IMMUNOL, V171, P3056, DOI 10.4049/jimmunol.171.6.3056; Biron CA, 1999, ANNU REV IMMUNOL, V17, P189, DOI 10.1146/annurev.immunol.17.1.189; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; Britt W. J., 1996, FIELDS VIROLOGY, P2493; Brown MG, 1997, IMMUNOL REV, V155, P53, DOI 10.1111/j.1600-065X.1997.tb00939.x; Brown MG, 1997, GENOMICS, V42, P16, DOI 10.1006/geno.1997.4721; CHALMER JE, 1977, J GEN VIROL, V37, P107, DOI 10.1099/0022-1317-37-1-107; Dam J, 2003, NAT IMMUNOL, V4, P1213, DOI 10.1038/ni1006; Depatie C, 1997, GENOMICS, V39, P154, DOI 10.1006/geno.1996.4498; Depatie C, 1999, INT IMMUNOL, V11, P1541, DOI 10.1093/intimm/11.9.1541; Depatie C, 2000, GENOMICS, V66, P161, DOI 10.1006/geno.2000.6186; Franksson L, 1999, EUR J IMMUNOL, V29, P2748, DOI 10.1002/(SICI)1521-4141(199909)29:09<2748::AID-IMMU2748>3.0.CO;2-C; GRUNDY JE, 1981, INFECT IMMUN, V32, P277, DOI 10.1128/IAI.32.1.277-286.1981; Khakoo SI, 2004, SCIENCE, V305, P872, DOI 10.1126/science.1097670; Lee SH, 2001, IMMUNOGENETICS, V53, P501, DOI 10.1007/s002510100359; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; Makrigiannis AP, 1999, J IMMUNOL, V163, P4931; Makrigiannis AP, 2002, GENOMICS, V79, P437, DOI 10.1006/geno.2002.6724; Makrigiannis AP, 2001, J IMMUNOL, V166, P5034, DOI 10.4049/jimmunol.166.8.5034; Manly KF, 1999, MAMM GENOME, V10, P327, DOI 10.1007/s003359900997; Martin MP, 2002, NAT GENET, V31, P429, DOI 10.1038/ng934; Nakamura MC, 2000, J EXP MED, V192, P447, DOI 10.1084/jem.192.3.447; Nakamura MC, 2001, IMMUNOL REV, V181, P138, DOI 10.1034/j.1600-065X.2001.1810111.x; Peng SL, 1996, BIOTECHNIQUES, V21, P362; Peruzzi M, 1996, J EXP MED, V184, P1585, DOI 10.1084/jem.184.4.1585; Pierce CA, 2004, EDUC PSYCHOL MEAS, V64, P916, DOI 10.1177/0013164404264848; Radaev S, 2003, ANNU REV BIOPH BIOM, V32, P93, DOI 10.1146/annurev.biophys.32.110601.142347; Reusser PE, 2002, SWISS MED WKLY, V132, P374; Scalzo AA, 2000, METH MOL B, V121, P163; SCALZO AA, 1992, J IMMUNOL, V149, P581; SCALZO AA, 1990, J EXP MED, V171, P1469, DOI 10.1084/jem.171.5.1469; SCALZO AA, 1995, GENOMICS, V27, P435, DOI 10.1006/geno.1995.1074; Silver ET, 2000, J IMMUNOL, V165, P1771, DOI 10.4049/jimmunol.165.4.1771; Silver ET, 2001, J IMMUNOL, V166, P2333, DOI 10.4049/jimmunol.166.4.2333; Smith HRC, 2002, P NATL ACAD SCI USA, V99, P8826, DOI 10.1073/pnas.092258599; Soderberg-Naucler C, 2001, TRANSPLANTATION, V71, pSS24; Trincado DE, 2001, J PAEDIATR CHILD H, V37, P187, DOI 10.1046/j.1440-1754.2001.00645.x; Trowsdale J, 2001, IMMUNOL REV, V181, P20, DOI 10.1034/j.1600-065X.2001.1810102.x; Truett GE, 2000, BIOTECHNIQUES, V29, P52, DOI 10.2144/00291bm09; Yokoyama WM, 2003, NAT REV IMMUNOL, V3, P304, DOI 10.1038/nri1055	42	125	127	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2005	37	6					593	599		10.1038/ng1564	http://dx.doi.org/10.1038/ng1564			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	931OT	15895081	Green Accepted			2022-12-25	WOS:000229495300012
J	Kopelman, NM; Lancet, D; Yanai, I				Kopelman, NM; Lancet, D; Yanai, I			Alternative splicing and gene duplication are inversely correlated evolutionary mechanisms	NATURE GENETICS			English	Article							EXON DUPLICATION; COMPLEMENTARY; EXPRESSION; ORIGIN	Gene duplication and alternative splicing are distinct evolutionary mechanisms that provide the raw material for new biological functions. We explored their relationships in human and mouse and found an inverse correlation between the size of a gene's family and its use of alternatively spliced isoforms. A cross-organism analysis suggests that selection for genome-wide genic proliferation might be interchangeably met by either evolutionary mechanism.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Yanai, I (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	yanai@mcb.harvard.edu		Yanai, Itai/0000-0002-8438-2741				Ast G, 2004, NAT REV GENET, V5, P773, DOI 10.1038/nrg1451; Brett D, 2002, NAT GENET, V30, P29, DOI 10.1038/ng803; Force A, 1999, GENETICS, V151, P1531; Hedges SB, 2002, NAT REV GENET, V3, P838, DOI 10.1038/nrg929; HUGHES AL, 1994, P ROY SOC B-BIOL SCI, V256, P119, DOI 10.1098/rspb.1994.0058; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Kondrashov FA, 2001, HUM MOL GENET, V10, P2661, DOI 10.1093/hmg/10.23.2661; Letunic I, 2002, HUM MOL GENET, V11, P1561, DOI 10.1093/hmg/11.13.1561; Lister JA, 2001, DEV BIOL, V237, P333, DOI 10.1006/dbio.2001.0379; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; Makova KD, 2003, GENOME RES, V13, P1638, DOI 10.1101/gr.1133803; Modrek B, 2003, NAT GENET, V34, P177, DOI 10.1038/ng1159; Ohno S., 1970, EVOLUTION GENE DUPLI; Remm M, 2001, J MOL BIOL, V314, P1041, DOI 10.1006/jmbi.2000.5197; Thanaraj TA, 2004, NUCLEIC ACIDS RES, V32, pD64, DOI 10.1093/nar/gkh030	15	124	126	0	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2005	37	6					588	589		10.1038/ng1575	http://dx.doi.org/10.1038/ng1575			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	931OT	15895079				2022-12-25	WOS:000229495300010
J	MacKeigan, JP; Murphy, LO; Blenis, J				MacKeigan, JP; Murphy, LO; Blenis, J			Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance	NATURE CELL BIOLOGY			English	Article							DRUG-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR PTEN; GROWTH-FACTOR-BETA; HUMAN GENOME; CANCER; MUTATIONS; SURVIVAL; PATHWAY; GENE; CHEMOTHERAPY	Evasion from apoptosis is a hallmark of cancer, and recent success using targeted therapeutics underscores the importance of identifying anti-apoptotic survival pathways. Here we utilize RNA interference (RNAi) to systematically screen the kinase and phosphatase component of the human genome. In addition to known kinases, we identified several new survival kinases. Interestingly, numerous phosphatases and associated regulatory subunits contribute to cell survival, revealing a previously unrecognized general role for phosphatases as negative regulators of apoptosis. We also identified a subset of phosphatases with tumour-suppressor-like activity. Finally, RNAi targeting of specific protein kinases sensitizes resistant cells to chemotherapeutic agents. The development of inhibitors that target these kinases or phosphatases may lead to new anti-cancer strategies.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Blenis, J (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	john_blenis@hms.harvard.edu		MacKeigan, Jeffrey/0000-0002-0198-5679	NATIONAL CANCER INSTITUTE [R01CA046595] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA46595] Funding Source: Medline; NIGMS NIH HHS [GM51405] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870; Huang Shile, 2002, Curr Opin Investig Drugs, V3, P295; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; MacKeigan JP, 2003, CANCER RES, V63, P6928; MacKeigan JP, 2002, CLIN CANCER RES, V8, P2091; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; Makin G, 2001, BREAST CANCER RES, V3, P150, DOI 10.1186/bcr289; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Mohi MG, 2005, CANCER CELL, V7, P179, DOI 10.1016/j.ccr.2005.01.010; Muraoka RS, 2003, MOL CELL BIOL, V23, P8691, DOI 10.1128/MCB.23.23.8691-8703.2003; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; Narayan G, 2003, ONCOGENE, V22, P3489, DOI 10.1038/sj.onc.1206432; PASLEAU F, 1993, ONCOGENE, V8, P849; Pietras K, 2002, CANCER RES, V62, P5476; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038/sj.onc.1206954; Seton-Rogers SE, 2004, P NATL ACAD SCI USA, V101, P1257, DOI 10.1073/pnas.0308090100; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Tassi E, 1999, J BIOL CHEM, V274, P33287, DOI 10.1074/jbc.274.47.33287; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; VANMAANEN JMS, 1988, J NATL CANCER I, V80, P1526, DOI 10.1093/jnci/80.19.1526; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Wishart MJ, 1998, TRENDS BIOCHEM SCI, V23, P301, DOI 10.1016/S0968-0004(98)01241-9; WISHART MJ, 1995, J BIOL CHEM, V270, P26782, DOI 10.1074/jbc.270.45.26782; Yang BF, 2003, J BIOL CHEM, V278, P7043, DOI 10.1074/jbc.M211278200	43	448	482	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2005	7	6					591	U19		10.1038/ncb1258	http://dx.doi.org/10.1038/ncb1258			14	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	932OD	15864305				2022-12-25	WOS:000229562100013
J	Munoz-Elias, EJ; McKinney, JD				Munoz-Elias, EJ; McKinney, JD			Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence	NATURE MEDICINE			English	Article							ESCHERICHIA-COLI; CORYNEBACTERIUM-GLUTAMICUM; GLYOXYLATE CYCLE; PYRUVATE-KINASE; GENE-EXPRESSION; PATHOGENICITY; MACROPHAGES; PERSISTENCE; BOVIS; MICE	Genes involved in fatty acid catabolism have undergone extensive duplication in the genus Mycobacterium, which includes the etiologic agents of leprosy and tuberculosis. Here, we show that prokaryotic- and eukaryotic-like isoforms of the glyoxylate cycle enzyme isocitrate lyase (ICL) are jointly required for fatty acid catabolism and virulence in Mycobacterium tuberculosis. Although deletion of icl1 or icl2, the genes that encode ICL1 and ICL2, respectively, had little effect on bacterial growth in macrophages and mice, deletion of both genes resulted in complete impairment of intracellular replication and rapid elimination from the lungs. The feasibility of targeting ICL1 and ICL2 for chemical inhibition was shown using a dual-specific ICL inhibitor, which blocked growth of M. tuberculosis on fatty acids and in macrophages. The absence of ICL orthologs in mammals should facilitate the development of glyoxylate cycle inhibitors as new drugs for the treatment of tuberculosis.	Rockefeller Univ, Lab Infect Biol, New York, NY 10021 USA	Rockefeller University	McKinney, JD (corresponding author), Rockefeller Univ, Lab Infect Biol, 1230 York Ave, New York, NY 10021 USA.	mckinney@rockefeller.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI046392] Funding Source: NIH RePORTER; NIAID NIH HHS [P01 AI046392-050001, AI 46392] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bentrup KHZ, 1999, J BACTERIOL, V181, P7161; Blokpoel MCJ, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni023; Boshoff HIM, 2005, NAT REV MICROBIOL, V3, P70, DOI 10.1038/nrmicro1065; Britton KL, 2000, STRUCTURE, V8, P349, DOI 10.1016/S0969-2126(00)00117-9; Chang DE, 2004, P NATL ACAD SCI USA, V101, P7427, DOI 10.1073/pnas.0307888101; Charpentier E, 2000, MICROBES INFECT, V2, P1855, DOI 10.1016/S1286-4579(00)01345-9; Chico-Calero I, 2002, P NATL ACAD SCI USA, V99, P431, DOI 10.1073/pnas.012363899; Claes WA, 2002, J BACTERIOL, V184, P2728, DOI 10.1128/JB.184.10.2728-2739.2002; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Collins DM, 2002, MICROBIOL-SGM, V148, P3019, DOI 10.1099/00221287-148-10-3019; Daniel J, 2004, J BACTERIOL, V186, P5017, DOI 10.1128/jb.186.15.5017-5030.2004; Ehrt S, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni013; El-Sadr WM, 2001, CLIN INFECT DIS, V32, P623, DOI 10.1086/318706; Eriksson S, 2003, MOL MICROBIOL, V47, P103, DOI 10.1046/j.1365-2958.2003.03313.x; Fischer E, 2003, J BIOL CHEM, V278, P46446, DOI 10.1074/jbc.M307968200; Fleischmann RD, 2002, J BACTERIOL, V184, P5479, DOI 10.1128/JB.184.19.5479-5490.2002; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Gomez JE, 2004, TUBERCULOSIS, V84, P29, DOI 10.1016/j.tube.2003.08.003; Idnurm A, 2002, EUKARYOT CELL, V1, P719, DOI 10.1128/EC.1.5.719-724.2002; Keating LA, 2005, MOL MICROBIOL, V56, P163, DOI 10.1111/j.1365-2958.2005.04524.x; KONDO E, 1976, JPN J MED SCI BIOL, V29, P109, DOI 10.7883/yoken1952.29.109; KORNBERG HL, 1957, NATURE, V179, P988, DOI 10.1038/179988a0; Liu KY, 2003, MICROBIOL-SGM, V149, P1829, DOI 10.1099/mic.0.26234-0; Lorenz MC, 2001, NATURE, V412, P83, DOI 10.1038/35083594; Luttik MAH, 2000, J BACTERIOL, V182, P7007, DOI 10.1128/JB.182.24.7007-7013.2000; McDERMOTT WALSH, 1958, YALE JOUR BIOL AND MED, V30, P257; McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074; Nishino H, 1997, NEUROSCI RES, V27, P343, DOI 10.1016/S0168-0102(97)01170-X; Pavelka MS, 1999, J BACTERIOL, V181, P4780, DOI 10.1128/JB.181.16.4780-4789.1999; PERTIERRA AG, 1977, J BACTERIOL, V129, P1208, DOI 10.1128/JB.129.3.1208-1214.1977; Peters-Wendisch PG, 1998, MICROBIOL-UK, V144, P915, DOI 10.1099/00221287-144-4-915; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; RANES MG, 1990, J BACTERIOL, V172, P2793, DOI 10.1128/jb.172.5.2793-2797.1990; Raynaud C, 2002, MOL MICROBIOL, V45, P203, DOI 10.1046/j.1365-2958.2002.03009.x; Russell DG, 2001, NAT REV MOL CELL BIO, V2, P569, DOI 10.1038/35085034; Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100; Schnappinger D, 2003, J EXP MED, V198, P693, DOI 10.1084/jem.20030846; SEGAL W, 1956, J BACTERIOL, V72, P132, DOI 10.1128/JB.72.2.132-141.1956; Sharma V, 2000, NAT STRUCT BIOL, V7, P663, DOI 10.1038/77964; Smith H, 2000, PHILOS T R SOC B, V355, P551, DOI 10.1098/rstb.2000.0597; Solomon PS, 2004, MOL MICROBIOL, V53, P1065, DOI 10.1111/j.1365-2958.2004.04178.x; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; TABUCHI T, 1975, AGR BIOL CHEM TOKYO, V39, P2035, DOI 10.1080/00021369.1975.10861896; Timm J, 2003, P NATL ACAD SCI USA, V100, P14321, DOI 10.1073/pnas.2436197100; VANNI P, 1970, COMP BIOCH PHYSL, V958, P431; Vereecke D, 2002, J BACTERIOL, V184, P1112, DOI 10.1128/jb.184.4.1112-1120.2002; Wang ZY, 2003, MOL MICROBIOL, V47, P1601, DOI 10.1046/j.1365-2958.2003.03412.x; Wendisch VF, 2000, J BACTERIOL, V182, P3088, DOI 10.1128/JB.182.11.3088-3096.2000	48	549	575	2	57	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2005	11	6					638	644		10.1038/nm1252	http://dx.doi.org/10.1038/nm1252			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	932YD	15895072	Green Accepted			2022-12-25	WOS:000229589800030
J	Papoulas, O; Hays, TS; Sisson, JC				Papoulas, O; Hays, TS; Sisson, JC			The golgin Lava lamp mediates dynein-based Golgi movements during Drosophila cellularization	NATURE CELL BIOLOGY			English	Article							CYTOPLASMIC DYNEIN; OOCYTE DIFFERENTIATION; DYNACTIN COMPLEX; MOTOR; PROTEIN; TRANSPORT; MICROTUBULES; BINDING; EMBRYOS; PHOSPHORYLATION	Drosophila melanogaster cellularization is a dramatic form of cytokinesis in which a membrane furrow simultaneously encapsulates thousands of cortical nuclei of the syncytial embryo to generate a polarized cell layer. Formation of this cleavage furrow depends on Golgi-based secretion and microtubules(1-3). During cellularization, specific Golgi move along microtubules, first to sites of furrow formation and later to accumulate within the apical cytoplasm of the newly forming cells(3). Here we show that Golgi movements and furrow formation depend on cytoplasmic dynein. Furthermore, we demonstrate that Lava lamp (Lva), a golgin protein that is required for cellularization, specifically associates with dynein, dynactin, cytoplasmic linker protein-190 (CLIP-190) and Golgi spectrin, and is required for the dynein-dependent targeting of the secretory machinery. The Lva domains that bind these microtubule-dependent motility factors inhibit Golgi movement and cellularization in a live embryo injection assay. Our results provide new evidence that golgins promote dynein-based motility of Golgi membranes.	Univ Texas, Sect MCD Biol, Austin, TX 78712 USA; Univ Texas, Inst Cellular & Mol Biol, Austin, TX 78712 USA; Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Minnesota System; University of Minnesota Twin Cities	Sisson, JC (corresponding author), Univ Texas, Sect MCD Biol, Austin, TX 78712 USA.	sisson@icmb.utexas.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067013, R01GM053695] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM067013, R01 GM067013, GM053695] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akhmanova A, 2005, CURR OPIN CELL BIOL, V17, P47, DOI 10.1016/j.ceb.2004.11.001; Burkhardt JK, 1998, BBA-MOL CELL RES, V1404, P113, DOI 10.1016/S0167-4889(98)00052-4; BYERS TJ, 1987, J CELL BIOL, V105, P2103, DOI 10.1083/jcb.105.5.2103; Fan SS, 1997, DEVELOPMENT, V124, P1497; FIELD CM, 1995, J CELL BIOL, V131, P165, DOI 10.1083/jcb.131.1.165; Foe Victoria E., 1993, P149; FULLILOVE SL, 1971, DEV BIOL, V26, P560, DOI 10.1016/0012-1606(71)90141-2; Holleran EA, 2001, J BIOL CHEM, V276, P36598, DOI 10.1074/jbc.M104838200; Hoogenraad CC, 2001, EMBO J, V20, P4041, DOI 10.1093/emboj/20.15.4041; Hoogenraad CC, 2003, EMBO J, V22, P6004, DOI 10.1093/emboj/cdg592; King SJ, 2000, NAT CELL BIOL, V2, P20, DOI 10.1038/71338; Kumar S, 2000, J BIOL CHEM, V275, P31798, DOI 10.1074/jbc.M000449200; Lansbergen G, 2004, J CELL BIOL, V166, P1003, DOI 10.1083/jcb.200402082; Lantz VA, 1998, J CELL BIOL, V140, P897, DOI 10.1083/jcb.140.4.897; Lecuit T, 2000, J CELL BIOL, V150, P849, DOI 10.1083/jcb.150.4.849; Matanis T, 2002, NAT CELL BIOL, V4, P986, DOI 10.1038/ncb891; McGrail M, 1997, DEVELOPMENT, V124, P2409; Mimori-Kiyosue Y, 2003, J BIOCHEM, V134, P321, DOI 10.1093/jb/mvg148; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; Robinson JT, 1999, J CELL BIOL, V146, P597, DOI 10.1083/jcb.146.3.597; Royou A, 2004, MOL BIOL CELL, V15, P838, DOI 10.1091/mbc.E03-06-0440; Sharp DJ, 2000, MOL BIOL CELL, V11, P241, DOI 10.1091/mbc.11.1.241; Short B, 2002, CURR BIOL, V12, P1792, DOI 10.1016/S0960-9822(02)01221-6; Sisson JC, 2000, J CELL BIOL, V151, P905, DOI 10.1083/jcb.151.4.905; SUTER B, 1991, CELL, V67, P917, DOI 10.1016/0092-8674(91)90365-6; TURNER FR, 1976, DEV BIOL, V50, P95, DOI 10.1016/0012-1606(76)90070-1; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; Vallee RB, 2004, J NEUROBIOL, V58, P189, DOI 10.1002/neu.10314; WatermanStorer CM, 1996, J BIOL CHEM, V271, P1153, DOI 10.1074/jbc.271.2.1153	29	80	82	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2005	7	6					612	U23		10.1038/ncb1264	http://dx.doi.org/10.1038/ncb1264			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	932OD	15908943				2022-12-25	WOS:000229562100015
J	Fang, JM; Qian, JJ; Yi, SL; Harding, TC; Tu, GH; VanRoey, M; Jooss, K				Fang, JM; Qian, JJ; Yi, SL; Harding, TC; Tu, GH; VanRoey, M; Jooss, K			Stable antibody expression at therapeutic levels using the 2A peptide	NATURE BIOTECHNOLOGY			English	Article							RECOMBINANT ADENOASSOCIATED VIRUS; HUMAN MONOCLONAL-ANTIBODIES; ENDOTHELIAL GROWTH-FACTOR; NON-HODGKINS-LYMPHOMA; PHASE-I TRIAL; GENE-TRANSFER; VECTOR; CLEAVAGE; DISEASE; POLYPROTEIN	Therapeutic monoclonal antibodies (mAbs) are currently being developed for the treatment of cancer and other diseases. Despite clinical success, widespread application of mAb therapies may be limited by manufacturing capabilities. In this paper, we describe a mAb delivery system that allows continuous production of a full-length antibody at high-concentrations in vivo after gene transfer. The mAb is expressed from a single open reading frame by linking the heavy and light chains with a 2A self-processing peptide derived from the foot-and-mouth disease virus. Using this expression system, we generated a recombinant adeno-associated virus vector encoding the VEGFR2-neutralizing mAb DC101 (rAAV8-DC101). A single dose of rAAV8-DC101 resulted in long-term expression of > 1,000 mu g/ml of DC101 in mice, demonstrating significant anti-tumor efficacy. This report describes the first feasible gene therapy approach for stable delivery of mAbs at therapeutic levels, which may serve as an attractive alternative to direct injection of mAbs.	Cell Genesys Inc, Dept Preclin Oncol & Immunol, San Francisco, CA 94080 USA	Cell Genesys Inc	Fang, JM (corresponding author), Cell Genesys Inc, Dept Preclin Oncol & Immunol, 500 Forbes Blvd, San Francisco, CA 94080 USA.	jianminf@cellgenesys.com						Armbruster C, 2002, AIDS, V16, P227, DOI 10.1097/00002030-200201250-00012; Bakker JM, 2004, MOL THER, V10, P411, DOI 10.1016/j.ymthe.2004.06.865; Davis TA, 2000, J CLIN ONCOL, V18, P3135, DOI 10.1200/JCO.2000.18.17.3135; de Felipe P, 2004, TRAFFIC, V5, P616, DOI 10.1111/j.1398-9219.2004.00205.x; de Felipe P, 2003, J BIOL CHEM, V278, P11441, DOI 10.1074/jbc.M211644200; Donnelly MLL, 2001, J GEN VIROL, V82, P1013, DOI 10.1099/0022-1317-82-5-1013; Donnelly MLL, 1997, J GEN VIROL, V78, P13, DOI 10.1099/0022-1317-78-1-13; Flotte TR, 2004, HUM GENE THER, V15, P93; Gao GP, 2002, P NATL ACAD SCI USA, V99, P11854, DOI 10.1073/pnas.182412299; Green LL, 1999, J IMMUNOL METHODS, V231, P11, DOI 10.1016/S0022-1759(99)00137-4; Grimm D., 2003, Current Gene Therapy, V3, P281, DOI 10.2174/1566523034578285; Hudson PJ, 2003, NAT MED, V9, P129, DOI 10.1038/nm0103-129; JANG SK, 1990, ENZYME, V44, P292, DOI 10.1159/000468766; Janson C, 2002, HUM GENE THER, V13, P1391, DOI 10.1089/104303402760128612; Jooss K, 2003, GENE THER, V10, P955, DOI 10.1038/sj.gt.3302037; Lewis AD, 2002, J VIROL, V76, P8769, DOI 10.1128/JVI.76.17.8769-8775.2002; Lin YS, 1999, J PHARMACOL EXP THER, V288, P371; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; Lu Y, 2004, STEM CELLS DEV, V13, P133, DOI 10.1089/154732804773099335; Luo J, 2002, SCIENCE, V298, P425, DOI 10.1126/science.1074549; Maloney DG, 1997, BLOOD, V90, P2188; Manno CS, 2003, BLOOD, V101, P2963, DOI 10.1182/blood-2002-10-3296; Mizuguchi H, 2000, MOL THER, V1, P376, DOI 10.1006/mthe.2000.0050; Monahan Paul E, 2002, Expert Opin Drug Saf, V1, P79, DOI 10.1517/14740338.1.1.79; Moss RB, 2004, CHEST, V125, P509, DOI 10.1378/chest.125.2.509; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Noel D, 2000, J INVEST DERMATOL, V115, P740, DOI 10.1046/j.1523-1747.2000.00106.x; Noel D, 1997, HUM GENE THER, V8, P1219, DOI 10.1089/hum.1997.8.10-1219; Noel D, 2002, HUM GENE THER, V13, P1483, DOI 10.1089/10430340260185111; Perez Norma, 2004, Genet Vaccines Ther, V2, P2, DOI 10.1186/1479-0556-2-2; Prewett M, 1999, CANCER RES, V59, P5209; RYAN MD, 1991, J GEN VIROL, V72, P2727, DOI 10.1099/0022-1317-72-11-2727; RYAN MD, 1994, EMBO J, V13, P928, DOI 10.1002/j.1460-2075.1994.tb06337.x; Szymczak AL, 2004, NAT BIOTECHNOL, V22, P589, DOI 10.1038/nbt957; Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224-2232.1998	35	299	355	5	36	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2005	23	5					584	590		10.1038/nbt1087	http://dx.doi.org/10.1038/nbt1087			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	923XS	15834403				2022-12-25	WOS:000228943500031
J	Swanberg, M; Lidman, O; Padyukov, L; Eriksson, P; Akesson, E; Jagodic, M; Lobell, A; Khademi, M; Borjesson, O; Lindgren, CM; Lundman, P; Brookes, AJ; Kere, J; Luthman, H; Alfredsson, L; Hillert, J; Klareskog, L; Hamsten, A; Piehl, F; Olsson, T				Swanberg, M; Lidman, O; Padyukov, L; Eriksson, P; Akesson, E; Jagodic, M; Lobell, A; Khademi, M; Borjesson, O; Lindgren, CM; Lundman, P; Brookes, AJ; Kere, J; Luthman, H; Alfredsson, L; Hillert, J; Klareskog, L; Hamsten, A; Piehl, F; Olsson, T			MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction	NATURE GENETICS			English	Article							CLASS-II TRANSACTIVATOR; CENTRAL-NERVOUS-SYSTEM; ANTIGEN PRESENTATION; TH2 BIAS; GENE; POPULATION; CELLS; CIITA; NEURODEGENERATION; ENCEPHALOMYELITIS	Antigen presentation to T cells by MHC molecules is essential for adaptive immune responses. To determine the exact position of a gene affecting expression of MHC molecules, we finely mapped a previously defined rat quantitative trait locus regulating MHC class II on microglia in an advanced intercross line. We identified a small interval including the gene MHC class II transactivator (Mhc2ta) and, using a map over six inbred strains combined with gene sequencing and expression analysis, two conserved Mhc2ta haplotypes segregating with MHC class II levels. In humans, a - 168A --> G polymorphism in the type III promoter of the MHC class II transactivator (MHC2TA) was associated with increased susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction, as well as lower expression of MHC2TA after stimulation of leukocytes with interferon-gamma. We conclude that polymorphisms in Mhc2ta and MHC2TA result in differential MHC molecule expression and are associated with susceptibility to common complex diseases with inflammatory components.	Karolinska Inst, Dept Clin Neurosci, Neuroimmunol Unit, Stockholm, Sweden; Karolinska Inst, Dept Med, Rheumatol Unit, Stockholm, Sweden; Karolinska Inst, Atherosclerosis Res Unit, King Gustaf V Res Inst, Stockholm, Sweden; Huddinge Univ Hosp, Karolinska Inst, Dept Neurol, S-14186 Huddinge, Sweden; Huddinge Univ Hosp, Karolinska Inst, Novum, Dept Biosci, S-14186 Huddinge, Sweden; Danderyd Hosp, Dept Med, Stockholm, Sweden; Karolinska Inst, Ctr Genom & Bioinformat, Stockholm, Sweden; Lund Univ, Dept Clin Sci, Malmo, Sweden; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Danderyds Hospital; Karolinska Institutet; Lund University; Karolinska Institutet	Olsson, T (corresponding author), Karolinska Inst, Dept Clin Neurosci, Neuroimmunol Unit, Stockholm, Sweden.	tomas.olsson@cmm.ki.se	Padyukov, Leonid/A-4890-2009; Kere, Juha/AAX-9117-2021; Piehl, Fredrik/E-3451-2013; Kere, Juha/A-9179-2008; Alfredsson, Lars/AAC-9007-2019	Padyukov, Leonid/0000-0003-2950-5670; Kere, Juha/0000-0003-1974-0271; Kere, Juha/0000-0003-1974-0271; Alfredsson, Lars/0000-0003-1688-6697; Khademi, Mohsen/0000-0003-0801-1444; Swanberg, Maria/0000-0002-1829-1008; Olsson, Tomas/0000-0002-2938-1877; Piehl, Fredrik/0000-0001-8329-5219; Klareskog, Lars/0000-0001-9601-6186; Lindgren, Cecilia/0000-0002-4903-9374; Eriksson, Per/0000-0002-5635-2692	Wellcome Trust [090532] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Baumgart M, 1998, P NATL ACAD SCI USA, V95, P6936, DOI 10.1073/pnas.95.12.6936; Boss JM, 2003, CURR OPIN IMMUNOL, V15, P105, DOI 10.1016/S0952-7915(02)00015-8; Cao D, 2003, EUR J IMMUNOL, V33, P215, DOI 10.1002/immu.200390024; CHANG CH, 1995, J EXP MED, V181, P765, DOI 10.1084/jem.181.2.765; Chang CH, 1996, IMMUNITY, V4, P167, DOI 10.1016/S1074-7613(00)80681-0; Dahlman I, 1999, J IMMUNOL, V162, P2581; DARVASI A, 1995, GENETICS, V141, P1199; Eriksson P, 2004, ARTERIOSCL THROM VAS, V24, P551, DOI 10.1161/01.ATV.0000117180.57731.36; Flugel A, 2001, IMMUNITY, V14, P547, DOI 10.1016/s1074-7613(01)00143-1; Hammarberg H, 2000, J NEUROSCI, V20, P5283, DOI 10.1523/JNEUROSCI.20-14-05283.2000; Hegde NR, 2003, TRENDS IMMUNOL, V24, P278, DOI 10.1016/S1471-4906(03)00099-1; Jagodic M, 2004, J IMMUNOL, V173, P1366, DOI 10.4049/jimmunol.173.2.1366; Janitz M, 2001, EXP CLIN IMMUNOGENET, V18, P199, DOI 10.1159/000049198; Jobs M, 2003, GENOME RES, V13, P916, DOI 10.1101/gr.801103; Jurinke Christian, 2002, Methods Mol Biol, V187, P179; KERN I, 1995, INT IMMUNOL, V7, P1295, DOI 10.1093/intimm/7.8.1295; Khademi M, 2004, J IMMUNOL, V172, P7169, DOI 10.4049/jimmunol.172.11.7169; Kwak B, 2000, NAT MED, V6, P1399, DOI 10.1038/82219; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LANDER ES, 1989, GENETICS, V121, P185; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lidman O, 2003, J NEUROSCI, V23, P9817; Lundberg C, 2001, J COMP NEUROL, V431, P75; MAEHLEN J, 1988, NEUROSCI LETT, V92, P8, DOI 10.1016/0304-3940(88)90733-1; Mallat Z, 2003, CIRCULATION, V108, P1232, DOI 10.1161/01.CIR.0000089083.61317.A1; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; Nagarajan UM, 2002, J IMMUNOL, V169, P5078, DOI 10.4049/jimmunol.169.9.5078; Olsson T, 2003, TRENDS IMMUNOL, V24, P5, DOI 10.1016/S1471-4906(02)00003-0; Otten LA, 1998, EUR J IMMUNOL, V28, P473, DOI 10.1002/(SICI)1521-4141(199802)28:02<473::AID-IMMU473>3.0.CO;2-E; Otten LA, 2003, J IMMUNOL, V170, P1150, DOI 10.4049/jimmunol.170.3.1150; Padyukov L, 2004, ARTHRITIS RHEUM, V50, P3085, DOI 10.1002/art.20553; Patarroyo JC, 2002, GENES IMMUN, V3, P34, DOI 10.1038/sj.gene.6363808; Piehl F, 1999, J NEUROIMMUNOL, V101, P87, DOI 10.1016/S0165-5728(99)00136-8; Rasmussen HB, 2001, HUM IMMUNOL, V62, P371, DOI 10.1016/S0198-8859(01)00215-4; Sartoris S, 2000, HUM IMMUNOL, V61, P599, DOI 10.1016/S0198-8859(00)00121-X; Schneider S., 2000, ARLEQUIN SOFTWARE PO; SEDGWICK JD, 1993, J EXP MED, V177, P1145, DOI 10.1084/jem.177.4.1145; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378; Stolt P, 2003, ANN RHEUM DIS, V62, P835, DOI 10.1136/ard.62.9.835; STREIT WJ, 1989, J NEUROIMMUNOL, V21, P117, DOI 10.1016/0165-5728(89)90167-7; Stuve O, 2002, J IMMUNOL, V169, P6720, DOI 10.4049/jimmunol.169.12.6720; Ting JPY, 2002, CELL, V109, pS21, DOI 10.1016/S0092-8674(02)00696-7; Tompkins SM, 2002, J IMMUNOL, V168, P4173, DOI 10.4049/jimmunol.168.8.4173; Turesson C, 2004, ANN RHEUM DIS, V63, P952, DOI 10.1136/ard.2003.018101; Ueda H, 2003, NATURE, V423, P506, DOI 10.1038/nature01621; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158	49	244	258	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2005	37	5					486	494		10.1038/ng1544	http://dx.doi.org/10.1038/ng1544			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	922TU	15821736				2022-12-25	WOS:000228862300017
J	Van Driessche, N; Demsar, J; Booth, EO; Hill, P; Juvan, P; Zupan, B; Kuspa, A; Shaulsky, G				Van Driessche, N; Demsar, J; Booth, EO; Hill, P; Juvan, P; Zupan, B; Kuspa, A; Shaulsky, G			Epistasis analysis with global transcriptional phenotypes	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE GENOME; GENE-EXPRESSION PATTERNS; DEPENDENT PROTEIN-KINASE; HUNCHBACK MESSENGER-RNA; DICTYOSTELIUM DEVELOPMENT; CELL-DIFFERENTIATION; DROSOPHILA EMBRYOS; DISCOIDEUM; CAMP; PUMILIO	Classical epistasis analysis can determine the order of function of genes in pathways using morphological, biochemical and other phenotypes. It requires knowledge of the pathway's phenotypic output and a variety of experimental expertise and so is unsuitable for genome-scale analysis. Here we used microarray profiles of mutants as phenotypes for epistasis analysis. Considering genes that regulate activity of protein kinase A in Dictyostelium, we identified known and unknown epistatic relationships and reconstructed a genetic network with microarray phenotypes alone. This work shows that microarray data can provide a uniform, quantitative tool for large-scale genetic network analysis.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Grad Program Dev Biol, Houston, TX 77030 USA; Univ Ljubljana, Fac Comp & Informat Sci, Ljubljana, Slovenia; Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Grad Program Struct Computat Biol & Mol Biophys, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; University of Ljubljana; Baylor College of Medicine; Baylor College of Medicine	Shaulsky, G (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.	gadi@bcm.tmc.edu	Zupan, Blaz/L-1595-2019	Shaulsky, Gad/0000-0002-0532-0551; Juvan, Peter/0000-0003-2873-5247; Kuspa, Adam/0000-0002-9156-149X; Zupan, Blaz/0000-0002-5864-7056	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD039691] Funding Source: NIH RePORTER; NICHD NIH HHS [P01 HD039691] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABE K, 1983, DEV BIOL, V95, P200, DOI 10.1016/0012-1606(83)90018-0; Alizadeh AA, 2000, CURR OPIN IMMUNOL, V12, P219, DOI 10.1016/S0952-7915(99)00078-3; ANJARD C, 1992, DEVELOPMENT, V115, P785; Asaoka-Taguchi M, 1999, NAT CELL BIOL, V1, P431, DOI 10.1038/15666; AVERY L, 1992, TRENDS GENET, V8, P312, DOI 10.1016/0168-9525(92)90263-4; DEGUNZBURG J, 1986, EMBO J, V5, P363, DOI 10.1002/j.1460-2075.1986.tb04220.x; DEMSAR J, 2001, MEDINFO, V10, P956; Efron B, 1996, P NATL ACAD SCI USA, V93, P13429, DOI 10.1073/pnas.93.23.13429; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gerber AP, 2004, PLOS BIOL, V2, P342, DOI 10.1371/journal.pbio.0020079; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Katoh M, 2004, P NATL ACAD SCI USA, V101, P7005, DOI 10.1073/pnas.0306983101; Kibler K, 2003, DEV BIOL, V264, P506, DOI 10.1016/j.ydbio.2003.08.025; Kibler K, 2003, DEV BIOL, V259, P193, DOI 10.1016/S0012-1606(03)00204-5; King RD, 2004, NATURE, V427, P247, DOI 10.1038/nature02236; Kniesmeijer Joke, 1987, PAROOL 1109; Loomis WF, 1998, MICROBIOL MOL BIOL R, V62, P684, DOI 10.1128/MMBR.62.3.684-694.1998; Loomis WF., 1975, DICTYOSTELIUM DISCOI; MANN SKO, 1992, P NATL ACAD SCI USA, V89, P10701, DOI 10.1073/pnas.89.22.10701; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Shaulsky G, 2002, PROTIST, V153, P93, DOI 10.1078/1434-4610-00087; SHAULSKY G, 1993, DEV BIOL, V160, P85, DOI 10.1006/dbio.1993.1288; Shaulsky G, 1998, DEVELOPMENT, V125, P691; Shaulsky G, 1996, P NATL ACAD SCI USA, V93, P15260, DOI 10.1073/pnas.93.26.15260; SIMON MN, 1992, NATURE, V356, P171, DOI 10.1038/356171a0; Sonoda J, 1999, GENE DEV, V13, P2704, DOI 10.1101/gad.13.20.2704; Souza GM, 1998, DEVELOPMENT, V125, P2291; Souza GM, 1999, DEVELOPMENT, V126, P3263; Spassov DS, 2003, IUBMB LIFE, V55, P359, DOI 10.1080/15216540310001603093; Thomason PA, 1998, EMBO J, V17, P2838, DOI 10.1093/emboj/17.10.2838; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Van Driessche N, 2002, DEVELOPMENT, V129, P1543; Wang B, 2002, EUKARYOT CELL, V1, P126, DOI 10.1128/EC.1.1.126-136.2002; Wang B, 1997, SCIENCE, V277, P251, DOI 10.1126/science.277.5323.251; WETTERAUER BW, 1995, BBA-MOL CELL RES, V1265, P97, DOI 10.1016/0167-4889(94)00241-6; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; Wharton RP, 1998, MOL CELL, V1, P863, DOI 10.1016/S1097-2765(00)80085-4; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Zupan B, 2003, BIOINFORMATICS, V19, P383, DOI 10.1093/bioinformatics/btf871	47	76	80	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2005	37	5					471	477		10.1038/ng1545	http://dx.doi.org/10.1038/ng1545			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	922TU	15821735				2022-12-25	WOS:000228862300015
J	Gong, P; Epton, MJ; Fu, GL; Scaife, S; Hiscox, A; Condon, KC; Condon, GC; Morrison, NI; Kelly, DW; Dafa'alla, T; Coleman, PG; Alphey, L				Gong, P; Epton, MJ; Fu, GL; Scaife, S; Hiscox, A; Condon, KC; Condon, GC; Morrison, NI; Kelly, DW; Dafa'alla, T; Coleman, PG; Alphey, L			A dominant lethal genetic system for autocidal control of the Mediterranean fruitfly	NATURE BIOTECHNOLOGY			English	Article							STERILE INSECT TECHNIQUE; CERATITIS-CAPITATA DIPTERA; ACTIVATION DOMAIN; TEPHRITIDAE; EXPRESSION; CELLS; ERADICATION; STRAINS; RELEASE	The Sterile Insect Technique (SIT) used to control insect pests relies on the release of large numbers of radiation-sterilized insects. Irradiation can have a negative impact on the subsequent performance of the released insects(1-4) and therefore on the cost and effectiveness of a control program(5). This and other problems associated with current SIT programs could be overcome by the use of recombinant DNA methods and molecular genetics(6-12). Here we describe the construction of strains of the Mediterranean fruit fly (medfly) harboring a tetracycline-repressible transactivator (tTA) that causes lethality in early developmental stages of the heterozygous progeny but has little effect on the survival of the parental transgenic tTA insects. We show that these properties should prove advantageous for the implementation of insect pest control programs.	Univ Oxford, Dept Zool, Oxford OX1 3PS, England; Oxitec Ltd, Oxford OX14 4RX, England; Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England	University of Oxford; University of London; London School of Hygiene & Tropical Medicine	Alphey, L (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.	luke.alphey@zoo.ox.ac.uk		Alphey, Luke/0000-0002-2916-3802				Alphey L, 2002, INSECT BIOCHEM MOLEC, V32, P1243, DOI 10.1016/S0965-1748(02)00087-5; Barry JD, 2003, J ECON ENTOMOL, V96, P615, DOI 10.1603/0022-0493-96.3.615; Benedict MQ, 2003, TRENDS PARASITOL, V19, P349, DOI 10.1016/S1471-4922(03)00144-2; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; DAMKE H, 1995, METHOD ENZYMOL, V257, P209; del Valle J., 2003, DIS INFORMATION, V16, P49; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gould F, 2004, ANNU REV ENTOMOL, V49, P193, DOI 10.1146/annurev.ento.49.061802.123344; Handler AM, 2002, GENETICA, V116, P137, DOI 10.1023/A:1020924028450; Heinrich JC, 2000, P NATL ACAD SCI USA, V97, P8229, DOI 10.1073/pnas.140142697; Horn C, 2003, NAT BIOTECHNOL, V21, P64, DOI 10.1038/nbt769; KENGHONG T, 2000, AREA WIDE CONTROL FR; Koyama J, 2004, ANNU REV ENTOMOL, V49, P331, DOI 10.1146/annurev.ento.49.061802.123224; Kraaijeveld K, 2004, P ROY SOC B-BIOL SCI, V271, pS209, DOI 10.1098/rsbl.2003.0116; Krafsur ES, 1998, J AGR ENTOMOL, V15, P303; Lance DR, 2000, ANN ENTOMOL SOC AM, V93, P1179, DOI 10.1603/0013-8746(2000)093[1179:CASAWC]2.0.CO;2; LINDQUIST DA, 1992, MED VET ENTOMOL, V6, P2, DOI 10.1111/j.1365-2915.1992.tb00027.x; Robinson AS, 2004, INSECT BIOCHEM MOLEC, V34, P113, DOI 10.1016/j.ibmb.2003.10.004; Robinson AS, 2002, GENETICA, V116, P5, DOI 10.1023/A:1020951407069; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; SHELLY TE, 1994, ANN ENTOMOL SOC AM, V87, P470, DOI 10.1093/aesa/87.4.470; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; Thomas DD, 2000, SCIENCE, V287, P2474, DOI 10.1126/science.287.5462.2474; Wyss J. H., 2000, Area-wide control of fruit flies and other insect pests. Joint proceedings of the international conference on area-wide control of insect pests, 28 May-2 June, 1998 and the Fifth International Symposium on Fruit Flies of Economic Importance, Penang, Malaysia, 1-5 June, 1998, P79	25	139	164	3	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2005	23	4					453	456		10.1038/nbt1071	http://dx.doi.org/10.1038/nbt1071			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	914AR	15750586				2022-12-25	WOS:000228197300028
J	Gonzalo, S; Garcia-Cao, M; Fraga, MF; Schotta, G; Peters, AHFM; Cotter, SE; Eguia, R; Dean, DC; Esteller, M; Jenuwein, T; Blasco, MA				Gonzalo, S; Garcia-Cao, M; Fraga, MF; Schotta, G; Peters, AHFM; Cotter, SE; Eguia, R; Dean, DC; Esteller, M; Jenuwein, T; Blasco, MA			Role of the RB1 family in stabilizing histone methylation at constitutive heterochromatin	NATURE CELL BIOLOGY			English	Article							TELOMERE LENGTH; G(1) CONTROL; P53; REREPLICATION; INHIBITORS; PROTEINS; PATHWAY; TARGETS; GENES; CELLS	Here, we show a role for the RB1 family proteins in directing full heterochromatin formation. Mouse embryonic fibroblasts that are triply deficient for RB1 (retinoblastoma 1), RBL1 (retinoblastoma-like 1) and RBL2 (retinoblastoma-like 2) - known as TKO cells - show a marked genomic instability, which is coincidental with decreased DNA methylation, increased acetylation of histone H3 and decreased tri-methylation of histone H4 at lysine 20 (H4K20). Chromatin immunoprecipitation showed that H4K20 tri-methylation was specifically decreased at pericentric and telomeric chromatin. These defects are independent of E2F family function. Indeed, we show a direct interaction between the RB1 proteins and the H4K20 tri-methylating enzymes Suv4-20h1 and Suv4-20h2, indicating that the RB1 family has a role in controlling H4K20 tri-methylation by these histone methyltransferases. These observations indicate that the RB1 family is involved in maintaining overall chromatin structure and, in particular, that of constitutive heterochromatin, linking tumour suppression and the epigenetic definition of chromatin.	Spanish Natl Canc Ctr CNIO, Mol Oncol Program, Telomeres & Telomerase Grp, E-28029 Madrid, Spain; Spanish Natl Canc Ctr CNIO, Mol Pathol Program, Epigenet Grp, E-28029 Madrid, Spain; Vienna Bioctr, Res Inst Mol Pathol, A-1030 Vienna, Austria; Washington Univ, Sch Med, Div Mol Oncol, St Louis, MO 63110 USA	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Washington University (WUSTL)	Blasco, MA (corresponding author), Spanish Natl Canc Ctr CNIO, Mol Oncol Program, Telomeres & Telomerase Grp, E-28029 Madrid, Spain.	mblasco@cnio.es	Esteller, Manel/L-5956-2014; Gonzalo, Susana/T-8275-2019; Fraga, Mario F/H-7824-2017; Blasco, Maria A./M-1694-2014	Esteller, Manel/0000-0003-4490-6093; Fraga, Mario F/0000-0001-8450-2603; Blasco, Maria A./0000-0002-4211-233X; Gonzalo, Susana/0000-0001-9631-1206; Peters, Antoine/0000-0002-0311-1887; Schotta, Gunnar/0000-0003-4940-6135				Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Bernard P, 2002, TRENDS CELL BIOL, V12, P419, DOI 10.1016/S0962-8924(02)02344-9; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Bosco G, 2001, NAT CELL BIOL, V3, P289, DOI 10.1038/35060086; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Di Leonardo A, 1997, CANCER RES, V57, P1013; Fraga ME, 2002, BIOTECHNIQUES, V33, P632, DOI 10.2144/02333rv01; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Garcia-Cao M, 2004, NAT GENET, V36, P94, DOI 10.1038/ng1278; Garcia-Cao M, 2002, NAT GENET, V32, P415, DOI 10.1038/ng1011; GOODWIN GH, 1977, BIOCHEM J, V167, P485, DOI 10.1042/bj1670485; GURLEY LR, 1983, ANAL BIOCHEM, V131, P465, DOI 10.1016/0003-2697(83)90200-2; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 2000, CURR OPIN CELL BIOL, V12, P685, DOI 10.1016/S0955-0674(00)00152-6; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Khan SH, 1998, CANCER RES, V58, P396; Kourmouli N, 2004, J CELL SCI, V117, P2491, DOI 10.1242/jcs.01238; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LINDNER H, 1992, J CHROMATOGR, V608, P211, DOI 10.1016/0021-9673(92)87126-S; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Pantoja C, 2001, EXP GERONTOL, V36, P1289, DOI 10.1016/S0531-5565(01)00104-8; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Samper E, 2001, J CELL BIOL, V154, P49, DOI 10.1083/jcb.200103049; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6	31	266	280	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2005	7	4					420	U52		10.1038/ncb1235	http://dx.doi.org/10.1038/ncb1235			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	912KA	15750587				2022-12-25	WOS:000228075500020
J	Wee, S; Geyer, RK; Toda, T; Wolf, DA				Wee, S; Geyer, RK; Toda, T; Wolf, DA			CSN facilitates Cullin-RING ubiquitin ligase function by counteracting autocatalytic adapter instability	NATURE CELL BIOLOGY			English	Article							BOX PROTEIN SKP2; COP9 SIGNALOSOME; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; DNA-DAMAGE; DEGRADATION; SCF; COMPLEX; SUBUNITS; CLEAVAGE	The COP9 signalosome (CSN) is known to bind cullin-RING ubiquitin ligases (CRLs) and to promote their activity in vivo(1-3). The mechanism of this stimulation has remained enigmatic because CSN's intrinsic and associated enzymatic activities paradoxically inhibit CRL activity in vitro(4,5). Reconciling this paradox, we show here that Csn5-catalysed cullin (Cul) deneddylation and Ubp12-mediated deubiquitination cooperate in maintaining the stability of labile substrate adapters, thus facilitating CRL function. Various fission-yeast csn and ubp12 deletion mutants have lower levels of the Cul3p adapter Btb3p. This decrease is due to increased autocatalytic, Cul3p dependent, ubiquitination and the subsequent degradation of Btb3p. The CSN-Ubp12p pathway also maintains the stability of the Cul1p adapter Pop1p, a mechanism required for the efficient destruction of its cognate substrate Rum1p. Emphasizing the physiological importance of this mechanism, we found that the dispensable csn5 and ubp12 genes become essential for viability when adapter recruitment to Cul1p is compromised. Our data suggest that maintenance of adapter stability is a general mechanism of CRL control by the CSN.	Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA; Canc Res UK, Lab Cell Regulat, London Res Inst, Lincolns Inn Fields Labs, London WC2A 3PX, England	Harvard University; Harvard T.H. Chan School of Public Health; Cancer Research UK	Wolf, DA (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave, Boston, MA 02115 USA.	dwolf@hsph.harvard.edu	Wolf, Dieter/AAE-5890-2021	Wolf, Dieter/0000-0002-3761-1070	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002, T32ES007155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059780] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES00002, ES07155] Funding Source: Medline; NIGMS NIH HHS [R01 GM059780, GM59780] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Cope GA, 2003, CELL, V114, P663, DOI 10.1016/S0092-8674(03)00722-0; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Deffenbaugh AE, 2003, CELL, V114, P611, DOI 10.1016/S0092-8674(03)00641-X; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Kominami K, 1998, GENES CELLS, V3, P721, DOI 10.1046/j.1365-2443.1998.00225.x; Lehmann A, 2004, GENES CELLS, V9, P367, DOI 10.1111/j.1356-9597.2004.00730.x; Lu LF, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-22; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Mundt KE, 1999, CURR BIOL, V9, P1427, DOI 10.1016/S0960-9822(00)80091-3; Mundt KE, 2002, MOL BIOL CELL, V13, P493, DOI 10.1091/mbc.01-10-0521; Pan ZQ, 2004, ONCOGENE, V23, P1985, DOI 10.1038/sj.onc.1207414; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Pintard L, 2003, CURR BIOL, V13, P911, DOI 10.1016/S0960-9822(03)00336-1; Rouillon A, 2000, EMBO J, V19, P282, DOI 10.1093/emboj/19.2.282; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Wei N, 2003, ANNU REV CELL DEV BI, V19, P261, DOI 10.1146/annurev.cellbio.19.111301.112449; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Wolf DA, 2003, NAT CELL BIOL, V5, P1029, DOI 10.1038/ncb1203-1029; XU L, NATURE, V425, P316; Zhou CS, 2001, BMC BIOCHEM, V2, DOI 10.1186/1471-2091-2-7; Zhou CS, 2003, MOL CELL, V11, P927, DOI 10.1016/S1097-2765(03)00136-9; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	27	144	148	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2005	7	4					387	U39		10.1038/ncb1241	http://dx.doi.org/10.1038/ncb1241			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	912KA	15793566				2022-12-25	WOS:000228075500015
J	Loeys, BL; Chen, JJ; Neptune, ER; Judge, DP; Podowski, M; Holm, T; Meyers, J; Leitch, CC; Katsanis, N; Sharifi, N; Xu, FL; Myers, LA; Spevak, PJ; Cameron, DE; De Backer, J; Hellemans, J; Chen, Y; Davis, EC; Webb, CL; Kress, W; Coucke, P; Rifkin, DB; De Paepe, AM; Dietz, HC				Loeys, BL; Chen, JJ; Neptune, ER; Judge, DP; Podowski, M; Holm, T; Meyers, J; Leitch, CC; Katsanis, N; Sharifi, N; Xu, FL; Myers, LA; Spevak, PJ; Cameron, DE; De Backer, J; Hellemans, J; Chen, Y; Davis, EC; Webb, CL; Kress, W; Coucke, P; Rifkin, DB; De Paepe, AM; Dietz, HC			A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2	NATURE GENETICS			English	Article							GROWTH-FACTOR-BETA; MARFAN-SYNDROME; TRANSGENIC MICE; ACTIVATION; RECEPTOR; FIBRILLIN; GENE; INACTIVATION; PATHOGENESIS; EXPRESSION	We report heterozygous mutations in the genes encoding either type I or type II transforming growth factor beta receptor in ten families with a newly described human phenotype that includes widespread perturbations in cardiovascular, craniofacial, neurocognitive and skeletal development. Despite evidence that receptors derived from selected mutated alleles cannot support TGFbeta signal propagation, cells derived from individuals heterozygous with respect to these mutations did not show altered kinetics of the acute phase response to administered ligand. Furthermore, tissues derived from affected individuals showed increased expression of both collagen and connective tissue growth factor, as well as nuclear enrichment of phosphorylated Smad2, indicative of increased TGFbeta signaling. These data definitively implicate perturbation of TGFbeta signaling in many common human phenotypes, including craniosynostosis, cleft palate, arterial aneurysms, congenital heart disease and mental retardation, and suggest that comprehensive mechanistic insight will require consideration of both primary and compensatory events.	Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Div Cardiol, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Div Pediat Cardiol, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Div Cardiac Surg, Baltimore, MD USA; Ghent Univ Hosp, Ctr Med Genet, B-9000 Ghent, Belgium; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Dept Med, New York, NY 10016 USA; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ, Canada; Northwestern Univ, Childrens Mem Hosp, Sch Med, Div Cardiol, Chicago, IL 60614 USA; Univ Wurzburg, Inst Human Genet, D-8700 Wurzburg, Germany	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Ghent University; Ghent University Hospital; New York University; New York University; McGill University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; University of Wurzburg	Dietz, HC (corresponding author), Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA.	hdietz@jhmi.edu	De Backer, Julie/B-2897-2014; Davis, Elaine/F-3449-2012; Coucke, Paul J/AAO-2954-2020; Katsanis, Nicholas/E-1837-2012; Loeys, Bart/B-3236-2017	De Backer, Julie/0000-0001-8878-1507; Coucke, Paul J/0000-0001-7119-586X; Loeys, Bart/0000-0003-3703-9518; Judge, Daniel/0000-0002-3407-0248; Katsanis, Nicholas/0000-0002-2480-0171				Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Arteaga-Solis E, 2001, J CELL BIOL, V154, P275, DOI 10.1083/jcb.200105046; Azhar M, 2003, CYTOKINE GROWTH F R, V14, P391, DOI 10.1016/S1359-6101(03)00044-3; Bottinger EP, 1997, EMBO J, V16, P2621, DOI 10.1093/emboj/16.10.2621; Charbonneau Noe L, 2004, Birth Defects Res C Embryo Today, V72, P37, DOI 10.1002/bdrc.20000; Cohen MM, 2003, AM J MED GENET A, V116A, P1, DOI 10.1002/ajmg.a.10750; de Caestecker M, 2004, CYTOKINE GROWTH F R, V15, P1, DOI 10.1016/j.cytogfr.2003.10.004; Denton CP, 2003, J BIOL CHEM, V278, P25109, DOI 10.1074/jbc.M300636200; DePaepe A, 1996, AM J MED GENET, V62, P417, DOI 10.1002/(SICI)1096-8628(19960424)62:4<417::AID-AJMG15>3.3.CO;2-S; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; Grady WM, 1999, CANCER RES, V59, P320; Greally MT, 1998, AM J MED GENET, V76, P202, DOI 10.1002/(SICI)1096-8628(19980319)76:3<202::AID-AJMG2>3.0.CO;2-S; Isogai Z, 2003, J BIOL CHEM, V278, P2750, DOI 10.1074/jbc.M209256200; Ito Y, 2003, DEVELOPMENT, V130, P5269, DOI 10.1242/dev.00708; Kaartinen V, 2003, NAT GENET, V33, P331, DOI 10.1038/ng0303-331; Koli K, 2004, J CELL BIOL, V167, P123, DOI 10.1083/jcb.200403067; Kouchoukos NT, 1997, NEW ENGL J MED, V336, P1876, DOI 10.1056/NEJM199706263362606; Leask A, 2001, J CLIN PATHOL-MOL PA, V54, P180, DOI 10.1136/mp.54.3.180; Loeys B, 2004, HUM MUTAT, V24, P140, DOI 10.1002/humu.20070; Mizuguchi T, 2004, NAT GENET, V36, P855, DOI 10.1038/ng1392; Neptune ER, 2003, NAT GENET, V33, P407, DOI 10.1038/ng1116; Ng CM, 2004, J CLIN INVEST, V114, P1586, DOI 10.1172/JCI22715; Sanford LP, 1997, DEVELOPMENT, V124, P2659; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x	26	1159	1208	2	75	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2005	37	3					275	281		10.1038/ng1511	http://dx.doi.org/10.1038/ng1511			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	901QU	15731757	Green Published			2022-12-25	WOS:000227297800018
J	Toshima, J; Toshima, JY; Martin, AC; Drubin, DG				Toshima, J; Toshima, JY; Martin, AC; Drubin, DG			Phosphoregulation of Arp2/3-dependent actin assembly during receptor-mediated endocytosis	NATURE CELL BIOLOGY			English	Article							REGULATING KINASE PRK1P; ARP2/3 COMPLEX; CYTOSKELETON ORGANIZATION; BUDDING YEAST; MYOSIN-I; PROTEIN; DOMAIN; PAN1P; DYNAMICS; CLATHRIN	In both yeast and mammals, endocytic internalization is accompanied by a transient burst of actin polymerization(1,2). The yeast protein kinases Prk1p and Ark1p, which are related to the mammalian proteins GAK and AAK1, are key regulators of this process(3-6). However, the molecular mechanism(s) by which they regulate actin assembly at endocytic sites have not yet been determined. The Eps15-like yeast protein Pan1p is a Prk1p substrate that is essential for endocytic internalization and for proper actin organization(7-9). Pan1p is an Arp2/3 activator and here we show that this activity is dependent on F-actin binding. Mutation of all 15 Prk1p-targeted threonines in Pan1p to alanines mimicked the ark1Delta. prk1Delta. phenotype, demonstrating that Pan1p is a key Prk1p target in vivo. Moreover, phosphorylation by Prk1p inhibited the ability of Pan1p to bind to F-actin and to activate the Arp2/3 complex, thereby identifying the endocytic phosphoregulation mechanism of Prk1p. We conclude that Prk1p phosphorylation of Pan1p shuts off Arp2/3-mediated actin polymerization on endocytic vesicles, allowing them to fuse with endosomes.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Drubin, DG (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 16 Barker Hall, Berkeley, CA 94720 USA.	drubin@socrates.berkeley.edu	純子, 十島 Y/GRS-7321-2022					Cheeseman IM, 2001, J CELL BIOL, V155, P1137, DOI 10.1083/jcb.200109063; Cope MJTV, 1999, J CELL BIOL, V144, P1203, DOI 10.1083/jcb.144.6.1203; Cousin MA, 2001, TRENDS NEUROSCI, V24, P659, DOI 10.1016/S0166-2236(00)01930-5; Duncan MC, 2001, NAT CELL BIOL, V3, P687, DOI 10.1038/35083087; Evangelista M, 2000, J CELL BIOL, V148, P353, DOI 10.1083/jcb.148.2.353; Goode BL, 1999, J CELL BIOL, V144, P83, DOI 10.1083/jcb.144.1.83; Goode BL, 2001, J CELL BIOL, V153, P627, DOI 10.1083/jcb.153.3.627; Gourlay CW, 2003, J CELL SCI, V116, P2551, DOI 10.1242/jcs.00454; Henry KR, 2003, CURR BIOL, V13, P1564, DOI 10.1016/S0960-9822(03)00579-7; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; Huang B, 2003, MOL BIOL CELL, V14, P4871, DOI 10.1091/mbc.E03-06-0362; Jonsdottir GA, 2004, CURR BIOL, V14, P1604, DOI 10.1016/j.cub.2004.08.055; Kaksonen M, 2003, CELL, V115, P475, DOI 10.1016/S0092-8674(03)00883-3; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Miliaras NB, 2004, TRAFFIC, V5, P963, DOI 10.1111/j.1600-0854.2004.00238.x; Moreau V, 1997, MOL BIOL CELL, V8, P1361, DOI 10.1091/mbc.8.7.1361; Paunola E, 2002, FEBS LETT, V513, P92, DOI 10.1016/S0014-5793(01)03242-2; Peranen J, 1996, ANAL BIOCHEM, V236, P371, DOI 10.1006/abio.1996.0187; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rodal AA, 2003, CURR BIOL, V13, P1000, DOI 10.1016/S0960-9822(03)00383-X; Schafer DA, 2002, CURR OPIN CELL BIOL, V14, P76, DOI 10.1016/S0955-0674(01)00297-6; Sekiya-Kawasaki M, 2003, J CELL BIOL, V162, P765, DOI 10.1083/jcb.200305077; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Tang HY, 2000, MOL CELL BIOL, V20, P12, DOI 10.1128/MCB.20.1.12-25.2000; Tang HY, 1997, MOL CELL BIOL, V17, P4294, DOI 10.1128/MCB.17.8.4294; Toshima J, 2001, MOL BIOL CELL, V12, P1131, DOI 10.1091/mbc.12.4.1131; Watson HA, 2001, MOL BIOL CELL, V12, P3668, DOI 10.1091/mbc.12.11.3668; Wendland B, 1996, J CELL BIOL, V135, P1485, DOI 10.1083/jcb.135.6.1485; Wendland B, 1999, EMBO J, V18, P4383, DOI 10.1093/emboj/18.16.4383; Zeng GH, 2001, MOL BIOL CELL, V12, P3759, DOI 10.1091/mbc.12.12.3759; Zeng GS, 1999, J CELL BIOL, V144, P71, DOI 10.1083/jcb.144.1.71	31	84	86	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2005	7	3					246	U44		10.1038/ncb1229	http://dx.doi.org/10.1038/ncb1229			14	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	902CU	15711538				2022-12-25	WOS:000227329800012
J	Li, HY; Pellegrini, M; Eisenberg, D				Li, HY; Pellegrini, M; Eisenberg, D			Detection of parallel functional modules by comparative analysis of genome sequences	NATURE BIOTECHNOLOGY			English	Article							RNA-POLYMERASE-I; ESCHERICHIA-COLI; PROTEIN INTERACTIONS; PEPTIDE-TRANSPORT; GENE DUPLICATIONS; BINDING-PROTEIN; LARGEST SUBUNIT; DROSOPHILA; IDENTIFICATION; FAMILY	Parallel functional modules are separate sets of proteins in an organism that catalyze the same or similar biochemical reactions but act on different substrates or use different cofactors. They originate by gene duplication during evolution. Parallel functional modules provide versatility and complexity to organisms, and increase cellular flexibility and robustness. We have developed a four-step approach for genome-wide discovery of parallel modules from protein functional linkages. From ten genomes, we identified 37 cellular systems that consist of parallel functional modules. This approach recovers known parallel complexes and pathways, and discovers new ones that conventional homology-based methods did not previously reveal, as illustrated by examples of peptide transporters in Escherichia coli and nitrogenases in Rhodopseudomonas palustris. The approach untangles intertwined functional linkages between parallel functional modules and expands our ability to decode protein functions from genome sequences.	Univ Calif Los Angeles, Howard Hughes Med Inst, UCLA DOE Inst Genom & Proteom, Dept Chem & Biochem, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; United States Department of Energy (DOE); University of California System; University of California Los Angeles	Eisenberg, D (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, UCLA DOE Inst Genom & Proteom, Dept Chem & Biochem, Box 951570, Los Angeles, CA 90095 USA.	david@mbi.ucla.edu		Pellegrini, Matteo/0000-0001-9355-9564				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARCHAMBAULT J, 1993, MICROBIOL REV, V57, P703, DOI 10.1128/MMBR.57.3.703-724.1993; BAUMANN P, 1995, TRENDS GENET, V11, P279, DOI 10.1016/S0168-9525(00)89075-7; Bettencourt BR, 2002, J MOL EVOL, V54, P569, DOI 10.1007/s00239-001-0044-7; Bettencourt BR, 2001, MOL BIOL EVOL, V18, P1272, DOI 10.1093/oxfordjournals.molbev.a003912; Borner GHH, 2002, PLANT PHYSIOL, V129, P486, DOI 10.1104/pp.010884; Bowers PM, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-r35; BRENNER SE, 1995, NATURE, V378, P140, DOI 10.1038/378140a0; BRIGLE KE, 1987, J BACTERIOL, V169, P1547, DOI 10.1128/jb.169.4.1547-1553.1987; Chen HY, 2000, BIOCHEM BIOPH RES CO, V269, P743, DOI 10.1006/bbrc.1999.1506; Dandekar T, 1998, TRENDS BIOCHEM SCI, V23, P324, DOI 10.1016/S0968-0004(98)01274-2; Eady RR, 1996, CHEM REV, V96, P3013, DOI 10.1021/cr950057h; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eisenberg D, 2000, NATURE, V405, P823, DOI 10.1038/35015694; Enright AJ, 1999, NATURE, V402, P86, DOI 10.1038/47056; FALKENBURG D, 1987, J MOL BIOL, V195, P929, DOI 10.1016/0022-2836(87)90496-7; Gelbart W, 2003, NUCLEIC ACIDS RES, V31, P172, DOI 10.1093/nar/gkg094; Gelfand MS, 1997, NUCLEIC ACIDS RES, V25, P2430, DOI 10.1093/nar/25.12.2430; Gertz J, 2003, BIOINFORMATICS, V19, P2039, DOI 10.1093/bioinformatics/btg278; Gough J, 2001, J MOL BIOL, V313, P903, DOI 10.1006/jmbi.2001.5080; Gur E, 2004, J BACTERIOL, V186, P7236, DOI 10.1128/JB.186.21.7236-7242.2004; HAGTING A, 1994, J BIOL CHEM, V269, P11391; Henikoff S, 1997, SCIENCE, V278, P609, DOI 10.1126/science.278.5338.609; HESCHL MFP, 1990, COMP BIOCHEM PHYS B, V96, P633, DOI 10.1016/0305-0491(90)90206-9; HIGGINS CF, 1986, METHOD ENZYMOL, V125, P365; HOGARTH BG, 1983, J BACTERIOL, V153, P1548, DOI 10.1128/JB.153.3.1548-1551.1983; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; Huynen MA, 2003, CURR OPIN CELL BIOL, V15, P191, DOI 10.1016/S0955-0674(03)00009-7; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; Kaneko T, 2002, DNA RES, V9, P189, DOI 10.1093/dnares/9.6.189; Kelley BP, 2003, P NATL ACAD SCI USA, V100, P11394, DOI 10.1073/pnas.1534710100; Knackmuss S, 1997, MOL GEN GENET, V253, P529, DOI 10.1007/s004380050354; Larimer FW, 2004, NAT BIOTECHNOL, V22, P55, DOI 10.1038/nbt923; Lin BL, 2001, CELL STRESS CHAPERON, V6, P201, DOI 10.1379/1466-1268(2001)006<0201:GAOTHS>2.0.CO;2; Linton KJ, 1998, MOL MICROBIOL, V28, P5, DOI 10.1046/j.1365-2958.1998.00764.x; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Morano KA, 1998, CURR OPIN MICROBIOL, V1, P197, DOI 10.1016/S1369-5274(98)80011-8; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; NAVARRO C, 1993, MOL MICROBIOL, V9, P1181, DOI 10.1111/j.1365-2958.1993.tb01247.x; Overbeek R, 1999, P NATL ACAD SCI USA, V96, P2896, DOI 10.1073/pnas.96.6.2896; PARRALOPEZ C, 1993, EMBO J, V12, P4053, DOI 10.1002/j.1460-2075.1993.tb06089.x; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; Pellegrini M, 2001, J CELL BIOCHEM, V84, P106, DOI 10.1002/jcb.10071; Piekny AJ, 2003, DEVELOPMENT, V130, P5695, DOI 10.1242/dev.00807; Price NT, 1998, BIOCHEM J, V329, P321; Ramani AK, 2003, J MOL BIOL, V327, P273, DOI 10.1016/S0022-2836(03)00114-1; SEIFARTH W, 1991, MOL GEN GENET, V228, P424, DOI 10.1007/BF00260636; Smith MW, 1999, MICROBIOL-SGM, V145, P2891, DOI 10.1099/00221287-145-10-2891; Strong M, 2003, NUCLEIC ACIDS RES, V31, P7099, DOI 10.1093/nar/gkg924; Teichmann SA, 1998, P NATL ACAD SCI USA, V95, P14658, DOI 10.1073/pnas.95.25.14658; WOLFINGER ED, 1991, J BACTERIOL, V173, P7565, DOI 10.1128/jb.173.23.7565-7572.1991	51	24	24	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2005	23	2					253	260		10.1038/nbt1065	http://dx.doi.org/10.1038/nbt1065			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	894NC	15696156				2022-12-25	WOS:000226797600034
J	Lin, TX; Chao, C; Saito, S; Mazur, SJ; Murphy, ME; Appella, E; Xu, Y				Lin, TX; Chao, C; Saito, S; Mazur, SJ; Murphy, ME; Appella, E; Xu, Y			P53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression	NATURE CELL BIOLOGY			English	Article							WILD-TYPE P53; DNA-DAMAGE; ES CELLS; TRANSCRIPTIONAL REPRESSION; CELLULAR-DIFFERENTIATION; RESPONSES; APOPTOSIS; PHOSPHORYLATION; PLURIPOTENCY; MUTATION	The tumour suppressor p53 becomes activated in response to upstream stress signals, such as DNA damage, and causes cell-cycle arrest or apoptosis(1). Here we report a novel role for p53 in the differentiation of mouse embryonic stem cells (ESCs). p53 binds to the promoter of Nanog, a gene required for ESC self-renewal(2,3), and suppresses Nanog expression after DNA damage. The rapid down-regulation of Nanog mRNA during ESC differentiation correlates with the induction of p53 transcriptional activity and Ser 315 phosphorylation. The importance of Ser 315 phosphorylation was revealed by the finding that induction of p53 activity is impaired in p53(S315A) knock-in ESCs during differentiation, leading to inefficient suppression of Nanog expression. The decreased inhibition of Nanog expression in p53(S315A) ESCs during differentiation is due to an impaired recruitment of the co-repressor mSin3a to the Nanog promoter. These findings indicate an alternative mechanism for p53 to maintain genetic stability in ESCs, by inducing the differentiation of ESCs into other cell types that undergo efficient p53-dependent cell-cycle arrest and apoptosis.	Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, La Jolla, CA 92093 USA; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Fox Chase Canc Ctr, Dept Pharmacol, Philadelphia, PA 19111 USA	University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Fox Chase Cancer Center	Xu, Y (corresponding author), Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, 9500 Gilman Dr, La Jolla, CA 92093 USA.	yangxu@ucsd.edu	Lin, Tongxiang/I-4695-2013	Lin, Tongxiang/0000-0001-7033-6982; Xu, Yang/0000-0001-5574-921X; Murphy, Maureen/0000-0001-7644-7296	NCI NIH HHS [CA94254] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094254, Z01BC005599] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Boley SE, 2002, TOXICOL SCI, V66, P209, DOI 10.1093/toxsci/66.2.209; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; Chao C, 2003, J BIOL CHEM, V278, P41028, DOI 10.1074/jbc.M306938200; Corbet SW, 1999, ONCOGENE, V18, P1537, DOI 10.1038/sj.onc.1202436; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Luo JL, 2001, ONCOGENE, V20, P320, DOI 10.1038/sj.onc.1204080; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; Rohwedel J, 1999, CELLS TISSUES ORGANS, V165, P190, DOI 10.1159/000016699; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; Savatier P, 1996, ONCOGENE, V12, P309; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Wu ZQ, 2002, MOL CELL BIOL, V22, P2441, DOI 10.1128/MCB.22.8.2441-2449.2002; Xu Y, 2003, CELL DEATH DIFFER, V10, P1213, DOI 10.1038/sj.cdd.4401292; Yoshida-Koide U, 2004, BIOCHEM BIOPH RES CO, V313, P475, DOI 10.1016/j.bbrc.2003.11.138	23	666	704	3	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2005	7	2					165	U80		10.1038/ncb1211	http://dx.doi.org/10.1038/ncb1211			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	893LC	15619621				2022-12-25	WOS:000226719500013
J	Walkley, CR; Fero, ML; Chien, WM; Purton, LE; McArthur, GA				Walkley, CR; Fero, ML; Chien, WM; Purton, LE; McArthur, GA			Negative cell-cycle regulators cooperatively control self-renewal and differentiation of haematopoietic stem cells	NATURE CELL BIOLOGY			English	Article							COMPETITIVE REPOPULATION; CD34(+) CELLS; EXPRESSION; IDENTIFICATION; REQUIREMENTS; QUIESCENCE; SURVIVAL; ASSAY; MAD1	Haematopoietic stem cells (HSCs) are capable of shifting from a state of relative quiescence under homeostatic conditions to rapid proliferation under conditions of stress. The mechanisms that regulate the relative quiescence of stem cells and its association with self-renewal are unclear, as is the contribution of molecular regulators of the cell cycle to these decisions. Understanding the mechanisms that govern these transitions will provide important insights into cell-cycle regulation of HSCs and possible therapeutic approaches to expand HSCs. We have investigated the role of two negative regulators of the cell cycle, p27(Kip1) and MAD1, in controlling this transition. Here we show that Mad1(-/-) p27(Kip1-/-) bone marrow has a 5.7-fold increase in the frequency of stem cells, and surprisingly, an expanded pool of quiescent HSCs. However, Mad1(-/-) p27(Kip1-/-) stem cells exhibit an enhanced proliferative response under conditions of stress, such as cytokine stimulation in vitro and regeneration of the haematopoietic system after ablation in vivo. Together these data demonstrate that the MYC-antagonist MAD1 and cyclin-dependent kinase inhibitor p27(Kip1) cooperate to regulate the self-renewal and differentiation of HSCs in a context-dependent manner.	Peter MacCallum Canc Ctr, Div Res, Melbourne, Vic 3002, Australia; Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia; Peter MacCallum Canc Ctr, Dept Hematol & Med Oncol, Melbourne, Vic 3002, Australia; Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA	Peter Maccallum Cancer Center; St Vincent's Hospital Melbourne; University of Melbourne; Peter Maccallum Cancer Center; Fred Hutchinson Cancer Center	Purton, LE (corresponding author), Massachusetts Gen Hosp, Ctr Regenerat Med & Technol, Boston, MA 02129 USA.	lpurton@partners.org; grant.mcarthur@petermac.org	Purton, Louise/AAI-8956-2021; Walkley, Carl/AAO-6021-2020	Purton, Louise/0000-0001-6593-3168; Walkley, Carl/0000-0002-4784-9031; Fero, Matthew/0000-0002-9967-4659; McArthur, Grant/0000-0001-8908-6071	NCI NIH HHS [K22 CA087731] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Bradford GB, 1997, EXP HEMATOL, V25, P445; Cheng T, 2000, NAT MED, V6, P1235, DOI 10.1038/81335; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Gothot A, 1997, BLOOD, V90, P4384, DOI 10.1182/blood.V90.11.4384.4384_4384_4393; Gothot A, 1998, BLOOD, V92, P2641, DOI 10.1182/blood.V92.8.2641.420k36_2641_2649; HARRISON DE, 1993, EXP HEMATOL, V21, P206; HODGSON GS, 1982, EXP HEMATOL, V10, P26; Holzel M, 2001, EMBO REP, V2, P1125, DOI 10.1093/embo-reports/kve251; Jordan CT, 1996, EXP HEMATOL, V24, P1347; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; LEARY AG, 1992, P NATL ACAD SCI USA, V89, P4013, DOI 10.1073/pnas.89.9.4013; LEMISCHKA IR, 1986, CELL, V45, P917, DOI 10.1016/0092-8674(86)90566-0; LERNER C, 1990, EXP HEMATOL, V18, P114; LI CL, 1994, BLOOD, V84, P408, DOI 10.1182/blood.V84.2.408.bloodjournal842408; McArthur GA, 2002, MOL CELL BIOL, V22, P3014, DOI 10.1128/MCB.22.9.3014-3023.2002; OKADA S, 1992, BLOOD, V80, P3044; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Purton LE, 1999, BLOOD, V94, P483, DOI 10.1182/blood.V94.2.483.414k12_483_495; Sato T, 1999, BLOOD, V94, P2548, DOI 10.1182/blood.V94.8.2548.420k38_2548_2554; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPANGRUDE GJ, 1990, EXP HEMATOL, V18, P920; SZILVASSY SJ, 1990, P NATL ACAD SCI USA, V87, P8736, DOI 10.1073/pnas.87.22.8736; Tajima F, 2000, BLOOD, V96, P1989, DOI 10.1182/blood.V96.5.1989.h8001989_1989_1993; TASWELL C, 1981, J IMMUNOL, V126, P1614; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; Walkley CR, 2004, BLOOD, V103, P1286, DOI 10.1182/blood-2003-07-2391; Zezula J, 2001, EMBO REP, V2, P27, DOI 10.1093/embo-reports/kve008	30	92	99	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2005	7	2					172	U90		10.1038/ncb1214	http://dx.doi.org/10.1038/ncb1214			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	893LC	15654333				2022-12-25	WOS:000226719500014
J	Allen, RS; Millgate, AG; Chitty, JA; Thisleton, J; Miller, JAC; Fist, AJ; Gerlach, WL; Larkin, PJ				Allen, RS; Millgate, AG; Chitty, JA; Thisleton, J; Miller, JAC; Fist, AJ; Gerlach, WL; Larkin, PJ			RNAi-mediated replacement of morphine with the nonnarcotic alkaloid reticuline in opium poppy	NATURE BIOTECHNOLOGY			English	Article							BERBERINE BRIDGE ENZYME; BRANCH-POINT ENZYME; PAPAVER-SOMNIFERUM; MOLECULAR-CLONING; BISBENZYLISOQUINOLINE ALKALOIDS; BENZOPHENANTHRIDINE ALKALOIDS; BIOSYNTHETIC-PATHWAY; PLANT BIOTECHNOLOGY; CODEINONE REDUCTASE; CALIFORNIA POPPY	We report on the silencing of codeinone reductase (COR) in the opium poppy, Papaver somniferum, using a chimeric hairpin RNA construct designed to silence all members of the multigene COR family through RNA interference (RNAi). After gene silencing, the precursor alkaloid (S)-reticuline-seven enzymatic steps upstream of codeinone-accumulated in transgenic plants at the expense of morphine, codeine, oripavine and thebaine. Methylated derivatives of reticuline also accumulated. Analysis verified loss of Cor gene transcript, appearance of 22-mer degradation products and reduction of enzyme activity. The surprising accumulation of (S)- reticuline suggests a feedback mechanism preventing intermediates from general benzylisoquinoline synthesis entering the morphine-specific branch. However transcript levels for seven other enzymes in the pathway, both before and after (S)- reticuline, were unaffected. This is the first report of gene silencing in transgenic opium poppy and of metabolic engineering to cause the high-yield accumulation of the nonnarcotic alkaloid reticuline.	CSIRO Plant Ind, Canberra, ACT 2601, Australia; Tasmanian Alkaloids Pty Ltd, Westbury, Tas 7303, Australia; Johnson & Johnson Res Pty Ltd, Strawberry Hills, NSW 2012, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO); Johnson & Johnson	Larkin, PJ (corresponding author), CSIRO Plant Ind, POB 1600, Canberra, ACT 2601, Australia.	philip.larkin@csiro.au	Larkin, Philip/AAU-3195-2021; Larkin, Philip J/A-9468-2008; Allen, Robert/K-9356-2013	Larkin, Philip/0000-0002-2608-1924; Larkin, Philip J/0000-0002-2608-1924; Allen, Robert/0000-0002-2994-2996				Angerhofer CK, 1999, J NAT PROD, V62, P59, DOI 10.1021/np980144f; Bird DA, 2003, PLANT CELL, V15, P2626, DOI 10.1105/tpc.015396; Bird DA, 2001, PLANTA, V213, P888, DOI 10.1007/s004250100582; Bock A, 2002, PLANTA, V216, P57, DOI 10.1007/s00425-002-0867-5; BROCHMANNHANSSEN E, 1984, PLANTA MED, V50, P343, DOI 10.1055/s-2007-969727; Burbulis IE, 1999, P NATL ACAD SCI USA, V96, P12929, DOI 10.1073/pnas.96.22.12929; Camacho MD, 2002, PHYTOTHER RES, V16, P432, DOI 10.1002/ptr.929; CAPORALE LH, 1995, P NATL ACAD SCI USA, V92, P75, DOI 10.1073/pnas.92.1.75; Chen Q, 2002, PLANTA MED, V68, P550, DOI 10.1055/s-2002-32546; Chitty JA, 2003, FUNCT PLANT BIOL, V30, P1045, DOI 10.1071/FP03126; DEUSNEUMANN B, 1986, PLANTA, V167, P44, DOI 10.1007/BF00446367; Dewick P. M., 2002, MED NATURAL PRODUCTS, P291; DITTRICH H, 1991, P NATL ACAD SCI USA, V88, P9969, DOI 10.1073/pnas.88.22.9969; Facchini PJ, 2003, RECENT ADV PHYTOCHEM, V37, P143; Facchini PJ, 2003, PHYTOCHEMISTRY, V64, P177, DOI 10.1016/S0031-9422(03)00292-9; GERARDY R, 1993, PHYTOCHEMISTRY, V32, P79, DOI 10.1016/0031-9422(92)80111-Q; Grothe T, 2001, J BIOL CHEM, V276, P30717, DOI 10.1074/jbc.M102688200; He XZ, 2000, PLANT CELL, V12, P1689, DOI 10.1105/tpc.12.9.1689; Helliwell CA, 2002, FUNCT PLANT BIOL, V29, P1217, DOI 10.1071/FP02033; Hirata K, 2004, PHYTOCHEMISTRY, V65, P1039, DOI 10.1016/j.phytochem.2004.02.015; Kutchan TM, 1998, ALKALOIDS, V50, P253; LAUGHLIN JC, 1998, POPPY GENUS PAPAVER, P249; LAZO GR, 1991, BIO-TECHNOL, V9, P963, DOI 10.1038/nbt1091-963; LENZ R, 1995, EUR J BIOCHEM, V233, P132, DOI 10.1111/j.1432-1033.1995.132_1.x; Meijerink WJHJ, 1999, SHOCK, V12, P165, DOI 10.1097/00024382-199909000-00001; Millgate AG, 2004, NATURE, V431, P413, DOI 10.1038/431413a; Nakaoji K, 1997, BIOL PHARM BULL, V20, P586, DOI 10.1248/bpb.20.586; NIELSEN B, 1983, PLANTA MED, V48, P205, DOI 10.1055/s-2007-969921; Ounaroon A, 2003, PLANT J, V36, P808, DOI 10.1046/j.1365-313X.2003.01928.x; Panicot M, 2002, PLANT CELL, V14, P2539, DOI 10.1105/tpc.004077; Park SU, 2003, PLANT MOL BIOL, V51, P153, DOI 10.1023/A:1021199311049; Park SU, 2002, PLANT PHYSIOL, V128, P696, DOI 10.1104/pp.010741; Pauli HH, 1998, PLANT J, V13, P793, DOI 10.1046/j.1365-313X.1998.00085.x; Rasoanaivo P, 1998, PLANTA MED, V64, P58, DOI 10.1055/s-2006-957367; Schiff PL, 2002, AM J PHARM EDUC, V66, P186; Schunmann PHD, 2003, FUNCT PLANT BIOL, V30, P443, DOI 10.1071/FP02166; Schunmann PHD, 2003, FUNCT PLANT BIOL, V30, P453, DOI 10.1071/FP02167; Seifert F, 1996, J CANCER RES CLIN, V122, P707, DOI 10.1007/BF01209037; Tetenyi P., 1997, Horticultural Reviews, V19, P373, DOI 10.1002/9780470650622.ch7; Tshibangu JN, 2003, PHYTOCHEM ANALYSIS, V14, P13, DOI 10.1002/pca.673; Unterlinner B, 1999, PLANT J, V18, P465, DOI 10.1046/j.1365-313X.1999.00470.x; Wang MB, 2002, CURR OPIN PLANT BIOL, V5, P146, DOI 10.1016/S1369-5266(02)00236-4; Weid M, 2004, P NATL ACAD SCI USA, V101, P13957, DOI 10.1073/pnas.0405704101; Wesley SV, 2001, PLANT J, V27, P581, DOI 10.1046/j.1365-313X.2001.01105.x	44	176	242	2	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2004	22	12					1559	1566		10.1038/nbt1033	http://dx.doi.org/10.1038/nbt1033			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	878HX	15543134				2022-12-25	WOS:000225638600027
J	Kim, SW; Park, JI; Spring, CM; Sater, AK; Ji, H; Otchere, AA; Daniel, JM; McCrea, PD				Kim, SW; Park, JI; Spring, CM; Sater, AK; Ji, H; Otchere, AA; Daniel, JM; McCrea, PD			Non-canonical Wnt signals are modulated by the Kaiso transcriptional repressor and p120-catenin	NATURE CELL BIOLOGY			English	Article							VERTEBRATE GASTRULATION; XENOPUS-EMBRYOS; BINDING-PROTEIN; PARTNER KAISO; P120; EXPRESSION; DIFFERENTIATION; CANCER; RHO; LOCALIZATION	Gastrulation movements are critical for establishing the three principal germ layers and the basic architecture of vertebrate embryos. Although the individual molecules and pathways involved are not clearly understood, non-canonical Wnt signals are known to participate in developmental processes, including planar cell polarity and directed cell rearrangements(1,2). Here we demonstrate that the dual-specificity transcriptional repressor Kaiso(3-5), first identified in association with p120-catenin(6,7), is required for Xenopus gastrulation movements. In addition, depletion of xKaiso results in increased expression of the non-canonical xWnt11, which contributes to the xKaiso knockdown phenotype as it is significantly rescued by dominant-negative Wnt11. We further demonstrate that xWnt11 is a direct gene target of xKaiso and that p120-catenin association relieves xKaiso repression in vivo. Our results indicate that p120-catenin and Kaiso are essential components of a new developmental gene regulatory pathway that controls vertebrate morphogenesis.	Univ Texas, MD Anderson Canc Ctr, Univ Texas Grad Sch Biomed Sci, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Univ Texas Grad Sch Biomed Sci, Program Genes & Dev, Houston, TX 77030 USA; Univ Houston, Dept Biol, Houston, TX 77204 USA; McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Houston System; University of Houston; McMaster University	McCrea, PD (corresponding author), Univ Texas, MD Anderson Canc Ctr, Univ Texas Grad Sch Biomed Sci, Dept Biochem & Mol Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	pmccrea@odin.mdacc.tmc.edu	park, jaeil/AAS-5894-2021	PARK, JAE-IL/0000-0002-0737-2654	NCI NIH HHS [CA-16672] Funding Source: Medline; NIGMS NIH HHS [R01 GM52112, R01 GM052112] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052112] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Chen XY, 2003, J CELL BIOL, V163, P547, DOI 10.1083/jcb.200305137; Daniel JM, 2002, NUCLEIC ACIDS RES, V30, P2911, DOI 10.1093/nar/gkf398; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; Eisenberg CA, 1997, DEVELOPMENT, V124, P525; Fang X, 2004, J CELL BIOL, V165, P87, DOI 10.1083/jcb.200307109; Franz CM, 2004, J BIOL CHEM, V279, P6588, DOI 10.1074/jbc.M312812200; Geis K, 1998, DEV GENES EVOL, V207, P471, DOI 10.1007/s004270050138; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203; Heasman J, 2002, DEV BIOL, V243, P209, DOI 10.1006/dbio.2001.0565; Keller R, 2002, SCIENCE, V298, P1950, DOI 10.1126/science.1079478; KELLER R, 1988, DEVELOPMENT, V103, P193; Kelly KF, 2004, J CELL SCI, V117, P2675, DOI 10.1242/jcs.01101; Kim SW, 2002, J BIOL CHEM, V277, P8202, DOI 10.1074/jbc.M109508200; Medina A, 2000, MECH DEVELOP, V92, P227, DOI 10.1016/S0925-4773(00)00240-9; Mlodzik M, 2002, TRENDS GENET, V18, P564, DOI 10.1016/S0168-9525(02)02770-1; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Paulson AF, 1999, DEV BIOL, V207, P350, DOI 10.1006/dbio.1998.9158; Prokhortchouk A, 2001, GENE DEV, V15, P1613, DOI 10.1101/gad.198501; Rothbacher U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010; SATER AK, 1993, DEV DYNAM, V197, P268, DOI 10.1002/aja.1001970405; Smith JC, 2000, PHILOS T ROY SOC B, V355, P923, DOI 10.1098/rstb.2000.0627; Strutt H, 1997, EMBO J, V16, P3621, DOI 10.1093/emboj/16.12.3621; Tada M, 2000, DEVELOPMENT, V127, P2227; Thoreson MA, 2002, DIFFERENTIATION, V70, P583, DOI 10.1046/j.1432-0436.2002.700911.x; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; Wallingford JB, 2002, DEV CELL, V2, P695, DOI 10.1016/S1534-5807(02)00197-1; Yoon HG, 2003, MOL CELL, V12, P723, DOI 10.1016/j.molcel.2003.08.008	30	128	135	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2004	6	12					1212	1220		10.1038/ncb1191	http://dx.doi.org/10.1038/ncb1191			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	875WQ	15543138				2022-12-25	WOS:000225453300014
J	Rotz, LD; Hughes, JM				Rotz, LD; Hughes, JM			Advances in detecting and responding to threats from bioterrorism and emerging infectious disease	NATURE MEDICINE			English	Editorial Material							BIOLOGICAL WARFARE AGENTS; SYNDROMIC SURVEILLANCE; OUTBREAK; TIME; ATTACK; CRITERIA; SYSTEMS	Much progress has been made in recent years to strengthen local, state, national and international capacities to detect and respond to bioterrorism events and naturally occurring outbreaks of disease. New tools and systems are available to estimate the potential impact of a biological event and predict resource needs for effective response, enable earlier detection of an attack or outbreak, enhance diagnostic capacity and facilitate rapid intervention to mitigate the impact of an event on a community. These advances have required new approaches to preparedness, planning and surveillance, as well as new partnerships and collaborations across a range of disciplines. We examine some of these developments, discuss potential uses and limitations of these approaches, and identify priorities for the future.	Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Rotz, LD (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA 30333 USA.	lrotz@cdc.gov						*AG HEALTHC RES QU, 2004, COMM BAS MASS PROPH; American Psychological Association Guidelines for Preventing Health-Care-Associated Pneumonia, 2004, REC CDC HLTHC INF CO, DOI [10.1037/e548652006-001, DOI 10.1037/E548652006-001]; Andress Knox, 2003, Disaster Manag Response, V1, P54, DOI 10.1016/S1540-2487(03)00004-X; Centers of Disease Control and Prevention, 2001, MMWR Recomm Rep, V50, P1, DOI 10.1103/PhysRevE.106.055304; BERGER E, 2003, HOUSTON TX CHRO 1010; Bravata DM, 2004, ANN INTERN MED, V140, P910, DOI 10.7326/0003-4819-140-11-200406010-00013; Bravata DM, 2004, MED DECIS MAKING, V24, P192, DOI 10.1177/0272989X04263254; BRAVATA DM, 2002, BIOTERRORISM PREPARE, P1; Brookmeyer R, 2003, P NATL ACAD SCI USA, V100, P10129, DOI 10.1073/pnas.1631983100; Buehler JW, 2003, EMERG INFECT DIS, V9, P1197, DOI 10.3201/eid0910.030231; *CDCP, 2000, J AM STAT ASSOC, V95, P992; Das D, 2003, J URBAN HEALTH, V80, pI76; Fitch JP, 2003, SCIENCE, V302, P1350, DOI 10.1126/science.1085922; Fitch JP, 2002, P IEEE, V90, P1708, DOI 10.1109/JPROC.2002.804680; FLEISCHAUER AT, IN PRESS ACAD EMERGE; Gani R, 2004, EMERG INFECT DIS, V10, P608, DOI 10.3201/eid1004.030509; Gerhold DL, 2002, NAT GENET, V32, P547, DOI 10.1038/ng1042; Gilfillan L, 2004, BIOSECUR BIOTERROR, V2, P320, DOI 10.1089/bsp.2004.2.320; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Grunow R, 2002, CLIN MICROBIOL INFEC, V8, P510, DOI 10.1046/j.1469-0691.2002.00524.x; Heffernan R, 2004, EMERG INFECT DIS, V10, P858, DOI 10.3201/eid1005.030646; Heymann D L, 2001, Lancet Infect Dis, V1, P345, DOI 10.1016/S1473-3099(01)00148-7; Heymann DL, 2004, EMERG INFECT DIS, V10, P173, DOI 10.3201/eid1002.031038; Hoffmaster AR, 2002, EMERG INFECT DIS, V8, P1178, DOI 10.3201/eid0810.020393; Hutwagner L, 2003, J URBAN HEALTH, V80, pI89; Kaufmann AF, 1997, EMERG INFECT DIS, V3, P83, DOI 10.3201/eid0302.970201; KLEIN RW, 1993, MED DECIS MAKING, V13, P347, DOI 10.1177/0272989X9301300411; LANGLOIS RG, 2000, P JOINT C POINT DET; LeDuc J. W., 1999, Emerging infections 3., P219; Lober WB, 2003, J URBAN HEALTH, V80, pI97; Lombardo J, 2003, J URBAN HEALTH, V80, pI32; McBride MT, 2003, ANAL CHEM, V75, P1924, DOI 10.1021/ac026379k; Meltzer MI, 2001, EMERG INFECT DIS, V7, P959, DOI 10.3201/eid0706.010607; Morse SA, 2003, ASM NEWS, V69, P433; Mostashari F, 2003, J URBAN HEALTH, V80, pI43; Noah DL, 1998, MIL MED, V163, P198, DOI 10.1093/milmed/163.4.198; O'Toole T, 2002, CLIN INFECT DIS, V34, P972, DOI 10.1086/339909; PAVLIN JA, 2001, ESSENCE ELECT SURVEI; Quenel P, 1998, EUR J EPIDEMIOL, V14, P275, DOI 10.1023/A:1007467814485; Rao RS, 2004, J PROTEOME RES, V3, P736, DOI 10.1021/pr034130t; Reingold Arthur, 2003, Biosecur Bioterror, V1, P77, DOI 10.1089/153871303766275745; Reis BY, 2004, ANN EMERG MED, V44, P235, DOI 10.1016/j.annemergmed.2004.03.030; Reissman Dori B, 2003, Biosecur Bioterror, V1, P111, DOI 10.1089/153871303766275772; Rotz LD, 2002, EMERG INFECT DIS, V8, P225, DOI 10.3201/eid0802.010164; Schuler A, 2004, BIOSECUR BIOTERROR, V2, P86, DOI 10.1089/153871304323146388; Steyn B, 2001, NATO SCI PRT 1 DISAR, V35, P87; American Medical Association, 2004, MMWR Recomm Rep, V53, P1; Takahashi T, 2001, JPN J INFECT DIS, V54, P27; Torok TJ, 1997, JAMA-J AM MED ASSOC, V278, P389, DOI 10.1001/jama.278.5.389; Treadwell TA, 2003, PUBLIC HEALTH REP, V118, P92, DOI 10.1016/S0033-3549(04)50224-8; Tsui FC, 2003, J AM MED INFORM ASSN, V10, P399, DOI 10.1197/jamia.M1345; Walden J, 2004, EMERG INFECT DIS, V10, P1202, DOI 10.3201/eid1007.030632; Wein LM, 2003, P NATL ACAD SCI USA, V100, P4346, DOI 10.1073/pnas.0636861100; Zubieta Juan Carlos, 2003, Int J Health Geogr, V2, P8, DOI 10.1186/1476-072X-2-8	54	40	40	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2004	10	12		S			S130	S136		10.1038/nm1152	http://dx.doi.org/10.1038/nm1152			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	879RC	15577931	Bronze			2022-12-25	WOS:000225733900009
J	Webby, R; Hoffmann, E; Webster, R				Webby, R; Hoffmann, E; Webster, R			Molecular constraints to interspecies transmission of viral pathogens	NATURE MEDICINE			English	Article							INFLUENZA-A VIRUSES; 1918 PANDEMIC VIRUS; DOUBLE-STRANDED-RNA; NS1 PROTEIN; RECEPTOR SPECIFICITY; V-PROTEIN; NUCLEAR ACCUMULATION; SPIKE GLYCOPROTEIN; PREVENTING STAT1; HOST-RANGE	The successful replication of a viral pathogen in a host is a complex process involving many interactions. These interactions develop from the coevolution of pathogen and host and often lead to a species specificity of the virus that can make interspecies transmissions difficult. Nevertheless, viruses do sporadically cross species barriers into other host populations, including humans. In zoonotic infections, many of these interspecies transfer events are dead end, where transmission is confined only to the animal-to-human route but sometimes viruses adapt to enable spread from human to human. A pathogen must overcome many hurdles to replicate successfully in a foreign host. The viral pathogen must enter the host cell, replicate with the assistance of host factors, evade inhibitory host products, exit the first cell and move on to the next, and possibly leave the initial host and transmit to another. Each of these stages may require adaptive changes in the pathogen. Although the factors that influence each stage of the replication and transmission of most agents have not been resolved, the genomics of both hosts and pathogens are now at hand and we have begun to understand some of the molecular changes that enable some viruses to adapt to a new host.	St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Webster, R (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA.	robert.webster@stjude.org	Webby, Richard J/N-5657-2018		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI095357] Funding Source: NIH RePORTER; NIAID NIH HHS [AI95357, N01AI95357] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baranowski E, 2001, SCIENCE, V292, P1102, DOI 10.1126/science.1058613; BEARE AS, 1991, ARCH VIROL, V119, P37, DOI 10.1007/BF01314321; Bieniasz PD, 2003, TRENDS MICROBIOL, V11, P286, DOI 10.1016/S0966-842X(03)00123-9; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Chen ZY, 1999, EMBO J, V18, P2273, DOI 10.1093/emboj/18.8.2273; Enomoto N, 1996, NEW ENGL J MED, V334, P77, DOI 10.1056/NEJM199601113340203; Fujii Y, 2003, P NATL ACAD SCI USA, V100, P2002, DOI 10.1073/pnas.0437772100; Garcia-Sastre A, 1998, VIROLOGY, V252, P324, DOI 10.1006/viro.1998.9508; Goff SP, 2004, ANNU REV GENET, V38, P61, DOI 10.1146/annurev.genet.38.072902.094136; Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139; Hahn BH, 2000, SCIENCE, V287, P607, DOI 10.1126/science.287.5453.607; Harcourt BH, 1998, VIROLOGY, V252, P179, DOI 10.1006/viro.1998.9446; HINSHAW VS, 1983, VIROLOGY, V128, P260, DOI 10.1016/0042-6822(83)90337-9; HINSHAW VS, 1981, INFECT IMMUN, V34, P354, DOI 10.1128/IAI.34.2.354-361.1981; Holmes KV, 2001, ADV EXP MED BIOL, V494, P173; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; ISAACS A, 1958, NATURE, V182, P1073, DOI 10.1038/1821073a0; Ito T, 1998, J VIROL, V72, P7367, DOI 10.1128/JVI.72.9.7367-7373.1998; Katze MG, 2002, NAT REV IMMUNOL, V2, P675, DOI 10.1038/nri888; KAWAOKA Y, 1989, J VIROL, V63, P4603, DOI 10.1128/JVI.63.11.4603-4608.1989; Kobasa D, 2004, NATURE, V431, P703, DOI 10.1038/nature02951; Krug RM, 2003, VIROLOGY, V309, P181, DOI 10.1016/S0042-6822(03)00119-3; LAI MMC, 1992, CURR TOP MICROBIOL, V176, P21; LERNEY P, 2003, P NATL ACAD SCI USA, V100, P6588; Li KS, 2004, NATURE, V430, P209, DOI 10.1038/nature02746; LU Y, 1995, VIROLOGY, V214, P222, DOI 10.1006/viro.1995.9937; Matrosovich M, 1999, J VIROL, V73, P1146, DOI 10.1128/JVI.73.2.1146-1155.1999; Matrosovich MN, 2004, P NATL ACAD SCI USA, V101, P4620, DOI 10.1073/pnas.0308001101; Matrosovich MN, 2001, VIROLOGY, V281, P156, DOI 10.1006/viro.2000.0799; Meyer BJ, 2002, CURR TOP MICROBIOL, V262, P139; MURPHY BR, 1982, INFECT IMMUN, V37, P1119, DOI 10.1128/IAI.37.3.1119-1126.1982; Nagy PD, 1997, VIROLOGY, V235, P1, DOI 10.1006/viro.1997.8681; NELSON J, 1993, VIRUS RES, V29, P155, DOI 10.1016/0168-1702(93)90056-S; Nemeroff ME, 1998, MOL CELL, V1, P991, DOI 10.1016/S1097-2765(00)80099-4; Nie YC, 2004, BIOCHEM BIOPH RES CO, V321, P994, DOI 10.1016/j.bbrc.2004.07.060; Parisien JP, 2002, J VIROL, V76, P6435, DOI 10.1128/JVI.76.13.6435-6441.2002; Park MS, 2003, J VIROL, V77, P1501, DOI 10.1128/JVI.77.2.1501-1511.2003; Rodriguez JJ, 2003, J VIROL, V77, P11842, DOI 10.1128/JVI.77.21.11842-11845.2003; Rodriguez JJ, 2002, J VIROL, V76, P11476, DOI 10.1128/JVI.76.22.11476-11483.2002; SCHOLTISSEK C, 1978, VIROLOGY, V87, P13, DOI 10.1016/0042-6822(78)90153-8; Sevilla N, 2002, CURR TOP MICROBIOL, V263, P197; Smolinsky M.S., 2003, MICROBIAL THREATS HL; Suarez DL, 2004, EMERG INFECT DIS, V10, P693, DOI 10.3201/eid1004.030396; Thackray LB, 2004, VIROLOGY, V324, P510, DOI 10.1016/j.virol.2004.04.005; Tumpey TM, 2004, P NATL ACAD SCI USA, V101, P3166, DOI 10.1073/pnas.0308391100; Webby RJ, 2004, LANCET, V363, P1099, DOI 10.1016/S0140-6736(04)15892-3; Webster RG, 2004, LANCET, V363, P234, DOI 10.1016/S0140-6736(03)15329-9	47	84	92	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	DEC	2004	10	12		S			S77	S81		10.1038/nm1151	http://dx.doi.org/10.1038/nm1151			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	879RC	15577935	Green Published			2022-12-25	WOS:000225733900003
J	Jorde, LB; Wooding, SP				Jorde, LB; Wooding, SP			Genetic variation, classification and 'race'	NATURE GENETICS			English	Article							EVOLUTIONARY HISTORY; POPULATION-STRUCTURE; DEMOGRAPHIC HISTORY; POSITIVE SELECTION; SEQUENCE VARIATION; HUMAN-DIVERSITY; HIGH-RESOLUTION; WHITE PATIENTS; ALU-INSERTION; MITOCHONDRIAL	New genetic data has enabled scientists to re-examine the relationship between human genetic variation and 'race'. We review the results of genetic analyses that show that human genetic variation is geographically structured, in accord with historical patterns of gene flow and genetic drift. Analysis of many loci now yields reasonably accurate estimates of genetic similarity among individuals, rather than populations. Clustering of individuals is correlated with geographic origin or ancestry. These clusters are also correlated with some traditional concepts of race, but the correlations are imperfect because genetic variation tends to be distributed in a continuous, overlapping fashion among populations. Therefore, ancestry, or even race, may in some cases prove useful in the biomedical setting, but direct assessment of disease-related genetic variation will ultimately yield more accurate and beneficial information.	Univ Utah, Sch Med, Dept Human Genet, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Jorde, LB (corresponding author), Univ Utah, Sch Med, Dept Human Genet, Salt Lake City, UT 84112 USA.	lbj@genetics.utah.edu						Altshuler D, 2000, NAT GENET, V26, P76, DOI 10.1038/79216; Bamshad M, 2004, NAT REV GENET, V5, P598, DOI 10.1038/nrg1401; Bamshad M, 2001, GENOME RES, V11, P994, DOI 10.1101/gr.GR-1733RR; Barbujani G, 1997, P NATL ACAD SCI USA, V94, P4516, DOI 10.1073/pnas.94.9.4516; BARMSHAD MJ, 2003, AM J HUM GENET, V72, P578; Blumenbach Johann Friedrich, 1969, NATURAL VARIETIES MA; Bouchard TJ, 2001, BEHAV GENET, V31, P243; BOWCOCK AM, 1994, NATURE, V368, P455, DOI 10.1038/368455a0; BOYD WC, 1950, GENETICS RACES MAN I; Bradford LD, 2002, PHARMACOGENOMICS, V3, P229, DOI 10.1517/14622416.3.2.229; Burchard EG, 2003, NEW ENGL J MED, V348, P1170, DOI 10.1056/NEJMsb025007; Calafell F, 1998, EUR J HUM GENET, V6, P38, DOI 10.1038/sj.ejhg.5200151; Cavalli-Sforza L.L., 1971, GENETICS HUMAN POPUL; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; CAVALLISFORZA LL, 1993, SCIENCE, V259, P639, DOI 10.1126/science.8430313; Chung CH, 2002, NAT GENET, V32, P533, DOI 10.1038/ng1038; Cooper RS, 1999, SCI AM, V280, P56, DOI 10.1038/scientificamerican0299-56; Cooper RS, 2003, NEW ENGL J MED, V348, P1166, DOI 10.1056/NEJMsb022863; Darwin G., 1871, P423; Ding YC, 2002, P NATL ACAD SCI USA, V99, P309, DOI 10.1073/pnas.012464099; Edwards AWF, 2003, BIOESSAYS, V25, P798, DOI 10.1002/bies.10315; Evans WE, 2004, NATURE, V429, P464, DOI 10.1038/nature02626; Excoffier L, 2003, SCIENCE, V300; Exner DV, 2001, NEW ENGL J MED, V344, P1351, DOI 10.1056/NEJM200105033441802; Feldman MW, 2003, NATURE, V424, P374, DOI 10.1038/424374a; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; Fischer A, 2004, MOL BIOL EVOL, V21, P799, DOI 10.1093/molbev/msh083; Foster MW, 2002, GENOME RES, V12, P844, DOI 10.1101/gr.99202; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gilad Y, 2002, P NATL ACAD SCI USA, V99, P862, DOI 10.1073/pnas.022614799; Haga SB, 2003, SCIENCE, V301, P466, DOI 10.1126/science.1087004; Harpending H, 2002, P NATL ACAD SCI USA, V99, P10, DOI 10.1073/pnas.012612799; Harpending HC, 1998, P NATL ACAD SCI USA, V95, P1961, DOI 10.1073/pnas.95.4.1961; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Ingman M, 2000, NATURE, V408, P708, DOI 10.1038/35047064; Jorde LB, 2000, AM J HUM GENET, V66, P979, DOI 10.1086/302825; Jorde LB, 1997, P NATL ACAD SCI USA, V94, P3100, DOI 10.1073/pnas.94.7.3100; Jorde LB, 1998, BIOESSAYS, V20, P126, DOI 10.1002/(SICI)1521-1878(199802)20:2<126::AID-BIES5>3.0.CO;2-R; Jorde LB, 2001, HUM MOL GENET, V10, P2199, DOI 10.1093/hmg/10.20.2199; Kunz R, 1997, HYPERTENSION, V30, P1331, DOI 10.1161/01.HYP.30.6.1331; Laitinen T, 2004, SCIENCE, V304, P300, DOI 10.1126/science.1090010; Lewontin R.C., 1972, EVOLUTIONARY BIOL, V14, P381, DOI DOI 10.1007/978-1-4684-9063-3_14; LI WH, 1991, GENETICS, V129, P513; Mountain JL, 1997, AM J HUM GENET, V61, P705, DOI 10.1086/515510; Nakajima T, 2004, AM J HUM GENET, V74, P898, DOI 10.1086/420793; NEI M, 1989, HUM HERED, V39, P276, DOI 10.1159/000153872; Patil N, 2001, SCIENCE, V294, P1719, DOI 10.1126/science.1065573; Pritchard JK, 2000, GENETICS, V155, P945; Risch Neil, 2002, GENOME BIO, V3, P1, DOI DOI 10.1186/GB-2002-3-7-COMMENT2007; Romualdi C, 2002, GENOME RES, V12, P602, DOI 10.1101/gr.214902; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; Roses AD, 2000, NATURE, V405, P857, DOI 10.1038/35015728; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Sakate R, 2003, GENOME RES, V13, P1022, DOI 10.1101/gr.783103; Sankar P, 2002, SCIENCE, V298, P1337, DOI 10.1126/science.1074447; Schneider JA, 2003, MECH AGEING DEV, V124, P17, DOI 10.1016/S0047-6374(02)00165-3; Schwartz RS, 2001, NEW ENGL J MED, V344, P1392, DOI 10.1056/NEJM200105033441810; Sehgal AR, 2004, HYPERTENSION, V43, P566, DOI 10.1161/01.HYP.0000118019.28487.9c; Selkoe DJ, 2002, ANNU REV GENOM HUM G, V3, P67, DOI 10.1146/annurev.genom.3.022502.103022; Shriver Mark D, 2004, Hum Genomics, V1, P274; Smedley A, 1999, RACE N AM ORIGIN EVO; Strickland TL, 1997, ARCH FAM MED, V6, P371, DOI 10.1001/archfami.6.4.371; Tishkoff SA, 2003, ANNU REV GENOM HUM G, V4, P293, DOI 10.1146/annurev.genom.4.070802.110226; TISHKOFF X, 2004, NAT GENET S, V36; Underhill PA, 2000, NAT GENET, V26, P358, DOI 10.1038/81685; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Varner RV, 1998, PSYCHIAT QUART, V69, P117, DOI 10.1023/A:1024762503100; Watkins WS, 2003, GENOME RES, V13, P1607, DOI 10.1101/gr.894603; Watkins WS, 2001, AM J HUM GENET, V68, P738, DOI 10.1086/318793; Weinshilboum R, 2003, NEW ENGL J MED, V348, P529, DOI 10.1056/NEJMra020021; Wildman DE, 2002, BIOESSAYS, V24, P490, DOI 10.1002/bies.10103; Wilson JF, 2001, NAT GENET, V29, P265, DOI 10.1038/ng761; Wood AJJ, 2001, NEW ENGL J MED, V344, P1393, DOI 10.1056/NEJM200105033441811; Yu N, 2002, GENETICS, V161, P269	74	363	381	3	68	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2004	36	11		S			S28	S33		10.1038/ng1435	http://dx.doi.org/10.1038/ng1435			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	867PH	15508000	Bronze			2022-12-25	WOS:000224854000008
J	Keita, SOY; Kittles, RA; Royal, CDM; Bonney, GE; Furbert-Harris, P; Dunston, GM; Rotimi, CN				Keita, SOY; Kittles, RA; Royal, CDM; Bonney, GE; Furbert-Harris, P; Dunston, GM; Rotimi, CN			Conceptualizing human variation	NATURE GENETICS			English	Article							LINKAGE-DISEQUILIBRIUM; HUMAN-POPULATIONS; GENETIC DIVERSITY; ASSOCIATION; RACE; DISEASE; GENOME	What is the relationship between the patterns of biological and sociocultural variation in extant humans? Is this relationship accurately described, or best explained, by the term 'race' and the schema of 'racial' classification? What is the relationship between 'race', genetics and the demographic groups of society? Can extant humans be categorized into units that can scientifically be called 'races'? These questions underlie the discussions that address the explanations for the observed differences in many domains between named demographic groups across societies. These domains include disease incidence and prevalence and other variables studied by biologists and social scientists. Here, we offer a perspective on understanding human variation by exploring the meaning and use of the term 'race' and its relationship to a range of data. The quest is for a more useful approach with which to understand human biological variation, one that may provide better research designs and inform public policy.	Howard Univ, Coll Med, Natl Human Genome Ctr, Washington, DC 20060 USA; Smithsonian Inst, Dept Anthropol, Washington, DC 20560 USA; Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA	Howard University; Smithsonian Institution; Smithsonian National Museum of Natural History; University System of Ohio; Ohio State University	Kittles, RA (corresponding author), Howard Univ, Coll Med, Natl Human Genome Ctr, Washington, DC 20060 USA.	kittles-1@medctr.osu.edu						ALLEN M, 1993, J FORENSIC SCI, V38, P554; Andreasen RO, 1998, BRIT J PHILOS SCI, V49, P199, DOI 10.1093/bjps/49.2.199; Andreasen RO, 2000, PHILOS SCI, V67, pS653, DOI 10.1086/392853; Avise J.C., 1990, Oxford Surveys in Evolutionary Biology, V7, P45; Barker DJP, 1998, CLIN SCI, V95, P115, DOI 10.1042/CS19980019; BROWN WH, 1953, SYST ZOOL, V3, P174; Carlson CS, 2003, NAT GENET, V33, P518, DOI 10.1038/ng1128; Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; Collins FS, 1998, GENOME RES, V8, P1229, DOI 10.1101/gr.8.12.1229; DENIKER J, 2000, RACES MAN; Garn S. M., 1961, HUMAN RACES; GORDON HYMIE, 1965, S AFR MED J, V39, P533; Keita SOY, 1997, AM ANTHROPOL, V99, P534, DOI 10.1525/aa.1997.99.3.534; Keita SOY, 2001, AM J HUM BIOL, V13, P569, DOI 10.1002/ajhb.1095; Kruglyak L, 2001, NAT GENET, V27, P234, DOI 10.1038/85776; LATTER BDH, 1980, AM NAT, V116, P220, DOI 10.1086/283624; Lewontin R.C., 1972, EVOLUTIONARY BIOL, V14, P381, DOI DOI 10.1007/978-1-4684-9063-3_14; Lewontin RC, 1984, NOT OUR GENES; LIVINGSTONE FB, 1962, CURR ANTHROPOL, V3, P279, DOI 10.1086/200290; Long JC, 2003, HUM BIOL, V75, P449, DOI 10.1353/hub.2003.0058; Mayr E., 1991, PRINCIPLES SYSTEMATI; Neale BM, 2004, AM J HUM GENET, V75, P353, DOI 10.1086/423901; NEI M, 1993, MOL BIOL EVOL, V10, P927; Pritchard JK, 2002, HUM MOL GENET, V11, P2417, DOI 10.1093/hmg/11.20.2417; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; Rout Leslie B., 1976, AFRICAN EXPERIENCE S; Ruvolo M, 1997, ANNU REV ANTHROPOL, V26, P515, DOI 10.1146/annurev.anthro.26.1.515; Sallout B, 2003, J Obstet Gynaecol, V23, P555; Serre D, 2004, GENOME RES, V14, P1679, DOI 10.1101/gr.2529604; Stanford JL, 1999, NIH PUB, V99-4543; Stepan N, 1982, IDEA RACE SCI GREAT; Underhill PA, 2001, ANN HUM GENET, V65, P43, DOI 10.1046/j.1469-1809.2001.6510043.x; Weiss KM, 2002, TRENDS GENET, V18, P19, DOI 10.1016/S0168-9525(01)02550-1; WILSON EO, 1953, SYST ZOOL, V2, P97, DOI 10.2307/2411818	36	100	103	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2004	36	11		S			S17	S20		10.1038/ng1455	http://dx.doi.org/10.1038/ng1455			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	867PH	15507998	Bronze			2022-12-25	WOS:000224854000006
J	Bhende, PM; Seaman, WT; Delecluse, HJ; Kenney, SC				Bhende, PM; Seaman, WT; Delecluse, HJ; Kenney, SC			The EBV lytic switch protein, Z, preferentially binds to and activates the methylated viral genome	NATURE GENETICS			English	Article							EPSTEIN-BARR-VIRUS; LATENT MEMBRANE-PROTEIN; NUCLEAR ANTIGEN-2; DNA METHYLATION; BRLF1 PROMOTER; BZLF1 PROTEIN; TRANSCRIPTION; ZTA; TRANSACTIVATOR; ACETYLATION	DNA methylation promotes gene silencing, yet the Epstein-Barr virus immediate-early protein, BZLF1 (Z), converts the virus from the latent to the lytic form of infection even when the viral genome is highly methylated. Here we show that methylation of CpG motifs in Z-responsive elements of the viral BRLF1 immediate-early promoter enhances Z binding to, and activation of, this promoter. Demethylation of the viral genome impairs Z activation of lytic viral genes. Z is the first transcription factor that preferentially binds to, and activates, a methylated promoter. These results identify an unexpected mechanism by which Epstein-Barr virus circumvents the inhibitory effects of viral genome methylation.	Univ N Carolina, Dept Med, Chapel Hill, NC 27515 USA; Univ N Carolina, Dept Microbiol, Chapel Hill, NC USA; Univ N Carolina, Dept Immunol, Chapel Hill, NC USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; German Canc Res Ctr, Dept Virus Associated Tumours, D-6900 Heidelberg, Germany	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Helmholtz Association; German Cancer Research Center (DKFZ)	Kenney, SC (corresponding author), Univ N Carolina, Dept Med, Chapel Hill, NC 27515 USA.	shann@med.unc.edu		Delecluse, Henri-Jacques/0000-0002-1744-6274				Adamson AL, 1999, J VIROL, V73, P6551, DOI 10.1128/JVI.73.8.6551-6558.1999; Adamson AL, 1998, VIROLOGY, V251, P187, DOI 10.1006/viro.1998.9396; Adamson AL, 2000, J VIROL, V74, P1224, DOI 10.1128/JVI.74.3.1224-1233.2000; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3243, DOI 10.1002/j.1460-2075.1986.tb04635.x; COUNTRYMAN J, 1985, P NATL ACAD SCI USA, V82, P4085, DOI 10.1073/pnas.82.12.4085; Deng Z, 2003, MOL CELL BIOL, V23, P2633, DOI 10.1128/MCB.23.8.2633-2644.2003; ERNBERG I, 1989, J GEN VIROL, V70, P2989, DOI 10.1099/0022-1317-70-11-2989; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; Feederle R, 2000, EMBO J, V19, P3080, DOI 10.1093/emboj/19.12.3080; FLEMINGTON E, 1990, P NATL ACAD SCI USA, V87, P9459, DOI 10.1073/pnas.87.23.9459; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jenkins PJ, 2000, J VIROL, V74, P710, DOI 10.1128/JVI.74.2.710-720.2000; Kieff E., 1996, FIELDS VIROLOGY, V2, P2343; Liu PF, 2003, VIROLOGY, V310, P199, DOI 10.1016/S0042-6822(03)00145-4; MASUCCI MG, 1989, J VIROL, V63, P3135, DOI 10.1128/JVI.63.7.3135-3141.1989; PACKHAM G, 1990, J VIROL, V64, P2110, DOI 10.1128/JVI.64.5.2110-2116.1990; Paulson EJ, 1999, J VIROL, V73, P9959, DOI 10.1128/JVI.73.12.9959-9968.1999; Ragoczy T, 1998, J VIROL, V72, P7978, DOI 10.1128/JVI.72.10.7978-7984.1998; Ragoczy T, 2001, J VIROL, V75, P5240, DOI 10.1128/JVI.75.11.5240-5251.2001; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; Robertson KD, 1997, BLOOD, V90, P4480, DOI 10.1182/blood.V90.11.4480.4480_4480_4484; TAKADA K, 1986, J VIROL, V57, P1016, DOI 10.1128/JVI.57.3.1016-1022.1986; THOMPSON JP, 1986, P NATL ACAD SCI USA, V83, P7688, DOI 10.1073/pnas.83.20.7688; Wade PA, 2001, BIOESSAYS, V23, P1131, DOI 10.1002/bies.10008; Zalani S, 1996, P NATL ACAD SCI USA, V93, P9194, DOI 10.1073/pnas.93.17.9194	30	142	148	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2004	36	10					1099	1104		10.1038/ng1424	http://dx.doi.org/10.1038/ng1424			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	857YN	15361873	Bronze			2022-12-25	WOS:000224156500019
J	Fong, SS; Palsson, BO				Fong, SS; Palsson, BO			Metabolic gene-deletion strains of Escherichia coli evolve to computationally predicted growth phenotypes	NATURE GENETICS			English	Article							ADAPTIVE EVOLUTION; CAPABILITIES; MG1655; MODELS	Genome-scale metabolic models have a promising ability to describe cellular phenotypes accurately. Here we show that strains of Escherichia coli carrying a deletion of a single metabolic gene increase their growth rates (by 87% on average) during adaptive evolution and that the endpoint growth rates can be predicted computationally in 39 of 50 (78%) strains tested. These results show that computational models can be used to predict the eventual effects of genetic modifications.	Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Palsson, BO (corresponding author), Univ Calif San Diego, Dept Bioengn, 9500 Gilman Dr, La Jolla, CA 92093 USA.	palsson@ucsd.edu		Palsson, Bernhard/0000-0003-2357-6785				COOPER RA, 1970, FEBS LETT, V11, P273, DOI 10.1016/0014-5793(70)80546-4; Covert MW, 2004, NATURE, V429, P92, DOI 10.1038/nature02456; Edwards J., 1999, METABOLIC ENG; Edwards JS, 2000, BMC BIOINFORMATICS, V1, DOI 10.1186/1471-2105-1-1; Edwards JS, 2000, P NATL ACAD SCI USA, V97, P5528, DOI 10.1073/pnas.97.10.5528; Edwards JS, 2001, NAT BIOTECHNOL, V19, P125, DOI 10.1038/84379; Fong SS, 2003, J BACTERIOL, V185, P6400, DOI 10.1128/JB.185.21.6400-6408.2003; Forster Jochen, 2003, OMICS A Journal of Integrative Biology, V7, P193, DOI 10.1089/153623103322246584; Ibarra RU, 2002, NATURE, V420, P186, DOI 10.1038/nature01149; Mahadevan R, 2003, METAB ENG, V5, P264, DOI 10.1016/j.ymben.2003.09.002; Price ND, 2003, TRENDS BIOTECHNOL, V21, P162, DOI 10.1016/S0167-7799(03)00030-1; Reed JL, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r54	12	225	272	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2004	36	10					1056	1058		10.1038/ng1432	http://dx.doi.org/10.1038/ng1432			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	857YN	15448692	Bronze			2022-12-25	WOS:000224156500011
J	He, XC; Zhang, JW; Tong, WG; Tawfik, O; Ross, J; Scoville, DH; Tian, Q; Zeng, X; He, X; Wiedemann, LM; Mishina, Y; Li, LH				He, XC; Zhang, JW; Tong, WG; Tawfik, O; Ross, J; Scoville, DH; Tian, Q; Zeng, X; He, X; Wiedemann, LM; Mishina, Y; Li, LH			BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling	NATURE GENETICS			English	Article							MORPHOGENETIC PROTEIN-RECEPTOR; TUMOR-SUPPRESSOR; JUVENILE POLYPOSIS; TRANSCRIPTIONAL ACTIVATION; NEGATIVE REGULATION; GERMLINE MUTATIONS; PTEN; GENE; TRANSDUCTION; GROWTH	In humans, mutations in BMPR1A, SMAD4 and PTEN are responsible for juvenile polyposis syndrome(1), juvenile intestinal polyposis(2) and Cowden disease(3), respectively. The development of polyposis is a common feature of these diseases, suggesting that there is an association between BMP and PTEN pathways(4,5). The mechanistic link between BMP and PTEN pathways and the related etiology of juvenile polyposis is unresolved. Here we show that conditional inactivation of Bmpr1a in mice disturbs homeostasis of intestinal epithelial regeneration with an expansion of the stem and progenitor cell populations, eventually leading to intestinal polyposis resembling human juvenile polyposis syndrome. We show that BMP signaling suppresses Wnt signaling to ensure a balanced control of stem cell self-renewal. Mechanistically, PTEN, through phosphatidylinosital-3 kinase-Akt, mediates the convergence of the BMP and Wnt pathways on control of beta-catenin. Thus, BMP signaling may control the duplication of intestinal stem cells, thereby preventing crypt fission and the subsequent increase in crypt number.	Stowers Inst Med Res, Kansas City, MO 64110 USA; Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66160 USA; Inst Systemsbiol, Seattle, WA 98103 USA; Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; NIEHS, Reprod & Dev Toxicol Lab, Res Triangle Pk, NC 27709 USA	Stowers Institute for Medical Research; University of Kansas; University of Kansas Medical Center; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Li, LH (corresponding author), Stowers Inst Med Res, 1000 E 50th St, Kansas City, MO 64110 USA.	lil@stowers-institute.org	Wiedemann, Leanne/E-3316-2010	Wiedemann, Leanne/0000-0002-0964-4676; Li, Linheng/0000-0001-9963-430X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071004] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Besson A, 1999, EUR J BIOCHEM, V263, P605, DOI 10.1046/j.1432-1327.1999.00542.x; Brittan M, 2002, J PATHOL, V197, P492, DOI 10.1002/path.1155; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Haramis APG, 2004, SCIENCE, V303, P1684, DOI 10.1126/science.1093587; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Jamora C, 2003, NATURE, V422, P317, DOI 10.1038/nature01458; Kimura T, 2003, DEVELOPMENT, V130, P1691, DOI 10.1242/dev.00392; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lim DA, 2000, NEURON, V28, P713, DOI 10.1016/S0896-6273(00)00148-3; McMahon JA, 1998, GENE DEV, V12, P1438, DOI 10.1101/gad.12.10.1438; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Mutter GL, 2001, AM J PATHOL, V158, P1895, DOI 10.1016/S0002-9440(10)64656-1; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Potten CS, 2002, J CELL SCI, V115, P2381; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Roberts DJ, 2000, DEV DYNAM, V219, P109, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1047>3.3.CO;2-Y; ROTH KA, 1991, P NATL ACAD SCI USA, V88, P9407, DOI 10.1073/pnas.88.21.9407; Sancho E, 2003, CURR OPIN CELL BIOL, V15, P763, DOI 10.1016/j.ceb.2003.10.012; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Waite KA, 2003, HUM MOL GENET, V12, P679, DOI 10.1093/hmg/ddg069; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041	30	781	824	0	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2004	36	10					1117	1121		10.1038/ng1430	http://dx.doi.org/10.1038/ng1430			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	857YN	15378062	Bronze			2022-12-25	WOS:000224156500022
J	Auwerx, J; Avner, P; Baldock, R; Ballabio, A; Balling, R; Barbacid, M; Berns, A; Bradley, A; Brown, S; Carmeliet, P; Chambon, P; Cox, R; Davidson, D; Davies, K; Duboule, D; Forejt, J; Granucci, F; Hastie, N; de Angelis, MH; Jackson, I; Kioussis, D; Kollias, G; Lathrop, M; Lendahl, U; Malumbres, M; von Melchner, H; Muller, W; Partanen, J; Ricciardi-Castagnoli, P; Rigby, P; Rosen, B; Rosenthal, N; Skarnes, B; Stewart, AF; Thornton, J; Tocchini-Valentini, G; Wagner, E; Wahli, W; Wurst, W				Auwerx, J; Avner, P; Baldock, R; Ballabio, A; Balling, R; Barbacid, M; Berns, A; Bradley, A; Brown, S; Carmeliet, P; Chambon, P; Cox, R; Davidson, D; Davies, K; Duboule, D; Forejt, J; Granucci, F; Hastie, N; de Angelis, MH; Jackson, I; Kioussis, D; Kollias, G; Lathrop, M; Lendahl, U; Malumbres, M; von Melchner, H; Muller, W; Partanen, J; Ricciardi-Castagnoli, P; Rigby, P; Rosen, B; Rosenthal, N; Skarnes, B; Stewart, AF; Thornton, J; Tocchini-Valentini, G; Wagner, E; Wahli, W; Wurst, W		European Mouse Mutagenesis Consort	The European dimension for the mouse genome mutagenesis program	NATURE GENETICS			English	Article							EMBRYONIC STEM-CELLS; SITE-SPECIFIC RECOMBINATION; GENE-EXPRESSION; MUTANT MICE; LARGE-SCALE; ESTABLISHMENT; CONSTRUCTS; RESOURCE; WIDE	The European Mouse Mutagenesis Consortium is the European initiative contributing to the international effort on functional annotation of the mouse genome. Its objectives are to establish and integrate mutagenesis platforms, gene expression resources, phenotyping units, storage and distribution centers and bioinformatics resources. The combined efforts will accelerate our understanding of gene function and of human health and disease.	GSF Natl Res Ctr Environm & Hlth, Inst Dev Genet, D-85764 Munich, Germany; IGBMC, Strasbourg, France; Inst Pasteur, Unite Genet Mol Murine, Paris, France; Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; TIGEM Inst, Naples, Italy; Gesell Biotechnol Forsch mbH, Mol Biotechnol, Braunschweig, Germany; CNIO, Madrid, Spain; Netherlands Canc Inst, Amsterdam, Netherlands; Sanger Ctr, Cambridge, England; MRC, Mouse Genome Ctr, Mammalian Genet Unit, Didcot OX11 0RD, Oxon, England; Univ Louvain, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium; Univ Oxford, Dept Human Anat & Genet, MRC, Funct Genet Unit, Oxford, England; Univ Geneva, Dept Zool, Geneva, Switzerland; ASCR, Inst Mol Genet, Prague, Czech Republic; Univ Milano Bicocca, Dept Biosci & Biotechnol, Milan, Italy; GSF Natl Res Ctr Environm & Hlth GmbH, Inst Expt Genet, Munich, Germany; Natl Inst Med Res, MRC, Div Mol Immunol, London NW7 1AA, England; Biomed Sci Res Ctr Alexander Fleming, Athens, Greece; Ctr Natl Genotypage, Consortium Natl Rech Genom, Evry, France; Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden; Ctr Nacl Invest Oncol, Madrid, Spain; Goethe Univ Frankfurt, D-6000 Frankfurt, Germany; Gesell Biotechnol Forsch mbH, Expt Immunol, Braunschweig, Germany; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Inst Canc Res, Chester Beatty Labs, London SW3 6JB, England; Wellcome Trust Sanger Inst, Cambridge, England; EMBL Monterotondo, Mouse Biol Programme, Rome, Italy; Tech Univ Dresden, BioInnovat Zentrum, D-01307 Dresden, Germany; European Bioinformat Inst, Cambridge, England; CNR, Ist Biol Cellulare, I-00137 Rome, Italy; Univ Vienna, Res Inst Mol Pathol, Vienna, Austria; Univ Lausanne, Inst Biol Anim, CH-1015 Lausanne, Switzerland	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Edinburgh; Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); Gesellschaft fur Biotechnologische Forschung mbH; Centro Nacional de Investigaciones Oncologicas (CNIO); Netherlands Cancer Institute; Wellcome Trust Sanger Institute; MRC Harwell; University of Oxford; University of Geneva; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; University of Milano-Bicocca; MRC National Institute for Medical Research; Alexander Fleming Biomedical Sciences Research Center; CEA; UDICE-French Research Universities; Universite Paris Saclay; Karolinska Institutet; Goethe University Frankfurt; Gesellschaft fur Biotechnologische Forschung mbH; University of Helsinki; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Wellcome Trust Sanger Institute; European Molecular Biology Laboratory (EMBL); Technische Universitat Dresden; European Molecular Biology Laboratory (EMBL); Consiglio Nazionale delle Ricerche (CNR); University of Vienna; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of Lausanne	Wurst, W (corresponding author), GSF Natl Res Ctr Environm & Hlth, Inst Dev Genet, Ingolstadter Landstr 1, D-85764 Munich, Germany.	wurst@gsf.de	Balling, Rudi/E-9680-2010; Holt, Janet E/B-2415-2013; Wahli, Walter/I-3194-2019; Castagnoli, Paola/E-8288-2010; Forejt, Jiri/G-7719-2012; GRANUCCI, Francesca/K-6150-2019; Stewart, A. Francis/E-7789-2010; Carmeliet, Peter/AAQ-5140-2020; Malumbres, Marcos/E-8834-2011; Muller, Werner/B-9044-2008; Kollias, George/A-7079-2012; Forejt, Jiri/AAF-5276-2019; de Angelis, Martin Hrabe/F-5531-2012; Wahli, Walter/B-1398-2009; BALLABIO, Andrea/AAL-2672-2020	Balling, Rudi/0000-0003-2902-5650; Forejt, Jiri/0000-0002-2793-3623; Carmeliet, Peter/0000-0001-7961-1821; Malumbres, Marcos/0000-0002-0829-6315; Muller, Werner/0000-0002-1297-9725; Kollias, George/0000-0003-1867-3150; Forejt, Jiri/0000-0002-2793-3623; de Angelis, Martin Hrabe/0000-0002-7898-2353; Wahli, Walter/0000-0002-5966-9089; BALLABIO, Andrea/0000-0003-1381-4604; Rosenthal, Nadia/0000-0002-7599-7365; Gkoutos, Georgios/0000-0002-2061-091X; duboule, denis/0000-0001-9961-2960; Wurst, Wolfgang/0000-0003-4422-7410; Bradley, Allan/0000-0002-2349-8839; Lendahl, Urban/0000-0001-9543-8141; Baldock, Richard/0000-0003-0332-6877; Cox, Roger/0000-0001-7170-5014; Thornton, Janet/0000-0003-0824-4096; Jackson, Ian/0000-0001-6526-0688; granucci, francesca/0000-0002-7046-4914; Auwerx, Johan/0000-0002-5065-5393	MRC [MC_U127527203] Funding Source: UKRI; Medical Research Council [MC_U127527203] Funding Source: Medline; Telethon [TGM06S01, TGM03S01] Funding Source: Medline; Wellcome Trust [077188] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Telethon(Fondazione Telethon); Wellcome Trust(Wellcome Trust)		ANGRAND PO, 1999, NUCLEIC ACIDS RES, V27, pE136; Austin CP, 2004, NAT GENET, V36, P921, DOI 10.1038/ng0904-921; Battey J, 1999, NAT GENET, V21, P73, DOI 10.1038/5012; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; Branda CS, 2004, DEV CELL, V6, P7, DOI 10.1016/S1534-5807(03)00399-X; Buchholz F, 1998, NAT BIOTECHNOL, V16, P657, DOI 10.1038/nbt0798-657; Copeland NG, 2001, NAT REV GENET, V2, P769, DOI 10.1038/35093556; de Angelis MH, 2000, NAT GENET, V25, P444, DOI 10.1038/78146; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Feil R, 1996, P NATL ACAD SCI USA, V93, P10887, DOI 10.1073/pnas.93.20.10887; Gitton Y, 2002, NATURE, V420, P586, DOI 10.1038/nature01178; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Hansen J, 2003, P NATL ACAD SCI USA, V100, P9918, DOI 10.1073/pnas.1633296100; LOGIE C, 1995, P NATL ACAD SCI USA, V92, P5940, DOI 10.1073/pnas.92.13.5940; Metzger D, 2001, METHODS, V24, P71, DOI 10.1006/meth.2001.1159; Nadeau JH, 2001, SCIENCE, V291, P1251, DOI 10.1126/science.1058244; Nolan PM, 2000, NAT GENET, V25, P440, DOI 10.1038/78140; Reymond A, 2002, NATURE, V420, P582, DOI 10.1038/nature01178; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; Skarnes WC, 2004, NAT GENET, V36, P543, DOI 10.1038/ng0604-543; Stryke D, 2003, NUCLEIC ACIDS RES, V31, P278, DOI 10.1093/nar/gkg064; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Valenzuela DM, 2003, NAT BIOTECHNOL, V21, P652, DOI 10.1038/nbt822; Wiles MV, 2000, NAT GENET, V24, P13, DOI 10.1038/71622; Zhang YM, 1998, NAT GENET, V20, P123, DOI 10.1038/2417	28	150	166	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2004	36	9					925	927		10.1038/ng0904-925	http://dx.doi.org/10.1038/ng0904-925			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	851AY	15340424	Green Published, Green Accepted			2022-12-25	WOS:000223658100006
J	Chin, K; de Solorzano, CO; Knowles, D; Jones, A; Chou, W; Rodriguez, EG; Kuo, WL; Ljung, BM; Chew, K; Myambo, K; Miranda, M; Krig, S; Garbe, J; Stampfer, M; Yaswen, P; Gray, JW; Lockett, SJ				Chin, K; de Solorzano, CO; Knowles, D; Jones, A; Chou, W; Rodriguez, EG; Kuo, WL; Ljung, BM; Chew, K; Myambo, K; Miranda, M; Krig, S; Garbe, J; Stampfer, M; Yaswen, P; Gray, JW; Lockett, SJ			In situ analyses of genome instability in breast cancer	NATURE GENETICS			English	Article							MAMMARY EPITHELIAL-CELLS; TELOMERE DYSFUNCTION; HYBRIDIZATION; CARCINOMA; AMPLIFICATION; EXPRESSION; EVOLUTION; OCCURS; MICE	Transition through telomere crisis is thought to be a crucial event in the development of most breast carcinomas. Our goal in this study was to determine where this occurs in the context of histologically defined breast cancer progression. To this end, we assessed genome instability (using fluorescence in situ hybridization) and other features associated with telomere crisis in normal ductal epithelium, usual ductal hyperplasia, ductal carcinoma in situ and invasive cancer. We modeled this process in vitro by measuring these same features in human mammary epithelial cell cultures during ZNF217-mediated transition through telomere crisis and immortalization. Taken together, the data suggest that transition through telomere crisis and immortalization in breast cancer occurs during progression from usual ductal hyperplasia to ductal carcinoma in situ.	Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Engn, Berkeley, CA 94720 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California San Francisco	Gray, JW (corresponding author), Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.	jwgray@lbl.gov	Gray, Joe/AAX-9549-2020; Ortiz-de-Solorzano, Carlos/G-3278-2010	Ortiz-de-Solorzano, Carlos/0000-0001-8720-0205	NATIONAL CANCER INSTITUTE [R01CA101359, R01CA090421] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA090421, R01 CA101359] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; de Solorzano CO, 1999, J MICROSC-OXFORD, V193, P212, DOI 10.1046/j.1365-2818.1999.00463.x; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Herbert BS, 2001, BREAST CANCER RES, V3, P146, DOI 10.1186/bcr288; Holst CR, 2003, CANCER RES, V63, P1596; ISOLA JJ, 1995, AM J PATHOL, V147, P905; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; KALLIONIEMI OP, 1992, P NATL ACAD SCI USA, V89, P5321, DOI 10.1073/pnas.89.12.5321; Kelland LR, 2001, LANCET ONCOL, V2, P95, DOI 10.1016/S1470-2045(00)00226-6; Kim MM, 2001, P NATL ACAD SCI USA, V98, P7982, DOI 10.1073/pnas.131211098; Kuukasjarvi T, 1997, CANCER RES, V57, P1597; Kuukasjarvi T, 1997, AM J PATHOL, V150, P1465; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; Meeker AK, 2004, AM J PATHOL, V164, P925, DOI 10.1016/S0002-9440(10)63180-X; Nishizaki T, 1997, GENE CHROMOSOME CANC, V19, P267, DOI 10.1002/(SICI)1098-2264(199708)19:4<267::AID-GCC9>3.0.CO;2-V; Nonet GH, 2001, CANCER RES, V61, P1250; O'Connell P, 1998, JNCI-J NATL CANCER I, V90, P697, DOI 10.1093/jnci/90.9.697; O'Hagan RC, 2002, CANCER CELL, V2, P149, DOI 10.1016/S1535-6108(02)00094-6; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Smalley M, 2003, NAT REV CANCER, V3, P832, DOI 10.1038/nrc1212; Smogorzewska A, 2004, ANNU REV BIOCHEM, V73, P177, DOI 10.1146/annurev.biochem.73.071403.160049; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Takimoto R, 2002, CANCER BIOL THER, V1, P47, DOI 10.4161/cbt.1.1.41; THOMPSON CT, 1994, AM J PATHOL, V144, P237; Waldman FM, 2000, JNCI-J NATL CANCER I, V92, P313, DOI 10.1093/jnci/92.4.313; Yashima K, 1998, CLIN CANCER RES, V4, P229	30	290	304	1	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2004	36	9					984	988		10.1038/ng1409	http://dx.doi.org/10.1038/ng1409			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	851AY	15300252	Bronze			2022-12-25	WOS:000223658100025
J	O'Sullivan, JM; Tan-Wong, SM; Morillon, A; Lee, B; Coles, J; Mellor, J; Proudfoot, NJ				O'Sullivan, JM; Tan-Wong, SM; Morillon, A; Lee, B; Coles, J; Mellor, J; Proudfoot, NJ			Gene loops juxtapose promoters and terminators in yeast	NATURE GENETICS			English	Article							RNA-POLYMERASE-II; 3 END; TRANSCRIPTION; SSU72; POLYADENYLATION; ARCHITECTURE; ELONGATION; COMPLEXES	Mechanistic analysis of transcriptional initiation and termination by RNA polymerase II (PolII) indicates that some factors are common to both processes(1,2). Here we show that two long genes of Saccharomyces cerevisiae, FMP27 and SEN1, exist in a looped conformation, effectively bringing together their promoter and terminator regions. We also show that PolII is located at both ends of FMP27 when this gene is transcribed from a GAL1 promoter under induced and noninduced conditions. Under these conditions, the C-terminal domain of the large subunit of PolII is phosphorylated at Ser5. Notably, inactivation of Kin28p causes a loss of both Ser5 phosphorylation and the loop conformation. These data suggest that gene loops are involved in the early stages of transcriptional activation. They also predict a previously unknown structural dimension to gene regulation, in which both ends of the transcription unit are defined before and during the transcription cycle.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Oxford, Dept Biochem, Oxford OX1 3RE, England	University of Oxford; University of Oxford	Proudfoot, NJ (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	nicholas.proudfoot@path.ox.ac.uk	O'Sullivan, Justin/HDO-1639-2022; Morillon, Antonin/M-4751-2017	O'Sullivan, Justin/0000-0003-2927-450X; Morillon, Antonin/0000-0002-0575-5264; Proudfoot, Nicholas/0000-0001-8646-3222				Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Bhat PJ, 2001, MOL MICROBIOL, V40, P1059, DOI 10.1046/j.1365-2958.2001.02421.x; Birse CE, 1998, SCIENCE, V280, P298, DOI 10.1126/science.280.5361.298; Bryant GO, 2003, MOL CELL, V11, P1301, DOI 10.1016/S1097-2765(03)00144-8; Calvo O, 2001, MOL CELL, V7, P1013, DOI 10.1016/S1097-2765(01)00236-2; Calvo O, 2003, GENE DEV, V17, P1321, DOI 10.1101/gad.1093603; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; Cohen BA, 2000, NAT GENET, V26, P183, DOI 10.1038/79896; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Dichtl B, 2002, MOL CELL, V10, P1139, DOI 10.1016/S1097-2765(02)00707-4; Dieci G, 2003, TRENDS BIOCHEM SCI, V28, P202, DOI 10.1016/S0968-0004(03)00054-9; Dujon B, 1996, TRENDS GENET, V12, P263, DOI 10.1016/0168-9525(96)10027-5; Feuerbach F, 2002, NAT CELL BIOL, V4, P214, DOI 10.1038/ncb756; Ganem C, 2003, EMBO J, V22, P1588, DOI 10.1093/emboj/cdg141; He XY, 2003, GENE DEV, V17, P1030, DOI 10.1101/gad.1075203; Kim M, 2004, EMBO J, V23, P354, DOI 10.1038/sj.emboj.7600053; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Lis J, 1998, COLD SPRING HARB SYM, V63, P347, DOI 10.1101/sqb.1998.63.347; Mason PB, 2003, MOL CELL BIOL, V23, P8323, DOI 10.1128/MCB.23.22.8323-8333.2003; Morillon A, 2003, CELL, V115, P425, DOI 10.1016/S0092-8674(03)00880-8; Proudfoot N, 2004, CURR OPIN CELL BIOL, V16, P272, DOI 10.1016/j.ceb.2004.03.007; Sawado T, 2003, GENE DEV, V17, P1009, DOI 10.1101/gad.1072303; Spector DL, 2003, ANNU REV BIOCHEM, V72, P573, DOI 10.1146/annurev.biochem.72.121801.161724; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; Webb CD, 1997, CELL, V88, P667, DOI 10.1016/S0092-8674(00)81909-1	27	270	276	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2004	36	9					1014	1018		10.1038/ng1411	http://dx.doi.org/10.1038/ng1411			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	851AY	15314641	Bronze			2022-12-25	WOS:000223658100031
J	Chiarle, R; Simmons, WJ; Cai, HY; Dhall, G; Zamo', A; Raz, R; Karras, JG; Levy, DE; Inghirami, G				Chiarle, R; Simmons, WJ; Cai, HY; Dhall, G; Zamo', A; Raz, R; Karras, JG; Levy, DE; Inghirami, G			Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target	NATURE MEDICINE			English	Article							ABL KINASE-ACTIVITY; CYCLIN D1 PROMOTER; CONSTITUTIVE ACTIVATION; ANAPLASTIC LYMPHOMA; NPM-ALK; CELL LYMPHOMA; EXPRESSION; INHIBITION; APOPTOSIS; GROWTH	Anaplastic large cell lymphomas (ALCLs) are caused by chromosomal translocations that juxtapose the anaplastic lymphoma kinase (ALK) proto-oncogene to a dimerization partner, resulting in constitutive expression of ALK and ALK tyrosine kinase activity. One substrate of activated ALK in human ALCLs is the transcription factor Stat3, and its phosphorylation is accurately recapitulated in a new nucleophosmin (NPM)-ALK transgenic mouse model of lymphomagenesis. Here we show by gene targeting that Stat3 is required for the transformation of mouse embryonic fibroblasts in vitro, for the development of B-cell lymphoma in transgenic mice and for the growth and survival of both human and mouse NPM-ALK-transformed B and T cells. Ablation of Stat3 expression by antisense oligonucleotides significantly ( P < 0.0001) impaired the growth of human and mouse NPM-ALK tumors in vivo. Pharmacological ablation of Stat3 represents a new candidate approach for the treatment of human lymphoma.	NYU, Dept Pathol, Sch Med, New York, NY 10016 USA; NYU, Inst Canc, Sch Med, New York, NY 10016 USA; Univ Turin, Ctr Expt Res & Med Studies, I-10126 Turin, Italy; Univ Turin, Dept Biomed Sci & Human Oncol, I-10126 Turin, Italy; NYU, Dept Pediat Oncol, Sch Med, New York, NY 10016 USA; Univ Verona, Dept Pathol, I-37100 Verona, Italy; ISIS Pharmaceut, Carlsbad, CA 92008 USA	New York University; New York University; University of Turin; University of Turin; New York University; University of Verona; Isis Pharmaceuticals Inc	Inghirami, G (corresponding author), NYU, Dept Pathol, Sch Med, 550 1st Ave, New York, NY 10016 USA.	inghig01@med.nyu.edu	Levy, David/GPS-4945-2022; Levy, David/AAG-6202-2019; Zamò, Alberto/ABF-4436-2020	Levy, David/0000-0002-7320-7788; Zamo, Alberto/0000-0001-6203-7966; CHIARLE, Roberto/0000-0003-1564-8531				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Butler M, 2002, DIABETES, V51, P1028, DOI 10.2337/diabetes.51.4.1028; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Cessna MH, 2002, MODERN PATHOL, V15, P931, DOI 10.1097/01.MP.0000026615.04130.1F; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Chiarle R, 2003, BLOOD, V101, P1919, DOI 10.1182/blood-2002-05-1343; Chiarle R, 1999, J IMMUNOL, V163, P194; De Paepe P, 2003, BLOOD, V102, P2638, DOI 10.1182/blood-2003-04-1050; Delsol G, 1997, BLOOD, V89, P1483, DOI 10.1182/blood.V89.5.1483.1483_1483_1490; Drexler HG, 2000, LEUKEMIA, V14, P1533, DOI 10.1038/sj.leu.2401878; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; Goldman JM, 2003, NEW ENGL J MED, V349, P1451, DOI 10.1056/NEJMra020777; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARRIS NL, 1994, BLOOD, V84, P1361; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Huang M, 2002, ONCOGENE, V21, P8804, DOI 10.1038/sj.onc.1206028; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Lee CK, 1999, J EXP MED, V190, P1451, DOI 10.1084/jem.190.10.1451; Lee CK, 2002, IMMUNITY, V17, P63, DOI 10.1016/S1074-7613(02)00336-9; Liang Y, 2004, DIABETES, V53, pA134, DOI 10.2337/diabetes.53.2.410; Loonstra A, 2001, P NATL ACAD SCI USA, V98, P9209, DOI 10.1073/pnas.161269798; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Nieborowska-Skorska M, 2001, CANCER RES, V61, P6517; Raz R, 1999, P NATL ACAD SCI USA, V96, P2846, DOI 10.1073/pnas.96.6.2846; Rickert RC, 1997, NUCLEIC ACIDS RES, V25, P1317, DOI 10.1093/nar/25.6.1317; SCHLESSINGER K, IN PRESS CANC RES; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Sloop KW, 2004, J CLIN INVEST, V113, P1571, DOI 10.1172/JCI200420911; Wolfer A, 2001, NAT IMMUNOL, V2, P235, DOI 10.1038/85294; Zamo A, 2002, ONCOGENE, V21, P1038, DOI 10.1038/sj.onc.1205152	41	336	347	0	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2005	11	6					623	629		10.1038/nm1249	http://dx.doi.org/10.1038/nm1249			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	932YD	15895073				2022-12-25	WOS:000229589800028
J	Davies, JE; Wang, L; Garcia-Oroz, L; Cook, LJ; Vacher, C; O'Donovan, DG; Rubinsztein, DC				Davies, JE; Wang, L; Garcia-Oroz, L; Cook, LJ; Vacher, C; O'Donovan, DG; Rubinsztein, DC			Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice	NATURE MEDICINE			English	Article							REDUCE AGGREGATE FORMATION; CELL-DEATH; HUNTINGTONS-DISEASE; MODEL; MINOCYCLINE; PHENOTYPE; GENE; EXPANSIONS; CHAPERONES; APOPTOSIS	The muscular dystrophies are a heterogeneous group of disorders for which there are currently no cures. Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant late-onset, progressive disease that generally presents in the fifth or sixth decade with dysphagia, ptosis and proximal limb weakness. OPMD is caused by the abnormal expansion of a (GCG)(n) trinucleotide repeat in the coding region of the poly-(A) binding protein nuclear 1 (PABPN1) gene(1). In unaffected individuals, (GCG)(6) codes for the first six alanines in a homopolymeric stretch of ten alanines. In most individuals with OPMD this (GCG)(6) repeat is expanded to (GCG)(8-13), leading to a stretch of 12 - 17 alanines in mutant PABPN1. PABPN1 with an expanded polyalanine tract forms aggregates consisting of tubular filaments within the nuclei of skeletal muscle fibers(2-4). We have developed a transgenic mouse model of OPMD that manifests progressive muscle weakness accompanied by intranuclear aggregates and TUNEL-stained nuclei in skeletal muscle fibers. The onset and severity of these abnormalities were substantially delayed and attenuated by doxycycline treatment, which may exert its therapeutic effect by reducing aggregates and by distinct antiapoptotic properties. Doxycycline may represent a safe and feasible therapeutic for this disease.	Addenbrookes Hosp, Dept Med Genet, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Addenbrookes Hosp, Dept Histopathol, Cambridge CB2 2QQ, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Rubinsztein, DC (corresponding author), Addenbrookes Hosp, Dept Med Genet, Cambridge Inst Med Res, Hills Rd, Cambridge CB2 2XY, England.	dcr1000@hermes.cam.ac.uk	Rubinsztein, David C/C-3472-2011	Davies, Janet/0000-0002-8853-8328				Abu-Baker A, 2003, HUM MOL GENET, V12, P2609, DOI 10.1093/hmg/ddg293; Albrecht AN, 2004, HUM MOL GENET, V13, P2351, DOI 10.1093/hmg/ddh277; Bao YP, 2004, J MED GENET, V41, P47, DOI 10.1136/jmg.2003.014548; Bao YP, 2002, J BIOL CHEM, V277, P12263, DOI 10.1074/jbc.M109633200; Brais B, 1998, NAT GENET, V18, P164, DOI 10.1038/ng0298-164; BRENNAN KJ, 1993, J BIOL CHEM, V268, P719; Calado A, 2000, HUM MOL GENET, V9, P2321, DOI 10.1093/oxfordjournals.hmg.a018924; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Fan XP, 2001, HUM MOL GENET, V10, P2341, DOI 10.1093/hmg/10.21.2341; Forloni G, 2001, FEBS LETT, V487, P404, DOI 10.1016/S0014-5793(00)02380-2; Girgenrath M, 2004, J CLIN INVEST, V114, P1635, DOI 10.1172/JCI200422928; Hino H, 2004, HUM MOL GENET, V13, P181, DOI 10.1093/hmg/ddh017; NEMETH A, 1995, NUCLEIC ACIDS RES, V23, P4034, DOI 10.1093/nar/23.20.4034; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Rogers DC, 1997, MAMM GENOME, V8, P711, DOI 10.1007/s003359900551; Smith DL, 2003, ANN NEUROL, V54, P186, DOI 10.1002/ana.10614; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; TOME FMS, 1997, NEUROMUSCUL DISOR S1, V7, P63; Uyama E, 2000, MUSCLE NERVE, V23, P1549, DOI 10.1002/1097-4598(200010)23:10<1549::AID-MUS11>3.0.CO;2-0; Wang X, 2003, P NATL ACAD SCI USA, V100, P10483, DOI 10.1073/pnas.1832501100; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	22	109	111	1	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2005	11	6					672	677		10.1038/nm1242	http://dx.doi.org/10.1038/nm1242			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	932YD	15864313				2022-12-25	WOS:000229589800035
J	Li, Z; Godinho, FJ; Klusmann, JH; Garriga-Canut, M; Yu, CN; Orkin, SH				Li, Z; Godinho, FJ; Klusmann, JH; Garriga-Canut, M; Yu, CN; Orkin, SH			Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1	NATURE GENETICS			English	Article							EMBRYONIC STEM-CELLS; MEGAKARYOBLASTIC LEUKEMIA; GENE; MUTATIONS; DIFFERENTIATION; EXPRESSION; SPECIFICITY; INSIGHTS; BINDING; RESCUE	Acquired mutations in the hematopoietic transcription factor GATA binding protein-1 (GATA1) are found in megakaryoblasts from nearly all individuals with Down syndrome with transient myeloproliferative disorder (TMD, also called transient leukemia) and the related acute megakaryoblastic leukemia (DS-AMKL, also called DS-AML M7)(1-6). These mutations lead to production of a variant GATA1 protein ( GATA1s) that is truncated at its N terminus. To understand the biological properties of GATA1s and its relation to DS-AMKL and TMD, we used gene targeting to generate Gata1 alleles that express GATA1s in mice. We show that the dominant action of GATA1s leads to hyperproliferation of a unique, previously unrecognized yolk sac and fetal liver progenitor, which we propose accounts for the transient nature of TMD and the restriction of DS-AMKL to infants. Our observations raise the possibility that the target cells in other leukemias of infancy and early childhood are distinct from those in adult leukemias and underscore the interplay between specific oncoproteins and potential target cells.	Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute	Orkin, SH (corresponding author), Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.	orkin@bloodgroup.tch.harvard.edu	Klusmann, Jan-Henning/M-9655-2015	Klusmann, Jan-Henning/0000-0002-1070-0727; Yu, Channing/0000-0002-3231-2565				Ahmed M, 2004, BLOOD, V103, P2480, DOI 10.1182/blood-2003-10-3383; BLOBEL GA, 1995, MOL CELL BIOL, V15, P626; Crispino JD, 2005, PEDIATR BLOOD CANCER, V44, P40, DOI 10.1002/pbc.20066; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; Gagneten S, 1997, NUCLEIC ACIDS RES, V25, P3326, DOI 10.1093/nar/25.16.3326; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; Gurbuxani S, 2004, BLOOD, V103, P399, DOI 10.1182/blood-2003-05-1556; Hitzler JK, 2003, BLOOD, V101, P4301, DOI 10.1182/blood-2003-01-0013; Hitzler JK, 2005, NAT REV CANCER, V5, P11, DOI 10.1038/nrc1525; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P7976, DOI 10.1073/pnas.94.15.7976; Mundschau G, 2003, BLOOD, V101, P4298, DOI 10.1182/blood-2002-12-3904; Rainis L, 2003, BLOOD, V102, P981, DOI 10.1182/blood-2002-11-3599; Rylski M, 2003, MOL CELL BIOL, V23, P5031, DOI 10.1128/MCB.23.14.5031-5042.2003; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Shimizu R, 2001, EMBO J, V20, P5250, DOI 10.1093/emboj/20.18.5250; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; VISVADER JE, 1995, MOL CELL BIOL, V15, P634; Vyas P, 2000, P NATL ACAD SCI USA, V97, P13696, DOI 10.1073/pnas.250476397; Vyas P, 1999, BLOOD, V93, P2867; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; Welch JJ, 2004, BLOOD, V104, P3136, DOI 10.1182/blood-2004-04-1603; Xu G, 2003, BLOOD, V102, P2960, DOI 10.1182/blood-2003-02-0390	29	210	217	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2005	37	6					613	619		10.1038/ng1566	http://dx.doi.org/10.1038/ng1566			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	931OT	15895080				2022-12-25	WOS:000229495300015
J	Lin, JM; Patel, SR; Cheng, X; Cho, EA; Levitan, I; Ullenbruch, M; Phan, SH; Park, JM; Dressler, GR				Lin, JM; Patel, SR; Cheng, X; Cho, EA; Levitan, I; Ullenbruch, M; Phan, SH; Park, JM; Dressler, GR			Kielin/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease	NATURE MEDICINE			English	Article							BONE MORPHOGENETIC PROTEIN-7; TGF-BETA; MESENCHYMAL TRANSITION; EMBRYONIC-DEVELOPMENT; FIBROSIS; CHORDIN; KIDNEY; INJURY; GENE; IDENTIFICATION	The bone morphogenetic proteins (BMPs) profoundly affect embryonic development, differentiation and disease. BMP signaling is suppressed by cysteine-rich domain proteins, such as chordin, that sequester ligands from the BMP receptor. We describe a novel protein, KCP, with 18 cysteine-rich domains. Unlike chordin, KCP enhances BMP signaling in a paracrine manner. Smad1-dependent transcription and phosphorylated Smad1 (P-Smad1) levels are increased, as KCP binds to BMP7 and enhances binding to the type I receptor. In vivo, Kcp(-/-) mice are viable and fertile. Because BMPs have a pivotal role in renal disease, we examined the phenotype of Kcp(-/-) mice in two different models of renal injury. Kcp(-/-) animals show reduced levels of P-Smad1, are more susceptible to developing renal interstitial fibrosis, are more sensitive to tubular injury and show substantial pathology after recovery. The data indicate an important role for KCP in attenuating the pathology of renal fibrotic disease.	Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Dressler, GR (corresponding author), Univ Michigan, Dept Pathol, 1301 Catherine St, Ann Arbor, MI 48109 USA.	dressler@umich.edu	Phan, Sem H/A-7033-2009	Phan, Sem H/0000-0002-3711-2159	NHLBI NIH HHS [HL52285] Funding Source: Medline; NIDDK NIH HHS [DK02803, DK062914] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052285] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062914, K08DK002803] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abreu JG, 2002, GENE, V287, P39, DOI 10.1016/S0378-1119(01)00827-7; Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Almanzar MM, 1998, J AM SOC NEPHROL, V9, P1456; Brophy PD, 2001, DEVELOPMENT, V128, P4747; Capdevila J, 1999, CURR OPIN GENET DEV, V9, P427, DOI 10.1016/S0959-437X(99)80065-3; Chevalier RL, 1999, PEDIATR NEPHROL, V13, P612, DOI 10.1007/s004670050756; Christian JL, 2000, CURR OPIN CELL BIOL, V12, P244, DOI 10.1016/S0955-0674(99)00082-4; Coles E, 2004, DEVELOPMENT, V131, P5309, DOI 10.1242/dev.01419; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; Gould SE, 2002, KIDNEY INT, V61, P51, DOI 10.1046/j.1523-1755.2002.00103.x; Herzlinger D, 2002, J CLIN INVEST, V110, P305, DOI 10.1172/JCI200216377; Hruska KA, 2000, AM J PHYSIOL-RENAL, V279, pF130, DOI 10.1152/ajprenal.2000.279.1.F130; Imgrund M, 1999, KIDNEY INT, V56, P1423, DOI 10.1046/j.1523-1755.1999.00663.x; Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518; JOYNER AL, 1993, GENE TARGETING PRACT, P33; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Klahr S, 2003, KIDNEY INT, V64, pS105, DOI 10.1046/j.1523-1755.64.s87.16.x; Kopp JB, 2000, KIDNEY INT, V58, P2237, DOI 10.1046/j.1523-1755.2000.00402.x; Kopp JB, 1996, LAB INVEST, V74, P991; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Laitinen L, 1987, J HISTOCHEM CYTOCHEM, V35, P55, DOI 10.1177/35.1.3794309; Larrain J, 2000, DEVELOPMENT, V127, P821; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Matsui M, 2000, P NATL ACAD SCI USA, V97, P5291, DOI 10.1073/pnas.090020497; Miyazaki Y, 2000, J CLIN INVEST, V105, P863, DOI 10.1172/JCI8256; Moser M, 2003, MOL CELL BIOL, V23, P5664, DOI 10.1128/MCB.23.16.5664-5679.2003; Nishimura R, 2003, FRONT BIOSCI, V8, pS275, DOI 10.2741/1049; Nony PA, 2003, J PHARMACOL EXP THER, V304, P905, DOI 10.1124/jpet.102.035022; PHAN SH, 1980, AM REV RESPIR DIS, V121, P501, DOI 10.1164/arrd.1980.121.3.501; Safirstein R, 1999, KIDNEY INT, V56, P1599, DOI 10.1046/j.1523-1755.1999.00718.x; Schnaper HW, 2003, AM J PHYSIOL-RENAL, V284, pF243, DOI 10.1152/ajprenal.00300.2002; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; Vukicevic S, 1998, J CLIN INVEST, V102, P202, DOI 10.1172/JCI2237; Zeisberg M, 2003, AM J PHYSIOL-RENAL, V285, pF1060, DOI 10.1152/ajprenal.00191.2002; Zeisberg M, 2003, NAT MED, V9, P964, DOI 10.1038/nm888; Zwijsen A, 2003, FEBS LETT, V546, P133, DOI 10.1016/S0014-5793(03)00566-0	37	144	155	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2005	11	4					387	393		10.1038/nm1217	http://dx.doi.org/10.1038/nm1217			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15793581				2022-12-25	WOS:000228180500029
J	van Es, JH; Jay, P; Gregorieff, A; van Gijn, ME; Jonkheer, S; Hatzis, P; Thiele, A; van den Born, M; Begthel, H; Brabletz, T; Taketo, MM; Clevers, H				van Es, JH; Jay, P; Gregorieff, A; van Gijn, ME; Jonkheer, S; Hatzis, P; Thiele, A; van den Born, M; Begthel, H; Brabletz, T; Taketo, MM; Clevers, H			Wnt signalling induces maturation of Paneth cells in intestinal crypts	NATURE CELL BIOLOGY			English	Article							BETA-CATENIN; METALLOPROTEINASE MATRILYSIN; FUNCTIONAL INTERACTION; COLORECTAL-CANCER; ALPHA-DEFENSINS; ACTIVATION; COMPLEX; MICE; AXIN	Wnt signalling, which is transduced through beta-catenin/TCF4, maintains the undifferentiated state of intestinal crypt progenitor cells(1,2). Mutational activation of the pathway initiates the adenomacarcinoma sequence(3,4). Whereas all other differentiated epithelial cells migrate from the crypt onto the villus, Paneth cells home towards the source of Wnt signals - that is, the crypt bottom. Here, we show that expression of a Paneth gene programme is critically dependent on TCF4 in embryonic intestine. Moreover, conditional deletion of the Wnt receptor Frizzled-5 abrogates expression of these genes in Paneth cells in the adult intestine. Conversely, adenomas in Apc-mutant mice and colorectal cancers in humans inappropriately express these Paneth-cell genes. These observations imply that Wnt signals in the crypt can separately drive a stem-cell/progenitor gene programme and a Paneth-cell maturation programme. In intestinal cancer, both gene programmes are activated simultaneously.	Netherlands Inst Dev Biol, Hubrecht Inst, NL-3584 CT Utrecht, Netherlands; CNRS, UPR 1142, Inst Genet Humaine, F-34396 Montpellier, France; Univ Erlangen Nurnberg, Dept Pathol, D-91054 Erlangen, Germany; Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; University of Erlangen Nuremberg; Kyoto University	Clevers, H (corresponding author), Netherlands Inst Dev Biol, Hubrecht Inst, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	clevers@niob.knaw.nl	Jay, Philippe/ABD-9223-2020; Eckhardt, Erik/G-1567-2010; van+Es, Johan/ABD-5411-2021; Jay, Philippe/I-7116-2016	Jay, Philippe/0000-0003-0156-5700; Jay, Philippe/0000-0003-0156-5700				Ayabe T, 2002, J BIOL CHEM, V277, P5219, DOI 10.1074/jbc.M109410200; Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; BANCROFT JD, 1996, THEORY PRACTICE HIST, P304; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hatzis P, 2001, MOL CELL BIOL, V21, P7320, DOI 10.1128/MCB.21.21.7320-7330.2001; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ishikawa T, 2001, DEVELOPMENT, V128, P25; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Krause R, 1998, DIFFERENTIATION, V63, P285, DOI 10.1046/j.1432-0436.1998.6350285.x; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Marshman E, 2002, BIOESSAYS, V24, P91, DOI 10.1002/bies.10028; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moller P, 1996, AM J PATHOL, V149, P9; Moorman AFM, 2001, J HISTOCHEM CYTOCHEM, V49, P1, DOI 10.1177/002215540104900101; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Porter EM, 2002, CELL MOL LIFE SCI, V59, P156, DOI 10.1007/s00018-002-8412-z; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Salzman NH, 2003, NATURE, V422, P522, DOI 10.1038/nature01520; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; van Beest M, 2000, J BIOL CHEM, V275, P27266; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113	30	467	477	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2005	7	4					381	U37		10.1038/ncb1240	http://dx.doi.org/10.1038/ncb1240			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	912KA	15778706				2022-12-25	WOS:000228075500014
J	Aharoni, A; Gaidukov, L; Khersonsky, O; Gould, SM; Roodveldt, C; Tawfik, DS				Aharoni, A; Gaidukov, L; Khersonsky, O; Gould, SM; Roodveldt, C; Tawfik, DS			The 'evolvability' of promiscuous protein functions	NATURE GENETICS			English	Article							CONFORMATIONAL DIVERSITY; CATALYTIC PROMISCUITY; DIRECTED EVOLUTION; ENZYME; SPECIFICITY; SUBSTRATE; PARAOXONASES; MECHANISM; BINDING; FAMILY	How proteins with new functions (e. g., drug or antibiotic resistance or degradation of man-made chemicals) evolve in a matter of months or years is still unclear. This ability is dependent on the induction of new phenotypic traits by a small number of mutations (plasticity). But mutations often have deleterious effects on functions that are essential for survival. How are these seemingly conflicting demands met at the single-protein level? Results from directed laboratory evolution experiments indicate that the evolution of a new function is driven by mutations that have little effect on the native function but large effects on the promiscuous functions that serve as starting point. Thus, an evolving protein can initially acquire increased fitness for a new function without losing its original function. Gene duplication and the divergence of a completely new protein may then follow.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Tawfik, DS (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	tawfik@weizmann.ac.il	Roodveldt, Cintia/I-9118-2014	Roodveldt, Cintia/0000-0003-4124-8769; Aharoni, Amir/0000-0003-2701-6996				Aharoni A, 2004, P NATL ACAD SCI USA, V101, P482, DOI 10.1073/pnas.2536901100; Arnold FH, 2001, TRENDS BIOCHEM SCI, V26, P100, DOI 10.1016/S0968-0004(00)01755-2; BONE R, 1989, NATURE, V339, P191, DOI 10.1038/339191a0; BORNSCHEUER UT, 2004, ANGEW CHEM INT EDIT, V43, P2; Chong YH, 2004, FRONT BIOSCI-LANDMRK, V9, P164, DOI 10.2741/1220; Copley SD, 2003, CURR OPIN CHEM BIOL, V7, P265, DOI 10.1016/S1367-5931(03)00032-2; Draganov DI, 2004, N-S ARCH PHARMACOL, V369, P78, DOI 10.1007/s00210-003-0833-1; Earl DJ, 2004, P NATL ACAD SCI USA, V101, P11531, DOI 10.1073/pnas.0404656101; Giraud A, 2001, SCIENCE, V291, P2606, DOI 10.1126/science.1056421; Harel M, 2004, NAT STRUCT MOL BIOL, V11, P412, DOI 10.1038/nsmb767; James LC, 2003, SCIENCE, V299, P1362, DOI 10.1126/science.1079731; James LC, 2003, PROTEIN SCI, V12, P2183, DOI 10.1110/ps.03172703; James LC, 2003, TRENDS BIOCHEM SCI, V28, P361, DOI 10.1016/S0968-0004(03)00135-X; James LC, 2001, PROTEIN SCI, V10, P2600, DOI 10.1110/ps.ps.14601; JENSEN RA, 1976, ANNU REV MICROBIOL, V30, P409, DOI 10.1146/annurev.mi.30.100176.002205; Kirschner M, 1998, P NATL ACAD SCI USA, V95, P8420, DOI 10.1073/pnas.95.15.8420; KREBS JF, 1993, J BIOL CHEM, V268, P27458; Lynch M, 2004, TRENDS GENET, V20, P544, DOI 10.1016/j.tig.2004.09.001; Matsumura I, 2001, J MOL BIOL, V305, P331, DOI 10.1006/jmbi.2000.4259; Miller BG, 2004, BIOCHEMISTRY-US, V43, P6387, DOI 10.1021/bi049424m; O'Brien PJ, 1999, CHEM BIOL, V6, pR91, DOI 10.1016/S1074-5521(99)80033-7; Pata JD, 2004, P NATL ACAD SCI USA, V101, P10548, DOI 10.1073/pnas.0404151101; Perona JJ, 1997, J BIOL CHEM, V272, P29987, DOI 10.1074/jbc.272.48.29987; Radman M, 1999, ANN NY ACAD SCI, V870, P146, DOI 10.1111/j.1749-6632.1999.tb08874.x; Raushel FM, 2000, ADV ENZYMOL RAMB, V74, P51; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; Taverna DM, 2002, J MOL BIOL, V315, P479, DOI 10.1006/jmbi.2001.5226; True HL, 2000, NATURE, V407, P477, DOI 10.1038/35035005; Wouters MA, 2003, MOL CELL, V12, P343, DOI 10.1016/S1097-2765(03)00308-3; Yang KC, 2004, P NATL ACAD SCI USA, V101, P7919, DOI 10.1073/pnas.0400664101	30	633	643	4	129	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2005	37	1					73	76		10.1038/ng1482	http://dx.doi.org/10.1038/ng1482			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	883FX	15568024				2022-12-25	WOS:000225997500023
J	Cohen, JI				Cohen, JI			Poorer nations turn to publicly developed GM crops	NATURE BIOTECHNOLOGY			English	Article							CARTAGENA		Int Food Policy Res Inst, Environm & Prod Technol Div, 2033 K St NW, Washington, DC 20036 USA	CGIAR; International Food Policy Research Institute (IFPRI)	Cohen, JI (corresponding author), Int Food Policy Res Inst, Environm & Prod Technol Div, 2033 K St NW, Washington, DC 20036 USA.	j.cohen@cgiar.org	Cohen, Joel I/L-7478-2016	Cohen, Joel I/0000-0002-2390-5983				ABDALLAH R, 2004, INITIATING AGR BIOTE; [Anonymous], 2004, EPTD DISCUSSION PAPE; *AS DEV BANK, 2001, AGR BIOT POV RED FOO; COHEN J, 2001, J HUMAN DEV, V2, P239; Cohen JI, 2004, WORLD DEV, V32, P1563, DOI 10.1016/j.worlddev.2004.05.003; De Greef W, 2004, NAT BIOTECHNOL, V22, P811, DOI 10.1038/nbt0704-811; *FAO BIODEC, 2003, DAT BIOT DEV COUNTR; *FOOD AGR ORG, 2004, STAT FOOD AGR SOFA R; GOODMAN MM, 2000, ANN CORN SORGHUM RES, V55, P149; Hall A., 2002, Agricultural research policy in an era of privatization, P155, DOI 10.1079/9780851996004.0155; Josling T, 2004, FOOD REGULATION TRAD; KAMERIMBOTE P, 2001, PUBLIC PRIVATE PARTN; MAHONEY MM, 2004, 78 ISNAR PROGR; MUGOYA C, 2004, RESOURCE BOOK IMPLEM; PARDEY B, 2003, BIOTECHNOL GENET ENG, P1; PHILLIPS PWB, 2003, BIOTECHNOL GENET ENG, P1; PUTTAANYYAWONG T, 2004, THAI CABINET OVERTUR; SPIELMAN D, 2004, 11 EPTD INT FOOD POL; Swaminathan M, 2004, REPORT TASK FORCE AP; *UN EC COMM AFR, 2002, HARN TECHN SUST DEV; Watanabe KN, 2004, NAT BIOTECHNOL, V22, P1207, DOI 10.1038/nbt1004-1207b; WONGANAN N, 2004, USA TODAY       0823	22	86	95	0	27	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2005	23	1					27	33		10.1038/nbt0105-27	http://dx.doi.org/10.1038/nbt0105-27			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	885ZK	15637614				2022-12-25	WOS:000226195700017
J	Hirasawa, A; Tsumaya, K; Awaji, T; Katsuma, S; Adachi, T; Yamada, M; Sugimoto, Y; Miyazaki, S; Tsujimoto, G				Hirasawa, A; Tsumaya, K; Awaji, T; Katsuma, S; Adachi, T; Yamada, M; Sugimoto, Y; Miyazaki, S; Tsujimoto, G			Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120	NATURE MEDICINE			English	Article							PROTEIN-COUPLED RECEPTORS; GREEN FLUORESCENT PROTEIN; INSULIN-SECRETION; GENE-EXPRESSION; ALPHA(1B)-ADRENOCEPTOR; CELLS; GPR40	Diabetes, a disease in which the body does not produce or use insulin properly, is a serious global health problem(1-3). Gut polypeptides secreted in response to food intake, such as glucagon-like peptide-1 (GLP-1), are potent incretin hormones that enhance the glucose-dependent secretion of insulin from pancreatic beta cells(4-6). Free fatty acids (FFAs) provide an important energy source and also act as signaling molecules in various cellular processes, including the secretion of gut incretin peptides(7,8). Here we show that a G-protein-coupled receptor, GPR120, which is abundantly expressed in intestine, functions as a receptor for unsaturated long-chain FFAs. Furthermore, we show that the stimulation of GPR120 by FFAs promotes the secretion of GLP-1 in vitro and in vivo, and increases circulating insulin. Because GLP-1 is the most potent insulinotropic incretin(9,10), our results indicate that GPR120-mediated GLP-1 secretion induced by dietary FFAs is important in the treatment of diabetes.	Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Genom Drug Discovery Sci, Sakyo Ku, Kyoto 6068501, Japan; Natl Res Inst Child Hlth & Dev, Dept Mol Cell Pharmacol, Setagaya Ku, Tokyo 1548567, Japan; Keio Univ, Tokyo 1608582, Japan; Tokyo Womens Med Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo 1628666, Japan; Kyoto Univ, Inst Chem Res, Bioinformat Ctr, Kyoto 6110011, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University; National Center for Child Health & Development - Japan; Keio University; Tokyo Women's Medical University; Kyoto University; Kyoto University	Tsujimoto, G (corresponding author), Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Genom Drug Discovery Sci, Sakyo Ku, 46-29 Yoshida Shimoadachi Cho, Kyoto 6068501, Japan.	gtsuji@pharm.kyoto-u.ac.jp	Sugimoto, Yukihiko/AAV-6470-2021; Adachi, Tetsuya/A-3330-2014	Sugimoto, Yukihiko/0000-0001-6973-932X; Adachi, Tetsuya/0000-0002-5746-5031				Awaji T, 1998, MOL ENDOCRINOL, V12, P1099, DOI 10.1210/me.12.8.1099; Awaji T, 2001, BIOCHEM BIOPH RES CO, V289, P457, DOI 10.1006/bbrc.2001.6004; Briscoe CP, 2003, J BIOL CHEM, V278, P11303, DOI 10.1074/jbc.M211495200; Brown AJ, 2003, J BIOL CHEM, V278, P11312, DOI 10.1074/jbc.M211609200; Cao XM, 2003, ENDOCRINOLOGY, V144, P2025, DOI 10.1210/en.2002-0049; CREUTZFELDT W, 1985, DIABETOLOGIA, V28, P565, DOI 10.1007/BF00281990; Ding GJF, 1998, J BIOL CHEM, V273, P28897, DOI 10.1074/jbc.273.44.28897; Drucker DJ, 2003, MOL ENDOCRINOL, V17, P161, DOI 10.1210/me.2002-0306; Fredriksson R, 2003, FEBS LETT, V554, P381, DOI 10.1016/S0014-5793(03)01196-7; Gadsby R, 2002, ADV DRUG DELIVER REV, V54, P1165, DOI 10.1016/S0169-409X(02)00094-7; Gevrey JC, 2002, J BIOL CHEM, V277, P22407, DOI 10.1074/jbc.M201624200; Guimbaud R, 1997, PANCREAS, V14, P76, DOI 10.1097/00006676-199701000-00012; Hirasawa A, 1997, MOL PHARMACOL, V52, P764, DOI 10.1124/mol.52.5.764; Holst JJ, 2001, SCAND J CLIN LAB INV, V61, P75, DOI 10.1080/713783697; HORIE K, 1994, EUR J PHARM-MOLEC PH, V268, P399, DOI 10.1016/0922-4106(94)90065-5; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; Jovanovic L, 1999, ANN CLIN LAB SCI, V29, P33; Kieffer TJ, 1999, ENDOCR REV, V20, P876, DOI 10.1210/er.20.6.876; KREYMANN B, 1987, LANCET, V2, P1300; MacDonald PE, 2002, DIABETES, V51, pS434, DOI 10.2337/diabetes.51.2007.S434; Milligan G, 1996, TRENDS PHARMACOL SCI, V17, P235, DOI 10.1016/0165-6147(96)10026-2; Nilsson NE, 2003, BIOCHEM BIOPH RES CO, V303, P1047, DOI 10.1016/S0006-291X(03)00488-1; Nunez EA, 1997, PROSTAG LEUKOTR ESS, V57, P107, DOI 10.1016/S0952-3278(97)90500-7; Reimer RA, 2001, ENDOCRINOLOGY, V142, P4522, DOI 10.1210/en.142.10.4522; Sidhu SS, 2000, J PHYSIOL-LONDON, V528, P165, DOI 10.1111/j.1469-7793.2000.00165.x; Thomsen C, 2003, AM J CLIN NUTR, V77, P605, DOI 10.1093/ajcn/77.3.605; Trogan E, 2002, P NATL ACAD SCI USA, V99, P2234, DOI 10.1073/pnas.042683999; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; Vilsboll T, 2003, J CLIN ENDOCR METAB, V88, P2706, DOI 10.1210/jc.2002-021873; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	30	1083	1168	3	159	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2005	11	1					90	94		10.1038/nm1168	http://dx.doi.org/10.1038/nm1168			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	884ZJ	15619630				2022-12-25	WOS:000226124900038
J	Segre, D; DeLuna, A; Church, GM; Kishony, R				Segre, D; DeLuna, A; Church, GM; Kishony, R			Modular epistasis in yeast metabolism	NATURE GENETICS			English	Article							DELETERIOUS MUTATIONS; NETWORK; ORGANIZATION; PRINCIPLES; EVOLUTION; STRAINS; BIOLOGY; FLUX	Epistatic interactions, manifested in the effects of mutations on the phenotypes caused by other mutations, may help uncover the functional organization of complex biological networks(1-3). Here, we studied system-level epistatic interactions by computing growth phenotypes of all single and double knockouts of 890 metabolic genes in Saccharomyces cerevisiae, using the framework of flux balance analysis(4). A new scale for epistasis identified a distinctive trimodal distribution of these epistatic effects, allowing gene pairs to be classified as buffering, aggravating or noninteracting(2,5). We found that the ensuing epistatic interaction network(6) could be organized hierarchically into function-enriched modules that interact with each other 'monochromatically' (i.e., with purely aggravating or purely buffering epistatic links). This property extends the concept of epistasis from single genes to functional units and provides a new definition of biological modularity, which emphasizes interactions between, rather than within, functional modules. Our approach can be used to infer functional gene modules from purely phenotypic epistasis measurements.	Harvard Univ, Bauer Ctr Genom Res, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Lipper Ctr Computat Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Kishony, R (corresponding author), Harvard Univ, Bauer Ctr Genom Res, 7 Divin Ave, Cambridge, MA 02138 USA.	rkishony@cgr.harvard.edu	DeLuna, Alexander/H-9986-2016; Segrè, Daniel/A-1993-2009	DeLuna, Alexander/0000-0002-9236-2804; Segrè, Daniel/0000-0003-4859-1914; church, george/0000-0001-6232-9969				Anholt RRH, 2003, NAT GENET, V35, P180, DOI 10.1038/ng1240; Burch CL, 2003, J EVOLUTION BIOL, V16, P1223, DOI 10.1046/j.1420-9101.2003.00632.x; DYKHUIZEN DE, 1987, GENETICS, V115, P25; Elena SF, 1997, NATURE, V390, P395, DOI 10.1038/37108; Elena SF, 1999, J MOL EVOL, V49, P703, DOI 10.1007/PL00000082; Famili I, 2003, P NATL ACAD SCI USA, V100, P13134, DOI 10.1073/pnas.2235812100; Fong SS, 2004, NAT GENET, V36, P1056, DOI 10.1038/ng1432; Forster J, 2003, GENOME RES, V13, P244, DOI 10.1101/gr.234503; Hartman JL, 2001, SCIENCE, V291, P1001, DOI 10.1126/science.291.5506.1001; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Ihmels J, 2004, NAT BIOTECHNOL, V22, P86, DOI 10.1038/nbt918; Kauffman KJ, 2003, CURR OPIN BIOTECH, V14, P491, DOI 10.1016/j.copbio.2003.08.001; Kaufman A, 2004, 2004 IEEE COMPUTATIONAL SYSTEMS BIOINFORMATICS CONFERENCE, PROCEEDINGS, P332; Kishony Roy, 2003, J Biol, V2, P14, DOI 10.1186/1475-4924-2-14; Klamt S, 2004, BIOINFORMATICS, V20, P226, DOI 10.1093/bioinformatics/btg395; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; Lenski RE, 1999, NATURE, V400, P661, DOI 10.1038/23245; Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824; Papin JA, 2004, TRENDS BIOCHEM SCI, V29, P641, DOI 10.1016/j.tibs.2004.10.001; Papp B, 2004, NATURE, V429, P661, DOI 10.1038/nature02636; Phillips PC., 2000, EPISTASIS EVOLUTIONA, P20; Ravasz E, 2002, SCIENCE, V297, P1551, DOI 10.1126/science.1073374; Remold SK, 2004, NAT GENET, V36, P423, DOI 10.1038/ng1324; Salthe S., 1985, EVOLVING HIERARCHICA; Segal E, 2003, NAT GENET, V34, P166, DOI 10.1038/ng1165; Segre D, 2002, P NATL ACAD SCI USA, V99, P15112, DOI 10.1073/pnas.232349399; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Wloch DM, 2001, J EVOLUTION BIOL, V14, P310, DOI 10.1046/j.1420-9101.2001.00267.x; You LC, 2002, GENETICS, V160, P1273	30	439	452	1	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2005	37	1					77	83		10.1038/ng1489	http://dx.doi.org/10.1038/ng1489			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	883FX	15592468				2022-12-25	WOS:000225997500024
J	Turner, JMA; Mahadevaiah, SK; Fernandez-Capetillo, O; Nussenzweig, A; Xu, XL; Deng, CX; Burgoyne, PS				Turner, JMA; Mahadevaiah, SK; Fernandez-Capetillo, O; Nussenzweig, A; Xu, XL; Deng, CX; Burgoyne, PS			Silencing of unsynapsed meiotic chromosomes in the mouse	NATURE GENETICS			English	Article							X-CHROMOSOME; SYNAPTONEMAL COMPLEXES; MICE; BRCA1; MEIOSIS; PROTEIN; CELLS; SPERMATOGENESIS; ASSOCIATION; MUTATION	In Neurospora, DNA unpaired in meiosis both is silenced and induces silencing of all DNA homologous to it. This process, called meiotic silencing by unpaired DNA, is thought to protect the host genome from invasion by transposable elements. We now show that silencing of unpaired (unsynapsed) chromosome regions also takes place in the mouse during both male and female meiosis. The tumor suppressor protein BRCA1 is implicated in this silencing, mirroring its role in the meiotic silencing of the X and Y chromosomes in normal male meiosis. These findings impact on the interpretation of the relationship between synaptic errors and sterility in mammals and extend our understanding of the biology of Brca1.	Natl Inst Med Res, MRC, Div Stem Cell Res & Dev Genet, London NW7 1AA, England; NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA	MRC National Institute for Medical Research; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Turner, JMA (corresponding author), Natl Inst Med Res, MRC, Div Stem Cell Res & Dev Genet, Mill Hill, London NW7 1AA, England.	jturner@nimr.mrc.ac.uk	deng, chuxia/N-6713-2016; Fernandez-Capetillo, Oscar/H-3508-2015	Fernandez-Capetillo, Oscar/0000-0002-2690-6885	MRC [MC_U117532009] Funding Source: UKRI; Medical Research Council [MC_U117532009, MC_U117588498] Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC010283, Z01BC010283] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056001, ZIADK056001] Funding Source: NIH RePORTER	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON LK, 1988, CHROMOSOMA, V96, P295, DOI 10.1007/BF00286917; Ashley T, 2000, Results Probl Cell Differ, V28, P131; BAARENDS WM, IN PRESS MOL CELL BI; Bean CJ, 2004, NAT GENET, V36, P100, DOI 10.1038/ng1283; Boer P. de, 1989, Fertility and chromosome pairing: recent studies in plants and animals., P37; Burgoyne P S, 1984, Symp Soc Exp Biol, V38, P349; Burgoyne P. S., 1993, Chromosomes today: volume 11., P243; BURGOYNE PS, 1985, J REPROD FERTIL, V75, P633, DOI 10.1530/jrf.0.0750633; Burgoyne PS, 2000, CYTOGENET CELL GENET, V91, P57, DOI 10.1159/000056819; BURGOYNE PS, 1981, J REPROD FERTIL, V61, P207, DOI 10.1530/jrf.0.0610207; Fernandez-Capetillo O, 2003, J CELL BIOL, V163, P15, DOI 10.1083/jcb.200305124; FORD CE, 1964, CYTOGENETICS, V3, P295, DOI 10.1159/000129819; Hall LL, 2002, P NATL ACAD SCI USA, V99, P8677, DOI 10.1073/pnas.132468999; Handel MA, 2004, EXP CELL RES, V296, P57, DOI 10.1016/j.yexcr.2004.03.008; Huynh KD, 2003, NATURE, V426, P857, DOI 10.1038/nature02222; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; LAMMERS JHM, 1994, MOL CELL BIOL, V14, P1137, DOI 10.1128/MCB.14.2.1137; LYON MF, 1973, GENET RES, V21, P185, DOI 10.1017/S0016672300013355; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; MAHADEVAIAH SK, 1993, J REPROD FERTIL, V97, P151, DOI 10.1530/jrf.0.0970151; MIKLOS GLG, 1974, CYTOGENET CELL GENET, V13, P558, DOI 10.1159/000130307; Moens PB, 1999, CHROMOSOMA, V108, P95, DOI 10.1007/s004120050356; Moens PB, 2002, J CELL SCI, V115, P1611; MOORE GPM, 1971, EXP CELL RES, V68, P462, DOI 10.1016/0014-4827(71)90176-5; Odorisio T, 1998, NAT GENET, V18, P257, DOI 10.1038/ng0398-257; Peters AHFM, 1997, CHROMOSOME RES, V5, P313, DOI 10.1023/B:CHRO.0000038762.60086.ef; Plug AW, 1998, J CELL SCI, V111, P413; Roeder GS, 2000, TRENDS GENET, V16, P395, DOI 10.1016/S0168-9525(00)02080-1; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shiu PKT, 2001, CELL, V107, P905, DOI 10.1016/S0092-8674(01)00609-2; SPEED RM, 1986, CHROMOSOMA, V94, P115, DOI 10.1007/BF00286989; Turner JMA, 2000, CHROMOSOMA, V109, P426, DOI 10.1007/s004120000097; TURNER JMA, IN PRESS CURR BIOL; Wang PJ, 2004, TRENDS ENDOCRIN MET, V15, P79, DOI 10.1016/j.tem.2004.01.007; Xu LH, 1997, GENE DEV, V11, P106, DOI 10.1101/gad.11.1.106; Xu XL, 2003, DEVELOPMENT, V130, P2001, DOI 10.1242/dev.00410; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Zickler D, 1999, ANNU REV GENET, V33, P603, DOI 10.1146/annurev.genet.33.1.603	39	424	442	0	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2005	37	1					41	47		10.1038/ng1484	http://dx.doi.org/10.1038/ng1484			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	883FX	15580272				2022-12-25	WOS:000225997500019
J	Rotimi, CN				Rotimi, CN			Are medical and nonmedical uses of large-scale genomic markers conflating genetics and 'race'?	NATURE GENETICS			English	Article							LINKAGE DISEQUILIBRIUM; APOLIPOPROTEIN-E; COMPLEX DISEASE; SUSCEPTIBILITY; GENES; DIVERSITY; RISK; POLYMORPHISM; ASSOCIATION; ETHNICITY		Howard Univ, Coll Med, Natl Human Genome Ctr, Washington, DC 20059 USA	Howard University	Rotimi, CN (corresponding author), Howard Univ, Coll Med, Natl Human Genome Ctr, Washington, DC 20059 USA.	crotimi@howard.edu						Allen M, 2003, NAT GENET, V35, P258, DOI 10.1038/ng1256; Altshuler D, 2000, NAT GENET, V26, P76, DOI 10.1038/79216; [Anonymous], 2002, NAT BIOTECHNOL, V20, P637, DOI 10.1038/nbt0702-637; Bamshad M, 2004, NAT REV GENET, V5, P598, DOI 10.1038/nrg1401; Bamshad MJ, 2003, AM J HUM GENET, V72, P578, DOI 10.1086/368061; Barbujani G, 1997, P NATL ACAD SCI USA, V94, P4516, DOI 10.1073/pnas.94.9.4516; BELL GI, 1984, DIABETES, V33, P176, DOI 10.2337/diabetes.33.2.176; Bell J, 2004, NATURE, V429, P453, DOI 10.1038/nature02624; Beutler E, 1996, BLOOD CELL MOL DIS, V22, P49, DOI 10.1006/bcmd.1996.0008; Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090; Braun L, 2002, PERSPECT BIOL MED, V45, P159, DOI 10.1353/pbm.2002.0023; Burchard EG, 2003, NEW ENGL J MED, V348, P1170, DOI 10.1056/NEJMsb025007; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; Cardon LR, 2003, TRENDS GENET, V19, P135, DOI 10.1016/S0168-9525(03)00022-2; Carlson CS, 2004, NATURE, V429, P446, DOI 10.1038/nature02623; Clark AG, 2003, CURR OPIN GENET DEV, V13, P296, DOI 10.1016/S0959-437X(03)00056-X; Clayton EW, 2002, J LAW MED ETHICS, V30, P290, DOI 10.1111/j.1748-720X.2002.tb00395.x; Cooper RS, 2003, NEW ENGL J MED, V348, P1166, DOI 10.1056/NEJMsb022863; Cooper RS, 2003, ANN INTERN MED, V138, P576, DOI 10.7326/0003-4819-138-7-200304010-00014; Dahlback B, 1997, REV INVEST CLIN, V49, P3; Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229; Deloukas P, 2004, PHARMACOGENOMICS J, V4, P88, DOI 10.1038/sj.tpj.6500226; DORMAN JS, 1990, P NATL ACAD SCI USA, V87, P7370, DOI 10.1073/pnas.87.19.7370; DUSTER T, 2003, SAN FRANCISCO CHRONI; Elias, 1992, GENE MAPPING USING L, P94; ELLISON GTH, 2002, PSYCHOPATHOLOGY SOCI, P130; ELLISON GTH, 2002, CRITICAL PUBLIC HLTH, V12, P265; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Foster MW, 2004, NAT REV GENET, V5, P467, DOI 10.1038/nrg1351; Foster MW, 2002, GENOME RES, V12, P844, DOI 10.1101/gr.99202; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Goldstein DB, 2001, CURR BIOL, V11, pR576, DOI 10.1016/S0960-9822(01)00348-7; Gretarsdottir S, 2003, NAT GENET, V35, P131, DOI 10.1038/ng1245; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Juengst ET, 1998, AM J HUM GENET, V63, P673, DOI 10.1086/302032; Kahn J, 2003, PERSPECT BIOL MED, V46, P473, DOI 10.1353/pbm.2003.0087; KAHN J, 2004, YALE J HLTH POLICY L, V6, P1; Kevles, 1995, NAME EUGENICS GENETI; Kittles RA, 2003, ANNU REV GENOM HUM G, V4, P33, DOI 10.1146/annurev.genom.4.070802.110356; LAZAROU J, 1998, JAMA-J AM MED ASSOC, V15, P200; LUZZATTO L, 1995, METABOLIC MOL BASES, P3367; Nebert D. W., 2001, Pharmacogenomics Journal, V1, P19; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; OLSON S, 2001, ATLANTIC MONTHLY APR; Pollack A., 2003, NY TIMES; Pollack A., 2004, NY TIMES; Pritchard JK, 2001, AM J HUM GENET, V69, P124, DOI 10.1086/321272; Pritchard JK, 2002, HUM MOL GENET, V11, P2417, DOI 10.1093/hmg/11.20.2417; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; RISCH N, 2002, GENOME BIOL, V1, P3; Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; Sankar P, 2002, SCIENCE, V298, P1337, DOI 10.1126/science.1074447; Shriver MD, 2004, NAT REV GENET, V5, P611, DOI 10.1038/nrg1405; Smedley A, 1999, RACE N AM ORIGIN EVO; Stefansson H, 2002, AM J HUM GENET, V71, P877, DOI 10.1086/342734; Strittmatter WJ, 1996, ANNU REV NEUROSCI, V19, P53, DOI 10.1146/annurev.ne.19.030196.000413; Taylor AL, 2002, J NATL MED ASSOC, V94, P762; Tishkoff SA, 2002, NAT REV GENET, V3, P611, DOI 10.1038/nrg865; Tishkoff SA, 2003, ANNU REV GENOM HUM G, V4, P293, DOI 10.1146/annurev.genom.4.070802.110226; Tishkoff SA, 2001, SCIENCE, V293, P455, DOI 10.1126/science.1061573; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; VANDEVIJVER MJ, 2002, NEW ENGL J MED, V25, P347; Weiss KM, 2002, TRENDS GENET, V18, P19, DOI 10.1016/S0168-9525(01)02550-1; Wilson JF, 2001, NAT GENET, V29, P265, DOI 10.1038/ng761; Witzig R, 1996, ANN INTERN MED, V125, P675, DOI 10.7326/0003-4819-125-8-199610150-00008; Yu N, 2002, MOL BIOL EVOL, V19, P2131, DOI 10.1093/oxfordjournals.molbev.a004038; [No title captured]; 2003, NAT GENET, V29, P239	71	54	55	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2004	36	11		S			S43	S47		10.1038/ng1439	http://dx.doi.org/10.1038/ng1439			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	867PH	15508002	Bronze			2022-12-25	WOS:000224854000010
J	Mack, GS				Mack, GS			Can complexity be commercialized?	NATURE BIOTECHNOLOGY			English	Article																		Skomorovski K, 2003, BRIT J HAEMATOL, V123, P683, DOI 10.1046/j.1365-2141.2003.04696.x	1	22	24	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2004	22	10					1223	1229		10.1038/nbt1004-1223	http://dx.doi.org/10.1038/nbt1004-1223			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	860EU	15470456				2022-12-25	WOS:000224326100018
J	Fan, YL; Esmail, MA; Ansley, SJ; Blacque, OE; Boroevich, K; Ross, AJ; Moore, SJ; Badano, JL; May-Simera, H; Compton, DS; Green, JS; Lewis, RA; van Haelst, MM; Parfrey, PS; Baillie, DL; Beales, PL; Katsanis, N; Davidson, WS; Leroux, MR				Fan, YL; Esmail, MA; Ansley, SJ; Blacque, OE; Boroevich, K; Ross, AJ; Moore, SJ; Badano, JL; May-Simera, H; Compton, DS; Green, JS; Lewis, RA; van Haelst, MM; Parfrey, PS; Baillie, DL; Beales, PL; Katsanis, N; Davidson, WS; Leroux, MR			Mutations in a member of the Ras superfamily of small GTP-binding proteins causes Bardet-Biedl syndrome	NATURE GENETICS			English	Article							INTRAFLAGELLAR TRANSPORT; FAMILY; IDENTIFICATION; LOCALIZATION; REGION; LOCUS; CYCLE; ARF	RAB, ADP-ribosylation factors (ARFs) and ARF-like (ARL) proteins belong to the Ras superfamily of small GTP-binding proteins and are essential for various membrane-associated intracellular trafficking processes(1,2). None of the similar to50 known members of this family are linked to human disease. Using a bioinformatic screen for ciliary genes in combination with mutational analyses, we identified ARL6 as the gene underlying Bardet-Biedl syndrome type 3, a multisystemic disorder characterized by obesity, blindness, polydactyly, renal abnormalities and cognitive impairment(3,4). We uncovered four different homozygous substitutions in ARL6 in four unrelated families affected with Bardet-Biedl syndrome, two of which disrupt a threonine residue important for GTP binding(5) and function(5-7) of several related small GTP-binding proteins. Analysis of the Caenorhabditis elegans ARL6 homolog indicates that it is specifically expressed in ciliated cells, and that, in addition to the postulated cytoplasmic functions of ARL proteins, it undergoes intraflagellar transport. These findings implicate a small GTP-binding protein in ciliary transport and the pathogenesis of a pleiotropic disorder.	Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; Johns Hopkins Univ, Inst Med Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21205 USA; UCL, Inst Child Hlth, Mol Med Unit, London WC1 1EH, England; Mem Univ Newfoundland, Dept Clin Epidemiol, St John, NF, Canada; Mem Univ Newfoundland, Dept Med Genet, St John, NF, Canada; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Ophthalmol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Erasmus Univ, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands	Simon Fraser University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; University of London; University College London; Memorial University Newfoundland; Memorial University Newfoundland; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Erasmus University Rotterdam	Davidson, WS (corresponding author), Simon Fraser Univ, Dept Mol Biol & Biochem, 8888 Univ Dr, Burnaby, BC V5A 1S6, Canada.	wdavidso@sfu.ca; leroux@sfu.ca	Blacque, Oliver/AAL-8860-2021; Katsanis, Nicholas/E-1837-2012; Beales, Philip L/C-7367-2009	Blacque, Oliver/0000-0003-1598-2695; Badano, Jose/0000-0002-0706-8652; Boroevich, Keith/0000-0001-7095-7332; May-Simera, Helen/0000-0002-9477-4036; Katsanis, Nicholas/0000-0002-2480-0171				Ansley SJ, 2003, NATURE, V425, P628, DOI 10.1038/nature02030; Avidor-Reiss T, 2004, CELL, V117, P527, DOI 10.1016/S0092-8674(04)00412-X; Badano JL, 2003, HUM MOL GENET, V12, P1651, DOI 10.1093/hmg/ddg188; Beales PL, 1999, J MED GENET, V36, P437; Blacque OE, 2004, GENE DEV, V18, P1630, DOI 10.1101/gad.1194004; Cuvillier A, 2000, J CELL SCI, V113, P2065; DASCHER C, 1994, J BIOL CHEM, V269, P1437; Eddy SR, 1998, BIOINFORMATICS, V14, P755, DOI 10.1093/bioinformatics/14.9.755; Engel T, 2004, FEBS LETT, V566, P241, DOI 10.1016/j.febslet.2004.04.048; Ghadami M, 2000, AM J MED GENET, V94, P433, DOI 10.1002/1096-8628(20001023)94:5<433::AID-AJMG17>3.0.CO;2-X; Grayson C, 2002, HUM MOL GENET, V11, P3065, DOI 10.1093/hmg/11.24.3065; Haycraft CJ, 2003, EXP CELL RES, V284, P251, DOI 10.1016/S0014-4827(02)00089-7; Hickson GRX, 2003, MOL BIOL CELL, V14, P2908, DOI 10.1091/mbc.E03-03-0160; Huang CF, 2003, MOL BIOL CELL, V14, P3834, DOI 10.1091/mbc.E03-01-0013; Huber H, 1996, PLANT MOL BIOL, V31, P279, DOI 10.1007/BF00021790; Ingley E, 1999, FEBS LETT, V459, P69, DOI 10.1016/S0014-5793(99)01188-6; Katsanis N, 2001, SCIENCE, V293, P2256, DOI 10.1126/science.1063525; Katsanis N, 2004, HUM MOL GENET, V13, pR65, DOI 10.1093/hmg/ddh092; Kim JC, 2004, NAT GENET, V36, P462, DOI 10.1038/ng1352; Li JB, 2004, CELL, V117, P541, DOI 10.1016/S0092-8674(04)00450-7; Lu L, 2001, J CELL SCI, V114, P4543; Pasqualato S, 2002, EMBO REP, V3, P1035, DOI 10.1093/embo-reports/kvf221; Pasqualato S, 2001, EMBO REP, V2, P234, DOI 10.1093/embo-reports/kve043; Pazour GJ, 2002, TRENDS CELL BIOL, V12, P551, DOI 10.1016/S0962-8924(02)02410-8; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; SHEFFIELD VC, 1994, HUM MOL GENET, V3, P1331, DOI 10.1093/hmg/3.8.1331; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Young TL, 1998, AM J MED GENET, V78, P461, DOI 10.1002/(SICI)1096-8628(19980806)78:5<461::AID-AJMG12>3.0.CO;2-D	28	256	272	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2004	36	9					989	993		10.1038/ng1414	http://dx.doi.org/10.1038/ng1414			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	851AY	15314642	Bronze			2022-12-25	WOS:000223658100026
J	Bezzerides, VJ; Ramsey, IS; Kotecha, S; Greka, A; Clapham, DE				Bezzerides, VJ; Ramsey, IS; Kotecha, S; Greka, A; Clapham, DE			Rapid vesicular translocation and insertion of TRP channels	NATURE CELL BIOLOGY			English	Article							RHO-GTPASES; PLASMA-MEMBRANE; CALCIUM TRANSIENTS; CATION CHANNEL; GROWTH; RAC; EXOCYTOSIS; CELLS; PROTEINS; GUIDANCE	The broadly expressed transient receptor potential (TRP) family of ion channels are permeant to cations, most resulting in increased intracellular calcium. However, their regulation and gating is not well understood. Here, we report that growth factor stimulation initiates the rapid translocation of the transient receptor potential ion channel, TRPC5, from vesicles held in reserve just under the plasma membrane. This process, which we term 'rapid vesicular insertion of TRP' ( RiVIT), dramatically increases membrane-associated TRPC5 channels and functional TRPC5 current, resulting in tight spatial-temporal control of these Ca2+-permeant nonselective channels. Epidermal growth factor (EGF)-induced incorporation of functional TRP channels requires phosphatidylinositide 3-kinase (PI(3)K), the Rho GTPase Rac1 and phosphatidylinositol 4-phosphate 5-kinase (PIP(5)Kalpha). The increase in TRPC5 availability affects neurite extension rates in cultured hippocampal neurons, and may be a general mechanism for initiating Ca2+ influx and cell morphological changes in response to stimuli.	Childrens Hosp, Howard Hughes Med Inst, Cardiovasc Dept, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Grad Sch Arts & Sci, Program Biophys, Cambridge, MA 02318 USA; Harvard MIT Div Hlth Sci & Technol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Harvard University	Clapham, DE (corresponding author), Childrens Hosp, Howard Hughes Med Inst, Cardiovasc Dept, Enders 1309 32 Longwood Ave, Boston, MA 02115 USA.	dclapham@enders.tch.harvard.edu	Clapham, David/S-1123-2019; Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428; 	NHLBI NIH HHS [T32 HL007572] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Bai JH, 2004, TRENDS BIOCHEM SCI, V29, P143, DOI 10.1016/j.tibs.2004.01.008; Bai JH, 2004, NAT STRUCT MOL BIOL, V11, P36, DOI 10.1038/nsmb709; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Daub H, 2001, J BIOL CHEM, V276, P1677, DOI 10.1074/jbc.C000635200; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; Dietrich A, 2003, J BIOL CHEM, V278, P47842, DOI 10.1074/jbc.M302983200; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Gomez TM, 1999, NATURE, V397, P350, DOI 10.1038/16927; Gomez TM, 2001, SCIENCE, V291, P1983, DOI 10.1126/science.1056490; Greka A, 2003, NAT NEUROSCI, V6, P837, DOI 10.1038/nn1092; Gundelfinger ED, 2003, NAT REV MOL CELL BIO, V4, P127, DOI 10.1038/nrm1016; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HILGEMANN DW, 2001, SCI STKE; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Holz RW, 2000, J BIOL CHEM, V275, P17878, DOI 10.1074/jbc.M000925200; Jung S, 2003, J BIOL CHEM, V278, P3562, DOI 10.1074/jbc.M211484200; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Micheva KD, 2001, J CELL BIOL, V154, P355, DOI 10.1083/jcb.200102098; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; MLINAR B, 1993, J PHYSIOL-LONDON, V469, P639, DOI 10.1113/jphysiol.1993.sp019835; MONTELL C, 2001, SCI STKE, V90, P1; Ng J, 2002, NATURE, V416, P442, DOI 10.1038/416442a; Pinxteren JA, 2000, BIOCHIMIE, V82, P385, DOI 10.1016/S0300-9084(00)00197-8; Ren XD, 1998, CURR OPIN GENET DEV, V8, P63, DOI 10.1016/S0959-437X(98)80063-4; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Spitzer NC, 2002, J PHYSIOLOGY-PARIS, V96, P73, DOI 10.1016/S0928-4257(01)00082-1; Steyer JA, 1999, BIOPHYS J, V76, P2262, DOI 10.1016/S0006-3495(99)77382-0; Steyer JA, 2001, NAT REV MOL CELL BIO, V2, P268, DOI 10.1038/35067069; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Symons M, 2003, CURR BIOL, V13, pR409, DOI 10.1016/S0960-9822(03)00324-5; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tengholm A, 2002, CURR BIOL, V12, P1871, DOI 10.1016/S0960-9822(02)01223-X; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; van Horck FPG, 2002, CURR BIOL, V12, P241, DOI 10.1016/S0960-9822(01)00660-1; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; Xu XZS, 2003, CELL, V114, P285, DOI 10.1016/S0092-8674(03)00565-8; Yuan XB, 2003, NAT CELL BIOL, V5, P38, DOI 10.1038/ncb895; Zenisek D, 2002, NEURON, V35, P1085, DOI 10.1016/S0896-6273(02)00896-6; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	50	423	445	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2004	6	8					709	720		10.1038/ncb1150	http://dx.doi.org/10.1038/ncb1150			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	842YA	15258588				2022-12-25	WOS:000223039400009
J	Cao, L; Jiao, XY; Zuzga, DS; Liu, YH; Fong, DM; Young, D; During, MJ				Cao, L; Jiao, XY; Zuzga, DS; Liu, YH; Fong, DM; Young, D; During, MJ			VEGF links hippocampal activity with neurogenesis, learning and memory	NATURE GENETICS			English	Article							ENDOTHELIAL GROWTH-FACTOR; IN-VITRO; ENVIRONMENTAL ENRICHMENT; CELL-PROLIFERATION; RESPONSE ELEMENT; RAT-BRAIN; EXPRESSION; ANGIOGENESIS; VIVO; DIFFERENTIATION	An enriched environment is associated with hippocampal plasticity, including improved cognitive performance and increased neurogenesis. Here, we show that hippocampal expression of vascular endothelial growth factor ( VEGF) is increased by both an enriched environment and performance in a spatial maze. Hippocampal gene transfer of VEGF in adult rats resulted in similar to2 times more neurogenesis associated with improved cognition. In contrast, overexpression of placental growth factor, which signals through Flt1 but not kinase insert domain protein receptors (KDRs), had negative effects on neurogenesis and inhibited learning, although it similarly increased endothelial cell proliferation. Expression of a dominant-negative mutant KDR inhibited basal neurogenesis and impaired learning. Coexpression of mutant KDR antagonized VEGF-enhanced neurogenesis and learning without inhibiting endothelial cell proliferation. Furthermore, inhibition of VEGF expression by RNA interference completely blocked the environmental induction of neurogenesis. These data support a model in which VEGF, acting through KDR, mediates the effect of the environment on neurogenesis and cognition.	Cornell Univ, Weill Med Coll, Dept Neurol Surg, New York, NY 10021 USA; Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA; Univ Auckland, Dept Mol Med & Pathol, Lab Funct Genom & Translat Neurosci, Auckland, New Zealand	Cornell University; Jefferson University; University of Auckland	During, MJ (corresponding author), Cornell Univ, Weill Med Coll, Dept Neurol Surg, New York, NY 10021 USA.	mjd2002@med.cornell.edu	Cao, Lei/H-3185-2019; Cao, Lei/E-2841-2011; During, Matthew/AAC-1388-2020	Young, Deborah/0000-0003-1085-2824; Cao, Lei/0000-0003-0322-4985				Acker T, 2001, MECH DEVELOP, V108, P45, DOI 10.1016/S0925-4773(01)00471-3; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Cao L, 2000, J VIROL, V74, P11456, DOI 10.1128/JVI.74.24.11456-11463.2000; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Chen H, 1998, NEURON, V21, P1283, DOI 10.1016/S0896-6273(00)80648-0; Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721; Eriksson A, 2002, CANCER CELL, V1, P99, DOI 10.1016/S1535-6108(02)00028-4; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; Gustafsson T, 1999, AM J PHYSIOL-HEART C, V276, pH679, DOI 10.1152/ajpheart.1999.276.2.H679; Impey S, 1998, NAT NEUROSCI, V1, P595, DOI 10.1038/2830; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Klein RL, 2002, EXP NEUROL, V176, P66, DOI 10.1006/exnr.2002.7942; Lammert E, 2001, SCIENCE, V294, P564, DOI 10.1126/science.1064344; Lee MY, 1999, NEUROSCI LETT, V265, P107, DOI 10.1016/S0304-3940(99)00219-0; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Matsumoto K, 2001, SCIENCE, V294, P559, DOI 10.1126/science.1063889; Matsuzaki H, 2001, FASEB J, V15, P1218, DOI 10.1096/fj.00-0495fje; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Mukouyama Y, 2002, CELL, V109, P693, DOI 10.1016/S0092-8674(02)00757-2; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Ogunshola OO, 2002, J BIOL CHEM, V277, P11410, DOI 10.1074/jbc.M111085200; Ogunshola OO, 2000, DEV BRAIN RES, V119, P139, DOI 10.1016/S0165-3806(99)00125-X; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; PARK JE, 1994, J BIOL CHEM, V269, P25646; Rampon C, 2000, P NATL ACAD SCI USA, V97, P12880, DOI 10.1073/pnas.97.23.12880; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; WEATHERLY LS, 1996, BRAIN RES, V716, P29; Xu R, 2001, GENE THER, V8, P1323, DOI 10.1038/sj.gt.3301529; YARASHESKI KE, 1992, AM J PHYSIOL, V262, pE261, DOI 10.1152/ajpendo.1992.262.3.E261; Young D, 1999, NAT MED, V5, P448, DOI 10.1038/7449; Yourey PA, 2000, J NEUROSCI, V20, P6781, DOI 10.1523/JNEUROSCI.20-18-06781.2000; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200; Ziegler BL, 1999, SCIENCE, V285, P1553, DOI 10.1126/science.285.5433.1553	43	625	670	1	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2004	36	8					827	835		10.1038/ng1395	http://dx.doi.org/10.1038/ng1395			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	842AG	15258583				2022-12-25	WOS:000222974000014
J	Chudnovsky, Y; Adams, AE; Robbins, PB; Lin, Q; Khavari, PA				Chudnovsky, Y; Adams, AE; Robbins, PB; Lin, Q; Khavari, PA			Use of human tissue to assess the oncogenic activity of melanoma-associated mutations	NATURE GENETICS			English	Article							MALIGNANT-MELANOMA; BRAF MUTATIONS; GENE; TUMORIGENESIS; PROGRESSION; EXPRESSION; CANCER	Multiple genetic alterations occur in melanoma, a lethal skin malignancy of increasing incidence(1,2). These include mutations that activate Ras and two of its effector cascades, Raf and phosphoinositide 3- kinase ( PI3K). Induction of Ras and Raf can be caused by active N- Ras and B- Raf mutants as well as by gene amplification(3-5). Activation of PI3K pathway components occurs by PTEN loss and by AKT3 amplification(6-8). Melanomas also commonly show impairment of the p16(INK4A)- CDK4- Rb and ARF- HDM2- p53 tumor suppressor pathways. CDKN2A mutations can produce p16(INK4A) and ARF protein loss(5,9-11). Rb bypass can also occur through activating CDK4 mutations as well as by CDK4 amplification(5,12). In addition to ARF deletion, p53 pathway disruption can result from dominant negative TP53 mutations(5,13). TERT amplification also occurs in melanoma(5). The extent to which these mutations can induce human melanocytic neoplasia is unknown. Here we characterize pathways sufficient to generate human melanocytic neoplasia and show that genetically altered human tissue facilitates functional analysis of mutations observed in human tumors.	Vet Affairs Palo Alto Healthcare Syst, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Khavari, PA (corresponding author), Vet Affairs Palo Alto Healthcare Syst, Palo Alto, CA 94304 USA.	khavari@CMGM.stanford.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043799] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR043799, R01 AR043799-07] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBINO AP, 1994, MELANOMA RES, V4, P35, DOI 10.1097/00008390-199402000-00006; Beer S, 2004, PLOS BIOL, V2, P1785, DOI 10.1371/journal.pbio.0020332; Brooke S, 2004, EXP CELL RES, V298, P549, DOI 10.1016/j.yexcr.2004.04.035; Chang S, 2002, P NATL ACAD SCI USA, V99, P12520, DOI 10.1073/pnas.212514699; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Deng H, 1998, BIOTECHNIQUES, V25, P274, DOI 10.2144/98252gt02; Gilchrest BA, 1999, NEW ENGL J MED, V340, P1341, DOI 10.1056/NEJM199904293401707; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Hayward NK, 2003, ONCOGENE, V22, P3053, DOI 10.1038/sj.onc.1206445; Hsu MY, 2000, J CELL SCI, V113, P1535; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Kamb A, 1994, Nat Genet, V8, P23; Kannan K, 2003, P NATL ACAD SCI USA, V100, P1221, DOI 10.1073/pnas.0336397100; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Lazarov M, 2002, NAT MED, V8, P1105, DOI 10.1038/nm779; Nishimura EK, 2002, NATURE, V416, P854, DOI 10.1038/416854a; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Rodolfo M, 2004, CANCER LETT, V214, P133, DOI 10.1016/j.canlet.2004.06.049; Schaffer JV, 2004, J AM ACAD DERMATOL, V51, pS65, DOI 10.1016/j.jaad.2004.01.030; Sharpless NE, 2003, ONCOGENE, V22, P5055, DOI 10.1038/sj.onc.1206809; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; Weitzman JB, 1999, NATURE, V400, P401, DOI 10.1038/22637; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451	30	144	146	0	5	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2005	37	7					745	749		10.1038/ng1586	http://dx.doi.org/10.1038/ng1586			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	941EA	15951821	Green Accepted			2022-12-25	WOS:000230196400022
J	Gunderson, KL; Steemers, FJ; Lee, G; Mendoza, LG; Chee, MS				Gunderson, KL; Steemers, FJ; Lee, G; Mendoza, LG; Chee, MS			A genome-wide scalable SNP genotyping assay using microarray technology	NATURE GENETICS			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISMS; LARGE-SCALE IDENTIFICATION; MUTATION DETECTION; PRIMER EXTENSION; DNA ARRAYS; HYBRIDIZATION; AMPLIFICATION; PROBES	Oligonucleotide probe arrays have enabled massively parallel analysis of gene expression levels from a single cDNA sample. Application of microarray technology to analyzing genomic DNA has been stymied by the sequence complexity of the entire human genome. A robust, single base - resolution direct genomic assay would extend the reach of microarray technology. We developed an array-based whole-genome genotyping assay that does not require PCR and enables effectively unlimited multiplexing. The assay achieves a high signal-to-noise ratio by combining specific hybridization of picomolar concentrations of whole genome - amplified DNA to arrayed probes with allele-specific primer extension and signal amplification. As proof of principle, we genotyped several hundred previously characterized SNPs. The conversion rate, call rate and accuracy were comparable to those of high-performance PCR-based genotyping assays.	Illumina Inc, San Diego, CA 92121 USA; Ambion Inc, Austin, TX 78744 USA; Prognosys Biosci Inc, San Diego, CA 92121 USA	Illumina	Gunderson, KL (corresponding author), Illumina Inc, 9885 Town Ctr Dr, San Diego, CA 92121 USA.	kgunderson@illumina.com			NATIONAL CANCER INSTITUTE [R43CA103406] Funding Source: NIH RePORTER; NCI NIH HHS [R43 CA103406] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOBROW MN, 1989, J IMMUNOL METHODS, V125, P979; Borevitz JO, 2003, GENOME RES, V13, P513, DOI 10.1101/gr.541303; Carvalho B, 2004, J CLIN PATHOL, V57, P644, DOI 10.1136/jcp.2003.013029; Chen Y, 2004, J AM CHEM SOC, V126, P3016, DOI 10.1021/ja039355j; Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229; Dean FB, 2002, P NATL ACAD SCI USA, V99, P5261, DOI 10.1073/pnas.082089499; DI X, 2005, BIOINFORMATICS   JAN; Erdogan F, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.7.e36; Fan JB, 2003, COLD SPRING HARB SYM, V68, P69, DOI 10.1101/sqb.2003.68.69; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Gunderson KL, 2004, GENOME RES, V14, P870, DOI 10.1101/gr.2255804; Gunderson KL, 1998, GENOME RES, V8, P1142, DOI 10.1101/gr.8.11.1142; Hacker GW, 1998, EUR J HISTOCHEM, V42, P111; Hardenbol P, 2003, NAT BIOTECHNOL, V21, P673, DOI 10.1038/nbt821; Johnson GCL, 2001, NAT GENET, V29, P233, DOI 10.1038/ng1001-233; Judson R, 2002, PHARMACOGENOMICS, V3, P379, DOI 10.1517/14622416.3.3.379; Kennedy GC, 2003, NAT BIOTECHNOL, V21, P1233, DOI 10.1038/nbt869; Kwok Pui-Yan, 2003, Current Issues in Molecular Biology, V5, P43; Lucito R, 1998, P NATL ACAD SCI USA, V95, P4487, DOI 10.1073/pnas.95.8.4487; Matsuzaki H, 2004, GENOME RES, V14, P414, DOI 10.1101/gr.2014904; Pastinen T, 1997, GENOME RES, V7, P606, DOI 10.1101/gr.7.6.606; Pastinen T, 2000, GENOME RES, V10, P1031, DOI 10.1101/gr.10.7.1031; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Rao KVN, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng066; Shumaker JM, 1996, HUM MUTAT, V7, P346, DOI 10.1002/(SICI)1098-1004(1996)7:4<346::AID-HUMU9>3.3.CO;2-9; Simpson CL, 2004, BIOTECHNIQUES, V37, P996, DOI 10.2144/04376BIN03; Stephens JC, 2001, SCIENCE, V293, P489, DOI 10.1126/science.1059431; Storhoff JJ, 2002, P SOC PHOTO-OPT INS, V4937, P1, DOI 10.1117/12.476069; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; Wang G, 2004, GENOME RES, V14, P2357, DOI 10.1101/gr.2813404; Winzeler EA, 1998, SCIENCE, V281, P1194, DOI 10.1126/science.281.5380.1194; WU DY, 1989, DNA-J MOLEC CELL BIO, V8, P135, DOI 10.1089/dna.1.1989.8.135	35	460	543	1	67	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2005	37	5					549	554		10.1038/ng1547	http://dx.doi.org/10.1038/ng1547			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	922TU	15838508				2022-12-25	WOS:000228862300027
J	Ching, YH; Ghosh, TK; Cross, SJ; Packham, EA; Honeyman, L; Loughna, S; Robinson, TE; Dearlove, AM; Ribas, G; Bonser, AJ; Thomas, NR; Scotter, AJ; Caves, LSD; Tyrrell, GP; Newbury-Ecob, RA; Munnich, A; Bonnet, D; Brook, JD				Ching, YH; Ghosh, TK; Cross, SJ; Packham, EA; Honeyman, L; Loughna, S; Robinson, TE; Dearlove, AM; Ribas, G; Bonser, AJ; Thomas, NR; Scotter, AJ; Caves, LSD; Tyrrell, GP; Newbury-Ecob, RA; Munnich, A; Bonnet, D; Brook, JD			Mutation in myosin heavy chain 6 causes atrial septal defect	NATURE GENETICS			English	Article							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; HOLT-ORAM-SYNDROME; BINDING-SITE; EXPRESSION; TBX5; HEART; PATTERNS; SEQUENCE; TISSUE; GATA4	Atrial septal defect is one of the most common forms of congenital heart malformation. We identified a new locus linked with atrial septal defect on chromosome 14q12 in a large family with dominantly inherited atrial septal defect. The underlying mutation is a missense substitution, I820N, in alpha-myosin heavy chain (MYH6), a structural protein expressed at high levels in the developing atria, which affects the binding of the heavy chain to its regulatory light chain. The cardiac transcription factor TBX5 strongly regulates expression of MYH6, but mutant forms of TBX5, which cause Holt-Oram syndrome, do not. Morpholino knock-down of expression of the chick MYH6 homolog eliminates the formation of the atrial septum without overtly affecting atrial chamber formation. These data provide evidence for a link between a transcription factor, a structural protein and congenital heart disease.	Univ Nottingham, Queens Med Ctr, Inst Genet, Nottingham NG7 2UH, England; Univ Nottingham, Queens Med Ctr, Ctr Biochem & Cell Biol, Nottingham NG7 2UH, England; MRC UK HGMP Resource Ctr, Cambridge CB10 1SB, England; Univ Nottingham, Sch Chem, Nottingham NG7 2RD, England; Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England; Univ York, Dept Chem, York YO10 5YW, N Yorkshire, England; Royal Hosp Sick Children, Dept Clin Genet, Bristol BS2 8JJ, Avon, England; Hop Necker Enfants Malad, INSERM, Dept Pediat, U 393, F-75743 Paris, France; Hop Necker Enfants Malad, Serv Cardiol Pediat, F-75743 Paris, France	University of Nottingham; University of Nottingham; University of Nottingham; University of York - UK; University of York - UK; Bristol Royal Hospital For Children; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Brook, JD (corresponding author), Univ Nottingham, Queens Med Ctr, Inst Genet, Nottingham NG7 2UH, England.	david.brook@nottingham.ac.uk	Ribas-Despuig, Gloria/M-6190-2017; Ribas, Gloria/K-3379-2013	Ribas, Gloria/0000-0001-6883-4130; Loughna, Siobhan/0000-0002-3277-1438; Brook, John David/0000-0002-5946-6740; Warner, Louise/0000-0001-9161-3272; Bowcock, Anne/0000-0001-8691-9090				ARRECHEDERA H, 1987, J MOL CELL CARDIOL, V19, P641, DOI 10.1016/S0022-2828(87)80372-3; Basson CT, 1997, NAT GENET, V15, P30, DOI 10.1038/ng0197-30; Becker DL, 1999, EXP NEUROL, V156, P326, DOI 10.1006/exnr.1999.7027; BECKER W, 1999, VAR FODA, V1, P24; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; Charron P, 1998, EUR HEART J, V19, P1377, DOI 10.1053/euhj.1998.1049; DEGROOT IJM, 1987, ANAT EMBRYOL, V176, P515; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; Franco D, 1998, CARDIOVASC RES, V38, P25, DOI 10.1016/S0008-6363(97)00321-0; Garg V, 2003, NATURE, V424, P443, DOI 10.1038/nature01827; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; Ghosh TK, 2001, HUM MOL GENET, V10, P1983, DOI 10.1093/hmg/10.18.1983; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; KURABAYASHI M, 1988, J CLIN INVEST, V82, P524, DOI 10.1172/JCI113627; LATHROP GM, 1985, AM J HUM GENET, V37, P482; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Li QY, 1997, NAT GENET, V15, P21; Miyata S, 2000, CIRC RES, V86, P386, DOI 10.1161/01.RES.86.4.386; Niimura H, 2002, CIRCULATION, V105, P446, DOI 10.1161/hc0402.102990; Oana S, 1998, BIOL CELL, V90, P605; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; Reiser PJ, 2001, AM J PHYSIOL-HEART C, V280, pH1814, DOI 10.1152/ajpheart.2001.280.4.H1814; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Underhill PA, 1997, GENOME RES, V7, P996, DOI 10.1101/gr.7.10.996; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	30	197	210	1	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2005	37	4					423	428		10.1038/ng1526	http://dx.doi.org/10.1038/ng1526			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	911XL	15735645				2022-12-25	WOS:000228040000027
J	Baker, M				Baker, M			In biomarkers we trust?	NATURE BIOTECHNOLOGY			English	Article							DRUG DISCOVERY					monya_baker@yahoo.com						DEMEYER G, 2003, CURR DRUG DISCOV, V12, P23; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Rolan P, 2003, CLIN PHARMACOL THER, V73, P284, DOI 10.1016/S0009-9236(02)17625-9; RUBENSTEIN K, 2003, POST GENOMIC BIOMARK; WEI CM, 1994, CIRCULATION, V89, P1580, DOI 10.1161/01.CIR.89.4.1580; Woodcock J., FRAMEWORK BIOMARKER	8	114	142	0	11	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2005	23	3					297	304		10.1038/nbt0305-297	http://dx.doi.org/10.1038/nbt0305-297			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	906IW	15765081				2022-12-25	WOS:000227635400013
J	Hornung, V; Guenthner-Biller, M; Bourquin, C; Ablasser, A; Schlee, M; Uematsu, S; Noronha, A; Manoharan, M; Akira, S; de Fougerolles, A; Endres, S; Hartmann, G				Hornung, V; Guenthner-Biller, M; Bourquin, C; Ablasser, A; Schlee, M; Uematsu, S; Noronha, A; Manoharan, M; Akira, S; de Fougerolles, A; Endres, S; Hartmann, G			Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7	NATURE MEDICINE			English	Article							DOUBLE-STRANDED-RNA; CPG DNA; NUCLEOSIDE ANALOGS; MESSENGER-RNA; BACTERIAL-DNA; RECOGNITION; ACTIVATION; EXPRESSION; IDENTIFICATION; RESPONSES	Short interfering RNA ( siRNA) is used in RNA interference technology to avoid non-target-related induction of type I interferon (IFN) typical for long double-stranded RNA. Here we show that in plasmacytoid dendritic cells (PDC), an immune cell subset specialized in the detection of viral nucleic acids and production of type I IFN, some siRNA sequences, independent of their GU content, are potent stimuli of IFN-alpha production. Localization of the immunostimulatory motif on the sense strand of a potent IFN-alpha-inducing siRNA allowed dissection of immunostimulation and target silencing. Injection into mice of immunostimulatory siRNA, when complexed with cationic liposomes, induced systemic immune responses in the same range as the TLR9 ligand CpG, including IFN-alpha in serum and activation of T cells and dendritic cells in spleen. Immunostimulation by siRNA was absent in TLR7-deficient mice. Thus sequence-specific TLR7-dependent immune recognition in PDC needs to be considered as an additional biological activity of siRNA, which then should be termed immunostimulatory RNA (isRNA).	Univ Munich, Dept Internal Med, Div Clin Pharmacol, D-80336 Munich, Germany; GSF Munich, Natl Res Ctr & Environm & Hlth, Inst Clin Mol Biol & Tumor Genet, D-81377 Munich, Germany; Alnylam Pharmaceut Inc, Cambridge, MA 02142 USA; Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Osaka 5650871, Japan	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Osaka University	Hartmann, G (corresponding author), Univ Munich, Dept Internal Med, Div Clin Pharmacol, Ziemssenstr 1, D-80336 Munich, Germany.	ghartmann@lrz.uni-muenchen.de	Schlee, Martin/AAL-1238-2021; Bourquin, Carole/AAU-1418-2020; Hornung, Veit/C-3565-2012; Hartmann, Gunther/P-7492-2017; Akira, Shizuo/C-3134-2009	Bourquin, Carole/0000-0003-3862-4583; Hornung, Veit/0000-0002-4150-194X; Hartmann, Gunther/0000-0003-1021-2018; Karsten, Maria Margarete/0000-0001-7587-7550; Schlee, Martin/0000-0003-3671-7639				Ahlquist P, 2002, SCIENCE, V296, P1270, DOI 10.1126/science.1069132; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Bitko V, 2001, BMC Microbiol, V1, P34, DOI 10.1186/1471-2180-1-34; Davidson BL, 2003, NEW ENGL J MED, V349, P2357, DOI 10.1056/NEJMcibr031609; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Dittmer U, 2003, CURR OPIN MICROBIOL, V6, P472, DOI 10.1016/j.mib.2003.09.007; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hartmann E, 2003, CANCER RES, V63, P6478; Hartmann G, 2000, J IMMUNOL, V164, P944, DOI 10.4049/jimmunol.164.2.944; Heckelsmiller K, 2002, EUR J IMMUNOL, V32, P3235, DOI 10.1002/1521-4141(200211)32:11<3235::AID-IMMU3235>3.0.CO;2-J; Heckelsmiller K, 2002, J IMMUNOL, V169, P3892, DOI 10.4049/jimmunol.169.7.3892; Heil F, 2003, EUR J IMMUNOL, V33, P2987, DOI 10.1002/eji.200324238; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hoebe K, 2003, NAT IMMUNOL, V4, P1223, DOI 10.1038/ni1010; Hornung V, 2004, J IMMUNOL, V173, P5935, DOI 10.4049/jimmunol.173.10.5935; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Kariko K, 2004, CELLS TISSUES ORGANS, V177, P132, DOI 10.1159/000079987; Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; Kim DH, 2004, NAT BIOTECHNOL, V22, P321, DOI 10.1038/nbt940; Klein C, 2003, GASTROENTEROLOGY, V125, P9, DOI 10.1016/S0016-5085(03)00720-0; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 2003, NAT MED, V9, P831, DOI 10.1038/nm0703-831; Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U; Krug A, 2003, J IMMUNOL, V170, P3468, DOI 10.4049/jimmunol.170.7.3468; Krug A, 2004, BLOOD, V103, P1433, DOI 10.1182/blood-2003-08-2674; Krug A, 2001, EUR J IMMUNOL, V31, P3026, DOI 10.1002/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO;2-H; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; Lund J, 2003, J EXP MED, V198, P513, DOI 10.1084/jem.20030162; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; Novina CD, 2004, NATURE, V430, P161, DOI 10.1038/430161a; Plasterk RHA, 2002, SCIENCE, V296, P1263, DOI 10.1126/science.1072148; Poeck H, 2004, BLOOD, V103, P3058, DOI 10.1182/blood-2003-08-2972; Rothenfusser S, 2004, BLOOD, V103, P2162, DOI 10.1182/blood-2003-04-1091; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Spies B, 2003, J IMMUNOL, V171, P5908, DOI 10.4049/jimmunol.171.11.5908; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tuschl Thomas, 2002, Mol Interv, V2, P158, DOI 10.1124/mi.2.3.158; Weiner GJ, 2000, CURR TOP MICROBIOL, V247, P157; Williams B R, 2001, Sci STKE, V2001, pre2, DOI 10.1126/stke.2001.89.re2; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	47	960	1119	2	72	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					263	270		10.1038/nm1191	http://dx.doi.org/10.1038/nm1191			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15723075				2022-12-25	WOS:000227541300020
J	Lam, TKT; Pocai, A; Gutierrez-Juarez, R; Obici, S; Bryan, J; Aguilar-Bryan, L; Schwartz, GJ; Rossetti, L				Lam, TKT; Pocai, A; Gutierrez-Juarez, R; Obici, S; Bryan, J; Aguilar-Bryan, L; Schwartz, GJ; Rossetti, L			Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis	NATURE MEDICINE			English	Article							INSULIN-RESISTANCE; INDUCED INHIBITION; POTASSIUM CHANNEL; FOOD-INTAKE; GLUCONEOGENESIS; MECHANISMS; CELL; RECEPTORS; LEPTIN; GLYCOGENOLYSIS	Increased glucose production is a hallmark of type 2 diabetes and alterations in lipid metabolism have a causative role in its pathophysiology. Here we postulate that physiological increments in plasma fatty acids can be sensed within the hypothalamus and that this sensing is required to balance their direct stimulatory action on hepatic gluconeogenesis. In the presence of physiologically-relevant increases in the levels of plasma fatty acids, negating their central action on hepatic glucose fluxes through (i) inhibition of the hypothalamic esterification of fatty acids, (ii) genetic deletion (Sur1-deficient mice) of hypothalamic K-ATP channels or pharmacological blockade (KATP blocker) of their activation by fatty acids, or (iii) surgical resection of the hepatic branch of the vagus nerve led to a marked increase in liver glucose production. These findings indicate that a physiological elevation in circulating lipids can be sensed within the hypothalamus and that a defect in hypothalamic lipid sensing disrupts glucose homeostasis.	Yeshiva Univ Albert Einstein Coll Med, Diabet Res Ctr, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Diabet Res Ctr, Dept Neurosci, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Diabet Res Ctr, Dept Mol Pharmacol, Bronx, NY 10461 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Rossetti, L (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Diabet Res Ctr, Dept Med, 1300 Morris Pk Ave,Belfer 701, Bronx, NY 10461 USA.	rossetti@aecom.yu.edu			NIA NIH HHS [T32-AG023475, AG 21654] Funding Source: Medline; NIDDK NIH HHS [DK 48321, DK 47208, DK 45024, DK 20541, DK52771, DK57671] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047208, R01DK057671, R01DK052771, P60DK020541, R37DK048321, P30DK020541, R01DK045024, R29DK045024, R01DK048321] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG023475, P01AG021654] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Barzilai N, 1997, J CLIN INVEST, V100, P3105, DOI 10.1172/JCI119865; BODEN G, 1994, J CLIN INVEST, V93, P2438, DOI 10.1172/JCI117252; Boden G, 2001, DIABETES, V50, P810, DOI 10.2337/diabetes.50.4.810; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Branstrom R, 1997, J BIOL CHEM, V272, P17390, DOI 10.1074/jbc.272.28.17390; Chen XH, 1999, J CLIN INVEST, V103, P365, DOI 10.1172/JCI5479; Chu CA, 2002, AM J PHYSIOL-ENDOC M, V282, pE402, DOI 10.1152/ajpendo.00136.2001; CLORE JN, 1991, AM J PHYSIOL, V261, pE425, DOI 10.1152/ajpendo.1991.261.4.E425; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Dunn-Meynell AA, 1998, BRAIN RES, V814, P41, DOI 10.1016/S0006-8993(98)00956-1; Flier JS, 2004, CELL, V116, P337, DOI 10.1016/S0092-8674(03)01081-X; Gribble FM, 1998, J BIOL CHEM, V273, P26383, DOI 10.1074/jbc.273.41.26383; Hansen AMK, 2002, DIABETES, V51, P2789, DOI 10.2337/diabetes.51.9.2789; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; la Fleur SE, 2003, DIABETES, V52, P2321, DOI 10.2337/diabetes.52.9.2321; Lam TKT, 2003, AM J PHYSIOL-ENDOC M, V284, pE281, DOI 10.1152/ajpendo.00332.2002; Lam TKT, 2003, AM J PHYSIOL-ENDOC M, V284, pE863, DOI 10.1152/ajpendo.00033.2003; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; Matsuhisa M, 2000, METABOLISM, V49, P11, DOI 10.1016/S0026-0495(00)90538-9; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; McKhann GM, 1997, J NEUROSCI, V17, P6850; Miki T, 2001, NAT NEUROSCI, V4, P507, DOI 10.1038/87455; MILLER JC, 1987, J NEUROCHEM, V49, P1507, DOI 10.1111/j.1471-4159.1987.tb01021.x; MOORE MC, 1993, AM J PHYSIOL, V265, pE487, DOI 10.1152/ajpendo.1993.265.3.E487; Morgan K, 2004, J BIOL CHEM, V279, P31139, DOI 10.1074/jbc.M400458200; Morton GJ, 2003, ENDOCRINOLOGY, V144, P2016, DOI 10.1210/en.2002-0115; NORGREN R, 1994, AM J PHYSIOL-REG I, V267, pR1136, DOI 10.1152/ajpregu.1994.267.4.R1136; Obici S, 2003, NAT MED, V9, P756, DOI 10.1038/nm873; Obici S, 2002, DIABETES, V51, P271, DOI 10.2337/diabetes.51.2.271; Obici S, 2001, J CLIN INVEST, V108, P1079, DOI 10.1172/JCI200112954; Obici S, 2002, NAT MED, V8, P1376, DOI 10.1038/nm798; Pocai A, 2005, CELL METAB, V1, P53, DOI 10.1016/j.cmet.2004.11.001; Rebrin K, 1996, J CLIN INVEST, V98, P741, DOI 10.1172/JCI118846; Roden M, 2000, DIABETES, V49, P701, DOI 10.2337/diabetes.49.5.701; Sclafani A, 2003, PHYSIOL BEHAV, V78, P285, DOI 10.1016/S0031-9384(02)00968-X; Seino S, 2003, PROG BIOPHYS MOL BIO, V81, P133, DOI 10.1016/S0079-6107(02)00053-6; SHULMAN GI, 2000, J CLIN INVEST, V106, P171, DOI DOI 10.1172/JCI10583; Sindelar DK, 1997, DIABETES, V46, P187, DOI 10.2337/diabetes.46.2.187; Taylor SI, 1999, CELL, V97, P9, DOI 10.1016/S0092-8674(00)80709-6; TOMODA H, 1991, J BIOL CHEM, V266, P4214; Vatamaniuk MZ, 2003, LIFE SCI, V72, P1871, DOI 10.1016/S0024-3205(02)02506-7; Wang JL, 2001, DIABETES, V50, P2786, DOI 10.2337/diabetes.50.12.2786; WILLIAMSON JR, 1966, P NATL ACAD SCI USA, V56, P247, DOI 10.1073/pnas.56.1.247; WILLIAMSON JR, 1969, J BIOL CHEM, V244, P4607; WOJTCZAK AB, 1978, BIOCHEM J, V170, P379, DOI 10.1042/bj1700379; Xue CR, 2000, J SURG RES, V90, P19, DOI 10.1006/jsre.2000.5820	49	323	333	0	22	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					320	327		10.1038/nm1201	http://dx.doi.org/10.1038/nm1201			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15735652				2022-12-25	WOS:000227541300028
J	Nichols, KE; Hom, J; Gong, SY; Ganguly, A; Ma, CS; Cannons, JL; Tangye, SG; Schwartzberg, PL; Koretzky, GA; Stein, PL				Nichols, KE; Hom, J; Gong, SY; Ganguly, A; Ma, CS; Cannons, JL; Tangye, SG; Schwartzberg, PL; Koretzky, GA; Stein, PL			Regulation of NKT cell development by SAP, the protein defective in XLP	NATURE MEDICINE			English	Article							LINKED LYMPHOPROLIFERATIVE-DISEASE; CONTROLS T-CELL; SH2 DOMAIN; MICE DEFICIENT; CUTTING EDGE; MUTANT MICE; B-CELLS; GENE; DIFFERENTIATION; MUTATIONS	The adaptor molecule SAP is expressed in T lymphocytes and natural killer (NK) cells, where it regulates cytokine production and cytotoxicity(1-3). Here, we show that SAP, encoded by the SH2D1A gene locus, also has a crucial role during the development of NKT cells, a lymphocyte subset with immunoregulatory functions in response to infection, cancer and autoimmune disease(4). Following stimulation with the NKT cell-specific agonist alpha-galactosyl ceramide (alpha GC), Sh2d1a(-/-) splenocytes did not produce cytokines or activate other lymphoid lineages in an NKT cell-dependent manner. While evaluating the abnormalities in alpha GC-induced immune responses, we observed that Sh2d1a(-/-) animals lacked NKT cells in the thymus and peripheral organs. The defect in NKT cell ontogeny was hematopoietic cell autonomous and could be rescued by reconstitution of SAP expression within Sh2d1a(-/-) bone marrow cells. Seventeen individuals with X-linked lymphoproliferative disease (XLP), who harbored germline mutations in SH2D1A, also lacked NKT cells. Furthermore, a female XLP carrier showed completely skewed X chromosome inactivation within NKT cells, but not T or B cells. Thus, SAP is a crucial regulator of NKT cell ontogeny in humans and in mice. The absence of NKT cells may contribute to the phenotypes of SAP deficiency, including abnormal antiviral and antitumor immunity and hypogammaglobulinemia.	Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Centenary Inst Canc Med & Cell Biol, Newtown, NSW 2014, Australia; NHGRI, NIH, Bethesda, MD 20892 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; University of Sydney; Centenary Institute; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Nichols, KE (corresponding author), Childrens Hosp Philadelphia, 4th Floor,3615 Civic Ctr Blvd, Philadelphia, PA 19104 USA.	nicholsk@email.chop.edu; p-stein2@northwestern.edu	Nichols, Kim/AAP-8592-2020; Tangye, Stuart G/H-4023-2014; S, Cindy/B-2340-2012; Nichols, Kim/E-9353-2016; Koretzky, Gary/AAU-5381-2021; Gong, Shunyou/ABE-1345-2021	Nichols, Kim/0000-0002-5581-6555; Tangye, Stuart G/0000-0002-5360-5180; S, Cindy/0000-0001-5387-8413; Nichols, Kim/0000-0002-5581-6555; Gong, Shunyou/0000-0002-7883-4879	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG000123, Z01HG000123] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Cannons JL, 2004, IMMUNITY, V21, P693, DOI 10.1016/j.immuni.2004.09.012; Carnaud C, 1999, J IMMUNOL, V163, P4647; Chen YH, 1997, IMMUNITY, V6, P459, DOI 10.1016/S1074-7613(00)80289-7; Coffey AJ, 1998, NAT GENET, V20, P129, DOI 10.1038/2424; Crotty S, 2003, NATURE, V421, P282, DOI 10.1038/nature01318; Czar MJ, 2001, P NATL ACAD SCI USA, V98, P7449, DOI 10.1073/pnas.131193098; Eberl G, 1999, J IMMUNOL, V163, P4091; Gadue P, 1999, J EXP MED, V190, P1189, DOI 10.1084/jem.190.8.1189; Galli G, 2003, J EXP MED, V197, P1051, DOI 10.1084/jem.20021616; Hron JD, 2004, J EXP MED, V200, P261, DOI 10.1084/jem.20040526; Kronenberg M, 2002, NAT REV IMMUNOL, V2, P557, DOI 10.1038/nri854; Latour S, 2003, IMMUNOL REV, V192, P212, DOI 10.1034/j.1600-065X.2003.00023.x; Latour S, 2003, NAT CELL BIOL, V5, P149, DOI 10.1038/ncb919; Malbran A, 2004, BLOOD, V103, P1625, DOI 10.1182/blood-2003-07-2525; Mendiratta SK, 1997, IMMUNITY, V6, P469, DOI 10.1016/S1074-7613(00)80290-3; Nichols KE, 1998, P NATL ACAD SCI USA, V95, P13765, DOI 10.1073/pnas.95.23.13765; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PURTILO D T, 1975, Lancet, V1, P935; Roberts TJ, 2004, J IMMUNOL, V172, P3454, DOI 10.4049/jimmunol.172.6.3454; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Schuster V, 2000, IMMUNOL REV, V178, P21, DOI 10.1034/j.1600-065X.2000.17819.x; Seemayer TA, 2000, INFEC DIS S, P51; Sharifi R, 2004, BLOOD, V103, P3821, DOI 10.1182/blood-2003-09-3359; Smiley ST, 1997, SCIENCE, V275, P977, DOI 10.1126/science.275.5302.977; Smyth MJ, 2002, CURR OPIN IMMUNOL, V14, P165, DOI 10.1016/S0952-7915(02)00316-3; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; Wang NH, 2004, J EXP MED, V199, P1255, DOI 10.1084/jem.20031835; Wengler GS, 1997, LIFE SCI, V61, P1405, DOI 10.1016/S0024-3205(97)00686-3; Wu CB, 2001, NAT IMMUNOL, V2, P410, DOI 10.1038/87713; Yin L, 2003, J MED VIROL, V71, P446, DOI 10.1002/jmv.10504	30	302	307	0	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					340	345		10.1038/nm1189	http://dx.doi.org/10.1038/nm1189			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15711562				2022-12-25	WOS:000227541300031
J	Tanaka, H; Bergstrom, DA; Yao, MC; Tapscott, SJ				Tanaka, H; Bergstrom, DA; Yao, MC; Tapscott, SJ			Widespread and nonrandom distribution of DNA palindromes in cancer cells provides a structural platform for subsequent gene amplification	NATURE GENETICS			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; SHORT INVERTED REPEATS; HAMSTER CELLS; SOLID TUMORS; FUSION GENE; CHROMOSOMES; TETRAHYMENA; MECHANISMS; EXPRESSION; INDUCTION	Breakage-fusion-bridge cycles contribute to chromosome instability and generate large DNA palindromes that facilitate gene amplification in human cancers. The prevalence of large DNA palindromes in cancer is not known. Here, by using a new microarray-based approach called genome-wide analysis of palindrome formation, we show that palindromes occur frequently and are widespread in human cancers. Individual tumors seem to have a nonrandom distribution of palindromes in their genomes, and a subset of palindromic loci is associated with gene amplification. This indicates that the location of palindromes in the cancer genome can serve as a structural platform that supports subsequent gene amplification. Genome-wide analysis of palindrome formation is a new approach to identify structural chromosome aberrations associated with cancer.	Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA; Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; Acad Sinica, Inst Mol Biol, Taipei, Taiwan	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Academia Sinica - Taiwan	Tapscott, SJ (corresponding author), Fred Hutchinson Canc Res Ctr, Div Human Biol, Mailstop C3-168,1100 Fairview Ave N, Seattle, WA 98109 USA.	mcyao@imb.sinica.edu.tw; stapscot@fhcrc.org	Tanaka, Hisashi/ABE-7637-2020	Tanaka, Hisashi/0000-0001-9223-4186; Tapscott, Stephen/0000-0002-0319-0968				Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Albrecht EB, 2000, MOL BIOL CELL, V11, P873, DOI 10.1091/mbc.11.3.873; Anderson J, 1999, GENE CHROMOSOME CANC, V26, P275, DOI 10.1002/(SICI)1098-2264(199912)26:4<275::AID-GCC1>3.0.CO;2-3; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Barber G, 2004, CALL CENT MAG, V17, P10; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Butler DK, 1996, CELL, V87, P1115, DOI 10.1016/S0092-8674(00)81805-X; BUTLER DK, 1995, MOL CELL BIOL, V15, P7117; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Ciullo M, 2002, HUM MOL GENET, V11, P2887, DOI 10.1093/hmg/11.23.2887; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; Fan X, 2003, AM J PATHOL, V162, P1763, DOI 10.1016/S0002-9440(10)64311-8; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; FORD M, 1986, CELL, V45, P425, DOI 10.1016/0092-8674(86)90328-4; Gisselsson D, 2001, AM J PATHOL, V158, P199, DOI 10.1016/S0002-9440(10)63958-2; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; Graf L, 2002, BLOOD, V100, P1509, DOI 10.1182/blood-2002-03-0844; Grondin K, 1996, MOL CELL BIOL, V16, P3587; HECHT F, 1984, SCIENCE, V226, P1445, DOI 10.1126/science.6438800; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Inoue K, 2002, ANNU REV GENOM HUM G, V3, P199, DOI 10.1146/annurev.genom.3.032802.120023; ISHHOROWICZ D, 1980, J MOL BIOL, V142, P231, DOI 10.1016/0022-2836(80)90047-9; Kuwahara Y, 2004, GENE CHROMOSOME CANC, V41, P125, DOI 10.1002/gcc.20075; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lobachev KS, 2002, CELL, V108, P183, DOI 10.1016/S0092-8674(02)00614-1; MA C, 1988, MOL CELL BIOL, V8, P2316, DOI 10.1128/MCB.8.6.2316; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; Maringele L, 2004, GENE DEV, V18, P2663, DOI 10.1101/gad.316504; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; MCCLINTOCK B, 1951, COLD SPRING HARB SYM, V16, P13, DOI 10.1101/SQB.1951.016.01.004; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; Michiels EMC, 2002, J PEDIAT HEMATOL ONC, V24, P205, DOI 10.1097/00043426-200203000-00009; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; RUIZ JC, 1988, MOL CELL BIOL, V8, P4302, DOI 10.1128/MCB.8.10.4302; Shlomit R, 2000, CANCER GENET CYTOGEN, V121, P67, DOI 10.1016/S0165-4608(00)00218-1; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; SMITH KA, 1992, P NATL ACAD SCI USA, V89, P5427, DOI 10.1073/pnas.89.12.5427; Smogorzewska A, 2002, CURR BIOL, V12, P1635, DOI 10.1016/S0960-9822(02)01179-X; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Swisshelm K, 1999, GENE, V226, P285, DOI 10.1016/S0378-1119(98)00553-8; Tanaka H, 2002, P NATL ACAD SCI USA, V99, P8772, DOI 10.1073/pnas.132275999; Tlsty TD, 1997, CURR TOP MICROBIOL, V221, P37; TOLEDO F, 1992, EMBO J, V11, P2665, DOI 10.1002/j.1460-2075.1992.tb05332.x; YAO MC, 1990, CELL, V63, P763, DOI 10.1016/0092-8674(90)90142-2; YASUDA LF, 1991, CELL, V67, P505, DOI 10.1016/0092-8674(91)90525-4; Yokota N, 2002, INT J CANCER, V101, P198, DOI 10.1002/ijc.10559; YonedaKato N, 1996, ONCOGENE, V12, P265	49	84	86	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2005	37	3					320	327		10.1038/ng1515	http://dx.doi.org/10.1038/ng1515			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	901QU	15711546				2022-12-25	WOS:000227297800025
J	Yoshida, K; Yamaguchi, T; Natsume, T; Kufe, D; Miki, Y				Yoshida, K; Yamaguchi, T; Natsume, T; Kufe, D; Miki, Y			JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-Abl in the apoptotic response to DNA damage	NATURE CELL BIOLOGY			English	Article							TYROSINE KINASE; 14-3-3 PROTEINS; SUBCELLULAR-LOCALIZATION; STRESS; CELLS; BCR; SPECIFICITY; BINDING; DEATH; DELTA	The ubiquitously expressed c-Abl tyrosine kinase localizes to the cytoplasm and nucleus(1,2). Nuclear c-Abl is activated by diverse genotoxic agents and induces apoptosis(3,4); however, the mechanisms that are responsible for nuclear targeting of c-Abl remain unclear. Here, we show that cytoplasmic c-Abl is targeted to the nucleus in the DNA damage response. The results show that c-Abl is sequestered into the cytoplasm by binding to 14-3-3 proteins. Phosphorylation of c-Abl on Thr 735 functions as a site for direct binding to 14-3-3 proteins. We also show that, in response to DNA damage, activation of the c-Jun N-terminal kinase (Jnk) induces phosphorylation of 14-3-3 proteins and their release from c-Abl. Together with these results, expression of an unphosphorylated 14-3-3 mutant attenuates DNA-damage-induced nuclear import of c-Abl and apoptosis. These findings indicate that 14-3-3 proteins are pivotal regulators of intracellular c-Abl localization and of the apoptotic response to genotoxic stress.	Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Genet, Tokyo 1138510, Japan; Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Kohtoh Ku, Tokyo 1350064, Japan; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Tokyo Medical & Dental University (TMDU); National Institute of Advanced Industrial Science & Technology (AIST); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Yoshida, K (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Genet, Tokyo 1138510, Japan.	yos.mgen@mri.tmd.ac.jp; miki.mgen@mri.tmd.ac.jp	Natsume, Tohru/M-7627-2018	Natsume, Tohru/0000-0002-1510-2582	NCI NIH HHS [CA98628, CA29431] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098628, R01CA029431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Aitken A, 2002, BIOCHEM SOC T, V30, P351, DOI 10.1042/bst0300351; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Gong JG, 1999, NATURE, V399, P806; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Masuyama N, 2001, J BIOL CHEM, V276, P32799, DOI 10.1074/jbc.M105431200; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Natsume T, 2002, ANAL CHEM, V74, P4725, DOI 10.1021/ac020018n; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; WETZLER M, 1993, J CLIN INVEST, V92, P1925, DOI 10.1172/JCI116786; Won J, 2003, J BIOL CHEM, V278, P19347, DOI 10.1074/jbc.M213098200; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yoshida K, 2000, MOL CELL BIOL, V20, P5370, DOI 10.1128/MCB.20.15.5370-5380.2000; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134; Yoshida K, 2002, MOL CELL BIOL, V22, P3292, DOI 10.1128/MCB.22.10.3292-3300.2002; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511	28	191	202	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2005	7	3					278	U97		10.1038/ncb1228	http://dx.doi.org/10.1038/ncb1228			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	902CU	15696159				2022-12-25	WOS:000227329800016
J	Dinulescu, DM; Ince, TA; Quade, BJ; Shafer, SA; Crowley, D; Jacks, T				Dinulescu, DM; Ince, TA; Quade, BJ; Shafer, SA; Crowley, D; Jacks, T			Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer	NATURE MEDICINE			English	Article							GENE-MUTATIONS; P53; INACTIVATION; PROGRESSION; EXPRESSION; INDUCTION; TUMORS	Epithelial ovarian tumors present a complex clinical, diagnostic and therapeutic challenge because of the difficulty of early detection, lack of known precursor lesions and high mortality rates. Endometrioid ovarian carcinomas are frequently associated with endometriosis, but the mechanism for this association remains unknown. Here we present the first genetic models of peritoneal endometriosis and endometrioid ovarian adenocarcinoma in mice, both based on the activation of an oncogenic K-ras allele. In addition, we find that expression of oncogenic K-ras or conditional Pten deletion within the ovarian surface epithelium gives rise to preneoplastic ovarian lesions with an endometrioid glandular morphology. Furthermore, the combination of the two mutations in the ovary leads to the induction of invasive and widely metastatic endometrioid ovarian adenocarcinomas with complete penetrance and a disease latency of only 7 weeks. The ovarian cancer model described in this study recapitulates the specific tumor histomorphology and metastatic potential of the human disease.	MIT, Ctr Canc Res, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Whitehead Inst, Cambridge, MA 02142 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol,Div Womens & Perinatal Pathol, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Jacks, T (corresponding author), MIT, Ctr Canc Res, 40 Ames St, Cambridge, MA 02139 USA.	tjacks@mit.edu		Ince, Tan/0000-0003-0315-6425	NCI NIH HHS [KO8CA92013] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA092013] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amemiya S, 2004, INT J GYNECOL OBSTET, V86, P371, DOI 10.1016/j.ijgo.2004.04.036; Arimoto-Ishida E, 2004, ENDOCRINOLOGY, V145, P2014, DOI 10.1210/en.2003-1199; CLEMENT PB, 2002, BLAUSTEINS PATHOLOGY, P746; Connolly DC, 2003, CANCER RES, V63, P1389; Cuatrecasas M, 1998, CANCER-AM CANCER SOC, V82, P1088; Flesken-Nikitin A, 2003, CANCER RES, V63, P3459; Gemignani ML, 2003, GYNECOL ONCOL, V90, P378, DOI 10.1016/S0090-8258(03)00264-6; Grunwald V, 2002, CANCER RES, V62, P6141; HOGAN B, 1994, MANIPULATING MOUSE E, P185; Hogdall EVS, 2003, GYNECOL ONCOL, V89, P31, DOI 10.1016/S0090-8258(03)00005-2; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Obata K, 1998, CANCER RES, V58, P2095; Okuda T, 2003, GYNECOL ONCOL, V88, P318, DOI 10.1016/S0090-8258(02)00149-X; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Otsuka Junko, 2004, Medical Electron Microscopy, V37, P188; Ozols RF, 2004, CANCER CELL, V5, P19, DOI 10.1016/S1535-6108(04)00002-9; Sato N, 2000, CANCER RES, V60, P7052; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Swiersz LM, 2002, ANN NY ACAD SCI, V955, P281, DOI 10.1111/j.1749-6632.2002.tb02788.x; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; VERCELLINI P, 1994, GYNECOL OBSTET INVES, V38, P70, DOI 10.1159/000292450	22	437	460	1	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2005	11	1					63	70		10.1038/nm1173	http://dx.doi.org/10.1038/nm1173			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	884ZJ	15619626				2022-12-25	WOS:000226124900034
J	Jenkins, H; Hardy, N; Beckmann, M; Draper, J; Smith, AR; Taylor, J; Fiehn, O; Goodacre, R; Bino, RJ; Hall, R; Kopka, J; Lane, GA; Lange, BM; Liu, JR; Mendes, P; Nikolau, BJ; Oliver, SG; Paton, NW; Rhee, S; Roessner-Tunali, U; Saito, K; Smedsgaard, J; Sumner, LW; Wang, T; Walsh, S; Wurtele, ES; Kell, DB				Jenkins, H; Hardy, N; Beckmann, M; Draper, J; Smith, AR; Taylor, J; Fiehn, O; Goodacre, R; Bino, RJ; Hall, R; Kopka, J; Lane, GA; Lange, BM; Liu, JR; Mendes, P; Nikolau, BJ; Oliver, SG; Paton, NW; Rhee, S; Roessner-Tunali, U; Saito, K; Smedsgaard, J; Sumner, LW; Wang, T; Walsh, S; Wurtele, ES; Kell, DB			A proposed framework for the description of plant metabolomics experiments and their results	NATURE BIOTECHNOLOGY			English	Article							MASS-SPECTROMETRY; SYSTEMS BIOLOGY; STANDARDS; GENOMICS; DATABASE; MIAME; ALGORITHMS	The study of the metabolite complement of biological samples, known as metabolomics, is creating large amounts of data, and support for handling these data sets is required to facilitate meaningful analyses that will answer biological questions. We present a data model for plant metabolomics known as ArMet (architecture for metabolomics). It encompasses the entire experimental time line from experiment definition and description of biological source material, through sample growth and preparation to the results of chemical analysis. Such formal data descriptions, which specify the full experimental context, enable principled comparison of data sets, allow proper interpretation of experimental results, permit the repetition of experiments and provide a basis for the design of systems for data storage and transmission. The current design and example implementations are freely available (http://www.armet.org/). We seek to advance discussion and community adoption of a standard for metabolomics, which would promote principled collection, storage and transmission of experiment data.	Univ Wales, Dept Comp Sci, Aberystwyth SY23 3DB, Ceredigion, Wales; Univ Wales, Inst Biol Sci, Aberystwyth SY23 3DB, Ceredigion, Wales; Max Planck Inst Mol Plant Physiol, D-14424 Potsdam, Germany; Univ Manchester, Sch Chem, Manchester M60 1QD, Lancs, England; Plant Res Int, NL-6700 AA Wageningen, Netherlands; Ctr BioSyst Gen, NL-6700 AB Wageningen, Netherlands; AgRes Grasslands Res Ctr, Palmerston North, New Zealand; Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA; Washington State Univ, Ctr Integrated Biotechnol, Pullman, WA 99164 USA; KRIBB, Plant Cell Biotechnol Lab, Taejon 305600, South Korea; Eugentech Inc, NRL, Taejon 305600, South Korea; Virginia Tech, Virginia Bioinformat Inst, Blacksburg, VA 24061 USA; Iowa State Univ, Dept Biochem Biophys & Mol Biol, WM Keck Metabol Res Lab, Ctr Designer Crops, Ames, IA 50011 USA; Univ Manchester, Sch Biol Sci, Manchester M13 9PL, Lancs, England; Univ Manchester, Dept Comp Sci, Manchester M13 9PL, Lancs, England; Carnegie Inst Sci, Arabidopsis Informat Resource, Dept Plant Biol, Stanford, CA 94305 USA; Univ Melbourne, Sch Bot, Australian Ctr Plant Funct Gen, Parkville, Vic 3010, Australia; Chiba Univ, Grad Sch Pharmaceut Sci, Inage Ku, Chiba 2638522, Japan; Tech Univ Denmark, BioCtr DTU, DK-2800 Lyngby, Denmark; Samuel Roberts Noble Fdn Inc, Ardmore, OK 73401 USA; John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England; Iowa State Univ, Dept Genet Dev & Cell Biol, Ames, IA 50011 USA	Aberystwyth University; Aberystwyth University; Max Planck Society; University of Manchester; Centre for BioSystems Genomics; AgResearch - New Zealand; Washington State University; Washington State University; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Virginia Polytechnic Institute & State University; Iowa State University; University of Manchester; University of Manchester; Carnegie Institution for Science; University of Melbourne; Chiba University; Technical University of Denmark; Noble Research Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Iowa State University	Hardy, N (corresponding author), Univ Wales, Dept Comp Sci, Aberystwyth SY23 3DB, Ceredigion, Wales.	nwh@aber.ac.uk	Saito, Kazuki/D-2670-2009; Beckmann, Manfred/AAX-9979-2021; Goodacre, Roy/J-1600-2012; HALL, ROBERT D/B-8707-2015; Roessner, Ute/E-9446-2015; Oliver, Stephen/AAQ-5992-2021; Goodacre, Roy/AAO-3194-2021; Kell, Douglas/E-8318-2011; Sumner, Lloyd W/A-3270-2013	Saito, Kazuki/0000-0001-6310-5342; Goodacre, Roy/0000-0003-2230-645X; HALL, ROBERT D/0000-0002-5786-768X; Roessner, Ute/0000-0002-6482-2615; Oliver, Stephen/0000-0003-3410-6439; Goodacre, Roy/0000-0003-2230-645X; Kell, Douglas/0000-0001-5838-7963; Sumner, Lloyd W/0000-0002-4086-663X; Beckmann, Manfred/0000-0002-4320-5001; Mendes, Pedro/0000-0001-6507-9168; Wurtele, Eve/0000-0003-1552-9495; Kopka, Joachim/0000-0001-9675-4883; Paton, Norman/0000-0003-2008-6617; Lange, Mark/0000-0001-6565-9584; Smedsgaard, Jorn/0000-0002-7748-0722	Biotechnology and Biological Sciences Research Council [E19354, E19355] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Allen J, 2003, NAT BIOTECHNOL, V21, P692, DOI 10.1038/nbt823; [Anonymous], 2002, NATURE, V419, P323, DOI 10.1038/419323a; Bino RJ, 2004, TRENDS PLANT SCI, V9, P418, DOI 10.1016/j.tplants.2004.07.004; BOOCH G, 1999, UNIFIED MODELING LAN; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Brazma A, 2003, NUCLEIC ACIDS RES, V31, P68, DOI 10.1093/nar/gkg091; Fiehn O, 2003, EUR J BIOCHEM, V270, P579, DOI 10.1046/j.1432-1033.2003.03427.x; Fiehn O, 2002, PLANT MOL BIOL, V48, P155, DOI 10.1023/A:1013713905833; Fiehn O, 2001, COMP FUNCT GENOM, V2, P155, DOI 10.1002/cfg.82; Glueck SB, 2003, PHYSIOL GENOMICS, V13, P1, DOI 10.1152/physiolgenomics.00019.2003; Goodacre R, 2004, TRENDS BIOTECHNOL, V22, P245, DOI 10.1016/j.tibtech.2004.03.007; Griffiths P., 1986, FOURIER TRANSFORM IN; Hall Robert, 2002, Plant Cell, V14, P1437, DOI 10.1105/tpc.140720; Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Killion PJ, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-32; Krieger CJ, 2004, NUCLEIC ACIDS RES, V32, pD438, DOI 10.1093/nar/gkh100; Lampen P, 1999, PURE APPL CHEM, V71, P1549, DOI 10.1351/pac199971081549; McLafferty FW, 1998, J AM SOC MASS SPECTR, V9, P92, DOI 10.1016/S1044-0305(97)00235-3; Mendes Pedro, 2002, Brief Bioinform, V3, P134; Mueller LA, 2003, PLANT PHYSIOL, V132, P453, DOI 10.1104/pp.102.017236; Nicholson JK, 1999, XENOBIOTICA, V29, P1181, DOI 10.1080/004982599238047; Oliver S, 2003, COMP FUNCT GENOM, V4, P1, DOI 10.1002/cfg.238; Oliver SG, 1998, TRENDS BIOTECHNOL, V16, P373, DOI 10.1016/S0167-7799(98)01214-1; Orchard S, 2004, PROTEOMICS, V4, P490, DOI 10.1002/pmic.200300694; Orchard S, 2003, PROTEOMICS, V3, P1374, DOI 10.1002/pmic.200300496; Quackenbush J, 2004, NAT BIOTECHNOL, V22, P613, DOI 10.1038/nbt0504-613; Raamsdonk LM, 2001, NAT BIOTECHNOL, V19, P45, DOI 10.1038/83496; Roessner U, 2001, PLANT CELL, V13, P11, DOI 10.1105/tpc.13.1.11; Roessner U, 2000, PLANT J, V23, P131, DOI 10.1046/j.1365-313x.2000.00774.x; Smedsgaard J, 1996, J MICROBIOL METH, V25, P5, DOI 10.1016/0167-7012(95)00073-9; Smedsgaard J, 1997, BIOCHEM SYST ECOL, V25, P65, DOI 10.1016/S0305-1978(96)00087-7; Spellman PT, 2002, GENOME BIOL, V3; STEIN SE, 1994, J AM SOC MASS SPECTR, V5, P859, DOI 10.1016/1044-0305(94)87009-8; Sumner LW, 2003, PHYTOCHEMISTRY, V62, P817, DOI 10.1016/S0031-9422(02)00708-2; Taylor CF, 2003, NAT BIOTECHNOL, V21, P247, DOI 10.1038/nbt0303-247; van der Greef J, 2004, ADV MASS SPECTROM, V16, P145; Weckwerth W, 2003, ANNU REV PLANT BIOL, V54, P669, DOI 10.1146/annurev.arplant.54.031902.135014; Xirasagar S, 2004, BIOINFORMATICS, V20, P2004, DOI 10.1093/bioinformatics/bth189	40	194	211	3	69	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2004	22	12					1601	1606		10.1038/nbt1041	http://dx.doi.org/10.1038/nbt1041			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	878HX	15583675				2022-12-25	WOS:000225638600040
J	Shimizu, S; Kanaseki, T; Mizushima, N; Mizuta, T; Arakawa-Kobayashi, S; Thompson, CB; Tsujimoto, Y				Shimizu, S; Kanaseki, T; Mizushima, N; Mizuta, T; Arakawa-Kobayashi, S; Thompson, CB; Tsujimoto, Y			Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes	NATURE CELL BIOLOGY			English	Article							BAX; CONVERSION; BECLIN	Programmed cell death can be divided into several categories including type I (apoptosis) and type II (autophagic death)(1,2). The Bcl-2 family of proteins are well-characterized regulators of apoptosis(3), and the multidomain pro-apoptotic members of this family, such as Bax and Bak, act as a mitochondrial gateway where a variety of apoptotic signals converge(4-6). Although embryonic fibroblasts from Bax/Bak double knockout mice are resistant to apoptosis(4-6), we found that these cells still underwent a non-apoptotic death after death stimulation. Electron microscopic and biochemical studies revealed that double knockout cell death was associated with autophagosomes/autolysosomes. This non-apoptotic death of double knockout cells was suppressed by inhibitors of autophagy, including 3-methyl adenine, was dependent on autophagic proteins APG5 and Beclin 1 (capable of binding to Bcl-2/Bcl-x(L)), and was also modulated by Bcl-x(L). These results indicate that the Bcl-2 family of proteins not only regulates apoptosis, but also controls non-apoptotic programmed cell death that depends on the autophagy genes.	Osaka Univ, Sch Med, Dept Post Genom & Dis, Suita, Osaka 5650871, Japan; JST, CREST, Suita, Osaka 5650871, Japan; JST, SORST, Suita, Osaka 5650871, Japan; JST, Natl Inst Bas Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan; JST, PRESTO, Okazaki, Aichi 4448585, Japan; Tokyo Metropolitan Inst Med Sci, Dept Bioregulat & Metab, Tokyo 1138613, Japan; Univ Penn, Abramson Family Canc Res Inst, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA	Osaka University; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Japan Science & Technology Agency (JST); Tokyo Metropolitan Institute of Medical Science; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Tsujimoto, Y (corresponding author), Osaka Univ, Sch Med, Dept Post Genom & Dis, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	tsujimot@gene.med.osaka-u.ac.jp	Arakawa, Satoko/AAM-9638-2020; Mizushima, Noboru/C-3635-2009	Arakawa, Satoko/0000-0002-4375-1643; Mizushima, Noboru/0000-0002-6258-6444				Baehrecke EH, 2002, NAT REV MOL CELL BIO, V3, P779, DOI 10.1038/nrm931; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Fannjiang Y, 2003, DEV CELL, V4, P575, DOI 10.1016/S1534-5807(03)00091-1; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; KUMA A, IN PRESS NATURE; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Shimizu S, 1996, ONCOGENE, V12, P2251; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	18	1134	1186	1	78	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2004	6	12					1221	1228		10.1038/ncb1192	http://dx.doi.org/10.1038/ncb1192			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	875WQ	15558033				2022-12-25	WOS:000225453300015
J	Simpson, MA; Cross, H; Proukakis, C; Priestman, DA; Neville, DCA; Reinkensmeier, G; Wang, H; Wiznitzer, M; Gurtz, K; Verganelaki, A; Pryde, A; Patton, MA; Dwek, RA; Butters, TD; Platt, FM; Crosby, AH				Simpson, MA; Cross, H; Proukakis, C; Priestman, DA; Neville, DCA; Reinkensmeier, G; Wang, H; Wiznitzer, M; Gurtz, K; Verganelaki, A; Pryde, A; Patton, MA; Dwek, RA; Butters, TD; Platt, FM; Crosby, AH			Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase	NATURE GENETICS			English	Article							HUMAN SERUM; GANGLIOSIDES; GLYCOSPHINGOLIPIDS; BIOSYNTHESIS; COMPLEX	We identified an autosomal recessive infantile-onset symptomatic epilepsy syndrome associated with developmental stagnation and blindness. Assuming a founder effect in a large Old Order Amish pedigree, we carried out a genome-wide screen for linkage and identified a single region of homozygosity on chromosome 2p12-p11.2 spanning 5.1 cM (maximum lod score of 6.84). We sequenced genes in the region and identified a nonsense mutation in SIAT9, which is predicted to result in the premature termination of the GM3 synthase enzyme (also called lactosylceramide alpha-2,3 sialyltransferase). GM3 synthase is a member of the sialyltransferase family and catalyzes the initial step in the biosynthesis of most complex gangliosides from lactosylceramide. Biochemical analysis of plasma glycosphingolipids confirmed that affected individuals lack GM3 synthase activity, as marked by a complete lack of GM3 ganglioside and its biosynthetic derivatives and an increase in lactosylceramide and its alternative derivatives. Although the relationship between defects in ganglioside catabolism and a range of lysosomal storage diseases is well documented, this is the first report, to our knowledge, of a disruption of ganglioside biosynthesis associated with human disease.	Univ London St Georges Hosp, Sch Med, Dept Med Genet, London SW17 0RE, England; Univ Arizona, Sch Med, Dept Ophthalmol, Tucson, AZ USA; Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England; Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; Windows Hope Genet Studies, Kimmeridge Trail, OH 44065 USA	St Georges University London; University of Arizona; University of Oxford; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital	Crosby, AH (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Med Genet, Cranmer Terrace, London SW17 0RE, England.	acrosby@sghms.ac.uk	Crosby, Andrew H/E-2218-2015; Proukakis, Christos/G-4548-2013; Simpson, Michael/F-4737-2011; proukakis, christos/ABE-3447-2020; Platt, Frances/G-1004-2010	Crosby, Andrew H/0000-0003-3667-9054; Simpson, Michael/0000-0002-8539-8753; proukakis, christos/0000-0001-6423-6539; Platt, Frances/0000-0001-7614-0403; Verganelaki, Argyro/0000-0001-8748-1078; Neville, David/0000-0003-2385-8993				Datta AK, 2001, J BIOL CHEM, V276, P15200, DOI 10.1074/jbc.M010542200; Gardiner RM, 2000, J NEUROL, V247, P327, DOI 10.1007/s004150050598; Hakomori S, 2000, GLYCOCONJUGATE J, V17, P627, DOI 10.1023/A:1011086929064; Inoue M, 2002, J BIOL CHEM, V277, P29881, DOI 10.1074/jbc.M201631200; IZUMI T, 1993, PEDIATR NEUROL, V9, P293, DOI 10.1016/0887-8994(93)90066-L; Kawai H, 2001, J BIOL CHEM, V276, P6885, DOI 10.1074/jbc.C000847200; Kobayashi T, 2000, GLYCOCONJUGATE J, V17, P163, DOI 10.1023/A:1026528921085; KUNDU SK, 1985, ARCH BIOCHEM BIOPHYS, V238, P388, DOI 10.1016/0003-9861(85)90179-1; MAX SR, 1974, NEW ENGL J MED, V291, P929, DOI 10.1056/NEJM197410312911802; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Negroni E, 1996, GLYCOCONJUGATE J, V13, P347, DOI 10.1007/BF00731466; Neville DCA, 2004, ANAL BIOCHEM, V331, P275, DOI 10.1016/j.ab.2004.03.051; Proia RL, 2003, PHILOS T R SOC B, V358, P879, DOI 10.1098/rstb.2003.1268; Sandhoff K, 2003, PHILOS T R SOC B, V358, P847, DOI 10.1098/rstb.2003.1265; Schapiro FB, 1998, AM J PHYSIOL-CELL PH, V274, pC319, DOI 10.1152/ajpcell.1998.274.2.C319; SENN HJ, 1992, ATHEROSCLEROSIS, V94, P109, DOI 10.1016/0021-9150(92)90235-9; Wraith J E, 2002, Semin Neonatol, V7, P75, DOI 10.1053/siny.2001.0088; Yamashita T, 2003, P NATL ACAD SCI USA, V100, P3445, DOI 10.1073/pnas.0635898100; Yu R K, 1975, Trans Am Neurol Assoc, V100, P261; YU RK, 1987, YALE J BIOL MED, V60, P107; ZEBDA N, 1995, FEBS LETT, V362, P161, DOI 10.1016/0014-5793(95)00234-Z; ZELLER CB, 1992, AM J PHYSIOL, V262, pC1341, DOI 10.1152/ajpcell.1992.262.6.C1341	22	267	279	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2004	36	11					1225	1229		10.1038/ng1460	http://dx.doi.org/10.1038/ng1460			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	867HI	15502825	Bronze			2022-12-25	WOS:000224832800028
J	Schubert, C				Schubert, C			Fish fix	NATURE MEDICINE			English	News Item																			0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2004	10	10					1051	1051						1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15459706				2022-12-25	WOS:000224245800025
J	Li, JZ; Jiang, T; Mao, JH; Balmain, A; Peterson, L; Harris, C; Rao, PH; Havlak, P; Gibbs, R; Cai, WW				Li, JZ; Jiang, T; Mao, JH; Balmain, A; Peterson, L; Harris, C; Rao, PH; Havlak, P; Gibbs, R; Cai, WW			Genomic segmental polymorphisms in inbred mouse strains	NATURE GENETICS			English	Article							DUPLICATIONS; MICROARRAYS	By analyzing genomic copy-number differences using high-resolution mouse whole-genome BAC arrays, we uncover substantial differences in regional DNA content between inbred strains of mice. The identification of these apparently common segmental polymorphisms suggests that these differences can contribute to genetic variability and pathologic susceptibility.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA	Baylor College of Medicine; University of California System; University of California San Francisco; Baylor College of Medicine; Baylor College of Medicine	Cai, WW (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.	wcai@bcm.tmc.edu	Mao, Jian-Hua/EIZ-8595-2022	Mao, Jian-Hua/0000-0001-9320-6021; Peterson, Leif/0000-0002-1187-0883				Adams DJ, 2004, NAT GENET, V36, P867, DOI 10.1038/ng1388; Bailey JA, 2004, GENOME RES, V14, P789, DOI 10.1101/gr.2238404; Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; Cai WW, 2002, NAT BIOTECHNOL, V20, P393, DOI 10.1038/nbt0402-393; Cheung J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-8-r47; Der-Sarkissian H, 2002, GENOME RES, V12, P1673, DOI 10.1101/gr.322802; Gregory SG, 2002, NATURE, V418, P743, DOI 10.1038/nature00957; Havlak P, 2004, GENOME RES, V14, P721, DOI 10.1101/gr.2264004; Lupski JR, 1998, TRENDS GENET, V14, P417, DOI 10.1016/S0168-9525(98)01555-8; Peterson LE, 2002, COMPUT METH PROG BIO, V69, P179, DOI 10.1016/S0169-2607(01)00189-4; Wade CM, 2002, NATURE, V420, P574, DOI 10.1038/nature01252; Wiltshire T, 2003, P NATL ACAD SCI USA, V100, P3380, DOI 10.1073/pnas.0130101100	12	78	79	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2004	36	9					952	954		10.1038/ng1417	http://dx.doi.org/10.1038/ng1417			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	851AY	15322544	Bronze			2022-12-25	WOS:000223658100019
J	Vissers, LELM; van Ravenswaaij, CMA; Admiraal, R; Hurst, JA; de Vries, BBA; Janssen, IM; van der Vliet, WA; Huys, EHLPG; de Jong, PJ; Hamel, BCJ; Schoenmakers, EFPM; Brunner, HG; Veltman, JA; van Kessel, AG				Vissers, LELM; van Ravenswaaij, CMA; Admiraal, R; Hurst, JA; de Vries, BBA; Janssen, IM; van der Vliet, WA; Huys, EHLPG; de Jong, PJ; Hamel, BCJ; Schoenmakers, EFPM; Brunner, HG; Veltman, JA; van Kessel, AG			Mutations in a new member of the chromodomain gene family cause CHARGE syndrome	NATURE GENETICS			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; ASSOCIATION; PROTEINS; EXCLUSION	CHARGE syndrome is a common cause of congenital anomalies affecting several tissues in a nonrandom fashion. We report a 2.3-Mb de novo overlapping microdeletion on chromosome 8q12 identified by array comparative genomic hybridization in two individuals with CHARGE syndrome. Sequence analysis of genes located in this region detected mutations in the gene CHD7 in 10 of 17 individuals with CHARGE syndrome without microdeletions, accounting for the disease in most affected individuals.	Univ Med Ctr Nijmegen, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Nijmegen, Dept Otorhinolaryngol, NL-6500 HB Nijmegen, Netherlands; Churchill Hosp, Dept Clin Genet, Oxford OX3 7LJ, England; Childrens Hosp, Oakland Res Inst, BACPAC Resources, Oakland, CA 94609 USA	Radboud University Nijmegen; Radboud University Nijmegen; University of Oxford; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute	Veltman, JA (corresponding author), Univ Med Ctr Nijmegen, Dept Human Genet, POB 9101, NL-6500 HB Nijmegen, Netherlands.	j.veltman@antrg.umcn.nl	van Kessel, Ad Geurts/A-2810-2010; Janssen, Irene M/V-3667-2018; Veltman, Joris A/F-5128-2010; Vissers, Lisenka ELM/A-2598-2015; Admiraal, R.J.C./L-4171-2015; Brunner, Han/C-9928-2013	Veltman, Joris A/0000-0002-3218-8250; Vissers, Lisenka ELM/0000-0001-6470-5497; 				Cavalli G, 1998, CURR OPIN CELL BIOL, V10, P354, DOI 10.1016/S0955-0674(98)80011-2; de Lonlay-Debeney P, 1997, J MED GENET, V34, P986, DOI 10.1136/jmg.34.12.986; DEKOK YJM, 1995, SCIENCE, V267, P685, DOI 10.1126/science.7839145; HURST JA, 1991, J MED GENET, V28, P54, DOI 10.1136/jmg.28.1.54; Johnson D, 1998, AM J HUM GENET, V63, P1282, DOI 10.1086/302122; Kallen K, 1999, TERATOLOGY, V60, P334; Lalani SR, 2003, AM J MED GENET A, V118A, P260, DOI 10.1002/ajmg.a.20002; Martin DM, 2002, AM J MED GENET, V111, P27, DOI 10.1002/ajmg.10473; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; PAGON RA, 1981, J PEDIATR-US, V99, P223, DOI 10.1016/S0022-3476(81)80454-4; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Sanlaville D, 2002, CLIN GENET, V61, P135, DOI 10.1034/j.1399-0004.2002.610208.x; Tellier AL, 2000, AM J MED GENET, V93, P85, DOI 10.1002/1096-8628(20000717)93:2<85::AID-AJMG1>3.0.CO;2-B; Vissers LELM, 2003, AM J HUM GENET, V73, P1261, DOI 10.1086/379977; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472	15	830	856	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2004	36	9					955	957		10.1038/ng1407	http://dx.doi.org/10.1038/ng1407			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	851AY	15300250	Bronze			2022-12-25	WOS:000223658100020
J	Giorgini, F; Guidetti, P; Nguyen, QV; Bennett, SC; Muchowski, PJ				Giorgini, F; Guidetti, P; Nguyen, QV; Bennett, SC; Muchowski, PJ			A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease	NATURE GENETICS			English	Article							INCLUSION-BODY FORMATION; MUTANT HUNTINGTIN; POLYGLUTAMINE AGGREGATION; QUINOLINIC ACID; IN-VIVO; TOXICITY; MODEL; BRAIN; INHIBITION; EXPANSIONS	Huntington disease is a fatal neurodegenerative disorder caused by expansion of a polyglutamine tract in the protein huntingtin (Htt)(1), which leads to its aggregation in nuclear and cytoplasmic inclusion bodies(2). We recently identified 52 loss-of-function mutations in yeast genes that enhance the toxicity of a mutant Htt fragment(3). Here we report the results from a genome-wide loss-of-function suppressor screen in which we identified 28 gene deletions that suppress toxicity of a mutant Htt fragment. The suppressors are known or predicted to have roles in vesicle transport, vacuolar degradation, transcription and prion-like aggregation. Among the most potent suppressors was Bna4 ( kynurenine 3-monooxygenase), an enzyme in the kynurenine pathway of tryptophan degradation that has been linked directly to the pathophysiology of Huntington disease in humans by a mechanism that may involve reactive oxygen species(4). This finding is suggestive of a conserved mechanism of polyglutamine toxicity from yeast to humans and identifies new candidate therapeutic targets for the treatment of Huntington disease.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Catonsville, MD 21228 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA; Univ Washington, Ctr Neurogenet & Neurotherapeut, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Muchowski, PJ (corresponding author), Univ Washington, Dept Pathol, Seattle, WA 98195 USA.	mucho@u.washington.edu		Giorgini, Flaviano/0000-0001-7881-9508	NINDS NIH HHS [R01 NS047237] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047237] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Ferrante RJ, 2003, J NEUROSCI, V23, P9418; Goda K, 1999, ADV EXP MED BIOL, V467, P397; Guidetti P, 2000, NEUROSCI LETT, V283, P233, DOI 10.1016/S0304-3940(00)00956-3; Guidetti P, 2004, NEUROBIOL DIS, V17, P455, DOI 10.1016/j.nbd.2004.07.006; Guidetti P, 1999, EUR J NEUROSCI, V11, P3857, DOI 10.1046/j.1460-9568.1999.00806.x; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mallory MJ, 2003, J BIOL CHEM, V278, P44727, DOI 10.1074/jbc.M308632200; Meriin AB, 2002, J CELL BIOL, V157, P997, DOI 10.1083/jcb.200112104; Michelitsch MD, 2000, P NATL ACAD SCI USA, V97, P11910, DOI 10.1073/pnas.97.22.11910; Moroni F, 1999, ADV EXP MED BIOL, V467, P199; Muchowski PJ, 2002, P NATL ACAD SCI USA, V99, P727, DOI 10.1073/pnas.022628699; Perez-Severiano F, 2004, NEUROCHEM RES, V29, P729, DOI 10.1023/B:NERE.0000018843.83770.4b; Qin ZH, 2003, HUM MOL GENET, V12, P3231, DOI 10.1093/hmg/ddg346; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107; Richter A, 2003, EUR J PHARMACOL, V478, P47, DOI 10.1016/j.ejphar.2003.08.038; Rover S, 1997, J MED CHEM, V40, P4378, DOI 10.1021/jm970467t; Ryu JK, 2004, EXP NEUROL, V187, P150, DOI 10.1016/j.expneurol.2004.01.006; Sapp E, 2001, J NEUROPATH EXP NEUR, V60, P161, DOI 10.1093/jnen/60.2.161; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SCHWARCZ R, 1983, SCIENCE, V219, P316, DOI 10.1126/science.6849138; Schwarcz R, 2004, CURR OPIN PHARMACOL, V4, P12, DOI 10.1016/j.coph.2003.10.006; Schwarcz R, 2002, J PHARMACOL EXP THER, V303, P1, DOI 10.1124/jpet.102.034439; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Sugars KL, 2003, TRENDS GENET, V19, P233, DOI 10.1016/S0168-9525(03)00074-X; Willingham S, 2003, SCIENCE, V302, P1769, DOI 10.1126/science.1090389; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137; Zhang XQ, 2005, P NATL ACAD SCI USA, V102, P892, DOI 10.1073/pnas.0408936102	30	265	274	2	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2005	37	5					526	531		10.1038/ng1542	http://dx.doi.org/10.1038/ng1542			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	922TU	15806102	Green Accepted			2022-12-25	WOS:000228862300023
J	Zuchner, S; Noureddine, M; Kennerson, M; Verhoeven, K; Claeys, K; De Jonghe, P; Merory, J; Oliveira, SA; Speer, MC; Stenger, JE; Walizada, G; Zhu, DQ; Pericak-Vance, MA; Nicholson, G; Timmerman, V; Vance, JM				Zuchner, S; Noureddine, M; Kennerson, M; Verhoeven, K; Claeys, K; De Jonghe, P; Merory, J; Oliveira, SA; Speer, MC; Stenger, JE; Walizada, G; Zhu, DQ; Pericak-Vance, MA; Nicholson, G; Timmerman, V; Vance, JM			Mutations in the pleckstrin homology domain of dynamin 2 cause dominant intermediate Charcot-Marie-Tooth disease	NATURE GENETICS			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; NEUROPATHY; IDENTIFICATION; LOCALIZATION; MICROTUBULES; MECHANISM; MUTANT; MAPS; FORM	Charcot-Marie-Tooth (CMT) disease is a clinically and genetically heterogeneous group of peripheral neuropathies. Different chromosomal loci have been linked with three autosomal dominant, `intermediate' types of CMT: DI-CMTA(1),DI-CMTB2 and DI-CMTC3. We refined the locus associated with DI-CMTB on chromosome 19p12- 13. 2 to 4.2 Mb in three unrelated families with CMT originating from Australia, Belgium and North America. After screening candidate genes, we identified unique mutations in dynamin 2 (DNM2) in all families. DNM2 belongs to the family of large GTPases and is part of the cellular fusion-fission apparatus(4). In transiently transfected cell lines, mutations of DNM2 substantially diminish binding of DNM2 to membranes by altering the conformation of the beta3/beta4 loop of the pleckstrin homology domain. Additionally, in the Australian and Belgian pedigrees, which carry two different mutations affecting the same amino acid, Lys558, CMT cosegregated with neutropenia, which has not previously been associated with CMT neuropathies.	Duke Univ, Med Ctr, Dept Human Genet, Durham, NC 27710 USA; Rhein Westfal TH Aachen, Univ Hosp, Dept Neuropathol, D-52074 Aachen, Germany; ANZAC Res Inst, Northcott Neurosci Lab, Sydney, NSW, Australia; Concord Hosp, Mol Med Lab, Concord, NSW, Australia; Univ Antwerp VIB, Dept Mol Genet, B-2020 Antwerp, Belgium; Univ Antwerp Hosp, Div Neurol, Antwerp, Belgium; Heidelberg Repatriat Hosp, Dept Neurol, Heidelberg West, Vic 3081, Australia	Duke University; RWTH Aachen University; RWTH Aachen University Hospital; University of Sydney; ANZAC Research Institute; Concord Repatriation General Hospital; Flanders Institute for Biotechnology (VIB); University of Antwerp; University of Antwerp	Zuchner, S (corresponding author), Duke Univ, Med Ctr, Dept Human Genet, Durham, NC 27710 USA.		Oliveira, Sofia/F-3386-2010; Research Institute, ANZAC/CAE-9030-2022	Vance, Jeffery/0000-0003-3815-8199; Claeys, Kristl/0000-0001-9937-443X; Oliveira, Sofia A/0000-0001-7919-4191; Kennerson, Marina/0000-0003-3332-5074; Nicholson, Garth/0000-0001-9694-066X				Achiriloaie M, 1999, MOL CELL BIOL, V19, P1410; Blomberg N, 1999, TRENDS BIOCHEM SCI, V24, P441, DOI 10.1016/S0968-0004(99)01472-3; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Horwitz M, 1999, NAT GENET, V23, P433, DOI 10.1038/70544; Jordanova A, 2003, AM J HUM GENET, V73, P1423, DOI 10.1086/379792; Kennerson ML, 2001, AM J HUM GENET, V69, P883, DOI 10.1086/323743; Kozlov MM, 1999, BIOPHYS J, V77, P604, DOI 10.1016/S0006-3495(99)76917-1; Lee A, 1999, CURR BIOL, V9, P261, DOI 10.1016/S0960-9822(99)80115-8; Muhlberg AB, 2000, METHODS, V20, P475, DOI 10.1006/meth.2000.0960; SCAIFE R, 1990, J CELL BIOL, V111, P3023, DOI 10.1083/jcb.111.6.3023; Schafer DA, 2002, CURR BIOL, V12, P1852, DOI 10.1016/S0960-9822(02)01228-9; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Speer MC, 2002, NEUROGENETICS, V4, P83, DOI 10.1007/s10048-002-0139-3; Thompson HM, 2004, NAT CELL BIOL, V6, P335, DOI 10.1038/ncb1112; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; Vance JM, 2000, ARCH NEUROL-CHICAGO, V57, P638, DOI 10.1001/archneur.57.5.638; Verhoeven K, 2001, AM J HUM GENET, V69, P889, DOI 10.1086/323742; Verhoeven K, 2003, AM J HUM GENET, V72, P722, DOI 10.1086/367847; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002; Zhu DQ, 2003, NEUROGENETICS, V4, P179, DOI 10.1007/s10048-003-0147-y; Zuchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341	27	259	270	1	6	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2005	37	3					289	294		10.1038/ng1514	http://dx.doi.org/10.1038/ng1514			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	901QU	15731758				2022-12-25	WOS:000227297800020
J	Esumi, S; Kakazu, N; Taguchi, Y; Hirayama, T; Sasaki, A; Hirabayashi, T; Koide, T; Kitsukawa, T; Hamada, S; Yagi, T				Esumi, S; Kakazu, N; Taguchi, Y; Hirayama, T; Sasaki, A; Hirabayashi, T; Koide, T; Kitsukawa, T; Hamada, S; Yagi, T			Monoallelic yet combinatorial expression of variable exons of the protocadherin-alpha gene cluster in single neurons	NATURE GENETICS			English	Article							GENOMIC ORGANIZATION; MOLECULAR-MECHANISMS; GAMMA-PROTOCADHERINS; FAMILY; DIVERSITY; PATTERNS; CELLS; TRANSCRIPTS; SELECTION; PROMOTER	Diverse protocadherin-alpha genes (Pcdha, also called cadherin-related neuronal receptor or CNR) are expressed in the vertebrate brain. Their genomic organization involves multiple variable exons and a set of constant exons, similar to the immunoglobulin (Ig) and T-cell receptor (TCR) genes. This diversity can be used to distinguish neurons. Using polymorphisms that distinguish the C57BL/6 and MSM mouse strains, we analyzed the allelic expression of the Pcdha gene cluster in individual neurons. Single-cell analysis of Purkinje cells using multiple RT-PCR reactions showed the monoallelic and combinatorial expression of each variable exon in the Pcdha genes. This report is the first description to our knowledge of the allelic expression of a diversified receptor family in the central nervous system. The allelic and combinatorial expression of distinct variable exons of the Pcdha genes is a potential mechanism for specifying neuron identity in the brain.	Osaka Univ, Grad Sch Frontier Biosci, Labs Integrated Biol, KOKORO Biol Grp, Suita, Osaka 5650871, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kamigyo Ku, Kyoto 6028566, Japan; Natl Inst Physiol Sci, Dept Informat Physiol, Div Neurobiol & Behav Genet, Okazaki, Aichi 4448585, Japan; Natl Inst Genet, Mouse Genom Resource Lab, Mishima, Shizuoka 4118540, Japan; Natl Inst Basic Biol, Div Brain Biol, Okazaki, Aichi 4440867, Japan	Osaka University; Japan Science & Technology Agency (JST); Kyoto Prefectural University of Medicine; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Yagi, T (corresponding author), Osaka Univ, Grad Sch Frontier Biosci, Labs Integrated Biol, KOKORO Biol Grp, 1-3 Yamadaoka, Suita, Osaka 5650871, Japan.	yagi@fbs.osaka-u.ac.jp	Kitsukawa, Takashi/X-3176-2018					CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; Hamada S, 2001, NEUROSCI RES, V41, P207, DOI 10.1016/S0168-0102(01)00281-4; HELD W, 1995, NATURE, V376, P355, DOI 10.1038/376355a0; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; LYON MF, 1986, NATURE, V320, P313, DOI 10.1038/320313b0; Neves G, 2004, NAT GENET, V36, P240, DOI 10.1038/ng1299; Oberdick J, 1998, TRENDS NEUROSCI, V21, P383, DOI 10.1016/S0166-2236(98)01325-3; PERNIS B, 1965, J EXP MED, V122, P853, DOI 10.1084/jem.122.5.853; Phillips GR, 2003, J NEUROSCI, V23, P5096; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Rhoades KL, 2000, CURR BIOL, V10, P789, DOI 10.1016/S0960-9822(00)00565-0; Rodriguez I, 1999, CELL, V97, P199, DOI 10.1016/S0092-8674(00)80730-8; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Serafini T, 1999, CELL, V98, P133, DOI 10.1016/S0092-8674(00)81008-9; Singh N, 2003, J EXP MED, V197, P743, DOI 10.1084/jem.20021392; Sugino H, 2004, BIOCHEM BIOPH RES CO, V316, P437, DOI 10.1016/j.bbrc.2004.02.067; Sugino H, 2000, GENOMICS, V63, P75, DOI 10.1006/geno.1999.6066; Tada MN, 2004, GENE, V340, P197, DOI 10.1016/j.gene.2004.07.014; Tasic B, 2002, MOL CELL, V10, P21, DOI 10.1016/S1097-2765(02)00578-6; Wang XZ, 2002, GENE DEV, V16, P1890, DOI 10.1101/gad.1004802; Wang XZ, 2002, NEURON, V36, P843, DOI 10.1016/S0896-6273(02)01090-5; Wu Q, 2000, P NATL ACAD SCI USA, V97, P3124, DOI 10.1073/pnas.060027397; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8; Yagi T, 1999, BIOCHEM PHARMACOL, V57, P845; Yagi T, 2000, GENE DEV, V14, P1169; Yanase H, 2004, GENOMICS, V83, P717, DOI 10.1016/j.ygeno.2003.09.022	27	191	196	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2005	37	2					171	176		10.1038/ng1500	http://dx.doi.org/10.1038/ng1500			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	893AB	15640798				2022-12-25	WOS:000226690100024
J	Youn, CK; Cho, HJ; Kim, SH; Kim, HB; Kim, MH; Chang, IY; Lee, JS; Chung, MH; Hahm, KS; You, HJ				Youn, CK; Cho, HJ; Kim, SH; Kim, HB; Kim, MH; Chang, IY; Lee, JS; Chung, MH; Hahm, KS; You, HJ			Bcl-2 expression suppresses mismatch repair activity through inhibition of E2F transcriptional activity	NATURE CELL BIOLOGY			English	Article							CELL-CYCLE ENTRY; TUMOR-CELLS; HUMAN FIBROBLASTS; PROTEIN FAMILY; DNA-REPAIR; GENE; CANCER; APOPTOSIS; REPLICATION; PROGRESSION	Bcl-2 stimulates mutagenesis after the exposure of cells to DNA-damaging agents. However, the biological mechanisms of Bcl-2-mediated mutagenesis have remained largely obscure. Here we demonstrate that the Bcl-2-mediated suppression of hMSH2 expression results in a reduced cellular capacity to repair mismatches. The pathway linking Bcl-2 expression to the suppression of mismatch repair (MMR) activity involves the hypophosphorylation of pRb, and then the enhancement of the E2F-pRb complex. This is followed by a decrease in hMSH2 expression. MMR has a key role in protection against deleterious mutation accumulation and in maintaining genomic stability. Therefore, the decreased MMR activity by Bcl-2 may be an underlying mechanism for Bcl-2-promoted oncogenesis.	Chosun Univ, Sch Med, Dept Pharmacol, Kwangju 501759, South Korea; Chosun Univ, Res Ctr Proteinous Mat, Kwangju 501759, South Korea; Seoul Natl Univ, Sch Med, Dept Pharmacol, Seoul 110799, South Korea	Chosun University; Chosun University; Seoul National University (SNU)	You, HJ (corresponding author), Chosun Univ, Sch Med, Dept Pharmacol, 375 Seusuk Dong, Kwangju 501759, South Korea.	hjyou@chosun.ac.kr		Chang, In-Youb/0000-0002-8911-7541; You, Ho Jin/0000-0002-0530-4017; KIM, HONGBEUM/0000-0001-9434-0708				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Binder C, 1995, ANN ONCOL, V6, P1005, DOI 10.1093/oxfordjournals.annonc.a059064; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; Chang DK, 2000, J BIOL CHEM, V275, P18424, DOI 10.1074/jbc.M001140200; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Crowson AN, 1996, HUM PATHOL, V27, P355, DOI 10.1016/S0046-8177(96)90108-2; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; Greider C, 2002, ONCOGENE, V21, P7765, DOI 10.1038/sj.onc.1205928; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; Hsieh P, 2001, MUTAT RES-DNA REPAIR, V486, P71, DOI 10.1016/S0921-8777(01)00088-X; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Iwahashi Y, 1998, GENE, V213, P141, DOI 10.1016/S0378-1119(98)00187-5; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Kaklamanis L, 1996, J PATHOL, V179, P10; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Kuo ML, 1999, MOL PHARMACOL, V55, P894; Lind EF, 1999, J IMMUNOL, V162, P5374; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Liu YF, 1997, CANCER RES, V57, P1650; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MITRA S, 1993, PROG NUCLEIC ACID RE, V44, P109, DOI 10.1016/S0079-6603(08)60218-4; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; PEGG AE, 1992, FASEB J, V6, P2302, DOI 10.1096/fasebj.6.6.1544541; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Saintigny Y, 2001, EMBO J, V20, P2596, DOI 10.1093/emboj/20.10.2596; Srivenugopal KS, 2000, CANCER RES, V60, P282; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; Takahashi Y, 2000, GENE DEV, V14, P804; Thomas David C., 1995, Methods (Orlando), V7, P187, DOI 10.1006/meth.1995.1024; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Umar A, 1997, CANCER RES, V57, P3949; Vairo G, 2000, MOL CELL BIOL, V20, P4745, DOI 10.1128/MCB.20.13.4745-4753.2000; Vogelstein B., 1998, GENETIC BASIS HUMAN; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; YANG JL, 1991, J MOL BIOL, V221, P421, DOI 10.1016/0022-2836(91)80063-Z; Yin DX, 1996, P NATL ACAD SCI USA, V93, P3394, DOI 10.1073/pnas.93.8.3394; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	48	63	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2005	7	2					137	U48		10.1038/ncb1215	http://dx.doi.org/10.1038/ncb1215			14	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	893LC	15619620				2022-12-25	WOS:000226719500010
J	Hasson, P; Egoz, N; Winkler, C; Volohonsky, G; Jia, ST; Dinur, T; Volk, T; Courey, AJ; Paroush, Z				Hasson, P; Egoz, N; Winkler, C; Volohonsky, G; Jia, ST; Dinur, T; Volk, T; Courey, AJ; Paroush, Z			EGFR signaling attenuates Groucho-dependent repression to antagonize Notch transcriptional output	NATURE GENETICS			English	Article							RECEPTOR TYROSINE KINASE; DROSOPHILA EMBRYO; PATHWAYS; RECRUITMENT; ACTIVATION; EXPRESSION; COREPRESSORS; INTERACTS; PROTEINS; BRINKER	Crosstalk between signaling pathways is crucial for the generation of complex and varied transcriptional networks. Antagonism between the EGF-receptor (EGFR) and Notch pathways in particular is well documented, although the underlying mechanism is poorly understood. The global corepressor Groucho (Gro) and its transducin-like Enhancer-of-split (TLE) mammalian homologs mediate repression by a myriad of repressors, including effectors of the Notch, Wnt (Wg) and TGF-beta (Dpp) signaling cascades(1-8). Given that there are genetic interactions between gro and components of the EGFR pathway(9) (ref. 9 and P. H. et al., unpublished results), we tested whether Gro is at a crossroad between this and other pathways. Here we show that phosphorylation of Gro in response to MAPK activation weakens its repressor capacity, attenuating Gro-dependent transcriptional silencing by the Enhancer-of-split proteins, effectors of the Notch cascade. Thus, Gro is a new junction between signaling pathways, enabling EGFR signaling to antagonize transcriptional output by Notch and potentially other Gro-dependent pathways.	Hebrew Univ Jerusalem, Fac Med, Dept Biochem, IL-91120 Jerusalem, Israel; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Hebrew University of Jerusalem; University of California System; University of California Los Angeles; Weizmann Institute of Science	Paroush, Z (corresponding author), Hebrew Univ Jerusalem, Fac Med, Dept Biochem, POB 12272, IL-91120 Jerusalem, Israel.	zparoush@cc.huji.ac.il			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044522] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM044522] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barolo S, 2002, GENE DEV, V16, P1964, DOI 10.1101/gad.987402; Bianchi-Frias D, 2004, PLOS BIOL, V2, P975, DOI 10.1371/journal.pbio.0020178; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chen GQ, 2000, GENE, V249, P1, DOI 10.1016/S0378-1119(00)00161-X; Courey AJ, 2001, GENE DEV, V15, P2786; Culi J, 2001, DEVELOPMENT, V128, P299; deCelis JF, 1997, DEVELOPMENT, V124, P1919; DECELIS JF, 1995, DEVELOPMENT, V121, P3467; Giagtzoglou N, 2003, DEVELOPMENT, V130, P259, DOI 10.1242/dev.00206; Hasson P, 2001, EMBO J, V20, P5725, DOI 10.1093/emboj/20.20.5725; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Nuthall HN, 2002, J BIOL CHEM, V277, P51049, DOI 10.1074/jbc.M111660200; Parkhurst SM, 1998, TRENDS GENET, V14, P130, DOI 10.1016/S0168-9525(98)01407-3; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Price JV, 1997, GENETICS, V147, P1139; Queenan AM, 1997, DEVELOPMENT, V124, P3871; Rohrbaugh M, 2002, CURR BIOL, V12, P576, DOI 10.1016/S0960-9822(02)00743-1; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; Shaye DD, 2002, NATURE, V420, P686, DOI 10.1038/nature01234; Simon MA, 2000, CELL, V103, P13, DOI 10.1016/S0092-8674(00)00100-8; Simpson P, 1997, CURR OPIN GENET DEV, V7, P537, DOI 10.1016/S0959-437X(97)80083-4; Wang SH, 2000, GENE DEV, V14, P2271, DOI 10.1101/gad.827000; Wessells RJ, 1999, DEV BIOL, V216, P243, DOI 10.1006/dbio.1999.9459; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1; Zecca M, 2002, DEVELOPMENT, V129, P1357; Zhang HL, 1999, P NATL ACAD SCI USA, V96, P535, DOI 10.1073/pnas.96.2.535; Zhang HL, 2001, GENE DEV, V15, P261, DOI 10.1101/gad.861201; zur Lage P, 1999, DEVELOPMENT, V126, P3149	30	104	105	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2005	37	1					101	105		10.1038/ng1486	http://dx.doi.org/10.1038/ng1486			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	883FX	15592470				2022-12-25	WOS:000225997500028
J	Zhang, WD; Yang, H; Kong, XY; Mohapatra, S; San Juan-Vergara, H; Hellermann, G; Behera, S; Singam, R; Lockey, RF; Mohapatra, SS				Zhang, WD; Yang, H; Kong, XY; Mohapatra, S; San Juan-Vergara, H; Hellermann, G; Behera, S; Singam, R; Lockey, RF; Mohapatra, SS			Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene	NATURE MEDICINE			English	Article							NONSTRUCTURAL PROTEINS NS1; PROTECTS BALB/C MICE; INTERFERON-GAMMA; CELLS; BRONCHIOLITIS; ASTHMA; INDUCTION; BETA; RNA; RSV	Respiratory syncytial virus (RSV) infection is one of the major causes of respiratory tract infection for which no vaccine or antiviral treatment is available. The RSV NS1 protein seems to antagonize the host interferon (IFN) response; however, its mechanism is unknown. Here, we used a plasmid-borne small interfering RNA targeting the NS1 gene (siNS1) to examine the role of NS1 in modulating RSV infection. RSV replication was reduced in A549 cells, but not IFN-deficient Vero cells, transfected with siNS1. siNS1 induced upregulated expression of IFN-beta and IFN-inducible genes in A549 cells. siNS1-transfected human dendritic cells, upon RSV infection, produced elevated type-1 IFN and induced differentiation of naive CD4+ T cells to T helper type 1 (TH1) cells. Mice treated intranasally with siNS1 nanoparticles before or after infection with RSV showed substantially decreased virus titers in the lung and decreased inflammation and airway reactivity compared to controls. Thus, siNS1 nanoparticles may provide an effective inhibition of RSV infection in humans.	Univ S Florida, Dept Internal Med, Joy McCann Culverhouse Airway Dis Res Ctr, Div Allergy Immunol, Tampa, FL 33612 USA; James A Haley Vet Hosp, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Transgenex Nanobiotech Inc, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; H Lee Moffitt Cancer Center & Research Institute	Mohapatra, SS (corresponding author), Univ S Florida, Dept Internal Med, Joy McCann Culverhouse Airway Dis Res Ctr, Div Allergy Immunol, MDC-19,Rm 2536,12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.	smohapat@hsc.usf.edu	Mohapatra, Subhra/A-1381-2012; Mohapatra, Shyam/C-2500-2012; Hellermann, Gary/A-8855-2013	San Juan Vergara, Homero/0000-0002-3808-4647	NHLBI NIH HHS [5R01HL71101-01A2] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071101] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNOLD R, 1994, IMMUNOLOGY, V82, P126; Atreya PL, 1998, J VIROL, V72, P1452, DOI 10.1128/JVI.72.2.1452-1461.1998; Barnes B, 2002, J INTERF CYTOK RES, V22, P59, DOI 10.1089/107999002753452665; Bartz H, 2003, IMMUNOLOGY, V109, P49, DOI 10.1046/j.1365-2567.2003.01629.x; Behera AK, 2002, HUM GENE THER, V13, P1697, DOI 10.1089/104303402760293547; Billy E, 2001, P NATL ACAD SCI USA, V98, P14428, DOI 10.1073/pnas.261562698; Bont L, 2000, J INFECT DIS, V181, P1772, DOI 10.1086/315433; Bossert B, 2003, J VIROL, V77, P8661, DOI 10.1128/JVI.77.16.8661-8668.2003; Bossert B, 2002, J VIROL, V76, P4287, DOI 10.1128/JVI.76.9.4287-4293.2002; Brandenburg AH, 2001, VACCINE, V19, P2769, DOI 10.1016/S0264-410X(00)00536-3; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Coffin SE, 1997, ADV PEDIATR INFECT D, V13, P333; COLLINS PL, 2001, FIELDS VIROLOGY, P1443; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; FISHER TL, 1993, NUCLEIC ACIDS RES, V21, P3857, DOI 10.1093/nar/21.16.3857; HALL CB, 1991, J INFECT DIS, V163, P693, DOI 10.1093/infdis/163.4.693; Hall CB, 2001, CLIN INFECT DIS, V33, P792, DOI 10.1086/322657; Hallak LK, 2000, VIROLOGY, V271, P264, DOI 10.1006/viro.2000.0293; Handforth J, 2000, Paediatr Respir Rev, V1, P210, DOI 10.1053/prrv.2000.0050; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Hellermann Gary R, 2003, Genet Vaccines Ther, V1, P1; Jin H, 2000, VIROLOGY, V273, P210, DOI 10.1006/viro.2000.0393; Kole R, 2001, CURR OPIN MOL THER, V3, P229; Kumar M, 2002, HUM GENE THER, V13, P1415, DOI 10.1089/10430340260185058; Kumar M, 1999, VACCINE, V18, P558, DOI 10.1016/S0264-410X(99)00185-1; Kumar Mukesh, 2003, Genet Vaccines Ther, V1, P3, DOI 10.1186/1479-0556-1-3; Leaman DW, 2002, VIROLOGY, V292, P70, DOI 10.1006/viro.2001.1213; Matsuse H, 2000, J IMMUNOL, V164, P6583, DOI 10.4049/jimmunol.164.12.6583; Mohapatra SS, 2003, PEDIATR INFECT DIS J, V22, pS100, DOI 10.1097/00006454-200302001-00015; MOSCA JD, 1986, MOL CELL BIOL, V6, P2279, DOI 10.1128/MCB.6.6.2279; Murphy BR, 2002, J CLIN INVEST, V110, P21, DOI 10.1172/JCI200216077; Pebernard S, 2004, DIFFERENTIATION, V72, P103, DOI 10.1111/j.1432-0436.2004.07202001.x; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; Roman M, 1997, AM J RESP CRIT CARE, V156, P190, DOI 10.1164/ajrccm.156.1.9611050; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; Schlender J, 2000, J VIROL, V74, P8234, DOI 10.1128/JVI.74.18.8234-8242.2000; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; SIGURS N, 1995, PEDIATRICS, V95, P500; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; SLY PD, 1989, PEDIATR PULM, V7, P153, DOI 10.1002/ppul.1950070307; Spann KM, 2004, J VIROL, V78, P4363, DOI 10.1128/JVI.78.8.4363-4369.2004; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Teng MN, 2000, J VIROL, V74, P9317, DOI 10.1128/JVI.74.19.9317-9321.2000; Teng MN, 1999, J VIROL, V73, P466, DOI 10.1128/JVI.73.1.466-473.1999; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Welliver RC, 2003, J PEDIATR-US, V143, pS112, DOI 10.1067/S0022-3476(03)00508-0; Zhang Weidong, 2004, Genet Vaccines Ther, V2, P8, DOI 10.1186/1479-0556-2-8	48	249	277	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2005	11	1					56	62		10.1038/nm1174	http://dx.doi.org/10.1038/nm1174			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	884ZJ	15619625				2022-12-25	WOS:000226124900033
J	Shen, L; Evel-Kabler, K; Strube, R; Chen, SY				Shen, L; Evel-Kabler, K; Strube, R; Chen, SY			Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity	NATURE BIOTECHNOLOGY			English	Article							SHORT-INTERFERING RNAS; T-CELL; CYTOKINE SIGNALING-1; METASTATIC MELANOMA; MAMMALIAN-CELLS; IN-VIVO; BLOCKADE; SYSTEM; AUTOIMMUNITY; ACTIVATION	Tumor vaccines represent a promising therapeutic approach, but thus far have achieved only limited success in the clinic. The major challenge is to find a means of overcoming inhibitory immune regulatory mechanisms and eliciting effective T-cell responses to antigens preferentially expressed by tumor cells. Here we show that the stimulatory capacity of dendritic cells (DCs) and the magnitude of adaptive immunity are critically regulated by the suppressor of cytokine signaling (SOCS) 1 in DCs. Silencing SOCS1 in antigen-presenting DCs strongly enhances antigen-specific anti-tumor immunity. Our findings indicate that SOCS1 represents an inhibitory mechanism for qualitatively and quantitatively controlling antigen presentation by DCs and the magnitude of adaptive immunity. This study has implications for understanding the regulation of antigen presentation and for developing more effective tumor vaccines by silencing the critical brake in antigen presentation.	Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Chen, SY (corresponding author), Baylor Coll Med, Ctr Cell & Gene Therapy, 1 Baylor Plaza, Houston, TX 77030 USA.	sychen@bcm.tmc.edu			NATIONAL CANCER INSTITUTE [R01CA090427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048711, T32AI007495, R01AI048480] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA90427] Funding Source: Medline; NIAID NIH HHS [T32-AI07495, R01AI48480, R01AI48711] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alegre ML, 2001, NAT REV IMMUNOL, V1, P220, DOI 10.1038/35105024; Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen JD, 1997, NAT MED, V3, P1110, DOI 10.1038/nm1097-1110; Chen LP, 2004, NAT REV IMMUNOL, V4, P336, DOI 10.1038/nri1349; Chong MMW, 2003, IMMUNITY, V18, P475, DOI 10.1016/S1074-7613(03)00078-5; Garg S, 2003, NAT IMMUNOL, V4, P907, DOI 10.1038/ni962; Hanada T, 2003, IMMUNITY, V19, P437, DOI 10.1016/S1074-7613(03)00240-1; Hill JA, 2003, J IMMUNOL, V171, P691, DOI 10.4049/jimmunol.171.2.691; Hodi FS, 2003, P NATL ACAD SCI USA, V100, P4712, DOI 10.1073/pnas.0830997100; Huang XF, 2003, CANCER RES, V63, P7321; Kinjyo I, 2002, IMMUNITY, V17, P583, DOI 10.1016/S1074-7613(02)00446-6; Kubo M, 2003, NAT IMMUNOL, V4, P1169, DOI 10.1038/ni1012; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Menges M, 2002, J EXP MED, V195, P15, DOI 10.1084/jem.20011341; Metcalf D, 2003, P NATL ACAD SCI USA, V100, P8436, DOI 10.1073/pnas.1032925100; Naka T, 2001, IMMUNITY, V14, P535, DOI 10.1016/S1074-7613(01)00132-7; Pardoll D, 2003, ANNU REV IMMUNOL, V21, P807, DOI 10.1146/annurev.immunol.21.120601.141135; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100; Porgador A, 1998, J EXP MED, V188, P1075, DOI 10.1084/jem.188.6.1075; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Schroers Roland, 2004, Methods Mol Biol, V246, P451; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Srivastava P, 2002, ANNU REV IMMUNOL, V20, P395, DOI 10.1146/annurev.immunol.20.100301.064801; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Timmerman JM, 1999, ANNU REV MED, V50, P507; van Elsas A, 2001, J EXP MED, V194, P481, DOI 10.1084/jem.194.4.481; Yang YP, 2004, NAT IMMUNOL, V5, P508, DOI 10.1038/ni1059; You ZY, 2000, J IMMUNOL, V165, P4581, DOI 10.4049/jimmunol.165.8.4581	33	211	269	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2004	22	12					1546	1553		10.1038/nbt1035	http://dx.doi.org/10.1038/nbt1035			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	878HX	15558048				2022-12-25	WOS:000225638600025
J	Hofmann, WA; Stojiljkovic, L; Fuchsova, B; Vargas, GM; Mavrommatis, E; Philimonenko, V; Kysela, K; Goodrich, JA; Lessard, JL; Hope, TJ; Hozak, P; de Lanerolle, P				Hofmann, WA; Stojiljkovic, L; Fuchsova, B; Vargas, GM; Mavrommatis, E; Philimonenko, V; Kysela, K; Goodrich, JA; Lessard, JL; Hope, TJ; Hozak, P; de Lanerolle, P			Actin is part of pre-initiation complexes and is necessary for transcription by RNA polymerase II	NATURE CELL BIOLOGY			English	Article							NUCLEAR ACTIN; MESSENGER-RNA; MYOSIN I; BINDING; EXPRESSION; ANTIBODIES; CHROMATIN; GENE; ASSOCIATION; INHIBITION	Actin is abundant in the nucleus and has been implicated in transcription; however, the nature of this involvement has not been established. Here we demonstrate that beta-actin is critically involved in transcription because antibodies directed against beta-actin, but not muscle actin, inhibited transcription in vivo and in vitro. Chromatin immunoprecipitation assays demonstrated the recruitment of actin to the promoter region of the interferon-gamma-inducible MHC2TA gene as well as the interferon-alpha-inducible G1P3 gene. Further investigation revealed that actin and RNA polymerase II co-localize in vivo and also co-purify. We employed an in vitro system with purified nuclear components to demonstrate that antibodies to beta-actin block the initiation of transcription. This assay also demonstrates that beta-actin stimulates transcription by RNA polymerase II. Finally, DNA-binding experiments established the presence of beta-actin in pre-initiation complexes and also showed that the depletion of actin prevented the formation of pre-initiation complexes. Together, these data suggest a fundamental role for actin in the initiation of transcription by RNA polymerase II.	Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60612 USA; Acad Sci Czech Republ, Inst Expt Med, Dept Cell Ultrastruct & Mol Biol, Prague 14220, Czech Republic; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Childrens Hosp Res Fdn, Div Dev Biol, Cincinnati, OH 45229 USA; Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Czech Academy of Sciences; Institute of Experimental Medicine of the Czech Academy of Sciences; University of Colorado System; University of Colorado Boulder; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	de Lanerolle, P (corresponding author), Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60612 USA.	primal@uic.edu	Gaplovska, Katarina/I-3472-2012; Hozak, Pavel/AAB-5359-2021; Hozak, Pavel/J-4182-2014; Philimonenko, Vlada/G-3522-2014	Gaplovska, Katarina/0000-0002-6264-8924; Hozak, Pavel/0000-0003-1901-1394; Hozak, Pavel/0000-0003-1901-1394; Hofmann, Wilma/0000-0003-2401-5154	NHLBI NIH HHS [HL56489, HL57291] Funding Source: Medline; NIAID NIH HHS [AI047770] Funding Source: Medline; NIGMS NIH HHS [GM55235] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057291] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI047770, R01AI047770] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bettinger BT, 2004, NAT REV MOL CELL BIO, V5, P410, DOI 10.1038/nrm1370; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Burke E, 1998, VIROLOGY, V252, P137, DOI 10.1006/viro.1998.9471; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EGLY JM, 1984, EMBO J, V3, P2363, DOI 10.1002/j.1460-2075.1984.tb02141.x; Fomproix N, 2004, EXP CELL RES, V294, P140, DOI 10.1016/j.yexcr.2003.10.028; GIMONA M, 1994, CELL MOTIL CYTOSKEL, V27, P108, DOI 10.1002/cm.970270203; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; Hofmann W, 2001, J CELL BIOL, V152, P895, DOI 10.1083/jcb.152.5.895; HOZAK P, 1994, J CELL SCI, V107, P2191; Huang M, 2002, NAT CELL BIOL, V4, P774, DOI 10.1038/ncb855; Jackson DA, 1998, MOL BIOL CELL, V9, P1523, DOI 10.1091/mbc.9.6.1523; Kimura T, 2000, GENES CELLS, V5, P289, DOI 10.1046/j.1365-2443.2000.00326.x; Krauss SW, 2003, P NATL ACAD SCI USA, V100, P10752, DOI 10.1073/pnas.1934680100; Kugel JF, 2000, J BIOL CHEM, V275, P40483, DOI 10.1074/jbc.M006401200; LESSARD JL, 1988, CELL MOTIL CYTOSKEL, V10, P349, DOI 10.1002/cm.970100302; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Morris AC, 2002, MOL CELL BIOL, V22, P4781, DOI 10.1128/MCB.22.13.4781-4791.2002; NAKAYASU H, 1985, EXP CELL RES, V160, P319, DOI 10.1016/0014-4827(85)90179-X; Nguyen VT, 1996, NUCLEIC ACIDS RES, V24, P2924, DOI 10.1093/nar/24.15.2924; Nowak G, 1997, J BIOL CHEM, V272, P17176, DOI 10.1074/jbc.272.27.17176; Pattenden SG, 2002, EMBO J, V21, P1978, DOI 10.1093/emboj/21.8.1978; Pederson T, 2002, J STRUCT BIOL, V140, P3, DOI 10.1016/S1047-8477(02)00528-2; Percipalle P, 2003, P NATL ACAD SCI USA, V100, P6475, DOI 10.1073/pnas.1131933100; Percipalle P, 2002, NUCLEIC ACIDS RES, V30, P1725, DOI 10.1093/nar/30.8.1725; Percipalle P, 2001, J CELL BIOL, V153, P229, DOI 10.1083/jcb.153.1.229; Pestic-Dragovich L, 2000, SCIENCE, V290, P337, DOI 10.1126/science.290.5490.337; Philimonenko AA, 2000, J STRUCT BIOL, V132, P201, DOI 10.1006/jsbi.2000.4326; REINBERG D, 1987, J BIOL CHEM, V262, P3331; RUNGGER D, 1979, NATURE, V282, P320, DOI 10.1038/282320a0; SAHLAS DJ, 1993, J CELL SCI, V105, P347; SAWTELL NM, 1989, J CELL BIOL, V109, P2929, DOI 10.1083/jcb.109.6.2929; SCHEER U, 1984, CELL, V39, P111, DOI 10.1016/0092-8674(84)90196-X; SMITH SS, 1979, BIOCHEM BIOPH RES CO, V86, P161, DOI 10.1016/0006-291X(79)90395-4; SWARTZ DR, 1992, J BIOL CHEM, V267, P20497; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	38	273	285	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2004	6	11					1094	U18		10.1038/ncb1182	http://dx.doi.org/10.1038/ncb1182			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	867BI	15502823				2022-12-25	WOS:000224816700014
J	Escote, X; Zapater, M; Clotet, J; Posas, F				Escote, X; Zapater, M; Clotet, J; Posas, F			Hog1 mediates cell-cycle arrest in G1 phase by the dual targeting of Sic1	NATURE CELL BIOLOGY			English	Article							ACTIVATED PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; TYROSINE PHOSPHATASES; STRESS-RESPONSE; YEAST; PHOSPHORYLATION; REPLICATION; OSMOSENSOR; PATHWAY; CASCADE	Activation of stress-activated protein kinases (SAPKs) is essential for proper cell adaptation to extracellular stimuli. The exposure of yeast cells to high osmolarity, or mutations that lead to activation of the Hog1 SAPK, result in cell-cycle arrest(1-4). The mechanisms by which Hog1 and SAPKs in general regulate cell-cycle progression are not completely understood(5-8). Here we show that Hog1 regulates cell cycle progression at the G1 phase by a dual mechanism that involves downregulation of cyclin expression and direct targeting of the CDK-inhibitor protein Sic1. Hog1 interacts physically with Sic1 in vivo and in vitro, and phosphorylates a single residue at the carboxyl terminus of Sic1, which, in combination with the downregulation of cyclin expression, results in Sic1 stabilization and inhibition of cell-cycle progression. Cells lacking Sic1 or containing a Sic1 allele mutated in the Hog1 phosphorylation site are unable to arrest at G1 phase after Hog1 activation, and become sensitive to osmostress. Together, our data indicate that the Sic1 CDK-inhibitor is the molecular target for the SAPK Hog1 that is required to modulate cell-cycle progression in response to stress.	Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Cell Signaling Unit, E-08003 Barcelona, Spain; Univ Int Catalunya, Dept Mol & Cellular Biol, E-08190 Sant Cugat Del Valles, Spain	Pompeu Fabra University; Universitat Internacional de Catalunya (UIC)	Posas, F (corresponding author), Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Cell Signaling Unit, E-08003 Barcelona, Spain.	francesc.posas@upf.edu	Escoté, Xavier/AAH-2973-2020; Escote, Xavier/AAC-6335-2019; Clotet, Josep/AAF-2618-2019; Posas, Francesc/K-1364-2013; Clotet, Josep/ABC-8727-2020; Escote, Xavier/G-3440-2015	Escote, Xavier/0000-0003-1172-3995; Posas, Francesc/0000-0002-4164-7076; Clotet, Josep/0000-0001-5462-8598; Escote, Xavier/0000-0003-1172-3995				Alexander MR, 2001, MOL BIOL CELL, V12, P53, DOI 10.1091/mbc.12.1.53; Ambrosino C, 2001, BIOL CELL, V93, P47, DOI 10.1016/S0248-4900(01)01124-8; Belli G, 2001, MOL MICROBIOL, V39, P1022, DOI 10.1046/j.1365-2958.2001.02297.x; Bilsland-Marchesan E, 2000, MOL CELL BIOL, V20, P3887, DOI 10.1128/MCB.20.11.3887-3895.2000; de Nadal E, 2004, NATURE, V427, P370, DOI 10.1038/nature02258; de Nadal E, 2003, MOL CELL BIOL, V23, P229, DOI 10.1128/MCB.23.1.229-237.2003; de Nadal E, 2002, EMBO REP, V3, P735, DOI 10.1093/embo-reports/kvf158; GAXIOLA R, 1992, EMBO J, V11, P3157, DOI 10.1002/j.1460-2075.1992.tb05392.x; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; Jacoby T, 1997, J BIOL CHEM, V272, P17749, DOI 10.1074/jbc.272.28.17749; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Pearce AK, 2001, TRENDS CELL BIOL, V11, P426, DOI 10.1016/S0962-8924(01)02119-5; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SPENCER F, 1990, GENETICS, V124, P237; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; WurglerMurphy SM, 1997, MOL CELL BIOL, V17, P1289, DOI 10.1128/MCB.17.3.1289; Yaakov G, 2003, MOL CELL BIOL, V23, P4826, DOI 10.1128/MCB.23.14.4826-4840.2003	23	170	176	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2004	6	10					997	+		10.1038/ncb1174	http://dx.doi.org/10.1038/ncb1174			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	859FY	15448699				2022-12-25	WOS:000224250000015
J	Lee, CG; Link, H; Baluk, P; Homer, RJ; Chapoval, S; Bhandari, V; Kang, MJ; Cohn, L; Kim, YK; McDonald, DM; Elias, JA				Lee, CG; Link, H; Baluk, P; Homer, RJ; Chapoval, S; Bhandari, V; Kang, MJ; Cohn, L; Kim, YK; McDonald, DM; Elias, JA			Vascular endothelial growth factor (VEGF) induces remodeling and enhances T(H)2-mediated sensitization and inflammation in the lung	NATURE MEDICINE			English	Article							PERMEABILITY FACTOR; ASTHMATIC AIRWAYS; IN-VITRO; EXPRESSION; OVEREXPRESSION; ANGIOGENESIS; PROTECTS; PATHOGENESIS; RECRUITMENT; CHILDREN	Exaggerated levels of VEGF (vascular endothelial growth factor) are present in persons with asthma, but the role(s) of VEGF in normal and asthmatic lungs has not been defined. We generated lung-targeted VEGF(165) transgenic mice and evaluated the role of VEGF in T-helper type 2 cell (T(H)2)-mediated inflammation. In these mice, VEGF induced, through IL-13-dependent and -independent pathways, an asthma-like phenotype with inflammation, parenchymal and vascular remodeling, edema, mucus metaplasia, myocyte hyperplasia and airway hyper-responsiveness. VEGF also enhanced respiratory antigen sensitization and T(H)2 inflammation and increased the number of activated DC2 dendritic cells. In antigen-induced inflammation, VEGF was produced by epithelial cells and preferentially by T(H)2 versus T(H)1 cells. In this setting, it had a critical role in T(H)2 inflammation, cytokine production and physiologic dysregulation. Thus, VEGF is a mediator of vascular and extravascular remodeling and inflammation that enhances antigen sensitization and is crucial in adaptive T(H)2 inflammation. VEGF regulation may be therapeutic in asthma and other T(H)2 disorders.	Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Yale University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Yale University	Elias, JA (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Med Sect, 300 Cedar St,441C TAC, New Haven, CT 06520 USA.	jack.elias@yale.edu	Lee, Chun Geun/AAC-2838-2021; homer, robert/P-3884-2019; Bhandari, Vineet/AAS-3365-2020	homer, robert/0000-0002-2055-5885; Kang, Min-Jong/0000-0003-3245-144X; Lee, Chun Geun/0000-0002-9514-3658; Chapoval, Svetlana/0000-0002-7590-4421	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061904, P50HL056389, R01HL059157, R01HL078744, P01HL024136, P01HL056389] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-78744, HL-61904, R01 HL061904, P01 HL056389, HL-56389, P01 HL024136, HL-59157, R01 HL078744, HL-24136, HL-64642, R01 HL059157, P50 HL056389] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antony AB, 2002, J ALLERGY CLIN IMMUN, V110, P589, DOI 10.1067/mai.2002.127798; Asai K, 2002, J ALLERGY CLIN IMMUN, V110, P571, DOI 10.1067/mai.2002.127797; BALUK P, IN PRESS AM J PATHOL; Charan NB, 1997, EUR RESPIR J, V10, P1173, DOI 10.1183/09031936.97.10051173; Clauss M, 2000, SEMIN THROMB HEMOST, V26, P561, DOI 10.1055/s-2000-13213; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; Corne J, 2000, J CLIN INVEST, V106, P783, DOI 10.1172/JCI9674; Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Elias JA, 2003, J CLIN INVEST, V111, P291, DOI 10.1172/JCI200317748; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Gabrilovich DI, 1999, CLIN CANCER RES, V5, P2963; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Hahn RG, 2003, J ENDOTOXIN RES, V9, P97, DOI 10.1177/09680519030090020401; Hogg JC, 1999, THORAX, V54, P283, DOI 10.1136/thx.54.4.283; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P1034, DOI 10.1067/mai.2001.115626; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P295, DOI 10.1067/mai.2001.111928; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Kanazawa H, 2002, THORAX, V57, P885, DOI 10.1136/thorax.57.10.885; Kaner RJ, 2000, AM J RESP CELL MOL, V22, P657, DOI 10.1165/ajrcmb.22.6.3779; Lee CG, 2002, J BIOL CHEM, V277, P35466, DOI 10.1074/jbc.M206395200; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Lee CG, 2000, AM J RESP CELL MOL, V23, P662, DOI 10.1165/ajrcmb.23.5.4188; Lee YC, 2002, J IMMUNOL, V168, P3595, DOI 10.4049/jimmunol.168.7.3595; Lee YC, 2001, J ALLERGY CLIN IMMUN, V107, P1106, DOI 10.1067/mai.2001.115628; Leigh R, 2004, AM J RESP CRIT CARE, V169, P860, DOI 10.1164/rccm.200305-706OC; Li X, 1997, AM J RESP CRIT CARE, V156, P229, DOI 10.1164/ajrccm.156.1.9607066; Matsui EC, 2003, J ALLERGY CLIN IMMUN, V112, P87, DOI 10.1067/mai.2003.1588; Matsuyama W, 2002, IMMUNOLOGY, V106, P96, DOI 10.1046/j.1365-2567.2002.01395.x; Meyer KC, 2000, J LAB CLIN MED, V135, P332, DOI 10.1067/mlc.2000.105618; Nishigaki Y, 2003, EUR RESPIR J, V21, P774, DOI 10.1183/09031936.03.00085903; Ohta Y, 2002, CHEST, V121, P1624, DOI 10.1378/chest.121.5.1624; Orsida BE, 2001, AM J RESP CRIT CARE, V164, P117, DOI 10.1164/ajrccm.164.1.2006003; Partovian C, 2000, AM J RESP CELL MOL, V23, P762, DOI 10.1165/ajrcmb.23.6.4106; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Ray P, 1997, J CLIN INVEST, V100, P2501, DOI 10.1172/JCI119792; Salvato G, 2001, THORAX, V56, P902, DOI 10.1136/thorax.56.12.902; Schwarze J, 2002, EUR RESPIR J, V19, P341, DOI 10.1183/09031936.02.00254302; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Tang WL, 1996, J CLIN INVEST, V98, P2845, DOI 10.1172/JCI119113; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1996, AM J PHYSIOL-HEART C, V271, pH2547, DOI 10.1152/ajpheart.1996.271.6.H2547; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; VERMAELEN KY, 2003, AM J RESP CELL MOL B; Vrugt B, 2000, EUR RESPIR J, V15, P1014, DOI 10.1034/j.1399-3003.2000.01507.x; Wang JM, 2000, J IMMUNOL, V165, P2222, DOI 10.4049/jimmunol.165.4.2222; Wills-Karp M, 2003, CURR OPIN PULM MED, V9, P21, DOI 10.1097/00063198-200301000-00004; Zeng X, 1998, DEV DYNAM, V211, P215, DOI 10.1002/(SICI)1097-0177(199803)211:3<215::AID-AJA3>3.0.CO;2-K; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	51	458	486	3	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2004	10	10					1095	1103		10.1038/nm1105	http://dx.doi.org/10.1038/nm1105			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15378055	Green Accepted			2022-12-25	WOS:000224245800040
J	Huynh, H; Bottini, N; Williams, S; Cherepanov, V; Musumeci, L; Saito, K; Bruckner, S; Vachon, E; Wang, XD; Kruger, J; Chow, CW; Pellecchia, M; Monosov, E; Greer, PA; Trimble, W; Downey, GP; Mustelin, T				Huynh, H; Bottini, N; Williams, S; Cherepanov, V; Musumeci, L; Saito, K; Bruckner, S; Vachon, E; Wang, XD; Kruger, J; Chow, CW; Pellecchia, M; Monosov, E; Greer, PA; Trimble, W; Downey, GP; Mustelin, T			Control of vesicle fusion by a tyrosine phosphatase	NATURE CELL BIOLOGY			English	Article							SECRETORY VESICLES; MAST-CELLS; PROTEIN; KINASE; PHOSPHORYLATION; NSF; IDENTIFICATION; LOCALIZATION; INHIBITION; ACTIVATION	The tyrosine phosphatase PTP-MEG2 is targeted by its amino-terminal Sec14p homology domain to the membrane of secretory vesicles. There it regulates vesicle size by promoting homotypic vesicle fusion by a mechanism that requires its catalytic activity. Here, we identify N-ethylmaleimide-sensitive factor (NSF), a key regulator of vesicle fusion, as a substrate for PTP-MEG2. PTP-MEG2 reduced the phosphotyrosine content of NSF and co-localized with NSF and syntaxin 6 in intact cells. Furthermore, endogenous PTP-MEG2 co-immunoprecipitated with endogenous NSF. Phosphorylation of NSF at Tyr 83, as well as an acidic substitution at the same site, increased its ATPase activity and prevented alphaSNAP binding. Conversely, expression of a Y83F mutant of NSF caused spontaneous fusion events. Our results suggest that the molecular mechanism by which PTP-MEG2 promotes secretory vesicle fusion involves the local release of NSF from a tyrosine-phosphorylated, inactive state. This represents a novel mechanism for localized regulation of NSF and the first demonstrated role for a protein tyrosine phosphatase in the regulated secretory pathway.	Burnham Inst, Infect & Inflammatory Dis Ctr, Program Inflammat, La Jolla, CA 92037 USA; Burnham Inst, Ctr Canc, Program Signal Transduct, La Jolla, CA 92037 USA; Univ Toronto, Dept Med, Div Respirol, Toronto, ON M5S 1A8, Canada; Queens Univ, Canc Res Inst, Div Canc Biol & Genet, Kingston, ON, Canada; Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1X8, Canada	Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute; University of Toronto; Queens University - Canada; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Mustelin, T (corresponding author), Burnham Inst, Infect & Inflammatory Dis Ctr, Program Inflammat, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	tmustelin@burnham-inst.org	Chow, Chung-Wai/AAP-5533-2020; Pellecchia, Maurizio/Y-7072-2018; Ingegnoli, Francesca/B-6226-2017	Chow, Chung-Wai/0000-0001-9344-8522; Downey, Gregory P/0000-0003-3253-5862; Ingegnoli, Francesca/0000-0002-6727-1273; Mustelin, Tomas/0000-0001-5912-8840	NATIONAL CANCER INSTITUTE [R01CA096949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI055741, R01AI053585, R01AI035603, R01AI048032] Funding Source: NIH RePORTER; Canadian Institutes of Health Research [13465] Funding Source: Medline; NCI NIH HHS [CA96949] Funding Source: Medline; NIAID NIH HHS [AI35603, AI53585, AI55741, AI48032] Funding Source: Medline; NIA NIH HHS [AG00252] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Alonso A, 2003, NAT IMMUNOL, V4, P44, DOI 10.1038/ni856; Austin CD, 1996, J CELL BIOL, V135, P1471, DOI 10.1083/jcb.135.6.1471; Bottini N, 2004, NAT GENET, V36, P337, DOI 10.1038/ng1323; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Gjorloff-Wingren A, 2000, EUR J IMMUNOL, V30, P2412, DOI 10.1002/1521-4141(2000)30:8<2412::AID-IMMU2412>3.0.CO;2-J; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Huynh H, 2003, J IMMUNOL, V171, P6661, DOI 10.4049/jimmunol.171.12.6661; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Kruger JM, 2002, J BIOL CHEM, V277, P2620, DOI 10.1074/jbc.M104550200; Krugmann S, 2002, MOL CELL, V9, P95, DOI 10.1016/S1097-2765(02)00434-3; Lavoie C, 2000, P NATL ACAD SCI USA, V97, P13637, DOI 10.1073/pnas.240278097; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; May AP, 1999, NAT CELL BIOL, V1, P175, DOI 10.1038/11097; Mustelin GS, 2002, FRONT BIOSCI, V7, P85; Mustelin T, 2004, MOL IMMUNOL, V41, P687, DOI 10.1016/j.molimm.2004.04.015; MUSTELIN T, 1994, SRC FAMILY TYROSINE, P1; Paumet F, 2000, J IMMUNOL, V164, P5850, DOI 10.4049/jimmunol.164.11.5850; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; Wang XD, 2002, J IMMUNOL, V168, P4612, DOI 10.4049/jimmunol.168.9.4612; Wendler F, 2001, MOL BIOL CELL, V12, P1699, DOI 10.1091/mbc.12.6.1699; Yu RC, 1999, MOL CELL, V4, P97, DOI 10.1016/S1097-2765(00)80191-4	31	85	87	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2004	6	9					831	U3		10.1038/ncb1164	http://dx.doi.org/10.1038/ncb1164			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	852IZ	15322554				2022-12-25	WOS:000223750300013
J	Phillips, C				Phillips, C			Cell of the month - Waves of glomerular podocytes	NATURE CELL BIOLOGY			English	Editorial Material									Indiana Univ, Sch Med, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Phillips, C (corresponding author), Indiana Univ, Sch Med, Indianapolis, IN 46202 USA.	cphilli3@iupui.edu		Phillips, Carrie/0000-0002-0256-0736					0	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2004	6	9					818	818		10.1038/ncb0904-818	http://dx.doi.org/10.1038/ncb0904-818			1	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	852IZ	15340449				2022-12-25	WOS:000223750300011
J	Lee, CK; Shibata, Y; Rao, B; Strahl, BD; Lieb, JD				Lee, CK; Shibata, Y; Rao, B; Strahl, BD; Lieb, JD			Evidence for nucleosome depletion at active regulatory regions genome-wide	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; IN-VIVO; ENVIRONMENTAL-CHANGES; CHROMATIN STRUCTURE; CROSS-LINKING; YEAST; GENES; TRANSCRIPTION; PROMOTER; ACTIVATION	The identification of nuclease-hypersensitive sites in an active globin gene(1) and in the 5' regions of fruit fly heat shock genes(2) first suggested that chromatin changes accompany gene regulation in vivo. Here we present evidence that the basic repeating units of eukaryotic chromatin, nucleosomes, are depleted from active regulatory elements throughout the Saccharomyces cerevisiae genome in vivo. We found that during rapid mitotic growth, the level of nucleosome occupancy is inversely proportional to the transcriptional initiation rate at the promoter. We also observed a partial loss of histone H3 and H4 tetramers from the coding regions of the most heavily transcribed genes. Alterations in the global transcriptional program caused by heat shock or a change in carbon source resulted in an increased nucleosome occupancy at repressed promoters, and a decreased nucleosome occupancy at promoters that became active. Nuclease-hypersensitive sites occur in species from yeast to humans and result from chromatin perturbation(3-5). Given the conservation of sequence and function among components of both chromatin and the transcriptional machinery, nucleosome depletion at promoters may be a fundamental feature of eukaryotic transcriptional regulation.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Carolina Ctr Genome Sci, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Lieb, JD (corresponding author), Univ N Carolina, Dept Biol, CB 3280,202 Fordham Hall, Chapel Hill, NC 27599 USA.	jlieb@bio.unc.edu	Lee, Cheol-Koo/F-2103-2013; Strahl, Brian/C-7601-2012	Lee, Cheol-Koo/0000-0003-3927-9195; Strahl, Brian/0000-0002-4947-6259; Lieb, Jason/0000-0001-7601-8061				Adkins MW, 2004, MOL CELL, V14, P657, DOI 10.1016/j.molcel.2004.05.016; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Boeger H, 2004, MOL CELL, V14, P667, DOI 10.1016/j.molcel.2004.05.013; Boeger H, 2003, MOL CELL, V11, P1587, DOI 10.1016/S1097-2765(03)00231-4; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; CAVALLI G, 1993, EMBO J, V12, P4603, DOI 10.1002/j.1460-2075.1993.tb06149.x; DAMMANN R, 1993, NUCLEIC ACIDS RES, V21, P2331, DOI 10.1093/nar/21.10.2331; ELGIN SCR, 1981, CELL, V27, P413, DOI 10.1016/0092-8674(81)90381-0; FEDOR MJ, 1989, MOL CELL BIOL, V9, P1721, DOI 10.1128/MCB.9.4.1721; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Jackson V, 1999, METHODS, V17, P125, DOI 10.1006/meth.1998.0724; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Li BJ, 1999, MOL CELL BIOL, V19, P5393; Li SS, 2002, J BIOL CHEM, V277, P44651, DOI 10.1074/jbc.M206623200; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Liu CL, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-19; Lohr D, 1997, J BIOL CHEM, V272, P26795, DOI 10.1074/jbc.272.43.26795; Lusser A, 2003, BIOESSAYS, V25, P1192, DOI 10.1002/bies.10359; Nagy PL, 2003, P NATL ACAD SCI USA, V100, P6364, DOI 10.1073/pnas.1131966100; Ng HH, 2003, P NATL ACAD SCI USA, V100, P1820, DOI 10.1073/pnas.0437846100; Reinke H, 2003, MOL CELL, V11, P1599, DOI 10.1016/S1097-2765(03)00186-2; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Svaren J, 1997, TRENDS BIOCHEM SCI, V22, P93, DOI 10.1016/S0968-0004(97)01001-3; WEINTRAUB H, 1976, SCIENCE, V193, P848, DOI 10.1126/science.948749; WU C, 1979, CELL, V16, P807, DOI 10.1016/0092-8674(79)90096-5; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Yu LN, 1999, MOL CELL BIOL, V19, P5279	29	553	567	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2004	36	8					900	905		10.1038/ng1400	http://dx.doi.org/10.1038/ng1400			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	842AG	15247917				2022-12-25	WOS:000222974000026
J	Moore, JP; Burton, DR				Moore, JP; Burton, DR			Urgently needed: a filter for the HIV-1 vaccine pipeline	NATURE MEDICINE			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1; NEUTRALIZATION; ANTIBODIES; SENSITIVITY; INFECTION; LENGTH; ASSAYS	Research groups worldwide are trying to make immunogens intended to elicit neutralizing antibody responses as part of a prophylactic vaccine to counter the spread of HIV-1. The relative merits of different designs can only be gauged properly through comparative studies, and particularly by evaluating human or animal antisera under identical, or comparable, conditions. Hence there is a need for assay standardization and for the creation of a centralized testing facility that could distribute consensus protocols and reagents.	Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA USA	Cornell University; Scripps Research Institute; Scripps Research Institute	Moore, JP (corresponding author), Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA.	jpm2003@med.cornell.edu; burton@scripps.edu						Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233; Collis AVJ, 2003, J MOL BIOL, V325, P337, DOI 10.1016/S0022-2836(02)01222-6; Derdeyn CA, 2004, SCIENCE, V303, P2019, DOI 10.1126/science.1093137; Dreyer K, 1999, AIDS RES HUM RETROV, V15, P1563, DOI 10.1089/088922299309856; DSouza MP, 1997, J INFECT DIS, V175, P1056, DOI 10.1086/516443; Klasse PJ, 2002, J GEN VIROL, V83, P2091, DOI 10.1099/0022-1317-83-9-2091; Klausner RD, 2003, SCIENCE, V300, P2036, DOI 10.1126/science.1086916; Letvin NL, 2003, NAT MED, V9, P861, DOI 10.1038/nm0703-861; Mascola JR, 2002, J VIROL, V76, P4810, DOI 10.1128/JVI.76.10.4810-4821.2002; Mascola JR, 2002, VACCINE, V20, P1922, DOI 10.1016/S0264-410X(02)00068-3; McMichael AJ, 2003, NAT MED, V9, P874, DOI 10.1038/nm0703-874; Moore JP, 2001, J VIROL, V75, P5721, DOI 10.1128/JVI.75.13.5721-5729.2001; Parren PWHI, 2001, ADV IMMUNOL, V77, P195, DOI 10.1016/S0065-2776(01)77018-6; Pugach P, 2004, VIROLOGY, V321, P8, DOI 10.1016/j.virol.2003.12.012; Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100; Spenlehauer C, 2001, VIROLOGY, V280, P292, DOI 10.1006/viro.2000.0780; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; WU TT, 1993, PROTEINS, V16, P1, DOI 10.1002/prot.340160102	18	37	41	0	4	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2004	10	8					769	771		10.1038/nm0804-769	http://dx.doi.org/10.1038/nm0804-769			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	843DK	15286768				2022-12-25	WOS:000223055700011
J	Foti, D; Chiefari, E; Fedele, M; Iuliano, R; Brunetti, L; Paonessa, F; Manfioletti, G; Barbetti, F; Brunetti, A; Croce, CM; Fusco, A; Brunetti, A				Foti, D; Chiefari, E; Fedele, M; Iuliano, R; Brunetti, L; Paonessa, F; Manfioletti, G; Barbetti, F; Brunetti, A; Croce, CM; Fusco, A; Brunetti, A			Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice	NATURE MEDICINE			English	Article							GROWTH-FACTOR-I; RECEPTOR GENE; GLUCOSE-TRANSPORTER; BETA-CELL; PROTEINS; KNOCKOUT; TRANSCRIPTION; EXPRESSION; INDUCTION; PROMOTER	Type 2 diabetes mellitus is a widespread disease, affecting millions of people globally. Although genetics and environmental factors seem to have a role, the cause of this metabolic disorder is largely unknown. Here we report a genetic flaw that markedly reduced the intracellular expression of the high mobility group A1 (HMGA1) protein, and adversely affected insulin receptor expression in cells and tissues from four subjects with insulin resistance and type 2 diabetes. Restoration of HMGA1 protein expression in subjects' cells enhanced INSR gene transcription, and restored cell-surface insulin receptor protein expression and insulin-binding capacity. Loss of Hmga1 expression, induced in mice by disrupting the Hmga1 gene, considerably decreased insulin receptor expression in the major targets of insulin action, largely impaired insulin signaling and severely reduced insulin secretion, causing a phenotype characteristic of human type 2 diabetes.	Univ Catanzaro Magna Graecia, Dipartimento Med Sperimentale & Clin G Salvatore, I-88100 Catanzaro, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Inst Endocrinol & Oncol Sperimentale, CNR, I-80131 Naples, Italy; Biotecnol Avanzate, CEINGE, NOGEC, I-80131 Naples, Italy; Univ Trieste, Dipartimento Biochim Biofis & Chim Macromol, I-34127 Trieste, Italy; Univ Naples Federico II, Ist Biostrutture & Bioimmagini, CNR, I-80131 Naples, Italy; Osped Bambino Gesu, IRCCS, I-00100 Rome, Italy; Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Columbus, OH 43210 USA	Magna Graecia University of Catanzaro; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; CEINGE Biotecnologie Avanzate; University of Trieste; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biostrutture e Bioimmagini (IBB-CNR); University of Naples Federico II; IRCCS Bambino Gesu; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Brunetti, A (corresponding author), Univ Catanzaro Magna Graecia, Dipartimento Med Sperimentale & Clin G Salvatore, Via T Campanella 115, I-88100 Catanzaro, Italy.	brunetti@unicz.it	Brunetti, Arturo/AAE-5261-2019; Fedele, Monica/C-1417-2015; Barbetti, Fabrizio/I-7351-2018; Barbetti, Fabrizio/AAK-9106-2021; Young, Richard A/F-6495-2012; Chiefari, Eusebio/Y-2558-2019; Foti, Daniela P/K-8038-2016; Brunetti, Antonio/K-7756-2016	Brunetti, Arturo/0000-0001-7057-3494; Fedele, Monica/0000-0002-9171-1312; Barbetti, Fabrizio/0000-0003-4687-980X; Barbetti, Fabrizio/0000-0003-4687-980X; Young, Richard A/0000-0001-8855-8647; Chiefari, Eusebio/0000-0001-5329-3124; Foti, Daniela/0000-0002-9536-5736; Paonessa, Francesco/0000-0002-4729-0928; Fusco, Alfredo/0000-0003-3332-5197; Brunetti, Antonio/0000-0003-1533-8779; MANFIOLETTI, GUIDALBERTO/0000-0001-7913-2601	Telethon [GGP04245, GTF04002] Funding Source: Medline	Telethon(Fondazione Telethon)		Allander SV, 1997, ENDOCRINOLOGY, V138, P4291, DOI 10.1210/en.138.10.4291; Belke DD, 2001, AM J PHYSIOL-ENDOC M, V280, pE420, DOI 10.1152/ajpendo.2001.280.3.E420; BILAN PJ, 1991, ADV EXP MED BIOL, V293, P273; Borrmann L, 2001, ONCOGENE, V20, P4537, DOI 10.1038/sj.onc.1204577; Brunetti A, 1996, J CLIN INVEST, V97, P258, DOI 10.1172/JCI118400; Brunetti A, 2001, FASEB J, V15, P492, DOI 10.1096/fj.00-0190com; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; DiCola G, 1997, J CLIN INVEST, V99, P2538, DOI 10.1172/JCI119438; EIZIRIK DL, 1994, P NATL ACAD SCI USA, V91, P9253, DOI 10.1073/pnas.91.20.9253; Fidanza V, 1996, CANCER RES, V56, P1179; Foti D, 2003, MOL CELL BIOL, V23, P2720, DOI 10.1128/MCB.23.8.2720-2732.2003; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; Holth LT, 1997, DNA CELL BIOL, V16, P1299, DOI 10.1089/dna.1997.16.1299; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KAHN CR, 1976, NEW ENGL J MED, V294, P739, DOI 10.1056/NEJM197604012941401; Kim SK, 2001, GENE DEV, V15, P111, DOI 10.1101/gad.859401; Kitamura T, 2003, ANNU REV PHYSIOL, V65, P313, DOI 10.1146/annurev.physiol.65.092101.142540; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; Polonsky KS, 1996, NEW ENGL J MED, V334, P777, DOI 10.1056/NEJM199603213341207; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Sandhu MS, 2002, LANCET, V359, P1740, DOI 10.1016/S0140-6736(02)08655-5; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; TAYLOR SI, 1992, ENDOCR REV, V13, P566, DOI 10.1210/er.13.3.566; Taylor SI, 1999, CELL, V97, P9, DOI 10.1016/S0092-8674(00)80709-6; TAYLOR SI, 1994, DIABETES, V43, P735, DOI 10.2337/diab.43.6.735; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; WEILAND M, 1991, J CELL PHYSIOL, V149, P428, DOI 10.1002/jcp.1041490311; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619	33	173	176	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2005	11	7					765	773		10.1038/nm1254	http://dx.doi.org/10.1038/nm1254			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	942TB	15924147				2022-12-25	WOS:000230304200033
J	Raefski, AS; O'Neill, MJ				Raefski, AS; O'Neill, MJ			Identification of a cluster of X-linked imprinted genes in mice	NATURE GENETICS			English	Article							TURNERS-SYNDROME; CHROMOSOME; MOUSE; ORIGIN; INACTIVATION; EXPRESSION; DISORDER; AUTISM	Complete or partial monosomy with respect to the X chromosome is the genetic basis of Turner syndrome in human females. Individuals with Turner syndrome have a spectrum of anatomical, physiological and behavioral phenotypes with expressivity dependent on the extent of monosomy and the parental origin of the single X-1. Parent- of- origin influences on social cognition in Turner syndrome might be due to the presence of imprinted genes on the X-2. Imprinting of X-linked genes has also been implicated in the male prevalence of autistic spectrum disorders(3), in male sexual orientation(4,5) and in the developmental delay of XO mouse embryos(6-8). The only molecular evidence for X-chromosome imprinting, however, concerns X-chromosome inactivation in specific circumstances(9,10) and does not account for these phenotypes. Using a mouse model for Turner syndrome, we searched for locus-specific imprinting of X-linked genes in developing brain. We identified a cluster of X-linked genes containing at least three genes that show transcriptional repression of paternal alleles. Imprinting of these three genes, Xlr3b, Xlr4b and Xlr4c, is independent of X-chromosome inactivation and has a dynamic and complex pattern of tissue and stage specificity.	Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA	University of Connecticut	O'Neill, MJ (corresponding author), Univ Connecticut, Dept Mol & Cell Biol, 354 Mansfield Rd,U-2131, Storrs, CT 06269 USA.	moneill@uconnvm.uconn.edu						ALLENET B, 1995, MAMM GENOME, V6, P640, DOI 10.1007/BF00352372; BAILEY A, 1995, PSYCHOL MED, V25, P63, DOI 10.1017/S0033291700028099; BERGSAGEL PL, 1994, GENE, V150, P345, DOI 10.1016/0378-1119(94)90450-2; Bocklandt S, 2003, J Endocrinol Invest, V26, P8; BURGOYNE PS, 1983, J REPROD FERTIL, V68, P387, DOI 10.1530/jrf.0.0680387; Burgoyne PS, 2000, CYTOGENET CELL GENET, V91, P57, DOI 10.1159/000056819; COHEN DI, 1985, NATURE, V314, P369, DOI 10.1038/314369a0; Escalier D, 2002, BIOL REPROD, V67, P1646, DOI 10.1095/biolreprod.102.006973; EVANS EP, 1975, NATURE, V256, P40, DOI 10.1038/256040a0; GARCHON HJ, 1989, J CELL BIOL, V108, P779, DOI 10.1083/jcb.108.3.779; Green R, 2000, J THEOR BIOL, V202, P55, DOI 10.1006/jtbi.1999.1039; Jamieson RV, 1998, DEV BIOL, V201, P13, DOI 10.1006/dbio.1998.8972; Lee JT, 2000, CELL, V103, P17, DOI 10.1016/S0092-8674(00)00101-X; Li YH, 1998, NAT GENET, V20, P309, DOI 10.1038/3129; Morison IM, 2001, NUCLEIC ACIDS RES, V29, P275, DOI 10.1093/nar/29.1.275; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Ranke MB, 2001, LANCET, V358, P309, DOI 10.1016/S0140-6736(01)05487-3; SHARMAN GB, 1971, NATURE, V230, P231, DOI 10.1038/230231a0; Skuse DH, 2000, PEDIATR RES, V47, P9, DOI 10.1203/00006450-200001000-00006; Skuse DH, 1997, NATURE, V387, P705, DOI 10.1038/42706; TAKAGI N, 1975, NATURE, V256, P640, DOI 10.1038/256640a0; THORNHILL AR, 1993, DEVELOPMENT, V118, P171; Wakefield MJ, 1997, P NATL ACAD SCI USA, V94, P9665, DOI 10.1073/pnas.94.18.9665	23	107	110	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2005	37	6					620	624		10.1038/ng1567	http://dx.doi.org/10.1038/ng1567			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	931OT	15908953				2022-12-25	WOS:000229495300016
J	Stroh, M; Zimmer, JP; Duda, DG; Levchenko, TS; Cohen, KS; Brown, EB; Scadden, DT; Torchilin, VP; Bawendi, MG; Fukumura, D; Jain, RK				Stroh, M; Zimmer, JP; Duda, DG; Levchenko, TS; Cohen, KS; Brown, EB; Scadden, DT; Torchilin, VP; Bawendi, MG; Fukumura, D; Jain, RK			Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo	NATURE MEDICINE			English	Article							CRANIAL WINDOWS; TAT PEPTIDE; CELLS; ANGIOGENESIS; NANOCRYSTALS; VESSELS; CANCER; MICROSCOPY; TARGETS; MICE	A solid tumor is an organ composed of cancer and host cells embedded in an extracellular matrix and nourished by blood vessels. A prerequisite to understanding tumor pathophysiology is the ability to distinguish and monitor each component in dynamic studies. Standard fluorophores hamper simultaneous intravital imaging of these components. Here, we used multiphoton microscopy techniques and transgenic mice that expressed green fluorescent protein, and combined them with the use of quantum dot preparations. We show that these fluorescent semiconductor nanocrystals can be customized to concurrently image and differentiate tumor vessels from both the perivascular cells and the matrix. Moreover, we used them to measure the ability of particles of different sizes to access the tumor. Finally, we successfully monitored the recruitment of quantum dot - labeled bone marrow - derived precursor cells to the tumor vasculature. These examples show the versatility of quantum dots for studying tumor pathophysiology and creating avenues for treatment.	Massachusetts Gen Hosp, EL Steele Lab Tumor Biol, Dept Radiat Oncol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; MIT, Dept Chem, Cambridge, MA 02139 USA; Northeastern Univ, Dept Pharmaceut Sci, Boston, MA 02115 USA; Massachusetts Gen Hosp, Ctr Regenerat Med & Technol, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Northeastern University; Harvard University; Massachusetts General Hospital	Jain, RK (corresponding author), Massachusetts Gen Hosp, EL Steele Lab Tumor Biol, Dept Radiat Oncol, 100 Blossom St, Boston, MA 02114 USA.	jain@steele.mgh.harvard.edu	Duda, Dan G/H-8523-2014; Jain, Rakesh K/I-1384-2017	Duda, Dan G/0000-0001-7065-8797; Jain, Rakesh K/0000-0001-7571-3548	NATIONAL CANCER INSTITUTE [R01CA085140, R24CA085140, P01CA080124, F32CA103386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB001961] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA103386-02, P01 CA080124-08, F32 CA103386, F32 CA 103386, R01 CA085140, R24 CA 85140, P01 CA080124, R24 CA085140, R01 CA085140-09, P01 CA 80124] Funding Source: Medline; NIBIB NIH HHS [5R01 EB 001951-06, R01 EB001961-06, R01 EB001961] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Bestvater F, 2002, J MICROSC-OXFORD, V208, P108, DOI 10.1046/j.1365-2818.2002.01074.x; Brown E, 2003, NAT MED, V9, P796, DOI 10.1038/nm879; Brown EB, 2001, NAT MED, V7, P864, DOI 10.1038/89997; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chan Y, 2004, ADV MATER, V16, P2092, DOI 10.1002/adma.200400237; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Dabbousi BO, 1997, J PHYS CHEM B, V101, P9463, DOI 10.1021/jp971091y; Dubertret B, 2002, SCIENCE, V298, P1759, DOI 10.1126/science.1077194; Fisher BR, 2004, J PHYS CHEM B, V108, P143, DOI 10.1021/jp035756+; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Gao XH, 2004, NAT BIOTECHNOL, V22, P969, DOI 10.1038/nbt994; Hines MA, 1996, J PHYS CHEM-US, V100, P468, DOI 10.1021/jp9530562; Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607; Jain RK, 2004, NAT BIOTECHNOL, V22, P959, DOI 10.1038/nbt0804-959; Jain RK, 2003, CANCER CELL, V3, P515, DOI 10.1016/S1535-6108(03)00138-7; Jain RK, 2002, NAT REV CANCER, V2, P266, DOI 10.1038/nrc778; Jaiswal JK, 2003, NAT BIOTECHNOL, V21, P47, DOI 10.1038/nbt767; Koike N, 2004, NATURE, V428, P138, DOI 10.1038/428138a; Larson DR, 2003, SCIENCE, V300, P1434, DOI 10.1126/science.1083780; LEUNIG M, 1992, CANCER RES, V52, P6553; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; MELDER RJ, 1995, MICROVASC RES, V50, P35, DOI 10.1006/mvre.1995.1036; MURRAY CB, 1993, J AM CHEM SOC, V115, P8706, DOI 10.1021/ja00072a025; Pluen A, 1999, BIOPHYS J, V77, P542, DOI 10.1016/S0006-3495(99)76911-0; Rafii S, 2002, NAT REV CANCER, V2, P826, DOI 10.1038/nrc925; Steckel JS, 2004, ANGEW CHEM INT EDIT, V43, P2154, DOI 10.1002/anie.200453728; Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498; Wu XY, 2003, NAT BIOTECHNOL, V21, P41, DOI 10.1038/nbt764; YUAN F, 1994, CANCER RES, V54, P4564; Zipfel WR, 2003, NAT BIOTECHNOL, V21, P1368, DOI 10.1038/nbt899	30	357	390	5	93	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2005	11	6					678	682		10.1038/nm1247	http://dx.doi.org/10.1038/nm1247			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	932YD	15880117	Green Accepted			2022-12-25	WOS:000229589800036
J	Kelley, R; Ideker, T				Kelley, R; Ideker, T			Systematic interpretation of genetic interactions using protein networks	NATURE BIOTECHNOLOGY			English	Article							INTERACTION MAP; SACCHAROMYCES-CEREVISIAE; COMPLEX; YEAST; IDENTIFICATION; DELETION; DATABASE; TOOL	Genetic interaction analysis, in which two mutations have a combined effect not exhibited by either mutation alone, is a powerful and widespread tool for establishing functional linkages between genes. In the yeast Saccharomyces cerevisiae, ongoing screens have generated > 4,800 such genetic interaction data. We demonstrate that by combining these data with information on protein-protein, prote in-DNA or metabolic networks, it is possible to uncover physical mechanisms behind many of the observed genetic effects. Using a probabilistic model, we found that 1,922 genetic interactions are significantly associated with either between- or within-pathway explanations encoded in the physical networks, covering similar to 40% of known genetic interactions. These models predict new functions for 343 proteins and suggest that between- pathway explanations are better than within-pathway explanations at interpreting genetic interactions identified in systematic screens. This study provides a road map for how genetic and physical interactions can be integrated to reveal pathway organization and function.	Univ Calif San Diego, Program Bioinformat, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Ideker, T (corresponding author), Univ Calif San Diego, Program Bioinformat, 9500 Gilman Dr, La Jolla, CA 92093 USA.	trey@bioeng.ucsd.edu		Ideker, Trey/0000-0002-1708-8454	NIGMS NIH HHS [R01 GM070743-02, GM070743-01, R01 GM070743, R01 GM070743-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070743] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashburner M, 2001, GENOME RES, V11, P1425; AVERY L, 1992, TRENDS GENET, V8, P312, DOI 10.1016/0168-9525(92)90263-4; Dolma S, 2003, CANCER CELL, V3, P285, DOI 10.1016/S1535-6108(03)00050-3; Forsburg SL, 2001, NAT REV GENET, V2, P659, DOI 10.1038/35088500; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Geissler S, 1998, EMBO J, V17, P952, DOI 10.1093/emboj/17.4.952; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; GUARENTE L, 1993, TRENDS GENET, V9, P362, DOI 10.1016/0168-9525(93)90042-G; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; Hartman JL, 2001, SCIENCE, V291, P1001, DOI 10.1126/science.291.5506.1001; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hwang WW, 2003, MOL CELL, V11, P261, DOI 10.1016/S1097-2765(02)00826-2; Ito T, 2000, P NATL ACAD SCI USA, V97, P1143, DOI 10.1073/pnas.97.3.1143; Kahana JA, 1998, MOL BIOL CELL, V9, P1741, DOI 10.1091/mbc.9.7.1741; Kanehisa M, 2002, NUCLEIC ACIDS RES, V30, P42, DOI 10.1093/nar/30.1.42; KENDALL SM, 1987, KENDALLS ADV THEORY; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Mewes HW, 2002, NUCLEIC ACIDS RES, V30, P31, DOI 10.1093/nar/30.1.31; Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824; Ooi SL, 2003, NAT GENET, V35, P277, DOI 10.1038/ng1258; Ozier O, 2003, NAT BIOTECHNOL, V21, P490, DOI 10.1038/nbt0503-490; Pfeffer SR, 2001, CURR BIOL, V11, pR109, DOI 10.1016/S0960-9822(01)00042-2; Pidoux AL, 2000, CURR OPIN CELL BIOL, V12, P308, DOI 10.1016/S0955-0674(00)00094-6; Rain JC, 2001, NATURE, V409, P211, DOI 10.1038/35051615; Sham P, 2001, PHARMACOGENOMICS, V2, P195, DOI 10.1517/14622416.2.3.195; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; SHARAN R, 2004, P 8 ANN INT C COMP M, P282; Siniossoglou S, 2000, EMBO J, V19, P4885, DOI 10.1093/emboj/19.18.4885; THOMAS JH, 1993, TRENDS GENET, V9, P395, DOI 10.1016/0168-9525(93)90140-D; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Tucker CL, 2003, NAT GENET, V35, P204, DOI 10.1038/ng1103-204; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Xenarios I, 2002, NUCLEIC ACIDS RES, V30, P303, DOI 10.1093/nar/30.1.303; Zar J. H., 1996, BIOSTATISTICAL ANAL	37	330	336	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2005	23	5					561	566		10.1038/nbt1096	http://dx.doi.org/10.1038/nbt1096			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	923XS	15877074	Green Accepted			2022-12-25	WOS:000228943500028
J	Wang, XH; Zeng, WZ; Soyombo, AA; Tang, W; Ross, EM; Barnes, AP; Milgram, SL; Penninger, JM; Allen, PB; Greengard, P; Muallem, S				Wang, XH; Zeng, WZ; Soyombo, AA; Tang, W; Ross, EM; Barnes, AP; Milgram, SL; Penninger, JM; Allen, PB; Greengard, P; Muallem, S			Spinophilin regulates Ca2+ signalling by binding the N-terminal domain of RGS2 and the third intracellular loop of G-protein-coupled receptors	NATURE CELL BIOLOGY			English	Article							ACINAR	Signalling by G proteins is controlled by the regulator of G-protein signalling (RGS) proteins that accelerate the GTPase activity of G alpha subunits and act in a G-protein-coupled receptor (GPCR)-specific manner(1-4). The conserved RGS domain accelerates the Ga subunit GTPase activity(5), whereas the variable amino-terminal domain participates in GPCR recognition(6). How receptor recognition is achieved is not known. Here, we show that the scaffold protein spinophilin (SPL)(7), which binds the third intracellualar loop (3iL) of several GPCRs(8-10), binds the N-terminal domain of RGS2. SPL also binds RGS1, RGS4, RGS16 and GAIP. When expressed in Xenopus laevis oocytes, SPL markedly increased inhibition of alpha-adrenergic receptor (alpha AR) Ca2+ signalling by RGS2. Notably, the constitutively active mutant alpha AR(A293E) (the mutation being in the 3iL) did not bind SPL and was relatively resistant to inhibition by RGS2. Use of beta AR-alpha AR chimaeras identified the (288)REKKAA(293) sequence as essential for the binding of SPL and inhibition of Ca2+ signalling by RGS2. Furthermore, alpha AR-evoked Ca2+ signalling is less sensitive to inhibition by SPL in rgs2(-/-) cells and less sensitive to inhibition by RGS2 in spl(-/-) cells. These findings provide a general mechanism by which RGS proteins recognize GPCRs to confer signalling specificity.	Univ Texas, SW Med Ctr Dallas, Dept Physiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Austrian Acad Sci, Inst Mol Biotechnol, IMBA, A-1030 Vienna, Austria; Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06508 USA; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of North Carolina; University of North Carolina Chapel Hill; Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); Yale University; Rockefeller University	Muallem, S (corresponding author), Univ Texas, SW Med Ctr Dallas, Dept Physiol, Dallas, TX 75390 USA.	SHMUEL.MUALLEM@utsouthwestern.edu	Penninger, Josef M/I-6860-2013	Penninger, Josef M/0000-0002-8194-3777; Soyombo, Abigail/0000-0003-0850-2593; Barnes, Anthony/0000-0002-4598-9591	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE12309] Funding Source: Medline; NIDDK NIH HHS [DK38938] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen PB, 1999, BIOCHEM SOC T, V27, P543, DOI 10.1042/bst0270543; Bernstein LS, 2004, J BIOL CHEM, V279, P21248, DOI 10.1074/jbc.M312407200; Brady AE, 2003, J BIOL CHEM, V278, P32405, DOI 10.1074/jbc.M304195200; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; DELAPENA P, 1995, J BIOL CHEM, V270, P3554, DOI 10.1074/jbc.270.8.3554; Feng J, 2000, P NATL ACAD SCI USA, V97, P9287, DOI 10.1073/pnas.97.16.9287; GILCHRIST A, 2002, SCI STKE, V5, pPL1; Ishii M, 2003, LIFE SCI, V74, P163, DOI 10.1016/j.lfs.2003.09.004; Ko SBH, 2002, EMBO J, V21, P5662, DOI 10.1093/emboj/cdf580; Luo X, 2001, MOL CELL, V7, P651, DOI 10.1016/S1097-2765(01)00211-8; Oliveira-dos-Santos AJ, 2000, P NATL ACAD SCI USA, V97, P12272, DOI 10.1073/pnas.220414397; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Richman JG, 2001, J BIOL CHEM, V276, P15003, DOI 10.1074/jbc.M011679200; Scheer A, 1997, J RECEPT SIGNAL TR R, V17, P57, DOI 10.3109/10799899709036594; Smith FD, 1999, J BIOL CHEM, V274, P19894, DOI 10.1074/jbc.274.28.19894; Wang Q, 2004, SCIENCE, V304, P1940, DOI 10.1126/science.1098274; Xu X, 1996, J PHYSIOL-LONDON, V491, P647, DOI 10.1113/jphysiol.1996.sp021246; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zeng WZ, 1996, J BIOL CHEM, V271, P18520, DOI 10.1074/jbc.271.31.18520; Zeng WZ, 1997, J BIOL CHEM, V272, P32956, DOI 10.1074/jbc.272.52.32956; Zheng B, 1999, TRENDS BIOCHEM SCI, V24, P411, DOI 10.1016/S0968-0004(99)01474-7	22	119	123	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2005	7	4					405	411		10.1038/ncb1237	http://dx.doi.org/10.1038/ncb1237			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	912KA	15793568				2022-12-25	WOS:000228075500018
J	Dietrich, J; Lacagnina, M; Gass, D; Richfield, E; Mayer-Proschel, M; Noble, M; Torres, C; Proschel, C				Dietrich, J; Lacagnina, M; Gass, D; Richfield, E; Mayer-Proschel, M; Noble, M; Torres, C; Proschel, C			EIF2B5 mutations compromise GFAP(+) astrocyte generation in vanishing white matter leukodystrophy	NATURE MEDICINE			English	Article							FIBRILLARY ACIDIC PROTEIN; INITIATION-FACTOR EIF2B; NERVOUS-SYSTEM HYPOMYELINATION; NEUROEPITHELIAL STEM-CELLS; RESTRICTED PRECURSOR CELLS; NUCLEOTIDE EXCHANGE FACTOR; TRANSLATION INITIATION; PROGENITOR CELLS; ALEXANDER-DISEASE; CHILDHOOD ATAXIA	Vanishing white matter disease (VWM) is a heritable leukodystrophy linked to mutations in translation initiation factor 2B (eIF2B). Although the clinical course of this disease has been relatively well described, the cellular consequences of EIF2B mutations on neural cells are unknown. Here we have established cell cultures from the brain of an individual with VWM carrying mutations in subunit 5 of eIF2B (encoded by EIF2B5). Despite the extensive demyelination apparent in this VWM patient, normal-appearing oligodendrocytes were readily generated in vitro. In contrast, few GFAP-expressing (GFAP(+)) astrocytes were present in primary cultures, induction of astrocytes was severely compromised, and the few astrocytes generated showed abnormal morphologies and antigenic phenotypes. Lesions in vivo also lacked GFAP(+) astrocytes. RNAi targeting of EIF2B5 severely compromised the induction of GFAP(+) cells from normal human glial progenitors. This raises the possibility that a deficiency in astrocyte function may contribute to the loss of white matter in VWM leukodystrophy.	Univ Rochester, Sch Med & Dent, Dept Biomed Genet, Aab Inst, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, Rochester, NY 14642 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Environm & Occupat Hlth Sci Inst, Piscataway, NJ 08854 USA; Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA	University of Rochester; University of Rochester; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Rochester	Proschel, C (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biomed Genet, Aab Inst, 601 Elmwood Ave, Rochester, NY 14642 USA.	chris_proschel@urmc.rochester.edu			NICHD NIH HHS [R01 HD039702, HD39702] Funding Source: Medline; NINDS NIH HHS [NS42820, R01 NS042820, NS047411] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS047411, R01NS042820] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anthony TG, 2000, BBA-GENE STRUCT EXPR, V1492, P56, DOI 10.1016/S0167-4781(00)00062-2; Asano K, 1999, EMBO J, V18, P1673, DOI 10.1093/emboj/18.6.1673; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; Brenner M, 2001, NAT GENET, V27, P117, DOI 10.1038/83679; Dietrich J, 2002, GLIA, V40, P65, DOI 10.1002/glia.10116; Fogli A, 2004, EUR J HUM GENET, V12, P561, DOI 10.1038/sj.ejhg.5201189; Fogli A, 2002, NEUROLOGY, V59, P1966, DOI 10.1212/01.WNL.0000041666.76863.47; Fogli A, 2002, ANN NEUROL, V52, P506, DOI 10.1002/ana.10339; Francalanci P, 2001, NEUROLOGY, V57, P265, DOI 10.1212/WNL.57.2.265; Gomez E, 2002, EMBO J, V21, P5292, DOI 10.1093/emboj/cdf515; Gomez E, 2000, MOL CELL BIOL, V20, P3965, DOI 10.1128/MCB.20.11.3965-3976.2000; GOMI H, 1995, NEURON, V14, P29, DOI 10.1016/0896-6273(95)90238-4; Gorospe JR, 2002, NEUROLOGY, V58, P1494, DOI 10.1212/WNL.58.10.1494; Gregori N, 2002, J NEUROSCI, V22, P248, DOI 10.1523/JNEUROSCI.22-01-00248.2002; Han SSW, 2004, GLIA, V45, P1, DOI 10.1002/glia.10282; HANEFELD F, 1993, NEUROPEDIATRICS, V24, P244, DOI 10.1055/s-2008-1071551; Herrera J, 2001, EXP NEUROL, V171, P11, DOI 10.1006/exnr.2001.7729; Hertz L, 1998, METHODS, V16, P293, DOI 10.1006/meth.1998.0686; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Leegwater PAJ, 2001, NAT GENET, V29, P383, DOI 10.1038/ng764; Liedtke W, 1996, NEURON, V17, P607, DOI 10.1016/S0896-6273(00)80194-4; MayerProschel M, 1997, NEURON, V19, P773, DOI 10.1016/S0896-6273(00)80960-5; McCall MA, 1996, P NATL ACAD SCI USA, V93, P6361, DOI 10.1073/pnas.93.13.6361; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Nawashiro H, 1998, NEUROREPORT, V9, P1691, DOI 10.1097/00001756-199806010-00004; Nawashiro H, 2000, J CEREBR BLOOD F MET, V20, P1040, DOI 10.1097/00004647-200007000-00003; Nedergaard M, 2003, TRENDS NEUROSCI, V26, P523, DOI 10.1016/j.tins.2003.08.008; Palmer TD, 2001, NATURE, V411, P42, DOI 10.1038/35075141; Pekny M, 1999, NEUROCHEM RES, V24, P1357, DOI 10.1023/A:1022572304626; PEKNY M, 1995, EMBO J, V14, P1590, DOI 10.1002/j.1460-2075.1995.tb07147.x; RAFF MC, 1983, J NEUROSCI, V3, P1289; Rao MS, 1998, P NATL ACAD SCI USA, V95, P3996, DOI 10.1073/pnas.95.7.3996; Rao MS, 1997, DEV BIOL, V188, P48, DOI 10.1006/dbio.1997.8597; Rodriguez D, 2001, AM J HUM GENET, V69, P1134, DOI 10.1086/323799; SCHIFFMANN R, 1994, ANN NEUROL, V35, P331, DOI 10.1002/ana.410350314; Schwartz PH, 2003, J NEUROSCI RES, V74, P838, DOI 10.1002/jnr.10854; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; van der Knaap MS, 2002, ANN NEUROL, V51, P264, DOI 10.1002/ana.10112; van der Knaap MS, 1998, NEUROLOGY, V51, P540, DOI 10.1212/WNL.51.2.540; van der Knaap MS, 2001, DEV MED CHILD NEUROL, V43, P705, DOI 10.1017/S001216220100127X; Van Haren K, 2004, J NEUROPATH EXP NEUR, V63, P618, DOI 10.1093/jnen/63.6.618; vanderKnaap MS, 1997, NEUROLOGY, V48, P845, DOI 10.1212/WNL.48.4.845; Westerlund U, 2003, EXP CELL RES, V289, P378, DOI 10.1016/S0014-4827(03)00291-X; Windrem MS, 2004, NAT MED, V10, P93, DOI 10.1038/nm974; Wong K, 2000, ACTA NEUROPATHOL, V100, P635, DOI 10.1007/s004010000234; Xu KX, 1999, GLIA, V25, P390, DOI 10.1002/(SICI)1098-1136(19990215)25:4<390::AID-GLIA8>3.0.CO;2-7; YONG VW, 1988, GLIA, V1, P113, DOI 10.1002/glia.440010203	47	95	99	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					277	283		10.1038/nm1195	http://dx.doi.org/10.1038/nm1195			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15723074				2022-12-25	WOS:000227541300022
J	Bahcall, O				Bahcall, O			Copy number and HIV/AIDS	NATURE GENETICS			English	News Item														Bahcall, Orli/0000-0002-2891-1637					0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2005	37	2					124	124						1	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	893AB	15702498				2022-12-25	WOS:000226690100016
J	Bradshaw, PS; Stavropoulos, DJ; Meyn, MS				Bradshaw, PS; Stavropoulos, DJ; Meyn, MS			Human telomeric protein TRF2 associates with genomic double-strand breaks as an early response to DNA damage	NATURE GENETICS			English	Article							ATM; END; BINDING	DNA damage surveillance networks in human cells can activate DNA repair, cell cycle checkpoints and apoptosis in response to fewer than four double-strand breaks (DSBs) per genome(1,2). These same networks tolerate telomeres, in part because the protein TRF2 prevents recognition of telomeric ends as DSBs 3 by facilitating their organization into T loops(4-6). We now show that TRF2 associates with photo-induced DSBs in nontelomeric DNA in human fibroblasts within 2 s of irradiation. Unlike gammaH2AX, a common marker for DSB damage, TRF2 forms transient foci that colocalize closely with DSBs. The TRF2 DSB response requires the TRF2 basic domain but not its Myb domain and occurs in the absence of functional ATM and DNA-PK protein kinases, MRE11/Rad50/NBS1 complex and Ku70, WRN and BLM repair proteins. Furthermore, overexpression of TRF2 inhibits DSB-induced phosphorylation of ATM signaling targets. Our results implicate TRF2 in an initial stage of DSB recognition and processing that occurs before association of ATM with DSBs and activation of the ATM-dependent DSB response network.	Hosp Sick Children, Res Inst, Program Genet & Genom Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Paediat, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	Meyn, MS (corresponding author), Hosp Sick Children, Res Inst, Program Genet & Genom Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	meyn@sickkids.ca						Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bouffler SD, 1998, MUTAT RES-FUND MOL M, V404, P199, DOI 10.1016/S0027-5107(98)00114-6; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Doherty AJ, 2001, CURR BIOL, V11, pR920, DOI 10.1016/S0960-9822(01)00555-3; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Karlseder J, 2004, PLOS BIOL, V2, P1150, DOI 10.1371/journal.pbio.0020240; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kim JS, 2002, J BIOL CHEM, V277, P45149, DOI 10.1074/jbc.M209123200; Lukas C, 2004, EMBO J, V23, P2674, DOI 10.1038/sj.emboj.7600269; MEYN MS, 1995, CANCER RES, V55, P5991; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Ouellette MM, 2000, HUM MOL GENET, V9, P403, DOI 10.1093/hmg/9.3.403; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Song K, 2000, FEBS LETT, V481, P81, DOI 10.1016/S0014-5793(00)01958-X; Stansel RM, 2001, EMBO J, V20, P5532; Stavropoulos DJ, 2002, HUM MOL GENET, V11, P3135, DOI 10.1093/hmg/11.25.3135; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Yoshimura SH, 2004, GENES CELLS, V9, P205, DOI 10.1111/j.1356-9597.2004.00719.x; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139; Zhu XD, 2003, MOL CELL, V12, P1489, DOI 10.1016/S1097-2765(03)00478-7; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	27	185	196	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2005	37	2					193	197		10.1038/ng1506	http://dx.doi.org/10.1038/ng1506			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	893AB	15665826				2022-12-25	WOS:000226690100028
J	Kondoh, G; Tojo, H; Nakatani, Y; Komazawa, N; Murata, C; Yamagata, K; Maeda, Y; Kinoshita, T; Okabe, M; Taguchi, R; Takeda, J				Kondoh, G; Tojo, H; Nakatani, Y; Komazawa, N; Murata, C; Yamagata, K; Maeda, Y; Kinoshita, T; Okabe, M; Taguchi, R; Takeda, J			Angiotensin-converting enzyme is a GPI-anchored protein releasing factor crucial for fertilization	NATURE MEDICINE			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; PIG-A GENE; PRION PROTEIN; PHOSPHOLIPASE-C; CELL-SURFACE; LIPID RAFTS; DEFICIENCY; KNOCKOUT; SPERM; MICE	The angiotensin-converting enzyme (ACE) is a key regulator of blood pressure. It is known to cleave small peptides, such as angiotensin I and bradykinin and changes their biological activities, leading to upregulation of blood pressure. Here we describe a new activity for ACE: a glycosylphosphatidylinositol (GPI)-anchored protein releasing activity (GPIase activity). Unlike its peptidase activity, GPIase activity is weakly inhibited by the tightly binding ACE inhibitor and not inactivated by substitutions of core amino acid residues for the peptidase activity, suggesting that the active site elements for GPIase differ from those for peptidase activity. ACE shed various GPI-anchored proteins from the cell surface, and the process was accelerated by the lipid raft disruptor filipin. The released products carried portions of the GPI anchor, indicating cleavage within the GPI moiety. Further analysis by high-performance liquid chromatography-mass spectrometry predicted the cleavage site at the mannose-mannose linkage. GPI-anchored proteins such as TESP5 and PH-20 were released from the sperm membrane of wild-type mice but not in Ace knockout sperm in vivo. Moreover, peptidase-inactivated E414D mutant ACE and also PI-PLC rescued the egg-binding deficiency of Ace knockout sperms, implying that ACE plays a crucial role in fertilization through this activity.	Osaka Univ, Grad Sch Med, Dept Social & Environm Med, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Biochem & Mol Biol, Suita, Osaka 5650871, Japan; Univ Tokyo, Grad Sch Med, Dept Metabolome, Bunkyo Ku, Tokyo 1130033, Japan; Osaka Univ, Genome Informat Res Ctr, Suita, Osaka 5650871, Japan; Osaka Univ, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan; Osaka Univ, Ctr Adv Sci & Innovat, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; University of Tokyo; Osaka University; Osaka University; Osaka University	Kondoh, G (corresponding author), Kyoto Univ, Lab Anim Expt Regenerat, Inst Frontier Med Sci, Kyoto, Japan.	kondohg@frontier.kyoto-u.ac.jp; takeda@mr-envi.med.osaka-u.ac.jp	Kinoshita, Taroh/C-7353-2009; Okabe, Masaru/B-6917-2015	Okabe, Masaru/0000-0002-0803-9044				Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6; Alfieri JA, 2003, J CELL SCI, V116, P2149, DOI 10.1242/jcs.00430; Bergaya S, 2001, CIRC RES, V88, P593, DOI 10.1161/01.RES.88.6.593; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Carvajal N, 2004, J INORG BIOCHEM, V98, P1465, DOI 10.1016/j.jinorgbio.2004.05.005; Chen R, 1998, P NATL ACAD SCI USA, V95, P9512, DOI 10.1073/pnas.95.16.9512; Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786; Doan TN, 2001, CURR OPIN NEPHROL HY, V10, P483, DOI 10.1097/00041552-200107000-00002; Hagaman JR, 1998, P NATL ACAD SCI USA, V95, P2552, DOI 10.1073/pnas.95.5.2552; HANADA K, 1993, J BIOL CHEM, V268, P13820; Honda A, 2002, J BIOL CHEM, V277, P16976, DOI 10.1074/jbc.M112470200; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; HOOPER NM, 1991, INT J BIOCHEM, V23, P641, DOI 10.1016/0020-711X(91)90032-I; Ikezawa H, 2002, BIOL PHARM BULL, V25, P409, DOI 10.1248/bpb.25.409; KASAHARA Y, 1981, CLIN CHEM, V27, P1922; Kinoshita T, 1997, J BIOCHEM-TOKYO, V122, P251; KINOSHITA T, 1985, J EXP MED, V162, P75, DOI 10.1084/jem.162.1.75; Kondoh G, 1999, FEBS LETT, V458, P299, DOI 10.1016/S0014-5793(99)01172-2; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; LIN Y, 1994, J CELL BIOL, V125, P1157, DOI 10.1083/jcb.125.5.1157; Marella M, 2002, J BIOL CHEM, V277, P25457, DOI 10.1074/jbc.M203248200; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; McLeskey SB, 1998, INT REV CYTOL, V177, P57; Meier P, 2003, CELL, V113, P49, DOI 10.1016/S0092-8674(03)00201-0; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; Natesh R, 2003, NATURE, V421, P551, DOI 10.1038/nature01370; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Nozaki M, 1999, LAB INVEST, V79, P293; Nyborg Jennifer K, 2004, Biochem J, V381, pe3; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; SCALLON BJ, 1991, SCIENCE, V252, P446, DOI 10.1126/science.2017684; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; Tojo H, 2004, J CHROMATOGR A, V1056, P223, DOI 10.1016/j.chroma.2004.06.122; Tujioka H, 1998, BIOCHEM BIOPH RES CO, V251, P737, DOI 10.1006/bbrc.1998.9542; Turner AJ, 2002, TRENDS PHARMACOL SCI, V23, P177, DOI 10.1016/S0165-6147(00)01994-5; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Vincent B, 2000, J BIOL CHEM, V275, P35612, DOI 10.1074/jbc.M004628200; WATANABE T, 1991, J BIOL CHEM, V266, P21174; WEI L, 1991, J BIOL CHEM, V266, P9002	44	176	193	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					160	166		10.1038/nm1179	http://dx.doi.org/10.1038/nm1179			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15665832	Green Published			2022-12-25	WOS:000226797300023
J	Urbich, C; Heeschen, C; Aicher, A; Sasaki, K; Bruhl, T; Farhadi, MR; Vajkoczy, P; Hofmann, WK; Peters, C; Pennacchio, LA; Abolmaali, ND; Chavakis, E; Reinheckel, T; Zeiher, AM; Dimmeler, S				Urbich, C; Heeschen, C; Aicher, A; Sasaki, K; Bruhl, T; Farhadi, MR; Vajkoczy, P; Hofmann, WK; Peters, C; Pennacchio, LA; Abolmaali, ND; Chavakis, E; Reinheckel, T; Zeiher, AM; Dimmeler, S			Cathepsin L is required for endothelial progenitor cell-induced neovascularization	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; CYSTEINE PROTEASES; MICE DEFICIENT; STEM-CELLS; ANGIOGENESIS; INHIBITORS; VIVO; TRANSPLANTATION; CONTRIBUTES; MECHANISMS	Infusion of endothelial progenitor cells (EPC), but not of mature endothelial cells, promotes neovascularization after ischemia. We performed gene expression profiling of EPC and endothelial cells to identify genes that might be important for the neovascularization capacity of EPC. Notably, the protease cathepsin L (CathL) was highly expressed in EPC as opposed to endothelial cells and was essential for matrix degradation and invasion by EPC in vitro. CathL-deficient mice showed impaired functional recovery following hind limb ischemia, supporting the concept of a crucial role for CathL in postnatal neovascularization. Infused CathL-deficient progenitor cells neither homed to sites of ischemia nor augmented neovascularization. Forced expression of CathL in mature endothelial cells considerably enhanced their invasive activity and sufficed to confer their capacity for neovascularization in vivo. We concluded that CathL has a critical role in the integration of circulating EPC into ischemic tissue and is required for EPC-mediated neovascularization.	Goethe Univ Frankfurt, Dept Internal Med 3, D-60590 Frankfurt, Germany; Heidelberg Univ, Dept Neurosurg, Fac Med, D-68167 Mannheim, Germany; Goethe Univ Frankfurt, Dept Hematol & Oncol, D-60590 Frankfurt, Germany; Univ Freiburg, Dept Mol Med & Cell Res, D-79104 Freiburg, Germany; Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Genome Sci, Berkeley, CA 94720 USA; Goethe Univ Frankfurt, Inst Diagnost & Intervent Radiol, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Ruprecht Karls University Heidelberg; Goethe University Frankfurt; University of Freiburg; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Goethe University Frankfurt	Dimmeler, S (corresponding author), Goethe Univ Frankfurt, Dept Internal Med 3, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	dimmeler@em.uni-frankfurt.de	Abolmaali, Nasreddin/A-1061-2012; Abolmaali, Nasreddin/AAG-7655-2022; Reinheckel, Thomas/AAL-9761-2021; Guba, Markus/M-4309-2019; Aicher, Alexandra/GZK-8031-2022; Abolmaali, Nasreddin/AFL-7713-2022	Reinheckel, Thomas/0000-0001-9866-9105; Heeschen, Christopher/0000-0002-1158-8554; Pennacchio, Len/0000-0002-8748-3732; Dimmeler, Stefanie/0000-0002-1045-2436; Aicher, Alexandra/0000-0002-8920-9577	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007195] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL071954A] Funding Source: Medline; NIDCR NIH HHS [DE-AC03-76SF00098] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aicher A, 2003, NAT MED, V9, P1370, DOI 10.1038/nm948; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Berchem G, 2002, ONCOGENE, V21, P5951, DOI 10.1038/sj.onc.1205745; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chauhan SS, 1998, BIOCHEMISTRY-US, V37, P8584, DOI 10.1021/bi972251z; Dennhofer R, 2003, INT J CANCER, V106, P316, DOI 10.1002/ijc.11255; Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com; Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI200113152; Fiebiger E, 2002, J EXP MED, V196, P1263, DOI 10.1084/jem.20020762; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Hinds KA, 2003, BLOOD, V102, P867, DOI 10.1182/blood-2002-12-3669; Houseweart MK, 2003, J NEUROBIOL, V56, P315, DOI 10.1002/neu.10253; Isner JM, 1999, J CLIN INVEST, V103, P1231, DOI 10.1172/JCI6889; Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535-6108(04)00111-4; Kaberdin VR, 2003, GENOME RES, V13, P1961, DOI 10.1101/gr.1277303; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kawamoto A, 2001, CIRCULATION, V103, P634; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Krueger S, 2001, CANCER GENE THER, V8, P522, DOI 10.1038/sj.cgt.7700341; Lelongt B, 2001, J EXP MED, V193, P793, DOI 10.1084/jem.193.7.793; Li ZQ, 2004, J BIOL CHEM, V279, P5470, DOI 10.1074/jbc.M310349200; Libby P, 2001, CIRC RES, V89, P195, DOI 10.1161/res.89.3.195; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; Premzl A, 2003, EXP CELL RES, V283, P206, DOI 10.1016/S0014-4827(02)00055-1; Rafii S, 2002, NAT REV CANCER, V2, P826, DOI 10.1038/nrc925; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rooprai HK, 1997, ANTICANCER RES, V17, P4151; Roth W, 2000, FASEB J, V14, P2075, DOI 10.1096/fj.99-0970com; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; Shi GP, 2003, CIRC RES, V92, P493, DOI 10.1161/01.RES.0000060485.20318.96; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; Stypmann J, 2002, P NATL ACAD SCI USA, V99, P6234, DOI 10.1073/pnas.092637699; Tobin DJ, 2002, AM J PATHOL, V160, P1807, DOI 10.1016/S0002-9440(10)61127-3; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; Urbich C, 2003, CIRCULATION, V108, P2511, DOI 10.1161/01.CIR.0000096483.29777.50; Urbich C, 2002, FASEB J, V16, P706, DOI 10.1096/fj.01-0637fje; Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953; Walker B, 2000, BIOCHEM BIOPH RES CO, V275, P401, DOI 10.1006/bbrc.2000.3311	41	242	264	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					206	213		10.1038/nm1182	http://dx.doi.org/10.1038/nm1182			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15665831	Green Submitted			2022-12-25	WOS:000226797300029
J	Bastepe, M; Frohlich, LF; Linglart, A; Abu-Zahra, HS; Tojo, K; Ward, LM; Juppner, H				Bastepe, M; Frohlich, LF; Linglart, A; Abu-Zahra, HS; Tojo, K; Ward, LM; Juppner, H			Deletion of the NESP55 differentially methylated region causes loss of maternal GNAS imprints and pseudohypoparathyroidism type Ib	NATURE GENETICS			English	Article							G-PROTEINS; LOCUS; GENE; IDENTIFICATION; TRANSCRIPT; ANTISENSE; ELEMENT; CLUSTER; DEFECT; MARK	Epigenetic defects in the imprinted GNAS cluster are associated with pseudohypoparathyroidism type Ib. In two kindreds with this disorder, we now report deletions that remove the differentially methylated region encompassing exon NESP55 and exons 3 and 4 of the antisense transcript. When inherited from a female, either deletion abolishes all maternal GNAS imprints and derepresses maternally silenced transcripts, suggesting that the deleted region contains a cis-acting element that controls imprinting of the maternal GNAS allele.	Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Jikei Univ, Sch Med, Dept Internal Med, Div Diabet & Endocrinol, Tokyo, Japan; Childrens Hosp Eastern Ontario, Div Endocrinol & Metab, Ottawa, ON, Canada; Massachusetts Gen Hosp, Massgen Hosp Children, Pediat Nephrol Unit, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Jikei University; University of Ottawa; Children's Hospital of Eastern Ontario; Harvard University; Massachusetts General Hospital	Bastepe, M (corresponding author), Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02114 USA.	bastepe@helix.mgh.harvard.edu; jueppner@helix.mgh.harvard.edu	Linglart, Agnès/A-8047-2016; Ward, Leanne Marie/AAF-8482-2020; Bastepe, Murat/GQQ-3389-2022	Linglart, Agnès/0000-0003-3455-002X; Ward, Leanne Marie/0000-0003-1557-9185; Bastepe, Murat/0000-0002-2643-3504				Bastepe M, 2003, J CLIN INVEST, V112, P1255, DOI 10.1172/JCI200319159; Bastepe M, 2001, HUM MOL GENET, V10, P1231, DOI 10.1093/hmg/10.12.1231; Bastepe M, 2001, AM J HUM GENET, V68, P1283, DOI 10.1086/320117; Coombes C, 2003, MOL CELL BIOL, V23, P5475, DOI 10.1128/MCB.23.16.5475-5488.2003; Hayward BE, 2000, HUM MOL GENET, V9, P835, DOI 10.1093/hmg/9.5.835; Hayward BE, 1998, P NATL ACAD SCI USA, V95, P15475, DOI 10.1073/pnas.95.26.15475; Hayward BE, 1998, P NATL ACAD SCI USA, V95, P10038, DOI 10.1073/pnas.95.17.10038; Liu J, 2000, MOL CELL BIOL, V20, P5808, DOI 10.1128/MCB.20.16.5808-5817.2000; Liu J, 2000, J CLIN INVEST, V106, P1167, DOI 10.1172/JCI10431; Peters J, 1999, P NATL ACAD SCI USA, V96, P3830, DOI 10.1073/pnas.96.7.3830; Plagge A, 2004, NAT GENET, V36, P818, DOI 10.1038/ng1397; Spiegel AM, 2004, ANNU REV MED, V55, P27, DOI 10.1146/annurev.med.55.091902.103843; Williamson CM, 2004, NAT GENET, V36, P894, DOI 10.1038/ng1398; Wroe SF, 2000, P NATL ACAD SCI USA, V97, P3342, DOI 10.1073/pnas.050015397; Yu SH, 1998, P NATL ACAD SCI USA, V95, P8715, DOI 10.1073/pnas.95.15.8715	15	185	194	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2005	37	1					25	27		10.1038/ng1487	http://dx.doi.org/10.1038/ng1487			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	883FX	15592469				2022-12-25	WOS:000225997500016
J	Lok, L; Brent, R				Lok, L; Brent, R			Automatic generation of cellular reaction networks with Moleculizer 1.0	NATURE BIOTECHNOLOGY			English	Article							TIME-EVOLUTION; SIMULATION; MODEL	Accurate simulation of intracellular biochemical networks is essential to furthering our understanding of biological system behavior. The number of protein complexes and of chemical interactions among them has traditionally posed significant problems for simulation algorithms. Here we describe an approach to the exact stochastic simulation of biochemical networks that emphasizes the contribution of protein complexes to these systems. This simulation approach starts from a description of monomeric proteins and specifications for binding, unbinding and other reactions. This manageable specification is reasonably intuitive for biologists. Rather than requiring the inclusion of all possible complexes and reactions from the outset, our approach incorporates new complexes and reactions only when needed as the simulation proceeds. As a result, the simulation generates much smaller reaction networks, which can be exported to other simulators for further analysis. We apply this approach to the automatic generation of reaction systems for the study of signal transduction networks.	Inst Mol Sci, Berkeley, CA 94704 USA	The Molecular Sciences Institute	Lok, L (corresponding author), Inst Mol Sci, 2168 Shattuck Ave, Berkeley, CA 94704 USA.	lok@molsci.org			NHGRI NIH HHS [P50 HG02370] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG002370] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Bormann Guy, 2001, P189; Bray D, 1997, P NATL ACAD SCI USA, V94, P13493, DOI 10.1073/pnas.94.25.13493; Brent R, 2000, CELL, V100, P169, DOI 10.1016/S0092-8674(00)81693-1; Chen KC, 2000, MOL BIOL CELL, V11, P369, DOI 10.1091/mbc.11.1.369; Cross FR, 2002, MOL BIOL CELL, V13, P52, DOI 10.1091/mbc.01-05-0265; Deuflhard P, 2002, SCI COMPUTING ORDINA; DOHLMAN H, 2001, ANN REV BIOCH, V70; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Elowitz MB, 1999, J BACTERIOL, V181, P197, DOI 10.1128/JB.181.1.197-203.1999; Endy D, 2001, NATURE, V409, P391, DOI 10.1038/35053181; Frenkel D., 1996, UNDERSTANDING MOL SI, V2; FRICKE T, 1995, INT J MOD PHYS C, V6, P277, DOI 10.1142/S0129183195000216; GIBSON M, 2000, THESIS CALTECH; Gibson MA, 2000, J PHYS CHEM A, V104, P1876, DOI 10.1021/jp993732q; GILLESPIE DT, 1976, J COMPUT PHYS, V22, P403, DOI 10.1016/0021-9991(76)90041-3; Gillespie DT, 2001, J CHEM PHYS, V115, P1716, DOI 10.1063/1.1378322; Gillespie DT, 2003, J CHEM PHYS, V119, P8229, DOI 10.1063/1.1613254; GILLESPIE DT, 1992, PHYSICA A, V188, P404, DOI 10.1016/0378-4371(92)90283-V; Gillespie DT, 1992, MARKOV PROCESSES INT; Haseltine EL, 2002, J CHEM PHYS, V117, P6959, DOI 10.1063/1.1505860; Hodges PE, 1998, NUCLEIC ACIDS RES, V26, P68, DOI 10.1093/nar/26.1.68; Hucka M, 2003, BIOINFORMATICS, V19, P524, DOI 10.1093/bioinformatics/btg015; KEANE J, 2004, ACM SIGDA INT S FIEL, V12, P233; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; MENDES P, 1994, THESIS U WALES ABERY; MORTONFIRTH C, 1998, THESIS U CAMBRIDGE; Pauling L, 1960, NATURE CHEM BOND, VThird, P644; Press W. H., 1992, ART SCI COMPUTING; Ptashne M, 1992, GENETIC SWITCH PHAGE; Rao CV, 2002, NATURE, V420, P231, DOI 10.1038/nature01258; Rao CV, 2003, J CHEM PHYS, V118, P4999, DOI 10.1063/1.1545446; Salwinski L, 2004, NAT BIOTECHNOL, V22, P1017, DOI 10.1038/nbt991; Stiles JR, 2001, METH NE FRO NEUROSCI, P87; Vaidehi Nagarajan, 2001, P161	34	113	116	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2005	23	1					131	136		10.1038/nbt1054	http://dx.doi.org/10.1038/nbt1054			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	885ZK	15637632				2022-12-25	WOS:000226195700042
J	Seo, JS; Chong, HY; Park, HS; Yoon, KO; Jung, C; Kim, JJ; Hong, JH; Kim, H; Kim, JH; Kil, JI; Park, CJ; Oh, HM; Lee, JS; Jin, SJ; Um, HW; Lee, HJ; Oh, SJ; Kim, JY; Kang, HL; Lee, SY; Lee, KJ; Kang, HS				Seo, JS; Chong, HY; Park, HS; Yoon, KO; Jung, C; Kim, JJ; Hong, JH; Kim, H; Kim, JH; Kil, JI; Park, CJ; Oh, HM; Lee, JS; Jin, SJ; Um, HW; Lee, HJ; Oh, SJ; Kim, JY; Kang, HL; Lee, SY; Lee, KJ; Kang, HS			The genome sequence of the ethanologenic bacterium Zymomonas mobilis ZM4	NATURE BIOTECHNOLOGY			English	Article							IDENTIFICATION; EVOLUTION; PATHWAY; STRAIN; GROWTH; TOOL	We report the complete genome sequence of Zymomonas mobilis ZM4 (ATCC31821), an ethanologenic microorganism of interest for the production of fuel ethanol. The genome consists of 2,056,416 base pairs forming a circular chromosome with 1,998 open reading frames (ORFs) and three ribosomal RNA transcription units. The genome lacks recognizable genes for 6-phosphofructokinase, an essential enzyme in the Embden-Meyerhof-Parnas pathway, and for two enzymes in the tricarboxylic acid cycle, the 2-oxoglutarate dehydrogenase complex and malate dehydrogenase, so glucose can be metabolized only by the Entner-Doudoroff pathway. Whole genome microarrays were used for genomic comparisons with the Z. mobilis type strain ZM1 (ATCC10988) revealing that 54 ORFs predicted to encode for transport and secretory proteins, transcriptional regulators and oxidoreductase in the ZM4 strain were absent from ZM1. Most of these ORFs were also found to be actively transcribed in association with ethanol production by ZM4.	Macrogen Inc, World Meridian Venture Ctr, Seoul 153781, South Korea; Seoul Natl Univ, Coll Med, Med Res Ctr, Dept Biochem, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Med Res Ctr, Dept Biochem, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Med Res Ctr, Ilchun Mol Med Inst, Seoul 110799, South Korea; Seoul Natl Univ, Sch Biol Sci, Dept Microbiol, Seoul 151742, South Korea; Ewha Womans Univ, Dept Comp Sci, Seoul 120750, South Korea	Macrogen, Inc.; Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Ewha Womans University	Seo, JS (corresponding author), Macrogen Inc, World Meridian Venture Ctr, 60-24 Gasan Dong, Seoul 153781, South Korea.	jeongsun@macrogen.com; khslab@snu.ac.kr	Seo, Jeong-Sun/J-2763-2012	/0000-0001-7230-1767				CONWAY T, 1992, FEMS MICROBIOL LETT, V103, P1; Cornish-Bowden A, 2000, NAT BIOTECHNOL, V18, P267, DOI 10.1038/73696; Deanda K, 1996, APPL ENVIRON MICROB, V62, P4465, DOI 10.1128/AEM.62.12.4465-4470.1996; Delcher AL, 1999, NUCLEIC ACIDS RES, V27, P4636, DOI 10.1093/nar/27.23.4636; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Hatzimanikatis V, 1998, BIOTECHNOL BIOENG, V58, P154, DOI 10.1002/(SICI)1097-0290(19980420)58:2/3<154::AID-BIT7>3.0.CO;2-K; Ingram LO, 1999, BIOTECHNOL PROGR, V15, P855, DOI 10.1021/bp9901062; Ingram LO, 1998, BIOTECHNOL BIOENG, V58, P204, DOI 10.1002/(SICI)1097-0290(19980420)58:2/3<204::AID-BIT13>3.0.CO;2-C; Kalnenieks U, 2000, MICROBIOL-UK, V146, P1259, DOI 10.1099/00221287-146-6-1259; Kane MD, 2000, NUCLEIC ACIDS RES, V28, P4552, DOI 10.1093/nar/28.22.4552; Kang HL, 1998, GENE, V206, P223, DOI 10.1016/S0378-1119(97)00589-1; Lee JS, 2001, MOL CELLS, V11, P68; LEE KJ, 1979, BIOTECHNOL LETT, V1, P421; LEE KJ, 1980, BIOTECHNOL LETT, V2, P487, DOI 10.1007/BF00129544; LEE KJ, 1980, BIOTECHNOL LETT, V2, P339, DOI 10.1007/BF00138666; LEWIN B, 1994, GENES, V5, P594; Lobry JR, 1996, MOL BIOL EVOL, V13, P660, DOI 10.1093/oxfordjournals.molbev.a025626; MOAT AG, 2002, MICROBIAL PHYSL, P351; Richmond CS, 1999, NUCLEIC ACIDS RES, V27, P3821, DOI 10.1093/nar/27.19.3821; Rogers P. L., 1982, MICROB REACT, V23, P37; ROGERS PL, 1979, BIOTECHNOL LETT, V1, P165, DOI 10.1007/BF01388142; Romano AH, 1996, RES MICROBIOL, V147, P448, DOI 10.1016/0923-2508(96)83998-2; Skotnicki M L, 1982, Basic Life Sci, V19, P271; STROHDEICHER M, 1990, ARCH MICROBIOL, V154, P536; SWINGS J, 1977, BACTERIOL REV, V41, P1; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; Tettelin H, 1999, GENOMICS, V62, P500, DOI 10.1006/geno.1999.6048; VIIKARI L, 1988, Critical Reviews in Biotechnology, V7, P237, DOI 10.3109/07388558809146603; YURA T, 1993, ANNU REV MICROBIOL, V47, P321, DOI 10.1146/annurev.mi.47.100193.001541; Zaldivar J, 2001, APPL MICROBIOL BIOT, V56, P17, DOI 10.1007/s002530100624; ZHANG M, 1995, SCIENCE, V267, P240, DOI 10.1126/science.267.5195.240; Zikmanis P, 1997, ARCH MICROBIOL, V167, P167, DOI 10.1007/s002030050430	33	206	590	2	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2005	23	1					63	68		10.1038/nbt1045	http://dx.doi.org/10.1038/nbt1045			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	885ZK	15592456	Green Published, hybrid			2022-12-25	WOS:000226195700030
J	Ridley, RG				Ridley, RG			Research on infectious diseases requires better coordination	NATURE MEDICINE			English	Editorial Material							PUBLIC-PRIVATE PARTNERSHIPS; NEGLECTED DISEASES; SARS; SURVEILLANCE; EXPERIENCE; HEALTH; TDR	This special supplement of Nature Medicine, directed at the topic of emerging infectious diseases, is very timely. Recent high-profile outbreaks have highlighted the global risk that infectious agents, both new and old, represent for society. The experience of severe acute respiratory syndrome (SARS) shows the risk posed by emerging infectious diseases, but also the power of strongly coordinated global surveillance and public health measures, coupled with scientific research, to keep infection under control(1,2). Diseases such as drug-resistant malaria continue to be threats. There is a need to enhance global resources to investigate, detect and respond to emerging infections, and to appropriately coordinate and direct research efforts to meet the challenges presented by these diseases.	WHO, UNICEF, UNDP, World Bank Special Program Res & Training Trop Di, CH-1211 Geneva, Switzerland	The World Bank; World Health Organization	Ridley, RG (corresponding author), WHO, UNICEF, UNDP, World Bank Special Program Res & Training Trop Di, CH-1211 Geneva, Switzerland.	ridleyr@who.int						Adjuik M, 2004, LANCET, V363, P9, DOI 10.1016/S0140-6736(03)15162-8; [Anonymous], 2004, SCAL HOM BAS MAN MAL; Breman JG, 2004, AM J TROP MED HYG, V71, P1; Brooks MJ, 2004, CURR OPIN PULM MED, V10, P197, DOI 10.1097/00063198-200405000-00009; Costello A, 2000, BRIT MED J, V321, P827, DOI 10.1136/bmj.321.7264.827; Goodman L, 2004, J CLIN INVEST, V114, P868, DOI 10.1172/JCI23259; Heymann D L, 2001, Lancet Infect Dis, V1, P345, DOI 10.1016/S1473-3099(01)00148-7; Heymann DL, 2004, LANCET, V363, P1566, DOI 10.1016/S0140-6736(04)16234-X; Heymann DL, 2004, EMERG INFECT DIS, V10, P173, DOI 10.3201/eid1002.031038; Heymann DL, 2004, PHILOS T ROY SOC B, V359, P1127, DOI 10.1098/rstb.2004.1484; Kachur SP, 2001, TROP MED INT HEALTH, V6, P324, DOI 10.1046/j.1365-3156.2001.0719a.x; Klausner RD, 2003, SCIENCE, V300, P2036, DOI 10.1126/science.1086916; McNabb SJN, 2002, BMC PUBLIC HEALTH, V2, DOI 10.1186/1471-2458-2-2; Morel CM, 2000, PARASITOL TODAY, V16, P522, DOI 10.1016/S0169-4758(00)01815-9; Ntoumi F, 2004, AM J TROP MED HYG, V71, pIV; Nwaka S, 2003, NAT REV DRUG DISCOV, V2, P919, DOI 10.1038/nrd1230; Remme JHF, 2004, TROP MED INT HEALTH, V9, P243, DOI 10.1046/j.1365-3156.2003.01192.x; Remme JHF, 2002, TRENDS PARASITOL, V18, P421, DOI 10.1016/S1471-4922(02)02387-5; Ridley RG, 2003, EMBO REP, V4, pS43, DOI 10.1038/sj.embor.embor858; Ridley RG, 2001, B WORLD HEALTH ORGAN, V79, P694; Rodier G, 2000, Med Trop (Mars), V60, P31; Widdus R, 2001, B WORLD HEALTH ORGAN, V79, P713	22	15	16	0	2	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2004	10	12		S			S137	S140		10.1038/nm1153	http://dx.doi.org/10.1038/nm1153			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	879RC	15577932	Green Published			2022-12-25	WOS:000225733900010
J	Huusko, P; Ponciano-Jackson, D; Wolf, M; Kiefer, JA; Azorsa, DO; Tuzmen, S; Weaver, D; Robbins, C; Moses, T; Allinen, M; Hautaniemi, S; Chen, YD; Elkahloun, A; Basik, M; Bova, GS; Bubendorf, L; Lugli, A; Sauter, G; Schleutker, J; Ozcelik, H; Elowe, S; Pawson, T; Trent, JM; Carpten, JD; Kallioniemi, OP; Mousses, S				Huusko, P; Ponciano-Jackson, D; Wolf, M; Kiefer, JA; Azorsa, DO; Tuzmen, S; Weaver, D; Robbins, C; Moses, T; Allinen, M; Hautaniemi, S; Chen, YD; Elkahloun, A; Basik, M; Bova, GS; Bubendorf, L; Lugli, A; Sauter, G; Schleutker, J; Ozcelik, H; Elowe, S; Pawson, T; Trent, JM; Carpten, JD; Kallioniemi, OP; Mousses, S			Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer	NATURE GENETICS			English	Article							GENE-EXPRESSION PATTERNS; COPY-NUMBER; RECEPTORS; EPHRIN-B2	The identification of tumor-suppressor genes in solid tumors by classical cancer genetics methods is difficult and slow. We combined nonsense-mediated RNA decay microarrays(1) and array-based comparative genomic hybridization(2,3) for the genome-wide identification of genes with biallelic inactivation involving nonsense mutations and loss of the wild-type allele. This approach enabled us to identify previously unknown mutations in the receptor tyrosine kinase gene EPHB2. The DU 145 prostate cancer cell line, originating from a brain metastasis, carries a truncating mutation of EPHB2 and a deletion of the remaining allele. Additional frameshift, splice site, missense and nonsense mutations are present in clinical prostate cancer samples. Transfection of DU 145 cells, which lack functional EphB2, with wild-type EPHB2 suppresses clonogenic growth. Taken together with studies indicating that EphB2 may have an essential role in cell migration and maintenance of normal tissue architecture, our findings suggest that mutational inactivation of EPHB2 may be important in the progression and metastasis of prostate cancer.	Translat Genom Res Inst, Genet Basis Human Dis Res Div, Phoenix, AZ 85004 USA; Univ Turku, Turku 20521, Finland; VTT Tech Res Ctr Finland, Turku 20521, Finland; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Tampere Univ Technol, Inst Signal Proc, FIN-33101 Tampere, Finland; Jewish Gen Hosp, Dept Oncol, Montreal, PQ H3T 1E2, Canada; Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21287 USA; Univ Basel, Inst Pathol, CH-4003 Basel, Switzerland; Univ Tampere, Inst Med Technol, Canc Genet Lab, Tampere 33520, Finland; Tampere Univ Hosp, Tampere 33520, Finland; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Translational Genomics Research Institute; University of Turku; VTT Technical Research Center Finland; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Tampere University; McGill University; Johns Hopkins University; Johns Hopkins University; University of Basel; Tampere University; Tampere University; Tampere University Hospital; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Kallioniemi, OP (corresponding author), Translat Genom Res Inst, Canc Durg Dev Lab, 20 Firstfield Rd,Suite 110, Gaithersburg, MD 20878 USA.	smousses@tgen.org; olli.kallioniemi@vtt.fi	Pawson, Tony J/E-4578-2013; Ozcelik, Hilmi/A-3952-2011; Kallioniemi, Olli P/H-5111-2011; Thomson, Axel/A-7893-2013; Tüzmen, Şükrü/AAH-9916-2021; Jeff/ABB-2636-2021; Bubendorfl, Lukas/H-5880-2011; Hautaniemi, Sampsa/CAG-0362-2022; Tuzmen, Sukru/I-5663-2013; Bubendorf, Lukas/G-5299-2015; Hautaniemi, Sampsa/A-3122-2009	Kallioniemi, Olli P/0000-0002-3231-0332; Tüzmen, Şükrü/0000-0003-4822-396X; Jeff/0000-0002-1238-3120; Hautaniemi, Sampsa/0000-0002-7749-2694; Tuzmen, Sukru/0000-0003-4822-396X; Bubendorf, Lukas/0000-0001-5970-1803; Hautaniemi, Sampsa/0000-0002-7749-2694; Bova, George/0000-0003-1639-3104; Schleutker, Johanna/0000-0002-1863-0305				Barrios A, 2003, CURR BIOL, V13, P1571, DOI 10.1016/j.cub.2003.08.030; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Chen Y, 1997, J Biomed Opt, V2, P364, DOI 10.1117/12.281504; Chen YD, 2002, BIOINFORMATICS, V18, P1207, DOI 10.1093/bioinformatics/18.9.1207; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; DeRisi J, 1996, NAT GENET, V14, P457; Elowe S, 2001, MOL CELL BIOL, V21, P7429, DOI 10.1128/MCB.21.21.7429-7441.2001; Gale NW, 2001, DEV BIOL, V230, P151, DOI 10.1006/dbio.2000.0112; Gibbs M, 1999, AM J HUM GENET, V64, P776, DOI 10.1086/302287; Hyman E, 2002, CANCER RES, V62, P6240; Knoll B, 2002, TRENDS NEUROSCI, V25, P145, DOI 10.1016/S0166-2236(00)02093-2; KNUDSON AG, 1985, CANCER RES, V45, P1437; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; LOSSON R, 1979, P NATL ACAD SCI USA, V76, P5134, DOI 10.1073/pnas.76.10.5134; Mellitzer G, 2000, CURR OPIN NEUROBIOL, V10, P400, DOI 10.1016/S0959-4388(00)00095-7; Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298; Mousses S, 2000, PRACT APPROACH SER, P113; Noensie EN, 2001, NAT BIOTECHNOL, V19, P434, DOI 10.1038/88099; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515	21	152	176	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2004	36	9					979	983		10.1038/ng1408	http://dx.doi.org/10.1038/ng1408			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	851AY	15300251	Green Published, Bronze			2022-12-25	WOS:000223658100024
J	Wen, Y; Eng, CH; Schmoranzer, J; Cabrera-Poch, N; Morris, EJS; Chen, M; Wallar, BJ; Alberts, AS; Gundersen, GG				Wen, Y; Eng, CH; Schmoranzer, J; Cabrera-Poch, N; Morris, EJS; Chen, M; Wallar, BJ; Alberts, AS; Gundersen, GG			EB1 and APC bind to mDia to stabilize microtubules downstream of Rho and promote cell migration	NATURE CELL BIOLOGY			English	Article							DETYROSINATED GLU MICROTUBULES; LINKING FACTOR MACF; INTERMEDIATE-FILAMENTS; MITOTIC SPINDLE; PROTEIN EB1; SELECTIVE STABILIZATION; IN-VIVO; CAPTURE; ACTIN; DYNACTIN	Lysophosphatidic acid (LPA) stimulates Rho GTPase and its effector, the formin mDia, to capture and stabilize microtubules in fibroblasts. We investigated whether mammalian EB1 and adenomatous polyposis coli (APC) function downstream of Rho-mDia in microtubule stabilization. A carboxy-terminal APC-binding fragment of EB1 (EB1-C) functioned as a dominant-negative inhibitor of microtubule stabilization induced by LPA or active mDia. Knockdown of EB1 with small interfering RNAs also prevented microtubule stabilization. Expression of either full-length EB1 or APC, but not an APC-binding mutant of EB1, was sufficient to stabilize microtubules. Binding and localization studies showed that EB1, APC and mDia may form a complex at stable microtubule ends. Furthermore, EB1-C, but not an APC-binding mutant, inhibited fibroblast migration in an in vitro wounding assay. These results show an evolutionarily conserved pathway for microtubule capture, and suggest that mDia functions as a scaffold protein for EB1 and APC to stabilize microtubules and promote cell migration.	Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Columbia Univ, Integrated Program Cellular Mol & Biophys Studies, New York, NY 10032 USA; Van Andel Inst, Lab Cell Struct & Signal Integrat, Grand Rapids, MI 49503 USA	Columbia University; Columbia University; Van Andel Institute	Gundersen, GG (corresponding author), Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA.	ggg1@columbia.edu		Schmoranzer, Jan/0000-0002-4482-7080; Morris, Edward/0000-0002-7960-2842	NIGMS NIH HHS [GM62939] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062939] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adames NR, 2000, J CELL BIOL, V149, P863, DOI 10.1083/jcb.149.4.863; Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Askham JM, 2000, ONCOGENE, V19, P1950, DOI 10.1038/sj.onc.1203498; Askham JM, 2002, MOL BIOL CELL, V13, P3627, DOI 10.1091/mbc.E02-01-0061; Beach DL, 2000, CURR BIOL, V10, P1497, DOI 10.1016/S0960-9822(00)00837-X; Berrueta L, 1999, CURR BIOL, V9, P425, DOI 10.1016/S0960-9822(99)80190-0; Berrueta L, 1998, P NATL ACAD SCI USA, V95, P10596, DOI 10.1073/pnas.95.18.10596; Bienz M, 2001, NAT CELL BIOL, V3, pE67, DOI 10.1038/35060140; Bloom K, 2000, NAT CELL BIOL, V2, pE96, DOI 10.1038/35014089; Cook TA, 1998, J CELL BIOL, V141, P175, DOI 10.1083/jcb.141.1.175; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Evangelista M, 2003, J CELL SCI, V116, P2603, DOI 10.1242/jcs.00611; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; GUNDERSEN GG, 1989, J CELL BIOL, V109, P2275, DOI 10.1083/jcb.109.5.2275; GUNDERSEN GG, 1986, EUR J CELL BIOL, V42, P288; GUNDERSEN GG, 1988, P NATL ACAD SCI USA, V85, P5946, DOI 10.1073/pnas.85.16.5946; Gundersen GG, 2002, NAT REV MOL CELL BIO, V3, P296, DOI 10.1038/nrm777; GUNDERSEN GG, 1984, CELL, V38, P779, DOI 10.1016/0092-8674(84)90273-3; GURLAND G, 1995, J CELL BIOL, V131, P1275, DOI 10.1083/jcb.131.5.1275; Infante AS, 2000, J CELL SCI, V113, P3907; Karakesisoglou I, 2000, J CELL BIOL, V149, P195, DOI 10.1083/jcb.149.1.195; Kodama A, 2003, CELL, V115, P343, DOI 10.1016/S0092-8674(03)00813-4; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; Kreitzer G, 1999, MOL BIOL CELL, V10, P1105, DOI 10.1091/mbc.10.4.1105; Kusch J, 2003, TRENDS CELL BIOL, V13, P562, DOI 10.1016/j.tcb.2003.09.008; Lee L, 1999, J CELL BIOL, V144, P947, DOI 10.1083/jcb.144.5.947; Leung CL, 1999, J CELL BIOL, V147, P1275, DOI 10.1083/jcb.147.6.1275; Liao GJ, 1998, J BIOL CHEM, V273, P9797, DOI 10.1074/jbc.273.16.9797; Ligon LA, 2003, MOL BIOL CELL, V14, P1405, DOI 10.1091/mbc.E02-03-0155; Lin SX, 2002, MOL BIOL CELL, V13, P96, DOI 10.1091/mbc.01-05-0224; Mimori-Kiyosue Y, 2000, CURR BIOL, V10, P865, DOI 10.1016/S0960-9822(00)00600-X; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Nakamura M, 2002, FEBS LETT, V514, P193, DOI 10.1016/S0014-5793(02)02363-3; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Palazzo AF, 2004, SCIENCE, V303, P836, DOI 10.1126/science.1091325; Palazzo AF, 2001, CURR BIOL, V11, P1536, DOI 10.1016/S0960-9822(01)00475-4; Rogers SL, 2002, J CELL BIOL, V158, P873, DOI 10.1083/jcb.200202032; Schuyler SC, 2001, J CELL SCI, V114, P247; Schuyler SC, 2001, CELL, V105, P421, DOI 10.1016/S0092-8674(01)00364-6; SU LK, 1995, CANCER RES, V55, P2972; Subramanian A, 2003, CURR BIOL, V13, P1086, DOI 10.1016/S0960-9822(03)00416-0; Sun DM, 2001, J CELL SCI, V114, P161; Tirnauer JS, 1999, J CELL BIOL, V145, P993, DOI 10.1083/jcb.145.5.993; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; WEBSTER DR, 1987, P NATL ACAD SCI USA, V84, P9040, DOI 10.1073/pnas.84.24.9040; Westermann S, 2003, NAT REV MOL CELL BIO, V4, P938, DOI 10.1038/nrm1260; Yasuda S, 2004, NATURE, V428, P767, DOI 10.1038/nature02452; Yin HW, 2000, NATURE, V406, P1013, DOI 10.1038/35023024; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	50	387	394	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2004	6	9					820	U1		10.1038/ncb1160	http://dx.doi.org/10.1038/ncb1160			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	852IZ	15311282				2022-12-25	WOS:000223750300012
J	Fukagawa, T; Nogami, M; Yoshikawa, M; Ikeno, M; Okazaki, T; Takami, Y; Nakayama, T; Oshimura, M				Fukagawa, T; Nogami, M; Yoshikawa, M; Ikeno, M; Okazaki, T; Takami, Y; Nakayama, T; Oshimura, M			Dicer is essential for formation of the heterochromatin structure in vertebrate cells	NATURE CELL BIOLOGY			English	Article							CENP-C; LYSINE-9 METHYLATION; CENTROMERE FUNCTION; RNA INTERFERENCE; HISTONE H3; HP1; LOCALIZATION; CHROMATIN; COHESION; DOMAINS	RNA interference is an evolutionarily conserved gene-silencing pathway in which the nuclease Dicer cleaves double-stranded RNA into small interfering RNAs1. The biological function of the RNAi-related pathway in vertebrate cells is not fully understood. Here, we report the generation of a conditional loss-of-function Dicer mutant in a chicken-human hybrid DT40 cell line that contains human chromosome 21. We show that loss of Dicer results in cell death with the accumulation of abnormal mitotic cells that show premature sister chromatid separation. Aberrant accumulation of transcripts from alpha-satellite sequences, which consist of human centromeric repeat DNAs, was detected in Dicer-deficient cells. Immunocytochemical analysis revealed abnormalities in the localization of two heterochromatin proteins, Rad21 cohesin protein and BubR1 checkpoint protein, but the localization of core kinetochore proteins such as centromere protein (CENP)-A and -C was normal. We conclude that Dicer-related RNA interference machinery is involved in the formation of the heterochromatin structure in higher vertebrate cells.	JST, PRESTO, Natl Inst Genet, Shizuoka 4118540, Japan; Grad Univ Adv Studies, Shizuoka 4118540, Japan; Fujita Hlth Univ, Inst Comprehens Med Sci, Aichi 4701101, Japan; Miyazaki Med Coll, Dept Biochem, Miyazaki 8891692, Japan; Tottori Univ, Grad Sch Med Sci, Inst Regenerat Med & Biofunct, Dept Biomed Sci, Tottori 6838503, Japan	Japan Science & Technology Agency (JST); Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Graduate University for Advanced Studies - Japan; Fujita Health University; University of Miyazaki; Tottori University	Fukagawa, T (corresponding author), JST, PRESTO, Natl Inst Genet, Shizuoka 4118540, Japan.	tfukagaw@lab.nig.ac.jp	Fukagawa, Tatsuo/AAK-3922-2021					Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bernard P, 2001, SCIENCE, V294, P2539, DOI 10.1126/science.1064027; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Blower MD, 2002, DEV CELL, V2, P319, DOI 10.1016/S1534-5807(02)00135-1; Brown WRA, 2003, NAT REV GENET, V4, P87, DOI 10.1038/nrg998; Choo KHA., 1997, CENTROMERE; Fukagawa T, 1999, EMBO J, V18, P4196, DOI 10.1093/emboj/18.15.4196; Fukagawa T, 1997, HUM MOL GENET, V6, P2301, DOI 10.1093/hmg/6.13.2301; Fukagawa T, 2001, EMBO J, V20, P4603, DOI 10.1093/emboj/20.16.4603; Hall IM, 2003, P NATL ACAD SCI USA, V100, P193, DOI 10.1073/pnas.232688099; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hayakawa T, 2003, J CELL SCI, V116, P3327, DOI 10.1242/jcs.00635; Hudson DF, 2002, TRENDS CELL BIOL, V12, P281, DOI 10.1016/S0962-8924(02)02281-X; IKENO M, 1994, HUM MOL GENET, V3, P1245, DOI 10.1093/hmg/3.8.1245; Ikeno M, 1998, NAT BIOTECHNOL, V16, P431, DOI 10.1038/nbt0598-431; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nishihashi A, 2002, DEV CELL, V2, P463, DOI 10.1016/S1534-5807(02)00144-2; Nonaka N, 2002, NAT CELL BIOL, V4, P89, DOI 10.1038/ncb739; Pal-Bhadra M, 2004, SCIENCE, V303, P669, DOI 10.1126/science.1092653; Partridge JF, 2000, GENE DEV, V14, P783; Provost P, 2002, P NATL ACAD SCI USA, V99, P16648, DOI 10.1073/pnas.212633199; Schramke V, 2003, SCIENCE, V301, P1069, DOI 10.1126/science.1086870; Schueler MG, 2001, SCIENCE, V294, P109, DOI 10.1126/science.1065042; Sonoda E, 2001, DEV CELL, V1, P759, DOI 10.1016/S1534-5807(01)00088-0; Spence JM, 2002, EMBO J, V21, P5269, DOI 10.1093/emboj/cdf511; Sullivan BA, 2002, TRENDS BIOTECHNOL, V20, P89, DOI 10.1016/S0167-7799(02)01902-9; Volpe T, 2003, CHROMOSOME RES, V11, P137, DOI 10.1023/A:1022815931524; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973	29	393	419	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2004	6	8					784	791		10.1038/ncb1155	http://dx.doi.org/10.1038/ncb1155			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	842YA	15247924				2022-12-25	WOS:000223039400018
J	Christophorou, MA; Martin-Zanca, D; Soucek, L; Lawlor, ER; Brown-Swigart, L; Verschuren, EW; Evan, GI				Christophorou, MA; Martin-Zanca, D; Soucek, L; Lawlor, ER; Brown-Swigart, L; Verschuren, EW; Evan, GI			Temporal dissection of p53 function in vitro and in vivo	NATURE GENETICS			English	Article							RADIATION-INDUCED APOPTOSIS; MOUSE EMBRYO FIBROBLASTS; TIME QUANTITATIVE PCR; P53-DEFICIENT MICE; CELLULAR SENESCENCE; INDUCTION; ACTIVATION; RAS; TAMOXIFEN; RESPONSES	To investigate the functions of the p53 tumor suppressor, we created a new knock- in gene replacement mouse model in which the endogenous Trp53 gene is substituted by one encoding p53ER(TAM), a p53 fusion protein whose function is completely dependent on ectopic provision of 4- hydroxytamoxifen. We show here that both tissues in vivo and cells in vitro derived from such mice can be rapidly toggled between wild- type and p53 knockout states. Using this rapid perturbation model, we define the kinetics, dependence, persistence and reversibility of p53- mediated responses to DNA damage in tissues in vivo and to activation of the Ras oncoprotein and stress in vitro. This is the first example to our knowledge of a new class of genetic model that allows the specific, rapid and reversible perturbation of the function of a single endogenous gene in vivo.	Univ Calif San Francisco, Ctr Comprehens Canc, Canc Res Inst, San Francisco, CA 94143 USA; Univ Salamanca, CSIC, Inst Microbiol Bioquim, Salamanca 37007, Spain	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca	Evan, GI (corresponding author), Univ Calif San Francisco, Ctr Comprehens Canc, Canc Res Inst, San Francisco, CA 94143 USA.	gevan@cc.ucsf.edu	Soucek, Laura/AAG-7393-2019; Soucek, Laura/AAG-8377-2019	Soucek, Laura/0000-0002-4750-7971; Christophorou, Maria/0000-0001-5455-7283; Verschuren, Emmy/0000-0001-5771-9129				Adimoolam S, 2003, DNA REPAIR, V2, P947, DOI 10.1016/S1568-7864(03)00087-9; Attardi LD, 2004, ONCOGENE, V23, P973, DOI 10.1038/sj.onc.1207026; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; Botchkarev VA, 2000, CANCER RES, V60, P5002; Cui Y. F., 1995, Journal of Environmental Pathology Toxicology and Oncology, V14, P159; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fei PW, 2002, CANCER RES, V62, P7316; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Fukatsu K, 1997, SEN-I GAKKAISHI, V53, P15, DOI 10.2115/fiber.53.15; Ginzinger DG, 2002, EXP HEMATOL, V30, P503, DOI 10.1016/S0301-472X(02)00806-8; Hanawalt PC, 2003, MUTAT RES-REV MUTAT, V544, P107, DOI 10.1016/j.mrrev.2003.06.002; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, ONCOGENE, V8, P2457; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Hayflick L, 2003, EXP GERONTOL, V38, P1231, DOI 10.1016/j.exger.2003.09.003; Kemp CJ, 2001, CANCER RES, V61, P327; Komarova EA, 2000, ONCOGENE, V19, P3791, DOI 10.1038/sj.onc.1203717; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; POTTEN CS, 1994, INT J RADIAT BIOL, V65, P71, DOI 10.1080/09553009414550101; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Song SY, 1999, AM J PATHOL, V155, P1121, DOI 10.1016/S0002-9440(10)65215-7; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Vater CA, 1996, ONCOGENE, V13, P739; White INH, 2003, CURR DRUG METAB, V4, P223, DOI 10.2174/1389200033489451	31	150	150	1	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2005	37	7					718	726		10.1038/ng1572	http://dx.doi.org/10.1038/ng1572			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	941EA	15924142				2022-12-25	WOS:000230196400018
J	Slotkin, RK; Freeling, M; Lisch, D				Slotkin, RK; Freeling, M; Lisch, D			Heritable transposon silencing initiated by a naturally occurring transposon inverted duplication	NATURE GENETICS			English	Article							RNA INTERFERENCE; DELETION DERIVATIVES; CYTOSINE METHYLATION; MUTATOR TRANSPOSONS; DNA METHYLATION; TANDEM REPEATS; C-ELEGANS; ARABIDOPSIS; GENE; ELEMENTS	It has been suggested that gene silencing evolved as a defense against genomic parasites such as transposons(1). This idea is based on analysis of mutations that reactivate transposons that are stably silenced(2-9): they affect maintenance rather than initiation of silencing. Here we describe the cloning and characterization of a naturally occurring locus able to heritably silence the otherwise highly active MuDR transposon in maize. This locus, Mu killer (Muk), results from the inverted duplication of a partially deleted autonomous MuDR element located at the breakpoint of a genomic deletion. Muk produces a hybrid hairpin transcript that is processed into small RNAs, which are amplified when the target MuDR transcript is present. Muk provides the first example of a naturally occurring transposon derivative capable of initiating the heritable silencing of an active transposon family. Further, transposon-generated inverted duplications may be important for the generation of double-stranded RNAs used in gene silencing.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Lisch, D (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, 111 Koshland Hall, Berkeley, CA 94720 USA.	dlisch@uclink.berkeley.edu	Lisch, Damon/A-9414-2010; Slotkin, R. Keith/H-6965-2013	Slotkin, R. Keith/0000-0001-9582-3533; Lisch, Damon/0000-0002-8693-8651				Allen E, 2004, NAT GENET, V36, P1282, DOI 10.1038/ng1478; Aravin AA, 2001, CURR BIOL, V11, P1017, DOI 10.1016/S0960-9822(01)00299-8; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Hamilton A, 2002, EMBO J, V21, P4671, DOI 10.1093/emboj/cdf464; Jiang N, 2004, NATURE, V431, P569, DOI 10.1038/nature02953; Kato M, 2003, CURR BIOL, V13, P421, DOI 10.1016/S0960-9822(03)00106-4; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Kidwell MG, 2000, TRENDS ECOL EVOL, V15, P95, DOI 10.1016/S0169-5347(99)01817-0; Kim SH, 2003, PLANT CELL, V15, P2430, DOI 10.1105/tpc.014605; Lippman Z, 2004, NATURE, V430, P471, DOI 10.1038/nature02651; Lisch D, 2002, TRENDS PLANT SCI, V7, P498, DOI 10.1016/S1360-1385(02)02347-6; Lisch D, 1999, GENETICS, V151, P331; Luff B, 1999, MOL CELL, V3, P505, DOI 10.1016/S1097-2765(00)80478-5; Martienssen RA, 2003, NAT GENET, V35, P213, DOI 10.1038/ng1252; Melquist S, 2003, GENE DEV, V17, P2036, DOI 10.1101/gad.1081603; Miura A, 2001, NATURE, V411, P212, DOI 10.1038/35075612; Puig M, 2004, P NATL ACAD SCI USA, V101, P9013, DOI 10.1073/pnas.0403090101; Rudenko GN, 2001, PLANT CELL, V13, P553, DOI 10.1105/tpc.13.3.553; Schramke V, 2003, SCIENCE, V301, P1069, DOI 10.1126/science.1086870; Sijen T, 2003, NATURE, V426, P310, DOI 10.1038/nature02107; Singer T, 2001, GENE DEV, V15, P591, DOI 10.1101/gad.193701; Slotkin RK, 2003, GENETICS, V165, P781; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Vazquez F, 2004, MOL CELL, V16, P69, DOI 10.1016/j.molcel.2004.09.028; Wu-Scharf D, 2000, SCIENCE, V290, P1159, DOI 10.1126/science.290.5494.1159; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Zilberman D, 2003, SCIENCE, V299, P716, DOI 10.1126/science.1079695; Zilberman D, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-12-249	28	123	132	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2005	37	6					641	644		10.1038/ng1576	http://dx.doi.org/10.1038/ng1576			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	931OT	15908951				2022-12-25	WOS:000229495300020
J	Krek, A; Grun, D; Poy, MN; Wolf, R; Rosenberg, L; Epstein, EJ; MacMenamin, P; da Piedade, I; Gunsalus, KC; Stoffel, M; Rajewsky, N				Krek, A; Grun, D; Poy, MN; Wolf, R; Rosenberg, L; Epstein, EJ; MacMenamin, P; da Piedade, I; Gunsalus, KC; Stoffel, M; Rajewsky, N			Combinatorial microRNA target predictions	NATURE GENETICS			English	Article								MicroRNAs are small noncoding RNAs that recognize and bind to partially complementary sites in the 3' untranslated regions of target genes in animals and, by unknown mechanisms, regulate protein production of the target transcript(1-3). Different combinations of microRNAs are expressed in different cell types and may coordinately regulate cell-specific target genes. Here, we present PicTar, a computational method for identifying common targets of microRNAs. Statistical tests using genome-wide alignments of eight vertebrate genomes, PicTar's ability to specifically recover published microRNA targets, and experimental validation of seven predicted targets suggest that PicTar has an excellent success rate in predicting targets for single microRNAs and for combinations of microRNAs. We find that vertebrate microRNAs target, on average, roughly 200 transcripts each. Furthermore, our results suggest widespread coordinate control executed by microRNAs. In particular, we experimentally validate common regulation of Mtpn by miR-375, miR-124 and let-7b and thus provide evidence for coordinate microRNA control in mammals.	NYU, Dept Biol, Ctr Comparat Funct Genom, New York, NY 10003 USA; NYU, Dept Phys, New York, NY 10003 USA; Rockefeller Univ, Lab Metab Dis, New York, NY 10021 USA	New York University; New York University; Rockefeller University	Rajewsky, N (corresponding author), NYU, Dept Biol, Ctr Comparat Funct Genom, 100 Washington Sq E, New York, NY 10003 USA.	nikolaus.rajewsky@nyu.edu	Poy, Matthew/F-6914-2017; ravegnini, gloria/K-1330-2016	Poy, Matthew/0000-0002-4904-2426; ravegnini, gloria/0000-0002-7774-402X; Rajewsky, Nikolaus/0000-0002-4785-4332; Stoffel, Markus/0000-0003-1304-5817				Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Banerjee D, 2002, BIOESSAYS, V24, P119, DOI 10.1002/bies.10046; Barad O, 2004, GENOME RES, V14, P2486, DOI 10.1101/gr.2845604; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Cullen BR, 2004, MOL CELL, V16, P861, DOI 10.1016/j.molcel.2004.12.002; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Enright AJ, 2004, GENOME BIOL, V5; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; Hillier LW, 2004, NATURE, V432, P695, DOI 10.1038/nature03154; Hobert O, 2004, TRENDS BIOCHEM SCI, V29, P462, DOI 10.1016/j.tibs.2004.07.001; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; Kiriakidou M, 2004, GENE DEV, V18, P1165, DOI 10.1101/gad.1184704; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Pruitt KD, 2005, NUCLEIC ACIDS RES, V33, pD501, DOI 10.1093/nar/gki025; Rajewsky N, 2004, DEV BIOL, V267, P529, DOI 10.1016/j.ydbio.2003.12.003; Rajewsky N, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-30; Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Schroeder MD, 2004, PLOS BIOL, V2, P1396, DOI 10.1371/journal.pbio.0020271; Sinha S, 2003, BIOINFORMATICS, V19, pi292, DOI 10.1093/bioinformatics/btg1040; Stark A, 2003, PLOS BIOL, V1, P397, DOI 10.1371/journal.pbio.0000060	26	3694	3966	2	215	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2005	37	5					495	500		10.1038/ng1536	http://dx.doi.org/10.1038/ng1536			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	922TU	15806104				2022-12-25	WOS:000228862300018
J	Reilein, A; Nelson, WJ				Reilein, A; Nelson, WJ			APC is a component of an organizing template for cortical microtubule networks	NATURE CELL BIOLOGY			English	Article							ADENOMATOUS POLYPOSIS-COLI; TUMOR-SUPPRESSOR PROTEIN; CYTOPLASMIC DYNEIN; GENE-PRODUCT; PLUS ENDS; EB1; BINDING; P150(GLUED); DYNAMICS; CDC42	A microtubule network on the basal cortex of polarized epithelial cells consists of non-centrosomal microtubules of mixed polarity. Here, we investigate the proteins that are involved in organizing this network, and we show that end-binding protein 1 (EB1), adenomatous polyposis coli protein (APC) and p150(Glued) - although considered to be microtubule plus-end-binding proteins - are localized along the entire length of microtubules within the network, and at T-junctions between microtubules. The network shows microtubule behaviours that arise from physical interactions between microtubules, including microtubule plus-end stabilization on the sides of other microtubules, and sliding of microtubule ends along other microtubules. APC also localizes to the basal cortex. Microtubules grew over and paused at APC puncta; an in vitro reconstituted microtubule network overlaid APC puncta; and microtubule network reconstitution was inhibited by function-blocking APC antibodies. Thus, APC is a component of a cortical template that guides microtubule network formation.	Stanford Univ, Sch Med, Beckman Ctr Mol & Genet Med B121, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA	Stanford University	Nelson, WJ (corresponding author), Stanford Univ, Sch Med, Beckman Ctr Mol & Genet Med B121, Dept Cellular & Mol Physiol, 279 Campus Dr, Stanford, CA 94305 USA.	wjnelson@stanford.edu			NATIONAL CANCER INSTITUTE [T32CA009151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042735] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA09151, T32 CA009151] Funding Source: Medline; NIGMS NIH HHS [R01 GM035527] Funding Source: Medline; NINDS NIH HHS [NS 42735, R01 NS042735] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLAN V, 1995, J CELL BIOL, V128, P879, DOI 10.1083/jcb.128.5.879; Amos LA, 1999, CHEM BIOL, V6, pR65, DOI 10.1016/S1074-5521(99)89002-4; Askham JM, 2000, ONCOGENE, V19, P1950, DOI 10.1038/sj.onc.1203498; Askham JM, 2002, MOL BIOL CELL, V13, P3627, DOI 10.1091/mbc.E02-01-0061; Barth AIM, 2002, J CELL SCI, V115, P1583; Brunner D, 2000, CELL, V102, P695, DOI 10.1016/S0092-8674(00)00091-X; Deacon SW, 2003, J CELL BIOL, V160, P297, DOI 10.1083/jcb.200210066; Drees Frauke, 2004, V294, P303; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Gundersen GG, 2004, CURR OPIN CELL BIOL, V16, P106, DOI 10.1016/j.ceb.2003.11.010; Heuser J, 2000, TRAFFIC, V1, P545, DOI 10.1034/j.1600-0854.2000.010704.x; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; HOWARD WD, 1988, J BIOL CHEM, V263, P1342; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; Komarova YA, 2002, J CELL BIOL, V159, P589, DOI 10.1083/jcb.200208058; Krylyshkina O, 2003, J CELL BIOL, V161, P853, DOI 10.1083/jcb.200301102; Mariadason JM, 2001, CANCER RES, V61, P3465; McCartney BM, 2001, NAT CELL BIOL, V3, P933, DOI 10.1038/ncb1001-933; Mimori-Kiyosue Y, 2000, CURR BIOL, V10, P865, DOI 10.1016/S0960-9822(00)00600-X; Mimori-Kiyosue Y, 2005, J CELL BIOL, V168, P141, DOI 10.1083/jcb.200405094; Mimori-Kiyosue Y, 2003, J BIOCHEM, V134, P321, DOI 10.1093/jb/mvg148; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; Mogensen MM, 2002, J CELL BIOL, V157, P1041, DOI 10.1083/jcb.200203001; Morrison EE, 1998, ONCOGENE, V17, P3471, DOI 10.1038/sj.onc.1202247; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Nakamura M, 2001, CURR BIOL, V11, P1062, DOI 10.1016/S0960-9822(01)00297-4; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; Rogers SL, 2002, J CELL BIOL, V158, P873, DOI 10.1083/jcb.200202032; Rosin-Arbesfeld R, 2001, EMBO J, V20, P5929, DOI 10.1093/emboj/20.21.5929; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SCHNAPP BJ, 1989, P NATL ACAD SCI USA, V86, P1548, DOI 10.1073/pnas.86.5.1548; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; Shimizu K, 1996, J BIOL CHEM, V271, P27013, DOI 10.1074/jbc.271.43.27013; SU LK, 1995, CANCER RES, V55, P2972; Svitkina TM, 1995, J STRUCT BIOL, V115, P290, DOI 10.1006/jsbi.1995.1054; Tirnauer JS, 2002, MOL BIOL CELL, V13, P3614, DOI 10.1091/mbc.E02-04-0210; Vaughan KT, 2004, TRENDS CELL BIOL, V14, P491, DOI 10.1016/j.tcb.2004.07.011; Vaughan PS, 2002, J CELL BIOL, V158, P305, DOI 10.1083/jcb.200201029; Watanabe T, 2004, DEV CELL, V7, P871, DOI 10.1016/j.devcel.2004.10.017; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634; Wen Y, 2004, NAT CELL BIOL, V6, P820, DOI 10.1038/ncb1160; Yamashita YM, 2003, SCIENCE, V301, P1547, DOI 10.1126/science.1087795; Yamazaki H, 1996, P NATL ACAD SCI USA, V93, P8443, DOI 10.1073/pnas.93.16.8443; Zhou FQ, 2004, NEURON, V42, P897, DOI 10.1016/j.neuron.2004.05.011; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	47	85	88	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2005	7	5					463	U20		10.1038/ncb1248	http://dx.doi.org/10.1038/ncb1248			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	926LA	15892196	Green Accepted			2022-12-25	WOS:000229123500013
J	Rush, J; Moritz, A; Lee, KA; Guo, A; Goss, VL; Spek, EJ; Zhang, H; Zha, XM; Polakiewicz, RD; Comb, MJ				Rush, J; Moritz, A; Lee, KA; Guo, A; Goss, VL; Spek, EJ; Zhang, H; Zha, XM; Polakiewicz, RD; Comb, MJ			Immunoaffinity profiling of tyrosine phosphorylation in cancer cells	NATURE BIOTECHNOLOGY			English	Article							ANAPLASTIC LYMPHOMA KINASE; RECEPTOR SIGNALING PATHWAYS; TANDEM MASS-SPECTROMETRY; FOCAL ADHESION KINASE; NON-HODGKINS-LYMPHOMA; ADAPTER PROTEIN; GROWTH-FACTOR; PHOSPHOPROTEOME ANALYSIS; CONTAINING MOLECULE; IDENTIFICATION	Tyrosine kinases play a prominent role in human cancer, yet the oncogenic signaling pathways driving cell proliferation and survival have been difficult to identify, in part because of the complexity of the pathways and in part because of low cellular levels of tyrosine phosphorylation. In general, global phosphoproteomic approaches reveal small numbers of peptides containing phosphotyrosine. We have developed a strategy that emphasizes the phosphotyrosine component of the phosphoproteome and identifies large numbers of tyrosine phosphorylation sites. Peptides containing phosphotyrosine are isolated directly from protease-digested cellular protein extracts with a phosphotyrosine-specific antibody and are identified by tandem mass spectrometry. Applying this approach to several cell systems, including cancer cell lines, shows it can be used to identify activated protein kinases and their phosphorylated substrates without prior knowledge of the signaling networks that are activated, a first step in profiling normal and oncogenic signaling networks.	Cell Signaling Technol Inc, Beverly, MA 01915 USA		Comb, MJ (corresponding author), Cell Signaling Technol Inc, 166B Cummings Ctr, Beverly, MA 01915 USA.	mcomb@cellsignal.com		Zha, Xiangming/0000-0001-9490-2731	NCI NIH HHS [1R43CA101106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R43CA101106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bache KG, 2002, EUR J BIOCHEM, V269, P3881, DOI 10.1046/j.1432-1033.2002.03046.x; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; BELSCHES AP, 1997, FRONT BIOSCI, V2, P501; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Brill LM, 2004, ANAL CHEM, V76, P2763, DOI 10.1021/ac035352d; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Carr S, 2004, MOL CELL PROTEOMICS, V3, P531, DOI 10.1074/mcp.T400006-MCP200; Curtis DJ, 2000, EXP HEMATOL, V28, P1250, DOI 10.1016/S0301-472X(00)00537-3; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Ficarro S, 2003, J BIOL CHEM, V278, P11579, DOI 10.1074/jbc.M202325200; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Gerber SA, 2003, P NATL ACAD SCI USA, V100, P6940, DOI 10.1073/pnas.0832254100; Hornbeck PV, 2004, PROTEOMICS, V4, P1551, DOI 10.1002/pmic.200300772; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Khoury JD, 2003, CLIN CANCER RES, V9, P3692; MacCoss MJ, 2002, P NATL ACAD SCI USA, V99, P7900, DOI 10.1073/pnas.122231399; Mann M, 2002, TRENDS BIOTECHNOL, V20, P261, DOI 10.1016/S0167-7799(02)01944-3; Marcus K, 2000, ELECTROPHORESIS, V21, P2622, DOI 10.1002/1522-2683(20000701)21:13<2622::AID-ELPS2622>3.0.CO;2-3; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; Pandey A, 2000, J BIOL CHEM, V275, P38633, DOI 10.1074/jbc.M007849200; Pandey A, 2000, P NATL ACAD SCI USA, V97, P179, DOI 10.1073/pnas.97.1.179; Pandey A, 2002, ONCOGENE, V21, P8029, DOI 10.1038/sj.onc.1205988; Pulford K, 1997, BLOOD, V89, P1394, DOI 10.1182/blood.V89.4.1394; Quadroni M, 2000, EXS, V88, P199; Rappsilber J, 2003, ANAL CHEM, V75, P663, DOI 10.1021/ac026117i; Salomon AR, 2003, P NATL ACAD SCI USA, V100, P443, DOI 10.1073/pnas.2436191100; Sawyers CL, 2002, CURR OPIN GENET DEV, V12, P111, DOI 10.1016/S0959-437X(01)00273-8; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505; Srivastava AK, 1997, MOL CELL BIOCHEM, V176, P47, DOI 10.1023/A:1006818810678; Szebeni A, 2003, J BIOL CHEM, V278, P9107, DOI 10.1074/jbc.M204411200; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; Wang YH, 2001, AM J PHYSIOL-CELL PH, V281, pC1667, DOI 10.1152/ajpcell.2001.281.5.C1667; Zamo A, 2002, ONCOGENE, V21, P1038, DOI 10.1038/sj.onc.1205152; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466	41	913	1248	5	98	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2005	23	1					94	101		10.1038/nbt1046	http://dx.doi.org/10.1038/nbt1046			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	885ZK	15592455				2022-12-25	WOS:000226195700035
J	Lu, W; Arraes, LC; Ferreira, WT; Andrieu, JM				Lu, W; Arraes, LC; Ferreira, WT; Andrieu, JM			Therapeutic dendritic-cell vaccine for chronic HIV-1 infection	NATURE MEDICINE			English	Article							CD8(+) T-CELLS; ACTIVE ANTIRETROVIRAL THERAPY; PBL-SCID MICE; MHC CLASS-II; HEPATITIS-C; NEUTRALIZATION SENSITIVITY; IMMUNE FUNCTION; RESPONSES; INDIVIDUALS; LYMPHOCYTES	We present the results of a preliminary investigation of the efficacy of a therapeutic dendritic cell (DC)-based vaccine for HIV-1. We immunized 18 chronically HIV-1-infected and currently untreated individuals showing stable viral loads for at least 6 months with autologous monocyte-derived DCs loaded with autologous aldrithiol-2-inactivated HIV-1. Plasma viral load levels were decreased by 80% ( median) over the first 112 d following immunization. Prolonged suppression of viral load of more than 90% was seen in 8 individuals for at least 1 year. The suppression of viral load was positively correlated with HIV-1-specifc interleukin-2 or interferon-gamma-expressing CD4(+) T cells and with HIV-1 gag - specific perforin-expressing CD8(+) effector cells, suggesting that a robust virus-specific CD4(+) T-helper type 1 (T(H)1) response is required for inducing and maintaining virus-specific CD8(+) effectors to contain HIV-1 in vivo. The results suggest that inactivated whole virus - pulsed DC vaccines could be a promising strategy for treating people with chronic HIV-1 infection.	Univ Paris 05, Inst Rech Vaccins & Immunotherapie Canc & Sida, F-75006 Paris, France; Univ Paris 05, Ctr Biomed St Peres, Fac Med Rene Descartes, Lab Oncol & Virol Mol, F-75006 Paris, France; Univ Fed Pernambuco, Inst Pesquisa Immunoterap Pernambuco, BR-50670901 Recife, PE, Brazil; Univ Fed Pernambuco, Lab Immunol Keizo Asami, BR-50670901 Recife, PE, Brazil	UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Universidade Federal de Pernambuco; Universidade Federal de Pernambuco	Lu, W (corresponding author), Univ Paris 05, Inst Rech Vaccins & Immunotherapie Canc & Sida, 45 Rue St Peres, F-75006 Paris, France.	louis.wei-lu@irvics.org; jean-marie.andrieu@irvics.org						Boaz MJ, 2002, J IMMUNOL, V169, P6376, DOI 10.4049/jimmunol.169.11.6376; Buseyne F, 2001, NAT MED, V7, P344, DOI 10.1038/85493; Chougnet C, 1999, J IMMUNOL, V163, P1666; Day CL, 2003, J CLIN INVEST, V112, P831, DOI 10.1172/JCI200318509; DIEPOLDER HM, 1995, LANCET, V346, P1006, DOI 10.1016/S0140-6736(95)91691-1; Donaghy H, 2001, BLOOD, V98, P2574, DOI 10.1182/blood.V98.8.2574; Frank I, 2002, J VIROL, V76, P2936, DOI 10.1128/JVI.76.6.2936-2951.2002; Goepfert PA, 2000, J VIROL, V74, P10249, DOI 10.1128/JVI.74.21.10249-10255.2000; Grassi F, 1999, AIDS, V13, P759, DOI 10.1097/00002030-199905070-00004; Gray CM, 1999, J IMMUNOL, V162, P1780; Harari A, 2004, BLOOD, V103, P966, DOI 10.1182/blood-2003-04-1203; Hess C, 2004, LANCET, V363, P863, DOI 10.1016/S0140-6736(04)15735-8; Kalams SA, 1999, J VIROL, V73, P6721, DOI 10.1128/JVI.73.8.6721-6728.1999; KNIGHT SC, 1993, CURR OPIN IMMUNOL, V5, P374, DOI 10.1016/0952-7915(93)90056-X; Kostense S, 2002, BLOOD, V99, P2505, DOI 10.1182/blood.V99.7.2505; Kundu SK, 1998, AIDS RES HUM RETROV, V14, P551, DOI 10.1089/aid.1998.14.551; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; Lapenta C, 2003, J EXP MED, V198, P361, DOI 10.1084/jem.20021924; Lu W, 1999, NAT MED, V5, P1081, DOI 10.1038/12520; Lu W, 2003, NAT MED, V9, P27, DOI 10.1038/nm806; Lu W, 2001, J IMMUNOL, V167, P2929, DOI 10.4049/jimmunol.167.5.2929; Lu W, 2001, J VIROL, V75, P8949, DOI 10.1128/JVI.75.19.8949-8956.2001; Malhotra U, 2000, J INFECT DIS, V181, P121, DOI 10.1086/315202; McIlroy D, 1998, AIDS RES HUM RETROV, V14, P505, DOI 10.1089/aid.1998.14.505; Means RE, 1997, J VIROL, V71, P7895, DOI 10.1128/JVI.71.10.7895-7902.1997; MIOTTI PG, 1989, JAMA-J AM MED ASSOC, V262, P779, DOI 10.1001/jama.262.6.779; Moris A, 2004, BLOOD, V103, P2648, DOI 10.1182/blood-2003-07-2532; O'Sullivan B, 2003, CRIT REV IMMUNOL, V23, P83, DOI 10.1615/CritRevImmunol.v23.i12.50; Oxenius A, 2000, P NATL ACAD SCI USA, V97, P3382, DOI 10.1073/pnas.97.7.3382; Pacanowski J, 2001, BLOOD, V98, P3016, DOI 10.1182/blood.V98.10.3016; Pantaleo G, 2004, NAT MED, V10, P806, DOI 10.1038/nm0804-806; Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Sapp M, 1999, IMMUNOL LETT, V66, P121, DOI 10.1016/S0165-2478(98)00169-2; Schirren CA, 2003, J HEPATOL, V39, P397, DOI 10.1016/S0168-8278(03)00266-6; SULLIVAN N, 1995, J VIROL, V69, P4413, DOI 10.1128/JVI.69.7.4413-4422.1995; Szkaradkiewicz A, 2003, VIRUS RES, V97, P127, DOI 10.1016/j.virusres.2003.08.013; Teleshova N, 2004, J IMMUNOL, V173, P1647, DOI 10.4049/jimmunol.173.3.1647; TERPSTRA FG, 1989, EUR J IMMUNOL, V19, P667, DOI 10.1002/eji.1830190415; Ulsenheimer A, 2003, HEPATOLOGY, V37, P1189, DOI 10.1053/jhep.2003.50194; WRIN T, 1995, J VIROL, V69, P39, DOI 10.1128/JVI.69.1.39-48.1995; Yoshida A, 2003, J VIROL, V77, P8719, DOI 10.1128/JVI.77.16.8719-8728.2003; Younes SA, 2003, J EXP MED, V198, P1909, DOI 10.1084/jem.20031598; Zaunders JJ, 2003, BLOOD	45	351	394	0	32	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2004	10	12					1359	1365		10.1038/nm1147	http://dx.doi.org/10.1038/nm1147			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	876MK	15568033				2022-12-25	WOS:000225500900030
J	Cazalet, C; Rusniok, C; Bruggemann, H; Zidane, N; Magnier, A; Ma, L; Tichit, M; Jarraud, S; Bouchier, C; Vandenesch, F; Kunst, F; Etienne, J; Glaser, P; Buchrieser, C				Cazalet, C; Rusniok, C; Bruggemann, H; Zidane, N; Magnier, A; Ma, L; Tichit, M; Jarraud, S; Bouchier, C; Vandenesch, F; Kunst, F; Etienne, J; Glaser, P; Buchrieser, C			Evidence in the Legionella pneumophila genome for exploitation of host cell functions and high genome plasticity	NATURE GENETICS			English	Article							LEGIONNAIRES-DISEASE; SEQUENCE-ANALYSIS; ESCHERICHIA-COLI; VIRULENCE SYSTEM; SECRETION SYSTEM; PROTEIN; STRAINS; GENE; AGROBACTERIUM; PLASMID	Legionella pneumophila, the causative agent of Legionnaires' disease, replicates as an intracellular parasite of amoebae and persists in the environment as a free-living microbe. Here we have analyzed the complete genome sequences of L. pneumophila Paris (3,503,610 bp, 3,077 genes), an endemic strain that is predominant in France, and Lens (3,345,687 bp, 2,932 genes), an epidemic strain responsible for a major outbreak of disease in France. The L. pneumophila genomes show marked plasticity, with three different plasmids and with about 13% of the sequence differing between the two strains. Only strain Paris contains a type V secretion system, and its Lvh type IV secretion system is encoded by a 36-kb region that is either carried on a multicopy plasmid or integrated into the chromosome. Genetic mobility may enhance the versatility of L. pneumophila. Numerous genes encode eukaryotic-like proteins or motifs that are predicted to modulate host cell functions to the pathogen's advantage. The genome thus reflects the history and lifestyle of L. pneumophila, a human pathogen of macrophages that coevolved with fresh-water amoebae.	Inst Pasteur, Lab Genom Microorganismes Pathogenes, F-75724 Paris 15, France; Inst Pasteur, CNRS, URA 2171, F-75724 Paris 15, France; Fac Med, Ctr Natl Reference Legionella, INSERM, Lab Bacteriol,E 0230,IFR 62, F-69372 Lyon, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm)	Buchrieser, C (corresponding author), Inst Pasteur, Lab Genom Microorganismes Pathogenes, 28 Rue Dr Roux, F-75724 Paris 15, France.	cbuch@pasteur.fr	ETIENNE, Jerome/C-5471-2014; Jarraud, Sophie/AAE-2345-2019; Glaser, Philippe/O-2641-2015; Jarraud, Sophie/M-4551-2014; Vandenesch, Francois/C-7209-2014	ETIENNE, Jerome/0000-0002-3348-3315; Jarraud, Sophie/0000-0001-5750-0215; Glaser, Philippe/0000-0003-4156-2782; Jarraud, Sophie/0000-0001-5750-0215; Vandenesch, Francois/0000-0001-9412-7106; Buchrieser, Carmen/0000-0003-3477-9190; Bruggemann, Holger/0000-0001-7433-0190				Atlas RM, 1999, ENVIRON MICROBIOL, V1, P283, DOI 10.1046/j.1462-2920.1999.00046.x; Aurell H, 2003, J CLIN MICROBIOL, V41, P3320, DOI 10.1128/JCM.41.7.3320-3322.2003; Barz C, 2000, FEBS LETT, V482, P139, DOI 10.1016/S0014-5793(00)02045-7; BENZ I, 1992, MOL MICROBIOL, V6, P1539, DOI 10.1111/j.1365-2958.1992.tb00875.x; BEZANSON G, 1994, CAN J MICROBIOL, V40, P426, DOI 10.1139/m94-070; Biederbick A, 1999, J CELL SCI, V112, P2473; Brassinga AKC, 2003, J BACTERIOL, V185, P4630, DOI 10.1128/JB.185.15.4630-4637.2003; BROWN A, 1982, J CLIN MICROBIOL, V16, P230, DOI 10.1128/JCM.16.2.230-235.1982; Buchrieser C, 1999, INFECT IMMUN, V67, P4851, DOI 10.1128/IAI.67.9.4851-4861.1999; Caturegli P, 2000, INFECT IMMUN, V68, P5277, DOI 10.1128/IAI.68.9.5277-5283.2000; Cirillo SLG, 2000, MICROBIOL-SGM, V146, P1345, DOI 10.1099/00221287-146-6-1345; Cirillo SLG, 2002, MICROBIOL-SGM, V148, P1667, DOI 10.1099/00221287-148-6-1667; Cirillo SLG, 2001, INFECT IMMUN, V69, P508, DOI 10.1128/IAI.69.1.508-517.2001; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Conover GM, 2003, MOL MICROBIOL, V48, P305, DOI 10.1046/j.1365-2958.2003.03400.x; Craig KL, 1999, PROG BIOPHYS MOL BIO, V72, P299, DOI 10.1016/S0079-6107(99)00010-3; Deng W, 2003, J BACTERIOL, V185, P2330, DOI 10.1128/JB.185.7.2330-2337.2003; Desvaux M, 2004, RES MICROBIOL, V155, P53, DOI 10.1016/j.resmic.2003.10.002; Doyle RM, 2002, INT J MED MICROBIOL, V292, P227, DOI 10.1078/1438-4221-00210; Fields BS, 2002, CLIN MICROBIOL REV, V15, P506, DOI 10.1128/CMR.15.3.506-526.2002; Fields BS, 2002, LEGIONELLA, P135; Frangeul L, 2004, BIOINFORMATICS, V20, P790, DOI 10.1093/bioinformatics/btg490; Glaser P, 2001, SCIENCE, V294, P849; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; Hryniewicz-Jankowska A, 2002, FOLIA HISTOCHEM CYTO, V40, P239; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Klemm P, 2004, MOL MICROBIOL, V51, P283, DOI 10.1046/j.1365-2958.2003.03833.x; Li GC, 2001, DEVELOPMENT, V128, P3473; Luneberg E, 2001, MOL MICROBIOL, V39, P1259, DOI 10.1111/j.1365-2958.2001.02314.x; Luo ZQ, 2004, P NATL ACAD SCI USA, V101, P841, DOI 10.1073/pnas.0304916101; MCDADE JE, 1977, NEW ENGL J MED, V297, P1197, DOI 10.1056/NEJM197712012972202; Miyamoto H, 2003, J BACTERIOL, V185, P6712, DOI 10.1128/JB.185.22.6712-6718.2003; Molofsky AB, 2004, MOL MICROBIOL, V53, P29, DOI 10.1111/j.1365-2958.2004.04129.x; Molofsky AB, 2003, MOL MICROBIOL, V50, P445, DOI 10.1046/j.1365-2958.2003.03706.x; Morozova I, 2004, PLASMID, V51, P127, DOI 10.1016/j.plasmid.2003.12.004; Nagai H, 2002, SCIENCE, V295, P679, DOI 10.1126/science.1067025; Rankin S, 2002, INFECT IMMUN, V70, P3637, DOI 10.1128/IAI.70.7.3637-3648.2002; Reiss U, 2004, J BIOL CHEM, V279, P1281, DOI 10.1074/jbc.M309646200; Schrammeijer B, 2001, CURR BIOL, V11, P258, DOI 10.1016/S0960-9822(01)00069-0; Segal G, 1999, MOL MICROBIOL, V34, P799, DOI 10.1046/j.1365-2958.1999.01642.x; Seshadri R, 2003, P NATL ACAD SCI USA, V100, P5455, DOI 10.1073/pnas.0931379100; Smith RS, 2004, INFECT IMMUN, V72, P1677, DOI 10.1128/IAI.72.3.1677-1684.2004; Steinert M, 2002, FEMS MICROBIOL REV, V26, P149, DOI 10.1111/j.1574-6976.2002.tb00607.x; Stone BJ, 1999, J BACTERIOL, V181, P1395, DOI 10.1128/JB.181.5.1395-1402.1999; Vergunst AC, 2000, SCIENCE, V290, P979, DOI 10.1126/science.290.5493.979; Vogel JP, 1998, SCIENCE, V279, P873, DOI 10.1126/science.279.5352.873; Walburger A, 2004, SCIENCE, V304, P1800, DOI 10.1126/science.1099384; Wu M, 2004, PLOS BIOL, V2, P327, DOI 10.1371/journal.pbio.0020069; Yu VL, 2002, J INFECT DIS, V186, P127, DOI 10.1086/341087	50	485	1266	0	47	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2004	36	11					1165	1173		10.1038/ng1447	http://dx.doi.org/10.1038/ng1447			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	867HI	15467720	Bronze			2022-12-25	WOS:000224832800019
J	Cheng, IH; Palop, JJ; Esposito, LA; Bien-Ly, N; Yan, FG; Mucke, L				Cheng, IH; Palop, JJ; Esposito, LA; Bien-Ly, N; Yan, FG; Mucke, L			Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation	NATURE MEDICINE			English	Article							ALZHEIMERS-DISEASE; A-BETA; PRECURSOR PROTEIN; PLAQUE-FORMATION; TRANSGENIC MICE; MOUSE MODEL; DEGRADATION; APP	The Arctic mutation within the amyloid-(A) peptide causes Alzheimer disease. In vitro, Arctic-mutant A forms (proto) fibrils more effectively than wild-type A. We generated transgenic mouse lines expressing Arctic-mutant human amyloid precursor proteins (hAPP). Amyloid plaques formed faster and were more extensive in Arctic mice than in hAPP mice expressing wild-type A, even though Arctic mice had lower Abeta(1-42/1-40) ratios. Thus, the Arctic mutation is highly amyloidogenic in vivo.	Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Mucke, L (corresponding author), Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA.	lmucke@gladstone.ucsf.edu	Palop, Jorge/AAH-9014-2020; Palop, Jorge J./D-8128-2011	Palop, Jorge/0000-0001-6086-1070	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041787] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011385, P01AG022074, T32AG000278, R37AG011385] Funding Source: NIH RePORTER; NIA NIH HHS [AG022074, AG11385, T32 AG00278] Funding Source: Medline; NINDS NIH HHS [NS41787] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Austen BM, 2000, J PEPT SCI, V6, P459, DOI 10.1002/1099-1387(200009)6:9<459::AID-PSC286>3.0.CO;2-B; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; DeMattos RB, 2002, P NATL ACAD SCI USA, V99, P10843, DOI 10.1073/pnas.162228299; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Herzig MC, 2004, NAT NEUROSCI, V7, P954, DOI 10.1038/nn1302; Morelli L, 2003, J BIOL CHEM, V278, P23221, DOI 10.1074/jbc.M300276200; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Murakami K, 2003, J BIOL CHEM, V278, P46179, DOI 10.1074/jbc.M301874200; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; Palop JJ, 2003, P NATL ACAD SCI USA, V100, P9572, DOI 10.1073/pnas.1133381100; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; SISODIA SS, 1993, J NEUROSCI, V13, P3136; Stenh C, 2002, NEUROREPORT, V13, P1857, DOI 10.1097/00001756-200210280-00005; Tsubuki S, 2003, LANCET, V361, P1957, DOI 10.1016/S0140-6736(03)13555-6	15	103	105	1	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2004	10	11					1190	1192		10.1038/nm1123	http://dx.doi.org/10.1038/nm1123			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	866PR	15502844				2022-12-25	WOS:000224785900039
J	Subbramanian, RA; Moriya, C; Martin, KL; Peyerl, FW; Hasegawa, A; Naoi, A; Chhay, H; Autissier, P; Gorgone, DA; Lifton, MA; Kuus-Reichel, K; Schmitz, JE; Letvin, NL; Kuroda, MJ				Subbramanian, RA; Moriya, C; Martin, KL; Peyerl, FW; Hasegawa, A; Naoi, A; Chhay, H; Autissier, P; Gorgone, DA; Lifton, MA; Kuus-Reichel, K; Schmitz, JE; Letvin, NL; Kuroda, MJ			Engineered T-cell receptor tetramers bind MHC-peptide complexes with high affinity	NATURE BIOTECHNOLOGY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; IMMUNODEFICIENCY-VIRUS TYPE-1; INFECTED RHESUS-MONKEYS; CLASS-I GENES; ANTIGEN RECOGNITION; LYMPHOCYTES; EXPRESSION; CD8(+); RESPONSES; EVOLUTION	In this study we extend tetramerization technology to T-cell receptors (TCRs). We identified TCR ab pairs in the absence of accessory molecules, ensuring isolation of high-affinity TCRs that maintain stable binding characteristics after tetramerization. Subtle changes in cognate peptide levels bound to the class I molecule were accurately reflected by parallel changes in the mean fluorescence intensity of cells that bound TCR tetramers, allowing us to accurately assess the binding affinity of a panel of peptides to major histocompatibility complex (MHC) class I. Using a TCR tetramer specific for the Mamu-A*01 allele, we identified animals expressing this restricting class I allele from a large cohort of outbred rhesus macaques. TCR tetramers should facilitate analysis of the MHC-peptide interface and, more generally, the design of immunotherapeutics and vaccines.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Viral Pathogenesis, Boston, MA 02215 USA; Beckman Coulter, Immun Operat, San Diego, CA 92121 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Beckman Coulter Inc.	Kuroda, MJ (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Viral Pathogenesis, 330 Brookline Ave, Boston, MA 02215 USA.	mkuroda@bidmc.harvard.edu	Schmitz, Joern/A-4929-2018	Schmitz, Joern/0000-0001-8803-0922	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028691, R01AI020279, R01AI048400, R01AI048394, N01AI085343] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00168, P51 RR000168] Funding Source: Medline; NIAID NIH HHS [AI85343, AI20279, R01 AI48400, R01 AI048394, AI48394, P30 AI28691, R01 AI048400] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams EJ, 2001, IMMUNOL REV, V183, P41, DOI 10.1034/j.1600-065x.2001.1830104.x; Allen TM, 2001, J VIROL, V75, P738, DOI 10.1128/JVI.75.2.738-749.2001; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; Boyson JE, 1996, J IMMUNOL, V156, P4656; CHANG HC, 1994, P NATL ACAD SCI USA, V91, P11408, DOI 10.1073/pnas.91.24.11408; Cho BK, 2001, P NATL ACAD SCI USA, V98, P1723, DOI 10.1073/pnas.98.4.1723; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; De Rosa SC, 2003, NAT MED, V9, P112, DOI 10.1038/nm0103-112; Egan MA, 1999, J VIROL, V73, P5466, DOI 10.1128/JVI.73.7.5466-5472.1999; Garcia KC, 1996, NATURE, V384, P577, DOI 10.1038/384577a0; Holler PD, 2003, IMMUNITY, V18, P255, DOI 10.1016/S1074-7613(03)00019-0; Holler PD, 2003, NAT IMMUNOL, V4, P55, DOI 10.1038/ni863; Holler PD, 2001, J EXP MED, V194, P1043, DOI 10.1084/jem.194.8.1043; Holmberg K, 2003, J IMMUNOL, V171, P2427, DOI 10.4049/jimmunol.171.5.2427; KAGEYAMA S, 1995, J IMMUNOL, V154, P567; Kuroda MJ, 2000, J VIROL, V74, P8751, DOI 10.1128/JVI.74.18.8751-8756.2000; Kuroda MJ, 1998, J EXP MED, V187, P1373, DOI 10.1084/jem.187.9.1373; Lebowitz MS, 1999, CELL IMMUNOL, V192, P175, DOI 10.1006/cimm.1999.1441; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; Manning TC, 1998, IMMUNITY, V8, P413, DOI 10.1016/S1074-7613(00)80547-6; Meyerson H, 2002, FRONT BIOSCI-LANDMRK, V7, pC33, DOI 10.2741/meyerson; Ogg GS, 1998, CURR OPIN IMMUNOL, V10, P393, DOI 10.1016/S0952-7915(98)80110-6; OHerrin SM, 1997, J EXP MED, V186, P1333, DOI 10.1084/jem.186.8.1333; Plaksin D, 1997, J IMMUNOL, V158, P2218; Shusta EV, 2000, NAT BIOTECHNOL, V18, P754, DOI 10.1038/77325; Starr TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI 10.1146/annurev.immunol.21.120601.141107; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; TSOMIDES TJ, 1994, J EXP MED, V180, P1283, DOI 10.1084/jem.180.4.1283; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0	30	23	26	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2004	22	11					1429	1434		10.1038/nbt1024	http://dx.doi.org/10.1038/nbt1024			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	869CL	15502816				2022-12-25	WOS:000224960600034
J	Danis, E; Brodolin, K; Menut, S; Maiorano, D; Girard-Reydet, C; Mechali, M				Danis, E; Brodolin, K; Menut, S; Maiorano, D; Girard-Reydet, C; Mechali, M			Specification of a DNA replication origin by a transcription complex	NATURE CELL BIOLOGY			English	Article							RECOGNITION COMPLEX; SEQUENCE SPECIFICITY; INITIATION ZONE; START SITES; GENE DOMAIN; HISTONE H1; CHROMATIN; BINDING; YEAST; PROTEIN	In early Xenopus development, transcription is repressed and DNA replication initiates at non-specific sites. Here, we show that a site-specific DNA replication origin can be induced in this context by the assembly of a transcription domain. Deletion of the promoter element abolishes site-specific initiation, and its relocalization to an ectopic site induces a new origin of replication. This process does not require active transcription, and specification of the origin occurs mainly through a decrease in nonspecific initiation at sites distant from the promoter. Finally, chromatin immunoprecipitation experiments suggest that site-specific acetylation of histones favours the selection of the active DNA replication origin. We propose that the specification of active DNA replication origins occurs by secondary epigenetic events and that the programming of chromatin for transcription during development contributes to this selection in higher eukaryotes.	CNRS, Inst Human Genet, F-34396 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Mechali, M (corresponding author), CNRS, Inst Human Genet, 141 Rue Cardonille, F-34396 Montpellier 5, France.	mechali@igh.cnrs.fr	Maiorano, Domenico/N-5755-2017; Brodolin, Konstantin/S-5499-2019; Brodolin, Konstantin/I-2996-2016	Maiorano, Domenico/0000-0003-4229-5903; Brodolin, Konstantin/0000-0003-3124-7586; Brodolin, Konstantin/0000-0003-3124-7586				Abdurashidova G, 2000, SCIENCE, V287, P2023, DOI 10.1126/science.287.5460.2023; Bielinsky AK, 1998, SCIENCE, V279, P95, DOI 10.1126/science.279.5347.95; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DePamphilis ML, 1999, BIOESSAYS, V21, P5, DOI 10.1002/(SICI)1521-1878(199901)21:1<5::AID-BIES2>3.0.CO;2-6; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; Giacca M, 1997, METHODS, V13, P301, DOI 10.1006/meth.1997.0529; GIACCA M, 1994, P NATL ACAD SCI USA, V91, P7119, DOI 10.1073/pnas.91.15.7119; Gilbert DM, 2001, SCIENCE, V294, P96, DOI 10.1126/science.1061724; Gomez M, 1999, EMBO J, V18, P5683, DOI 10.1093/emboj/18.20.5683; GUO ZS, 1992, MOL CELL BIOL, V12, P2514, DOI 10.1128/MCB.12.6.2514; HARLAND RM, 1980, CELL, V21, P761, DOI 10.1016/0092-8674(80)90439-0; Harvey KJ, 2003, MOL CELL BIOL, V23, P6769, DOI 10.1128/MCB.23.19.6769-6779.2003; HYRIEN O, 1995, SCIENCE, V270, P994, DOI 10.1126/science.270.5238.994; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; Kobayashi T, 1998, MOL CELL BIOL, V18, P3266, DOI 10.1128/MCB.18.6.3266; Kong DC, 2003, EMBO J, V22, P3441, DOI 10.1093/emboj/cdg319; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; LI R, 1994, P NATL ACAD SCI USA, V91, P7051, DOI 10.1073/pnas.91.15.7051; Lu ZH, 1998, MOL BIOL CELL, V9, P1163, DOI 10.1091/mbc.9.5.1163; Lunyak VV, 2002, MOL CELL BIOL, V22, P8426, DOI 10.1128/MCB.22.24.8426-8437.2002; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; Maric C, 2003, EMBO REP, V4, P474, DOI 10.1038/sj.embor.embor822; MECHALI M, 1984, CELL, V38, P55, DOI 10.1016/0092-8674(84)90526-9; Mechali M, 2001, NAT REV GENET, V2, P640, DOI 10.1038/35084598; MODAK SP, 1993, ONCOGENE, V8, P645; Pelizon C, 1996, MOL CELL BIOL, V16, P5358; Prasanth SG, 2002, SCIENCE, V297, P1026, DOI 10.1126/science.1072802; PRIOLEAU MN, 1995, EMBO J, V14, P5073, DOI 10.1002/j.1460-2075.1995.tb00189.x; PRIOLEAU MN, 1994, CELL, V77, P439, DOI 10.1016/0092-8674(94)90158-9; Rein T, 1999, J BIOL CHEM, V274, P25792, DOI 10.1074/jbc.274.36.25792; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Royzman I, 1999, GENE DEV, V13, P827, DOI 10.1101/gad.13.7.827; Ryan MP, 2000, MOL CELL BIOL, V20, P5847, DOI 10.1128/MCB.20.16.5847-5857.2000; Sasaki T, 1999, MOL CELL BIOL, V19, P547; Schaarschmidt D, 2004, EMBO J, V23, P191, DOI 10.1038/sj.emboj.7600029; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; van Der Vliet Peter C., 1999, P87; Vashee S, 2003, GENE DEV, V17, P1894, DOI 10.1101/gad.1084203; Wolffe A., 1998, CHROMATIN STRUCTURE; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613; Wu JR, 1996, SCIENCE, V271, P1270, DOI 10.1126/science.271.5253.1270	46	125	126	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2004	6	8					721	730		10.1038/ncb1149	http://dx.doi.org/10.1038/ncb1149			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	842YA	15247921				2022-12-25	WOS:000223039400010
J	Giglia-Mari, G; Coin, F; Ranish, JA; Hoogstraten, D; Theil, A; Wijgers, N; Jaspers, NGJ; Raams, A; Argentini, M; van der Spek, PJ; Botta, E; Stefanini, M; Egly, JM; Aebersold, R; Hoeijmakers, JHJ; Vermeulen, W				Giglia-Mari, G; Coin, F; Ranish, JA; Hoogstraten, D; Theil, A; Wijgers, N; Jaspers, NGJ; Raams, A; Argentini, M; van der Spek, PJ; Botta, E; Stefanini, M; Egly, JM; Aebersold, R; Hoeijmakers, JHJ; Vermeulen, W			A new, tenth subunit of TFIIH is responsible for the DNA repair syndrome trichothiodystrophy group A	NATURE GENETICS			English	Article							XERODERMA-PIGMENTOSUM; TRANSCRIPTION FACTOR; XPD GENE; IN-VIVO; MUTATIONS; DISORDER; SUBUNITS; COMPLEX	DNA repair-deficient trichothiodystrophy (TTD) results from mutations in the XPD and XPB subunits of the DNA repair and transcription factor TFIIH. In a third form of DNA repair deficient TTD, called group A, none of the nine subunits encoding TFIIH carried mutations; instead, the steady-state level of the entire complex was severely reduced(1). A new, tenth TFIIH subunit (TFB5) was recently identified in yeast(2). Here, we describe the identification of the human TFB5 ortholog and its association with human TFIIH. Microinjection of cDNA encoding TFB5 (GTF2H5, also called TTDA) corrected the DNA-repair defect of TTD-A cells, and we identified three functional inactivating mutations in this gene in three unrelated families with TTD-A. The GTF2H5 gene product has a role in regulating the level of TFIIH. The identification of a new evolutionarily conserved subunit of TFIIH implicated in TTD-A provides insight into TFIIH function in transcription, DNA repair and human disease.	Erasmus MC, Med Genet Cluster, Dept Genet, NL-3000 DR Rotterdam, Netherlands; ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, Illkirch Graffenstaden, France; Inst Syst Biol, Seattle, WA USA; Erasmus MC, Dept Bioinformat, NL-3000 DR Rotterdam, Netherlands; CNR, Ist Genet Biochim & Evoluzionist, I-27100 Pavia, Italy	Erasmus University Rotterdam; Erasmus MC; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institute for Systems Biology (ISB); Erasmus University Rotterdam; Erasmus MC; Consiglio Nazionale delle Ricerche (CNR)	Vermeulen, W (corresponding author), Erasmus MC, Med Genet Cluster, Dept Genet, POB 1738, NL-3000 DR Rotterdam, Netherlands.	w.vermeulen@erasmusmc.nl	Coin, Frédéric/F-5925-2013; Botta, Elena/B-9065-2015; Vermeulen, Wim/W-8708-2019; Hoeijmakers, Jan/AAX-6972-2021; Giglia-Mari, Giuseppina/F-5114-2010; BOTTA, ELENA/O-3892-2019	Coin, Frédéric/0000-0002-5620-8519; Vermeulen, Wim/0000-0003-3616-734X; Giglia-Mari, Giuseppina/0000-0003-2001-1965; BOTTA, ELENA/0000-0003-2060-0110				Bootsma D., 1998, GENETIC BASIS HUMAN, P245; Botta E, 1998, AM J HUM GENET, V63, P1036, DOI 10.1086/302063; Broughton BC, 2001, HUM MOL GENET, V10, P2539, DOI 10.1093/hmg/10.22.2539; Cavusoglu N, 2003, PROTEOMICS, V3, P217, DOI 10.1002/pmic.200390030; Cenkci B, 2003, J BIOL CHEM, V278, P22574, DOI 10.1074/jbc.M303249200; Chang WH, 2000, CELL, V102, P609, DOI 10.1016/S0092-8674(00)00083-0; de Boer J, 2002, SCIENCE, V296, P1276, DOI 10.1126/science.1070174; Egly JM, 2001, FEBS LETT, V498, P124, DOI 10.1016/S0014-5793(01)02458-9; GERARD M, 1991, J BIOL CHEM, V266, P20940; Graham JM, 2001, AM J HUM GENET, V69, P291, DOI 10.1086/321295; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hoogstraten D, 2002, MOL CELL, V10, P1163, DOI 10.1016/S1097-2765(02)00709-8; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Lehmann AR, 2001, GENE DEV, V15, P15, DOI 10.1101/gad.859501; Mone MJ, 2001, EMBO REP, V2, P1013, DOI 10.1093/embo-reports/kve224; Petrini JHJ, 2000, NAT GENET, V26, P257, DOI 10.1038/81529; Rabilloud T, 1999, METH MOL B, V112, P297; Rademakers S, 2003, MOL CELL BIOL, V23, P5755, DOI 10.1128/MCB.23.16.5755-5767.2003; Ranish JA, 2004, NAT GENET, V36, P707, DOI 10.1038/ng1385; Riedl T, 2003, EMBO J, V22, P5293, DOI 10.1093/emboj/cdg489; Schultz P, 2000, CELL, V102, P599, DOI 10.1016/S0092-8674(00)00082-9; Sijbers AM, 1996, NUCLEIC ACIDS RES, V24, P3370, DOI 10.1093/nar/24.17.3370; STEFANINI M, 1993, AM J HUM GENET, V53, P817; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; Vermeulen W, 2000, NAT GENET, V26, P307, DOI 10.1038/81603; VERMEULEN W, 1994, AM J HUM GENET, V54, P191; VERMEULEN W, 1994, COLD SPRING HARB SYM, V59, P317, DOI 10.1101/SQB.1994.059.01.036; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Weeda G, 1997, AM J HUM GENET, V60, P320	30	251	255	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2004	36	7					714	719		10.1038/ng1387	http://dx.doi.org/10.1038/ng1387			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	833QT	15220921	Bronze			2022-12-25	WOS:000222354100021
J	Hong, YK; Foreman, K; Shin, JW; Hirakawa, S; Curry, CL; Sage, DR; Libermann, T; Dezube, BJ; Fingeroth, JD; Detmar, M				Hong, YK; Foreman, K; Shin, JW; Hirakawa, S; Curry, CL; Sage, DR; Libermann, T; Dezube, BJ; Fingeroth, JD; Detmar, M			Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus	NATURE GENETICS			English	Article							GROWTH-FACTOR RECEPTOR-3; GENE-EXPRESSION; CELLS; IDENTIFICATION; ORIGIN; PROX1; KSHV	Kaposi sarcoma is considered a neoplasm of lymphatic endothelium infected with Kaposi sarcoma-associated herpesvirus. It is characterized by the expression of lymphatic lineage-specific genes by Kaposi sarcoma tumor cells. Here we show that infection of differentiated blood vascular endothelial cells with Kaposi sarcoma-associated herpesvirus leads to their lymphatic reprogramming; induction of similar to70% of the main lymphatic lineage-specific genes, including PROX1, a master regulator of lymphatic development; and downregulation of blood vascular genes.	Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Loyola Univ, Med Ctr, Maywood, IL 60153 USA; Beth Israel Deaconess Med Ctr, Dept Med, BIDMC Genom Ctr, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Massachusetts General Hospital; Harvard University; Loyola University Chicago; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Detmar, M (corresponding author), Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Bldg 149,13th St, Charlestown, MA 02129 USA.	michael.detmar@cbrc2.mgh.harvard.edu		Libermann, Towia/0000-0002-4006-8179; Curry, Christine L/0000-0003-4783-9623				Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; BECKSTEAD JH, 1985, AM J PATHOL, V119, P294; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Hirakawa S, 2003, AM J PATHOL, V162, P575, DOI 10.1016/S0002-9440(10)63851-5; Hong YK, 2002, DEV DYNAM, V225, P351, DOI 10.1002/dvdy.10163; Jussila L, 1998, CANCER RES, V58, P1599; Moses AV, 2002, J VIROL, V76, P8383, DOI 10.1128/JVI.76.16.8383-8399.2002; Petrova TV, 2002, EMBO J, V21, P4593, DOI 10.1093/emboj/cdf470; Poole LJ, 2002, J VIROL, V76, P3395, DOI 10.1128/JVI.76.7.3395-3420.2002; SCHALLING M, 1995, NAT MED, V1, P707, DOI 10.1038/nm0795-707; Skobe M, 1999, J INVEST DERMATOL, V113, P1047, DOI 10.1046/j.1523-1747.1999.00798.x; Tang J, 2003, J VIROL, V77, P5975, DOI 10.1128/JVI.77.10.5975-5984.2003; Wang HW, 2004, NAT GENET, V36, P687, DOI 10.1038/ng1384; Weninger W, 1999, LAB INVEST, V79, P243; Wigle JT, 2002, EMBO J, V21, P1505, DOI 10.1093/emboj/21.7.1505	15	279	287	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2004	36	7					683	685		10.1038/ng1383	http://dx.doi.org/10.1038/ng1383			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	833QT	15220917	Bronze			2022-12-25	WOS:000222354100016
J	Castor, A; Nilsson, L; Astrand-Grundstrom, I; Buitenhuis, M; Ramirez, C; Anderson, K; Strombeck, B; Garwicz, S; Bekassy, AN; Schmiegelow, K; Lausen, B; Hokland, P; Lehmann, S; Juliusson, G; Johansson, B; Jacobsen, SEW				Castor, A; Nilsson, L; Astrand-Grundstrom, I; Buitenhuis, M; Ramirez, C; Anderson, K; Strombeck, B; Garwicz, S; Bekassy, AN; Schmiegelow, K; Lausen, B; Hokland, P; Lehmann, S; Juliusson, G; Johansson, B; Jacobsen, SEW			Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia	NATURE MEDICINE			English	Article							ACUTE MYELOID-LEUKEMIA; IN-SITU HYBRIDIZATION; PHILADELPHIA-CHROMOSOME; MYELODYSPLASTIC SYNDROMES; PROGENITOR/STEM CELLS; MYELOGENOUS LEUKEMIA; CHILDREN; IDENTIFICATION; EXPRESSION; CANCER	The cellular targets of primary mutations and malignant transformation remain elusive in most cancers. Here, we show that clinically and genetically different subtypes of acute lymphoblastic leukemia ( ALL) originate and transform at distinct stages of hematopoietic development. Primary ETV6-RUNX1 ( also known as TEL-AML1) fusions and subsequent leukemic transformations were targeted to committed B-cell progenitors. Major breakpoint BCR-ABL1 fusions ( encoding P210 BCR-ABL1) originated in hematopoietic stem cells (HSCs), whereas minor BCR-ABL1 fusions ( encoding P190 BCR-ABL1) had a B-cell progenitor origin, suggesting that P190 and P210 BCR-ABL1 ALLs represent largely distinct tumor biological and clinical entities. The transformed leukemia-initiating stem cells in both P190 and P210 BCR-ABL1 ALLs had, as in ETV6-RUNX1 ALLs, a committed B progenitor phenotype. In all patients, normal and leukemic repopulating stem cells could successfully be separated prospectively, and notably, the size of the normal HSC compartment in ETV6-RUNX1 and P190 BCR-ABL1 ALLs was found to be unaffected by the expansive leukemic stem cell population.	Lund Strateg Res Ctr Stem Cell Biol & Cell Therap, Hematopoiet Stem Cell Lab, S-22184 Lund, Sweden; Univ Lund Hosp, Dept Pediat, Hematol Oncol Sect, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Hematol, S-22185 Lund, Sweden; Univ Med Ctr, Dept Pulm Dis, Utrecht, Netherlands; Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden; Univ Hosp, Pediat Clin 2, Juliane Marie Ctr, Rigshosp, Copenhagen, Denmark; Arhus Amtssygehus, Dept Hematol, Aarhus, Denmark; Karolinska Inst, Huddinge Hosp, Dept Hematol, S-14186 Stockholm, Sweden	Lund University; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Utrecht University; Utrecht University Medical Center; Lund University; Skane University Hospital; Rigshospitalet; University of Copenhagen; Aarhus University; Karolinska Institutet	Jacobsen, SEW (corresponding author), Lund Strateg Res Ctr Stem Cell Biol & Cell Therap, Hematopoiet Stem Cell Lab, S-22184 Lund, Sweden.	sten.jacobsen@med.lu.se	Jacobsen, Sten Eirik W/D-3974-2018; , Anders/V-6166-2019	Jacobsen, Sten Eirik W/0000-0002-1362-3659; Hokland, Peter/0000-0002-1177-9756				Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Baumgarth N, 2000, J IMMUNOL METHODS, V243, P77, DOI 10.1016/S0022-1759(00)00229-5; Bhatia M, 1998, NAT MED, V4, P1038, DOI 10.1038/2023; Bhatia M, 1997, P NATL ACAD SCI USA, V94, P5320, DOI 10.1073/pnas.94.10.5320; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; CHAUDHARY PM, 1991, CELL, V66, P85, DOI 10.1016/0092-8674(91)90141-K; Clarkson B, 2003, LEUKEMIA, V17, P1211, DOI 10.1038/sj.leu.2402912; Cobaleda C, 2000, BLOOD, V95, P1007, DOI 10.1182/blood.V95.3.1007.003k35_1007_1013; Costello RT, 2000, CANCER RES, V60, P4403; Cox CV, 2004, BLOOD, V104, P2919, DOI 10.1182/blood-2004-03-0901; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; Darzynkiewicz Z, 2001, METHOD CELL BIOL, V63, P527; Dorrell C, 2000, BLOOD, V95, P102; Dybedal I, 2001, BLOOD, V98, P1782, DOI 10.1182/blood.V98.6.1782; Faderl Stefan, 2002, Rev Clin Exp Hematol, V6, P142, DOI 10.1046/j.1468-0734.2002.00066.x; FIALKOW PJ, 1978, J CLIN INVEST, V62, P815, DOI 10.1172/JCI109193; George AA, 2001, BLOOD, V97, P3925, DOI 10.1182/blood.V97.12.3925; Haferlach T, 1997, BRIT J HAEMATOL, V99, P452, DOI 10.1046/j.1365-2141.1997.4203237.x; Hogge DE, 1996, BLOOD, V88, P3765, DOI 10.1182/blood.V88.10.3765.bloodjournal88103765; Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080; Hotfilder M, 2002, BLOOD, V100, P640, DOI 10.1182/blood.V100.2.640; JACKSON GH, 1992, BRIT J HAEMATOL, V81, P77, DOI 10.1111/j.1365-2141.1992.tb08175.x; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Jordan CT, 2000, LEUKEMIA, V14, P1777, DOI 10.1038/sj.leu.2401903; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; Lock RB, 2002, BLOOD, V99, P4100, DOI 10.1182/blood.V99.11.4100; Maloney KW, 1999, LEUKEMIA, V13, P1708, DOI 10.1038/sj.leu.2401548; Mori H, 2002, P NATL ACAD SCI USA, V99, P8242, DOI 10.1073/pnas.112218799; Nilsson L, 2000, BLOOD, V96, P2012, DOI 10.1182/blood.V96.6.2012.h8002012a_2012_2021; Nilsson L, 2002, BLOOD, V100, P259, DOI 10.1182/blood-2001-12-0188; Pajor L, 2000, LEUKEMIA, V14, P1122, DOI 10.1038/sj.leu.2401794; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Petzer AL, 1996, BLOOD, V88, P2162, DOI 10.1182/blood.V88.6.2162.bloodjournal8862162; Pui Ching-Hon, 2002, Rev Clin Exp Hematol, V6, P161, DOI 10.1046/j.1468-0734.2002.00067.x; Quijano CA, 1997, LEUKEMIA, V11, P1508, DOI 10.1038/sj.leu.2400754; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; Schenk TM, 1998, LEUKEMIA, V12, P666, DOI 10.1038/sj.leu.2400986; Tajima F, 2001, BLOOD, V97, P2618, DOI 10.1182/blood.V97.9.2618; Takahashi N, 1998, BLOOD, V92, P4758, DOI 10.1182/blood.V92.12.4758; TOUGH DF, 1995, IMMUNOL RES, V14, P1, DOI 10.1007/BF02918494; Wiemels JL, 1999, BLOOD, V94, P1057, DOI 10.1182/blood.V94.3.1057.415k10_1057_1062; Wiemels JL, 1999, LANCET, V354, P1499, DOI 10.1016/S0140-6736(99)09403-9; Zanjani ED, 2003, EXP HEMATOL, V31, P406, DOI 10.1016/S0301-472X(03)00051-1; Zelent A, 2004, ONCOGENE, V23, P4275, DOI 10.1038/sj.onc.1207672; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	49	245	261	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2005	11	6					630	637		10.1038/nm1253	http://dx.doi.org/10.1038/nm1253			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	932YD	15908956				2022-12-25	WOS:000229589800029
J	Marillonnet, S; Thoeringer, C; Kandzia, R; Klimyuk, V; Gleba, Y				Marillonnet, S; Thoeringer, C; Kandzia, R; Klimyuk, V; Gleba, Y			Systemic Agrobacterium tumefaciens-mediated transfection of viral replicons for efficient transient expression in plants	NATURE BIOTECHNOLOGY			English	Article							PRE-MESSENGER-RNA; ESCHERICHIA-COLI; INTRON-INSERTION; VIRE2 PROTEIN; VIRUS; CDNA; CONSTRUCTION; SUPPRESSION; VECTORS; DNA	Plant biotechnology relies on two approaches for delivery and expression of heterologous genes in plants: stable genetic transformation and transient expression using viral vectors. Although much faster, the transient route is limited by low infectivity of viral vectors carrying average-sized or large genes. We have developed constructs for the efficient delivery of RNA viral vectors as DNA precursors and show here that Agrobacterium-mediated delivery of these constructs results in gene amplification in all mature leaves of a plant simultaneously (systemic transfection). This process, called 'magnifection', can be performed on a large scale and with different plant species. This technology combines advantages of three biological systems (the transfection efficiency of A. tumefaciens, the high expression yield obtained with viral vectors, and the post-translational capabilities of a plant), does not require genetic modification of plants and is faster than other existing methods.	Biozentrum Halle, Icon Genet, D-06120 Halle An Der Saale, Germany		Gleba, Y (corresponding author), Biozentrum Halle, Icon Genet, Weinbergweg 22, D-06120 Halle An Der Saale, Germany.	gleba@icongenetics.de		Gleba, Yuri/0000-0003-4675-7474				Almazan F, 2000, P NATL ACAD SCI USA, V97, P5516, DOI 10.1073/pnas.97.10.5516; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; CITOVSKY V, 1992, SCIENCE, V256, P1802, DOI 10.1126/science.1615325; Collens JI, 2004, BIOTECHNOL PROGR, V20, P890, DOI 10.1021/bp034306w; GALLAGHER SR, 1992, GUS PROTOCOLS; Gleba Y, 2005, VACCINE, V23, P2042, DOI 10.1016/j.vaccine.2005.01.006; Gleba Y, 2004, CURR OPIN PLANT BIOL, V7, P182, DOI 10.1016/j.pbi.2004.01.003; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; Johansen IE, 1996, P NATL ACAD SCI USA, V93, P12400, DOI 10.1073/pnas.93.22.12400; Kapila J, 1997, PLANT SCI, V122, P101, DOI 10.1016/S0168-9452(96)04541-4; Lai MMC, 2000, P NATL ACAD SCI USA, V97, P5025, DOI 10.1073/pnas.97.10.5025; Lee LY, 1999, J BACTERIOL, V181, P186, DOI 10.1128/JB.181.1.186-196.1999; Lopez-Moya JJ, 2000, VIRUS RES, V68, P99, DOI 10.1016/S0168-1702(00)00161-1; Mallory AC, 2002, NAT BIOTECHNOL, V20, P622, DOI 10.1038/nbt0602-622; Marillonnet S, 2004, P NATL ACAD SCI USA, V101, P6852, DOI 10.1073/pnas.0400149101; Pogue GP, 2002, ANNU REV PHYTOPATHOL, V40, P45, DOI 10.1146/annurev.phyto.40.021102.150133; Porta C, 2002, BIOTECHNOL GENET ENG, V19, P245, DOI 10.1080/02648725.2002.10648031; RACANIELLO VR, 1981, SCIENCE, V214, P916, DOI 10.1126/science.6272391; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; REGENSBURGTUINK AJG, 1993, NATURE, V363, P69, DOI 10.1038/363069a0; TURPEN TH, 1993, J VIROL METHODS, V42, P227, DOI 10.1016/0166-0934(93)90035-P; Voinnet O, 2003, PLANT J, V33, P949, DOI 10.1046/j.1365-313X.2003.01676.x; Yang SJ, 1998, ARCH VIROL, V143, P2443, DOI 10.1007/s007050050474	23	364	432	2	85	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2005	23	6					718	723		10.1038/nbt1094	http://dx.doi.org/10.1038/nbt1094			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	933LA	15883585				2022-12-25	WOS:000229628700032
J	Song, EW; Zhu, PC; Lee, SK; Chowdhury, D; Kussman, S; Dykxhoorn, DM; Feng, Y; Palliser, D; Weiner, DB; Shankar, P; Marasco, WA; Lieberman, J				Song, EW; Zhu, PC; Lee, SK; Chowdhury, D; Kussman, S; Dykxhoorn, DM; Feng, Y; Palliser, D; Weiner, DB; Shankar, P; Marasco, WA; Lieberman, J			Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors	NATURE BIOTECHNOLOGY			English	Article							HUMAN-BREAST-CANCER; HEPATITIS-B-VIRUS; FAS PROTECTS MICE; GENE-EXPRESSION; ADULT MICE; INHIBITION; SIRNAS; ACTIVATION; ONCOGENE; SURVIVAL	Delivery of small interfering RNAs (siRNAs) into cells is a key obstacle to their therapeutic application. We designed a protamine-antibody fusion protein to deliver siRNA to HIV-infected or envelope-transfected cells. The fusion protein (F105-P) was designed with the protamine coding sequence linked to the C terminus of the heavy chain Fab fragment of an HIV-1 envelope antibody. siRNAs bound to F105-P induced silencing only in cells expressing HIV-1 envelope. Additionally, siRNAs targeted against the HIV-1 capsid gene gag, inhibited HIV replication in hard-to-transfect, HIV-infected primary T cells. Intratumoral or intravenous injection of F105-P-complexed siRNAs into mice targeted HIV envelope-expressing B16 melanoma cells, but not normal tissue or envelope-negative B16 cells; injection of F105-P with siRNAs targeting c-myc, MDM2 and VEGF inhibited envelope-expressing subcutaneous B16 tumors. Furthermore, an ErbB2 single-chain antibody fused with protamine delivered siRNAs specifically into ErbB2-expressing cancer cells. This study demonstrates the potential for systemic, cell-type specific, antibody-mediated siRNA delivery.	Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; University of Pennsylvania; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Lieberman, J (corresponding author), Harvard Univ, Sch Med, CBR Inst Biomed Res, 200 Longwood Ave, Boston, MA 02115 USA.	lieberman@cbr.med.harvard.edu	Lieberman, Judy/A-2717-2015; Dykxhoorn, Derek M/D-1357-2015; Weiner, David B/H-8579-2014		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI056900] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 056900] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bitko V, 2005, NAT MED, V11, P50, DOI 10.1038/nm1164; Brody JR, 2004, AM J PATHOL, V164, P273, DOI 10.1016/S0002-9440(10)63117-3; CHEN SY, 1995, GENE THER, V2, P116; CHEN SY, 1994, P NATL ACAD SCI USA, V91, P5932, DOI 10.1073/pnas.91.13.5932; Chen TH, 1996, MOL BIOL CELL, V7, P2045, DOI 10.1091/mbc.7.12.2045; Contreras JL, 2004, SURGERY, V136, P390, DOI 10.1016/j.surg.2004.05.015; Dykxhoorn DM, 2005, ANNU REV MED, V56, P401, DOI 10.1146/annurev.med.56.082103.104606; Ge Q, 2004, P NATL ACAD SCI USA, V101, P8676, DOI 10.1073/pnas.0402486101; Hamar P, 2004, P NATL ACAD SCI USA, V101, P14883, DOI 10.1073/pnas.0406421101; HASSANI Z, 2004, J GENE MED; Hung L, 2004, FEBS LETT, V560, P210, DOI 10.1016/S0014-5793(04)00113-9; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545; Layzer JM, 2004, RNA, V10, P766, DOI 10.1261/rna.5239604; Li XG, 2001, CANCER GENE THER, V8, P555, DOI 10.1038/sj.cgt.7700337; Massaro D, 2004, AM J PHYSIOL-LUNG C, V287, pL1066, DOI 10.1152/ajplung.00067.2004; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; McCaffrey AP, 2003, NAT BIOTECHNOL, V21, P639, DOI 10.1038/nbt824; Minakuchi Y, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh093; Muthumani K, 2003, VIROLOGY, V314, P134, DOI 10.1016/S0042-6822(03)00459-8; Reich S, 2003, MOL VIS, V9, P210; Schiffelers RM, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh140; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Song EW, 2003, J VIROL, V77, P7174, DOI 10.1128/JVI.77.13.7174-7181.2003; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Sorensen DR, 2003, J MOL BIOL, V327, P761, DOI 10.1016/S0022-2836(03)00181-5; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Zhang XC, 2004, J BIOL CHEM, V279, P10677, DOI 10.1074/jbc.M312941200; Zhang Y, 2004, CLIN CANCER RES, V10, P3667, DOI 10.1158/1078-0432.CCR-03-0740	31	810	1008	8	182	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2005	23	6					709	717		10.1038/nbt1101	http://dx.doi.org/10.1038/nbt1101			9	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	933LA	15908939				2022-12-25	WOS:000229628700031
J	Wolfrum, C; Poy, MN; Stoffel, M				Wolfrum, C; Poy, MN; Stoffel, M			Apolipoprotein M is required for pre beta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis	NATURE MEDICINE			English	Article							HIGH-DENSITY-LIPOPROTEIN; HEPATOCYTE NUCLEAR FACTOR-1-ALPHA; GENE-EXPRESSION; A-I; PLASMA; ACYLTRANSFERASE; PROTEINS; LESIONS; ARTERY; MICE	High-density lipoproteins (HDLs) are considered antiatherogenic because they mediate reverse cholesterol transport from the periphery to the liver for excretion and degradation. Here we show that mice deficient in apolipoprotein M ( apoM), a component of the HDL particle, accumulated cholesterol in large HDL particles (HDL1) while the conversion of HDL to pre beta-HDL was impaired. Accordingly, apoM-deficient mice lacked pre beta-HDL, a subclass of lipid-poor apolipoproteins that serves as a key acceptor of peripheral cellular cholesterol. This deficiency led to a markedly reduced cholesterol efflux from macrophages to apoM-deficient HDL compared to normal HDL in vitro. Overexpression of apoM in Ldlr(-/-) mice protected against atherosclerosis when the mice were challenged with a cholesterol-enriched diet, showing that apoM is important for the formation of pre-HDL and cholesterol efflux to HDL, and thereby inhibits formation of atherosclerotic lesions.	Rockefeller Univ, Lab Metab Dis, New York, NY 10021 USA	Rockefeller University	Stoffel, M (corresponding author), Rockefeller Univ, Lab Metab Dis, 1230 York Ave, New York, NY 10021 USA.	stoffel@rockefeller.edu	Poy, Matthew/F-6914-2017	Poy, Matthew/0000-0002-4904-2426; Stoffel, Markus/0000-0003-1304-5817; Wolfrum, Christian/0000-0002-3862-6805	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000102] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00102] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ashavaid T F, 2003, J Assoc Physicians India, V51, P345; Assmann G, 2003, ANNU REV MED, V54, P321, DOI 10.1146/annurev.med.54.101601.152409; BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63, DOI 10.1016/0006-291X(87)90451-7; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; Fielding CJ, 2001, BBA-MOL CELL BIOL L, V1533, P175, DOI 10.1016/S1388-1981(01)00162-7; FRANCONE OL, 1995, J CLIN INVEST, V96, P1440, DOI 10.1172/JCI118180; Isomaa B, 1998, DIABETOLOGIA, V41, P467, DOI 10.1007/s001250050931; Law S W, 1986, Adv Exp Med Biol, V201, P151; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; OConnor PM, 1997, ANAL BIOCHEM, V251, P234, DOI 10.1006/abio.1997.2258; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; Phillips MC, 1998, ATHEROSCLEROSIS, V137, pS13, DOI 10.1016/S0021-9150(97)00312-2; PITTMAN RC, 1983, BIOCHEM J, V212, P791, DOI 10.1042/bj2120791; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; PUCHOIS P, 1987, ATHEROSCLEROSIS, V68, P35, DOI 10.1016/0021-9150(87)90091-8; Richter S, 2003, DIABETES, V52, P2989, DOI 10.2337/diabetes.52.12.2989; Rye KA, 2002, BIOCHEMISTRY-US, V41, P12538, DOI 10.1021/bi025998k; Santamarina-Fojo S, 2000, CURR OPIN LIPIDOL, V11, P267, DOI 10.1097/00041433-200006000-00007; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Shih DQ, 2001, NAT GENET, V27, P375, DOI 10.1038/86871; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; Silver DL, 2000, ANN NY ACAD SCI, V902, P103; SPARKS DL, 1989, J LIPID RES, V30, P1491; Stein O, 1999, ATHEROSCLEROSIS, V144, P285, DOI 10.1016/S0021-9150(99)00065-9; Teupser D, 2003, ARTERIOSCL THROM VAS, V23, P1907, DOI 10.1161/01.ATV.0000090126.34881.B1; Xu N, 1999, J BIOL CHEM, V274, P31286, DOI 10.1074/jbc.274.44.31286; Zhang GF, 1999, HUM GENE THER, V10, P1735, DOI 10.1089/10430349950017734	27	250	301	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2005	11	4					418	422		10.1038/nm1211	http://dx.doi.org/10.1038/nm1211			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15793583				2022-12-25	WOS:000228180500033
J	Faccio, R; Teitelbaum, SL; Fujikawa, K; Chappel, J; Zallone, A; Tybulewicz, VL; Ross, FP; Swat, W				Faccio, R; Teitelbaum, SL; Fujikawa, K; Chappel, J; Zallone, A; Tybulewicz, VL; Ross, FP; Swat, W			Vav3 regulates osteoclast function and bone mass	NATURE MEDICINE			English	Article							GTP-BINDING PROTEIN; TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; FAMILY PROTEINS; RHO-GTPASES; CYTOSKELETAL ORGANIZATION; INTEGRIN ENGAGEMENT; BETA-3 INTEGRIN; MICE LACKING; KINASE SYK	Osteoporosis, a leading cause of morbidity in the elderly, is characterized by progressive loss of bone mass resulting from excess osteoclastic bone resorption relative to osteoblastic bone formation. Here we identify Vav3, a Rho family guanine nucleotide exchange factor, as essential for stimulated osteoclast activation and bone density in vivo. Vav3-deficient osteoclasts show defective actin cytoskeleton organization, polarization, spreading and resorptive activity resulting from impaired signaling downstream of the M-CSF receptor and alpha(v)beta(3) integrin. Vav3-deficient mice have increased bone mass and are protected from bone loss induced by systemic bone resorption stimuli such as parathyroid hormone or RANKL. Moreover, we provide genetic and biochemical evidence for the role of Syk tyrosine kinase as a crucial upstream regulator of Vav3 in osteoclasts. Thus, Vav3 is a potential new target for antiosteoporosis therapy.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Orthoped Surg, St Louis, MO 63110 USA; Univ Bari, Sch Med, I-70100 Bari, Italy; Natl Inst Med Res, Div Immune Cell Biol, London NW7 1AA, England	Washington University (WUSTL); Washington University (WUSTL); Universita degli Studi di Bari Aldo Moro; MRC National Institute for Medical Research	Swat, W (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, 660 S Euclid Ave, St Louis, MO 63110 USA.	rossf@wustl.edu; swat@pathbox.wustl.edu		Teitelbaum, Steven/0000-0002-4054-6679; Tybulewicz, Victor/0000-0003-2439-0798	NIAMS NIH HHS [AR46523, AR32788, AR46852, AR48812, AR48853] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR046523, R01AR048812, R01AR032788, R01AR046523, R01AR048853, R01AR046852] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bustelo XR, 2001, ONCOGENE, V20, P6372, DOI 10.1038/sj.onc.1204780; Calle Y, 2004, BLOOD, V103, P3552, DOI 10.1182/blood-2003-04-1259; Cella M, 2004, J EXP MED, V200, P817, DOI 10.1084/jem.20031847; Cichowski K, 1996, J BIOL CHEM, V271, P7544, DOI 10.1074/jbc.271.13.7544; del Pozo MA, 2003, J IMMUNOL, V170, P41, DOI 10.4049/jimmunol.170.1.41; Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02-07-0389; Doody GM, 2001, NAT IMMUNOL, V2, P542, DOI 10.1038/88748; Duran A, 2004, DEV CELL, V6, P303, DOI 10.1016/S1534-5807(03)00403-9; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Faccio R, 2003, J CELL BIOL, V162, P499, DOI 10.1083/jcb.200212082; Faccio R, 2003, J CLIN INVEST, V111, P749, DOI 10.1172/JCI200316924; Faccio R, 2003, J CELL BIOCHEM, V90, P871, DOI 10.1002/jcb.10694; Faccio R, 2002, J CELL SCI, V115, P2919; Feng X, 2001, J CLIN INVEST, V107, P1137, DOI 10.1172/JCI12040; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Fujikawa K, 2003, J EXP MED, V198, P1595, DOI 10.1084/jem.20030874; Fukuda A, 2003, J BONE MINER RES, V18, pS79; Gakidis MAM, 2004, J CELL BIOL, V166, P273, DOI 10.1083/jcb.200404166; Gotoh A, 1997, CELL GROWTH DIFFER, V8, P721; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Kaifu T, 2003, J CLIN INVEST, V111, P323, DOI 10.1172/JCI200316923; LAKKAKORPI PT, 1991, J BONE MINER RES, V6, P817; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Manetz TS, 2001, MOL CELL BIOL, V21, P3763, DOI 10.1128/MCB.21.11.3763-3774.2001; Marignani PA, 2001, J CELL BIOL, V154, P177, DOI 10.1083/jcb.200103134; McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Miyamoto T, 2001, BLOOD, V98, P2544, DOI 10.1182/blood.V98.8.2544; Mocsai A, 2002, IMMUNITY, V16, P547, DOI 10.1016/S1074-7613(02)00303-5; Moores SL, 2000, MOL CELL BIOL, V20, P6364, DOI 10.1128/MCB.20.17.6364-6373.2000; Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ridley AJ, 2001, J CELL SCI, V114, P2713; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Riteau B, 2003, J EXP MED, V198, P469, DOI 10.1084/jem.20021995; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; Tybulewicz VLJ, 2003, IMMUNOL REV, V192, P42, DOI 10.1034/j.1600-065X.2003.00032.x; Vaananen HK, 2000, J CELL SCI, V113, P377; Yron I, 1999, CELL ADHES COMMUN, V7, P1, DOI 10.3109/15419069909034388; ZAMBONINZALLONE A, 1989, EXP CELL RES, V182, P645, DOI 10.1016/0014-4827(89)90266-8; Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212-9224.2000; ZHANG D, 1995, J CELL SCI, V108, P2285; Zhao WG, 1999, J CLIN INVEST, V103, P517, DOI 10.1172/JCI5481; Zheng LM, 1996, P NATL ACAD SCI USA, V93, P8431, DOI 10.1073/pnas.93.16.8431	50	216	220	1	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					284	290		10.1038/nm1194	http://dx.doi.org/10.1038/nm1194			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15711558				2022-12-25	WOS:000227541300023
J	Greter, M; Heppner, FL; Lemos, MP; Odermatt, BM; Goebels, N; Laufer, T; Noelle, RJ; Becher, B				Greter, M; Heppner, FL; Lemos, MP; Odermatt, BM; Goebels, N; Laufer, T; Noelle, RJ; Becher, B			Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; ANTIGEN-PRESENTING CELLS; MARROW-DERIVED ELEMENTS; CLASS-II EXPRESSION; MICROGLIAL CELLS; RESIDENT CELLS; T-CELLS; EX-VIVO; BRAIN	Immunization with myelin antigens leads to the development of experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. The disease can also be induced by the transfer of encephalitogenic CD4(+) T helper (TH) lymphocytes into naive mice. These T cells need to re-encounter their cognate antigen in the context of major histocompatibility complex (MHC) class II-bearing antigen-presenting cells (APCs) in order to recognize their target. The cell type and location of the APC mediating T-cell entry into the central nervous system (CNS) remain unknown. Here, we show that APCs of the lymphoreticular system and of the CNS parenchyma are dispensable for the immune invasion of the CNS. We also describe that a discrete population of vessel-associated dendritic cells (DCs) is present in human brain tissue. In mice, CD11c(+) DCs alone are sufficient to present antigen in vivo to primed myelin-reactive T cells in order to mediate CNS inflammation and clinical disease development.	Univ Zurich Hosp, Dept Neurol, Neuroimmunol Unit, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Pathol, Inst Neuropathol, CH-8091 Zurich, Switzerland; Univ Penn, Div Rheumatol, Philadelphia, PA 19104 USA; Univ Zurich Hosp, Dept Pathol, Inst Clin Pathol, CH-8091 Zurich, Switzerland; Dartmouth Coll Sch Med, Dept Microbiol & Immunol, Lebanon, NH 03755 USA	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Pennsylvania; University of Zurich; University Zurich Hospital; Dartmouth College	Becher, B (corresponding author), Univ Zurich Hosp, Dept Neurol, Neuroimmunol Unit, Frauenklin Str 10, CH-8091 Zurich, Switzerland.	burkhard.becher@usz.ch	Calabrese, Massimiliano/I-6195-2012; Becher, Burkhard/ABE-4225-2020; Heppner, Frank/ABH-8393-2020	Becher, Burkhard/0000-0002-1541-7867; Heppner, Frank/0000-0001-9816-8917; Greter, Melanie/0000-0002-7220-5369	NIAID NIH HHS [AI49580] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049580] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aloisi F, 1998, J IMMUNOL, V160, P4671; Asheuer M, 2004, P NATL ACAD SCI USA, V101, P3557, DOI 10.1073/pnas.0306431101; Becher B, 2000, GLIA, V29, P293; Becher B, 2003, J CLIN INVEST, V112, P1186, DOI 10.1172/JCI200319079; Becher B, 1996, GLIA, V18, P1; Becher B, 2001, J EXP MED, V193, P967, DOI 10.1084/jem.193.8.967; Carson MJ, 1998, GLIA, V22, P72, DOI 10.1002/(SICI)1098-1136(199801)22:1<72::AID-GLIA7>3.0.CO;2-A; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; FIERZ W, 1985, J IMMUNOL, V134, P3785; Flugel A, 2001, IMMUNITY, V14, P547, DOI 10.1016/s1074-7613(01)00143-1; Ford AL, 1996, J EXP MED, V184, P1737, DOI 10.1084/jem.184.5.1737; FORD AL, 1995, J IMMUNOL, V154, P4309; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; HICKEY WF, 1992, J NEUROPATH EXP NEUR, V51, P246, DOI 10.1097/00005072-199205000-00002; Hickey WF, 1991, BRAIN PATHOL, V1, P97, DOI 10.1111/j.1750-3639.1991.tb00646.x; Juedes AE, 2001, J IMMUNOL, V166, P5168, DOI 10.4049/jimmunol.166.8.5168; Kivisakk P, 2004, ANN NEUROL, V55, P627, DOI 10.1002/ana.20049; Krummel MF, 2002, CURR OPIN IMMUNOL, V14, P66, DOI 10.1016/S0952-7915(01)00299-0; LASSMANN H, 1993, GLIA, V7, P19, DOI 10.1002/glia.440070106; LEE SC, 1989, J NEUROIMMUNOL, V25, P261, DOI 10.1016/0165-5728(89)90145-8; Lemos MP, 2004, J EXP MED, V199, P725, DOI 10.1084/jem.20030795; Lemos MP, 2003, J IMMUNOL, V171, P5077, DOI 10.4049/jimmunol.171.10.5077; Maraskovsky E, 1996, J EXP MED, V184, P1953, DOI 10.1084/jem.184.5.1953; Matyszak MK, 1999, EUR J IMMUNOL, V29, P3063, DOI 10.1002/(SICI)1521-4141(199910)29:10<3063::AID-IMMU3063>3.0.CO;2-G; Matyszak MK, 1996, NEUROSCIENCE, V74, P599, DOI 10.1016/0306-4522(96)00160-1; McMahon EJ, 2005, NAT MED, V11, P335, DOI 10.1038/nm1202; McMenamin PG, 1999, J COMP NEUROL, V405, P553, DOI 10.1002/(SICI)1096-9861(19990322)405:4<553::AID-CNE8>3.0.CO;2-6; MOSSNER R, 1990, ADV EXP MED BIOL, V276, P647; O'Keeffe M, 2002, BLOOD, V99, P2122, DOI 10.1182/blood.V99.6.2122; PRINEAS JW, 1979, SCIENCE, V203, P1123, DOI 10.1126/science.424741; RAINE CS, 1984, LAB INVEST, V51, P534; Serafini B, 2000, AM J PATHOL, V157, P1991, DOI 10.1016/S0002-9440(10)64838-9; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; Slavin AJ, 2001, J CLIN INVEST, V108, P1133, DOI 10.1172/JCI200113360; Steinman L, 1996, CELL, V85, P299, DOI 10.1016/S0092-8674(00)81107-1; Stuve O, 2002, J IMMUNOL, V169, P6720, DOI 10.4049/jimmunol.169.12.6720; ULVESTAD E, 1994, J LEUKOCYTE BIOL, V56, P732, DOI 10.1002/jlb.56.6.732; WONG GHW, 1984, NATURE, V310, P688, DOI 10.1038/310688a0	40	653	674	0	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					328	334		10.1038/nm1197	http://dx.doi.org/10.1038/nm1197			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15735653				2022-12-25	WOS:000227541300029
J	Jacobs, T				Jacobs, T			Bugs or drugs, tortoises or hares?	NATURE BIOTECHNOLOGY			English	Editorial Material												tom@completegrowth.com							0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2005	23	3					293	293		10.1038/nbt0305-293	http://dx.doi.org/10.1038/nbt0305-293			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	906IW	15765079	Bronze			2022-12-25	WOS:000227635400012
J	Litvak, V; Dahan, N; Ramachandran, S; Sabanay, H; Lev, S				Litvak, V; Dahan, N; Ramachandran, S; Sabanay, H; Lev, S			Maintenance of the diacylglycerol level in the Golgi apparatus by the Nir2 protein is critical for Golgi secretory function	NATURE CELL BIOLOGY			English	Article							PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; RETINAL-DEGENERATION-B; CDP-CHOLINE PATHWAY; LIPID-METABOLISM; PHOSPHATIDYLCHOLINE SYNTHESIS; SPHINGOLIPID BIOSYNTHESIS; MEMBRANE TRAFFICKING; PLASMA-MEMBRANE; KINASE-D; TRANSPORT	The level of diacylglycerol (DAG) in the Golgi apparatus is crucial for protein transport to the plasma membrane. Studies in budding yeast indicate that Sec14p, a phosphatidylinositol ( PI)-transfer protein, is involved in regulating DAG homeostasis in the Golgi complex. Here, we show that Nir2, a peripheral Golgi protein containing a PI-transfer domain, is essential for maintaining the structural and functional integrity of the Golgi apparatus in mammalian cells. Depletion of Nir2 by RNAi leads to substantial inhibition of protein transport from the trans-Golgi network to the plasma membrane, and causes a reduction in the DAG level in the Golgi apparatus. Remarkably, inactivation of the cytosine 5'-diphosphate (CDP)-choline pathway for phosphatidylcholine biosynthesis restores both effects. These results indicate that Nir2 is involved in maintaining a critical DAG pool in the Golgi apparatus by regulating its consumption via the CDP-choline pathway, demonstrating the interface between secretion from the Golgi and lipid homeostasis.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Electron Microscopy Unit, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Lev, S (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	sima.lev@weizmann.ac.il	Lev, Sima/AAP-7880-2020; Ramachandran, Sreekumar/H-4746-2019	Lev, Sima/0000-0002-2108-3330; Ramachandran, Sreekumar/0000-0002-6020-1344				Allen-Baume V, 2002, FEBS LETT, V531, P74, DOI 10.1016/S0014-5793(02)03412-9; BALCH WE, 1986, J BIOL CHEM, V261, P4690; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; Bankaitis VA, 2002, SCIENCE, V295, P290, DOI 10.1126/science.1068446; Baron CL, 2002, SCIENCE, V295, P325, DOI 10.1126/science.1066759; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; Buccione R, 1996, J BIOL CHEM, V271, P3523; CHERNOMORDIK L, 1995, J MEMBRANE BIOL, V146, P1; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; Cockcroft S, 1998, BIOESSAYS, V20, P423, DOI 10.1002/(SICI)1521-1878(199805)20:5<423::AID-BIES9>3.3.CO;2-U; Corda D, 2002, CELL MOL LIFE SCI, V59, P1819, DOI 10.1007/PL00012508; Donaldson JG, 2000, CELL, V101, P693, DOI 10.1016/S0092-8674(00)80881-8; Farquhar MG, 1998, TRENDS CELL BIOL, V8, P2, DOI 10.1016/S0962-8924(97)01187-2; Godi A, 2004, NAT CELL BIOL, V6, P393, DOI 10.1038/ncb1119; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; Henneberry AL, 2002, MOL BIOL CELL, V13, P3148, DOI 10.1091/mbc.01-11-0540; Henneberry AL, 2001, MOL BIOL CELL, V12, P511, DOI 10.1091/mbc.12.3.511; Huijbregts RPH, 2000, TRAFFIC, V1, P195, DOI 10.1034/j.1600-0854.2000.010301.x; Ichikawa S, 1998, TRENDS CELL BIOL, V8, P198, DOI 10.1016/S0962-8924(98)01249-5; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; Kearns BG, 1998, TRENDS CELL BIOL, V8, P276, DOI 10.1016/S0962-8924(98)01281-1; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; Lev S, 2004, EXP CELL RES, V297, P1, DOI 10.1016/j.yexcr.2004.02.033; Lev S, 1999, MOL CELL BIOL, V19, P2278; Levine TP, 2002, CURR BIOL, V12, P695, DOI 10.1016/S0960-9822(02)00779-0; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; LIPSKY NG, 1983, P NATL ACAD SCI-BIOL, V80, P2608, DOI 10.1073/pnas.80.9.2608; Litvak V, 2004, MOL CELL, V14, P319, DOI 10.1016/S1097-2765(04)00214-X; Litvak V, 2002, CURR BIOL, V12, P1513, DOI 10.1016/S0960-9822(02)01107-7; Litvak V, 2002, MOL CELL BIOL, V22, P5064, DOI 10.1128/MCB.22.14.5064-5075.2002; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; McMaster CR, 2001, BIOCHEM CELL BIOL, V79, P681, DOI 10.1139/bcb-79-6-681; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; MOLLENHAUER HH, 1991, J ELECTRON MICR TECH, V17, P2, DOI 10.1002/jemt.1060170103; PAGANO RE, 1988, TRENDS BIOCHEM SCI, V13, P202, DOI 10.1016/0968-0004(88)90082-5; RANDAZZO PA, 1995, METHOD ENZYMOL, V250, P394; Riebeling C, 2003, J BIOL CHEM, V278, P43452, DOI 10.1074/jbc.M307104200; Roth MG, 1999, TRENDS CELL BIOL, V9, P174, DOI 10.1016/S0962-8924(99)01535-4; Rothman JE, 1996, PROTEIN SCI, V5, P185; Shemesh T, 2003, BIOPHYS J, V85, P3813, DOI 10.1016/S0006-3495(03)74796-1; Simon JP, 1998, P NATL ACAD SCI USA, V95, P11181, DOI 10.1073/pnas.95.19.11181; SKINNER HB, 1995, P NATL ACAD SCI USA, V92, P112, DOI 10.1073/pnas.92.1.112; van Tiel CM, 2002, FEBS LETT, V531, P69, DOI 10.1016/S0014-5793(02)03403-8; VIHTELIC TS, 1993, J CELL BIOL, V122, P1013, DOI 10.1083/jcb.122.5.1013; WANG E, 1991, J BIOL CHEM, V266, P14486; Wang YJ, 2003, CELL, V114, P299, DOI 10.1016/S0092-8674(03)00603-2; Warren G, 1998, CURR OPIN CELL BIOL, V10, P493, DOI 10.1016/S0955-0674(98)80064-1; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; Wirtz KWA, 1997, BIOCHEM J, V324, P353, DOI 10.1042/bj3240353	50	136	142	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2005	7	3					225	U14		10.1038/ncb1221	http://dx.doi.org/10.1038/ncb1221			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	902CU	15723057				2022-12-25	WOS:000227329800010
J	Rosenblatt, J				Rosenblatt, J			Spindle assembly: asters part their separate ways	NATURE CELL BIOLOGY			English	Editorial Material							KINESIN-LIKE PROTEIN; MITOTIC SPINDLE; CYTOPLASMIC DYNEIN; CORTICAL FLOW; CELL-DIVISION; MITOSIS; CENTROSOME; MOTOR; MICROTUBULES; DROSOPHILA	Cells have developed diverse ways to separate two microtubule asters to form a mitotic spindle. Here, I focus on two mechanisms used to position asters around chromosomes during mitosis: first, aster migration around the nuclear envelope and, second, aster attachment to a contractile cortex at the plasma membrane after the nuclear envelope has broken down. Although certain cell types use one mechanism predominantly, most rely on both to ensure proper spindle assembly.	UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England	University of London; University College London	Rosenblatt, J (corresponding author), UCL, MRC, Mol Cell Biol Lab, Mortimer St, London WC1E 6BT, England.	jody.rosenblatt@ucl.ac.uk	Rosenblatt, Jody/AAD-4260-2019	Rosenblatt, Jody/0000-0001-9460-5868				BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/science.3277283; Busson S, 1998, CURR BIOL, V8, P541, DOI 10.1016/S0960-9822(98)70208-8; Canman JC, 1997, J CELL SCI, V110, P1907; Dasso M, 2001, CELL, V104, P321, DOI 10.1016/S0092-8674(01)00218-5; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; Giet R, 2000, EXP CELL RES, V258, P145, DOI 10.1006/excr.2000.4903; Goshima G, 2003, J CELL BIOL, V162, P1003, DOI 10.1083/jcb.200303022; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; Heald R, 1999, CURR OPIN STRUC BIOL, V9, P268, DOI 10.1016/S0959-440X(99)80037-2; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; Holaska JM, 2004, PLOS BIOL, V2, P1354, DOI 10.1371/journal.pbio.0020231; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; Kalab P, 2002, SCIENCE, V295, P2452, DOI 10.1126/science.1068798; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Karsenti E, 2001, SCIENCE, V294, P543, DOI 10.1126/science.1063488; Khodjakov A, 2003, J CELL BIOL, V160, P671, DOI 10.1083/jcb.200208143; Lampson MA, 2004, NAT CELL BIOL, V6, P232, DOI 10.1038/ncb1102; Lee KK, 2000, MOL BIOL CELL, V11, P3089, DOI 10.1091/mbc.11.9.3089; Malone CJ, 2003, CELL, V115, P825, DOI 10.1016/S0092-8674(03)00985-1; Moore WJ, 2002, CURR BIOL, V12, P1442, DOI 10.1016/S0960-9822(02)01076-X; Nedelec F, 2003, CURR OPIN CELL BIOL, V15, P118, DOI 10.1016/S0955-0674(02)00014-5; Phalle BD, 1998, J CELL BIOL, V141, P1383, DOI 10.1083/jcb.141.6.1383; RATTNER JB, 1976, CHROMOSOMA, V54, P387, DOI 10.1007/BF00292817; Rieder CL, 2003, SCIENCE, V300, P91, DOI 10.1126/science.1082177; Robinson JT, 1999, J CELL BIOL, V146, P597, DOI 10.1083/jcb.146.3.597; Rosenblatt J, 2004, CELL, V117, P361, DOI 10.1016/S0092-8674(04)00341-1; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; SCHROEDER TE, 1981, EXP CELL RES, V134, P231, DOI 10.1016/0014-4827(81)90480-8; Sharp DJ, 2000, NATURE, V407, P41, DOI 10.1038/35024000; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; Tulu US, 2003, CURR BIOL, V13, P1894, DOI 10.1016/j.cub.2003.10.002; Ueda M, 1999, MOL BIOL CELL, V10, P151, DOI 10.1091/mbc.10.1.151; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; Wadsworth P, 2004, TRENDS CELL BIOL, V14, P413, DOI 10.1016/j.tcb.2004.07.004; WOLPERT L, 1960, INT REV CYTOL, V10, P163	35	37	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2005	7	3					219	222		10.1038/ncb0305-219	http://dx.doi.org/10.1038/ncb0305-219			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	902CU	15738974				2022-12-25	WOS:000227329800009
J	Arkan, MC; Hevener, AL; Greten, FR; Maeda, S; Li, ZW; Long, JM; Wynshaw-Boris, A; Poli, G; Olefsky, J; Karin, M				Arkan, MC; Hevener, AL; Greten, FR; Maeda, S; Li, ZW; Long, JM; Wynshaw-Boris, A; Poli, G; Olefsky, J; Karin, M			IKK-beta links inflammation to obesity-induced insulin resistance	NATURE MEDICINE			English	Article							KAPPA-B ACTIVATION; TRANSCRIPTION FACTOR; PREVENTION; DISEASE; INTERLEUKIN-6; DISRUPTION; MECHANISMS; SYSTEM; FAILS; PLAYS	Inflammation may underlie the metabolic disorders of insulin resistance and type 2 diabetes. IkappaB kinase beta (IKK-beta, encoded by Ikbkb) is a central coordinator of inflammatory responses through activation of NF-kappaB. To understand the role of IKK-beta in insulin resistance, we used mice lacking this enzyme in hepatocytes (Ikbkb(Deltahep)) or myeloid cells (Ikbkb(Deltamye)). Ikbkb(Deltahep) mice retain liver insulin responsiveness, but develop insulin resistance in muscle and fat in response to high fat diet, obesity or aging. In contrast, Ikbkb(Deltamye) mice retain global insulin sensitivity and are protected from insulin resistance. Thus, IKK-beta acts locally in liver and systemically in myeloid cells, where NF-kappaB activation induces inflammatory mediators that cause insulin resistance. These findings demonstrate the importance of liver cell IKK-beta in hepatic insulin resistance and the central role of myeloid cells in development of systemic insulin resistance. We suggest that inhibition of IKK-beta, especially in myeloid cells, may be used to treat insulin resistance.	Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Turin, Dept Clin & Biol Sci, S Luigi Hosp, I-10043 Turin, Italy	University of California System; University of California San Diego; University of California System; University of California San Diego; H Lee Moffitt Cancer Center & Research Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Turin	Karin, M (corresponding author), Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jolefsky@ucsd.edu; karinoffice@ucsd.edu	Greten, Florian R/AAF-5196-2020	Greten, Florian R/0000-0002-3928-6080	NIDDK NIH HHS [DK60484, DK33651] Funding Source: Medline; NIEHS NIH HHS [ES06376] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK060484, R37DK033651, R01DK033651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006376] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARENA FP, 1978, ARCH INTERN MED, V138, P1153, DOI 10.1001/archinte.138.7.1153; Arkan MC, 2001, FREE RADICAL BIO MED, V31, P374, DOI 10.1016/S0891-5849(01)00601-3; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bruun JM, 2002, MOL CELL ENDOCRINOL, V190, P91, DOI 10.1016/S0303-7207(02)00007-2; Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027; Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; Festa A, 2002, DIABETES, V51, P1131, DOI 10.2337/diabetes.51.4.1131; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grimble RF, 2002, CURR OPIN CLIN NUTR, V5, P551, DOI 10.1097/00075197-200209000-00015; Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956; Hotamisligil GS, 2003, INT J OBESITY, V27, pS53, DOI 10.1038/sj.ijo.0802502; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kim JK, 2001, J CLIN INVEST, V108, P437, DOI 10.1172/JCI11559; Klover PJ, 2003, DIABETES, V52, P2784, DOI 10.2337/diabetes.52.11.2784; Koistinen HA, 2002, ANN MED, V34, P410, DOI 10.1080/078538902321012351; Leffert H L, 1979, Methods Enzymol, V58, P536; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lovejoy Jennifer C, 2002, Curr Diab Rep, V2, P435, DOI 10.1007/s11892-002-0098-y; Maeda S, 2003, IMMUNITY, V19, P725, DOI 10.1016/S1074-7613(03)00301-7; Miyazaki Y, 2003, INT J OBESITY, V27, P88, DOI 10.1038/sj.ijo.0802187; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; Patti ME, 2004, CURR OPIN CLIN NUTR, V7, P383, DOI 10.1097/01.mco.0000134359.23288.72; Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314; Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822; Pickup JC, 1998, DIABETOLOGIA, V41, P1241, DOI 10.1007/s001250051058; Rohl M, 2004, J CLIN INVEST, V113, P474, DOI 10.1172/JCI200418712; Samuel VT, 2004, J BIOL CHEM, V279, P32345, DOI 10.1074/jbc.M313478200; Sugita H, 2002, AM J PHYSIOL-ENDOC M, V282, pE386, DOI 10.1152/ajpendo.00087.2001; VIRKAMAKI A, 1994, ENDOCRINOLOGY, V134, P2072, DOI 10.1210/en.134.5.2072; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	42	1375	1465	3	91	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					191	198		10.1038/nm1185	http://dx.doi.org/10.1038/nm1185			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15685170				2022-12-25	WOS:000226797300027
J	Bosch, X				Bosch, X			Spain launches cancer research project	NATURE MEDICINE			English	News Item								Spain's Catalan government has approved a cancer research project which will focus on translational research on metastasis. The collaborative effort on cancer research will take place between the Barcelona-based Institut de Recerca Biomedica and New York's Memorial Sloan-Kettering Cancer Center.											0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2005	11	2					106	106		10.1038/nm0205-106b	http://dx.doi.org/10.1038/nm0205-106b			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15692577	Bronze			2022-12-25	WOS:000226797300004
J	Jonathan, C; Pertsemlidis, A; Kotowski, IK; Graham, R; Christine, KG; Garcia, CK; Hobbs, HH				Jonathan, C; Pertsemlidis, A; Kotowski, IK; Graham, R; Christine, KG; Garcia, CK; Hobbs, HH			Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9	NATURE GENETICS			English	Article							PLANT STEROLS; PLASMA-LEVELS; RECEPTOR; MICE	The low-density lipoprotein receptor (LDLR) prevents hypercholesterolemia and atherosclerosis by removing low-density lipoprotein (LDL) from circulation. Mutations in the genes encoding either LDLR1 or its ligand (APOB)(2) cause severe hypercholesterolemia. Missense mutations in PCSK9, encoding a serine protease in the secretory pathway(3), also cause hypercholesterolemia(4). These mutations are probably gain-of-function mutations, as overexpression of PCSK9 in the liver of mice produces hypercholesterolemia(5-7) by reducing LDLR number. To test whether loss-of-function mutations in PCSK9 have the opposite effect, we sequenced the coding region of PCSK9 in 128 subjects (50% African American) with low plasma levels of LDL and found two nonsense mutations (Y142X and C679X). These mutations were common in African Americans (combined frequency, 2%) but rare in European Americans (<0.1%) and were associated with a 40% reduction in plasma levels of LDL cholesterol. These data indicate that common sequence variations have large effects on plasma cholesterol levels in selected populations.	Univ Texas, SW Med Ctr, Donald W Reynolds Cardiovasc Clin Res Ctr, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hobbs, HH (corresponding author), Univ Texas, SW Med Ctr, Donald W Reynolds Cardiovasc Clin Res Ctr, 5323 Harry Hines, Dallas, TX 75390 USA.	helen.hobbs@utsouthwestern.edu	Pertsemlidis, Alexander/Q-7899-2017	Pertsemlidis, Alexander/0000-0003-1624-9372				Abifadel M, 2003, NAT GENET, V34, P154, DOI 10.1038/ng1161; Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766; Benjannet S, 2004, J BIOL CHEM, V279, P48865, DOI 10.1074/jbc.M409699200; Cohen JC, 2004, SCIENCE, V305, P869, DOI 10.1126/science.1099870; Goldstein JL, 2001, METABOLIC MOL BASES, V8th, P2863; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; INNERARITY TL, 1990, J LIPID RES, V31, P1337; Leren TP, 2004, CLIN GENET, V65, P419, DOI 10.1111/j.0009-9163.2004.0238.x; MARCOVINA SM, 1995, CLIN CHEM, V41, P246; Maxwell KN, 2004, P NATL ACAD SCI USA, V101, P7100, DOI 10.1073/pnas.0402133101; MIETTINEN TA, 1990, AM J EPIDEMIOL, V131, P20, DOI 10.1093/oxfordjournals.aje.a115479; Mostaza JM, 1997, AM J CARDIOL, V79, P1298, DOI 10.1016/S0002-9149(97)00109-4; OTVOS JD, 1997, HDB LIPOPROTEIN TEST, P497; Park SW, 2004, J BIOL CHEM, V279, P50630, DOI 10.1074/jbc.M410077200; Qin ZHS, 2002, AM J HUM GENET, V71, P1242, DOI 10.1086/344207; Seidah NG, 2003, P NATL ACAD SCI USA, V100, P928, DOI 10.1073/pnas.0335507100; Shioji K, 2004, J HUM GENET, V49, P109, DOI 10.1007/s10038-003-0114-3; Timms KM, 2004, HUM GENET, V114, P349, DOI 10.1007/s00439-003-1071-9; Victor RG, 2004, AM J CARDIOL, V93, P1473, DOI 10.1016/j.amjcard.2004.02.058; Wilund KR, 2004, ARTERIOSCL THROM VAS, V24, P2326, DOI 10.1161/01.ATV.0000149140.00499.92	21	497	539	1	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2005	37	2					161	165		10.1038/ng1509	http://dx.doi.org/10.1038/ng1509			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	893AB	15654334				2022-12-25	WOS:000226690100022
J	Descargues, P; Deraison, C; Bonnart, C; Kreft, M; Kishibe, M; Ishida-Yamamoto, A; Elias, P; Barrandon, Y; Zambruno, G; Sonnenberg, A; Hovnanian, A				Descargues, P; Deraison, C; Bonnart, C; Kreft, M; Kishibe, M; Ishida-Yamamoto, A; Elias, P; Barrandon, Y; Zambruno, G; Sonnenberg, A; Hovnanian, A			Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity	NATURE GENETICS			English	Article							SERINE PROTEINASE-INHIBITOR; CORNEUM CHYMOTRYPTIC ENZYME; STRATUM-CORNEUM; BARRIER FUNCTION; PERMEABILITY BARRIER; SUBTILISIN-A; LEKTI; EXPRESSION; SKIN; DESQUAMATION	Mutations in SPINK5, encoding the serine protease inhibitor LEKTI, cause Netherton syndrome, a severe autosomal recessive genodermatosis. Spink5(-/-) mice faithfully replicate key features of Netherton syndrome, including altered desquamation, impaired keratinization, hair malformation and a skin barrier defect. LEKTI deficiency causes abnormal desmosome cleavage in the upper granular layer through degradation of desmoglein 1 due to stratum corneum tryptic enzyme and stratum corneum chymotryptic enzyme-like hyperactivity. This leads to defective stratum corneum adhesion and resultant loss of skin barrier function. Profilaggrin processing is increased and implicates LEKTI in the cornification process. This work identifies LEKTI as a key regulator of epidermal protease activity and degradation of desmoglein 1 as the primary pathogenic event in Netherton syndrome.	Univ Toulouse 3, INSERM, U563, F-31059 Toulouse 3, France; Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands; Asahikawa Med Coll, Dept Dermatol, Asahikawa, Hokkaido 0788510, Japan; Univ Calif San Francisco, Vet Affairs Med Ctr, Dept Dermatol, San Francisco, CA 94121 USA; Swiss Fed Inst Technol, Sch Life Sci, Lab Stem Cell Dynam, CH-1015 Lausanne, Switzerland; IRCCS, Ist Dermopat Immacolata, Lab Mol & Cell Biol, I-00167 Rome, Italy; Hop Purpan, Dept Med Genet, F-31059 Toulouse 3, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Netherlands Cancer Institute; Asahikawa Medical College; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; IRCCS Istituto Dermopatico dell'Immacolata (IDI); CHU de Toulouse	Hovnanian, A (corresponding author), Univ Toulouse 3, INSERM, U563, Pl Dr Baylac, F-31059 Toulouse 3, France.	alain.hovnanian@toulouse.inserm.fr	Hovnanian, Alain/I-4711-2017; Zambruno, Giavanna/K-2933-2018; deraison, celine/P-6255-2016; BONNART, Chrystelle/A-1309-2011	Hovnanian, Alain/0000-0003-3412-7512; deraison, celine/0000-0002-9013-4592; Zambruno, Giovanna/0000-0002-1295-056X				Amagai M, 2000, NAT MED, V6, P1275, DOI 10.1038/81385; BARRANDON Y, 1988, J INVEST DERMATOL, V91, P315, DOI 10.1111/1523-1747.ep12475646; Bernard BA, 2003, J AM ACAD DERMATOL, V48, pS120, DOI 10.1067/mjd.2003.279; Bitoun E, 2003, HUM MOL GENET, V12, P2417, DOI 10.1093/hmg/ddg247; Bitoun E, 2002, J INVEST DERMATOL, V118, P352, DOI 10.1046/j.1523-1747.2002.01603.x; Brattsand M, 1999, J BIOL CHEM, V274, P30033, DOI 10.1074/jbc.274.42.30033; Caubet C, 2004, J INVEST DERMATOL, V122, P1235, DOI 10.1111/j.0022-202X.2004.22512.x; Chavanas S, 2000, NAT GENET, V25, P141, DOI 10.1038/75977; COMEL M, 1949, Dermatologica, V98, P133; deWolf K, 1996, DERMATOLOGY, V192, P400, DOI 10.1159/000246431; Ding X, 1999, J INVEST DERMATOL, V112, P739, DOI 10.1046/j.1523-1747.1999.00585.x; Ekholm IE, 2000, J INVEST DERMATOL, V114, P56, DOI 10.1046/j.1523-1747.2000.00820.x; ELIAS PM, 1991, ADV LIPID RES, V24, P1; ELIAS PM, 2004, J INVEST DERMATOL, V122, pR6; Fartasch M, 1999, ARCH DERMATOL, V135, P823, DOI 10.1001/archderm.135.7.823; Franzke CW, 1996, J BIOL CHEM, V271, P21886, DOI 10.1074/jbc.271.36.21886; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; HANSSON L, 1994, J BIOL CHEM, V269, P19420; Hardman MJ, 1998, DEVELOPMENT, V125, P1541; Hausser I, 1996, PEDIATR DERMATOL, V13, P183, DOI 10.1111/j.1442-200X.1996.tb02615.x; ISHIDAYAMAMOTO A, IN PRESS J INVEST DE; ITO M, 1984, J INVEST DERMATOL, V83, P1, DOI 10.1111/1523-1747.ep12261618; Jayakumar A, 2004, PROTEIN EXPRES PURIF, V35, P93, DOI 10.1016/j.pep.2003.12.004; JUDGE MR, 1994, BRIT J DERMATOL, V131, P615, DOI 10.1111/j.1365-2133.1994.tb04971.x; Kljuic A, 2003, EXP DERMATOL, V12, P20, DOI 10.1034/j.1600-0625.2003.120103.x; Komatsu N, 2002, J INVEST DERMATOL, V118, P436, DOI 10.1046/j.0022-202x.2001.01663.x; Kreutzmann P, 2004, J CHROMATOGR B, V803, P75, DOI 10.1016/j.jchromb.2003.07.016; Kuramoto N, 2002, J CLIN INVEST, V109, P243, DOI 10.1172/JCI200213563; Levy-Nissenbaum E, 2003, NAT GENET, V34, P151, DOI 10.1038/ng1163; List K, 2003, J CELL BIOL, V163, P901, DOI 10.1083/jcb.200304161; Magert HJ, 1999, J BIOL CHEM, V274, P21499, DOI 10.1074/jbc.274.31.21499; Magert HJ, 2002, INT J BIOCHEM CELL B, V34, P573, DOI 10.1016/S1357-2725(01)00179-0; Magert HJ, 2002, EUR J MED RES, V7, P49; Mitsudo K, 2003, BIOCHEMISTRY-US, V42, P3874, DOI 10.1021/bi027029v; NETHERTON EW, 1958, ARCH DERMATOL, V78, P483, DOI 10.1001/archderm.1958.01560100059009; Pulkkinen L, 2003, EXP DERMATOL, V12, P11, DOI 10.1034/j.1600-0625.2003.120102.x; Raghunath M, 2004, J INVEST DERMATOL, V123, P474, DOI 10.1111/j.0022-202X.2004.23220.x; RESING KA, 1984, J CELL BIOL, V99, P1372, DOI 10.1083/jcb.99.4.1372; Scheimberg I, 1996, PEDIATR PATHOL LAB M, V16, P359, DOI 10.1080/15513819609168677; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Simon M, 1997, J BIOL CHEM, V272, P31770, DOI 10.1074/jbc.272.50.31770; SMITH DL, 1995, BRIT J DERMATOL, V133, P153; Sprecher E, 2001, J INVEST DERMATOL, V117, P179, DOI 10.1046/j.1523-1747.2001.01389.x; STEVANOVIC DV, 1969, BRIT J DERMATOL, V81, P851, DOI 10.1111/j.1365-2133.1969.tb15956.x; SUZUKI Y, 1994, ARCH DERMATOL RES, V286, P249, DOI 10.1007/BF00387596; TRAUPE H, 1989, ICHTYOSIS GUIDE CLIN; Van Gysel D, 2001, DERMATOLOGY, V202, P99, DOI 10.1159/000051607; vanderNeut R, 1996, NAT GENET, V13, P366, DOI 10.1038/ng0796-366; Vasioukhin V, 2001, NAT CELL BIOL, V3, P1076, DOI 10.1038/ncb1201-1076; Yang T, 2004, GENE DEV, V18, P2354, DOI 10.1101/gad.1232104	50	284	293	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2005	37	1					56	65		10.1038/ng1493	http://dx.doi.org/10.1038/ng1493			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	883FX	15619623				2022-12-25	WOS:000225997500021
J	Kern, AD; Kondrashov, FA				Kern, AD; Kondrashov, FA			Mechanisms and convergence of compensatory evolution in mammalian mitochondrial tRNAs	NATURE GENETICS			English	Article							MUTATIONS; SUBSTITUTIONS; NUCLEAR	The function of protein and RNA molecules depends on complex epistatic interactions between sites. Therefore, the deleterious effect of a mutation can be suppressed by a compensatory second-site substitution(1,2). In relating a list of 86 pathogenic mutations in human tRNAs encoded by mitochondrial genes to the sequences of their mammalian orthologs, we noted that 52 pathogenic mutations were present in normal tRNAs of one or several nonhuman mammals. We found at least five mechanisms of compensation for 32 pathogenic mutations that destroyed a Watson-Crick pair in one of the four tRNA stems: restoration of the affected Watson-Crick interaction (25 cases), strengthening of another pair (4 cases), creation of a new pair (8 cases), changes of multiple interactions in the affected stem (11 cases) and changes involving the interaction between the loop and stem structures (3 cases). A pathogenic mutation and its compensating substitution are fixed in a lineage in rapid succession, and often a compensatory interaction evolves convergently in different clades. At least 10%, and perhaps as many as 50%, of all nucleotide substitutions in evolving mammalian tRNAs participate in such interactions, indicating that the evolution of tRNAs proceeds along highly epistatic fitness ridges.	Univ Calif Davis, Ctr Populat Biol, Sect Evolut & Ecol, Davis, CA 95616 USA	University of California System; University of California Davis	Kondrashov, FA (corresponding author), Univ Calif Davis, Ctr Populat Biol, Sect Evolut & Ecol, Davis, CA 95616 USA.	kondrashov@ucdavis.edu	Kondrashov, Fyodor Alexeevich/H-6331-2015	Kondrashov, Fyodor Alexeevich/0000-0001-8243-4694				Andreu AL, 2003, J NEUROL, V250, P1403, DOI 10.1007/s00415-003-0281-3; Burch CL, 1999, GENETICS, V151, P921; Chen Y, 1999, GENES GENET SYST, V74, P271, DOI 10.1266/ggs.74.271; De Rijk P, 2003, BIOINFORMATICS, V19, P299, DOI 10.1093/bioinformatics/19.2.299; Florentz C, 2001, EMBO REP, V2, P481, DOI 10.1093/embo-reports/kve111; Gao LZ, 2003, TRENDS GENET, V19, P678, DOI 10.1016/j.tig.2003.10.002; GILLESPIE JH, 1986, GENETICS, V113, P1077; Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047; Higgs PG, 1998, GENETICA, V102-3, P91, DOI 10.1023/A:1017059530664; Innan H, 2001, GENETICS, V159, P389; Kelley SO, 2000, NAT STRUCT BIOL, V7, P862, DOI 10.1038/79612; KIMURA M, 1991, P NATL ACAD SCI USA, V88, P5969, DOI 10.1073/pnas.88.14.5969; Kimura M., 1985, J GENET, V64, P7, DOI [10.1007/BF02923549, DOI 10.1007/BF02923549]; Kondrashov AS, 2002, P NATL ACAD SCI USA, V99, P14878, DOI 10.1073/pnas.232565499; LODISH H, 2000, MOL CELL BIOL, P265; Lynch M, 1997, MOL BIOL EVOL, V14, P914, DOI 10.1093/oxfordjournals.molbev.a025834; MADDISON WP, 1992, MACCLADE ANAL PHYLOG; Murphy WJ, 2001, NATURE, V409, P614, DOI 10.1038/35054550; Orr HA, 2001, EVOLUTION, V55, P1085; Parsch J, 2000, GENETICS, V154, P909; Reyes A, 2004, MOL BIOL EVOL, V21, P397, DOI 10.1093/molbev/msh033; ROUSSET F, 1991, P NATL ACAD SCI USA, V88, P10032, DOI 10.1073/pnas.88.22.10032; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tillier ERM, 1998, GENETICS, V148, P1993; Wheeler DL, 2003, NUCLEIC ACIDS RES, V31, P28, DOI 10.1093/nar/gkg033; Wittenhagen LM, 2003, TRENDS BIOCHEM SCI, V28, P605, DOI 10.1016/j.tibs.2003.09.006; Wittenhagen LM, 2002, NAT STRUCT BIOL, V9, P586, DOI 10.1038/nsb820; ZUKER M, 1999, NATO ASI SER, P1	29	83	86	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2004	36	11					1207	1212		10.1038/ng1451	http://dx.doi.org/10.1038/ng1451			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	867HI	15502829	Bronze			2022-12-25	WOS:000224832800025
J	Graux, C; Cools, J; Melotte, C; Quentmeier, H; Ferrando, A; Levine, R; Vermeesch, JR; Stul, M; Dutta, B; Boeckx, N; Bosly, A; Heimann, P; Uyttebroeck, A; Mentens, N; Somers, R; MacLeod, RAF; Drexler, HG; Look, AT; Gilliland, DG; Michaux, L; Vandenberghe, P; Wlodarska, I; Marynen, P; Hagemeijer, A				Graux, C; Cools, J; Melotte, C; Quentmeier, H; Ferrando, A; Levine, R; Vermeesch, JR; Stul, M; Dutta, B; Boeckx, N; Bosly, A; Heimann, P; Uyttebroeck, A; Mentens, N; Somers, R; MacLeod, RAF; Drexler, HG; Look, AT; Gilliland, DG; Michaux, L; Vandenberghe, P; Wlodarska, I; Marynen, P; Hagemeijer, A			Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia	NATURE GENETICS			English	Article							DOUBLE-MINUTE CHROMOSOMES; TYROSINE KINASE; MYELOID LEUKEMIAS; GENES; PROTEIN; TRANSLOCATION; AMPLIFICATION; EXPRESSION; DELETIONS; IMATINIB	In T-cell acute lymphoblastic leukemia (T-ALL), transcription factors are known to be deregulated by chromosomal translocations, but mutations in protein tyrosine kinases have only rarely been identified(1-3). Here we describe the extrachromosomal (episomal)(4) amplification of ABL1 in 5 of 90 (5.6%) individuals with T-ALL, an aberration that is not detectable by conventional cytogenetics. Molecular analyses delineated the amplicon as a 500-kb region from chromosome band 9q34, containing the oncogenes ABL1 and NUP214 (refs.(5,6)). We identified a previously undescribed mechanism for activation of tyrosine kinases in cancer: the formation of episomes resulting in a fusion between NUP214 and ABL1. We detected the NUP214-ABL1 transcript in five individuals with the ABL1 amplification, in 5 of 85 (5.8%) additional individuals with T-ALL and in 3 of 22 T-ALL cell lines. The constitutively phosphorylated tyrosine kinase NUP214-ABL1 is sensitive to the tyrosine kinase inhibitor imatinib(7,8). The recurrent cryptic NUP214-ABL1 rearrangement is associated with increased HOX expression(1) and deletion of CDKN2A(9), consistent with a multistep pathogenesis of T-ALL. NUP214-ABL1 expression defines a new subgroup of individuals with T-ALL who could benefit from treatment with imatinib.	Univ Leuven, Dept Human Genet, Louvain, Belgium; Univ Leuven, Dept Hematol, Louvain, Belgium; Flanders Interuniv Inst Biotechnol, Dept Human Genet, Louvain, Belgium; German Collect Microorganisms & Cell Cultures, Braunschweig, Germany; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Flanders Interuniv Inst Biotechnol, Microarray Facil, Louvain, Belgium; Clin Univ UCL Mt Godinne, Dept Hematol, Brussels, Belgium; Free Univ Brussels, Erasme Hosp, Dept Med Genet, B-1050 Brussels, Belgium; Univ Leuven, Dept Pediat Hematooncol, Louvain, Belgium; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA USA; St Luc, Brussels, Belgium	KU Leuven; KU Leuven; Leibniz Institut fur Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Universite Catholique Louvain; Universite Catholique Louvain Hospital; Universite Libre de Bruxelles; Vrije Universiteit Brussel; KU Leuven; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Marynen, P (corresponding author), Univ Leuven, Dept Human Genet, Louvain, Belgium.	peter.marynen@med.kuleuven.ac.be; anne.hagemeijer@med.kuleuven.ac.be	Melotte, Cindy/GXV-5465-2022	Cools, Jan/0000-0001-6626-5843; Vandenberghe, Peter/0000-0003-4719-1935; Vermeesch, Joris/0000-0002-3071-1191				Barber KE, 2004, LEUKEMIA, V18, P1153, DOI 10.1038/sj.leu.2403357; BENE MC, 1995, LEUKEMIA, V9, P1783; Capdeville R, 2002, NAT REV DRUG DISCOV, V1, P493, DOI 10.1038/nrd839; CARROLL SM, 1988, MOL CELL BIOL, V8, P1525, DOI 10.1128/MCB.8.4.1525; Cools J, 1999, BLOOD, V94, P1820, DOI 10.1182/blood.V94.5.1820.417k09_1820_1824; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; DEKLEIN A, 1986, BLOOD, V68, P1369; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; Dierlamm J, 1996, GENE CHROMOSOME CANC, V16, P261, DOI 10.1002/(SICI)1098-2264(199608)16:4<261::AID-GCC6>3.0.CO;2-W; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; FORNEROD M, 1995, ONCOGENE, V10, P1739; Golub TR, 1996, MOL CELL BIOL, V16, P4107; HAHN PJ, 1993, BIOESSAYS, V15, P477, DOI 10.1002/bies.950150707; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; Kelly LM, 2002, ANNU REV GENOM HUM G, V3, P179, DOI 10.1146/annurev.genom.3.032802.115046; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; MAURER BJ, 1987, NATURE, V327, P434, DOI 10.1038/327434a0; MITELMAN F, 1995, INT SYSTEM HUMAN N S; Nagel S, 2003, CANCER RES, V63, P5329; Nieborowska-Skorska M, 2000, ONCOGENE, V19, P4117, DOI 10.1038/sj.onc.1203754; ODA T, 1994, J BIOL CHEM, V269, P22925; Paietta E, 2004, BLOOD, V104, P558, DOI 10.1182/blood-2004-01-0168; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Van Buggenhout G, 2004, J MED GENET, V41, P691, DOI 10.1136/jmg.2003.016865; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687	27	293	314	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2004	36	10					1084	1089		10.1038/ng1425	http://dx.doi.org/10.1038/ng1425			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	857YN	15361874	Green Published, Bronze			2022-12-25	WOS:000224156500017
J	Mansfield, JH; Harfe, BD; Nissen, R; Obenauer, J; Srineel, J; Chaudhuri, A; Farzan-Kashani, R; Zuker, M; Pasquinelli, AE; Ruvkun, G; Sharp, PA; Tabin, CJ; McManus, MT				Mansfield, JH; Harfe, BD; Nissen, R; Obenauer, J; Srineel, J; Chaudhuri, A; Farzan-Kashani, R; Zuker, M; Pasquinelli, AE; Ruvkun, G; Sharp, PA; Tabin, CJ; McManus, MT			MicroRNA-responsive 'sensor' transgenes uncover Hox-like and other developmentally regulated patterns of vertebrate microRNA expression	NATURE GENETICS			English	Article							CAENORHABDITIS-ELEGANS; MESSENGER-RNA; GENES; IDENTIFICATION; DROSOPHILA; CLEAVAGE; ELEMENT; DOMAIN; MOUSE; MIRNA	MicroRNAs (miRNAs) are a class of short (similar to22-nt) noncoding RNA molecules that downregulate expression of their mRNA targets. Since their discovery as regulators of developmental timing in Caenorhabditis elegans, hundreds of miRNAs have been identified in both animals and plants(1). Here, we report a technique for visualizing detailed miRNA expression patterns in mouse embryos. We elucidate the tissue-specific expression of several miRNAs during embryogenesis, including two encoded by genes embedded in homeobox (Hox) clusters, miR-10a and miR-196a. These two miRNAs are expressed in patterns that are markedly reminiscent of those of Hox genes. Furthermore, miR-196a negatively regulates Hoxb8, indicating that its restricted expression pattern probably reflects a role in the patterning function of the Hox complex.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; St Jude Childrens Res Hosp, Memphis, TN 38105 USA; Rensselaer Polytech Inst, Dept Comp Sci, Troy, NY 12180 USA; Rensselaer Polytech Inst, Dept Math Sci, Troy, NY 12180 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; MIT, NcGovern Inst, Dept Biol, Cambridge, MA 02139 USA	Harvard University; Harvard Medical School; State University System of Florida; University of Florida; Massachusetts Institute of Technology (MIT); St Jude Children's Research Hospital; Rensselaer Polytechnic Institute; Rensselaer Polytechnic Institute; Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT)	Tabin, CJ (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.	tabin@genetics.med.harvard.edu; mmcmanus@diabetes.ucsf.edu	mcmanus, michael/AAB-1239-2020	mcmanus, michael/0000-0003-3013-6569; Nissen, Robert/0000-0002-0591-1167	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD041826] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARAKI K, 1995, P NATL ACAD SCI USA, V92, P160, DOI 10.1073/pnas.92.1.160; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brend T, 2003, DEVELOPMENT, V130, P2717, DOI 10.1242/dev.00471; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Chen XM, 2004, SCIENCE, V303, P2022, DOI 10.1126/science.1088060; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; Dietrich S, 1997, DEVELOPMENT, V124, P3895; ERSELIUS JR, 1990, DEVELOPMENT, V110, P629; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Johnson SM, 2003, DEV BIOL, V259, P364, DOI 10.1016/S0012-1606(03)00202-1; Juarez MT, 2004, NATURE, V428, P84, DOI 10.1038/nature02363; Kasschau KD, 2003, DEV CELL, V4, P205, DOI 10.1016/S1534-5807(03)00025-X; Krichevsky AM, 2003, RNA, V9, P1274, DOI 10.1261/rna.5980303; Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; Lim LP, 2003, SCIENCE, V299, P1540, DOI 10.1126/science.1080372; Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; van den Akker E, 2001, DEVELOPMENT, V128, P1911; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434	27	345	393	1	37	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2004	36	10					1079	1083		10.1038/ng1421	http://dx.doi.org/10.1038/ng1421			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	857YN	15361871	Bronze			2022-12-25	WOS:000224156500016
J	Heinemann, JA; Traavik, T				Heinemann, JA; Traavik, T			Problems in monitoring horizontal gene transfer in field trials of transgenic plants	NATURE BIOTECHNOLOGY			English	Article							PENICILLIN-BINDING PROTEINS; STREPTOCOCCUS-PNEUMONIAE; NATURAL TRANSFORMATION; ESCHERICHIA-COLI; RECOMBINANT-DNA; RESISTANCE; EVOLUTION; BACTERIA; QUANTIFICATION; ENVIRONMENT	Transgenic crops are approved for release in some countries, while many more countries are wrestling with the issue of how to conduct risk assessments. Controls on field trials often include monitoring of horizontal gene transfer (HGT) from crops to surrounding soil microorganisms. Our analysis of antibiotic-resistant bacteria and of the sensitivity of current techniques for monitoring HGT from transgenic plants to soil microorganisms has two major implications for field trial assessments of transgenic crops: first, HGT from transgenic plants to microbes could still have an environmental impact at a frequency approximately a trillion times lower than the current risk assessment literature estimates the frequency to be; and second, current methods of environmental sampling to capture genes or traits in a recombinant are too insensitive for monitoring evolution by HGT. A model for HGT involving iterative short-patch events explains how HGT can occur at high frequencies but be detected at extremely low frequencies.	Univ Canterbury, New Zealand Inst Gene Ecol, Christchurch 1, New Zealand; Norwegian Inst Gene Ecol, N-9294 Tromso, Norway	University of Canterbury	Heinemann, JA (corresponding author), Univ Canterbury, New Zealand Inst Gene Ecol, 8020,Private Bag 4800, Christchurch 1, New Zealand.	jack.heinemann@canterbury.ac.nz						Amabile-Cuevas C. F., 2003, MULTIPLE DRUG RESIST; AMANN RI, 1995, MICROBIOL REV, V59, P143, DOI 10.1128/MMBR.59.1.143-169.1995; Amoroso A, 2001, ANTIMICROB AGENTS CH, V45, P2075, DOI 10.1128/AAC.45.7.2075-2081.2001; ANDERSON ES, 1968, ANNU REV MICROBIOL, V22, P131, DOI 10.1146/annurev.mi.22.100168.001023; Balsalobre L, 2003, ANTIMICROB AGENTS CH, V47, P2072, DOI 10.1128/AAC.47.7.2072-2081.2003; Chowdhury EH, 2003, J ANIM SCI, V81, P2546; Claverys JP, 2000, MOL MICROBIOL, V35, P251, DOI 10.1046/j.1365-2958.2000.01718.x; Conner AJ, 2003, PLANT J, V33, P19, DOI 10.1046/j.0960-7412.2002.001607.x; Cooper TF, 2000, P NATL ACAD SCI USA, V97, P12643, DOI 10.1073/pnas.220077897; CUPPLES CG, 1990, GENETICS, V125, P275; Curtis TP, 2002, P NATL ACAD SCI USA, V99, P10494, DOI 10.1073/pnas.142680199; de Maagd RA, 2001, TRENDS GENET, V17, P193, DOI 10.1016/S0168-9525(01)02237-5; de Vries J, 2003, APPL ENVIRON MICROB, V69, P4455, DOI 10.1128/AEM.69.8.4455-4462.2003; DELACRUZ F, 2002, BACTERIAL RESISTANCE, P19; Denamur E, 2000, CELL, V103, P711, DOI 10.1016/S0092-8674(00)00175-6; Doern GV, 2001, ANTIMICROB AGENTS CH, V45, P1721, DOI 10.1128/AAC.45.6.1721-1729.2001; Doolittle WF, 1999, SCIENCE, V284, P2124, DOI 10.1126/science.284.5423.2124; du Plessis M, 2002, ANTIMICROB AGENTS CH, V46, P2349, DOI 10.1128/AAC.46.8.2349-2357.2002; Evans E, 2000, MOL CELL BIOL, V20, P7839, DOI 10.1128/MCB.20.21.7839-7844.2000; Gasson M, 2001, NAT REV GENET, V2, P217, DOI 10.1038/35056066; Gebhard F, 1998, APPL ENVIRON MICROB, V64, P1550; Gibbs MJ, 1999, P NATL ACAD SCI USA, V96, P8022, DOI 10.1073/pnas.96.14.8022; Hakenbeck R, 1999, MOL MICROBIOL, V33, P673, DOI 10.1046/j.1365-2958.1999.01521.x; Harremoes P., 2002, LATE LESSONS EARLY W; HEINEMANN JA, 1991, TRENDS GENET, V7, P181, DOI 10.1016/0168-9525(91)90122-7; Heinemann JA, 2000, DRUG DISCOV TODAY, V5, P195, DOI 10.1016/S1359-6446(00)01483-5; Heinemann JA, 1999, DRUG DISCOV TODAY, V4, P72, DOI 10.1016/S1359-6446(98)01294-X; Heinemann JA, 2004, TRENDS BIOTECHNOL, V22, P331, DOI 10.1016/j.tibtech.2004.05.002; HEINEMANN JA, 2000, ENCY MICROBIOLOGY, P698; Humayun MZ, 1998, MOL MICROBIOL, V30, P905, DOI 10.1046/j.1365-2958.1998.01120.x; Jain R, 1999, P NATL ACAD SCI USA, V96, P3801, DOI 10.1073/pnas.96.7.3801; Kaeberlein T, 2002, SCIENCE, V296, P1127, DOI 10.1126/science.1070633; Kay E, 2002, APPL ENVIRON MICROB, V68, P3345, DOI 10.1128/AEM.68.7.3345-3351.2002; Keeling PJ, 2001, P NATL ACAD SCI USA, V98, P10745, DOI 10.1073/pnas.191337098; Knols BGJ, 2003, NAT BIOTECHNOL, V21, P973, DOI 10.1038/nbt0903-973; Kuiper HA, 2001, PLANT J, V27, P503, DOI 10.1046/j.1365-313X.2001.01119.x; Lawrence JG, 1996, GENETICS, V143, P1843; Levy SB, 1998, SCI AM, V278, P46, DOI 10.1038/scientificamerican0398-46; Lilley AK, 2003, MOL ECOL, V12, P3097, DOI 10.1046/j.1365-294X.2003.01960.x; Maiden MCJ, 1996, MOL MICROBIOL, V21, P1297, DOI 10.1046/j.1365-2958.1996.981457.x; Majewski J, 2000, J BACTERIOL, V182, P1016, DOI 10.1128/JB.182.4.1016-1023.2000; Marvier M, 2001, AM SCI, V89, P160; Massova I, 1998, ANTIMICROB AGENTS CH, V42, P1; MATIC I, 1995, CELL, V80, P507, DOI 10.1016/0092-8674(95)90501-4; Mendelsohn M, 2003, NAT BIOTECHNOL, V21, P1003, DOI 10.1038/nbt0903-1003; Michael CA, 2004, AM NAT, V164, P1, DOI 10.1086/421733; Mihaylova VT, 2003, MOL CELL BIOL, V23, P3265, DOI 10.1128/MCB.23.9.3265-3273.2003; Molbak L, 2003, APPL ENVIRON MICROB, V69, P5536, DOI 10.1128/AEM.69.9.5536-5542.2003; Nemergut DR, 2004, APPL ENVIRON MICROB, V70, P1160, DOI 10.1128/AEM.70.2.1160-1168.2004; Nichol KA, 2002, ANTIMICROB AGENTS CH, V46, P3261, DOI 10.1128/AAC.46.10.3261-3264.2002; Nielsen KM, 1997, APPL ENVIRON MICROB, V63, P1945, DOI 10.1128/AEM.63.5.1945-1952.1997; Nielsen KM, 1998, FEMS MICROBIOL REV, V22, P79, DOI 10.1111/j.1574-6976.1998.tb00362.x; Nielsen KM, 2000, APPL ENVIRON MICROB, V66, P1237, DOI 10.1128/AEM.66.3.1237-1242.2000; Ochman H, 2000, NATURE, V405, P299, DOI 10.1038/35012500; Prudhomme M, 2002, P NATL ACAD SCI USA, V99, P2100, DOI 10.1073/pnas.032262999; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; Rujan T, 2001, TRENDS GENET, V17, P113, DOI 10.1016/S0168-9525(00)02209-5; Saxena D, 1999, NATURE, V402, P480, DOI 10.1038/44997; SCHLUTER K, 1995, BIO-TECHNOL, V13, P1094, DOI 10.1038/nbt1095-1094; Sorensen SJ, 2003, CURR MICROBIOL, V47, P129, DOI 10.1007/s00284-002-3978-0; SPRATT BG, 1994, SCIENCE, V264, P388, DOI 10.1126/science.8153626; Springael D, 2004, TRENDS MICROBIOL, V12, P53, DOI 10.1016/j.tim.2003.12.010; Stokes HW, 2001, APPL ENVIRON MICROB, V67, P5240, DOI 10.1128/AEM.67.11.5240-5246.2001; Stokstad E, 2004, SCIENCE, V304, P1088; Syvanen M., 2002, HORIZONTAL GENE TRAN; Taber Harry, 2002, BACTERIAL RESISTANCE, P161; Tepfer D, 2003, TRANSGENIC RES, V12, P425, DOI 10.1023/A:1024387510243; Traavik T., 2002, GENETICALLY ENG ORGA, P331; Walsh C., 2003, ANTIBIOTICS ACTIONS; Whitman WB, 1998, P NATL ACAD SCI USA, V95, P6578, DOI 10.1073/pnas.95.12.6578; Woese CR, 2002, P NATL ACAD SCI USA, V99, P8742, DOI 10.1073/pnas.132266999; 1995, ANTIMICROB AGENTS CH, V39, P2	72	52	65	1	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2004	22	9					1105	1109		10.1038/nbt1009	http://dx.doi.org/10.1038/nbt1009			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	850ZR	15340480				2022-12-25	WOS:000223653400028
J	Pardoll, D; Allison, J				Pardoll, D; Allison, J			Cancer immunotherapy: breaking the barriers to harvest the crop	NATURE MEDICINE			English	Editorial Material							METASTATIC MELANOMA; ANTIGEN-4 BLOCKADE; T-CELLS; ANTIBODY; THERAPY; AUTOIMMUNITY; REGRESSION; RESPONSES; PLUS	Successful translation of modern molecular immunology into effective cancer immunotherapy is threatened by regulatory barriers and challenges to the development of novel agents and combinatorial strategies through effective public-private partnerships. For its promise to be fully realized, both the National Cancer Institute and Food and Drug Administration must take active steps to help academic investigators and companies jointly navigate the pathways from laboratory to clinic.	Johns Hopkins Univ, Sch Med, Sidney Kimmel Canc Ctr, Baltimore, MD 21218 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Johns Hopkins University; Memorial Sloan Kettering Cancer Center	Pardoll, D (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Canc Ctr, Baltimore, MD 21218 USA.	dmpardol@jhmi.edu		Allison, James/0000-0001-8980-5697				Akhtar S, 2002, NEW ENGL J MED, V346, P1830; Blattman JN, 2004, SCIENCE, V305, P200, DOI 10.1126/science.1100369; Chambers CA, 2001, ANNU REV IMMUNOL, V19, P565, DOI 10.1146/annurev.immunol.19.1.565; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Ergenzinger E, 2003, SCIENTIST, V17, P43; Grilley BJ, 2003, CYTOTHERAPY, V5, P197, DOI 10.1080/14653240310001271; Hersey P, 2003, INTERN MED J, V33, P33, DOI 10.1046/j.1445-5994.2002.00289.x; Levitsky HI, 2000, CANCER J, V6, pS281; Pardoll D, 2003, ANNU REV IMMUNOL, V21, P807, DOI 10.1146/annurev.immunol.21.120601.141135; Pardoll DM, 2002, NAT REV IMMUNOL, V2, P227, DOI 10.1038/nri774; Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Smith MA, 2002, ACTA NEUROPATHOL, V104, P110, DOI 10.1007/s00401-002-0572-2; Stolberg Sheryl Gay, 1999, N Y Times Mag, P136; Sutmuller RPM, 2001, J EXP MED, V194, P823, DOI 10.1084/jem.194.6.823; Waldmann H, 2002, MED ONCOL, V19, pS3, DOI 10.1385/MO:19:2S:S03; Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988; WINTER G, 1993, TRENDS PHARMACOL SCI, V14, P139, DOI 10.1016/0165-6147(93)90197-R; Yee C, 2002, P NATL ACAD SCI USA, V99, P16168, DOI 10.1073/pnas.242600099	20	110	114	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2004	10	9					887	892		10.1038/nm0904-887	http://dx.doi.org/10.1038/nm0904-887			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	851AZ	15340404				2022-12-25	WOS:000223658400010
J	Hamamoto, R; Furukawa, Y; Morita, M; Iimura, Y; Silva, FP; Li, MH; Yagyu, R; Nakamura, Y				Hamamoto, R; Furukawa, Y; Morita, M; Iimura, Y; Silva, FP; Li, MH; Yagyu, R; Nakamura, Y			SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells	NATURE CELL BIOLOGY			English	Article							METHYLATION; GENE; CARCINOGENESIS; DOMAIN; H3; DOWNSTREAM; EXPRESSION; PROTEIN; EZH2	Colorectal and hepatocellular carcinomas are some of the leading causes of cancer deaths worldwide, but the mechanisms that underly these malignancies are not fully understood. Here we report the identification of SMYD3, a gene that is over-expressed in the majority of colorectal carcinomas and hepatocellular carcinomas. Introduction of SMYD3 into NIH3T3 cells enhanced cell growth, whereas genetic knockdown with small-interfering RNAs (siRNAs) in cancer cells resulted in significant growth suppression. SMYD3 formed a complex with RNA polymerase II through an interaction with the RNA helicase HELZ and transactivated a set of genes that included oncogenes, homeobox genes and genes associated with cell-cycle regulation. SMYD3 bound to a motif, 5'-CCCTCC-3', present in the promoter region of downstream genes such as Nkx2.8. The SET domain of SMYD3 showed histone H3-lysine 4 (H3-K4)-specific methyltransferase activity, which was enhanced in the presence of the heat-shock protein HSP90A. Our findings suggest that SMYD3 has histone methyltransferase activity and plays an important role in transcriptional regulation as a member of an RNA polymerase complex. Furthermore, activation of SMYD3 may be a key factor in human carcinogenesis.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Mol Med,Minato Ku, Tokyo 1088639, Japan; Banyu Tsukuba Res Inst, Tsukuba, Ibaraki 3002611, Japan	University of Tokyo; Merck & Company	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Mol Med,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Hamamoto, Ryuji/AAF-9600-2019; Silva, Fabio Pittella/B-2621-2013	Hamamoto, Ryuji/0000-0002-2632-1334; Silva, Fabio Pittella/0000-0002-9644-7098				Apergis GA, 1998, J BIOL CHEM, V273, P2917, DOI 10.1074/jbc.273.5.2917; Archer SY, 1999, CURR OPIN GENET DEV, V9, P171, DOI 10.1016/S0959-437X(99)80026-4; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; Huntsman DG, 1999, ONCOGENE, V18, P7975, DOI 10.1038/sj.onc.1203291; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Kwon T, 2003, EMBO J, V22, P292, DOI 10.1093/emboj/cdg025; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; LEVIN B, 1995, NEW ENGL J MED, V332, P1294, DOI 10.1056/NEJM199505113321910; Li JX, 2002, J BIOL CHEM, V277, P49383, DOI 10.1074/jbc.M209294200; Lin YM, 2002, ONCOGENE, V21, P4120, DOI 10.1038/sj.onc.1205518; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; MURTHY RS, 2001, WORLD HLTH REPORT 20, P144; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Okabe H, 2001, CANCER RES, V61, P2129; Okabe H, 2003, CANCER RES, V63, P3043; Parkin DM, 1999, CA-CANCER J CLIN, V49, P33, DOI 10.3322/canjclin.49.1.33; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Shimokawa T, 2003, CANCER RES, V63, P6116; So CW, 2003, CANCER CELL, V4, P99, DOI 10.1016/S1535-6108(03)00188-0; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Tang CJC, 2001, J BIOL CHEM, V276, P19631, DOI 10.1074/jbc.M100170200; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Xiao B, 2003, CURR OPIN STRUC BIOL, V13, P699, DOI 10.1016/j.sbi.2003.10.003; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	35	568	638	1	66	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2004	6	8					731	740		10.1038/ncb1151	http://dx.doi.org/10.1038/ncb1151			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	842YA	15235609				2022-12-25	WOS:000223039400011
J	Saito, RM; Perreault, A; Peach, B; Satterlee, JS; van den Heuvel, S				Saito, RM; Perreault, A; Peach, B; Satterlee, JS; van den Heuvel, S			The CDC-14 phosphatase controls developmental cell-cycle arrest in C-elegans	NATURE CELL BIOLOGY			English	Article							DEPENDENT KINASE INHIBITOR; HUMAN CDC14A PHOSPHATASE; CAENORHABDITIS-ELEGANS; SACCHAROMYCES-CEREVISIAE; CHROMOSOME SEGREGATION; MITOTIC EXIT; S PHASE; PROGRESSION; MITOSIS; COMPLEX	Temporal control of cell division is critical for proper animal development. To identify mechanisms involved in developmental arrest of cell division, we screened for cell-cycle mutants that disrupt the reproducible pattern of somatic divisions in the nematode C. elegans. Here, we show that the cdc-14 phosphatase is required for the quiescent state of specific precursor cells. Whereas budding yeast Cdc14p is essential for mitotic exit, inactivation of C. elegans cdc-14 resulted in extra divisions in multiple lineages, with no apparent defects in mitosis or cell-fate determination. CDC-14 fused to the green fluorescent protein (GFP-CDC-14) localized dynamically and accumulated in the cytoplasm during G1 phase. Genetic interaction and transgene expression studies suggest that cdc-14 functions upstream of the cki-1 Cip/Kip inhibitor to promote accumulation of CKI-1 in the nucleus. Our data support a model in which CDC-14 promotes a hypophosphorylated and stable form of CKI-1 required for developmentally programmed cell-cycle arrest.	Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University	van den Heuvel, S (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Bldg 149,13th St, Charlestown, MA 02129 USA.	heuvel@helix.mgh.harvard.edu	van den Heuvel, Sander J.L./B-8892-2011	van den Heuvel, Sander J.L./0000-0001-9015-7463				Bardin AJ, 2000, CELL, V102, P21, DOI 10.1016/S0092-8674(00)00007-6; Boxem M, 1999, DEVELOPMENT, V126, P2227; Boxem M, 2001, DEVELOPMENT, V128, P4349; Cueille N, 2001, J CELL SCI, V114, P2649; deNooij JC, 1996, CELL, V87, P1237, DOI 10.1016/S0092-8674(00)81819-X; Gruneberg U, 2002, J CELL BIOL, V158, P901, DOI 10.1083/jcb.200202054; Hong Y, 1998, DEVELOPMENT, V125, P3585; Kaiser BK, 2002, MOL BIOL CELL, V13, P2289, DOI 10.1091/mbc.01-11-0535; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Kornfeld K, 1997, TRENDS GENET, V13, P55, DOI 10.1016/S0168-9525(97)01005-6; Lane ME, 1996, CELL, V87, P1225, DOI 10.1016/S0092-8674(00)81818-8; Mailand N, 2002, NAT CELL BIOL, V4, P317, DOI 10.1038/ncb777; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pereira G, 2000, MOL CELL, V6, P1, DOI 10.1016/S1097-2765(05)00017-1; Pereira G, 2002, J CELL BIOL, V157, P367, DOI 10.1083/jcb.200112085; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; Tan PB, 1998, CELL, V93, P569, DOI 10.1016/S0092-8674(00)81186-1; Trautmann S, 2001, CURR BIOL, V11, P931, DOI 10.1016/S0960-9822(01)00268-8; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Wei AG, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf109; Wong AKC, 1999, GENOMICS, V59, P248, DOI 10.1006/geno.1999.5863; Wood WB, 1988, NEMATODE CAENORHABDI	30	72	82	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2004	6	8					777	783		10.1038/ncb1154	http://dx.doi.org/10.1038/ncb1154			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	842YA	15247923				2022-12-25	WOS:000223039400017
J	Traggiai, E; Becker, S; Subbarao, K; Kolesnikova, L; Uematsu, Y; Gismondo, MR; Murphy, BR; Rappuoli, R; Lanzavecchia, A				Traggiai, E; Becker, S; Subbarao, K; Kolesnikova, L; Uematsu, Y; Gismondo, MR; Murphy, BR; Rappuoli, R; Lanzavecchia, A			An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus	NATURE MEDICINE			English	Article							ACUTE RESPIRATORY SYNDROME; SYNCYTIAL VIRUS-INFECTION; HONG-KONG; MOUSE; IDENTIFICATION; GENERATION; DISEASES; MYELOMA; STRAINS; MICE	Passive serotherapy can confer immediate protection against microbial infection, but methods to rapidly generate human neutralizing monoclonal antibodies are not yet available. We have developed an improved method for Epstein-Barr virus transformation of human B cells. We used this method to analyze the memory repertoire of a patient who recovered from severe acute respiratory syndrome coronavirus (SARS-CoV) infection and to isolate monoclonal antibodies specific for different viral proteins, including 35 antibodies with in vitro neutralizing activity ranging from 10(-8)M to 10(-11)M. One such antibody confers protection in vivo in a mouse model of SARS-CoV infection. These results show that it is possible to interrogate the memory repertoire of immune donors to rapidly and efficiently isolate neutralizing antibodies that have been selected in the course of natural infection.	Inst Res Biomed, CH-6500 Belllinzona, Switzerland; Inst Virol, D-35037 Marburg, Germany; NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA; Chiron Vaccines, I-53100 Siena, Italy; Osped L Sacco, Ist Microbiol, I-20175 Milan, Italy	Universita della Svizzera Italiana; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Novartis; University of Milan; Luigi Sacco Hospital	Lanzavecchia, A (corresponding author), Inst Res Biomed, Via Vela 6, CH-6500 Belllinzona, Switzerland.	lanzavecchia@irb.unisi.ch	traggiai, elisabetta/A-2316-2009; Gismondo, Maria Rita/I-3965-2017	Subbarao, Kanta/0000-0003-1713-3056; Gismondo, Maria Rita/0000-0001-6926-8660	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000934, Z01AI000934] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECKER S, 1992, MED MICROBIOL IMMUN, V181, P43, DOI 10.1007/BF00193395; BEHRING E, 1965, DEUT MED WOCHENSCHR, V90, P2183; Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071; Brekke OH, 2003, NAT REV DRUG DISCOV, V2, P52, DOI 10.1038/nrd984; Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a; GEBAUER F, 1991, VIROLOGY, V183, P225, DOI 10.1016/0042-6822(91)90135-X; GIACHINO C, 1995, J EXP MED, V181, P1245, DOI 10.1084/jem.181.3.1245; GRAHAM BS, 1988, J MED VIROL, V26, P153, DOI 10.1002/jmv.1890260207; Green LL, 1999, J IMMUNOL METHODS, V231, P11, DOI 10.1016/S0022-1759(99)00137-4; Hartmann G, 2000, J IMMUNOL, V164, P944, DOI 10.4049/jimmunol.164.2.944; Johnson S, 1997, J INFECT DIS, V176, P1215, DOI 10.1086/514115; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; Karber G., 1931, ARCH EXP PATHOL PH, V162, P480, DOI DOI 10.1007/BF01863914; Karpas A, 2001, P NATL ACAD SCI USA, V98, P1799, DOI 10.1073/pnas.98.4.1799; Keller MA, 2000, CLIN MICROBIOL REV, V13, P602, DOI 10.1128/CMR.13.4.602-614.2000; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOZBOR D, 1981, J IMMUNOL, V127, P1275; KOZBOR D, 1982, HYBRIDOMA, V1, P323, DOI 10.1089/hyb.1.1982.1.323; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; Perri S, 2003, J VIROL, V77, P10394, DOI 10.1128/JVI.77.19.10394-10403.2003; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Stack AM, 2000, VACCINE, V18, P1412, DOI 10.1016/S0264-410X(99)00399-0; STEINITZ M, 1977, NATURE, V269, P420, DOI 10.1038/269420a0; Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004	30	526	677	1	48	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2004	10	8					871	875		10.1038/nm1080	http://dx.doi.org/10.1038/nm1080			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	843DK	15247913	Green Published, Bronze			2022-12-25	WOS:000223055700043
J	Davuluri, GR; van Tuinen, A; Fraser, PD; Manfredonia, A; Newman, R; Burgess, D; Brummell, DA; King, SR; Palys, J; Uhlig, J; Bramley, PM; Pennings, HMJ; Bowler, C				Davuluri, GR; van Tuinen, A; Fraser, PD; Manfredonia, A; Newman, R; Burgess, D; Brummell, DA; King, SR; Palys, J; Uhlig, J; Bramley, PM; Pennings, HMJ; Bowler, C			Fruit-specific RNAi-mediated suppression of DET1 enhances carotenoid and flavonoid content in tomatoes	NATURE BIOTECHNOLOGY			English	Article							SIGNAL-TRANSDUCTION; MUTATION; MANIPULATION; EXPRESSION; LYCOPENE; HOMOLOG; PLANTS	Tomatoes are a principal dietary source of carotenoids and flavonoids, both of which are highly beneficial for human health(1,2). Overexpression of genes encoding biosynthetic enzymes or transcription factors have resulted in tomatoes with improved carotenoid or flavonoid content, but never with both(3-7). We attempted to increase tomato fruit nutritional value by suppressing an endogenous photomorphogenesis regulatory gene, DET1, using fruit-specific promoters combined with RNA interference (RNAi) technology. Molecular analysis indicated that DET1 transcripts were indeed specifically degraded in transgenic fruits. Both carotenoid and flavonoid contents were increased significantly, whereas other parameters of fruit quality were largely unchanged. These results demonstrate that manipulation of a plant regulatory gene can simultaneously influence the production of several phytonutrients generated from independent biosynthetic pathways, and provide a novel example of the use of organ-specific gene silencing to improve the nutritional value of plant-derived products.	Stn Zool, Cell Signaling Lab, I-80121 Naples, Italy; Univ London, Royal Holloway & Bedford New Coll, Egham TW20 0EX, Surrey, England; DNA Plant Technol Corp, Oakland, CA 94608 USA; Seminis Vegetable Seeds Inc, Woodland, CA 95695 USA; Ecole Normale Super, CNRS, ENS, FRE2910, F-75230 Paris, France	University of London; Royal Holloway University London; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Bowler, C (corresponding author), Stn Zool, Cell Signaling Lab, Villa Comunale, I-80121 Naples, Italy.	cbowler@biologie.ens.fr	Bowler, Chris/AAC-6256-2019; Brummell, David A/F-1498-2010	Brummell, David A/0000-0002-2754-6340; Bowler, Chris/0000-0003-3835-6187	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007914] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL007914] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams-Phillips L, 2004, TRENDS PLANT SCI, V9, P331, DOI 10.1016/j.tplants.2004.05.004; Baulcombe D, 2004, NATURE, V431, P356, DOI 10.1038/nature02874; Bino RJ, 2005, NEW PHYTOL, V166, P427, DOI 10.1111/j.1469-8137.2005.01362.x; Bovy A, 2002, PLANT CELL, V14, P2509, DOI 10.1105/tpc.004218; Burgess DG, 2002, PLANT J, V31, P113, DOI 10.1046/j.1365-313X.2002.01330.x; Cooper DA, 2004, J NUTR, V134, p221S, DOI 10.1093/jn/134.1.221S; Davuluri GR, 2004, PLANT J, V40, P344, DOI 10.1111/j.1365-313X.2004.02218.x; DellaPenna D, 2001, PLANT PHYSIOL, V125, P160, DOI 10.1104/pp.125.1.160; DUNSMUIR P, 1997, Patent No. 5633440; Fraser PD, 2002, P NATL ACAD SCI USA, V99, P1092, DOI 10.1073/pnas.241374598; Giliberto L, 2005, PLANT PHYSIOL, V137, P199, DOI 10.1104/pp.104.051987; Giovannoni J, 2001, ANNU REV PLANT PHYS, V52, P725, DOI 10.1146/annurev.arplant.52.1.725; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Heber D, 2002, EXP BIOL MED, V227, P920, DOI 10.1177/153537020222701013; HUMPHREY JH, 1992, B WORLD HEALTH ORGAN, V70, P225; Key TJ, 2002, LANCET, V360, P861, DOI 10.1016/S0140-6736(02)09958-0; Kucuk O, 2002, PURE APPL CHEM, V74, P1443, DOI 10.1351/pac200274081443; Levin I, 2003, THEOR APPL GENET, V106, P454, DOI 10.1007/s00122-002-1080-4; MCCORMICK S, 1991, PLANT TISSUE CULTU B, V6, P1; Miller EC, 2002, PURE APPL CHEM, V74, P1435, DOI 10.1351/pac200274081435; Muir SR, 2001, NAT BIOTECHNOL, V19, P470, DOI 10.1038/88150; Mustilli AC, 1999, PLANT CELL, V11, P145, DOI 10.1105/tpc.11.2.145; Niggeweg R, 2004, NAT BIOTECHNOL, V22, P746, DOI 10.1038/nbt966; Paine JA, 2005, NAT BIOTECHNOL, V23, P482, DOI 10.1038/nbt1082; PEAR JR, 1989, PLANT MOL BIOL, V13, P639, DOI 10.1007/BF00016019; RiceEvans CA, 1997, TRENDS PLANT SCI, V2, P152, DOI 10.1016/S1360-1385(97)01018-2; Romer S, 2000, NAT BIOTECHNOL, V18, P666, DOI 10.1038/76523; Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957; Santino CG, 1997, PLANT MOL BIOL, V33, P405, DOI 10.1023/A:1005738910743; Schafer E, 2002, EMBO REP, V3, P1042, DOI 10.1093/embo-reports/kvf222; Wesley SV, 2001, PLANT J, V27, P581, DOI 10.1046/j.1365-313X.2001.01105.x; Yen HC, 1997, THEOR APPL GENET, V95, P1069, DOI 10.1007/s001220050664; YODER JI, 1988, MOL GEN GENET, V213, P291, DOI 10.1007/BF00339594	33	323	391	2	86	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2005	23	7					890	895		10.1038/nbt1108	http://dx.doi.org/10.1038/nbt1108			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	944KT	15951803	Green Accepted			2022-12-25	WOS:000230427700038
J	Jeffreys, AJ; Neumann, R; Panayi, M; Myers, S; Donnelly, P				Jeffreys, AJ; Neumann, R; Panayi, M; Myers, S; Donnelly, P			Human recombination hot spots hidden in regions of strong marker association	NATURE GENETICS			English	Article							LINKAGE-DISEQUILIBRIUM; HAPLOTYPE BLOCKS; HUMAN GENOME; MEIOTIC CROSSOVER; RATES; DIVERSITY; HISTORY	The fine-scale distribution of meiotic recombination events in the human genome can be inferred from patterns of haplotype diversity in human populations(1-5) but directly studied only by high-resolution sperm typing(6-8). Both approaches indicate that crossovers are heavily clustered into narrow recombination hot spots. But our direct understanding of hot-spot properties and distributions is largely limited to sperm typing in the major histocompatibility complex (MHC)(7). We now describe the analysis of an unremarkable 206-kb region on human chromosome 1, which identified localized regions of linkage disequilibrium breakdown that mark the locations of sperm crossover hot spots. The distribution, intensity and morphology of these hot spots are markedly similar to those in the MHC. But we also accidentally detected additional hot spots in regions of strong association. Coalescent analysis of genotype data detected most of the hot spots but showed significant differences between sperm crossover frequencies and historical recombination rates. This raises the possibility that some hot spots, particularly those in regions of strong association, may have evolved very recently and not left their full imprint on haplotype diversity. These results suggest that hot spots could be very abundant and possibly fluid features of the human genome.	Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England; Univ Oxford, Dept Stat, Oxford OX1 3TG, England	University of Leicester; University of Oxford	Jeffreys, AJ (corresponding author), Univ Leicester, Dept Genet, Univ Rd, Leicester LE1 7RH, Leics, England.	ajj@le.ac.uk	Myers, Simon R/A-6792-2015	Myers, Simon R/0000-0002-2585-9626; Donnelly, Peter/0000-0001-9495-3408				Akey JM, 2004, PLOS BIOL, V2, P1591, DOI 10.1371/journal.pbio.0020286; CHAKRAVARTI A, 1984, AM J HUM GENET, V36, P1239; Crawford DC, 2004, NAT GENET, V36, P700, DOI 10.1038/ng1376; Dean FB, 2002, P NATL ACAD SCI USA, V99, P5261, DOI 10.1073/pnas.082089499; Fearnhead P, 2004, GENETICS, V167, P2067, DOI 10.1534/genetics.103.021584; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; GRIFFITHS RC, 1996, IMA VOLUME MATH POPU, P257; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; Jeffreys AJ, 2000, HUM MOL GENET, V9, P725, DOI 10.1093/hmg/9.5.725; Jeffreys AJ, 2004, NAT GENET, V36, P151, DOI 10.1038/ng1287; Jeffreys AJ, 2001, NAT GENET, V29, P217, DOI 10.1038/ng1001-217; Jeffreys AJ, 1998, MOL CELL, V2, P267, DOI 10.1016/S1097-2765(00)80138-0; Kauppi L, 2004, NAT REV GENET, V5, P413, DOI 10.1038/nrg1346; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Li N, 2003, GENETICS, V165, P2213; May CA, 2002, NAT GENET, V31, P272, DOI 10.1038/ng918; McVean GAT, 2004, SCIENCE, V304, P581, DOI 10.1126/science.1092500; Morton N. E., 1982, OUTLINE GENETIC EPID; Phillips MS, 2003, NAT GENET, V33, P382, DOI 10.1038/ng1100; Ptak SE, 2004, PLOS BIOL, V2, P849, DOI 10.1371/journal.pbio.0020155; Ptak SE, 2005, NAT GENET, V37, P429, DOI 10.1038/ng1529; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; Reich DE, 2002, NAT GENET, V32, P135, DOI 10.1038/ng947; Sabeti PC, 2002, NATURE, V419, P832, DOI 10.1038/nature01140; Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378; Stumpf MPH, 2004, EUR J HUM GENET, V12, P469, DOI 10.1038/sj.ejhg.5201179; Stumpf MPH, 2003, NAT REV GENET, V4, P959, DOI 10.1038/nrg1227; Wall JD, 2003, AM J HUM GENET, V73, P1330, DOI 10.1086/380311; Wang N, 2002, AM J HUM GENET, V71, P1227, DOI 10.1086/344398; Winckler W, 2005, SCIENCE, V308, P107, DOI 10.1126/science.1105322	30	138	146	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2005	37	6					601	606		10.1038/ng1565	http://dx.doi.org/10.1038/ng1565			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	931OT	15880103				2022-12-25	WOS:000229495300013
J	Chen, XY; Macara, IG				Chen, XY; Macara, IG			Par-3 controls tight junction assembly through the Rac exchange factor Tiam1	NATURE CELL BIOLOGY			English	Article							ASYMMETRIC CELL-DIVISION; POLARITY PROTEIN PAR-3; EPITHELIAL TIGHT; KINASE-C; DROSOPHILA; RHO; DOMAIN; PHOSPHORYLATION; LOCALIZATION; ASIP/PAR-3	The par (partitioning-defective) genes express a set of conserved proteins that function in polarization and asymmetric cell division(1,2). Par-3 has multiple protein-interaction domains, and associates with Par-6 and atypical protein kinase C (aPKC)(3-5). In Drosophila, Par-3 is essential for epithelial cell polarization(6). However, its function in mammals is unclear. Here we show that depletion of Par-3 in mammalian epithelial cells profoundly disrupts tight junction assembly. Expression of a carboxyterminal fragment plus the third PDZ domain of Par-3 partially rescues junction assembly, but neither Par-6 nor aPKC binding is required. Unexpectedly, Rac is constitutively activated in cells lacking Par-3, and the assembly of tight junctions is efficiently restored by a dominant-negative Rac mutant. The Rac exchange factor Tiam1 (ref. 7) binds directly to the carboxy-terminal region of Par-3, and knockdown of Tiam1 enhances tight junction formation in cells lacking Par-3. These results define a critical function for Par-3 in tight junction assembly, and reveal a novel mechanism through which Par-3 engages in the spatial regulation of Rac activity and establishment of epithelial polarity.	Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Ctr Cell Signaling, Charlottesville, VA 22908 USA	University of Virginia	Chen, XY (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Ctr Cell Signaling, Charlottesville, VA 22908 USA.	xc2d@virginia.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070902] Funding Source: NIH RePORTER; NCI NIH HHS [CA40042] Funding Source: Medline; NIGMS NIH HHS [GM070902] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benton R, 2003, CURR BIOL, V13, P1330, DOI 10.1016/S0960-9822(03)00508-6; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Doe CQ, 2001, CURR OPIN CELL BIOL, V13, P68, DOI 10.1016/S0955-0674(00)00176-9; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Furuse M, 2001, J CELL BIOL, V153, P263, DOI 10.1083/jcb.153.2.263; Gao L, 2002, CURR BIOL, V12, P221, DOI 10.1016/S0960-9822(01)00663-7; Gibson MC, 2003, CURR OPIN CELL BIOL, V15, P747, DOI 10.1016/j.ceb.2003.10.008; Hirose T, 2002, J CELL SCI, V115, P2485; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Jan YN, 2001, NAT REV NEUROSCI, V2, P772, DOI 10.1038/35097516; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Knoblich JA, 2001, NAT REV MOL CELL BIO, V2, P11, DOI 10.1038/35048085; Kosako H, 2000, ONCOGENE, V19, P6059, DOI 10.1038/sj.onc.1203987; Kovacs M, 2004, J BIOL CHEM, V279, P35557, DOI 10.1074/jbc.M405319200; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Macara IG, 2004, NAT REV MOL CELL BIO, V5, P220, DOI 10.1038/nrm1332; Malliri A, 2004, J BIOL CHEM, V279, P30092, DOI 10.1074/jbc.M401192200; Matter K, 2003, METHODS, V30, P228, DOI 10.1016/S1046-2023(03)00029-X; Mertens AE, 2003, FEBS LETT, V546, P11, DOI 10.1016/S0014-5793(03)00435-6; Mizuno K, 2003, J BIOL CHEM, V278, P31240, DOI 10.1074/jbc.M303593200; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Takekuni K, 2003, J BIOL CHEM, V278, P5497, DOI 10.1074/jbc.C200707200; Tepass U, 2001, ANNU REV GENET, V35, P747, DOI 10.1146/annurev.genet.35.102401.091415; Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797; Wodarz A, 2000, J CELL BIOL, V150, P1361, DOI 10.1083/jcb.150.6.1361	30	348	354	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2005	7	3					262	U72		10.1038/ncb1226	http://dx.doi.org/10.1038/ncb1226			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	902CU	15723052				2022-12-25	WOS:000227329800014
J	Oleksiak, MF; Roach, JL; Crawford, DL				Oleksiak, MF; Roach, JL; Crawford, DL			Natural variation in cardiac metabolism and gene expression in Fundulus heteroclitus	NATURE GENETICS			English	Article							GLYCOLYTIC ENZYME EXPRESSION; PATTERNS; POPULATIONS; VARIANCE; YEAST; BLOOD	Individual variation in gene expression is important for evolutionary adaptation(1,2) and susceptibility to diseases and pathologies(3,4). In this study, we address the functional importance of this variation by comparing cardiac metabolism to patterns of mRNA expression using microarrays. There is extensive variation in both cardiac metabolism and the expression of metabolic genes among individuals of the teleost fish Fundulus heteroclitus from natural outbred populations raised in a common environment: metabolism differed among individuals by a factor of more than 2, and expression levels of 94% of genes were significantly different (P < 0.01) between individuals in a population. This unexpectedly high variation in metabolic gene expression explains much of the variation in metabolism, suggesting that it is biologically relevant. The patterns of gene expression that are most important in explaining cardiac metabolism differ between groups of individuals. Apparently, the variation in metabolism seems to be related to different patterns of gene expression in the different groups of individuals. The magnitude of differences in gene expression in these groups is not important; large changes in expression have no greater predictive value than small changes. These data suggest that variation in physiological performance is related to the subtle variation in gene expression and that this relationship differs among individuals.	Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Div Marine Biol & Fisheries, NIEHS,Marine & Freshwater Biomed Sci Ctr, Miami, FL 33149 USA; N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Miami; University of North Carolina; North Carolina State University	Crawford, DL (corresponding author), Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Div Marine Biol & Fisheries, NIEHS,Marine & Freshwater Biomed Sci Ctr, Miami, FL 33149 USA.	dcrawford@rsmas.miami.edu		Crawford, Douglas/0000-0002-6239-4012	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065470] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL065470-03, R01 HL065470-02, R01 HL065470-01A2] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bray NJ, 2003, HUM GENET, V113, P149, DOI 10.1007/s00439-003-0956-y; Brem RB, 2002, SCIENCE, V296, P752, DOI 10.1126/science.1069516; BROWN BL, 1991, EVOLUTION, V45, P1147, DOI 10.1111/j.1558-5646.1991.tb04381.x; CRAWFORD DL, 1989, P NATL ACAD SCI USA, V86, P9365, DOI 10.1073/pnas.86.23.9365; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ferea TL, 1999, P NATL ACAD SCI USA, V96, P9721, DOI 10.1073/pnas.96.17.9721; Jin W, 2001, NAT GENET, V29, P389, DOI 10.1038/ng766; Kerr MK, 2002, STAT SINICA, V12, P203; Kerr MK, 2001, GENET RES, V77, P123; Knight JC, 2004, TRENDS GENET, V20, P113, DOI 10.1016/j.tig.2004.01.001; Oleksiak MF, 2002, NAT GENET, V32, P261, DOI 10.1038/ng983; Oleksiak MF, 2001, MAR BIOTECHNOL, V3, pS203, DOI 10.1007/s10126-001-0043-0; PASCHALL JE, IN PRESS BMC GENOMIC; Pierce VA, 1997, SCIENCE, V276, P256, DOI 10.1126/science.276.5310.256; Podrabsky JE, 2000, AM J PHYSIOL-REG I, V279, pR2344, DOI 10.1152/ajpregu.2000.279.6.R2344; Powers Dennis A., 1993, Oxford Surveys in Evolutionary Biology, V9, P43; Pritchard CC, 2001, P NATL ACAD SCI USA, V98, P13266, DOI 10.1073/pnas.221465998; Radich JP, 2004, GENOMICS, V83, P980, DOI 10.1016/j.ygeno.2003.12.013; Sokal R. R, 1981, BIOMETRY; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Westfall P.H., 1993, RESAMPLING BASED MUL, P340; Whitney AR, 2003, P NATL ACAD SCI USA, V100, P1896, DOI 10.1073/pnas.252784499; Yvert G, 2003, NAT GENET, V35, P57, DOI 10.1038/ng1222	25	157	161	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2005	37	1					67	72		10.1038/ng1483	http://dx.doi.org/10.1038/ng1483			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	883FX	15568023	Green Accepted			2022-12-25	WOS:000225997500022
J	Bolotin, A; Quinquis, B; Renault, P; Sorokin, A; Ehrlich, SD; Kulakauskas, S; Lapidus, A; Goltsman, E; Mazur, M; Pusch, GD; Fonstein, M; Overbeek, R; Kyprides, N; Purnelle, B; Prozzi, D; Ngui, K; Masuy, D; Hancy, F; Burteau, S; Boutry, M; Delcour, J; Goffeau, A; Hols, P				Bolotin, A; Quinquis, B; Renault, P; Sorokin, A; Ehrlich, SD; Kulakauskas, S; Lapidus, A; Goltsman, E; Mazur, M; Pusch, GD; Fonstein, M; Overbeek, R; Kyprides, N; Purnelle, B; Prozzi, D; Ngui, K; Masuy, D; Hancy, F; Burteau, S; Boutry, M; Delcour, J; Goffeau, A; Hols, P			Complete sequence and comparative genome analysis of the dairy bacterium Streptococcus thermophilus	NATURE BIOTECHNOLOGY			English	Article							GENE; IDENTIFICATION; EVOLUTION; PATHOGEN; BIOCHEMISTRY; AGALACTIAE; DECAY	The lactic acid bacterium Streptococcus thermophilus is widely used for the manufacture of yogurt and cheese. This dairy species of major economic importance is phylogenetically close to pathogenic streptococci, raising the possibility that it has a potential for virulence. Here we report the genome sequences of two yogurt strains of S. thermophilus. We found a striking level of gene decay (10% pseudogenes) in both microorganisms. Many genes involved in carbon utilization are nonfunctional, in line with the paucity of carbon sources in milk. Notably, most streptococcal virulence-related genes that are not involved in basic cellular processes are either inactivated or absent in the dairy streptococcus. Adaptation to the constant milk environment appears to have resulted in the stabilization of the genome structure. We conclude that S. thermophilus has evolved mainly through loss-of-function events that remarkably mirror the environment of the dairy niche resulting in a severely diminished pathogenic potential.	INRA, Ctr Rech Jouy En Josas, Unite Rech Latiere & Genet Appl, F-78352 Jouy En Josas, France; Integrated Gen, Chicago, IL 60612 USA; Univ Catholique Louvain, Inst Sci Vie, B-1348 Louvain, Belgium	INRAE; UDICE-French Research Universities; Universite Paris Saclay; Universite Catholique Louvain	Ehrlich, SD (corresponding author), INRA, Ctr Rech Jouy En Josas, Unite Rech Latiere & Genet Appl, F-78352 Jouy En Josas, France.	ehrlich@diamant.jouy.inra.fr	Sorokin, Alexei/AAV-4666-2020; Bolotine, Alexandre/AAW-1156-2020; Lapidus, Alla L/I-4348-2013; Ehrlich, S./Y-2423-2019; Kyrpides, Nikos C./A-6305-2014	Sorokin, Alexei/0000-0002-8653-9896; Bolotine, Alexandre/0000-0002-5878-8270; Lapidus, Alla L/0000-0003-0427-8731; Ehrlich, S./0000-0002-7563-4046; Kyrpides, Nikos C./0000-0002-6131-0462; Boutry, Marc/0000-0002-2315-6900				Ajdic D, 2002, P NATL ACAD SCI USA, V99, P14434, DOI 10.1073/pnas.172501299; Badger JH, 1999, MOL BIOL EVOL, V16, P512, DOI 10.1093/oxfordjournals.molbev.a026133; Bidnenko V, 1999, MOL MICROBIOL, V33, P846, DOI 10.1046/j.1365-2958.1999.01532.x; Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R; Broadbent JR, 2003, J DAIRY SCI, V86, P407, DOI 10.3168/jds.S0022-0302(03)73619-4; CHAUSSON F, 2002, EC LAITIERE CHIFFRES; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Comfort D, 2004, INFECT IMMUN, V72, P2710, DOI 10.1128/IAI.72.5.2710-2722.2004; Delcher AL, 1999, NUCLEIC ACIDS RES, V27, P2369, DOI 10.1093/nar/27.11.2369; Delcher AL, 1999, NUCLEIC ACIDS RES, V27, P4636, DOI 10.1093/nar/27.23.4636; Dobrindt U, 2001, CURR OPIN MICROBIOL, V4, P550, DOI 10.1016/S1369-5274(00)00250-2; ELSEN JA, 2000, GENOME BIOL, V1, P1101; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; Fox P.P., 1993, CHEESE CHEM PHYS MIC; Glaser P, 2002, MOL MICROBIOL, V45, P1499, DOI 10.1046/j.1365-2958.2002.03126.x; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Hirsh AE, 2001, NATURE, V411, P1046, DOI 10.1038/35082561; HUYEN M, 1998, P NATL ACAD SCI USA, V96, P5849; Jansen R, 2002, MOL MICROBIOL, V43, P1565, DOI 10.1046/j.1365-2958.2002.02839.x; Mitchell TJ, 2003, NAT REV MICROBIOL, V1, P219, DOI 10.1038/nrmicro771; Ochman H, 1999, P NATL ACAD SCI USA, V96, P12638, DOI 10.1073/pnas.96.22.12638; Overbeek R, 2000, NUCLEIC ACIDS RES, V28, P123, DOI 10.1093/nar/28.1.123; Overbeek R, 1999, P NATL ACAD SCI USA, V96, P2896, DOI 10.1073/pnas.96.6.2896; Paterson GK, 2004, TRENDS MICROBIOL, V12, P89, DOI 10.1016/j.tim.2003.12.007; STACKEBRANDT E, 1988, BIOCHIMIE, V70, P317, DOI 10.1016/0300-9084(88)90204-0; TAMIME AY, 1980, J FOOD PROTECT, V43, P939, DOI 10.4315/0362-028X-43.12.939; Tettelin H, 2001, SCIENCE, V293, P498, DOI 10.1126/science.1061217; Tettelin H, 2002, P NATL ACAD SCI USA, V99, P12391, DOI 10.1073/pnas.182380799; Wren BW, 2000, NAT REV GENET, V1, P30, DOI 10.1038/35049551; Zhang JR, 1999, MOL MICROBIOL, V31, P1477, DOI 10.1046/j.1365-2958.1999.01291.x	30	381	1062	6	100	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2004	22	12					1554	1558		10.1038/nbt1034	http://dx.doi.org/10.1038/nbt1034			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	878HX	15543133	Green Published, hybrid			2022-12-25	WOS:000225638600026
J	Patrinos, A				Patrinos, A			'Race' and the human genome	NATURE GENETICS			English	Editorial Material									US DOE, Off Sci, Washington, DC 20585 USA	United States Department of Energy (DOE)	Patrinos, A (corresponding author), US DOE, Off Sci, Washington, DC 20585 USA.							Barsh GS, 2003, PLOS BIOL, V1, P19, DOI 10.1371/journal.pbio.0000027; 2001, NAT GENET, V409, P860	2	14	14	1	4	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2004	36	11		S			S1	S2		10.1038/ng2150	http://dx.doi.org/10.1038/ng2150			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Genetics & Heredity	867PH	15510100	Bronze			2022-12-25	WOS:000224854000001
J	Weber, W; Rimann, M; Spielmann, M; Keller, B; Daoud-El Baba, M; Aubel, D; Weber, CC; Fussenegger, M				Weber, W; Rimann, M; Spielmann, M; Keller, B; Daoud-El Baba, M; Aubel, D; Weber, CC; Fussenegger, M			Gas-inducible transgene expression in mammalian cells and mice	NATURE BIOTECHNOLOGY			English	Article							HAMSTER OVARY CELLS; GENE-EXPRESSION; ASPERGILLUS-NIDULANS; TRANSCRIPTION FACTOR; SYSTEM; SWITCH; DOXYCYCLINE; SEQUENCE; VECTORS	We describe the design and detailed characterization of a gas-inducible transgene control system functional in different mammalian cells, mice and prototype biopharmaceutical manufacturing. The acetaldehyde-inducible AlcR-P-alcA transactivator-promoter interaction of the Aspergillus nidulans ethanol-catabolizing regulon(1) was engineered for gas-adjustable transgene expression in mammalian cells. Fungal AlcR retained its transactivation characteristics in a variety of mammalian cell lines and reversibly adjusted transgene transcription from chimeric mammalian promoters (P-AIR) containing P-alcA-derived operators in a gaseous acetaldehyde-dependent manner. Mice implanted with microencapsulated cells engineered for acetaldehyde-inducible regulation (AIR) of the human glycoprotein secreted placental alkaline phosphatase showed adjustable serum phosphatase levels after exposure to different gaseous acetaldehyde concentrations. AIR-controlled interferon-beta production in transgenic CHO-K1-derived serum-free suspension cultures could be modulated by fine-tuning inflow and outflow of acetaldehyde-containing gas during standard bioreactor operation. AIR technology could serve as a tool for therapeutic transgene dosing as well as biopharmaceutical manufacturing.	ETH Honggerberg, Swiss Fed Inst Technol, Inst Chem & Bioengn, CH-8093 Zurich, Switzerland; Inst Univ Technol, IUTA, Dept Genie Biol, F-69622 Villeurbanne, France; ETH Zentrum, Swiss Fed Inst Technol, Inst Biomed Engn, CH-8044 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Fussenegger, M (corresponding author), ETH Honggerberg, Swiss Fed Inst Technol, Inst Chem & Bioengn, HCI F115, CH-8093 Zurich, Switzerland.	fussenegger@chem.ethz.ch	Weber, Wilfried/B-4732-2012	Weber, Wilfried/0000-0003-4340-4446				Aubel D, 2001, J ANTIBIOT, V54, P44, DOI 10.7164/antibiotics.54.44; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; Bohl D, 1997, NAT MED, V3, P299, DOI 10.1038/nm0397-299; Boorsma M, 2000, NAT BIOTECHNOL, V18, P429, DOI 10.1038/74493; Dioum EM, 2002, SCIENCE, V298, P2385, DOI 10.1126/science.1078456; Favre D, 2002, J VIROL, V76, P11605, DOI 10.1128/JVI.76.22.11605-11611.2002; FELENBOK B, 1988, GENE, V73, P385, DOI 10.1016/0378-1119(88)90503-3; Felenbok B, 2001, PROG NUCLEIC ACID RE, V69, P149, DOI 10.1016/S0079-6603(01)69047-0; Flipphi M, 2002, BIOCHEM J, V364, P25, DOI 10.1042/bj3640025; Fussenegger M, 2000, NAT BIOTECHNOL, V18, P1203, DOI 10.1038/81208; Fussenegger M, 1998, NAT BIOTECHNOL, V16, P468, DOI 10.1038/nbt0598-468; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Kramer BP, 2004, NAT BIOTECHNOL, V22, P867, DOI 10.1038/nbt980; Kramer BP, 2003, BIOTECHNOL BIOENG, V83, P810, DOI 10.1002/bit.10731; Malleret G, 2001, CELL, V104, P675, DOI 10.1016/S0092-8674(01)00264-1; Mitta B, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf112; Moser S, 2001, J GENE MED, V3, P529, DOI 10.1002/jgm.219; Neddermann P, 2003, EMBO REP, V4, P159, DOI 10.1038/sj.embor.embor734; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Rivera VM, 1996, NAT MED, V2, P1028, DOI 10.1038/nm0996-1028; Schlatter S, 2002, GENE, V282, P19, DOI 10.1016/S0378-1119(01)00824-1; Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197; Wang XJ, 1999, P NATL ACAD SCI USA, V96, P8483, DOI 10.1073/pnas.96.15.8483; Weber W, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng071; Weber W, 2002, J GENE MED, V4, P676, DOI 10.1002/jgm.314; Weber W, 2002, BIOTECHNOL BIOENG, V80, P691, DOI 10.1002/bit.10461; Weber W, 2002, NAT BIOTECHNOL, V20, P901, DOI 10.1038/nbt731; Weikert S, 1999, NAT BIOTECHNOL, V17, P1116, DOI 10.1038/15104	30	95	100	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2004	22	11					1440	1444		10.1038/nbt1021	http://dx.doi.org/10.1038/nbt1021			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	869CL	15502819				2022-12-25	WOS:000224960600036
J	Franco, SJ; Rodgers, MA; Perrin, BJ; Han, JW; Bennin, DA; Critchley, DR; Huttenlocher, A				Franco, SJ; Rodgers, MA; Perrin, BJ; Han, JW; Bennin, DA; Critchley, DR; Huttenlocher, A			Calpain-mediated proteolysis of talin regulates adhesion dynamics	NATURE CELL BIOLOGY			English	Article							DEPENDENT PROTEASE CALPAIN; CELL-MIGRATION; FOCAL ADHESIONS; CYTOSKELETON; ACTIVATION; MOTILITY; BINDING; DOMAIN; FIBRONECTIN; DISRUPTION	Dynamic regulation of adhesion complexes is required for cell migration and has therefore emerged as a key issue in the study of cell motility(1). Recent progress has been made in defining some of the molecular mechanisms by which adhesion disassembly is regulated, including the contributions of adhesion adaptor proteins and tyrosine kinases(2). However, little is known about the potential contribution of proteolytic mechanisms to the regulation of adhesion complex dynamics. Here, we show that proteolysis of talin by the intracellular calcium-dependent protease calpain is critical for focal adhesion disassembly. We have generated a single point mutation in talin that renders it resistant to proteolysis by calpain. Quantification of adhesion assembly and disassembly rates demonstrates that calpain-mediated talin proteolysis is a rate-limiting step during adhesion turnover. Furthermore, we demonstrate that disassembly of other adhesion components, including paxillin, vinculin and zyxin, is also dependent on the ability of calpain to cleave talin, suggesting a general role for talin proteolysis in regulating adhesion turnover. Together, these findings identify calpain-mediated proteolysis of talin as a mechanism by which adhesion dynamics are regulated.	Univ Wisconsin, Dept Pediat, Madison, WI 53706 USA; Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; Univ Wisconsin, Mol & Cellular Biol Program, Madison, WI 53706 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California San Diego; University of Leicester	Huttenlocher, A (corresponding author), Univ Wisconsin, Dept Pediat, Madison, WI 53706 USA.	huttenlocher@wisc.edu	Franco, Santos/V-3413-2019	Franco, Santos/0000-0002-4478-5634; Rodgers, Mary/0000-0001-8815-8651	NCI NIH HHS [R01CA85862-01] Funding Source: Medline; NIGMS NIH HHS [T32GM07215-25] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhatt A, 2002, J CELL SCI, V115, P3415; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; CHEN YP, 1994, J BIOL CHEM, V269, P18307; Dourdin N, 2001, J BIOL CHEM, V276, P48382, DOI 10.1074/jbc.M108893200; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Franco S, 2004, EXP CELL RES, V299, P179, DOI 10.1016/j.yexcr.2004.05.021; Giannone G, 2003, J CELL BIOL, V163, P409, DOI 10.1083/jcb.200302001; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; Huttenlocher A, 1996, J CELL BIOL, V134, P1551, DOI 10.1083/jcb.134.6.1551; ILLC D, 1995, NATURE, V377, P539; Jiang GY, 2003, NATURE, V424, P334, DOI 10.1038/nature01805; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Nayal A, 2004, CURR OPIN CELL BIOL, V16, P94, DOI 10.1016/j.ceb.2003.11.007; OHALLORAN T, 1985, NATURE, V317, P449, DOI 10.1038/317449a0; Priddle H, 1998, J CELL BIOL, V142, P1121, DOI 10.1083/jcb.142.4.1121; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; RUOSLAHTI E, 1982, METHOD ENZYMOL, V82, P803; Stabach PR, 1997, BIOCHEMISTRY-US, V36, P57, DOI 10.1021/bi962034i; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Webb DJ, 2003, CURR OPIN CELL BIOL, V15, P614, DOI 10.1016/S0955-0674(03)00105-4; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200; Zamir E, 1999, J CELL SCI, V112, P1655	26	410	415	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2004	6	10					977	+		10.1038/ncb1175	http://dx.doi.org/10.1038/ncb1175			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	859FY	15448700				2022-12-25	WOS:000224250000012
J	Seo, SK; Choi, JH; Kim, YH; Kang, WJ; Park, HY; Suh, JH; Choi, BK; Vinay, DS; Kwon, BS				Seo, SK; Choi, JH; Kim, YH; Kang, WJ; Park, HY; Suh, JH; Choi, BK; Vinay, DS; Kwon, BS			4-1BB-mediated immunotherapy of rheumatoid arthritis	NATURE MEDICINE			English	Article							T-CELL PROLIFERATION; MONOCLONAL-ANTIBODIES; TRYPTOPHAN CATABOLISM; IN-VIVO; 4-1BB LIGAND; EXPRESSION; PATHOGENESIS; DISEASE	Collagen type II-induced arthritis is a CD4(+) T-cell-dependent chronic inflammation in susceptible DBA/1 mice and represents an animal model of human rheumatoid arthritis. We found that development of this condition, and even established disease, are inhibited by an agonistic anti-4-1BB monoclonal antibody. Anti-4-1BB suppressed serum antibodies to collagen type II and CD4(+) T-cell recall responses to collagen type II. Crosslinking of 4-1BB evoked an antigen-specific, active suppression mechanism that differed from the results of blocking the interaction between 4-1BB and its ligand, 4-1BBL. Anti-4-1BB monoclonal antibodies induced massive, antigen-dependent clonal expansion of CD11c(+)CD8(+) T cells and accumulation of indoleamine 2,3-dioxygenase in CD11b(+) monocytes and CD11c(+) dendritic cells. Both anti-interferon-gamma and 1-methyltryptophan, a pharmacological inhibitor of indoleamine 2,3-dioxygenase, reversed the anti-4-1BB effect. We conclude that the suppression of collagen-induced arthritis was caused by an expansion of new CD11c(+)CD8(+) T cells, and that interferon-gamma produced by these cells suppresses antigen-specific CD4(+) T cells through an indoleamine 2,3-dioxygenase-dependent mechanism.	Univ Ulsan, Immunomodulat Res Ctr, Ulsan 680749, South Korea; Univ Ulsan, Coll Med, Ulsan Univ Hosp, Dept Pathol, Ulsan 682060, South Korea; Louisiana State Univ, Ctr Eye, Hlth Sci Ctr, New Orleans, LA 70112 USA	University of Ulsan; University of Ulsan; Ulsan University Hospital; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Kwon, BS (corresponding author), Univ Ulsan, Immunomodulat Res Ctr, 29 Mukeo Dong, Ulsan 680749, South Korea.	bskwon@mail.ulsan.ac.kr	康, 宇鎭/GRO-6256-2022	Kang, Woojin/0000-0002-4880-3406	NATIONAL EYE INSTITUTE [R01EY013325, P30EY002377] Funding Source: NIH RePORTER; NEI NIH HHS [R01EY013325, P30EY002377] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Arend WP, 1997, ARTHRITIS RHEUM, V40, P595, DOI 10.1002/art.1780400402; Bertram EM, 2002, J IMMUNOL, V168, P3777, DOI 10.4049/jimmunol.168.8.3777; Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.3.CO;2-U; EDWARDS D, 1987, BIOMETRICS, V43, P913, DOI 10.2307/2531545; Fallarino F, 2003, NAT IMMUNOL, V4, P1206, DOI 10.1038/ni1003; Foell J, 2003, J CLIN INVEST, V111, P1505, DOI 10.1172/JCI200317662; Futagawa T, 2002, INT IMMUNOL, V14, P275, DOI 10.1093/intimm/14.3.275; Grohmann U, 2002, NAT IMMUNOL, V3, P1097, DOI 10.1038/ni846; Halstead ES, 2002, NAT IMMUNOL, V3, P536, DOI 10.1038/ni798; Holmdahl R, 2002, AGEING RES REV, V1, P135, DOI 10.1016/S0047-6374(01)00371-2; KWON BS, 1989, P NATL ACAD SCI USA, V86, P1963, DOI 10.1073/pnas.86.6.1963; Mauri C, 2000, NAT MED, V6, P673, DOI 10.1038/76251; Melero I, 1997, NAT MED, V3, P682, DOI 10.1038/nm0697-682; Mellor AL, 2003, J IMMUNOL, V171, P1652, DOI 10.4049/jimmunol.171.4.1652; Mellor AL, 2003, J IMMUNOL, V170, P5809, DOI 10.4049/jimmunol.170.12.5809; Milliken G. A., 1984, ANAL MESSY DATA; Mittler RS, 1999, J EXP MED, V190, P1535, DOI 10.1084/jem.190.10.1535; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Myers L, 2003, P NATL ACAD SCI USA, V100, P5348, DOI 10.1073/pnas.0837611100; NAKAJIMA H, 1990, CLIN EXP IMMUNOL, V81, P441; POLLOK KE, 1993, J IMMUNOL, V150, P771; Shuford WW, 1997, J EXP MED, V186, P47, DOI 10.1084/jem.186.1.47; Sun YL, 2002, NAT MED, V8, P1405, DOI 10.1038/nm796; Terness P, 2002, J EXP MED, V196, P447, DOI 10.1084/jem.20020052; WILLIAMS RO, 1994, P NATL ACAD SCI USA, V91, P2762, DOI 10.1073/pnas.91.7.2762; Ye ZM, 2002, NAT MED, V8, P343, DOI 10.1038/nm0402-343; ZVAIFLER NJ, 1983, AM J MED, V75, P3, DOI 10.1016/0002-9343(83)90469-2	28	263	286	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2004	10	10					1088	1094		10.1038/nm1107	http://dx.doi.org/10.1038/nm1107			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15448685				2022-12-25	WOS:000224245800039
J	Deng, XZ; Hofmann, ER; Villanueva, A; Hobert, O; Capodieci, P; Veach, DR; Yin, XL; Campodonico, L; Glekas, A; Cordon-Cardo, C; Clarkson, B; Bornmann, WG; Fuks, Z; Hengartner, MO; Kolesnick, R				Deng, XZ; Hofmann, ER; Villanueva, A; Hobert, O; Capodieci, P; Veach, DR; Yin, XL; Campodonico, L; Glekas, A; Cordon-Cardo, C; Clarkson, B; Bornmann, WG; Fuks, Z; Hengartner, MO; Kolesnick, R			Caenorhabditis elegans ABL-1 antagonizes p53-mediated germline apoptosis after ionizing irradiation	NATURE GENETICS			English	Article							PROGRAMMED CELL-DEATH; C-ABL; TUMOR-SUPPRESSOR; BCR-ABL; GENE; P53; EXPRESSION; RADIATION; MEIOSIS; HOMOLOG	c-Abl, a conserved nonreceptor tyrosine kinase, integrates genotoxic stress responses, acting as a transducer of both pro- and antiapoptotic effector pathways(1). Nuclear c-Abl seems to interact with the p53 homolog p73 to elicit apoptosis(2,3). Although several observations suggest that cytoplasmic localization of c-Abl is required for antiapoptotic function(4,5), the signals that mediate its antiapoptotic effect are largely unknown. Here we show that worms carrying an abl-1 deletion allele, abl-1(ok171), are specifically hypersensitive to radiation-induced apoptosis in the Caenorhabditis elegans germ line. Our findings delineate an apoptotic pathway antagonized by ABL-1, which requires sequentially the cell cycle checkpoint genes clk-2, hus-1 and mrt-2; the C. elegans p53 homolog, cep-1; and the genes encoding the components of the conserved apoptotic machinery, ced-3, ced-9 and egl-1. ABL-1 does not antagonize germline apoptosis induced by the DNA-alkylating agent ethylnitrosourea. Furthermore, worms treated with the c-Abl inhibitor STI-571 ( Gleevec; used in human cancer therapy), two newly synthesized STI-571 variants or PD166326 had a phenotype similar to that generated by abl-1( ok171). These studies indicate that ABL-1 distinguishes proapoptotic signals triggered by two different DNA-damaging agents and suggest that C. elegans might provide tissue models for development of anticancer drugs.	Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA; Univ Zurich, Dept Mol Biol, CH-8057 Zurich, Switzerland; Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Organ Synth Core Facil, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; University of Zurich; Columbia University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Kolesnick, R (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, 1275 York Ave, New York, NY 10021 USA.	r-kolesnick@ski.mskcc.org	Hengartner, Michael O/E-6235-2011; Hengartner, Michael O/A-7058-2008	Hobert, Oliver/0000-0002-7634-2854; Veach, Darren/0000-0002-8201-622X; Hengartner, Michael/0000-0002-7584-596X	NCI NIH HHS [P30 CA008748, P01 CA064593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA064593, P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Barila D, 2003, MOL CELL BIOL, V23, P2790, DOI 10.1128/MCB.23.8.2790-2799.2003; Berman E, 2000, LEUKEMIA RES, V24, P289, DOI 10.1016/S0145-2126(99)00179-4; Boulton SJ, 2002, SCIENCE, V295, P127, DOI 10.1126/science.1065986; Buchdunger E, 1996, CANCER RES, V56, P100; Chin GM, 2001, GENE DEV, V15, P522, DOI 10.1101/gad.864101; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; Druker BJ, 2002, TRENDS MOL MED, V8, pS14, DOI 10.1016/S1471-4914(02)02305-5; ELLIS RE, 1991, GENETICS, V129, P79; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gartner A, 2000, MOL CELL, V5, P435, DOI 10.1016/S1097-2765(00)80438-4; Gong JG, 1999, NATURE, V399, P806; Gumienny TL, 1999, DEVELOPMENT, V126, P1011; Hamby JM, 1997, J MED CHEM, V40, P2296, DOI 10.1021/jm970367n; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Hofmann ER, 2002, CURR BIOL, V12, P1908, DOI 10.1016/S0960-9822(02)01262-9; Hsieh J, 1999, GENE DEV, V13, P2958, DOI 10.1101/gad.13.22.2958; KRAUSE M, 1994, DEV BIOL, V166, P133, DOI 10.1006/dbio.1994.1302; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; la Cour T, 2003, NUCLEIC ACIDS RES, V31, P393, DOI 10.1093/nar/gkg101; Rinaldo C, 2002, GENETICS, V160, P471; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; Shah A, 1999, AGING MENT HEALTH, V3, P153, DOI 10.1080/13607869956316; Takanami T, 2000, NUCLEIC ACIDS RES, V28, P4232, DOI 10.1093/nar/28.21.4232; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Wisniewski D, 2002, CANCER RES, V62, P4244; Zhou Z, 2001, DEV CELL, V1, P477, DOI 10.1016/S1534-5807(01)00058-2	29	63	91	1	11	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2004	36	8					906	912		10.1038/ng1396	http://dx.doi.org/10.1038/ng1396			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	842AG	15273685				2022-12-25	WOS:000222974000027
J	Fredman, D; White, SJ; Potter, S; Eichler, EE; Den Dunnen, JT; Brookes, AJ				Fredman, D; White, SJ; Potter, S; Eichler, EE; Den Dunnen, JT; Brookes, AJ			Complex SNP-related sequence variation in segmental genome duplications	NATURE GENETICS			English	Article							DEPENDENT PROBE AMPLIFICATION; NUCLEOTIDE POLYMORPHISMS SNPS; MICROARRAY ANALYSIS; GENE CONVERSION; REARRANGEMENTS; DESIGN; IMPACT; MAP	There is uncertainty about the true nature of predicted single-nucleotide polymorphisms ( SNPs) in segmental duplications (duplicons) and whether these markers genuinely exist at increased density as indicated in public databases. We explored these issues by genotyping 157 predicted SNPs in duplicons and control regions in normal diploid genomes and fully homozygous complete hydatidiform moles. Our data identified many true SNPs in duplicon regions and few paralogous sequence variants. Twenty-eight percent of the polymorphic duplicon sequences we tested involved multisite variation, a new type of polymorphism representing the sum of the signals from many individual duplicon copies that vary in sequence content due to duplication, deletion or gene conversion. Multisite variations can masquerade as normal SNPs when genotyped. Given that duplicons comprise at least 5% of the genome and many are yet to be annotated in the genome draft, effective strategies to identify multisite variation must be established and deployed.	Karolinska Inst, Ctr Gen & Bioinformat, S-17177 Stockholm, Sweden; Leiden Univ, Med Ctr, NL-2333 AL Leiden, Netherlands; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA	Karolinska Institutet; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Case Western Reserve University	Brookes, AJ (corresponding author), Univ Leicester, Dept Genet, Univ Rd, Leicester LE1 7RH, Leics, England.	anthony.brookes@cgb.ki.se	dunnen, johan den/ABH-4228-2020; Fredman, David J/H-3566-2013	dunnen, johan den/0000-0002-6304-1710; Fredman, David J/0000-0003-3507-0554				Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; Bailey JA, 2001, GENOME RES, V11, P1005, DOI 10.1101/gr.GR-1871R; Birney E, 2004, NUCLEIC ACIDS RES, V32, pD468, DOI 10.1093/nar/gkh038; Carlson CS, 2003, NAT GENET, V33, P518, DOI 10.1038/ng1128; Cheung J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r25; Conant GC, 2003, GENOME RES, V13, P2052, DOI 10.1101/gr.1252603; Estivill X, 2002, HUM MOL GENET, V11, P1987, DOI 10.1093/hmg/11.17.1987; Fredman D, 2004, HUM MUTAT, V24, P1, DOI 10.1002/humu.20066; Hollox EJ, 2003, AM J HUM GENET, V73, P591, DOI 10.1086/378157; Hurles M, 2002, SCIENCE, V298; Hurles M E, 2001, BMC Genomics, V2, P11, DOI 10.1186/1471-2164-2-11; Istrail S, 2004, P NATL ACAD SCI USA, V101, P1916, DOI 10.1073/pnas.0307971100; Jeffreys AJ, 2004, NAT GENET, V36, P151, DOI 10.1038/ng1287; Kruglyak L, 2001, NAT GENET, V27, P234, DOI 10.1038/85776; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Locke DP, 2004, J MED GENET, V41, P175, DOI 10.1136/jmg.2003.013813; Lucito R, 2003, GENOME RES, V13, P2291, DOI 10.1101/gr.1349003; Prince JA, 2001, GENOME RES, V11, P152, DOI 10.1101/gr.150201; Rozen S, 2003, NATURE, V423, P873, DOI 10.1038/nature01723; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056; Sebire NJ, 2003, PEDIATR DEVEL PATHOL, V6, P69, DOI 10.1007/s10024-002-0079-9; Shaw CJ, 2004, HUM MOL GENET, V13, pR57, DOI 10.1093/hmg/ddh073; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Smit AFA, 1999, CURR OPIN GENET DEV, V9, P657, DOI 10.1016/S0959-437X(99)00031-3; Tsui C, 2003, NUCLEIC ACIDS RES, V31, P4910, DOI 10.1093/nar/gkg664; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; White S, 2002, AM J HUM GENET, V71, P365, DOI 10.1086/341942; White SJ, 2004, HUM MUTAT, V24, P86, DOI 10.1002/humu.20054	29	179	190	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2004	36	8					861	866		10.1038/ng1401	http://dx.doi.org/10.1038/ng1401			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	842AG	15247918				2022-12-25	WOS:000222974000019
J	Li, YG; Cu, YTH; Luo, D				Li, YG; Cu, YTH; Luo, D			Multiplexed detection of pathogen DNA with DNA-based fluorescence nanobarcodes	NATURE BIOTECHNOLOGY			English	Article							GENE-EXPRESSION PATTERNS; OLIGONUCLEOTIDE DENDRIMERS; PROBES	Rapid, multiplexed, sensitive and specific molecular detection is of great demand in gene profiling, drug screening, clinical diagnostics and environmental analysis(1-3). One of the major challenges in multiplexed analysis is to identify each specific reaction with a distinct label or 'code'(4). Two encoding strategies are currently used: positional encoding, in which every potential reaction is preassigned a particular position on a solid-phase support such as a DNA microarray(5-8), and reaction encoding, where every possible reaction is uniquely tagged with a code that is most often optical or particle based(4,9-13). The micrometer size, polydispersity, complex fabrication process and nonbiocompatibility of current codes limit their usability(1,4,12). Here we demonstrate the synthesis of dendrimer-like DNA-based, fluorescence-intensity-coded nanobarcodes, which contain a built-in code and a probe for molecular recognition. Their application to multiplexed detection of the DNA of several pathogens is first shown using fluorescence microscopy and dot blotting, and further demonstrated using flow cytometry that resulted in detection that was sensitive (attomole) and rapid.	Cornell Univ, Dept Biol & Environm Engn, Ithaca, NY 14853 USA	Cornell University	Luo, D (corresponding author), Cornell Univ, Dept Biol & Environm Engn, Ithaca, NY 14853 USA.	DL79@cornell.edu	Taylor, Graham/A-4027-2012					Braeckmans K, 2002, NAT REV DRUG DISCOV, V1, P447, DOI 10.1038/nrd817; Capaldi S, 2000, Nucleic Acids Res, V28, pE21, DOI 10.1093/nar/28.7.e21; Chan WCW, 2002, CURR OPIN BIOTECH, V13, P40, DOI 10.1016/S0958-1669(02)00282-3; Cheung VG, 1999, NAT GENET, V21, P15, DOI 10.1038/4439; Cunin F, 2002, NAT MATER, V1, P39, DOI 10.1038/nmat702; DeRisi J, 1996, NAT GENET, V14, P457; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Fuja T, 2004, J BIOTECHNOL, V108, P193, DOI 10.1016/j.jbiotec.2003.11.012; Fulton RJ, 1997, CLIN CHEM, V43, P1749; Han MY, 2001, NAT BIOTECHNOL, V19, P631, DOI 10.1038/90228; Li YG, 2004, NAT MATER, V3, P38, DOI 10.1038/nmat1045; Lowe M, 2004, CYTOM PART A, V60A, P135, DOI 10.1002/cyto.a.20021; Luo D., 2003, MATER TODAY, V6, P38, DOI DOI 10.1016/S1369-7021(03)01130-1); Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755; Nicewarner-Pena SR, 2001, SCIENCE, V294, P137, DOI 10.1126/science.294.5540.137; Nilsen TW, 1997, J THEOR BIOL, V187, P273, DOI 10.1006/jtbi.1997.0446; Poon LLM, 2004, CLIN CHEM, V50, P67, DOI 10.1373/clinchem.2003.023663; RIED T, 1992, P NATL ACAD SCI USA, V89, P1388, DOI 10.1073/pnas.89.4.1388; Sanchez A, 1999, J INFECT DIS, V179, pS164, DOI 10.1086/514282; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shchepinov MS, 1997, NUCLEIC ACIDS RES, V25, P4447, DOI 10.1093/nar/25.22.4447; Shchepinov MS, 1999, NUCLEIC ACIDS RES, V27, P3035, DOI 10.1093/nar/27.15.3035; Sjostedt A, 1997, J CLIN MICROBIOL, V35, P1045; Steemers FJ, 2000, NAT BIOTECHNOL, V18, P91, DOI 10.1038/72006; Taton TA, 2000, SCIENCE, V289, P1757, DOI 10.1126/science.289.5485.1757; Vignali DAA, 2000, J IMMUNOL METHODS, V243, P243, DOI 10.1016/S0022-1759(00)00238-6; Wang J, 1998, J AM CHEM SOC, V120, P8281, DOI 10.1021/ja980619p; Wang J, 2003, ANAL CHEM, V75, P4667, DOI 10.1021/ac034411k; Wang J, 1998, ELECTROANAL, V10, P553, DOI 10.1002/(SICI)1521-4109(199807)10:8<553::AID-ELAN553>3.0.CO;2-7	29	359	389	6	200	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2005	23	7					885	889		10.1038/nbt1106	http://dx.doi.org/10.1038/nbt1106			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	944KT	15951805	Green Published, Bronze			2022-12-25	WOS:000230427700037
J	Ishikawa, H; Kubo, A; Tsukita, S; Tsukita, S				Ishikawa, H; Kubo, A; Tsukita, S; Tsukita, S			Odf2-deficient mother centrioles lack distal/subdistal appendages and the ability to generate primary cilia	NATURE CELL BIOLOGY			English	Article							POLYCYSTIC KIDNEY-DISEASE; LEFT-RIGHT ASYMMETRY; MICROTUBULE ORGANIZATION; INTRAFLAGELLAR TRANSPORT; CENTROSOME CYCLE; NODAL CILIA; CELL-CYCLE; PROTEIN; MOUSE; DUPLICATION	Outer dense fibre 2 (Odf2; also known as cenexin) was initially identified as a main component of the sperm tail cytoskeleton, but was later shown to be a general scaffold protein that is specifically localized at the distal/subdistal appendages of mother centrioles(1,2). Here we show that Odf2 expression is suppressed in mouse F9 cells when both alleles of Odf2 genes are deleted. Unexpectedly, the cell cycle of Odf2(-/-) cells does not seem to be affected. Immunofluorescence and ultrathin-section electron microscopy reveals that in Odf2(-/-) cells, distal/subdistal appendages disappear from mother centrioles, making it difficult to distinguish mother from daughter centrioles. In Odf2(-/-) cells, however, the formation of primary cilia is completely suppressed, although similar to 25% of wild-type F9 cells are ciliated under the steady-state cell cycle. The loss of primary cilia in Odf2(-/-) F9 cells can be rescued by exogenous Odf2 expression. These findings indicate that Odf2 is indispensable for the formation of distal/subdistal appendages and the generation of primary cilia, but not for other cell-cycle-related centriolar functions.	Kyoto Univ, Fac Med, Dept Cell Biol, Sakyo Ku, Kyoto 6068501, Japan; Japan Sci & Technol Corp, Solut Oriented Res Sci & Technol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Fac Med, Sch Hlth Sci, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; Japan Science & Technology Agency (JST); Kyoto University	Tsukita, S (corresponding author), Kyoto Univ, Fac Med, Dept Cell Biol, Sakyo Ku, Kyoto 6068501, Japan.	atsukita@mfour.med.kyoto-u.ac.jp	Kubo, Akiharu/I-2711-2014	Kubo, Akiharu/0000-0003-0902-3586				Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; Chang P, 2003, NAT CELL BIOL, V5, P71, DOI 10.1038/ncb900; Chretien D, 1997, J STRUCT BIOL, V120, P117, DOI 10.1006/jsbi.1997.3928; Dammermann A, 2002, J CELL BIOL, V159, P255, DOI 10.1083/jcb.200204023; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Gromley A, 2003, J CELL BIOL, V161, P535, DOI 10.1083/jcb.200301105; Hou XY, 2002, J CLIN INVEST, V109, P533, DOI 10.1172/JC1200214099; Jurczyk A, 2004, J CELL BIOL, V166, P637, DOI 10.1083/jcb.200405023; KOCHANSKI RS, 1990, J CELL BIOL, V110, P1599, DOI 10.1083/jcb.110.5.1599; LANGE BMH, 1995, J CELL BIOL, V130, P919, DOI 10.1083/jcb.130.4.919; McGrath J, 2003, CELL, V114, P61, DOI 10.1016/S0092-8674(03)00511-7; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Mogensen MM, 2000, J CELL SCI, V113, P3013; Nakagawa Y, 2001, MOL BIOL CELL, V12, P1687, DOI 10.1091/mbc.12.6.1687; Nauli SM, 2004, BIOESSAYS, V26, P844, DOI 10.1002/bies.20069; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Ou YY, 2002, J CELL SCI, V115, P1825; PAINTRAND M, 1992, J STRUCT BIOL, V108, P107, DOI 10.1016/1047-8477(92)90011-X; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; PIPERNO G, 1987, J CELL BIOL, V104, P289, DOI 10.1083/jcb.104.2.289; Praetorius HA, 2001, J MEMBRANE BIOL, V184, P71, DOI 10.1007/s00232-001-0075-4; RIEDER CL, 1982, BIOL CELL, V44, P117; Rieder CL, 2001, TRENDS CELL BIOL, V11, P413, DOI 10.1016/S0962-8924(01)02085-2; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; SOROKIN SP, 1968, J CELL SCI, V3, P207; VOROBJEV IA, 1982, J CELL BIOL, V93, P938, DOI 10.1083/jcb.93.3.938; WARD CJ, 1994, CELL, V77, P881; Watnick T, 2003, NAT GENET, V34, P355, DOI 10.1038/ng0803-355; WHEATLEY DN, 1982, CENTRIOLE CENTRAL EN; Yoder BK, 2002, J AM SOC NEPHROL, V13, P2508, DOI 10.1097/01.ASN.0000029587.47950.25	30	216	224	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2005	7	5					517	U79		10.1038/ncb1251	http://dx.doi.org/10.1038/ncb1251			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	926LA	15852003				2022-12-25	WOS:000229123500019
J	Teng, JL; Rai, T; Tanaka, Y; Takei, Y; Nakata, T; Hirasawa, M; Kulkarni, AB; Hirokawa, N				Teng, JL; Rai, T; Tanaka, Y; Takei, Y; Nakata, T; Hirasawa, M; Kulkarni, AB; Hirokawa, N			The KIF3 motor transports N-cadherin and organizes the developing neuroepithelium	NATURE CELL BIOLOGY			English	Article							KINESIN SUPERFAMILY PROTEIN; LEFT-RIGHT ASYMMETRY; CYCLIN D1; CRE RECOMBINASE; BETA-CATENIN; WNT; EXPRESSION; MORPHOGENESIS; MECHANISM; MEMBRANE	In the developing brain, the organization of the neuroepithelium is maintained by a critical balance between proliferation and cell - cell adhesion of neural progenitor cells. The molecular mechanisms that underlie this are still largely unknown. Here, through analysis of a conditional knockout mouse for the Kap3 gene, we show that post-Golgi transport of N-cadherin by the KIF3 molecular motor complex is crucial for maintaining this balance. N-cadherin and beta-catenin associate with the KIF3 complex by co-immunoprecipitation, and colocalize with KIF3 in cells. Furthermore, in KAP3-deficient cells, the subcellular localization of N-cadherin was disrupted. Taken together, these results suggest a potential tumour-suppressing activity for this molecular motor.	Univ Tokyo, Grad Sch Med, Dept Cell Biol & Anat, Bunkyo Ku, Tokyo 1130033, Japan; Natl Inst Dent & Craniofacial Res, Funct Genom Sect, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	University of Tokyo; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Hirokawa, N (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cell Biol & Anat, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	hirokawa@m.u-tokyo.ac.jp		Nakata, Takao/0000-0002-0629-0518; Tanaka, Yosuke/0000-0001-5376-5726	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000664] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000664] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Betz UAK, 1996, CURR BIOL, V6, P1307, DOI 10.1016/S0960-9822(02)70717-3; BURGER PC, 1994, ATLAS TUMOR PATHOLOG; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chen XY, 2003, J CELL BIOL, V163, P547, DOI 10.1083/jcb.200305137; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Ganzler-Odenthal SII, 1998, J NEUROSCI, V18, P5415; Gottardi CJ, 2001, CURR BIOL, V11, pR792, DOI 10.1016/S0960-9822(01)00473-0; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; Herrup Karl, 1994, Current Opinion in Neurobiology, V4, P108, DOI 10.1016/0959-4388(94)90039-6; Hirasawa M, 2001, NEUROSCI RES, V40, P125, DOI 10.1016/S0168-0102(01)00216-4; Hirokawa N, 2000, TRAFFIC, V1, P29, DOI 10.1034/j.1600-0854.2000.010105.x; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hirokawa N, 2005, NAT REV NEUROSCI, V6, P201, DOI 10.1038/nrn1624; Huangfu DW, 2003, NATURE, V426, P83, DOI 10.1038/nature02061; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; KONDO S, 1994, J CELL BIOL, V125, P1095, DOI 10.1083/jcb.125.5.1095; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Lele Z, 2002, DEVELOPMENT, V129, P3281; Lewis JE, 1997, J CELL BIOL, V136, P919, DOI 10.1083/jcb.136.4.919; Lin FM, 2003, P NATL ACAD SCI USA, V100, P5286, DOI 10.1073/pnas.0836980100; Marszalek JR, 1999, P NATL ACAD SCI USA, V96, P5043, DOI 10.1073/pnas.96.9.5043; Marszalek JR, 2000, CELL, V102, P175, DOI 10.1016/S0092-8674(00)00023-4; Mary S, 2002, MOL BIOL CELL, V13, P285, DOI 10.1091/mbc.01-07-0337; MIYATANI S, 1989, SCIENCE, V245, P631, DOI 10.1126/science.2762814; Nakagawa T, 2000, CELL, V103, P569, DOI 10.1016/S0092-8674(00)00161-6; Nakata T, 2003, J CELL BIOL, V162, P1045, DOI 10.1083/jcb.200302175; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nishimura T, 2004, NAT CELL BIOL, V6, P328, DOI 10.1038/ncb1118; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 2000, GENE DEV, V14, P1837; REDIES C, 1993, DEV DYNAM, V197, P26, DOI 10.1002/aja.1001970104; Sakai K, 1997, BIOCHEM BIOPH RES CO, V237, P318, DOI 10.1006/bbrc.1997.7111; Shimizu K, 1996, J BIOL CHEM, V271, P27013, DOI 10.1074/jbc.271.43.27013; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Takeda S, 2000, J CELL BIOL, V148, P1255, DOI 10.1083/jcb.148.6.1255; Takeda S, 1999, J CELL BIOL, V145, P825, DOI 10.1083/jcb.145.4.825; TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2; Taniguchi M, 1998, NUCLEIC ACIDS RES, V26, P679, DOI 10.1093/nar/26.2.679; Teng JL, 2001, J CELL BIOL, V155, P65, DOI 10.1083/jcb.200106025; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Yamazaki H, 1996, P NATL ACAD SCI USA, V93, P8443, DOI 10.1073/pnas.93.16.8443; YAMAZAKI H, 1995, J CELL BIOL, V130, P1387, DOI 10.1083/jcb.130.6.1387; Yanagisawa M, 2004, J BIOL CHEM, V279, P9512, DOI 10.1074/jbc.M310895200	50	133	138	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2005	7	5					474	U31		10.1038/ncb1249	http://dx.doi.org/10.1038/ncb1249			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	926LA	15834408				2022-12-25	WOS:000229123500014
J	Bystrykh, L; Weersing, E; Dontje, B; Sutton, S; Pletcher, MT; Wiltshire, T; Su, AI; Vellenga, E; Wang, JT; Manly, KF; Lu, L; Chesler, EJ; Alberts, R; Jansen, RC; Williams, RW; Cooke, MP; de Haan, G				Bystrykh, L; Weersing, E; Dontje, B; Sutton, S; Pletcher, MT; Wiltshire, T; Su, AI; Vellenga, E; Wang, JT; Manly, KF; Lu, L; Chesler, EJ; Alberts, R; Jansen, RC; Williams, RW; Cooke, MP; de Haan, G			Uncovering regulatory pathways that affect hematopoietic stem cell function using 'genetical genomics'	NATURE GENETICS			English	Article							MICE; DISSECTION; LESSONS; MOUSE	We combined large-scale mRNA expression analysis and gene mapping to identify genes and loci that control hematopoietic stem cell (HSC) function. We measured mRNA expression levels in purified HSCs isolated from a panel of densely genotyped recombinant inbred mouse strains. We mapped quantitative trait loci (QTLs) associated with variation in expression of thousands of transcripts. By comparing the physical transcript position with the location of the controlling QTL, we identified polymorphic cis-acting stem cell genes. We also identified multiple trans-acting control loci that modify expression of large numbers of genes. These groups of coregulated transcripts identify pathways that specify variation in stem cells. We illustrate this concept with the identification of candidate genes involved with HSC turnover. We compared expression QTLs in HSCs and brain from the same mice and identified both shared and tissue- specific QTLs. Our data are accessible through WebQTL, a web-based interface that allows custom genetic linkage analysis and identification of coregulated transcripts.	Univ Groningen, Dept Stem Cell Biol, NL-9713 AV Groningen, Netherlands; Novartis Res Fdn, Gen Inst, San Diego, CA 92121 USA; Acad Hosp, Dept Haematol, Groningen, Netherlands; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA; Univ Groningen, Groningen Bioinformat Ctr, Groningen, Netherlands	University of Groningen; Novartis; University of Groningen; Roswell Park Cancer Institute; University of Tennessee System; University of Tennessee Health Science Center; University of Groningen	de Haan, G (corresponding author), Univ Groningen, Dept Stem Cell Biol, Antonius Deusinglaan 1, NL-9713 AV Groningen, Netherlands.	g.de.haan@med.rug.nl	Chesler, Elissa/K-4641-2019; de Haan, Gerald/D-2081-2015; Jansen, Ritsert C/C-1160-2013; de Haan, Gerald/AAF-8963-2019; Williams, Robert W./H-8789-2016	Chesler, Elissa/0000-0002-5642-5062; de Haan, Gerald/0000-0001-9706-0138; Jansen, Ritsert C/0000-0003-2977-9110; de Haan, Gerald/0000-0001-9706-0138; Su, Andrew I./0000-0002-9859-4104; Williams, Robert W./0000-0001-8924-4447				BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BOULTWOOD J, 1994, BLOOD, V84, P3253; Brem RB, 2002, SCIENCE, V296, P752, DOI 10.1126/science.1069516; Chesler EJ, 2005, NAT GENET, V37, P233, DOI 10.1038/ng1518; De Haan G, 1999, FASEB J, V13, P707, DOI 10.1096/fasebj.13.6.707; de Haan G, 2002, BLOOD, V100, P2056, DOI 10.1182/blood-2002-03-0808; deHaan G, 1997, J EXP MED, V186, P529, DOI 10.1084/jem.186.4.529; Fortunel NO, 2003, SCIENCE, V302, P393; Hasty P, 2003, SCIENCE, V299, P1355, DOI 10.1126/science.1079161; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Jansen RC, 2003, NAT REV GENET, V4, P145, DOI 10.1038/nrg996; Jansen RC, 2001, TRENDS GENET, V17, P388, DOI 10.1016/S0168-9525(01)02310-1; Kamminga LM, 2000, EXP HEMATOL, V28, P1451, DOI 10.1016/S0301-472X(00)00543-9; Klose J, 2002, NAT GENET, V30, P385, DOI 10.1038/ng861; Lai F, 2001, GENOMICS, V71, P235, DOI 10.1006/geno.2000.6414; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Muller-Sieburg CE, 2000, BLOOD, V95, P2446, DOI 10.1182/blood.V95.7.2446.007k13_2446_2448; PEARCE SR, 1995, MAMM GENOME, V6, P537, DOI 10.1007/BF00356172; Peirce JL, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-7; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434; Scherer A, 2003, BIOTECHNIQUES, V34, P546, DOI 10.2144/03343rr01; Wayne ML, 2002, P NATL ACAD SCI USA, V99, P14903, DOI 10.1073/pnas.222549199; Wiltshire T, 2003, P NATL ACAD SCI USA, V100, P3380, DOI 10.1073/pnas.0130101100; Yvert G, 2003, NAT GENET, V35, P57, DOI 10.1038/ng1222	26	310	319	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2005	37	3					225	232		10.1038/ng1497	http://dx.doi.org/10.1038/ng1497			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	901QU	15711547				2022-12-25	WOS:000227297800013
J	Zheng, M; Messerschmidt, D; Jungblut, B; Sommer, RJ				Zheng, M; Messerschmidt, D; Jungblut, B; Sommer, RJ			Conservation and diversification of Wnt signaling function during the evolution of nematode vulva development	NATURE GENETICS			English	Article							C-ELEGANS; CAENORHABDITIS-ELEGANS; PRISTIONCHUS-PACIFICUS; EQUIVALENCE GROUP; GENE LIN-39; INDUCTION; ENCODES; CELLS	Cell-fate specification and cell-cell signaling have been well studied during vulva development in Caenorhabditis elegans and provide a paradigm in evolutionary developmental biology(1,2). Pristionchus pacificus has been developed as a 'satellite' organism with an integrated physical and genetic map that allows detailed comparisons to C. elegans(3-5).A common aspect of vulva formation in both species is the polarization of the P7. p lineage, which is responsible for vulval symmetry. In C. elegans, Wnt signaling is crucial for P7. p cell-fate patterning(6); nothing is known about vulval symmetry in P. pacificus. We isolated mutations that disrupt polarization of the P7. p lineage in P. pacificus and found that the corresponding gene encodes a Frizzled-like molecule. In addition, mutations in Ppa-lin-17 (encoding Frizzled) and morpholino knock-down of Ppa-lin-44 (encoding Wnt), Ppa-egl-20 (encoding Wnt), Ppa-mig-5 (encoding Dsh), Ppa-apr-1 (encoding APC) and Ppa-bar-1 (encoding beta-catenin) results in gonad-independent vulva differentiation, indicating that these genes have a role in a negative signaling process. In contrast, in C. elegans, Wnt signaling has a positive role in vulva induction, and mutations in bar-1 result in a hypoinduced phenotype(7). Therefore, whereas the molecular mechanisms that generate vulval symmetry are conserved, the genetic control of vulva induction diversified during evolution.	Max Planck Inst Entwicklungsbiol, Abt Evolut Biol, D-72076 Tubingen, Germany	Max Planck Society	Sommer, RJ (corresponding author), Max Planck Inst Entwicklungsbiol, Abt Evolut Biol, Spemannstr 37-39, D-72076 Tubingen, Germany.	ralf.sommer@tuebingen.mpg.de	Messerschmidt, Daniel Martin/W-7193-2019	Messerschmidt, Daniel Martin/0000-0003-2022-4696				Ceol CJ, 2004, DEV CELL, V6, P563, DOI 10.1016/S1534-5807(04)00065-6; Ceol CJ, 2001, MOL CELL, V7, P461, DOI 10.1016/S1097-2765(01)00194-0; Chen N, 2004, DEV CELL, V6, P183, DOI 10.1016/S1534-5807(04)00021-8; Eisenmann DM, 1998, DEVELOPMENT, V125, P3667; Eizinger A, 1997, SCIENCE, V278, P452, DOI 10.1126/science.278.5337.452; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; Inoue T, 2004, CELL, V118, P795, DOI 10.1016/j.cell.2004.09.001; Jungblut B, 2000, DEVELOPMENT, V127, P3295; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; LAMBSHEAD PJD, 1993, OCEANIS S D, V19, P5; Maloof JN, 1999, DEVELOPMENT, V126, P37; Pires-DaSilva A, 2004, GENE DEV, V18, P1198, DOI 10.1101/gad.293504; Sawa H, 1996, GENE DEV, V10, P2189, DOI 10.1101/gad.10.17.2189; Sigrist CB, 1999, DEV GENES EVOL, V209, P451, DOI 10.1007/s004270050278; Simpson P, 2002, NAT REV GENET, V3, P907, DOI 10.1038/nrg947; Sommer RJ, 1998, DEVELOPMENT, V125, P3865; Sommer RJ, 1996, CURR BIOL, V6, P52, DOI 10.1016/S0960-9822(02)00421-9; Sommer RJ, 2001, CURR OPIN CELL BIOL, V13, P715, DOI 10.1016/S0955-0674(00)00275-1; Srinivasan J, 2003, MOL GENET GENOMICS, V269, P715, DOI 10.1007/s00438-003-0881-8; Wang MQ, 2001, CURR TOP DEV BIOL, V51, P189, DOI 10.1016/S0070-2153(01)51006-6	20	48	56	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2005	37	3					300	304		10.1038/ng1512	http://dx.doi.org/10.1038/ng1512			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	901QU	15696167				2022-12-25	WOS:000227297800022
J	Hanks, BA; Jiang, JH; Singh, RAK; Song, WT; Barry, M; Huls, MH; Slawin, KM; Spencer, DM				Hanks, BA; Jiang, JH; Singh, RAK; Song, WT; Barry, M; Huls, MH; Slawin, KM; Spencer, DM			Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo	NATURE MEDICINE			English	Article							LIGAND; CD154; INDUCTION; RESPONSES; LIGATION; DISTINCT; SIGNALS; HELP	Modest clinical outcomes of dendritic-cell (DC) vaccine trials call for the refinement of DC vaccine design. Although many potential antigens have been identified, development of methods to enhance antigen presentation by DCs has lagged. We have engineered a potent, drug-inducible CD40 (iCD40) receptor that permits temporally controlled, lymphoid-localized, DC-specific activation. iCD40 is comprised of a membrane-localized cytoplasmic domain of CD40 fused to drug-binding domains. This allows it to respond to a lipid-permeable, high-affinity dimerizer drug while circumventing ectodomain-dependent negative-feedback mechanisms. These modifications permit prolonged activation of iCD40-expressing DCs in vivo, resulting in more potent CD8(+) T-cell effector responses, including the eradication of previously established solid tumors, relative to activation of DCs ex vivo (P < 0.01), typical of most clinical DC protocols. In addition, iCD40-mediated DC activation exceeded that achieved by stimulating the full-length, endogenous CD40 receptor both in vitro and in vivo. Because iCD40 is insulated from the extracellular environment and can be activated within the context of an immunological synapse, iCD40-expressing DCs have a prolonged lifespan and should lead to more potent vaccines, perhaps even in immune-compromised patients.	Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Baylor Coll Med, Med Sci Training Program, Houston, TX 77030 USA; Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; Methodist Hosp, Scott Dept Urol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston	Spencer, DM (corresponding author), Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA.	dspencer@bcm.tmc.edu	Hanks, Brent A./V-3835-2019	Hanks, Brent A./0000-0002-2803-3272				Ahonen CL, 2004, J EXP MED, V199, P775, DOI 10.1084/jem.20031591; Albert ML, 2001, NAT IMMUNOL, V2, P1010, DOI 10.1038/ni722; Andre P, 2002, NAT MED, V8, P247, DOI 10.1038/nm0302-247; BANCHEREAU J, 1998, SCIENCE, V392, P245; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Clackson T, 1998, P NATL ACAD SCI USA, V95, P10437, DOI 10.1073/pnas.95.18.10437; Contin C, 2003, J BIOL CHEM, V278, P32801, DOI 10.1074/jbc.M209993200; Coombes BK, 2001, IMMUNOL LETT, V78, P103, DOI 10.1016/S0165-2478(01)00242-5; Diehl L, 1999, NAT MED, V5, P774, DOI 10.1038/10495; Garlichs CD, 2003, STROKE, V34, P1412, DOI 10.1161/01.STR.0000074032.64049.47; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Hermans IF, 2000, J IMMUNOL, V164, P3095, DOI 10.4049/jimmunol.164.6.3095; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Iuliucci JD, 2001, J CLIN PHARMACOL, V41, P870, DOI 10.1177/00912700122010771; Kaykas A, 2001, EMBO J, V20, P2641, DOI 10.1093/emboj/20.11.2641; Kikuchi T, 2000, BLOOD, V96, P91, DOI 10.1182/blood.V96.1.91.013k19_91_99; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Lanzavecchia A, 2000, SCIENCE, V290, P92, DOI 10.1126/science.290.5489.92; Lindmark E, 2000, ARTERIOSCL THROM VAS, V20, P2322, DOI 10.1161/01.ATV.20.10.2322; Lutgens E, 1999, NAT MED, V5, P1313, DOI 10.1038/15271; LUTZ MB, 1994, J IMMUNOL METHODS, V174, P269, DOI 10.1016/0022-1759(94)90031-0; Mach F, 1998, NATURE, V394, P200, DOI 10.1038/28204; Martin E, 2003, IMMUNITY, V18, P155, DOI 10.1016/S1074-7613(02)00503-4; Mathur RK, 2004, NAT MED, V10, P540, DOI 10.1038/nm1045; Mauri C, 2000, NAT MED, V6, P673, DOI 10.1038/76251; Mazouz Naima, 2002, Cancer Immun, V2, P2; Melter M, 2000, BLOOD, V96, P3801, DOI 10.1182/blood.V96.12.3801.h8003801_3801_3808; Nestle FO, 2001, NAT MED, V7, P761, DOI 10.1038/89863; O'Sullivan BJ, 2002, J IMMUNOL, V168, P5491, DOI 10.4049/jimmunol.168.11.5491; Pettit AR, 1997, J IMMUNOL, V159, P3681; Pullen SS, 1999, J BIOL CHEM, V274, P14246, DOI 10.1074/jbc.274.20.14246; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Ridgway D, 2003, CANCER INVEST, V21, P873, DOI 10.1081/CNV-120025091; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Schulz O, 2000, IMMUNITY, V13, P453, DOI 10.1016/S1074-7613(00)00045-5; Seddon B, 2003, CURR OPIN IMMUNOL, V15, P321, DOI 10.1016/S0952-7915(03)00049-9; Singh RAK, 2002, J IMMUNOL, V169, P6779, DOI 10.4049/jimmunol.169.12.6779; Sousa CRE, 2001, IMMUNITY, V14, P495; Sousa CRE, 1999, IMMUNITY, V11, P637, DOI 10.1016/S1074-7613(00)80138-7; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Tone M, 2001, P NATL ACAD SCI USA, V98, P1751, DOI 10.1073/pnas.98.4.1751; Vonderheide RH, 2001, J CLIN ONCOL, V19, P3280, DOI 10.1200/JCO.2001.19.13.3280; Wong P, 2003, IMMUNITY, V18, P499, DOI 10.1016/S1074-7613(03)00081-5; Yang YP, 2004, NAT IMMUNOL, V5, P508, DOI 10.1038/ni1059	44	70	87	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					130	137		10.1038/nm1183	http://dx.doi.org/10.1038/nm1183			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15665830				2022-12-25	WOS:000226797300019
J	Meshel, AS; Wei, Q; Adelstein, RS; Sheetz, MP				Meshel, AS; Wei, Q; Adelstein, RS; Sheetz, MP			Basic mechanism of three-dimensional collagen fibre transport by fibroblasts	NATURE CELL BIOLOGY			English	Article							MYOSIN HEAVY-CHAIN; CELL-MIGRATION; II-B; MATRIX; EXPRESSION; REORGANIZATION; CYTOSKELETON; CONTRACTION; LOCOMOTION; RECEPTORS	Collagen remodelling by fibroblasts has a crucial role in organizing tissue structures that are essential to motility during wound repair, development and regulation of cell growth. However, the mechanism of collagen fibre movement in three-dimensional (3D) matrices is not understood. Here, we show that fibroblast lamellipodia extend along held collagen fibres, bind, and retract them in a 'hand-over-hand' cycle, involving alpha2beta1 integrin. Wild-type fibroblasts move collagen fibres three to four times farther per cycle than fibroblasts lacking myosin II-B (myosin II- B-/-). Similarly, myosin II-B-/- fibroblasts contract 3D collagen gels threefold less than controls. On two-dimensional (2D) substrates, however, rates of collagen bead and cell movement are not affected by loss of myosin II- B. Green fluorescent protein (GFP)-tagged myosin II- B, but not II- A, restores normal function in knockout cells and localizes to cell processes, whereas myosin II- A is more centrally located. Additionally, GFP - myosin II- B moves out to the periphery and back during hand-over-hand fibre movement, whereas on 2D collagen, myosin II- B is more centrally distributed. Thus, we suggest that cyclic myosin II- B assembly and contraction in lamellipodia power 3D fibre movements.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	Columbia University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Sheetz, MP (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	ms2001@columbia.edu		Adelstein, Robert/0000-0002-8683-2144	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL004235, ZIAHL004235] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; Brown ME, 2003, J CELL SCI, V116, P1087, DOI 10.1242/jcs.00335; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Defilippi P, 1999, MICROSC RES TECHNIQ, V47, P67, DOI 10.1002/(SICI)1097-0029(19991001)47:1<67::AID-JEMT7>3.3.CO;2-G; EASTWOOD M, 1994, BBA-GEN SUBJECTS, V1201, P186, DOI 10.1016/0304-4165(94)90040-X; Friedl P, 2004, CURR OPIN CELL BIOL, V16, P14, DOI 10.1016/j.ceb.2003.11.001; Friedl P, 2000, CELL MOL LIFE SCI, V57, P41, DOI 10.1007/s000180050498; Giannone G, 2004, CELL, V116, P431, DOI 10.1016/S0092-8674(04)00058-3; Golomb E, 2004, J BIOL CHEM, V279, P2800, DOI 10.1074/jbc.M309981200; Grinnell F, 2003, MOL BIOL CELL, V14, P384, DOI 10.1091/mbc.E02-08-0493; JAY PY, 1995, J CELL SCI, V108, P387; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; Kelley CA, 1996, J CELL BIOL, V134, P675, DOI 10.1083/jcb.134.3.675; Kolega J, 2003, MOL BIOL CELL, V14, P4745, DOI 10.1091/mbc.E03-04-0205; Kovacs M, 2003, J BIOL CHEM, V278, P38132, DOI 10.1074/jbc.M305453200; Lee GM, 1999, EXP CELL RES, V248, P294, DOI 10.1006/excr.1999.4418; Lo CM, 2004, MOL BIOL CELL, V15, P982, DOI 10.1091/mbc.E03-06-0359; Maaser K, 1999, MOL BIOL CELL, V10, P3067, DOI 10.1091/mbc.10.10.3067; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Nishizaka T, 2000, P NATL ACAD SCI USA, V97, P692, DOI 10.1073/pnas.97.2.692; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Saitoh T, 2001, FEBS LETT, V509, P365, DOI 10.1016/S0014-5793(01)03186-6; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; Tullio AN, 1997, P NATL ACAD SCI USA, V94, P12407, DOI 10.1073/pnas.94.23.12407; Uren D, 2000, J CLIN INVEST, V105, P663, DOI 10.1172/JCI8199; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; Wei QZ, 2000, MOL BIOL CELL, V11, P3617, DOI 10.1091/mbc.11.10.3617; YOUNG PE, 1993, GENE DEV, V7, P29, DOI 10.1101/gad.7.1.29	30	227	230	1	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2005	7	2					157	U70		10.1038/ncb1216	http://dx.doi.org/10.1038/ncb1216			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	893LC	15654332				2022-12-25	WOS:000226719500012
J	Beltramello, M; Piazza, V; Bukauskas, FF; Pozzan, T; Mammano, F				Beltramello, M; Piazza, V; Bukauskas, FF; Pozzan, T; Mammano, F			Impaired permeability to Ins(1,4,5)P-3 in a mutant connexin underlies recessive hereditary deafness	NATURE CELL BIOLOGY			English	Article							GAP-JUNCTION CHANNELS; GUINEA-PIG COCHLEA; INOSITOL 1,4,5-TRISPHOSPHATE; INNER-EAR; HEARING-LOSS; HELA-CELLS; MUTATIONS; ROLES; FREQUENCY; CALCIUM	Connexins are membrane proteins that assemble into gap-junction channels and are responsible for direct, electrical and metabolic coupling between connected cells. Here we describe an investigation of the properties of a recombinantly expressed recessive mutant of connexin 26 (Cx26), the V84L mutant, associated with deafness. Unlike other Cx26 mutations, V84L affects neither intracellular sorting nor electrical coupling, but specifically reduces permeability to the Ca2+-mobilizing messenger inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3). Both the permeability to Lucifer Yellow and the unitary channel conductance of V84L-mutant channels are indistinguishable from those of the wildtype Cx26. Injection of Ins(1,4,5)P-3 into supporting cells of the rat organ of Corti, which abundantly express Cx26, ensues in a regenerative wave of Ca2+ throughout the tissue. Blocking the gap junction communication abolishes wave propagation. We propose that the V84L mutation reduces metabolic coupling mediated by Ins(1,4,5)P-3 to an extent sufficient to impair the propagation of Ca2+ waves and the formation of a functional syncytium. Our data provide the first demonstration of a specific defect of metabolic coupling and offer a mechanistic explanation for the pathogenesis of an inherited human disease.	Venetian Inst Mol Med, I-35129 Padua, Italy; Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA; Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, Consiglio Nazl Ric, Inst Neurosci, I-35121 Padua, Italy; Univ Padua, Dept Phys, I-35132 Padua, Italy	Veneto Institute Molecular Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua	Mammano, F (corresponding author), Venetian Inst Mol Med, Via G Orus 2, I-35129 Padua, Italy.	fabio.mammano@unipd.it	Mammano, Fabio/I-5064-2012; Mammano, Fabio/AAM-3902-2020	Mammano, Fabio/0000-0003-3751-1691; Mammano, Fabio/0000-0003-3751-1691	Telethon [GGP02043] Funding Source: Medline	Telethon(Fondazione Telethon)		ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; Beltramello M, 2003, BIOCHEM BIOPH RES CO, V305, P1024, DOI 10.1016/S0006-291X(03)00868-4; Bennett MVL, 2003, TRENDS NEUROSCI, V26, P610, DOI 10.1016/j.tins.2003.09.008; Boettger T, 2002, NATURE, V416, P874, DOI 10.1038/416874a; Bruzzone R, 2003, FEBS LETT, V533, P79, DOI 10.1016/S0014-5793(02)03755-9; Bukauskas FF, 2004, BBA-BIOMEMBRANES, V1662, P42, DOI 10.1016/j.bbamem.2004.01.008; Cohen-Salmon M, 2002, CURR BIOL, V12, P1106, DOI 10.1016/S0960-9822(02)00904-1; D'Andrea P, 2002, BIOCHEM BIOPH RES CO, V296, P685, DOI 10.1016/S0006-291X(02)00891-4; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; Forge A, 2003, CELL COMMUN ADHES, V10, P341, DOI 10.1080/cac.10.4-6.341.346; Gale JE, 2004, CURR BIOL, V14, P526, DOI 10.1016/j.cub.2004.03.002; Gerido DA, 2004, BBA-BIOMEMBRANES, V1662, P159, DOI 10.1016/j.bbamem.2003.10.017; Goodenough DA, 2003, NAT REV MOL CELL BIO, V4, P285, DOI 10.1038/nrm1072; Harris AL, 2001, Q REV BIOPHYS, V34, P325, DOI 10.1017/S0033583501003705; Jentsch TJ, 2000, NAT REV NEUROSCI, V1, P21, DOI 10.1038/35036198; Kam Y, 1998, BBA-BIOMEMBRANES, V1372, P384, DOI 10.1016/S0005-2736(98)00075-3; Kelley PM, 1998, AM J HUM GENET, V62, P792, DOI 10.1086/301807; Kenna MA, 2001, ARCH OTOLARYNGOL, V127, P1037, DOI 10.1001/archotol.127.9.1037; Lagostena L, 2001, CELL COMMUN ADHES, V8, P393, DOI 10.3109/15419060109080760; Lagostena L, 2001, J PHYSIOL-LONDON, V531, P693, DOI 10.1111/j.1469-7793.2001.0693h.x; Lautermann J, 1998, CELL TISSUE RES, V294, P415, DOI 10.1007/s004410051192; Niessen H, 2000, J CELL SCI, V113, P1365; Niessen H, 2000, FEBS LETT, V466, P112, DOI 10.1016/S0014-5793(99)01770-6; Oh S, 1997, NEURON, V19, P927, DOI 10.1016/S0896-6273(00)80973-3; Peracchia C, 2004, BBA-BIOMEMBRANES, V1662, P61, DOI 10.1016/j.bbamem.2003.10.020; SAEZ JC, 1989, P NATL ACAD SCI USA, V86, P2708, DOI 10.1073/pnas.86.8.2708; Skerrett IM, 2004, FASEB J, V18, P860, DOI 10.1096/fj.03-0763fje; Thomas GH, 2000, TRENDS MICROBIOL, V8, P15, DOI 10.1016/S0966-842X(99)01668-6; Verselis V.K., 2000, ADV MOL CEL, V30, P129; Wang HL, 2003, J NEUROCHEM, V84, P735, DOI 10.1046/j.1471-4159.2003.01555.x	30	197	209	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2005	7	1					63	+		10.1038/ncb1205	http://dx.doi.org/10.1038/ncb1205			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	884UZ	15592461				2022-12-25	WOS:000226113500016
J	Kohler, C; Page, DR; Gagliardini, V; Grossniklaus, U				Kohler, C; Page, DR; Gagliardini, V; Grossniklaus, U			The Arabidopsis thaliana MEDEA Polycomb group protein controls expression of PHERES1 by parental imprinting	NATURE GENETICS			English	Article							SEED DEVELOPMENT; GROUP GENE; METHYLATION; ENDOSPERM; GENOME	The maternally expressed Arabidopsis thaliana Polycomb group protein MEDEA (MEA) controls expression of the MADS-box gene PHERES1 (PHE1). Here, we show that PHE1 is mainly paternally expressed but maternally repressed and that this maternal repression of PHE1 breaks down in seeds lacking maternal MEA activity. Because Polycomb group proteins control parental imprinting in mammals as well, the independent recruitment of similar protein machineries for the imprinting of genes is a notable example of convergent evolution.	Univ Zurich, Inst Plant Biol, CH-8008 Zurich, Switzerland; Univ Zurich, Zurich Basel Plant Sci Ctr, CH-8008 Zurich, Switzerland	University of Zurich; University of Zurich	Kohler, C (corresponding author), Univ Zurich, Inst Plant Biol, Zollikerstr 107, CH-8008 Zurich, Switzerland.	ckoehler@botinst.unizh.ch	Grossniklaus, Ueli/A-2736-2012; Köhler, Claudia/G-9668-2011; Grossniklaus, Ueli/E-9995-2016	Köhler, Claudia/0000-0002-2619-4857; Grossniklaus, Ueli/0000-0002-0522-8974; Gagliardini, Valeria/0000-0001-9471-0764				Grossniklaus U, 1998, SCIENCE, V280, P446, DOI 10.1126/science.280.5362.446; HAIG D, 1989, AM NAT, V134, P147, DOI 10.1086/284971; Hurst LD, 1998, CURR OPIN GENET DEV, V8, P701, DOI 10.1016/S0959-437X(98)80040-3; Kiyosue T, 1999, P NATL ACAD SCI USA, V96, P4186, DOI 10.1073/pnas.96.7.4186; Kohler C, 2003, GENE DEV, V17, P1540, DOI 10.1101/gad.257403; Lewis A, 2004, NAT GENET, V36, P1291, DOI 10.1038/ng1468; Luo M, 1999, P NATL ACAD SCI USA, V96, P296, DOI 10.1073/pnas.96.1.296; Mager J, 2003, NAT GENET, V33, P502, DOI 10.1038/ng1125; Schubert D, 2003, CURR BIOL, V13, pR638, DOI 10.1016/S0960-9822(03)00569-4; Silva J, 2003, DEV CELL, V4, P481, DOI 10.1016/S1534-5807(03)00068-6; Spielman M, 2001, TRENDS GENET, V17, P705, DOI 10.1016/S0168-9525(01)02519-7; Tilghman SM, 1999, CELL, V96, P185, DOI 10.1016/S0092-8674(00)80559-0; Vielle-Calzada JP, 2000, NATURE, V404, P91, DOI 10.1038/35003595; Vielle-Calzada JP, 1999, GENE DEV, V13, P2971, DOI 10.1101/gad.13.22.2971; Wang JB, 2001, NAT GENET, V28, P371, DOI 10.1038/ng574	15	207	223	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2005	37	1					28	30		10.1038/ng1495	http://dx.doi.org/10.1038/ng1495			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	883FX	15619622				2022-12-25	WOS:000225997500017
J	Slade, AJ; Fuerstenberg, SI; Loeffler, D; Steine, MN; Facciotti, D				Slade, AJ; Fuerstenberg, SI; Loeffler, D; Steine, MN; Facciotti, D			A reverse genetic, nontransgenic approach to wheat crop improvement by TILLING	NATURE BIOTECHNOLOGY			English	Article							BOUND STARCH SYNTHASE; WAXY WHEATS; PROTEINS; ALLELES; IDENTIFICATION; POLYMORPHISM; MUTAGENESIS; MUTATIONS; TOOL	We report the use of TILLING (targeting induced local lesions in genomes), a reverse genetic, nontransgenic method, to improve a quality trait in a polyploid crop plant. Waxy starches, composed mostly of amylopectin, have unique physiochemical properties. Wheat with only one or two functional waxy genes (granule-bound starch synthase I, or GBSSI) produces starch with intermediate levels of amylopectin. We have identified 246 alleles of the waxy genes by TILLING each homoeolog in 1,920 allohexaploid and allotetraploid wheat individuals. These alleles encode waxy enzymes ranging in activity from near wild type to null, and they represent more genetic diversity than had been described in the preceding 25 years. A line of bread wheat containing homozygous mutations in two waxy homoeologs created through TILLING and a preexisting deletion of the third waxy homoeolog displays a near-null waxy phenotype. This approach to creating and identifying genetic variation shows potential as a tool for crop improvement.	Anawah Inc, Seattle, WA 98104 USA; Anawah Inc, Davis, CA 95616 USA		Slade, AJ (corresponding author), Anawah Inc, 1102 Columbia St,Suite 600, Seattle, WA 98104 USA.	ann@anawah.com						Ahloowalia BS, 2004, EUPHYTICA, V135, P187, DOI 10.1023/B:EUPH.0000014914.85465.4f; AHN S, 1993, MOL GEN GENET, V241, P483, DOI 10.1007/BF00279889; Anderson P, 1995, METHOD CELL BIOL, V48, P31; Burrell MM, 2003, J EXP BOT, V54, P451, DOI 10.1093/jxb/erg049; CHAO S, 1989, THEOR APPL GENET, V78, P495, DOI 10.1007/BF00290833; Colbert T, 2001, PLANT PHYSIOL, V126, P480, DOI 10.1104/pp.126.2.480; Collins GN, 1920, SCIENCE, V52, P48, DOI 10.1126/science.52.1333.48; Demeke T, 1997, CEREAL CHEM, V74, P442, DOI 10.1094/CCHEM.1997.74.4.442; Fox JL, 2004, NAT BIOTECHNOL, V22, P1062, DOI 10.1038/nbt0904-1062; Gale MD, 1998, P NATL ACAD SCI USA, V95, P1971, DOI 10.1073/pnas.95.5.1971; Graybosch RA, 2003, J CEREAL SCI, V38, P69, DOI 10.1016/S0733-5210(02)00139-X; Graybosch RA, 1998, TRENDS FOOD SCI TECH, V9, P135, DOI 10.1016/S0924-2244(98)00034-X; Greene EA, 2003, GENETICS, V164, P731; Henikoff JG, 1996, COMPUT APPL BIOSCI, V12, P135; Henikoff S, 2004, PLANT PHYSIOL, V135, P630, DOI 10.1104/pp.104.041061; Hucl P, 2001, CROP SCI, V41, P1348, DOI 10.2135/cropsci2001.4141348x; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; Marcoz-Ragot C, 2000, PLANT BREEDING, V119, P305, DOI 10.1046/j.1439-0523.2000.00510.x; McCallum CM, 2000, PLANT PHYSIOL, V123, P439, DOI 10.1104/pp.123.2.439; Miura H, 1999, EUPHYTICA, V108, P91, DOI 10.1023/A:1003604328227; Miura H, 2002, EUPHYTICA, V123, P353, DOI 10.1023/A:1015042322687; Mochida K., 2003, MGG Molecular Genetics and Genomics, V270, P371, DOI 10.1007/s00438-003-0939-7; MOORE G, 1995, CURR BIOL, V5, P737, DOI 10.1016/S0960-9822(95)00148-5; Murai J, 1999, GENE, V234, P71, DOI 10.1016/S0378-1119(99)00178-X; Nakamura T, 2002, GENOME, V45, P1150, DOI [10.1139/g02-090, 10.1139/G02-090]; NAKAMURA T, 1993, BIOCHEM GENET, V31, P75, DOI 10.1007/BF02399821; NAKAMURA T, 1995, MOL GEN GENET, V248, P253, DOI 10.1007/BF02191591; Neff MM, 2002, TRENDS GENET, V18, P613, DOI 10.1016/S0168-9525(02)02820-2; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Oleykowski CA, 1998, NUCLEIC ACIDS RES, V26, P4597, DOI 10.1093/nar/26.20.4597; Perry JA, 2003, PLANT PHYSIOL, V131, P866, DOI 10.1104/pp.102.017384; *R DEV COR TEAM, 2004, R LANG ENV STAT COMP; Rodriguez-Quijano M, 1998, PLANT BREEDING, V117, P341, DOI 10.1111/j.1439-0523.1998.tb01951.x; Saito M, 2004, THEOR APPL GENET, V108, P1205, DOI 10.1007/s00122-003-1549-9; Shariflou MR, 2001, PLANT BREEDING, V120, P121, DOI 10.1046/j.1439-0523.2001.00577.x; Smits BMG, 2004, GENOME RES, V14, P1285, DOI 10.1101/gr.2155004; Sorrells ME, 2003, GENOME RES, V13, P1818, DOI 10.1101/gr.1113003; Stadler LJ, 1929, P NATL ACAD SCI USA, V15, P876, DOI 10.1073/pnas.15.12.876; Taylor NE, 2003, NUCLEIC ACIDS RES, V31, P3808, DOI 10.1093/nar/gkg574; Wienholds E, 2003, GENOME RES, V13, P2700, DOI 10.1101/gr.1725103; YAMAMORI M, 1994, THEOR APPL GENET, V89, P179, DOI 10.1007/BF00225138; YAMAMORI M, 1998, MISC PUBL NATL I AGR, V12, P57; Yan LL, 2004, SCIENCE, V303, P1640, DOI 10.1126/science.1094305	43	366	441	1	81	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2005	23	1					75	81		10.1038/nbt1043	http://dx.doi.org/10.1038/nbt1043			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	885ZK	15580263				2022-12-25	WOS:000226195700032
J	Snow, JJ; Ou, GS; Gunnarson, AL; Walker, MRS; Zhou, HM; Brust-Mascher, I; Scholey, JM				Snow, JJ; Ou, GS; Gunnarson, AL; Walker, MRS; Zhou, HM; Brust-Mascher, I; Scholey, JM			Two anterograde intraflagellar transport motors cooperate to build sensory cilia on C-elegans neurons	NATURE CELL BIOLOGY			English	Article							KINESIN-II; CHEMOSENSORY NEURONS; CHLAMYDOMONAS; PARTICLES; MUTATIONS; MOVEMENT; PROTEIN; KINASE; MOUSE; IFT	Cilia have diverse roles in motility and sensory reception and their dysfunction contributes to cilia-related diseases. Assembly and maintenance of cilia depends on the intraflagellar transport (IFT) of axoneme, membrane, matrix and signalling proteins to appropriate destinations within the organelle(1-4). In the current model, these diverse cargo proteins bind to multiple sites on macromolecular IFT particles, which are moved by a single anterograde IFT motor, kinesin-II, from the ciliary base to its distal tip(5,6), where cargo-unloading occurs(1-4,7). Here, we describe the observation of fluorescent IFT motors and IFT particles moving along distinct domains within sensory cilia of wild-type and IFT-motor-mutant Caenorhabditis elegans. We show that two anterograde IFT motor holoenzymes, kinesin-II and Osm-3-kinesin(8), cooperate in a surprising way to control two pathways of IFT that build distinct parts of cilia. Instead of each motor independently moving its own specific cargo to a distinct destination, the two motors function redundantly to transport IFT particles along doublet microtubules adjacent to the transition zone to form the axoneme middle segment(9). Next, Osm-3-kinesin alone transports IFT particles along the distal singlet microtubules to stabilize the distal segment. Thus, the subtle coordinate activity of these IFT motors creates two sequential transport pathways.	Univ Calif Davis, Ctr Genet & Dev, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis	Scholey, JM (corresponding author), Univ Calif Davis, Ctr Genet & Dev, Sect Mol & Cellular Biol, Davis, CA 95616 USA.	jmscholey@ucdavis.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050718] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM050718] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Awan A, 2004, CELL MOTIL CYTOSKEL, V58, P1, DOI 10.1002/cm.10170; Bargmann C. I., 1997, C ELEGANS, P717; Berman SA, 2003, CURR BIOL, V13, P1145, DOI 10.1016/S0960-9822(03)00415-9; Brown JM, 1999, MOL BIOL CELL, V10, P3081, DOI 10.1091/mbc.10.10.3081; Cole DG, 1998, J CELL BIOL, V141, P993, DOI 10.1083/jcb.141.4.993; COLE DG, 1993, NATURE, V366, P268, DOI 10.1038/366268a0; Cordaux R, 2004, CURR BIOL, V14, P231, DOI 10.1016/j.cub.2004.01.024; Fan J, 2004, J CELL SCI, V117, P619, DOI 10.1242/jcs.00892; Goldstein LSB, 2000, ANNU REV NEUROSCI, V23, P39, DOI 10.1146/annurev.neuro.23.1.39; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; MESLAND DAM, 1980, J CELL BIOL, V84, P599, DOI 10.1083/jcb.84.3.599; Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398; Morris RL, 1997, J CELL BIOL, V138, P1009, DOI 10.1083/jcb.138.5.1009; Orozco JT, 1999, NATURE, V398, P674, DOI 10.1038/19448; Pan JM, 2004, DEV CELL, V6, P445, DOI 10.1016/S1534-5807(04)00064-4; Pan JM, 2002, MOL BIOL CELL, V13, P1417, DOI 10.1091/mbc.01-11-0531; Pazour GJ, 2003, CURR OPIN CELL BIOL, V15, P105, DOI 10.1016/S0955-0674(02)00012-1; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; Pierce-Shimomura JT, 1999, J NEUROSCI, V19, P9557; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; Sarpal R, 2003, CURR BIOL, V13, P1687, DOI 10.1016/j.cub.2003.09.025; Scholey JM, 2003, ANNU REV CELL DEV BI, V19, P423, DOI 10.1146/annurev.cellbio.19.111401.091318; Signor D, 1999, J CELL BIOL, V147, P519, DOI 10.1083/jcb.147.3.519; Signor D, 1999, MOL BIOL CELL, V10, P345, DOI 10.1091/mbc.10.2.345; Snell WJ, 2004, CELL, V117, P693, DOI 10.1016/j.cell.2004.05.019; STARICH TA, 1995, GENETICS, V139, P171; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; YANDELL MD, 1994, P NATL ACAD SCI USA, V91, P1381, DOI 10.1073/pnas.91.4.1381; Yang ZH, 2001, MOL CELL BIOL, V21, P5306, DOI 10.1128/MCB.21.16.5306-5311.2001; Zhou HM, 2001, J NEUROSCI, V21, P3749, DOI 10.1523/JNEUROSCI.21-11-03749.2001	30	287	297	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2004	6	11					1109	U23		10.1038/ncb1186	http://dx.doi.org/10.1038/ncb1186			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	867BI	15489852	Green Submitted			2022-12-25	WOS:000224816700016
J	Schubert, C				Schubert, C			Asthma edges ahead	NATURE MEDICINE			English	News Item																			0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2004	10	10					1051	1051						1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15459706				2022-12-25	WOS:000224245800026
J	Leveillard, T; Mohand-Said, S; Lorentz, O; Hicks, D; Fintz, AC; Clerin, E; Simonutti, M; Forster, V; Cavusoglu, N; Chalmel, F; Dolle, P; Poch, O; Lambrou, G; Sahel, JA				Leveillard, T; Mohand-Said, S; Lorentz, O; Hicks, D; Fintz, AC; Clerin, E; Simonutti, M; Forster, V; Cavusoglu, N; Chalmel, F; Dolle, P; Poch, O; Lambrou, G; Sahel, JA			Identification and characterization of rod-derived cone viability factor	NATURE GENETICS			English	Article							RETINITIS-PIGMENTOSA; SURVIVAL; DEGENERATION; THIOREDOXIN; MOUSE; CELLS; PHOTORECEPTORS; MUTATIONS; PROTEINS	Retinitis pigmentosa is an untreatable, inherited retinal disease that leads to blindness. The disease initiates with the loss of night vision due to rod photoreceptor degeneration, followed by irreversible, progressive loss of cone photoreceptor(1-3). Cone loss is responsible for the main visual handicap, as cones are essential for day and high-acuity vision(4). Their loss is indirect, as most genes associated with retinitis pigmentosa are not expressed by these cells. We previously showed that factors secreted from rods are essential for cone viability(5-8). Here we identified one such trophic factor by expression cloning and named it rod-derived cone viability factor (RdCVF). RdCVF is a truncated thioredoxin-like protein specifically expressed by photoreceptors. The identification of this protein offers new treatment possibilities for retinitis pigmentosa.	Univ Paris 06, Hop St Antoine, INSERM, U592,Lab Physiopathol Cellulaire & Mol & Retine, F-75571 Paris 12, France; Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Novartis Pharma AG Ophthalmol Res WKL127 1 04, CH-4002 Basel, Switzerland; UCL, Inst Ophthalmol, London WC1E 6BT, England	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Novartis; University of London; University College London	Leveillard, T (corresponding author), Univ Paris 06, Hop St Antoine, INSERM, U592,Lab Physiopathol Cellulaire & Mol & Retine, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.	leveilla@st-antoine.inserm.fr	Léveillard, Thierry/AAR-1804-2020; Dolle, Pascal/A-8037-2010; Sahel, Jose-Alain/F-3172-2017; Chalmel, Frédéric/AAM-1079-2021; Chalmel, Frederic/M-1297-2016; Chalmel, Frédéric/L-5360-2018	Léveillard, Thierry/0000-0001-5692-8770; Dolle, Pascal/0000-0002-9294-9090; Sahel, Jose-Alain/0000-0002-4831-1153; Chalmel, Frédéric/0000-0002-0535-3628; Chalmel, Frédéric/0000-0002-0535-3628; Clerin, Emmanuelle/0000-0003-1451-6051; Cavusoglu, Nukhet/0000-0001-9350-5312				ADLER R, 1989, SCIENCE, V243, P391, DOI 10.1126/science.2911751; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; CARTERDAWSON LD, 1978, INVEST OPHTH VIS SCI, V17, P489; Cau E, 1997, DEVELOPMENT, V124, P1611; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Dixon W. J., 1969, INTRO STAT ANAL; DOWLING JE, 1987, RETINAL CELLS PROCES; Fintz AC, 2003, INVEST OPHTH VIS SCI, V44, P818, DOI 10.1167/iovs.01-1144; Fontaine V, 1998, J NEUROSCI, V18, P9662; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; MCLAUGHLIN ME, 1993, NAT GENET, V4, P130, DOI 10.1038/ng0693-130; Mohand-Said S, 2000, ARCH OPHTHALMOL-CHIC, V118, P807, DOI 10.1001/archopht.118.6.807; Mohand-Said S, 1998, P NATL ACAD SCI USA, V95, P8357, DOI 10.1073/pnas.95.14.8357; MohandSaid S, 1997, OPHTHALMIC RES, V29, P290, DOI 10.1159/000268027; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; ROSENFELD PJ, 1992, NAT GENET, V1, P209, DOI 10.1038/ng0692-209; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; Zack DJ, 2000, NEURON, V26, P285, DOI 10.1016/S0896-6273(00)81160-5	21	320	342	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2004	36	7					755	759		10.1038/ng1386	http://dx.doi.org/10.1038/ng1386			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	833QT	15220920	Green Submitted, Bronze			2022-12-25	WOS:000222354100028
J	Jenny, A; Reynolds-Kenneally, J; Das, G; Burnett, M; Mlodzik, M				Jenny, A; Reynolds-Kenneally, J; Das, G; Burnett, M; Mlodzik, M			Diego and Prickle regulate Frizzled planar cell polarity signalling by competing for Dishevelled binding	NATURE CELL BIOLOGY			English	Letter							DROSOPHILA TISSUE POLARITY; ASYMMETRIC LOCALIZATION; PROTEIN; GENE; POLARIZATION; STRABISMUS; FATE; GASTRULATION; MECHANISMS; MOVEMENTS	Epithelial planar cell polarity ( PCP) is evident in the cellular organization of many tissues in vertebrates and invertebrates(1-5). In mammals, PCP signalling governs convergent extension during gastrulation and the organization of a wide variety of structures, including the orientation of body hair and sensory hair cells of the inner ear(6,7). In Drosophila melanogaster, PCP is manifest in adult tissues, including ommatidial arrangement in the compound eye and hair orientation in wing cells(1,2,4). PCP establishment requires the conserved Frizzled/ Dishevelled PCP pathway(1-5). Mutations in PCP- pathway- associated genes cause aberrant orientation of body hair or inner- ear sensory cells in mice(6,7), or misorientation of ommatidia and wing hair in D. melanogaster(1,2,4). Here we provide mechanistic insight into Frizzled/ Dishevelled signalling regulation. We show that the ankyrin- repeat protein Diego binds directly to Dishevelled and promotes Frizzled signalling. Dishevelled can also be bound by the Frizzled PCP antagonist Prickle(8). Strikingly, Diego and Prickle compete with one another for Dishevelled binding, thereby modulating Frizzled/ Dishevelled activity and ensuring tight control over Frizzled PCP signalling.	CUNY Mt Sinai Sch Med, Brookdale Dept Mol Cellular & Dev Biol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Mlodzik, M (corresponding author), CUNY Mt Sinai Sch Med, Brookdale Dept Mol Cellular & Dev Biol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	marek.mlodzik@mssm.edu			NIGMS NIH HHS [R01 GM62917] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062917] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adler PN, 2002, DEV CELL, V2, P525, DOI 10.1016/S1534-5807(02)00176-4; Adler PN, 1997, CURR BIOL, V7, P940, DOI 10.1016/S0960-9822(06)00413-1; Axelrod JD, 2001, GENE DEV, V15, P1182; Bastock R, 2003, DEVELOPMENT, V130, P3007, DOI 10.1242/dev.00526; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BRAND AH, 1993, DEVELOPMENT, V118, P401; Carreira-Barbosa F, 2003, DEVELOPMENT, V130, P4037, DOI 10.1242/dev.00567; Das G, 2004, DEVELOPMENT, V131, P4467, DOI 10.1242/dev.01317; Feiguin F, 2001, DEV CELL, V1, P93, DOI 10.1016/S1534-5807(01)00010-7; Gubb D, 1999, GENE DEV, V13, P2315, DOI 10.1101/gad.13.17.2315; Guo N, 2004, P NATL ACAD SCI USA, V101, P9277, DOI 10.1073/pnas.0402802101; Jenny A, 2003, EMBO J, V22, P4409, DOI 10.1093/emboj/cdg424; Katanaev VL, 2005, CELL, V120, P111, DOI 10.1016/j.cell.2004.11.014; Keller R, 2002, SCIENCE, V298, P1950, DOI 10.1126/science.1079478; Mlodzik M, 2002, TRENDS GENET, V18, P564, DOI 10.1016/S0168-9525(02)02770-1; Montcouquiol M, 2003, NATURE, V423, P173, DOI 10.1038/nature01618; Park M, 2002, NAT CELL BIOL, V4, P20, DOI 10.1038/ncb716; Penton A, 2002, GENETICS, V161, P747; Rothbacher U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010; Schwarz-Romond T, 2002, GENE DEV, V16, P2073, DOI 10.1101/gad.230402; Strutt D, 2003, DEVELOPMENT, V130, P4501, DOI 10.1242/dev.00695; Strutt D, 2002, CURR BIOL, V12, P813, DOI 10.1016/S0960-9822(02)00841-2; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Strutt DI, 2001, MOL CELL, V7, P367, DOI 10.1016/S1097-2765(01)00184-8; Taylor J, 1998, GENETICS, V150, P199; Tree DRP, 2002, CELL, V109, P371, DOI 10.1016/S0092-8674(02)00715-8; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Wolff T, 1998, DEVELOPMENT, V125, P1149; Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097-2765(03)00427-1; ZHENG L, 1995, DEVELOPMENT, V121, P3045	30	147	151	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2005	7	7					691	U78		10.1038/ncb1271	http://dx.doi.org/10.1038/ncb1271			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	941BX	15937478				2022-12-25	WOS:000230190800013
J	Tuzun, E; Sharp, AJ; Bailey, JA; Kaul, R; Morrison, VA; Pertz, LM; Haugen, E; Hayden, H; Albertson, D; Pinkel, D; Olson, MV; Eichler, EE				Tuzun, E; Sharp, AJ; Bailey, JA; Kaul, R; Morrison, VA; Pertz, LM; Haugen, E; Hayden, H; Albertson, D; Pinkel, D; Olson, MV; Eichler, EE			Fine-scale structural variation of the human genome	NATURE GENETICS			English	Article							RECENT SEGMENTAL DUPLICATIONS; SEQUENCE; GENE; POLYMORPHISM; INVERSION; DNA; ANEUPLOIDY; GENOTYPES; DELETION; REPEATS	Inversions, deletions and insertions are important mediators of disease and disease susceptibility(1). We systematically compared the human genome reference sequence with a second genome ( represented by fosmid paired- end sequences) to detect intermediate- sized structural variants > 8 kb in length. We identified 297 sites of structural variation: 139 insertions, 102 deletions and 56 inversion breakpoints. Using combined literature, sequence and experimental analyses, we validated 112 of the structural variants, including several that are of biomedical relevance. These data provide a fine- scale structural variation map of the human genome and the requisite sequence precision for subsequent genetic studies of human disease.	Univ Washington, Sch Med, Dept Genome Sci, Seattle, WA 98195 USA; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Univ Washington Genome Sequencing Ctr, Seattle, WA 98195 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA	University of Washington; University of Washington Seattle; Case Western Reserve University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Eichler, EE (corresponding author), Univ Washington, Sch Med, Dept Genome Sci, 1705 NE Pacific St, Seattle, WA 98195 USA.	eee@gs.washington.edu	Sharp, Andrew/A-5783-2008; Tuzun, Eray/B-5949-2018; Tuzun, Eray/AAD-7282-2021	Tuzun, Eray/0000-0002-5550-7816; Tuzun, Eray/0000-0002-5550-7816; Kaul, Rajinder/0000-0002-7895-9284; Haugen, Eric/0000-0001-7444-8981				Aklillu E, 1996, J PHARMACOL EXP THER, V278, P441; Badge RM, 2003, AM J HUM GENET, V72, P823, DOI 10.1086/373939; Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090; Brewer C, 1999, AM J HUM GENET, V64, P1702, DOI 10.1086/302410; Buckland PR, 2003, ANN MED, V35, P308, DOI 10.1080/07853890310001276; COLIN Y, 1991, BLOOD, V78, P2747; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; Gonzalez E, 2005, SCIENCE, V307, P1434, DOI 10.1126/science.1101160; Horvath JE, 2000, GENOME RES, V10, P839, DOI 10.1101/gr.10.6.839; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Koppens PFJ, 2002, HUM GENET, V111, P405, DOI 10.1007/s00439-002-0810-7; Kruglyak L, 2001, NAT GENET, V27, P234, DOI 10.1038/85776; LACKNER C, 1993, HUM MOL GENET, V2, P933, DOI 10.1093/hmg/2.7.933; LEE GF, 1995, HUM ECOL RISK ASSESS, V1, P5; LINDSLEY DL, 1972, GENETICS, V71, P157; Locke DP, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-8-r50; McLellan RA, 1997, PHARMACOGENETICS, V7, P187, DOI 10.1097/00008571-199706000-00003; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; She XW, 2004, NATURE, V431, P927, DOI 10.1038/nature03062; Small K, 1997, NAT GENET, V16, P96, DOI 10.1038/ng0597-96; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Sprenger R, 2000, PHARMACOGENETICS, V10, P557, DOI 10.1097/00008571-200008000-00009; Stefansson H, 2005, NAT GENET, V37, P129, DOI 10.1038/ng1508; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wong GKS, 1997, P NATL ACAD SCI USA, V94, P5225, DOI 10.1073/pnas.94.10.5225	27	748	813	0	57	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2005	37	7					727	732		10.1038/ng1562	http://dx.doi.org/10.1038/ng1562			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	941EA	15895083				2022-12-25	WOS:000230196400019
J	Arnaoutov, A; Azuma, Y; Ribbeck, K; Joseph, J; Boyarchuk, Y; Karpova, T; McNally, J; Dasso, M				Arnaoutov, A; Azuma, Y; Ribbeck, K; Joseph, J; Boyarchuk, Y; Karpova, T; McNally, J; Dasso, M			Crm1 is a mitotic effector of Ran-GTP in somatic cells	NATURE CELL BIOLOGY			English	Article							KINETOCHORE FIBERS; BINDING PROTEIN-2; MICROTUBULE; SPINDLE; ATTACHMENT; NUCLEOPORIN; ASSOCIATION; TRANSPORT; DYNAMICS; COMPLEX	The Ran GTPase controls multiple cellular processes, including nuclear transport, mitotic checkpoints, spindle assembly and post-mitotic nuclear envelope reassembly(1,2). Here we examine the mitotic function of Crm1, the Ran-GTP-binding nuclear export receptor for leucine-rich cargo ( bearing nuclear export sequence) and Snurportin-1 (ref. 3). We find that Crm1 localizes to kinetochores, and that Crm1 ternary complex assembly is essential for Ran-GTP-dependent recruitment of Ran GTPase-activating protein 1 (Ran-GAP1) and Ran-binding protein 2 (Ran-BP2) to kinetochores. We further show that Crm1 inhibition by leptomycin B disrupts mitotic progression and chromosome segregation. Analysis of spindles within leptomycin B-treated cells shows that their centromeres were under increased tension. In leptomycin B-treated cells, centromeres frequently associated with continuous microtubule bundles that spanned the centromeres, indicating that their kinetochores do not maintain discrete end-on attachments to single kinetochore fibres. Similar spindle defects were observed in temperature-sensitive Ran pathway mutants (tsBN2 cells). Taken together, our findings demonstrate that Crm1 and Ran-GTP are essential for Ran-BP2/Ran-GAP1 recruitment to kinetochores, for definition of kinetochore fibres and for chromosome segregation at anaphase. Thus, Crm1 is a critical Ran-GTP effector for mitotic spindle assembly and function in somatic cells.	NICHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA; European Mol Biol Lab, Gene Express Programme, D-69117 Heidelberg, Germany; NCI Core Fluorescence Imaging Facil, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); European Molecular Biology Laboratory (EMBL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Dasso, M (corresponding author), NICHD, Lab Gene Regulat & Dev, NIH, Bldg 18,Room 16, Bethesda, MD 20892 USA.	mdasso@helix.nih.gov	Joseph, Jomon/C-1397-2009	Dasso, Mary/0000-0002-5410-1371; Joseph, Jomon/0000-0002-3042-6286; Arnaoutov, Alexei/0000-0001-7647-7217; Karpova, Tatiana/0000-0001-6025-2128	Intramural NIH HHS [Z01 HD008740-06] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008740] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [Z01BC010571] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnaoutov A, 2003, DEV CELL, V5, P99, DOI 10.1016/S1534-5807(03)00194-1; Askjaer P, 1998, J BIOL CHEM, V273, P33414, DOI 10.1074/jbc.273.50.33414; Cai YF, 2001, J BIOL CHEM, V276, P41594, DOI 10.1074/jbc.M104514200; Dasso M, 2002, CURR BIOL, V12, pR502, DOI 10.1016/S0960-9822(02)00970-3; DeLuca JG, 2005, MOL BIOL CELL, V16, P519, DOI 10.1091/mbc.E04-09-0852; Ferreira PA, 1998, J BIOL CHEM, V273, P24676, DOI 10.1074/jbc.273.38.24676; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Howell BJ, 2004, CURR BIOL, V14, P953, DOI 10.1016/j.cub.2004.05.053; Joseph J, 2004, CURR BIOL, V14, P611, DOI 10.1016/j.cub.2004.03.031; Joseph J, 2002, J CELL BIOL, V156, P595, DOI 10.1083/jcb.200110109; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Maiato H, 2004, J CELL BIOL, V167, P831, DOI 10.1083/jcb.200407090; MCDONALD KL, 1992, J CELL BIOL, V118, P369, DOI 10.1083/jcb.118.2.369; MERDES A, 1990, EUR J CELL BIOL, V53, P313; MITCHISON TJ, 1985, J CELL BIOL, V101, P766, DOI 10.1083/jcb.101.3.766; NISHI K, 1994, J BIOL CHEM, V269, P6320; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; RIEDER CL, 1981, CHROMOSOMA, V84, P145, DOI 10.1007/BF00293368; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; Saitoh H, 1996, MOL BIOL CELL, V7, P1319, DOI 10.1091/mbc.7.9.1319; Salina D, 2003, J CELL BIOL, V162, P991, DOI 10.1083/jcb.200304080; Waters JC, 1996, J CELL SCI, V109, P2823; WITT PL, 1981, CHROMOSOMA, V83, P523, DOI 10.1007/BF00328277; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518; Yaseen NR, 1999, P NATL ACAD SCI USA, V96, P5516, DOI 10.1073/pnas.96.10.5516; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	30	157	158	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2005	7	6					626	U27		10.1038/ncb1263	http://dx.doi.org/10.1038/ncb1263			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	932OD	15908946				2022-12-25	WOS:000229562100017
J	Lau, A; Swinbank, KM; Ahmed, PS; Taylor, DL; Jackson, SP; Smith, GCM; O'Connor, MJ				Lau, A; Swinbank, KM; Ahmed, PS; Taylor, DL; Jackson, SP; Smith, GCM; O'Connor, MJ			Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase	NATURE CELL BIOLOGY			English	Article							RETROVIRAL DNA INTEGRATION; EARLY EMBRYONIC LETHALITY; DEPENDENT PROTEIN-KINASE; VIRUS TYPE-1 INTEGRATION; POLY(ADP-RIBOSE) POLYMERASE-1; STABLE TRANSDUCTION; IONIZING-RADIATION; IN-VIVO; DAMAGE; CHECKPOINT	Chemotherapy that is used to treat human immunodeficiency virus type-1 (HIV-1) infection focuses primarily on targeting virally encoded proteins. However, the combination of a short retroviral life cycle and high mutation rate leads to the selection of drug-resistant HIV-1 variants. One way to address this problem is to inhibit non-essential host cell proteins that are required for viral replication. Here we show that the activity of HIV-1 integrase stimulates an ataxia-telangiectasia-mutated (ATM)-dependent DNA damage response, and that a deficiency of this ATM kinase sensitizes cells to retrovirus-induced cell death. Consistent with these observations, we demonstrate that a novel and specific small molecule inhibitor of ATM kinase activity, KU-55933, is capable of suppressing the replication of both wild-type and drug-resistant HIV-1.	KuDOS Pharmaceut Ltd, Cambridge CB4 0WG, England; MRC Technol, London NW7 1AD, England; Wellcome Trust Canc Res UK Gurdon Inst, Cambridge CB3 1QN, England	AstraZeneca	O'Connor, MJ (corresponding author), KuDOS Pharmaceut Ltd, 327 Cambridge Sci Pk,Milton Rd, Cambridge CB4 0WG, England.	mjoconnor@kudospharma.co.uk	Dry, Kate/I-2328-2014; Jackson, Stephen Philip/R-4548-2019	Jackson, Stephen Philip/0000-0001-9317-7937; Lau, Alan/0000-0003-1055-9812				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ariumi Y, 2005, J VIROL, V79, P2973, DOI 10.1128/JVI.79.5.2973-2978.2005; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Block WD, 2004, NUCLEIC ACIDS RES, V32, P1967, DOI 10.1093/nar/gkh508; Borghesani PR, 2000, P NATL ACAD SCI USA, V97, P3336, DOI 10.1073/pnas.050584897; Brown EJ, 2000, GENE DEV, V14, P397; Brown P. O., 1997, P161; Butler SL, 2001, NAT MED, V7, P631, DOI 10.1038/87979; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cortez D, 2003, J BIOL CHEM, V278, P37139, DOI 10.1074/jbc.M307088200; Daniel R, 2004, J BIOL CHEM, V279, P45810, DOI 10.1074/jbc.M407886200; Daniel R, 2003, P NATL ACAD SCI USA, V100, P4778, DOI 10.1073/pnas.0730887100; Daniel R, 2001, MOL CELL BIOL, V21, P1164, DOI 10.1128/MCB.21.4.1164-1172.2001; Daniel R, 1999, SCIENCE, V284, P644, DOI 10.1126/science.284.5414.644; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; DeHart JL, 2005, J VIROL, V79, P1389, DOI 10.1128/JVI.79.3.1389-1396.2005; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Faust EA, 2002, J BIOMED SCI, V9, P273, DOI 10.1007/BF02256074; Foukas LC, 2002, J BIOL CHEM, V277, P37124, DOI 10.1074/jbc.M202101200; Gaken JA, 1996, J VIROL, V70, P3992; Ha HC, 2001, P NATL ACAD SCI USA, V98, P3364, DOI 10.1073/pnas.051633498; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Jeanson L, 2002, VIROLOGY, V300, P100, DOI 10.1006/viro.2002.1515; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kilzer JM, 2003, VIROLOGY, V314, P460, DOI 10.1016/S0042-6822(03)00455-0; Lau A, 2004, EMBO J, V23, P3421, DOI 10.1038/sj.emboj.7600348; Leavitt AD, 1996, J VIROL, V70, P721, DOI 10.1128/JVI.70.2.721-728.1996; Li L, 2001, EMBO J, V20, P3272, DOI 10.1093/emboj/20.12.3272; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; ROEHM NW, 1991, J IMMUNOL METHODS, V142, P257, DOI 10.1016/0022-1759(91)90114-U; Rumbaugh JA, 1998, J BIOL CHEM, V273, P28740, DOI 10.1074/jbc.273.44.28740; SAKARIA JN, 1999, CANCER RES, V59, P4375; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Siva AC, 2002, J VIROL, V76, P11904, DOI 10.1128/JVI.76.23.11904-11910.2002; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; SUHNEL J, 1990, ANTIVIR RES, V13, P23, DOI 10.1016/0166-3542(90)90042-6; Taylor DL, 2000, ANTIVIR CHEM CHEMOTH, V11, P291, DOI 10.1177/095632020001100405; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Veuger SJ, 2003, CANCER RES, V63, P6008; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	46	123	133	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2005	7	5					493	U57		10.1038/ncb1250	http://dx.doi.org/10.1038/ncb1250			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	926LA	15834407				2022-12-25	WOS:000229123500016
J	Maschke, KJ				Maschke, KJ			Navigating an ethical patchwork - human gene banks	NATURE BIOTECHNOLOGY			English	Article								Population genetics research collaborations are reaching increasingly across national boundaries to access human tissue repositories. Will discrepancies in national policies on informed consent and IP rights hinder progress?	Hastings Ctr, Garrison, NY 10524 USA		Maschke, KJ (corresponding author), Hastings Ctr, 21 Malcolm Gordon Rd, Garrison, NY 10524 USA.	maschkek@thehastingscenter.org						AMASON E, 2002, J INFORM LAW TECHNOL, V2; ANDREWS L, 2002, FUTURE PERFECT CONFR; Arnason V, 2004, BIOETHICS, V18, P27, DOI 10.1111/j.1467-8519.2004.00377.x; Bauer K, 2004, THEOR MED BIOETH, V25, P113, DOI 10.1023/B:META.0000033772.84738.ad; Bouchie A, 2004, NAT BIOTECHNOL, V22, P1071, DOI 10.1038/nbt0904-1071; Eiseman E., 1999, HDB HUMAN TISSUE SOU; Godard B, 2004, SCI ENG ETHICS, V10, P457, DOI 10.1007/s11948-004-0003-y; KAYE J, 2004, TRAMES-J HUMANIT SOC, V8, P15; Maschke KJ, 2004, THEOR MED BIOETH, V25, P143, DOI 10.1023/B:META.0000033773.44765.7c	9	45	47	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2005	23	5					539	545		10.1038/nbt0505-539	http://dx.doi.org/10.1038/nbt0505-539			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	923XS	15877066				2022-12-25	WOS:000228943500017
J	Firulli, BA; Krawchuk, D; Centonze, VE; Vargesson, N; Virshup, DM; Conway, SJ; Cserjesi, P; Laufer, E; Firulli, AB				Firulli, BA; Krawchuk, D; Centonze, VE; Vargesson, N; Virshup, DM; Conway, SJ; Cserjesi, P; Laufer, E; Firulli, AB			Altered Twist1 and Hand2 dimerization is associated with Saethre-Chotzen syndrome and limb abnormalities	NATURE GENETICS			English	Article							BHLH TRANSCRIPTION FACTOR; OSTEOBLAST DIFFERENTIATION; BASIC DOMAIN; DNA-BINDING; CHICK LIMB; MUTATIONS; PROTEIN; HEDGEHOG; DHAND; GENE	Autosomal dominant mutations in the gene encoding the basic helix-loop-helix transcription factor Twist1 are associated with limb and craniofacial defects in humans with Saethre-Chotzen syndrome. The molecular mechanism underlying these phenotypes is poorly understood. We show that ectopic expression of the related basic helix-loop-helix factor Hand2 phenocopies Twist1 loss of function in the limb and that the two factors have a gene dosage - dependent antagonistic interaction. Dimerization partner choice by Twist1 and Hand2 can be modulated by protein kinase A - and protein phosphatase 2A - regulated phosphorylation of conserved helix I residues. Notably, multiple Twist1 mutations associated with Saethre-Chotzen syndrome alter protein kinase A - mediated phosphorylation of Twist1, suggesting that misregulation of Twist1 dimerization through either stoichiometric or post-translational mechanisms underlies phenotypes of individuals with Saethre-Chotzen syndrome.	Indiana Univ, Sch Med, James Whitcomb Riley Hosp Children, Wells Ctr Pediat Res,Dept Pediat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, James Whitcomb Riley Hosp Children, Wells Ctr Pediat Res,Dept Med & Mol Genet, Indianapolis, IN 46202 USA; Columbia Univ, Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular Biol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Biol Struct, San Antonio, TX 78229 USA; Univ Utah, Huntsman Canc Inst Ctr Children, Salt Lake City, UT 84112 USA; Tulane Univ, Dept Cell & Mol Biol, New Orleans, LA 70118 USA	Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; Columbia University; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Tulane University	Laufer, E (corresponding author), Indiana Univ, Sch Med, James Whitcomb Riley Hosp Children, Wells Ctr Pediat Res,Dept Pediat, 1044 W Walnut R4 371, Indianapolis, IN 46202 USA.	elaufer@columbia.edu	Virshup, David M/C-1449-2009	Virshup, David M/0000-0001-6976-850X; /0000-0001-6687-8949; Laufer, Edward/0000-0002-4933-1017; Vargesson, Neil/0000-0001-8027-114X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061677] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL061677-08, R01 HL061677] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9; Bourgeois P, 1998, HUM MOL GENET, V7, P945, DOI 10.1093/hmg/7.6.945; Castanon I, 2002, GENE, V287, P11, DOI 10.1016/S0378-1119(01)00893-9; Castanon I, 2001, DEVELOPMENT, V128, P3145; Centonze VE, 2003, METHOD ENZYMOL, V360, P542; Charite J, 2000, DEVELOPMENT, V127, P2461; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; Corsi AK, 2002, DEVELOPMENT, V129, P2761; El Ghouzzi V, 2000, HUM MOL GENET, V9, P813, DOI 10.1093/hmg/9.5.813; El Ghouzzi V, 2001, FEBS LETT, V492, P112, DOI 10.1016/S0014-5793(01)02238-4; ElGhouzzi V, 1997, NAT GENET, V15, P42; Fernandez-Teran M, 2000, DEVELOPMENT, V127, P2133; Firulli AB, 2003, GENE, V312, P27, DOI 10.1016/S0378-1119(03)00669-3; Firulli BA, 2000, J BIOL CHEM, V275, P33567, DOI 10.1074/jbc.M005888200; Firulli BA, 2003, MOL CELL, V12, P1225, DOI 10.1016/S1097-2765(03)00425-8; Gripp KW, 2000, HUM MUTAT, V15, P150, DOI 10.1002/(SICI)1098-1004(200002)15:2<150::AID-HUMU3>3.0.CO;2-D; Hamamori Y, 1997, MOL CELL BIOL, V17, P6563, DOI 10.1128/MCB.17.11.6563; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; Jabs Ethylin Wang, 2004, P401; Johnson D, 1998, AM J HUM GENET, V63, P1282, DOI 10.1086/302122; KASPARCOVA VS, 1998, AM J HUM GENET S, V65, pA367; Kaufman M.H., 1992, ATLAS MOUSE DEV; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; Logan M, 1998, METHODS, V14, P407, DOI 10.1006/meth.1998.0595; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; McFadden DG, 2002, DEVELOPMENT, V129, P3077; O'Rourke MP, 2002, DEV BIOL, V248, P143, DOI 10.1006/dbio.2002.0730; O'Rourke MP, 2002, INT J DEV BIOL, V46, P401; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; OLSON EN, 1993, CIRC RES, V72, P1, DOI 10.1161/01.RES.72.1.1; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pathi S, 2001, MECH DEVELOP, V106, P107, DOI 10.1016/S0925-4773(01)00427-0; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; Srivastava D, 1997, NAT GENET, V16, P154, DOI 10.1038/ng0697-154; Tavares AT, 2001, INT J DEV BIOL, V45, P707; TICKLE C, 1981, NATURE, V289, P295, DOI 10.1038/289295a0; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I; Yang Y, 1997, DEVELOPMENT, V124, P4393; Yelon D, 2000, DEVELOPMENT, V127, P2573; Yoshida CA, 2004, GENE DEV, V18, P952, DOI 10.1101/gad.1174704; Zuniga A, 2002, MECH DEVELOP, V114, P51, DOI 10.1016/S0925-4773(02)00048-5	44	144	152	1	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2005	37	4					373	381		10.1038/ng1525	http://dx.doi.org/10.1038/ng1525			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	911XL	15735646	Green Accepted			2022-12-25	WOS:000228040000020
J	Sun, XD; Frierson, HF; Chen, C; Li, CL; Ran, QM; Otto, KB; Cantarel, BM; Vessella, RL; Gao, AC; Petros, J; Miura, Y; Simons, JW; Dong, JT				Sun, XD; Frierson, HF; Chen, C; Li, CL; Ran, QM; Otto, KB; Cantarel, BM; Vessella, RL; Gao, AC; Petros, J; Miura, Y; Simons, JW; Dong, JT			Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer	NATURE GENETICS			English	Article							TUMOR-SUPPRESSOR GENES; NEURONAL DIFFERENTIATION; CARCINOMA-CELLS; PROTEIN; ACTIVATION; DELETIONS; IDENTIFICATION; BINDING; REGION; 16Q	Cancer often results from the accumulation of multiple genetic alterations. Although most malignancies are sporadic, only a small number of genes have been shown to undergo frequent mutations in sporadic cancers. The long arm of chromosome 16 is frequently deleted in human cancers, but the target gene for this deletion has not been identified(1-4). Here we report that ATBF1, which encodes a transcription factor that negatively regulates AFP and MYB5,6 but transactivates CDKN1A(7), is a good candidate for the 16q22 tumor-suppressor gene. We narrowed the region of deletion at 16q22 to 861 kb containing ATBF1. ATBF1 mRNA was abundant in normal prostates but more scarce in approximately half of prostate cancers tested. In 24 of 66 (36%) cancers examined, we identified 22 unique somatic mutations, many of which impair ATBF1 function. Furthermore, ATBF1 inhibited cell proliferation. Hence, loss of ATBF1 is one mechanism that defines the absence of growth control in prostate cancer.	Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Oncol, Atlanta, GA 30322 USA; Univ Virginia Hlth Syst, Dept Pathol, Charlottesville, VA 22901 USA; Chinese Acad Med Sci, Canc Inst Hosp, Dept Urol Oncol, Beijing 100021, Peoples R China; Univ Virginia Hlth Syst, Dept Biochem & Mol Genet, Charlottesville, VA 22901 USA; Univ Washington, Med Ctr, Dept Urol, Seattle, WA 98195 USA; Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Pharmacol, Buffalo, NY 14263 USA; Emory Univ, Sch Med, Dept Urol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA; Nagoya City Univ, Grad Sch Med Sci, Dept Mol Neurobiol, Nagoya, Aichi 4678601, Japan; Emory Univ, Sch Med, Dept Urol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Program Genet & Mol Biol, Atlanta, GA 30322 USA	Emory University; University of Virginia; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; University of Virginia; University of Washington; University of Washington Seattle; Roswell Park Cancer Institute; Roswell Park Cancer Institute; Emory University; Emory University; Nagoya City University; Emory University; Emory University	Dong, JT (corresponding author), Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Oncol, Atlanta, GA 30322 USA.	jdong2@emory.edu		Dong, Jin-Tang/0000-0003-2349-5782				Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Chen C, 2003, PROSTATE, V55, P81, DOI 10.1002/pros.10205; Chen CS, 2003, AM J PATHOL, V162, P1349, DOI 10.1016/S0002-9440(10)63930-2; Chen CS, 2001, GENOMICS, V77, P135, DOI 10.1006/geno.2001.6631; Coolidge CJ, 1997, NUCLEIC ACIDS RES, V25, P888, DOI 10.1093/nar/25.4.888; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dong JT, 2000, CANCER RES, V60, P3880; Dong JT, 2001, CANCER METAST REV, V20, P173, DOI 10.1023/A:1015575125780; Goldberg EK, 2000, AM J HUM GENET, V67, P417, DOI 10.1086/302999; IDO A, 1994, DEV BIOL, V163, P184, DOI 10.1006/dbio.1994.1134; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Ishii Y, 2003, J COMP NEUROL, V465, P57, DOI 10.1002/cne.10807; Kaspar P, 1999, J BIOL CHEM, V274, P14422, DOI 10.1074/jbc.274.20.14422; Kataoka H, 2003, CANCER RES, V63, P5785; Kataoka H, 2001, ONCOGENE, V20, P869, DOI 10.1038/sj.onc.1204160; Kawaguchi M, 2001, BBA-PROTEIN STRUCT M, V1550, P164, DOI 10.1016/S0167-4838(01)00284-9; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Kukita Y, 1997, HUM MUTAT, V10, P400, DOI 10.1002/(SICI)1098-1004(1997)10:5<400::AID-HUMU11>3.3.CO;2-1; Latil A, 1997, CANCER RES, V57, P1058; Matsuyama H, 2003, PROSTATE, V54, P103, DOI 10.1002/pros.10173; MIURA Y, 1995, J BIOL CHEM, V270, P26840, DOI 10.1074/jbc.270.45.26840; MORINAGA T, 1991, MOL CELL BIOL, V11, P6041, DOI 10.1128/MCB.11.12.6041; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Ninomiya T, 2002, HEPATOLOGY, V35, P82, DOI 10.1053/jhep.2002.30420; Remacle JE, 1997, EMBO J, V16, P5722, DOI 10.1093/emboj/16.18.5722; Strup SE, 1999, J UROLOGY, V162, P590, DOI 10.1016/S0022-5347(05)68631-4; Sun SY, 1997, CANCER RES, V57, P4931; Takada N, 1999, CANCER RES, V59, P2810	29	123	133	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	APR	2005	37	4					407	412		10.1038/ng1528	http://dx.doi.org/10.1038/ng1528			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	911XL	15750593				2022-12-25	WOS:000228040000024
J	Arabi, A; Wu, SQ; Ridderstrale, K; Bierhoff, H; Shiue, C; Fatyol, K; Fahlen, S; Hydbring, P; Soderberg, O; Grummt, I; Larsson, LG; Wright, APH				Arabi, A; Wu, SQ; Ridderstrale, K; Bierhoff, H; Shiue, C; Fatyol, K; Fahlen, S; Hydbring, P; Soderberg, O; Grummt, I; Larsson, LG; Wright, APH			c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription	NATURE CELL BIOLOGY			English	Article							PROTEIN-DEGRADATION; GENE-TRANSCRIPTION; BINDING; CELLS; NUCLEOLUS; CHROMATIN; COFACTOR; RECRUITS; COMPLEX; GROWTH	The c-Myc oncoprotein regulates transcription of genes that are associated with cell growth, proliferation and apoptosis(1). c-Myc levels are modulated by ubiquitin/proteasome-mediated degradation(1). Proteasome inhibition leads to c-Myc accumulation within nucleoli(2), indicating that c-Myc might have a nucleolar function. Here we show that the proteins c-Myc and Max interact in nucleoli and are associated with ribosomal DNA. This association is increased upon activation of quiescent cells and is followed by recruitment of the Myc cofactor TRRAP, enhanced histone acetylation, recruitment of RNA polymerase I (Pol I), and activation of rDNA transcription. Using small interfering RNAs (siRNAs) against c-Myc and an inhibitor of Myc - Max interactions, we demonstrate that c-Myc is required for activating rDNA transcription in response to mitogenic signals. Furthermore, using the ligand-activated MycER ( ER, oestrogen receptor) system, we show that c-Myc can activate Pol I transcription in the absence of Pol II transcription. These results suggest that c-Myc coordinates the activity of all three nuclear RNA polymerases, and thereby plays a key role in regulating ribosome biogenesis and cell growth.	Sodertorns Hogskola, S-14189 Huddinge, Sweden; Karolinska Inst, Dept Biosci, S-14157 Huddinge, Sweden; Swedish Univ Agr Sci, Dept Plant Biol & Forest Genet, S-75007 Uppsala, Sweden; German Canc Res Ctr, Div Mol Biol Cell 2, D-69120 Heidelberg, Germany; Univ Uppsala, Rudbeck Lab, Dept Genet & Pathol, S-75185 Uppsala, Sweden	Sodertorn University; Karolinska Institutet; Swedish University of Agricultural Sciences; Helmholtz Association; German Cancer Research Center (DKFZ); Uppsala University	Arabi, A (corresponding author), Sodertorns Hogskola, S-14189 Huddinge, Sweden.	azadeh.arabi@sh.se	Larsson, Lars-Gunnar/D-9747-2012; Söderberg, Ola/O-5130-2017; Wright, Anthony/J-8187-2015	Söderberg, Ola/0000-0003-2883-1925; Wright, Anthony/0000-0003-1029-9969				Arabi A, 2003, J CELL SCI, V116, P1707, DOI 10.1242/jcs.00370; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Cheutin T, 2002, J CELL SCI, V115, P3297; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Grinberg AV, 2004, MOL CELL BIOL, V24, P4294, DOI 10.1128/MCB.24.10.4294-4308.2004; Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; Halkidou K, 2004, NUCLEIC ACIDS RES, V32, P1654, DOI 10.1093/nar/gkh296; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Koberna K, 2002, J CELL BIOL, V157, P743, DOI 10.1083/jcb.200202007; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Mutskov VJ, 1996, J BIOL CHEM, V271, P11852, DOI 10.1074/jbc.271.20.11852; O'Sullivan AC, 2002, MOL CELL BIOL, V22, P657, DOI 10.1128/MCB.22.2.657-668.2002; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Poortinga G, 2004, EMBO J, V23, P3325, DOI 10.1038/sj.emboj.7600335; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Santoro R, 2002, NAT GENET, V32, P393, DOI 10.1038/ng1010; Schlosser I, 2003, NUCLEIC ACIDS RES, V31, P6148, DOI 10.1093/nar/gkg794; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; Seither P, 1996, GENOMICS, V37, P135, DOI 10.1006/geno.1996.0531; Visintin R, 2000, CURR OPIN CELL BIOL, V12, P752, DOI 10.1016/S0955-0674(00)00165-4; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641	30	353	365	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2005	7	3					303	310		10.1038/ncb1225	http://dx.doi.org/10.1038/ncb1225			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	902CU	15723053				2022-12-25	WOS:000227329800019
J	Grandori, C; Gomez-Roman, N; Felton-Edkins, ZA; Ngouenet, C; Galloway, DA; Eisenman, RN; White, RJ				Grandori, C; Gomez-Roman, N; Felton-Edkins, ZA; Ngouenet, C; Galloway, DA; Eisenman, RN; White, RJ			c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I	NATURE CELL BIOLOGY			English	Article							PROTEIN-SYNTHESIS; DROSOPHILA-MYC; CELL-GROWTH; N-MYC; SIZE; MAX; DIFFERENTIATION; DEGRADATION; ONCOPROTEIN; EXPRESSION	c-Myc coordinates cell growth and division through a transcriptional programme that involves both RNA polymerase (Pol) II- and Pol III-transcribed genes. Here, we demonstrate that human c-Myc also directly enhances Pol I transcription of ribosomal RNA ( rRNA) genes. rRNA synthesis and accumulation occurs rapidly following activation of a conditional MYC-ER allele ( coding for a Myc-oestrogen-receptor fusion protein), is resistant to inhibition of Pol II transcription and is markedly reduced by c-MYC RNA interference. Furthermore, by using combined immunofluorescence and rRNA-FISH, we have detected endogenous c-Myc in nucleoli at sites of active ribosomal DNA ( rDNA) transcription. Our data also show that c-Myc binds to specific consensus elements located in human rDNA and associates with the Pol I-specific factor SL1. The presence of c-Myc at specific sites on rDNA coincides with the recruitment of SL1 to the rDNA promoter and with increased histone acetylation. We propose that stimulation of rRNA synthesis by c-Myc is a key pathway driving cell growth and tumorigenesis.	Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Univ Glasgow, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; University of Glasgow; Fred Hutchinson Cancer Center	Grandori, C (corresponding author), Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA.	cgrandor@fhcrc.org		Gomez-Roman, Natividad/0000-0002-2325-7517				Arabi A, 2003, J CELL SCI, V116, P1707, DOI 10.1242/jcs.00370; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dang CV, 1999, MOL CELL BIOL, V19, P1; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; GONZALEZ IL, 1995, GENOMICS, V27, P320, DOI 10.1006/geno.1995.1049; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; Guo QM, 2000, CANCER RES, V60, P5922; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Knoepfler PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202; KULKENS T, 1992, EMBO J, V11, P4665, DOI 10.1002/j.1460-2075.1992.tb05568.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lutz W, 2002, BBA-REV CANCER, V1602, P61, DOI 10.1016/S0304-419X(02)00036-7; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Nair SK, 2003, CELL, V112, P193, DOI 10.1016/S0092-8674(02)01284-9; O'Sullivan AC, 2002, MOL CELL BIOL, V22, P657, DOI 10.1128/MCB.22.2.657-668.2002; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Pierce SB, 2004, DEVELOPMENT, V131, P2317, DOI 10.1242/dev.01108; Poortinga G, 2004, EMBO J, V23, P3325, DOI 10.1038/sj.emboj.7600335; Schlosser I, 2003, NUCLEIC ACIDS RES, V31, P6148, DOI 10.1093/nar/gkg794; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; Shiio Y, 2002, EMBO J, V21, P5088, DOI 10.1093/emboj/cdf525; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Welcker M, 2004, CURR BIOL, V14, P1852, DOI 10.1016/j.cub.2004.09.083; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; White RJ, 2005, NAT REV MOL CELL BIO, V6, P69, DOI 10.1038/nrm1551	33	472	485	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2005	7	3					311	U121		10.1038/ncb1224	http://dx.doi.org/10.1038/ncb1224			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	902CU	15723054				2022-12-25	WOS:000227329800020
J	Grewal, SS; Li, L; Orian, A; Eisenman, RN; Edgar, BA				Grewal, SS; Li, L; Orian, A; Eisenman, RN; Edgar, BA			Myc-dependent regulation of ribosomal RNA synthesis during Drosophila development	NATURE CELL BIOLOGY			English	Article							CELL-GROWTH; C-MYC; IN-VIVO; TRANSLATIONAL CONTROL; POLYMERASE-III; GENES; IDENTIFICATION; PROTEIN; YEAST; DMYC	Regulating ribosome number is thought to control cellular growth(1). Synthesis of ribosomal RNA ( rRNA) is a limiting step in ribosome biogenesis and rates of rRNA synthesis are generally altered depending on the growth status of a cell(2,3). Although studies in unicellular systems have addressed the mechanisms by which this occurs(4,5), few studies have applied a genetic approach to examine growth-dependent control of rRNA synthesis in metazoans. Here, we show that in Drosophila melanogaster Myc ( dMyc) is a regulator of rRNA synthesis. Expression of dMyc is both necessary and sufficient to control rRNA synthesis and ribosome biogenesis during larval development. Stimulation of rRNA synthesis by dMyc is mediated through a rapid, coordinated increase in the levels of the Pol I transcriptional machinery. In addition, the growth effects of dMyc in larval wing imaginal discs require de novo rRNA synthesis. We suggest that during animal development, the control of rRNA synthesis and ribosome biogenesis is an essential Myc function.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Edgar, BA (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA.	bedgar@fhcrc.org			NCI NIH HHS [R01CA57138] Funding Source: Medline; NIGMS NIH HHS [GM51186] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057138] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Campbell G, 1998, DEVELOPMENT, V125, P4483; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Daga RR, 1999, J CELL SCI, V112, P3137; de la Cova C, 2004, CELL, V117, P107, DOI 10.1016/S0092-8674(04)00214-4; Derenzini M, 1998, AM J PATHOL, V152, P1291; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; Guo QM, 2000, CANCER RES, V60, P5922; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Jorgensen P, 2002, SCIENCE, V297, P395, DOI 10.1126/science.1070850; Kim S, 2000, P NATL ACAD SCI USA, V97, P11198, DOI 10.1073/pnas.200372597; Lambertsson A, 1998, ADV GENET, V38, P69, DOI 10.1016/S0065-2660(08)60142-X; Lee TM, 2001, TRENDS NEUROSCI, V24, P251, DOI 10.1016/S0166-2236(00)01791-4; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Maines JZ, 2004, DEVELOPMENT, V131, P775, DOI 10.1242/dev.00932; Moberg KH, 2004, CURR BIOL, V14, P965, DOI 10.1016/j.cub.2004.04.040; Moreno E, 2004, CELL, V117, P117, DOI 10.1016/S0092-8674(04)00262-4; Moss T, 2002, CELL, V109, P545, DOI 10.1016/S0092-8674(02)00761-4; Nomura M, 1999, J BACTERIOL, V181, P6857, DOI 10.1128/JB.181.22.6857-6864.1999; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Perrin L, 2003, MECH DEVELOP, V120, P645, DOI 10.1016/S0925-4773(03)00049-2; Pierce SB, 2004, DEVELOPMENT, V131, P2317, DOI 10.1242/dev.01108; Polymenis M, 1997, GENE DEV, V11, P2522, DOI 10.1101/gad.11.19.2522; Prober DA, 2000, CELL, V100, P435, DOI 10.1016/S0092-8674(00)80679-0; Rudra D, 2004, GENE DEV, V18, P2431, DOI 10.1101/gad.1256704; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Saucedo LJ, 2002, CURR OPIN GENET DEV, V12, P565, DOI 10.1016/S0959-437X(02)00341-6; Schlosser I, 2003, NUCLEIC ACIDS RES, V31, P6148, DOI 10.1093/nar/gkg794; SchreiberAgus N, 1997, P NATL ACAD SCI USA, V94, P1235, DOI 10.1073/pnas.94.4.1235; SEIFARTH W, 1991, MOL GEN GENET, V228, P424, DOI 10.1007/BF00260636; van Steensel B, 2000, NAT BIOTECHNOL, V18, P424, DOI 10.1038/74487; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Zaffran S, 1998, DEVELOPMENT, V125, P3571	37	290	292	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2005	7	3					295	U109		10.1038/ncb1223	http://dx.doi.org/10.1038/ncb1223			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	902CU	15723055				2022-12-25	WOS:000227329800018
J	Kafri, R; Bar-Even, A; Pilpel, Y				Kafri, R; Bar-Even, A; Pilpel, Y			Transcription control reprogramming in genetic backup circuits	NATURE GENETICS			English	Article							DUPLICATE GENES; SACCHAROMYCES-CEREVISIAE; EXPRESSION; EVOLUTION; PRESERVATION; CONSEQUENCES; ROBUSTNESS	A key question in molecular genetics is why severe mutations often do not result in a detectably abnormal phenotype. This robustness was partially ascribed to redundant paralogs(1,2) that may provide backup for one another in case of mutation. Mining mutant viability and mRNA expression data in Saccharomyces cerevisiae, we found that backup was provided predominantly by paralogs that are expressed dissimilarly in most growth conditions. We considered that this apparent inconsistency might be resolved by a transcriptional reprogramming mechanism that allows the intact paralog to rescue the organism upon mutation of its counterpart. We found that in wild-type cells, partial coregulation across growth conditions predicted the ability of paralogs to alter their transcription patterns and to provide backup for one another. Notably, the sets of regulatory motifs that controlled the paralogs with the most efficient backup activity deliberately overlapped only partially; paralogs with highly similar or dissimilar sets of motifs had suboptimal backup activity. Such an arrangement of partially shared regulatory motifs reconciles the differential expression of paralogs with their ability to back each other up.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Pilpel, Y (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	pilpel@weizmann.ac.il		Bar-Even, Arren/0000-0002-1039-4328				Cavalcanti ARO, 2003, J MOL EVOL, V56, P28, DOI 10.1007/s00239-002-2377-2; Conant GC, 2004, P ROY SOC B-BIOL SCI, V271, P89, DOI 10.1098/rspb.2003.2560; Force A, 1999, GENETICS, V151, P1531; Garcia-Rodriguez LJ, 2000, FEBS LETT, V478, P84, DOI 10.1016/S0014-5793(00)01835-4; Ge H, 2001, NAT GENET, V29, P482, DOI 10.1038/ng776; GOLDMAN N, 1994, MOL BIOL EVOL, V11, P725; Gu ZL, 2003, NATURE, V421, P63, DOI 10.1038/nature01198; Gu ZL, 2002, TRENDS GENET, V18, P609, DOI 10.1016/S0168-9525(02)02837-8; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Jansen R, 2002, GENOME RES, V12, P37, DOI 10.1101/gr.205602; Kellis M, 2004, NATURE, V428, P617, DOI 10.1038/nature02424; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Kondrashov FA, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-2-research0008; Kratzer S, 1997, MOL MICROBIOL, V26, P631, DOI 10.1046/j.1365-2958.1997.5611937.x; Lord PW, 2003, BIOINFORMATICS, V19, P1275, DOI 10.1093/bioinformatics/btg153; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; Lynch M, 2001, GENETICS, V159, P1789; Lynch M, 2004, TRENDS GENET, V20, P544, DOI 10.1016/j.tig.2004.09.001; McCammon MT, 2003, ARCH BIOCHEM BIOPHYS, V419, P222, DOI 10.1016/j.abb.2003.08.022; Nowak MA, 1997, NATURE, V388, P167, DOI 10.1038/40618; Ozcan S, 2002, J BIOL CHEM, V277, P46993, DOI 10.1074/jbc.M208726200; Papp B, 2004, NATURE, V429, P661, DOI 10.1038/nature02636; Papp B, 2003, TRENDS GENET, V19, P417, DOI 10.1016/S0168-9525(03)00174-4; Pilpel Y, 2001, NAT GENET, V29, P153, DOI 10.1038/ng724; Steinmetz LM, 2002, NAT GENET, V31, P400, DOI 10.1038/ng929; Teichmann SA, 2004, NAT GENET, V36, P492, DOI 10.1038/ng1340; vandenBerg MA, 1996, J BIOL CHEM, V271, P28953, DOI 10.1074/jbc.271.46.28953; Wagner A, 2000, GENETICS, V154, P1389	30	140	147	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2005	37	3					295	299		10.1038/ng1523	http://dx.doi.org/10.1038/ng1523			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	901QU	15723064				2022-12-25	WOS:000227297800021
J	Mennella, V; Rogers, GC; Rogers, SL; Buster, DW; Vale, RD; Sharp, DJ				Mennella, V; Rogers, GC; Rogers, SL; Buster, DW; Vale, RD; Sharp, DJ			Functionally distinct kinesin-13 family members cooperate to regulate microtubule dynamics during interphase	NATURE CELL BIOLOGY			English	Article							DEPOLYMERIZING ACTIVITY; SUPERFAMILY PROTEIN; CENTROMERIC MCAK; PLUS; INSTABILITY; XKCM1; STABILIZATION; DOWNSTREAM; STATE; EB1	Regulation of microtubule polymerization and depolymerization is required for proper cell development. Here, we report that two proteins of the Drosophila melanogaster kinesin-13 family, KLP10A and KLP59C, cooperate to drive microtubule depolymerization in interphase cells. Analyses of microtubule dynamics in S2 cells depleted of these proteins indicate that both proteins stimulate depolymerization, but alter distinct parameters of dynamic instability; KLP10A stimulates catastrophe ( a switch from growth to shrinkage) whereas KLP59C suppresses rescue ( a switch from shrinkage to growth). Moreover, immunofluorescence and live analyses of cells expressing tagged kinesins reveal that KLP10A and KLP59C target to polymerizing and depolymerizing microtubule plus ends, respectively. Our data also suggest that KLP10A is deposited on microtubules by the plus-end tracking protein, EB1. Our findings support a model in which these two members of the kinesin-13 family divide the labour of microtubule depolymerization.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94107 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94107 USA	Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Sharp, DJ (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA.	dsharp@aecom.yu.edu	Mennella, Vito/GZL-7765-2022	Mennella, Vito/0000-0002-4842-9012				Andrews PD, 2004, DEV CELL, V6, P253, DOI 10.1016/S1534-5807(04)00025-5; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; Browning H, 2003, NAT CELL BIOL, V5, P812, DOI 10.1038/ncb1034; Busch KE, 2004, DEV CELL, V6, P831, DOI 10.1016/j.devcel.2004.05.008; Carvalho P, 2004, DEV CELL, V6, P815, DOI 10.1016/j.devcel.2004.05.001; Carvalho P, 2003, TRENDS CELL BIOL, V13, P229, DOI 10.1016/S0962-8924(03)00074-6; Cassimeris L, 2001, INT REV CYTOL, V210, P163; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Gaetz J, 2004, J CELL BIOL, V166, P465, DOI 10.1083/jcb.200404015; Galjart N, 2003, CURR OPIN CELL BIOL, V15, P48, DOI 10.1016/S0955-0674(02)00007-8; Gandhi R, 2004, MOL BIOL CELL, V15, P121, DOI 10.1091/mbc.E03-05-0342; Holmfeldt P, 2004, EMBO J, V23, P627, DOI 10.1038/sj.emboj.7600076; Homma N, 2003, CELL, V114, P229, DOI 10.1016/S0092-8674(03)00522-1; Howard J, 2003, NATURE, V422, P753, DOI 10.1038/nature01600; Hunter AW, 2003, MOL CELL, V11, P445, DOI 10.1016/S1097-2765(03)00049-2; Kaverina I, 1998, J CELL BIOL, V142, P181, DOI 10.1083/jcb.142.1.181; Kinoshita K, 2001, SCIENCE, V294, P1340, DOI 10.1126/science.1064629; Kline-Smith SL, 2004, MOL BIOL CELL, V15, P1146, DOI 10.1091/mbc.E03-08-0581; Kline-Smith SL, 2002, MOL BIOL CELL, V13, P2718, DOI 10.1091/mbc.E01-12-0143; Komarova YA, 2002, J CELL BIOL, V159, P589, DOI 10.1083/jcb.200208058; Krylyshkina O, 2003, J CELL BIOL, V161, P853, DOI 10.1083/jcb.200301102; Lan WJ, 2004, CURR BIOL, V14, P273, DOI 10.1016/j.cub.2004.01.055; Lantz VA, 1998, J CELL BIOL, V140, P897, DOI 10.1083/jcb.140.4.897; Lawrence CJ, 2004, J CELL BIOL, V167, P19, DOI 10.1083/jcb.200408113; Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398; Miller RK, 1998, MOL BIOL CELL, V9, P2051, DOI 10.1091/mbc.9.8.2051; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Moores CA, 2002, MOL CELL, V9, P903, DOI 10.1016/S1097-2765(02)00503-8; Newton CN, 2004, FEBS LETT, V572, P80, DOI 10.1016/j.febslet.2004.06.093; Ohi R, 2003, DEV CELL, V5, P309, DOI 10.1016/S1534-5807(03)00229-6; Ohi R, 2004, MOL BIOL CELL, V15, P2895, DOI 10.1091/mbc.E04-02-0082; Ovechkina Y, 2002, J CELL BIOL, V159, P557, DOI 10.1083/jcb.200205089; Rogers GC, 2004, NATURE, V427, P364, DOI 10.1038/nature02256; Rogers SL, 2004, CURR BIOL, V14, P1827, DOI 10.1016/j.cub.2004.09.078; Rogers SL, 2002, J CELL BIOL, V158, P873, DOI 10.1083/jcb.200202032; Small JV, 2003, CURR OPIN CELL BIOL, V15, P40, DOI 10.1016/S0955-0674(02)00008-X; SU LK, 1995, CANCER RES, V55, P2972; Tirnauer JS, 1999, J CELL BIOL, V145, P993, DOI 10.1083/jcb.145.5.993; Tirnauer JS, 2002, MOL BIOL CELL, V13, P3614, DOI 10.1091/mbc.E02-04-0210; Tournebize R, 2000, NAT CELL BIOL, V2, P13, DOI 10.1038/71330; Tran PT, 1997, J CELL BIOL, V138, P105, DOI 10.1083/jcb.138.1.105; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Wittmann T, 2004, J BIOL CHEM, V279, P6196, DOI 10.1074/jbc.M307261200; Wittmann T, 2003, J CELL BIOL, V161, P845, DOI 10.1083/jcb.200303082	46	115	118	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2005	7	3					235	U39		10.1038/ncb1222	http://dx.doi.org/10.1038/ncb1222			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	902CU	15723056				2022-12-25	WOS:000227329800011
J	Nishimura, T; Yamaguchi, T; Kato, K; Yoshizawa, M; Nabeshima, Y; Ohno, S; Hoshino, M; Kaibuchi, K				Nishimura, T; Yamaguchi, T; Kato, K; Yoshizawa, M; Nabeshima, Y; Ohno, S; Hoshino, M; Kaibuchi, K			PAR-6-PAR-3 mediates Cdc42-induced Rac activation through the Rac GEFs STEF/Tiam1	NATURE CELL BIOLOGY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; RHO-FAMILY GTPASES; NEURONAL POLARITY; HIPPOCAMPAL-NEURONS; EPITHELIAL-CELLS; AXON FORMATION; GROWTH; APKC; COMPLEX; TIAM1	A polarity complex of PAR-3, PAR-6 and atypical protein kinase C ( aPKC) functions in various cell-polarization events, including neuron specification(1-4). The small GTPase Cdc42 binds to PAR-6 and regulates cell polarity. However, little is known about the downstream signals of the Cdc42 - PAR protein complex. Here, we found that PAR-3 directly interacted with STEF/Tiam1, which are Rac-specific guanine nucleotide-exchange factors, and that STEF formed a complex with PAR-3 - aPKC - PAR-6 - Cdc42-GTP. Cdc42 induces lamellipodia in a Rac-dependent manner in N1E-115 neuroblastoma cells. Disruption of Cdc42 PAR- 6 or PAR- 3 - STEF binding inhibited Cdc42-induced lamellipodia but not filopodia. The isolated STEF-binding PAR-3 fragment was sufficient to induce lamellipodia independently of Cdc42 and PAR-6. PAR-3 is required for Cdc42-induced Rac activation, but is not essential for lamellipodia formation itself. In cultured hippocampal neurons, STEF accumulated at the tip of the growing axon and colocalized with PAR-3. The spatio-temporal activation and signalling of Cdc42 - PAR- 6 - PAR-3 - STEF/Tiam1 - Rac seem to be involved in neurite growth and axon specification. We propose that the PAR- 6 - PAR- 3 complex mediates Cdc42-induced Rac activation by means of STEF/Tiam1, and that this process seems to be required for the establishment of neuronal polarity.	Nagoya Univ, Grad Sch Med, Dept Cell Pharmacol, Showa Ku, Aichi 4668550, Japan; Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Sakyo Ku, Kyoto 6068501, Japan; Yokohama City Univ, Sch Med, Dept Mol Biol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; JST, PRESTO, Kawaguchi, Saitama 3320012, Japan	Nagoya University; Kyoto University; Yokohama City University; Japan Science & Technology Agency (JST)	Kaibuchi, K (corresponding author), Nagoya Univ, Grad Sch Med, Dept Cell Pharmacol, Showa Ku, 65 Tsurumai, Aichi 4668550, Japan.	kaibuchi@med.nagoya-u.ac.jp	Yoshizawa, Masato/AAE-9415-2022; Yoshizawa, Masato/D-6276-2013; Nishimura, Takashi/AAQ-9299-2020; Yoshizawa, Masato/AFD-8467-2022; Nishimura, Takashi/D-7672-2017; Yamaguchi, Tomoya/AAN-7524-2020; Kato, Katsuhiro/AAV-8356-2020; Ohno, Shigeo/B-1768-2010	Yoshizawa, Masato/0000-0001-8455-8252; Yoshizawa, Masato/0000-0001-9488-2283; Nishimura, Takashi/0000-0002-6773-0302; Yoshizawa, Masato/0000-0001-8455-8252; Nishimura, Takashi/0000-0002-6773-0302; Yamaguchi, Tomoya/0000-0001-6933-543X; Ohno, Shigeo/0000-0002-1294-5269				Bradke F, 2000, CURR OPIN NEUROBIOL, V10, P574, DOI 10.1016/S0959-4388(00)00124-0; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fleming IN, 2000, BIOCHEM J, V351, P173, DOI 10.1042/0264-6021:3510173; Fukata Y, 2002, NEUROSCI RES, V43, P305, DOI 10.1016/S0168-0102(02)00062-7; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Hoshinoso M, 1999, J BIOL CHEM, V274, P17837, DOI 10.1074/jbc.274.25.17837; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Kunda P, 2001, J NEUROSCI, V21, P2361, DOI 10.1523/JNEUROSCI.21-07-02361.2001; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Macara IG, 2004, NAT REV MOL CELL BIO, V5, P220, DOI 10.1038/nrm1332; Matsuo N, 2003, MOL CELL NEUROSCI, V24, P69, DOI 10.1016/S1044-7431(03)00122-2; Matsuo N, 2002, J BIOL CHEM, V277, P2860, DOI 10.1074/jbc.M106186200; Menager C, 2004, J NEUROCHEM, V89, P109, DOI 10.1046/j.1471-4159.2004.02302.x; Mertens AE, 2003, FEBS LETT, V546, P11, DOI 10.1016/S0014-5793(03)00435-6; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Mishima A, 2002, GENES CELLS, V7, P581, DOI 10.1046/j.1365-2443.2002.00540.x; Nishimura T, 2004, NAT CELL BIOL, V6, P328, DOI 10.1038/ncb1118; Nishimura T, 2003, NAT CELL BIOL, V5, P819, DOI 10.1038/ncb1039; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Rolls MM, 2004, NAT NEUROSCI, V7, P1293, DOI 10.1038/nn1346; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schwamborn JC, 2004, NAT NEUROSCI, V7, P923, DOI 10.1038/nn1295; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Yamanaka T, 2001, GENES CELLS, V6, P721, DOI 10.1046/j.1365-2443.2001.00453.x	30	289	301	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2005	7	3					270	U77		10.1038/ncb1227	http://dx.doi.org/10.1038/ncb1227			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	902CU	15723051				2022-12-25	WOS:000227329800015
J	Cai, DS; Yuan, MS; Frantz, DF; Melendez, PA; Hansen, L; Lee, J; Shoelson, SE				Cai, DS; Yuan, MS; Frantz, DF; Melendez, PA; Hansen, L; Lee, J; Shoelson, SE			Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappa B	NATURE MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; FREE FATTY-ACIDS; TYPE-2 DIABETES-MELLITUS; GLUCOSE-METABOLISM; OBESITY; INTERLEUKIN-6; PHOSPHORYLATION; INFLAMMATION; LIVER; RISK	We show that NF-kappaB and transcriptional targets are activated in liver by obesity and high-fat diet (HFD). We have matched this state of chronic, subacute 'inflammation' by low-level activation of NF-kappaB in the liver of transgenic mice, designated LIKK, by selectively expressing constitutively active IKK-beta in hepatocytes. These mice exhibit a type 2 diabetes phenotype, characterized by hyperglycemia, profound hepatic insulin resistance, and moderate systemic insulin resistance, including effects in muscle. The hepatic production of proinflammatory cytokines, including IL-6, IL-1beta and TNF-alpha, was increased in LIKK mice to a similar extent as induced by HFD in in wild-type mice. Parallel increases were observed in cytokine signaling in liver and mucscle of LIKK mice. Insulin resistance was improved by systemic neutralization of IL-6 or salicylate inhibition of IKK-beta. Hepatic expression of the IkappaBalpha superrepressor (LISR) reversed the phenotype of both LIKK mice and wild-type mice fed an HFD. These findings indicate that lipid accumulation in the liver leads to subacute hepatic 'inflammation' through NF-kappaB activation and downstream cytokine production. This causes insulin resistance both locally in liver and systemically.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Shoelson, SE (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02115 USA.	steven.shoelson@joslin.harvard.edu	Lee, Jongsoon/AAG-1674-2020	Lee, Jongsoon/0000-0002-0891-5059	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051729, R37DK051729, P30DK036836, R01DK045943] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK051729, R37 DK051729, R01 DK45493, R01 DK51729, R01 DK045943, P30 DK36836, P30 DK036836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMS JS, 1992, IMMUNOL REV, V127, P5, DOI 10.1111/j.1600-065X.1992.tb01406.x; [Anonymous], 1979, STEREOLOGICAL METHOD; Barzilay JI, 2003, METAB SYNDR RELAT D, V1, P55, DOI 10.1089/154041903321648252; Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; Burant CF, 1997, J CLIN INVEST, V100, P2900, DOI 10.1172/JCI119839; Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; Festa A, 2002, DIABETES, V51, P1131, DOI 10.2337/diabetes.51.4.1131; Haddad E, 2001, BLOOD, V97, P1590, DOI 10.1182/blood.V97.6.1590; Hotamisligil GS, 2003, INT J OBESITY, V27, pS53, DOI 10.1038/sj.ijo.0802502; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hundal RS, 2002, J CLIN INVEST, V109, P1321, DOI 10.1172/JCI200214955; Kanemaki T, 1998, HEPATOLOGY, V27, P1296, DOI 10.1002/hep.510270515; Kelley DE, 2003, AM J PHYSIOL-ENDOC M, V285, pE906, DOI 10.1152/ajpendo.00117.2003; Kim HJ, 2004, DIABETES, V53, P1060, DOI 10.2337/diabetes.53.4.1060; Kim JK, 2001, J CLIN INVEST, V108, P437, DOI 10.1172/JCI11559; Klover PJ, 2003, DIABETES, V52, P2784, DOI 10.2337/diabetes.52.11.2784; Lagathu C, 2003, BIOCHEM BIOPH RES CO, V311, P372, DOI 10.1016/j.bbrc.2003.10.013; Li NX, 2000, METHOD ENZYMOL, V319, P273; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Marchesini G, 2001, LANCET, V358, P893, DOI 10.1016/S0140-6736(01)06042-1; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Moller DE, 2000, TRENDS ENDOCRIN MET, V11, P212, DOI 10.1016/S1043-2760(00)00272-1; *NAT DIAB DAT GROU, 1995, DIAB AM; Neuschwander-Tetri BA, 2003, HEPATOLOGY, V38, P1008, DOI 10.1053/jhep.2003.50420; Pickup JC, 1998, DIABETOLOGIA, V41, P1241, DOI 10.1007/s001250051058; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; Promrat K, 2004, HEPATOLOGY, V39, P188, DOI 10.1002/hep.20012; Radziuk J, 2000, J CLIN ENDOCR METAB, V85, P4426, DOI 10.1210/jc.85.12.4426; Rohl M, 2004, J CLIN INVEST, V113, P474, DOI 10.1172/JCI200418712; Rotter V, 2003, J BIOL CHEM, V278, P45777, DOI 10.1074/jbc.M301977200; Ryysy L, 2000, DIABETES, V49, P749, DOI 10.2337/diabetes.49.5.749; Seppala-Lindroos A, 2002, J CLIN ENDOCR METAB, V87, P3023, DOI 10.1210/jc.87.7.3023; Shoelson S, 2002, J MOL MED-JMM, V80, P618, DOI 10.1007/s00109-002-0383-x; Shoelson SE, 2003, INT J OBESITY, V27, pS49, DOI 10.1038/sj.ijo.0802501; Spranger J, 2003, DIABETES, V52, P812, DOI 10.2337/diabetes.52.3.812; STARNES HF, 1990, J IMMUNOL, V145, P4185; VAN AD, 1996, SCIENCE, V274, P787; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620	45	1688	1801	4	151	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					183	190		10.1038/nm1166	http://dx.doi.org/10.1038/nm1166			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15685173	Green Accepted			2022-12-25	WOS:000226797300026
J	Reynolds, LE; Conti, FJ; Lucas, M; Grose, R; Robinson, S; Stone, M; Saunders, G; Dickson, C; Hynes, RO; Lacy-Hulbert, A; Hodivala-Dilke, K				Reynolds, LE; Conti, FJ; Lucas, M; Grose, R; Robinson, S; Stone, M; Saunders, G; Dickson, C; Hynes, RO; Lacy-Hulbert, A; Hodivala-Dilke, K			Accelerated re-epithelialization in beta(3)-integrin-deficient mice is associated with enhanced TGF-beta 1 signaling	NATURE MEDICINE			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; EXTRACELLULAR-MATRIX; WOUND REPAIR; TRANSFORMING GROWTH-FACTOR-BETA-1; HUMAN KERATINOCYTES; CELL-MIGRATION; IN-VITRO; EXPRESSION; INTEGRIN	The upregulation of TGF-beta1 and integrin expression during wound healing has implicated these molecules in this process, but their precise regulation and roles remain unclear. Here we report that, notably, mice lacking beta(3)-integrins show enhanced wound healing with re-epithelialization complete several days earlier than in wild-type mice. We show that this effect is the result of an increase in TGF-beta1 and enhanced dermal fibroblast infiltration into wounds of beta(3)-null mice. Specifically, beta(3)-integrin deficiency is associated with elevated TGF-beta receptor I and receptor II expression, reduced Smad3 levels, sustained Smad2 and Smad4 nuclear localization and enhanced TGF-beta1-mediated dermal fibroblast migration. These data indicate that alpha(v)beta(3)-integrin can suppress TGF-beta1-mediated signaling, thereby controlling the rate of wound healing, and highlight a new mechanism for TGF-beta1 regulation by beta(3)-integrins.	Univ London St Bartholomews Hosp Med Coll, Queen Marys Sch Med & Dent, Cell Adhes & Dis Lab, Dept Tumor Biol,Canc Res UK,John Vane Sci Ctr, London EC1M 6BQ, England; Canc Res UK, London Res Inst, Viral Carcinogenesis Lab 213, London WC2A 3PX, England; Univ Edinburgh, MRC Ctr Inflammat Res, Coll Med & Vet Med, Edinburgh, Midlothian, Scotland; MIT, Ctr Canc Res, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Cancer Research UK; University of London; Queen Mary University London; Cancer Research UK; University of Edinburgh; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Hodivala-Dilke, K (corresponding author), Univ London St Bartholomews Hosp Med Coll, Queen Marys Sch Med & Dent, Cell Adhes & Dis Lab, Dept Tumor Biol,Canc Res UK,John Vane Sci Ctr, Charterhouse Sq, London EC1M 6BQ, England.	kairbaan.hodivala-dilke@cancer.org.uk		Grose, Richard/0000-0002-4738-0173; Lacy-Hulbert, Adam/0000-0003-2162-0156; Robinson, Stephen/0000-0002-6606-7588; Hodivala-Dilke, Kairbaan/0000-0002-2859-749X				Amendt C, 2002, J CELL SCI, V115, P2189; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; BASSON CT, 1992, J CELL PHYSIOL, V153, P118, DOI 10.1002/jcp.1041530116; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; CLARK R. A. F., 1995, MOL CELLULAR BIOL WO; Clark RAF, 1996, AM J PATHOL, V148, P1407; Cordeiro MF, 2003, CIRCULATION, V107, pE37, DOI 10.1161/01.CIR.0000053951.16591.20; Crowe MJ, 2000, J INVEST DERMATOL, V115, P3, DOI 10.1046/j.1523-1747.2000.00010.x; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; Direkze NC, 2003, STEM CELLS, V21, P514, DOI 10.1634/stemcells.21-5-514; GAILIT J, 1994, J INVEST DERMATOL, V103, P221, DOI 10.1111/1523-1747.ep12393176; GARLICK JA, 1994, LAB INVEST, V70, P916; GARLICK JA, 1994, J INVEST DERMATOL, V103, P554, DOI 10.1111/1523-1747.ep12396847; Greiling D, 1997, J CELL SCI, V110, P861; Grose R, 2002, DEVELOPMENT, V129, P2303; HEBDA PA, 1988, J INVEST DERMATOL, V91, P440, DOI 10.1111/1523-1747.ep12476480; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; Huang XZ, 1996, J CELL BIOL, V133, P921, DOI 10.1083/jcb.133.4.921; Huang XZ, 2000, MOL CELL BIOL, V20, P755, DOI 10.1128/MCB.20.3.755-759.2000; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Jang YC, 1999, WOUND REPAIR REGEN, V7, P375, DOI 10.1046/j.1524-475X.1999.00375.x; Lai CF, 2000, J BIOL CHEM, V275, P36400, DOI 10.1074/jbc.M002131200; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; LEIBOVICH SJ, 1975, AM J PATHOL, V78, P71; Liaw L, 1998, J CLIN INVEST, V101, P1468; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Martin P, 2003, CURR BIOL, V13, P1122, DOI 10.1016/S0960-9822(03)00396-8; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Owens DM, 2003, J CELL SCI, V116, P3783, DOI 10.1242/jcs.00725; QUAGLINO D, 1991, J INVEST DERMATOL, V97, P34; Reynolds AR, 2004, CANCER RES, V64, P8643, DOI 10.1158/0008-5472.CAN-04-2760; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shah M, 1999, AM J PATHOL, V154, P1115, DOI 10.1016/S0002-9440(10)65364-3; SHAH M, 1995, J CELL SCI, V108, P985; SHAH M, 1994, J CELL SCI, V107, P1137; SHATTIL SJ, 1995, THROMB HAEMOSTASIS, V74, P149; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Yanagisawa K, 1998, ONCOGENE, V17, P1743, DOI 10.1038/sj.onc.1202052; Yang LJ, 2001, AM J PATHOL, V159, P2147, DOI 10.1016/S0002-9440(10)63066-0; ZAMBRUNO G, 1995, J CELL BIOL, V129, P853, DOI 10.1083/jcb.129.3.853	50	110	114	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					167	174		10.1038/nm1165	http://dx.doi.org/10.1038/nm1165			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15654327				2022-12-25	WOS:000226797300024
J	Kuwaki, K; Tseng, YL; Dor, FJMF; Shimizu, A; Houser, SL; Sanderson, TM; Lancos, CJ; Prabharasuth, DD; Cheng, J; Moran, K; Hisashi, Y; Mueller, N; Yamada, K; Greenstein, JL; Hawley, RJ; Patience, C; Awwad, M; Fishman, JA; Robson, SC; Schuurman, HJ; Sachs, DH; Cooper, DKC				Kuwaki, K; Tseng, YL; Dor, FJMF; Shimizu, A; Houser, SL; Sanderson, TM; Lancos, CJ; Prabharasuth, DD; Cheng, J; Moran, K; Hisashi, Y; Mueller, N; Yamada, K; Greenstein, JL; Hawley, RJ; Patience, C; Awwad, M; Fishman, JA; Robson, SC; Schuurman, HJ; Sachs, DH; Cooper, DKC			Heart transplantation in baboons using 1,3-galactosyl transferase gene-knockout pigs as donors: initial experience	NATURE MEDICINE			English	Article							ANTI-GAL-ALPHA-1-3GAL IGM; MONOCLONAL-ANTIBODY; NATURAL ANTIBODIES; VASCULAR REJECTION; ACTIVATION	Hearts from alpha1,3-galactosyltransferase knockout pigs (GalT-KO, n = 8) were transplanted heterotopically into baboons using an anti-CD154 monoclonal antibody-based regimen. The elimination of the galactose-alpha1,3-galactose epitope prevented hyperacute rejection and extended survival of pig hearts in baboons for 2-6 months (median, 78 d); the predominant lesion associated with graft failure was a thrombotic microangiopathy, with resulting ischemic injury. There were no infectious complications directly related to the immunosuppressive regimen. The transplantation of hearts from GalT-KO pigs increased graft survival over previous studies.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr, Boston, MA 02129 USA; Immerge BioTherapeut Inc, Cambridge, MA 02139 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA 02114 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Immunobiol, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Cooper, DKC (corresponding author), Univ Pittsburgh, Med Ctr, Starzl Transplantat Inst, Biomed Sci Tower E,Room E1550A,200 Lothrop St, Pittsburgh, PA 15261 USA.	cooperdk@upmc.edu	Robson, Simon C./AAA-8537-2021; Dor, Frank JMF/E-1032-2013; Mueller, Nicolas J./B-6864-2013	Dor, Frank JMF/0000-0001-7845-3075; Mueller, Nicolas J./0000-0002-1059-3191	PHS HHS [1PO1A45897] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Buhler L, 2001, TRANSPLANTATION, V72, P1743, DOI 10.1097/00007890-200112150-00007; COOPER DKC, 1993, LANCET, V342, P682, DOI 10.1016/0140-6736(93)91791-J; COOPER DKC, 1992, CLIN TRANSPLANT, V6, P178; Dor FJMF, 2004, TRANSPLANTATION, V78, P15, DOI 10.1097/01.TP.0000130487.68051.EB; GOOD AH, 1992, TRANSPL P, V24, P559; Kawai T, 2000, NAT MED, V6, P114, DOI 10.1038/72162; Knosalla C, 2002, TRANSPLANTATION, V74, P416, DOI 10.1097/00007890-200208150-00024; Kolber-Simonds D, 2004, P NATL ACAD SCI USA, V101, P7335, DOI 10.1073/pnas.0307819101; Kuwaki K, 2004, AM J TRANSPLANT, V4, P363, DOI 10.1111/j.1600-6143.2004.00353.x; Lin SS, 2000, TRANSPLANTATION, V70, P1667, DOI 10.1097/00007890-200012270-00002; Mueller NJ, 2002, J VIROL, V76, P4734, DOI 10.1128/JVI.76.10.4734-4740.2002; ORIOL R, 1993, TRANSPLANTATION, V56, P1433, DOI 10.1097/00007890-199312000-00031; Phelps CJ, 2003, SCIENCE, V299, P411, DOI 10.1126/science.1078942; Robson SC, 2000, XENOTRANSPLANTATION, V7, P166, DOI 10.1034/j.1399-3089.2000.00067.x; Teranishi K, 2002, XENOTRANSPLANTATION, V9, P148, DOI 10.1034/j.1399-3089.2002.1o058.x	15	528	550	1	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2005	11	1					29	31		10.1038/nm1171	http://dx.doi.org/10.1038/nm1171			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	884ZJ	15619628				2022-12-25	WOS:000226124900028
J	Tenev, T; Zachariou, A; Wilson, R; Ditzel, M; Meier, P				Tenev, T; Zachariou, A; Wilson, R; Ditzel, M; Meier, P			IAPs are functionally non-equivalent and regulate effector caspases through distinct mechanisms	NATURE CELL BIOLOGY			English	Article							STRUCTURAL BASIS; INHIBITION; DIAP1; APOPTOSIS; XIAP; DROSOPHILA; HID; PROTEIN; DRONC; GRIM	Some members of the inhibitor of apoptosis (IAP) family suppress apoptosis by neutralizing caspases. The current model suggests that all caspase-regulatory IAPs function as direct enzyme inhibitors, blocking effector caspases by binding to their catalytically active pockets. Here we show that IAPs are functionally non-equivalent and regulate effector caspases through distinct mechanisms. Whereas XIAP binds directly to the active-site pockets of effector caspases, we find that regulation of effector caspases by Drosophila IAP1 (DIAP1) requires an evolutionarily conserved IAP-binding motif (IBM) at the neo-amino terminus of the large caspase subunit. Remarkably, unlike XIAP, DIAP1-sequestered effector caspases remain catalytically active, suggesting that DIAP1 does not function as a bona fide enzyme inhibitor. Moreover, we demonstrate that the mammalian IAP c-IAP1 interacts with caspase-7 in an exclusively IBM-dependent, but active site pocket-independent, manner that is mechanistically similar to DIAP1. The importance of IBM-mediated regulation of effector-caspases in vivo is substantiated by the enhanced apoptotic potency of IBM-mutant versions of drICE, DCP-1 and caspase-7.	Inst Canc Res, Chester Beatty Labs, Breakthrough Toby Robins Breast Canc Res Ctr, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Meier, P (corresponding author), Inst Canc Res, Chester Beatty Labs, Breakthrough Toby Robins Breast Canc Res Ctr, Mary Jean Mitchell Green Bldg,Fulham Rd, London SW3 6JB, England.	pmeier@icr.ac.uk		Meier, Pascal/0000-0003-2760-6523	Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline	Breast Cancer Now		BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Ditzel M, 2003, NAT CELL BIOL, V5, P467, DOI 10.1038/ncb984; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; Hawkins CJ, 2000, J BIOL CHEM, V275, P27084; Hawkins CJ, 1999, P NATL ACAD SCI USA, V96, P2885, DOI 10.1073/pnas.96.6.2885; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Lisi S, 2000, GENETICS, V154, P669; Meier P, 2000, EMBO J, V19, P598, DOI 10.1093/emboj/19.4.598; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6; Silke J, 2001, EMBO J, V20, P3114, DOI 10.1093/emboj/20.12.3114; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Suzuki Y, 2001, J BIOL CHEM, V276, P27058, DOI 10.1074/jbc.M102415200; Tenev T, 2000, EUR J CELL BIOL, V79, P261, DOI 10.1078/S0171-9335(04)70029-1; Tenev T, 2002, EMBO J, V21, P5118, DOI 10.1093/emboj/cdf530; Varshavsky A, 2000, METHOD ENZYMOL, V327, P578, DOI 10.1016/S0076-6879(00)27303-5; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Wu JW, 2001, MOL CELL, V8, P95, DOI 10.1016/S1097-2765(01)00282-9; Yan N, 2004, NAT STRUCT MOL BIOL, V11, P420, DOI 10.1038/nsmb764; YOKOKURA T, 2004, J BIOL CHEM; Zachariou A, 2003, EMBO J, V22, P6642, DOI 10.1093/emboj/cdg617	30	120	131	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2005	7	1					70	+		10.1038/ncb1204	http://dx.doi.org/10.1038/ncb1204			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	884UZ	15580265				2022-12-25	WOS:000226113500017
J	Kamura, T; Hara, T; Matsumoto, M; Ishida, N; Okumura, F; Hatakeyama, S; Yoshida, M; Nakayama, K; Nakayama, KI				Kamura, T; Hara, T; Matsumoto, M; Ishida, N; Okumura, F; Hatakeyama, S; Yoshida, M; Nakayama, K; Nakayama, KI			Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase	NATURE CELL BIOLOGY			English	Article							KINASE INHIBITOR P27(KIP1); MEDIATED DEGRADATION; NUCLEAR EXPORT; S-PHASE; P27; PHOSPHORYLATION; SCFSKP2; COMPLEX; LOCALIZATION; PROGRESSION	The cyclin-dependent kinase inhibitor p27(Kip1) is degraded at the G0-G1 transition of the cell cycle by the ubiquitin proteasome pathway(1,2). Although the nuclear ubiquitin ligase (E3) SCFSkp2 is implicated in p27(Kip1) degradation(3-6), proteolysis of p27(Kip1) at the G0 - G1 transition proceeds normally in Skp2(-/-) cells(7,8). Moreover, p27(Kip1) is exported from the nucleus to the cytoplasm at G0 - G1 ( refs 9 - 11). These data suggest the existence of a Skp2- independent pathway for the degradation of p27(Kip1) at G1 phase. We now describe a previously unidentified E3 complex: KPC ( Kip1 ubiquitination- promoting complex), consisting of KPC1 and KPC2. KPC1 contains a RING- finger domain, and KPC2 contains a ubiquitinlike domain and two ubiquitin- associated domains. KPC interacts with and ubiquitinates p27Kip1 and is localized to the cytoplasm. Overexpression of KPC promoted the degradation of p27(Kip1), whereas a dominant- negative mutant of KPC1 delayed p27(Kip1) degradation. The nuclear export of p27(Kip1) by CRM1 seems to be necessary for KPC- mediated proteolysis. Depletion of KPC1 by RNA interference also inhibited p27(Kip1) degradation. KPC thus probably controls degradation of p27(Kip1) in G1 phase after export of the latter from the nucleus.	Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cell Biol, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan; Tohoku Univ, Grad Sch Med, Ctr Translat & Adv Anim Res Human Dis, Dept Dev Biol, Sendai, Miyagi 9808575, Japan; RIKEN, Discovery Res Inst, Chem Genet Lab, Wako, Saitama 3510198, Japan	Kyushu University; Japan Science & Technology Agency (JST); Tohoku University; RIKEN	Nakayama, KI (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cell Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	nakayak1@bioreg.kyushu-u.ac.jp	Hatakeyama, Shigetsugu/C-8333-2012; Yoshida, Minoru/C-8049-2014	Hatakeyama, Shigetsugu/0000-0002-2150-9979; Yoshida, Minoru/0000-0002-4376-5674; Matsumoto, Masaki/0000-0002-6987-0288				Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chen L, 2001, EMBO REP, V2, P933, DOI 10.1093/embo-reports/kve203; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 2003, P NATL ACAD SCI USA, V100, P10231, DOI 10.1073/pnas.1831009100; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Li CY, 2000, GENOMICS, V65, P243, DOI 10.1006/geno.2000.6176; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Ponting C, 1997, TRENDS BIOCHEM SCI, V22, P193, DOI 10.1016/S0968-0004(97)01049-9; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Yoshida M, 1999, ANN NY ACAD SCI, V886, P23, DOI 10.1111/j.1749-6632.1999.tb09397.x	26	344	356	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2004	6	12					1229	1235		10.1038/ncb1194	http://dx.doi.org/10.1038/ncb1194			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	875WQ	15531880				2022-12-25	WOS:000225453300016
J	Obuse, C; Iwasaki, O; Kiyomitsu, T; Goshima, G; Toyoda, Y; Yanagida, M				Obuse, C; Iwasaki, O; Kiyomitsu, T; Goshima, G; Toyoda, Y; Yanagida, M			A conserved Mis12 centromere complex is linked to heterochromatic HP1 and outer kinetochore protein Zwint-1	NATURE CELL BIOLOGY			English	Article							BUDDING YEAST KINETOCHORE; CHROMOSOME SEGREGATION; FISSION YEAST; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; EQUAL SEGREGATION; MAMMALIAN-CELLS; DROSOPHILA; CHROMATIN; SPINDLE	Defects in kinetochore proteins often lead to aneuploidy and cancer. Mis12-Mtw1 is a conserved, essential kinetochore protein family. Here, we show that a Mis12 core complex exists in Schizosaccharomyces pombe and human cells. Nine polypeptides bind to human hMis12; two of these, HEC1 and Zwint-1, are authentic kinetochore proteins. Four other human proteins of unknown function (c20orf172, DC8, PMF1 and KIAA1570) correspond to yeast Mis12-Mtw1 complex components and are shown to be required for chromosome segregation in HeLa cells using RNA interference (RNAi). Surprisingly, hMis12 also forms a stable complex with the centromeric heterochromatin components HP1alpha and HP1gamma. Double HP1 RNAi abolishes kinetochore localization of hMis12 and DC8. Therefore, centromeric HP1 may be the base to anchor the hMis12 core complex that is enriched with coiled coils and extends to outer Zwint-1 during mitosis.	Kyoto Univ, Grad Sch Biostudies, Dept Gene Mech, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Yanagida, M (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Gene Mech, Sakyo Ku, Yoshida Honmachi, Kyoto 6068501, Japan.	yanagida@kozo.lif.kyoto-u.ac.jp	Obuse, Chikashi/F-5273-2011	Toyoda, Yusuke/0000-0003-0534-6898				Ainsztein AM, 1998, J CELL BIOL, V143, P1763, DOI 10.1083/jcb.143.7.1763; Amor DJ, 2004, TRENDS CELL BIOL, V14, P359, DOI 10.1016/j.tcb.2004.05.009; Blower MD, 2001, NAT CELL BIOL, V3, P730, DOI 10.1038/35087045; De Wulf P, 2003, GENE DEV, V17, P2902, DOI 10.1101/gad.1144403; DeLuca JG, 2003, CURR BIOL, V13, P2103, DOI 10.1016/j.cub.2003.10.056; Euskirchen GM, 2002, EUKARYOT CELL, V1, P229, DOI 10.1128/EC.1.2.229-240.2002; Goshima G, 2003, EMBO J, V22, P2752, DOI 10.1093/emboj/cdg266; Goshima G, 1999, GENE DEV, V13, P1664, DOI 10.1101/gad.13.13.1664; Goshima G, 2003, J CELL BIOL, V160, P25, DOI 10.1083/jcb.200210005; Hayakawa T, 2003, J CELL SCI, V116, P3327, DOI 10.1242/jcs.00635; Hayashi T, 2004, CELL, V118, P715, DOI 10.1016/j.cell.2004.09.002; JAMES TC, 1989, EUR J CELL BIOL, V50, P170; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Maison C, 2004, NAT REV MOL CELL BIO, V5, P296, DOI 10.1038/nrm1355; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; McCleland ML, 2004, CURR BIOL, V14, P131, DOI 10.1016/j.cub.2003.12.058; Nabeshima K, 1998, MOL BIOL CELL, V9, P3211, DOI 10.1091/mbc.9.11.3211; Nekrasov VS, 2003, MOL BIOL CELL, V14, P4931, DOI 10.1091/mbc.E03-06-0419; Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0; Ohta S, 2003, J BIOL CHEM, V278, P41535, DOI 10.1074/jbc.M307535200; Ohta S, 2002, J BIOL CHEM, V277, P40362, DOI 10.1074/jbc.M206194200; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Pinsky BA, 2003, DEV CELL, V5, P735, DOI 10.1016/S1534-5807(03)00322-8; Quivy JP, 2004, EMBO J, V23, P3516, DOI 10.1038/sj.emboj.7600362; Saitoh S, 1997, CELL, V90, P131, DOI 10.1016/S0092-8674(00)80320-7; SAUNDERS WS, 1993, J CELL SCI, V104, P573; Scharfenberger M, 2003, EMBO J, V22, P6584, DOI 10.1093/emboj/cdg636; Shelby RD, 2000, J CELL BIOL, V151, P1113, DOI 10.1083/jcb.151.5.1113; Starr DA, 2000, J CELL SCI, V113, P1939; Takahashi K, 2000, SCIENCE, V288, P2215, DOI 10.1126/science.288.5474.2215; Tatebayashi K, 1998, GENETICS, V148, P49; Van Hooser AA, 2001, J CELL SCI, V114, P3529; Westermann S, 2003, J CELL BIOL, V163, P215, DOI 10.1083/jcb.200305100; WILLIAMS BC, 1994, J CELL SCI, V107, P785	34	211	232	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2004	6	11					1135	U37		10.1038/ncb1187	http://dx.doi.org/10.1038/ncb1187			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	867BI	15502821				2022-12-25	WOS:000224816700020
J	Iafrate, AJ; Feuk, L; Rivera, MN; Listewnik, ML; Donahoe, PK; Qi, Y; Scherer, SW; Lee, C				Iafrate, AJ; Feuk, L; Rivera, MN; Listewnik, ML; Donahoe, PK; Qi, Y; Scherer, SW; Lee, C			Detection of large-scale variation in the human genome	NATURE GENETICS			English	Article							SEGMENTAL DUPLICATIONS; SEQUENCE; DISEASE	We identified 255 loci across the human genome that contain genomic imbalances among unrelated individuals. Twenty-four variants are present in >10% of the individuals that we examined. Half of these regions overlap with genes, and many coincide with segmental duplications or gaps in the human genome assembly. This previously unappreciated heterogeneity may underlie certain human phenotypic variation and susceptibility to disease and argues for a more dynamic human genome structure.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Hosp Sick Children, Dept Genet & Genom Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON, Canada; Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; Massachusetts Gen Hosp, Pediat Surg Res Labs, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Lee, C (corresponding author), Brigham & Womens Hosp, Dept Pathol, 20 Shattuck St,Thorn 6-28, Boston, MA 02115 USA.	clee@rics.bwh.harvard.edu	Scherer, Stephen W./B-3785-2013; Maestrini, Elena/K-7508-2012	Scherer, Stephen W./0000-0002-8326-1999; Maestrini, Elena/0000-0001-5924-3179				Albertson DG, 2003, HUM MOL GENET, V12, pR145, DOI 10.1093/hmg/ddg261; Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; Cheung J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r25; Eichler EE, 2004, NAT REV GENET, V5, P345, DOI 10.1038/nrg1322; Giglio S, 2001, AM J HUM GENET, V68, P874, DOI 10.1086/319506; GROOT PC, 1991, GENOMICS, V10, P779, DOI 10.1016/0888-7543(91)90463-O; Hollox EJ, 2003, AM J HUM GENET, V73, P591, DOI 10.1086/378157; Ishkanian AS, 2004, NAT GENET, V36, P299, DOI 10.1038/ng1307; Osborne LR, 2001, NAT GENET, V29, P321, DOI 10.1038/ng753; Scherer SW, 2003, SCIENCE, V300, P767, DOI 10.1126/science.1083423; Shaw CJ, 2004, HUM MOL GENET, V13, pR57, DOI 10.1093/hmg/ddh073; WRIGHT AF, 2003, NATURE ENCY HUMAN GE, V2, P959	12	2153	2306	0	70	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2004	36	9					949	951		10.1038/ng1416	http://dx.doi.org/10.1038/ng1416			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	851AY	15286789	Bronze			2022-12-25	WOS:000223658100018
J	Engel, N; West, AG; Felsenfeld, G; Bartolomei, MS				Engel, N; West, AG; Felsenfeld, G; Bartolomei, MS			Antagonism between DNA hypermethylation and enhancer-blocking activity at the H19 DMD is uncovered by CpG mutations	NATURE GENETICS			English	Article							IMPRINTED EXPRESSION; SEQUENCE UPSTREAM; PROTEIN CTCF; METHYLATION; GENE; IGF2; INSULATOR; ELEMENT; REGION; DELETION	Imprinted expression at the H19-Igf2 locus depends on a differentially methylated domain (DMD) that acts both as a maternal-specific, methylation-sensitive insulator and as a paternal-specific site of hypermethylation. Four repeats in the DMD bind CCCTC-binding factor ( CTCF) on the maternal allele and have been proposed to attract methylation on the paternal allele. We introduced point mutations into the DMD to deplete the repeats of CpGs while retaining CTCF-binding and enhancer-blocking activity. Maternal inheritance of the mutations left H19 expression and Igf2 imprinting intact, consistent with the idea that the DMD acts as an insulator. Conversely, paternal inheritance of these mutations disrupted maintenance of DMD methylation, resulting in biallelic H19 expression. Furthermore, an insulator was established on the paternally inherited mutated allele in vivo, reducing Igf2 expression and resulting in a 40% reduction in size of newborn offspring. Thus, the nine CpG mutations in the DMD showed that the two parental-specific roles of the H19 DMD, methylation maintenance and insulator assembly, are antagonistic.	Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Bartolomei, MS (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA.	bartolom@mail.med.upenn.edu		Engel, Nora/0000-0002-0618-3624; West, Adam/0000-0003-3502-7804	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK034001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ainscough JFX, 2000, MECH DEVELOP, V91, P365, DOI 10.1016/S0925-4773(99)00289-0; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Chung JH, 1997, P NATL ACAD SCI USA, V94, P575, DOI 10.1073/pnas.94.2.575; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; Davis TL, 1999, GENOMICS, V58, P18, DOI 10.1006/geno.1999.5813; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; Eden S, 2001, EMBO J, V20, P3518, DOI 10.1093/emboj/20.13.3518; Fedoriw AM, 2004, SCIENCE, V303, P238, DOI 10.1126/science.1090934; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; Frevel MAE, 1999, TRENDS GENET, V15, P216, DOI 10.1016/S0168-9525(99)01752-7; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960-9822(00)00597-2; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; Lewandoski M, 1997, CURR BIOL, V7, P148, DOI 10.1016/S0960-9822(06)00059-5; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Lopes S, 2003, HUM MOL GENET, V12, P295, DOI 10.1093/hmg/ddg022; Mann MRW, 2003, BIOL REPROD, V69, P902, DOI 10.1095/biolreprod.103.017293; NEUMANN B, 1995, NAT GENET, V9, P12, DOI 10.1038/ng0195-12; Pant V, 2003, GENE DEV, V17, P586, DOI 10.1101/gad.254903; Schoenherr CJ, 2003, NAT GENET, V33, P66, DOI 10.1038/ng1057; Srivastava M, 2000, GENE DEV, V14, P1186; Stadnick MP, 1999, DEV GENES EVOL, V209, P239, DOI 10.1007/s004270050248; Thorvaldsen JL, 2002, MOL CELL BIOL, V22, P2450, DOI 10.1128/MCB.22.8.2450-2462.2002; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Tremblay KD, 1997, MOL CELL BIOL, V17, P4322, DOI 10.1128/MCB.17.8.4322; Verona RI, 2003, ANNU REV CELL DEV BI, V19, P237, DOI 10.1146/annurev.cellbio.19.111401.092717; Yoon BJ, 2002, NAT GENET, V30, P92, DOI 10.1038/ng795	30	95	100	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2004	36	8					883	888		10.1038/ng1399	http://dx.doi.org/10.1038/ng1399			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	842AG	15273688				2022-12-25	WOS:000222974000023
J	Du, W; Bautista, JF; Yang, HH; Diez-Sampedro, A; You, SA; Wang, LJ; Kotagal, P; Luders, HO; Shi, JY; Cui, JM; Richerson, GB; Wang, QK				Du, W; Bautista, JF; Yang, HH; Diez-Sampedro, A; You, SA; Wang, LJ; Kotagal, P; Luders, HO; Shi, JY; Cui, JM; Richerson, GB; Wang, QK			Calcium-sensitive potassium channelopathy in human epilepsy and paroxysmal movement disorder	NATURE GENETICS			English	Article							BETA-SUBUNIT; ATAXIA; GENE; OSCILLATION; MUTATIONS; MYOKYMIA; FEATURES	The large conductance calcium- sensitive potassium ( BK) channel is widely expressed in many organs and tissues, but its in vivo physiological functions have not been fully defined. Here we report a genetic locus associated with a human syndrome of coexistent generalized epilepsy and paroxysmal dyskinesia on chromosome 10q22 and show that a mutation of the a subunit of the BK channel causes this syndrome. The mutant BK channel had a markedly greater macroscopic current. Single- channel recordings showed an increase in open-channel probability due to a three- to fivefold increase in Ca2+ sensitivity. We propose that enhancement of BK channels in vivo leads to increased excitability by inducing rapid repolarization of action potentials, resulting in generalized epilepsy and paroxysmal dyskinesia by allowing neurons to fire at a faster rate. These results identify a gene that is mutated in generalized epilepsy and paroxysmal dyskinesia and have implications for the pathogenesis of human epilepsy, the neurophysiology of paroxysmal movement disorders and the role of BK channels in neurological disease.	Cleveland Clin Fdn, Ctr Mol Sci, Dept Mol Cardiol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Ctr Cardiovasc Genet, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Mol Med, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Biol Geol & Environm Sci, Cleveland, OH 44115 USA; Cleveland Clin Fdn, Dept Neurol, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA; Washington Univ, Dept Biomed Engn, St Louis, MO 63130 USA; Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Vet Adm Med Ctr, West Haven, CT 06516 USA; Huazhong Univ Sci & Technol, Human Genome Res Ctr, Wuhan, Peoples R China	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation; University System of Ohio; Cleveland State University; Cleveland Clinic Foundation; Case Western Reserve University; Washington University (WUSTL); Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Huazhong University of Science & Technology	Wang, QK (corresponding author), Cleveland Clin Fdn, Ctr Mol Sci, Dept Mol Cardiol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	wangq2@ccf.org	Bautista, Jocelyn F./AAP-6901-2021	Richerson, George/0000-0001-5696-1554; Yang, Huanghe/0000-0001-9521-9328	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070393] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL070393] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS PR, 1982, NATURE, V296, P746, DOI 10.1038/296746a0; [Anonymous], 1981, Epilepsia, V22, P489; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Bao L, 2002, J GEN PHYSIOL, V120, P173, DOI 10.1085/jgp.20028627; BARRETT JN, 1982, J PHYSIOL-LONDON, V331, P211, DOI 10.1113/jphysiol.1982.sp014370; BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; Davies AG, 2003, CELL, V115, P655, DOI 10.1016/S0092-8674(03)00979-6; DEMIRKIRAN M, 1995, ANN NEUROL, V38, P571, DOI 10.1002/ana.410380405; Eunson LH, 2000, ANN NEUROL, V48, P647; Fernandez-Fernandez JM, 2004, J CLIN INVEST, V113, P1032, DOI 10.1172/JCI200420347; Guerrini R, 2002, EPILEPSIA, V43, P1224, DOI 10.1046/j.1528-1157.2002.13802.x; Guerrini R, 2001, EPILEPSIA, V42, P36, DOI 10.1046/j.1528-1157.2001.042suppl.3036.x; Guerrini R, 1999, ANN NEUROL, V45, P344, DOI 10.1002/1531-8249(199903)45:3<344::AID-ANA10>3.0.CO;2-9; Jin W, 2000, BRAIN RES, V860, P21, DOI 10.1016/S0006-8993(00)01943-0; LANCASTER B, 1987, J PHYSIOL-LONDON, V389, P187, DOI 10.1113/jphysiol.1987.sp016653; Lee HY, 2004, HUM MOL GENET, V13, P3161, DOI 10.1093/hmg/ddh330; LUBBERS WJ, 1995, J NEUROL NEUROSUR PS, V59, P400, DOI 10.1136/jnnp.59.4.400; MCCORMICK DA, 1990, J PHYSIOL-LONDON, V431, P291, DOI 10.1113/jphysiol.1990.sp018331; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Nimigean CM, 1999, J GEN PHYSIOL, V113, P425, DOI 10.1085/jgp.113.3.425; Noebels JL, 2003, ANNU REV NEUROSCI, V26, P599, DOI 10.1146/annurev.neuro.26.010302.081210; Rutten F, 2001, J TURBUL, V2, P1, DOI 10.1088/1468-5248/2/1/003; Sausbier M, 2004, P NATL ACAD SCI USA, V101, P9474, DOI 10.1073/pnas.0401702101; Shi JY, 2002, NATURE, V418, P876, DOI 10.1038/nature00941; Szepetowski P, 1997, AM J HUM GENET, V61, P889, DOI 10.1086/514877; VONKROSIGK M, 1993, SCIENCE, V261, P361, DOI 10.1126/science.8392750; Wang LJ, 2003, SCIENCE, V302, P1578, DOI 10.1126/science.1088477; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20; Xia XM, 2002, NATURE, V418, P880, DOI 10.1038/nature00956	29	407	423	0	39	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2005	37	7					733	738		10.1038/ng1585	http://dx.doi.org/10.1038/ng1585			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	941EA	15937479				2022-12-25	WOS:000230196400020
J	Garber, K				Garber, K			New apoptosis drugs face critical test	NATURE BIOTECHNOLOGY			English	News Item								Surging numbers of therapeutic proteins and small molecules, rationally designed to trigger cell death, are entering the clinic against cancer. In theory, they should provide an entirely new kind of targeted therapy, but troubling questions of basic biology remain.										Diehl GE, 2004, IMMUNITY, V21, P877, DOI 10.1016/j.immuni.2004.11.008; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231	2	33	35	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2005	23	4					409	411		10.1038/nbt0405-409	http://dx.doi.org/10.1038/nbt0405-409			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	914AR	15815657				2022-12-25	WOS:000228197300009
J	Harikrishnan, KN; Chow, MZ; Baker, EK; Pal, S; Bassal, S; Brasacchio, D; Wang, L; Craig, JM; Jones, PL; Sif, S; El-Osta, A				Harikrishnan, KN; Chow, MZ; Baker, EK; Pal, S; Bassal, S; Brasacchio, D; Wang, L; Craig, JM; Jones, PL; Sif, S; El-Osta, A			Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing	NATURE GENETICS			English	Article							CPG-BINDING-PROTEIN; FRAGILE-X; DNA METHYLATION; REPRESSION; MECP2; GENE; FMR1; DEACETYLATION; PURIFICATION; RECRUITMENT	Transcriptional repression of methylated genes can be mediated by the methyl-CpG binding protein MeCP2. Here we show that human Brahma (Brm), a catalytic component of the SWI/SNF-related chromatin-remodeling complex, associates with MeCP2 in vivo and is functionally linked with repression. We used a number of different molecular approaches and chromatin immunoprecipitation strategies to show a unique cooperation between Brm, BAF57 and MeCP2. We show that Brm and MeCP2 assembly on chromatin occurs on methylated genes in cancer and the gene FMR1 in fragile X syndrome. These experimental findings identify a new role for SWI/SNF in gene repression by MeCP2.	Baker Med Res Inst, Alfred Med Res & Educ Precinct, Epigenet Human Hlth & Dis Lab, Prahran, Vic 3181, Australia; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61802 USA	Baker Heart and Diabetes Institute; University System of Ohio; Ohio State University; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Illinois System; University of Illinois Urbana-Champaign	El-Osta, A (corresponding author), Baker Med Res Inst, Alfred Med Res & Educ Precinct, Epigenet Human Hlth & Dis Lab, 2nd Floor,Commercial Rd, Prahran, Vic 3181, Australia.	assam.el-osta@baker.edu.au	Craig, Jeffrey M/B-3484-2012	Craig, Jeffrey M/0000-0003-3979-7849; El-Osta, Assam/0000-0003-2969-9137; Kaipananickal, Harikrishnan/0000-0002-4662-659X; El-Osta, Assam/0000-0001-7968-7375; Sif, Said/0000-0001-6268-1145				Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Battaglioli E, 2002, J BIOL CHEM, V277, P41038, DOI 10.1074/jbc.M205691200; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Coffee B, 2002, AM J HUM GENET, V71, P923, DOI 10.1086/342931; Coffee B, 1999, NAT GENET, V22, P98, DOI 10.1038/8807; Damelin M, 2002, MOL CELL, V9, P563, DOI 10.1016/S1097-2765(02)00475-6; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; El-Osta A, 2000, GENE EXPRESSION, V9, P63; El-Osta A, 2001, BIOCHEM BIOPH RES CO, V289, P733, DOI 10.1006/bbrc.2001.6023; El-Osta A, 2001, MOL BIOL REP, V28, P209, DOI 10.1023/A:1015744625049; El-Osta A, 2002, MOL CELL BIOL, V22, P1844, DOI 10.1128/MCB.22.6.1844-1857.2002; Flaus A, 2003, MOL CELL BIOL, V23, P7767, DOI 10.1128/MCB.23.21.7767-7779.2003; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Fyodorov DV, 2004, GENE DEV, V18, P170, DOI 10.1101/gad.1139604; Godde JS, 1996, J BIOL CHEM, V271, P24325, DOI 10.1074/jbc.271.40.24325; Goldmark JP, 2000, CELL, V103, P423, DOI 10.1016/S0092-8674(00)00134-3; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Jin P, 2000, HUM MOL GENET, V9, P901, DOI 10.1093/hmg/9.6.901; JONES A, 1967, ECON BOT, V21, P163, DOI 10.1007/BF02897864; Jones BE, 1998, EXTREMOPHILES, V2, P191, DOI 10.1007/s007920050060; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; Kimura H, 2003, J BIOL CHEM, V278, P4806, DOI 10.1074/jbc.M209923200; Klose RJ, 2004, J BIOL CHEM, V279, P46490, DOI 10.1074/jbc.M408284200; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; Li Q, 1999, ONCOGENE, V18, P3284, DOI 10.1038/sj.onc.1202663; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; Martens JA, 2004, NATURE, V429, P571, DOI 10.1038/nature02538; Martens JA, 2002, GENE DEV, V16, P2231, DOI 10.1101/gad.1009902; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Ng HH, 2002, GENE DEV, V16, P806, DOI 10.1101/gad.978902; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; Pal S, 2003, MOL CELL BIOL, V23, P7475, DOI 10.1128/MCB.23.21.7475-7487.2003; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Valerius O, 2002, J BIOL CHEM, V277, P21440, DOI 10.1074/jbc.M201841200; VERHEIJ C, 1995, HUM MOL GENET, V4, P895, DOI 10.1093/hmg/4.5.895; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	50	226	237	1	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2005	37	3					254	264		10.1038/ng1516	http://dx.doi.org/10.1038/ng1516			11	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	901QU	15696166				2022-12-25	WOS:000227297800016
J	Li, MZ; Elledge, SJ				Li, MZ; Elledge, SJ			MAGIC, an in vivo genetic method for the rapid construction of recombinant DNA molecules	NATURE GENETICS			English	Article							LAC OPERATOR DNA; ESCHERICHIA-COLI; CLONING; PLASMID; REPLACEMENT; MUTAGENESIS; EXPRESSION; PROMOTER; VECTOR; SYSTEM	We describe a highly engineered in vivo cloning method, mating-assisted genetically integrated cloning (MAGIC), that facilitates the rapid construction of recombinant DNA molecules. MAGIC uses bacterial mating, in vivo site-specific endonuclease cleavage and homologous recombination to catalyze the transfer of a DNA fragment between a donor vector in one bacterial strain and a recipient plasmid in a separate bacterial strain. Recombination events are genetically selected and result in placement of the gene of interest under the control of new regulatory elements with high efficiency. MAGIC eliminates the need for restriction enzymes, DNA ligases, preparation of DNA and all in vitro manipulations required for subcloning and allows the rapid construction of multiple constructs with minimal effort. We show that MAGIC can generate constructs for expression in multiple organisms. As this new method requires only the simple mixing of bacterial strains, it represents a substantial advance in high-throughput recombinant DNA production that will save time, effort and expense in functional genomics studies.	Harvard Univ, Sch Med, Harvard Partners Ctr Genet & Genom, Howard Hughes Med Inst,Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Elledge, SJ (corresponding author), Harvard Univ, Sch Med, Harvard Partners Ctr Genet & Genom, Howard Hughes Med Inst,Dept Genet, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	selledge@genetics.med.harvard.edu						BACKMAN K, 1978, CELL, V13, P65, DOI 10.1016/0092-8674(78)90138-1; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bethke B, 1997, NUCLEIC ACIDS RES, V25, P2828, DOI 10.1093/nar/25.14.2828; CHEREPANOV PP, 1995, GENE, V158, P9, DOI 10.1016/0378-1119(95)00193-A; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P3240, DOI 10.1073/pnas.70.11.3240; DANNA K, 1971, P NATL ACAD SCI USA, V68, P2913, DOI 10.1073/pnas.68.12.2913; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; FROST LS, 1994, MICROBIOL REV, V58, P162, DOI 10.1128/MMBR.58.2.162-210.1994; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gumbiner-Russo LM, 2001, GENE, V273, P97, DOI 10.1016/S0378-1119(01)00565-0; Haldimann A, 1998, J BACTERIOL, V180, P1277, DOI 10.1128/JB.180.5.1277-1286.1998; Hartley JL, 2000, GENOME RES, V10, P1788, DOI 10.1101/gr.143000; HASHIMOTO T, 1976, J BACTERIOL, V127, P1561, DOI 10.1128/JB.127.3.1561-1563.1976; HEYNEKER HL, 1976, NATURE, V263, P748, DOI 10.1038/263748a0; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; KAISER K, 1980, MOL GEN GENET, V179, P555, DOI 10.1007/BF00271745; KAST P, 1994, GENE, V138, P109, DOI 10.1016/0378-1119(94)90790-0; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; MARIANS KJ, 1976, NATURE, V263, P744, DOI 10.1038/263744a0; METCALF WW, 1994, GENE, V138, P1, DOI 10.1016/0378-1119(94)90776-5; Nebert D W, 2000, Ann N Y Acad Sci, V919, P148; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; Siegel RW, 2004, GENOME RES, V14, P1119, DOI 10.1101/gr.1821804; SMITH HO, 1970, J MOL BIOL, V51, P379, DOI 10.1016/0022-2836(70)90149-X; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Walhout AJM, 2000, METHOD ENZYMOL, V328, P575, DOI 10.1016/S0076-6879(00)28419-X; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; Zhang PM, 2002, NAT GENET, V30, P31, DOI 10.1038/ng797	33	95	106	1	22	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2005	37	3					311	319		10.1038/ng1505	http://dx.doi.org/10.1038/ng1505			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	901QU	15731760				2022-12-25	WOS:000227297800024
J	Laoukili, J; Kooistra, MRH; Bras, A; Kauw, J; Kerkhoven, RM; Morrison, A; Clevers, H; Medema, RH				Laoukili, J; Kooistra, MRH; Bras, A; Kauw, J; Kerkhoven, RM; Morrison, A; Clevers, H; Medema, RH			FoxM1 is required for execution of the mitotic programme and chromosome stability	NATURE CELL BIOLOGY			English	Article							FORKHEAD TRANSCRIPTION FACTORS; YEAST-CELL CYCLE; CENP-F; BINDING DOMAIN; FACTOR TRIDENT; S PHASE; PROTEIN; EXPRESSION; MITOSIS; CHECKPOINT	Transcriptional induction of cell-cycle regulatory proteins ensures proper timing of subsequent cell-cycle events. Here we show that the Forkhead transcription factor FoxM1 regulates expression of many G2-specific genes and is essential for chromosome stability. Loss of FoxM1 leads to pleiotropic cell-cycle defects, including a delay in G2, chromosome mis-segregation and frequent failure of cytokinesis. We show that transcriptional activation of cyclin B by FoxM1 is essential for timely mitotic entry, whereas CENP-F, another direct target of FoxM1 identified here, is essential for precise functioning of the mitotic spindle checkpoint. Thus, our data uncover a transcriptional cluster regulated by FoxM1 that is essential for proper mitotic progression.	Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Baylor College of Medicine; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Medema, RH (corresponding author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	r.medema@nki.nl	Medema, Rene H/E-2981-2013; Morrison, Ashby/AHE-2820-2022; Medema, Rene H/G-5415-2011	Morrison, Ashby/0000-0003-1228-5093; Medema, Rene/0000-0002-6754-0381	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM056929] Funding Source: NIH RePORTER; NIGMS NIH HHS [R25 GM056929] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2003, J LEUKOCYTE BIOL, V73, P689, DOI 10.1189/jlb.1202629; Chan GKT, 1998, J CELL BIOL, V143, P49, DOI 10.1083/jcb.143.1.49; Cho RJ, 2001, NAT GENET, V27, P48, DOI 10.1038/83751; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Futcher B, 2002, CURR OPIN CELL BIOL, V14, P676, DOI 10.1016/S0955-0674(02)00391-5; Hussein D, 2002, J CELL SCI, V115, P3403; Jablonski SA, 1998, CHROMOSOMA, V107, P386, DOI 10.1007/s004120050322; Johnson VL, 2004, J CELL SCI, V117, P1577, DOI 10.1242/jcs.01006; Jorgensen P, 2000, GENOME BIOL, V1, DOI [10.1186/gb-2000-1-3-reviews1022, DOI 10.1186/GB-2000-1-3-REVIEWS1022]; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Koranda M, 2000, NATURE, V406, P94, DOI 10.1038/35017589; Korver W, 1997, IMMUNOBIOLOGY, V198, P157, DOI 10.1016/S0171-2985(97)80036-8; Korver W, 1998, CURR BIOL, V8, P1327, DOI 10.1016/S0960-9822(07)00563-5; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; Kumar R, 2000, CURR BIOL, V10, P896, DOI 10.1016/S0960-9822(00)00618-7; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Liu ST, 2003, NAT CELL BIOL, V5, P341, DOI 10.1038/ncb953; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Morrison AJ, 2002, MOL CELL BIOL, V22, P856, DOI 10.1128/MCB.22.3.856-865.2002; Pic A, 2000, EMBO J, V19, P3750, DOI 10.1093/emboj/19.14.3750; Putkey FR, 2002, DEV CELL, V3, P351, DOI 10.1016/S1534-5807(02)00255-1; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Yao KM, 1997, J BIOL CHEM, V272, P19827, DOI 10.1074/jbc.272.32.19827; Ye HG, 1999, MOL CELL BIOL, V19, P8570; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; Zhu GF, 2000, NATURE, V406, P90, DOI 10.1038/35017581	36	610	632	2	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2005	7	2					126	U34		10.1038/ncb1217	http://dx.doi.org/10.1038/ncb1217			15	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	893LC	15654331				2022-12-25	WOS:000226719500009
J	Lampson, MA; Kapoor, TM				Lampson, MA; Kapoor, TM			The human mitotic checkpoint protein BubR1 regulates chromosome-spindle attachments	NATURE CELL BIOLOGY			English	Article							SMALL-MOLECULE INHIBITOR; AURORA-B; MICROTUBULE ATTACHMENT; KINETOCHORE FIBER; HUMAN CANCERS; CENP-A; KINASE; CELLS; MAD2; CENTROMERE	Loss or gain of whole chromosomes, the form of chromosomal instability (CIN) most commonly associated with human cancers, is expected to arise from the failure to accurately segregate chromosomes in mitosis(1). The mitotic checkpoint is one pathway that prevents segregation errors by blocking the onset of anaphase until all chromosomes make proper attachments to the spindle. Another process that prevents errors is stabilization and destabilization of connections between chromosomes and spindle microtubules. An outstanding question is how these two pathways are coordinated to ensure accurate chromosome segregation. Here we show that in human cells depleted of BubR1 - a critical component of the mitotic checkpoint that can directly regulate the onset of anaphase(2-4) - chromosomes do not form stable attachments to spindle microtubules. Attachments in these cells are restored by inhibition of Aurora kinase, which is known to stabilize kinetochore - microtubule attachments(5-7). Loss of BubR1 function thus perturbs regulation of attachments rather than the ability of kinetochores to bind to microtubules. Consistent with this finding, depletion of BubR1 increases phosphorylation of CENP-A, a kinetochore-specific Aurora kinase substrate. We propose that BubR1 links regulation of chromosome-spindle attachment to mitotic checkpoint signalling.	Rockefeller Univ, Lab Chem & Cell Biol, New York, NY 10021 USA	Rockefeller University	Lampson, MA (corresponding author), Rockefeller Univ, Lab Chem & Cell Biol, 1230 York Ave, New York, NY 10021 USA.	lampsom@rockefeller.edu			NIGMS NIH HHS [GM65933, R01 GM065933-03] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065933] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrews PD, 2004, DEV CELL, V6, P253, DOI 10.1016/S1534-5807(04)00025-5; Biggins S, 2001, GENE DEV, V15, P3118, DOI 10.1101/gad.934801; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Hanks S, 2004, NAT GENET, V36, P1159, DOI 10.1038/ng1449; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; King JM, 2000, J CELL BIOL, V151, P739, DOI 10.1083/jcb.151.4.739; Kops GJPL, 2004, P NATL ACAD SCI USA, V101, P8699, DOI 10.1073/pnas.0401142101; Kunitoku N, 2003, DEV CELL, V5, P853, DOI 10.1016/S1534-5807(03)00364-2; Lampson MA, 2004, NAT CELL BIOL, V6, P232, DOI 10.1038/ncb1102; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; McEwen BF, 1997, J CELL BIOL, V137, P1567, DOI 10.1083/jcb.137.7.1567; RIEDER CL, 1981, CHROMOSOMA, V84, P145, DOI 10.1007/BF00293368; Shichiri M, 2002, CANCER RES, V62, P13; Shin HJ, 2003, CANCER CELL, V4, P483, DOI 10.1016/S1535-6108(03)00302-7; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Tanaka TU, 2002, CELL, V108, P317, DOI 10.1016/S0092-8674(02)00633-5; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Wang XH, 2002, CANCER RES, V62, P1662; Waters JC, 1998, J CELL BIOL, V141, P1181, DOI 10.1083/jcb.141.5.1181; Weaver BAA, 2003, J CELL BIOL, V162, P551, DOI 10.1083/jcb.200303167; Zeitlin SG, 2001, J CELL BIOL, V155, P1147, DOI 10.1083/jcb.200108125	28	240	247	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2005	7	1					93	+		10.1038/ncb1208	http://dx.doi.org/10.1038/ncb1208			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	884UZ	15592459				2022-12-25	WOS:000226113500020
J	Suematsu, S; Watanabe, T				Suematsu, S; Watanabe, T			Generation of a synthetic lymphoid tissue-like organoid in mice	NATURE BIOTECHNOLOGY			English	Article							LYMPHOTOXIN BETA-RECEPTOR; HIGH ENDOTHELIAL VENULES; TUMOR-NECROSIS-FACTOR; DENDRITIC CELLS; ECTOPIC EXPRESSION; PEYERS-PATCHES; DEFICIENT MICE; STROMAL CELLS; CUTTING EDGE; CHEMOKINES	Stromal cells play an important role in the formation of the normal organized microarchitecture of secondary lymphoid organs. Here we demonstrate that a tissue-engineered, lymphoid tissue-like organoid, which was constructed by transplantation of stromal cells embedded in biocompatible scaffolds into the renal subcapsular space in mice, had an organized tissue structure similar to secondary lymphoid organs. This organoid contained compartmentalized B-cell and T-cell clusters, high endothelial venule-like vessels, germinal centers and follicular dendritic cell networks. Furthermore, the organoid was transplantable to naive normal or severe combined immunodeficiency (SCID) mice, and antigen-specific, IgG-isotype antibody formation could be induced soon after intravenous administration of the antigen. This simplified system of lymphoid tissue-like organoid construction will facilitate analyses of cell-cell interactions required for development of secondary lymphoid organs and efficient induction of adaptive immune responses, and may have possible applications in the treatment of immune deficiency.	RIKEN, Res Ctr Allergy & Immunol, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan	RIKEN	Suematsu, S (corresponding author), RIKEN, Res Ctr Allergy & Immunol, Tsurumi Ku, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	sachiko@rcai.riken.jp						Ansel KM, 2001, CURR OPIN IMMUNOL, V13, P172, DOI 10.1016/S0952-7915(00)00201-6; Baekkevold ES, 2001, J EXP MED, V193, P1105, DOI 10.1084/jem.193.9.1105; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BANKS TA, 1995, J IMMUNOL, V155, P1685; Chen SC, 2002, J IMMUNOL, V168, P1001, DOI 10.4049/jimmunol.168.3.1001; Cyster JG, 1999, SCIENCE, V286, P2098, DOI 10.1126/science.286.5447.2098; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; Drayton DL, 2003, J EXP MED, V197, P1153, DOI 10.1084/jem.20021761; Ebisuno Y, 2003, J IMMUNOL, V171, P1642, DOI 10.4049/jimmunol.171.4.1642; Endres R, 1999, J EXP MED, V189, P159, DOI 10.1084/jem.189.1.159; Fan L, 2000, J IMMUNOL, V164, P3955, DOI 10.4049/jimmunol.164.8.3955; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; Kratz A, 1996, J EXP MED, V183, P1461, DOI 10.1084/jem.183.4.1461; Luther SA, 2000, P NATL ACAD SCI USA, V97, P12694, DOI 10.1073/pnas.97.23.12694; Luther SA, 2000, IMMUNITY, V12, P471, DOI 10.1016/S1074-7613(00)80199-5; Luther SA, 2002, J IMMUNOL, V169, P424, DOI 10.4049/jimmunol.169.1.424; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Mebius RE, 2003, NAT REV IMMUNOL, V3, P292, DOI 10.1038/nri1054; Nakano H, 2001, J IMMUNOL, V166, P361, DOI 10.4049/jimmunol.166.1.361; NAKASHIMA M, 1990, EUR J IMMUNOL, V20, P47, DOI 10.1002/eji.1830200108; Ngo VN, 1999, J EXP MED, V189, P403, DOI 10.1084/jem.189.2.403; Nishikawa S, 2000, CURR OPIN IMMUNOL, V12, P342, DOI 10.1016/S0952-7915(00)00097-2; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Okada T, 2002, J EXP MED, V196, P65, DOI 10.1084/jem.20020201; Rennert PD, 1996, J EXP MED, V184, P1999, DOI 10.1084/jem.184.5.1999; Rennert PD, 1998, IMMUNITY, V9, P71, DOI 10.1016/S1074-7613(00)80589-0; Schrama D, 2001, IMMUNITY, V14, P111, DOI 10.1016/S1074-7613(01)00094-2; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Vassileva G, 1999, J EXP MED, V190, P1183, DOI 10.1084/jem.190.8.1183	34	101	123	6	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2004	22	12					1539	1545		10.1038/nbt1039	http://dx.doi.org/10.1038/nbt1039			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	878HX	15568019				2022-12-25	WOS:000225638600024
J	Bakalova, R; Ohba, H; Zhelev, Z; Ishikawa, M; Baba, Y				Bakalova, R; Ohba, H; Zhelev, Z; Ishikawa, M; Baba, Y			Quantum dots as photosensitizers?	NATURE BIOTECHNOLOGY			English	Editorial Material									Natl Inst Adv Ind Sci & Technol, Single Mol Bioanal Lab, Takamatsu, Kagawa 7610395, Japan; Nagoya Univ, Grad Sch Engn, Dept Appl Chem, Chikusa Ku, Nagoya, Aichi 4648603, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Nagoya University	Bakalova, R (corresponding author), Natl Inst Adv Ind Sci & Technol, Single Mol Bioanal Lab, 2217-14 Hayashi Cho, Takamatsu, Kagawa 7610395, Japan.	r.bakalova-zheleva@aist.go.jp	Bakalova, Rumiana/AHD-6998-2022	Bakalova, Rumiana/0000-0002-5309-3250				Alivisatos P, 2000, PURE APPL CHEM, V72, P3, DOI 10.1351/pac200072010003; Bakalova R, 2004, NANO LETT, V4, P1567, DOI 10.1021/nl049627w; Clapp AR, 2004, J AM CHEM SOC, V126, P301, DOI 10.1021/ja037088b; Derfus AM, 2004, NANO LETT, V4, P11, DOI 10.1021/nl0347334; Fisher BR, 2004, J PHYS CHEM B, V108, P143, DOI 10.1021/jp035756+; Medintz IL, 2004, J AM CHEM SOC, V126, P30, DOI 10.1021/ja037970h; Samia ACS, 2003, J AM CHEM SOC, V125, P15736, DOI 10.1021/ja0386905; Willard DM, 2003, NAT MATER, V2, P575, DOI 10.1038/nmat972	8	292	311	2	99	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2004	22	11					1360	1361		10.1038/nbt1104-1360	http://dx.doi.org/10.1038/nbt1104-1360			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	869CL	15529155				2022-12-25	WOS:000224960600021
J	Lemos, B; Meiklejohn, CD; Hartl, DL				Lemos, B; Meiklejohn, CD; Hartl, DL			Regulatory evolution across the protein interaction network	NATURE GENETICS			English	Article							GENE-EXPRESSION; DROSOPHILA-MELANOGASTER; DEPENDENCE; NUMBER	Protein-protein interactions may impose constraints on both structural and regulatory evolution. Here we show that protein-protein interactions are negatively associated with evolutionary variation in gene expression. Moreover, interacting proteins have similar levels of variation in expression, and their expression levels are positively correlated across strains. Our results suggest that interacting proteins undergo similar evolutionary dynamics, and that their expression levels are evolutionarily coupled. These patterns hold for organisms as diverse as budding yeast and fruit flies.	Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA	Harvard University	Lemos, B (corresponding author), Harvard Univ, Dept Organism & Evolutionary Biol, 16 Divin Ave,Hartl Lab,Room 2105, Cambridge, MA 02138 USA.	blemos@oeb.harvard.edu	Lemos, Bernardo/AAL-2429-2020	Lemos, Bernardo/0000-0001-6996-9483; Meiklejohn, Colin/0000-0003-2708-8316				Bader JS, 2004, NAT BIOTECHNOL, V22, P78, DOI 10.1038/nbt924; Bloom JD, 2003, BMC EVOL BIOL, V3, DOI 10.1186/1471-2148-3-21; Fraser HB, 2002, SCIENCE, V296, P750, DOI 10.1126/science.1068696; Fraser HB, 2004, PLOS BIOL, V2, P834, DOI 10.1371/journal.pbio.0020137; Fraser HB, 2003, BMC EVOL BIOL, V3, DOI 10.1186/1471-2148-3-11; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Kimura MA, 1985, NEUTRAL THEORY MOL E; LANDE R, 1975, GENET RES, V26, P221, DOI 10.1017/S0016672300016037; Meiklejohn CD, 2003, P NATL ACAD SCI USA, V100, P9894, DOI 10.1073/pnas.1630690100; Pal C, 2003, NATURE, V421, P496, DOI 10.1038/421496b; Papp B, 2003, NATURE, V424, P194, DOI 10.1038/nature01771; Ranz JM, 2003, SCIENCE, V300, P1742, DOI 10.1126/science.1085881; Rifkin SA, 2003, NAT GENET, V33, P138, DOI 10.1038/ng1086; Townsend JP, 2003, MOL BIOL EVOL, V20, P955, DOI 10.1093/molbev/msg106; Veitia RA, 2002, BIOESSAYS, V24, P175, DOI 10.1002/bies.10023	15	51	51	0	13	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2004	36	10					1059	1060		10.1038/ng1427	http://dx.doi.org/10.1038/ng1427			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	857YN	15378060	Bronze			2022-12-25	WOS:000224156500012
J	Takahashi, TS; Yiu, PY; Chou, MF; Gygi, S; Walter, JC				Takahashi, TS; Yiu, PY; Chou, MF; Gygi, S; Walter, JC			Recruitment of Xenopus Scc2 and cohesin to chromatin requires the pre-replication complex	NATURE CELL BIOLOGY			English	Article							EUKARYOTIC DNA-REPLICATION; DE-LANGE-SYNDROME; SISTER CHROMATIDS; CELL-CYCLE; YEAST COHESIN; NIPPED-B; PROTEINS; INITIATION; GEMININ; IDENTIFICATION	Cohesin is a multi-subunit, ring-shaped protein complex that holds sister chromatids together from the time of their synthesis in S phase until they are segregated in anaphase(1-7). In yeast, the loading of cohesin onto chromosomes requires the Scc2 protein(8-10). In vertebrates, cohesins first bind to chromosomes as cells exit mitosis, but the mechanism is unknown(3,11,12). Concurrent with cohesin binding, pre-replication complexes (pre-RCs) are assembled at origins of DNA replication through the sequential loading of the initiation factors ORC, Cdc6, Cdt1 and MCM2-7 (the 'licensing' reaction)(13). In S phase, the protein kinase Cdk2 activates pre-RCs, causing origin unwinding and DNA replication. Here, we use Xenopus egg extracts to show that the recruitment of cohesins to chromosomes requires fully licensed chromatin and is dependent on ORC, Cdc6, Cdt1 and MCM2-7, but is independent of Cdk2. We further show that Xenopus Scc2 is required for cohesin loading and that binding of XScc2 to chromatin is MCM2-7 dependent. Our results define a novel pre-RC-dependent pathway for cohesin recruitment to chromosomes in a vertebrate model system.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Walter, JC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	johannes_walter@hms.harvard.edu	Takahashi, Tatsuro/AAD-9936-2020; Takahashi, Tatsuro/F-4669-2016	Takahashi, Tatsuro/0000-0002-1947-7680; Takahashi, Tatsuro/0000-0002-1947-7680; Walter, Johannes/0000-0002-4186-7570	NIGMS NIH HHS [GM62267] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062267] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; Ciosk R, 2000, MOL CELL, V5, P243, DOI 10.1016/S1097-2765(00)80420-7; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Darwiche N, 1999, GENE, V233, P39, DOI 10.1016/S0378-1119(99)00160-2; Gruber S, 2003, CELL, V112, P765, DOI 10.1016/S0092-8674(03)00162-4; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Hodgson B, 2002, CURR BIOL, V12, P678, DOI 10.1016/S0960-9822(02)00778-9; Krantz ID, 2004, NAT GENET, V36, P631, DOI 10.1038/ng1364; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; Peng JM, 2001, J MASS SPECTROM, V36, P1083, DOI 10.1002/jms.229; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Tomonaga T, 2000, GENE DEV, V14, P2757, DOI 10.1101/gad.832000; Tonkin ET, 2004, NAT GENET, V36, P636, DOI 10.1038/ng1363; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; Waiter J, 1997, SCIENCE, V275, P993, DOI 10.1126/science.275.5302.993; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309	31	147	150	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2004	6	10					991	+		10.1038/ncb1177	http://dx.doi.org/10.1038/ncb1177			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	859FY	15448702				2022-12-25	WOS:000224250000014
J	Chang, S; Multani, AS; Cabrera, NG; Naylor, ML; Laud, P; Lombard, D; Pathak, S; Guarente, L; DePinho, RA				Chang, S; Multani, AS; Cabrera, NG; Naylor, ML; Laud, P; Lombard, D; Pathak, S; Guarente, L; DePinho, RA			Essential role of limiting telomeres in the pathogenesis of Werner syndrome	NATURE GENETICS			English	Article							SYNDROME GENE-PRODUCT; IONIZING-RADIATION; WRN; TOPOISOMERASE; DYSFUNCTION; SENSITIVITY; FIBROBLASTS; HELICASES; HOMOLOG; GENOME	Mutational inactivation of the gene WRN causes Werner syndrome, an autosomal recessive disease characterized by premature aging, elevated genomic instability and increased cancer incidence(1,2). The capacity of enforced telomerase expression to rescue premature senescence of cultured cells from individuals with Werner syndrome(3) and the lack of a disease phenotype in Wrn-deficient mice with long telomeres(4) implicate telomere attrition in the pathogenesis of Werner syndrome. Here, we show that the varied and complex cellular phenotypes of Werner syndrome are precipitated by exhaustion of telomere reserves in mice. In late-generation mice null with respect to both Wrn and Terc ( encoding the telomerase RNA component), telomere dysfunction elicits a classical Werner-like premature aging syndrome typified by premature death, hair graying, alopecia, osteoporosis, type II diabetes and cataracts. This mouse model also showed accelerated replicative senescence and accumulation of DNA-damage foci in cultured cells, as well as increased chromosomal instability and cancer, particularly nonepithelial malignancies typical of Werner syndrome. These genetic data indicate that the delayed manifestation of the complex pleiotropic of Wrn deficiency relates to telomere shortening.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	University of Texas System; UTMD Anderson Cancer Center; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Massachusetts Institute of Technology (MIT)	Chang, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Box 11,1515 Holcombe Blvd, Houston, TX 77030 USA.	schang@mdanderson.org; ron_depinho@dfci.harvard.edu		Lombard, David/0000-0002-4292-0185; DePinho, Ronald/0000-0002-5625-577X	NATIONAL INSTITUTE ON AGING [K08AG024873, K08AG001019] Funding Source: NIH RePORTER; NIA NIH HHS [K08 AG001019, K08 AG024873] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; EPSTEIN CJ, 1966, MEDICINE, V45, P5893; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; Goytisolo FA, 2000, J EXP MED, V192, P1625, DOI 10.1084/jem.192.11.1625; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Kaneko H, 1999, CLIN EXP IMMUNOL, V118, P285; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; Lombard DB, 2000, MOL CELL BIOL, V20, P3286, DOI 10.1128/MCB.20.9.3286-3291.2000; Martin GM, 2000, NATURE, V408, P263, DOI 10.1038/35041705; Melcher R, 2000, CYTOGENET CELL GENET, V91, P180, DOI 10.1159/000056841; Myung K, 2001, NAT GENET, V27, P113, DOI 10.1038/83673; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Orren DK, 2002, BIOCHEMISTRY-US, V41, P13483, DOI 10.1021/bi0266986; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; Schulz VP, 1996, HUM GENET, V97, P750; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Wong KK, 2003, NATURE, V421, P643, DOI 10.1038/nature01385; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	24	350	365	2	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2004	36	8					877	882		10.1038/ng1389	http://dx.doi.org/10.1038/ng1389			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	842AG	15235603				2022-12-25	WOS:000222974000022
J	Suzuki, T; Delgado-Escueta, AV; Aguan, K; Alonso, ME; Shi, J; Hara, Y; Nishida, M; Numata, T; Medina, MT; Takeuchi, T; Morita, R; Bai, DS; Ganesh, S; Sugimoto, Y; Inazawa, J; Bailey, JN; Ochoa, A; Jara-Prado, A; Rasmussen, A; Ramos-Peek, J; Cordova, S; Rubio-Donnadieu, F; Inoue, Y; Osawa, M; Kaneko, S; Oguni, H; Mori, Y; Yamakawa, K				Suzuki, T; Delgado-Escueta, AV; Aguan, K; Alonso, ME; Shi, J; Hara, Y; Nishida, M; Numata, T; Medina, MT; Takeuchi, T; Morita, R; Bai, DS; Ganesh, S; Sugimoto, Y; Inazawa, J; Bailey, JN; Ochoa, A; Jara-Prado, A; Rasmussen, A; Ramos-Peek, J; Cordova, S; Rubio-Donnadieu, F; Inoue, Y; Osawa, M; Kaneko, S; Oguni, H; Mori, Y; Yamakawa, K			Mutations in EFHC1 cause juvenile myoclonic epilepsy	NATURE GENETICS			English	Article							IDIOPATHIC GENERALIZED EPILEPSY; CHILDHOOD ABSENCE EPILEPSY; E CALCIUM-CHANNEL; GENE; LINKAGE; CANDIDATE; LOCUS; HETEROGENEITY; SUBUNIT; MICE	Juvenile myoclonic epilepsy (JME) is the most frequent cause of hereditary grand mal seizures(1,2). We previously mapped and narrowed a region associated with JME on chromosome 6p12-p11 (EJM1)(3-5). Here, we describe a new gene in this region, EFHC1, which encodes a protein with an EF-hand motif. Mutation analyses identified five missense mutations in EFHC1 that cosegregated with epilepsy or EEG polyspike wave in affected members of six unrelated families with JME and did not occur in 382 control individuals. Overexpression of EFHC1 in mouse hippocampal primary culture neurons induced apoptosis that was significantly lowered by the mutations. Apoptosis was specifically suppressed by SNX-482, an antagonist of R-type voltage-dependent Ca2+ channel (Ca(v)2.3). EFHC1 and Ca(v)2.3 immunomaterials overlapped in mouse brain, and EFHC1 coimmunoprecipitated with the Cav2.3 C terminus. In patch-clamp analysis, EFHC1 specifically increased R-type Ca2+ currents that were reversed by the mutations associated with JME.	RIKEN, Brain Sci Inst, Neurogenet Lab, Wako, Saitama 3510198, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Tokyo, Japan; Univ Calif Los Angeles, David Geffen Sch Med, Comprehens Epilepsy Program, Epilepsy Genet Gen Labs, Los Angeles, CA 90024 USA; VA GLAHS W Los Angeles, W Los Angeles DVA Med Ctr, Los Angeles, CA 90073 USA; Natl Inst Neurol & Neurosurg, Mexico City, DF, Mexico; Grad Univ Adv Studies, Ctr Integrat Biosci, Okazaki, Aichi, Japan; Kyoto Univ, Grad Sch Engn, Kyoto, Japan; Natl Autonomous Univ, Tegucigalpa, Honduras; Univ Calif Los Angeles, David Geffen Sch Med, Inst Neuropsychiat, Los Angeles, CA USA; Shizuoka Med Inst Neurol Disorders, Natl Epilepsy Ctr, Shizuoka, Japan; Tokyo Womens Med Univ, Dept Pediat, Tokyo, Japan; Hirosaki Univ, Sch Med, Dept Neuropsychiat, Aomori, Japan	RIKEN; Tokyo Medical & Dental University (TMDU); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; Graduate University for Advanced Studies - Japan; National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Kyoto University; Universidad Nacional Autonoma de Honduras; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Tokyo Women's Medical University; Hirosaki University	Delgado-Escueta, AV (corresponding author), RIKEN, Brain Sci Inst, Neurogenet Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	escueta@ucla.edu; yamakawa@brain.riken.go.jp	Numata, Tomohiro/AAW-2453-2020; shi, jun/C-2389-2011; Ochoa, Adriana/AAU-2918-2020; Jara-Prado, Aurelio/AAU-3017-2020; Numata, Tomohiro/AAC-2330-2021; Ganesh, Subramniam/B-4131-2009; Yamakawa, Kazuhiro/N-5050-2015; Rasmussen, Astrid/A-4878-2013	Numata, Tomohiro/0000-0002-5719-4884; Ochoa, Adriana/0000-0003-1084-2984; Numata, Tomohiro/0000-0002-5719-4884; Yamakawa, Kazuhiro/0000-0002-1478-4390; Rasmussen, Astrid/0000-0001-7744-2948; Medina, Marco Tulio/0000-0003-0469-054X; Delgado-Escueta, Antonio V./0000-0002-1581-6999; Suzuki, Toshimitsu/0000-0003-0585-5692; Jara-Prado, Aurelio/0000-0001-8985-3744; Nishida, Motohiro/0000-0002-2587-5458				Bai DS, 2002, AM J MED GENET, V113, P268, DOI 10.1002/ajmg.10724; Braunewell KH, 1999, CELL TISSUE RES, V295, P1, DOI 10.1007/s004410051207; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Chen Y, 2003, CELL, V115, P37, DOI 10.1016/S0092-8674(03)00726-8; Delgado-Escueta A V, 1999, Adv Neurol, V79, P351; Escayg A, 2000, AM J HUM GENET, V66, P1531, DOI 10.1086/302909; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; Greenberg DA, 2000, AM J HUM GENET, V66, P508, DOI 10.1086/302763; JANZ D, 1957, J NEUROL, V176, P344; Jouvenceau A, 2001, LANCET, V358, P801, DOI 10.1016/S0140-6736(01)05971-2; Letts VA, 1998, NAT GENET, V19, P340, DOI 10.1038/1228; LIU AW, 1995, AM J HUM GENET, V57, P368; Liu AW, 1996, AM J MED GENET, V63, P438; Meencke H J, 1999, Adv Neurol, V79, P123; Morita R, 1999, EPILEPSY RES, V37, P151, DOI 10.1016/S0920-1211(99)00061-3; Newcomb R, 1998, BIOCHEMISTRY-US, V37, P15353, DOI 10.1021/bi981255g; NIIDOME T, 1992, FEBS LETT, V308, P7, DOI 10.1016/0014-5793(92)81038-N; Pal DK, 2003, AM J HUM GENET, V73, P261, DOI 10.1086/377006; Pennacchio LA, 1996, SCIENCE, V271, P1731, DOI 10.1126/science.271.5256.1731; Pinto D, 2004, EPILEPSIA, V45, P211, DOI 10.1111/j.0013-9580.2004.36003.x; Saegusa H, 2000, P NATL ACAD SCI USA, V97, P6132, DOI 10.1073/pnas.100124197; Sander T, 1997, NEUROLOGY, V49, P842, DOI 10.1212/WNL.49.3.842; Sugimoto Y, 2000, GENOMICS, V68, P264, DOI 10.1006/geno.2000.6296; Suzuki T, 2002, EPILEPSY RES, V50, P265, DOI 10.1016/S0920-1211(02)00052-9; Virtaneva K, 1997, NAT GENET, V15, P393, DOI 10.1038/ng0497-393; Wakamori M, 1998, J BIOL CHEM, V273, P34857, DOI 10.1074/jbc.273.52.34857; Woermann FG, 1998, BRAIN, V121, P1661, DOI 10.1093/brain/121.9.1661; YOKOYAMA CT, 1995, J NEUROSCI, V15, P6419	29	244	259	1	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2004	36	8					842	849		10.1038/ng1393	http://dx.doi.org/10.1038/ng1393			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	842AG	15258581				2022-12-25	WOS:000222974000016
J	Yang, XL; Yu, KP; Hao, YW; Li, DM; Stewart, R; Insogna, KL; Xu, T				Yang, XL; Yu, KP; Hao, YW; Li, DM; Stewart, R; Insogna, KL; Xu, T			LATS1 tumour suppressor affects cytokinesis by inhibiting LIMK1	NATURE CELL BIOLOGY			English	Article							MYOTONIC-DYSTROPHY KINASE; PROTEIN-KINASE; HUMAN HOMOLOG; COFILIN PHOSPHORYLATION; GENETIC INSTABILITY; DROSOPHILA LATS; ACTIN DYNAMICS; CITRON KINASE; RHO-GTPASES; CELL-CYCLE	LATS (large tumour suppressor) is a family of conserved tumour suppressors identified in Drosophila and mammals. Here we show that human LATS1 binds to LIMK1 in vitro and in vivo and colocalizes with LIMK1 at the actomyosin contractile ring during cytokinesis. LATS1 inhibits both the phosphorylation of cofilin by LIMK1 and LIMK1-induced cytokinesis defects. Inactivation of LATS1 by antibody microinjection or RNA-mediated interference in cells, or gene knockout in mice, abrogates cytokinesis and increases the percentage of multinucleate cells. Our findings indicate that LATS1 is a novel cytoskeleton regulator that affects cytokinesis by regulating actin polymerization through negative modulation of LIMK1.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Genet, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Med, New Haven, CT 06536 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University	Xu, T (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst, 295 Congress Ave, New Haven, CT 06536 USA.	tian.xu@yale.edu	Stewart, Rodney/ABA-6757-2020	Stewart, Rodney/0000-0003-1220-1830; Insogna, Karl/0000-0001-6973-5679	NCI NIH HHS [CA69408] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069408] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amano T, 2002, J BIOL CHEM, V277, P22093, DOI 10.1074/jbc.M201444200; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bidlingmaier S, 2001, MOL CELL BIOL, V21, P2449, DOI 10.1128/MCB.21.7.2449-2462.2001; Condeelis J, 2001, TRENDS CELL BIOL, V11, P288, DOI 10.1016/S0962-8924(01)02008-6; Di Cunto F, 2000, NEURON, V28, P115, DOI 10.1016/S0896-6273(00)00090-8; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Field C, 1999, CURR OPIN CELL BIOL, V11, P68, DOI 10.1016/S0955-0674(99)80009-X; Frenz LM, 2000, J CELL SCI, V113, P3399; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; Geng W, 2000, GENETICS, V156, P1817; Glotzer M, 2001, ANNU REV CELL DEV BI, V17, P351, DOI 10.1146/annurev.cellbio.17.1.351; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Hisaoka M, 2002, LAB INVEST, V82, P1427, DOI 10.1097/01.LAB.0000032381.68634.CA; JOHNSTON LH, 1990, MOL CELL BIOL, V10, P1358, DOI 10.1128/MCB.10.4.1358; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; Kosako H, 2000, ONCOGENE, V19, P6059, DOI 10.1038/sj.onc.1203987; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; MIZUNO K, 1994, ONCOGENE, V9, P1605; Oegema K, 2000, J CELL BIOL, V150, P539, DOI 10.1083/jcb.150.3.539; Pelham RJ, 2002, NATURE, V419, P82, DOI 10.1038/nature00999; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; Prokopenko SN, 2000, J CELL BIOL, V148, P843, DOI 10.1083/jcb.148.5.843; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Robinson DN, 2000, TRENDS CELL BIOL, V10, P228, DOI 10.1016/S0962-8924(00)01747-5; Ross J S, 1996, Oncology (Williston Park), V10, P867; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Sparks CA, 1999, J CELL BIOL, V146, P777, DOI 10.1083/jcb.146.4.777; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Stanyon CA, 1999, INT J BIOCHEM CELL B, V31, P389, DOI 10.1016/S1357-2725(98)00116-2; Stewart RA, 2003, ONCOGENE, V22, P6436, DOI 10.1038/sj.onc.1206820; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tatsuka M, 1998, CANCER RES, V58, P4811; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Verde F, 1998, P NATL ACAD SCI USA, V95, P7526, DOI 10.1073/pnas.95.13.7526; Xia H, 2002, ONCOGENE, V21, P1233, DOI 10.1038/sj.onc.1205174; XU TA, 1995, DEVELOPMENT, V121, P1053; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yabuta N, 2000, GENOMICS, V63, P263, DOI 10.1006/geno.1999.6065; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yang XL, 2001, ONCOGENE, V20, P6516, DOI 10.1038/sj.onc.1204817; Yoshioka K, 2003, P NATL ACAD SCI USA, V100, P7247, DOI 10.1073/pnas.1232344100; Zallen JA, 2000, MOL BIOL CELL, V11, P3177, DOI 10.1091/mbc.11.9.3177	48	149	152	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2004	6	7					609	617		10.1038/ncb1140	http://dx.doi.org/10.1038/ncb1140			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	834TX	15220930				2022-12-25	WOS:000222434900015
J	Wakita, T; Pietschmann, T; Kato, T; Date, T; Miyamoto, M; Zhao, ZJ; Murthy, K; Habermann, A; Krausslich, HG; Mizokami, M; Bartenschlager, R; Liang, TJ				Wakita, T; Pietschmann, T; Kato, T; Date, T; Miyamoto, M; Zhao, ZJ; Murthy, K; Habermann, A; Krausslich, HG; Mizokami, M; Bartenschlager, R; Liang, TJ			Production of infectious hepatitis C virus in tissue culture from a cloned viral genome	NATURE MEDICINE			English	Article							NON-B HEPATITIS; EFFICIENT REPLICATION; GENOTYPE 2A; NON-A; ENVELOPE PROTEIN; MOLECULAR CLONE; CDNA-CLONE; CHIMPANZEES; PERSISTENT	Hepatitis C virus (HCV) infection causes chronic liver diseases and is a global public health problem. Detailed analyses of HCV have been hampered by the lack of viral culture systems. Subgenomic replicons of the JFH1 genotype 2a strain cloned from an individual with fulminant hepatitis replicate efficiently in cell culture. Here we show that the JFH1 genome replicates efficiently and supports secretion of viral particles after transfection into a human hepatoma cell line (Huh7). Particles have a density of about 1.15 - 1.17 g/ml and a spherical morphology with an average diameter of about 55 nm. Secreted virus is infectious for Huh7 cells and infectivity can be neutralized by CD81-specific antibodies and by immunoglobulins from chronically infected individuals. The cell culture - generated HCV is infectious for chimpanzee. This system provides a powerful tool for studying the viral life cycle and developing antiviral strategies.	Tokyo Metropolitan Inst Neurosci, Dept Microbiol, Tokyo 1838526, Japan; Heidelberg Univ, Dept Mol Virol, D-69120 Heidelberg, Germany; Nagoya City Univ, Grad Sch Med Sci, Dept Clin Mol Informat Med, Nagoya, Aichi 4678601, Japan; NIDDK, Liver Dis Branch, NIH, Bethesda, MD 20892 USA; SW Fdn Biomed Res, San Antonio, TX 78227 USA; Heidelberg Univ, Dept Virol, D-69120 Heidelberg, Germany	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Ruprecht Karls University Heidelberg; Nagoya City University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Texas Biomedical Research Institute; Ruprecht Karls University Heidelberg	Wakita, T (corresponding author), Tokyo Metropolitan Inst Neurosci, Dept Microbiol, Tokyo 1838526, Japan.	wakita@tmin.ac.jp	Pietschmann, Thomas/E-9241-2015; Bartenschlager, Ralf/L-2582-2015	Pietschmann, Thomas/0000-0001-5138-6239; Bartenschlager, Ralf/0000-0001-5601-9307; Habermann, Anja/0000-0003-3686-9050	DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB027091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK054505, Z01DK054504, Z01DK054503] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 DK999999, Z01 DK054504-11] Funding Source: Medline; NHLBI NIH HHS [N01-HB-27091, N01HB27091] Funding Source: Medline	DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aoyagi K, 1999, J CLIN MICROBIOL, V37, P1802, DOI 10.1128/JCM.37.6.1802-1808.1999; Bartenschlager R, 2000, J GEN VIROL, V81, P1631, DOI 10.1099/0022-1317-81-7-1631; Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756; Bukh J, 2002, P NATL ACAD SCI USA, V99, P14416, DOI 10.1073/pnas.212532699; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Date T, 2004, J BIOL CHEM, V279, P22371, DOI 10.1074/jbc.M311120200; Forns X, 2000, P NATL ACAD SCI USA, V97, P13318, DOI 10.1073/pnas.230453597; Hadlock KG, 2000, J VIROL, V74, P10407, DOI 10.1128/JVI.74.22.10407-10416.2000; HE LF, 1987, J INFECT DIS, V156, P636, DOI 10.1093/infdis/156.4.636; HIJIKATA M, 1993, J VIROL, V67, P1953, DOI 10.1128/JVI.67.4.1953-1958.1993; Hsu M, 2003, P NATL ACAD SCI USA, V100, P7271, DOI 10.1073/pnas.0832180100; Ikeda M, 2002, J VIROL, V76, P2997, DOI 10.1128/JVI.76.6.2997-3006.2002; KAITO M, 1994, J GEN VIROL, V75, P1755, DOI 10.1099/0022-1317-75-7-1755; Kato T, 2003, GASTROENTEROLOGY, V125, P1808, DOI 10.1053/j.gastro.2003.09.023; Kato T, 2005, J VIROL, V79, P592, DOI 10.1128/JVI.79.1.592-596.2005; Kato T, 2003, J MED VIROL, V69, P357, DOI 10.1002/jmv.10297; Kato T, 2001, J MED VIROL, V64, P334, DOI 10.1002/jmv.1055; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Major ME, 2002, J VIROL, V76, P6586, DOI 10.1128/JVI.76.13.6586-6595.2002; Pietschmann T, 2002, J VIROL, V76, P4008, DOI 10.1128/JVI.76.8.4008-4021.2002; Shimizu YK, 1996, HEPATOLOGY, V23, P205; TAKAHASHI K, 1992, VIROLOGY, V191, P431, DOI 10.1016/0042-6822(92)90204-3; Takeuchi T, 1999, GASTROENTEROLOGY, V116, P636, DOI 10.1016/S0016-5085(99)70185-X; Thomson M, 2003, J VIROL, V77, P862, DOI 10.1128/JVI.77.2.862-870.2003; THOMSSEN R, 1992, MED MICROBIOL IMMUN, V181, P293, DOI 10.1007/BF00198849; Yanagi M, 1999, VIROLOGY, V262, P250, DOI 10.1006/viro.1999.9889; Yanagi M, 1997, P NATL ACAD SCI USA, V94, P8738, DOI 10.1073/pnas.94.16.8738	29	2258	2460	3	160	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2005	11	7					791	796		10.1038/nm1268	http://dx.doi.org/10.1038/nm1268			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	942TB	15951748	Green Accepted			2022-12-25	WOS:000230304200037
J	Liu, SH; Redeye, V; Kuremsky, JG; Kuhnen, M; Molinolo, A; Bugge, TH; Leppla, SH				Liu, SH; Redeye, V; Kuremsky, JG; Kuhnen, M; Molinolo, A; Bugge, TH; Leppla, SH			Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin	NATURE BIOTECHNOLOGY			English	Article							PROTECTIVE ANTIGEN; LETHAL FACTOR; CELLULAR RECEPTOR; EDEMA FACTOR; BINDING; METASTASIS; INVASION; IDENTIFICATION; SEQUENCE; PROTEASE	Anthrax toxin protective antigen (PrAg) forms a heptamer in which the binding site for lethal factor (LF) spans two adjacent monomers(1,2). This suggested that high cell-type specificity in tumor targeting could be obtained using monomers that generate functional LF-binding sites only through intermolecular complementation. We created PrAg mutants with mutations affecting different LF-binding subsites and containing either urokinase plasminogen activator (uPA) or matrix metalloproteinase (MMP) cleavage sites. Individually, these PrAg mutants had low toxicity as a result of impaired LF binding, but when administered together to uPA- and MMP-expressing tumor cells, they assembled into functional LF-binding heteroheptamers. The mixture of two complementing PrAg variants had greatly reduced toxicity in mice and was highly effective in the treatment of aggressive transplanted tumors of diverse origin. These results show that anthrax toxin, and by implication other multimeric toxins, offer excellent opportunities to introduce multiple-specificity determinants and thereby achieve high therapeutic indices.	Natl Inst Dent & Craniofacial Res, Oral Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; NIAID, Microbial Pathogenesis Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Bugge, TH (corresponding author), Natl Inst Dent & Craniofacial Res, Oral Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA.	thomas.bugge@nih.gov; sleppla@niaid.nih.gov		Liu, Shihui/0000-0003-3444-1069	Intramural NIH HHS [Z01 AI000929-05, Z01 DE000699-08] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000929] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000699] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; ARORA N, 1993, J BIOL CHEM, V268, P3334; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Coombs GS, 1998, CHEM BIOL, V5, P475, DOI 10.1016/S1074-5521(98)90004-7; Cunningham K, 2002, P NATL ACAD SCI USA, V99, P7049, DOI 10.1073/pnas.062160399; Dano K, 1999, APMIS, V107, P120, DOI 10.1111/j.1699-0463.1999.tb01534.x; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; GERAN RI, 1972, CANC CHEMOTHER REP, V3, P1; Hoang CD, 2004, CHEST, V125, P1843, DOI 10.1378/chest.125.5.1843; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; KLIMPEL KR, 1994, MOL MICROBIOL, V13, P1093, DOI 10.1111/j.1365-2958.1994.tb00500.x; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; Liu SH, 2000, CANCER RES, V60, P6061; Liu SH, 2003, EXPERT OPIN BIOL TH, V3, P843, DOI 10.1517/14712598.3.5.843; Liu SH, 2003, J BIOL CHEM, V278, P5227, DOI 10.1074/jbc.M210321200; Liu SH, 2003, P NATL ACAD SCI USA, V100, P657, DOI 10.1073/pnas.0236849100; Liu SH, 2001, J BIOL CHEM, V276, P17976, DOI 10.1074/jbc.M011085200; Malatynska E, 1998, PHARMACOLOGY, V57, P117, DOI 10.1159/000028232; Mogridge J, 2002, P NATL ACAD SCI USA, V99, P7045, DOI 10.1073/pnas.052160199; Mogridge J, 2002, BIOCHEMISTRY-US, V41, P1079, DOI 10.1021/bi015860m; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; Rosovitz MJ, 2003, J BIOL CHEM, V278, P30936, DOI 10.1074/jbc.M301154200; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Ullmann R, 2004, J PATHOL, V203, P798, DOI 10.1002/path.1584; Varughese M, 1999, INFECT IMMUN, V67, P1860; Wasenius VM, 2003, CLIN CANCER RES, V9, P68	30	56	65	2	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2005	23	6					725	730		10.1038/nbt1091	http://dx.doi.org/10.1038/nbt1091			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	933LA	15895075	Green Accepted			2022-12-25	WOS:000229628700033
J	Bond, J; Roberts, E; Springell, K; Lizarraga, S; Scott, S; Higgins, J; Hampshire, DJ; Morrison, EE; Leal, GF; Silva, EO; Costa, SMR; Baralle, D; Raponi, M; Karbani, G; Rashid, Y; Jafri, H; Bennett, C; Corry, P; Walsh, CA; Woods, CG				Bond, J; Roberts, E; Springell, K; Lizarraga, S; Scott, S; Higgins, J; Hampshire, DJ; Morrison, EE; Leal, GF; Silva, EO; Costa, SMR; Baralle, D; Raponi, M; Karbani, G; Rashid, Y; Jafri, H; Bennett, C; Corry, P; Walsh, CA; Woods, CG			A centrosomal mechanism involving CDK5RAP2 and CENPJ controls brain size	NATURE GENETICS			English	Article							MICROCEPHALIN; MUTATIONS; LOCUS; ASPM; IDENTIFICATION; MAPS	Autosomal recessive primary microcephaly is a potential model in which to research genes involved in human brain growth. We show that two forms of the disorder result from homozygous mutations in the genes CDK5RAP2 and CENPJ. We found neuroepithelial expression of the genes during prenatal neurogenesis and protein localization to the spindle poles of mitotic cells, suggesting that a centrosomal mechanism controls neuron number in the developing mammalian brain.	Univ Cambridge, Addenbrookes Hosp, Dept Med Genet, CIMR, Cambridge CB2 2BP, England; Univ Leeds, St James Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England; Harvard Univ, Sch Med, Dept Neurol, Beth Israel Deaconess Med Ctr,Harvard Inst Med, Boston, MA 02115 USA; St James Univ Hosp, Canc Res UK Ctr Leeds, Div Canc Med Res, Leeds LS9 7TF, W Yorkshire, England; Inst Maternoinfantil Pernambuco, Recife, PE, Brazil; Univ Fed Pernambuco, Dept Genet, Recife, PE, Brazil; St James Univ Hosp, Dept Clin Genet, Leeds LS9 7TF, W Yorkshire, England; Lady Wellington Hosp, Dept Obstet & Gynaecol, Lahore, Pakistan; St Lukes Hosp, Dept Paediat, Bradford BD5 0NA, W Yorkshire, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Saint James's University Hospital; University of Leeds; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Cancer Research UK; Saint James's University Hospital; Universidade Federal de Pernambuco; Saint James's University Hospital	Woods, CG (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Med Genet, CIMR, Cambridge CB2 2BP, England.	cw347@cam.ac.uk	Hampshire, Daniel/Q-3540-2019; woods, christopher g/A-1361-2010; raponi, michela/E-3500-2014	raponi, michela/0000-0001-7570-828X; Baralle, Diana/0000-0003-3217-4833				Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Bond J, 2003, AM J HUM GENET, V73, P1170, DOI 10.1086/379085; Bond J, 2002, NAT GENET, V32, P316, DOI 10.1038/ng995; Hung LY, 2004, MOL BIOL CELL, V15, P2697, DOI 10.1091/mbc.E04-02-0121; Jackson AP, 2002, AM J HUM GENET, V71, P136, DOI 10.1086/341283; Kumar A, 2004, CLIN GENET, V66, P341, DOI 10.1111/j.1399-0004.2004.00304.x; Leal GF, 2003, J MED GENET, V40, P540, DOI 10.1136/jmg.40.7.540; Mochida GH, 2001, CURR OPIN NEUROL, V14, P151, DOI 10.1097/00019052-200104000-00003; Moynihan L, 2000, AM J HUM GENET, V66, P724, DOI 10.1086/302777; Pagani F, 2000, J BIOL CHEM, V275, P21041, DOI 10.1074/jbc.M910165199; Roberts E, 2002, J MED GENET, V39, P718, DOI 10.1136/jmg.39.10.718; Trimborn M, 2004, AM J HUM GENET, V75, P261, DOI 10.1086/422855; Wakefield JG, 2001, J CELL BIOL, V153, P637, DOI 10.1083/jcb.153.4.637; Woods CG, 2004, CURR OPIN NEUROBIOL, V14, P112, DOI 10.1016/j.conb.2004.01.003; Xu XZ, 2004, J BIOL CHEM, V279, P34091, DOI 10.1074/jbc.C400139200	15	411	419	1	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2005	37	4					353	355		10.1038/ng1539	http://dx.doi.org/10.1038/ng1539			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	911XL	15793586				2022-12-25	WOS:000228040000017
J	Raoul, C; Abbas-Terki, T; Bensadoun, JC; Guillot, S; Haase, G; Szulc, J; Henderson, CE; Aebischer, P				Raoul, C; Abbas-Terki, T; Bensadoun, JC; Guillot, S; Haase, G; Szulc, J; Henderson, CE; Aebischer, P			Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS	NATURE MEDICINE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; CU/ZN SUPEROXIDE-DISMUTASE; MOTOR-NEURON DEGENERATION; PROLONGS SURVIVAL; MAMMALIAN-CELLS; MICE; EXPRESSION; MUTATION; VECTOR; SYSTEM	Mutations in Cu/Zn superoxide dismutase ( encoded by SOD1), one of the causes of familial amyotrophic lateral sclerosis (ALS), lead to progressive death of motoneurons through a gain-of-function mechanism. RNA interference (RNAi) mediated by viral vectors allows for long-term reduction in gene expression and represents an attractive therapeutic approach for genetic diseases characterized by acquired toxic properties. We report that in SOD1(G93A) transgenic mice, a model for familial ALS, intraspinal injection of a lentiviral vector that produces RNAi-mediated silencing of SOD1 substantially retards both the onset and the progression rate of the disease.	Ecole Polytech Fed Lausanne, Integrat Biosci Inst, CH-1015 Lausanne, Switzerland; INSERM, U29, Avenir Team, INMED, F-13273 Marseille, France; Dev Biol Inst Marseille, INSERM, UMR 623, F-13288 Marseille, France	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Aebischer, P (corresponding author), Ecole Polytech Fed Lausanne, Integrat Biosci Inst, CH-1015 Lausanne, Switzerland.	patrick.aebischer@epfl.ch	Dunnett, Stephen B/A-5869-2010; Aebischer, Patrick/E-1387-2013; Raoul, Cedric/H-6517-2016	Dunnett, Stephen B/0000-0003-1826-1578; Raoul, Cedric/0000-0003-0561-6851; Henderson, Christopher/0000-0002-9936-3279				Abbas-Terki T, 2002, HUM GENE THER, V13, P2197, DOI 10.1089/104303402320987888; Al-Chalabi A, 1998, HUM MOL GENET, V7, P2045, DOI 10.1093/hmg/7.13.2045; Azzouz M, 2000, HUM MOL GENET, V9, P803, DOI 10.1093/hmg/9.5.803; Azzouz M, 2004, NATURE, V429, P413, DOI 10.1038/nature02544; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carter RJ, 1999, J NEUROSCI, V19, P3248; Clement AM, 2003, SCIENCE, V302, P113, DOI 10.1126/science.1086071; Deglon N, 2000, HUM GENE THER, V11, P179, DOI 10.1089/10430340050016256; Ding HL, 2003, AGING CELL, V2, P209, DOI 10.1046/j.1474-9728.2003.00054.x; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; FINGER S, 1988, J NEUROL SCI, V86, P203, DOI 10.1016/0022-510X(88)90099-8; Gong YH, 2000, J NEUROSCI, V20, P660, DOI 10.1523/JNEUROSCI.20-02-00660.2000; Guillot S, 2004, NEUROBIOL DIS, V16, P139, DOI 10.1016/j.nbd.2004.01.017; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Howland DS, 2002, P NATL ACAD SCI USA, V99, P1604, DOI 10.1073/pnas.032539299; Kaspar BK, 2003, SCIENCE, V301, P839, DOI 10.1126/science.1086137; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Lino MM, 2002, J NEUROSCI, V22, P4825, DOI 10.1523/JNEUROSCI.22-12-04825.2002; Nagai M, 2001, J NEUROSCI, V21, P9246, DOI 10.1523/JNEUROSCI.21-23-09246.2001; Newbery H J, 2001, Trends Genet, V17, pS2, DOI 10.1016/S0168-9525(01)02459-3; Raoul C, 2002, NEURON, V35, P1067, DOI 10.1016/S0896-6273(02)00905-4; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; Vila M, 2003, NAT REV NEUROSCI, V4, P365, DOI 10.1038/nrn1100; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Wong PC, 2000, P NATL ACAD SCI USA, V97, P2886, DOI 10.1073/pnas.040461197; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155	30	350	412	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2005	11	4					423	428		10.1038/nm1207	http://dx.doi.org/10.1038/nm1207			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15768028				2022-12-25	WOS:000228180500034
J	Sebastiani, P; Ramoni, MF; Nolan, V; Baldwin, CT; Steinberg, MH				Sebastiani, P; Ramoni, MF; Nolan, V; Baldwin, CT; Steinberg, MH			Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia	NATURE GENETICS			English	Article							RISK; DISEASE; CHILDREN; NETWORKS; TRANSFUSIONS; PREVENTION; PHENOTYPES; FUTURE; LOCI	Sickle cell anemia (SCA) is a paradigmatic single gene disorder caused by homozygosity with respect to a unique mutation at the beta-globin locus. SCA is phenotypically complex, with different clinical courses ranging from early childhood mortality to a virtually unrecognized condition. Overt stroke is a severe complication affecting 6 - 8% of individuals with SCA. Modifier genes might interact to determine the susceptibility to stroke, but such genes have not yet been identified. Using Bayesian networks, we analyzed 108 SNPs in 39 candidate genes in 1,398 individuals with SCA. We found that 31 SNPs in 12 genes interact with fetal hemoglobin to modulate the risk of stroke. This network of interactions includes three genes in the TGF-beta pathway and SELP, which is associated with stroke in the general population. We validated this model in a different population by predicting the occurrence of stroke in 114 individuals with 98.2% accuracy.	Harvard Univ, Sch Med, Childrens Hosp Informat Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Harvard Partners Ctr Genet & Genom, Boston, MA 02115 USA; Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Ctr Human Genet, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pediat, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Boston University; Boston University; Boston University; Boston University	Ramoni, MF (corresponding author), Harvard Univ, Sch Med, Childrens Hosp Informat Program, Boston, MA 02115 USA.	marco_ramoni@harvard.edu		Baldwin, Clinton/0000-0002-3275-9463; Steinberg, Martin/0000-0001-8800-8020; sebastiani, paola/0000-0001-6419-1545	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL080463] Funding Source: NIH RePORTER; NHLBI NIH HHS [R21 HL080463, R21 HL080463-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams RJ, 2004, BLOOD, V103, P3689, DOI 10.1182/blood-2003-08-2733; Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056/NEJM199807023390102; ADAMS RJ, 1994, AM J HEMATOL, V45, P279, DOI 10.1002/ajh.2830450402; Alexander N, 2004, BRIT J HAEMATOL, V126, P606, DOI 10.1111/j.1365-2141.2004.05025.x; Angerio Allan D, 2003, Crit Care Nurs Q, V26, P225; Beaumont MA, 2004, NAT REV GENET, V5, P251, DOI 10.1038/nrg1318; Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090; Brown CB, 1999, SCIENCE, V283, P2080, DOI 10.1126/science.283.5410.2080; Carlson CS, 2004, NATURE, V429, P446, DOI 10.1038/nature02623; Chakravarti A, 1999, NAT GENET, V21, P56, DOI 10.1038/4482; Chiu NHL, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e31; Collins FS, 2003, NATURE, V422, P835, DOI 10.1038/nature01626; COOPER GF, 1992, MACH LEARN, V9, P309, DOI 10.1007/BF00994110; Cowell R.G., 1999, PROBABILISTIC NETWOR; Friedman N, 2004, SCIENCE, V303, P799, DOI 10.1126/science.1094068; Gabriel SB, 2002, NAT GENET, V31, P89, DOI 10.1038/ng868; GASTON M, 1987, CONTROL CLIN TRIALS, V8, pS131; Hand D., 2001, ADAP COMP MACH LEARN; Hardison R., 2001, DISORDERS HEMOGLOBIN, P95, DOI 10.1017/CBO9780511596582; Hoh J, 2003, NAT REV GENET, V4, P701, DOI 10.1038/nrg1155; Hoppe C, 2004, BLOOD, V103, P2391, DOI 10.1182/blood-2003-09-3015; Jansen R, 2003, SCIENCE, V302, P449, DOI 10.1126/science.1087361; Lauritzen SL, 2003, STAT SCI, V18, P489, DOI 10.1214/ss/1081443232; Ling Q, 2004, J CLIN INVEST, V113, P38, DOI 10.1172/JCI200419684; Ohene-Frempong K, 1998, BLOOD, V91, P288; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; Steinberg MH, 2003, BLOOD, V102, p262A; Taylor JG, 2002, BLOOD, V100, P4303, DOI 10.1182/blood-2001-12-0306; Ware RE, 1999, BLOOD, V94, P3022, DOI 10.1182/blood.V94.9.3022.421k17_3022_3026; Zee RYL, 2004, HUM MOL GENET, V13, P389, DOI 10.1093/hmg/ddh039	30	226	237	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2005	37	4					435	440		10.1038/ng1533	http://dx.doi.org/10.1038/ng1533			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	911XL	15778708	Green Accepted			2022-12-25	WOS:000228040000029
J	Crespi, RS				Crespi, RS			Erythropoietin in the UK: a setback for gene patents?	NATURE BIOTECHNOLOGY			English	Editorial Material												crespi@f2s.com							0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2005	23	3					367	368		10.1038/nbt0305-367	http://dx.doi.org/10.1038/nbt0305-367			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	906IW	15765090				2022-12-25	WOS:000227635400028
J	Morizono, K; Xie, YM; Ringpis, GE; Johnson, M; Nassanian, H; Lee, B; Wu, L; Chen, ISY				Morizono, K; Xie, YM; Ringpis, GE; Johnson, M; Nassanian, H; Lee, B; Wu, L; Chen, ISY			Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection	NATURE MEDICINE			English	Article							VIRUS-DERIVED VIRUSES; COMPLEX CLASS-I; RETROVIRAL VECTORS; GENE-THERAPY; SINDBIS VIRUS; HUMAN-CELLS; EXPRESSION; RECEPTOR; TRANSDUCTION; INFECTION	Targeted gene transduction to specific tissues and organs through intravenous injection would be the ultimate preferred method of gene delivery. Here, we report successful targeting in a living animal through intravenous injection of a lentiviral vector pseudotyped with a modified chimeric Sindbis virus envelope (termed m168). m168 pseudotypes have high titer and high targeting specificity and, unlike other retroviral pseudotypes, have low nonspecific infectivity in liver and spleen. A mouse cancer model of metastatic melanoma was used to test intravenous targeting with m168. Human P-glycoprotein was ectopically expressed on the surface of melanoma cells and targeted by the m168 pseudotyped lentiviral vector conjugated with antibody specific for P-glycoprotein. m168 pseudotypes successfully targeted metastatic melanoma cells growing in the lung after systemic administration by tail vein injection. Further development of this targeting technology should result in applications not only for cancers but also for genetic, infectious and immune diseases.	Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, AIDS Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Urol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Chen, ISY (corresponding author), Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	syuchen@mednet.ucla.edu	Lee, Benhur/A-8554-2016	Lee, Benhur/0000-0003-0760-1709	NCI NIH HHS [CA-92194] Funding Source: Medline; NIAID NIH HHS [AI039975, AI028697] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039975, P30AI028697] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aiuti A, 2002, SCIENCE, V296, P2410, DOI 10.1126/science.1070104; Akporiaye ET, 1999, CURR OPIN MOL THER, V1, P443; Allen PJ, 2002, CURR OPIN ONCOL, V14, P221, DOI 10.1097/00001622-200203000-00014; Ambudkar SV, 2003, ONCOGENE, V22, P7468, DOI 10.1038/sj.onc.1206948; Barry SC, 2001, HUM GENE THER, V12, P1103, DOI 10.1089/104303401750214311; BERGER W, 1994, INT J CANCER, V59, P717, DOI 10.1002/ijc.2910590522; Bhaumik S, 2002, P NATL ACAD SCI USA, V99, P377, DOI 10.1073/pnas.012611099; Boerger AL, 1999, P NATL ACAD SCI USA, V96, P9867, DOI 10.1073/pnas.96.17.9867; Bunting KD, 1998, BLOOD, V92, P2269, DOI 10.1182/blood.V92.7.2269.2269_2269_2279; Cameron MD, 2000, CANCER RES, V60, P2541; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; HAN XL, 1995, P NATL ACAD SCI USA, V92, P9747, DOI 10.1073/pnas.92.21.9747; HEIDNER HW, 1994, J VIROL, V68, P2683, DOI 10.1128/JVI.68.4.2683-2692.1994; Jiang A, 1999, GENE THER, V6, P1982, DOI 10.1038/sj.gt.3301043; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; Klimstra WB, 1998, J VIROL, V72, P7357, DOI 10.1128/JVI.72.9.7357-7366.1998; Lehrman S, 1999, NATURE, V401, P517, DOI 10.1038/43977; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Marin M, 1996, J VIROL, V70, P2957, DOI 10.1128/JVI.70.5.2957-2962.1996; Martin F, 2002, MOL THER, V5, P269, DOI 10.1006/mthe.2002.0550; Martin K, 2003, MOL THER, V8, P485, DOI 10.1016/S1525-0016(03)00182-5; Morizono K, 2001, J VIROL, V75, P8016, DOI 10.1128/JVI.75.17.8016-8020.2001; Muller OJ, 2003, NAT BIOTECHNOL, V21, P1040, DOI 10.1038/nbt856; Nicklin Stuart A., 2002, Current Gene Therapy, V2, P273, DOI 10.2174/1566523023347797; Nilson BHK, 1996, GENE THER, V3, P280; ROUX P, 1989, P NATL ACAD SCI USA, V86, P9079, DOI 10.1073/pnas.86.23.9079; Sandrin V, 2003, CURR TOP MICROBIOL, V281, P137; Sawai K, 1998, BIOCHEM BIOPH RES CO, V248, P315, DOI 10.1006/bbrc.1998.8922; SOMIA NV, 1995, P NATL ACAD SCI USA, V92, P7570, DOI 10.1073/pnas.92.16.7570; VALSESIAWITTMANN S, 1994, J VIROL, V68, P4609, DOI 10.1128/JVI.68.7.4609-4619.1994; WANG KS, 1992, J VIROL, V66, P4992, DOI 10.1128/JVI.66.8.4992-5001.1992; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zhao Y, 1999, P NATL ACAD SCI USA, V96, P4005, DOI 10.1073/pnas.96.7.4005	33	169	189	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					346	352		10.1038/nm1192	http://dx.doi.org/10.1038/nm1192			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15711560				2022-12-25	WOS:000227541300032
J	Muller, AJ; DuHadaway, JB; Donover, PS; Sutanto-Ward, E; Prendergast, GC				Muller, AJ; DuHadaway, JB; Donover, PS; Sutanto-Ward, E; Prendergast, GC			Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy	NATURE MEDICINE			English	Article							TUMOR-SUPPRESSOR; CELL-PROLIFERATION; EXPRESSION; TRYPTOPHAN; MYC; ENDOCYTOSIS; MECHANISM; CARCINOMA; PROTEIN; BIN1/AMPHIPHYSIN-II	Immune escape is a crucial feature of cancer progression about which little is known. Elevation of the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) in tumor cells can facilitate immune escape. Not known is how IDO becomes elevated or whether IDO inhibitors will be useful for cancer treatment. Here we show that IDO is under genetic control of Bin1, which is attenuated in many human malignancies. Mouse knockout studies indicate that Bin1 loss elevates the STAT1- and NF-kappa B-dependent expression of IDO, driving escape of oncogenically transformed cells from T cell-dependent antitumor immunity. In MMTV-Neu mice, an established breast cancer model, we show that small-molecule inhibitors of IDO cooperate with cytotoxic agents to elicit regression of established tumors refractory to single-agent therapy. Our findings suggest that Bin1 loss promotes immune escape in cancer by deregulating IDO and that IDO inhibitors may improve responses to cancer chemotherapy.	Lankenau Inst Med Res, Wynnewood, PA 19096 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Lankenau Medical Center; Lankenau Institute for Medical Research; Jefferson University	Prendergast, GC (corresponding author), Lankenau Inst Med Res, 100 Lancaster Ave, Wynnewood, PA 19096 USA.	prendergasgt@mlhs.org		Muller, Alexander/0000-0001-7854-6933				BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; Bild AH, 2002, EMBO J, V21, P3255, DOI 10.1093/emboj/cdf351; BOYLAND E, 1956, BIOCHEM J, V64, P578, DOI 10.1042/bj0640578; Brandt R, 2001, ONCOGENE, V20, P5459, DOI 10.1038/sj.onc.1204709; DEBRICK JE, 1991, J IMMUNOL, V147, P2846; Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252; Du MX, 2000, J INTERF CYTOK RES, V20, P133, DOI 10.1089/107999000312531; DuHadaway JB, 2003, ONCOGENE, V22, P3578, DOI 10.1038/sj.onc.1206481; DuHadaway JB, 2003, J CELL BIOCHEM, V88, P635, DOI 10.1002/jcb.10380; DuHadaway JB, 2001, CANCER RES, V61, P3151; Elliott K, 1999, ONCOGENE, V18, P3564, DOI 10.1038/sj.onc.1202670; Elliott K, 2000, ONCOGENE, V19, P4669, DOI 10.1038/sj.onc.1203681; Friberg M, 2002, INT J CANCER, V101, P151, DOI 10.1002/ijc.10645; Ge K, 2000, INT J CANCER, V86, P155, DOI 10.1002/(SICI)1097-0215(20000415)86:2<155::AID-IJC2>3.0.CO;2-M; Ge K, 1999, P NATL ACAD SCI USA, V96, P9689, DOI 10.1073/pnas.96.17.9689; Ge K, 2000, INT J CANCER, V85, P376; Gilmour SK, 1999, CELL GROWTH DIFFER, V10, P739; Grohmann U, 2003, TRENDS IMMUNOL, V24, P242, DOI 10.1016/S1471-4906(03)00072-3; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Huang HT, 2000, CANCER RES, V60, P6868; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; KOPROWSKI H, 1979, SOMAT CELL GENET, V5, P957, DOI 10.1007/BF01542654; KRUISBEEK AD, 1991, CURRENT PROTOCOLS IM; Leprince C, 2003, J CELL SCI, V116, P1937, DOI 10.1242/jcs.00403; Littlejohn TK, 2000, PROTEIN EXPRES PURIF, V19, P22, DOI 10.1006/prep.2000.1214; Machiels JPH, 2001, CANCER RES, V61, P3689; Marincola F M, 2000, Adv Immunol, V74, P181, DOI 10.1016/S0065-2776(08)60911-6; Mason K, 2001, INT J ONCOL, V18, P599; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Miaczynska M, 2004, CELL, V116, P445, DOI 10.1016/S0092-8674(04)00117-5; Muller AJ, 2003, MOL CELL BIOL, V23, P4295, DOI 10.1128/MCB.23.12.4295-4306.2003; MULLER AJ, 2004, CANC BIOL THER, V3; Munn DH, 2002, SCIENCE, V297, P1867, DOI 10.1126/science.1073514; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Munn DH, 1999, J EXP MED, V189, P1363, DOI 10.1084/jem.189.9.1363; Nowak AK, 2003, CANCER RES, V63, P4490; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; ROSE DP, 1967, LANCET, V1, P239; Routhier EL, 2003, ONCOGENE, V22, P637, DOI 10.1038/sj.onc.1206162; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; SHIMIZU F, 1978, INFECT IMMUN, V22, P752, DOI 10.1128/IAI.22.3.752-757.1978; Tajiri T, 2003, CLIN CANCER RES, V9, P3345; Uyttenhove C, 2003, NAT MED, V9, P1269, DOI 10.1038/nm934; Vecchi M, 2001, J CELL BIOL, V153, P1511, DOI 10.1083/jcb.153.7.1511; VERSTEEG R, 1988, EMBO J, V7, P1023, DOI 10.1002/j.1460-2075.1988.tb02909.x; Wechsler-Reya RJ, 1998, MOL CELL BIOL, V18, P566, DOI 10.1128/MCB.18.1.566; WechslerReya R, 1997, CANCER RES, V57, P3258; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; Zelhof AC, 2001, DEVELOPMENT, V128, P5005	50	831	936	2	114	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					312	319		10.1038/nm1196	http://dx.doi.org/10.1038/nm1196			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15711557				2022-12-25	WOS:000227541300027
J	Lang, KS; Recher, M; Junt, T; Navarini, AA; Harris, NL; Freigang, S; Odermatt, B; Conrad, C; Ittner, LM; Bauer, S; Luther, SA; Uematsu, S; Akira, S; Hengartner, H; Zinkernagel, RM				Lang, KS; Recher, M; Junt, T; Navarini, AA; Harris, NL; Freigang, S; Odermatt, B; Conrad, C; Ittner, LM; Bauer, S; Luther, SA; Uematsu, S; Akira, S; Hengartner, H; Zinkernagel, RM			Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease	NATURE MEDICINE			English	Article							PLASMACYTOID DENDRITIC CELLS; DOUBLE-STRANDED-RNA; DIABETES-MELLITUS; VIRAL-INFECTION; MOLECULAR MIMICRY; PANCREATIC-ISLETS; IMMUNE-RESPONSES; VIRUS-INFECTION; IFN-ALPHA/BETA; BETA-CELLS	Autoimmune diabetes mellitus in humans is characterized by immunological destruction of pancreatic beta islet cells. We investigated the circumstances under which CD8(+) T cells specific for pancreatic beta-islet antigens induce disease in mice expressing lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP) as a transgene under the control of the rat insulin promoter. In contrast to infection with LCMV, immunization with LCMV-GP derived peptide did not induce autoimmune diabetes despite large numbers of autoreactive cytotoxic T cells. Only subsequent treatment with Toll-like receptor ligands elicited overt autoimmune disease. This difference was critically regulated by the peripheral target organ itself, which upregulated class I major histocompatibility complex (MHC) in response to systemic Toll-like receptor-triggered interferon-alpha production. These data identify the 'inflammatory status' of the target organ as a separate and limiting factor determining the development of autoimmune disease.	Univ Zurich Hosp, Inst Expt Immunol, Zurich, Switzerland; Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland; Univ Zurich, Res Lab Calcium Metab, Clin Balgrist, Zurich, Switzerland; Tech Univ Munich, Inst Med Mikrobiol Immunol & Hyg, D-8000 Munich, Germany; Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland; Osaka Univ, Dept Hosp Defense, Suita, Osaka, Japan	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Zurich; Technical University of Munich; University of Lausanne; Osaka University	Lang, KS (corresponding author), Univ Zurich Hosp, Inst Expt Immunol, Schmelzbergstr 12, Zurich, Switzerland.	karl.lang@usz.ch	Luther, Sanjiv A/B-4380-2016; Luther, Sanjiv/AAP-6525-2020; Junt, Tobias/AAE-4389-2021; Navarini, Alexander/C-5504-2014; harris, nicola/E-5342-2019; Lang, Karl S/R-2505-2016; Akira, Shizuo/C-3134-2009; Freigang, Stefan/A-8682-2013; , Sanjiv/B-4380-2016	Luther, Sanjiv A/0000-0002-8758-957X; Luther, Sanjiv/0000-0002-8758-957X; Navarini, Alexander/0000-0001-7059-632X; harris, nicola/0000-0003-2922-0210; Freigang, Stefan/0000-0003-4438-7828; Lang, Karl/0000-0001-9783-7605; , Sanjiv/0000-0002-0614-561X; Conrad, Curdin/0000-0002-2547-3440; Bauer, Stefan/0000-0002-8462-1845; Ittner, Lars/0000-0001-6738-3825; Recher, Mike/0000-0002-9121-6936				Akira S, 2000, CURR OPIN IMMUNOL, V12, P59, DOI 10.1016/S0952-7915(99)00051-5; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Asselin-Paturel C, 2001, NAT IMMUNOL, V2, P1144, DOI 10.1038/ni736; BATTEGAY M, 1992, J VIROL METHODS, V38, P263; Betterle C, 2000, DIABETES CARE, V23, P1177, DOI 10.2337/diacare.23.8.1177; Biron CA, 1998, SEMIN IMMUNOL, V10, P383, DOI 10.1006/smim.1998.0138; Dalod M, 2002, J EXP MED, V195, P517, DOI 10.1084/jem.20011672; Diebold SS, 2003, NATURE, V424, P324, DOI 10.1038/nature01783; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Doughty LA, 2001, J IMMUNOL, V166, P2658, DOI 10.4049/jimmunol.166.4.2658; ERLICH HA, 1991, BAILLIERE CLIN ENDOC, V5, P395, DOI 10.1016/S0950-351X(05)80138-7; EWEL CH, 1992, DIABETES, V41, P1016, DOI 10.2337/diabetes.41.8.1016; Frigerio S, 2002, NAT MED, V8, P1414, DOI 10.1038/nm792; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hiemstra HS, 1998, J IMMUNOL, V161, P4078; Honda K, 2003, P NATL ACAD SCI USA, V100, P10872, DOI 10.1073/pnas.1934678100; Hoshino K, 2002, INT IMMUNOL, V14, P1225, DOI 10.1093/intimm/dxf089; Hyoty H, 2002, DIABETOLOGIA, V45, P1353, DOI 10.1007/s00125-002-0852-3; ISHIKAWA R, 1993, J IMMUNOL, V150, P3713; Junt T, 2002, J IMMUNOL, V168, P6032, DOI 10.4049/jimmunol.168.12.6032; Kaisho T, 2003, CURR MOL MED, V3, P759, DOI 10.2174/1566524033479366; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Krug A, 2001, EUR J IMMUNOL, V31, P3026, DOI 10.1002/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO;2-H; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Ludewig B, 1998, J EXP MED, V188, P1493, DOI 10.1084/jem.188.8.1493; Luther SA, 2000, IMMUNITY, V12, P471, DOI 10.1016/S1074-7613(00)80199-5; Malmgaard L, 2002, J VIROL, V76, P4520, DOI 10.1128/JVI.76.9.4520-4525.2002; Meagher C, 2003, ADV EXP MED BIOL, V520, P133; Nansen A, 2000, EUR J IMMUNOL, V30, P1797, DOI 10.1002/1521-4141(200007)30:7<1797::AID-IMMU1797>3.0.CO;2-B; O'Neill L A, 2000, Sci STKE, V2000, pre1; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OHASHI PS, 1993, J IMMUNOL, V150, P5185; Ou R, 2001, J VIROL, V75, P8407, DOI 10.1128/JVI.75.18.8407-8423.2001; Pien GC, 2002, J IMMUNOL, V169, P5827, DOI 10.4049/jimmunol.169.10.5827; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Potena L, 2004, CIRCULATION, V109, P532, DOI 10.1161/01.CIR.0000109485.79183.81; ROEP BO, 1995, DIABETES, V44, P278, DOI 10.2337/diabetes.44.3.278; Roep BO, 1996, DIABETES, V45, P1147, DOI 10.2337/diabetes.45.9.1147; Roep BO, 2002, ANN NY ACAD SCI, V958, P163; Schloot NC, 2001, HUM IMMUNOL, V62, P299, DOI 10.1016/S0198-8859(01)00223-3; SERREZE DV, 1989, J AUTOIMMUN, V2, P759, DOI 10.1016/0896-8411(89)90003-6; Sobel DO, 1998, J AUTOIMMUN, V11, P343, DOI 10.1006/jaut.1998.0203; SOBEL DO, 1992, DIABETES, V41, P515, DOI 10.2337/diabetes.41.4.515; TRUCCO M, 1989, CRIT REV IMMUNOL, V9, P201; vonHerrath MG, 1997, J EXP MED, V185, P531, DOI 10.1084/jem.185.3.531; Yang Y, 2003, DIABETOLOGIA, V46, P1447, DOI 10.1007/s00125-003-1218-1; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	50	315	330	1	15	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					138	145		10.1038/nm1176	http://dx.doi.org/10.1038/nm1176			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15654326	Green Published, Green Submitted			2022-12-25	WOS:000226797300020
J	Takimoto, E; Champion, HC; Li, MX; Belardi, D; Ren, SX; Rodriguez, ER; Bedja, D; Gabrielson, KL; Wang, YB; Kass, DA				Takimoto, E; Champion, HC; Li, MX; Belardi, D; Ren, SX; Rodriguez, ER; Bedja, D; Gabrielson, KL; Wang, YB; Kass, DA			Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy	NATURE MEDICINE			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; NATRIURETIC-PEPTIDE RECEPTOR; GUANYLYL CYCLASE-A; PROTEIN-KINASE-C; IN-VIVO; NITRIC-OXIDE; MYOCARDIAL-CONTRACTILITY; SIGNALING PATHWAYS; DIASTOLIC FUNCTION; PRESSURE-OVERLOAD	Sustained cardiac pressure overload induces hypertrophy and pathological remodeling, frequently leading to heart failure. Genetically engineered hyperstimulation of guanosine 3',5'-cyclic monophosphate (cGMP) synthesis counters this response. Here, we show that blocking the intrinsic catabolism of cGMP with an oral phosphodiesterase-5A (PDE5A) inhibitor (sildenafil) suppresses chamber and myocyte hypertrophy, and improves in vivo heart function in mice exposed to chronic pressure overload induced by transverse aortic constriction. Sildenafil also reverses pre-established hypertrophy induced by pressure load while restoring chamber function to normal. cGMP catabolism by PDE5A increases in pressure-loaded hearts, leading to activation of cGMP-dependent protein kinase with inhibition of PDE5A. PDE5A inhibition deactivates multiple hypertrophy signaling pathways triggered by pressure load (the calcineurin/NFAT, phosphoinositide-3 kinase (PI3K)/Akt, and ERK1/2 signaling pathways). But it does not suppress hypertrophy induced by overexpression of calcineurin in vitro or Akt in vivo, suggesting upstream targeting of these pathways. PDE5A inhibition may provide a new treatment strategy for cardiac hypertrophy and remodeling.	Johns Hopkins Med Inst, Dept Med, Div Cardiol, Baltimore, MD 21205 USA; Univ Calif Los Angeles, Dept Anesthesiol, Div Mol Med, David Geffen Sch Med, Los Angeles, CA 90095 USA; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21287 USA; Johns Hopkins Med Inst, Div Comparat Med, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Kass, DA (corresponding author), Johns Hopkins Med Inst, Dept Med, Div Cardiol, Ross 835,720 Rutland Ave, Baltimore, MD 21205 USA.	dkass@jhmi.edu	Takimoto, Eiki/AAC-5100-2021	Wang, Yibin/0000-0003-0852-0767	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047511, P01HL059408] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018324] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-47511, P01-HL59408] Funding Source: Medline; NIA NIH HHS [AG18324] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akao M, 2001, CIRC RES, V88, P1267, DOI 10.1161/hh1201.092094; Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; Bueno OF, 2002, CIRC RES, V91, P776, DOI 10.1161/01.RES.0000038488.38975.1A; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P4586, DOI 10.1073/pnas.072647999; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Champion HC, 2004, CIRC RES, V94, P657, DOI 10.1161/01.RES.0000119323.79644.20; Condorelli G, 2002, P NATL ACAD SCI USA, V99, P12333, DOI 10.1073/pnas.172376399; Corbin J, 2003, CURR MED RES OPIN, V19, P747, DOI 10.1185/030079903125002522; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; De Windt LJ, 2000, CIRC RES, V86, P255, DOI 10.1161/01.RES.86.3.255; Esposito G, 2002, CIRCULATION, V105, P85, DOI 10.1161/hc0102.101365; Fiedler B, 2002, P NATL ACAD SCI USA, V99, P11363, DOI 10.1073/pnas.162100799; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; Francis SH, 2002, J BIOL CHEM, V277, P47581, DOI 10.1074/jbc.M206088200; Frey N, 2003, ANNU REV PHYSIOL, V65, P45, DOI 10.1146/annurev.physiol.65.092101.142243; Frey N, 2004, CIRCULATION, V109, P1580, DOI 10.1161/01.CIR.0000120390.68287.BB; Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001; Hardt SE, 2002, CIRC RES, V90, P1055, DOI 10.1161/01.RES.0000018952.70505.F1; Holtwick R, 2003, J CLIN INVEST, V111, P1399, DOI 10.1172/JCI200317061; Juhaszova M, 2004, J CLIN INVEST, V113, P1535, DOI 10.1172/JCI200419906; Kim D, 2001, CIRCULATION, V104, P2338, DOI 10.1161/hc4401.098432; Kishimoto I, 2001, P NATL ACAD SCI USA, V98, P2703, DOI 10.1073/pnas.051625598; Knowles JW, 2001, J CLIN INVEST, V107, P975, DOI 10.1172/JCI11273; Kotera J, 2003, BIOCHEM J, V372, P419, DOI 10.1042/BJ20030107; Massion PB, 2003, CIRC RES, V93, P388, DOI 10.1161/01.RES.0000088351.58510.21; Matsui T, 2002, J BIOL CHEM, V277, P22896, DOI 10.1074/jbc.M200347200; Matsui T, 2003, CELL CYCLE, V2, P220, DOI 10.4161/cc.2.3.381; Michael A, 2004, J BIOL CHEM, V279, P21383, DOI 10.1074/jbc.M401413200; Minamino T, 2002, P NATL ACAD SCI USA, V99, P3866, DOI 10.1073/pnas.062453699; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Ni XP, 2004, J AM SOC NEPHROL, V15, P1254, DOI 10.1097/01.ASN.0000125613.96927.38; Oliver PM, 1997, P NATL ACAD SCI USA, V94, P14730, DOI 10.1073/pnas.94.26.14730; Oudit GY, 2004, J MOL CELL CARDIOL, V37, P449, DOI 10.1016/j.yjmcc.2004.05.015; Patrucco E, 2004, CELL, V118, P375, DOI 10.1016/j.cell.2004.07.017; Pilz RB, 2003, CIRC RES, V93, P1034, DOI 10.1161/01.RES.0000103311.52853.48; Reffelmann T, 2003, CIRCULATION, V108, P239, DOI 10.1161/01.CIR.0000081166.87607.E2; Rybalkin SD, 2003, CIRC RES, V93, P280, DOI 10.1161/01.RES.0000087541.15600.2B; Rybalkin SD, 2003, EMBO J, V22, P469, DOI 10.1093/emboj/cdg051; Sastry BKS, 2004, J AM COLL CARDIOL, V43, P1149, DOI 10.1016/j.jacc.2003.10.056; Semeniuk LM, 2003, AM J PHYSIOL-HEART C, V284, pH425, DOI 10.1152/ajpheart.00546.2002; Senzaki H, 2001, FASEB J, V15, P1718, DOI 10.1096/fj.00-0538com; Shin SY, 2002, EXP MOL MED, V34, P444, DOI 10.1038/emm.2002.62; Takimoto E, 2005, CIRC RES, V96, P100, DOI 10.1161/01.RES.0000152262.22968.72; Tanji C, 2002, J BIOL CHEM, V277, P36955, DOI 10.1074/jbc.M206210200; Walker DK, 1999, XENOBIOTICA, V29, P297, DOI 10.1080/004982599238687; Wilkins BJ, 2004, CIRC RES, V94, P110, DOI 10.1161/01.RES.0000109415.17511.18; Wollert KC, 2002, HYPERTENSION, V39, P87, DOI 10.1161/hy1201.097292; Zahabi A, 2003, J BIOL CHEM, V278, P47694, DOI 10.1074/jbc.M309661200; Zou YZ, 2001, CIRCULATION, V104, P102, DOI 10.1161/hc2601.090987	50	693	722	1	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					214	222		10.1038/nm1175	http://dx.doi.org/10.1038/nm1175			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15665834				2022-12-25	WOS:000226797300030
J	Abdelgafar, B; Thorsteinsdottir, H; Quach, U; Singer, PA; Daar, AS				Abdelgafar, B; Thorsteinsdottir, H; Quach, U; Singer, PA; Daar, AS			The emergence of Egyptian biotechnology from generics	NATURE BIOTECHNOLOGY			English	Editorial Material									Amer Univ Cairo, Dept Management, Cairo 11511, Egypt; Univ Toronto, Joint Ctr Bioeth, Canadian Program Gen & Global Hlth, Toronto, ON M5G 1L4, Canada; Dept Publ Hlth Sci, Toronto, ON M5G 1L4, Canada; Univ Toronto, McLaughlin Ctr Mol Med, Toronto, ON, Canada	Egyptian Knowledge Bank (EKB); American University Cairo; University of Toronto; University of Toronto	Abdelgafar, B (corresponding author), Amer Univ Cairo, Dept Management, 113 Kasr El Aini St,POB 2511, Cairo 11511, Egypt.	halla.thorsteinsdottir@utoronto.ca						ELAWADY MK, 2003, BIOEXCHANGE     0114; ELJESRI M, 2004, EGYPT TODAY, V25, P87; ELNAHHAS M, 2002, AL AHRAM ONLINE 0822; GALAL EE, 1983, WORLD DEV, V11, P237, DOI 10.1016/0305-750X(83)90031-1; *MOSR, 1997, 28836 WB MOSR; *SCI METR, 2004, BENCHM GEN HLTH BIOT; *UNCTAD, 1999, INV POL REV EG; *WHO, 2000, ROL PAR ANT THER SPR; Zahlan A. B., 1997, SCI COMMUNITIES DEV, P81	9	4	4	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2004	22			S			DC25	DC30		10.1038/nbt1204supp-DC25	http://dx.doi.org/10.1038/nbt1204supp-DC25			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	879QF	15583680	hybrid			2022-12-25	WOS:000225731600006
J	Pavlou, AK; Reichert, JM				Pavlou, AK; Reichert, JM			Recombinant protein therapeutics - success rates, market trends and values to 2010	NATURE BIOTECHNOLOGY			English	Article							MONOCLONAL-ANTIBODIES; US		Datamonitor PLC, London NW3 5JJ, England; Tufts Ctr Study Drug Dev, Boston, MA 02111 USA		Pavlou, AK (corresponding author), Datamonitor PLC, Charles House 108-110 Finchley Rd, London NW3 5JJ, England.	apavlou@datamonitor.com; janice.reichert@tufts.edu		Reichert, Janice/0000-0003-0400-1951				Reichert J, 2004, NAT REV DRUG DISCOV, V3, P383, DOI 10.1038/nrd1386; Reichert JM, 2003, CURR OPIN MOL THER, V5, P139; Reichert JM, 2002, CURR OPIN MOL THER, V4, P110; Reichert JM, 2001, NAT BIOTECHNOL, V19, P819, DOI 10.1038/nbt0901-819; Reichert JM, 2004, REG AFFAIRS J PHARM, V15, P491	5	229	256	0	36	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2004	22	12					1513	1519		10.1038/nbt1204-1513	http://dx.doi.org/10.1038/nbt1204-1513			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	878HX	15583654				2022-12-25	WOS:000225638600016
J	Philimonenko, VV; Zhao, J; Iben, S; Dingova, H; Kysela, K; Kahle, M; Zentgraf, H; Hofmann, WA; de Lanerolle, P; Hozak, P; Grummt, I				Philimonenko, VV; Zhao, J; Iben, S; Dingova, H; Kysela, K; Kahle, M; Zentgraf, H; Hofmann, WA; de Lanerolle, P; Hozak, P; Grummt, I			Nuclear actin and myosin I are required for RNA polymerase I transcription	NATURE CELL BIOLOGY			English	Article							FACTOR TIF-IA; INITIATION-FACTOR; MESSENGER-RNA; MOUSE; GENE; LOCALIZATION; CHROMATIN; PROTEINS; COMPLEX; GROWTH	The presence of actin and nuclear myosin I (NMI) in the nucleus suggests a role for these motor proteins in nuclear functions. We have investigated the role of actin and nuclear myosin I ( NMI) in the transcription of ribosomal RNA genes ( rDNA). Both proteins are associated with rDNA and are required for RNA polymerase I (Pol I) transcription. Microinjection of antibodies against actin or NMI, as well as short interfering RNA-mediated depletion of NMI, decreased Pol I transcription in vivo, whereas overexpression of NMI augmented pre-rRNA synthesis. In vitro, recombinant NMI activated Pol I transcription, and antibodies to NMI or actin inhibited Pol I transcription both on naked DNA and pre-assembled chromatin templates. Whereas actin associated with Pol I, NMI bound to Pol I through the transcription-initiation factor TIF-IA. The association with Pol I requires phosphorylation of TIF-IA at Ser 649 by RSK kinase, indicating a role for NMI in the growth-dependent regulation of rRNA synthesis.	German Canc Res Ctr, Div Mol Biol Cell 2, D-69118 Heidelberg, Germany; Acad Sci Czech Republ, Inst Expt Med, Dept Cell Ultrastruct & Mol Biol, Prague 14220, Czech Republic; German Canc Res Ctr, D-69118 Heidelberg, Germany; Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60612 USA	Helmholtz Association; German Cancer Research Center (DKFZ); Czech Academy of Sciences; Institute of Experimental Medicine of the Czech Academy of Sciences; Helmholtz Association; German Cancer Research Center (DKFZ); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Grummt, I (corresponding author), German Canc Res Ctr, Div Mol Biol Cell 2, D-69118 Heidelberg, Germany.	i.grummt@dkfz.de	Gaplovska, Katarina/I-3472-2012; Kahle, Michal/K-9936-2016; Hozak, Pavel/AAB-5359-2021; Zhao, Jian/E-2008-2019; Philimonenko, Vlada/G-3522-2014; Hozak, Pavel/J-4182-2014	Gaplovska, Katarina/0000-0002-6264-8924; Kahle, Michal/0000-0002-3854-0390; Hozak, Pavel/0000-0003-1901-1394; Zhao, Jian/0000-0002-8862-0591; Hozak, Pavel/0000-0003-1901-1394; Hofmann, Wilma/0000-0003-2401-5154	NIGMS NIH HHS [GM 59648] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bettinger BT, 2004, NAT REV MOL CELL BIO, V5, P410, DOI 10.1038/nrm1370; Bodem J, 2000, EMBO REP, V1, P171, DOI 10.1093/embo-reports/kvd032; BRUN RP, 1994, MOL CELL BIOL, V14, P5010, DOI 10.1128/MCB.14.7.5010; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; Cavanaugh AH, 2002, J BIOL CHEM, V277, P27423, DOI 10.1074/jbc.M201232200; EGLY JM, 1984, EMBO J, V3, P2363, DOI 10.1002/j.1460-2075.1984.tb02141.x; Fomproix N, 2004, EXP CELL RES, V294, P140, DOI 10.1016/j.yexcr.2003.10.028; Funaki K, 1995, BIOL CELL, V84, P139, DOI 10.1016/0248-4900(96)89423-8; Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; Hirschler-Laszkiewicz I, 2003, J BIOL CHEM, V278, P18953, DOI 10.1074/jbc.M301093200; Hofmann WA, 2004, NAT CELL BIOL, V6, P1094, DOI 10.1038/ncb1182; Langst G, 1998, EMBO J, V17, P3135, DOI 10.1093/emboj/17.11.3135; Miller G, 2001, EMBO J, V20, P1373, DOI 10.1093/emboj/20.6.1373; Muratani M, 2002, NAT CELL BIOL, V4, P106, DOI 10.1038/ncb740; NAKAYASU H, 1985, CELL STRUCT FUNCT, V10, P305; Nguyen E, 1998, MOL REPROD DEV, V50, P263, DOI 10.1002/(SICI)1098-2795(199807)50:3&lt;263::AID-MRD2&gt;3.0.CO;2-H; Nowak G, 1997, J BIOL CHEM, V272, P17176, DOI 10.1074/jbc.272.27.17176; Olave IA, 2002, ANNU REV BIOCHEM, V71, P755, DOI 10.1146/annurev.biochem.71.110601.135507; Pederson T, 2000, MOL BIOL CELL, V11, P799, DOI 10.1091/mbc.11.3.799; Pederson T, 2002, J STRUCT BIOL, V140, P3, DOI 10.1016/S1047-8477(02)00528-2; Percipalle P, 2003, P NATL ACAD SCI USA, V100, P6475, DOI 10.1073/pnas.1131933100; Percipalle P, 2002, NUCLEIC ACIDS RES, V30, P1725, DOI 10.1093/nar/30.8.1725; Percipalle P, 2001, J CELL BIOL, V153, P229, DOI 10.1083/jcb.153.1.229; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; Pestic-Dragovich L, 2000, SCIENCE, V290, P337, DOI 10.1126/science.290.5490.337; Rando OJ, 2000, TRENDS CELL BIOL, V10, P92, DOI 10.1016/S0962-8924(99)01713-4; SCHEER U, 1984, CELL, V39, P111, DOI 10.1016/0092-8674(84)90196-X; Schnapp A, 1996, METHOD ENZYMOL, V273, P233; SCHNAPP A, 1990, EMBO J, V9, P2857, DOI 10.1002/j.1460-2075.1990.tb07475.x; SCHRODER HC, 1987, EUR J BIOCHEM, V167, P239, DOI 10.1111/j.1432-1033.1987.tb13329.x; Seither P, 1996, GENOMICS, V37, P135, DOI 10.1006/geno.1996.0531; SMITH SS, 1979, BIOCHEM BIOPH RES CO, V86, P161, DOI 10.1016/0006-291X(79)90395-4; SoyerGobillard MO, 1996, BIOL CELL, V87, P17, DOI 10.1016/S0248-4900(97)89834-6; TOWER J, 1987, CELL, V50, P873, DOI 10.1016/0092-8674(87)90514-9; Yuan XJ, 2002, EMBO REP, V3, P1082, DOI 10.1093/embo-reports/kvf212; Zhao J, 2003, MOL CELL, V11, P405, DOI 10.1016/S1097-2765(03)00036-4; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	37	300	316	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2004	6	12					1165	1172		10.1038/ncb1190	http://dx.doi.org/10.1038/ncb1190			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	875WQ	15558034				2022-12-25	WOS:000225453300008
J	Fan, XH; Ang, A; BarZiv, SMP; Dipchand, AI; Ruiz, P; Wilson, G; Platt, JL; West, LJ				Fan, XH; Ang, A; BarZiv, SMP; Dipchand, AI; Ruiz, P; Wilson, G; Platt, JL; West, LJ			Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation	NATURE MEDICINE			English	Article							REACTIVE LYMPHOCYTES-B; IMMUNE-SYSTEM; CARDIAC TRANSPLANTATION; CLONAL ELIMINATION; ESCAPE TOLERANCE; RENAL-ALLOGRAFTS; SELF-TOLERANCE; ANTIGENS; MAINTENANCE; DELETION	Although over 50 years have passed since its first laboratory description, intentional induction of immune tolerance to foreign antigens has remained an elusive clinical goal. We previously reported that the requirement for ABO compatibility in heart transplantation is not applicable to infants. Here, we show that ABO-incompatible heart transplantation during infancy results in development of B-cell tolerance to donor blood group A and B antigens. This mimics animal models of neonatal tolerance and indicates that the human infant is susceptible to intentional tolerance induction. Tolerance in this setting occurs by elimination of donor-reactive B lymphocytes and may be dependent upon persistence of some degree of antigen expression. These findings suggest that intentional exposure to nonself A and B antigens may prolong the window of opportunity for ABO-incompatible transplantation, and have profound implications for clinical research on tolerance induction to T-independent antigens relevant to xenotransplantation.	Hosp Sick Children, Dept Pediat, Infect Immun Injury & Repair Program, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Pediat, Div Cardiol, Toronto, ON M5G 1X8, Canada; Univ Miami, Sch Med, Jackson Mem Hosp, Dept Pathol, Miami, FL 33136 USA; Hosp Sick Children, Dept Pediat Lab Med, Toronto, ON M5G 1X8, Canada; Mayo Clin, Dept Transplantat Biol, Rochester, MN 55905 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Miami; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Mayo Clinic	West, LJ (corresponding author), Hosp Sick Children, Dept Pediat, Infect Immun Injury & Repair Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	lori.west@sickkids.ca	Platt, Jeffrey/AHB-0480-2022	West, Lori/0000-0002-1990-3651; Platt, Jeffrey/0000-0002-4915-0419				ALEXANDRE GPJ, 1987, TRANSPLANT P, V19, P4538; BANNETT AD, 1989, TRANSPLANT P, V21, P783; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; Burnet FM, 1949, PRODUCTION ANTIBODIE; Cadoz M, 1998, VACCINE, V16, P1391, DOI 10.1016/S0264-410X(98)00097-8; Chelvarajan RL, 1998, J IMMUNOL, V161, P3315; CHEN C, 1995, NATURE, V373, P252, DOI 10.1038/373252a0; CHOPEK MW, 1987, TRANSPLANT P, V19, P4553; COOPER DKC, 1990, TRANSPLANT P, V22, P1457; DORSCH S, 1982, TRANSPLANTATION, V33, P518, DOI 10.1097/00007890-198205000-00011; ERIKSON J, 1991, NATURE, V349, P331, DOI 10.1038/349331a0; FONG SW, 1974, TRANSFUSION, V14, P551, DOI 10.1111/j.1537-2995.1974.tb04576.x; GALILI U, 1993, IMMUNOL TODAY, V14, P480, DOI 10.1016/0167-5699(93)90261-I; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; Gennery AR, 1998, LANCET, V351, P1778, DOI 10.1016/S0140-6736(97)08486-9; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GUGENHEIM J, 1990, LANCET, V336, P519, DOI 10.1016/0140-6736(90)92082-S; Hamano K, 1996, TRANSPLANTATION, V62, P856, DOI 10.1097/00007890-199609270-00026; HAMMARSTROM L, 1986, CLIN EXP IMMUNOL, V66, P457; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; Holsapple MP, 2003, BIRTH DEFECTS RES B, V68, P321, DOI 10.1002/bdrb.10035; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; Klinman NR, 1996, IMMUNITY, V5, P189, DOI 10.1016/S1074-7613(00)80314-3; Lang J, 2000, EUR J IMMUNOL, V30, P689, DOI 10.1002/1521-4141(200002)30:2<689::AID-IMMU689>3.0.CO;2-I; Lin SS, 2000, TRANSPLANTATION, V70, P1667, DOI 10.1097/00007890-200012270-00002; Luo W, 1999, CELL IMMUNOL, V195, P1, DOI 10.1006/cimm.1999.1516; MCCARTHY SA, 1983, J IMMUNOL, V131, P1676; MOLLISON PL, 1993, BLOOD TRANSFUSION CL, P155; MOND JJ, 1995, ANNU REV IMMUNOL, V13, P655, DOI 10.1146/annurev.iy.13.040195.003255; MORECKI S, 1987, J EXP MED, V165, P1468, DOI 10.1084/jem.165.6.1468; NAKAFUSA Y, 1993, SURGERY, V114, P183; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; Noris M, 2001, J AM SOC NEPHROL, V12, P2815, DOI 10.1681/ASN.V12122815; OWEN RD, 1945, SCIENCE, V102, P400, DOI 10.1126/science.102.2651.400; PERICO N, 1995, J AM SOC NEPHROL, V5, P1618; RADIC MZ, 1993, J EXP MED, V177, P1165, DOI 10.1084/jem.177.4.1165; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; SMALLEY CE, 1983, BRIT J HAEMATOL, V54, P209, DOI 10.1111/j.1365-2141.1983.tb02089.x; SPLAWSKI JB, 1991, J CLIN INVEST, V88, P967, DOI 10.1172/JCI115400; SPRINGER GF, 1969, J CLIN INVEST, V48, P1280, DOI 10.1172/JCI106094; STREILEIN JW, 1991, TRANSPLANTATION, V52, P1, DOI 10.1097/00007890-199107000-00001; SUTHERLAND DER, 1984, TRANSPLANTATION, V38, P619, DOI 10.1097/00007890-198412000-00015; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; Wang CM, 2001, TRANSPLANTATION, V72, P44, DOI 10.1097/00007890-200107150-00011; West LJ, 2002, HUM EXP TOXICOL, V21, P499, DOI 10.1191/0960327102ht288oa; West LJ, 2002, TRANSPL IMMUNOL, V9, P149, DOI 10.1016/S0966-3274(02)00044-8; West LJ, 2001, NEW ENGL J MED, V344, P793, DOI 10.1056/NEJM200103153441102; WILSON CB, 1986, J PEDIATR-US, V108, P1, DOI 10.1016/S0022-3476(86)80761-2; Yamada K, 1997, J EXP MED, V186, P497, DOI 10.1084/jem.186.4.497	50	161	165	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2004	10	11					1227	1233		10.1038/nm1126	http://dx.doi.org/10.1038/nm1126			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	866PR	15502841				2022-12-25	WOS:000224785900045
J	Chadee, DN; Kyriakis, JM				Chadee, DN; Kyriakis, JM			MLK3 is required for mitogen activation of B-Raf, ERK and cell proliferation	NATURE CELL BIOLOGY			English	Article							GENE-EXPRESSION; PROTEIN-KINASE; CYCLIN D1; TNF-ALPHA; CANCER; BRAF; MUTATIONS	The ERK group of mitogen-activated protein kinases (MAPKs) is essential for cell proliferation stimulated by mitogens, oncogenic ras and raf (ref. 1). All MAPKs are activated by MAP3K/MEK/MAPK core pathways(1) and the Raf protooncoproteins, especially B-Raf, are ERK-specific MAP3Ks (refs 1-3). Mixed lineage kinase-3 (MLK3) is a MAP3K that was thought to be a cytokine-activated, and comparatively selective, regulator of the JNK group of MAPKs (refs 1, 4-6). Here we report that silencing of mlk3 by RNAi suppressed mitogen and cytokine activation not only of JNK but of ERK and p38 as well. Silencing mlk3 also blocked mitogen-stimulated phosphorylation of B-Raf at Thr 598 and Ser 601, a step required for B-Raf activation(7,8). Furthermore, silencing mlk3 prevented serum-stimulated cell proliferation and the proliferation of tumour cells bearing either oncogenic Ki-Ras or loss-of-function neurofibromatosis-1 (NF1) or NF2 mutations. The proliferation of tumour cells containing activating B-raf or raf-1 mutations was unaffected by silencing mlk3. Our results define an unexpected role for MLK3 in mitogen regulation of B-Raf, ERK and cell proliferation.	Tufts Univ New England Med Ctr, Dept Med, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Kyriakis, JM (corresponding author), Tufts Univ New England Med Ctr, Dept Med, Mol Cardiol Res Inst, 750 Washington St,Box 8486, Boston, MA 02111 USA.	jkyriakis@tufts-nemc.org						Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Chi JT, 2003, P NATL ACAD SCI USA, V100, P6343, DOI 10.1073/pnas.1037853100; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092-8674(01)00245-8; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 2000, FR MOLEC B, V29, P40; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lynch TM, 2002, NEUROL CLIN, V20, P841, DOI 10.1016/S0733-8619(01)00019-6; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; McClatchey AI, 2003, NAT REV CANCER, V3, P877, DOI 10.1038/nrc1213; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Sathyanarayana P, 2002, MOL CELL, V10, P1527, DOI 10.1016/S1097-2765(02)00734-7; Semizarov D, 2003, P NATL ACAD SCI USA, V100, P6347, DOI 10.1073/pnas.1131959100; Shen YH, 2003, J BIOL CHEM, V278, P26715, DOI 10.1074/jbc.M303264200; Sherr CJ, 2000, CANCER RES, V60, P3689; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Swenson KI, 2003, MOL BIOL CELL, V14, P156, DOI 10.1091/mbc.E02-02-0115; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Wojnowski L, 2000, MECH DEVELOP, V91, P97, DOI 10.1016/S0925-4773(99)00276-2; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429	30	133	137	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2004	6	8					770	776		10.1038/ncb1152	http://dx.doi.org/10.1038/ncb1152			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	842YA	15258589				2022-12-25	WOS:000223039400016
J	Idris, AI; Hof, RJV; Greig, IR; Ridge, SA; Baker, D; Ross, RA; Ralston, SH				Idris, AI; Hof, RJV; Greig, IR; Ridge, SA; Baker, D; Ross, RA; Ralston, SH			Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; MICE; INHIBITION; RESORPTION; ACTIVATION; DISEASES		Univ Aberdeen, Inst Med Sci, Aberdeen AB25 2ZD, Scotland; UCL, Inst Neurol, London WC1N 1PJ, England; Univ Edinburgh, Rheumat Dis Unit, Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland	University of Aberdeen; University of London; University College London; University of Edinburgh	Ralston, SH (corresponding author), Univ Aberdeen, Inst Med Sci, Aberdeen AB25 2ZD, Scotland.	stuart.ralston@ed.ac.uk	Idris, Aymen I/AAX-1138-2020; Ross, R./AAG-7468-2019	Idris, Aymen I/0000-0003-4327-5306; van 't Hof, Rob/0000-0002-8193-6788; Greig, Iain/0000-0003-0603-3383	NATIONAL INSTITUTE ON DRUG ABUSE [P01DA009789] Funding Source: NIH RePORTER; Multiple Sclerosis Society [541] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); Multiple Sclerosis Society(National Multiple Sclerosis Society)		Armour KE, 2001, ENDOCRINOLOGY, V142, P760, DOI 10.1210/en.142.2.760; Baldock PA, 2002, J CLIN INVEST, V109, P915, DOI 10.1172/JCI14588; Casanova ML, 2003, J CLIN INVEST, V111, P43, DOI 10.1172/JCI200316116; Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467; David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; GRIORGADIS AE, 1994, SCIENCE, V266, P443; Helfrich MH, 2003, MICROSC RES TECHNIQ, V61, P514, DOI 10.1002/jemt.10375; Hildebrandt AL, 2003, EUR J PHARMACOL, V462, P125, DOI 10.1016/S0014-2999(03)01343-8; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; Howlett AC, 1998, MOL PHARMACOL, V53, P504, DOI 10.1124/mol.53.3.504; Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050; Pertwee RG, 2002, PROSTAG LEUKOTR ESS, V66, P101, DOI 10.1054/plef.2001.0341; Pryce G, 2003, BRAIN, V126, P2191, DOI 10.1093/brain/awg224; RAVINET TC, 2003, AM J PHYSIOL-REG I, V284, pR345, DOI DOI 10.1152/AJPREGU.00545.2002; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Shearman LP, 2003, BEHAV PHARMACOL, V14, P573, DOI 10.1097/00008877-200312000-00001; Skerry TM, 2001, TRENDS PHARMACOL SCI, V22, P174, DOI 10.1016/S0165-6147(00)01642-4; Takahashi N, 2003, METH MOLEC MED, V80, P129; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; van't Hof RJ, 2004, ENDOCRINOLOGY, V145, P5068, DOI 10.1210/en.2004-0205; van't Hof RJ, 2004, J BONE MINER RES, V19, P1651, DOI 10.1359/jbmr.2004.19.10.1651	24	259	300	2	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2005	11	7					774	779		10.1038/nm1255	http://dx.doi.org/10.1038/nm1255			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	942TB	15908955	Green Accepted			2022-12-25	WOS:000230304200034
J	Reiser, J; Polu, KR; Moller, CC; Kenlan, P; Altintas, MM; Wei, CL; Faul, C; Herbert, S; Villegas, I; Avila-Casado, C; McGee, M; Sugimoto, H; Brown, D; Kalluri, R; Mundel, P; Smith, PL; Clapham, DE; Pollak, MR				Reiser, J; Polu, KR; Moller, CC; Kenlan, P; Altintas, MM; Wei, CL; Faul, C; Herbert, S; Villegas, I; Avila-Casado, C; McGee, M; Sugimoto, H; Brown, D; Kalluri, R; Mundel, P; Smith, PL; Clapham, DE; Pollak, MR			TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function	NATURE GENETICS			English	Article							PROTEIN; NEPHRIN; KIDNEY; RAT; PODOCYTES; GENE	Progressive kidney failure is a genetically and clinically heterogeneous group of disorders. Podocyte foot processes and the interposed glomerular slit diaphragm are essential components of the permeability barrier in the kidney. Mutations in genes encoding structural proteins of the podocyte lead to the development of proteinuria, resulting in progressive kidney failure and focal segmental glomerulosclerosis. Here, we show that the canonical transient receptor potential 6 ( TRPC6) ion channel is expressed in podocytes and is a component of the glomerular slit diaphragm. We identified five families with autosomal dominant focal segmental glomerulosclerosis in which disease segregated with mutations in the gene TRPC6 on chromosome 11q. Two of the TRPC6 mutants had increased current amplitudes. These data show that TRPC6 channel activity at the slit diaphragm is essential for proper regulation of podocyte structure and function.	Massachusetts Gen Hosp, Dept Med, Renal Unit, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA; Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Inst Nacl Cardiol Ignacio Chavez, Dept Pathol, Mexico City 14080, DF, Mexico; Massachusetts Gen Hosp, Program Membrane Biol, Boston, MA 02129 USA; Beth Israel Deaconess Med Ctr, Ctr Matrix Biol, Dept Med, Boston, MA 02115 USA; Childrens Hosp, Howard Hughes Med Inst, Dept Cardiol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Icahn School of Medicine at Mount Sinai; National Institute of Cardiology - Mexico; Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute	Reiser, J (corresponding author), Massachusetts Gen Hosp, Dept Med, Renal Unit, Boston, MA 02129 USA.	jreiser@partners.org; mpollak@rics.bwh.harvard.edu	Altintas, Mehmet Mete/T-5333-2018; Clapham, David/S-1123-2019; Faul, Christian/D-1549-2011; Clapham, David/R-5974-2019; Altintas, Mehmet Mete/ABI-5904-2020; Kalluri, Raghu/E-2677-2015	Altintas, Mehmet Mete/0000-0002-1871-6985; Clapham, David/0000-0002-4459-9428; Kalluri, Raghu/0000-0002-2190-547X	NHLBI NIH HHS [T32 HL007572] Funding Source: Medline; NIDDK NIH HHS [R01 DK055001, R01 DK057683, R56 DK054931, R01 DK054931] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK054931, R01DK057683, R01DK055001, R01DK054931] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bandyopadhyay BC, 2005, J BIOL CHEM, V280, P12908, DOI 10.1074/jbc.M410013200; Boute N, 2000, NAT GENET, V24, P349, DOI 10.1038/74166; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; DRENCKHAHN D, 1988, LAB INVEST, V59, P673; Facemire CS, 2004, AM J PHYSIOL-RENAL, V286, pF546, DOI 10.1152/ajprenal.00338.2003; Hamano Y, 2002, J BIOL CHEM, V277, P31154, DOI 10.1074/jbc.M204806200; Hisatsune C, 2004, J BIOL CHEM, V279, P18887, DOI 10.1074/jbc.M311274200; Huber TB, 2003, MOL CELL BIOL, V23, P4917, DOI 10.1128/MCB.23.14.4917-4928.2003; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Kim JM, 2003, SCIENCE, V300, P1298, DOI 10.1126/science.1081068; Montell Craig, 2005, Sci STKE, V2005, pre3, DOI 10.1126/stke.2722005re3; Mundel P, 1997, J CELL BIOL, V139, P193, DOI 10.1083/jcb.139.1.193; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Pavenstadt H, 2003, PHYSIOL REV, V83, P253, DOI 10.1152/physrev.00020.2002; Pavenstadt H, 2002, MICROSC RES TECHNIQ, V57, P224, DOI 10.1002/jemt.10078; Pollak MR, 2002, J AM SOC NEPHROL, V13, P3016, DOI 10.1097/01.ASN.0000039569.34360.5E; Putaala H, 2001, HUM MOL GENET, V10, P1, DOI 10.1093/hmg/10.1.1; Reiser J, 2000, J AM SOC NEPHROL, V11, P1, DOI 10.1681/ASN.V1111; Reiser J, 2004, J CLIN INVEST, V113, P1390, DOI 10.1172/JCI200420402; SCHNABEL E, 1989, EUR J CELL BIOL, V48, P313; Somlo S, 2000, NAT GENET, V24, P333, DOI 10.1038/74139; Verma R, 2003, J BIOL CHEM, V278, P20716, DOI 10.1074/jbc.M301689200; WINN MP, 2005, SCIENCE         0505, DOI DOI 10.1126/SCIENCE.1106215; Zandi-Nejad K, 2004, KIDNEY INT, V66, pS76, DOI 10.1111/j.1523-1755.2004.09220.x	26	604	663	0	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2005	37	7					739	744		10.1038/ng1592	http://dx.doi.org/10.1038/ng1592			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	941EA	15924139	Green Accepted			2022-12-25	WOS:000230196400021
J	Ching, TT; Maunakea, AK; Jun, P; Hong, CB; Zardo, G; Pinkel, D; Albertson, DG; Fridlyand, J; Mao, JH; Shchors, K; Weiss, WA; Costello, JF				Ching, TT; Maunakea, AK; Jun, P; Hong, CB; Zardo, G; Pinkel, D; Albertson, DG; Fridlyand, J; Mao, JH; Shchors, K; Weiss, WA; Costello, JF			Epigenome analyses using BAC microarrays identify evolutionary conservation of tissue-specific methylation of SHANK3	NATURE GENETICS			English	Article							DNA METHYLTRANSFERASE GENE; 22Q13 DELETION SYNDROME; CPG-ISLANDS; HUMAN GENOME; ARRAY CGH; IMMUNODEFICIENCY SYNDROME; COPY NUMBER; GERM-LINE; MOUSE; EXPRESSION	CpG islands are present in one-half of all human and mouse genes and typically overlap with promoters or exons. We developed a method for high-resolution analysis of the methylation status of CpG islands genome-wide, using arrays of BAC clones and the methylation-sensitive restriction enzyme NotI. Here we demonstrate the accuracy and specificity of the method. By computationally mapping all NotI sites, methylation events can be defined with single-nucleotide precision throughout the genome. We also demonstrate the unique expandability of the array method using a different methylation-sensitive restriction enzyme, BssHII. We identified and validated new CpG island loci that are methylated in a tissue-specific manner in normal human tissues. The methylation status of the CpG islands is associated with gene expression for several genes, including SHANK3, which encodes a structural protein in neuronal postsynaptic densities. Defects in SHANK3 seem to underlie human 22q13 deletion syndrome. Furthermore, these patterns for SHANK3 are conserved in mice and rats.	Univ Calif San Francisco, Dept Neurol Surg, Brain Tumor Res Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Biomed Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Costello, JF (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, Brain Tumor Res Ctr, San Francisco, CA 94143 USA.	jcostello@cc.ucsf.edu	Mao, Jian-Hua/EIZ-8595-2022	Mao, Jian-Hua/0000-0001-9320-6021; Ching, Tsui-Ting/0000-0001-7650-1766; Weiss, William/0000-0003-2230-9132				Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; Bonaglia MC, 2001, AM J HUM GENET, V69, P261, DOI 10.1086/321293; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; De Smet C, 1999, MOL CELL BIOL, V19, P7327; DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149; EHRLICH M, 1982, NUCLEIC ACIDS RES, V10, P2709, DOI 10.1093/nar/10.8.2709; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gartler S M, 1992, Mol Genet Med, V2, P121; Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Hershko AY, 2003, GENE, V302, P65, DOI 10.1016/S0378111902010910; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; Huang THM, 1997, CANCER RES, V57, P1030; IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI DOI 10.2307/1390807; Ishkanian AS, 2004, NAT GENET, V36, P299, DOI 10.1038/ng1307; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; Lippman Z, 2004, NATURE, V430, P471, DOI 10.1038/nature02651; Lorincz MC, 2004, NAT STRUCT MOL BIOL, V11, P1068, DOI 10.1038/nsmb840; MARASCHIO P, 1988, J MED GENET, V25, P173, DOI 10.1136/jmg.25.3.173; MCCLELLAND M, 1982, NUCLEIC ACIDS RES, V10, P7865, DOI 10.1093/nar/10.23.7865; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Phelan MC, 2001, AM J MED GENET, V101, P91, DOI 10.1002/1096-8628(20010615)101:2<91::AID-AJMG1340>3.0.CO;2-C; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Qualmann B, 2004, J NEUROSCI, V24, P2481, DOI 10.1523/JNEUROSCI.5479-03.2004; Rakyan VK, 2004, PLOS BIOL, V2, P2170, DOI 10.1371/journal.pbio.0020405; Snijders AM, 2005, GENOME RES, V15, P302, DOI 10.1101/gr.2902505; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Song F, 2005, P NATL ACAD SCI USA, V102, P3336, DOI 10.1073/pnas.0408436102; Surani MA, 1998, CELL, V93, P309, DOI 10.1016/S0092-8674(00)81156-3; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Trasler JM, 1996, DEV DYNAM, V206, P239, DOI 10.1002/(SICI)1097-0177(199607)206:3<239::AID-AJA2>3.3.CO;2-M; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; WATT JL, 1985, J MED GENET, V22, P283, DOI 10.1136/jmg.22.4.283; Wilson HL, 2003, J MED GENET, V40, P575, DOI 10.1136/jmg.40.8.575; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052	43	127	138	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2005	37	6					645	651		10.1038/ng1563	http://dx.doi.org/10.1038/ng1563			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	931OT	15895082				2022-12-25	WOS:000229495300021
J	Majander, K; Anton, L; Antikainen, J; Lang, H; Brummer, M; Korhonen, TK; Westerlund-Wikstrom, B				Majander, K; Anton, L; Antikainen, J; Lang, H; Brummer, M; Korhonen, TK; Westerlund-Wikstrom, B			Extracellular secretion of polypeptides using a modified Escherichia coli flagellar secretion apparatus	NATURE BIOTECHNOLOGY			English	Article							III SECRETION; CAMPYLOBACTER-JEJUNI; PROTEIN-SECRETION; MESSENGER-RNA; EXPORT; CHAPERONES; VIRULENCE; SEQUENCE; BINDING; IDENTIFICATION	We developed a modified flagellar type III secretion apparatus to secrete heterologous polypeptides into the growth medium of Escherichia coli. The secretion was facilitated by fusing the 173-bp untranslated DNA fragment upstream of the gene fliC (encoding flagellin) as well as a transcriptional terminator from fliC, into the gene encoding the polypeptide of interest. The polypeptides secreted into the growth medium at concentrations ranging from 1 to 15 mg/l were from Campylobacter jejuni (262 residues in length), Streptococcus pneumoniae (434 residues), Staphylococcus aureus (115 residues), and N-terminal FliC hybrid proteins, for example, the eukaryotic green fluorescent protein (238 residues). The expressed proteins represented >50% of total secreted protein. Previously reported protein yields from extracellular secretion of foreign proteins in E. coli have been low, approximately 100 mu g/l(1). The strengths of our method are the concentration and purity of the secreted proteins and its versatility with regard to the proteins' length and origin.	Univ Helsinki, Fac Biosci, FIN-00014 Helsinki, Finland; Orion Diagnost Oy, FIN-02101 Espoo, Finland	University of Helsinki	Westerlund-Wikstrom, B (corresponding author), Univ Helsinki, Fac Biosci, POB 56, FIN-00014 Helsinki, Finland.	benita.westerlund@helsinki.fi		Westerlund-Wikstrom, Benita/0000-0002-5307-3858				Aldridge P, 2002, CURR OPIN MICROBIOL, V5, P160, DOI 10.1016/S1369-5274(02)00302-8; Anderson DM, 1999, MOL MICROBIOL, V31, P1139, DOI 10.1046/j.1365-2958.1999.01254.x; Bergmann S, 2003, MOL MICROBIOL, V49, P411, DOI 10.1046/j.1365-2958.2003.03557.x; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Blocker A, 2003, P NATL ACAD SCI USA, V100, P3027, DOI 10.1073/pnas.0535335100; BLOMFIELD IC, 1991, MOL MICROBIOL, V5, P1439, DOI 10.1111/j.1365-2958.1991.tb00790.x; Chilcott GS, 2000, MICROBIOL MOL BIOL R, V64, P694, DOI 10.1128/MMBR.64.4.694-708.2000; Choi JH, 2004, APPL MICROBIOL BIOT, V64, P625, DOI 10.1007/s00253-004-1559-9; Davis SJ, 1998, PLANT MOL BIOL, V36, P521, DOI 10.1023/A:1005991617182; Deckers D, 2004, CELL MOL LIFE SCI, V61, P1229, DOI 10.1007/s00018-004-4066-3; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; Evdokimov AG, 2003, NAT STRUCT BIOL, V10, P789, DOI 10.1038/nsb982; Hirano T, 2003, J BACTERIOL, V185, P2485, DOI 10.1128/JB.185.8.2485-2492.2003; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; Ide N, 1999, GENES GENET SYST, V74, P113, DOI 10.1266/ggs.74.113; Karlinsey JE, 2000, MOL MICROBIOL, V37, P1220, DOI 10.1046/j.1365-2958.2000.02081.x; Konkel ME, 2004, J BACTERIOL, V186, P3296, DOI 10.1128/JB.186.11.3296-3303.2004; KOVACH ME, 1994, BIOTECHNIQUES, V16, P800; KUWAJIMA G, 1989, P NATL ACAD SCI USA, V86, P4953, DOI 10.1073/pnas.86.13.4953; Lee SH, 2004, MOL MICROBIOL, V51, P483, DOI 10.1046/j.1365-2958.2003.03840.x; Lloyd SA, 2001, MOL MICROBIOL, V39, P520, DOI 10.1046/j.1365-2958.2001.02271.x; Minamino T, 2004, J MOL MICROB BIOTECH, V7, P5, DOI 10.1159/000077865; MOBLEY HLT, 1993, MOL MICROBIOL, V10, P143, DOI 10.1111/j.1365-2958.1993.tb00911.x; NIKAIDO H, 1989, ANTIMICROB AGENTS CH, V33, P1831, DOI 10.1128/AAC.33.11.1831; Parsot C, 2003, CURR OPIN MICROBIOL, V6, P7, DOI 10.1016/S1369-5274(02)00002-4; PEI ZH, 1993, J BIOL CHEM, V268, P18717; Sambrook J, 2001, MOL CLONING LAB MANU; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; Stebbins CE, 2001, NATURE, V414, P77, DOI 10.1038/35102073; Thanassi DG, 2000, CURR OPIN CELL BIOL, V12, P420, DOI 10.1016/S0955-0674(00)00111-3; Thomas NA, 2003, TRENDS MICROBIOL, V11, P398, DOI 10.1016/S0966-842X(03)00155-0; Westerlund-Wikstrom B, 1997, PROTEIN ENG, V10, P1319, DOI 10.1093/protein/10.11.1319; Yonekura K, 2003, NATURE, V424, P643, DOI 10.1038/nature01830; Young GM, 1999, P NATL ACAD SCI USA, V96, P6456, DOI 10.1073/pnas.96.11.6456	34	75	88	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0733-222X	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2005	23	4					475	481		10.1038/nbt1077	http://dx.doi.org/10.1038/nbt1077			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	914AR	15806100				2022-12-25	WOS:000228197300032
J	Coombes, KR; Morris, JRS; Hu, JH; Edmonson, SR; Baggerly, KA				Coombes, KR; Morris, JRS; Hu, JH; Edmonson, SR; Baggerly, KA			Serum proteomics profiling - a young technology begins to mature	NATURE BIOTECHNOLOGY			English	Editorial Material							ENHANCED LASER-DESORPTION; FLIGHT MASS-SPECTROMETRY; OVARIAN-CANCER; BIOMARKER DISCOVERY; PATTERNS; TIME; RESOLUTION; IDENTIFICATION; PROTEINS; HEAD		Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Sect Bioinformat, Houston, TX 77030 USA; Baylor Coll Med, Dept Family & Community Med, Houston, TX 77098 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Coombes, KR (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Sect Bioinformat, 1515 Holcombe Blvd,Box 447, Houston, TX 77030 USA.	kcoombes@mail.mdanderson.org		Coombes, Kevin/0000-0002-7630-2123	NATIONAL CANCER INSTITUTE [R01CA107304] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA107304-01, R01 CA107304, R01 CA107304-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baggerly KA, 2004, ENDOCR-RELAT CANCER, V11, P583, DOI 10.1677/erc.1.00868; Baggerly KA, 2004, BIOINFORMATICS, V20, P777, DOI 10.1093/bioinformatics/btg484; BAGGERLY KA, 2005, IN PRESS J NATL CANC, V97; Conrads TP, 2004, ENDOCR-RELAT CANCER, V11, P163, DOI 10.1677/erc.0.0110163; Coombes KR, 2003, CLIN CHEM, V49, P1615, DOI 10.1373/49.10.1615; COOMBES KR, 2005, IN PRESS PROTEOMICS; COOMBES KR, IN PRESS CANC INFORA; Diamandis EP, 2004, EXPERT REV MOL DIAGN, V4, P575, DOI 10.1586/14737159.4.5.575; Diamandis EP, 2004, MOL CELL PROTEOMICS, V3, P367, DOI 10.1074/mcp.R400007-MCP200; Fung ET, 2002, BIOTECHNIQUES, P34; Grizzle WE, 2003, DIS MARKERS, V19, P185, DOI 10.1155/2004/546293; Hu Jianhua, 2005, Briefings in Functional Genomics & Proteomics, V3, P322, DOI 10.1093/bfgp/3.4.322; Johnson KL, 2004, ANAL CHEM, V76, P5097, DOI 10.1021/ac0497003; Koomen JM, 2004, RAPID COMMUN MASS SP, V18, P2537, DOI 10.1002/rcm.1657; Lin ZS, 2004, MODERN PATHOL, V17, P670, DOI 10.1038/modpathol.3800100; Malyarenko DI, 2005, CLIN CHEM, V51, P65, DOI 10.1373/clinchem.2004.037283; MORRIS JS, 2005, BIOINFORMATICS  0126; Petricoin EF, 2002, J NATL CANCER I, V94, P1576; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; Pusztai L, 2004, CANCER, V100, P1814, DOI 10.1002/cncr.20203; Qu YS, 2003, BIOMETRICS, V59, P143, DOI 10.1111/1541-0420.00017; Ransohoff DF, 2004, NAT REV CANCER, V4, P309, DOI 10.1038/nrc1322; Rogers MA, 2003, CANCER RES, V63, P6971; SAUVE AC, 2005, IN PRESS P GENSIPS 2; Semmes OJ, 2005, CLIN CHEM, V51, P102, DOI 10.1373/clinchem.2004.038950; Soltys SG, 2004, CLIN CANCER RES, V10, P4806, DOI 10.1158/1078-0432.CCR-03-0469; Sorace JM, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-24; Villanueva J, 2004, ANAL CHEM, V76, P1560, DOI 10.1021/ac0352171; Vlahou A, 2004, CLIN CHEM, V50, P1438, DOI 10.1373/clinchem.2003.028035; Wadsworth JT, 2004, CLIN CANCER RES, V10, P1625, DOI 10.1158/1078-0432.CCR-0297-3; Yasui Y, 2003, BIOSTATISTICS, V4, P449, DOI 10.1093/biostatistics/4.3.449; Yasui Y, 2003, J BIOMED BIOTECHNOL, P242, DOI 10.1155/S111072430320927X; Zhang Z, 2004, CANCER RES, V64, P5882, DOI 10.1158/0008-5472.CAN-04-0746; Zhen XA, 2004, CANCER RES, V64, P2904, DOI 10.1158/0008-5472.CAN-03-3754	34	133	142	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2005	23	3					291	292		10.1038/nbt0305-291	http://dx.doi.org/10.1038/nbt0305-291			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	906IW	15765078				2022-12-25	WOS:000227635400011
J	Petzelbauer, P; Zacharowski, PA; Miyazaki, Y; Friedl, P; Wickenhauser, G; Castellino, FJ; Groger, M; Wolff, K; Zacharowski, K				Petzelbauer, P; Zacharowski, PA; Miyazaki, Y; Friedl, P; Wickenhauser, G; Castellino, FJ; Groger, M; Wolff, K; Zacharowski, K			The fibrin-derived peptide B beta(15-42) protects the myocardium against ischemia-reperfusion injury	NATURE MEDICINE			English	Article							ENDOTHELIAL-CELLS; DEFICIENT MICE; BINDING-SITE; BETA-CHAIN; IN-VITRO; LEUKOCYTE TRANSMIGRATION; PROTOFIBRIL FORMATION; PLATELET-AGGREGATION; PULMONARY-FIBROSIS; INFARCT SIZE	In the event of a myocardial infarction, current interventions aim to reopen the occluded vessel to reduce myocardial damage and injury. Although reperfusion is essential for tissue salvage, it can cause further damage and the onset of inflammation. We show a novel anti-inflammatory effect of a fibrin-derived peptide, B beta(15-42). This peptide competes with the fibrin fragment N-terminal disulfide knot-II (an analog of the fibrin E1 fragment) for binding to vascular endothelial (VE)-cadherin, thereby preventing transmigration of leukocytes across endothelial cell monolayers. In acute or chronic rat models of myocardial ischemia-reperfusion injury, B beta(15-42) substantially reduces leukocyte infiltration, infarct size and subsequent scar formation. The pathogenic role of fibrinogen products is further confirmed in fibrinogen knockout mice, in which infarct size was substantially smaller than in wild-type animals. Our findings conclude that the interplay of fibrin fragments, leukocytes and VE-cadherin contribute to the pathogenesis of myocardial damage and reperfusion injury. The naturally occurring peptide B beta(15-42) represents a potential candidate for reperfusion therapy in humans.	Univ Hosp Dusseldorf, Dept Anesthesia, Mol Cardioprotect & Inflammat Grp, D-40225 Dusseldorf, Germany; Med Univ Vienna, Dept Gen Dermatol, A-1090 Vienna, Austria; Med Univ Vienna, Ludwig Boltzmann Inst Angiogenesis Microcirculat, A-1090 Vienna, Austria; Univ Notre Dame, WM Keck Ctr Transgene Res, Notre Dame, IN 46556 USA	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; Medical University of Vienna; Ludwig Boltzmann Institute; Medical University of Vienna; University of Notre Dame	Zacharowski, K (corresponding author), Univ Hosp Dusseldorf, Dept Anesthesia, Mol Cardioprotect & Inflammat Grp, Moorenstr 5, D-40225 Dusseldorf, Germany.	kai.zacharowski@uni-duesseldorf.de	petzelbauer, peter/GLU-3941-2022	Petzelbauer, Peter/0000-0001-7080-5259				ALTIERI DC, 1995, J BIOL CHEM, V270, P696, DOI 10.1074/jbc.270.2.696; ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; Bach TL, 1998, J BIOL CHEM, V273, P30719, DOI 10.1074/jbc.273.46.30719; CHALUPOWICZ DG, 1995, J CELL BIOL, V130, P207, DOI 10.1083/jcb.130.1.207; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Dempfle CE, 2000, BLOOD, V96, P2793; Drew AF, 2001, BLOOD, V97, P3691, DOI 10.1182/blood.V97.12.3691; Drew AF, 2001, AM J PHYSIOL-RENAL, V281, pF1157, DOI 10.1152/ajprenal.0002.2001; Erlich JH, 2000, AM J PATHOL, V157, P1849, DOI 10.1016/S0002-9440(10)64824-9; Everse SJ, 1998, BIOCHEMISTRY-US, V37, P8637, DOI 10.1021/bi9804129; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FERRANS VJ, 1975, ANN THORAC SURG, V20, P11, DOI 10.1016/S0003-4975(10)63845-3; Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5; FURLAN M, 1982, THROMB HAEMOSTASIS, V47, P118; Gorlatov S, 2002, BIOCHEMISTRY-US, V41, P4107, DOI 10.1021/bi0160314; Groger M, 1999, J IMMUNOL METHODS, V222, P101, DOI 10.1016/S0022-1759(98)00187-2; Halama T, 2001, J INVEST DERMATOL, V116, P110, DOI 10.1046/j.1523-1747.2001.00176.x; HAMAGUCHI M, 1993, BLOOD, V81, P2348; HARENBERG J, 1985, FIBRINOGEN STRUCTURE, P271; Harley SL, 2000, ARTERIOSCL THROM VAS, V20, P652, DOI 10.1161/01.ATV.20.3.652; Hsieh KH, 1997, BIOCHEMISTRY-US, V36, P9381, DOI 10.1021/bi962741b; Hsieh KH, 1997, THROMB RES, V86, P301, DOI 10.1016/S0049-3848(97)00073-X; Kakkar AK, 2004, CURR OPIN PHARMACOL, V4, P154, DOI 10.1016/j.coph.2004.01.003; Koenig W, 2001, ARTERIOSCL THROM VAS, V21, P1701, DOI 10.1161/hq1001.097020; Kostelansky MS, 2002, BIOCHEMISTRY-US, V41, P12124, DOI 10.1021/bi0261894; KUDRYK B, 1982, THROMB RES, V25, P277, DOI 10.1016/0049-3848(82)90247-X; Latta RV, 2003, ARCH ORAL BIOL, V48, P263, DOI 10.1016/S0003-9969(02)0005-0; LOIKE JD, 1991, P NATL ACAD SCI USA, V88, P1044, DOI 10.1073/pnas.88.3.1044; Lounes KC, 2002, BIOCHEMISTRY-US, V41, P5291, DOI 10.1021/bi011988s; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; OLEXA SA, 1981, BIOCHEMISTRY-US, V20, P6139, DOI 10.1021/bi00524a035; Palumbo JS, 2002, CANCER RES, V62, P6966; PETZELBAUER P, 1995, CYTOKINE, V7, P267, DOI 10.1006/cyto.1995.0031; Ploplis VA, 2000, AM J PATHOL, V157, P703, DOI 10.1016/S0002-9440(10)64582-8; Qi JF, 1997, BLOOD, V90, P3595, DOI 10.1182/blood.V90.9.3595; RIBES JA, 1989, J CLIN INVEST, V84, P435, DOI 10.1172/JCI114184; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Schoots IG, 2003, SURGERY, V133, P411, DOI 10.1067/msy.2003.104; Shaw SK, 2001, J IMMUNOL, V167, P2323, DOI 10.4049/jimmunol.167.4.2323; Sherman DG, 2000, JAMA-J AM MED ASSOC, V283, P2395, DOI 10.1001/jama.283.18.2395; SIMPSON PJ, 1991, J PHARMACOL EXP THER, V256, P780; Unger RE, 2002, MICROVASC RES, V64, P384, DOI 10.1006/mvre.2002.2434; VALI Z, 1988, BIOCHEMISTRY-US, V27, P1956, DOI 10.1021/bi00406a023; Weber C, 2003, J MOL MED, V81, P4, DOI 10.1007/s00109-002-0391-x; WEISEL JW, 1993, J MOL BIOL, V232, P285, DOI 10.1006/jmbi.1993.1382; Wilberding JA, 2001, ANN NY ACAD SCI, V936, P542; Yokoyama K, 1999, BIOCHEMISTRY-US, V38, P5872, DOI 10.1021/bi9827619; Zacharowski K, 1999, ARTERIOSCL THROM VAS, V19, P2141, DOI 10.1161/01.ATV.19.9.2141	48	165	175	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					298	304		10.1038/nm1198	http://dx.doi.org/10.1038/nm1198			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15723073				2022-12-25	WOS:000227541300025
J	Sorensen, CS; Hansen, LT; Dziegielewski, J; Syljuasen, RG; Lundin, C; Bartek, J; Helleday, T				Sorensen, CS; Hansen, LT; Dziegielewski, J; Syljuasen, RG; Lundin, C; Bartek, J; Helleday, T			The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair	NATURE CELL BIOLOGY			English	Article							DOUBLE-STRAND BREAKS; S-PHASE CHECKPOINT; EARLY EMBRYONIC LETHALITY; DNA-DAMAGE CHECKPOINT; RADIOSENSITIZING AGENT; TARGETED DISRUPTION; REPLICATION ARREST; IONIZING-RADIATION; ATR; GENE	The essential checkpoint kinase Chk1 is required for cell-cycle delays after DNA damage or blocked DNA replication(1,2). However, it is unclear whether Chk1 is involved in the repair of damaged DNA. Here we establish that Chk1 is a key regulator of genome maintenance by the homologous recombination repair (HRR) system. Abrogation of Chk1 function with small interfering RNA or chemical antagonists inhibits HRR, leading to persistent unrepaired DNA double-strand breaks (DSBs) and cell death after replication inhibition with hydroxyurea or DNA-damage caused by camptothecin. After hydroxyurea treatment, the essential recombination repair protein RAD51 is recruited to DNA repair foci performing a vital role in correct HRR3,4. We demonstrate that Chk1 interacts with RAD51, and that RAD51 is phosphorylated on Thr 309 in a Chk1-dependent manner. Consistent with a functional interplay between Chk1 and RAD51, Chk1-depleted cells failed to form RAD51 nuclear foci after exposure to hydroxyurea, and cells expressing a phosphorylation-deficient mutant RAD51(T309A) were hypersensitive to hydroxyurea. These results highlight a crucial role for the Chk1 signalling pathway in protecting cells against lethal DNA lesions through regulation of HRR.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Inst Mol Pathol, DK-2100 Copenhagen, Denmark; Univ Sheffield, Inst Canc Studies, Sheffield S10 2RX, S Yorkshire, England; Stockholm Univ, Dept Genet Microbiol & Toxicol, S-10691 Stockholm, Sweden	Danish Cancer Society; University of Copenhagen; University of Sheffield; Stockholm University	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark.	jb@cancer.dk; t.helleday@sheffield.ac.uk	Helleday, Thomas/D-5224-2013; Bartek, Jiri/G-5870-2014	Sorensen, Claus/0000-0001-6022-9710; Helleday, Thomas/0000-0002-7384-092X				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Arnaudeau C, 2001, J MOL BIOL, V307, P1235, DOI 10.1006/jmbi.2001.4564; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Brown EJ, 2000, GENE DEV, V14, P397; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Busby EC, 2000, CANCER RES, V60, P2108; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Deans B, 2000, EMBO J, V19, P6675, DOI 10.1093/emboj/19.24.6675; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; Liu QH, 2000, GENE DEV, V14, P1448; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Lundin C, 2002, MOL CELL BIOL, V22, P5869, DOI 10.1128/MCB.22.16.5869-5878.2002; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; Mohindra A, 2002, HUM MOL GENET, V11, P2189, DOI 10.1093/hmg/11.18.2189; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Saleh-Gohari N, 2004, NUCLEIC ACIDS RES, V32, P3683, DOI 10.1093/nar/gkh703; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sigurdsson S, 2001, GENE DEV, V15, P3308, DOI 10.1101/gad.935501; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Takai H, 2000, GENE DEV, V14, P1439; TEBBS RS, 1995, P NATL ACAD SCI USA, V92, P6354, DOI 10.1073/pnas.92.14.6354; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	32	499	519	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2005	7	2					195	U121		10.1038/ncb1212	http://dx.doi.org/10.1038/ncb1212			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	893LC	15665856				2022-12-25	WOS:000226719500017
J	Giarratana, MC; Kobari, L; Lapillonne, H; Chalmers, D; Kiger, L; Cynober, T; Marden, MC; Wajcman, H; Douay, L				Giarratana, MC; Kobari, L; Lapillonne, H; Chalmers, D; Kiger, L; Cynober, T; Marden, MC; Wajcman, H; Douay, L			Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells	NATURE BIOTECHNOLOGY			English	Article							HUMAN ERYTHROID-CELLS; IN-VITRO; PROGENITOR CELLS; LIQUID CULTURE; C-KIT; DIFFERENTIATION; MARROW; PROLIFERATION; MATURATION; PROTEIN	We describe here the large-scale ex vivo production of mature human red blood cells (RBCs) from hematopoietic stem cells of diverse origins. By mimicking the marrow microenvironment through the application of cytokines and coculture on stromal cells, we coupled substantial amplification of CD34(+) stem cells (up to 1.95 x 10(6)-fold) with 100% terminal differentiation into fully mature, functional RBCs. These cells survived in nonobese diabetic/severe combined immunodeficient mice, as do native RBCs. Our system for producing 'cultured RBCs' lends itself to a fundamental analysis of erythropoiesis and provides a simple in vitro model for studying important human viral or parasitic infections that target erythroid cells. Further development of large-scale production of cultured RBCs will have implications for gene therapy, blood transfusion and tropical medicine.	Univ Paris 06, CHU Saint Antoine, Lab Hematol EA1638, F-75571 Paris 12, France; Hop Armand Trousseau, Assistance Publ Hop Paris, Serv Hematol Biol, F-75571 Paris 12, France; EFS Bourgogne Franche Comte, F-25290 Besancon, France; INSERM, U473, F-94276 Le Kremlin Bicetre, France; Ctr Hosp Bicetre, Hematol Lab, F-94276 Le Kremlin Bicetre, France; Hop Henri Mondor, INSERM, U468, F-94010 Creteil, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Douay, L (corresponding author), Univ Paris 06, CHU Saint Antoine, Lab Hematol EA1638, 27 Rue Chaligny, F-75571 Paris 12, France.	luc.douay@trs.aphp.fr	Marden, Michael C/G-3139-2012; Marden, Michael/AAA-5923-2020; Kiger, Laurent/Q-1686-2018	Marden, Michael C/0000-0002-5254-6385; 				BESSIS M, 1958, Rev Hematol, V13, P8; BEUTLER E, 1977, BRIT J HAEMATOL, V35, P331, DOI 10.1111/j.1365-2141.1977.tb00589.x; Bianchi G, 2003, EXP CELL RES, V287, P98, DOI 10.1016/S0014-4827(03)00138-1; Brott DA, 2003, CYTOM PART A, V53A, P22, DOI 10.1002/cyto.a.10034; Carlile GW, 2004, BLOOD, V103, P4310, DOI 10.1182/blood-2003-09-3362; Carotta S, 2004, BLOOD, V104, P1873, DOI 10.1182/blood-2004-02-0570; Cynober T, 1996, J LAB CLIN MED, V128, P259, DOI 10.1016/S0022-2143(96)90027-X; Douay L, 2001, J HEMATOTH STEM CELL, V10, P341, DOI 10.1089/152581601750288948; FIBACH E, 1989, BLOOD, V73, P100; Freyssinier JM, 1999, BRIT J HAEMATOL, V106, P912; FRIEDENSTEIN AJ, 1974, EXP HEMATOL, V2, P83; Giarratana MC, 2000, EXP HEMATOL, V28, P46, DOI 10.1016/S0301-472X(99)00131-9; Giarratana MC, 1998, BONE MARROW TRANSPL, V22, P707, DOI 10.1038/sj.bmt.1701399; GREGORY CJ, 1978, BLOOD, V51, P527; HANSPAL M, 1994, BLOOD, V84, P3494; Hanspal M, 1998, BLOOD, V92, P2940, DOI 10.1182/blood.V92.8.2940.420k31_2940_2950; JANSEN G, 1985, AM J HEMATOL, V20, P203, DOI 10.1002/ajh.2830200302; KISTER J, 1987, BIOPHYS J, V52, P527, DOI 10.1016/S0006-3495(87)83242-3; Kobari L, 2000, EXP HEMATOL, V28, P1470, DOI 10.1016/S0301-472X(00)00557-9; Koller MR, 1998, BONE MARROW TRANSPL, V21, P653, DOI 10.1038/sj.bmt.1701157; Koller MR, 1999, EXP HEMATOL, V27, P734, DOI 10.1016/S0301-472X(98)00080-0; Lemischka IR, 1997, STEM CELLS, V15, P63, DOI 10.1002/stem.5530150810; LICHTMAN MA, 1981, EXP HEMATOL, V9, P391; Loeuillet C, 2001, CELL GROWTH DIFFER, V12, P233; Loeuillet C, 2001, EXP HEMATOL, V29, P736, DOI 10.1016/S0301-472X(01)00644-0; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; Lyons BL, 2003, EXP HEMATOL, V31, P234, DOI 10.1016/S0301-472X(02)01031-7; Malik P, 1998, BLOOD, V91, P2664, DOI 10.1182/blood.V91.8.2664.2664_2664_2671; MARDEN MC, 1988, BIOCHEMISTRY-US, V27, P1659, DOI 10.1021/bi00405a041; Mendonca RZ, 2002, J BIOTECHNOL, V97, P13, DOI 10.1016/S0168-1656(02)00048-2; METCALF D, 1993, BLOOD, V82, P3515; Migliaccio G, 2002, BLOOD CELL MOL DIS, V28, P169, DOI 10.1006/bcmd.2002.0502; Miller AD, 1996, J VIROL, V70, P5564, DOI 10.1128/JVI.70.8.5564-5571.1996; MOORE JM, 1995, J EXP MED, V181, P2265, DOI 10.1084/jem.181.6.2265; Morita E, 2003, J VIROL, V77, P2915, DOI 10.1128/JVI.77.5.2915-2921.2003; Neildez-Nguyen TMA, 2002, NAT BIOTECHNOL, V20, P467, DOI 10.1038/nbt0502-467; OGAWA M, 1993, BLOOD, V81, P2844; Ohneda O, 1997, BRIT J HAEMATOL, V98, P798, DOI 10.1046/j.1365-2141.1997.3163133.x; Panzenbock B, 1998, BLOOD, V92, P3658, DOI 10.1182/blood.V92.10.3658.422k18_3658_3668; Papassotiriou I, 1998, HEMOGLOBIN, V22, P469, DOI 10.3109/03630269809071544; PIC P, 1994, ANN BIOL CLIN-PARIS, V52, P129; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; QIU LB, 1995, BLOOD, V85, P1630, DOI 10.1182/blood.V85.6.1630.bloodjournal8561630; Sui XW, 1996, J EXP MED, V183, P837, DOI 10.1084/jem.183.3.837; SUZUKI J, 1992, LEUKEMIA, V6, P452; TERSTAPPEN LW, 1991, BLOOD CELLS, V17, P603; TERSTAPPEN LWMM, 1991, BLOOD CELLS, V17, P585; VERFAILLIE CM, 1993, BLOOD, V82, P2045; von Lindern M, 1999, BLOOD, V94, P550, DOI 10.1182/blood.V94.2.550.414k39_550_559; WADA H, 1990, BLOOD, V75, P505, DOI 10.1182/blood.V75.2.505.505; Yanai Nobuaki, 1997, Leukemia (Basingstoke), V11, P484	51	416	464	0	58	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2005	23	1					69	74		10.1038/nbt1047	http://dx.doi.org/10.1038/nbt1047			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	885ZK	15619619				2022-12-25	WOS:000226195700031
J	Sweet-Cordero, A; Mukherjee, S; Subramanian, A; You, H; Roix, JJ; Ladd-Acosta, C; Mesirov, J; Golub, TR; Jacks, T				Sweet-Cordero, A; Mukherjee, S; Subramanian, A; You, H; Roix, JJ; Ladd-Acosta, C; Mesirov, J; Golub, TR; Jacks, T			An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis	NATURE GENETICS			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; GROWTH-FACTOR; LUNG ADENOCARCINOMA; BREAST-CANCER; RAS; CLASSIFICATION; MUTATIONS; PATTERNS; PROTEIN; TUMORS	Using advanced gene targeting methods, generating mouse models of cancer that accurately reproduce the genetic alterations present in human tumors is now relatively straightforward. The challenge is to determine to what extent such models faithfully mimic human disease with respect to the underlying molecular mechanisms that accompany tumor progression. Here we describe a method for comparing mouse models of cancer with human tumors using gene-expression profiling. We applied this method to the analysis of a model of Kras2-mediated lung cancer and found a good relationship to human lung adenocarcinoma, thereby validating the model. Furthermore, we found that whereas a gene-expression signature of KRAS2 activation was not identifiable when analyzing human tumors with known KRAS2 mutation status alone, integrating mouse and human data uncovered a gene-expression signature of KRAS2 mutation in human lung cancer. We confirmed the importance of this signature by gene-expression analysis of short hairpin RNA-mediated inhibition of oncogenic Kras2. These experiments identified both a pattern of gene expression indicative of KRAS2 mutation and potential effectors of oncogenic KRAS2 activity in human cancer. This approach provides a strategy for using genomic analysis of animal models to probe human disease.	MIT, Ctr Canc Res, Cambridge, MA 02139 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; MIT, Eli & Edyth L Broad Inst, Cambridge, MA 02141 USA; Harvard Univ, Eli & Edyth L Broad Inst, Cambridge, MA 02141 USA	Massachusetts Institute of Technology (MIT); Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Jacks, T (corresponding author), MIT, Ctr Canc Res, Bldg E17-517,40 Ames St, Cambridge, MA 02139 USA.	tjacks@mit.edu	Mesirov, Jill/AGF-7626-2022	Mukherjee, Sayan/0000-0002-6715-3920				Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bonner AE, 2004, ONCOGENE, V23, P1166, DOI 10.1038/sj.onc.1207234; Camps M, 1998, FEBS LETT, V425, P271, DOI 10.1016/S0014-5793(98)00250-6; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Desai KV, 2002, P NATL ACAD SCI USA, V99, P6967, DOI 10.1073/pnas.102172399; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Huang E, 2003, NAT GENET, V34, P226, DOI 10.1038/ng1167; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kawakami Y, 2003, NAT CELL BIOL, V5, P513, DOI 10.1038/ncb989; KLIMSTRA DS, 1994, AM J PATHOL, V145, P1547; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Lo RS, 2001, EMBO J, V20, P128, DOI 10.1093/emboj/20.1.128; MANTEL N, 1967, CANCER RES, V27, P209; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Naoki K, 2002, CANCER RES, V62, P7001; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Repasky GA, 2004, TRENDS CELL BIOL, V14, P639, DOI 10.1016/j.tcb.2004.09.014; Ross ME, 2003, BLOOD, V102, P2951, DOI 10.1182/blood-2003-01-0338; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Tchernitsa OI, 2004, ONCOGENE, V23, P4536, DOI 10.1038/sj.onc.1207585; Toyoshima Y, 2004, J BIOL CHEM, V279, P25898, DOI 10.1074/jbc.M400661200; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; van 't Veer LJ, 2003, BREAST CANCER RES, V5, P57, DOI 10.1186/bcr562; Vapnik Y. N., 1998, STAT LEARNING THEORY; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	36	330	346	1	12	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2005	37	1					48	55		10.1038/ng1490	http://dx.doi.org/10.1038/ng1490			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	883FX	15608639				2022-12-25	WOS:000225997500020
J	Ptasznik, A; Nakata, Y; Kalota, A; Emerson, SG; Gewirtz, AM				Ptasznik, A; Nakata, Y; Kalota, A; Emerson, SG; Gewirtz, AM			Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells	NATURE MEDICINE			English	Article							ACTIVATION; BIOLOGY	We studied the effects of Lyn ablation on the survival of drug-resistant chronic myelogenous leukemia (CML) blast crisis cells using siRNA. Lyn siRNA reduced Lyn protein in both normal hematopoietic cells and BCR-ABL1-expressing (BCR-ABL1(+)) blasts by 80-95%. Within 48 h, siRNA-treated BCR-ABL1(+) blasts underwent apoptosis, whereas normal cells remained viable. This increased dependence on Lyn signaling for BCR-ABL1(+) blast survival provides the basis for rational treatment of drug-resistant CML blast crisis, particularly when lymphoid in nature.	Univ Penn, Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Ptasznik, A (corresponding author), Univ Penn, Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA.	andrzejp@mail.med.upenn.edu; gewirtz@mail.med.upenn.edu			NCI NIH HHS [1R01CA101859-01, R01CA90833] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090833, R01CA101859] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Calabretta B, 2004, BLOOD, V103, P4010, DOI 10.1182/blood-2003-12-4111; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; Dorsett Y, 2004, NAT REV DRUG DISCOV, V3, P318, DOI 10.1038/nrd1345; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Goldman JM, 2003, NEW ENGL J MED, V349, P1451, DOI 10.1056/NEJMra020777; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Luger SM, 2002, BLOOD, V99, P1150, DOI 10.1182/blood.V99.4.1150; NOWELL PC, 1960, SCIENCE, V132, P1497; Opalinska JB, 2002, NAT REV DRUG DISCOV, V1, P503, DOI 10.1038/nrd837; Ptasznik A, 2002, J EXP MED, V196, P667, DOI 10.1084/jem.20020519; Tatton L, 2003, J BIOL CHEM, V278, P4847, DOI 10.1074/jbc.M209321200	15	186	204	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2004	10	11					1187	1189		10.1038/nm1127	http://dx.doi.org/10.1038/nm1127			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	866PR	15502840				2022-12-25	WOS:000224785900038
J	Osborne, CS; Chakalova, L; Brown, KE; Carter, D; Horton, A; Debrand, E; Goyenechea, B; Mitchell, JA; Lopes, S; Reik, W; Fraser, P				Osborne, CS; Chakalova, L; Brown, KE; Carter, D; Horton, A; Debrand, E; Goyenechea, B; Mitchell, JA; Lopes, S; Reik, W; Fraser, P			Active genes dynamically colocalize to shared sites of ongoing transcription	NATURE GENETICS			English	Article							BETA-GLOBIN LOCUS; RNA-POLYMERASE-II; CHROMOSOME TERRITORIES; IN-VIVO; CENTROMERIC HETEROCHROMATIN; INTERGENIC TRANSCRIPTION; INTERPHASE NUCLEI; EXPRESSED GENES; CHROMATIN; CELLS	The intranuclear position of many genes has been correlated with their activity state, suggesting that migration to functional subcompartments may influence gene expression. Indeed, nascent RNA production and RNA polymerase II seem to be localized into discrete foci or '`transcription factories'. Current estimates from cultured cells indicate that multiple genes could occupy the same factory, although this has not yet been observed. Here we show that, during transcription in vivo, distal genes colocalize to the same transcription factory at high frequencies. Active genes are dynamically organized into shared nuclear subcompartments, and movement into or out of these factories results in activation or abatement of transcription. Thus, rather than recruiting and assembling transcription complexes, active genes migrate to preassembled transcription sites.	Babraham Inst, Lab Chromatin & Gene Express, Cambridge CB2 4AT, England; Imperial Coll Fac Med, Chromosome Biol Grp, London W12 0NN, England; Babraham Inst, Lab Dev Genet & Imprinting, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Imperial College London; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Fraser, P (corresponding author), Babraham Inst, Lab Chromatin & Gene Express, Babraham Res Campus, Cambridge CB2 4AT, England.	peter.fraser@bbsrc.ac.uk	Osborne, Cameron/N-1398-2017; Fraser, Peter/B-7549-2009; Reik, Wolf/I-6794-2012; Chakalova, Lyubomira/C-6810-2012	Osborne, Cameron/0000-0003-4126-2499; Mitchell, Jennifer/0000-0002-7147-4604; Fraser, Peter/0000-0002-0041-1227; Reik, Wolf/0000-0003-0216-9881	Medical Research Council [MC_U120081295] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bolland DJ, 2004, NAT IMMUNOL, V5, P630, DOI 10.1038/ni1068; Brown KE, 1999, MOL CELL, V3, P207, DOI 10.1016/S1097-2765(00)80311-1; Brown KE, 2001, NAT CELL BIOL, V3, P602, DOI 10.1038/35078577; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Caron H, 2001, SCIENCE, V291, P1289, DOI 10.1126/science.1056794; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; Chakalova L, 2004, METHOD ENZYMOL, V375, P479; Chambeyron S, 2004, GENE DEV, V18, P1119, DOI 10.1101/gad.292104; Chubb JR, 2002, CURR BIOL, V12, P439, DOI 10.1016/S0960-9822(02)00695-4; Cook PR, 2002, NAT GENET, V32, P347, DOI 10.1038/ng1102-347; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; DICKERMAN HW, 1976, ARCH BIOCHEM BIOPHYS, V177, P1, DOI 10.1016/0003-9861(76)90408-2; Femino A, 1998, SCIENCE, V280, P585, DOI 10.1126/science.280.5363.585; Francastel C, 1999, CELL, V99, P259, DOI 10.1016/S0092-8674(00)81657-8; Gerlich D, 2003, CELL, V112, P751, DOI 10.1016/S0092-8674(03)00189-2; Grande MA, 1997, J CELL SCI, V110, P1781; Gribnau J, 2000, MOL CELL, V5, P377, DOI 10.1016/S1097-2765(00)80432-3; Heun P, 2001, SCIENCE, V294, P2181, DOI 10.1126/science.1065366; HUNT JA, 1974, BIOCHEM J, V138, P499, DOI 10.1042/bj1380499; Iborra FJ, 1996, J CELL SCI, V109, P1427; Jackson DA, 1998, MOL BIOL CELL, V9, P1523, DOI 10.1091/mbc.9.6.1523; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; Kihm AJ, 2002, NATURE, V417, P758, DOI 10.1038/nature00803; Kimura H, 2002, J CELL BIOL, V159, P777, DOI 10.1083/jcb.200206019; Levsky JM, 2002, SCIENCE, V297, P836, DOI 10.1126/science.1072241; Lukasova E, 1997, HUM GENET, V100, P525, DOI 10.1007/s004390050547; Mahy NL, 2002, J CELL BIOL, V159, P753, DOI 10.1083/jcb.200207115; Mahy NL, 2002, J CELL BIOL, V157, P579, DOI 10.1083/jcb.200111071; Milot E, 1996, CELL, V87, P105, DOI 10.1016/S0092-8674(00)81327-6; Misteli T, 2001, J CELL BIOL, V155, P181, DOI 10.1083/jcb.200108110; Neves H, 1999, BLOOD, V93, P1197, DOI 10.1182/blood.V93.4.1197.404k33_1197_1207; OSHEIM YN, 1985, CELL, V43, P143, DOI 10.1016/0092-8674(85)90019-4; Parada LA, 2002, CURR BIOL, V12, P1692, DOI 10.1016/S0960-9822(02)01166-1; Ragoczy T, 2003, CHROMOSOME RES, V11, P513, DOI 10.1023/A:1024939130361; Roix JJ, 2003, NAT GENET, V34, P287, DOI 10.1038/ng1177; ROSS IL, 1994, IMMUNOL CELL BIOL, V72, P177, DOI 10.1038/icb.1994.26; Schubeler D, 2000, GENE DEV, V14, P940; Shopland LS, 2003, J CELL BIOL, V162, P981, DOI 10.1083/jcb.200303131; Solovei I, 2002, EXP CELL RES, V276, P10, DOI 10.1006/excr.2002.5513; Sutherland HGE, 1997, MOL CELL BIOL, V17, P1607, DOI 10.1128/MCB.17.3.1607; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; Trimborn T, 1999, GENE DEV, V13, P112, DOI 10.1101/gad.13.1.112; Vazquez J, 2001, CURR BIOL, V11, P1227, DOI 10.1016/S0960-9822(01)00390-6; Verschure PJ, 1999, J CELL BIOL, V147, P13, DOI 10.1083/jcb.147.1.13; Versteeg R, 2003, GENOME RES, V13, P1998, DOI 10.1101/gr.1649303; Volpi EV, 2000, J CELL SCI, V113, P1565; Walter J, 2003, J CELL BIOL, V160, P685, DOI 10.1083/jcb.200211103; Wang J, 2004, J CELL BIOL, V164, P515, DOI 10.1083/jcb.200305142; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499	50	782	815	0	42	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2004	36	10					1065	1071		10.1038/ng1423	http://dx.doi.org/10.1038/ng1423			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	857YN	15361872	Bronze			2022-12-25	WOS:000224156500014
J	Palsson, B				Palsson, B			Two-dimensional annotation of genomes	NATURE BIOTECHNOLOGY			English	Editorial Material							IN-SILICO MODELS; METABOLIC NETWORKS; MATHEMATICAL-MODEL; RECONSTRUCTION; BIOLOGY		Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; Genomatica Inc, Sci Advisory Board, San Diego, CA USA	University of California System; University of California San Diego	Palsson, B (corresponding author), Univ Calif San Diego, Dept Bioengn, 9500 Gilman Dr 0412, La Jolla, CA 92093 USA.	palsson@ucsd.edu		Palsson, Bernhard/0000-0003-2357-6785				Covert MW, 2004, NATURE, V429, P92, DOI 10.1038/nature02456; Covert MW, 2001, TRENDS BIOCHEM SCI, V26, P179, DOI 10.1016/S0968-0004(00)01754-0; Edwards JS, 1999, J BIOL CHEM, V274, P17410, DOI 10.1074/jbc.274.25.17410; Forster J, 2003, GENOME RES, V13, P244, DOI 10.1101/gr.234503; Fussenegger M, 2000, NAT BIOTECHNOL, V18, P768, DOI 10.1038/77589; Gilman AG, 2002, NATURE, V420, P703, DOI 10.1038/nature01304; Goryanin I, 1999, BIOINFORMATICS, V15, P749, DOI 10.1093/bioinformatics/15.9.749; Herrgard MJ, 2004, CURR OPIN BIOTECH, V15, P70, DOI 10.1016/j.copbio.2003.11.002; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; Ideker T, 2003, TRENDS BIOTECHNOL, V21, P255, DOI 10.1016/S0167-7799(03)00115-X; Li J, 2002, NATURE, V420, P716, DOI 10.1038/nature01307; Lovley DR, 2003, NAT REV MICROBIOL, V1, P35, DOI 10.1038/nrmicro731; Novak B, 1998, BIOPHYS CHEM, V72, P185, DOI 10.1016/S0301-4622(98)00133-1; Palsson B, 2000, NAT BIOTECHNOL, V18, P1147, DOI 10.1038/81125; PALSSON BO, 1987, FASEB J, V46, P2485; Papin J, 2004, CURR OPIN BIOTECH, V15, P78, DOI 10.1016/j.copbio.2004.01.003; Papin JA, 2002, GENOME RES, V12, P1889, DOI 10.1101/gr.327702; Price ND, 2003, TRENDS BIOTECHNOL, V21, P162, DOI 10.1016/S0167-7799(03)00030-1; Reed JL, 2003, J BACTERIOL, V185, P2692, DOI 10.1128/JB.185.9.2692-2699.2003; REICH JG, 1981, ENERGY METABOLISM CE; Schuster S, 2000, NAT BIOTECHNOL, V18, P326, DOI 10.1038/73786	21	51	53	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2004	22	10					1218	1219		10.1038/nbt1004-1218	http://dx.doi.org/10.1038/nbt1004-1218			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	860EU	15470454				2022-12-25	WOS:000224326100016
J	Schubert, C				Schubert, C			HIV's lair	NATURE MEDICINE			English	News Item																			0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2004	10	10					1051	1051		10.1038/nm1004-1051	http://dx.doi.org/10.1038/nm1004-1051			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15459706				2022-12-25	WOS:000224245800024
J	Sparago, A; Cerrato, F; Vernucci, M; Ferrero, GB; Silengo, MC; Riccio, A				Sparago, A; Cerrato, F; Vernucci, M; Ferrero, GB; Silengo, MC; Riccio, A			Microdeletions in the human H19 DMR result in loss of IGF2 imprinting and Beckwith-Wiedemann syndrome	NATURE GENETICS			English	Article							CTCF-BINDING-SITES; CONTROL REGION; METHYLATION; EXPRESSION; PARENT; CANCER; LOCUS; GENE	The overgrowth- and tumor-associated Beckwith-Wiedemann syndrome results from dysregulation of imprinted genes on chromosome 11p15.5. Here we show that inherited microdeletions in the H19 differentially methylated region (DMR) that abolish two CTCF target sites cause this disease. Maternal transmission of the deletions results in hypermethylation of the H19 DMR, biallelic IGF2 expression, H19 silencing and Beckwith-Wiedemann syndrome, indicative of loss of function of the IGF2-H19 imprinting control element.	Univ Naples 2, Dipartimento Sci Ambientali, I-81100 Caserta, Italy; Univ Turin, Dipartimento Sci Pediat & Adolescenza, I-10126 Turin, Italy	Universita della Campania Vanvitelli; University of Turin	Riccio, A (corresponding author), Univ Naples 2, Dipartimento Sci Ambientali, Via Vivaldi 43, I-81100 Caserta, Italy.	andrea.riccio@unina2.it	Sparago, Angela/O-8324-2015; Riccio, Andrea/AAY-7571-2020; Riccio, Andrea/A-4991-2015; Ferrero, Giovanni Battista/K-5265-2018	Sparago, Angela/0000-0003-4352-945X; Riccio, Andrea/0000-0001-7990-3576; Riccio, Andrea/0000-0001-7990-3576; Ferrero, Giovanni Battista/0000-0002-3793-5788; Silengo, Margherita/0000-0002-6255-1532				Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; BUITING K, 1995, NAT GENET, V9, P395, DOI 10.1038/ng0495-395; Eggenschwiler J, 1997, GENE DEV, V11, P3128, DOI 10.1101/gad.11.23.3128; Feinberg AP, 2002, SEMIN CANCER BIOL, V12, P389, DOI 10.1016/S1044-579X(02)00059-7; Frevel MAE, 1999, J BIOL CHEM, V274, P29331, DOI 10.1074/jbc.274.41.29331; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960-9822(00)00597-2; Maher ER, 2000, J CLIN INVEST, V105, P247, DOI 10.1172/JCI9340; Pant V, 2003, GENE DEV, V17, P586, DOI 10.1101/gad.254903; Schoenherr CJ, 2003, NAT GENET, V33, P66, DOI 10.1038/ng1057; Szabo PE, 2000, CURR BIOL, V10, P607, DOI 10.1016/S0960-9822(00)00489-9; Szabo PE, 2004, MOL CELL BIOL, V24, P4791, DOI 10.1128/MCB.24.11.4791-4800.2004; Takai D, 2001, HUM MOL GENET, V10, P2619, DOI 10.1093/hmg/10.23.2619; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Weksberg R, 2003, HUM MOL GENET, V12, pR61, DOI 10.1093/hmg/ddg067	15	219	229	0	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2004	36	9					958	960		10.1038/ng1410	http://dx.doi.org/10.1038/ng1410			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	851AY	15314640	Bronze			2022-12-25	WOS:000223658100021
J	Wang, HW; Trotter, MWB; Lagos, D; Bourboulia, D; Henderson, S; Makinen, T; Elliman, S; Flanagan, AM; Alitalo, K; Boshoff, C				Wang, HW; Trotter, MWB; Lagos, D; Bourboulia, D; Henderson, S; Makinen, T; Elliman, S; Flanagan, AM; Alitalo, K; Boshoff, C			Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma	NATURE GENETICS			English	Article							GROWTH-FACTOR; CELLS; HUMAN-HERPESVIRUS-8; TRANSFORMATION; INFECTION; CULTURE; LESIONS; VEGF	The biology of Kaposi sarcoma is poorly understood because the dominant cell type in Kaposi sarcoma lesions is not known(1-4). We show by gene expression microarrays that neoplastic cells of Kaposi sarcoma are closely related to lymphatic endothelial cells (LECs) and that Kaposi sarcoma herpesvirus (KSHV)(5,6) infects both LECs and blood vascular endothelial cells (BECs) in vitro. The gene expression microarray profiles of infected LECs and BECs show that KSHV induces transcriptional reprogramming of both cell types. The lymphangiogenic molecules VEGF-D and angiopoietin-2 were elevated in the plasma of individuals with acquired immune deficiency syndrome and Kaposi sarcoma. These data show that the gene expression profile of Kaposi sarcoma resembles that of LECs, that KSHV induces a transcriptional drift in both LECs and BECs and that lymphangiogenic molecules are involved in the pathogenesis of Kaposi sarcoma.	UCL, Wolfson Inst Biomed Res, Viral Oncol Grp, Canc Res UK, London WC1E 6BT, England; Univ Helsinki, Biomedicum Helsinki, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Biomedicum Helsinki, Ludwig Inst Canc Res, FIN-00014 Helsinki, Finland; Univ Helsinki, Helsinki Univ Cent Hosp, FIN-00014 Helsinki, Finland; UCL, Inst Orthopaed, London WC1E 6BT, England	Cancer Research UK; University of London; University College London; University of Helsinki; Ludwig Institute for Cancer Research; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of London; University College London	Boshoff, C (corresponding author), UCL, Wolfson Inst Biomed Res, Viral Oncol Grp, Canc Res UK, Cruciform Bldg,Gower St, London WC1E 6BT, England.	c.boshoff@ucl.ac.uk	Alitalo, Kari K/J-5013-2014; Makinen, Taija/CAI-2233-2022; Makinen, Taija/C-5765-2014	Alitalo, Kari K/0000-0002-7331-0902; Makinen, Taija/0000-0002-9338-1257; Makinen, Taija/0000-0002-9338-1257; Trotter, Matthew/0000-0003-3702-915X; Lagos, Dimitris/0000-0003-0637-281X; Flanagan, Adrienne/0000-0002-2832-1303; Henderson, Stephen/0000-0002-9032-3828				Ascherl G, 1999, BLOOD, V93, P4232; Boshoff C, 2002, NAT REV CANCER, V2, P373, DOI 10.1038/nrc797; Brockmeyer N H, 1999, Eur J Med Res, V4, P95; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Ciufo DM, 2001, J VIROL, V75, P5614, DOI 10.1128/JVI.75.12.5614-5626.2001; Dupin N, 1999, P NATL ACAD SCI USA, V96, P4546, DOI 10.1073/pnas.96.8.4546; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4; Gallo RC, 1998, SCIENCE, V282, P1837, DOI 10.1126/science.282.5395.1837; Ganem D, 1997, CELL, V91, P157, DOI 10.1016/S0092-8674(00)80398-0; HONG YK, 2004, NAT GENET       0627, DOI DOI 10.1038/NG1383; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; KAAYA EE, 1995, J ACQ IMMUN DEF SYND, V10, P295; Kahn HJ, 2002, MODERN PATHOL, V15, P434, DOI 10.1038/modpathol.3880543; KRUSKAL JB, 1964, PSYCHOMETRIKA, V29, P1, DOI 10.1007/BF02289565; Lebbe C, 1997, ARCH DERMATOL RES, V289, P421, DOI 10.1007/s004030050215; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Moses AV, 1999, J VIROL, V73, P6892, DOI 10.1128/JVI.73.8.6892-6902.1999; Petrova TV, 2002, EMBO J, V21, P4593, DOI 10.1093/emboj/cdf470; Poole LJ, 2002, J VIROL, V76, P3395, DOI 10.1128/JVI.76.7.3395-3420.2002; REGEZI JA, 1993, AM J PATHOL, V143, P240; Renwick N, 2002, AIDS RES HUM RETROV, V18, P695, DOI 10.1089/088922202760072302; Samaniego F, 1997, J IMMUNOL, V158, P1887; Shin D, 2001, DEV BIOL, V230, P139, DOI 10.1006/dbio.2000.9957; Stacker SA, 2002, NAT REV CANCER, V2, P573, DOI 10.1038/nrc863; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Vieira J, 2001, J VIROL, V75, P1378, DOI 10.1128/JVI.75.3.1378-1386.2001; [No title captured]	30	308	320	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2004	36	7					687	693		10.1038/ng1384	http://dx.doi.org/10.1038/ng1384			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	833QT	15220918	Bronze			2022-12-25	WOS:000222354100017
J	Fernandez, DC; Bhargava, R; Hewitt, SM; Levin, IW				Fernandez, DC; Bhargava, R; Hewitt, SM; Levin, IW			Infrared spectroscopic imaging for histopathologic recognition	NATURE BIOTECHNOLOGY			English	Article							TISSUE MICROARRAYS; PROSTATE-CANCER; SPECIMENS; CELLS; MICROSPECTROSCOPY; ADENOCARCINOMA; PHENOTYPE	The process of histopathology, comprising tissue staining and morphological pattern recognition, has remained largely unchanged for over 140 years(1). Although it is integral to clinical and research activities, histopathologic recognition remains a time-consuming, subjective process to which only limited statistical confidence can be assigned because of inherent operator variability(2,3). Although immunohistochemical approaches allow limited molecular detection, significant challenges remain in using them for quantitative, automated pathology. Vibrational spectroscopic approaches, by contrast, directly provide nonperturbing molecular descriptors(4), but a practical spectroscopic protocol for histopathology is lacking. Here we couple high-throughput Fourier transform infrared (FTIR) spectroscopic imaging(5) of tissue microarrays(6) with statistical pattern recognition of spectra indicative of endogenous molecular composition and demonstrate histopathologic characterization of prostatic tissue. This automated histologic segmentation is applied to routine archival tissue samples, incorporates well-defined tests of statistical significance(7) and eliminates any requirement for dyes or molecular probes. Finally, we differentiate benign from malignant prostatic epithelium by spectroscopic analyses.	NIDDKD, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; NCI, Tissue Array Res Program, Pathol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Levin, IW (corresponding author), NIDDKD, Chem Phys Lab, NIH, Bldg 2, Bethesda, MD 20892 USA.	iwl@helix.nih.gov		Hewitt, Stephen/0000-0001-8283-1788; Bhargava, Rohit/0000-0001-7360-994X	NATIONAL CANCER INSTITUTE [Z01SC010364] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK029001, ZIADK029001] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allsbrook WC, 2001, HUM PATHOL, V32, P74, DOI 10.1053/hupa.2001.21134; Andrus PGL, 1998, BIOSPECTROSCOPY, V4, P37, DOI 10.1002/(SICI)1520-6343(1998)4:1<37::AID-BSPY4>3.0.CO;2-P; Baak JPA, 2002, J PATHOL, V198, P277, DOI 10.1002/path.1233; Bhargava R, 2001, ANAL CHEM, V73, P5157, DOI 10.1021/ac010380m; Boydston-White S, 1999, BIOSPECTROSCOPY, V5, P219, DOI 10.1002/(SICI)1520-6343(1999)5:4<219::AID-BSPY2>3.0.CO;2-O; Bradley AP, 1997, PATTERN RECOGN, V30, P1145, DOI 10.1016/S0031-3203(96)00142-2; Diem M, 2004, ANALYST, V129, P880, DOI 10.1039/b408952a; Emmert-Buck MR, 2000, AM J PATHOL, V156, P1109, DOI 10.1016/S0002-9440(10)64979-6; Goodacre R, 2003, VIB SPECTROSC, V32, P33, DOI 10.1016/S0924-2031(03)00045-6; Heise HM, 2002, SPECTROCHIM ACTA B, V57, P1649, DOI 10.1016/S0584-8547(02)00103-9; Jackson M, 1997, J MOL STRUCT, V408, P105, DOI 10.1016/S0022-2860(96)09461-6; Kidder LH, 1997, NAT MED, V3, P235, DOI 10.1038/nm0297-235; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; KWIATKOSKI JM, 1987, NATURE, V328, P837, DOI 10.1038/328837a0; Lasch P, 2002, APPL SPECTROSC, V56, P1, DOI 10.1366/0003702021954322; Levin IW, 2005, ANNU REV PHYS CHEM, V56, P429, DOI 10.1146/annurev.physchem.56.092503.141205; LEWIS EN, 1995, ANAL CHEM, V67, P3377, DOI 10.1021/ac00115a003; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Luna LG, 1968, MANUAL HISTOLOGIC ST, V3; Malins DC, 1997, P NATL ACAD SCI USA, V94, P259, DOI 10.1073/pnas.94.1.259; MALINS DC, 1995, CANCER, V75, P503, DOI 10.1002/1097-0142(19950115)75:2<503::AID-CNCR2820750213>3.0.CO;2-0; Mansfield JR, 1999, APPL SPECTROSC, V53, P1323, DOI 10.1366/0003702991945920; McIntosh LM, 1999, J INVEST DERMATOL, V112, P951, DOI 10.1046/j.1523-1747.1999.00612.x; NAUMANN D, 1991, NATURE, V351, P81, DOI 10.1038/351081a0; Ou-Yang H, 2001, J BONE MINER RES, V16, P893, DOI 10.1359/jbmr.2001.16.5.893; Rubin MA, 2001, J PATHOL, V195, P80, DOI 10.1002/path.892; Shaw RA, 1999, ANAL QUANT CYTOL, V21, P292; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; Tuxhorn JA, 2002, CLIN CANCER RES, V8, P2912; Webb A. R., 2003, STAT PATTERN RECOGNI; Wetzel DL, 1999, SCIENCE, V285, P1224, DOI 10.1126/science.285.5431.1224; WONG PTT, 1991, P NATL ACAD SCI USA, V88, P10988, DOI 10.1073/pnas.88.24.10988; Wood BR, 2004, GYNECOL ONCOL, V93, P59, DOI 10.1016/j.ygyno.2003.12.028	33	455	485	4	105	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2005	23	4					469	474		10.1038/nbt1080	http://dx.doi.org/10.1038/nbt1080			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	914AR	15793574				2022-12-25	WOS:000228197300031
J	Chesler, EJ; Lu, L; Shou, SM; Qu, YH; Gu, J; Wang, JT; Hsu, HC; Mountz, JD; Baldwin, NE; Langston, MA; Threadgill, DW; Manly, KF; Williams, RW				Chesler, EJ; Lu, L; Shou, SM; Qu, YH; Gu, J; Wang, JT; Hsu, HC; Mountz, JD; Baldwin, NE; Langston, MA; Threadgill, DW; Manly, KF; Williams, RW			Complex trait analysis of gene expression uncovers polygenic and pleiotropic networks that modulate nervous system function	NATURE GENETICS			English	Article							LOCOMOTOR-ACTIVITY; MOUSE; BXD; ETHANOL; GENOMICS; LOCI; IDENTIFICATION; LOCALIZATION; HIPPOCAMPUS; DISSECTION	Patterns of gene expression in the central nervous system are highly variable and heritable. This genetic variation among normal individuals leads to considerable structural, functional and behavioral differences. We devised a general approach to dissect genetic networks systematically across biological scale, from base pairs to behavior, using a reference population of recombinant inbred strains. We profiled gene expression using Affymetrix oligonucleotide arrays in the BXD recombinant inbred strains, for which we have extensive SNP and haplotype data. We integrated a complementary database comprising 25 years of legacy phenotypic data on these strains. Covariance among gene expression and pharmacological and behavioral traits is often highly significant, corroborates known functional relations and is often generated by common quantitative trait loci. We found that a small number of major-effect quantitative trait loci jointly modulated large sets of transcripts and classical neural phenotypes in patterns specific to each tissue. We developed new analytic and graph theoretical approaches to study shared genetic modulation of networks of traits using gene sets involved in neural synapse function as an example. We built these tools into an open web resource called WebQTL that can be used to test a broad array of hypotheses.	Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; Univ Tennessee, Dept Comp Sci, Knoxville, TN 37996 USA; Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Alabama System; University of Alabama Birmingham; University of Tennessee System; University of Tennessee Knoxville; University of North Carolina; University of North Carolina Chapel Hill	Williams, RW (corresponding author), Univ Tennessee, Ctr Hlth Sci, 855 Monroe Ave, Memphis, TN 38163 USA.	rwilliam@nb.utmem.edu	Threadgill, David W/N-4425-2013; Langston, Michael/A-9484-2011; Chesler, Elissa/K-4641-2019; Williams, Robert W./H-8789-2016	Threadgill, David W/0000-0003-3538-1635; Chesler, Elissa/0000-0002-5642-5062; Williams, Robert W./0000-0001-8924-4447				Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BALDWIN NE, IN PRESS J BIOMED BI; Bartoli M, 1999, J NEUROBIOL, V40, P234, DOI 10.1002/(SICI)1097-4695(199908)40:2<234::AID-NEU9>3.3.CO;2-K; Becamel C, 2002, EMBO J, V21, P2332, DOI 10.1093/emboj/21.10.2332; Belknap JK, 1998, BEHAV GENET, V28, P29, DOI 10.1023/A:1021404714631; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blichenberg A, 1999, J NEUROSCI, V19, P8818, DOI 10.1523/JNEUROSCI.19-20-08818.1999; Brem RB, 2002, SCIENCE, V296, P752, DOI 10.1126/science.1069516; Broman KW, 2003, BIOINFORMATICS, V19, P889, DOI 10.1093/bioinformatics/btg112; Bystrykh L, 2005, NAT GENET, V37, P225, DOI 10.1038/ng1497; Chesler EJ, 2004, INT REV NEUROBIOL, V60, P59; Chesler EJ, 2004, NAT NEUROSCI, V7, P485, DOI 10.1038/nn0504-485; Chesler EJ, 2003, NEUROINFORMATICS, V1, P343, DOI 10.1385/NI:1:4:343; Churchill G, 2004, NAT GENET, V36, P1133, DOI 10.1038/ng1104-1133; CHURCHILL GA, 1994, GENETICS, V138, P963; Cowles CR, 2002, NAT GENET, V32, P432, DOI 10.1038/ng992; CRABBE JC, 1983, NEUROBEH TOXICOL TER, V5, P181; CUNNINGHAM CL, 1995, PSYCHOPHARMACOLOGY, V120, P28, DOI 10.1007/BF02246142; Flint J, 2003, J NEUROBIOL, V54, P46, DOI 10.1002/neu.10161; Hitzemann R, 2003, ALCOHOL CLIN EXP RES, V27, P1, DOI 10.1097/01.ALC.000047862.40562.27; HUTSON AD, 2002, BOOTSTRAP SMOOTHING; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jansen RC, 2001, TRENDS GENET, V17, P388, DOI 10.1016/S0168-9525(01)02310-1; Jeong H, 2000, NATURE, V407, P651, DOI 10.1038/35036627; Jones BC, 2003, NUTR NEUROSCI, V6, P369, DOI 10.1080/10284150310001624192; Klose J, 2002, NAT GENET, V30, P385, DOI 10.1038/ng861; Li X, 2001, MAMM GENOME, V12, P13, DOI 10.1007/s003350010236; Lu L, 2001, J NEUROSCI, V21, P3503, DOI 10.1523/JNEUROSCI.21-10-03503.2001; Manly KF, 2004, GENOME RES, V14, P997, DOI 10.1101/gr.2156804; Mogil JS, 2003, P NATL ACAD SCI USA, V100, P4867, DOI 10.1073/pnas.0730053100; Paigen K, 2000, MAMM GENOME, V11, P715, DOI 10.1007/s003350010152; Peirce JL, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-7; Peirce JL, 2003, GENES BRAIN BEHAV, V2, P238, DOI 10.1034/j.1601-183X.2003.00030.x; PHILLIPS TJ, 1994, ALCOHOL CLIN EXP RES, V18, P931, DOI 10.1111/j.1530-0277.1994.tb00062.x; PHILLIPS TJ, 1995, ALCOHOL CLIN EXP RES, V19, P269, DOI 10.1111/j.1530-0277.1995.tb01502.x; Rikke BA, 1998, MAMM GENOME, V9, P963, DOI 10.1007/s003359900907; Risinger FO, 1998, ALCOHOL CLIN EXP RES, V22, P1234, DOI 10.1111/j.1530-0277.1998.tb03904.x; Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434; Shirley RL, 2004, NAT NEUROSCI, V7, P699, DOI 10.1038/nn1271; Storey JD, 2004, J R STAT SOC B, V66, P187, DOI 10.1111/j.1467-9868.2004.00439.x; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Taylor BA, 1999, MAMM GENOME, V10, P335, DOI 10.1007/s003359900998; Threadgill DW, 2002, MAMM GENOME, V13, P175, DOI 10.1007/s00335-001-4001-Y; Visscher PM, 1999, GENET RES, V74, P81, DOI 10.1017/S0016672399003857; Visscher PM, 1996, GENETICS, V143, P1013; Wang JT, 2003, NEUROINFORMATICS, V1, P299, DOI 10.1385/NI:1:4:299; WILLIAMS RW, 2002, GENOME BIOL, V2; Yalcin B, 2004, NAT GENET, V36, P1197, DOI 10.1038/ng1450; Zhang B, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-16	50	543	559	1	36	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2005	37	3					233	242		10.1038/ng1518	http://dx.doi.org/10.1038/ng1518			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	901QU	15711545				2022-12-25	WOS:000227297800014
J	Lee, Y; Lee, Y; Lee, J; Bang, S; Hyun, S; Kang, J; Hong, ST; Bae, E; Kaang, BK; Kim, J				Lee, Y; Lee, Y; Lee, J; Bang, S; Hyun, S; Kang, J; Hong, ST; Bae, E; Kaang, BK; Kim, J			Pyrexia is a new thermal transient receptor potential channel endowing tolerance to high temperatures in Drosophila melanogaster	NATURE GENETICS			English	Article							HEAT-EVOKED ACTIVATION; CAPSAICIN-RECEPTOR; EXPRESSION SYSTEM; TRP CHANNEL; ION-CHANNEL; THERMOSENSATION; IDENTIFICATION; NOCICEPTION; PROTEIN; NEURONS	Several transient receptor potential channels were recently found to be activated by temperature stimuli in vitro(1-1)4. Their physiological and behavioral roles are largely unknown. From a temperature-preference behavior screen of 27, 000 Drosophila melanogaster P-insertion mutants, we isolated a gene, named pyrexia (pyx), encoding a new transient receptor potential channel. Pyx was opened by temperatures above 40 degreesC in Xenopus laevis oocytes and HEK293T cells. It was ubiquitously expressed along the dendrites of a subset of peripheral nervous system neurons and was more permeable to K+ than to Na+. Although some pyx alleles resulted in abnormal temperature preferences, pyx null flies did not have significantly different temperature preferences than wild-type flies. But 60% of pyx null flies were paralyzed within 3 min of exposure to 40 degreesC, whereas only 9% of wild-type flies were paralyzed by the same stimulus. From these findings, we propose that the primary in vivo role of Pyx is to protect flies from high-temperature stress.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Seoul Natl Univ, Div Biol Sci, Seoul 151742, South Korea; Korea Adv Inst Sci & Technol, GenExel Inc, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Seoul National University (SNU); Korea Advanced Institute of Science & Technology (KAIST)	Kim, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 373-1 Guseong Dong, Taejon 305701, South Korea.	kjaeseob@kaist.ac.kr	Kang, Jongkyun/AAT-7581-2021	Kang, Jongkyun/0000-0003-0259-110X; Lee, Youngseok/0000-0003-0459-1138; Hong, Sung-Tae/0000-0001-5981-4859				Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; Gao FB, 1999, GENE DEV, V13, P2549, DOI 10.1101/gad.13.19.2549; Gilchrist GW, 1999, HEREDITY, V83, P15, DOI 10.1038/sj.hdy.6885330; Guler AD, 2002, J NEUROSCI, V22, P6408; HEIINRICH B, 1993, HOT BLOODED INSECTS; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; Lee Y, 2003, J NEUROSCI RES, V73, P255, DOI 10.1002/jnr.10652; Liu L, 2003, NAT NEUROSCI, V6, P267, DOI 10.1038/nn1009; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Peier AM, 2002, SCIENCE, V296, P2046, DOI 10.1126/science.1073140; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Sayeed O, 1996, P NATL ACAD SCI USA, V93, P6079, DOI 10.1073/pnas.93.12.6079; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Story GM, 2003, CELL, V112, P819, DOI 10.1016/S0092-8674(03)00158-2; Tracey WD, 2003, CELL, V113, P261, DOI 10.1016/S0092-8674(03)00272-1; Viswanath V, 2003, NATURE, V423, P822, DOI 10.1038/423822a; Watanabe H, 2002, J BIOL CHEM, V277, P47044, DOI 10.1074/jbc.M208277200; Xu HX, 2002, NATURE, V418, P181, DOI 10.1038/nature00882	21	137	147	1	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2005	37	3					305	310		10.1038/ng1513	http://dx.doi.org/10.1038/ng1513			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	901QU	15731759				2022-12-25	WOS:000227297800023
J	McMahon, EJ; Bailey, SL; Castenada, CV; Waldner, H; Miller, SD				McMahon, EJ; Bailey, SL; Castenada, CV; Waldner, H; Miller, SD			Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; DENDRITIC CELLS; LYMPH-NODES; ANTIGEN; PROGRESSION; BRAIN; EXPRESSION; RESPONSES; IMMUNITY	Chronic progression of two T cell-mediated central nervous system (CNS) demyelinating models of multiple sclerosis, relapsing EAE (R-EAE) and Theiler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD) is dependent on the activation of T cells to endogenous myelin epitopes (epitope spreading). Using transfer of carboxyfluorescein succinyl ester (CFSE)-labeled T-cell receptor (TCR)-transgenic T cells and mixed bone marrow chimeras, we show that activation of naive proteolipid protein (PLP)(139-151)-specific T cells in SJL mice undergoing PLP178-191-induced R-EAE or TMEV-IDD occurs directly in the CNS and not in the cervical lymph nodes or other peripheral lymphoid organs. Examination of the antigen-presentation capacity of antigen-presenting cell (APC) populations purified from the CNS of mice with PLP178-191-induced R-EAE shows that only F4/80(-)CD11c(+)CD45(hi) dendritic cells (DCs) efficiently present endogenous antigen to activate naive PLP139-151-specific T cells in vitro. In contrast, DCs as well as F4/80(+)CD45(hi) macrophages and F4/80(+)CD45(lo) microglia activate a PLP139-151-specific helper T cell line. The data suggest that naive T cells enter the inflamed CNS and are activated by local APCs, possibly DCs, to initiate epitope spreading.	Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Interdept Immunobiol Ctr, Chicago, IL 60611 USA; Brigham & Womens Hosp, Dept Neurol, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Northwestern University; Northwestern University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Miller, SD (corresponding author), Northwestern Univ, Sch Med, Dept Microbiol Immunol, 303 E Chicago Ave, Chicago, IL 60611 USA.	s-d-miller@northwestern.edu			NIAID NIH HHS [AI-07476] Funding Source: Medline; NINDS NIH HHS [NS-23349, NS-30871] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS023349, R01NS030871] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		de Vos AF, 2002, J IMMUNOL, V169, P5415, DOI 10.4049/jimmunol.169.10.5415; Fischer HG, 2001, J IMMUNOL, V166, P2717, DOI 10.4049/jimmunol.166.4.2717; Greter M, 2005, NAT MED, V11, P328, DOI 10.1038/nm1197; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; HOCHWALD GM, 1988, INT J NEUROSCI, V39, P299, DOI 10.3109/00207458808985717; Karman J, 2004, J IMMUNOL, V173, P2353, DOI 10.4049/jimmunol.173.4.2353; Katz-Levy Y, 2000, J IMMUNOL, V165, P5304, DOI 10.4049/jimmunol.165.9.5304; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; Kivisakk P, 2004, ANN NEUROL, V55, P627, DOI 10.1002/ana.20049; Krakowski ML, 2000, EUR J IMMUNOL, V30, P1002, DOI 10.1002/(SICI)1521-4141(200004)30:4<1002::AID-IMMU1002>3.0.CO;2-2; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; Ling CY, 2003, J NEUROIMMUNOL, V141, P90, DOI 10.1016/S0165-5728(03)00249-2; Mack CL, 2003, J NEUROIMMUNOL, V144, P68, DOI 10.1016/j.jneuroim.2003.08.032; MCRAE BL, 1995, J EXP MED, V182, P75, DOI 10.1084/jem.182.1.75; Miller SD, 1997, NAT MED, V3, P1133, DOI 10.1038/nm1097-1133; Muldoon LL, 2004, NEUROPATH APPL NEURO, V30, P70, DOI 10.1046/j.0305-1846.2003.00512.x; Neville KL, 2002, J NEUROIMMUNOL, V123, P18, DOI 10.1016/S0165-5728(01)00479-9; Ngo VN, 1999, J EXP MED, V189, P403, DOI 10.1084/jem.189.2.403; OEHMICHEN M, 1979, ACTA NEUROPATHOL, V45, P61, DOI 10.1007/BF00691806; Pashenkov M, 2001, BRAIN, V124, P480, DOI 10.1093/brain/124.3.480; Plumb J, 2003, MULT SCLER, V9, P142, DOI 10.1191/1352458503ms890oa; Serafini B, 2000, AM J PATHOL, V157, P1991, DOI 10.1016/S0002-9440(10)64838-9; Suter T, 2000, EUR J IMMUNOL, V30, P794, DOI 10.1002/1521-4141(200003)30:3<794::AID-IMMU794>3.3.CO;2-H; Tompkins SM, 2002, J IMMUNOL, V168, P4173, DOI 10.4049/jimmunol.168.8.4173; Tuohy VK, 1999, J EXP MED, V189, P1033, DOI 10.1084/jem.189.7.1033; Vanderlugt CL, 2002, NAT REV IMMUNOL, V2, P85, DOI 10.1038/nri724; Vanderlugt CL, 2000, J IMMUNOL, V164, P670, DOI 10.4049/jimmunol.164.2.670; Waldner H, 2000, P NATL ACAD SCI USA, V97, P3412, DOI 10.1073/pnas.97.7.3412; YAMADA S, 1991, AM J PHYSIOL, V261, pH1197, DOI 10.1152/ajpheart.1991.261.4.H1197; Yu M, 1996, J EXP MED, V183, P1777, DOI 10.1084/jem.183.4.1777	30	509	535	2	33	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					335	339		10.1038/nm1202	http://dx.doi.org/10.1038/nm1202			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15735651				2022-12-25	WOS:000227541300030
J	Wilkinson, S; Paterson, HF; Marshall, CJ				Wilkinson, S; Paterson, HF; Marshall, CJ			Cdc42-MRCK and Rho-ROCK signalling cooperate in myosin phosphorylation and cell invasion	NATURE CELL BIOLOGY			English	Article							SMOOTH-MUSCLE MYOSIN; BINDING SUBUNIT; PROTEIN-KINASE; MIGRATION; PHOSPHATASE; MOTILITY; INHIBITION; ACTIVATION; MECHANISM; GTPASES	Actomyosin contractility is a mechanism by which cells exert locomotory force against their environment(1). Signalling downstream of the small GTPase Rho increases contractility through Rho-kinase (ROCK)-mediated regulation of myosin-II light chain (MLC2) phosphorylation. Cdc42 signalling has been shown to control cell polarity(2). Tumour cells can move through a three-dimensional matrix with either a rounded morphology(3,4) characterized by Rho - ROCK dependence(5) or with an elongated morphology3,4 characterized by Rho - ROCK independence(5). Here we show that contractility necessary for elongated morphology and invasion can be generated by Cdc42 - MRCK signalling. MRCK ( myotonic dystrophy kinase-related Cdc42-binding kinase) cooperates with ROCK in the maintenance of elongated morphology and invasion and either MRCK or ROCK is sufficient for MLC2 phosphorylation, through the inhibitory phosphorylation of myosin phosphatase. By contrast, in rounded ROCK-dependent movement, where MLC2 phosphorylation is higher, MRCK has a smaller role. Our data show that a Cdc42 MRCK signal mediates myosin-dependent cell motility and highlight convergence between Rho and Cdc42 signalling.	Inst Canc Res, Canc Res UK Ctr Cell & Mol Biol, London SW3 6JB, England	Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Marshall, CJ (corresponding author), Inst Canc Res, Canc Res UK Ctr Cell & Mol Biol, 237 Fulham Rd, London SW3 6JB, England.	chris.marshall@icr.ac.uk		Wilkinson, Simon/0000-0003-1082-8218				Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; De Wever O, 2004, FASEB J, V18, P1016, DOI 10.1096/fj.03-1110fje; Dong JM, 2002, EUR J CELL BIOL, V81, P231, DOI 10.1078/0171-9335-00238; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Friedl Peter, 2004, Methods Mol Biol, V239, P77; Ichikawa K, 1996, J BIOL CHEM, V271, P4733; IKEBE M, 1985, J BIOL CHEM, V260, P27; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Komatsu S, 2004, J CELL BIOL, V165, P243, DOI 10.1083/jcb.200309056; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Leung T, 1996, MOL CELL BIOL, V16, P5313; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Mukai H, 2003, J BIOCHEM, V133, P17, DOI 10.1093/jb/mvg019; Nakamura N, 2000, GENES CELLS, V5, P571, DOI 10.1046/j.1365-2443.2000.00348.x; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; Tan I, 2001, J BIOL CHEM, V276, P21209, DOI 10.1074/jbc.M102615200; Tan I, 2001, MOL CELL BIOL, V21, P2767, DOI 10.1128/MCB.21.8.2767-2778.2001; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006	30	297	307	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2005	7	3					255	U45		10.1038/ncb1230	http://dx.doi.org/10.1038/ncb1230			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	902CU	15723050				2022-12-25	WOS:000227329800013
J	Cornett, J; Cao, FK; Wang, CE; Ross, CA; Bates, GP; Li, SH; Li, XJ				Cornett, J; Cao, FK; Wang, CE; Ross, CA; Bates, GP; Li, SH; Li, XJ			Polyglutamine expansion of huntingtin impairs its nuclear export	NATURE GENETICS			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; PORE COMPLEX; NUCLEOCYTOPLASMIC TRANSPORT; PROTEIN; DISEASE; BRAIN; TPR; GENE; IDENTIFICATION; ABNORMALITIES	Proteins with polyglutamine (polyQ) expansions accumulate in the nucleus and affect gene expression(1,2). The mechanism by which mutant huntingtin (htt) accumulates intranuclearly is not known; wild-type htt, a 350-kDa protein of unknown function, is normally found in the cytoplasm(3-5).N-terminal fragments of mutant htt, which contain a polyQ expansion (>37 glutamines), have no conserved nuclear localization sequences or nuclear export sequences but can accumulate in the nucleus and cause neurological problems in transgenic mice(6,7). Here we report that N-terminal htt shuttles between the cytoplasm and nucleus in a Ran GTPase-independent manner. Small N-terminal htt fragments interact with the nuclear pore protein translocated promoter region(Tpr), which is involved in nuclear export. PolyQ expansion and aggregation decrease this interaction and increase the nuclear accumulation of htt. Reducing the expression of Tpr by RNA interference or deletion of ten amino acids of N-terminal htt, which are essential for the interaction of htt with Tpr, increased the nuclear accumulation of htt. These results suggest that Tpr has a role in the nuclear export of N-terminal htt and that polyQ expansion reduces this nuclear export to cause the nuclear accumulation of htt.	Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Univ London Kings Coll, Guys Hosp, GKT Sch Med, Dept Med & Mol Genet, London WC2R 2LS, England	Emory University; Johns Hopkins University; Johns Hopkins University; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Li, XJ (corresponding author), Emory Univ, Sch Med, Dept Human Genet, 615 Michael St, Atlanta, GA 30322 USA.	xiaoli@genetics.emory.edu	Bates, Gillian/E-1146-2012	Bates, Gillian/0000-0002-4041-6305				Boche I, 1997, J CELL BIOL, V139, P313, DOI 10.1083/jcb.139.2.313; BYRD DA, 1994, J CELL BIOL, V127, P1515, DOI 10.1083/jcb.127.6.1515; Cordes VC, 1997, J CELL BIOL, V136, P515, DOI 10.1083/jcb.136.3.515; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; Frosst P, 2002, J CELL BIOL, V156, P617, DOI 10.1083/jcb.200106046; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; GUTEKUNST CA, 1995, P NATL ACAD SCI USA, V92, P8710, DOI 10.1073/pnas.92.19.8710; Harjes P, 2003, TRENDS BIOCHEM SCI, V28, P425, DOI 10.1016/S0968-0004(03)00168-3; Jackson WS, 2003, HUM MOL GENET, V12, P1621, DOI 10.1093/hmg/ddg163; Kaytor MD, 2004, J NEUROCHEM, V89, P962, DOI 10.1111/j.1471-4159.2004.02376.x; Kose S, 1999, J BIOL CHEM, V274, P3946, DOI 10.1074/jbc.274.7.3946; Kuznetsov NV, 2002, CHROMOSOMA, V111, P236, DOI 10.1007/s00412-002-0208-2; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Lunkes A, 2002, MOL CELL, V10, P259, DOI 10.1016/S1097-2765(02)00602-0; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; Schilling G, 1999, HUM MOL GENET, V8, P397, DOI 10.1093/hmg/8.3.397; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; Shibata S, 2002, GENES CELLS, V7, P421, DOI 10.1046/j.1365-2443.2002.00525.x; Steffan JS, 2004, SCIENCE, V304, P100, DOI 10.1126/science.1092194; Sugars KL, 2003, TRENDS GENET, V19, P233, DOI 10.1016/S0168-9525(03)00074-X; Xia JR, 2003, HUM MOL GENET, V12, P1393, DOI 10.1093/hmg/ddg156; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119; Zhou H, 2003, J CELL BIOL, V163, P109, DOI 10.1083/jcb.200306038; Zhou H, 2001, J BIOL CHEM, V276, P48417, DOI 10.1074/jbc.M104140200; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217; Zuccato C, 2003, NAT GENET, V35, P76, DOI 10.1038/ng1219	29	132	137	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2005	37	2					198	204		10.1038/ng1503	http://dx.doi.org/10.1038/ng1503			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	893AB	15654337				2022-12-25	WOS:000226690100029
J	Takeda, T; Kawate, T; Chang, F				Takeda, T; Kawate, T; Chang, F			Organization of a sterol-rich membrane domain by cdc15p during cytokinesis in fission yeast	NATURE CELL BIOLOGY			English	Article							SCHIZOSACCHAROMYCES-POMBE; ACTIN RING; BACILLUS-SUBTILIS; CONTRACTILE RING; CELL-DIVISION; F-ACTIN; PROTEINS; DYNAMICS; REVEALS; SURFACE	Many membrane processes occur in discrete membrane domains containing lipid rafts(1), but little is known about how these domains are organized and positioned. In the fission yeast Schizosaccharomyces pombe, a sterol-rich membrane domain forms at the cell-division site(2). Here, we show that formation of this membrane domain is independent of the contractile actin ring, septation, mid1p and the septins, and also requires cdc15p(3), an essential contractile ring protein that associates with lipid rafts. cdc15 mutants have membrane domains in the shape of spirals. Overexpression of cdc15p in interphase cells induces abnormal membrane domain formation in an actin-independent manner. We propose that cdc15p functions to organize lipid rafts at the cleavage site for cytokinesis.	Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA	Columbia University	Chang, F (corresponding author), Columbia Univ Coll Phys & Surg, Dept Microbiol, 701 W 168th St, New York, NY 10032 USA.	fc99@columbia.edu			NIGMS NIH HHS [R01 GM056836] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056836] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Bagnat M, 2002, P NATL ACAD SCI USA, V99, P14183, DOI 10.1073/pnas.172517799; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Balasubramanian MK, 1998, GENETICS, V149, P1265; Baumgart T, 2003, NATURE, V425, P821, DOI 10.1038/nature02013; Ben-Yehuda S, 2002, CELL, V109, P257, DOI 10.1016/S0092-8674(02)00698-0; Berlin A, 2003, J CELL BIOL, V160, P1083, DOI 10.1083/jcb.200212016; CAMAHAN RH, 2003, J CELL BIOL, V162, P851; Carnahan RH, 2003, J CELL BIOL, V162, P851, DOI 10.1083/jcb.200305012; Chang F, 1996, J CELL SCI, V109, P131; Demeter J, 1998, J CELL BIOL, V143, P415, DOI 10.1083/jcb.143.2.415; Facanha ALO, 2002, J CELL BIOL, V157, P1029, DOI 10.1083/jcb.200111012; FANKHAUSER C, 1995, CELL, V82, P435, DOI 10.1016/0092-8674(95)90432-8; Jones LJF, 2001, CELL, V104, P913, DOI 10.1016/S0092-8674(01)00287-2; Krapp A, 2004, CURR BIOL, V14, pR722, DOI 10.1016/j.cub.2004.08.049; Le Goff X, 1999, CURR GENET, V35, P571, DOI 10.1007/s002940050455; Lippincott J, 2000, MICROSC RES TECHNIQ, V49, P168, DOI 10.1002/(SICI)1097-0029(20000415)49:2<168::AID-JEMT9>3.0.CO;2-T; Malathi K, 2004, J CELL BIOL, V164, P547, DOI 10.1083/jcb.200310046; Morrell JL, 1999, MOL BIOL CELL, V10, P4201, DOI 10.1091/mbc.10.12.4201; Mukherjee S, 2004, ANNU REV CELL DEV BI, V20, P839, DOI 10.1146/annurev.cellbio.20.010403.095451; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; O'Halloran TJ, 2000, TRAFFIC, V1, P921, DOI 10.1034/j.1600-0854.2000.011201.x; Pelham RJ, 2002, NATURE, V419, P82, DOI 10.1038/nature00999; ROBINSON JM, 1980, J HISTOCHEM CYTOCHEM, V28, P161, DOI 10.1177/28.2.6766487; Skop AR, 2004, SCIENCE, V305, P61, DOI 10.1126/science.1097931; Tran PT, 2001, J CELL BIOL, V153, P397, DOI 10.1083/jcb.153.2.397; Valdez-Taubas J, 2003, CURR BIOL, V13, P1636, DOI 10.1016/j.cub.2003.09.001; Wachtler V, 2003, J CELL SCI, V116, P867, DOI 10.1242/jcs.00299; Wu JQ, 2003, DEV CELL, V5, P723, DOI 10.1016/S1534-5807(03)00324-1; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	30	70	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2004	6	11					1142	U40		10.1038/ncb1189	http://dx.doi.org/10.1038/ncb1189			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	867BI	15517003				2022-12-25	WOS:000224816700021
J	Thiel, KA				Thiel, KA			Biomanufacturing, from bust to boom ... to bubble?	NATURE BIOTECHNOLOGY			English	Article																		*BIOT IND ORG, 2004, ADV PLANTS PROD THER; FOX S, 2004, CONTRACT PHARM   JUN, P72; MOLOWA D, 2001, IND ANAL STATE BIOL	3	45	49	2	14	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2004	22	11					1365	1372		10.1038/nbt1104-1365	http://dx.doi.org/10.1038/nbt1104-1365			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	869CL	15529157				2022-12-25	WOS:000224960600023
J	Janecke, AR; Thompson, DA; Utermann, G; Becker, C; Hubner, CA; Schmid, E; McHenry, CL; Nair, AR; Ruschendorf, F; Heckenlively, J; Wissinger, B; Nurnberg, P; Gal, A				Janecke, AR; Thompson, DA; Utermann, G; Becker, C; Hubner, CA; Schmid, E; McHenry, CL; Nair, AR; Ruschendorf, F; Heckenlively, J; Wissinger, B; Nurnberg, P; Gal, A			Mutations in RDH12 encoding a photoreceptor cell retinol dehydrogenase cause childhood-onset severe retinal dystrophy	NATURE GENETICS			English	Article							LEBER CONGENITAL AMAUROSIS; LINKAGE ANALYSIS; VERTEBRATE RETINA; IDENTIFICATION; METABOLISM; DISEASES; GENES	members affected by autosomal recessive childhood-onset severe retinal dystrophy, a genetically heterogeneous group of disorders characterized by degeneration of the photoreceptor cells(1). A whole-genome scan by microarray analysis of single-nucleotide polymorphisms (ref. 2) identified a founder haplotype and defined a critical interval of 1.53 cM on chromosome 14q23.3-q24.1 that contains the gene associated with this form of retinal dystrophy. RDH12 maps in this region and encodes a retinol dehydrogenase proposed to function in the visual cycle(3). A homozygous 677A --> G transition (resulting in Y226C) in RDH12 was present in all affected family members studied, as well as in two Austrian individuals with sporadic retinal dystrophy. We identified additional mutations in RDH12 in 3 of 89 non-Austrian individuals with retinal dystrophy: a 5-nucleotide deletion (806delCCCTG) and the transition 565C --> T ( resulting in Q189X), each in the homozygous state, and 146C --> T (resulting in T49M) and 184C --> T (resulting in R62X) in compound heterozygosity. When expressed in COS-7 cells, Cys226 and Met49 variants had diminished and aberrant activity, respectively, in interconverting isomers of retinol and retinal. The severe visual impairment of individuals with mutations in RDH12 is in marked contrast to the mild visual deficiency in individuals with fundus albipunctatus caused by mutations in RDH5, encoding another retinal dehydrogenase(4). Our studies show that RDH12 is associated with retinal dystrophy and encodes an enzyme with a unique, nonredundant role in the photoreceptor cells.	Med Univ Innsbruck, Inst Med Biol & Humangenet, Innsbruck, Austria; Univ Michigan, Sch Med, Dept Ophthalmol & Visual Sci, Ann Arbor, MI USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Max Delbruck Ctr Mol Med, Gene Mapping Ctr, Berlin, Germany; Univ Klinikum Hamburg Eppendorf, Inst Humangenet, D-22529 Hamburg, Germany; Med Univ Innsbruck, Klin Augenheilkunde, Innsbruck, Austria; Univ Tubingen, Klin Augenheilkunde, Tubingen, Germany; Hsch Med Berlin, Charite, Inst Med Genet, Berlin, Germany	Medical University of Innsbruck; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Hamburg; University Medical Center Hamburg-Eppendorf; Medical University of Innsbruck; Eberhard Karls University of Tubingen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Utermann, G (corresponding author), Med Univ Innsbruck, Inst Med Biol & Humangenet, Innsbruck, Austria.	Gerd.Utermann@uibk.ac.at	Hübner, Christian/A-2950-2017; Janecke, Andreas/AAA-5227-2019	Hübner, Christian/0000-0002-1030-4943; Janecke, Andreas/0000-0001-7155-0315; Thompson, Debra/0000-0003-3485-0794				Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786; Abecasis GR, 2001, BIOINFORMATICS, V17, P742, DOI 10.1093/bioinformatics/17.8.742; Garwin GG, 2000, METHOD ENZYMOL, V316, P313; Haeseleer F, 2002, J BIOL CHEM, V277, P45537, DOI 10.1074/jbc.M208882200; Haeseleer F, 1998, J BIOL CHEM, V273, P21790, DOI 10.1074/jbc.273.34.21790; Kennedy GC, 2003, NAT BIOTECHNOL, V21, P1233, DOI 10.1038/nbt869; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034; Rivolta C, 2002, HUM MOL GENET, V11, P1219, DOI 10.1093/hmg/11.10.1219; Stockton DW, 1998, HUM GENET, V103, P328, DOI 10.1007/s004390050825; Strauch K, 2000, AM J HUM GENET, V66, P1945, DOI 10.1086/302911; Thompson DA, 2003, PROG RETIN EYE RES, V22, P683, DOI 10.1016/S1350-9462(03)00051-X; Woodruff ML, 2003, NAT GENET, V35, P158, DOI 10.1038/ng1246; Yamamoto H, 1999, NAT GENET, V22, P188, DOI 10.1038/9707	16	182	188	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2004	36	8					850	854		10.1038/ng1394	http://dx.doi.org/10.1038/ng1394			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	842AG	15258582				2022-12-25	WOS:000222974000017
J	Sato, M; Sato, K; Fonarev, P; Huang, CJ; Liou, W; Grant, BD				Sato, M; Sato, K; Fonarev, P; Huang, CJ; Liou, W; Grant, BD			Caenorhabditis elegans RME-6 is a novel regulator of RAB-5 at the clathrin-coated pit	NATURE CELL BIOLOGY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; SMALL GTPASE RAB5; J-DOMAIN PROTEIN; C-ELEGANS; EARLY ENDOSOMES; MEDIATED ENDOCYTOSIS; VULVAR INDUCTION; MEMBRANE-FUSION; EFFECTOR; ACTIVATION	Here we identify a new regulator of endocytosis called RME-6. RME-6 is evolutionarily conserved among metazoans and contains Ras-GAP (GTPase-activating protein)-like and Vps9 domains. Consistent with the known catalytic function of Vps9 domains in Rab5 GDP/GTP exchange, we found that RME-6 binds specifically to Caenorhabditis elegans RAB-5 in the GDP-bound conformation, and rme-6 mutants have phenotypes that indicate low RAB-5 activity. However, unlike other Rab5-associated proteins, a rescuing green fluorescent protein (GFP)-RME-6 fusion protein primarily localizes to clathrin-coated pits, physically interacts with alpha-adaptin, a clathrin adaptor protein, and requires clathrin to achieve its cortical localization. In rme-6 mutants, transport from the plasma membrane to endosomes is defective, and small 110-nm endocytic vesicles accumulate just below the plasma membrane. These results suggest a mechanism for the activation of Rab5 in clathrin-coated pits or clathrin-coated vesicles that is essential for the delivery of endocytic cargo to early endosomes.	Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Chang Gung Univ, Dept Anat, Taoyuan 333, Taiwan; RIKEN, Mol Membrane Biol Lab, Wako, Saitama 3510198, Japan	Rutgers State University New Brunswick; Chang Gung University; RIKEN	Grant, BD (corresponding author), Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA.	grant@biology.rutgers.edu	Sato, Miyuki/S-5112-2018	Sato, Miyuki/0000-0002-1944-4918; Huang, Chih-Jen/0000-0001-7791-6656; Grant, Barth/0000-0002-5943-8336; Liou, Willisa/0000-0002-3280-9635	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067237] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM67237, R01 GM067237] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barbieri MA, 2000, J CELL BIOL, V151, P539, DOI 10.1083/jcb.151.3.539; Bernards A, 2003, BBA-REV CANCER, V1603, P47, DOI 10.1016/S0304-419X(02)00082-3; BRENNER S, 1974, GENETICS, V77, P71; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Christoforidis S, 1999, NAT CELL BIOL, V1, P249, DOI 10.1038/12075; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Dang H, 2004, MOL BIOL CELL, V15, P189, DOI 10.1091/mbc.E03-08-0605; De Renzis S, 2002, NAT CELL BIOL, V4, P124, DOI 10.1038/ncb744; Delprato A, 2004, CELL, V118, P607, DOI 10.1016/j.cell.2004.08.009; Fares H, 2002, TRAFFIC, V3, P11, DOI 10.1034/j.1600-0854.2002.30103.x; Fares H, 2001, GENETICS, V159, P133; Fares H, 2001, NAT GENET, V28, P64, DOI 10.1038/ng0501-64; Galperin E, 2003, J CELL SCI, V116, P4799, DOI 10.1242/jcs.00801; Grant B, 1999, MOL BIOL CELL, V10, P4311, DOI 10.1091/mbc.10.12.4311; Grant B, 2001, NAT CELL BIOL, V3, P573, DOI 10.1038/35078549; Greener T, 2001, NAT CELL BIOL, V3, P215, DOI 10.1038/35055137; Hajnal A, 1997, GENE DEV, V11, P2715, DOI 10.1101/gad.11.20.2715; Hama H, 1999, J BIOL CHEM, V274, P15284, DOI 10.1074/jbc.274.21.15284; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Hayashizaki S, 1998, GENES CELLS, V3, P189, DOI 10.1046/j.1365-2443.1998.00179.x; HORIUCHI H, 1995, J BIOL CHEM, V270, P11257, DOI 10.1074/jbc.270.19.11257; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Kamath RS, 2003, METHODS, V30, P313, DOI 10.1016/S1046-2023(03)00050-1; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; Mattera R, 2003, EMBO J, V22, P78, DOI 10.1093/emboj/cdg015; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; McLauchlan H, 1998, CURR BIOL, V8, P34, DOI 10.1016/S0960-9822(98)70018-1; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MISHRA SK, 2004, J BIOL CHEM; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; Pellettieri J, 2003, DEV CELL, V5, P451, DOI 10.1016/S1534-5807(03)00231-4; Praitis V, 2001, GENETICS, V157, P1217; Rubino M, 2000, J BIOL CHEM, V275, P3745, DOI 10.1074/jbc.275.6.3745; Shaye DD, 2002, NATURE, V420, P686, DOI 10.1038/nature01234; Shiba Y, 2002, J BIOCHEM, V131, P327, DOI 10.1093/oxfordjournals.jbchem.a003107; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; Tall GG, 2001, DEV CELL, V1, P73, DOI 10.1016/S1534-5807(01)00008-9; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Topp JD, 2004, J BIOL CHEM, V279, P24612, DOI 10.1074/jbc.M313504200; WILLIAMS BD, 1992, GENETICS, V131, P609; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhang YH, 2001, MOL BIOL CELL, V12, P2011, DOI 10.1091/mbc.12.7.2011	46	125	138	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2005	7	6					559	U7		10.1038/ncb1261	http://dx.doi.org/10.1038/ncb1261			15	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	932OD	15895077	Green Accepted			2022-12-25	WOS:000229562100010
J	Srinivasan, BS; Caberoy, NB; Suen, G; Taylor, RG; Shah, R; Tengra, F; Goldman, BS; Garza, AG; Welch, RD				Srinivasan, BS; Caberoy, NB; Suen, G; Taylor, RG; Shah, R; Tengra, F; Goldman, BS; Garza, AG; Welch, RD			Functional genome annotation through phylogenomic mapping	NATURE BIOTECHNOLOGY			English	Article							FRUITING BODY DEVELOPMENT; MYXOCOCCUS-XANTHUS; GENE ONTOLOGY; PROTEIN INTERACTIONS; GLIDING MOTILITY; EXPRESSION; DATABASE; LIPOPOLYSACCHARIDE; MYXOBACTERIA; PROFILES	Accurate determination of functional interactions among proteins at the genome level remains a challenge for genomic research. Here we introduce a genome-scale approach to functional protein annotation-phylogenomic mapping-that requires only sequence data, can be applied equally well to both finished and unfinished genomes, and can be extended beyond single genomes to annotate multiple genomes simultaneously. We have developed and applied it to more than 200 sequenced bacterial genomes. Proteins with similar evolutionary histories were grouped together, placed on a three dimensional map and visualized as a topographical landscape. The resulting phylogenomic maps display thousands of proteins clustered in mountains on the basis of coinheritance, a strong indicator of shared function. In addition to systematic computational validation, we have experimentally confirmed the ability of phylogenomic maps to predict both mutant phenotype and gene function in the delta proteobacterium Myxococcus xanthus.	Syracuse Univ, Dept Biol, Syracuse, NY 13244 USA; Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Dept Elect Engn, Stanford, CA 94305 USA; Monsanto Co, St Louis, MO 63198 USA	Syracuse University; Stanford University; Stanford University; Monsanto	Welch, RD (corresponding author), Syracuse Univ, Dept Biol, 130 Coll Pl,BRL Room 702A, Syracuse, NY 13244 USA.	rowelch@syr.edu	Suen, Garret/B-3296-2008; Suen, Garret/AAF-2080-2019	Suen, Garret/0000-0002-6170-711X; Welch, Roy/0000-0002-9946-108X				Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Boyle EI, 2004, BIOINFORMATICS, V20, P3710, DOI 10.1093/bioinformatics/bth456; Caberoy NB, 2003, J BACTERIOL, V185, P6083, DOI 10.1128/JB.185.20.6083-6094.2003; Camon E, 2004, NUCLEIC ACIDS RES, V32, pD262, DOI 10.1093/nar/gkh021; Daubin V, 2003, SCIENCE, V301, P829, DOI 10.1126/science.1086568; Davidson GS, 2001, IEEE SYMPOSIUM ON INFORMATION VISUALIZATION 2001, PROCEEDINGS, P23, DOI 10.1109/INFVIS.2001.963275; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Enault F, 2004, NUCLEIC ACIDS RES, V32, pW336, DOI 10.1093/nar/gkh365; FINK JM, 1989, J BACTERIOL, V171, P2042, DOI 10.1128/jb.171.4.2042-2048.1989; Florea L, 2003, NUCLEIC ACIDS RES, V31, P3527, DOI 10.1093/nar/gkg551; Galperin MY, 2000, NAT BIOTECHNOL, V18, P609, DOI 10.1038/76443; Gaspar JA, 2000, MOL MICROBIOL, V38, P262, DOI 10.1046/j.1365-2958.2000.02094.x; GERTH K, 1983, J ANTIBIOT, V36, P1150, DOI 10.7164/antibiotics.36.1150; Gertz J, 2003, BIOINFORMATICS, V19, P2039, DOI 10.1093/bioinformatics/btg278; Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Holder M, 2003, NAT REV GENET, V4, P275, DOI 10.1038/nrg1044; Huynen MA, 2003, CURR OPIN CELL BIOL, V15, P191, DOI 10.1016/S0955-0674(03)00009-7; Julien B, 2002, ANTIMICROB AGENTS CH, V46, P2772, DOI 10.1128/AAC.46.9.2772-2778.2002; Kaiser D, 2003, NAT REV MICROBIOL, V1, P45, DOI 10.1038/nrmicro733; Kaiser D, 2004, J BACTERIOL, V186, P919, DOI 10.1128/JB.186.4.919-927.2004; Kim SK, 2001, SCIENCE, V293, P2087, DOI 10.1126/science.1061603; KROOS L, 1990, J BACTERIOL, V172, P484, DOI 10.1128/JB.172.1.484-487.1990; Lowe J, 2004, ANNU REV BIOPH BIOM, V33, P177, DOI 10.1146/annurev.biophys.33.110502.132647; Marcotte EM, 2000, P NATL ACAD SCI USA, V97, P12115, DOI 10.1073/pnas.220399497; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; McAdams HH, 2004, NAT REV GENET, V5, P169, DOI 10.1038/nrg1292; Michalickova K, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-32; Overbeek R, 1999, P NATL ACAD SCI USA, V96, P2896, DOI 10.1073/pnas.96.6.2896; Pazos F, 2002, PROTEINS, V47, P219, DOI 10.1002/prot.10074; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; POSPIECH A, 1995, MICROBIOL-SGM, V141, P1793, DOI 10.1099/13500872-141-8-1793; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; SHI WY, 1993, P NATL ACAD SCI USA, V90, P3378, DOI 10.1073/pnas.90.8.3378; Stuart JM, 2003, SCIENCE, V302, P249, DOI 10.1126/science.1087447; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; Werner-Washburne M, 2002, GENOME RES, V12, P1564, DOI 10.1101/gr.225402; Wolgemuth C, 2002, CURR BIOL, V12, P369, DOI 10.1016/S0960-9822(02)00716-9; WU SS, 1995, MOL MICROBIOL, V18, P547, DOI 10.1111/j.1365-2958.1995.mmi_18030547.x; Youderian P, 2003, MOL MICROBIOL, V49, P555, DOI 10.1046/j.1365-2958.2003.03582.x	43	21	21	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2005	23	6					691	698		10.1038/nbt1098	http://dx.doi.org/10.1038/nbt1098			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	933LA	15940241				2022-12-25	WOS:000229628700029
J	Schmid, M; Davison, TS; Henz, SR; Pape, UJ; Demar, M; Vingron, M; Scholkopf, B; Weigel, D; Lohmann, JU				Schmid, M; Davison, TS; Henz, SR; Pape, UJ; Demar, M; Vingron, M; Scholkopf, B; Weigel, D; Lohmann, JU			A gene expression map of Arabidopsis thaliana development	NATURE GENETICS			English	Article							DUPLICATE GENES; TRANSCRIPTION FACTORS; NEIGHBORING GENES; GENOME; DIVERGENCE; REVEALS; COEXPRESSION; SUPERFAMILY; MICROARRAY; EVOLUTION	Regulatory regions of plant genes tend to be more compact than those of animal genes, but the complement of transcription factors encoded in plant genomes is as large or larger than that found in those of animals(1). Plants therefore provide an opportunity to study how transcriptional programs control multicellular development. We analyzed global gene expression during development of the reference plant Arabidopsis thaliana in samples covering many stages, from embryogenesis to senescence, and diverse organs. Here, we provide a first analysis of this data set, which is part of the AtGenExpress expression atlas. We observed that the expression levels of transcription factor genes and signal transduction components are similar to those of metabolic genes. Examining the expression patterns of large gene families, we found that they are often more similar than would be expected by chance, indicating that many gene families have been co-opted for specific developmental processes.	Max Planck Inst Dev Biol, D-72076 Tubingen, Germany; Max Planck Inst Biol Cybernet, D-72076 Tubingen, Germany; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Salk Inst Biol Studies, La Jolla, CA 92037 USA	Max Planck Society; Max Planck Society; Max Planck Society; Salk Institute	Weigel, D (corresponding author), Max Planck Inst Dev Biol, Spemannstr 37-39, D-72076 Tubingen, Germany.	weigel@weigelworld.org	Weigel, Detlef/GSJ-0799-2022; Schmid, Markus/I-4384-2015; Lohmann, Jan/T-3776-2019; Schölkopf, Bernhard/A-7570-2013; Weigel, Detlef/C-1418-2008; Weigel, Detlef/AAR-3312-2021	Weigel, Detlef/0000-0002-2114-7963; Schmid, Markus/0000-0002-0068-2967; Lohmann, Jan/0000-0003-3667-187X; Schölkopf, Bernhard/0000-0002-8177-0925; Weigel, Detlef/0000-0002-2114-7963; 				Allemeersch J, 2005, PLANT PHYSIOL, V137, P588, DOI 10.1104/pp.104.051300; Becker A, 2003, MOL PHYLOGENET EVOL, V29, P464, DOI 10.1016/S1055-7903(03)00207-0; Becker JD, 2003, PLANT PHYSIOL, V133, P713, DOI 10.1104/pp.103.028241; Beyer A, 2004, MOL CELL PROTEOMICS, V3, P1083, DOI 10.1074/mcp.M400099-MCP200; Birnbaum K, 2003, SCIENCE, V302, P1956, DOI 10.1126/science.1090022; Blanc G, 2004, PLANT CELL, V16, P1679, DOI 10.1105/tpc.021410; Cohen BA, 2000, NAT GENET, V26, P183, DOI 10.1038/79896; Copenhaver GP, 1999, SCIENCE, V286, P2468, DOI 10.1126/science.286.5449.2468; Czechowski T, 2004, PLANT J, V38, P366, DOI 10.1111/j.1365-313X.2004.02051.x; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eulgem T, 2000, TRENDS PLANT SCI, V5, P199, DOI 10.1016/S1360-1385(00)01600-9; Force A, 1999, GENETICS, V151, P1531; Fransz PF, 2000, CELL, V100, P367, DOI 10.1016/S0092-8674(00)80672-8; Gagne JM, 2002, P NATL ACAD SCI USA, V99, P11519, DOI 10.1073/pnas.162339999; Gu ZL, 2002, TRENDS GENET, V18, P609, DOI 10.1016/S0168-9525(02)02837-8; Haberer G, 2004, PLANT PHYSIOL, V136, P3009, DOI 10.1104/pp.104.046466; HISING T, 2004, MACH LEARN, V52, P11; Huminiecki L, 2004, GENOME RES, V14, P1870, DOI 10.1101/gr.2705204; Jansen R, 2002, GENOME RES, V12, P37, DOI 10.1101/gr.205602; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Lercher MJ, 2003, GENOME RES, V13, P238, DOI 10.1101/gr.553803; Lercher MJ, 2002, NAT GENET, V31, P180, DOI 10.1038/ng887; Lippman Z, 2004, NATURE, V431, P364, DOI 10.1038/nature02875; Scholkopf B, 1998, NEURAL COMPUT, V10, P1299, DOI 10.1162/089976698300017467; Spellman Paul T, 2002, J Biol, V1, P5, DOI 10.1186/1475-4924-1-5; Tornow S, 2003, NUCLEIC ACIDS RES, V31, P6283, DOI 10.1093/nar/gkg838; Wellmer F, 2004, PLANT CELL, V16, P1314, DOI 10.1105/tpc.021741; Williams EJB, 2004, GENOME RES, V14, P1060, DOI 10.1101/gr.2131104; Wu Z., 2004, DEP BIOSTATISTICS WO; Yamada K, 2003, SCIENCE, V302, P842, DOI 10.1126/science.1088305	30	1904	1982	6	276	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2005	37	5					501	506		10.1038/ng1543	http://dx.doi.org/10.1038/ng1543			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	922TU	15806101				2022-12-25	WOS:000228862300019
J	Parker, JA; Arango, M; Abderrahmane, S; Lambert, E; Tourette, C; Catoire, H; Neri, C				Parker, JA; Arango, M; Abderrahmane, S; Lambert, E; Tourette, C; Catoire, H; Neri, C			Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons	NATURE GENETICS			English	Article							LIFE-SPAN; CAENORHABDITIS-ELEGANS; TRANSCRIPTION FACTORS; SIRT1 DEACETYLASE; C-ELEGANS; DAF-16; RESTRICTION; ACTIVATORS; MODELS; GENES	We report that Sir2 activation through increased sir-2.1 dosage or treatment with the sirtuin activator resveratrol specifically rescued early neuronal dysfunction phenotypes induced by mutant polyglutamines in transgenic Caenorhabditis elegans. These effects are dependent on daf-16 ( Forkhead). Additionally, resveratrol rescued mutant polyglutamine - specific cell death in neuronal cells derived from HdhQ111 knock-in mice. We conclude that Sir2 activation may protect against mutant polyglutamines.	INSERM, Avenir Grp, Lab Genom Biol, Ctr Paul Broca, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Neri, C (corresponding author), INSERM, Avenir Grp, Lab Genom Biol, Ctr Paul Broca, F-75014 Paris, France.	christian.neri@broca.inserm.fr	Tourette, Cendrine/U-2540-2017; Neri, Christian/F-6729-2013; Parker, Alex/F-4953-2014	Neri, Christian/0000-0002-3790-2978; Parker, Alex/0000-0002-3333-2445				Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Lee SS, 2003, SCIENCE, V300, P644, DOI 10.1126/science.1083614; Levine MS, 2004, TRENDS NEUROSCI, V27, P691, DOI 10.1016/j.tins.2004.08.008; Morley JF, 2002, P NATL ACAD SCI USA, V99, P10417, DOI 10.1073/pnas.152161099; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Rubinsztein DC, 2002, TRENDS GENET, V18, P202, DOI 10.1016/S0168-9525(01)02625-7; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Trettel F, 2000, HUM MOL GENET, V9, P2799, DOI 10.1093/hmg/9.19.2799; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789	15	404	426	0	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	APR	2005	37	4					349	350		10.1038/ng1534	http://dx.doi.org/10.1038/ng1534			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	911XL	15793589				2022-12-25	WOS:000228040000015
J	Schubert, C				Schubert, C			Healing brain hemorrhage	NATURE MEDICINE			English	News Item								Investigators introduce a targeted treatment for intracerebral hemorrhage, a recombinant form of a molecule that promotes clotting. Recombinant activated factor VIIa (rFVIIa), which is used to treat hemophilia improved survival of patients. The investigators report that the area affected by bleeding was smallerin the patients treated with the drug.										Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991	1	0	0	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2005	11	4					385	385						1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15812519				2022-12-25	WOS:000228180500025
J	Zhu, DC; Kepley, CL; Zhang, K; Terada, T; Yamada, T; Saxon, A				Zhu, DC; Kepley, CL; Zhang, K; Terada, T; Yamada, T; Saxon, A			A chimeric human-cat fusion protein blocks cat-induced allergy	NATURE MEDICINE			English	Article							FC-EPSILON-RI; MAST-CELL ACTIVATION; AFFINITY IGE RECEPTOR; GAMMA-RII; NEGATIVE REGULATION; PHOSPHATASE SHIP; BASOPHILS; IDENTIFICATION; DEGRANULATION; ANAPHYLAXIS	Animal allergens are an important cause of asthma and allergic rhinitis. We designed and tested a chimeric human-cat fusion protein composed of a truncated human IgG Fc gamma 1 and the major cat allergen Fel d1, as a proof of concept for a new approach to allergy immunotherapy. This Fc gamma-Fel d1 protein induced dose-dependent inhibition of Fel d1-driven IgE-mediated histamine release from cat-allergic donors' basophils and sensitized human cord blood-derived mast cells. Such inhibition was associated with altered Syk and ERK signaling. The Fc gamma-Fel d1 protein also blocked in vivo reactivity in Fc epsilon RI alpha transgenic mice passively sensitized with human IgE antibody to cat and in Balb/c mice actively sensitized against Fel d1. The Fc gamma-Fel d1 protein alone did not induce mediator release. Chimeric human Fc gamma-allergen fusion proteins may provide a new therapeutic platform for the immune-based therapy of allergic disease.	Univ Calif Los Angeles, Sch Med, Dept Med,Div Clin Immunol Allergy, Hart & Louise Lyon Lab, Los Angeles, CA 90095 USA; Virginia Commonwealth Univ, Dept Internal Med, Div Rheumatol Allergy & Immunol, Richmond, VA 23298 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Virginia Commonwealth University	Zhu, DC (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med,Div Clin Immunol Allergy, Hart & Louise Lyon Lab, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	dczhu@ucla.edu; asaxon@mednet.ucla.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015251, R21AI015251] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI015251-26, AI-15251, R01 AI015251-25, R01 AI015251-24] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Dombrowicz D, 1996, J IMMUNOL, V157, P1645; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; Fong DC, 1996, IMMUNOL LETT, V54, P83, DOI 10.1016/S0165-2478(96)02654-5; FungLeung WP, 1996, J EXP MED, V183, P49, DOI 10.1084/jem.183.1.49; HULETT MD, 1994, J BIOL CHEM, V269, P15287; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; Kepley CL, 2000, J IMMUNOL, V165, P5913, DOI 10.4049/jimmunol.165.10.5913; Kepley CL, 2000, J ALLERGY CLIN IMMUN, V106, P337, DOI 10.1067/mai.2000.107931; Kepley CL, 2004, J BIOL CHEM, V279, P35139, DOI 10.1074/jbc.M404318200; KEPLEY CL, 1995, J IMMUNOL, V154, P6548; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Malbec O, 1998, J IMMUNOL, V160, P1647; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; Oliver JM, 2000, IMMUNOPHARMACOLOGY, V48, P269, DOI 10.1016/S0162-3109(00)00224-1; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ott VL, 2000, J ALLERGY CLIN IMMUN, V106, P429, DOI 10.1067/mai.2000.109428; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; SCHUESSLER TF, 1995, IEEE T BIO-MED ENG, V42, P860, DOI 10.1109/10.412653; Suzuki H, 1997, J IMMUNOL, V159, P5881; Tam SW, 2004, ALLERGY, V59, P772, DOI 10.1111/j.1398-9995.2004.00332.x; Vailes LD, 2002, J ALLERGY CLIN IMMUN, V110, P757, DOI 10.1067/mai.2002.129035; Wedi B, 1996, ARCH DERMATOL RES, V289, P21, DOI 10.1007/s004030050147; Witteman AM, 1996, INT ARCH ALLERGY IMM, V109, P369, DOI 10.1159/000237265; Zhang K, 2004, J ALLERGY CLIN IMMUN, V114, P321, DOI 10.1016/j.jaci.2004.03.058; Zhu DC, 2002, NAT MED, V8, P518, DOI 10.1038/nm0502-518	28	163	175	1	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2005	11	4					446	449		10.1038/nm1219	http://dx.doi.org/10.1038/nm1219			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15793580				2022-12-25	WOS:000228180500038
J	Heppner, FL; Greter, M; Marino, D; Falsig, J; Raivich, G; Hovelmeyer, N; Waisman, A; Rulicke, T; Prinz, M; Priller, J; Becher, B; Aguzzi, A				Heppner, FL; Greter, M; Marino, D; Falsig, J; Raivich, G; Hovelmeyer, N; Waisman, A; Rulicke, T; Prinz, M; Priller, J; Becher, B; Aguzzi, A			Experimental autoimmune encephalomyelitis repressed by microglial paralysis	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; ANTIGEN-PRESENTING CELLS; CNS-RESIDENT CELLS; MULTIPLE-SCLEROSIS; THYMIDINE KINASE; TRANSGENIC MICE; HEMATOPOIETIC-CELLS; BONE-MARROW; STEM-CELLS	Although microglial activation occurs in inflammatory, degenerative and neoplastic central nervous system (CNS) disorders, its role in pathogenesis is unclear. We studied this question by generating CD11b-HSVTK transgenic mice, which express herpes simplex thymidine kinase in macrophages and microglia. Ganciclovir treatment of organotypic brain slice cultures derived from CD11b-HSVTK mice abolished microglial release of nitrite, proinflammatory cytokines and chemokines. Systemic ganciclovir administration to CD11b-HSVTK mice elicited hematopoietic toxicity, which was prevented by transfer of wild-type bone marrow. In bone marrow chimeras, ganciclovir blocked microglial activation in the facial nucleus upon axotomy and repressed the development of experimental autoimmune encephalomyelitis. We conclude that microglial paralysis inhibits the development and maintenance of inflammatory CNS lesions. The microglial compartment thus provides a potential therapeutic target in inflammatory CNS disorders. These results validate CD11b-HSVTK mice as a tool to study the impact of microglial activation on CNS diseases in vivo.	Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Neurol, Neuroimmunol Unit, CH-8091 Zurich, Switzerland; UCL, Perinatal Brain Repair Grp, Dept Obstet & Gynaecol, London WC1E 6HX, England; UCL, Perinatal Brain Repair Grp, Dept Anat, London WC1E 6HX, England; Univ Cologne, Lab Mol Immunol, Inst Genet, D-50931 Cologne, Germany; Univ Zurich, Inst Lab Anim Sci, CH-8091 Zurich, Switzerland; Humboldt Univ, Dept Psychiat, Charite, D-10117 Berlin, Germany; Humboldt Univ, Dept Expt Neurol, Charite, D-10117 Berlin, Germany	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of London; University College London; University of London; University College London; University of Cologne; University of Zurich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Aguzzi, A (corresponding author), Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland.	adriano@pathol.unizh.ch	Calabrese, Massimiliano/I-6195-2012; Becher, Burkhard/ABE-4225-2020; Raivich, Gennadij/AAL-7229-2021; Aguzzi, Adriano/A-3351-2008; Heppner, Frank/ABH-8393-2020; Marino, Denis/AAU-7962-2020; Priller, Josef/ABW-3835-2022; Waisman, Ari/C-7383-2015; Raivich, Gennadij/A-6770-2011	Becher, Burkhard/0000-0002-1541-7867; Heppner, Frank/0000-0001-9816-8917; Marino, Denis/0000-0002-5197-6682; Waisman, Ari/0000-0003-4304-8234; Hovelmeyer, Nadine/0000-0002-1807-4556; Aguzzi, Adriano/0000-0002-0344-6708; Greter, Melanie/0000-0002-7220-5369; Priller, Josef/0000-0001-7596-0979				Ambrosini E, 2004, NEUROCHEM RES, V29, P1017, DOI 10.1023/B:NERE.0000021246.96864.89; Asheuer M, 2004, P NATL ACAD SCI USA, V101, P3557, DOI 10.1073/pnas.0306431101; Becher B, 2000, GLIA, V29, P293; Becher B, 2003, J CLIN INVEST, V112, P1186, DOI 10.1172/JCI200319079; Becher B, 2001, J EXP MED, V193, P967, DOI 10.1084/jem.193.8.967; Benveniste EN, 1997, J MOL MED-JMM, V75, P165, DOI 10.1007/s001090050101; Black ME, 1996, P NATL ACAD SCI USA, V93, P3525, DOI 10.1073/pnas.93.8.3525; BRAUN RE, 1990, BIOL REPROD, V43, P684, DOI 10.1095/biolreprod43.4.684; Bush TG, 1998, CELL, V93, P189, DOI 10.1016/S0092-8674(00)81571-8; Carson MJ, 2002, GLIA, V40, P218, DOI 10.1002/glia.10145; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DZIENNIS S, 1995, BLOOD, V85, P319; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Ellison AR, 1998, BBA-GENE STRUCT EXPR, V1442, P28, DOI 10.1016/S0167-4781(98)00112-2; Fisher RC, 1999, BLOOD, V94, P1283, DOI 10.1182/blood.V94.4.1283.416k16_1283_1290; Flugel A, 2001, IMMUNITY, V14, P547, DOI 10.1016/s1074-7613(01)00143-1; FORD AL, 1995, J IMMUNOL, V154, P4309; FYFE JA, 1978, J BIOL CHEM, V253, P8721; Hailer NP, 1998, BRAIN PATHOL, V8, P459; Heppner FL, 1998, EUR J NEUROSCI, V10, P3284, DOI 10.1046/j.1460-9568.1998.00379.x; Heppner FL, 1998, GLIA, V22, P180, DOI 10.1002/(SICI)1098-1136(199802)22:2<180::AID-GLIA9>3.0.CO;2-B; Heppner FL, 2001, SCIENCE, V294, P178, DOI 10.1126/science.1063093; Herraiz M, 2003, HUM GENE THER, V14, P463, DOI 10.1089/104303403321467225; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; Kerschensteiner M, 2003, ANN NEUROL, V53, P292, DOI 10.1002/ana.10446; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lassmann H, 2001, TRENDS MOL MED, V7, P115, DOI 10.1016/S1471-4914(00)01909-2; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Marin-Teva JL, 2004, NEURON, V41, P535, DOI 10.1016/S0896-6273(04)00069-8; Martiney JA, 1998, J IMMUNOL, V160, P5588; Matyszak MK, 1999, EUR J IMMUNOL, V29, P3063, DOI 10.1002/(SICI)1521-4141(199910)29:10<3063::AID-IMMU3063>3.0.CO;2-G; Miranda KM, 2001, NITRIC OXIDE-BIOL CH, V5, P62, DOI 10.1006/niox.2000.0319; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Pedchenko TV, 1999, EXP NEUROL, V158, P459, DOI 10.1006/exnr.1999.7125; Priller J, 2001, NAT MED, V7, P1356, DOI 10.1038/nm1201-1356; Raivich G, 1998, J NEUROSCI, V18, P5804; Sasaki Y, 2001, BIOCHEM BIOPH RES CO, V286, P292, DOI 10.1006/bbrc.2001.5388; Schwartz M, 2001, J NEUROIMMUNOL, V113, P185, DOI 10.1016/S0165-5728(00)00447-1; Steinman L, 2002, ANNU REV NEUROSCI, V25, P491, DOI 10.1146/annurev.neuro.25.112701.142913; Tran EH, 1998, J IMMUNOL, V161, P3767; ULVESTAD E, 1994, J LEUKOCYTE BIOL, V56, P732, DOI 10.1002/jlb.56.6.732; Weiner HL, 2002, NATURE, V420, P879, DOI 10.1038/nature01325; Willenborg DO, 1999, J NEUROIMMUNOL, V100, P21, DOI 10.1016/S0165-5728(99)00212-X; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158	46	572	588	0	36	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					146	152		10.1038/nm1177	http://dx.doi.org/10.1038/nm1177			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15665833				2022-12-25	WOS:000226797300021
J	Kizawa, H; Kou, I; Iida, A; Sudo, A; Miyamoto, Y; Fukuda, A; Mabuchi, A; Kotani, A; Kawakami, A; Yamamoto, S; Uchida, A; Nakamura, K; Notoya, K; Nakamura, Y; Ikegawa, S				Kizawa, H; Kou, I; Iida, A; Sudo, A; Miyamoto, Y; Fukuda, A; Mabuchi, A; Kotani, A; Kawakami, A; Yamamoto, S; Uchida, A; Nakamura, K; Notoya, K; Nakamura, Y; Ikegawa, S			An aspartic acid repeat polymorphism in asporin inhibits chondrogenesis and increases susceptibility to osteoarthritis	NATURE GENETICS			English	Article							MAXIMUM-LIKELIHOOD-ESTIMATION; TGF-BETA; SEQUENCE POLYMORPHISMS; OSTEOPHYTE FORMATION; GENE-CLUSTER; KNEE; ASSOCIATION; EXPRESSION; DECORIN; DIFFERENTIATION	Osteoarthritis is the most common form of human arthritis. We investigated the potential role of asporin, an extracellular matrix component expressed abundantly in the articular cartilage of individuals with osteoarthritis, in the pathogenesis of osteoarthritis. Here we report a significant association between a polymorphism in the aspartic acid (D) repeat of the gene encoding asporin (ASPN) and osteoarthritis. In two independent populations of individuals with knee osteoarthritis, the D14 allele of ASPN is overrepresented relative to the common D13 allele, and its frequency increases with disease severity. The D14 allele is also overrepresented in individuals with hip osteoarthritis. Asporin suppresses TGF-beta-mediated expression of the genes aggrecan (AGC1) and type II collagen (COL2A1) and reduced proteoglycan accumulation in an in vitro model of chondrogenesis. The effect on TGF-beta activity is allele-specific, with the D14 allele resulting in greater inhibition than other alleles. In vitro binding assays showed a direct interaction between asporin and TGF-beta. Taken together, these findings provide another functional link between extracellular matrix proteins, TGF-beta activity and disease, suggesting new therapeutic strategies for osteoarthritis.	RIKEN, Inst Phys & Chem Res, SNP Res Ctr, Lab Bone & Joint Dis,Minato Ku, Tokyo 1088639, Japan; Takeda Chem Ind Ltd, Div Pharmaceut Res, Pharmaceut Res Labs 1, Yodogawa Ku, Osaka 5328686, Japan; RIKEN, Inst Phys & Chem Res, SNP Res Ctr, Lab Genotyping,Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Mie Univ, Fac Med, Dept Orthopaed Surg, Tsu, Mie 5148507, Japan; Univ Tokyo, Dept Orthopaed Surg, Bunkyo Ku, Tokyo 1138655, Japan; Kyorin Univ, Sch Med, Dept Orthopaed Surg, Tokyo 1818611, Japan; Tokyo Teishin Hosp, Dept Orthoped Surg, Chiyoda Ku, Tokyo 1028798, Japan; Tokyo Metropolitan Geriatr Hosp, Dept Orthoped Surg, Itabashi Ku, Tokyo 1730015, Japan	RIKEN; Takeda Chemical Industries; RIKEN; Mie University; University of Tokyo; Kyorin University	Ikegawa, S (corresponding author), RIKEN, Inst Phys & Chem Res, SNP Res Ctr, Lab Bone & Joint Dis,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	sikegawa@ims.u-tokyo.ac.jp	Iida, Aritoshi/CAA-1373-2022; Ikegawa, Shiro/N-6895-2015	Iida, Aritoshi/0000-0001-7538-1651; Ikegawa, Shiro/0000-0003-0316-2147				Ameye L, 2002, GLYCOBIOLOGY, V12, p107R, DOI 10.1093/glycob/cwf065; Ameye L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0848com; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; Dugan TA, 2003, J BIOL CHEM, V278, P13655, DOI 10.1074/jbc.M300171200; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; FELSON DT, 1987, ARTHRITIS RHEUM, V30, P914, DOI 10.1002/art.1780300811; Gill MR, 2002, OSTEOARTHR CARTILAGE, V10, P751, DOI 10.1053/joca.2002.0527; Grimaud E, 2002, CYTOKINE GROWTH F R, V13, P241, DOI 10.1016/S1359-6101(02)00004-7; Haga H, 2002, J HUM GENET, V47, P605, DOI 10.1007/s100380200092; Henry SP, 2001, J BIOL CHEM, V276, P12212, DOI 10.1074/jbc.M011290200; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Ikeda T, 2001, J HUM GENET, V46, P538, DOI 10.1007/s100380170036; Isaka Y, 1996, NAT MED, V2, P418, DOI 10.1038/nm0496-418; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; KELLGREN JH, 1963, ANN RHEUM DIS, V22, P237, DOI 10.1136/ard.22.4.237; Lorenzo P, 2001, J BIOL CHEM, V276, P12201, DOI 10.1074/jbc.M010932200; Loughlin J, 2002, ARTHRITIS RHEUM, V46, P1519, DOI 10.1002/art.10260; Loughlin J, 2001, CURR OPIN RHEUMATOL, V13, P111, DOI 10.1097/00002281-200103000-00004; Mabuchi A, 2001, J HUM GENET, V46, P456, DOI 10.1007/s100380170045; Meulenbelt I, 1997, ARTHRITIS RHEUM, V40, P1760, DOI 10.1002/art.1780401006; Neptune ER, 2003, NAT GENET, V33, P407, DOI 10.1038/ng1116; Scharstuhl A, 2002, J IMMUNOL, V169, P507, DOI 10.4049/jimmunol.169.1.507; Serra R, 1997, J CELL BIOL, V139, P541, DOI 10.1083/jcb.139.2.541; Shukunami C, 1998, EXP CELL RES, V241, P1, DOI 10.1006/excr.1998.4045; Shukunami C, 1997, J BONE MINER RES, V12, P1174, DOI 10.1359/jbmr.1997.12.8.1174; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; SINGH K, 1993, J BIOCHEM-TOKYO, V114, P702, DOI 10.1093/oxfordjournals.jbchem.a124240; Smith AJP, 2004, GENES IMMUN, V5, P451, DOI 10.1038/sj.gene.6364107; Spector TD, 1996, BRIT MED J, V312, P940; Spector Tim D, 2004, Osteoarthritis Cartilage, V12 Suppl A, pS39; Suzuki A, 2003, NAT GENET, V34, P395, DOI 10.1038/ng1206; Uitterlinden AG, 2000, ARTHRITIS RHEUM-US, V43, P1456, DOI 10.1002/1529-0131(200007)43:7<1456::AID-ANR7>3.0.CO;2-M; VANBEUNINGEN HM, 1994, LAB INVEST, V71, P279; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; Yamada R, 2001, AM J HUM GENET, V68, P674, DOI 10.1086/318789; Yang VWC, 1999, J BIOL CHEM, V274, P12454, DOI 10.1074/jbc.274.18.12454; Yang X, 2001, J CELL BIOL, V153, P35, DOI 10.1083/jcb.153.1.35	37	339	354	2	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2005	37	2					138	144		10.1038/ng1496	http://dx.doi.org/10.1038/ng1496			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	893AB	15640800				2022-12-25	WOS:000226690100019
J	Prust, C; Hoffmeister, M; Liesegang, H; Wiezer, A; Fricke, WF; Ehrenreich, A; Gottschalk, G; Deppenmeier, U				Prust, C; Hoffmeister, M; Liesegang, H; Wiezer, A; Fricke, WF; Ehrenreich, A; Gottschalk, G; Deppenmeier, U			Complete genome sequence of the acetic acid bacterium Gluconobacter oxydans	NATURE BIOTECHNOLOGY			English	Article							D-SORBITOL DEHYDROGENASE; CLONING; GENE; GLYCEROL; PLASMID; GLUCOSE; ENZYME	Gluconobacter oxydans is unsurpassed by other organisms in its ability to incompletely oxidize a great variety of carbohydrates, alcohols and related compounds. Furthermore, the organism is used for several biotechnological processes, such as vitamin C production. To further our understanding of its overall metabolism, we sequenced the complete genome of G. oxydans 621H. The chromosome consists of 2,702,173 base pairs and contains 2,432 open reading frames. In addition, five plasmids were identified that comprised 232 open reading frames. The sequence data can be used for metabolic reconstruction of the pathways leading to industrially important products derived from sugars and alcohols. Although the respiratory chain of G. oxydans was found to be rather simple, the organism contains many membrane-bound dehydrogenases that are critical for the incomplete oxidation of biotechnologically important substrates. Moreover, the genome project revealed the unique biochemistry of G. oxydans with respect to the process of incomplete oxidation.	Univ Wisconsin, Dept Biol Sci, Milwaukee, WI 53211 USA; Univ Gottingen, Inst Microbiol & Genet, Dept Gen Microbiol, D-37077 Gottingen, Germany; Univ Gottingen, Goettingen Genom Lab, D-37077 Gottingen, Germany; Univ Gottingen, Competence Ctr Genome Res Bacteria, Inst Microbiol & Genet, D-37077 Gottingen, Germany	University of Wisconsin System; University of Wisconsin Milwaukee; University of Gottingen; University of Gottingen; University of Gottingen	Deppenmeier, U (corresponding author), Univ Wisconsin, Dept Biol Sci, 3209 N Maryland Ave, Milwaukee, WI 53211 USA.	udeppen@uwm.edu		Liesegang, Heiko/0000-0003-1792-2047; Fricke, W. Florian/0000-0003-1586-0962; Ehrenreich, Armin/0000-0001-9580-3620				Adachi O, 2003, APPL MICROBIOL BIOT, V60, P643, DOI 10.1007/s00253-002-1155-9; ADACHI O, 2003, BIOCH BIOPYHS ACTA, V164, P10; ASAI T, 1964, J GEN APPL MICROBIOL, V10, P95, DOI 10.2323/jgam.10.95; Asai T., 1968, ACETIC ACID BACTERIA; Battey AS, 2001, J APPL MICROBIOL, V91, P237, DOI 10.1046/j.1365-2672.2001.01381.x; Bren A, 2000, J BACTERIOL, V182, P6865, DOI 10.1128/JB.182.24.6865-6873.2000; Cotton NPJ, 2001, STRUCTURE, V9, P165, DOI 10.1016/S0969-2126(01)00571-8; De Ley J., 1984, BERGEYS MANUAL SYSTE, V1, P267; Deppenmeier U, 2002, J MOL MICROB BIOTECH, V4, P453; Deppenmeier U, 2002, APPL MICROBIOL BIOT, V60, P233, DOI 10.1007/s00253-002-1114-5; Felder M, 2000, FEMS MICROBIOL LETT, V193, P231, DOI 10.1111/j.1574-6968.2000.tb09429.x; GREENFIELD S, 1972, J BACTERIOL, V112, P1295, DOI 10.1128/JB.112.3.1295-1301.1972; Grigoriev A, 1998, NUCLEIC ACIDS RES, V26, P2286, DOI 10.1093/nar/26.10.2286; Gupta A, 2001, J MOL MICROB BIOTECH, V3, P445; Hekmat D, 2003, BIOPROC BIOSYST ENG, V26, P109, DOI 10.1007/s00449-003-0338-9; Herrmann U, 2004, APPL MICROBIOL BIOT, V64, P86, DOI 10.1007/s00253-003-1455-8; Hoshino T, 2003, BBA-PROTEINS PROTEOM, V1647, P278, DOI 10.1016/S1570-9639(03)00071-2; Kondo K, 1997, APPL ENVIRON MICROB, V63, P1139, DOI 10.1128/AEM.63.3.1139-1142.1997; LODI T, 1993, MOL GEN GENET, V238, P315, DOI 10.1007/BF00291989; Macauley S, 2001, CRIT REV BIOTECHNOL, V21, P1, DOI 10.1080/07388550490465817; Mahillon J, 1998, MICROBIOL MOL BIOL R, V62, P725, DOI 10.1128/MMBR.62.3.725-774.1998; Matsushita K, 2003, APPL ENVIRON MICROB, V69, P1959, DOI 10.1128/AEM.69.4.1959-1966.2003; MATSUSHITA K, 1987, BIOCHIM BIOPHYS ACTA, V894, P304, DOI 10.1016/0005-2728(87)90200-3; MATSUSHITA K, 1994, ADV MICROB PHYSIOL, V36, P247, DOI 10.1016/S0065-2911(08)60181-2; MATSUSHITA K, 1989, AGR BIOL CHEM TOKYO, V53, P2895, DOI 10.1080/00021369.1989.10869793; OLIJVE W, 1979, ARCH MICROBIOL, V121, P291, DOI 10.1007/BF00425070; Overbeek R, 2003, NUCLEIC ACIDS RES, V31, P164, DOI 10.1093/nar/gkg148; PRONK JT, 1989, ENZYME MICROB TECH, V11, P160, DOI 10.1016/0141-0229(89)90075-6; Rabenhorst J, 2001, Patent, Patent No. [EP1078990, 1078990]; Raj KC, 2001, ARCH MICROBIOL, V176, P443, DOI 10.1007/s002030100348; REICHSTEIN T, 1934, HELV CHIM ACTA, V17, P160; ROBAKIS NK, 1985, J GEN MICROBIOL, V131, P2467; RULE GS, 1985, J BACTERIOL, V161, P1059, DOI 10.1128/JB.161.3.1059-1068.1985; SCHEDEL M, 2000, BIOTECHNOLOGY B, V8, P296; Shibata T, 2000, J BIOSCI BIOENG, V89, P463, DOI 10.1016/S1389-1723(00)89097-0; Shinjoh M, 2002, J BACTERIOL, V184, P861, DOI 10.1128/JB.184.3.861-863.2002; Sugiyama M, 2003, BIOSCI BIOTECH BIOCH, V67, P584, DOI 10.1271/bbb.67.584; Tech Maike, 2003, In Silico Biology, V3, P441; THONYMEYER L, 2003, BIOCHEMISTRY-US, V42, P13100; Tonouchi N, 2003, BIOSCI BIOTECH BIOCH, V67, P211, DOI 10.1271/bbb.67.211; Trcek J, 2000, APPL MICROBIOL BIOT, V53, P289, DOI 10.1007/s002530050023; WILLIAMS R, 1994, MICROBIOL-UK, V140, P1595, DOI 10.1099/13500872-140-7-1595	42	319	702	5	86	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2005	23	2					195	200		10.1038/nbt1062	http://dx.doi.org/10.1038/nbt1062			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	894NC	15665824	hybrid			2022-12-25	WOS:000226797600025
J	Rao, BM; Lauffenburger, DA; Wittrup, KD				Rao, BM; Lauffenburger, DA; Wittrup, KD			Integrating cell-level kinetic modeling into the design of engineered protein therapeutics	NATURE BIOTECHNOLOGY			English	Article							EPIDERMAL-GROWTH-FACTOR; MONOCLONAL-ANTIBODY; RATIONAL DESIGN; BINDING; AFFINITY; POTENCY; SURFACE; DYNAMICS; THERAPY; OPTIMIZATION	Functional genomics and proteomics are identifying many potential drug targets for novel therapeutic proteins, and both rational and combinatorial protein engineering methods are available for creating drug candidates. A central challenge is the definition of the most appropriate design criteria, which will benefit critically from computational kinetic models that incorporate integration from the molecular level to the whole systems level. Interpretation of these processes will require mathematical models that are refined in combination with relevant data derived from quantitative assays, to correctly set biophysical objectives for protein design.	MIT, Dept Chem Engn, Cambridge, MA 02139 USA; MIT, Biol Engn Div, Cambridge, MA 02139 USA; MIT, Biotechnol Proc Engn Ctr, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Wittrup, KD (corresponding author), MIT, Dept Chem Engn, MIT 66-552, Cambridge, MA 02139 USA.	wittrup@mit.edu		Rao, Balaji/0000-0001-5695-8953	NATIONAL CANCER INSTITUTE [R01CA096504] Funding Source: NIH RePORTER; NCI NIH HHS [CA96504] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams GP, 2001, CANCER RES, V61, P4750; Angeli D, 2004, P NATL ACAD SCI USA, V101, P1822, DOI 10.1073/pnas.0308265100; Ashkenazi A, 1997, CURR OPIN IMMUNOL, V9, P195, DOI 10.1016/S0952-7915(97)80135-5; Bander NH, 2003, SEMIN ONCOL, V30, P667, DOI 10.1016/S0093-7754(03)00358-0; Bialek W, 2004, SCIENCE, V303, P788, DOI 10.1126/science.1095480; Brekke OH, 2003, NAT REV DRUG DISCOV, V2, P52, DOI 10.1038/nrd984; Butte A, 2002, NAT REV DRUG DISCOV, V1, P951, DOI 10.1038/nrd961; Chakraborty AK, 2003, NAT IMMUNOL, V4, P933, DOI 10.1038/ni1003-933; Chang TW, 2000, NAT BIOTECHNOL, V18, P157, DOI 10.1038/72601; Dennis MS, 2002, J BIOL CHEM, V277, P35035, DOI 10.1074/jbc.M205854200; Dubois S, 2002, IMMUNITY, V17, P537, DOI 10.1016/S1074-7613(02)00429-6; Egrie JC, 2003, EXP HEMATOL, V31, P290, DOI 10.1016/S0301-472X(03)00006-7; Fallon EM, 2000, BIOTECHNOL PROGR, V16, P905, DOI 10.1021/bp000097t; Flynn AA, 2002, CANCER-AM CANCER SOC, V94, P1249, DOI 10.1002/cncr.10293; FOOTE J, 1995, P NATL ACAD SCI USA, V92, P1254, DOI 10.1073/pnas.92.5.1254; FORSTEN KE, 1992, BIOPHYS J, V63, P857, DOI 10.1016/S0006-3495(92)81661-2; FUJIMORI K, 1990, J NUCL MED, V31, P1191; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; Giovannoni G, 2003, NEUROLOGY, V61, pS13, DOI 10.1212/01.WNL.0000092379.75791.5D; Goffe B, 2003, J AM ACAD DERMATOL, V49, pS105, DOI 10.1016/mjd.2003.554; GOLDBETER A, 1981, P NATL ACAD SCI-BIOL, V78, P6840, DOI 10.1073/pnas.78.11.6840; Graff CP, 2003, CANCER RES, V63, P1288; Griffith LG, 2001, JAMA-J AM MED ASSOC, V285, P556, DOI 10.1001/jama.285.5.556; Grossmann M, 1998, NAT BIOTECHNOL, V16, P871, DOI 10.1038/nbt0998-871; Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033; Haugh JM, 2004, BIOTECHNOL PROGR, V20, P1337, DOI 10.1021/bp0499101; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; Horrobin DE, 2001, NAT BIOTECHNOL, V19, P1099, DOI 10.1038/nbt1201-1099; Jain RK, 1999, ANNU REV BIOMED ENG, V1, P241, DOI 10.1146/annurev.bioeng.1.1.241; Kortemme T, 2002, P NATL ACAD SCI USA, V99, P14116, DOI 10.1073/pnas.202485799; Lauffenburger D. A., 1993, RECEPTORS MODELS BIN; Lauffenburger DA, 1998, CHEM BIOL, V5, pR257, DOI 10.1016/S1074-5521(98)90110-7; Lazar GA, 2003, CURR OPIN STRUC BIOL, V13, P513, DOI 10.1016/S0959-440X(03)00104-0; Li QJ, 2004, NAT IMMUNOL, V5, P791, DOI 10.1038/ni1095; LU ZY, 1992, EUR J IMMUNOL, V22, P2819, DOI 10.1002/eji.1830221110; Marshall SA, 2003, DRUG DISCOV TODAY, V8, P212, DOI 10.1016/S1359-6446(03)02610-2; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; MONTEROJULIAN FA, 1995, BLOOD, V85, P917, DOI 10.1182/blood.V85.4.917.bloodjournal854917; Osbourn J, 2003, DRUG DISCOV TODAY, V8, P845, DOI 10.1016/S1359-6446(03)02803-4; Patten P A, 2003, Dev Biol (Basel), V112, P81; Pearce KH, 1999, BIOCHEMISTRY-US, V38, P81, DOI 10.1021/bi9817008; Perelson AS, 2002, NAT REV IMMUNOL, V2, P28, DOI 10.1038/nri700; Rao BM, 2004, MOL PHARMACOL, V66, P864, DOI 10.1124/mol.66.4.864; Reddy CC, 1996, NAT BIOTECHNOL, V14, P1696, DOI 10.1038/nbt1296-1696; Rees J, 2002, SCIENCE, V296, P698, DOI 10.1126/science.296.5568.698; Rosenberg A S, 2003, Dev Biol (Basel), V112, P15; Sanna PP, 2000, VIROLOGY, V270, P386; Sarkar CA, 2003, MOL PHARMACOL, V63, P147, DOI 10.1124/mol.63.1.147; Sarkar CA, 2002, NAT BIOTECHNOL, V20, P908, DOI 10.1038/nbt725; Schellekens H, 2002, NAT REV DRUG DISCOV, V1, P457, DOI 10.1038/nrd818; Schoeberl B, 2002, NAT BIOTECHNOL, V20, P370, DOI 10.1038/nbt0402-370; Smith KA, 1995, ANN NY ACAD SCI, V766, P263, DOI 10.1111/j.1749-6632.1995.tb26674.x; Steed PM, 2003, SCIENCE, V301, P1895, DOI 10.1126/science.1081297; Stroud Robert M, 2004, Sci STKE, V2004, pre7, DOI 10.1126/stke.2312004re7; Tyson JJ, 2003, CURR OPIN CELL BIOL, V15, P221, DOI 10.1016/S0955-0674(03)00017-6; Vasserot AP, 2003, DRUG DISCOV TODAY, V8, P118, DOI 10.1016/S1359-6446(02)02590-4; Wiley HS, 2003, TRENDS CELL BIOL, V13, P43; Wittrup KD, 2001, CURR OPIN BIOTECH, V12, P395, DOI 10.1016/S0958-1669(00)00233-0	58	37	42	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2005	23	2					191	194		10.1038/nbt1064	http://dx.doi.org/10.1038/nbt1064			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	894NC	15696150				2022-12-25	WOS:000226797600024
J	Zhu, XF; Luke, A; Cooper, RS; Quertermous, T; Hanis, C; Mosley, T; Gu, CC; Tang, H; Rao, DC; Risch, N; Weder, A				Zhu, XF; Luke, A; Cooper, RS; Quertermous, T; Hanis, C; Mosley, T; Gu, CC; Tang, H; Rao, DC; Risch, N; Weder, A			Admixture mapping for hypertension loci with genome-scan markers	NATURE GENETICS			English	Article							MULTILOCUS GENOTYPE DATA; LINKAGE DISEQUILIBRIUM; BLOOD-PRESSURE; POPULATION-STRUCTURE; ADMIXED POPULATIONS; AFRICAN-AMERICANS; DISEASE; GENES; INFERENCE	Identification of genetic variants that contribute to risk of hypertension is challenging. As a complement to linkage and candidate gene association studies, we carried out admixture mapping using genome-scan microsatellite markers among the African American participants in the US National Heart, Lung, and Blood Institute's Family Blood Pressure Program. This population was assumed to have experienced recent admixture from ancestral groups originating in Africa and Europe. We used a set of unrelated individuals from Nigeria to represent the African ancestral population and used the European Americans in the Family Blood Pressure Program to provide estimates of allele frequencies for the European ancestors. We genotyped a common set of 269 microsatellite markers in the three groups at the same laboratory. The distribution of marker location-specific African ancestry, based on multipoint analysis, was shifted upward in hypertensive cases versus normotensive controls, consistent with linkage to genes conferring susceptibility. This shift was largely due to a small number of loci, including five adjacent markers on chromosome 6q and two on chromosome 21q. These results suggest that chromosome 6q24 and 21q21 may contain genes influencing risk of hypertension in African Americans.	Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Univ Michigan, Sch Med, Dept Med, Ann Arbor, MI 48104 USA; Kaiser Permanente, Div Res, Oakland, CA USA; Loyola Univ, Med Ctr, Dept Prevent Med & Epidemiol, Maywood, IL 60153 USA; Stanford Univ, Sch Med, Div Cardiovasc Med, Stanford, CA 94305 USA; Univ Texas, Dept Genet, Houston, TX USA; Univ Mississippi, Med Ctr, Dept Geriatr Med, Jackson, MS 39216 USA; Washington Univ, Div Biostat, St Louis, MO USA; Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA	Stanford University; University of Michigan System; University of Michigan; Kaiser Permanente; Loyola University Chicago; Stanford University; University of Texas System; University of Mississippi; University of Mississippi Medical Center; Washington University (WUSTL); Fred Hutchinson Cancer Center	Risch, N (corresponding author), Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA.	risch@lahmed.stanford.edu	Zhu, Xiaofeng/O-6874-2019; Peng, Bo/A-6920-2009; Gu, C. Charles/A-7934-2010	Peng, Bo/0000-0001-8225-2284; Gu, C. Charles/0000-0002-8527-8145; Quertermous, Thomas/0000-0002-7645-9067; Zhu, Xiaofeng/0000-0003-0037-411X				Arya R, 2002, DIABETES, V51, P841, DOI 10.2337/diabetes.51.3.841; Collins-Schramm HE, 2002, AM J HUM GENET, V70, P737, DOI 10.1086/339368; Cooper RS, 2002, HYPERTENSION, V40, P629, DOI 10.1161/01.HYP.0000035708.02789.39; Doris PA, 2002, HYPERTENSION, V39, P323, DOI 10.1161/hy0202.104087; Falush D, 2003, GENETICS, V164, P1567; Fernandez JR, 2003, OBES RES, V11, P904, DOI 10.1038/oby.2003.124; Harrap SB, 2003, LANCET, V361, P2149, DOI 10.1016/S0140-6736(03)13694-X; Hoggart CJ, 2004, AM J HUM GENET, V74, P965, DOI 10.1086/420855; KRUGLYAK L, 1995, AM J HUM GENET, V57, P439; Krushkal J, 1999, CIRCULATION, V99, P1407, DOI 10.1161/01.CIR.99.11.1407; Lautenberger JA, 2000, AM J HUM GENET, V66, P969, DOI 10.1086/302820; McKeigue PM, 1998, AM J HUM GENET, V63, P241, DOI 10.1086/301908; Mountain JL, 2004, NAT GENET, V36, pS48, DOI 10.1038/ng1456; Parra EJ, 1998, AM J HUM GENET, V63, P1839, DOI 10.1086/302148; Patterson N, 2004, AM J HUM GENET, V74, P979, DOI 10.1086/420871; Pfaff CL, 2001, AM J HUM GENET, V68, P198, DOI 10.1086/316935; Pritchard JK, 2000, GENETICS, V155, P945; Province MA, 2003, AM J HYPERTENS, V16, P144, DOI 10.1016/S0895-7061(02)03248-X; Risch NJ, 1992, AM J HUM GENET S, V51, P13; Shriver MD, 2003, HUM GENET, V112, P387, DOI 10.1007/s00439-002-0896-y; Smith MW, 2004, AM J HUM GENET, V74, P1001, DOI 10.1086/420856; Smith MW, 2001, AM J HUM GENET, V69, P1080, DOI 10.1086/323922; STEPHENS JC, 1994, AM J HUM GENET, V55, P809; Zhu XF, 2004, AM J HUM GENET, V74, P1136, DOI 10.1086/421329	24	220	225	1	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2005	37	2					177	181		10.1038/ng1510	http://dx.doi.org/10.1038/ng1510			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	893AB	15665825				2022-12-25	WOS:000226690100025
J	Berger, C; Pallavi, SK; Prasad, M; Shashidhara, LS; Technau, GM				Berger, C; Pallavi, SK; Prasad, M; Shashidhara, LS; Technau, GM			A critical role for Cyclin E in cell fate determination in the central nervous system of Drosophila melanogaster	NATURE CELL BIOLOGY			English	Article							DEPENDENT KINASE INHIBITOR; ASYMMETRIC DIVISION; EMBRYOGENESIS; LINEAGES; NEUROECTODERM; SPECIFICATION; TRANSCRIPTION; EXPRESSION; COMPLEX; DACAPO	We have examined the process by which cell diversity is generated in neuroblast ( NB) lineages in the central nervous system of Drosophila melanogaster. Thoracic NB6-4 (NB6-4t) generates both neurons and glial cells, whereas NB6-4a generates only glial cells in abdominal segments(1). This is attributed to an asymmetric first division of NB6-4t, localizing prospero ( pros) and glial cell missing (gcm) only to the glial precursor cell, and a symmetric division of NB6-4a, where both daughter cells express pros and gcm(2-5). Here we show that the NB6-4t lineage represents the ground state, which does not require the input of any homeotic gene, whereas the NB6-4a lineage is specified by the homeotic genes abd-A and Abd-B. They specify the NB6-4a lineage by down-regulating levels of the G1 cyclin, DmCycE (CycE). CycE, which is asymmetrically expressed after the first division of NB6-4t, functions upstream of pros and gcm to specify the neuronal sublineage. Loss of CycE function causes homeotic transformation of NB6-4t to NB6-4a, whereas ectopic CycE induces reverse transformations. However, other components of the cell cycle seem to have a minor role in this process, suggesting a critical role for CycE in regulating cell fate in segment-specific neural lineages.	Univ Mainz, Inst Genet, D-55099 Mainz, Germany; Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Johannes Gutenberg University of Mainz; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Shashidhara, LS (corresponding author), Univ Mainz, Inst Genet, D-55099 Mainz, Germany.	shashi@ccmb.res.in; technau@uni-mainz.de						Akiyama-Oda Y, 2000, DEVELOPMENT, V127, P3513; Akiyama-Oda Y, 2000, DEV BIOL, V222, P429, DOI 10.1006/dbio.2000.9727; Bernardoni R, 1999, DEV BIOL, V216, P265, DOI 10.1006/dbio.1999.9511; Bhat KM, 1999, BIOESSAYS, V21, P472, DOI 10.1002/(SICI)1521-1878(199906)21:6<472::AID-BIES4>3.0.CO;2-W; Bossing T, 1996, DEV BIOL, V179, P41, DOI 10.1006/dbio.1996.0240; BRAND AH, 1993, DEVELOPMENT, V118, P401; Campos-Ortega J, 1997, EMBRYONIC DEV DROSOP; CARROLL SB, 1995, NATURE, V375, P58, DOI 10.1038/375058a0; deNooij JC, 1996, CELL, V87, P1237, DOI 10.1016/S0092-8674(00)81819-X; DENOOIJ JC, 1995, SCIENCE, V270, P983, DOI 10.1126/science.270.5238.983; Doe Chris Q., 1992, P119; Du W, 1999, EMBO J, V18, P916, DOI 10.1093/emboj/18.4.916; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; Freeman MR, 2001, DEVELOPMENT, V128, P4103; HARPER JW, 1993, CELL, V75, P805; Hayashi S, 1996, DEVELOPMENT, V122, P1051; Jones L, 2000, DEVELOPMENT, V127, P4619; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lane ME, 1996, CELL, V87, P1225, DOI 10.1016/S0092-8674(00)81818-8; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MANAK JR, 1994, DEVELOPMENT, V120, P3605; Ohnuma S, 1999, CELL, V99, P499, DOI 10.1016/S0092-8674(00)81538-X; Prokop Andreas, 1993, P33; RICHARDSON HE, 1993, DEVELOPMENT, V119, P673; Schmidt H, 1997, DEV BIOL, V189, P186, DOI 10.1006/dbio.1997.8660; Skeath JB, 1999, BIOESSAYS, V21, P922, DOI 10.1002/(SICI)1521-1878(199911)21:11<922::AID-BIES4>3.0.CO;2-T; STRUHL G, 1982, CELL, V31, P285, DOI 10.1016/0092-8674(82)90428-7; Tio M, 2001, NATURE, V409, P1063, DOI 10.1038/35059124	30	81	82	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2005	7	1					56	+		10.1038/ncb1203	http://dx.doi.org/10.1038/ncb1203			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	884UZ	15580266				2022-12-25	WOS:000226113500015
J	Parra, EJ; Kittles, RA; Shriver, MD				Parra, EJ; Kittles, RA; Shriver, MD			Implications of correlations between skin color and genetic ancestry for biomedical research	NATURE GENETICS			English	Article							POPULATION-STRUCTURE; ADMIXED POPULATIONS; ADMIXTURE; ASSOCIATION; DISEASE; PIGMENTATION; LINKAGE; DENSITY; PROPORTIONS; DIFFERENCE	Skin pigmentation is a central element of most discussions on 'race' and genetics. Research on the genetic basis of population variation in this phenotype, which is important in mediating both social experiences and environmental exposures, is sparse. We studied the relationship between pigmentation and ancestry in five populations of mixed ancestry with a wide range of pigmentation and ancestral proportions (African Americans from Washington, DC; African Caribbeans living in England; Puerto Ricans from New York; Mexicans from Guerrero; and Hispanics from San Luis Valley). The strength of the relationship between skin color and ancestry was quite variable, with the correlations ranging in intensity from moderately strong (Puerto Rico, rho = 0.633) to weak (Mexico, rho = 0.212). These results demonstrate the utility of ancestry-informative genetic markers and admixture methods and emphasize the need to be cautious when using pigmentation as a proxy of ancestry or when extrapolating the results from one admixed population to another.	Penn State Univ, Dept Anthropol, University Pk, PA 16802 USA; Univ Toronto, Dept Anthropol, Mississauga, ON L5L 1C6, Canada; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Penn State Univ, Dept Anthropol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Toronto; University Toronto Mississauga; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Shriver, MD (corresponding author), Penn State Univ, Dept Anthropol, 409 Carpenter Bldg, University Pk, PA 16802 USA.	mds17@psu.edu	Parra, Esteban J/A-4957-2008	parra, esteban J/0000-0002-2057-8577; Shriver, Mark/0000-0003-0006-0479				Akey JM, 2001, BIOTECHNIQUES, V30, P358, DOI 10.2144/01302tt05; Barsh GS, 1996, TRENDS GENET, V12, P299, DOI 10.1016/0168-9525(96)10031-7; Bonilla C, 2004, HUM GENET, V115, P57, DOI 10.1007/s00439-004-1125-7; Bonilla C, 2004, ANN HUM GENET, V68, P139, DOI 10.1046/j.1529-8817.2003.00084.x; BONILLA C, IN PRESS AM J PHYS A; CHAKRABORTY R, 1988, P NATL ACAD SCI USA, V85, P9119, DOI 10.1073/pnas.85.23.9119; Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x; Fernandez JR, 2003, OBES RES, V11, P904, DOI 10.1038/oby.2003.124; Halder Indrani, 2003, Human Genomics, V1, P52; HANIS CL, 1986, AM J PHYS ANTHROPOL, V70, P433, DOI 10.1002/ajpa.1330700404; Hoggart CJ, 2004, AM J HUM GENET, V74, P965, DOI 10.1086/420855; Hoggart CJ, 2003, AM J HUM GENET, V72, P1492, DOI 10.1086/375613; Jablonski NG, 2000, J HUM EVOL, V39, P57, DOI 10.1006/jhev.2000.0403; Kittles RA, 2002, HUM GENET, V110, P553, DOI 10.1007/s00439-002-0731-5; LONG JC, 1991, GENETICS, V127, P417; McKeigue PM, 1998, AM J HUM GENET, V63, P241, DOI 10.1086/301908; McKeigue PM, 2000, ANN HUM GENET, V64, P171, DOI 10.1017/S0003480000008022; Nordlund J.J., 1998, PIGMENTARY SYSTEM PH, V1st; Parra EJ, 1998, AM J HUM GENET, V63, P1839, DOI 10.1086/302148; Parra FC, 2003, P NATL ACAD SCI USA, V100, P177, DOI 10.1073/pnas.0126614100; Patterson N, 2004, AM J HUM GENET, V74, P979, DOI 10.1086/420871; Pfaff CL, 2001, AM J HUM GENET, V68, P198, DOI 10.1086/316935; Pritchard JK, 2001, THEOR POPUL BIOL, V60, P227, DOI 10.1006/tpbi.2001.1543; Pritchard JK, 2000, GENETICS, V155, P945; Relethford JH, 2002, AM J PHYS ANTHROPOL, V118, P393, DOI 10.1002/ajpa.10079; Relethford JH, 1997, AM J PHYS ANTHROPOL, V104, P449, DOI 10.1002/(SICI)1096-8644(199712)104:4<449::AID-AJPA2>3.0.CO;2-N; Risch Neil, 2002, GENOME BIO, V3, P1, DOI DOI 10.1186/GB-2002-3-7-COMMENT2007; Robins A.H., 1991, BIOL PERSPECTIVES HU; Rybicki BA, 2002, HUM HERED, V53, P187, DOI 10.1159/000066193; Shriver MD, 2003, HUM GENET, V112, P387, DOI 10.1007/s00439-002-0896-y; Shriver MD, 2000, AM J PHYS ANTHROPOL, V112, P17, DOI 10.1002/(SICI)1096-8644(200005)112:1<17::AID-AJPA3>3.0.CO;2-D; Smith MW, 2004, AM J HUM GENET, V74, P1001, DOI 10.1086/420856; Sturm RA, 2001, GENE, V277, P49, DOI 10.1016/S0378-1119(01)00694-1; Ye J, 2002, J FORENSIC SCI, V47, P593	34	144	150	1	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2004	36	11		S			S54	S60		10.1038/ng1440	http://dx.doi.org/10.1038/ng1440			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	867PH	15508005	Bronze			2022-12-25	WOS:000224854000012
J	Murrell, A; Heeson, S; Reik, W				Murrell, A; Heeson, S; Reik, W			Interaction between differentially methylated regions partitions the imprinted genes Igf2 and H19 into parent-specific chromatin loops	NATURE GENETICS			English	Article							CTCF; MECHANISMS; INSULATOR; UPSTREAM; DELETION; SITES; EXPRESSION; ELEMENT	Imprinted genes are expressed from only one of the parental alleles and are marked epigenetically by DNA methylation and histone modifications(1-5). The paternally expressed gene insulin-like growth-factor 2 (Igf2) is separated by similar to100 kb from the maternally expressed noncoding gene H19 on mouse distal chromosome 7. Differentially methylated regions in Igf2 and H19 contain chromatin boundaries(6-9), silencers(10,11) and activators(12) and regulate the reciprocal expression of the two genes in a methylation-sensitive manner by allowing them exclusive access to a shared set of enhancers(13-15). Various chromatin models have been proposed that separate Igf2 and H19 into active and silent domains(16-19). Here we used a GAL4 knock-in approach as well as the chromosome conformation capture technique to show that the differentially methylated regions in the imprinted genes Igf2 and H19 interact in mice. These interactions are epigenetically regulated and partition maternal and paternal chromatin into distinct loops. This generates a simple epigenetic switch for Igf2 through which it moves between an active and a silent chromatin domain.	Babraham Inst, Dev Genet Programme, Lab Dev Genet & Imprinting, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Murrell, A (corresponding author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Hinxton CB10 1SA, Cambs, England.	amm@sanger.ac.uk; wolf.reik@bbsrc.ac.uk	Reik, Wolf/I-6794-2012	Reik, Wolf/0000-0003-0216-9881; Murrell, adele/0000-0003-2647-3511				Banerjee Subhasis, 2001, TheScientificWorld, V1, P218; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; Chubb JR, 2003, CELL, V112, P403, DOI 10.1016/S0092-8674(03)00078-3; Constancia M, 2000, NAT GENET, V26, P203, DOI 10.1038/79930; Davies K, 2002, DEVELOPMENT, V129, P1657; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Eden S, 2001, EMBO J, V20, P3518, DOI 10.1093/emboj/20.13.3518; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEIL R, 1994, DEVELOPMENT, V120, P2933; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Ferguson-Smith AC, 2001, SCIENCE, V293, P1086, DOI 10.1126/science.1064020; Fournier C, 2002, EMBO J, V21, P6560, DOI 10.1093/emboj/cdf655; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Kaffer CR, 2001, MOL CELL BIOL, V21, P8189, DOI 10.1128/MCB.21.23.8189-8196.2001; Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960-9822(00)00597-2; Labrador M, 2002, CELL, V111, P151, DOI 10.1016/S0092-8674(02)01004-8; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; Lopes S, 2003, HUM MOL GENET, V12, P295, DOI 10.1093/hmg/ddg022; Moore T, 1997, P NATL ACAD SCI USA, V94, P12509, DOI 10.1073/pnas.94.23.12509; Murrell A, 2001, EMBO REP, V2, P1101, DOI 10.1093/embo-reports/kve248; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Sasaki H, 2000, J BIOCHEM, V127, P711, DOI 10.1093/oxfordjournals.jbchem.a022661; Sleutels F, 2002, ADV GENET, V46, P119; Szabo PE, 2000, CURR BIOL, V10, P607, DOI 10.1016/S0960-9822(00)00489-9; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; Verona RI, 2003, ANNU REV CELL DEV BI, V19, P237, DOI 10.1146/annurev.cellbio.19.111401.092717; Weber M, 2003, MOL CELL BIOL, V23, P8953, DOI 10.1128/MCB.23.24.8953-8959.2003; Yusufzai TM, 2004, MOL CELL, V13, P291, DOI 10.1016/S1097-2765(04)00029-2	30	413	431	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2004	36	8					889	893		10.1038/ng1402	http://dx.doi.org/10.1038/ng1402			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	842AG	15273689				2022-12-25	WOS:000222974000024
J	Baker, M				Baker, M			Better living through microbes	NATURE BIOTECHNOLOGY			English	News Item																		Agrawal N, 2004, P NATL ACAD SCI USA, V101, P15172, DOI 10.1073/pnas.0406242101; Brockstedt DG, 2004, P NATL ACAD SCI USA, V101, P13832, DOI 10.1073/pnas.0406035101; Nemunaitis J, 2003, CANCER GENE THER, V10, P737, DOI 10.1038/sj.cgt.7700634; Steidler L, 2003, NAT BIOTECHNOL, V21, P785, DOI 10.1038/nbt840; Steidler L, 2000, SCIENCE, V289, P1352, DOI 10.1126/science.289.5483.1352	5	10	10	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0733-222X	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2005	23	6					645	647		10.1038/nbt0605-645	http://dx.doi.org/10.1038/nbt0605-645			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	933LA	15940227				2022-12-25	WOS:000229628700010
J	Fischer, E; Sauer, U				Fischer, E; Sauer, U			Large-scale in vivo flux analysis shows rigidity and suboptimal performance of Bacillus subtilis metabolism	NATURE GENETICS			English	Article							PENTOSE-PHOSPHATE PATHWAY; ESCHERICHIA-COLI; GROWTH; ORGANIZATION; EVOLUTION; NETWORKS; GENOME	Qualitative theoretical approaches such as graph theory(1,2) and stoichiometric analyses(3-6) are beginning to uncover the architecture and systemic functions of complex metabolic reaction networks. At present, however, only a few, largely unproven quantitative concepts propose functional design principles of the global flux distribution(7,8). As operational units of function, molecular fluxes determine the systemic cell phenotype by linking genes, proteins and metabolites to higher-level biological functions(9). In sharp contrast to other 'omics' analyses, 'fluxome' analysis remained tedious(10). By large-scale quantification of in vivo flux responses, we identified a robust flux distribution in 137 null mutants of Bacillus subtilis. On its preferred substrate, B. subtilis has suboptimal metabolism because regulators of developmental programs maintain a 'standby' mode that invests substantial resources in anticipation of changing environmental conditions at the expense of optimal growth. Network rigidity and robustness are probably universal functional design principles, whereas the standby mode may be more specific.	ETH, Inst Biotechnol, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Sauer, U (corresponding author), ETH, Inst Biotechnol, CH-8093 Zurich, Switzerland.	sauer@biotech.biol.ethz.ch	Fischer, Eliane/M-2590-2013; Sauer, Uwe/Y-3556-2019	Fischer, Eliane/0000-0002-3399-3737; 				Arita M, 2004, P NATL ACAD SCI USA, V101, P1543, DOI 10.1073/pnas.0306458101; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Burgard AP, 2004, GENOME RES, V14, P301, DOI 10.1101/gr.1926504; Csete M, 2004, TRENDS BIOTECHNOL, V22, P446, DOI 10.1016/j.tibtech.2004.07.007; Dauner M, 2001, J BACTERIOL, V183, P7308, DOI 10.1128/JB.183.24.7308-7317.2001; Dauner M, 2001, BIOTECHNOL BIOENG, V76, P132, DOI 10.1002/bit.1153; Duetz WA, 2000, APPL ENVIRON MICROB, V66, P2641, DOI 10.1128/AEM.66.6.2641-2646.2000; Edwards JS, 2001, NAT BIOTECHNOL, V19, P125, DOI 10.1038/84379; Fischer E, 2003, EUR J BIOCHEM, V270, P880, DOI 10.1046/j.1432-1033.2003.03448.x; Fischer E, 2004, ANAL BIOCHEM, V325, P308, DOI 10.1016/j.ab.2003.10.036; Fischer E, 2003, J BIOL CHEM, V278, P46446, DOI 10.1074/jbc.M307968200; Fischer S.H., 2002, BACILLUS SUBTILIS IT, P181; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Hellerstein MK, 2003, ANNU REV NUTR, V23, P379, DOI 10.1146/annurev.nutr.23.011702.073045; Ibarra RU, 2002, NATURE, V420, P186, DOI 10.1038/nature01149; Moritz B, 2000, EUR J BIOCHEM, V267, P3442, DOI 10.1046/j.1432-1327.2000.01354.x; Msadek T, 1999, TRENDS MICROBIOL, V7, P201, DOI 10.1016/S0966-842X(99)01479-1; Nudler E, 2004, TRENDS BIOCHEM SCI, V29, P11, DOI 10.1016/j.tibs.2003.11.004; Papin JA, 2004, TRENDS BIOTECHNOL, V22, P400, DOI 10.1016/j.tibtech.2004.06.010; Pfeiffer T, 2001, SCIENCE, V292, P504, DOI 10.1126/science.1058079; Sauer U, 1997, NAT BIOTECHNOL, V15, P448, DOI 10.1038/nbt0597-448; Sauer U, 2004, CURR OPIN BIOTECH, V15, P58, DOI 10.1016/j.copbio.2003.11.001; Segre D, 2002, P NATL ACAD SCI USA, V99, P15112, DOI 10.1073/pnas.232349399; Servant P, 2005, MOL MICROBIOL, V55, P1435, DOI 10.1111/j.1365-2958.2005.04473.x; Stelling J, 2002, NATURE, V420, P190, DOI 10.1038/nature01166; Stelling J, 2004, CELL, V118, P675, DOI 10.1016/j.cell.2004.09.008; Zamboni N, 2005, BIOTECHNOL BIOENG, V89, P219, DOI 10.1002/bit.20338; Zamboni N, 2004, J BACTERIOL, V186, P4528, DOI 10.1128/JB.186.14.4528-4534.2004; Zamboni N, 2003, FEMS MICROBIOL LETT, V226, P121, DOI 10.1016/S0378-1097(03)00614-1	30	243	251	2	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2005	37	6					636	640		10.1038/ng1555	http://dx.doi.org/10.1038/ng1555			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	931OT	15880104				2022-12-25	WOS:000229495300019
J	Buckland, BC				Buckland, BC			The process development challenge for a new vaccine	NATURE MEDICINE			English	Editorial Material								The challenges of vaccine development are not limited to identification of suitable antigens, adjuvants and delivery methods, but include regulatory, technical and manufacturing hurdles in translating a vaccine candidate to the clinic. Process development is the technological foundation that underlies the manufacture of new vaccines and is central to successful commercialization.	Merck Res Labs, West Point, PA 19486 USA	Merck & Company	Buckland, BC (corresponding author), Merck Res Labs, West Point, PA 19486 USA.	barry_buckland@merck.com						Brown DR, 2004, VACCINE, V22, P2936, DOI 10.1016/j.vaccine.2003.11.059; Clark HF, 2004, J PEDIATR-US, V144, P184, DOI 10.1016/j.jpeds.2003.10.054; Clark HF, 2003, PEDIATR INFECT DIS J, V22, P914, DOI 10.1097/01.inf.0000091887.48999.77; Fife KH, 2004, VACCINE, V22, P2943, DOI 10.1016/j.vaccine.2003.11.058; JANSEN KU, 1995, VACCINE, V13, P1509, DOI 10.1016/0264-410X(95)00103-8; KNICKSEN PJ, 1992, VACCINES NEW APPROAC, P177; Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586; PISANO GP, 1997, DEV FACTORY	8	65	67	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2005	11	4		S			S16	S19		10.1038/nm1218	http://dx.doi.org/10.1038/nm1218			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	915VO	15812483	Bronze			2022-12-25	WOS:000228339600006
J	Fraga, MF; Ballestar, E; Villar-Garea, A; Boix-Chornet, M; Espada, J; Schotta, G; Bonaldi, T; Haydon, C; Ropero, S; Petrie, K; Iyer, NG; Perez-Rosado, A; Calvo, E; Lopez, JA; Cano, A; Calasanz, MJ; Colomer, D; Piris, MA; Ahn, N; Imhof, A; Caldas, C; Jenuwein, T; Esteller, M				Fraga, MF; Ballestar, E; Villar-Garea, A; Boix-Chornet, M; Espada, J; Schotta, G; Bonaldi, T; Haydon, C; Ropero, S; Petrie, K; Iyer, NG; Perez-Rosado, A; Calvo, E; Lopez, JA; Cano, A; Calasanz, MJ; Colomer, D; Piris, MA; Ahn, N; Imhof, A; Caldas, C; Jenuwein, T; Esteller, M			Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer	NATURE GENETICS			English	Article							DNA METHYLATION; GENE-EXPRESSION; HUMAN-CELLS; HYPOMETHYLATION; METHYLTRANSFERASE; HYPERMETHYLATION; PATTERNS; HETEROCHROMATIN; DEACETYLASE; ANTIBODIES	CpG island hypermethylation and global genomic hypomethylation are common epigenetic features of cancer cells. Less attention has been focused on histone modifications in cancer cells. We characterized post-translational modifications to histone H4 in a comprehensive panel of normal tissues, cancer cell lines and primary tumors. Using immunodetection, high-performance capillary electrophoresis and mass spectrometry, we found that cancer cells had a loss of monoacetylated and trimethylated forms of histone H4. These changes appeared early and accumulated during the tumorigenic process, as we showed in a mouse model of multistage skin carcinogenesis. The losses occurred predominantly at the acetylated Lys16 and trimethylated Lys20 residues of histone H4 and were associated with the hypomethylation of DNA repetitive sequences, a well-known characteristic of cancer cells. Our data suggest that the global loss of monoacetylation and trimethylation of histone H4 is a common hallmark of human tumor cells.	Spanish Natl Canc Ctr, Canc Epigenet Lab, Mol Pathol Program, Madrid 28029, Spain; Vienna Bioctr, Res Inst Mol Pathol, A-1030 Vienna, Austria; Univ Munich, Histone Modificat Grp, Munich, Germany; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Univ Cambridge, Canc Genom Program, Dept Oncol, Hutchison MRC Res Ctr, Cambridge CB2 2XZ, England; Spanish Natl Canc Ctr, Lymphoma Lab, Mol Pathol Program, Madrid, Spain; Fdn Ctr Nacl invest Cardiovasc, Proteom Unit, Madrid, Spain; Univ Autonoma Madrid, Dept Biochem, Sch Med, Inst Invest Biomed, Madrid, Spain; Univ Navarra, Dept Genet, Sch Sci, E-31080 Pamplona, Spain; Univ Barcelona, Hematopathol Unit, Hosp Clin, Catalonia, Spain; Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Boulder, CO 80309 USA	Centro Nacional de Investigaciones Oncologicas (CNIO); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of Munich; University of Colorado System; University of Colorado Boulder; University of Cambridge; Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Cardiovasculares (CNIC); Autonomous University of Madrid; University of Navarra; University of Barcelona; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder	Esteller, M (corresponding author), Spanish Natl Canc Ctr, Canc Epigenet Lab, Mol Pathol Program, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	mesteller@cnio.es	Fraga, Mario F/H-7824-2017; Petrie, Kevin/I-7115-2015; Caldas, Carlos/A-7543-2008; Piris, Miguel A/AAP-1445-2020; Piris, Miguel A/B-7067-2008; COLOMER, DOLORS/ABG-6894-2020; Ballestar, Esteban/ABG-8561-2020; jia, xu/A-8386-2016; Lopez, Juan Antonio/G-7750-2015; Calasanz, MJ/R-5813-2016; Bonaldi, Tiziana/K-5075-2016; Espada, Jesús/AAA-3198-2019; Imhof, Axel/AAU-5313-2021; Esteller, Manel/L-5956-2014; Caldas, Carlos/U-7250-2019; Eyers, Claire/C-6291-2013	Fraga, Mario F/0000-0001-8450-2603; Petrie, Kevin/0000-0002-9805-9152; Piris, Miguel A/0000-0001-5839-3634; Piris, Miguel A/0000-0001-5839-3634; Lopez, Juan Antonio/0000-0002-9097-6060; Calasanz, MJ/0000-0002-0374-3008; Bonaldi, Tiziana/0000-0003-3556-1265; Espada, Jesús/0000-0002-4202-4938; Imhof, Axel/0000-0003-2993-8249; Esteller, Manel/0000-0003-4490-6093; Caldas, Carlos/0000-0003-3547-1489; Ballestar, Esteban/0000-0002-1400-2440; Schotta, Gunnar/0000-0003-4940-6135; Eyers, Claire/0000-0002-3223-5926; COLOMER, DOLORS/0000-0001-7486-8484; Iyer, N. Gopalakrishna/0000-0002-8812-6219; Villar Garea, Ana/0000-0001-8960-1635				Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Balmain A, 2000, CARCINOGENESIS, V21, P371, DOI 10.1093/carcin/21.3.371; Bannister AJ, 2004, METHOD ENZYMOL, V376, P269; Baxter J, 2004, EMBO J, V23, P4462, DOI 10.1038/sj.emboj.7600414; Belyaev ND, 1996, HUM GENET, V97, P573; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; Cho KS, 2004, CURR OPIN GENET DEV, V14, P308, DOI 10.1016/j.gde.2004.04.015; Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Ehrlich M, 2002, J NUTR, V132, p2424S, DOI 10.1093/jn/132.8.2424S; Espada J, 2004, J BIOL CHEM, V279, P37175, DOI 10.1074/jbc.M404842200; Esteller M, 2005, CURR OPIN ONCOL, V17, P55, DOI 10.1097/01.cco.0000147383.04709.10; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Esteller M, 2001, CANCER RES, V61, P3225; Fahrner JA, 2002, CANCER RES, V62, P7213; Fang J, 2002, CURR BIOL, V12, P1086, DOI 10.1016/S0960-9822(02)00924-7; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Fraga MF, 2004, CANCER RES, V64, P5527, DOI 10.1158/0008-5472.CAN-03-4061; Galasinski SC, 2003, METHODS, V31, P3, DOI 10.1016/S1046-2023(03)00082-3; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Iyer NG, 2004, P NATL ACAD SCI USA, V101, P7386, DOI 10.1073/pnas.0401002101; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; JONES A, 1967, ECON BOT, V21, P163, DOI 10.1007/BF02897864; Keohane AM, 1996, DEV BIOL, V180, P618, DOI 10.1006/dbio.1996.0333; Kourmouli N, 2004, J CELL SCI, V117, P2491, DOI 10.1242/jcs.01238; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; LINDNER H, 1992, BIOCHEM J, V283, P467, DOI 10.1042/bj2830467; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nguyen CT, 2002, CANCER RES, V62, P6456; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Paz MF, 2003, CANCER RES, V63, P1114; Richon VM, 2004, METHOD ENZYMOL, V376, P199; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Sarg B, 2002, J BIOL CHEM, V277, P39195, DOI 10.1074/jbc.M205166200; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; THORNE AW, 1990, EUR J BIOCHEM, V193, P701, DOI 10.1111/j.1432-1033.1990.tb19390.x; TURNER BM, 1989, EUR J BIOCHEM, V179, P131, DOI 10.1111/j.1432-1033.1989.tb14530.x; TURNER BM, 1989, FEBS LETT, V253, P141, DOI 10.1016/0014-5793(89)80947-0; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252; Zhang DJ, 2000, MULTIBODY SYST DYN, V4, P1, DOI 10.1023/A:1009849313860	50	1318	1401	2	157	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2005	37	4					391	400		10.1038/ng1531	http://dx.doi.org/10.1038/ng1531			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	911XL	15765097				2022-12-25	WOS:000228040000022
J	Rokyta, DR; Joyce, P; Caudle, SB; Wichman, HA				Rokyta, DR; Joyce, P; Caudle, SB; Wichman, HA			An empirical test of the mutational landscape model of adaptation using a single-stranded DNA virus	NATURE GENETICS			English	Article							POPULATION-GENETICS; EVOLUTION	The primary impediment to formulating a general theory for adaptive evolution has been the unknown distribution of fitness effects for new beneficial mutations(1). By applying extreme value theory(2), Gillespie circumvented this issue in his mutational landscape model for the adaptation of DNA sequences(3-5), and Orr recently extended Gillespie's model(1,6), generating testable predictions regarding the course of adaptive evolution. Here we provide the first empirical examination of this model, using a single-stranded DNA bacteriophage related to phi X174, and find that our data are consistent with Orr's predictions, provided that the model is adjusted to incorporate mutation bias. Orr's work suggests that there may be generalities in adaptive molecular evolution that transcend the biological details of a system, but we show that for the model to be useful as a predictive or inferential tool, some adjustments for the biology of the system will be necessary.	Univ Idaho, Dept Biol Sci, Moscow, ID 83844 USA; Univ Idaho, Program Bioinformat & Computat Biol, Moscow, ID 83844 USA; Univ Idaho, Initiat Bioinformat & Evolutionary Studies, Moscow, ID 83844 USA; Univ Idaho, Dept Math, Moscow, ID 83844 USA; Univ Idaho, Dept Stat, Moscow, ID 83844 USA	Idaho; University of Idaho; Idaho; University of Idaho; Idaho; University of Idaho; Idaho; University of Idaho; Idaho; University of Idaho	Wichman, HA (corresponding author), Univ Idaho, Dept Biol Sci, Moscow, ID 83844 USA.	hwichman@uidaho.edu		Rokyta, Darin/0000-0002-0356-2178				[Anonymous], 1958, STAT EXTREMES, DOI DOI 10.7312/GUMB92958; Fisher R.A., 1930, GENETICAL THEORY NAT; Gillespie J. H., 1991, CAUSES MOL EVOLUTION; GILLESPIE JH, 1984, EVOLUTION, V38, P1116, DOI 10.1111/j.1558-5646.1984.tb00380.x; GILLESPIE JH, 1983, THEOR POPUL BIOL, V23, P202, DOI 10.1016/0040-5809(83)90014-X; Haldane JBS, 1927, P CAMB PHILOS SOC, V23, P838, DOI 10.1017/S0305004100015644; Hartl DL, 1998, GENETICA, V102-3, P525, DOI 10.1023/A:1017071901530; Minin V, 2003, SYST BIOL, V52, P674, DOI 10.1080/10635150390235494; Orr HA, 2000, EVOLUTION, V54, P13, DOI 10.1111/j.0014-3820.2000.tb00002.x; Orr HA, 2003, GENETICS, V163, P1519; Orr HA, 2003, J THEOR BIOL, V220, P241, DOI 10.1006/jtbi.2003.3161; Orr HA, 2002, EVOLUTION, V56, P1317, DOI 10.1111/j.0014-3820.2002.tb01446.x; Orr HA, 1998, EVOLUTION, V52, P935, DOI [10.2307/2411226, 10.1111/j.1558-5646.1998.tb01823.x]; Rokyta D, 2002, MOL BIOL EVOL, V19, P230, DOI 10.1093/oxfordjournals.molbev.a004076; Swofford DL, 1998, PHYLOGENETIC ANAL US; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wahl LM, 2002, GENETICS, V162, P961; Wahl LM, 2001, EVOLUTION, V55, P2606	18	141	143	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2005	37	4					441	444		10.1038/ng1535	http://dx.doi.org/10.1038/ng1535			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	911XL	15778707				2022-12-25	WOS:000228040000030
J	Leidel, S; Delattre, M; Cerutti, L; Baumer, K; Gonczy, P				Leidel, S; Delattre, M; Cerutti, L; Baumer, K; Gonczy, P			SAS-6 defines a protein family required for centrosome duplication in C-elegans and in human cells	NATURE CELL BIOLOGY			English	Article							COILED-COIL PROTEIN; CENTRIOLE DUPLICATION; TUBULIN; SUBSTRATE; NEMATODE; ENCODES; GENE	The mechanisms that ensure centrosome duplication are poorly understood. In Caenorhabditis elegans, ZYG-1,SAS- 4, SAS- 5 and SPD-2 are required for centriole formation. However, it is unclear whether these proteins have functional homologues in other organisms. Here, we identify SAS- 6 as a component that is required for daughter centriole formation in C. elegans. SAS- 6 is a coiled-coil protein that is recruited to centrioles at the onset of the centrosome duplication cycle. Our analysis indicates that SAS-6 and SAS- 5 associate and that this interaction, as well as ZYG-1 function, is required for SAS- 6 centriolar recruitment. SAS- 6 is the founding member of an evolutionarily conserved protein family that contains the novel PISA motif. We investigated the function of the human homologue of SAS-6. GFP - HsSAS-6 localizes to centrosomes and its overexpression results in excess foci-bearing centriolar markers. Furthermore, siRNA-mediated inactivation of HsSAS-6 in U2OS cells abrogates centrosome overduplication following aphidicolin treatment and interferes with the normal centrosome duplication cycle. Therefore, HsSAS-6 is also required for centrosome duplication, indicating that the function of SAS-6-related proteins has been widely conserved during evolution.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; Swiss Inst Bioinformat, CH-1066 Epalinges, Switzerland	Swiss Institute Experimental Cancer Research; Swiss Institute of Bioinformatics	Gonczy, P (corresponding author), Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland.	Pierre.Gonczy@isrec.unil.ch	Delattre, Marie/AAJ-1491-2020; Leidel, Sebastian/K-9507-2019; Delattre, Marie/CAG-5526-2022	Delattre, Marie/0000-0003-1640-0300; Leidel, Sebastian/0000-0002-0523-6325; Delattre, Marie/0000-0003-1640-0300; Gonczy, Pierre/0000-0002-6305-6883				Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Azimzadeh J., 2004, CENTROSOMES DEV DIS, P93; Bellanger JM, 2003, CURR BIOL, V13, P1488, DOI 10.1016/S0960-9822(03)00582-7; Braun P, 2002, P NATL ACAD SCI USA, V99, P2654, DOI 10.1073/pnas.042684199; BRENNER S, 1974, GENETICS, V77, P71; Chase D, 2000, GENESIS, V26, P26, DOI 10.1002/(SICI)1526-968X(200001)26:1<26::AID-GENE6>3.0.CO;2-O; Clamp M, 2004, BIOINFORMATICS, V20, P426, DOI 10.1093/bioinformatics/btg430; Dammermann A, 2004, DEV CELL, V7, P815, DOI 10.1016/j.devcel.2004.10.015; de Loubresse NG, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-4; Delattre M, 2004, NAT CELL BIOL, V6, P656, DOI 10.1038/ncb1146; Dutcher SK, 1998, MOL BIOL CELL, V9, P1293, DOI 10.1091/mbc.9.6.1293; Dutcher SK, 2002, MOL BIOL CELL, V13, P3859, DOI 10.1091/mbc.E02-04-0205; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; Hung LY, 2000, MOL CELL BIOL, V20, P7813, DOI 10.1128/MCB.20.20.7813-7825.2000; Kemp CA, 2004, DEV CELL, V6, P511, DOI 10.1016/S1534-5807(04)00066-8; Kirkham M, 2003, CELL, V112, P575, DOI 10.1016/S0092-8674(03)00117-X; Leidel S, 2003, DEV CELL, V4, P431, DOI 10.1016/S1534-5807(03)00062-5; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Middendorp S, 2000, J CELL BIOL, V148, P405, DOI 10.1083/jcb.148.3.405; NELSON GA, 1978, DEV BIOL, V66, P386, DOI 10.1016/0012-1606(78)90247-6; O'Connell KF, 2001, CELL, V105, P547, DOI 10.1016/S0092-8674(01)00338-5; Pagni M, 2004, NUCLEIC ACIDS RES, V32, pW332, DOI 10.1093/nar/gkh479; Pelletier L, 2004, CURR BIOL, V14, P863, DOI 10.1016/j.cub.2004.04.012; Piano F, 2000, CURR BIOL, V10, P1619, DOI 10.1016/S0960-9822(00)00869-1; Pihan GA, 2003, CANCER RES, V63, P1398; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Praitis V, 2001, GENETICS, V157, P1217; Salisbury JL, 2002, CURR BIOL, V12, P1287, DOI 10.1016/S0960-9822(02)01019-9; Sigrist Christian J A, 2002, Brief Bioinform, V3, P265, DOI 10.1093/bib/3.3.265; SONNICHSEN B, IN PRESS NATURE; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Warnke S, 2004, CURR BIOL, V14, P1200, DOI 10.1016/j.cub.2004.06.059; WOLF N, 1978, J ULTRA MOL STRUCT R, V63, P155, DOI 10.1016/S0022-5320(78)80071-9; WOLFF A, 1992, EUR J CELL BIOL, V59, P425; WOOD WB, 1980, DEV BIOL, V74, P446, DOI 10.1016/0012-1606(80)90445-5	36	284	294	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2005	7	2					115	U19		10.1038/ncb1220	http://dx.doi.org/10.1038/ncb1220			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	893LC	15665853				2022-12-25	WOS:000226719500008
J	Metherell, LA; Chapple, JP; Cooray, S; David, A; Becker, C; Ruschendorf, F; Naville, D; Begeot, M; Khoo, B; Nurnberg, P; Huebner, A; Cheetham, ME; Clark, AJL				Metherell, LA; Chapple, JP; Cooray, S; David, A; Becker, C; Ruschendorf, F; Naville, D; Begeot, M; Khoo, B; Nurnberg, P; Huebner, A; Cheetham, ME; Clark, AJL			Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2	NATURE GENETICS			English	Article							ADRENOCORTICOTROPIN RECEPTOR; ENDOPLASMIC-RETICULUM; CALCITONIN-RECEPTOR; LINKAGE ANALYSIS; GENE; IDENTIFICATION; ADIPOCYTES; EXPRESSION; PROTEINS; CELLS	Familial glucocorticoid deficiency (FGD), or hereditary unresponsiveness to adrenocorticotropin (ACTH; OMIM 202200), is an autosomal recessive disorder resulting from resistance to the action of ACTH on the adrenal cortex, which stimulates glucocorticoid production. Affected individuals are deficient in cortisol and, if untreated, are likely to succumb to hypoglycemia or overwhelming infection in infancy or childhood(1-3). Mutations of the ACTH receptor (melanocortin 2 receptor, MC2R) account for similar to25% of cases of FGD(4-7). FGD without mutations of MC2R is called FGD type 2. Using SNP array genotyping, we mapped a locus involved in FGD type 2 to chromosome 21q22.1. We identified mutations in a gene encoding a 19-kDa single-transmembrane domain protein(8), now known as melanocortin 2 receptor accessory protein (MRAP). We show that MRAP interacts with MC2R and may have a role in the trafficking of MC2R from the endoplasmic reticulum to the cell surface.	Barts & London Queen Mary Univ London, William Harvey Res Inst, Dept Endocrinol, London EC1A 7BE, England; UCL, Inst Ophthalmol, Div Pathol, London EC1V 9EL, England; Max Delbruck Ctr Mol Med, Mol Genet & Gene Mapping Ctr, Berlin, Germany; Hop Debrousse, INSERM, U418, F-69322 Lyon, France; Univ Med Berlin, Charite, Inst Med Genet, Berlin, Germany; Tech Univ Dresden, Childrens Hosp, D-8027 Dresden, Germany	University of London; Queen Mary University London; University of London; University College London; Helmholtz Association; Max Delbruck Center for Molecular Medicine; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Technische Universitat Dresden	Clark, AJL (corresponding author), Barts & London Queen Mary Univ London, William Harvey Res Inst, Dept Endocrinol, London EC1A 7BE, England.	a.j.clark@qmul.ac.uk	Metherell, Louise A/E-8695-2012; Naville, Danielle/N-1200-2017; Khoo, Bernard/B-1247-2009; Cheetham, Michael/B-4672-2011	Metherell, Louise A/0000-0002-0530-3524; Naville, Danielle/0000-0003-2615-6161; Khoo, Bernard/0000-0002-4223-9736; Cheetham, Michael/0000-0001-6429-654X; Huebner, Angela/0000-0003-1338-5192; Chapple, Paul/0000-0003-1876-1505				Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786; Boston BA, 1996, ENDOCRINOLOGY, V137, P2043, DOI 10.1210/en.137.5.2043; Chapple JP, 2003, J BIOL CHEM, V278, P19087, DOI 10.1074/jbc.M212349200; Clark AJL, 1998, ENDOCR REV, V19, P828, DOI 10.1210/er.19.6.828; CLARK AJL, 1993, LANCET, V341, P461, DOI 10.1016/0140-6736(93)90208-X; Elias LLK, 1999, J CLIN ENDOCR METAB, V84, P2766, DOI 10.1210/jc.84.8.2766; Genin E, 2002, HUM GENET, V111, P428, DOI 10.1007/s00439-002-0806-3; GOZANI O, 1994, EMBO J, V13, P3356, DOI 10.1002/j.1460-2075.1994.tb06638.x; GRUNFELD C, 1985, ENDOCRINOLOGY, V116, P113, DOI 10.1210/endo-116-1-113; Longshaw VM, 2004, J CELL SCI, V117, P701, DOI 10.1242/jcs.00905; Matsuzaki H, 2004, GENOME RES, V14, P414, DOI 10.1101/gr.2014904; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Metherell Louise A., 2001, American Journal of Human Genetics, V69, P641, DOI 10.1086/323266; MIGEON CJ, 1968, PEDIATR RES, V2, P501, DOI 10.1203/00006450-196811000-00008; Muff R, 1999, ENDOCRINOLOGY, V140, P2924, DOI 10.1210/en.140.6.2924; Naville D, 1996, J CLIN ENDOCR METAB, V81, P1442, DOI 10.1210/jc.81.4.1442; Noon LA, 2004, J BIOL CHEM, V279, P22803, DOI 10.1074/jbc.M401861200; Noon LA, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740017; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; Saito H, 2004, CELL, V119, P679, DOI 10.1016/j.cell.2004.11.021; SHEPARD TH, 1959, AMA J DIS CHILD, V97, P154, DOI 10.1001/archpedi.1959.02070010156002; Strauch K, 2000, AM J HUM GENET, V66, P1945, DOI 10.1086/302911; TSIGOS C, 1993, J CLIN INVEST, V92, P2458, DOI 10.1172/JCI116853; WEBER A, 1995, J CLIN ENDOCR METAB, V80, P65, DOI 10.1210/jc.80.1.65; Xu AM, 2002, BIOCHEM BIOPH RES CO, V293, P1161, DOI 10.1016/S0006-291X(02)00354-6; Yang YK, 1997, MOL ENDOCRINOL, V11, P274, DOI 10.1210/me.11.3.274	26	296	308	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2005	37	2					166	170		10.1038/ng1501	http://dx.doi.org/10.1038/ng1501			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	893AB	15654338				2022-12-25	WOS:000226690100023
J	Apionishev, S; Katanayeva, NM; Marks, SA; Kalderon, D; Tomlinson, A				Apionishev, S; Katanayeva, NM; Marks, SA; Kalderon, D; Tomlinson, A			Drosophila Smoothened phosphorylation sites essential for Hedgehog signal transduction	NATURE CELL BIOLOGY			English	Article							PROTEIN-KINASE-A; CUBITUS-INTERRUPTUS; REQUIRES PHOSPHORYLATION; PATHWAYS; IDENTIFICATION; PROTEOLYSIS; MECHANISM; ACTIVATOR; COSTAL2; CELLS	The Hedgehog (Hh) signalling pathway is crucial for animal development and is aberrantly activated in several types of cancer(1). In Drosophila melanogaster, Hh signalling regulates target gene expression through the transcription factor Cubitus interruptus (Ci). Together, Protein Kinase A, Casein Kinase 1 and Glycogen Synthase Kinase 3 silence the pathway in the absence of ligand by phosphorylating Ci at a defined cluster of sites, thereby promoting its proteolytic conversion to a transcriptional repressor (Ci-75)(2,3). In the presence of Hh, Ci-155 is no longer converted to Ci-75 and its ability to activate transcription is potentiated. All Hh responses require the seven transmembrane domain protein Smoothened(1,4), which itself becomes hyperphosphorylated during Hh signalling(5). Here we show that a cluster of protein kinase A and protein kinase A-primed casein kinase 1 phosphorylation sites in Smoothened, similarly distributed to those regulating Ci, are essential for Smoothened to transduce a Hh signal and for normal regulation of Smoothened protein levels.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, Dept Genet & Dev, New York, NY 10032 USA	Columbia University; Columbia University	Kalderon, D (corresponding author), Columbia Univ, Dept Biol Sci, 1212 Amsterdam Ave, New York, NY 10027 USA.	ddk1@columbia.edu						Alcedo J, 2000, MOL CELL, V6, P457, DOI 10.1016/S1097-2765(00)00044-7; Brinkworth RI, 2003, P NATL ACAD SCI USA, V100, P74, DOI 10.1073/pnas.0134224100; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chen Y, 1999, DEVELOPMENT, V126, P3607; Crozatier M, 2002, DEVELOPMENT, V129, P4261; Dai P, 2003, DEV CELL, V4, P917, DOI 10.1016/S1534-5807(03)00158-8; Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8; Glise B, 2002, DEV BIOL, V248, P93, DOI 10.1006/dbio.2002.0720; Ingham PW, 2000, CURR BIOL, V10, P1315, DOI 10.1016/S0960-9822(00)00755-7; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jia JH, 2002, NATURE, V416, P548, DOI 10.1038/nature733; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kalderon D, 2002, TRENDS CELL BIOL, V12, P523, DOI 10.1016/S0962-8924(02)02388-7; LANE ME, 1993, GENE DEV, V7, P1229, DOI 10.1101/gad.7.7a.1229; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; Nakano Y, 2004, MECH DEVELOP, V121, P507, DOI 10.1016/j.mod.2004.04.015; Ogden SK, 2003, CURR BIOL, V13, P1998, DOI 10.1016/j.cub.2003.10.004; Ohlmeyer JT, 1998, NATURE, V396, P749, DOI 10.1038/25533; Ohlmeyer JT, 1997, GENE DEV, V11, P2250, DOI 10.1101/gad.11.17.2250; Price MA, 1999, DEVELOPMENT, V126, P4331; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Ruel L, 2003, NAT CELL BIOL, V5, P907, DOI 10.1038/ncb1052; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; Vervoort M, 2000, BIOESSAYS, V22, P460, DOI 10.1002/(SICI)1521-1878(200005)22:5&lt;460::AID-BIES8&gt;3.0.CO;2-G; Wang GL, 1999, GENE DEV, V13, P2828, DOI 10.1101/gad.13.21.2828	28	124	129	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2005	7	1					86	+		10.1038/ncb1210	http://dx.doi.org/10.1038/ncb1210			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	884UZ	15592457				2022-12-25	WOS:000226113500019
J	Morag-Sela, T; Cohn, I; Kowalski, TJ; Jarecki-Black, J; Clyde-Watson, Z				Morag-Sela, T; Cohn, I; Kowalski, TJ; Jarecki-Black, J; Clyde-Watson, Z			Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity	NATURE BIOTECHNOLOGY			English	Editorial Material									Reinhold Cohn & Partners, IL-61040 Tel Aviv, Israel; Frommer Lawrence & Haug LLP, New York, NY 10151 USA; Merial Ltd, Duluth, GA 30096 USA; D Young & Co, London EC1N 2DY, England		Morag-Sela, T (corresponding author), Reinhold Cohn & Partners, POB 4060, IL-61040 Tel Aviv, Israel.	tkowalski@flhlaw.com						*US, 2004, IP LAW B; 2004, GLOBES ONLINE   0926; 1981, PHARM ORDINANCE NEW; 2004, JERUSALEM POST  0909	4	1	1	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2004	22	12					1591	1592		10.1038/nbt1204-1591	http://dx.doi.org/10.1038/nbt1204-1591			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	878HX	15583670				2022-12-25	WOS:000225638600039
J	Demonacos, C; Krstic-Demonacos, M; Smith, L; Xu, DM; O'Connor, DP; Jansson, M; La Thangue, NB				Demonacos, C; Krstic-Demonacos, M; Smith, L; Xu, DM; O'Connor, DP; Jansson, M; La Thangue, NB			A new effector pathway links ATM kinase with the DNA damage response	NATURE CELL BIOLOGY			English	Article							DEPENDENT PHOSPHORYLATION; ATAXIA-TELANGIECTASIA; CELL-CYCLE; CHECKPOINT KINASES; P53 RESPONSE; ACTIVATION; CHK2; P300; MDM2; ACETYLATION	The related kinases ATM (ataxia-telangiectasia mutated) and ATR (ataxia-telangiectasia and Rad3-related) phosphorylate a limited number of downstream protein targets in response to DNA damage. Here we report a new pathway in which ATM kinase signals the DNA damage response by targeting the transcriptional cofactor Strap. ATM phosphorylates Strap at a serine residue, stabilizing nuclear Strap and facilitating formation of a stress-responsive co-activator complex. Strap activity enhances p53 acetylation, and augments the response to DNA damage. Strap remains localized in the cytoplasm in cells derived from ataxia telangiectasia individuals with defective ATM, as well as in cells expressing a Strap mutant that cannot be phosphorylated by ATM. Targeting Strap to the nucleus reinstates protein stabilization and activates the DNA damage response. These results indicate that the nuclear accumulation of Strap is a critical regulator in the damage response, and argue that this function can be assigned to ATM through the DNA damage-dependent phosphorylation of Strap.	Univ Glasgow, Dept Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	La Thangue, NB (corresponding author), Univ Glasgow, Dept Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	n.lathangue@bio.gla.ac.uk	Demonacos, Constantinos/K-1277-2019	Demonacos, Constantinos/0000-0002-4515-755X; Jansson, Martin/0000-0002-6946-145X; O'Connor, Darran/0000-0002-8835-1547; Xu, Danmei/0000-0001-8476-9623	MRC [G9400953] Funding Source: UKRI; Cancer Research UK [13058] Funding Source: Medline; Medical Research Council [G9400953] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Barlow C, 1999, P NATL ACAD SCI USA, V96, P9915, DOI 10.1073/pnas.96.17.9915; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chan HM, 2001, J CELL SCI, V114, P2363; Chehab NH, 2000, GENE DEV, V14, P278; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Crighton D, 2003, EMBO J, V22, P2810, DOI 10.1093/emboj/cdg265; Demonacos C, 2001, MOL CELL, V8, P71, DOI 10.1016/S1097-2765(01)00277-5; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Khanna KK, 2001, CELL DEATH DIFFER, V8, P1052, DOI 10.1038/sj.cdd.4400874; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Liu L, 1999, MOL CELL BIOL, V19, P1202; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Meyn MS, 1999, CLIN GENET, V55, P289, DOI 10.1034/j.1399-0004.1999.550501.x; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shieh SY, 2000, GENE DEV, V14, P289; Shikama N, 1999, MOL CELL, V4, P365, DOI 10.1016/S1097-2765(00)80338-X; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Stein RC, 2000, MOL MED TODAY, V6, P347, DOI 10.1016/S1357-4310(00)01770-6; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Walworth NC, 2000, CURR OPIN CELL BIOL, V12, P697, DOI 10.1016/S0955-0674(00)00154-X; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	36	49	51	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2004	6	10					968	+		10.1038/ncb1170	http://dx.doi.org/10.1038/ncb1170			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	859FY	15448695				2022-12-25	WOS:000224250000011
J	Stephanopoulos, G; Alper, H; Moxley, J				Stephanopoulos, G; Alper, H; Moxley, J			Exploiting biological complexity for strain improvement through systems biology	NATURE BIOTECHNOLOGY			English	Review							ESCHERICHIA-COLI; CORYNEBACTERIUM-GLUTAMICUM; METABOLIC FLUXES; OVEREXPRESSION; EXPRESSION; STRATEGIES; MUTANTS	Cellular complexity makes it difficult to build a complete understanding of cellular function but also offers innumerable possibilities for modifying the cellular machinery to achieve a specific purpose. The exploitation of cellular complexity for strain improvement has been a challenging goal for applied biological research because it requires the coordinated understanding of multiple cellular processes. It is therefore pursued most efficiently in the framework of systems biology. Progress in strain improvement will depend not only on advances in technologies for high-throughput measurements but, more importantly, on the development of theoretical methods that increase the information content of these measurements and, as such, facilitate the elucidation of mechanisms and the identification of genetic targets for modification.	MIT, Dept Chem Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Stephanopoulos, G (corresponding author), MIT, Dept Chem Engn, Room 56-469, Cambridge, MA 02139 USA.	gregstep@mit.edu						Allen J, 2003, NAT BIOTECHNOL, V21, P692, DOI 10.1038/nbt823; Askenazi M, 2003, NAT BIOTECHNOL, V21, P150, DOI 10.1038/nbt781; Badarinarayana V, 2001, NAT BIOTECHNOL, V19, P1060, DOI 10.1038/nbt1101-1060; Berrios-Rivera SJ, 2002, METAB ENG, V4, P230, DOI 10.1006/mben.2002.0228; Cameron DC, 1998, BIOTECHNOL PROGR, V14, P116, DOI 10.1021/bp9701325; Causey TB, 2004, P NATL ACAD SCI USA, V101, P2235, DOI 10.1073/pnas.0308171100; COLON GE, 1995, APPL MICROBIOL BIOT, V43, P482, DOI 10.1007/s002530050438; CREMER J, 1991, APPL ENVIRON MICROB, V57, P1746, DOI 10.1128/AEM.57.6.1746-1752.1991; Edwards JS, 2000, P NATL ACAD SCI USA, V97, P5528, DOI 10.1073/pnas.97.10.5528; Farmer WR, 2000, NAT BIOTECHNOL, V18, P533, DOI 10.1038/75398; Fussenegger M, 2002, BIOTECHNOL BIOENG, V79, P509, DOI 10.1002/bit.10405; Hemmi H, 1998, J BIOCHEM-TOKYO, V123, P1088; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; Ideker T, 2003, TRENDS BIOTECHNOL, V21, P255, DOI 10.1016/S0167-7799(03)00115-X; Ideker Trey, 2002, Bioinformatics, V18 Suppl 1, pS233; Kacser H, 1973, Symp Soc Exp Biol, V27, P65; Kaup B, 2004, APPL MICROBIOL BIOT, V64, P333, DOI 10.1007/s00253-003-1470-9; KHOSLA C, 1988, NATURE, V331, P633, DOI 10.1038/331633a0; Koffas MAG, 2003, METAB ENG, V5, P32, DOI 10.1016/S1096-7176(03)00002-8; Koffas MAG, 2002, APPL ENVIRON MICROB, V68, P5422, DOI 10.1128/AEM.68.11.5422-5428.2002; Lee SY, 2003, APPL ENVIRON MICROB, V69, P3421, DOI 10.1128/AEM.69.6.3421-3426.2003; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Martin VJJ, 2003, NAT BIOTECHNOL, V21, P796, DOI 10.1038/nbt833; Nakamura CE, 2003, CURR OPIN BIOTECH, V14, P454, DOI 10.1016/j.copbio.2003.08.005; Ostergaard S, 2000, NAT BIOTECHNOL, V18, P1283, DOI 10.1038/82400; Segre D, 2002, P NATL ACAD SCI USA, V99, P15112, DOI 10.1073/pnas.232349399; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Snell KD, 2002, METAB ENG, V4, P29, DOI 10.1006/mben.2001.0214; Stafford DE, 2002, P NATL ACAD SCI USA, V99, P1801, DOI 10.1073/pnas.032681699; Stephanopoulos G, 2002, BIOINFORMATICS, V18, P1054, DOI 10.1093/bioinformatics/18.8.1054; STEPHANOPOULOS G, 1991, SCIENCE, V252, P1675, DOI 10.1126/science.1904627; Stephanopoulos G, 2001, SCIENCE, V292, P2024, DOI 10.1126/science.1062556; Stephanopoulos G., 1998, METAB ENG; Stephanopoulos G, 1999, METAB ENG, V1, P1, DOI 10.1006/mben.1998.0101; Viswanathan K, 2003, BIOCHEMISTRY-US, V42, P15215, DOI 10.1021/bi034994s; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; Xue YQ, 2000, NATURE, V403, P571, DOI 10.1038/35000624	37	130	170	1	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2004	22	10					1261	1267		10.1038/nbt1016	http://dx.doi.org/10.1038/nbt1016			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	860EU	15470466				2022-12-25	WOS:000224326100027
J	Acquaviva, C; Herzog, F; Kraft, C; Pines, J				Acquaviva, C; Herzog, F; Kraft, C; Pines, J			The anaphase promoting complex/cyclosome is recruited to centromeres by the spindle assembly checkpoint	NATURE CELL BIOLOGY			English	Article							AURORA-B; CYCLIN-B; KINETOCHORE LOCALIZATION; MITOTIC SPINDLE; PROTEIN; COMPLEX; MAD2; APC/C; DESTRUCTION; DYNAMICS	The anaphase promoting complex/cyclosome (APC/C) is crucial to the control of cell division (for a review, see ref. 1). It is a multi-subunit ubiquitin ligase that, at defined points during mitosis, targets specific proteins for proteasomal degradation. The APC/C is itself regulated by the spindle or kinetochore checkpoint, which has an important role in maintaining genomic stability by preventing sister chromatid separation until all chromosomes are correctly aligned on the mitotic spindle. The spindle checkpoint regulates the APC/C by inactivating Cdc20, an important co-activator of the APC/C. There is also evidence to indicate that the spindle checkpoint components and Cdc20 are spatially regulated by the mitotic apparatus, in particular they are recruited to improperly attached kinetochores. Here, we show that the APC/C itself co-localizes with components of the spindle checkpoint to improperly attached kinetochores. Indeed, we provide evidence that the spindle checkpoint machinery is required to recruit the APC/C to kinetochores. Our data indicate that the APC/C could be regulated directly by the spindle checkpoint.	Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB2 1QR, England; Inst Mol Pathol, A-1030 Vienna, Austria	University of Cambridge; University of Cambridge; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Pines, J (corresponding author), Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst, Tennis Court Rd, Cambridge CB2 1QR, England.	jp103@cam.ac.uk	Herzog, Franz/G-4832-2012; Acquaviva, Claire/N-4306-2017	Herzog, Franz/0000-0001-8270-1449; Acquaviva, Claire/0000-0002-0227-9813; Pines, Jonathon/0000-0002-5227-6004				Andrews PD, 2004, DEV CELL, V6, P253, DOI 10.1016/S1534-5807(04)00025-5; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Daum JR, 2000, CURR BIOL, V10, pR850, DOI 10.1016/S0960-9822(00)00836-8; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Gieffers C, 2001, MOL CELL, V7, P907, DOI 10.1016/S1097-2765(01)00234-9; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; Gorbsky GJ, 1997, BIOESSAYS, V19, P193, DOI 10.1002/bies.950190303; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; Hagting A, 2002, J CELL BIOL, V157, P1125, DOI 10.1083/jcb.200111001; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; Howell BJ, 2001, J CELL BIOL, V155, P1159, DOI 10.1083/jcb.200105093; Howell BJ, 2004, CURR BIOL, V14, P953, DOI 10.1016/j.cub.2004.05.053; Huang JY, 2002, J CELL SCI, V115, P2847; Huang JY, 1999, EMBO J, V18, P2184, DOI 10.1093/emboj/18.8.2184; Jorgensen PM, 1998, MOL CELL BIOL, V18, P468; Koloteva-Levine N, 2004, MOL CELL BIOL, V24, P3577, DOI 10.1128/MCB.24.9.3577-3587.2004; Kraft C, 2003, EMBO J, V22, P6598, DOI 10.1093/emboj/cdg627; Kurasawa Y, 1999, ONCOGENE, V18, P5131, DOI 10.1038/sj.onc.1203133; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Raff JW, 2002, J CELL BIOL, V157, P1139, DOI 10.1083/jcb.200203035; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Shah JV, 2004, CURR BIOL, V14, P942, DOI 10.1016/j.cub.2004.05.046; Skoufias DA, 2001, P NATL ACAD SCI USA, V98, P4492, DOI 10.1073/pnas.081076898; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Taylor SS, 2001, J CELL SCI, V114, P4385; Thornton BR, 2003, NAT CELL BIOL, V5, P1090, DOI 10.1038/ncb1066; Topper LM, 2002, CELL CYCLE, V1, P282, DOI 10.4161/cc.1.4.139; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; VIGNERON S, 2004, MOL BIOL CELL, DOI DOI 10.1091/MBC.E04-010051; Waters JC, 1999, CURR BIOL, V9, P649, DOI 10.1016/S0960-9822(99)80287-5; Yamano H, 2004, MOL CELL, V13, P137, DOI 10.1016/S1097-2765(03)00480-5; Yoon HJ, 2002, CURR BIOL, V12, P2048, DOI 10.1016/S0960-9822(02)01331-3	36	84	86	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2004	6	9					892	U82		10.1038/ncb1167	http://dx.doi.org/10.1038/ncb1167			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	852IZ	15322556				2022-12-25	WOS:000223750300019
J	Chen, KH; Guo, XM; Ma, DL; Guo, YH; Li, QA; Yang, DM; Li, PF; Qiu, XY; Wen, SJ; Xiao, RP; Tang, JA				Chen, KH; Guo, XM; Ma, DL; Guo, YH; Li, QA; Yang, DM; Li, PF; Qiu, XY; Wen, SJ; Xiao, RP; Tang, JA			Dysregulation of HSG triggers vascular proliferative disorders	NATURE CELL BIOLOGY			English	Article							MUSCLE CELL-PROLIFERATION; SPONTANEOUSLY HYPERTENSIVE-RAT; DEPENDENT KINASE INHIBITOR; SMOOTH-MUSCLE; GENE-THERAPY; MITOCHONDRIAL FUSION; INTIMAL HYPERPLASIA; CYCLE MACHINERY; P27(KIP1); GROWTH	Vascular proliferative disorders, such as atherosclerosis and restenosis, are the most common causes of severe cardiovascular diseases, but a common molecular mechanism remains elusive. Here, we identify and characterize a novel hyperplasia suppressor gene, named HSG (later re-named rat mitofusin-2). HSG expression was markedly reduced in hyper-proliferative vascular smooth muscle cells (VSMCs) from spontaneously hypertensive rat arteries, balloon-injured Wistar Kyoto rat arteries, or ApoE-knockout mouse atherosclerotic arteries. Overexpression of HSG overtly suppressed serum-evoked VSMC proliferation in culture, and blocked balloon injury induced neointimal VSMC proliferation and restenosis in rat carotid arteries. The HSG anti-proliferative effect was mediated by inhibition of ERK/MAPK signalling and subsequent cell-cycle arrest. Deletion of the p21(ras) signature motif, but not the mitochondrial targeting domain, abolished HSG-induced growth arrest, indicating that rHSG-induced anti-proliferation was independent of mitochondrial fusion. Thus, rHSG functions as a cell proliferation suppressor, whereas dysregulation of rHSG results in proliferative disorders.	Peking Univ, Inst Cardiovasc Sci, Beijing 100083, Peoples R China; Peking Univ, Inst Mol Med, Beijing 100083, Peoples R China; NIA, Cardiovasc Sci Lab, NIH, Baltimore, MD 21224 USA; Peking Univ, Ctr Human Dis Gen, Beijing 100083, Peoples R China; Peking Univ, Dept Immunol, Ctr Hlth, Beijing 100083, Peoples R China	Peking University; Peking University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Peking University; Peking University	Xiao, RP (corresponding author), Peking Univ, Inst Cardiovasc Sci, Beijing 100083, Peoples R China.	xiaor@grc.nia.nih.gov	Guo, Yanhong/D-9764-2012; Xiao, Rui-Ping/AAE-2629-2019; GUO, Yanhong/B-5325-2012; Yimei, Wang/AAE-4083-2019		NATIONAL INSTITUTE ON AGING [Z01AG000289] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Benson DA, 1999, NUCLEIC ACIDS RES, V27, P12, DOI 10.1093/nar/27.1.12; BING OHL, 1995, J MOL CELL CARDIOL, V27, P383, DOI 10.1016/S0022-2828(08)80035-1; Braun-Dullaeus RC, 1998, CIRCULATION, V98, P82, DOI 10.1161/01.CIR.98.1.82; Chakir K, 2003, MOL PHARMACOL, V64, P1048, DOI 10.1124/mol.64.5.1048; CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; CLOWES AW, 1983, LAB INVEST, V49, P327; CLOWES AW, 1985, CIRC RES, V56, P139, DOI 10.1161/01.RES.56.1.139; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Delmas C, 2001, J BIOL CHEM, V276, P34958, DOI 10.1074/jbc.M101714200; DEVLIN AM, 1995, J HYPERTENS, V13, P211; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; Dzau VJ, 2002, NAT MED, V8, P1249, DOI 10.1038/nm1102-1249; FELICIELLO I, 1993, ANAL BIOCHEM, V212, P394, DOI 10.1006/abio.1993.1346; Ferguson JE, 2003, CELL CYCLE, V2, P211, DOI 10.4161/cc.2.3.366; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FORRESTER JS, 1991, J AM COLL CARDIOL, V17, P758, DOI 10.1016/S0735-1097(10)80196-2; Garas SM, 2001, PHARMACOL THERAPEUT, V92, P165, DOI 10.1016/S0163-7258(01)00168-1; Hales KG, 1997, CELL, V90, P121, DOI 10.1016/S0092-8674(00)80319-0; HANKE H, 1990, CIRC RES, V67, P651, DOI 10.1161/01.RES.67.3.651; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Johns DG, 2001, J HYPERTENS, V19, P63, DOI 10.1097/00004872-200101000-00009; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Kim S, 1997, J CLIN INVEST, V100, P1006, DOI 10.1172/JCI119611; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Libby P, 2003, AM J CARDIOL, V91, p3A; Maillard L, 2000, GENE THER, V7, P1353, DOI 10.1038/sj.gt.3301255; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Morishita R, 2002, CIRC J, V66, P1077, DOI 10.1253/circj.66.1077; Moses JW, 2003, NEW ENGL J MED, V349, P1315, DOI 10.1056/NEJMoa035071; NABEL EG, 1993, J CLIN INVEST, V91, P1822, DOI 10.1172/JCI116394; NABEL EG, 1993, NATURE, V362, P844, DOI 10.1038/362844a0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Novak K, 1998, NAT MED, V4, P989, DOI 10.1038/1965; OHNO T, 1994, SCIENCE, V265, P781, DOI 10.1126/science.8047883; OKAMOTO KOZO, 1963, JAPAN CIRCULATION JOUR, V27, P282; Ooboshi H, 1997, MOL CELL BIOCHEM, V172, P37, DOI 10.1023/A:1006803202179; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Rojo M, 2002, J CELL SCI, V115, P1663; Santel A, 2001, J CELL SCI, V114, P867; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Taylor DS, 1999, P NATL ACAD SCI USA, V96, P1633, DOI 10.1073/pnas.96.4.1633; Tulis DA, 2001, CIRCULATION, V104, P2710, DOI 10.1161/hc4701.099585; Tunstall-Pedoe H, 1999, LANCET, V353, P1547, DOI 10.1016/S0140-6736(99)04021-0; Woods TC, 2004, ANNU REV MED, V55, P169, DOI 10.1146/annurev.med.55.091902.105243	49	294	378	3	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2004	6	9					872	U8		10.1038/ncb1161	http://dx.doi.org/10.1038/ncb1161			16	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	852IZ	15322553				2022-12-25	WOS:000223750300017
J	Mohammed, FF; Smookler, DS; Taylor, SEM; Fingleton, B; Kassiri, Z; Sanchez, OH; English, JL; Matrisian, LM; Au, B; Yeh, WC; Khokha, R				Mohammed, FF; Smookler, DS; Taylor, SEM; Fingleton, B; Kassiri, Z; Sanchez, OH; English, JL; Matrisian, LM; Au, B; Yeh, WC; Khokha, R			Abnormal TNF activity in Timp3(-/-) mice leads to chronic hepatic inflammation and failure of liver regeneration	NATURE GENETICS			English	Article							NECROSIS-FACTOR-ALPHA; SORSBYS FUNDUS DYSTROPHY; NF-KAPPA-B; CONVERTING-ENZYME TACE; TISSUE INHIBITOR; METALLOPROTEINASE INHIBITOR; MATRIX METALLOPROTEINASES; EXTRACELLULAR-MATRIX; TRANSGENIC MICE; FACTOR-RECEPTOR	Tumor-necrosis factor (TNF), a pleiotropic cytokine, triggers physiological and pathological responses in several organs. Here we show that deletion of the mouse gene Timp3 resulted in an increase in TNF-alpha converting enzyme activity, constitutive release of TNF and activation of TNF signaling in the liver. The increase in TNF in Timp3(-/-) mice culminated in hepatic lymphocyte infiltration and necrosis, features that are also seen in chronic active hepatitis in humans. This pathology was prevented when deletion of Timp3 was combined with Tnfrsf1a deficiency. In a liver regeneration model that requires TNF signaling, Timp3(-/-) mice succumbed to liver failure. Hepatocytes from Timp3(-/-) mice completed the cell cycle but then underwent cell death owing to sustained activation of TNF. This hepatocyte cell death was completely rescued by a neutralizing antibody to TNF. Dysregulation of TNF occurred specifically in Timp3(-/-), and not Timp1(-/-) mice. These data indicate that TIMP3 is a crucial innate negative regulator of TNF in both tissue homeostasis and tissue response to injury.	Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada	Vanderbilt University; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Khokha, R (corresponding author), Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada.	rkhokha@uhnres.utoronto.ca		Fingleton, Barbara/0000-0003-1132-0782				Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Alcamo E, 2001, J IMMUNOL, V167, P1592, DOI 10.4049/jimmunol.167.3.1592; Aldeguer X, 2002, HEPATOLOGY, V35, P40, DOI 10.1053/jhep.2002.30081; Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BLENIS J, 1984, J BIOL CHEM, V259, P1563; Bouwens L, 1988, Revis Biol Celular, V16, P69; Butler DM, 1997, J IMMUNOL, V159, P2867; Bzowska M, 2004, EUR J BIOCHEM, V271, P2808, DOI 10.1111/j.1432-1033.2004.04215.x; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Contin C, 2003, J BIOL CHEM, V278, P32801, DOI 10.1074/jbc.M209993200; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Dory D, 2003, J LEUKOCYTE BIOL, V74, P49, DOI 10.1189/jlb.0302133; English WR, 2000, J BIOL CHEM, V275, P14046, DOI 10.1074/jbc.275.19.14046; Fata JE, 2001, J CLIN INVEST, V108, P831, DOI 10.1172/JCI13171; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Georgopoulos S, 1996, J INFLAMM, V46, P86; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Haro H, 2000, J CLIN INVEST, V105, P143, DOI 10.1172/JCI7091; Higgins GM, 1931, ARCH PATHOL, V12, P186; Jevon GP, 2001, PEDIATR DEVEL PATHOL, V4, P372, DOI 10.1007/s10024001-0006-5; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Jin GX, 2002, ANAL BIOCHEM, V302, P269, DOI 10.1006/abio.2001.5549; Killar L, 1999, ANN NY ACAD SCI, V878, P442, DOI 10.1111/j.1749-6632.1999.tb07701.x; Knittel T, 1999, J HEPATOL, V30, P48, DOI 10.1016/S0168-8278(99)80007-5; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kyriakis JM, 2001, NATURE, V414, P265, DOI 10.1038/35104735; Leco KJ, 2001, J CLIN INVEST, V108, P817, DOI 10.1172/JCI12067; Lee DC, 2003, ANN NY ACAD SCI, V995, P22, DOI 10.1111/j.1749-6632.2003.tb03207.x; Lee MH, 2001, BIOCHEM BIOPH RES CO, V280, P945, DOI 10.1006/bbrc.2000.4192; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; McIntyre JO, 2004, BIOCHEM J, V377, P617, DOI 10.1042/BJ20030582; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Mueller C, 1999, J BIOL CHEM, V274, P38112, DOI 10.1074/jbc.274.53.38112; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Nuttall RK, 2004, FEBS LETT, V563, P129, DOI 10.1016/S0014-5793(04)00281-9; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Qi JH, 2002, J BIOL CHEM, V277, P13394, DOI 10.1074/jbc.M110870200; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rizvi NA, 2004, CLIN CANCER RES, V10, P1963, DOI 10.1158/1078-0432.CCR-1183-02; Rovida E, 2001, J IMMUNOL, V166, P1583, DOI 10.4049/jimmunol.166.3.1583; Ruuls SR, 2001, IMMUNITY, V15, P533, DOI 10.1016/S1074-7613(01)00215-1; TOYONAGA T, 1994, P NATL ACAD SCI USA, V91, P614, DOI 10.1073/pnas.91.2.614; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yeow KM, 2002, MATRIX BIOL, V21, P75, DOI 10.1016/S0945-053X(01)00180-9	50	230	237	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2004	36	9					969	977		10.1038/ng1413	http://dx.doi.org/10.1038/ng1413			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	851AY	15322543	Bronze			2022-12-25	WOS:000223658100023
J	Nguyen, A; Rothman, DM; Stehn, J; Imperiali, B; Yaffe, MB				Nguyen, A; Rothman, DM; Stehn, J; Imperiali, B; Yaffe, MB			Caged phosphopeptides reveal a temporal role for 14-3-3 in G1 arrest and S-phase checkpoint function	NATURE BIOTECHNOLOGY			English	Article							PHOSPHOSERINE/THREONINE-BINDING DOMAINS; DNA-DAMAGE; SIGNALING PATHWAYS; KINASE-ACTIVITY; CELL MOTILITY; HIGH-AFFINITY; EXOENZYME-S; IN-VIVO; PROTEINS; PHOSPHORYLATION	Using classical genetics to study modular phosphopeptide-binding domains within a family of proteins that are functionally redundant is difficult when other members of the domain family compensate for the product of the knocked-out gene. Here we describe a chemical genetics approach that overcomes this limitation by using UV-activatable caged phosphopeptides. By incorporating a caged phosphoserine residue within a consensus motif, these reagents simultaneously and synchronously inactivate all phosphoserine/phosphothreonine-binding domain family members in a rapid and temporally regulated manner. We applied this approach to study the global function of 14-3-3 proteins in cell cycle control. Activation of the caged phosphopeptides by UV irradiation displaced endogenous proteins from 14-3-3-binding, causing premature cell cycle entry, release of G1 cells from interphase arrest and loss of the S-phase checkpoint after DNA damage, accompanied by high levels of cell death. This class of reagents will greatly facilitate molecular dissection of kinase-dependent signaling pathways when applied to other phosphopeptide-binding domains including SH2, Polo-box and tandem BRCT domains.	MIT, Ctr Canc Res, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Dept Chem, Cambridge, MA 02139 USA; MIT, Div Biol Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Yaffe, MB (corresponding author), MIT, Ctr Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	myaffe@mit.edu	Stehn, Justine/G-5115-2013	Stehn, Justine/0000-0002-2136-5450; Imperiali, Barbara/0000-0002-5749-7869; Rothman, Deborah/0000-0001-8922-9263	NIGMS NIH HHS [GM63436, GM60594] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060594] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; AlberolaIla J, 1996, J EXP MED, V184, P9, DOI 10.1084/jem.184.1.9; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chen L, 2001, CHEM BIOL, V8, P1123, DOI 10.1016/S1074-5521(01)00076-X; Chen MS, 2003, MOL CELL BIOL, V23, P7488, DOI 10.1128/MCB.23.21.7488-7497.2003; CORRIE JET, 1993, BIOL APPL PHOTOCHEMI, P243; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; de Gruijl FR, 2000, METHOD ENZYMOL, V319, P359; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Dunican DJ, 2001, BIOPOLYMERS, V60, P45, DOI 10.1002/1097-0282(2001)60:1<45::AID-BIP1003>3.3.CO;2-0; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Ellis-Davies GCR, 2003, METHOD ENZYMOL, V360, P226; ELLISDAVIES GCR, 1994, P NATL ACAD SCI USA, V91, P187, DOI 10.1073/pnas.91.1.187; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Ghosh M, 2004, SCIENCE, V304, P743, DOI 10.1126/science.1094561; Henriksson ML, 2002, EUR J BIOCHEM, V269, P4921, DOI 10.1046/j.1432-1033.2002.03191.x; Jiang KC, 2003, J BIOL CHEM, V278, P25207, DOI 10.1074/jbc.M300070200; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; KLEIMAN NJ, 1990, CURR EYE RES, V9, P1185, DOI 10.3109/02713689009003475; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Park CH, 1997, J AM CHEM SOC, V119, P2453, DOI 10.1021/ja9635589; PATTON WF, 1991, ANAL BIOCHEM, V196, P31, DOI 10.1016/0003-2697(91)90113-8; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Ravanat JL, 2001, J PHOTOCH PHOTOBIO B, V63, P88, DOI 10.1016/S1011-1344(01)00206-8; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Rothblum-Oviatt CJ, 2001, CELL GROWTH DIFFER, V12, P581; Rothman DM, 2003, J ORG CHEM, V68, P6795, DOI 10.1021/jo0344891; Rothman DM, 2002, ORG LETT, V4, P2865, DOI 10.1021/ol0262587; Subramanian RR, 2001, EXP CELL RES, V271, P142, DOI 10.1006/excr.2001.5376; Tong YH, 2001, J GEN PHYSIOL, V117, P103, DOI 10.1085/jgp.117.2.103; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Vazquez ME, 2003, J AM CHEM SOC, V125, P10150, DOI 10.1021/ja0351847; Walker JW, 1998, P NATL ACAD SCI USA, V95, P1568, DOI 10.1073/pnas.95.4.1568; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; Wang YL, 2000, CELL GROWTH DIFFER, V11, P211; WOOTTON JF, 1995, BIOPHYS J, V68, P2601, DOI 10.1016/S0006-3495(95)80444-3; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe MB, 2001, STRUCTURE, V9, pR33, DOI 10.1016/S0969-2126(01)00580-9; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717	50	70	72	2	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2004	22	8					993	1000		10.1038/nbt997	http://dx.doi.org/10.1038/nbt997			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	842YB	15273693				2022-12-25	WOS:000223039500027
J	Jonsson, H; Allen, P; Peng, SL				Jonsson, H; Allen, P; Peng, SL			Inflammatory arthritis requires Foxo3a to prevent Fas ligand-induced neutrophil apoptosis	NATURE MEDICINE			English	Article							FORKHEAD TRANSCRIPTION FACTORS; TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE; CELL-SURVIVAL; INTERLEUKIN-1; ACTIVATION; WITHDRAWAL; REGULATORS; SYNOVITIS; PATHWAYS	In inflammatory arthridities such as rheumatoid arthritis, cognate lymphocytes have long been considered instigators of autoimmunity, but accumulating evidence indicates that innate immune cells such as neutrophils and mast cells are responsible for a vast majority of acute and ongoing inflammation(1-3); however, the molecular mechanisms that govern them remain largely unknown. Here we show that such inflammation requires the forkhead transcription factor Foxo3a: Foxo3a-deficient mice are resistant to two models of neutrophilic inflammation, immune complex - mediated inflammatory arthritis and thioglycollate-induced peritonitis. This reflects a need for Foxo3a to maintain neutrophil vitality during inflammation by suppressing Fas ligand; because Foxo3a can bind and suppress the Fasl promoter, Foxo3a-deficient neutrophils upregulate Fas ligand and undergo apoptosis in response to TNF-alpha and IL-1, and Fas ligand blockade renders Foxo3a-deficient mice susceptible to both arthritis and peritonitis. Thus, Foxo3a ensures neutrophil survival during inflammation, identifying Foxo3a as therapeutic target in inflammation.	Washington Univ, Sch Med, Dept Internal Med, Div Rheumatol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Peng, SL (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Rheumatol, 660 S Euclid Ave, St Louis, MO 63110 USA.	speng@im.wustl.edu	Peng, Stanford/S-6723-2019	Jonsson, Anna Helena/0000-0002-9558-2474	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI061478, R01AI057471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 061478, AI 057471] Funding Source: Medline; NIDDK NIH HHS [DK 52574] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altznauer F, 2004, J EXP MED, V199, P1343, DOI 10.1084/jem.20032033; Alvarado-Kristensson M, 2004, J EXP MED, V199, P449, DOI 10.1084/jem.20031771; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Asselin-Labat ML, 2004, BLOOD, V104, P215, DOI 10.1182/blood-2003-12-4295; Birkenkamp KU, 2003, J IMMUNOL, V171, P1623, DOI 10.4049/jimmunol.171.4.1623; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; COLLART MA, 1986, J EXP MED, V164, P2113, DOI 10.1084/jem.164.6.2113; Crossley LJ, 2003, J LEUKOCYTE BIOL, V74, P583, DOI 10.1189/jlb.0103020; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Firestein GS, 2002, ARTHRITIS RHEUM, V46, P298, DOI 10.1002/art.502; Gerth AJ, 2004, ARTHRITIS RHEUM, V50, P3392, DOI 10.1002/art.20579; Gerth AJ, 2003, INT IMMUNOL, V15, P937, DOI 10.1093/intimm/dxg093; Ji H, 2002, IMMUNITY, V16, P157, DOI 10.1016/S1074-7613(02)00275-3; Ji H, 2002, J EXP MED, V196, P77, DOI 10.1084/jem.20020439; Kouskoff V, 1996, CELL, V87, P811, DOI 10.1016/S0092-8674(00)81989-3; Lee DM, 2001, LANCET, V358, P903, DOI 10.1016/S0140-6736(01)06075-5; Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Lin L, 2004, IMMUNITY, V21, P203, DOI 10.1016/j.immuni.2004.06.016; LUO Y, 1997, CURRENT PROTOCOLS IM; Matsumoto I, 1999, SCIENCE, V286, P1732, DOI 10.1126/science.286.5445.1732; Matsumoto I, 2002, NAT IMMUNOL, V3, P360, DOI 10.1038/ni772; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Norris J. S., 2001, Current Gene Therapy, V1, P123, DOI 10.2174/1566523013348977; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Villunger A, 2000, J EXP MED, V192, P647, DOI 10.1084/jem.192.5.647; Wang XW, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng154; Wipke BT, 2001, J IMMUNOL, V167, P1601, DOI 10.4049/jimmunol.167.3.1601; Yang KY, 2003, CELL SIGNAL, V15, P225, DOI 10.1016/S0898-6568(02)00063-3	30	166	174	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2005	11	6					666	671		10.1038/nm1248	http://dx.doi.org/10.1038/nm1248			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	932YD	15895074				2022-12-25	WOS:000229589800034
J	Zuger, S; Iwai, H				Zuger, S; Iwai, H			Intein-based biosynthetic incorporation of unlabeled protein tags into isotopically labeled proteins for NMR studies	NATURE BIOTECHNOLOGY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; HIGH-LEVEL EXPRESSION; IN-VIVO; BIOLOGICAL MACROMOLECULES; ESCHERICHIA-COLI; LARGER PROTEIN; SPLIT INTEIN; DNAE GENE; SPECTROSCOPY; LIGATION	Segmental isotopic labeling of proteins using protein ligation is a recently established in vitro method for incorporating isotopes into one domain or region of a protein to reduce the complexity of NMR spectra, thereby facilitating the NMR analysis of larger proteins(1-3). Here we demonstrate that segmental isotopic labeling of proteins can be conveniently achieved in Escherichia coli using intein-based protein ligation. Our method is based on a dual expression system that allows sequential expression of two precursor fragments in media enriched with different isotopes. Using this in vivo approach, unlabeled protein tags can be incorporated into isotopically labeled target proteins to improve protein stability and solubility for study by solution NMR spectroscopy.	Univ Saskatchewan, Dept Chem, Saskatoon, SK S7N 5C9, Canada; Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5C9, Canada	University of Saskatchewan; University of Saskatchewan	Iwai, H (corresponding author), Univ Saskatchewan, Dept Chem, 110 Sci Pl, Saskatoon, SK S7N 5C9, Canada.	h.iwai@usask.ca	Iwaï, Hideo/A-6416-2009	Iwaï, Hideo/0000-0001-7376-5264				BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Boomershine WP, 2003, PROTEIN EXPRES PURIF, V28, P246, DOI 10.1016/S1046-5928(02)00707-6; Christendat D, 2000, NAT STRUCT BIOL, V7, P903; Evans TC, 2000, J BIOL CHEM, V275, P9091, DOI 10.1074/jbc.275.13.9091; Giriat I, 2003, J AM CHEM SOC, V125, P7180, DOI 10.1021/ja034736i; GUNTERT P, 1992, J BIOMOL NMR, V2, P619, DOI 10.1007/BF02192850; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Ikegami T, 2000, J BIOL CHEM, V275, P13654, DOI 10.1074/jbc.275.18.13654; Inoue Y, 2001, J BIOL CHEM, V276, P35227, DOI 10.1074/jbc.C100304200; Iwai H, 2001, J BIOL CHEM, V276, P16548, DOI 10.1074/jbc.M011639200; King CY, 2004, NATURE, V428, P319, DOI 10.1038/nature02391; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; Makrides SC, 1996, MICROBIOL REV, V60, P512, DOI 10.1128/MMBR.60.3.512-538.1996; MCINTOSH LP, 1990, Q REV BIOPHYS, V23, P1, DOI 10.1017/S0033583500005400; Mills KV, 2001, J BIOL CHEM, V276, P10832, DOI 10.1074/jbc.M011149200; ORBAN J, 1995, BIOCHEMISTRY-US, V34, P15291, DOI 10.1021/bi00046a038; Otomo T, 1999, J BIOMOL NMR, V14, P105, DOI 10.1023/A:1008308128050; Otomo T, 1999, BIOCHEMISTRY-US, V38, P16040, DOI 10.1021/bi991902j; Ozawa T, 2000, ANAL CHEM, V72, P5151, DOI 10.1021/ac000617z; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Scott CP, 1999, P NATL ACAD SCI USA, V96, P13638, DOI 10.1073/pnas.96.24.13638; Serber Z, 2001, BIOCHEMISTRY-US, V40, P14317, DOI 10.1021/bi011751w; Wider G, 1999, CURR OPIN STRUC BIOL, V9, P594, DOI 10.1016/S0959-440X(99)00011-1; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Wu H, 1998, P NATL ACAD SCI USA, V95, P9226, DOI 10.1073/pnas.95.16.9226; Xu R, 1999, P NATL ACAD SCI USA, V96, P388, DOI 10.1073/pnas.96.2.388; Yamazaki T, 1998, J AM CHEM SOC, V120, P5591, DOI 10.1021/ja980776o; Yu HT, 1999, P NATL ACAD SCI USA, V96, P332, DOI 10.1073/pnas.96.2.332; Zhou P, 2001, J BIOMOL NMR, V20, P11, DOI 10.1023/A:1011258906244	30	95	101	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2005	23	6					736	740		10.1038/nbt1097	http://dx.doi.org/10.1038/nbt1097			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	933LA	15908942				2022-12-25	WOS:000229628700035
J	Bradford, KJ; Van Deynze, A; Gutterson, N; Parrott, W; Strauss, SH				Bradford, KJ; Van Deynze, A; Gutterson, N; Parrott, W; Strauss, SH			Regulating transgenic crops sensibly: lessons from plant breeding, biotechnology and genomics	NATURE BIOTECHNOLOGY			English	Article							GREEN FLUORESCENT PROTEIN; SAFETY ASSESSMENT; MAIZE; DNA; SIZE; TOMATO; VIRUS; GENES; RISKS; LINES	The costs of meeting regulatory requirements and market restrictions guided by regulatory criteria are substantial impediments to the commercialization of transgenic crops. Although a cautious approach may have been prudent initially, we argue that some regulatory requirements can now be modified to reduce costs and uncertainty without compromising safety. Long-accepted plant breeding methods for incorporating new diversity into crop varieties, experience from two decades of research on and commercialization of transgenic crops, and expanding knowledge of plant genome structure and dynamics all indicate that if a gene or trait is safe, the genetic engineering process itself presents little potential for unexpected consequences that would not be identified or eliminated in the variety development process before commercialization. We propose that as in conventional breeding, regulatory emphasis should be on phenotypic rather than genomic characteristics once a gene or trait has been shown to be safe.	Oregon State Univ, Dept Forest Sci, Corvallis, OR 97331 USA; Univ Calif Davis, Seed Biotechnol Ctr, Davis, CA 95616 USA; Mendel Biotechnol Inc, Hayward, CA 94545 USA; Univ Georgia, Dept Crop & Soil Sci, Athens, GA 30602 USA	Oregon State University; University of California System; University of California Davis; University System of Georgia; University of Georgia	Strauss, SH (corresponding author), Oregon State Univ, Dept Forest Sci, Peavy Hall 154, Corvallis, OR 97331 USA.	steve.strauss@oregonstate.edu						Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; [Anonymous], 1992, FED REG, V57, P6753; Arumuganathan K., 1991, PLANT MOL BIOL REP, V9, P208, DOI [10.1007/BF02672069, DOI 10.1007/BF02672069]; Barton J, 1997, NAT BIOTECHNOL, V15, P845, DOI 10.1038/nbt0997-845; Bennett PM, 2004, J ANTIMICROB CHEMOTH, V53, P418, DOI 10.1093/jac/dkh087; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; Ceccarelli M, 1997, THEOR APPL GENET, V94, P309, DOI 10.1007/s001220050416; Ching A, 2002, BMC GENET, V3, DOI 10.1186/1471-2156-3-19; Clark D., 2004, California Agriculture, V58, P89, DOI 10.3733/ca.v058n02p89; *EC RES SERV, 2003, FARM INC COSTS 2003; Ellstrand N. C., 2003, DANGEROUS LIAISONS C; FDA, 1998, GUID IND US ANT RES; Federoff N. V., 2004, MENDEL KITCHEN SCI V; FLAVELL RB, 1992, BIO-TECHNOL, V10, P141, DOI 10.1038/nbt0292-141; Fu HH, 2002, P NATL ACAD SCI USA, V99, P9573, DOI 10.1073/pnas.132259199; FUCHS RL, 1993, BIO-TECHNOL, V11, P1543, DOI 10.1038/nbt1293-1543; GIANESSI L, 2004, CALIF AGR, V58, P94; Gilissen LJW, 1998, TRANSGENIC RES, V7, P157, DOI 10.1023/A:1008832711805; Gonsalves D, 1998, ANNU REV PHYTOPATHOL, V36, P415, DOI 10.1146/annurev.phyto.36.1.415; Graff G. D., 2004, California Agriculture, V58, P120, DOI 10.3733/ca.v058n02p120; GRAHAM MJ, 1994, THEOR APPL GENET, V88, P429, DOI 10.1007/BF00223656; HARDWICK NV, 1994, PLANT PATHOL, V43, P1045, DOI 10.1111/j.1365-3059.1994.tb01656.x; Harper G, 2002, ANNU REV PHYTOPATHOL, V40, P119, DOI 10.1146/annurev.phyto.40.120301.105642; Haslberger AG, 2003, NAT BIOTECHNOL, V21, P739, DOI 10.1038/nbt0703-739; HO JY, 1992, PLANT J, V2, P971; Ho Mae-Wan, 1999, Microbial Ecology in Health and Disease, V11, P194, DOI 10.1080/08910609908540827; Hoa TTC, 2003, PLANT PHYSIOL, V133, P161, DOI 10.1104/pp.103.023457; Hodgson J, 2000, NAT BIOTECHNOL, V18, P13, DOI 10.1038/71838; Ilic K, 2003, P NATL ACAD SCI USA, V100, P12265, DOI 10.1073/pnas.1434476100; JAFFE G, 2005, WITHERING VINE WILL; Jain SM, 2001, EUPHYTICA, V118, P153, DOI 10.1023/A:1004124519479; JAMES C, 2004, PREVIEW GLOBAL STATU; James J. S., 2004, California Agriculture, V58, P99, DOI 10.3733/ca.v058n02p99; Kalaitzandonakes N, 2001, BIOFUTUR, V2001, P38; Kuiper HA, 2001, PLANT J, V27, P503, DOI 10.1046/j.1365-313X.2001.01119.x; Landsmann J., 1996, Transgenic organisms and biosafety: horizontal gene transfer, stability of DNA, and expression of transgenes., P223; McElroy D, 2003, NAT BIOTECHNOL, V21, P996, DOI 10.1038/nbt0903-996; Miller H.I., 2004, FRANKENFOOD MYTH PRO; MUKHERJEE S, 1990, P INDIAN AS-PLANT SC, V100, P1; *NAT RES COUNC, 2000, GEN MOD PEST PROT PL; *NAT RES COUNC, 2004, BIOL CONF GEN ENG OR; *NAT RES COUNC, 2002, ENV EFF TRANSG PLANT; National Research Council, 2004, SAF GEN ENG FOODS AP; National Research Council, 1989, FIELD TEST GEN MOD O; Ozkan H, 2001, PLANT CELL, V13, P1735, DOI 10.1105/tpc.13.8.1735; *PEW IN FOOD BIOT, 2004, IMP BIOT REG SMALL B; *PEW IN FOOD BIOT, 2004, ISS REG GEN ENG PLAN; RAYBURN AL, 1989, J EXP BOT, V40, P1179, DOI 10.1093/jxb/40.11.1179; Redenbaugh K., 2004, California Agriculture, V58, P106, DOI 10.3733/ca.v058n02p106; Redenbaugh K., 1992, SAFETY ASSESSMENT GE; Richards HA, 2003, J NUTR, V133, P1909, DOI 10.1093/jn/133.6.1909; Sakamoto T, 2004, CURR OPIN BIOTECH, V15, P144, DOI 10.1016/j.copbio.2004.02.003; SanMiguel P, 1996, SCIENCE, V274, P765, DOI 10.1126/science.274.5288.765; Schubert D, 2004, PLANT CELL, V16, P2561, DOI 10.1105/tpc.104.024547; Shirasu K, 2000, GENOME RES, V10, P908, DOI 10.1101/gr.10.7.908; Song R, 2002, GENOME RES, V12, P1549, DOI 10.1101/gr.268302; Song RT, 2003, P NATL ACAD SCI USA, V100, P9055, DOI 10.1073/pnas.1032999100; Stewart CN, 2001, PLANT CELL REP, V20, P376, DOI 10.1007/s002990100346; Strauss SH, 2003, SCIENCE, V300, P61, DOI 10.1126/science.1079514; Strauss SH, 2003, BIOSCIENCE, V53, P453, DOI 10.1641/0006-3568(2003)053[0453:RBATGF]2.0.CO;2; Tanksley SD, 2004, PLANT CELL, V16, pS181, DOI 10.1105/tpc.018119; *USDA, 1996, GUID PREP SUBM PET G; van Harten A.M., 1998, MUTATION BREEDING TH; Wessler SR, 2001, PLANT PHYSIOL, V125, P149, DOI 10.1104/pp.125.1.149; Wilson A, 2004, GENOME SCRAMBLING MY; YOUNG ND, 1989, THEOR APPL GENET, V77, P353, DOI 10.1007/BF00305828	66	158	166	0	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2005	23	4					439	444		10.1038/nbt1084	http://dx.doi.org/10.1038/nbt1084			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	914AR	15815671				2022-12-25	WOS:000228197300026
J	Oike, Y; Akao, M; Yasunaga, K; Yamauchi, T; Morisada, T; Ito, Y; Urano, T; Kimura, Y; Kubota, Y; Maekawa, H; Miyamoto, T; Miyata, K; Matsumoto, S; Sakai, J; Nakagata, N; Takeya, M; Koseki, H; Ogawa, Y; Kadowaki, T; Suda, T				Oike, Y; Akao, M; Yasunaga, K; Yamauchi, T; Morisada, T; Ito, Y; Urano, T; Kimura, Y; Kubota, Y; Maekawa, H; Miyamoto, T; Miyata, K; Matsumoto, S; Sakai, J; Nakagata, N; Takeya, M; Koseki, H; Ogawa, Y; Kadowaki, T; Suda, T			Angiopoietin-related growth factor antagonizes obesity and insulin resistance	NATURE MEDICINE			English	Article							SKELETAL-MUSCLE; ENERGY-EXPENDITURE; DIABETES-MELLITUS; TRANSGENIC MICE; ADIPOSE-TISSUE; RECEPTOR; EXPRESSION; PROTEIN; COACTIVATOR; METABOLISM	Angiopoietin-related growth factor (AGF), a member of the angiopoietin-like protein (Angptl) family, is secreted predominantly from the liver into the systemic circulation. Here, we show that most (> 80%) of the AGF-deficient mice die at about embryonic day 13, whereas the surviving AGF-deficient mice develop marked obesity, lipid accumulation in skeletal muscle and liver, and insulin resistance accompanied by reduced energy expenditure relative to controls. In parallel, mice with targeted activation of AGF show leanness and increased insulin sensitivity resulting from increased energy expenditure. They are also protected from high-fat diet - induced obesity, insulin resistance and nonadipose tissue steatosis. Hepatic overexpression of AGF by adenoviral transduction, which leads to an approximately 2.5-fold increase in serum AGF concentrations, results in a significant ( P < 0.01) body weight loss and increases insulin sensitivity in mice fed a high-fat diet. This study establishes AGF as a new hepatocyte-derived circulating factor that counteracts obesity and related insulin resistance.	Keio Univ, Sch Med, Sakaguchi Lab, Dept Cell Differentiat,Shinjuku Ku, Tokyo 1608582, Japan; Yamanouchi Pharmaceut Co Ltd, Mol Med Labs, Tsukuba, Ibaraki 3058585, Japan; Univ Tokyo, Grad Sch Med, Dept Internal Med, Tokyo 1138655, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo 1538904, Japan; Kumamoto Univ, Ctr Anim Resources & Dev, Kumamoto 8600811, Japan; Kumamoto Univ, Dept Pathol, Kumamoto 8600811, Japan; RIKEN, Res Ctr Allergy & Immunol, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Med & Metab, Tokyo 1010062, Japan	Keio University; Astellas Pharmaceuticals; University of Tokyo; University of Tokyo; Kumamoto University; Kumamoto University; RIKEN; Tokyo Medical & Dental University (TMDU)	Oike, Y (corresponding author), Keio Univ, Sch Med, Sakaguchi Lab, Dept Cell Differentiat,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	oike@sc.itc.keio.ac.jp	Suda, Toshio/H-6761-2013; Miyata, Keishi/HGF-1876-2022; Kubota, Yoshiaki/L-2231-2013; Koseki, Haruhiko/I-3825-2014	Suda, Toshio/0000-0001-7540-1771; Miyata, Keishi/0000-0003-0336-1859; Koseki, Haruhiko/0000-0001-8424-5854; Yasunaga, Kunio/0000-0002-6259-4743; Sakai, Juro/0000-0003-4043-1035; Nakagata, Naomi/0000-0002-5737-9993				Barger PM, 2001, J BIOL CHEM, V276, P44495, DOI 10.1074/jbc.M105945200; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Camenisch G, 2002, J BIOL CHEM, V277, P17281, DOI 10.1074/jbc.M109768200; Dressel U, 2003, MOL ENDOCRINOL, V17, P2477, DOI 10.1210/me.2003-0151; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Gavrilova O, 2000, J CLIN INVEST, V105, P271, DOI 10.1172/JCI7901; Inaba T, 2003, J BIOL CHEM, V278, P21344, DOI 10.1074/jbc.M213202200; Ito Y, 2003, CANCER RES, V63, P6651; Kamei Y, 2003, P NATL ACAD SCI USA, V100, P12378, DOI 10.1073/pnas.2135217100; Kersten S, 2000, J BIOL CHEM, V275, P28488, DOI 10.1074/jbc.M004029200; Kim I, 1999, J BIOL CHEM, V274, P26523, DOI 10.1074/jbc.274.37.26523; Koishi R, 2002, NAT GENET, V30, P151, DOI 10.1038/ng814; Levine JA, 1999, SCIENCE, V283, P212, DOI 10.1126/science.283.5399.212; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; Matsuzawa Y, 1999, ANN NY ACAD SCI, V892, P146, DOI 10.1111/j.1749-6632.1999.tb07793.x; Moller DE, 2003, INT J OBESITY, V27, pS17, DOI 10.1038/sj.ijo.0802494; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Oike Y, 2004, INT J HEMATOL, V80, P21, DOI 10.1532/ijh97.04034; Oike Y, 2004, BLOOD, V103, P3760, DOI 10.1182/blood-2003-04-1272; Oike Y, 2003, P NATL ACAD SCI USA, V100, P9494, DOI 10.1073/pnas.1531901100; Peraldi P, 1997, J CLIN INVEST, V100, P1863, DOI 10.1172/JCI119715; Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Sarmiento U, 1997, LAB INVEST, V77, P243; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yoon JC, 2000, MOL CELL BIOL, V20, P5343, DOI 10.1128/MCB.20.14.5343-5349.2000; ZURLO F, 1990, J CLIN INVEST, V86, P1423, DOI 10.1172/JCI114857	41	176	193	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2005	11	4					400	408		10.1038/nm1214	http://dx.doi.org/10.1038/nm1214			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15778720				2022-12-25	WOS:000228180500031
J	Ralph, GS; Radcliffe, PA; Day, DM; Carthy, JM; Leroux, MA; Lee, DCP; Wong, LF; Bilsland, LG; Greensmith, L; Kingsman, SM; Mitrophanous, KA; Mazarakis, ND; Azzouz, M				Ralph, GS; Radcliffe, PA; Day, DM; Carthy, JM; Leroux, MA; Lee, DCP; Wong, LF; Bilsland, LG; Greensmith, L; Kingsman, SM; Mitrophanous, KA; Mazarakis, ND; Azzouz, M			(S)ilencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model	NATURE MEDICINE			English	Article							TRANSGENIC MOUSE MODEL; LENTIVIRAL VECTORS; PROLONGS SURVIVAL; NERVOUS-SYSTEM; GENE; EXPRESSION; DEGENERATION; DELIVERY; DISEASE; DEATH	Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease resulting in the selective death of motor neurons in the brain and spinal cord(1). Some familial cases of ALS are caused by dominant mutations in the gene encoding superoxide dismutase (SOD1)(2-4). The emergence of interfering RNA (RNAi) for specific gene silencing could be therapeutically beneficial for the treatment of such dominantly inherited diseases(5-7). We generated a lentiviral vector to mediate expression of RNAi molecules specifically targeting the human SOD1 gene ( SOD1). Injection of this vector into various muscle groups of mice engineered to overexpress a mutated form of human SOD1 (SOD1(G93A)) resulted in an efficient and specific reduction of SOD1 expression and improved survival of vulnerable motor neurons in the brainstem and spinal cord. Furthermore, SOD1 silencing mediated an improved motor performance in these animals, resulting in a considerable delay in the onset of ALS symptoms by more than 100% and an extension in survival by nearly 80% of their normal life span. These data are the first to show a substantial extension of survival in an animal model of a fatal, dominantly inherited neurodegenerative condition using RNAi and provide the highest therapeutic efficacy observed in this field to date.	Oxford Biomed UK Ltd, Medawar Ctr, Oxford OX4 4GA, England; Inst Neurol, Sobell Dept Motor Neurosci & Movement Disorders, London WC1N 3BG, England	Oxford Biomedica (UK) Ltd; University of London; University College London	Ralph, GS (corresponding author), Oxford Biomed UK Ltd, Medawar Ctr, Oxford Sci Pk, Oxford OX4 4GA, England.	s.ralph@oxfordbiomedica.co.uk; m.azzouz@oxfordbiomedica.co.uk	Azzouz, Mimoun/B-3979-2009	Azzouz, Mimoun/0000-0001-6564-5967; Shaw, Pamela/0000-0002-8925-2567				ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Adachi H, 2001, HUM MOL GENET, V10, P1039, DOI 10.1093/hmg/10.10.1039; Azzouz M, 2004, NATURE, V429, P413, DOI 10.1038/nature02544; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Clement AM, 2003, SCIENCE, V302, P113, DOI 10.1126/science.1086071; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Ding HL, 2003, AGING CELL, V2, P209, DOI 10.1046/j.1474-9728.2003.00054.x; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hommel JD, 2003, NAT MED, V9, P1539, DOI 10.1038/nm964; Kaspar BK, 2003, SCIENCE, V301, P839, DOI 10.1126/science.1086137; Katsuno M, 2003, NAT MED, V9, P768, DOI 10.1038/nm878; Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6; Martin-Rendon E, 2002, MOL THER, V5, P566, DOI 10.1006/mthe.2002.0576; Maxwell MM, 2004, P NATL ACAD SCI USA, V101, P3178, DOI 10.1073/pnas.0308726100; Mazarakis ND, 2001, HUM MOL GENET, V10, P2109, DOI 10.1093/hmg/10.19.2109; Mitrophanous KA, 1999, GENE THER, V6, P1808, DOI 10.1038/sj.gt.3301023; Mulder D W, 1982, Adv Neurol, V36, P15; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; Wong LF, 2004, MOL THER, V9, P101, DOI 10.1016/j.ymthe.2003.09.017; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739; Xia HB, 2004, NAT MED, V10, P816, DOI 10.1038/nm1076	25	362	446	2	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2005	11	4					429	433		10.1038/nm1205	http://dx.doi.org/10.1038/nm1205			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15768029				2022-12-25	WOS:000228180500035
J	Torres-Rosell, J; Machin, F; Farmer, S; Jarmuz, A; Eydmann, T; Dalgaard, JZ; Aragon, L				Torres-Rosell, J; Machin, F; Farmer, S; Jarmuz, A; Eydmann, T; Dalgaard, JZ; Aragon, L			SMC5 and SMC6 genes are required for the segregation of repetitive chromosome regions	NATURE CELL BIOLOGY			English	Article							REPLICATION FORK PROGRESSION; DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; SMC5-SMC6 COMPLEX; HOLLIDAY JUNCTIONS; FISSION YEAST; CHECKPOINT; PROTEINS; MEIOSIS; CDC14	Structure chromosome (SMC) proteins organize the core of cohesin, condensin and Smc5-Smc6 complexes(1). The Smc5-Smc6 complex is required for DNA repair, as well as having another essential but enigmatic function(1). Here, we generated conditional mutants of SMC5 and SMC6 in budding yeast, in which the essential function was affected. We show that mutant smc5-6 and smc6-9 cells undergo an aberrant mitosis in which chromosome segregation of repetitive regions is impaired; this leads to DNA damage and RAD9-dependent activation of the Rad53 protein kinase. Consistent with a requirement for the segregation of repetitive regions, Smc5 and Smc6 proteins are enriched at ribosomal DNA (rDNA) and at some telomeres. We show that, following Smc5-Smc6 inactivation, metaphase-arrested cells show increased levels of X-shaped DNA (Holliday junctions) at the rDNA locus. Furthermore, deletion of RAD52 partially suppresses the temperature sensitivity of smc5-6 and smc6-9 mutants. We also present evidence showing that the rDNA segregation defects of smc5/smc6 mutants are mechanistically different from those previously observed for condensin mutants(2,3). These results point towards a role for the Smc5-Smc6 complex in preventing the formation of sister chromatid junctions, thereby ensuring the correct partitioning of chromosomes during anaphase.	Univ London Imperial Coll Sci Technol & Med, MRC, Ctr Clin Sci, Cell Cycle Grp, London W12 0NN, England; Marie Curie Res Inst, Surrey RH8 0TL, England	Imperial College London	Aragon, L (corresponding author), Univ London Imperial Coll Sci Technol & Med, MRC, Ctr Clin Sci, Cell Cycle Grp, London W12 0NN, England.	luis.aragon@csc.mrc.ac.uk	Torres-Rosell, Jordi/A-4213-2010; Machín, Félix/K-6569-2017	Torres-Rosell, Jordi/0000-0003-1308-6926; Machín, Félix/0000-0003-4559-7798; Dalgaard, Jacob/0000-0001-9545-7254	MRC [MC_U120074328] Funding Source: UKRI; Medical Research Council [MC_U120074328] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Boddy MN, 2003, MOL CELL BIOL, V23, P5939, DOI 10.1128/MCB.23.16.5939-5946.2003; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; COLLINS I, 1994, CELL, V76, P65, DOI 10.1016/0092-8674(94)90173-2; D'Amours D, 2004, CELL, V117, P455, DOI 10.1016/S0092-8674(04)00413-1; Fujioka Y, 2002, J BIOL CHEM, V277, P21585, DOI 10.1074/jbc.M201523200; Gotta M, 1996, J CELL BIOL, V134, P1349, DOI 10.1083/jcb.134.6.1349; Hazbun TR, 2003, MOL CELL, V12, P1353, DOI 10.1016/S1097-2765(03)00476-3; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; Ira G, 2003, CELL, V115, P401, DOI 10.1016/S0092-8674(03)00886-9; Jessberger R, 2002, NAT REV MOL CELL BIO, V3, P767, DOI 10.1038/nrm930; LEHMANN AR, 1995, MOL CELL BIOL, V15, P7067; Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015; Machin F, 2005, J CELL BIOL, V168, P209, DOI 10.1083/jcb.200408087; Machin F, 2004, CURR BIOL, V14, P125, DOI 10.1016/j.cub.2004.01.001; McDonald WH, 2003, J BIOL CHEM, V278, P45460, DOI 10.1074/jbc.M308828200; McGlynn P, 2000, CELL, V101, P35, DOI 10.1016/S0092-8674(00)80621-2; Melo JA, 2001, GENE DEV, V15, P2809; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Onoda F, 2004, DNA REPAIR, V3, P429, DOI 10.1016/j.dnarep.2003.12.007; Osman F, 2003, MOL CELL, V12, P761, DOI 10.1016/S1097-2765(03)00343-5; Pearson CG, 2001, J CELL BIOL, V152, P1255, DOI 10.1083/jcb.152.6.1255; Pebernard S, 2004, MOL BIOL CELL, V15, P4866, DOI 10.1091/mbc.E04-05-0436; SCHWACHA A, 1994, CELL, V76, P51, DOI 10.1016/0092-8674(94)90172-4; Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Sullivan M, 2004, CELL, V117, P471, DOI 10.1016/S0092-8674(04)00415-5; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Torres-Rosell J, 2004, CELL CYCLE, V3, P496; Verkade HM, 1999, MOL BIOL CELL, V10, P2905, DOI 10.1091/mbc.10.9.2905; Wotton D, 1997, GENE DEV, V11, P748, DOI 10.1101/gad.11.6.748; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Zhu Q, 2001, P NATL ACAD SCI USA, V98, P9766, DOI 10.1073/pnas.171579898; Zou H, 1997, CELL, V90, P87, DOI 10.1016/S0092-8674(00)80316-5	33	152	156	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2005	7	4					412	U48		10.1038/ncb1239	http://dx.doi.org/10.1038/ncb1239			14	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	912KA	15793567				2022-12-25	WOS:000228075500019
J	Hubner, N; Wallace, CA; Zimdahl, H; Petretto, E; Schulz, H; Maciver, F; Mueller, M; Hummel, O; Monti, J; Zidek, V; Musilova, A; Kren, V; Causton, H; Game, L; Born, G; Schmidt, S; Muller, A; Cook, SA; Kurtz, TW; Whittaker, J; Pravenec, M; Aitman, TJ				Hubner, N; Wallace, CA; Zimdahl, H; Petretto, E; Schulz, H; Maciver, F; Mueller, M; Hummel, O; Monti, J; Zidek, V; Musilova, A; Kren, V; Causton, H; Game, L; Born, G; Schmidt, S; Muller, A; Cook, SA; Kurtz, TW; Whittaker, J; Pravenec, M; Aitman, TJ			Integrated transcriptional profiling and linkage analysis for identification of genes underlying disease	NATURE GENETICS			English	Article							QUANTITATIVE TRAIT LOCI; RECOMBINANT INBRED STRAINS; SPONTANEOUSLY HYPERTENSIVE RATS; ANGIOTENSIN-CONVERTING-ENZYME; FATTY-ACID-METABOLISM; BLOOD-PRESSURE; INSULIN-RESISTANCE; CHROMOSOME 1; CONGENIC STRAINS; COMPLEX TRAITS	Integration of genome-wide expression profiling with linkage analysis is a new approach to identifying genes underlying complex traits. We applied this approach to the regulation of gene expression in the BXH/HXB panel of rat recombinant inbred strains, one of the largest available rodent recombinant inbred panels and a leading resource for genetic analysis of the highly prevalent metabolic syndrome. In two tissues important to the pathogenesis of the metabolic syndrome, we mapped cis- and transregulatory control elements for expression of thousands of genes across the genome. Many of the most highly linked expression quantitative trait loci are regulated in cis, are inherited essentially as monogenic traits and are good candidate genes for previously mapped physiological quantitative trait loci in the rat. By comparative mapping we generated a data set of 73 candidate genes for hypertension that merit testing in human populations. Mining of this publicly available data set is expected to lead to new insights into the genes and regulatory pathways underlying the extensive range of metabolic and cardiovascular disease phenotypes that segregate in these recombinant inbred strains.	Acad Sci Czech Republic, Inst Physiol, CR-14220 Prague 4, Czech Republic; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Univ London Imperial Coll Sci & Technol, Fac Med, Ctr Clin Sci, MRC, London W12 0NN, England; Ctr Appl Gen, Prague 14220 4, Czech Republic; Charles Univ Prague, Inst Biol & Med Genet, Prague 12000 2, Czech Republic; Univ Calif San Francisco, San Francisco, CA 94143 USA; Univ London Imperial Coll Sci & Technol, Dept Epidemiol & Publ Hlth, London W2 1PG, England	Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Imperial College London; Charles University Prague; University of California System; University of California San Francisco; Imperial College London	Pravenec, M (corresponding author), Acad Sci Czech Republic, Inst Physiol, Videnska 1083, CR-14220 Prague 4, Czech Republic.	pravenec@biomed.cas.cz; t.aitman@csc.mrc.ac.uk	Zidek, Vaclav/C-6685-2012; Cook, Stuart/G-9567-2011; Pravenec, Michal/B-1666-2012; Whittaker, John C/B-8609-2012	Pravenec, Michal/0000-0001-9197-5871; Whittaker, John C/0000-0002-3529-2379; Aitman, Timothy/0000-0002-7875-4502; Cook, Stuart/0000-0001-6628-194X; Causton, Helen/0000-0003-4630-6569	MRC [MC_U120061454] Funding Source: UKRI; Medical Research Council [MC_U120061454, MC_U120097112] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abiola O, 2003, NAT REV GENET, V4, P911, DOI 10.1038/nrg1206; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; Aitman TJ, 1997, NAT GENET, V16, P197, DOI 10.1038/ng0697-197; Belknap JK, 1996, BEHAV GENET, V26, P149, DOI 10.1007/BF02359892; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Bottger A, 1996, J CLIN INVEST, V98, P856, DOI 10.1172/JCI118858; Brem RB, 2002, SCIENCE, V296, P752, DOI 10.1126/science.1069516; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; Cheung VG, 2003, NAT GENET, V33, P422, DOI 10.1038/ng1094; CHURCHILL GA, 1994, GENETICS, V138, P963; Cowley AW, 2004, J PHYSIOL-LONDON, V554, P46, DOI 10.1113/jphysiol.2003.052613; Frantz S, 2001, HYPERTENSION, V38, P216, DOI 10.1161/01.HYP.38.2.216; Frantz SA, 1998, HYPERTENSION, V32, P639, DOI 10.1161/01.HYP.32.4.639; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; Glazier AM, 2002, SCIENCE, V298, P2345, DOI 10.1126/science.1076641; Glazier AN, 2002, MAMM GENOME, V13, P108, DOI 10.1007/s00335-001-2132-9; Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6; Hubner N, 1999, HYPERTENSION, V34, P643, DOI 10.1161/01.HYP.34.4.643; HULMAN S, 1993, METABOLISM, V42, P14, DOI 10.1016/0026-0495(93)90165-K; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jacob HJ, 2002, NAT REV GENET, V3, P33, DOI 10.1038/nrg702; Jansen RC, 2001, TRENDS GENET, V17, P388, DOI 10.1016/S0168-9525(01)02310-1; Jirout M, 2003, MAMM GENOME, V14, P537, DOI 10.1007/s00335-003-2266-z; Karp CL, 2000, NAT IMMUNOL, V1, P221, DOI 10.1038/79759; Kato N, 1999, MAMM GENOME, V10, P259, DOI 10.1007/s003359900983; Kovacs P, 1997, BIOCHEM BIOPH RES CO, V235, P343, DOI 10.1006/bbrc.1997.6782; Krushkal J, 1999, CIRCULATION, V99, P1407, DOI 10.1161/01.CIR.99.11.1407; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; LINDPAINTNER K, 1995, NEW ENGL J MED, V332, P706, DOI 10.1056/NEJM199503163321103; McBride MW, 2003, HYPERTENSION, V41, P847, DOI 10.1161/01.HYP.0000047103.07205.03; Morley M, 2004, NATURE, V430, P743, DOI 10.1038/nature02797; OKAMOTO K, 1972, SPONTANEOUS HYPERTEN; Pravenec M., 2001, American Journal of Hypertension, V14, p82A, DOI 10.1016/S0895-7061(01)01767-8; Pravenec M, 2004, PHYSIOL RES, V53, pS15; PRAVENEC M, 1989, J HYPERTENS, V7, P217; Pravenec M, 1999, FOLIA BIOL-PRAGUE, V45, P203; Pravenec M, 1996, MAMM GENOME, V7, P117, DOI 10.1007/s003359900031; Pravenec M, 2001, NAT GENET, V27, P156, DOI 10.1038/84777; PRAVENEC M, 1995, J CLIN INVEST, V96, P1973, DOI 10.1172/JCI118244; Printz MP, 2003, J APPL PHYSIOL, V94, P2510, DOI 10.1152/japplphysiol.00064.2003; RAO RH, 1993, DIABETES, V42, P1364, DOI 10.2337/diabetes.42.9.1364; Rice T, 2000, CIRCULATION, V102, P1956, DOI 10.1161/01.CIR.102.16.1956; Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434; Silver L.M., 1995, MOUSE GENETICS CONCE; Singer JB, 2004, SCIENCE, V304, P445, DOI 10.1126/science.1093139; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Wallace CA, 2004, NAT GENET, V36, P441, DOI 10.1038/ng1349; Yvert G, 2003, NAT GENET, V35, P57, DOI 10.1038/ng1222; Zimdahl H, 2004, SCIENCE, V303, P807, DOI 10.1126/science.1092427	50	416	433	1	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2005	37	3					243	253		10.1038/ng1522	http://dx.doi.org/10.1038/ng1522			11	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	901QU	15711544				2022-12-25	WOS:000227297800015
J	Izumikawa, M; Minoda, R; Kawamoto, K; Abrashkin, KA; Swiderski, DL; Dolan, DF; Brough, DE; Raphael, Y				Izumikawa, M; Minoda, R; Kawamoto, K; Abrashkin, KA; Swiderski, DL; Dolan, DF; Brough, DE; Raphael, Y			Auditory hair cell replacement and hearing improvement by Atoh1 gene therapy in deaf mammals	NATURE MEDICINE			English	Article							CHICK BASILAR PAPILLA; INNER-EAR; IN-VIVO; MATH1; EXPRESSION; COCHLEA; NOISE; REORGANIZATION; DEGENERATION; GENERATION	In the mammalian auditory system, sensory cell loss resulting from aging, ototoxic drugs, infections, overstimulation and other causes is irreversible and leads to permanent sensorineural hearing loss. To restore hearing, it is necessary to generate new functional hair cells. One potential way to regenerate hair cells is to induce a phenotypic transdifferentiation of nonsensory cells that remain in the deaf cochlea. Here we report that Atoh1, a gene also known as Math1 encoding a basic helix-loop-helix transcription factor and key regulator of hair cell development, induces regeneration of hair cells and substantially improves hearing thresholds in the mature deaf inner ear after delivery to nonsensory cells through adenovectors. This is the first demonstration of cellular and functional repair in the organ of Corti of a mature deaf mammal. The data suggest a new therapeutic approach based on expressing crucial developmental genes for cellular and functional restoration in the damaged auditory epithelium and other sensory systems.	Univ Michigan, Dept Otolaryngol, Kresge Hearing Res Inst, Ann Arbor, MI 48109 USA; Kansai Med Univ, Dept Otolaryngol, Osaka 5708506, Japan; Kumamoto Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Kumamoto 8608556, Japan; GenVec Inc, Dept Vector Sci, Gaithersburg, MD 20879 USA	University of Michigan System; University of Michigan; Kansai Medical University; Kumamoto University	Raphael, Y (corresponding author), Univ Michigan, Dept Otolaryngol, Kresge Hearing Res Inst, MSRB 3,Room 9303,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	yoash@umich.edu			NIDCD NIH HHS [R01 DC01634, P30 DC05188, DC05401, P30 DC005188] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001634, P30DC005188, R01DC005401] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bermingham NA, 1999, SCIENCE, V284, P1837, DOI 10.1126/science.284.5421.1837; Beyer LA, 2000, J NEUROCYTOL, V29, P227, DOI 10.1023/A:1026515619443; Brough DE, 1997, J VIROL, V71, P9206, DOI 10.1128/JVI.71.12.9206-9213.1997; Chen P, 2002, DEVELOPMENT, V129, P2495; Cotanche DA, 1995, HEARING RES, V91, P148, DOI 10.1016/0378-5955(95)00185-9; DALLOS P, 1978, J NEUROPHYSIOL, V41, P365, DOI 10.1152/jn.1978.41.2.365; DAVIS H, 1976, ANN OTOL RHINOL LA S, V28, P1; Fekete D M, 2000, Trends Neurosci, V23, P386, DOI 10.1016/S0166-2236(00)01668-4; Fekete DM, 1996, CURR OPIN NEUROBIOL, V6, P533, DOI 10.1016/S0959-4388(96)80061-4; GREENWOOD D, 1961, J ACOUST SOC AM, V33, P1344, DOI 10.1121/1.1908437; HASSON T, 1995, P NATL ACAD SCI USA, V92, P9815, DOI 10.1073/pnas.92.21.9815; Ishimoto S, 2002, HEARING RES, V173, P187, DOI 10.1016/S0378-5955(02)00579-8; Kawamoto K, 2003, J NEUROSCI, V23, P4395; Li HW, 2003, NAT MED, V9, P1293, DOI 10.1038/nm925; RAPHAEL Y, 1991, CELL MOTIL CYTOSKEL, V18, P215, DOI 10.1002/cm.970180307; RAPHAEL Y, 1993, J COMP NEUROL, V330, P521, DOI 10.1002/cne.903300408; Shou JY, 2003, MOL CELL NEUROSCI, V23, P169, DOI 10.1016/S1044-7431(03)00066-6; TEAS DC, 1975, J ACOUST SOC AM, V58, P1066, DOI 10.1121/1.380766; Torres M, 1998, MECH DEVELOP, V71, P5, DOI 10.1016/S0925-4773(97)00155-X; Turner CW, 2004, J ACOUST SOC AM, V115, P1729, DOI 10.1121/1.1687425; Woods C, 2004, NAT NEUROSCI, V7, P1310, DOI 10.1038/nn1349; Yagi M, 2000, JARO-J ASSOC RES OTO, V1, P315, DOI 10.1007/s101620010011; Yamasoba T, 1997, HEARING RES, V112, P13, DOI 10.1016/S0378-5955(97)00092-0; Zheng JL, 2000, NAT NEUROSCI, V3, P580, DOI 10.1038/75753	24	510	605	3	76	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					271	276		10.1038/nm1193	http://dx.doi.org/10.1038/nm1193			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15711559				2022-12-25	WOS:000227541300021
J	Ohanna, M; Sobering, AK; Lapointe, T; Lorenzo, L; Praud, C; Petroulakis, E; Sonenberg, N; Kelly, PA; Sotiropoulos, A; Pende, M				Ohanna, M; Sobering, AK; Lapointe, T; Lorenzo, L; Praud, C; Petroulakis, E; Sonenberg, N; Kelly, PA; Sotiropoulos, A; Pende, M			Atrophy of S6K1(-/-) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control	NATURE CELL BIOLOGY			English	Article							S6 KINASE; GROWTH; TRANSCRIPTION; TRANSLATION; PATHWAY; HYPERTROPHY; REGULATOR	The mammalian target of rapamycin ( mTOR) and Akt proteins regulate various steps of muscle development and growth, but the physiological relevance and the downstream effectors are under investigation(1-6). Here we show that S6 kinase 1 (S6K1), a protein kinase activated by nutrients and insulin- like growth factors (IGFs), is essential for the control of muscle cytoplasmic volume by Akt and mTOR. Deletion of S6K1 does not affect myoblast cell proliferation but reduces myoblast size to the same extent as that observed with mTOR inhibition by rapamycin. In the differentiated state, S6K1(-/-) myotubes have a normal number of nuclei but are smaller, and their hypertrophic response to IGF1, nutrients and membrane-targeted Akt is blunted. These growth defects reveal that mTOR requires distinct effectors for the control of muscle cell cycle and size, potentially opening new avenues of therapeutic intervention against neoplasia or muscle atrophy.	Univ Paris 05, INSERM, Avenir,U584, Fac Med Necker Enfants Malad, F-75730 Paris, France; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; McGill University; McGill University	Sotiropoulos, A (corresponding author), Univ Paris 05, INSERM, Avenir,U584, Fac Med Necker Enfants Malad, 156 Rue Vaugirard, F-75730 Paris, France.	sotiropoulos@necker.fr; pende@necker.fr	Ohanna, Mickael/O-5784-2016; Sotiropoulos, Athanassia/P-4269-2017; Lorenzo, Lazaro/H-7902-2017; Pende, Mario/AFR-1348-2022; Praud, Christophe/AAT-9553-2020	Ohanna, Mickael/0000-0002-7751-9164; Lorenzo, Lazaro/0000-0001-6648-8684; Pende, Mario/0000-0002-7864-8937; Sotiropoulos, Athanassia/0000-0002-7265-1473				Abraham RT, 2002, CELL, V111, P9, DOI 10.1016/S0092-8674(02)01009-7; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Conlon Ian, 2003, J Biol, V2, P7, DOI 10.1186/1475-4924-2-7; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Dolznig H, 2004, NAT CELL BIOL, V6, P899, DOI 10.1038/ncb1166; Erbay E, 2003, J CELL BIOL, V163, P931, DOI 10.1083/jcb.200307158; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Gingras AC, 2001, GENE DEV, V15, P2852; Glass DJ, 2003, TRENDS MOL MED, V9, P344, DOI 10.1016/S1471-4914(03)00138-2; Huang S, 2003, MOL CELL, V11, P1491, DOI 10.1016/S1097-2765(03)00180-1; Lorberg A, 2003, CURR TOP MICROBIOL, V279, P1; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Miron M, 2001, NAT CELL BIOL, V3, P596, DOI 10.1038/35078571; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Pallafacchina G, 2002, P NATL ACAD SCI USA, V99, P9213, DOI 10.1073/pnas.142166599; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; Pinset C, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 1, P226; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000	25	301	316	0	24	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2005	7	3					286	294		10.1038/ncb1231	http://dx.doi.org/10.1038/ncb1231			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	902CU	15723049	Green Published			2022-12-25	WOS:000227329800017
J	Jankowski, V; Tolle, M; Vanholder, R; Schonfelder, G; van der Giet, M; Henning, L; Schluter, H; Paul, M; Zidek, W; Jankowski, J				Jankowski, V; Tolle, M; Vanholder, R; Schonfelder, G; van der Giet, M; Henning, L; Schluter, H; Paul, M; Zidek, W; Jankowski, J			Uridine adenosine tetraphosphate: a novel endothelium-derived vasoconstrictive factor	NATURE MEDICINE			English	Article							VASCULAR SMOOTH-MUSCLE; RECEPTOR SUBTYPES; P2X RECEPTORS; RAT-KIDNEY; TNP-ATP; ANTAGONIST; CELLS; POLYPHOSPHATES; CHROMATOGRAPHY; AFFINITY	Beyond serving as a mechanical barrier, the endothelium has important regulatory functions. The discovery of nitric oxide 1 revolutionized our understanding of vasoregulation. In contrast, the identity of endothelium-derived vasoconstrictive factors (EDCFs) remains unclear. The supernatant obtained from mechanically stimulated human endothelial cells obtained from dermal vessels elicited a vasoconstrictive response in an isolated perfused rat kidney. A purinoceptor blocker had a greater effect than an endothelin receptor blocker in decreasing endothelially derived vasoconstriction in the isolated perfused rat kidney. The nucleotide uridine adenosine tetraphosphate (Up(4)A) was isolated from the supernatant of stimulated human endothelium and identified by mass spectrometry. Up(4)A is likely to exert vasoconstriction predominantly through P2X1 receptors, and probably also through P2Y2 and P2Y4 receptors. Plasma concentrations of Up(4)A that cause vasoconstriction are found in healthy subjects. Stimulation with adenosine 5'-triphosphate (ATP), uridine 5'-triphosphate (UTP), acetylcholine, endothelin, A23187 and mechanical stress releases Up(4)A from endothelium, suggesting that Up(4)A contributes to vascular autoregulation. To our knowledge, Up(4)A is the first dinucleotide isolated from living organisms that contains both purine and pyrimidine moieties. We conclude that Up(4)A is a novel potent nonpeptidic EDCF. Its vasoactive effects, plasma concentrations and its release upon endothelial stimulation strongly suggest that Up(4)A has a functional vasoregulatory role.	Charite Univ Med Berlin, Med Klin 4, D-12200 Berlin, Germany; Univ Hosp, Dept Internal Med, Nephrol Sect, B-9000 Ghent, Belgium; Charite Univ Med Berlin, Inst Clin Pharmacol & Toxicol, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ghent University; Ghent University Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Jankowski, J (corresponding author), Charite Univ Med Berlin, Med Klin 4, Campus Benjamin Franklin,Hindenburgdamm 30, D-12200 Berlin, Germany.	joachim.jankowski@charite.de	Paul, Martin/K-5425-2015; Schluter, Hartmut/D-1371-2015; Tölle, Markus/GPP-7157-2022	Schluter, Hartmut/0000-0002-9358-7036; van der Giet, Markus/0000-0003-3590-5451; Schonfelder, Gilbert/0000-0001-6134-1990				BARNES LD, 1985, ANAL BIOCHEM, V144, P296, DOI 10.1016/0003-2697(85)90120-4; Bo XN, 1998, EUR J PHARMACOL, V353, P59, DOI 10.1016/S0014-2999(98)00383-5; Burnstock G, 2002, ARTERIOSCL THROM VAS, V22, P364, DOI 10.1161/hq0302.105360; Burnstock G, 1999, J ANAT, V194, P335, DOI 10.1046/j.1469-7580.1999.19430335.x; Gorman MW, 2003, LUMINESCENCE, V18, P173, DOI 10.1002/bio.721; Honore P, 2002, PAIN, V96, P99, DOI 10.1016/S0304-3959(01)00434-1; Jankowski J, 1998, J CHROMATOGR B, V719, P63, DOI 10.1016/S0378-4347(98)00408-3; KASAKOV L, 1982, EUR J PHARMACOL, V86, P291, DOI 10.1016/0014-2999(82)90330-2; King BF, 1999, BRIT J PHARMACOL, V128, P981, DOI 10.1038/sj.bjp.0702876; Kunapuli SP, 1998, BIOCHEM J, V336, P513, DOI 10.1042/bj3360513; Lazarowski ER, 2001, NEWS PHYSIOL SCI, V16, P1; Lewis CJ, 1998, BRIT J PHARMACOL, V124, P1463, DOI 10.1038/sj.bjp.0702001; Nofer JR, 2004, J CLIN INVEST, V113, P569, DOI 10.1172/JCI200418004; Nori S, 1998, J VASC RES, V35, P179, DOI 10.1159/000025582; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Pulvirenti TJ, 2000, J NEUROCYTOL, V29, P623, DOI 10.1023/A:1010828302936; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Turner CM, 2003, CELLS TISSUES ORGANS, V175, P105, DOI 10.1159/000073754; van der Giet M, 2001, BRIT J PHARMACOL, V132, P467, DOI 10.1038/sj.bjp.0703817; Vial C, 2002, MOL PHARMACOL, V62, P1438, DOI 10.1124/mol.62.6.1438; Wang LW, 2002, J CARDIOVASC PHARM, V40, P841, DOI 10.1097/00005344-200212000-00005	22	131	134	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					223	227		10.1038/nm1188	http://dx.doi.org/10.1038/nm1188			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15665829				2022-12-25	WOS:000226797300031
J	Kong, A; Barnard, J; Gudbjartsson, DF; Thorleifsson, G; Jonsdottir, G; Sigurdardottir, S; Richardsson, B; Jonsdottir, J; Thorgeirsson, T; Frigge, ML; Lamb, NE; Sherman, S; Gulcher, JR; Stefansson, K				Kong, A; Barnard, J; Gudbjartsson, DF; Thorleifsson, G; Jonsdottir, G; Sigurdardottir, S; Richardsson, B; Jonsdottir, J; Thorgeirsson, T; Frigge, ML; Lamb, NE; Sherman, S; Gulcher, JR; Stefansson, K			Recombination rate and reproductive success in humans	NATURE GENETICS			English	Article							MAXIMUM-LIKELIHOOD; LINKAGE ANALYSIS; MATERNAL AGE; NAIL-PATELLA; SEX; MEIOSIS; NONDISJUNCTION; CHROMOSOME-21; FRACTIONS; MAMMALS	Intergenerational mixing of DNA through meiotic recombinations of homologous chromosomes during gametogenesis is a major event that generates diversity in the eukaryotic genome. We examined genome-wide microsatellite data for 23,066 individuals, providing information on recombination events of 14,140 maternal and paternal meioses each, and found a positive correlation between maternal recombination counts of an offspring and maternal age. We postulated that the recombination rate of eggs does not increase with maternal age, but that the apparent increase is the consequence of selection. Specifically, a high recombination count increased the chance of a gamete becoming a live birth, and this effect became more pronounced with advancing maternal age. Further support for this hypothesis came from our observation that mothers with high oocyte recombination rate tend to have more children. Hence, not only do recombinations have a role in evolution by yielding diverse combinations of gene variants for natural selection, but they are also under selection themselves.	deCODE Genet, IS-101 Reykjavik, Iceland; Cleveland Clin Fdn, Dept Biostat & Epidemiol, Cleveland, OH 44195 USA; Emory Univ, Dept Human Genet, Atlanta, GA USA	Cleveland Clinic Foundation; Emory University	Kong, A (corresponding author), deCODE Genet, Sturlugata 8, IS-101 Reykjavik, Iceland.	kong@decode.is; kstefans@decode.is	Stefansson, Kari/AAE-7187-2019	Thorgeirsson, Thorgeir/0000-0002-5149-7040; Kong, Augustine/0000-0001-8193-5438; Gudbjartsson, Daniel/0000-0002-5222-9857				Broman KW, 2000, AM J HUM GENET, V66, P1911, DOI 10.1086/302923; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; ELSTON RC, 1976, AM J HUM GENET, V28, P69; Gudbjartsson DF, 2000, NAT GENET, V25, P12, DOI 10.1038/75514; Gulcher JR, 2000, EUR J HUM GENET, V8, P739, DOI 10.1038/sj.ejhg.5200530; Haines J L, 1993, Prog Clin Biol Res, V384, P51; Hassold T, 2000, HUM MOL GENET, V9, P2409, DOI 10.1093/hmg/9.16.2409; HENDERSON SA, 1968, NATURE, V218, P22, DOI 10.1038/218022a0; Hodges CA, 2002, HUM REPROD, V17, P1171, DOI 10.1093/humrep/17.5.1171; Hunt PA, 2002, SCIENCE, V296, P2181, DOI 10.1126/science.1071907; IRWIN M, 1994, P NATL ACAD SCI USA, V91, P11684, DOI 10.1073/pnas.91.24.11684; Johnson J, 2004, NATURE, V428, P145, DOI 10.1038/nature02316; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Lamb NE, 1997, HUM MOL GENET, V6, P1391, DOI 10.1093/hmg/6.9.1391; Little R. J. A., 1987, STAT ANAL MISSING DA; LYNCH M, 1998, GENETICS ANAL QUANTU; Lynn A, 2002, SCIENCE, V296, P2222, DOI 10.1126/science.1071220; McCulloch CE, 1997, J AM STAT ASSOC, V92, P162, DOI 10.2307/2291460; POLANI PE, 1991, HUM GENET, V88, P64, DOI 10.1007/BF00204931; POLANI PE, 1976, CYTOGENET CELL GENET, V16, P505, DOI 10.1159/000130668; Quintana FA, 1999, COMPUT STAT DATA AN, V29, P429, DOI 10.1016/S0167-9473(98)00075-9; RENWICK JH, 1965, ANN HUM GENET, V28, P379, DOI 10.1111/j.1469-1809.1965.tb00493.x; Robinson WP, 1998, HUM MOL GENET, V7, P1011, DOI 10.1093/hmg/7.6.1011; SPEED RM, 1983, CHROMOSOMA, V88, P184, DOI 10.1007/BF00285618; TANZI RE, 1992, AM J HUM GENET, V50, P551; WEITKAMP LR, 1973, HUM HERED, V23, P197, DOI 10.1159/000152574	27	141	149	1	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2004	36	11					1203	1206		10.1038/ng1445	http://dx.doi.org/10.1038/ng1445			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	867HI	15467721	Bronze			2022-12-25	WOS:000224832800024
J	Simonsson, S; Gurdon, J				Simonsson, S; Gurdon, J			DNA demethylation is necessary for the epigenetic reprogramming of somatic cell nuclei	NATURE CELL BIOLOGY			English	Article							XENOPUS-LAEVIS EMBRYOS; MAMMALIAN DEVELOPMENT; REGULATORY ELEMENTS; AMPHIBIAN OOCYTES; GENE ACTIVATION; ACTIN GENE; IN-VIVO; EXPRESSION; METHYLATION; OCT-4	Nuclear transplantation experiments in amphibia and mammals have shown that oocyte and egg cytoplasm can extensively reprogram somatic cell nuclei with new patterns of gene expression and new pathways of cell differentiation(1-3); however, very little is known about the molecular mechanism of nuclear reprogramming. Here we have used nuclear and DNA transfer from mammalian somatic cells to analyse the mechanism of activation of the stem cell marker gene oct4 by Xenopus oocytes. We find that the removal of nuclear protein accelerates the rate of reprogramming, but even more important is the demethylation of somatic cell DNA. DNA demethylation seems to precede gene reprogramming, and is absolutely necessary for oct4 transcription. Reprogramming by oocytes occurs in the absence of DNA replication and RNA/protein synthesis. It is also selective, operating only on the promoter, but not enhancers, of oct4; both a putative Sp1/Sp3 and a GGGAGGG binding site are required for demethylation and transcription. We conclude that the demethylation of promoter DNA may be a necessary step in the epigenetic reprogramming of somatic cell nuclei.	Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB2 1QR, England	University of Cambridge; University of Cambridge	Gurdon, J (corresponding author), Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst, Cambridge CB2 1QR, England.	j.gurdon@gurdon.cam.ac.uk	Simonsson, Stina/R-2699-2016	Simonsson, Stina/0000-0001-9020-3714; GURDON, JOHN/0000-0002-5621-3799				Belikov S, 2000, EMBO J, V19, P1023, DOI 10.1093/emboj/19.5.1023; Boiani M, 2002, GENE DEV, V16, P1209, DOI 10.1101/gad.966002; Bortvin A, 2003, DEVELOPMENT, V130, P1673, DOI 10.1242/dev.00366; Byrne JA, 2003, CURR BIOL, V13, P1206, DOI 10.1016/S0960-9822(03)00462-7; Curradi M, 2002, MOL CELL BIOL, V22, P3157, DOI 10.1128/MCB.22.9.3157-3173.2002; Dean W, 2003, SEMIN CELL DEV BIOL, V14, P93, DOI 10.1016/S1084-9521(02)00141-6; DEROBERTIS EM, 1977, P NATL ACAD SCI USA, V74, P2470; Gidekel S, 2002, J BIOL CHEM, V277, P34521, DOI 10.1074/jbc.M203338200; Gonda K, 2003, NAT CELL BIOL, V5, P205, DOI 10.1038/ncb939; GURDON JB, 1981, ANNU REV GENET, V15, P189, DOI 10.1146/annurev.ge.15.120181.001201; GURDON JB, 1962, J EMBRYOL EXP MORPH, V10, P622; GURDON JB, 1986, J CELL SCI, P287; Gurdon JB, 2003, P NATL ACAD SCI USA, V100, P11819, DOI 10.1073/pnas.1834207100; Hattori N, 2004, J BIOL CHEM, V279, P17063, DOI 10.1074/jbc.M309002200; HINKLEY CS, 1992, MOL CELL BIOL, V12, P638, DOI 10.1128/MCB.12.2.638; Kikyo N, 2000, SCIENCE, V289, P2360, DOI 10.1126/science.289.5488.2360; Kimura H, 1999, J BIOCHEM, V125, P1175, DOI 10.1093/oxfordjournals.jbchem.a022401; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Matsuo K, 1998, EMBO J, V17, P1446, DOI 10.1093/emboj/17.5.1446; MODAK SP, 1993, ONCOGENE, V8, P645; MOHUN TJ, 1986, EMBO J, V5, P3185, DOI 10.1002/j.1460-2075.1986.tb04628.x; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Nordhoff V, 2001, MAMM GENOME, V12, P309, DOI 10.1007/s003350010279; Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; Stancheva I, 2002, DEV BIOL, V243, P155, DOI 10.1006/dbio.2001.0560; STEINBEISSER H, 1988, NUCLEIC ACIDS RES, V16, P3223, DOI 10.1093/nar/16.8.3223; Surani MA, 2001, NATURE, V414, P122, DOI 10.1038/35102186; Wade PA, 2002, EUR J BIOCHEM, V269, P2284, DOI 10.1046/j.1432-1033.2002.02887.x; Wilmut I, 2002, NATURE, V419, P583, DOI 10.1038/nature01079	30	239	267	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2004	6	10					984	990		10.1038/ncb1176	http://dx.doi.org/10.1038/ncb1176			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	859FY	15448701				2022-12-25	WOS:000224250000013
J	Hao, YY; Sekine, K; Kawabata, A; Nakamura, H; Ishioka, T; Ohata, H; Katayama, R; Hashimoto, C; Zhang, XD; Noda, T; Tsuruo, T; Naito, M				Hao, YY; Sekine, K; Kawabata, A; Nakamura, H; Ishioka, T; Ohata, H; Katayama, R; Hashimoto, C; Zhang, XD; Noda, T; Tsuruo, T; Naito, M			Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function	NATURE CELL BIOLOGY			English	Article							PROTEIN LIGASE ACTIVITY; CELL-DEATH; CYTOCHROME-C; APOPTOSIS PROTEIN; IAP PROTEINS; ACTIVATION; INHIBITOR; FAMILY; MITOCHONDRIA; SMAC/DIABLO	Apollon ( also known as BRUCE or BIRC6) is a large protein containing baculoviral-IAP- repeat (BIR) and ubiquitin-conjugating enzyme (UBC) domains at the amino- and carboxy termini, respectively. Apollon inhibits apoptosis, but its molecular and physiological function remains unclear. Here we report that Apollon binds to, ubiquitinates and facilitates proteasomal degradation of SMAC and caspase-9, which both contain IAP-binding motifs. Targeted disruption of Apollon in mice caused embryonic and neonatal lethality. Notably, SMAC induced apoptosis in Apollon-deficient cells, but not in Apollon-expressing cells. Furthermore, the IAP-binding motif of SMAC was required to induce apoptosis in Apollon-deficient cells. These results suggest that Apollon has an essential function in preventing SMAC-induced apoptosis.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Inst Canc, Tokyo 1708455, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research	Naito, M (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	mnaito@iam.u-tokyo.ac.jp	Ishioka, Toshiyasu/AAB-9020-2021; Noda, Tetsuo/B-1667-2016; Katayama, Ryohei/K-8537-2014	Ishioka, Toshiyasu/0000-0002-4065-7328; Katayama, Ryohei/0000-0001-7394-895X				Arama E, 2003, DEV CELL, V4, P687, DOI 10.1016/S1534-5807(03)00120-5; CHAI J, 2003, NATURE STRUCT; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chen ZH, 1999, BIOCHEM BIOPH RES CO, V264, P847, DOI 10.1006/bbrc.1999.1585; Dan S, 1999, ONCOGENE, V18, P1277, DOI 10.1038/sj.onc.1202423; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Hauser HP, 1998, J CELL BIOL, V141, P1415, DOI 10.1083/jcb.141.6.1415; Hay BA, 2000, CELL DEATH DIFFER, V7, P1045, DOI 10.1038/sj.cdd.4400765; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hunter AM, 2003, J BIOL CHEM, V278, P7494, DOI 10.1074/jbc.C200695200; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Naito M, 1997, BLOOD, V89, P2060, DOI 10.1182/blood.V89.6.2060; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Okada H, 2002, MOL CELL BIOL, V22, P3509, DOI 10.1128/MCB.22.10.3509-3517.2002; Qiu XB, 2004, EMBO J, V23, P800, DOI 10.1038/sj.emboj.7600075; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reed JC, 2000, CELL DEATH DIFFER, V7, P1145, DOI 10.1038/sj.cdd.4400777; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Sakai K, 1997, BIOCHEM BIOPH RES CO, V237, P318, DOI 10.1006/bbrc.1997.7111; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vernooy SY, 2002, CURR BIOL, V12, P1164, DOI 10.1016/S0960-9822(02)00935-1; Wang XD, 2001, GENE DEV, V15, P2922; Yang LL, 2003, CANCER RES, V63, P831; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yuan J, 2003, NEURON, V40, P401, DOI 10.1016/S0896-6273(03)00601-9; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	43	178	196	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2004	6	9					849	860		10.1038/ncb1159	http://dx.doi.org/10.1038/ncb1159			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	852IZ	15300255				2022-12-25	WOS:000223750300015
J	Kleta, R; Romeo, E; Ristic, Z; Ohura, T; Stuart, C; Arcos-Burgos, M; Dave, MH; Wagner, CA; Camargo, SRM; Inoue, S; Matsuura, N; Helip-Wooley, A; Bockenhauer, D; Warth, R; Bernardini, I; Visser, G; Eggermann, T; Lee, P; Chairoungdua, A; Jutabha, P; Babu, E; Nilwarangkoon, S; Anzai, N; Kanai, Y; Verrey, F; Gahl, WA; Koizumi, A				Kleta, R; Romeo, E; Ristic, Z; Ohura, T; Stuart, C; Arcos-Burgos, M; Dave, MH; Wagner, CA; Camargo, SRM; Inoue, S; Matsuura, N; Helip-Wooley, A; Bockenhauer, D; Warth, R; Bernardini, I; Visser, G; Eggermann, T; Lee, P; Chairoungdua, A; Jutabha, P; Babu, E; Nilwarangkoon, S; Anzai, N; Kanai, Y; Verrey, F; Gahl, WA; Koizumi, A			Mutations in SLC6A19, encoding B(0)AT1, cause Hartnup disorder	NATURE GENETICS			English	Article							RECESSIVE TRAITS; TRANSPORTER; NEPHRON	Hartnup disorder, an autosomal recessive defect named after an English family described in 1956 (ref. 1), results from impaired transport of neutral amino acids across epithelial cells in renal proximal tubules and intestinal mucosa. Symptoms include transient manifestations of pellagra (rashes), cerebellar ataxia and psychosis(1,2). Using homozygosity mapping in the original family in whom Hartnup disorder was discovered, we confirmed that the critical region for one causative gene was located on chromosome 5p15 (ref. 3). This region is homologous to the area of mouse chromosome 13 that encodes the sodium-dependent amino acid transporter B(0)AT1 (ref. 4). We isolated the human homolog of B(0)AT1, called SLC6A19, and determined its size and molecular organization. We then identified mutations in SLC6A19 in members of the original family in whom Hartnup disorder was discovered and of three Japanese families. The protein product of SLC6A19, the Hartnup transporter, is expressed primarily in intestine and renal proximal tubule and functions as a neutral amino acid transporter.	NHGRI, Med Genet Branch, NIH, Bethesda, MD 20892 USA; NIH, Off Rare Dis, Intramural Program, Off Director, Bethesda, MD 20892 USA; Univ Zurich, Inst Physiol, Zurich, Switzerland; Tohoku Univ, Sch Med, Dept Pediat, Sendai, Miyagi 980, Japan; Kyoto Univ, Grad Sch Med, Kyoto, Japan; Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA; Univ Regensburg, Inst Physiol, D-8400 Regensburg, Germany; Univ Utrecht Hosp, Wilhelmina Childrens Hosp, Dept Metab Dis, Utrecht, Netherlands; Aachen Univ Hosp, Inst Human Genet, Aachen, Germany; UCL Natl Hosp Neurol & Neurosurg, Charles Dent Metab Unit, London, England; Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, Tokyo, Japan	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; University of Zurich; Tohoku University; Kyoto University; Yale University; University of Regensburg; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; RWTH Aachen University; RWTH Aachen University Hospital; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Kyorin University	Kleta, R (corresponding author), NHGRI, Med Genet Branch, NIH, 10 Ctr Dr,MSC 1851,Bldg 10,Room 10C-107, Bethesda, MD 20892 USA.	kletar@mail.nih.gov	ANZAI, NAOHIKO/K-9492-2017; Jutabha, Promsuk/AFF-4363-2022; Eggermann, Thomas/F-3807-2014; Bockenhauer, Detlef/AAF-6495-2020; Bockenhauer, Detlef/C-5951-2008; Warth, Richard/N-7119-2014; Jutabha, Promsuk/AAE-9872-2022; Arcos-Burgos, Mauricio/H-1326-2017	ANZAI, NAOHIKO/0000-0003-0605-0458; Bockenhauer, Detlef/0000-0001-5878-941X; Bockenhauer, Detlef/0000-0001-5878-941X; Warth, Richard/0000-0001-6084-0659; Arcos-Burgos, Mauricio/0000-0002-8529-0574; Verrey, Francois/0000-0003-3250-9824; Camargo, Simone/0000-0003-0091-7380	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000215, ZIAHG000215] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BARON DN, 1956, LANCET, V271, P421; Bernardini I, 2001, AM J HUM GENET, V69, P486; Broer A, 2004, J BIOL CHEM, V279, P24467, DOI 10.1074/jbc.M400904200; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Kleta R, 2004, MOL GENET METAB, V82, P56, DOI 10.1016/j.ymgme.2004.01.018; KRUGLYAK L, 1995, AM J HUM GENET, V56, P519; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; Levy DI, 2004, KIDNEY INT, V65, P918, DOI 10.1111/j.1523-1755.2004.00458.x; LEVY HL, 2001, METABOLIC MOL BASES, V3, P4957; Nozaki J, 2001, BIOCHEM BIOPH RES CO, V284, P255, DOI 10.1006/bbrc.2001.4961; PALACIN M, 2001, METABOLIC MOL BASES, V3, P4909; Schafer JA, 1997, AM J PHYSIOL-RENAL, V273, pF650, DOI 10.1152/ajprenal.1997.273.4.F650; SEOW HF, 2004, NAT GENET       0801, DOI DOI 10.1038/NG; SHIH VE, 1971, GASTROENTEROLOGY, V61, P445; Verrey F, 2004, PFLUG ARCH EUR J PHY, V447, P532, DOI 10.1007/s00424-003-1086-z; Virlon B, 1999, P NATL ACAD SCI USA, V96, P15286, DOI 10.1073/pnas.96.26.15286	17	190	194	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2004	36	9					999	1002		10.1038/ng1405	http://dx.doi.org/10.1038/ng1405			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	851AY	15286787				2022-12-25	WOS:000223658100028
J	Sasai, N; Nakazawa, Y; Haraguchi, T; Sasai, Y				Sasai, N; Nakazawa, Y; Haraguchi, T; Sasai, Y			The neurotrophin-receptor-related protein NRH1 is essential for convergent extension movements	NATURE CELL BIOLOGY			English	Article							BETA-CATENIN; XENOPUS; WNT; GASTRULATION; RHO; FRIZZLED-7; ACTIVATION; POLARITY; EMBRYOS; PATHWAY	Early spherical Xenopus laevis embryos are transformed into a streamlined shape through convergent extension movements. Here we report that a p75(NTR)-related transmembrane protein, NRH1, has an essential function in the regulation of these movements. NRH1 was expressed in marginal zone tissues of the gastrula and in the posterior ectoderm of the neurula. Attenuation of the NRH1 function inhibited convergent extension movements in the embryo and in activin-treated animal caps. NRH1 activated downstream effectors of the Wnt/planar cell polarity pathway: small GTPases and the cascade of MKK7-JNK. Furthermore, gain- and loss-of-function phenotypes of NRH1 were rescued by co-injection of dominant-negative and constitutively active forms of these downstream effectors, respectively, suggesting that NRH1 functions as a positive modulator of planar cell polarity signalling. Interestingly, NRH1 does not require Dishevelled ( Xdsh) for the activation of these downstream effectors or translocation of Xdsh to the membrane, suggesting that NRH1 signalling interacts with planar cell polarity signalling downstream of Xdsh. This demonstrates an essential role for p75(NTR)-related signalling in early embryonic morphogenesis.	RIKEN, Ctr Dev Biol, Organogenesis & Neurogenesis Grp, Chuo Ku, Kobe, Hyogo 6500047, Japan	RIKEN	Sasai, Y (corresponding author), RIKEN, Ctr Dev Biol, Organogenesis & Neurogenesis Grp, Chuo Ku, 2-2-3 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.	sasaicdb@mub.biglobe.ne.jp		Sasai, Noriaki/0000-0003-0360-1138				Choi SC, 2002, DEV BIOL, V244, P342, DOI 10.1006/dbio.2002.0602; Deardorff' MA, 1998, DEVELOPMENT, V125, P2687; Djiane A, 2000, DEVELOPMENT, V127, P3091; Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; HUSTON LD, 2001, J NEUROBIOL, V49, P79; Kinoshita N, 2003, GENE DEV, V17, P1663, DOI 10.1101/gad.1101303; Medina A, 2000, DEV DYNAM, V218, P671, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1017>3.0.CO;2-9; MOON RT, 1993, DEVELOPMENT, V119, P97; Nishinakamura R, 1999, DEV BIOL, V216, P481, DOI 10.1006/dbio.1999.9518; Numakawa T, 2003, J BIOL CHEM, V278, P41259, DOI 10.1074/jbc.M304409200; Penzo-Mendez A, 2003, DEV BIOL, V257, P302, DOI 10.1016/S0012-1606(03)00067-8; Rothbacher U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010; Roux PP, 2002, PROG NEUROBIOL, V67, P203, DOI 10.1016/S0301-0082(02)00016-3; Saneyoshi T, 2002, NATURE, V417, P295, DOI 10.1038/417295a; Sasai N, 2001, DEVELOPMENT, V128, P2525; Sheldahl LC, 2003, J CELL BIOL, V161, P769, DOI 10.1083/jcb.200211094; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Sumanas S, 2000, DEVELOPMENT, V127, P1981; Tada M, 2000, DEVELOPMENT, V127, P2227; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Wallingford JB, 2002, DEV CELL, V2, P695, DOI 10.1016/S1534-5807(02)00197-1; Wallingford JB, 2000, NATURE, V405, P81, DOI 10.1038/35011077; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Winklbauer R, 2001, NATURE, V413, P856, DOI 10.1038/35101621; Yamanaka H, 2002, EMBO REP, V3, P69, DOI 10.1093/embo-reports/kvf008; Yamashita S, 2002, DEV CELL, V2, P363, DOI 10.1016/S1534-5807(02)00126-0; Yamashita T, 2003, NAT NEUROSCI, V6, P461, DOI 10.1038/nn1045; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9	29	31	32	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2004	6	8					741	748		10.1038/ncb1158	http://dx.doi.org/10.1038/ncb1158			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	842YA	15258592				2022-12-25	WOS:000223039400012
J	Van Steen, K; McQueen, MB; Herbert, A; Raby, B; Lyon, H; DeMeo, DL; Murphy, A; Su, J; Datta, S; Rosenow, C; Christman, M; Silverman, EK; Laird, NM; Weiss, ST; Lange, C				Van Steen, K; McQueen, MB; Herbert, A; Raby, B; Lyon, H; DeMeo, DL; Murphy, A; Su, J; Datta, S; Rosenow, C; Christman, M; Silverman, EK; Laird, NM; Weiss, ST; Lange, C			Genomic screening and replication using the same data set in family-based association testing	NATURE GENETICS			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISMS; FALSE DISCOVERY RATE; GENERAL-CLASS; POWERFUL; GENETICS; ASTHMA; DISEQUILIBRIUM; PHENOTYPES	The Human Genome Project and its spin- offs are making it increasingly feasible to determine the genetic basis of complex traits using genome- wide association studies. The statistical challenge of analyzing such studies stems from the severe multiple-comparison problem resulting from the analysis of thousands of SNPs. Our methodology for genome- wide family- based association studies, using single SNPs or haplotypes, can identify associations that achieve genome- wide significance. In relation to developing guidelines for our screening tools, we determined lower bounds for the estimated power to detect the gene underlying the disease- susceptibility locus, which hold regardless of the linkage disequilibrium structure present in the data. We also assessed the power of our approach in the presence of multiple disease- susceptibility loci. Our screening tools accommodate genomic control and use the concept of haplotype- tagging SNPs. Our methods use the entire sample and do not require separate screening and validation samples to establish genome- wide significance, as population- based designs do.	Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Boston Univ, Sch Med, Dept Genet & Genom, Boston, MA 02115 USA; Harvard Univ, Sch Med, Channing Lab, Boston, MA 02115 USA; Childrens Hosp, Div Genet, Boston, MA 02115 USA; Affymetrix Inc, Genom Collaborat Genotyping, Santa Clara, CA 95051 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Boston University; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Affymetrix	Van Steen, K (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.	kvanstee@hsph.harvard.edu	Raby, Benjamin/AAK-3866-2021; Herbert, Alan/AAY-4286-2020; McQueen, Matthew/X-5845-2019	Herbert, Alan/0000-0002-0093-1572; Van Steen, Kristel/0000-0001-9868-5033	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD060726] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD060726] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Benjamini Y, 2001, ANN STAT, V29, P1165; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bonferroni CE., 1937, VOLUME ONORE RICARRD, V2, P1; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; CHURCHILL GA, 1994, GENETICS, V138, P963; Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x; Doerge RW, 1996, GENETICS, V142, P285; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351, DOI 10.1164/ajrccm/142.6_Pt_1.1351; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325; HOLM S, 1979, SCAND J STAT, V6, P65; Kennedy GC, 2003, NAT BIOTECHNOL, V21, P1233, DOI 10.1038/nbt869; Laird NM, 2000, GENET EPIDEMIOL, V19, pS36, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI6>3.3.CO;2-D; Lange C, 2003, HUM HERED, V56, P10, DOI 10.1159/000073728; Lange C, 2002, GENET EPIDEMIOL, V23, P165, DOI 10.1002/gepi.209; Lange C, 2003, BIOSTATISTICS, V4, P195, DOI 10.1093/biostatistics/4.2.195; Lange C, 2002, AM J HUM GENET, V71, P575, DOI 10.1086/342406; Lange C, 2003, AM J HUM GENET, V73, P801, DOI 10.1086/378591; Lange C, 2002, AM J HUM GENET, V71, P1330, DOI 10.1086/344696; Lange C, 2004, AM J HUM GENET, V74, P367, DOI 10.1086/381563; Lange C., 2004, STAT APPL GENET MOL, V3, P17, DOI [DOI 10.2202/1544-6115.1067, 10.2202/1544-6115.1067]; Lin S, 2004, NAT GENET, V36, P1181, DOI 10.1038/ng1457; Lyon H, 2004, GENET EPIDEMIOL, V26, P155, DOI 10.1002/gepi.10298; Marnellos G, 2003, CURR OPIN DRUG DI DE, V6, P317; Rabinowitz D, 2000, HUM HERED, V50, P211, DOI 10.1159/000022918; Randolph AG, 2004, AM J HUM GENET, V75, P709, DOI 10.1086/424886; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Satagopan JM, 2004, BIOMETRICS, V60, P589, DOI 10.1111/j.0006-341X.2004.00207.x; Schaid DJ, 2004, AM J HUM GENET, V75, P948, DOI 10.1086/425870; Sherry ST, 1999, GENOME RES, V9, P677; SIDAK Z, 1971, ANN MATH STAT, V42, P169, DOI 10.1214/aoms/1177693504; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Van Steen Kristel, 2005, Hum Genomics, V2, P67; Weiss ST, 2004, HUM MOL GENET, V13, pR83, DOI 10.1093/hmg/ddh080; Zhai WW, 2004, GENET EPIDEMIOL, V27, P80, DOI 10.1002/gepi.20014	35	136	142	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2005	37	7					683	691		10.1038/ng1582	http://dx.doi.org/10.1038/ng1582			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	941EA	15937480				2022-12-25	WOS:000230196400014
J	Irie, F; Okuno, M; Pasquale, EB; Yamaguchi, Y				Irie, F; Okuno, M; Pasquale, EB; Yamaguchi, Y			EphrinB-EphB signalling regulates clathrin-mediated endocytosis through tyrosine phosphorylation of synaptojanin 1	NATURE CELL BIOLOGY			English	Article							AMPA RECEPTOR ENDOCYTOSIS; VESICLE ENDOCYTOSIS; SYNAPTIC PLASTICITY; ENDOPHILIN; PROTEINS; GROWTH; REPULSION; DOMAIN; BRAIN; BIND	Recent studies show that Eph receptors act mainly through the regulation of actin reorganization(1). Here, we show a novel mode of action for EphB receptors. We identify synaptojanin 1 - a phosphatidylinositol 5'-phosphatase that is involved in clathrin-mediated endocytosis(2,3) - as a physiological substrate for EphB2. EphB2 causes tyrosine phosphorylation in the proline-rich domain of synaptojanin 1, and inhibits both the interaction with endophilin and the 5'-phosphatase activity of synaptojanin 1. Treatment with the EphB ligand, ephrinB2, elevates the cellular level of phosphatidylinositol 4,5-bisphosphate and promotes transferrin uptake. A kinase inactive mutant of EphB2 and a phosphorylation site mutant of synaptojanin 1 both neutralize the increase of transferrin uptake after ephrinB2 treatment. These mutants also inhibit AMPA glutamate receptor endocytosis in hippocampal neurons. Interestingly, incorporated transferrin does not reach endosomes, suggesting dual effects of EphB signalling on the early and late phases of clathrin-mediated endocytosis. Our results indicate that ephrinB-EphB signalling regulates clathrin-mediated endocytosis in various cellular contexts by influencing protein interactions and phosphoinositide turnover through tyrosine phosphorylation of synaptojanin 1.	Burnham Inst, Dev Neurobiol Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Irie, F (corresponding author), Burnham Inst, Dev Neurobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	firie@burnham.org			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD025938] Funding Source: NIH RePORTER; NICHD NIH HHS [P01 HD025938, P01 HD25938] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Beattie EC, 2000, NAT NEUROSCI, V3, P1291, DOI 10.1038/81823; Carroll RC, 2001, NAT REV NEUROSCI, V2, P315, DOI 10.1038/35072500; Carter N, 2002, NAT CELL BIOL, V4, P565, DOI 10.1038/ncb823; Cestra G, 1999, J BIOL CHEM, V274, P32001, DOI 10.1074/jbc.274.45.32001; Contractor A, 2002, SCIENCE, V296, P1864, DOI 10.1126/science.1069081; Cousin MA, 2001, TRENDS NEUROSCI, V24, P659, DOI 10.1016/S0166-2236(00)01930-5; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; Ethell IM, 2001, NEURON, V31, P1001, DOI 10.1016/S0896-6273(01)00440-8; Floyd SR, 2001, J BIOL CHEM, V276, P8104, DOI 10.1074/jbc.M008932200; Grunwald IC, 2001, NEURON, V32, P1027, DOI 10.1016/S0896-6273(01)00550-5; Henderson JT, 2001, NEURON, V32, P1041, DOI 10.1016/S0896-6273(01)00553-0; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Irie F, 2002, NAT NEUROSCI, V5, P1117, DOI 10.1038/nn964; Jurney WM, 2002, J NEUROSCI, V22, P6019; Kalo MS, 1999, CELL TISSUE RES, V298, P1, DOI 10.1007/PL00008807; Koh TW, 2004, NEURON, V43, P193, DOI 10.1016/j.neuron.2004.06.029; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lee SY, 2004, P NATL ACAD SCI USA, V101, P546, DOI 10.1073/pnas.0307813100; Marie B, 2004, NEURON, V43, P207, DOI 10.1016/j.neuron.2004.07.001; Marston DJ, 2003, NAT CELL BIOL, V5, P879, DOI 10.1038/ncb1044; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Penzes P, 2003, NEURON, V37, P263, DOI 10.1016/S0896-6273(02)01168-6; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Schuske KR, 2003, NEURON, V40, P749, DOI 10.1016/S0896-6273(03)00667-6; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Verstreken P, 2003, NEURON, V40, P733, DOI 10.1016/S0896-6273(03)00644-5; Yamaguchi Y, 2004, CURR OPIN NEUROBIOL, V14, P288, DOI 10.1016/j.conb.2004.04.003; Yu HH, 2001, ONCOGENE, V20, P3995, DOI 10.1038/sj.onc.1204524; Zimmer M, 2003, NAT CELL BIOL, V5, P869, DOI 10.1038/ncb1045; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813	32	88	90	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2005	7	5					501	U69		10.1038/ncb1252	http://dx.doi.org/10.1038/ncb1252			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	926LA	15821731	Green Accepted			2022-12-25	WOS:000229123500017
J	Lee, YH; Moon, IJ; Hur, B; Park, JH; Han, KH; Uhm, SY; Kim, YJ; Kang, KJ; Park, JW; Seu, YB; Kim, YH; Park, JG				Lee, YH; Moon, IJ; Hur, B; Park, JH; Han, KH; Uhm, SY; Kim, YJ; Kang, KJ; Park, JW; Seu, YB; Kim, YH; Park, JG			Gene knockdown by large circular antisense for high-throughput functional genomics	NATURE BIOTECHNOLOGY			English	Article							C-MYB; IN-VIVO; HEPATOCELLULAR-CARCINOMA; CELL-PROLIFERATION; MESSENGER-RNA; GROWTH ARREST; EXPRESSION; OLIGONUCLEOTIDE; OLIGODEOXYNUCLEOTIDES; INHIBITION	Single-stranded genomic DNA of recombinant M13 phages was tested as an antisense molecule and examined for its usefulness in high-throughput functional genomics. cDNA fragments of various genes (TNF-alpha, c-myc, c-myb, cdk2 and cdk4) were independently cloned into phagemid vectors. Using the life cycle of M13 bacteriophages, large circular (LC)-molecules, antisense to their respective genes, were prepared from the culture supernatant of bacterial transformants. LC-antisense molecules exhibited enhanced stability, target specificity and no need for target-site searches. High-throughput functional genomics was then attempted with an LC-antisense library, which was generated by using a phagemid vector that incorporated a unidirectional subtracted cDNA library derived from liver cancer tissue. We identified 56 genes involved in the growth of these cells. These results indicate that an antisense sequence as a part of single-stranded LC-genomic DNA of recombinant M13 phages exhibits effective antisense activity, and may have potential for high-throughput functional genomics.	WeIGENE Inc, Taegu 704230, South Korea; Keimyung Univ, Dongsan Med Ctr, Dept Gen Surg, Taegu 702701, South Korea; Keimyung Univ, Sch Med, Dept Immunol, Taegu 702701, South Korea; Kyungpook Natl Univ, Coll Nat Sci, Dept Microbiol, Taegu 702701, South Korea; Keimyung Univ, Sch Med, Dongsan Med Ctr, Dept Med Genet Engn, Taegu 700712, South Korea	Keimyung University; Keimyung University; Kyungpook National University; Keimyung University	Park, JG (corresponding author), WeIGENE Inc, 71B 4L,Dev Sector 2-3,Sungseo Ind Pk, Taegu 704230, South Korea.	jonggu@kmu.ac.kr						Ahn JD, 2002, CIRC RES, V90, P1325, DOI 10.1161/01.RES.0000023200.19316.D5; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; Bennett CF, 1999, BBA-GENE STRUCT EXPR, V1489, P19, DOI 10.1016/S0167-4781(99)00144-X; Beuken E, 1998, BIOTECHNIQUES, V24, P748, DOI 10.2144/98245bm10; Caplen NJ, 2003, EXPERT OPIN BIOL TH, V3, P575, DOI 10.1517/14712598.3.4.575; Chen Y, 2003, BIOTECHNIQUES, V34, P167, DOI 10.2144/03341dd04; De Backer MD, 2001, NAT BIOTECHNOL, V19, P235, DOI 10.1038/85677; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; DOLNICK BJ, 1991, CANCER INVEST, V9, P185, DOI 10.3109/07357909109044229; Fan Bing-Lin, 2004, Ai Zheng, V23, P249; FERRARI S, 1990, CELL GROWTH DIFFER, V1, P543; Gottschalk AR, 2001, CANCER RES, V61, P2105; Graham MJ, 1998, J PHARMACOL EXP THER, V286, P447; Hieter P, 1997, SCIENCE, V278, P601, DOI 10.1126/science.278.5338.601; JUPIN I, 1995, NUCLEIC ACIDS RES, V23, P535, DOI 10.1093/nar/23.3.535; KAMANO H, 1990, LEUKEMIA RES, V14, P831, DOI 10.1016/0145-2126(90)90171-5; Lander ES, 1999, NAT GENET, V21, P3, DOI 10.1038/4427; Li MS, 2004, WORLD J GASTROENTERO, V10, P819; Marcusson Eric G., 2004, Drug Discovery Today Targets, V3, P117, DOI 10.1016/S1741-8372(04)02430-2; Matsuda M, 1996, MOL BIOL CELL, V7, P1095, DOI 10.1091/mbc.7.7.1095; MELANI C, 1991, CANCER RES, V51, P2897; Melotti P, 1996, BLOOD, V87, P2221, DOI 10.1182/blood.V87.6.2221.bloodjournal8762221; Miyagishi M, 2003, OLIGONUCLEOTIDES, V13, P325, DOI 10.1089/154545703322617005; Moon IJ, 2000, BIOCHEM J, V346, P295, DOI 10.1042/0264-6021:3460295; Moon IJ, 2000, J BIOL CHEM, V275, P4647, DOI 10.1074/jbc.275.7.4647; Mulligan JM, 2003, BBA-MOL BASIS DIS, V1639, P43, DOI 10.1016/S0925-4439(03)00128-5; Oien KA, 2003, ONCOGENE, V22, P4287, DOI 10.1038/sj.onc.1206615; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; Prashar Y, 1999, METHOD ENZYMOL, V303, P258; Quackenbush J, 2001, NUCLEIC ACIDS RES, V29, P159, DOI 10.1093/nar/29.1.159; Roush W, 1997, SCIENCE, V276, P1192, DOI 10.1126/science.276.5316.1192; Sambrook J, 2001, MOL CLONING LAB MANU; Shuda M, 2000, ANTICANCER RES, V20, P2489; Smith L, 2000, EUR J PHARM SCI, V11, P191, DOI 10.1016/S0928-0987(00)00100-7; Suyama E, 2003, P NATL ACAD SCI USA, V100, P5616, DOI 10.1073/pnas.1035850100; Thaler DS, 1996, P NATL ACAD SCI USA, V93, P1352, DOI 10.1073/pnas.93.3.1352; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; TOMITA N, 1995, HYPERTENSION, V26, P131, DOI 10.1161/01.HYP.26.1.131; UMANS L, 1995, J BIOL CHEM, V270, P19778, DOI 10.1074/jbc.270.34.19778; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Vickers TA, 2000, NUCLEIC ACIDS RES, V28, P1340, DOI 10.1093/nar/28.6.1340; Yacyshyn BR, 1998, GASTROENTEROLOGY, V114, P1133, DOI 10.1016/S0016-5085(98)70418-4; Yonekura H, 1999, NUCLEIC ACIDS RES, V27, P2591, DOI 10.1093/nar/27.13.2591; Yu Bo, 2000, Molecular Cell Biology Research Communications, V3, P352, DOI 10.1006/mcbr.2000.0238; Zeng JZ, 2002, ONCOGENE, V21, P4932, DOI 10.1038/sj.onc.1205652; Zhang H, 2000, NAT BIOTECHNOL, V18, P862, DOI 10.1038/78475; Zimmermann K, 2002, J BIOL CHEM, V277, P18626, DOI 10.1074/jbc.M200572200	47	8	9	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2005	23	5					591	599		10.1038/nbt1089	http://dx.doi.org/10.1038/nbt1089			9	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	923XS	15867911				2022-12-25	WOS:000228943500032
J	van Dijk, M; Mulders, J; Poutsma, A; Konst, AAM; Lachmeijer, AMA; Dekker, GA; Blankenstein, MA; Oudejans, CBM				van Dijk, M; Mulders, J; Poutsma, A; Konst, AAM; Lachmeijer, AMA; Dekker, GA; Blankenstein, MA; Oudejans, CBM			Maternal segregation of the Dutch preeclampsia locus at 10q22 with a new member of the winged helix gene family	NATURE GENETICS			English	Article							LOW-MOLECULAR-WEIGHT; GENOME-WIDE SCAN; DNA; PHOSPHORYLATION; METHYLATION; EXPRESSION; PROTEINS; REVEALS; DISEASE; REGIONS	Preeclampsia is a pregnancy-associated disease with maternal symptoms but placental origin. Epigenetic inheritance is involved in some populations. By sequence analysis of 17 genes in the 10q22 region with maternal effects, we narrowed the minimal critical region linked with preeclampsia in the Netherlands to 444 kb. All but one gene in this region, which lies within a female-specific recombination hotspot, encode DNA- or RNA-binding proteins. One gene, STOX1 ( also called C10orf24), contained five different missense mutations, identical between affected sisters, cosegregating with the preeclamptic phenotype and following matrilineal inheritance. Four STOX1 transcripts are expressed in early placenta, including invasive extravillus trophoblast, generating three different isoforms. All contain a winged helix domain related to the forkhead ( FOX) family. The largest STOX1 isoform has exclusive nuclear or cytoplasmic expression, indicating activation and inactivation, respectively, of the PI3K-Akt-FOX pathway. Because all 38 FOX proteins and all 8 STOX1 homologs have either tyrosine or phenylalanine at position 153, the predominant Y153H variation is highly mutagenic by conservation criteria but subject to incomplete penetrance. STOX1 is a candidate for preeclampsia controlling polyploidization of extravillus trophoblast.	Vrije Univ Amsterdam, Med Ctr, Dept Clin Chem, NL-1081 HV Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Clin Genet & Human Genet, NL-1081 HV Amsterdam, Netherlands; Univ Adelaide, Dept Obstet Gynaecol, Adelaide, SA, Australia	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; University of Adelaide	Oudejans, CBM (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Clin Chem, Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.	cbm.oudejans@vumc.nl	van Dijk, Marie/L-1901-2014	van Dijk, Marie/0000-0003-1461-3441; Blankenstein, Marinus/0000-0003-1186-0770; Oudejans, Cees/0000-0003-0717-4946				Arngrimsson R, 1999, HUM MOL GENET, V8, P1799, DOI 10.1093/hmg/8.9.1799; Deloukas P, 2004, NATURE, V429, P375, DOI 10.1038/nature02462; Go ATJI, 2004, CLIN CHEM, V50, P1413, DOI 10.1373/clinchem.2004.032979; Guenther C, 1996, DEVELOPMENT, V122, P3509; Guidotti JE, 2003, J BIOL CHEM, V278, P19095, DOI 10.1074/jbc.M300982200; Harrison GA, 1997, AM J HUM GENET, V60, P1158; Hattori N, 2000, MOL BIOL CELL, V11, P1037, DOI 10.1091/mbc.11.3.1037; Kamei T, 2002, MOL ENDOCRINOL, V16, P1469, DOI 10.1210/me.16.7.1469; Kanayama N, 2002, MOL HUM REPROD, V8, P1129, DOI 10.1093/molehr/8.12.1129; Lachmeijer AMA, 2001, EUR J HUM GENET, V9, P758, DOI 10.1038/sj.ejhg.5200706; Laivuori H, 2003, AM J HUM GENET, V72, P168, DOI 10.1086/345311; Leegwater PAJ, 2001, NAT GENET, V29, P383, DOI 10.1038/ng764; Lewis A, 2004, NAT GENET, V36, P1291, DOI 10.1038/ng1468; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Mello G, 2005, HYPERTENSION, V45, P86, DOI 10.1161/01.HYP.0000149950.05182.a3; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; Ng PC, 2002, GENOME RES, V12, P436, DOI 10.1101/gr.212802; Nishimura DY, 1998, NAT GENET, V19, P140, DOI 10.1038/493; Obsil T, 2003, BIOCHEMISTRY-US, V42, P15264, DOI 10.1021/bi0352724; Oudejans CBM, 2004, MOL HUM REPROD, V10, P589, DOI 10.1093/molehr/gah080; PALDI A, 1995, CURR BIOL, V5, P1030, DOI 10.1016/S0960-9822(95)00207-7; Poon LLM, 2002, CLIN CHEM, V48, P35; Quenby S, 2004, OBSTET GYNECOL, V104, P354, DOI 10.1097/01.AOG.0000128902.84876.d4; Riyazi N, 1998, EUR J OBSTET GYN R B, V80, P49, DOI 10.1016/S0301-2115(98)00083-9; Saleem RA, 2001, AM J HUM GENET, V68, P627, DOI 10.1086/318792; Stevens K, 2000, J BIOL CHEM, V275, P30471, DOI 10.1074/jbc.M004891200; Valdez BC, 2002, GENE, V284, P53, DOI 10.1016/S0378-1119(01)00888-5; van der Vleuten G, 2004, ATHEROSCLEROSIS SUPP, V5, P61; van Steensel B, 2001, NAT GENET, V27, P304, DOI 10.1038/85871; Zhao XS, 2004, BIOCHEM J, V378, P839, DOI 10.1042/BJ20031450	30	151	163	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2005	37	5					514	519		10.1038/ng1541	http://dx.doi.org/10.1038/ng1541			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	922TU	15806103				2022-12-25	WOS:000228862300021
J	Abell, K; Bilancio, A; Clarkson, RWE; Tiffen, PG; Altaparmakov, AI; Burdon, TG; Asano, T; Vanhaesebroeck, B; Watson, CJ				Abell, K; Bilancio, A; Clarkson, RWE; Tiffen, PG; Altaparmakov, AI; Burdon, TG; Asano, T; Vanhaesebroeck, B; Watson, CJ			Stat3-induced apoptosis requires a molecular switch in PI(3)K subunit composition	NATURE CELL BIOLOGY			English	Article							MAMMARY-GLAND INVOLUTION; EMBRYONIC STEM-CELLS; P85 ALPHA-GENE; PHOSPHATIDYLINOSITOL 3-KINASE; REGULATORY SUBUNIT; NEGATIVE REGULATION; ACTIVATION; P85-ALPHA; INSULIN; CANCER	Physiological apoptosis is induced by a switch from survival to death signalling. Dysregulation of this process is frequently associated with cancer(1). A powerful model for this apoptotic switch is mammary gland involution, during which redundant milk-producing epithelial cells undergo apoptosis(2). Signal transducer and activator of transcription 3 (Stat3) is an essential mediator of this switch but the mechanism has not yet been defined(3). Stat3-dependent cell death during involution can be blocked by activation of Akt/protein kinase B (PKB)(4), a downstream effector of the phosphoinositide-3-OH kinase (PI(3)K) pathway(5). Here we show that expression of the PI(3) K regulatory subunits p55 alpha and p50 alpha is induced by Stat3 during involution. In the absence of Stat3 in vivo, upregulation of p55 alpha and p50 alpha is abrogated, levels of activated Akt are sustained and apoptosis is prevented. Chromatin immunoprecipitation assays show that Stat3 binds directly to the p55 alpha and p50 alpha promoters in vivo. Overexpression of either p55 alpha or p50 alpha reduces levels of activated Akt. We propose a novel mechanism in which Stat3 regulates apoptosis by inducing expression of distinct PI(3) K regulatory subunits to downregulate PI(3)K-Akt-mediated survival signalling.	Univ Cambridge, Dept Pathol, Mammary Apoptosis & Dev Grp, Cambridge CB2 1QP, England; Ludwig Inst Canc Res, Cell Signalling Lab, London W1W 7BS, England; Roslin Inst, Roslin EH25 9PS, Midlothian, Scotland; Univ Tokyo, Fac Med, Dept Internal Med 3, Tokyo 113, Japan; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	University of Cambridge; Ludwig Institute for Cancer Research; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Tokyo; University of London; University College London	Watson, CJ (corresponding author), Univ Cambridge, Dept Pathol, Mammary Apoptosis & Dev Grp, Tennis Court Rd, Cambridge CB2 1QP, England.	cjw53@mole.bio.cam.ac.uk	watson, Christine J/B-1431-2012; Clarkson, Richard/A-7505-2010	BILANCIO, Antonio/0000-0002-5118-3359; clarkson, richard/0000-0001-7389-8673	Biotechnology and Biological Sciences Research Council [BBS/E/R/00000664] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Antonetti DA, 1996, MOL CELL BIOL, V16, P2195; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Dani C, 1998, DEV BIOL, V203, P149, DOI 10.1006/dbio.1998.9026; Davuluri RV, 2001, NAT GENET, V29, P412, DOI 10.1038/ng780; Davuluri RV, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459a; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fruman DA, 1996, GENOMICS, V37, P113, DOI 10.1006/geno.1996.0527; Hallmann D, 2003, J BIOL CHEM, V278, P5099, DOI 10.1074/jbc.M208451200; Inukai I, 2001, FEBS LETT, V490, P32, DOI 10.1016/S0014-5793(01)02132-9; Inukai K, 1997, J BIOL CHEM, V272, P7873, DOI 10.1074/jbc.272.12.7873; Inukai K, 1996, J BIOL CHEM, V271, P5317, DOI 10.1074/jbc.271.10.5317; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Kritikou EA, 2003, DEVELOPMENT, V130, P3459, DOI 10.1242/dev.00578; Kumar R, 2000, ENDOCR-RELAT CANCER, V7, P257, DOI 10.1677/erc.0.0070257; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PONS S, 1995, MOL CELL BIOL, V15, P4453; Schulze-Bergkamen H, 2004, SEMIN ONCOL, V31, P90, DOI 10.1053/j.seminoncol.2003.11.006; Schwertfeger KL, 2001, MOL ENDOCRINOL, V15, P867, DOI 10.1210/me.15.6.867; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Torbenson M, 2002, AM J PATHOL, V161, P155, DOI 10.1016/S0002-9440(10)64167-3; Ueki K, 2000, MOL CELL BIOL, V20, P8035, DOI 10.1128/MCB.20.21.8035-8046.2000; Ueki K, 2002, MOL CELL BIOL, V22, P965, DOI 10.1128/MCB.22.3.965-977.2002; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	31	88	91	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2005	7	4					392	398		10.1038/ncb1242	http://dx.doi.org/10.1038/ncb1242			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	912KA	15793565				2022-12-25	WOS:000228075500016
J	Li, Z; Dong, XM; Wang, ZL; Liu, WZ; Deng, N; Ding, Y; Tang, LY; Hla, T; Zeng, R; Li, L; Wu, DQ				Li, Z; Dong, XM; Wang, ZL; Liu, WZ; Deng, N; Ding, Y; Tang, LY; Hla, T; Zeng, R; Li, L; Wu, DQ			Regulation of PTEN by Rho small GTPases	NATURE CELL BIOLOGY			English	Article							TUMOR-SUPPRESSOR PTEN; CELL-MIGRATION; FAMILY GTPASES; ACTIVATION; KINASE; 3-KINASE; CDC42; POLARIZATION; NEUTROPHILS; CHEMOTAXIS	PTEN ( phosphatase and tensin homologue) is a phosphatase that dephosphorylates both protein and phosphoinositide substrates. It is mutated in a variety of human tumours and has important roles in a diverse range of biological processes(1-4), including cell migration(5-7) and chemotaxis(8,9). PTEN's intracellular localization and presumably activity are regulated by chemoattractants in Dictyostelium(10,11) and mouse neutrophils(12). However, the mechanisms for its regulation remain elusive. Here we show that RhoA and Cdc42, members of the Rho family of small GTPases(13-16), regulate the intracellular localization of PTEN in leukocytes and human transfected embryonic kidney cells. In addition, active RhoA is able to stimulate the phospholipid phosphatase activity of PTEN in human embryonic kidney cells and leukocytes, and this regulation seems to require RhoA's downstream effector, RhoA-associated kinase (Rock). Furthermore, we have identified key residues on PTEN that are required for its regulation by the small GTPase, and show that small GTPase-mediated regulation of PTEN has a significant role in the regulation of chemotaxis.	Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, Farmington, CT 06030 USA; Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Prote, Res Ctr Prote Anal, Shanghai, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, Shanghai, Peoples R China	University of Connecticut; University of Connecticut; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Wu, DQ (corresponding author), Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA.	lli@sibs.ac.cn; dwu@neuron.uchc.edu	Wang, Zhenglong/H-4237-2016; Deng, Ning/H-6561-2014; Hla, Timothy/G-5873-2012; Ding, Yu/A-2949-2013	Wang, Zhenglong/0000-0002-3016-8598; Hla, Timothy/0000-0001-8355-4065; DENG, NING/0000-0002-1321-5508				Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Anzelon AN, 2003, NAT IMMUNOL, V4, P287, DOI 10.1038/ni892; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Blagoev B, 2003, NAT BIOTECHNOL, V21, P315, DOI 10.1038/nbt790; Bokoch GM, 2000, IMMUNOL RES, V21, P139, DOI 10.1385/IR:21:2-3:139; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Devreotes P, 2003, J BIOL CHEM, V278, P20445, DOI 10.1074/jbc.R300010200; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fukata M, 2003, CURR OPIN CELL BIOL, V15, P590, DOI 10.1016/S0955-0674(03)00097-8; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Parent CA, 2002, CELL, V109, P541, DOI 10.1016/S0092-8674(02)00765-1; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Sulis ML, 2003, TRENDS CELL BIOL, V13, P478, DOI 10.1016/S0962-8924(03)00175-2; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5	30	382	397	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2005	7	4					399	U42		10.1038/ncb1236	http://dx.doi.org/10.1038/ncb1236			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	912KA	15793569				2022-12-25	WOS:000228075500017
J	Otto, EA; Loeys, B; Khanna, H; Hellemans, J; Sudbrak, R; Fan, SL; Muerb, U; O'Toole, JF; Helou, J; Attanasio, M; Utsch, B; Sayer, JA; Lillo, C; Jimeno, D; Coucke, P; De Paepe, A; Reinhardt, R; Klages, S; Tsuda, M; Kawakami, I; Kusakabe, T; Omran, H; Imm, A; Tippens, M; Raymond, PA; Hill, J; Beales, P; He, S; Kispert, A; Margolis, B; Williams, DS; Swaroop, A; Hildebrandt, F				Otto, EA; Loeys, B; Khanna, H; Hellemans, J; Sudbrak, R; Fan, SL; Muerb, U; O'Toole, JF; Helou, J; Attanasio, M; Utsch, B; Sayer, JA; Lillo, C; Jimeno, D; Coucke, P; De Paepe, A; Reinhardt, R; Klages, S; Tsuda, M; Kawakami, I; Kusakabe, T; Omran, H; Imm, A; Tippens, M; Raymond, PA; Hill, J; Beales, P; He, S; Kispert, A; Margolis, B; Williams, DS; Swaroop, A; Hildebrandt, F			Nephrocystin-5, a ciliary IQ domain protein, is mutated in Senior-Loken syndrome and interacts with RPGR and calmodulin	NATURE GENETICS			English	Article							LINKED RETINITIS-PIGMENTOSA; RENAL CYSTIC-DISEASE; JUVENILE NEPHRONOPHTHISIS; ROD PHOTORECEPTORS; GENE; ENCODES; EXPRESSION; MUTATIONS; INVERSIN	Nephronophthisis (NPHP) is the most frequent genetic cause of chronic renal failure in children(1-3). Identification of four genes mutated in NPHP subtypes 1- 4 (refs. 4- 9) has linked the pathogenesis of NPHP to ciliary functions(9). Ten percent of affected individuals have retinitis pigmentosa, constituting the renal-retinal Senior-Loken syndrome (SLSN). Here we identify, by positional cloning, mutations in an evolutionarily conserved gene, IQCB1 (also called NPHP5), as the most frequent cause of SLSN. IQCB1 encodes an IQ-domain protein, nephrocystin-5. All individuals with IQCB1 mutations have retinitis pigmentosa. Hence, we examined the interaction of nephrocystin-5 with RPGR (retinitis pigmentosa GTPase regulator), which is expressed in photoreceptor cilia and associated with 10-20% of retinitis pigmentosa. We show that nephrocystin-5, RPGR and calmodulin can be coimmunoprecipitated from retinal extracts, and that these proteins localize to connecting cilia of photoreceptors and to primary cilia of renal epithelial cells. Our studies emphasize the central role of ciliary dysfunction in the pathogenesis of SLSN.	Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; Johns Hopkins Univ, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA; Univ Michigan, Dept Ophthalmol, Ann Arbor, MI 48109 USA; Ghent Univ Hosp, Ctr Med Genet, B-9000 Ghent, Belgium; Max Planck Inst Mol Genet, Berlin, Germany; Univ Kiel, Inst Clin Mol Biol, D-24105 Kiel, Germany; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Calif San Diego, Sch Med, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA; Univ Hyogo, Grad Sch Life Sci, Dept Life Sci, Hyogo 6781297, Japan; Univ Freiburg, Childrens Hosp, Freiburg, Germany; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; UCL, Inst Child Hlth, Mol Med Unit, London, England; Hannover Med Sch, Inst Mol Biol, D-30625 Hannover, Germany; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; Johns Hopkins University; University of Michigan System; University of Michigan; Ghent University; Ghent University Hospital; Max Planck Society; University of Kiel; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Hyogo; University of Freiburg; University of Michigan System; University of Michigan; University of London; University College London; Hannover Medical School; University of Michigan System; University of Michigan	Hildebrandt, F (corresponding author), Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA.	fhilde@umich.edu	Sayer, John A./AAN-2729-2020; Loeys, Bart/B-3236-2017; Lillo, Concepcion/A-6321-2009; Sudbrak, Ralf/HHZ-8821-2022; Kusakabe, Takehiro/H-7178-2012; Beales, Philip L/C-7367-2009; Coucke, Paul J/AAO-2954-2020; Jimeno, David/D-3096-2018	Sayer, John A./0000-0003-1881-3782; Loeys, Bart/0000-0003-3703-9518; Lillo, Concepcion/0000-0001-5814-9826; Kusakabe, Takehiro/0000-0002-8325-3665; Coucke, Paul J/0000-0001-7119-586X; Reinhardt, Richard/0000-0001-9376-2132; Utsch, Boris/0000-0003-4623-581X; Jimeno, David/0000-0001-7876-0083; Otto, Edgar/0000-0002-2387-9973; Attanasio, Massimo/0000-0002-1278-3650; Omran, Heymut/0000-0003-0282-6765; Raymond, Pamela/0000-0003-1083-5530; Swaroop, Anand/0000-0002-1975-1141	NEI NIH HHS [R01 EY007042] Funding Source: Medline; NIDDK NIH HHS [R01 DK084725] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK084725] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BESHARSE JC, 1990, PHOTORECEPTOR CONNEC, P409; Breuer DK, 2002, AM J HUM GENET, V70, P1545, DOI 10.1086/340848; CHEN TY, 1994, P NATL ACAD SCI USA, V91, P11757, DOI 10.1073/pnas.91.24.11757; Cheng H, 2004, HUM MOL GENET, V13, P1563, DOI 10.1093/hmg/ddh173; Cuenca N, 2002, J NEUROCYTOL, V31, P649, DOI 10.1023/A:1025791512555; Dehal P, 2002, SCIENCE, V298, P2157, DOI 10.1126/science.1080049; FANCONI G, 1951, Helv Paediatr Acta, V6, P1; Gattone VH, 2003, NAT MED, V9, P1323, DOI 10.1038/nm935; Gibbs D, 2004, J CELL SCI, V117, P6473, DOI 10.1242/jcs.01580; Hildebrandt F, 1997, NAT GENET, V17, P149, DOI 10.1038/ng1097-149; Hildebrandt F., 2004, PEDIATR NEPHROL, P665; Hong DH, 2002, INVEST OPHTH VIS SCI, V43, P3373; Hong DH, 2003, INVEST OPHTH VIS SCI, V44, P2413, DOI 10.1167/iovs.02-1206; Mollet G, 2002, NAT GENET, V32, P300, DOI 10.1038/ng996; Morgan D, 2002, HUM GENET, V110, P377, DOI 10.1007/s00439-002-0696-4; Olbrich H, 2003, NAT GENET, V34, P455, DOI 10.1038/ng1216; Otto E, 2002, AM J HUM GENET, V71, P1161, DOI 10.1086/344395; Otto E, 2000, J AM SOC NEPHROL, V11, P270, DOI 10.1681/ASN.V112270; Otto EA, 2003, NAT GENET, V34, P413, DOI 10.1038/ng1217; Roepman R, 2000, HUM MOL GENET, V9, P2095, DOI 10.1093/hmg/9.14.2095; Saunier S, 1997, HUM MOL GENET, V6, P2317, DOI 10.1093/hmg/6.13.2317; SMITH CH, 1945, AM J DIS CHILD, V69, P369; Vervoort R, 2000, NAT GENET, V25, P462, DOI 10.1038/78182; Watnick T, 2003, NAT GENET, V34, P355, DOI 10.1038/ng0803-355; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75	25	283	296	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2005	37	3					282	288		10.1038/ng1520	http://dx.doi.org/10.1038/ng1520			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	901QU	15723066				2022-12-25	WOS:000227297800019
J	Sleeman, MW; Wortley, KE; Lai, KMV; Gowen, LC; Kintner, J; Kline, WO; Garcia, K; Stitt, TN; Yancopoulos, GD; Wiegand, SJ; Glass, DJ				Sleeman, MW; Wortley, KE; Lai, KMV; Gowen, LC; Kintner, J; Kline, WO; Garcia, K; Stitt, TN; Yancopoulos, GD; Wiegand, SJ; Glass, DJ			Absence of the lipid phosphatase SHIP2 confers resistance to dietary obesity	NATURE MEDICINE			English	Article							PROTEIN-KINASE-B; INSULIN SENSITIVITY; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; GLUT4 TRANSLOCATION; SIGNAL-TRANSDUCTION; NEGATIVE REGULATION; PLASMA MEMBRANE; MICE LACKING; SH2 DOMAIN; ACTIVATION	Genetic ablation of Inppl1, which encodes SHIP2 (SH2-domain containing inositol 5-phosphatase 2), was previously reported to induce severe insulin sensitivity, leading to early postnatal death. In the previous study, the targeting construct left the first eighteen exons encoding Inppl1 intact, generating a Inppl1(EX19-28-/-) mouse, and apparently also deleted a second gene, Phox2a. We report a new SHIP2 knockout (Inppl1(-/-)) targeted to the translation-initiating ATG, which is null for Inppl1 mRNA and protein. Inppl1(-/-) mice are viable, have normal glucose and insulin levels, and normal insulin and glucose tolerances. The Inppl1(-/-) mice are, however, highly resistant to weight gain when placed on a high-fat diet. These results suggest that inhibition of SHIP2 would be useful in the effort to ameliorate diet-induced obesity, but call into question a dominant role of SHIP2 in modulating glucose homeostasis.	Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	Regeneron	Glass, DJ (corresponding author), Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.	david.glass@regeneron.com	Glass, David/AAI-3910-2021	Morton, Lori/0000-0002-5214-5784				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Asante-Appiah E, 2003, AM J PHYSIOL-ENDOC M, V284, pE663, DOI 10.1152/ajpendo.00462.2002; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Clement S, 2004, NATURE, V431, P878, DOI 10.1038/nature03003; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; CUATRECASAS P, 1971, J BIOL CHEM, V246, P7265; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FREYCHET P, 1971, P NATL ACAD SCI USA, V68, P1833, DOI 10.1073/pnas.68.8.1833; HADARI YR, 1992, J BIOL CHEM, V267, P17483; Hertweck M, 2004, DEV CELL, V6, P577, DOI 10.1016/S1534-5807(04)00095-4; Hill MM, 1999, MOL CELL BIOL, V19, P7771; HOUSE PDR, 1970, BIOCHEM BIOPH RES CO, V41, P541, DOI 10.1016/0006-291X(70)90046-X; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Lamkin TD, 1997, J BIOL CHEM, V272, P10396; Liu L, 1997, J BIOL CHEM, V272, P8983; Pesesse X, 1998, FEBS LETT, V437, P301, DOI 10.1016/S0014-5793(98)01255-1; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Sakoda H, 2003, J BIOL CHEM, V278, P25802, DOI 10.1074/jbc.M301127200; Sleeman MW, 2003, P NATL ACAD SCI USA, V100, P14297, DOI 10.1073/pnas.2335926100; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Valenzuela DM, 2003, NAT BIOTECHNOL, V21, P652, DOI 10.1038/nbt822; Wada T, 2001, MOL CELL BIOL, V21, P1633, DOI 10.1128/MCB.21.5.1633-1646.2001; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	40	194	203	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					199	205		10.1038/nm1178	http://dx.doi.org/10.1038/nm1178			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15654325				2022-12-25	WOS:000226797300028
J	Ahmadi, KR; Weale, ME; Xue, ZYY; Soranzo, N; Yarnall, DP; Briley, JD; Maruyama, Y; Kobayashi, M; Wood, NW; Spurr, NK; Burns, DK; Roses, AD; Saunders, AM; Goldstein, DB				Ahmadi, KR; Weale, ME; Xue, ZYY; Soranzo, N; Yarnall, DP; Briley, JD; Maruyama, Y; Kobayashi, M; Wood, NW; Spurr, NK; Burns, DK; Roses, AD; Saunders, AM; Goldstein, DB			A single-nucleotide polymorphism tagging set for human drug metabolism and transport	NATURE GENETICS			English	Article							LINKAGE-DISEQUILIBRIUM; HAPLOTYPE BLOCKS; SNP	Interindividual variability in drug response, ranging from no therapeutic benefit to life-threatening adverse reactions, is influenced by variation in genes that control the absorption, distribution, metabolism and excretion of drugs(1). We genotyped 904 single-nucleotide polymorphisms (SNPs) from 55 such genes in two population samples (European and Japanese) and identified a set of tagging SNPs that represents the common variation in these genes, both known and unknown. Extensive empirical evaluations, including a direct assessment of association with candidate functional SNPs in a new, larger population sample, validated the performance of these tagging SNPs and confirmed their utility for linkage-disequilibrium mapping in pharmacogenetics. The analyses also suggest that rare variation is not amenable to tagging strategies.	UCL, Dept Biol, Galton Lab, London WC1E 6BT, England; GlaxoSmithKline, Genet Res, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline, Tsukuba Res Labs, Genet Res, Tsukuba, Ibaraki 3004247, Japan; Inst Neurol, Dept Mol Neurosci, London WC1N 3BG, England	University of London; University College London; GlaxoSmithKline; Eisai Co Ltd; GlaxoSmithKline; University of London; University College London	Goldstein, DB (corresponding author), UCL, Dept Biol, Galton Lab, Darwin Bldg,Gower St, London WC1E 6BT, England.	d.goldstein@ucl.ac.uk	Wood, Nicholas W/C-2505-2009; Goldstein, David/AAY-8125-2020; Ahmadi, Kourosh R/B-6379-2012; Weale, Michael E/F-2587-2010	Wood, Nicholas W/0000-0002-9500-3348; Weale, Michael E/0000-0003-4593-1186; Soranzo, Nicole/0000-0003-1095-3852				Capelli C, 2003, CURR BIOL, V13, P979, DOI 10.1016/S0960-9822(03)00373-7; Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000; Chapman JM, 2003, HUM HERED, V56, P18, DOI 10.1159/000073729; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Goldstein DB, 2003, NAT REV GENET, V4, P937, DOI 10.1038/nrg1229; Goldstein DB, 2003, TRENDS GENET, V19, P615, DOI 10.1016/j.tig.2003.09.006; Kamatani N, 2004, AM J HUM GENET, V75, P190, DOI 10.1086/422853; Ke XY, 2004, HUM MOL GENET, V13, P577, DOI 10.1093/hmg/ddh060; Pritchard JK, 2001, AM J HUM GENET, V69, P1, DOI 10.1086/321275; Qin ZHS, 2002, AM J HUM GENET, V71, P1242, DOI 10.1086/344207; Salisbury BA, 2003, MUTAT RES-FUND MOL M, V526, P53, DOI 10.1016/S0027-5107(03)00014-9; Schulze TG, 2004, HUM MOL GENET, V13, P335, DOI 10.1093/hmg/ddh035; Taylor JD, 2001, BIOTECHNIQUES, V30, P661, DOI 10.2144/01303dd04; Weale ME, 2003, AM J HUM GENET, V73, P551, DOI 10.1086/378098	14	118	128	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2005	37	1					84	89		10.1038/ng1488	http://dx.doi.org/10.1038/ng1488			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	883FX	15608640				2022-12-25	WOS:000225997500025
J	Insinga, A; Monestiroli, S; Ronzoni, S; Gelmetti, V; Marchesi, F; Viale, A; Altucci, L; Nervi, C; Minucci, S; Pelicci, PG				Insinga, A; Monestiroli, S; Ronzoni, S; Gelmetti, V; Marchesi, F; Viale, A; Altucci, L; Nervi, C; Minucci, S; Pelicci, PG			Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway	NATURE MEDICINE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MYELOID-LEUKEMIA; ONCOGENIC TRANSCRIPTION FACTOR; RAR-ALPHA; FUSION PROTEINS; DECOY RECEPTORS; DIFFERENTIATION; TARGET; CANCER; EXPRESSION	Histone deacetylases (HDACs) regulate transcription and specific cellular functions, such as tumor suppression by p53, and are frequently altered in cancer(1-4). Inhibitors of HDACs (HDACIs) possess antitumor activity and are well tolerated, supporting the idea that their use might develop as a specific strategy for cancer treatment. The molecular basis for their selective antitumor activity is, however, unknown. We investigated the effects of HDACIs on leukemias expressing the PML-RAR or AML1-ETO oncoproteins, known to initiate leukemogenesis through deregulation of HDACs. Here we report that: (i) HDACIs induce apoptosis of leukemic blasts, although oncogene expression is not sufficient to confer HDACI sensitivity to normal cells; (ii) apoptosis is p53 independent and depends, both in vitro and in vivo, upon activation of the death receptor pathway (TRAIL and Fas signaling pathways); (iii) TRAIL, DR5, FasL and Fas are upregulated by HDACIs in the leukemic cells, but not in normal hematopoietic progenitors. These results show that sensitivity to HDACIs in leukemias is a property of the fully transformed phenotype and depends on activation of a specific death pathway.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; IFOM FIRC Inst, I-20139 Milan, Italy; San Raffaele Biomed Sci Pk Rome, I-00161 Rome, Italy; Univ Milan, Dept Vet Pathol, I-20133 Milan, Italy; Univ Naples, Dept Pathol, I-80138 Naples, Italy	IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology; University of Milan; University of Naples Federico II	Minucci, S (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.	saverio.minucci@ifom-ieo-campus.it; piergiuseppe.pelicci@ifom-ieo-campus.it	Insinga, Alessandra/AAR-9551-2020; Pelicci, Pier Giuseppe/AAL-6572-2020; Minucci, Saverio/J-9669-2012; Ronzoni, Simona/AAQ-1669-2020; Altucci, Lucia/S-8031-2019; Marchesi, Francesco/ABF-9255-2021	Marchesi, Francesco/0000-0003-1179-5788; altucci, lucia/0000-0002-7312-5387; NERVI, Clara/0000-0001-9341-0188; Insinga, Alessandra/0000-0002-6060-8339				Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Casini T, 1999, ONCOGENE, V18, P3235, DOI 10.1038/sj.onc.1202630; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Ferrara FF, 2001, CANCER RES, V61, P2; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Insinga A, 2004, EMBO J, V23, P1144, DOI 10.1038/sj.emboj.7600109; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Johnstone RW, 2003, CANCER CELL, V4, P13, DOI 10.1016/S1535-6108(03)00165-X; Kelly WK, 2002, EXPERT OPIN INV DRUG, V11, P1695, DOI 10.1517/13543784.11.12.1695; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Minucci S, 2002, BLOOD, V100, P2989, DOI 10.1182/blood-2001-11-0089; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Westervelt P, 2003, BLOOD, V102, P1857, DOI 10.1182/blood-2002-12-3779; Westervelt P, 1999, BLOOD, V93, P2143, DOI 10.1182/blood.V93.7.2143.407a32_2143_2148; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298	25	456	475	1	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2005	11	1					71	76		10.1038/nm1160	http://dx.doi.org/10.1038/nm1160			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	884ZJ	15619634				2022-12-25	WOS:000226124900035
J	Nebbioso, A; Clarke, N; Voltz, E; Germain, E; Ambrosino, C; Bontempo, P; Alvarez, R; Schiavone, EM; Ferrara, F; Bresciani, F; Weisz, A; de Lera, AR; Gronemeyer, H; Altucci, L				Nebbioso, A; Clarke, N; Voltz, E; Germain, E; Ambrosino, C; Bontempo, P; Alvarez, R; Schiavone, EM; Ferrara, F; Bresciani, F; Weisz, A; de Lera, AR; Gronemeyer, H; Altucci, L			Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells	NATURE MEDICINE			English	Article							HISTONE-DEACETYLASE INHIBITORS; DEATH LIGAND TRAIL; IN-VIVO; GENE-EXPRESSION; VALPROIC ACID; DIFFERENTIATION; APOPTOSIS; CANCER; TRANSCRIPTION; SP3	Chromatin is a dynamic macromolecular structure epigenetically modified to regulate specific gene expression. Altered chromatin function can lead to aberrant expression of growth regulators and may, ultimately, cause cancer. That many human diseases have epigenetic etiology has stimulated the development of 'epigenetic' therapies. Inhibitors of histone deacetylases (HDACIs) induce proliferation arrest, maturation and apoptosis of cancer cells, but not normal cells, in vitro and in vivo, and are currently being tested in clinical trials(1-5). We investigated the mechanism(s) underlying this tumor selectivity. We report that HDACIs induce, in addition to p21, expression of TRAIL (Apo2L, TNFSF10) by directly activating the TNFSF10 promoter, thereby triggering tumor-selective death signaling in acute myeloid leukemia (AML) cells and the blasts of individuals with AML. RNA interference revealed that the induction of p21, TRAIL and differentiation are separable activities of HDACIs. HDACIs induced proliferation arrest, TRAIL-mediated apoptosis and suppression of AML blast clonogenicity irrespective of French-American- British (FAB) classification status, karyotype and immunophenotype. No apoptosis was seen in normal CD34(+) progenitor cells. Our results identify TRAIL as a mediator of the anticancer action of HDACIs.	Seconda Univ Studi Napoli, Dipartimento Patol Gen, I-80138 Naples, Italy; IGBMC, CNRS, INSERM, ULP,Dept Cell Biol & Signal Transduct, F-67404 Illkirch Graffenstaden, CU De Strasbour, France; Univ Vigo, Dept Quim Organ, Fac Ciencias, Vigo, Spain; Osped Antonio Cardarelli, I-80131 Naples, Italy	Universita della Campania Vanvitelli; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universidade de Vigo; Antonio Cardarelli Hospital	Gronemeyer, H (corresponding author), Seconda Univ Studi Napoli, Dipartimento Patol Gen, Vico Luigi de Crecchio 7, I-80138 Naples, Italy.	hg@igbmc.u-strasbg.fr; lucia.altucci@unina2.it	ambrosino, concetta/AAB-3452-2019; Emmanuelle, germain/D-8159-2015; Weisz, Alessandro/A-1317-2014; Gronemeyer, Hinrich/G-6240-2011; Gronemeyer, Hinrich/H-7002-2016; Altucci, Lucia/S-8031-2019; NEBBIOSO, ANGELA/GVS-1294-2022; Garcia, Jose M Esteban/B-7691-2008; Rodríguez, Rosana Alvarez/AAA-1998-2019; Gronemeyer, Hinrich/AAH-5575-2019; germain, Emmanuelle/U-8127-2018; NEBBIOSO, Angela/C-3566-2016	Weisz, Alessandro/0000-0003-0455-2083; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; Rodríguez, Rosana Alvarez/0000-0001-5608-7561; Gronemeyer, Hinrich/0000-0001-9454-2449; germain, Emmanuelle/0000-0003-0552-7357; Clarke, Nicole/0000-0002-2770-3289; altucci, lucia/0000-0002-7312-5387; Rodriguez de Lera, Angel/0000-0001-6896-9078; NEBBIOSO, Angela/0000-0001-5374-3527; BONTEMPO, Paola/0000-0002-9834-229X				Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Amin HM, 2001, BRIT J HAEMATOL, V115, P287, DOI 10.1046/j.1365-2141.2001.03123.x; Ammanamanchi S, 2003, J BIOL CHEM, V278, P35775, DOI 10.1074/jbc.M305961200; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Camarero N, 2003, NUCLEIC ACIDS RES, V31, P1693, DOI 10.1093/nar/gkg262; Clarke N, 2004, EMBO J, V23, P3051, DOI 10.1038/sj.emboj.7600302; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Ferrara FF, 2001, CANCER RES, V61, P2; Glaser KB, 2003, MOL CANCER THER, V2, P151; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006; Litwack G, 2004, VITAM HORM, V67, P1; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Minucci S, 2001, ONCOGENE, V20, P3110, DOI 10.1038/sj.onc.1204336; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Rosato RR, 2003, MOL CANCER THER, V2, P1273; Rosato RR, 2003, CANCER RES, V63, P3637; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; Sasakawa Y, 2002, BIOCHEM PHARMACOL, V64, P1079, DOI 10.1016/S0006-2952(02)01261-3; Shiohara M, 1999, BLOOD, V93, P2057, DOI 10.1182/blood.V93.6.2057.406k04_2057_2066; Suzuki T, 1999, J MED CHEM, V42, P3001, DOI 10.1021/jm980565u; Vigushin DM, 2004, CURR CANCER DRUG TAR, V4, P205, DOI 10.2174/1568009043481560; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200	30	442	469	0	37	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2005	11	1					77	84		10.1038/nm1161	http://dx.doi.org/10.1038/nm1161			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	884ZJ	15619633				2022-12-25	WOS:000226124900036
J	Toyofuku, T; Zhang, H; Kumanogoh, A; Takegahara, N; Yabuki, M; Harada, K; Hori, M; Kikutani, H				Toyofuku, T; Zhang, H; Kumanogoh, A; Takegahara, N; Yabuki, M; Harada, K; Hori, M; Kikutani, H			Guidance of myocardial patterning in cardiac development by Sema6D reverse signalling	NATURE CELL BIOLOGY			English	Article							TYROSINE KINASE; FIBROBLAST MOTILITY; ENA/VASP PROTEINS; AXON GUIDANCE; ABL; PHOSPHORYLATION; RECEPTOR; HEART; PHOSPHATASE; LINEAGES	Cardiac chamber formation involves dynamic changes in myocardial organization, including trabeculation and expansion of the compact layer(1). The positional cues that regulate myocardial patterning, however, remain unclear. Through ligation of the Plexin-A1 receptor, the transmembrane-type semaphorin Sema6D regulates endocardial cell migration(2). Here, we demonstrate that knockdown of either Sema6D or Plexin-A1 leads to the generation of a small, thin ventricular compact layer and to defective trabeculation. In the heart, expression of the Plexin-A1 extracellular domain alone can rescue the defective trabeculation induced by suppression of Plexin-A1, but not that resulting from defective Sema6D expression. This indicates that reverse signalling by Sema6D occurs within the myocardium. In a ligand-dependent manner, Abl kinase is recruited to the cytoplasmic tail of Sema6D and activated, resulting in phosphorylation of Enabled and dissociation from Sema6D. Constitutive activation of Sema6D signalling enhances the migration of myocardial cells into the trabeculae, whereas inhibition arrests cells within the compact layer. Thus, Sema6D coordinates both compact-layer expansion and trabeculation, functioning as both a ligand and a receptor for Plexin-A1.	Osaka Univ, Dept Mol Immunol, Res Inst Microbial Dis, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Tokyo, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Kikutani, H (corresponding author), Osaka Univ, Dept Mol Immunol, Res Inst Microbial Dis, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	kikutani@ragtime.biken.osaka-u.ac.jp	Takegahara, Noriko/AAP-1694-2021; Kumanogoh, Atsushi/C-7354-2009; Kikutani, Hitoshi/C-9525-2009					Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; Dorey K, 2001, ONCOGENE, V20, P8075, DOI 10.1038/sj.onc.1205017; Godenschwege TA, 2002, NAT NEUROSCI, V5, P1294, DOI 10.1038/nn976; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Karimova G, 1998, P NATL ACAD SCI USA, V95, P5752, DOI 10.1073/pnas.95.10.5752; Klostermann A, 2000, J BIOL CHEM, V275, P39647, DOI 10.1074/jbc.M006316200; MANASEK FJ, 1968, J MORPHOL, V125, P329, DOI 10.1002/jmor.1051250306; Mikawa T, 1996, ANNU REV PHYSIOL, V58, P509, DOI 10.1146/annurev.ph.58.030196.002453; Ong LL, 1998, DEV BIOL, V193, P1, DOI 10.1006/dbio.1997.8775; Palmer A, 2002, MOL CELL, V9, P725, DOI 10.1016/S1097-2765(02)00488-4; Pekarik V, 2003, NAT BIOTECHNOL, V21, P93, DOI 10.1038/nbt770; Sedmera D, 2000, ANAT RECORD, V258, P319, DOI 10.1002/(SICI)1097-0185(20000401)258:4<319::AID-AR1>3.0.CO;2-O; Srivastava D, 2000, NATURE, V407, P221, DOI 10.1038/35025190; Sun XM, 2001, BLOOD, V97, P2008, DOI 10.1182/blood.V97.7.2008; Tani K, 2003, J BIOL CHEM, V278, P21685, DOI 10.1074/jbc.M301447200; Toyofuku T, 2004, GENE DEV, V18, P435, DOI 10.1101/gad.1167304; Wills Z, 1999, NEURON, V22, P301, DOI 10.1016/S0896-6273(00)81091-0; YUTZEY KE, 1995, CIRC RES, V77, P216, DOI 10.1161/01.RES.77.2.216	21	158	162	4	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2004	6	12					1204	1211		10.1038/ncb1193	http://dx.doi.org/10.1038/ncb1193			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	875WQ	15543137				2022-12-25	WOS:000225453300013
J	Ding, H; Wu, XL; Bostrom, H; Kim, I; Wong, N; Tsoi, B; O'Rourke, M; Koh, GY; Soriano, P; Betsholtz, C; Hart, TC; Marazita, ML; Field, LL; Tam, PPL; Nagy, A				Ding, H; Wu, XL; Bostrom, H; Kim, I; Wong, N; Tsoi, B; O'Rourke, M; Koh, GY; Soriano, P; Betsholtz, C; Hart, TC; Marazita, ML; Field, LL; Tam, PPL; Nagy, A			A specific requirement for PDGF-C in palate formation and PDGFR-alpha signaling	NATURE GENETICS			English	Article							CELL-CELL ADHESION; CLEFT-PALATE; KNOCKOUT MICE; BETA-RECEPTOR; EXPRESSION; ROLES; DEFICIENT; MUTATIONS; TISSUES; FUSION	PDGF-C is a member of the platelet-derived growth factor (PDGF) family, which signals through PDGF receptor (PDGFR) alphaalpha and alphabeta dimers(1,2). Here we show that Pdgfc(-/-) mice die in the perinatal period owing to feeding and respiratory difficulties associated with a complete cleft of the secondary palate. This phenotype was less severe than that of Pdgfra(-/-) embryos. Pdgfc(-/-) Pdgfa(-/-) embryos developed a cleft face, subepidermal blistering, deficiency of renal cortex mesenchyme, spina bifida and skeletal and vascular defects. Complete loss of function of both ligands, therefore, phenocopied the loss of PDGFR-alpha function, suggesting that both PDGF-A and PDGF-C signal through PDGFR-alpha to regulate the development of craniofacial structures, the neural tube and mesodermal organs. Our results also show that PDGF-C signaling is a new pathway in palatogenesis, different from, and independent of, those previously implicated.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Gothenburg Univ, Dept Biochem Med, S-41124 Gothenburg, Sweden; Korea Adv Inst Sci & Technol, Biomed Res Ctr, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Univ Sydney, Sydney, NSW 2006, Australia; Childrens Med Res Inst, Embryol Unit, Sydney, NSW, Australia; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Program Dev Biol, Seattle, WA 98104 USA; Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD USA; Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Ctr Craniofacial & Dent Genet, Pittsburgh, PA 15260 USA; Univ British Columbia, Dept Med Genet, Vancouver, BC V5Z 1M9, Canada; BC Res Inst Childrens & Womens Hlth, Vancouver, BC, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Gothenburg; Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST); University of Sydney; Children's Medical Research Institute - Australia; University of Sydney; Fred Hutchinson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of British Columbia; University of Toronto	Nagy, A (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	nagy@mshri.on.ca	Koh, Gou Young/C-1615-2011; Kim, Injune/C-1710-2011; Nagy, Andras/G-6465-2013; Ehrencrona, Hans/M-5619-2014; Ehrencrona, Hans/Q-4621-2019; Soriano, Philippe M/E-5797-2015	Kim, Injune/0000-0001-9244-815X; Nagy, Andras/0000-0003-4311-0413; Ehrencrona, Hans/0000-0002-5589-3622; Ehrencrona, Hans/0000-0002-5589-3622; Soriano, Philippe M/0000-0002-0427-926X	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [ZIADE000711, Z01DE000711] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aase K, 2002, MECH DEVELOP, V110, P187, DOI 10.1016/S0925-4773(01)00560-3; Betsholtz C, 2001, BIOESSAYS, V23, P494, DOI 10.1002/bies.1069; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; Ding H, 2000, MECH DEVELOP, V96, P209, DOI 10.1016/S0925-4773(00)00425-1; Ding H, 2001, CANCER RES, V61, P3826; Fruttiger M, 1999, DEVELOPMENT, V126, P457; Gertsenstein M, 2002, Methods Mol Biol, V185, P285; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; Hoch RV, 2003, DEVELOPMENT, V130, P4769, DOI 10.1242/dev.00721; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; Karlsson L, 2000, DEVELOPMENT, V127, P3457; Karlsson L, 1999, DEVELOPMENT, V126, P2611; Kondo S, 2002, NAT GENET, V32, P285, DOI 10.1038/ng985; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Marazita ML, 2002, AM J HUM GENET, V71, P349, DOI 10.1086/341944; Martinez-Alvarez C, 2000, DEV BIOL, V220, P343, DOI 10.1006/dbio.2000.9644; Murray JC, 2002, CLIN GENET, V61, P248, DOI 10.1034/j.1399-0004.2002.610402.x; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nagy A, 1998, CURR BIOL, V8, P661, DOI 10.1016/S0960-9822(98)70254-4; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; Raich WB, 1999, CURR BIOL, V9, P1139, DOI 10.1016/S0960-9822(00)80015-9; Schoonjans L, 2003, STEM CELLS, V21, P90, DOI 10.1634/stemcells.21-1-90; Soriano P, 1997, DEVELOPMENT, V124, P2691; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Suzuki K, 2000, NAT GENET, V25, P427, DOI 10.1038/78119; Tallquist MD, 2003, DEVELOPMENT, V130, P507, DOI 10.1242/dev.00241; Taya Y, 1999, DEVELOPMENT, V126, P3869; van den Boogaard MJH, 2000, NAT GENET, V24, P342, DOI 10.1038/74155; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7	30	167	173	1	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2004	36	10					1111	1116		10.1038/ng1415	http://dx.doi.org/10.1038/ng1415			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	857YN	15361870	Bronze			2022-12-25	WOS:000224156500021
J	Ferland, RJ; Eyaid, W; Collura, RV; Tully, LD; Hill, RS; Al-Nouri, D; Al-Rumayyan, A; Topcu, M; Gascon, G; Bodell, A; Shugart, YY; Ruvolo, M; Walsh, CA				Ferland, RJ; Eyaid, W; Collura, RV; Tully, LD; Hill, RS; Al-Nouri, D; Al-Rumayyan, A; Topcu, M; Gascon, G; Bodell, A; Shugart, YY; Ruvolo, M; Walsh, CA			Abnormal cerebellar development and axonal decussation due to mutations in AHI1 in Joubert syndrome	NATURE GENETICS			English	Article							EYE MOVEMENTS; VERMIS; LOCUS; RETARDATION; LIKELIHOOD; FAMILIES; FEATURES	Joubert syndrome is a congenital brain malformation of the cerebellar vermis and brainstem with abnormalities of axonal decussation (crossing in the brain) affecting the corticospinal tract and superior cerebellar peduncles(1-9). Individuals with Joubert syndrome have motor and behavioral abnormalities, including an inability to walk due to severe clumsiness and 'mirror' movements, and cognitive and behavioral disturbances(5-8,10-12). Here we identified a locus associated with Joubert syndrome, JBTS3, on chromosome 6q23.2-q23. 3 and found three deleterious mutations in AHI1, the first gene to be associated with Joubert syndrome. AHI1 is most highly expressed in brain, particularly in neurons that give rise to the crossing axons of the corticospinal tract and superior cerebellar peduncles. Comparative genetic analysis of AHI1 indicates that it has undergone positive evolutionary selection along the human lineage. Therefore, changes in AHI1 may have been important in the evolution of human-specific motor behaviors.	Harvard Univ, Sch Med, Div Neurogenet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Howard Hughes Med Inst,Dept Neurol, Boston, MA 02115 USA; King Fahad Natl Guard Hosp, Dept Pediat, Riyadh 11426, Saudi Arabia; Harvard Univ, Dept Anthropol, Cambridge, MA 02138 USA; King Fahad Natl Guard Hosp, Dept Neurol, Riyadh 11426, Saudi Arabia; Hacettepe Univ, Fac Med, Dept Pediat, Sect Child Neurol, TR-06100 Ankara, Turkey; King Faisal Specialist Hosp & Res Ctr, Dept Neurosci, Jeddah 21499, Saudi Arabia; Brown Univ, Sch Med, Providence, RI 02908 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; Harvard Univ, Sch Med, Program Biol & Biomed Sci, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Howard Hughes Medical Institute; King Saud Bin Abdulaziz University for Health Sciences; King Abdulaziz Medical City - Riyadh; Harvard University; King Saud Bin Abdulaziz University for Health Sciences; King Abdulaziz Medical City - Riyadh; Hacettepe University; King Faisal Specialist Hospital & Research Center; Brown University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Harvard University; Harvard Medical School	Walsh, CA (corresponding author), Harvard Univ, Sch Med, Div Neurogenet, NRB 266,77 Ave Louis Pasteur, Boston, MA 02115 USA.	cwalsh@bidmc.harvard.edu	Ferland, Russell/E-3500-2010; Ferland, Russell/Q-6793-2019	Ferland, Russell/0000-0002-8044-2479; YAO, YIN/0000-0003-3053-8429; Walsh, Christopher/0000-0002-0156-2238	NATIONAL INSTITUTE OF MENTAL HEALTH [K01MH071801] Funding Source: NIH RePORTER; NIMH NIH HHS [K01 MH071801, K01 MH071801-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Altman J, 2001, DEV HUMAN SPINAL COR; Blair IP, 2002, AM J MED GENET, V107, P190, DOI 10.1002/ajmg.10145; CANTANI A, 1990, ANN GENET-PARIS, V33, P96; Chance PF, 1999, J CHILD NEUROL, V14, P660, DOI 10.1177/088307389901401007; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Couch J, 2002, CURR BIOL, V12, pR741, DOI 10.1016/S0960-9822(02)01253-8; FRIEDE RL, 1978, DEV MED CHILD NEUROL, V20, P758; Jiang XY, 2002, J VIROL, V76, P9046, DOI 10.1128/JVI.76.18.9046-9059.2002; JOUBERT M, 1968, NEUROLOGY, V18, P302; JOUBERT M, 1969, NEUROLOGY, V19, P813, DOI 10.1212/WNL.19.9.813; Keeler LC, 2003, AM J HUM GENET, V73, P656, DOI 10.1086/378206; KENDALL B, 1990, NEURORADIOLOGY, V31, P502, DOI 10.1007/BF00340131; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lagier-Tourenne C, 2004, J MED GENET, V41, P273, DOI 10.1136/jmg.2003.014787; Maria BL, 1999, J CHILD NEUROL, V14, P583, DOI 10.1177/088307389901400906; Maria BL, 1999, J CHILD NEUROL, V14, P368, DOI 10.1177/088307389901400605; Maria BL, 1999, J CHILD NEUROL, V14, P590; Merritt Linda, 2003, Adv Neonatal Care, V3, P178, DOI 10.1016/S1536-0903(03)00137-1; Niesen Charles E, 2002, Semin Pediatr Neurol, V9, P320, DOI 10.1053/spen.2002.32508; Ozonoff S, 1999, J CHILD NEUROL, V14, P636, DOI 10.1177/088307389901401003; Quisling RG, 1999, J CHILD NEUROL, V14, P628, DOI 10.1177/088307389901401002; Saar K, 1999, AM J HUM GENET, V65, P1666, DOI 10.1086/302655; SARAIVA JM, 1992, AM J MED GENET, V43, P726, DOI 10.1002/ajmg.1320430415; Sobel E, 2001, HUM HERED, V52, P121, DOI 10.1159/000053366; Sobel E, 1996, AM J HUM GENET, V58, P1323; Valente EM, 2003, AM J HUM GENET, V73, P663, DOI 10.1086/378241; VANDORP DB, 1991, AM J MED GENET, V40, P100, DOI 10.1002/ajmg.1320400121; Watanabe H, 2004, NATURE, V429, P382, DOI 10.1038/nature02564; Yachnis AT, 1999, J CHILD NEUROL, V14, P655, DOI 10.1177/088307389901401006; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555; Yang ZH, 1998, MOL BIOL EVOL, V15, P568, DOI 10.1093/oxfordjournals.molbev.a025957	31	304	310	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2004	36	9					1008	1013		10.1038/ng1419	http://dx.doi.org/10.1038/ng1419			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	851AY	15322546	Bronze			2022-12-25	WOS:000223658100030
J	Williamson, CM; Ball, ST; Nottingham, WT; Skinner, JA; Plagge, A; Turner, MD; Powles, N; Hough, T; Papworth, D; Fraser, WD; Maconochie, M; Peters, J				Williamson, CM; Ball, ST; Nottingham, WT; Skinner, JA; Plagge, A; Turner, MD; Powles, N; Hough, T; Papworth, D; Fraser, WD; Maconochie, M; Peters, J			A cis-acting control region is required exclusively for the tissue-specific imprinting of Gnas	NATURE GENETICS			English	Article							GENE; ANTISENSE; CLUSTER; IDENTIFICATION; TRANSCRIPTS; METHYLATION; MUTATIONS; DELETION; MICE; NESP	Genomic imprinting brings about allele-specific silencing according to parental origin(1). Silencing is controlled by cis-acting regulatory regions that are differentially marked during gametogenesis and can act over hundreds of kilobases to silence many genes(2-6). Two candidate imprinting control regions (ICRs) have been identified at the compact imprinted Gnas cluster on distal mouse chromosome 2, one at exon 1A upstream of Gnas itself(7) and one covering the promoters for Gnasxl and the antisense Nespas (ref. 8). This imprinted cluster is complex, containing biallelic, maternally and paternally expressed transcripts that share exons(9). Gnas itself is mainly biallelically expressed but is weakly paternally repressed in specific tissues(10). Here we show that a paternally derived targeted deletion of the germline differentially methylated region at exon 1A abolishes tissue-specific imprinting of Gnas. This rescues the abnormal phenotype of mice with a maternally derived Gnas mutation(11,12). Imprinting of alternative transcripts, Nesp, Gnasxl and Nespas (ref. 13), in the cluster is unaffected. The results establish that the differentially methylated region at exon 1A contains an imprinting control element that specifically regulates Gnas and comprises a characterized ICR for a gene that is only weakly imprinted in a minority of tissues. There must be a second ICR regulating the alternative transcripts.	MRC, Mammalian Genet Unit, Didcot OX11 0RD, Oxon, England; Babraham Inst, Dev Genet Programme, Cambridge CB2 4AT, England; Univ Liverpool, Dept Clin Chem, Liverpool L69 3GA, Merseyside, England	MRC Harwell; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Liverpool	Peters, J (corresponding author), MRC, Mammalian Genet Unit, Didcot OX11 0RD, Oxon, England.	j.peters@har.mrc.ac.uk	Williamson, Christine/GSE-3696-2022; Plagge, Antonius/AAH-3877-2019; Turner, Martin/N-9976-2014	Plagge, Antonius/0000-0001-6592-1343; Turner, Martin/0000-0002-3801-9896				Bastepe M, 2003, J CLIN INVEST, V112, P1255, DOI 10.1172/JCI200319159; Bastepe M, 2001, AM J HUM GENET, V68, P1283, DOI 10.1086/320117; Bunting M, 1999, GENE DEV, V13, P1524, DOI 10.1101/gad.13.12.1524; Cattanach BM, 2000, HUM MOL GENET, V9, P2263, DOI 10.1093/oxfordjournals.hmg.a018917; CATTANACH BM, 1985, NATURE, V315, P496, DOI 10.1038/315496a0; CHANDRASEKARAN B, 1994, IEEE EXPERT, V9, P2, DOI 10.1109/64.363254; Coombes C, 2003, MOL CELL BIOL, V23, P5475, DOI 10.1128/MCB.23.16.5475-5488.2003; Fitzpatrick GV, 2002, NAT GENET, V32, P426, DOI 10.1038/ng988; Hayward BE, 2000, HUM MOL GENET, V9, P835, DOI 10.1093/hmg/9.5.835; Hayward BE, 1998, P NATL ACAD SCI USA, V95, P15475, DOI 10.1073/pnas.95.26.15475; Hayward BE, 1998, P NATL ACAD SCI USA, V95, P10038, DOI 10.1073/pnas.95.17.10038; Hough TA, 2002, MAMM GENOME, V13, P595, DOI 10.1007/s00335-002-2188-1; Ischia R, 1997, J BIOL CHEM, V272, P11657; KEHLENBACH RH, 1994, NATURE, V372, P804; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; Li T, 2000, GENOMICS, V69, P295, DOI 10.1006/geno.2000.6337; Lin SP, 2003, NAT GENET, V35, P97, DOI 10.1038/ng1233; Liu J, 2000, MOL CELL BIOL, V20, P5808, DOI 10.1128/MCB.20.16.5808-5817.2000; Liu J, 2000, J CLIN INVEST, V106, P1167, DOI 10.1172/JCI10431; Nicholls RD, 2001, ANNU REV GENOM HUM G, V2, P153, DOI 10.1146/annurev.genom.2.1.153; Peters J, 1999, P NATL ACAD SCI USA, V96, P3830, DOI 10.1073/pnas.96.7.3830; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; Skinner JA, 2002, GENOMICS, V80, P373, DOI 10.1006/geno.2002.6842; Spahn L, 2003, NAT GENET, V35, P11, DOI 10.1038/ng0903-11; Storck T, 1996, NUCLEIC ACIDS RES, V24, P4594, DOI 10.1093/nar/24.22.4594; Weinstein LS, 2001, ENDOCR REV, V22, P675, DOI 10.1210/er.22.5.675; Wroe SF, 2000, P NATL ACAD SCI USA, V97, P3342, DOI 10.1073/pnas.050015397; Yu SH, 1998, P NATL ACAD SCI USA, V95, P8715, DOI 10.1073/pnas.95.15.8715; Zwart R, 2001, GENE DEV, V15, P2361, DOI 10.1101/gad.206201	29	129	131	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2004	36	8					894	899		10.1038/ng1398	http://dx.doi.org/10.1038/ng1398			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	842AG	15273687				2022-12-25	WOS:000222974000025
J	Kaneider, NC; Agarwal, A; Leger, AJ; Kuliopulos, A				Kaneider, NC; Agarwal, A; Leger, AJ; Kuliopulos, A			Reversing systemic inflammatory response syndrome with chemokine receptor pepducins	NATURE MEDICINE			English	Article							INTERLEUKIN-8; ACTIVATION; CXCR2; NEUTROPHIL; SEPSIS; PLASMA; COAGULATION; INHIBITION; STRATEGIES; INFECTION	We describe a new therapeutic approach for the treatment of lethal sepsis using cell-penetrating lipopeptides - termed pepducins - that target either individual or multiple chemokine receptors. Interleukin-8 (IL-8), a ligand for the CXCR1 and CXCR2 receptors, is the most potent endogenous proinflammatory chemokine in sepsis. IL-8 levels rise in blood and lung fluids to activate neutrophils and other cells, and correlate with shock, lung injury and high mortality(1-5). We show that pepducins derived from either the i1 or i3 intracellular loops of CXCR1 and CXCR2 prevent the IL-8 response of both receptors and reverse the lethal sequelae of sepsis, including disseminated intravascular coagulation and multi-organ failure in mice. Conversely, pepducins selective for CXCR4 cause a massive leukocytosis that does not affect survival. CXCR1 and CXCR2 pepducins conferred nearly 100% survival even when treatment was postponed, suggesting that our approach might be beneficial in the setting of advanced disease.	Tufts Univ, New England Med Ctr, Sch Med, Mol Oncol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts University; Tufts University	Kuliopulos, A (corresponding author), Tufts Univ, New England Med Ctr, Sch Med, Mol Oncol Res Inst, 750 Washington St, Boston, MA 02111 USA.	athan.kuliopulos@tufts.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064701] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 64701] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen CDC, 2004, NAT IMMUNOL, V5, P943, DOI 10.1038/ni1100; Bertini R, 2004, P NATL ACAD SCI USA, V101, P11791, DOI 10.1073/pnas.0402090101; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; Bone RC, 1996, CRIT CARE MED, V24, P163, DOI 10.1097/00003246-199601000-00026; Bonecchi R, 2000, J IMMUNOL, V164, P3862, DOI 10.4049/jimmunol.164.7.3862; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; Covic L, 2000, BIOCHEMISTRY-US, V39, P5458, DOI 10.1021/bi9927078; Covic L, 2002, P NATL ACAD SCI USA, V99, P643, DOI 10.1073/pnas.022460899; Covic L, 2002, NAT MED, V8, P1161, DOI 10.1038/nm760; Darash-Yahana M, 2004, FASEB J, V18, P1240, DOI 10.1096/fj.03-0935fje; DINARELLO CA, 1993, JAMA-J AM MED ASSOC, V269, P1829, DOI 10.1001/jama.269.14.1829; ENDO S, 1995, J INFLAMM, V45, P136; FRIEDLAND JS, 1992, INFECT IMMUN, V60, P2402, DOI 10.1128/IAI.60.6.2402-2408.1992; Gando S, 2002, THROMB HAEMOSTASIS, V88, P943, DOI 10.1055/s-0037-1613338; HACK CE, 1992, INFECT IMMUN, V60, P2835, DOI 10.1128/IAI.60.7.2835-2842.1992; KULIOPULOS A, 1994, J AM CHEM SOC, V116, P4599, DOI 10.1021/ja00090a008; Levi M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807; Lomas-Neira JL, 2004, J LEUKOCYTE BIOL, V76, P58, DOI 10.1189/jlb.1103541; Martin C, 2003, IMMUNITY, V19, P583, DOI 10.1016/S1074-7613(03)00263-2; Matsukawa A, 2000, Rev Immunogenet, V2, P339; MILLER EJ, 1992, AM REV RESPIR DIS, V146, P427, DOI 10.1164/ajrccm/146.2.427; Ness TL, 2003, J IMMUNOL, V171, P3775, DOI 10.4049/jimmunol.171.7.3775; NICHOLS RL, 1984, NEW ENGL J MED, V311, P1065, DOI 10.1056/NEJM198410253111701; REDL H, 1991, J INFECT DIS, V164, P383, DOI 10.1093/infdis/164.2.383; Riedemann NC, 2003, NAT MED, V9, P517, DOI 10.1038/nm0503-517; Skelton NJ, 1999, STRUCTURE, V7, P157, DOI 10.1016/S0969-2126(99)80022-7; Suratt BT, 2004, BLOOD, V104, P565, DOI 10.1182/blood-2003-10-3638; Taub Dennis D., 1996, Cytokine and Growth Factor Reviews, V7, P355, DOI 10.1016/S1359-6101(97)89237-4; Wheeler AP, 1999, NEW ENGL J MED, V340, P207, DOI 10.1056/NEJM199901213400307; WIEDERMANN CJ, 1992, J CLIN INVEST, V89, P1580, DOI 10.1172/JCI115752	30	101	109	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2005	11	6					661	665		10.1038/nm1245	http://dx.doi.org/10.1038/nm1245			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	932YD	15880119				2022-12-25	WOS:000229589800033
J	Krutzik, SR; Tan, B; Li, HY; Ochoa, MT; Liu, PT; Sharfstein, SE; Graeber, TG; Sieling, PA; Liu, YJ; Rea, TH; Bloom, BR; Modlin, RL				Krutzik, SR; Tan, B; Li, HY; Ochoa, MT; Liu, PT; Sharfstein, SE; Graeber, TG; Sieling, PA; Liu, YJ; Rea, TH; Bloom, BR; Modlin, RL			TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells	NATURE MEDICINE			English	Article							TOLL-LIKE RECEPTORS; LECTIN DC-SIGN; T-CELLS; CUTTING EDGE; ANTIMICROBIAL ACTIVITY; INDUCED EXPRESSION; HOST-DEFENSE; ANTIGEN; CD209; GENE	Leprosy enables investigation of mechanisms by which the innate immune system contributes to host defense against infection, because in one form, the disease progresses, and in the other, the infection is limited. We report that Toll-like receptor (TLR) activation of human monocytes induces rapid differentiation into two distinct subsets: DC-SIGN(+)CD16(+) macrophages and CD1b(+) DC-SIGN(-) dendritic cells. DC-SIGN(+) phagocytic macrophages were expanded by TLR-mediated upregulation of interleukin ( IL)-15 and IL-15 receptor. CD1b(+) dendritic cells were expanded by TLR-mediated upregulation of granulocyte-macrophage colony-stimulating factor (GM-CSF) and its receptor, promoted T cell activation and secreted proinflammatory cytokines. Whereas DC-SIGN(+) macrophages were detected in lesions and after TLR activation in all leprosy patients, CD1b(+) dendritic cells were not detected in lesions or after TLR activation of peripheral monocytes in individuals with the progressive lepromatous form, except during reversal reactions in which bacilli were cleared by T helper type 1 ( T(H)1) responses. In tuberculoid lepromatous lesions, DC-SIGN(+) cells were positive for macrophage markers, but negative for dendritic cell markers. Thus, TLR-induced differentiation of monocytes into either macrophages or dendritic cells seems to crucially influence effective host defenses in human infectious disease.	Univ Calif Los Angeles, Div Dermatol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Microbiol & Immunol, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Energy, Inst Genom & Proteom, Los Angeles, CA 90095 USA; Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Ctr Canc Immunol Res, Houston, TX 77030 USA; Univ So Calif, Sch Med, Dermatol Sect, Los Angeles, CA 90033 USA; Harvard Univ, Sch Publ Hlth, Off Dean, Boston, MA 02115 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Southern California; Harvard University; Harvard T.H. Chan School of Public Health	Modlin, RL (corresponding author), Univ Calif Los Angeles, Div Dermatol, 611 Charles Young Dr E,536 Boyer Hall, Los Angeles, CA 90095 USA.	rmodlin@mednet.ucla.edu	Modlin, Robert L/M-7941-2014; Liu, Philip/C-9638-2011; Liu, Philip/C-2524-2009	Modlin, Robert L/0000-0003-4720-031X; Liu, Philip/0000-0002-6144-0304; Ochoa, Maria T/0000-0001-6550-5008; Graeber, Thomas/0000-0001-8574-9181	NIAID NIH HHS [R01 AI022553, AI 07126, R37 AI047868, AI 47866, R01 AI047866, AI 22553, T32 AI007126, N01 AI 75320] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI022553, R01AI022553, R01AI047866, N01AI075320, R37AI047868] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexopoulou L, 2002, NAT MED, V8, P878, DOI 10.1038/nm732; Appelmelk BJ, 2003, J IMMUNOL, V170, P1635, DOI 10.4049/jimmunol.170.4.1635; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; Blander JM, 2004, SCIENCE, V304, P1014, DOI 10.1126/science.1096158; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Cambi A, 2003, EUR J IMMUNOL, V33, P532, DOI 10.1002/immu.200310029; Chehimi J, 2003, J LEUKOCYTE BIOL, V74, P757, DOI 10.1189/jlb.0503231; Colmenares M, 2002, J BIOL CHEM, V277, P36766, DOI 10.1074/jbc.M205270200; Doyle SE, 2004, J EXP MED, V199, P81, DOI 10.1084/jem.20031237; Engering A, 2002, J IMMUNOL, V168, P2118, DOI 10.4049/jimmunol.168.5.2118; Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Giordano D, 2003, J IMMUNOL, V171, P6421, DOI 10.4049/jimmunol.171.12.6421; Graeber TG, 2001, NAT GENET, V29, P295, DOI 10.1038/ng755; Hertz CJ, 2001, J IMMUNOL, V166, P2444, DOI 10.4049/jimmunol.166.4.2444; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Judge AD, 2002, J EXP MED, V196, P935, DOI 10.1084/jem.20020772; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Kim J, 1997, J IMMUNOL, V159, P335; Krutzik SR, 2003, NAT MED, V9, P525, DOI 10.1038/nm864; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Moody DB, 1997, SCIENCE, V278, P283, DOI 10.1126/science.278.5336.283; OBRIEN AD, 1980, J IMMUNOL, V124, P20; Ochoa MT, 2001, NAT MED, V7, P174, DOI 10.1038/84620; Porcelli SA, 1999, ANNU REV IMMUNOL, V17, P297, DOI 10.1146/annurev.immunol.17.1.297; Pulendran B, 2004, EUR J IMMUNOL, V34, P66, DOI 10.1002/eji.200324567; Relloso M, 2002, J IMMUNOL, V168, P2634, DOI 10.4049/jimmunol.168.6.2634; Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; Schluns KS, 2002, J IMMUNOL, V168, P4827, DOI 10.4049/jimmunol.168.10.4827; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; Soilleux EJ, 2002, J LEUKOCYTE BIOL, V71, P445; Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121; Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; van Lent PLEM, 2003, ARTHRITIS RHEUM, V48, P360, DOI 10.1002/art.10786; WEMAMBU SNC, 1969, LANCET, V2, P933; YAMAMURA M, 1992, J IMMUNOL, V149, P1470; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582	43	309	328	1	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2005	11	6					653	660		10.1038/nm1246	http://dx.doi.org/10.1038/nm1246			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	932YD	15880118	Green Accepted			2022-12-25	WOS:000229589800032
J	Elshamy, WM; Livingston, DM				Elshamy, WM; Livingston, DM			Promoter usage of BRCA1-IRIS - Reply	NATURE CELL BIOLOGY			English	Letter									Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute	Elshamy, WM (corresponding author), Dana Farber Canc Inst, 44 Binney St,SM870, Boston, MA 02115 USA.	wael_elshamy@dfci.harvard.edu; david_livingston@dfci.harvard.edu	ElShamy, Wael M./L-1090-2018; ElShamy, Wael/AAF-2867-2019					ElShamy WM, 2004, NAT CELL BIOL, V6, P954, DOI 10.1038/ncb1171	1	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2005	7	4					326	326		10.1038/ncb0405-326a	http://dx.doi.org/10.1038/ncb0405-326a			1	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	912KA	15803127	Bronze			2022-12-25	WOS:000228075500003
J	Judge, AD; Sood, V; Shaw, JR; Fang, D; McClintock, K; MacLachlan, I				Judge, AD; Sood, V; Shaw, JR; Fang, D; McClintock, K; MacLachlan, I			Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA	NATURE BIOTECHNOLOGY			English	Article							TOLL-LIKE RECEPTOR-7; PLASMACYTOID DENDRITIC CELLS; HUMAN PERIPHERAL-BLOOD; STRANDED-RNA; INTERFERING RNAS; BACTERIAL-DNA; CPG MOTIFS; ACTIVATION; GENE; EXPRESSION	Short interfering RNAs (siRNAs) that mediate specific gene silencing through RNA interference (RNAi) are widely used to study gene function and are also being developed for therapeutic applications(1). Many nucleic acids, including double- (dsRNA)(2) and single-stranded RNA (ssRNA)(3-5), can stimulate innate cytokine responses in mammals. Despite this, few studies have questioned whether siRNA may have a similar effect on the immune system(6,7). This could significantly influence the in vivo application of siRNA owing to off-target effects and toxicities associated with immune stimulation. Here we report that synthetic siRNAs formulated in nonviral delivery vehicles can be potent inducers of interferons and inflammatory cytokines both in vivo in mice and in vitro in human blood. The immunostimulatory activity of formulated siRNAs and the associated toxicities are dependent on the nucleotide sequence. We have identified putative immunostimulatory motifs that have allowed the design of siRNAs that can mediate RNAi but induce minimal immune activation.	Protiva Biotherapeut, Burnaby, BC V5G 4Y1, Canada		MacLachlan, I (corresponding author), Protiva Biotherapeut, 100-3480 Gilmore Way, Burnaby, BC V5G 4Y1, Canada.	ian@protivabio.com						Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Asselin-Paturel C, 2003, J IMMUNOL, V171, P6466, DOI 10.4049/jimmunol.171.12.6466; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Dorsett Y, 2004, NAT REV DRUG DISCOV, V3, P318, DOI 10.1038/nrd1345; Dzionek A, 2000, J IMMUNOL, V165, P6037, DOI 10.4049/jimmunol.165.11.6037; Fu SW, 2003, BREAST CANCER RES, V5, pR82, DOI 10.1186/bcr602; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Heidel JD, 2004, NAT BIOTECHNOL, V22, P1579, DOI 10.1038/nbt1038; Heil F, 2003, EUR J IMMUNOL, V33, P2987, DOI 10.1002/eji.200324238; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hornung V, 2004, J IMMUNOL, V173, P5935, DOI 10.4049/jimmunol.173.10.5935; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Jeffs LB, 2005, PHARM RES-DORDR, V22, P362, DOI 10.1007/s11095-004-1873-z; Jego G, 2003, IMMUNITY, V19, P225, DOI 10.1016/S1074-7613(03)00208-5; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545; Kim DH, 2004, NAT BIOTECHNOL, V22, P321, DOI 10.1038/nbt940; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Saunders LR, 2003, FASEB J, V17, P961, DOI 10.1096/fj.02-0958rev; Sioud M, 2003, BIOCHEM BIOPH RES CO, V312, P1220, DOI 10.1016/j.bbrc.2003.11.057; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Weber SM, 2000, J IMMUNOL, V165, P1534, DOI 10.4049/jimmunol.165.3.1534; Yi AK, 1998, J IMMUNOL, V160, P4755	29	928	1034	8	96	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2005	23	4					457	462		10.1038/nbt1081	http://dx.doi.org/10.1038/nbt1081			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	914AR	15778705				2022-12-25	WOS:000228197300029
J	Schubert, C				Schubert, C			Gene variant thickens arteries	NATURE MEDICINE			English	News Item								Loss-of-function polymorphism in the gene encoding for tissue kallikrein has been found to cause narrowing of the arterial lumen.										Azizi M, 2005, J CLIN INVEST, V115, P780, DOI 10.1172/JCI200523669	1	0	0	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2005	11	4					385	385						1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15812519				2022-12-25	WOS:000228180500028
J	Ravichandran, V; Sriram, RD				Ravichandran, V; Sriram, RD			Toward data standards for proteomics	NATURE BIOTECHNOLOGY			English	Editorial Material									NIST, Mfg Metrol & Stand Hlth Care Enterprise Program, Mfg Syst Integrat Div, Gaithersburg, MD 20899 USA	National Institute of Standards & Technology (NIST) - USA	Ravichandran, V (corresponding author), NIST, Mfg Metrol & Stand Hlth Care Enterprise Program, Mfg Syst Integrat Div, 100 Bur Dr, Gaithersburg, MD 20899 USA.	vravi@cme.nist.gov						Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Ball CA, 2004, NAT BIOTECHNOL, V22, P1179, DOI 10.1038/nbt0904-1179; BERMAN JJ, 2003, BMC MED INFORM DECIS, V3, P1; Carr S, 2004, MOL CELL PROTEOMICS, V3, P531, DOI 10.1074/mcp.T400006-MCP200; CHUTE CG, 1998, AMIA ANN S P, P68; Galperin MY, 2004, NUCLEIC ACIDS RES, V32, pD3, DOI 10.1093/nar/gkh143; Hermjakob H, 2004, NAT BIOTECHNOL, V22, P177, DOI 10.1038/nbt926; LYMAN JA, 2003, AMIA ANN S P, V920; Ouzounis CA, 2003, NAT REV GENET, V4, P508, DOI 10.1038/nrg1113; Ravichandran V, 2004, ELECTROPHORESIS, V25, P297, DOI 10.1002/elps.200305748; Tyers M, 2003, NATURE, V422, P193, DOI 10.1038/nature01510; Verma M, 2003, NAT REV CANCER, V3, P789, DOI 10.1038/nrc1192; Westbrook JD, 2000, BIOINFORMATICS, V16, P159, DOI 10.1093/bioinformatics/16.2.159	13	8	11	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2005	23	3					373	376		10.1038/nbt0305-373	http://dx.doi.org/10.1038/nbt0305-373			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	906IW	15765093				2022-12-25	WOS:000227635400029
J	Larsson, P; Oyston, PCF; Chain, P; Chu, MC; Duffield, M; Fuxelius, HH; Garcia, E; Halltorp, G; Johansson, D; Isherwood, KE; Karp, PD; Larsson, E; Liu, Y; Michell, S; Prior, J; Prior, R; Malfatti, S; Sjostedt, A; Svensson, K; Thompson, N; Vergez, L; Wagg, JK; Wren, BW; Lindler, LE; Andersson, SGE; Forsman, M; Titball, RW				Larsson, P; Oyston, PCF; Chain, P; Chu, MC; Duffield, M; Fuxelius, HH; Garcia, E; Halltorp, G; Johansson, D; Isherwood, KE; Karp, PD; Larsson, E; Liu, Y; Michell, S; Prior, J; Prior, R; Malfatti, S; Sjostedt, A; Svensson, K; Thompson, N; Vergez, L; Wagg, JK; Wren, BW; Lindler, LE; Andersson, SGE; Forsman, M; Titball, RW			The complete genome sequence of Francisella tularensis, the causative agent of tularemia	NATURE GENETICS			English	Article							INTRACELLULAR INFECTION; METABOLIC PATHWAYS; GROWTH INITIATION; VIRULENCE FACTORS; GENE; IDENTIFICATION; ESCAPE; IRON; TRANSCRIPTION; PHAGOSOME	Francisella tularensis is one of the most infectious human pathogens known. In the past, both the former Soviet Union and the US had programs to develop weapons containing the bacterium. We report the complete genome sequence of a highly virulent isolate of F. tularensis (1,892, 819 bp). The sequence uncovers previously uncharacterized genes encoding type IV pili, a surface polysaccharide and iron-acquisition systems. Several virulence-associated genes were located in a putative pathogenicity island, which was duplicated in the genome. More than 10% of the putative coding sequences contained insertion-deletion or substitution mutations and seemed to be deteriorating. The genome is rich in IS elements, including IS630 Tc-1 mariner family transposons, which are not expected in a prokaryote. We used a computational method for predicting metabolic pathways and found an unexpectedly high proportion of disrupted pathways, explaining the fastidious nutritional requirements of the bacterium. The loss of biosynthetic pathways indicates that F. tularensis is an obligate host-dependent bacterium in its natural life cycle. Our results have implications for our understanding of how highly virulent human pathogens evolve and will expedite strategies to combat them.	Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, Livermore, CA 94550 USA; Def Sci & Technol Lab, Salisbury SP4 0JQ, Wilts, England; Swedish Def Res Agcy, SE-90182 Umea, Sweden; Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Ft Collins, CO USA; Uppsala Univ, Dept Mol Evolut, S-75236 Uppsala, Sweden; SRI Int, Bioinformat Res Grp, Menlo Pk, CA 94025 USA; Walter Reed Army Inst Res, Silver Spring, MD 20910 USA; Umea Univ, Dept Clin Microbiol, SE-90185 Umea, Sweden; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Defence Science & Technology Laboratory; Saab Group; Centers for Disease Control & Prevention - USA; Uppsala University; SRI International; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Umea University; Wellcome Trust Sanger Institute; University of London; London School of Hygiene & Tropical Medicine	Titball, RW (corresponding author), Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, Livermore, CA 94550 USA.	rtitball@dstl.gov.uk	Forsman, Mats/A-1426-2016; Chain, Patrick/O-4140-2019; chain, patrick/B-9777-2013; Sjöstedt, Anders/AAC-6575-2020; Karp, Peter/C-3514-2012	Forsman, Mats/0000-0002-4466-5325; Chain, Patrick/0000-0003-3949-3634; Sjöstedt, Anders/0000-0002-0768-8405; Karp, Peter/0000-0002-5876-6418; Malfatti, Stephanie/0000-0003-4225-9857				Andersson B, 1996, ANAL BIOCHEM, V236, P107, DOI 10.1006/abio.1996.0138; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; ARRUDA S, 1993, SCIENCE, V261, P1454, DOI 10.1126/science.8367727; BHATNAGAR NB, 1995, INFECT IMMUN, V63, P154, DOI 10.1128/IAI.63.1.154-159.1995; BORK P, 1994, PROTEIN SCI, V3, P1344, DOI 10.1002/pro.5560030821; Canback B, 2004, MOL BIOL EVOL, V21, P1110, DOI 10.1093/molbev/msh122; CHAMBERL.RE, 1965, APPL MICROBIOL, V13, P232, DOI 10.1128/AEM.13.2.232-235.1965; CIANCIOTTO NP, 1990, J INFECT DIS, V162, P121, DOI 10.1093/infdis/162.1.121; Clemens DL, 2004, INFECT IMMUN, V72, P3204, DOI 10.1128/IAI.72.6.3204-3217.2004; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Delcher AL, 1999, NUCLEIC ACIDS RES, V27, P4636, DOI 10.1093/nar/27.23.4636; Dennis DT, 2001, JAMA-J AM MED ASSOC, V285, P2763, DOI 10.1001/jama.285.21.2763; DOAK TG, 1994, P NATL ACAD SCI USA, V91, P942, DOI 10.1073/pnas.91.3.942; Eddy SR, 1998, BIOINFORMATICS, V14, P755, DOI 10.1093/bioinformatics/14.9.755; EIGELSBACH HT, 1951, J BACTERIOL, V61, P557, DOI 10.1128/JB.61.5.557-569.1951; Ellis J, 2002, CLIN MICROBIOL REV, V15, P631, DOI 10.1128/CMR.15.4.631-646.2002; Enright AJ, 2003, NUCLEIC ACIDS RES, V31, P4632, DOI 10.1093/nar/gkg495; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; FLEMING DE, 1955, J BACTERIOL, V70, P345, DOI 10.1128/JB.70.3.345-349.1955; FORSMAN M, 1994, INT J SYST BACTERIOL, V44, P38, DOI 10.1099/00207713-44-1-38; FORTIER AH, 1995, INFECT IMMUN, V63, P1478, DOI 10.1128/IAI.63.4.1478-1483.1995; Gil H, 2004, INFECT IMMUN, V72, P3042, DOI 10.1128/IAI.72.5.3042-3047.2004; Golovliov I, 2003, FEMS MICROBIOL LETT, V222, P273, DOI 10.1016/S0378-1097(03)00313-6; Golovliov I, 2003, INFECT IMMUN, V71, P5940, DOI 10.1128/IAI.71.10.5940-5950.2003; GORDON AH, 1980, NATURE, V286, P79, DOI 10.1038/286079a0; Green ML, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-76; HALMANN M, 1967, J GEN MICROBIOL, V49, P461, DOI 10.1099/00221287-49-3-461; Hickey EK, 1997, INFECT IMMUN, V65, P133, DOI 10.1128/IAI.65.1.133-143.1997; HOOD AM, 1977, J HYG-CAMBRIDGE, V79, P47, DOI 10.1017/S0022172400052840; Houng HSH, 1998, MICROB PATHOGENESIS, V25, P165, DOI 10.1006/mpat.1998.0222; Krieger CJ, 2004, NUCLEIC ACIDS RES, V32, pD438, DOI 10.1093/nar/gkh100; Lauriano CM, 2004, P NATL ACAD SCI USA, V101, P4246, DOI 10.1073/pnas.0307690101; Lindgren H, 2004, J MED MICROBIOL, V53, P953, DOI 10.1099/jmm.0.45685-0; MAGER J, 1964, NATURE, V203, P898, DOI 10.1038/203898a0; MAGER J, 1959, BIOCHIM BIOPHYS ACTA, V36, P529, DOI 10.1016/0006-3002(59)90195-7; Mahillon J, 1998, MICROBIOL MOL BIOL R, V62, P725, DOI 10.1128/MMBR.62.3.725-774.1998; NAGLE SC, 1960, J BACTERIOL, V79, P566, DOI 10.1128/JB.79.4.566-571.1960; Nano FE, 2004, J BACTERIOL, V186, P6430, DOI 10.1128/JB.186.19.6430-6436.2004; Osterman A, 2003, CURR OPIN CHEM BIOL, V7, P238, DOI 10.1016/S1367-5931(03)00027-9; Paley SM, 2002, BIOINFORMATICS, V18, P715, DOI 10.1093/bioinformatics/18.5.715; Parkhill J, 2001, NATURE, V413, P523, DOI 10.1038/35097083; Reed JL, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r54; Romero PR, 2004, BIOINFORMATICS, V20, P709, DOI 10.1093/bioinformatics/btg471; Russell P, 1998, J ANTIMICROB CHEMOTH, V41, P461, DOI 10.1093/jac/41.4.461; Seshadri R, 2003, P NATL ACAD SCI USA, V100, P5455, DOI 10.1073/pnas.0931379100; Sjostedt A, 2004, BERGEYS MANUAL SYSTE, P200; Telepnev M, 2003, CELL MICROBIOL, V5, P41, DOI 10.1046/j.1462-5822.2003.00251.x; Thomas R, 2003, J CLIN MICROBIOL, V41, P50, DOI 10.1128/JCM.41.1.50-57.2003; TRAUB A, 1955, J BACTERIOL, V70, P60, DOI 10.1128/JB.70.1.60-69.1955; Viswanathan VK, 2000, INFECT IMMUN, V68, P1069, DOI 10.1128/IAI.68.3.1069-1079.2000	50	364	679	2	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2005	37	2					153	159		10.1038/ng1499	http://dx.doi.org/10.1038/ng1499			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	893AB	15640799	Bronze			2022-12-25	WOS:000226690100021
J	Stefansson, H; Helgason, A; Thorleifsson, G; Steinthorsdottir, V; Masson, G; Barnard, J; Baker, A; Jonasdottir, A; Ingason, A; Gudnadottir, VG; Desnica, N; Hicks, A; Gylfason, A; Gudbjartsson, DF; Jonsdottir, GM; Sainz, J; Agnarsson, K; Birgisdottir, B; Ghosh, S; Olafsdottir, A; Cazier, JB; Kristjansson, K; Frigge, ML; Thorgeirsson, TE; Gulcher, JR; Kong, A; Stefansson, K				Stefansson, H; Helgason, A; Thorleifsson, G; Steinthorsdottir, V; Masson, G; Barnard, J; Baker, A; Jonasdottir, A; Ingason, A; Gudnadottir, VG; Desnica, N; Hicks, A; Gylfason, A; Gudbjartsson, DF; Jonsdottir, GM; Sainz, J; Agnarsson, K; Birgisdottir, B; Ghosh, S; Olafsdottir, A; Cazier, JB; Kristjansson, K; Frigge, ML; Thorgeirsson, TE; Gulcher, JR; Kong, A; Stefansson, K			A common inversion under selection in Europeans	NATURE GENETICS			English	Article							LINKAGE DISEQUILIBRIUM; HUMAN GENOME; NUCLEOTIDE VARIABILITY; POSITIVE SELECTION; TAU HAPLOTYPE; GENE; POPULATION; POLYMORPHISMS; EVOLUTION; ASSOCIATION	A refined physical map of chromosome 17q21.31 uncovered a 900-kb inversion polymorphism. Chromosomes with the inverted segment in different orientations represent two distinct lineages, H1 and H2, that have diverged for as much as 3 million years and show no evidence of having recombined. The H2 lineage is rare in Africans, almost absent in East Asians but found at a frequency of 20% in Europeans, in whom the haplotype structure is indicative of a history of positive selection. Here we show that the H2 lineage is undergoing positive selection in the Icelandic population, such that carrier females have more children and have higher recombination rates than noncarriers.	deCODE Genet, IS-101 Reykjavik, Iceland; Cleveland Clin Fdn, Dept Biostat & Epidemiol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stefansson, H (corresponding author), deCODE Genet, Sturlugata 8, IS-101 Reykjavik, Iceland.	kari.stefansson@decode.is; kong@decode.is	Hicks, Andrew Anthony/E-9518-2017; Stefansson, Kari/AAE-7187-2019; Cazier, Jean-Baptiste/GLR-2949-2022; Helgason, Agnar/K-1522-2015; Cazier, Jean-Baptiste/F-2369-2010	Hicks, Andrew Anthony/0000-0001-6320-0411; Cazier, Jean-Baptiste/0000-0001-7581-9051; Cazier, Jean-Baptiste/0000-0001-7581-9051; Gudbjartsson, Daniel/0000-0002-5222-9857; Thorgeirsson, Thorgeir/0000-0002-5149-7040; Kong, Augustine/0000-0001-8193-5438; Stefansson, Hreinn/0000-0002-9331-6666; Helgason, Agnar/0000-0002-8545-3767; Steinthorsdottir, Valgerdur/0000-0003-1846-6274				Akey JM, 2004, PLOS BIOL, V2, P1591, DOI 10.1371/journal.pbio.0020286; Andolfatto P, 2001, GENET RES, V77, P1, DOI 10.1017/S0016672301004955; Baker M, 1999, HUM MOL GENET, V8, P711, DOI 10.1093/hmg/8.4.711; Bamshad M, 2003, NAT REV GENET, V4, P99, DOI 10.1038/nrg999; Bandelt HJ, 1999, MOL BIOL EVOL, V16, P37, DOI 10.1093/oxfordjournals.molbev.a026036; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; Brown P, 2004, NATURE, V431, P1055, DOI 10.1038/nature02999; Carroll SB, 2003, NATURE, V422, P849, DOI 10.1038/nature01495; Chen FC, 2001, AM J HUM GENET, V68, P444, DOI 10.1086/318206; Conrad C, 2004, J NEUROCHEM, V89, P179, DOI 10.1046/j.1471-4159.2004.02320.x; Conrad C, 1997, ANN NEUROL, V41, P277, DOI 10.1002/ana.410410222; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; Evans W, 2004, NEUROSCI LETT, V369, P183, DOI 10.1016/j.neulet.2004.05.119; Excoffier L, 2002, CURR OPIN GENET DEV, V12, P675, DOI 10.1016/S0959-437X(02)00350-7; Farrer M, 2002, NEUROSCI LETT, V322, P83, DOI 10.1016/S0304-3940(02)00106-4; Foster MW, 2004, NAT REV GENET, V5, P467, DOI 10.1038/nrg1351; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Giglio S, 2001, AM J HUM GENET, V68, P874, DOI 10.1086/319506; Gilad Y, 2002, P NATL ACAD SCI USA, V99, P862, DOI 10.1073/pnas.022614799; Gretarsdottir S, 2003, NAT GENET, V35, P131, DOI 10.1038/ng1245; Gulcher JR, 2000, EUR J HUM GENET, V8, P739, DOI 10.1038/sj.ejhg.5200530; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Jin H, 2004, GENOMICS, V84, P1071, DOI 10.1016/j.ygeno.2004.08.019; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Kong A, 2004, NAT GENET, V36, P1203, DOI 10.1038/ng1445; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Kwok JBJ, 2004, ANN NEUROL, V55, P329, DOI 10.1002/ana.10826; Laval G, 2004, BIOINFORMATICS, V20, P2485, DOI 10.1093/bioinformatics/bth264; Lewin R, 2004, PRINCIPLES HUMAN EVO; Nachman MW, 2000, GENETICS, V155, P1855; Navarro A, 2000, GENETICS, V155, P685; Oliveira SA, 2004, NEUROGENETICS, V5, P147, DOI 10.1007/s10048-004-0180-5; Osier MV, 2002, AM J PHYS ANTHROPOL, V119, P77, DOI 10.1002/ajpa.10094; Pittman AM, 2004, HUM MOL GENET, V13, P1267, DOI 10.1093/hmg/ddh138; Reed DL, 2004, PLOS BIOL, V2, P1972, DOI 10.1371/journal.pbio.0020340; Sabeti PC, 2002, NATURE, V419, P832, DOI 10.1038/nature01140; Schaeffer SW, 2003, P NATL ACAD SCI USA, V100, P8319, DOI 10.1073/pnas.1432900100; Schwartz S, 2003, GENOME RES, V13, P103, DOI 10.1101/gr.809403; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Shaw CJ, 2004, HUM MOL GENET, V13, pR57, DOI 10.1093/hmg/ddh073; Skipper L, 2004, AM J HUM GENET, V75, P669, DOI 10.1086/424492; Slatkin M, 2001, GENETICS, V158, P865; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Thompson EE, 2004, AM J HUM GENET, V75, P1059, DOI 10.1086/426406; Toomajian C, 2003, GENETICS, V165, P287	45	581	597	0	47	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2005	37	2					129	137		10.1038/ng1508	http://dx.doi.org/10.1038/ng1508			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	893AB	15654335				2022-12-25	WOS:000226690100018
J	Gerull, B; Heuser, A; Wichter, T; Paul, M; Basson, CT; McDermott, DA; Lerman, BB; Markowitz, SM; Ellinor, PT; MacRae, CA; Peters, S; Grossmann, KS; Michely, B; Sasse-Klaassen, S; Birchmeier, W; Dietz, R; Breithardt, G; Schulze-Bahr, E; Thierfelder, L				Gerull, B; Heuser, A; Wichter, T; Paul, M; Basson, CT; McDermott, DA; Lerman, BB; Markowitz, SM; Ellinor, PT; MacRae, CA; Peters, S; Grossmann, KS; Michely, B; Sasse-Klaassen, S; Birchmeier, W; Dietz, R; Breithardt, G; Schulze-Bahr, E; Thierfelder, L			Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy	NATURE GENETICS			English	Article							DYSPLASIA	Arrhythmogenic right ventricular cardiomyopathy (ARVC) is associated with fibrofatty replacement of cardiac myocytes, ventricular tachyarrhythmias and sudden cardiac death. In 32 of 120 unrelated individuals with ARVC, we identified heterozygous mutations in PKP2, which encodes plakophilin-2, an essential armadillo-repeat protein of the cardiac desmosome. In two kindreds with ARVC, disease was incompletely penetrant in most carriers of PKP2 mutations.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Humboldt Univ, Dept Clin & Mol Cardiol, Franz Volhard Clin, HELIOS Clin GmbH,Charite, D-13125 Berlin, Germany; Univ Hosp Munster, Dept Cardiol & Angiol, D-48149 Munster, Germany; Univ Munster, Inst Arteriosclerosis Res, D-48149 Munster, Germany; Cornell Univ, Greenberg Cardiol Div, Dept Med, Weill Med Coll, New York, NY 10021 USA; Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA; Klinikum Quedlinburg, Dept Cardiol, D-06484 Quedlinburg, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Munster; University of Munster; Cornell University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Thierfelder, L (corresponding author), Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany.	lthier@mdc-berlin.de		Heuser, Arnd/0000-0002-3334-960X; Ellinor, Patrick/0000-0002-2067-0533; Drenckhahn, Jorg-Detlef/0000-0001-8347-7696	NHLBI NIH HHS [R01 HL075431] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075431] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chen XY, 2002, J BIOL CHEM, V277, P10512, DOI 10.1074/jbc.M108765200; Fontaine G, 1999, ANNU REV MED, V50, P17, DOI 10.1146/annurev.med.50.1.17; Garrod DR, 2002, CURR OPIN CELL BIOL, V14, P537, DOI 10.1016/S0955-0674(02)00366-6; Green KJ, 2000, NAT REV MOL CELL BIO, V1, P208, DOI 10.1038/35043032; GROSSMANN K, IN PRESS J CELL BIOL; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; Ko KS, 2001, J BIOL CHEM, V276, P35967, DOI 10.1074/jbc.M104106200; MARCUS FI, 1982, CIRCULATION, V65, P384, DOI 10.1161/01.CIR.65.2.384; McGrath JA, 1997, NAT GENET, V17, P240, DOI 10.1038/ng1097-240; MCKENNA WJ, 1994, BRIT HEART J, V71, P215; Mertens C, 2001, P NATL ACAD SCI USA, V98, P7795, DOI 10.1073/pnas.141219498; Mertens C, 1996, J CELL BIOL, V135, P1009, DOI 10.1083/jcb.135.4.1009; Paul M, 2003, Z KARDIOL, V92, P128, DOI 10.1007/s00392-003-0892-9; Rampazzo A, 1997, GENOMICS, V45, P259, DOI 10.1006/geno.1997.4927; THIENE G, 1988, NEW ENGL J MED, V318, P129, DOI 10.1056/NEJM198801213180301	15	573	596	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2004	36	11					1162	1164		10.1038/ng1461	http://dx.doi.org/10.1038/ng1461			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	867HI	15489853	Bronze			2022-12-25	WOS:000224832800018
J	Hanks, S; Coleman, K; Reid, S; Plaja, A; Firth, H; FitzPatrick, D; Kidd, A; Mehes, K; Nash, R; Robin, N; Shannon, N; Tolmie, J; Swansbury, J; Irrthum, A; Douglas, J; Rahman, N				Hanks, S; Coleman, K; Reid, S; Plaja, A; Firth, H; FitzPatrick, D; Kidd, A; Mehes, K; Nash, R; Robin, N; Shannon, N; Tolmie, J; Swansbury, J; Irrthum, A; Douglas, J; Rahman, N			Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B	NATURE GENETICS			English	Article							MOSAIC VARIEGATED ANEUPLOIDY; MITOTIC CHECKPOINT GENES; BUBR1	Mosaic variegated aneuploidy is a rare recessive condition characterized by growth retardation, microcephaly, childhood cancer and constitutional mosaicism for chromosomal gains and losses. In five families with mosaic variegated aneuploidy, including two with embryonal rhabdomyosarcoma, we identified truncating and missense mutations of BUB1B, which encodes BUBR1, a key protein in the mitotic spindle checkpoint. These data are the first to relate germline mutations in a spindle checkpoint gene with a human disorder and strongly support a causal link between aneuploidy and cancer development.	Inst Canc Res, Sect Canc Genet, Surrey, England; Hosp Materno Infantil Vall dHebron, Unitat Genet, Barcelona, Spain; Addenbrookes Hosp, Dept Med Genet, Cambridge, England; Wellington Hosp, Cent Reg Genet Serv, Wellington, New Zealand; MRC, Human Genet Unit, Edinburgh, Midlothian, Scotland; Univ Pecs, Dept Med Genet & Child Dev, Pecs, Hungary; Case Western Reserve Univ, Dept Human Genet, Cleveland, OH 44106 USA; Birmingham Womens Hosp, W Midland Reg Genet Serv, Birmingham, W Midlands, England; Inst Med Genet, Glasgow, Lanark, Scotland; Inst Canc Res, Sect Haematooncol, Surrey, England	University of London; Institute of Cancer Research - UK; Hospital Universitari Vall d'Hebron; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Edinburgh; University of Pecs; Case Western Reserve University; Birmingham Women's Hospital; University of Glasgow; University of London; Institute of Cancer Research - UK	Rahman, N (corresponding author), Inst Canc Res, Sect Canc Genet, Surrey, England.	nazneen.rahman@icr.ac.uk	FitzPatrick, David R/C-7301-2013; Rahman, Nazneen/B-8890-2012; FitzPatrick, David R/B-8311-2008; Rahman, Nazneen/D-2802-2013	Rahman, Nazneen/0000-0003-4376-0440; FitzPatrick, David R./0000-0003-4861-969X				Baker DJ, 2004, NAT GENET, V36, P744, DOI 10.1038/ng1382; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; Draviam VM, 2004, CURR OPIN GENET DEV, V14, P120, DOI 10.1016/j.gde.2004.02.007; Jacquemont S, 2002, AM J MED GENET, V109, P17, DOI 10.1002/ajmg.10281; Kajii T, 2001, AM J MED GENET, V104, P57, DOI 10.1002/ajmg.1580; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Limwongse C, 1999, AM J MED GENET, V82, P20, DOI 10.1002/(SICI)1096-8628(19990101)82:1<20::AID-AJMG4>3.0.CO;2-5; Mao YH, 2003, CELL, V114, P87, DOI 10.1016/S0092-8674(03)00475-6; Plaja A, 2001, AM J MED GENET, V98, P216, DOI 10.1002/1096-8628(20010122)98:3<216::AID-AJMG1091>3.0.CO;2-0; Shichiri M, 2002, CANCER RES, V62, P13; Shin HJ, 2003, CANCER CELL, V4, P483, DOI 10.1016/S1535-6108(03)00302-7; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; TOLMIE JL, 1988, HUM GENET, V80, P197, DOI 10.1007/BF00702872	15	447	461	1	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2004	36	11					1159	1161		10.1038/ng1449	http://dx.doi.org/10.1038/ng1449			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	867HI	15475955	Bronze			2022-12-25	WOS:000224832800017
J	Schellekens, H				Schellekens, H			How similar do 'biosimilars' need to be?	NATURE BIOTECHNOLOGY			English	Editorial Material									Univ Utrecht, Cent Lab Anim Inst, NL-3584 CJ Utrecht, Netherlands; Univ Utrecht, Dept Innovat Studies, NL-3584 CJ Utrecht, Netherlands	Utrecht University; Utrecht University	Schellekens, H (corresponding author), Univ Utrecht, Cent Lab Anim Inst, Bolognalaan 50, NL-3584 CJ Utrecht, Netherlands.	h.schellekens@gdl.uu.nl						Bennett CL, 2004, NEW ENGL J MED, V351, P1403, DOI 10.1056/NEJMoa040528; *EUR MED EV AG, 2002, EMEACPMP309702FINAL; *EUR MED EV AG, 2000, EMEACPMPBWP320700REV; Louet S, 2003, NAT BIOTECHNOL, V21, P956, DOI 10.1038/nbt0903-956; Mossinghoff GJ, 1999, FOOD DRUG LAW J, V54, P187; Schellekens H, 2004, TRENDS BIOTECHNOL, V22, P406, DOI 10.1016/j.tibtech.2004.06.003; Schellekens H, 2002, NAT REV DRUG DISCOV, V1, P457, DOI 10.1038/nrd818	7	68	75	0	10	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2004	22	11					1357	1359		10.1038/nbt1104-1357	http://dx.doi.org/10.1038/nbt1104-1357			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	869CL	15529154				2022-12-25	WOS:000224960600020
J	Cohen, T; Murray, M				Cohen, T; Murray, M			Modeling epidemics of multidrug-resistant M-tuberculosis of heterogeneous fitness	NATURE MEDICINE			English	Article							TRANSMISSION; COMMUNITY; DYNAMICS; DISEASE	Mathematical models have recently been used to predict the future burden of multidrug-resistant tuberculosis (MDRTB)(1-3). These models suggest the threat of multidrug resistance to TB control will depend on the relative `fitness' of MDR strains and imply that if the average fitness of MDR strains is considerably less than that of drug-sensitive strains, the emergence of resistance will not jeopardize the success of tuberculosis control efforts. Multidrug resistance in M. tuberculosis is conferred by the sequential acquisition of a number of different single-locus mutations that have been shown to have heterogeneous phenotypic effects. Here we model the impact of initial fitness estimates on the emergence of MDRTB assuming that the relative fitness of MDR strains is heterogeneous. We find that even when the average relative fitness of MDR strains is low and a well-functioning control program is in place, a small subpopulation of a relatively fit MDR strain may eventually outcompete both the drug-sensitive strains and the less fit MDR strains. These results imply that current epidemiological measures and short-term trends in the burden of MDRTB do not provide evidence that MDRTB strains can be contained in the absence of specific efforts to limit transmission from those with MDR disease.	Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital	Murray, M (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave, Boston, MA 02115 USA.	mmurray@hsph.harvard.edu	Cohen, Ted/G-8101-2011	Cohen, Ted/0000-0002-8091-7198	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI055985] Funding Source: NIH RePORTER; NIAID NIH HHS [K08 AI055985, K08 AI055985-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON R M, 1991; Andersson DI, 1999, CURR OPIN MICROBIOL, V2, P489, DOI 10.1016/S1369-5274(99)00005-3; BLOWER SM, 1995, NAT MED, V1, P815, DOI 10.1038/nm0895-815; Blower SM, 1998, J MOL MED, V76, P624, DOI 10.1007/s001090050260; Blower SM, 1996, SCIENCE, V273, P497, DOI 10.1126/science.273.5274.497; CastilloChavez C, 1997, J MATH BIOL, V35, P629, DOI 10.1007/s002850050069; Cohen T, 2003, LANCET INFECT DIS, V3, P13, DOI 10.1016/S1473-3099(03)00483-3; Dye C, 2000, P NATL ACAD SCI USA, V97, P8180, DOI 10.1073/pnas.140102797; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Dye C, 1998, LANCET, V352, P1886, DOI 10.1016/S0140-6736(98)03199-7; Dye C, 2001, P ROY SOC B-BIOL SCI, V268, P45, DOI 10.1098/rspb.2000.1328; Espinal MA, 2000, JAMA-J AM MED ASSOC, V283, P2537, DOI 10.1001/jama.283.19.2537; Espinal MA, 2001, NEW ENGL J MED, V344, P1294, DOI 10.1056/NEJM200104263441706; Farmer P, 1998, BRIT MED J, V317, P671, DOI 10.1136/bmj.317.7159.671; Garcia-Garcia MD, 2000, ARCH INTERN MED, V160, P630, DOI 10.1001/archinte.160.5.630; GRENFELL BT, 1989, P ROY SOC LOND B BIO, V22, P213; Khatri GR, 2002, NEW ENGL J MED, V347, P1420, DOI 10.1056/NEJMsa020098; Lipsitch M, 1997, ANTIMICROB AGENTS CH, V41, P363, DOI 10.1128/AAC.41.2.363; Murray CJL, 1998, P NATL ACAD SCI USA, V95, P13881, DOI 10.1073/pnas.95.23.13881; ORDWAY DJ, 1995, INFECT IMMUN, V63, P741, DOI 10.1128/IAI.63.2.741-743.1995; Schrag SJ, 1997, P ROY SOC B-BIOL SCI, V264, P1287, DOI 10.1098/rspb.1997.0178; Sherman DR, 1996, SCIENCE, V272, P1641, DOI 10.1126/science.272.5268.1641; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; Styblo K, 1991, EPIDEMIOLOGY TUBERCU; Teixeira L, 2001, INT J TUBERC LUNG D, V5, P321; Van Rie A, 1999, NEW ENGL J MED, V341, P1174, DOI 10.1056/NEJM199910143411602; Verver S, 2004, INT J EPIDEMIOL, V33, P351, DOI 10.1093/ije/dyh021; Vynnycky E, 1997, EPIDEMIOL INFECT, V119, P183, DOI 10.1017/S0950268897007917; *WHO, 2004, 3 WHO; World Health Organization, 1997, WHOCDSTB97220	30	206	213	1	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2004	10	10					1117	1121		10.1038/nm1110	http://dx.doi.org/10.1038/nm1110			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15378056	Green Accepted			2022-12-25	WOS:000224245800043
J	Jacobs, T				Jacobs, T			More than meets the eyes?	NATURE BIOTECHNOLOGY			English	Article												tom@completegrowth.com						VANBRUNT J, 2004, SIGNALS MAGAZINE MAY	1	2	2	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2004	22	10					1221	1221		10.1038/nbt1004-1221	http://dx.doi.org/10.1038/nbt1004-1221			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	860EU	15470455				2022-12-25	WOS:000224326100017
J	Su, QN; Cai, Q; Gerwin, C; Smith, CL; Sheng, ZH				Su, QN; Cai, Q; Gerwin, C; Smith, CL; Sheng, ZH			Syntabulin is a microtubule-associated protein implicated in syntaxin transport in neurons	NATURE CELL BIOLOGY			English	Article							PRESYNAPTIC ACTIVE ZONES; SYNAPTIC VESICLE; MEMBRANE-PROTEINS; AXONAL-TRANSPORT; PLASMA-MEMBRANE; KINESIN; MOTOR; CARGO; IDENTIFICATION; SYNTAPHILIN	Different types of cargo vesicles containing presynaptic proteins are transported from the nerve cell body to the nerve terminal, and participate in the formation of active zones. However, the identity of the membranous cargoes and the nature of the motor-cargo interactions remain unsolved. Here, we report the identification of a syntaxin-1-binding protein named syntabulin. Syntabulin attaches syntaxin-containing vesicles to microtubules and migrates with syntaxin within the processes of hippocampal neurons. Knock-down of syntabulin expression with targeted small interfering RNAs (siRNAs) or interference with the syntabulin-syntaxin interaction inhibit attachment of syntaxin-cargo vesicles to microtubules and reduce syntaxin-1 distribution in neuronal processes. Furthermore, conventional kinesin I heavy chain binds to syntabulin and associates with syntabulin-linked syntaxin vesicles in vivo. These findings suggest that syntabulin functions as a linker molecule that attaches syntaxin-cargo vesicles to kinesin I, enabling the transport of syntaxin-1 to neuronal processes.	NINDS, Synapt Funct Unit, NIH, Bethesda, MD 20892 USA; NINDS, Light Imaging Facil, NIH, Bethesda, MD 20892 USA; Shanghai Med Univ 2, Neurobiol Lab, Shanghai 200025, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Shanghai Jiao Tong University	Sheng, ZH (corresponding author), NINDS, Synapt Funct Unit, NIH, Bldg 35,Room 3B203,MSC 3701,35 Convent Dr, Bethesda, MD 20892 USA.	shengz@ninds.nih.gov						Ahmari SE, 2000, NAT NEUROSCI, V3, P445, DOI 10.1038/74814; Allan VJ, 2002, NAT CELL BIOL, V4, pE236, DOI 10.1038/ncb1002-e236; Almenar-Queralt A, 2001, CURR OPIN NEUROBIOL, V11, P550, DOI 10.1016/S0959-4388(00)00248-8; BAJJALIEH SM, 1995, J BIOL CHEM, V270, P1971, DOI 10.1074/jbc.270.5.1971; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; Bradke F, 1998, BBA-MOL CELL RES, V1404, P245, DOI 10.1016/S0167-4889(98)00060-3; Burack MA, 2000, NEURON, V26, P465, DOI 10.1016/S0896-6273(00)81178-2; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Das S, 2003, J BIOL CHEM, V278, P41221, DOI 10.1074/jbc.M304851200; Dell KR, 2003, J CELL BIOL, V160, P291, DOI 10.1083/jcb.200301040; Diefenbach RJ, 1998, BIOCHEMISTRY-US, V37, P16663, DOI 10.1021/bi981163r; Donaldson JG, 2000, CELL, V101, P693, DOI 10.1016/S0092-8674(00)80881-8; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; GARCIA EP, 1995, J CELL BIOL, V129, P105, DOI 10.1083/jcb.129.1.105; Goldstein LSB, 2000, ANNU REV NEUROSCI, V23, P39, DOI 10.1146/annurev.neuro.23.1.39; Goldstein LSB, 1999, ANNU REV CELL DEV BI, V15, P141, DOI 10.1146/annurev.cellbio.15.1.141; Goslin K., 1998, CULTURING NERVE CELL, P339; Gunawardena S, 2004, J NEUROBIOL, V58, P258, DOI 10.1002/neu.10319; Hilfiker S, 1999, NAT NEUROSCI, V2, P104, DOI 10.1038/5659; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Horton AC, 2003, NEURON, V40, P277, DOI 10.1016/S0896-6273(03)00629-9; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kamal A, 2002, CURR OPIN CELL BIOL, V14, P63, DOI 10.1016/S0955-0674(01)00295-2; KRASZEWSKI K, 1995, J NEUROSCI, V15, P4328; Lao GF, 2000, NEURON, V25, P191, DOI 10.1016/S0896-6273(00)80882-X; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Manning BD, 2000, TRENDS CELL BIOL, V10, P281, DOI 10.1016/S0962-8924(00)01774-8; Muresan V, 2001, MOL CELL, V7, P173, DOI 10.1016/S1097-2765(01)00165-4; Nakagawa T, 2000, CELL, V103, P569, DOI 10.1016/S0092-8674(00)00161-6; Nakata T, 1998, J CELL BIOL, V140, P659, DOI 10.1083/jcb.140.3.659; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Roos J, 2000, NAT NEUROSCI, V3, P415, DOI 10.1038/74773; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Safieddine S, 2002, MOL CELL NEUROSCI, V20, P343, DOI 10.1006/mcne.2002.1120; Sampo B, 2003, NEURON, V37, P611, DOI 10.1016/S0896-6273(03)00058-8; Schroer TA, 2000, TRAFFIC, V1, P3, DOI 10.1034/j.1600-0854.2000.010102.x; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Shapira M, 2003, NEURON, V38, P237, DOI 10.1016/S0896-6273(03)00207-1; Sheetz MP, 1998, PROG NEUROBIOL, V55, P577, DOI 10.1016/S0301-0082(98)00021-5; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Takeda S, 2000, J CELL BIOL, V148, P1255, DOI 10.1083/jcb.148.6.1255; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925; Zhai RG, 2001, NEURON, V29, P131, DOI 10.1016/S0896-6273(01)00185-4	48	113	119	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2004	6	10					941	+		10.1038/ncb1169	http://dx.doi.org/10.1038/ncb1169			17	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	859FY	15459722				2022-12-25	WOS:000224250000009
J	Seow, HF; Broer, S; Broer, A; Bailey, CG; Potter, SJ; Cavanaugh, JA; Rasko, JEJ				Seow, HF; Broer, S; Broer, A; Bailey, CG; Potter, SJ; Cavanaugh, JA; Rasko, JEJ			Hartnup disorder is caused by mutations in the gene encoding the neutral amino acid transporter SLC6A19	NATURE GENETICS			English	Article							CELL-LINE; CLONING; DISEASE; NA+; SPECIFICITY; VESICLES; PATHWAYS	Hartnup disorder (OMIM 234500) is an autosomal recessive abnormality of renal and gastrointestinal neutral amino acid transport noted for its clinical variability. We localized a gene causing Hartnup disorder to chromosome 5p15.33 and cloned a new gene, SLC6A19, in this region. SLC6A19 is a sodium-dependent and chloride-independent neutral amino acid transporter, expressed predominately in kidney and intestine, with properties of system B-0. We identified six mutations in SLC6A19 that cosegregated with disease in the predicted recessive manner, with most affected individuals being compound heterozygotes. The disease-causing mutations that we tested reduced neutral amino acid transport function in vitro. Population frequencies for the most common mutated SLC6A19 alleles are 0.007 for 517G-->A and 0.001 for 718C-->T. Our findings indicate that SLC6A19 is the long-sought gene that is mutated in Hartnup disorder; its identification provides the opportunity to examine the inconsistent multisystemic features of this disorder.	Univ Sydney, Centenary Inst Canc Med & Cell Biol, Sydney, NSW 2042, Australia; Australian Natl Univ, Fac Sci, Sch Biochem & Mol Biol, Canberra, ACT 0200, Australia; Australian Natl Univ, Sch Med, Canberra Hosp, Med Genet Res Unit, Canberra, ACT 2606, Australia; Royal Prince Alfred Hosp, Sydney Canc Ctr, Camperdown, NSW 2050, Australia	University of Sydney; Centenary Institute; Australian National University; Australian National University; Canberra Hospital; University of Sydney	Rasko, JEJ (corresponding author), Univ Sydney, Centenary Inst Canc Med & Cell Biol, Sydney, NSW 2042, Australia.	j.rasko@cenint.org	Cavanaugh, Juleen/C-9413-2009; Rasko, John EJ/F-5754-2013; Broer, Stefan/A-1286-2008	Broer, Stefan/0000-0002-8040-1634; Seow, Heng Fong/0000-0002-2189-327X; Bailey, Charles/0000-0002-4725-7829; rasko, John/0000-0003-2975-807X				Avissar NE, 2001, AM J PHYSIOL-CELL PH, V281, pC963, DOI 10.1152/ajpcell.2001.281.3.C963; BARON DN, 1956, LANCET, V2, P421; Broer A, 2004, J BIOL CHEM, V279, P24467, DOI 10.1074/jbc.M400904200; Broer Stefan, 2003, Methods Mol Biol, V227, P245, DOI 10.1385/1-59259-387-9:245; Chillaron J, 2001, AM J PHYSIOL-RENAL, V281, pF995, DOI 10.1152/ajprenal.2001.281.6.F995; DOYLE FA, 1992, BIOCHIM BIOPHYS ACTA, V1104, P55, DOI 10.1016/0005-2736(92)90131-5; Kekuda R, 1996, J BIOL CHEM, V271, P18657, DOI 10.1074/jbc.271.31.18657; KLETA R, 2004, NAT GENET       0801; Levy L. L., 2001, METABOLIC MOL BASES, P4957; MAILLIARD ME, 1995, GASTROENTEROLOGY, V108, P888, DOI 10.1016/0016-5085(95)90466-2; MUNCK LK, 1994, PHYSIOL RES, V43, P335; Nash SR, 1998, RECEPTOR CHANNEL, V6, P113; Nozaki J, 2001, BIOCHEM BIOPH RES CO, V284, P255, DOI 10.1006/bbrc.2001.4961; Pineda M, 2004, BIOCHEM J, V377, P665, DOI 10.1042/BJ20030956; Potter SJ, 2002, J INHERIT METAB DIS, V25, P437, DOI 10.1023/A:1021286714582; Rahman B, 1999, BIOCHEMISTRY-US, V38, P11577, DOI 10.1021/bi990973f; Rasko JEJ, 1999, P NATL ACAD SCI USA, V96, P2129, DOI 10.1073/pnas.96.5.2129; SCRIVER CR, 1965, NEW ENGL J MED, V273, P530, DOI 10.1056/NEJM196509022731005; SCRIVER CR, 1987, AM J HUM GENET, V40, P401; Sloan JL, 1999, J BIOL CHEM, V274, P23740, DOI 10.1074/jbc.274.34.23740; SOUBA WW, 1992, BIOCHEM BIOPH RES CO, V188, P746, DOI 10.1016/0006-291X(92)91119-B; STEVENS BR, 1982, J MEMBRANE BIOL, V66, P213, DOI 10.1007/BF01868496; TARLOW MJ, 1972, ARCH DIS CHILD, V47, P798, DOI 10.1136/adc.47.255.798; Verrey F, 2000, PFLUG ARCH EUR J PHY, V440, P503, DOI 10.1007/s004240050001; Wagner CA, 2001, AM J PHYSIOL-CELL PH, V281, pC1077, DOI 10.1152/ajpcell.2001.281.4.C1077; WARD CL, 1994, J BIOL CHEM, V269, P25710; WASSERMAN JC, 1994, AM J PHYSIOL-RENAL, V267, pF688, DOI 10.1152/ajprenal.1994.267.4.F688; WILCKEN B, 1980, J PEDIATR-US, V97, P492, DOI 10.1016/S0022-3476(80)80216-2	28	164	171	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2004	36	9					1003	1007		10.1038/ng1406	http://dx.doi.org/10.1038/ng1406			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	851AY	15286788	Bronze			2022-12-25	WOS:000223658100029
J	Shaunak, S; Thomas, S; Gianasi, E; Godwin, A; Jones, E; Teo, I; Mireskandari, K; Luthert, P; Duncan, R; Patterson, S; Khaw, P; Brocchini, S				Shaunak, S; Thomas, S; Gianasi, E; Godwin, A; Jones, E; Teo, I; Mireskandari, K; Luthert, P; Duncan, R; Patterson, S; Khaw, P; Brocchini, S			Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation	NATURE BIOTECHNOLOGY			English	Article							IMMUNE-SYSTEM; CUTTING EDGE; CELLS; ANTIBODY; TLR4; BIOCOMPATIBILITY; OLIGOSACCHARIDES; INVOLVEMENT; RECOGNITION; ABSORPTION	Dendrimers are hyperbranched macromolecules that can be chemically synthesized to have precise structural characteristics. We used anionic, polyamidoamine, generation 3.5 dendrimers to make novel water-soluble conjugates of D(+)-glucosamine and D(+)-glucosamine 6-sulfate with immuno-modulatory and antiangiogenic properties respectively. Dendrimer glucosamine inhibited Toll-like receptor 4-mediated lipopolysaccharide induced synthesis of pro-inflammatory chemokines (MIP-1alpha, MIP-1beta, IL-8) and cytokines (TNF-alpha, IL-1beta, IL-6) from human dendritic cells and macrophages but allowed upregulation of the costimulatory molecules CD25, CD80, CD83 and CD86. Dendrimer glucosamine 6-sulfate blocked fibroblast growth factor-2 mediated endothelial cell proliferation and neoangiogenesis in human Matrigel and placental angiogenesis assays. When dendrimer glucosamine and dendrimer glucosamine 6-sulfate were used together in a validated and clinically relevant rabbit model of scar tissue formation after glaucoma filtration surgery, they increased the long-term success of the surgery from 30% to 80% (P = 0.029). We conclude that synthetically engineered macromolecules such as the dendrimers described here can be tailored to have defined immuno-modulatory and antiangiogenic properties, and they can be used synergistically to prevent scar tissue formation.	Hammersmith Hosp, Imperial Coll London, Fac Med, London W12 0NN, England; Univ London, Sch Pharm, Biomed Polymers Grp, London WC1N 1AX, England; Inst Ophthalmol, Wound Healing Res Unit, London EC1V 9EL, England; Inst Ophthalmol, Dept Histopathol, London EC1V 9EL, England; Cardiff Univ, Welsh Sch Pharm, Ctr Polymer Therapeut, Cardiff CF10 3XF, S Glam, Wales; Chelsea & Westminster Hosp, Imperial Coll London, Fac Med, London SW10 9NH, England	Imperial College London; University of London; University College London; University of London School of Pharmacy; University of London; University College London; University of London; University College London; Cardiff University; Imperial College London	Shaunak, S (corresponding author), Hammersmith Hosp, Imperial Coll London, Fac Med, Ducane Rd, London W12 0NN, England.	s.shaunak@imperial.ac.uk		Luthert, Philip/0000-0001-7276-6898; Khaw, Sir Peng Tee/0000-0002-8087-2268	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI044694] Funding Source: NIH RePORTER; NIAID NIH HHS [1-R21-AI44694-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aghazadeh-Habashi A, 2002, J PHARM PHARM SCI, V5, P181; Brandtzaeg P, 1996, J EXP MED, V184, P51, DOI 10.1084/jem.184.1.51; Chang L, 2000, SURV OPHTHALMOL, V45, P49, DOI 10.1016/S0039-6257(00)00135-1; Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207; Cloninger MJ, 2002, CURR OPIN CHEM BIOL, V6, P742, DOI 10.1016/S1367-5931(02)00400-3; Cordeiro MF, 1999, INVEST OPHTH VIS SCI, V40, P2225; Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088; Esfand R., 2002, DENDRIMERS OTHER DEN, P587, DOI [DOI 10.1002/0470845821.CH25, 10.1002/0470845821.ch25]; Flo TH, 2002, J BIOL CHEM, V277, P35489, DOI 10.1074/jbc.M201366200; FUKASAWA M, 1989, J SURG RES, V46, P166, DOI 10.1016/0022-4804(89)90222-9; Garcia-Ramallo E, 2002, J IMMUNOL, V169, P6467, DOI 10.4049/jimmunol.169.11.6467; Gillitzer R, 2001, J LEUKOCYTE BIOL, V69, P513; GIRARD JP, 1995, IMMUNOL TODAY, V16, P449, DOI 10.1016/0167-5699(95)80023-9; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Hoshino K, 1999, J IMMUNOL, V162, P3749; Jevprasesphant R, 2003, PHARM RES-DORDR, V20, P1543, DOI 10.1023/A:1026166729873; Johnson GB, 2004, J IMMUNOL, V172, P20, DOI 10.4049/jimmunol.172.1.20; KHAW PT, 1993, OPHTHALMOLOGY, V100, P367; Koyanagi S, 2003, BIOCHEM PHARMACOL, V65, P173, DOI 10.1016/S0006-2952(02)01478-8; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Le Naour F, 2001, J BIOL CHEM, V276, P17920, DOI 10.1074/jbc.M100156200; LEHTO M, 1985, EUR SURG RES, V17, P179, DOI 10.1159/000128465; Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369; Lundin L, 2000, J BIOL CHEM, V275, P24653, DOI 10.1074/jbc.M908930199; Malik N, 2000, J CONTROL RELEASE, V65, P133, DOI 10.1016/S0168-3659(99)00246-1; Malik N, 1999, ANTI-CANCER DRUG, V10, P767, DOI 10.1097/00001813-199909000-00010; Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755; Mead AL, 2003, INVEST OPHTH VIS SCI, V44, P3394, DOI 10.1167/iovs.02-0978; Paterson HM, 2003, J IMMUNOL, V171, P1473, DOI 10.4049/jimmunol.171.3.1473; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Roberts JC, 1996, J BIOMED MATER RES, V30, P53, DOI 10.1002/(SICI)1097-4636(199601)30:1<53::AID-JBM8>3.0.CO;2-Q; Roy R, 1997, TOP CURR CHEM, V187, P241; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; SCHMIDT RJ, 1989, J PHARM PHARMACOL, V41, P781, DOI 10.1111/j.2042-7158.1989.tb06365.x; SETNIKAR I, 1984, PHARMATHERAPEUTICA, V3, P538; Setnikar I, 2001, ARZNEIMITTELFORSCH, V51, P699; SGOURAS D, 1990, J MATER SCI-MATER M, V1, P61, DOI 10.1007/BF00839070; Siriwardena D, 2002, OPHTHALMOLOGY, V109, P427, DOI 10.1016/S0161-6420(01)00997-6; Smiley ST, 2001, J IMMUNOL, V167, P2887, DOI 10.4049/jimmunol.167.5.2887; Spinks RL, 2003, J NEUROPHYSIOL, V90, P1324, DOI 10.1152/jn.00169.2003; Sweeney EA, 2002, BLOOD, V99, P44, DOI 10.1182/blood.V99.1.44; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Thornton M, 1999, ANTIMICROB AGENTS CH, V43, P2528, DOI 10.1128/AAC.43.10.2528; TOMALIA DA, 1990, ANGEW CHEM INT EDIT, V29, P138, DOI 10.1002/anie.199001381; Tumpey TM, 1998, J VIROL, V72, P3705, DOI 10.1128/JVI.72.5.3705-3710.1998; Van Veldhuisen PC, 2000, AM J OPHTHALMOL, V130, P429; Wang ZM, 2000, J BIOL CHEM, V275, P20260, DOI 10.1074/jbc.M909168199; Wells AP, 2003, OPHTHALMOLOGY, V110, P2192, DOI 10.1016/S0161-6420(03)00800-5; Zanini D, 1998, J ORG CHEM, V63, P3486, DOI 10.1021/jo972061u	50	238	256	1	57	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2004	22	8					977	984		10.1038/nbt995	http://dx.doi.org/10.1038/nbt995			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	842YB	15258595				2022-12-25	WOS:000223039500028
J	Griffin, LD; Gong, WH; Verot, L; Mellon, SH				Griffin, LD; Gong, WH; Verot, L; Mellon, SH			Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone	NATURE MEDICINE			English	Article							CHLORIDE-ION UPTAKE; NEUROFIBRILLARY TANGLES; CHOLESTEROL; RAT; MICE; GANGLIOSIDE; METABOLISM; MODULATION; STORAGE; NEURONS	Niemann-Pick type C (NP-C) disease is a fatal, autosomal recessive, childhood neurodegenerative disease. The NP-C mouse recapitulates the cholesterol and sphingolipid storage, onset of neurological deficits, histopathological lesions, Purkinje cell loss and early death typical of the most severe form of human NP-C. Neurosteroids, steroids made in the brain, affect neuronal growth and differentiation, and modulate neurotransmitter receptors. Disordered cholesterol trafficking might disrupt neurosteroidogenesis, thereby contributing to the NP-C phenotype. Here we show that NP-C mouse brain contains substantially less neurosteroid than wild-type brain and has an age-related decrease in the ability to synthesize 5alpha-dihydroprogesterone and allopregnanolone. Immunohistochemical assessment confirms a decrease in expression of 5alpha-reductase and 3alpha-hydroxysteroid dehydrogenase, especially in cerebellum. Neonatal administration of allopregnanolone delays the onset of neurological symptoms, increases Purkinje and granule cell survival, reduces cortical GM2 and GM3 ganglioside accumulation and doubles the lifespan of NP-C mice. Earlier administration increases effectiveness of treatment. Decreased production of allopregnanolone apparently contributes to the pathology of NP-C; thus, neurosteroid treatment may be useful in ameliorating progression of the disease.	Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Reprod Sci, San Francisco, CA 94143 USA; Lyon Sud Med Sch & Hosp, Lab Fdn Gillet Merieux, INSERM, U189, F-69310 Pierre Benite, France	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm)	Mellon, SH (corresponding author), Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, 513 Parnassus Ave, San Francisco, CA 94143 USA.	mellon@cgl.ucsf.edu						BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BELELLI D, 1989, EUR J PHARMACOL, V167, P173, DOI 10.1016/0014-2999(89)90760-7; BLACK SM, 1993, ENDOCRINOLOGY, V132, P539, DOI 10.1210/en.132.2.539; BRAAK H, 1983, J NEUROPATH EXP NEUR, V42, P671, DOI 10.1097/00005072-198311000-00007; BRINTON RD, 1994, J NEUROSCI, V14, P2763; Brussaard AB, 2000, P NATL ACAD SCI USA, V97, P3625, DOI 10.1073/pnas.050424697; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Compagnone NA, 2000, FRONT NEUROENDOCRIN, V21, P1, DOI 10.1006/frne.1999.0188; Concas A, 1998, P NATL ACAD SCI USA, V95, P13284, DOI 10.1073/pnas.95.22.13284; COSTA E, 1991, NEUROSTEROIDS BRAIN; Cruz JC, 2000, J BIOL CHEM, V275, P41309, DOI 10.1074/jbc.M008272200; DOODY KM, 1990, ENDOCRINOLOGY, V126, P2487, DOI 10.1210/endo-126-5-2487; FINK JK, 1989, NEUROLOGY, V39, P1040, DOI 10.1212/WNL.39.8.1040; Fujita N, 1996, HUM MOL GENET, V5, P711, DOI 10.1093/hmg/5.6.711; German DC, 2001, J COMP NEUROL, V433, P415, DOI 10.1002/cne.1149; Gondre-Lewis MC, 2003, CURR BIOL, V13, P1324, DOI 10.1016/S0960-9822(03)00531-1; Griffin LD, 2001, ENDOCRINOLOGY, V142, P4617, DOI 10.1210/en.142.11.4617; Griffin LD, 1999, P NATL ACAD SCI USA, V96, P13512, DOI 10.1073/pnas.96.23.13512; Grobin AC, 2003, J NEUROSCI, V23, P1832; Henderson LP, 2000, J BIOL CHEM, V275, P20179, DOI 10.1074/jbc.M001793200; HIGASHI Y, 1993, ACTA NEUROPATHOL, V85, P175; Karl T, 2003, EXP TOXICOL PATHOL, V55, P69, DOI 10.1078/0940-2993-00301; KYRKLUND T, 1987, LIPIDS, V22, P274, DOI 10.1007/BF02533991; Lambert JJ, 2003, PROG NEUROBIOL, V71, P67, DOI 10.1016/j.pneurobio.2003.09.001; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; Liu YJ, 2000, HUM MOL GENET, V9, P1087, DOI 10.1093/hmg/9.7.1087; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MORRIS MD, 1982, AM J PATHOL, V108, P140; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; Ong WY, 2001, EXP BRAIN RES, V141, P218, DOI 10.1007/s002210100870; Patterson M. C., 2001, METABOLIC MOL BASES, VIII, P3611; Prasad A, 2000, J NEUROCHEM, V75, P1250, DOI 10.1046/j.1471-4159.2000.0751250.x; PURDY RH, 1990, J MED CHEM, V33, P1572, DOI 10.1021/jm00168a008; PURDY RH, 1990, STEROIDS, V55, P290, DOI 10.1016/0039-128X(90)90031-6; ROFF CF, 1992, AM J MED GENET, V42, P593, DOI 10.1002/ajmg.1320420433; ROFF CF, 1993, ENDOCRINOLOGY, V133, P2913, DOI 10.1210/en.133.6.2913; Soccio RE, 2003, J BIOL CHEM, V278, P22183, DOI 10.1074/jbc.R300003200; SUZUKI K, 1995, ACTA NEUROPATHOL, V89, P227; Vanier MT, 2003, CLIN GENET, V64, P269, DOI 10.1034/j.1399-0004.2003.00147.x; Vanier MT, 1996, AM J HUM GENET, V58, P118; VIGER RS, 1994, ENDOCRINOLOGY, V134, P2298, DOI 10.1210/en.134.5.2298; Vincent I, 2003, CURR OPIN NEUROL, V16, P155, DOI 10.1097/00019052-200304000-00006; Voikar V, 2001, PHYSIOL BEHAV, V72, P271, DOI 10.1016/S0031-9384(00)00405-4; Walkley SU, 1998, ANN NY ACAD SCI, V845, P188, DOI 10.1111/j.1749-6632.1998.tb09671.x; Wiebe JP, 1997, BRAIN RES, V764, P158, DOI 10.1016/S0006-8993(97)00452-6; Xie CL, 2003, J LIPID RES, V44, P1780, DOI 10.1194/jlr.M300164-JLR200; Xie CL, 2000, J NEUROPATH EXP NEUR, V59, P1106, DOI 10.1093/jnen/59.12.1106; Zervas M, 2001, J NEUROPATH EXP NEUR, V60, P49, DOI 10.1093/jnen/60.1.49; Zervas M, 2001, CURR BIOL, V11, P1283, DOI 10.1016/S0960-9822(01)00396-7	50	281	298	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7					704	711		10.1038/nm1073	http://dx.doi.org/10.1038/nm1073			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	835DM	15208706				2022-12-25	WOS:000222460400024
J	Kanno, T; Huettel, B; Mette, MF; Aufsatz, W; Jaligot, E; Daxinger, L; Kreil, DP; Matzke, M; Matzke, AJM				Kanno, T; Huettel, B; Mette, MF; Aufsatz, W; Jaligot, E; Daxinger, L; Kreil, DP; Matzke, M; Matzke, AJM			Atypical RNA polymerase subunits required for RNA-directed DNA methylation	NATURE GENETICS			English	Article							SMALL INTERFERING RNA; HUMAN-CELLS; GENE; ARABIDOPSIS; TRANSCRIPTION; TRANSPOSON; THALIANA; NUCLEAR; VIRUS	RNA- directed DNA methylation, one of several RNA interference - mediated pathways in the nucleus(1), has been documented in plants(2,3) and in human cells(4,5). Despite progress in identifying the DNA methyltransferases, histone-modifying enzymes and RNA interference proteins needed for RNA- directed DNA methylation(1), the mechanism remains incompletely understood. We screened for mutants defective in RNA- directed DNA methylation and silencing of a transgene promoter in Arabidopsis thaliana and identified three drd complementation groups(6). DRD1 is a SNF2- like protein(6) required for RNA- directed de novo methylation. We report here that DRD2 and DRD3 correspond to the second- largest subunit and largest subunit, respectively, of a fourth class of DNA- dependent RNA polymerase ( polymerase IV) that is unique to plants. DRD3 is a functionally diversified homolog of NRPD1a or SDE4, identified in a separate screen for mutants defective in post- transcriptional gene silencing(7,8). The identical DNA methylation patterns observed in all three drd mutants suggest that DRD proteins cooperate to create a substrate for RNA- directed de novo methylation.	Austrian Acad Sci, Gregor Mendel Inst Mol Plant Biol, Pharm Zentrum, A-1090 Vienna, Austria; IAM, WWTF Vienna Sci Chair Bioinformat, Dept Biotechnol, A-1190 Vienna, Austria	Austrian Academy of Sciences; Vienna Biocenter (VBC); Gregor Mendel Institute of Molecular Plant Biology (GMI)	Matzke, M (corresponding author), Austrian Acad Sci, Gregor Mendel Inst Mol Plant Biol, Pharm Zentrum, UZA2,Althanstr 14-2D-541, A-1090 Vienna, Austria.	marjori.matzke@gmi.oeaw.ac.at	Daxinger, Lucia/A-6840-2013; Matzke, Marjori/H-8689-2015; Kreil, D/O-1783-2013; Matzke, Antonius/H-8698-2015; Jaligot, Estelle/A-9035-2011	Kreil, D/0000-0001-7538-2056; Jaligot, Estelle/0000-0002-9252-5271; Daxinger, Lucia/0000-0001-6557-6201; KANNO, Tatsuo/0000-0001-5958-4686				Amedeo P, 2000, NATURE, V405, P203, DOI 10.1038/35012108; Aufsatz W, 2002, P NATL ACAD SCI USA, V99, P16499, DOI 10.1073/pnas.162371499; Bellaoui M, 2004, PLANTA, V219, P819, DOI 10.1007/s00425-004-1295-5; Chan SWL, 2004, SCIENCE, V303, P1336, DOI 10.1126/science.1095989; Dalmay T, 2000, CELL, V101, P543, DOI 10.1016/S0092-8674(00)80864-8; Hamilton A, 2002, EMBO J, V21, P4671, DOI 10.1093/emboj/cdf464; Herr AJ, 2005, SCIENCE, V308, P118, DOI 10.1126/science.1106910; Jones L, 2001, CURR BIOL, V11, P747, DOI 10.1016/S0960-9822(01)00226-3; Kanno T, 2004, CURR BIOL, V14, P801, DOI 10.1016/j.cub.2004.04.037; KANNO T, IN PRESS EMBO REP; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kawasaki H, 2004, NATURE, V431, P211, DOI 10.1038/nature02889; Lahmy S, 2004, PLANT J, V39, P809, DOI 10.1111/j.1365-313X.2004.02166.x; Lippman Z, 2003, PLOS BIOL, V1, P420, DOI 10.1371/journal.pbio.0000067; Liu J, 2004, GENE DEV, V18, P2873, DOI 10.1101/gad.1217304; Mathieu O, 2004, J CELL SCI, V117, P4881, DOI 10.1242/jcs.01479; Matzke M, 2004, BBA-GENE STRUCT EXPR, V1677, P129, DOI 10.1016/j.bbaexp.2003.10.015; Matzke MA, 2005, NAT REV GENET, V6, P24, DOI 10.1038/nrg1500; Melquist S, 2003, GENE DEV, V17, P2036, DOI 10.1101/gad.1081603; Mette MF, 2000, EMBO J, V19, P5194, DOI 10.1093/emboj/19.19.5194; Morris KV, 2004, SCIENCE, V305, P1289, DOI 10.1126/science.1101372; Mourrain P, 2000, CELL, V101, P533, DOI 10.1016/S0092-8674(00)80863-6; Onodera Y, 2005, CELL, V120, P613, DOI 10.1016/j.cell.2005.02.007; Singer T, 2001, GENE DEV, V15, P591, DOI 10.1101/gad.193701; Steimer A, 2000, PLANT CELL, V12, P1165, DOI 10.1105/tpc.12.7.1165; VONGS A, 1993, SCIENCE, V260, P1926, DOI 10.1126/science.8316832; Xie ZX, 2004, PLOS BIOL, V2, P642, DOI 10.1371/journal.pbio.0020104; Yu B, 2005, SCIENCE, V307, P932, DOI 10.1126/science.1107130; Zorio DAR, 2001, CURR BIOL, V11, pR144, DOI 10.1016/S0960-9822(01)00063-X	29	316	330	1	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2005	37	7					761	765		10.1038/ng1580	http://dx.doi.org/10.1038/ng1580			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	941EA	15924141				2022-12-25	WOS:000230196400025
J	Seo, H; Masuoka, M; Murofushi, H; Takeda, S; Shibata, T; Ohta, K				Seo, H; Masuoka, M; Murofushi, H; Takeda, S; Shibata, T; Ohta, K			Rapid generation of specific antibodies by enhanced homologous recombination	NATURE BIOTECHNOLOGY			English	Article							IMMUNOGLOBULIN GENE CONVERSION; B-CELL LINES; MEIOTIC RECOMBINATION; SOMATIC HYPERMUTATION; HISTONE ACETYLATION; PHAGE DISPLAY; IN-VITRO; DIVERSITY; AFFINITY; EXPRESSION	In the chicken immune system, gene conversion, a type of homologous recombination, primarily contributes to diversification of the immunoglobulin gene(1,2). Here, we report on the rapid generation of specific monoclonal antibodies using the chicken DT40 B-cell line undergoing gene conversion. We discovered that the gene conversion frequency at the immunoglobulin locus is increased by treating DT40 cells with a histone deacetylase inhibitor, trichostatin A (TSA)(3), thereby generating diversity at the immunoglobulin locus in the majority of treated cells. This indicates that TSA treatment accelerates the autonomous diversification of surface IgMs on DT40 cells. We took advantage of this effect to select DT40 cells producing specific antibodies with antigen-conjugated magnetic beads. This autonomously diversifying library (ADLib) selection system enables the quick establishment (similar to 1 week from a diversifying library) of various clones producing monoclonal IgMs with enough specificity and affinity for immunological assays, and is applicable to various biotechnologies including rational protein design.	RIKEN Discovery Res Inst, Genet Dynam Res Unit, Wako, Saitama 3510198, Japan; Saitama Small Enterprise Promot Corp, JST, REDS Grp, Prefecture Collaborat Reg Entities Advanc, Kawaguchi, Saitama 3330844, Japan; Yamaguchi Univ, Fac Sci, Dept Biol, Yamaguchi 7538512, Japan; Kyoto Univ, Fac Med, Sakyo Ku, Kyoto 6068315, Japan; RIKEN Discovery Res Inst, Mol & Cellular Biol Lab, Wako, Saitama 3510198, Japan	RIKEN; Japan Science & Technology Agency (JST); Yamaguchi University; Kyoto University; RIKEN	Ohta, K (corresponding author), RIKEN Discovery Res Inst, Genet Dynam Res Unit, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	kohta@riken.jp		Takeda, Shunichi/0000-0002-7924-7991				Arakawa H, 2002, SCIENCE, V295, P1301, DOI 10.1126/science.1067308; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; Chowdhury PS, 1999, NAT BIOTECHNOL, V17, P568, DOI 10.1038/9872; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; Cumbers SJ, 2002, NAT BIOTECHNOL, V20, P1129, DOI 10.1038/nbt752; Einhauer A, 2001, J CHROMATOGR A, V921, P25, DOI 10.1016/S0021-9673(01)00831-7; Griffiths AD, 1998, CURR OPIN BIOTECH, V9, P102, DOI 10.1016/S0958-1669(98)80092-X; Harris RS, 2002, CURR BIOL, V12, P435, DOI 10.1016/S0960-9822(02)00717-0; Mizuno K, 1997, GENE DEV, V11, P876, DOI 10.1101/gad.11.7.876; Papavasiliou FN, 2002, CELL, V109, pS35, DOI 10.1016/S0092-8674(02)00706-7; Pecina A, 2002, CELL, V111, P173, DOI 10.1016/S0092-8674(02)01002-4; REYNAUD CA, 1985, CELL, V40, P283, DOI 10.1016/0092-8674(85)90142-4; REYNAUD CA, 1987, CELL, V48, P379, DOI 10.1016/0092-8674(87)90189-9; Roth DB, 2000, CELL, V103, P699, DOI 10.1016/S0092-8674(00)00173-2; Sale JE, 2001, NATURE, V412, P921, DOI 10.1038/35091100; Schlissel MS, 2000, SCIENCE, V287, P438, DOI 10.1126/science.287.5452.438; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; TAKEDA S, 1992, P NATL ACAD SCI USA, V89, P4023, DOI 10.1073/pnas.89.9.4023; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; WEILL JC, 1987, SCIENCE, V238, P1094, DOI 10.1126/science.3317827; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; Yamada T, 2004, EMBO J, V23, P1792, DOI 10.1038/sj.emboj.7600138; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	24	71	85	2	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2005	23	6					731	735		10.1038/nbt1092	http://dx.doi.org/10.1038/nbt1092			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	933LA	15924134				2022-12-25	WOS:000229628700034
J	Nishiya, N; Kiosses, WB; Han, JW; Ginsberg, MH				Nishiya, N; Kiosses, WB; Han, JW; Ginsberg, MH			An alpha(4) integrin-paxillin-Arf-GAP complex restricts Rac activation to the leading edge of migrating cells	NATURE CELL BIOLOGY			English	Article							ALPHA(4) CYTOPLASMIC DOMAIN; PAXILLIN KINASE LINKER; EXCHANGE FACTOR; LD4 MOTIF; INTEGRIN; PROTEIN; ARF6; ADHESION; PHOSPHORYLATION; BINDING	Formation of a stable lamellipodium at the front of migrating cells requires localization of Rac activation to the leading edge. Restriction of alpha(4) integrin phosphorylation to the leading edge limits the interaction of alpha(4) with paxillin to the sides and rear of a migrating cell. The alpha(4)-paxillin complex inhibits stable lamellipodia, thus confining lamellipod formation to the cell anterior. Here we report that binding of paxillin to the alpha(4) integrin subunit inhibits adhesion-dependent lamellipodium formation by blocking Rac activation. The paxillin LD4 domain mediates this reduction in Rac activity by recruiting an ADP-ribosylation factor GTPase-activating protein (Arf-GAP) that decreases Arf activity, thereby inhibiting Rac. Finally, the localized formation of the alpha(4)-paxillin-Arf-GAP complex mediates the polarization of Rac activity and promotes directional cell migration. These findings establish a mechanism for the spatial localization of Rac activity to enhance cell migration.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Scripps Res Inst, La Jolla, CA 92037 USA	University of California System; University of California San Diego; Scripps Research Institute	Ginsberg, MH (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	mhginsberg@ucsd.edu		Nishiya, Naoyuki/0000-0003-1575-9944				Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Arroyo AG, 1996, CELL, V85, P997, DOI 10.1016/S0092-8674(00)81301-X; Boshans RL, 2000, MOL CELL BIOL, V20, P3685, DOI 10.1128/MCB.20.10.3685-3694.2000; Brown MC, 2002, MOL BIOL CELL, V13, P1550, DOI 10.1091/mbc.02-02-0015; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Fleming IN, 2000, BIOCHEM J, V351, P173, DOI 10.1042/0264-6021:3510173; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Goldfinger LE, 2003, J CELL BIOL, V162, P731, DOI 10.1083/jcb.200304031; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Han JW, 2003, J BIOL CHEM, V278, P34845, DOI 10.1074/jbc.M304691200; Han JW, 2001, J BIOL CHEM, V276, P40903, DOI 10.1074/jbc.M102665200; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Jongewaard IN, 1996, CELL ADHES COMMUN, V3, P487, DOI 10.3109/15419069609081025; Kain KH, 2001, J BIOL CHEM, V276, P16185, DOI 10.1074/jbc.M100095200; Kil SH, 1998, DEV BIOL, V202, P29, DOI 10.1006/dbio.1998.8985; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Krauss M, 2003, J CELL BIOL, V162, P113, DOI 10.1083/jcb.200301006; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; LAM SCT, 1989, J BIOL CHEM, V264, P3742; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Liu SC, 2002, J BIOL CHEM, V277, P20887, DOI 10.1074/jbc.M110928200; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nishiya N, 2001, MOL CELL BIOL, V21, P5332, DOI 10.1128/MCB.21.16.5332-5345.2001; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Radhakrishna H, 1999, J CELL SCI, V112, P855; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rodriguez OC, 2003, NAT CELL BIOL, V5, P599, DOI 10.1038/ncb0703-599; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Sengbusch JK, 2002, J CELL BIOL, V157, P873, DOI 10.1083/jcb.200203075; Song J, 1998, J CELL SCI, V111, P2257; Srinivasan S, 2003, J CELL BIOL, V160, P375, DOI 10.1083/jcb.200208179; Tarricone C, 2001, NATURE, V411, P215, DOI 10.1038/35075620; Tumbarello DA, 2002, FEBS LETT, V513, P114, DOI 10.1016/S0014-5793(01)03244-6; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Turner CE, 2000, J CELL SCI, V113, P4139; Tzima E, 2002, EMBO J, V21, P6791, DOI 10.1093/emboj/cdf688; Wade R, 2002, ONCOGENE, V21, P96, DOI 10.1038/sj.onc.1205013; West KA, 2001, J CELL BIOL, V154, P161, DOI 10.1083/jcb.200101039; YANG JT, 1995, DEVELOPMENT, V121, P549; Yano H, 2004, J CELL BIOL, V166, P283, DOI 10.1083/jcb.200312013; Yoshii S, 1999, ONCOGENE, V18, P5680, DOI 10.1038/sj.onc.1202936; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000	57	176	184	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2005	7	4					343	U7		10.1038/ncb1234	http://dx.doi.org/10.1038/ncb1234			14	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	912KA	15793570				2022-12-25	WOS:000228075500010
J	Ritvo, P; Wilson, K; Willms, D; Upshur, R				Ritvo, P; Wilson, K; Willms, D; Upshur, R		CANVAC Sociobehavioural Study Grp	Vaccines in the public eye	NATURE MEDICINE			English	Editorial Material							HEPATITIS-B VACCINATION; HIV IMMUNIZATION; HIGH-RISK; INFLUENZA VACCINATION; ATTITUDES; ACCEPTABILITY; PERCEPTION; INFECTION; KNOWLEDGE; CHILDREN	Preventive vaccines are widely acknowledged as the best hope for protection against infectious pathogens such as avian flu, HIV and SARS. As a result, they have received much recent attention in the media that has exposed some of the challenges involved in optimally using vaccine technology.	York Univ, Sch Kinesiol & Hlth Sci, N York, ON M3J 1P3, Canada; York Univ, Dept Psychol, N York, ON M3J 1P3, Canada; Univ Toronto, Toronto Gen Hosp, Dept Med, Toronto, ON M5G 2C4, Canada; Univ Toronto, Toronto Gen Hosp, Dept Hlth Policy Management & Evaluat, Toronto, ON M5G 2C4, Canada; McMaster Univ, Dept Anthropol, Hamilton, ON L8S 4L9, Canada; Sunnybrook Hlth Sci Ctr, Primary Care Res Unit, Toronto, ON M4N 3M5, Canada	York University - Canada; York University - Canada; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; McMaster University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Ritvo, P (corresponding author), York Univ, Sch Kinesiol & Hlth Sci, N York, ON M3J 1P3, Canada.	pritvo@yorku.ca		Krahn, Murray/0000-0001-5836-397X; Upshur, Ross/0000-0003-1128-0557				Abraham J, 2002, LANCET, V360, P1498, DOI 10.1016/S0140-6736(02)11477-2; Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1; Ascherio A, 2001, NEW ENGL J MED, V344, P327, DOI 10.1056/NEJM200102013440502; CAGE S, 2004, ASS PRESS       0630; Confavreux C, 2001, NEW ENGL J MED, V344, P319, DOI 10.1056/NEJM200102013440501; DeStefano F, 2003, ARCH NEUROL-CHICAGO, V60, P504, DOI 10.1001/archneur.60.4.504; Diamond J, 1999, GUNS GERMS STEEL; Donnelly CA, 2004, LANCET INFECT DIS, V4, P672, DOI 10.1016/S1473-3099(04)01173-9; FIEBACH NH, 1991, AM J MED, V91, P393, DOI 10.1016/0002-9343(91)90157-S; Gellin BG, 2000, PEDIATRICS, V106, P1097, DOI 10.1542/peds.106.5.1097; Greenberg SB, 2000, SOUTHERN MED J, V93, P763; Harper DM, 2004, LANCET, V364, P1757, DOI 10.1016/S0140-6736(04)17398-4; Hennock EP, 1998, SOC HIST MED, V11, P49, DOI 10.1093/shm/11.1.49; Hernan MA, 2004, NEUROLOGY, V63, P838, DOI 10.1212/01.WNL.0000138433.61870.82; HIRSCHLER B, 2005, TORONTO STAR    0127; Honkanen PO, 1996, PUBLIC HEALTH, V110, P163, DOI 10.1016/S0033-3506(96)80070-9; Horton R, 2004, LANCET, V364, P2071, DOI 10.1016/S0140-6736(04)17560-0; *IMM SAF COMM, 2002, IMM SAF REV HEP B VA; Jansen VAA, 2003, SCIENCE, V301, P804, DOI 10.1126/science.1086726; Keller-Stanislawski B, 2001, VACCINE, V20, pS45, DOI 10.1016/S0264-410X(01)00298-5; KNOBLER SL, 2004, THREAT PANDEMIC INFL; Krahn MD, 2005, VACCINE, V23, P1549, DOI 10.1016/j.vaccine.2004.09.023; Kremer M, 2002, Global Public Goods Financing: New Tools for New Challenges, P37; Levy-Bruhl D, 2002, VACCINE, V20, P2065, DOI 10.1016/S0264-410X(02)00053-1; Liau A, 2000, INT J STD AIDS, V11, P445, DOI 10.1258/0956462001916227; Liau A, 1998, SEX TRANSM DIS, V25, P76, DOI 10.1097/00007435-199802000-00004; Liau A, 2001, AIDS CARE, V13, P643, DOI 10.1080/09540120120075275; McPhillips HA, 2001, ARCH PEDIAT ADOL MED, V155, P1051, DOI 10.1001/archpedi.155.9.1051; Meszaros JR, 1996, J CLIN EPIDEMIOL, V49, P697, DOI 10.1016/0895-4356(96)00007-8; Mieczkowski TA, 2002, VACCINE, V20, P1383, DOI 10.1016/S0264-410X(01)00463-7; MURASKIN W, 2001, VACCINES DEV EC WHO; Murch SH, 2004, LANCET, V363, P750, DOI 10.1016/S0140-6736(04)15715-2; Nichol KL, 2001, ARCH INTERN MED, V161, P2702, DOI 10.1001/archinte.161.22.2702; NICHOL KL, 1992, ARCH INTERN MED, V152, P106, DOI 10.1001/archinte.152.1.106; POTTER CW, 1998, TXB INFLUENZA, P3; POWELL D, 1997, MAD COWS MOTHERS MIL; QADIR A, 2004, ASS PRESS       0828; Renn O., 1991, COMMUN RISKS PUBLIC, P175, DOI DOI 10.1007/978-94-009-1952-5_10; Ritvo Paul, 2003, J Immune Based Ther Vaccines, V1, P3, DOI 10.1186/1476-8518-1-3; Sadovnick AD, 2000, LANCET, V355, P549, DOI 10.1016/S0140-6736(99)02991-8; SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507; Sturkenboom MC, 1999, PHARMACOEPIDEM DR S, V8, pS170; Touze E, 2000, REV NEUROL, V156, P242; Touze E, 2002, NEUROEPIDEMIOLOGY, V21, P180, DOI 10.1159/000059520; *UK DEP HLTH, 2004, STAT B NHS IMM STAT; Ungchusak K, 2005, NEW ENGL J MED, V352, P333, DOI 10.1056/NEJMoa044021; Vidor E, 1999, COMBINATION VACCINES, P1; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; WARD L, 2002, GUARDIAN        0221; Webb PM, 1999, J ADOLESCENT HEALTH, V25, P320, DOI 10.1016/S1054-139X(99)00066-X; Weiss RA, 2004, NAT MED, V10, pS70, DOI 10.1038/nm1150; *WHO, 2004, NEUROLOGY       0914; WHO, 2003, SUMM TABL SARS CAS C; Zimet GD, 2000, INT J STD AIDS, V11, P143, DOI 10.1258/0956462001915570; Zimet GD, 1999, J PEDIATR PSYCHOL, V24, P67, DOI 10.1093/jpepsy/24.1.67	55	23	23	0	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2005	11	4		S			S20	S24		10.1038/nm1220	http://dx.doi.org/10.1038/nm1220			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	915VO	15812485				2022-12-25	WOS:000228339600007
J	Carr, AJF; Whitmore, D				Carr, AJF; Whitmore, D			Imaging of single light-responsive clock cells reveals fluctuating free-running periods	NATURE CELL BIOLOGY			English	Article							INDIVIDUAL FIBROBLASTS; CIRCADIAN-RHYTHMS; PERSISTENT; EXPRESSION; TIME	Zebrafish tissues and cell lines contain circadian clocks that respond directly to light(1,2). Using fluorescence-activated cell sorting, we have isolated clonal cell lines that contain the reporter construct, zfperiod4-luciferase(3). Bioluminescent assays show that oscillations within cell populations are dampened in constant darkness. However, single-cell imaging reveals that individual cells continue to oscillate, but with widely distributed phases and marked stochastic fluctuations in free-running period. Because these cells are directly light responsive, we can easily follow phase shifts to single light pulses. Here we show that light acts to reset desynchronous cellular oscillations to a common phase, as well as stabilize the subsequent free-running period.	UCL, Ctr Cell & Mol Dynam, Dept Anat & Dev Biol, London WC1E 6DE, England	University of London; University College London	Whitmore, D (corresponding author), UCL, Ctr Cell & Mol Dynam, Dept Anat & Dev Biol, Rockefeller Bldg,21 Univ St, London WC1E 6DE, England.	d.whitmore@ucl.ac.uk	Carr, Amanda/ABG-6282-2020; Zebrafish, UCL/A-3125-2009	Carr, Amanda/0000-0002-5469-0030; Whitmore, David/0000-0003-2420-8220				Gonze D, 2002, P NATL ACAD SCI USA, V99, P673, DOI 10.1073/pnas.022628299; Herzog ED, 2004, J BIOL RHYTHM, V19, P35, DOI 10.1177/0748730403260776; Mihalcescu I, 2004, NATURE, V430, P81, DOI 10.1038/nature02533; Nagoshi E, 2004, CELL, V119, P693, DOI 10.1016/j.cell.2004.11.015; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Tamai TK, 2004, CURR BIOL, V14, pR104, DOI 10.1016/j.cub.2004.01.014; Tamai TK, 2003, J NEUROENDOCRINOL, V15, P344; Vallone D, 2004, P NATL ACAD SCI USA, V101, P4106, DOI 10.1073/pnas.0305436101; Welsh DK, 2004, CURR BIOL, V14, P2289, DOI 10.1016/j.cub.2004.11.057; Whitmore D, 1998, NAT NEUROSCI, V1, P701, DOI 10.1038/3703; Whitmore D, 2000, NATURE, V404, P87, DOI 10.1038/35003589; Yoo SH, 2004, P NATL ACAD SCI USA, V101, P5339, DOI 10.1073/pnas.0308709101	12	100	104	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2005	7	3					319	U127		10.1038/ncb1232	http://dx.doi.org/10.1038/ncb1232			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	902CU	15738976				2022-12-25	WOS:000227329800021
J	Bates, SL; Zhao, JZ; Roush, RT; Shelton, AM				Bates, SL; Zhao, JZ; Roush, RT; Shelton, AM			Insect resistance management in GM crops: past, present and future	NATURE BIOTECHNOLOGY			English	Article							DIAMONDBACK MOTH LEPIDOPTERA; BACILLUS-THURINGIENSIS TOXINS; PINK-BOLLWORM LEPIDOPTERA; POTATO BEETLE COLEOPTERA; BT TRANSGENIC PLANTS; FITNESS COSTS; HELICOVERPA-ZEA; PLUTELLA-XYLOSTELLA; REFUGE STRATEGIES; DELTA-ENDOTOXIN	Transgenic plants expressing insecticidal proteins from the bacterium Bacillus thuringiensis (Bt) were first commercialized in 1996 amid concern from some scientists, regulators and environmentalists that the widespread use of Bt crops would inevitably lead to resistance and the loss of a 'public good,' specifically, the susceptibility of insect pests to Bt proteins. Eight years later, Bt corn and cotton have been grown on a cumulative area >80 million ha worldwide. Despite dire predictions to the contrary, resistance to a Bt crop has yet to be documented, suggesting that resistance management strategies have been effective thus far. However, current strategies to delay resistance remain far from ideal. Eight years without resistance provides a timely opportunity for researchers, regulators and industry to reassess the risk of resistance and the most effective strategies to preserve Bt and other novel insect-resistant crops in development.	Cornell Univ, New York State Agr Expt Stn, Dept Entomol, Geneva, NY 14456 USA; Univ Calif Davis, Statewide IPM Program, Davis, CA 95616 USA	Cornell University; University of California System; University of California Davis	Shelton, AM (corresponding author), Cornell Univ, New York State Agr Expt Stn, Dept Entomol, 630 W North St, Geneva, NY 14456 USA.	ams5@cornell.edu		Zhao, Jianzhou/0000-0001-9136-2442				Akhurst RJ, 2003, J ECON ENTOMOL, V96, P1290, DOI 10.1603/0022-0493-96.4.1290; ALSTAD DN, 1995, SCIENCE, V268, P1894, DOI 10.1126/science.268.5219.1894; Alyokhin AV, 1999, J ECON ENTOMOL, V92, P510, DOI 10.1093/jee/92.3.510; Andow DA, 1998, J ECON ENTOMOL, V91, P572, DOI 10.1093/jee/91.3.572; Andow DA, 2002, ECOL APPL, V12, P1378, DOI 10.2307/3099978; [Anonymous], 2003, 30 ISAAA; Arpaia S, 1997, ENTOMOL EXP APPL, V82, P91, DOI 10.1023/A:1002935706990; Burd AD, 2003, J ECON ENTOMOL, V96, P137, DOI 10.1603/0022-0493-96.1.137; Cao J, 2001, MOL BREEDING, V8, P207, DOI 10.1023/A:1013734923291; Caprio MA, 2001, J ECON ENTOMOL, V94, P698, DOI 10.1603/0022-0493-94.3.698; Carriere Y, 2003, P NATL ACAD SCI USA, V100, P1519, DOI 10.1073/pnas.0436708100; Carriere Y, 2001, J ECON ENTOMOL, V94, P1571, DOI 10.1603/0022-0493-94.6.1571; Carriere Y, 2001, J ECON ENTOMOL, V94, P935, DOI 10.1603/0022-0493-94.4.935; Chilcutt CF, 2004, P NATL ACAD SCI USA, V101, P7526, DOI 10.1073/pnas.0400546101; Dove A, 1999, NAT BIOTECHNOL, V17, P531, DOI 10.1038/9830; Fitt GP, 2000, CROP PROT, V19, P793, DOI 10.1016/S0261-2194(00)00106-X; Fox JL, 2003, NAT BIOTECHNOL, V21, P958, DOI 10.1038/nbt0903-958b; Frutos R, 1999, CRIT REV BIOTECHNOL, V19, P227, DOI 10.1080/0738-859991229251; Gahan LJ, 2001, SCIENCE, V293, P857, DOI 10.1126/science.1060949; Glaser JA, 2003, BIOTECHNOL ADV, V22, P45, DOI 10.1016/j.biotechadv.2003.08.016; Gould F, 1998, ANNU REV ENTOMOL, V43, P701, DOI 10.1146/annurev.ento.43.1.701; Gould F, 2000, NAT BIOTECHNOL, V18, P266, DOI 10.1038/73693; GOULD F, 1994, BIOCONTROL SCI TECHN, V4, P451, DOI 10.1080/09583159409355357; Gould F, 2002, P NATL ACAD SCI USA, V99, P16581, DOI 10.1073/pnas.242382499; GROETERS FR, 1994, EVOLUTION, V48, P197, DOI 10.2307/2410015; Hargrove TR, 1999, AM SCI, V87, P24; Hawthorne D. B., 2002, MONITORING RESISTANC; Huang F, 1999, B ENTOMOL RES, V89, P449, DOI 10.1017/S0007485399000589; Hurley TM, 2002, ENVIRON RESOUR ECON, V22, P537, DOI 10.1023/A:1019858732103; Ives AR, 2002, ECOL LETT, V5, P792, DOI 10.1046/j.1461-0248.2002.00392.x; Jackson RE, 2004, J ENTOMOL SCI, V39, P46, DOI 10.18474/0749-8004-39.1.46; JAFFE G, 2003, PLANTING TROUBLE UPD; JAMES C, 2002, 27 ISAA; Janmaat AF, 2003, P ROY SOC B-BIOL SCI, V270, P2263, DOI 10.1098/rspb.2003.2497; Lee MK, 2003, APPL ENVIRON MICROB, V69, P4648, DOI 10.1128/AEM.69.8.4648-4657.2003; Liu D, 2003, NAT BIOTECHNOL, V21, P1222, DOI 10.1038/nbt866; Liu YB, 2001, J ECON ENTOMOL, V94, P1237, DOI 10.1603/0022-0493-94.5.1237; MALLET J, 1992, P ROY SOC B-BIOL SCI, V250, P165, DOI 10.1098/rspb.1992.0145; McCaffery AR, 1998, PHILOS T R SOC B, V353, P1735, DOI 10.1098/rstb.1998.0326; Morin S, 2003, P NATL ACAD SCI USA, V100, P5004, DOI 10.1073/pnas.0831036100; Nagamatsu Y, 1999, FEBS LETT, V460, P385, DOI 10.1016/S0014-5793(99)01327-7; Oppert B, 2000, ENTOMOL EXP APPL, V96, P281, DOI 10.1023/A:1004061222318; Ramachandran S, 1998, J ECON ENTOMOL, V91, P1239, DOI 10.1093/jee/91.6.1239; Roush R. T., 1997, ADV INSECT CONTROL R, P271; ROUSH RT, 1989, PESTIC SCI, V26, P423, DOI 10.1002/ps.2780260409; Roush RT, 1998, PHILOS T R SOC B, V353, P1777, DOI 10.1098/rstb.1998.0330; Roush RT, 1997, PESTIC SCI, V51, P328, DOI 10.1002/(SICI)1096-9063(199711)51:3&lt;328::AID-PS650&gt;3.0.CO;2-B; Sayyed AH, 2001, ECOL ENTOMOL, V26, P502, DOI 10.1046/j.1365-2311.2001.00358.x; Schnepf E, 1998, MICROBIOL MOL BIOL R, V62, P775, DOI 10.1128/MMBR.62.3.775-806.1998; Sequeira RV, 2001, AUST J ENTOMOL, V40, P264, DOI 10.1046/j.1440-6055.2001.00234.x; Shelton AM, 2000, NAT BIOTECHNOL, V18, P339, DOI 10.1038/73804; Shelton AM, 2002, ANNU REV ENTOMOL, V47, P845, DOI 10.1146/annurev.ento.47.091201.145309; SMITH M, 2003, ONL P CAST PEST RES; Tabashnik BE, 2003, J ECON ENTOMOL, V96, P1031, DOI 10.1603/0022-0493-96.4.1031; TABASHNIK BE, 1994, BIOCONTROL SCI TECHN, V4, P419, DOI 10.1080/09583159409355352; TABASHNIK BE, 1994, ANNU REV ENTOMOL, V39, P47, DOI 10.1146/annurev.en.39.010194.000403; TABASHNIK BE, 1994, P ROY SOC B-BIOL SCI, V255, P7, DOI 10.1098/rspb.1994.0002; TABASHNIK BE, 1990, J ECON ENTOMOL, V83, P1671, DOI 10.1093/jee/83.5.1671; Tang JD, 1997, J ECON ENTOMOL, V90, P732, DOI 10.1093/jee/90.3.732; Tang JD, 2001, J ECON ENTOMOL, V94, P240, DOI 10.1603/0022-0493-94.1.240; Trisyono A, 1997, J ECON ENTOMOL, V90, P267, DOI 10.1093/jee/90.2.267; US EPA (U.S. Environmental Protection Agency), 2001, BIOP REG ACT DOC BAC; VADLAMUDI RK, 1995, J BIOL CHEM, V270, P5490, DOI 10.1074/jbc.270.10.5490; Warren G.W., 1997, ADV INSECT CONTROL R, P109, DOI DOI 10.1201/9780203211731.CH7; Williamson VM, 2003, NAT BIOTECHNOL, V21, P1294, DOI 10.1038/nbt1103-1294; Zhao JianZhou, 1998, Scientia Agricultura Sinica, V31, P1; Zhao JZ, 2003, NAT BIOTECHNOL, V21, P1493, DOI 10.1038/nbt907; Zhao JZ, 2002, J ECON ENTOMOL, V95, P14, DOI 10.1603/0022-0493-95.1.14; ZHAO JZ, 2001, TRANSGENIC COTTON, P165	69	395	491	1	198	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2005	23	1					57	62		10.1038/nbt1056	http://dx.doi.org/10.1038/nbt1056			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	885ZK	15637622				2022-12-25	WOS:000226195700029
J	Wanzel, M; Kleine-Kohlbrecher, D; Herold, S; Hock, A; Berns, K; Park, J; Hemmings, B; Eilers, M				Wanzel, M; Kleine-Kohlbrecher, D; Herold, S; Hock, A; Berns, K; Park, J; Hemmings, B; Eilers, M			Akt and 14-3-3 eta regulate Miz1 to control cell-cycle arrest after DNA damage	NATURE CELL BIOLOGY			English	Article							C-MYC; TRANSCRIPTIONAL REPRESSION; EXPRESSION; GENE; PROTEIN; GROWTH; APOPTOSIS; CANCER; MDM2; P21	The transcription factor Miz1 is required for DNA-damage-induced cell-cycle arrest. We have now identified 14-3-3. as a gene that inhibits Miz1 function through interaction with its DNA binding domain. Binding of 14-3-3. to Miz1 depends on phosphorylation by Akt and regulates the recovery of cells from arrest after DNA damage. Miz1 has two functions in response to DNA damage: first, it is required for upregulation of a large group of genes, a function that is regulated by c-Myc, but not by 14-3-3.; second, Miz1 represses the expression of many genes in response to DNA damage in an Akt- and 14-3-3-eta-regulated manner.	Univ Marburg, Inst Mol Biol & Tumor Res, D-35033 Marburg, Germany; Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands; Novartis Res Fdn, Friedrich Miescher Inst, CH-4058 Basel, Switzerland	Philipps University Marburg; Netherlands Cancer Institute; Friedrich Miescher Institute for Biomedical Research; Novartis	Eilers, M (corresponding author), Univ Marburg, Inst Mol Biol & Tumor Res, Emil Mannkopff Str 2, D-35033 Marburg, Germany.	eilers@imt.uni-marburg.de	Park, Jongsun/E-7465-2010	Park, Jongsun/0000-0002-4690-1854; Eilers, Martin/0000-0002-0376-6533				Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Berns K, 2000, ONCOGENE, V19, P3330, DOI 10.1038/sj.onc.1203639; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Brummelkamp TR, 2002, J BIOL CHEM, V277, P6567, DOI 10.1074/jbc.M110492200; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Cheyette BNR, 2002, DEV CELL, V2, P449, DOI 10.1016/S1534-5807(02)00140-5; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Eapen AK, 2001, MOL CELL BIOL, V21, P6113, DOI 10.1128/MCB.21.18.6113-6121.2001; ELGHORR AA, 1995, PHOTOCHEM PHOTOBIOL, V62, P326, DOI 10.1111/j.1751-1097.1995.tb05276.x; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Glaeser M, 2001, HORM METAB RES, V33, P121, DOI 10.1055/s-2001-14938; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; Itoh K, 1996, J BIOCHEM-TOKYO, V119, P385; Levens DL, 2003, GENE DEV, V17, P1071, DOI 10.1101/gad.1095203; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Masuyama N, 2001, J BIOL CHEM, V276, P32799, DOI 10.1074/jbc.M105431200; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Mollinari C, 2003, DEV CELL, V5, P295, DOI 10.1016/S1534-5807(03)00205-3; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Player A, 2003, INT J CANCER, V107, P238, DOI 10.1002/ijc.11391; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Sheen JH, 2002, MOL CELL BIOL, V22, P1819, DOI 10.1128/MCB.22.6.1819-1833.2002; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Su YA, 1996, MOL CARCINOGEN, V15, P270, DOI 10.1002/(SICI)1098-2744(199604)15:4<270::AID-MC4>3.0.CO;2-K; Teng SC, 2004, J BIOL CHEM, V279, P14649, DOI 10.1074/jbc.M308842200; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	38	71	73	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2005	7	1					30	+		10.1038/ncb1202	http://dx.doi.org/10.1038/ncb1202			21	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	884UZ	15580267				2022-12-25	WOS:000226113500012
J	Disanza, A; Carlier, MF; Stradal, TEB; Didry, D; Frittoli, E; Confalonieri, S; Croce, A; Wehland, J; Di Fiore, PP; Scita, G				Disanza, A; Carlier, MF; Stradal, TEB; Didry, D; Frittoli, E; Confalonieri, S; Croce, A; Wehland, J; Di Fiore, PP; Scita, G			Eps8 controls actin-based motility by capping the barbed ends of actin filaments	NATURE CELL BIOLOGY			English	Article							SHIGELLA-FLEXNERI; ARP2/3 COMPLEX; INTRACELLULAR MOTILITY; N-WASP; PROTEINS; FAMILY; ACTIVATION; GELSOLIN; CELLS; RAC	Actin filament barbed-end capping proteins are essential for cell motility, as they regulate the growth of actin filaments to generate propulsive force. One family of capping proteins, whose prototype is gelsolin, shares modular architecture, mechanism of action, and regulation through signalling-dependent mechanisms, such as Ca2+ or phosphatidylinositol-4,5- phosphate binding. Here we show that proteins of another family, the Eps8 family, also show barbed- end capping activity, which resides in their conserved carboxy-terminal effector domain. The isolated effector domain of Eps8 caps barbed ends with an affinity in the nanomolar range. Conversely, full-length Eps8 is auto-inhibited in vitro, and interaction with the Abi1 protein relieves this inhibition. In vivo, Eps8 is recruited to actin dynamic sites, and its removal impairs actin-based propulsion. Eps8-family proteins do not show any similarity to gelsolin-like proteins. Thus, our results identify a new family of actin cappers, and unveil novel modalities of regulation of capping through protein - protein interactions. One established function of the Eps8 - Abi1 complex is to participate in the activation of the small GTPase Rac, suggesting a multifaceted role for this complex in actin dynamics, possibly through the participation in alternative larger complexes.	IFOM Ist FIRC Oncol Mol, I-20139 Milan, Italy; IEO, Dept Expt Oncol, I-20141 Milan, Italy; CNRS, Dynam Cytosquelette Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; German Res Ctr Biotechnol, Dept Cell Biol, D-38124 Braunschweig, Germany; Univ Milan, Dipartimento Med Chirurg & Odontoiatria, I-20122 Milan, Italy	IFOM - FIRC Institute of Molecular Oncology; IRCCS European Institute of Oncology (IEO); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Helmholtz Association; Helmholtz-Center for Infection Research; University of Milan	Carlier, MF (corresponding author), IFOM Ist FIRC Oncol Mol, Via Adamello 16, I-20139 Milan, Italy.	carlier@lebs.cnrs-gif.fr; giorgio.scita@ifom-ieo-campus.it	Scita, Giorgio/J-9670-2012; Confalonieri, Stefano/AAQ-6786-2020; Di Fiore, Pier Paolo/K-2130-2012	Confalonieri, Stefano/0000-0001-6886-9851; Di Fiore, Pier Paolo/0000-0002-2252-0950; Disanza, Andrea/0000-0001-5101-2907; Scita, Giorgio/0000-0001-7984-1889; Stradal, Theresia/0000-0002-0352-9474				Allen PG, 2003, NAT CELL BIOL, V5, P972, DOI 10.1038/ncb1059; Bear JE, 2001, CURR OPIN CELL BIOL, V13, P158, DOI 10.1016/S0955-0674(00)00193-9; Bogdan S, 2003, DEVELOPMENT, V130, P4427, DOI 10.1242/dev.00663; Cooper JA, 2000, CURR OPIN CELL BIOL, V12, P97, DOI 10.1016/S0955-0674(99)00062-9; Cossart P, 2000, CELL MICROBIOL, V2, P195, DOI 10.1046/j.1462-5822.2000.00053.x; Croce A, 2004, NAT CELL BIOL, V6, P1173, DOI 10.1038/ncb1198; Di Fiore PP, 2002, INT J BIOCHEM CELL B, V34, P1178, DOI 10.1016/S1357-2725(02)00064-X; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Geese M, 2000, J CELL SCI, V113, P1415; Hofer D, 1998, ANN NY ACAD SCI, V859, P75, DOI 10.1111/j.1749-6632.1998.tb11112.x; Innocenti M, 2004, NAT CELL BIOL, V6, P319, DOI 10.1038/ncb1105; Kunda P, 2003, CURR BIOL, V13, P1867, DOI 10.1016/j.cub.2003.10.005; Littlefield R, 1998, ANNU REV CELL DEV BI, V14, P487, DOI 10.1146/annurev.cellbio.14.1.487; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Lommel S, 2001, EMBO REP, V2, P850, DOI 10.1093/embo-reports/kve197; McGough AM, 2003, FEBS LETT, V552, P75, DOI 10.1016/S0014-5793(03)00932-3; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Mounier J, 1999, J CELL SCI, V112, P2069; Offenhauser N, 2004, MOL BIOL CELL, V15, P91, DOI 10.1091/mbc.E03-06-0427; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Pantaloni D, 2000, NAT CELL BIOL, V2, P385, DOI 10.1038/35017011; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Schafer DA, 1998, J CELL BIOL, V143, P1919, DOI 10.1083/jcb.143.7.1919; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Scita G, 2001, J CELL BIOL, V154, P1031, DOI 10.1083/jcb.200103146; Shibata T, 2002, CURR BIOL, V12, P341, DOI 10.1016/S0960-9822(02)00689-9; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; Steffen A, 2004, EMBO J, V23, P749, DOI 10.1038/sj.emboj.7600084; Tocchetti A, 2003, GENOMICS, V81, P234, DOI 10.1016/S0888-7543(03)00002-8; Wiesner S, 2003, J CELL BIOL, V160, P387, DOI 10.1083/jcb.200207148; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; Witke W, 2001, J CELL BIOL, V154, P775, DOI 10.1083/jcb.200101113; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517; Zigmond SH, 2004, CURR OPIN CELL BIOL, V16, P99, DOI 10.1016/j.ceb.2003.10.019	34	155	160	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2004	6	12					1180	1188		10.1038/ncb1199	http://dx.doi.org/10.1038/ncb1199			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	875WQ	15558031				2022-12-25	WOS:000225453300010
J	Sellick, GS; Barker, KT; Stolte-Dijkstra, I; Fleischmann, C; Coleman, RJ; Garrett, C; Gloyn, AL; Edghill, EL; Hattersley, AT; Wellauer, PK; Goodwin, G; Houlston, RS				Sellick, GS; Barker, KT; Stolte-Dijkstra, I; Fleischmann, C; Coleman, RJ; Garrett, C; Gloyn, AL; Edghill, EL; Hattersley, AT; Wellauer, PK; Goodwin, G; Houlston, RS			Mutations in PTF1A cause pancreatic and cerebellar agenesis	NATURE GENETICS			English	Article							NEONATAL DIABETES-MELLITUS; GLUCOKINASE DEFICIENCY; EXOCRINE; SUBUNIT; GENE; PTF1-P48; PROTEIN	Individuals with permanent neonatal diabetes mellitus usually present within the first three months of life and require insulin treatment(1,2). We recently identified a locus on chromosome 10p13-p12.1 involved in permanent neonatal diabetes mellitus associated with pancreatic and cerebellar agenesis in a genome-wide linkage search of a consanguineous Pakistani family(3). Here we report the further linkage analysis of this family and a second family of Northern European descent segregating an identical phenotype. Positional cloning identified the mutations 705insG and C886T in the gene PTF1A, encoding pancreas transcription factor 1alpha, as disease-causing sequence changes. Both mutations cause truncation of the expressed PTF1A protein C-terminal to the basic-helix-loop-helix domain. Reporter-gene studies using a minimal PTF1A deletion mutant indicate that the deleted region defines a new domain that is crucial for the function of this protein. PTF1A is known to have a role in mammalian pancreatic development(4,5), and the clinical phenotype of the affected individuals implicated the protein as a key regulator of cerebellar neurogenesis. The essential role of PTF1A in normal cerebellar development was confirmed by detailed neuropathological analysis of Ptf1a(-/-) mice.	Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England; Univ Groningen Hosp, Dept Clin Genet, NL-9700 RB Groningen, Netherlands; NW London Hosp NHS Trust, NW Thames Reg Genet Serv, Kennedy Galton Ctr, Harrow HA1 3UJ, Middx, England; Peninsula Med Sch, Exeter EX2 5AX, Devon, England; Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; Inst Canc Res, Sect Mol Carcinogenesis, Sutton SM2 5NG, Surrey, England	University of London; Institute of Cancer Research - UK; University of Groningen; University of Exeter; Swiss Institute Experimental Cancer Research; University of London; Institute of Cancer Research - UK	Houlston, RS (corresponding author), Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England.	Richard.Houlston@icr.ac.uk		Hattersley, Andrew/0000-0001-5620-473X; Gloyn, Anna/0000-0003-1205-1844; Houlston, Richard/0000-0002-5268-0242				COCKELL M, 1989, MOL CELL BIOL, V9, P2464, DOI 10.1128/MCB.9.6.2464; Gentz J C, 1969, Adv Pediatr, V16, P345; Gloyn AL, 2004, NEW ENGL J MED, V350, P1838, DOI 10.1056/NEJMoa032922; Hoveyda N, 1999, J MED GENET, V36, P700; Kawaguchi Y, 2002, NAT GENET, V32, P128, DOI 10.1038/ng959; Krapp A, 1996, EMBO J, V15, P4317, DOI 10.1002/j.1460-2075.1996.tb00806.x; Krapp A, 1998, GENE DEV, V12, P3752, DOI 10.1101/gad.12.23.3752; KRUGLYAK L, 1995, AM J HUM GENET, V56, P519; Njolstad PR, 2001, NEW ENGL J MED, V344, P1588, DOI 10.1056/NEJM200105243442104; Njolstad PR, 2003, DIABETES, V52, P2854, DOI 10.2337/diabetes.52.11.2854; Obata J, 2001, GENES CELLS, V6, P345, DOI 10.1046/j.1365-2443.2001.00422.x; Rose SD, 2001, J BIOL CHEM, V276, P44018, DOI 10.1074/jbc.M106264200; Sellick GS, 2003, DIABETES, V52, P2636, DOI 10.2337/diabetes.52.10.2636; Shield JP, 1997, ARCH DIS CHILD-FETAL, V76, P39; Sigvardsson M, 2000, MOL CELL BIOL, V20, P3640, DOI 10.1128/MCB.20.10.3640-3654.2000; Zecchin E, 2004, DEV BIOL, V268, P174, DOI 10.1016/j.ydbio.2003.12.016	16	297	309	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2004	36	12					1301	1305		10.1038/ng1475	http://dx.doi.org/10.1038/ng1475			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	874MI	15543146				2022-12-25	WOS:000225354100018
J	Collins, FS				Collins, FS			What we do and don't know about 'race', 'ethnicity', genetics and health at the dawn of the genome era	NATURE GENETICS			English	Article								A true understanding of disease risk requires a thorough examination of root causes. 'Race' and 'ethnicity' are poorly defined terms that serve as flawed surrogates for multiple environmental and genetic factors in disease causation, including ancestral geographic origins, socioeconomic status, education and access to health care. Research must move beyond these weak and imperfect proxy relationships to define the more proximate factors that influence health.	NHGRI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Collins, FS (corresponding author), NHGRI, NIH, Bethesda, MD 20892 USA.	fc23a@nih.gov						Angier Natalie, 2000, NY TIMES        1107, pF1; Bamshad M, 2004, NAT REV GENET, V5, P598, DOI 10.1038/nrg1401; Burchard EG, 2003, NEW ENGL J MED, V348, P1170, DOI 10.1056/NEJMsb025007; Collins FS, 2003, NATURE, V422, P835, DOI 10.1038/nature01626; Collins FS, 2004, NATURE, V429, P475, DOI 10.1038/nature02628; Cooper RS, 2003, NEW ENGL J MED, V348, P1166, DOI 10.1056/NEJMsb022863; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Inoue N, 2002, GASTROENTEROLOGY, V123, P86, DOI 10.1053/gast.2002.34155; Marshall E, 1998, SCIENCE, V282, P654, DOI 10.1126/science.282.5389.654; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; Sankar P, 2004, JAMA-J AM MED ASSOC, V291, P2985, DOI 10.1001/jama.291.24.2985	11	196	197	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2004	36	11		S			S13	S15		10.1038/ng1436	http://dx.doi.org/10.1038/ng1436			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Genetics & Heredity	867PH	15507997	Bronze			2022-12-25	WOS:000224854000005
J	Trucco, A; Polishchuk, RS; Martella, O; Di Pentima, A; Fusella, A; Di Giandomenico, D; San Pietro, E; Beznoussenko, GV; Polishchuk, EV; Baldassarre, M; Buccione, R; Geerts, WJC; Koster, AJ; Burger, KNJ; Mironov, AA; Luini, A				Trucco, A; Polishchuk, RS; Martella, O; Di Pentima, A; Fusella, A; Di Giandomenico, D; San Pietro, E; Beznoussenko, GV; Polishchuk, EV; Baldassarre, M; Buccione, R; Geerts, WJC; Koster, AJ; Burger, KNJ; Mironov, AA; Luini, A			Secretory traffic triggers the formation of tubular continuities across Golgi sub-compartments	NATURE CELL BIOLOGY			English	Article							ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; ELECTRON TOMOGRAPHY; APPARATUS; PROTEINS; MEMBRANE; COMPLEX; CELLS; CISTERNAE; CHOLESTEROL		Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Chieti, Italy; Univ Utrecht, Inst Biomembranes, Dept Mol Cell Biol, NL-3584 CH Utrecht, Netherlands	Consorzio Mario Negri Sud; Utrecht University	Mironov, AA (corresponding author), Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Chieti, Italy.	mironov@dcbo.negrisud.it; luini@negrisud.it	Geerts, Willie J.C./B-7640-2011; Luini, Alberto/L-1372-2013; Baldassarre, Massimiliano/E-6236-2011; Baldassarre, Massimiliano/AAI-6581-2021; Koster, Abraham/I-7665-2017	Geerts, Willie J.C./0000-0002-4530-7458; Luini, Alberto/0000-0002-8729-2549; Baldassarre, Massimiliano/0000-0002-2498-4767; Baldassarre, Massimiliano/0000-0002-2498-4767; Koster, Abraham/0000-0003-1717-2549; Buccione, Roberto/0000-0001-9210-5261	Telethon [GGP04235] Funding Source: Medline	Telethon(Fondazione Telethon)		Aridor M, 1999, J BIOL CHEM, V274, P4389, DOI 10.1074/jbc.274.7.4389; Aridor M, 2001, J CELL BIOL, V152, P213, DOI 10.1083/jcb.152.1.213; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; Bergmann JE, 1989, METHOD CELL BIOL, V32, P85; Beznoussenko GV, 2002, ANAT RECORD, V268, P226, DOI 10.1002/ar.10157; Bonfanti L, 1998, CELL, V95, P993, DOI 10.1016/S0092-8674(00)81723-7; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Cluett EB, 1997, MOL BIOL CELL, V8, P2233, DOI 10.1091/mbc.8.11.2233; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; Cosson P, 2002, P NATL ACAD SCI USA, V99, P12831, DOI 10.1073/pnas.192460999; Glick BS, 1998, CELL, V95, P883, DOI 10.1016/S0092-8674(00)81713-4; Hauri HP, 2000, J CELL SCI, V113, P587; Hirschberg K, 2000, METHOD ENZYMOL, V327, P69, DOI 10.1016/S0076-6879(00)27268-6; Holthuis JCM, 2001, PHYSIOL REV, V81, P1689, DOI 10.1152/physrev.2001.81.4.1689; Horton AC, 2003, J NEUROSCI, V23, P6188; Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042; Klumperman J, 2000, CURR OPIN CELL BIOL, V12, P445, DOI 10.1016/S0955-0674(00)00115-0; Koster AJ, 1997, J STRUCT BIOL, V120, P276, DOI 10.1006/jsbi.1997.3933; KUISMANEN E, 1989, METHOD CELL BIOL, V32, P257; KWEON HS, IN PRESS MOL BIOL CE; Ladinsky MS, 1999, J CELL BIOL, V144, P1135, DOI 10.1083/jcb.144.6.1135; Lanoix J, 1999, EMBO J, V18, P4935, DOI 10.1093/emboj/18.18.4935; Marra P, 2001, NAT CELL BIOL, V3, P1101, DOI 10.1038/ncb1201-1101; Marsh BJ, 2004, P NATL ACAD SCI USA, V101, P5565, DOI 10.1073/pnas.0401242101; Marsh BJ, 2001, P NATL ACAD SCI USA, V98, P2399, DOI 10.1073/pnas.051631998; Martinez-Menarguez JA, 2001, J CELL BIOL, V155, P1213, DOI 10.1083/jcb.200108029; Maxfield FR, 2002, J CLIN INVEST, V110, P891, DOI 10.1172/JCI200216500; Mironov A, 1998, FASEB J, V12, P249; Mironov AA, 1997, J CELL BIOL, V138, P481, DOI 10.1083/jcb.138.3.481; Mironov AA, 2001, J CELL BIOL, V155, P1225, DOI 10.1083/jcb.200108073; Mitra K, 2004, P NATL ACAD SCI USA, V101, P4083, DOI 10.1073/pnas.0307332101; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; Neumann U, 2003, ANN BOT-LONDON, V92, P167, DOI 10.1093/aob/mcg134; NICOLAS MT, 1989, J HISTOCHEM CYTOCHEM, V37, P663, DOI 10.1177/37.5.2703702; Orci L, 1996, P NATL ACAD SCI USA, V93, P8968, DOI 10.1073/pnas.93.17.8968; Pelham H, 2000, TRAFFIC, V1, P191, DOI 10.1034/j.1600-0854.2000.010213.x; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; Pelham HRB, 2000, CELL, V102, P713, DOI 10.1016/S0092-8674(00)00060-X; Pelham HRB, 2001, J CELL BIOL, V155, P1099, DOI 10.1083/jcb.200110160; Pelham HRB, 1997, EUR J CELL BIOL, V74, P311; Polishchuk EV, 2003, MOL BIOL CELL, V14, P4470, DOI 10.1091/mbc.E03-01-0033; Polishchuk RS, 2000, J CELL BIOL, V148, P45, DOI 10.1083/jcb.148.1.45; Rabouille C, 1999, J CELL SCI, V112, P3319; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; Seemann J, 2000, NATURE, V407, P1022, DOI 10.1038/35039538; Thyberg J, 1999, EXP CELL RES, V246, P263, DOI 10.1006/excr.1998.4326; Volchuk A, 2004, MOL BIOL CELL, V15, P1506, DOI 10.1091/mbc.E03-08-0625; WEIDMAN PJ, 1995, TRENDS CELL BIOL, V5, P302, DOI 10.1016/S0962-8924(00)89046-7; Weiss M, 2000, FEBS LETT, V486, P2, DOI 10.1016/S0014-5793(00)02155-4	49	220	237	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2004	6	11					1071	U11		10.1038/ncb1180	http://dx.doi.org/10.1038/ncb1180			16	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	867BI	15502824				2022-12-25	WOS:000224816700012
J	Mendell, JT; Sharifi, NA; Meyers, JL; Martinez-Murillo, FM; Dietz, HC				Mendell, JT; Sharifi, NA; Meyers, JL; Martinez-Murillo, FM; Dietz, HC			Nonsense surveillance regulates expression of diverse classes of mammalian transcripts and mutes genomic noise	NATURE GENETICS			English	Article							MESSENGER-RNA DECAY; AMINO-ACID STARVATION; MEDIATED DECAY; TERMINATION-CODON; YEAST; GENE; PATHWAYS; CELLS; ABUNDANCE; MECHANISM	Premature termination codons induce rapid transcript degradation in eukaryotic cells through nonsense-mediated mRNA decay (NMD)(1,2). This pathway can modulate phenotypes arising from nonsense or frameshift mutations, but little is known about the physiologic role of NMD in higher eukaryotes. To address this issue, we examined expression profiles in mammalian cells depleted of Rent1 (also called hUpf1), a factor essential for NMD3,4. Upregulated transcripts included those with upstream open reading frames in the 5' untranslated region, alternative splicing that introduces nonsense codons or frameshifts, introns in the 3' untranslated region or selenocysteine codons. Transcripts derived from ancient transposons and endogenous retroviruses were also upregulated. These RNAs are unified by the presence of a spliced intron at least 50 nucleotides downstream of a termination codon, a context sufficient to initiate NMD5. Consistent with direct regulation by NMD, representative upregulated transcripts decayed more slowly in cells deficient in NMD. In addition, inhibition of NMD induced by amino acid starvation upregulated transcripts that promote amino acid homeostasis. These results document that nonsense surveillance is a crucial post-transcriptional regulatory event that influences the expression of broad classes of physiologic transcripts, has been functionally incorporated into essential homeostatic mechanisms and suppresses expression of evolutionary remnants.	Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University	Dietz, HC (corresponding author), Johns Hopkins Univ, Sch Med, Inst Med Genet, 539 Broadway Res Bldg,733 N Broadway, Baltimore, MD 21205 USA.	hdietz@jhmi.edu						Aubel C, 2003, INT J BIOCHEM CELL B, V35, P1388, DOI 10.1016/S1357-2725(03)00098-0; Averous J, 2004, J BIOL CHEM, V279, P5288, DOI 10.1074/jbc.M311862200; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; Forsberg H, 2001, CURR GENET, V40, P91, DOI 10.1007/s002940100244; Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893; Gatfield D, 2003, EMBO J, V22, P3960, DOI 10.1093/emboj/cdg371; GOODCHILD NL, 1995, VIROLOGY, V206, P164, DOI 10.1016/S0042-6822(95)80031-X; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; He F, 2003, MOL CELL, V12, P1439, DOI 10.1016/S1097-2765(03)00446-5; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Inoue K, 2004, NAT GENET, V36, P361, DOI 10.1038/ng1322; LEEDS P, 1991, GENE DEV, V5, P2303, DOI 10.1101/gad.5.12a.2303; LEEDS P, 1992, MOL CELL BIOL, V12, P2165, DOI 10.1128/MCB.12.5.2165; Lelivelt MJ, 1999, MOL CELL BIOL, V19, P6710; Lewis BP, 2003, P NATL ACAD SCI USA, V100, P189, DOI 10.1073/pnas.0136770100; Lindeskog M, 1997, J GEN VIROL, V78, P2575, DOI 10.1099/0022-1317-78-10-2575; Medghalchi SM, 2001, HUM MOL GENET, V10, P99, DOI 10.1093/hmg/10.2.99; Mendell JT, 2002, SCIENCE, V298, P419, DOI 10.1126/science.1074428; Moriarty PM, 1998, MOL CELL BIOL, V18, P2932, DOI 10.1128/MCB.18.5.2932; Nagy E, 1998, TRENDS BIOCHEM SCI, V23, P198, DOI 10.1016/S0968-0004(98)01208-0; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; PAIN VM, 1994, BIOCHIMIE, V76, P718, DOI 10.1016/0300-9084(94)90076-0; Pan YX, 2003, J BIOL CHEM, V278, P38402, DOI 10.1074/jbc.M304574200; Robertson HM, 1997, GENE, V205, P219, DOI 10.1016/S0378-1119(97)00471-X; Schreve JL, 2004, BIOCHEM BIOPH RES CO, V313, P745, DOI 10.1016/j.bbrc.2003.11.172; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; Sun XL, 1998, P NATL ACAD SCI USA, V95, P10009, DOI 10.1073/pnas.95.17.10009; Wagner E, 2002, J CELL SCI, V115, P3033; Zhang J, 1998, RNA, V4, P801, DOI 10.1017/S1355838298971849; ZHANG SA, 1995, MOL CELL BIOL, V15, P2231	30	619	629	1	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2004	36	10					1073	1078		10.1038/ng1429	http://dx.doi.org/10.1038/ng1429			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	857YN	15448691	Bronze			2022-12-25	WOS:000224156500015
J	Van Raamsdonk, CD; Fitch, KR; Fuchs, H; de Angelis, MH; Barsh, GS				Van Raamsdonk, CD; Fitch, KR; Fuchs, H; de Angelis, MH; Barsh, GS			Effects of G-protein mutations on skin color	NATURE GENETICS			English	Article							ENDOTHELIN RECEPTOR-B; CREST-DERIVED MELANOCYTES; NERVOUS-SYSTEM; GENOME-WIDE; COAT COLOR; MOUSE; MICE; EXPRESSION; KIT; MIGRATION	A new class of dominant dark skin (Dsk) mutations discovered in a screen of similar to30,000 mice is caused by increased dermal melanin. We identified three of four such mutations as hypermorphic alleles of Gnaq and Gna11, which encode widely expressed Galphaq subunits, act in an additive and quantitative manner, and require Ednrb. Interactions between Gq and Kit receptor tyrosine kinase signaling can mediate coordinate or independent control of skin and hair color. Our results provide a mechanism that can explain several aspects of human pigmentary variation and show how polymorphism of essential proteins and signaling pathways can affect a single physiologic system.	Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; GSF Natl res Ctr Environm & Hlth, Inst Expt Genet, D-85764 Neuherberg, Germany	Stanford University; Stanford University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Barsh, GS (corresponding author), Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA.	gbarsh@cmgm.stanford.edu	Fuchs, Helmut/M-7347-2014; de Angelis, Martin Hrabe/F-5531-2012; Van Raamsdonk, Catherine D./B-6207-2017	Fuchs, Helmut/0000-0002-5143-2677; de Angelis, Martin Hrabe/0000-0002-7898-2353; Van Raamsdonk, Catherine D./0000-0002-4309-3513	NIGMS NIH HHS [R01 GM068882] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bastiani CA, 2003, GENETICS, V165, P1805; Bennett DC, 2003, PIGM CELL RES, V16, P333, DOI 10.1034/j.1600-0749.2003.00067.x; Brundage L, 1996, NEURON, V16, P999, DOI 10.1016/S0896-6273(00)80123-3; BYRNE C, 1994, DEVELOPMENT, V120, P2369; Coghill EL, 2002, NAT GENET, V30, P255, DOI 10.1038/ng847; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; de Angelis MH, 2000, NAT GENET, V25, P444, DOI 10.1038/78146; Doi M, 2002, NEURON, V33, P249, DOI 10.1016/S0896-6273(01)00587-6; Dong QH, 1996, J CLIN ENDOCR METAB, V81, P1134, DOI 10.1210/jc.81.3.1134; Fitch KR, 2003, GENE DEV, V17, P214, DOI 10.1101/gad.1023703; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HIROBE T, 1984, ANAT REC, V208, P589, DOI 10.1002/ar.1092080414; Hornyak TJ, 2001, MECH DEVELOP, V101, P47, DOI 10.1016/S0925-4773(00)00569-4; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; Hou L, 2004, DEVELOPMENT, V131, P3239, DOI 10.1242/dev.01193; Hou L, 2000, DEVELOPMENT, V127, P5379; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; Ivey K, 2003, DEV BIOL, V255, P230, DOI 10.1016/S0012-1606(02)00097-0; Jordan SA, 2000, DEV BIOL, V225, P424, DOI 10.1006/dbio.2000.9856; Kunisada T, 2000, MECH DEVELOP, V94, P67, DOI 10.1016/S0925-4773(00)00308-7; Lee HO, 2003, DEV BIOL, V259, P162, DOI 10.1016/S0012-1606(03)00160-X; MacKenzie MAF, 1997, DEV BIOL, V192, P99, DOI 10.1006/dbio.1997.8738; MAYER TC, 1973, DEV BIOL, V34, P39, DOI 10.1016/0012-1606(73)90337-0; McGowan KM, 1998, J CELL BIOL, V143, P469, DOI 10.1083/jcb.143.2.469; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; Nolan PM, 2000, NAT GENET, V25, P440, DOI 10.1038/78140; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Opdecamp K, 1997, DEVELOPMENT, V124, P2377; Opdecamp K, 1998, BIOCHEM CELL BIOL, V76, P1093, DOI 10.1139/bcb-76-6-1093; PAVAN WJ, 1994, P NATL ACAD SCI USA, V91, P7159, DOI 10.1073/pnas.91.15.7159; Pollock PM, 2003, NAT GENET, V34, P108, DOI 10.1038/ng1148; Shin MK, 1999, NATURE, V402, P496, DOI 10.1038/990040; Shiroishi T, 2001, Tanpakushitsu Kakusan Koso, V46, P2613; Spiegel AM, 2004, ANNU REV MED, V55, P27, DOI 10.1146/annurev.med.55.091902.103843; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; Wilkie AL, 2002, DEVELOPMENT, V129, P3349; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WILKIE TM, 1994, SOC GEN PHY, V49, P249; Yoshida H, 2001, J INVEST DERM SYMP P, V6, P1, DOI 10.1046/j.0022-202x.2001.00006.x; Yoshida H, 1996, DEVELOPMENT, V122, P1207; Yoshida R, 2002, ZOOL SCI, V19, P1079, DOI 10.2108/zsj.19.1079; [No title captured]	43	130	134	1	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2004	36	9					961	968		10.1038/ng1412	http://dx.doi.org/10.1038/ng1412			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	851AY	15322542	Bronze, Green Accepted			2022-12-25	WOS:000223658100022
J	Hara, MR; Agrawal, N; Kim, SF; Cascio, MB; Fujimuro, M; Ozeki, Y; Takahashi, M; Cheah, JH; Tankou, SK; Hester, LD; Ferris, CD; Hayward, SD; Snyder, SH; Sawa, A				Hara, MR; Agrawal, N; Kim, SF; Cascio, MB; Fujimuro, M; Ozeki, Y; Takahashi, M; Cheah, JH; Tankou, SK; Hester, LD; Ferris, CD; Hayward, SD; Snyder, SH; Sawa, A			S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding	NATURE CELL BIOLOGY			English	Article							SHORT-INTERFERING RNAS; NEURONAL NITRIC-OXIDE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; OXIDATIVE-STRESS; CEREBRAL-ISCHEMIA; MAMMALIAN-CELLS; HISTONE H2B; PROTEIN; GENE; ACTIVATION	Glyceraldehyde- 3- phosphate dehydrogenase ( GAPDH) influences cytotoxicity, translocating to the nucleus during apoptosis. Here we report a signalling pathway in which nitric oxide ( NO) generation that follows apoptotic stimulation elicits S- nitrosylation of GAPDH, which triggers binding to Siah1 ( an E3 ubiquitin ligase), nuclear translocation and apoptosis. S- nitrosylation of GAPDH augments its binding to Siah1, whose nuclear localization signal mediates translocation of GAPDH. GAPDH stabilizes Siah1, facilitating its degradation of nuclear proteins. Activation of macrophages by endotoxin and of neurons by glutamate elicits GAPDH - Siah1 binding, nuclear translocation and apoptosis, which are prevented by NO deletion. The NO - S- nitrosylation GAPDH - Siah1 cascade may represent an important molecular mechanism of cytotoxicity.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.	ssnyder@jhmi.edu; asawa1@jhmi.edu	Fujimuro, Masahiro/AAC-4727-2020	Fujimuro, Masahiro/0000-0002-5165-0789	NIDA NIH HHS [DA-00074, DA-00266] Funding Source: Medline; NIMH NIH HHS [MH-069853] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH069853] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Almeida A, 2001, P NATL ACAD SCI USA, V98, P15294, DOI 10.1073/pnas.261560998; Almeida A, 2004, NAT CELL BIOL, V6, P45, DOI 10.1038/ncb1080; Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; BURKE JR, 1996, NAT MED, V347, P350; Bustamante J, 2002, NITRIC OXIDE-BIOL CH, V6, P333, DOI 10.1006/niox.2001.0420; CAPCO DG, 1982, CELL, V29, P847, DOI 10.1016/0092-8674(82)90446-9; Carlile GW, 2000, MOL PHARMACOL, V57, P2; Chen J, 2003, NUCLEIC ACIDS RES, V31, P474, DOI 10.1093/nar/gkg086; Cheung WL, 2003, CELL, V113, P507, DOI 10.1016/S0092-8674(03)00355-6; Cowan-Jacob SW, 2003, ACTA CRYSTALLOGR D, V59, P2218, DOI 10.1107/S0907444903020493; Dastoor Z, 2001, J CELL SCI, V114, P1643; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DELLA NG, 1993, DEVELOPMENT, V117, P1333; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Eu JP, 2000, BIOCHEMISTRY-US, V39, P1040, DOI 10.1021/bi992046e; Fiucci G, 2004, P NATL ACAD SCI USA, V101, P3510, DOI 10.1073/pnas.0400177101; Foster MW, 2003, TRENDS MOL MED, V9, P160, DOI 10.1016/S1471-4914(03)00028-5; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; House CM, 2003, P NATL ACAD SCI USA, V100, P3101, DOI 10.1073/pnas.0534783100; Hu G, 1999, MOL CELL BIOL, V19, P724; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; Ishitani R, 1998, MOL PHARMACOL, V53, P701, DOI 10.1124/mol.53.4.701; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Koshy B, 1996, HUM MOL GENET, V5, P1311, DOI 10.1093/hmg/5.9.1311; Kragten E, 1998, J BIOL CHEM, V273, P5821, DOI 10.1074/jbc.273.10.5821; Li HG, 2000, MOL PHARMACOL, V57, P427, DOI 10.1124/mol.57.3.427; Li Y, 2004, P NATL ACAD SCI USA, V101, P15688, DOI 10.1073/pnas.0403535101; Liu L, 2004, CELL, V116, P617, DOI 10.1016/S0092-8674(04)00131-X; Matsumoto A, 2003, SCIENCE, V301, P657, DOI 10.1126/science.1079319; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; Mohr S, 1996, J BIOL CHEM, V271, P4209; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; Reed JC, 2002, NAT STRUCT BIOL, V9, P8, DOI 10.1038/nsb0102-8; Roperch JP, 1999, P NATL ACAD SCI USA, V96, P8070, DOI 10.1073/pnas.96.14.8070; Saunders PA, 1997, J NEUROCHEM, V69, P1820; Sawa A, 1997, P NATL ACAD SCI USA, V94, P11669, DOI 10.1073/pnas.94.21.11669; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; Stefanelli C, 1997, BIOCHEM J, V322, P909, DOI 10.1042/bj3220909; STEIN GS, 1972, J CELL BIOL, V52, P292, DOI 10.1083/jcb.52.2.292; Tatton WG, 1996, NEUROLOGY, V47, pS171, DOI 10.1212/WNL.47.6_Suppl_3.171S; Waldmeier PC, 2000, ADV RES NEURODEGENER, V8, P197; Wheeler TC, 2002, J BIOL CHEM, V277, P10273, DOI 10.1074/jbc.M107857200; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775; Zheng L, 2003, CELL, V114, P255, DOI 10.1016/S0092-8674(03)00552-X	52	833	869	0	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2005	7	7					665	U40		10.1038/ncb1268	http://dx.doi.org/10.1038/ncb1268			15	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	941BX	15951807				2022-12-25	WOS:000230190800010
J	Bonazzi, M; Spano, S; Turacchio, G; Cericola, C; Valente, C; Colanzi, A; Kweon, HS; Hsu, VW; Polishchuck, EV; Polishchuck, RS; Sallese, M; Pulvirenti, T; Corda, D; Luini, A				Bonazzi, M; Spano, S; Turacchio, G; Cericola, C; Valente, C; Colanzi, A; Kweon, HS; Hsu, VW; Polishchuck, EV; Polishchuck, RS; Sallese, M; Pulvirenti, T; Corda, D; Luini, A			CtBP3/BARS drives membrane fission in dynamin-independent transport pathways	NATURE CELL BIOLOGY			English	Article							ADP-RIBOSYLATED SUBSTRATE; COATED VESICLE FORMATION; GPI-ANCHORED PROTEINS; PLASMA-MEMBRANE; GOLGI NETWORK; COREPRESSOR CTBP; MAMMALIAN-CELLS; MUTANT DYNAMIN; YEAST; EXIT	Membrane fission is a fundamental step in membrane transport. So far, the only fission protein machinery that has been implicated in in vivo transport involves dynamin, and functions in several, but not all, transport pathways. Thus, other fission machineries may exist. Here, we report that carboxy-terminal binding protein 3/brefeldin A-ribosylated substrate (CtBP3/BARS) controls fission in basolateral transport from the Golgi to the plasma membrane and in fluid-phase endocytosis, whereas dynamin is not involved in these steps. Conversely, CtBP3/BARS protein is inactive in apical transport to the plasma membrane and in receptor-mediated endocytosis, both steps being controlled by dynamin. This indicates that CtBP3/BARS controls membrane fission in endocytic and exocytic transport pathways, distinct from those that require dynamin.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Lab Membrane Traff, I-66030 Santa Maria Imbaro, Italy; Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Lab Cell Regulat, Dept Cell Biol & Oncol, I-66030 Santa Maria Imbaro, Italy; Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Luini, A (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Lab Membrane Traff, I-66030 Santa Maria Imbaro, Italy.	luini@dcbo.negrisud.it	Bonazzi, Matteo/G-1623-2011; Sallese, Michele/J-5347-2016; Corda, Daniela/K-6385-2016; Valente, Carmen/AAH-5261-2019; Bonazzi, Matteo/AAT-2653-2020; Colanzi, Antonino/D-6821-2012; Spanò, Stefania/F-4951-2011; Pulvirenti, Teodoro/AAJ-7661-2020; Luini, Alberto/L-1372-2013	Bonazzi, Matteo/0000-0001-5499-8759; Sallese, Michele/0000-0002-2555-3571; Corda, Daniela/0000-0002-3614-751X; Valente, Carmen/0000-0002-6244-9108; Bonazzi, Matteo/0000-0001-5499-8759; Colanzi, Antonino/0000-0002-5643-0216; Spanò, Stefania/0000-0001-9154-7463; Pulvirenti, Teodoro/0000-0001-9342-6614; Luini, Alberto/0000-0002-8729-2549	Telethon [GGP04235] Funding Source: Medline	Telethon(Fondazione Telethon)		Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Bigay J, 2003, NATURE, V426, P563, DOI 10.1038/nature02108; BOULAN ER, 1980, CELL, V20, P45, DOI 10.1016/0092-8674(80)90233-0; Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; Cao H, 2000, J CELL SCI, V113, P1993; Carcedo CH, 2004, SCIENCE, V305, P93, DOI 10.1126/science.1097775; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Corda D, 2002, CELL MOL LIFE SCI, V59, P1819, DOI 10.1007/PL00012508; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Di Paolo G, 2002, NEURON, V33, P789, DOI 10.1016/S0896-6273(02)00601-3; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; Guha A, 2003, J CELL SCI, V116, P3373, DOI 10.1242/jcs.00637; Gurunathan S, 2002, EMBO J, V21, P602, DOI 10.1093/emboj/21.4.602; Harsay E, 2002, J CELL BIOL, V156, P271, DOI 10.1083/jcb.200109077; Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; Kantheti P, 1998, NEURON, V21, P111, DOI 10.1016/S0896-6273(00)80519-X; Kasai K, 1999, J BIOCHEM, V125, P780, DOI 10.1093/oxfordjournals.jbchem.a022349; Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042; Kreitzer G, 2000, NAT CELL BIOL, V2, P125, DOI 10.1038/35000081; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; Lin X, 2003, MOL CELL, V11, P1389, DOI 10.1016/S1097-2765(03)00175-8; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; Luo WJ, 2000, MOL BIOL CELL, V11, P579, DOI 10.1091/mbc.11.2.579; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; Mironov A, 1997, J CELL BIOL, V139, P1109, DOI 10.1083/jcb.139.5.1109; Mironov AA, 2001, J CELL BIOL, V155, P1225, DOI 10.1083/jcb.200108073; Nardini M, 2003, EMBO J, V22, P3122, DOI 10.1093/emboj/cdg283; Nardini M, 2002, ACTA CRYSTALLOGR D, V58, P1068, DOI 10.1107/S0907444902006984; Pagano M, 2004, CELL, V118, P535, DOI 10.1016/j.cell.2004.08.013; Pelkmans L, 2003, CURR OPIN CELL BIOL, V15, P414, DOI 10.1016/S0955-0674(03)00081-4; Polishchuk EV, 2003, MOL BIOL CELL, V14, P4470, DOI 10.1091/mbc.E03-01-0033; Polishchuk R, 2004, NAT CELL BIOL, V6, P297, DOI 10.1038/ncb1109; Polishchuk RS, 2000, J CELL BIOL, V148, P45, DOI 10.1083/jcb.148.1.45; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; SCHALK EM, 1992, BIOCHEM BIOPH RES CO, V188, P780, DOI 10.1016/0006-291X(92)91124-9; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Spanfo S, 1999, J BIOL CHEM, V274, P17705, DOI 10.1074/jbc.274.25.17705; Sutterlin C, 2002, CELL, V109, P359, DOI 10.1016/S0092-8674(02)00720-1; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; Yang JS, 2002, J CELL BIOL, V159, P69, DOI 10.1083/jcb.200206015; Yeaman C, 2004, NAT CELL BIOL, V6, P106, DOI 10.1038/ncb1090; Zhang QH, 2002, SCIENCE, V295, P1895	51	140	142	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2005	7	6					570	U11		10.1038/ncb1260	http://dx.doi.org/10.1038/ncb1260			15	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	932OD	15880102				2022-12-25	WOS:000229562100011
J	Schubert, C				Schubert, C			Natural plaque-buster	NATURE MEDICINE			English	News Item								Researchers examined mice with transgenes expressing deviant forms of 2 proteins implicated in Alzheimer disease, APP (amyloid precursor protein) and presenilin, and found that these mice developed amyloid-beta plaques in the brain. When some of the mice were placed in an environment providing mental stimulation, fewer plaques were found to develop than in mice in ''boring'' environments. These findings help support the theory that Alzheimer disease can be staved off by keeping mentally alert.										Lazarov O, 2005, CELL, V120, P701, DOI 10.1016/j.cell.2005.01.015	1	0	0	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2005	11	4					385	385						1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15812519				2022-12-25	WOS:000228180500027
J	Yamada, K; Yazawa, K; Shimizu, A; Iwanaga, T; Hisashi, Y; Nuhn, M; O'Malley, P; Nobori, S; Vagefi, PA; Patience, C; Fishman, J; Cooper, DKC; Hawley, RJ; Greenstein, J; Schuurman, HJ; Awwad, M; Sykes, M; Sachs, DH				Yamada, K; Yazawa, K; Shimizu, A; Iwanaga, T; Hisashi, Y; Nuhn, M; O'Malley, P; Nobori, S; Vagefi, PA; Patience, C; Fishman, J; Cooper, DKC; Hawley, RJ; Greenstein, J; Schuurman, HJ; Awwad, M; Sykes, M; Sachs, DH			Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha 1,3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue	NATURE MEDICINE			English	Article							MINIATURE SWINE; COMPOSITE THYMOKIDNEYS; LOBE TRANSPLANTATION; TOLERANCE INDUCTION; MISMATCHED BARRIERS; NUCLEAR TRANSFER; PIGS; THYMOPOIESIS; ANTIBODIES	The use of animal organs could potentially alleviate the critical worldwide shortage of donor organs for clinical transplantation. Because of the strong immune response to xenografts, success will probably depend upon new strategies of immune suppression and induction of tolerance. Here we report our initial results using alpha-1,3-galactosyltransferase knockout (GalT-KO) donors and a tolerance induction approach. We have achieved life-supporting pig-to-baboon renal xenograft survivals of up to 83 d with normal creatinine levels.	Massachusetts Gen Hosp East, Transplantat Biol Res Ctr, Boston, MA 02129 USA; Immerge Biotherapeut, Cambridge, MA 02139 USA; Massachusetts Gen Hosp East, Infect Dis Unit, Boston, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Sachs, DH (corresponding author), Massachusetts Gen Hosp East, Transplantat Biol Res Ctr, Boston, MA 02129 USA.	sachs@helix.mgh.harvard.edu	Sano, Michael/E-1715-2011		PHS HHS [1P01A45897] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Barth RN, 2003, TRANSPLANTATION, V75, P1615, DOI 10.1097/01.TP.0000064335.50622.20; Dai YF, 2002, NAT BIOTECHNOL, V20, P251, DOI 10.1038/nbt0302-251; Galili U, 1999, Subcell Biochem, V32, P79; GOOD AH, 1992, TRANSPL P, V24, P559; Kamano C, 2004, P NATL ACAD SCI USA, V101, P3827, DOI 10.1073/pnas.0306666101; Kobayashi T, 1997, TRANSPLANTATION, V64, P1255, DOI 10.1097/00007890-199711150-00005; Kolber-Simonds D, 2004, P NATL ACAD SCI USA, V101, P7335, DOI 10.1073/pnas.0307819101; Kozlowski T, 1999, TRANSPLANTATION, V67, P18, DOI 10.1097/00007890-199901150-00004; Lai LX, 2002, SCIENCE, V295, P1089, DOI 10.1126/science.1068228; LaMattina JC, 2002, TRANSPLANTATION, V73, P826, DOI 10.1097/00007890-200203150-00032; Lambrigts D, 1998, TRANSPLANTATION, V66, P547, DOI 10.1097/00007890-199809150-00001; Xu Y, 1998, TRANSPLANTATION, V65, P172; Yamada K, 2000, J IMMUNOL, V164, P3079, DOI 10.4049/jimmunol.164.6.3079; Yamada K, 2003, TRANSPLANTATION, V76, P530, DOI 10.1097/01.TP.0000080608.42480.E8; Yamada K, 1999, TRANSPLANTATION, V68, P1684, DOI 10.1097/00007890-199912150-00011	15	472	495	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2005	11	1					32	34		10.1038/nm1172	http://dx.doi.org/10.1038/nm1172			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	884ZJ	15619627				2022-12-25	WOS:000226124900029
J	Otte, S; Barlowe, C				Otte, S; Barlowe, C			Sorting signals can direct receptor-mediated export of soluble proteins into COPII vesicles	NATURE CELL BIOLOGY			English	Article							ENDOPLASMIC-RETICULUM; ALPHA-FACTOR; QUALITY-CONTROL; PRO-SEQUENCE; BULK FLOW; TRANSPORT; ER; GOLGI; PRECURSOR; DEGRADATION	Soluble secretory proteins are first translocated across endoplasmic reticulum ( ER) membranes and folded in a specialized ER luminal environment. Fully folded and assembled secretory cargo are then segregated from ER-resident proteins into COPII-derived vesicles or tubular elements for anterograde transport. Mechanisms of bulk-flow, ER-retention and receptor-mediated export have been suggested to operate during this transport step, although these mechanisms are poorly understood(1-7). In yeast, there is evidence to suggest that Erv29p functions as a transmembrane receptor for the export of certain soluble cargo proteins including glycopro-alpha-factor (gpalphaf), the precursor of alpha-factor mating pheromone8. Here we identify a hydrophobic signal within the pro-region of gpaf that is necessary for efficient packaging into COPII vesicles and for binding to Erv29p. When fused to Kar2p, an ER-resident protein, the pro-region sorting signal was sufficient to direct Erv29p-dependent export of the fusion protein into COPII vesicles. These findings indicate that specific motifs within soluble secretory proteins function in receptor-mediated export from the ER. Moreover, positive sorting signals seem to predominate over potential ER-retention mechanisms that may operate in localizing ER-resident proteins such as Kar2p.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Barlowe, C (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA.	barlowe@dartmouth.edu						Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; Barlowe C, 2003, TRENDS CELL BIOL, V13, P295, DOI 10.1016/S0962-8924(03)00082-5; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Belden WJ, 2001, MOL BIOL CELL, V12, P957, DOI 10.1091/mbc.12.4.957; Belden WJ, 1996, J BIOL CHEM, V271, P26939, DOI 10.1074/jbc.271.43.26939; Belden WJ, 2001, SCIENCE, V294, P1528, DOI 10.1126/science.1065224; Caldwell SR, 2001, J BIOL CHEM, V276, P23296, DOI 10.1074/jbc.M102962200; CAPLAN S, 1991, J BACTERIOL, V173, P627, DOI 10.1128/jb.173.2.627-635.1991; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; EDER J, 1995, MOL MICROBIOL, V16, P609, DOI 10.1111/j.1365-2958.1995.tb02423.x; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; ElrodErickson MJ, 1996, MOL BIOL CELL, V7, P1043, DOI 10.1091/mbc.7.7.1043; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; JULIUS D, 1983, CELL, V32, P839, DOI 10.1016/0092-8674(83)90070-3; KAISER CA, 1997, YEAST, V3, P91; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; Martinez-Menarguez JA, 1999, CELL, V98, P81, DOI 10.1016/S0092-8674(00)80608-X; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; Muniz M, 2000, J CELL BIOL, V148, P925, DOI 10.1083/jcb.148.5.925; Oka C, 1999, BIOSCI BIOTECH BIOCH, V63, P1977, DOI 10.1271/bbb.63.1977; Otte S, 2001, J CELL BIOL, V152, P503, DOI 10.1083/jcb.152.3.503; Polishchuk EV, 2003, MOL BIOL CELL, V14, P4470, DOI 10.1091/mbc.E03-01-0033; Powers J, 1998, J CELL BIOL, V142, P1209, DOI 10.1083/jcb.142.5.1209; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; Yeung T, 1995, J BIOL CHEM, V270, P30567, DOI 10.1074/jbc.270.51.30567	30	75	78	3	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2004	6	12					1189	1194		10.1038/ncb1195	http://dx.doi.org/10.1038/ncb1195			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	875WQ	15516922				2022-12-25	WOS:000225453300011
J	Burki, F; Kaessmann, H				Burki, F; Kaessmann, H			Birth and adaptive evolution of a hominoid gene that supports high neurotransmitter flux	NATURE GENETICS			English	Article							HUMAN GLUTAMATE-DEHYDROGENASES; TISSUE-SPECIFIC GLUD2; MECHANISMS; ASTROCYTES; SIZE	The enzyme glutamate dehydrogenase (GDH) is important for recycling the chief excitatory neurotransmitter, glutamate, during neurotransmission. Human GDH exists in housekeeping and brain-specific isotypes encoded by the genes GLUD1 and GLUD2, respectively. Here we show that GLUD2 originated by retroposition from GLUD1 in the hominoid ancestor less than 23 million years ago. The amino acid changes responsible for the unique brain-specific properties of the enzyme derived from GLUD2 occurred during a period of positive selection after the duplication event.	Univ Lausanne, Ctr Integrat Genom, BEP, CH-1015 Lausanne, Switzerland	University of Lausanne	Kaessmann, H (corresponding author), Univ Lausanne, Ctr Integrat Genom, BEP, CH-1015 Lausanne, Switzerland.	Henrik.Kaessmann@cig.unil.ch	Burki, Fabien/F-4818-2010; Kaessmann, Henrik/B-4989-2013	Kaessmann, Henrik/0000-0001-7563-839X				Burbaeva GS, 2003, PROG NEURO-PSYCHOPH, V27, P675, DOI 10.1016/S0278-5846(03)00078-2; Caceres M, 2003, P NATL ACAD SCI USA, V100, P13030, DOI 10.1073/pnas.2135499100; Cavallaro S, 1997, P NATL ACAD SCI USA, V94, P9669, DOI 10.1073/pnas.94.18.9669; Evans PD, 2004, HUM MOL GENET, V13, P1139, DOI 10.1093/hmg/ddh126; Evans PD, 2004, HUM MOL GENET, V13, P489, DOI 10.1093/hmg/ddh055; Goodman M, 1998, MOL PHYLOGENET EVOL, V9, P585, DOI 10.1006/mpev.1998.0495; Hertz L, 1999, J NEUROSCI RES, V57, P417, DOI 10.1002/(SICI)1097-4547(19990815)57:4<417::AID-JNR1>3.3.CO;2-E; LI WH, 1997, MOL EVOLUTION ROLES; NOBACK CR, 1970, PRIMATE BRAIN EVOLUT; Plaitakis A, 2000, J NEUROCHEM, V75, P1862, DOI 10.1046/j.1471-4159.2000.0751862.x; Plaitakis A, 2003, NEUROCHEM INT, V43, P401, DOI 10.1016/S0197-0186(03)00028-7; SHASHIDHARAN P, 1994, J BIOL CHEM, V269, P16971; Sonnewald U, 1997, GLIA, V21, P56, DOI 10.1002/(SICI)1098-1136(199709)21:1<56::AID-GLIA6>3.0.CO;2-#; Wan MH, 1998, AM J MED GENET, V78, P169, DOI 10.1002/(SICI)1096-8628(19980630)78:2<169::AID-AJMG14>3.3.CO;2-D; Zhang ZL, 2004, TRENDS GENET, V20, P62, DOI 10.1016/j.tig.2003.12.005	15	149	159	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2004	36	10					1061	1063		10.1038/ng1431	http://dx.doi.org/10.1038/ng1431			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	857YN	15378063	Bronze			2022-12-25	WOS:000224156500013
J	Schubert, C				Schubert, C			Cancer's weak moment	NATURE MEDICINE			English	News Item																			0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2004	10	10					1051	1051						1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15459706				2022-12-25	WOS:000224245800027
J	Fischer, T; Rodriguez-Navarro, S; Pereira, G; Racz, A; Schiebel, E; Hurt, E				Fischer, T; Rodriguez-Navarro, S; Pereira, G; Racz, A; Schiebel, E; Hurt, E			Yeast centrin Cdc31 is linked to the nuclear mRNA export machinery	NATURE CELL BIOLOGY			English	Article							SPINDLE POLE BODY; HNRNP-LIKE PROTEINS; TRANSCRIPTION ELONGATION; SACCHAROMYCES-CEREVISIAE; COUPLING TRANSCRIPTION; GENE-EXPRESSION; BINDING PROTEIN; PORE COMPLEX; HALF-BRIDGE; COMPONENT	Centrins are calmodulin-like proteins that function in the duplication of microtubule-organizing centres. Here we describe a new function of the yeast centrin Cdc31. We show that overproduction of a sequence, termed CID, in the carboxy-terminal domain of the nuclear export factor Sac3 titrates Cdc31, causing a dominant-lethal phenotype and a block in spindle pole body (SPB) duplication. Under normal conditions, the CID motif recruits Cdc31 and Sus1 (a subunit of the SAGA transcription complex) to the Sac3-Thp1 complex, which functions in mRNA export together with specific nucleoporins at the nuclear basket. A previously reported cdc31 temperature-sensitive allele, which is neither defective in SPB duplication nor Kic1 kinase activation, induces mRNA export defects. Thus, Cdc31 has an unexpected link to the mRNA export machinery.	Univ Heidelberg BZH, Zentrum Biochem, D-69120 Heidelberg, Germany; Christie Hosp NHS Trust, Paterson Inst Canc Res, Manchester M20 4BX, Lancs, England	Ruprecht Karls University Heidelberg; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Hurt, E (corresponding author), Univ Heidelberg BZH, Zentrum Biochem, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	cg5@ix.urz.uni-heidelberg.de	Fischer, Tamas/A-7729-2016; Ed Hurt, Dr./AAE-8874-2019; Rodríguez-Navarro, Susana/B-5182-2014; Pereira, Gislene/D-4024-2014	Fischer, Tamas/0000-0002-7996-4042; Ed Hurt, Dr./0000-0002-4535-8255; Rodríguez-Navarro, Susana/0000-0001-7472-3111; Racz, Attila/0000-0002-5952-8294				Araki M, 2001, J BIOL CHEM, V276, P18665, DOI 10.1074/jbc.M100855200; Bassler J, 2001, MOL CELL, V8, P517, DOI 10.1016/S1097-2765(01)00342-2; BAUM P, 1986, P NATL ACAD SCI USA, V83, P5512, DOI 10.1073/pnas.83.15.5512; Belli G, 1998, NUCLEIC ACIDS RES, V26, P942, DOI 10.1093/nar/26.4.942; BIGGINS S, 1994, J CELL BIOL, V125, P843, DOI 10.1083/jcb.125.4.843; Chavez S, 2000, EMBO J, V19, P5824, DOI 10.1093/emboj/19.21.5824; Donaldson AD, 1996, J CELL BIOL, V132, P887, DOI 10.1083/jcb.132.5.887; Echevarria W, 2003, NAT CELL BIOL, V5, P440, DOI 10.1038/ncb980; Fahrenkrog B, 2003, NAT REV MOL CELL BIO, V4, P757, DOI 10.1038/nrm1230; Fischer T, 2002, EMBO J, V21, P5843, DOI 10.1093/emboj/cdf590; Gallardo M, 2003, J BIOL CHEM, V278, P24225, DOI 10.1074/jbc.M302900200; Gallardo M, 2001, GENETICS, V157, P79; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Geier BM, 1996, J BIOL CHEM, V271, P28366, DOI 10.1074/jbc.271.45.28366; Huertas P, 2003, MOL CELL, V12, P711, DOI 10.1016/j.molcel.2003.08.010; Huisinga KL, 2004, MOL CELL, V13, P573, DOI 10.1016/S1097-2765(04)00087-5; Hurt E, 2004, P NATL ACAD SCI USA, V101, P1858, DOI 10.1073/pnas.0308663100; Ivanovska I, 2001, GENETICS, V157, P503; Jensen TH, 2003, MOL CELL, V11, P1129, DOI 10.1016/S1097-2765(03)00191-6; Jones AL, 2000, P NATL ACAD SCI USA, V97, P3224, DOI 10.1073/pnas.050432997; Kilmartin JV, 2003, J CELL BIOL, V162, P1211, DOI 10.1083/jcb.200307064; Kim M, 2004, EMBO J, V23, P354, DOI 10.1038/sj.emboj.7600053; Lei EP, 2003, MOL BIOL CELL, V14, P836, DOI 10.1091/mbc.E02-08-0520; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; NOVICK P, 1989, GENETICS, V121, P659; Paoletti A, 2003, MOL BIOL CELL, V14, P2793, DOI 10.1091/mbc.E02-10-0661; Pulvermuller A, 2002, MOL CELL BIOL, V22, P2194, DOI 10.1128/MCB.22.7.2194-2203.2002; Reed R, 2003, CURR OPIN CELL BIOL, V15, P326, DOI 10.1016/S0955-0674(03)00048-6; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; Rodrigues JP, 2001, P NATL ACAD SCI USA, V98, P1030, DOI 10.1073/pnas.98.3.1030; Rodriguez-Navarro S, 2004, CELL, V116, P75, DOI 10.1016/S0092-8674(03)01025-0; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Siniossoglou S, 1996, CELL, V84, P265, DOI 10.1016/S0092-8674(00)80981-2; SPANG A, 1993, J CELL BIOL, V123, P405, DOI 10.1083/jcb.123.2.405; SPANG A, 1995, J CELL BIOL, V128, P863, DOI 10.1083/jcb.128.5.863; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Strasser K, 2000, EMBO J, V19, P410, DOI 10.1093/emboj/19.3.410; Stutz F, 2003, TRENDS CELL BIOL, V13, P319, DOI 10.1016/S0962-8924(03)00106-5; Stutz F, 2000, RNA, V6, P638, DOI 10.1017/S1355838200000078; Sullivan DS, 1998, J CELL BIOL, V143, P751, DOI 10.1083/jcb.143.3.751; Zenklusen D, 2002, MOL CELL BIOL, V22, P8241, DOI 10.1128/MCB.22.23.8241-8253.2002; Zenklusen D, 2001, MOL CELL BIOL, V21, P4219, DOI 10.1128/MCB.21.13.4219-4232.2001	42	140	146	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2004	6	9					840	U4		10.1038/ncb1163	http://dx.doi.org/10.1038/ncb1163			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	852IZ	15311284				2022-12-25	WOS:000223750300014
J	Prieto, P; Shaw, P; Moore, G				Prieto, P; Shaw, P; Moore, G			Homologue recognition during meiosis is associated with a change in chromatin conformation	NATURE CELL BIOLOGY			English	Article							WHEAT; ORGANIZATION; CHROMOSOMES	During meiosis, homologous chromosomes are sorted into pairs and are then intimately aligned, or synapsed, along their lengths while a proteinaceous structure, the synaptonemal complex, is assembled between them. However, little is known about how chromosomes first recognise each other(1). Here we show, by comparing the behaviour of wild-type wheat and wheat mutant for Ph1 (a suppressor of homologous chromosome pairing), that when chromosomes recognise a partner to pair with, a conformational change to the chromatin is triggered in both partners that is followed by their intimate alignment. Thus, a conformational change in the chromosomes at the onset of meiosis can be correlated directly with recognition.	John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Moore, G (corresponding author), John Innes Ctr Plant Sci Res, Norwich Res Pk, Norwich NR4 7UH, Norfolk, England.	graham.moore@bbsrc.ac.uk	shaw, peter j/E-5511-2011; Prieto, Pilar/N-6394-2014	shaw, peter j/0000-0003-1076-2669; Prieto, Pilar/0000-0002-8160-808X				AragonAlcaide L, 1997, CHROMOSOMA, V106, P327, DOI 10.1007/s004120050254; CURTIS CA, 1991, GENOME, V34, P553, DOI 10.1139/g91-085; DAWE RK, 1994, CELL, V76, P901, DOI 10.1016/0092-8674(94)90364-6; Francki MG, 2001, GENOME, V44, P266, DOI 10.1139/gen-44-2-266; MacQueen AJ, 2001, GENE DEV, V15, P1674, DOI 10.1101/gad.902601; Martinez-Perez E, 2003, PLANT J, V36, P21, DOI 10.1046/j.1365-313X.2003.01853.x; Martinez-Perez E, 2001, NATURE, V411, P204, DOI 10.1038/35075597; MOORE G, 1993, GENOMICS, V15, P472, DOI 10.1006/geno.1993.1097; Naranjo T, 2004, TRENDS PLANT SCI, V9, P214, DOI 10.1016/j.tplants.2004.03.001; RILEY R, 1958, NATURE, V182, P713, DOI 10.1038/182713a0; Roberts MA, 1999, GENETICS, V153, P1909; VERSHININ AV, 1995, PLANT CELL, V7, P1823, DOI 10.1105/tpc.7.11.1823; Zickler D, 1998, ANNU REV GENET, V32, P619, DOI 10.1146/annurev.genet.32.1.619	13	83	86	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2004	6	9					906	908		10.1038/ncb1168	http://dx.doi.org/10.1038/ncb1168			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	852IZ	15340450	Green Submitted			2022-12-25	WOS:000223750300021
J	Matsunaga, E; Tauszig-Delamasure, S; Monnier, PP; Mueller, BK; Strittmatter, SM; Mehlen, P; Chedotal, A				Matsunaga, E; Tauszig-Delamasure, S; Monnier, PP; Mueller, BK; Strittmatter, SM; Mehlen, P; Chedotal, A			RGM and its receptor neogenin regulate neuronal survival	NATURE CELL BIOLOGY			English	Article							REPULSIVE GUIDANCE MOLECULE; EXPRESSION PATTERNS; DCC; APOPTOSIS; GENES; UNC5H	Repulsive guidance molecule (RGM) is an axon guidance protein that repels retinal axons upon activation of the neogenin receptor. To understand the functions of RGM-neogenin complexes in vivo, we used gene transfer technology to perturb their expression in the developing neural tube of chick embryos. Surprisingly, neogenin over-expression or RGM down-expression in the neural tube induces apoptosis. Neogenin pro-apoptotic activity in immortalized neuronal cells and in the neural tube is associated with the cleavage of its cytoplasmic domain by caspases. Thus neogenin is a dependence receptor inducing cell death in the absence of RGM, whereas the presence of RGM inhibits this effect.	Univ Paris 06, CNRS, UMR 7102, F-75005 Paris, France; Univ Lyon, CNRS, UMR 5534, F-69622 Villeurbanne, France; MigraGen AG, D-72076 Tubingen, Germany; Toronto Western Hosp, Toronto, ON M5T 258, Canada; Abbott GmbH & Co KG, D-67601 Ludwigshafen, Germany; Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); University of Toronto; University Toronto Affiliates; University Health Network Toronto; ABBOTT GMBH & CO. KG; Yale University	Chedotal, A (corresponding author), Univ Paris 06, CNRS, UMR 7102, 9 Quai St Bernard, F-75005 Paris, France.	chedotal@infobiogen.fr	Tauszig-Delamasure, Servane/G-7192-2017; Tauszig-Delamasure, Servane/AAJ-6493-2020; Chedotal, Alain/F-2750-2017; Strittmatter, Stephen/F-5739-2011	Tauszig-Delamasure, Servane/0000-0003-4926-0199; Tauszig-Delamasure, Servane/0000-0003-4926-0199; Chedotal, Alain/0000-0001-7577-3794; Strittmatter, Stephen/0000-0001-8188-3092; monnier, philippe/0000-0002-6221-4130				Bai JL, 2003, NAT NEUROSCI, V6, P1277, DOI 10.1038/nn1153; BALLYCUIF L, 1994, DEVELOPMENT, V120, P3379; CHO KR, 1995, CURR OPIN GENET DEV, V5, P72, DOI 10.1016/S0959-437X(95)90056-X; FEKETE DM, 1993, P NATL ACAD SCI USA, V90, P2350, DOI 10.1073/pnas.90.6.2350; Funahashi J, 1999, DEV GROWTH DIFFER, V41, P59; Gad JM, 1997, DEV BIOL, V192, P258, DOI 10.1006/dbio.1997.8756; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Katahira T, 2003, DEV GROWTH DIFFER, V45, P361, DOI 10.1046/j.1440-169X.2003.00705.x; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Llambi F, 2001, EMBO J, V20, P2715, DOI 10.1093/emboj/20.11.2715; Marillat V, 2002, J COMP NEUROL, V442, P130, DOI 10.1002/cne.10068; Matsunaga E, 2000, DEVELOPMENT, V127, P2357; Mehlen P, 2004, APOPTOSIS, V9, P37, DOI 10.1023/B:APPT.0000012120.66221.b2; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; Monnier PP, 2002, NATURE, V419, P392, DOI 10.1038/nature01041; Niederkofler V, 2004, J NEUROSCI, V24, P808, DOI 10.1523/JNEUROSCI.4610-03.2004; Rajagopalan S, 2004, NAT CELL BIOL, V6, P756, DOI 10.1038/ncb1156; Srinivasan K, 2003, DEV CELL, V4, P371, DOI 10.1016/S1534-5807(03)00054-6; Thibert C, 2003, SCIENCE, V301, P843, DOI 10.1126/science.1085405; Thiebault K, 2003, P NATL ACAD SCI USA, V100, P4173, DOI 10.1073/pnas.0738063100; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; Zaidi AU, 2001, J NEUROSCI, V21, P169, DOI 10.1523/JNEUROSCI.21-01-00169.2001	24	222	240	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2004	6	8					749	755		10.1038/ncb1157	http://dx.doi.org/10.1038/ncb1157			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	842YA	15258591				2022-12-25	WOS:000223039400013
J	Korbel, JO; Jensen, LJ; von Mering, C; Bork, P				Korbel, JO; Jensen, LJ; von Mering, C; Bork, P			Analysis of genomic context: prediction of functional associations from conserved bidirectionally transcribed gene pairs	NATURE BIOTECHNOLOGY			English	Article							DETERMINING DIVERGENCE TIMES; PROTEIN-PROTEIN INTERACTIONS; ESCHERICHIA-COLI; COMPUTATIONAL METHODS; INTERACTION NETWORKS; PSI-BLAST; DISCOVERY; DATABASE; OPERON; EXPRESSION	Several widely used methods for predicting functional associations between proteins are based on the systematic analysis of genomic context. Efforts are ongoing to improve these methods and to search for novel aspects in genomes that could be exploited for function prediction. Here, we use gene expression data to demonstrate two functional implications of genome organization: first, chromosomal proximity indicates gene coregulation in prokaryotes independent of relative gene orientation; and second, adjacent bidirectionally transcribed genes (that is,'divergently' organized coding regions) with conserved gene orientation are strongly coregulated. We further demonstrate that such bidirectionally transcribed gene pairs are functionally associated and derive from this a novel genomic context method that reliably predicts links between >2,500 pairs of genes in similar to100 species. Around 650 of these functional associations are supported by other genomic context methods. In most instances, one gene encodes a transcriptional regulator, and the other a nonregulatory protein. In-depth analysis in Escherichia coli shows that the vast majority of these regulators both control transcription of the divergently transcribed target gene/operon and auto-regulate their own biosynthesis. The method thus enables the prediction of target processes and regulatory features for several hundred transcriptional regulators.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Max Delbruck Center for Molecular Medicine	Bork, P (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	bork@embl-heidelberg.de	Bork, Peer/F-1813-2013; von Mering, Christian/B-3300-2008; Jensen, Lars Juhl/C-6492-2008; Korbel, Jan O/G-6470-2012	Bork, Peer/0000-0002-2627-833X; von Mering, Christian/0000-0001-7734-9102; Jensen, Lars Juhl/0000-0001-7885-715X; Korbel, Jan O/0000-0002-2798-3794				Adachi N, 2002, CELL, V109, P807, DOI 10.1016/S0092-8674(02)00758-4; Alm E, 2003, CURR OPIN STRUC BIOL, V13, P193, DOI 10.1016/S0959-440X(03)00031-9; Aloy P, 2002, P NATL ACAD SCI USA, V99, P5896, DOI 10.1073/pnas.092147999; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Altschul SF, 1998, TRENDS BIOCHEM SCI, V23, P444, DOI 10.1016/S0968-0004(98)01298-5; Babu MM, 2003, NUCLEIC ACIDS RES, V31, P1234, DOI 10.1093/nar/gkg210; Bader GD, 2003, TRENDS CELL BIOL, V13, P344, DOI 10.1016/S0962-8924(03)00127-2; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BECK CF, 1988, MICROBIOL REV, V52, P318, DOI 10.1128/MMBR.52.3.318-326.1988; Bork P, 2004, CURR OPIN STRUC BIOL, V14, P292, DOI 10.1016/j.sbi.2004.05.003; BORK P, 2000, COMP GENOMICS, P281; CHANDLER MG, 1975, MOL GEN GENET, V138, P127, DOI 10.1007/BF02428117; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Coutts G, 2002, EMBO J, V21, P536, DOI 10.1093/emboj/21.4.536; Dandekar T, 1998, TRENDS BIOCHEM SCI, V23, P324, DOI 10.1016/S0968-0004(98)01274-2; Date SV, 2003, NAT BIOTECHNOL, V21, P1055, DOI 10.1038/nbt861; Daugherty M, 2001, J BACTERIOL, V183, P292, DOI 10.1128/JB.183.1.292-300.2001; Doolittle RF, 1996, SCIENCE, V271, P470, DOI 10.1126/science.271.5248.470; Dorman CJ, 2003, CURR OPIN GENET DEV, V13, P179, DOI 10.1016/S0959-437X(03)00025-X; Ehira S, 2003, DNA RES, V10, P97, DOI 10.1093/dnares/10.3.97; El-Robh MS, 2002, BIOCHEM J, V368, P835, DOI 10.1042/BJ20021003; Enright AJ, 1999, NATURE, V402, P86, DOI 10.1038/47056; Feng DF, 1997, P NATL ACAD SCI USA, V94, P13028, DOI 10.1073/pnas.94.24.13028; Gabaldon T, 2003, SCIENCE, V301, P609, DOI 10.1126/science.1085463; Galperin MY, 2000, NAT BIOTECHNOL, V18, P609, DOI 10.1038/76443; Gollub J, 2003, NUCLEIC ACIDS RES, V31, P94, DOI 10.1093/nar/gkg078; Hatfield GW, 2002, ANNU REV GENET, V36, P175, DOI 10.1146/annurev.genet.36.032902.111815; Hedges SB, 2002, NAT REV GENET, V3, P838, DOI 10.1038/nrg929; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Huynen MA, 2000, ADV PROTEIN CHEM, V54, P345, DOI 10.1016/S0065-3233(00)54010-8; Huynen MA, 2003, CURR OPIN CELL BIOL, V15, P191, DOI 10.1016/S0955-0674(03)00009-7; Huynen MA, 1998, P NATL ACAD SCI USA, V95, P5849, DOI 10.1073/pnas.95.11.5849; Huynen MA, 2001, HUM MOL GENET, V10, P2463, DOI 10.1093/hmg/10.21.2463; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; Jacob F, 1997, CR ACAD SCI III-VIE, V320, P199, DOI 10.1016/S0764-4469(97)86927-2; Jansen R, 2003, SCIENCE, V302, P449, DOI 10.1126/science.1087361; Kanehisa M, 2002, NUCLEIC ACIDS RES, V30, P42, DOI 10.1093/nar/30.1.42; Kolesov G, 2001, J MOL BIOL, V311, P639, DOI 10.1006/jmbi.2001.4701; Korbel JO, 2002, TRENDS GENET, V18, P158, DOI 10.1016/S0168-9525(01)02597-5; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Marcotte EM, 2000, P NATL ACAD SCI USA, V97, P12115, DOI 10.1073/pnas.220399497; Marcotte EM, 2000, CURR OPIN STRUC BIOL, V10, P359, DOI 10.1016/S0959-440X(00)00097-X; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Mellor JC, 2002, NUCLEIC ACIDS RES, V30, P306, DOI 10.1093/nar/30.1.306; Morett E, 2003, NAT BIOTECHNOL, V21, P790, DOI 10.1038/nbt834; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; Munch R, 2003, NUCLEIC ACIDS RES, V31, P266, DOI 10.1093/nar/gkg037; Myllykallio H, 2002, SCIENCE, V297, P105, DOI 10.1126/science.1072113; Osterman A, 2003, CURR OPIN CHEM BIOL, V7, P238, DOI 10.1016/S1367-5931(03)00027-9; Ouzounis CA, 2003, NAT REV GENET, V4, P508, DOI 10.1038/nrg1113; Overbeek R, 2003, NUCLEIC ACIDS RES, V31, P164, DOI 10.1093/nar/gkg148; Overbeek R, 1999, P NATL ACAD SCI USA, V96, P2896, DOI 10.1073/pnas.96.6.2896; Pazos F, 2001, PROTEIN ENG, V14, P609, DOI 10.1093/protein/14.9.609; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; Rhee KY, 1999, P NATL ACAD SCI USA, V96, P14294, DOI 10.1073/pnas.96.25.14294; Sabatti C, 2002, NUCLEIC ACIDS RES, V30, P2886, DOI 10.1093/nar/gkf388; Salgado H, 2000, P NATL ACAD SCI USA, V97, P6652, DOI 10.1073/pnas.110147297; Salgado H, 2001, NUCLEIC ACIDS RES, V29, P72, DOI 10.1093/nar/29.1.72; Salwinski L, 2003, CURR OPIN STRUC BIOL, V13, P377, DOI 10.1016/S0959-440X(03)00070-8; Snel B, 1999, NAT GENET, V21, P108, DOI 10.1038/5052; Steinmetz LM, 2002, NAT GENET, V31, P400, DOI 10.1038/ng929; Stuart JM, 2003, SCIENCE, V302, P249, DOI 10.1126/science.1087447; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41; Thomas G, 2000, TRENDS GENET, V16, P11, DOI 10.1016/S0168-9525(99)01887-9; Valencia A, 2002, CURR OPIN STRUC BIOL, V12, P368, DOI 10.1016/S0959-440X(02)00333-0; van Noort V, 2003, TRENDS GENET, V19, P238, DOI 10.1016/S0168-9525(03)00056-8; von Mering C, 2003, P NATL ACAD SCI USA, V100, P15428, DOI 10.1073/pnas.2136809100; von Mering C, 2003, NUCLEIC ACIDS RES, V31, P258, DOI 10.1093/nar/gkg034; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Weller GR, 2002, SCIENCE, V297, P1686, DOI 10.1126/science.1074584; WORKMAN C, 2002, GENOME BIOL, V0003; Wu J, 2003, BIOINFORMATICS, V19, P1524, DOI 10.1093/bioinformatics/btg187; Zheng Y, 2002, GENOME RES, V12, P1221, DOI 10.1101/gr.200602; Zhou XH, 2002, P NATL ACAD SCI USA, V99, P12783, DOI 10.1073/pnas.192159399	78	136	142	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0733-222X	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2004	22	7					911	917		10.1038/nbt988	http://dx.doi.org/10.1038/nbt988			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	836CO	15229555				2022-12-25	WOS:000222533000039
J	Han, BY; Serra, P; Amrani, A; Yamanouchi, J; Maree, AFM; Edelstein-Keshet, L; Santamaria, P				Han, BY; Serra, P; Amrani, A; Yamanouchi, J; Maree, AFM; Edelstein-Keshet, L; Santamaria, P			Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide	NATURE MEDICINE			English	Article							T-CELL-RECEPTOR; MULTIPLE-SCLEROSIS; II COLLAGEN; MICE; ENCEPHALOMYELITIS; TOLERANCE; LYMPHOCYTES; VACCINATION; DETERMINES; EXPANSION	Antigen therapy may hold great promise for the prevention of autoimmunity; however, most clinical trials have failed, suggesting that the principles guiding the choice of treatment remain ill defined. Here, we examine the antidiabetogenic properties of altered peptide ligands of CD8(+) T cells recognizing an epitope of islet-specific glucose-6-phosphatase catalytic subunit - related protein (IGRP(206-214)), a prevalent population of autoreactive T cells in autoimmune diabetes. We show that islet-associated CD8(+) T cells in nonobese diabetic mice recognize numerous IGRP epitopes, and that these cells have a role in the outcome of protocols designed to induce IGRP(206-214)-specific tolerance. Ligands targeting IGRP(206-214)-reactive T cells prevented disease, but only at doses that spared low-avidity clonotypes. Notably, near complete depletion of the IGRP(206-214)-reactive T-cell pool enhanced the recruitment of subdominant specificities and did not blunt diabetogenesis. Thus, peptide therapy in autoimmunity is most effective under conditions that foster occupation of the target organ lymphocyte niche by nonpathogenic, low-avidity clonotypes.	Univ Calgary, Fac Med, Julia McFarlane Diabet Res Ctr, Calgary, AB T2N 4N1, Canada; Univ Utrecht, Dept Theoret Biol, NL-3584 CH Utrecht, Netherlands; Univ British Columbia, Dept Math, Vancouver, BC V6T 1Z2, Canada	University of Calgary; Utrecht University; University of British Columbia	Santamaria, P (corresponding author), Univ Calgary, Fac Med, Julia McFarlane Diabet Res Ctr, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	psantama@ucalgary.ca	Santamaria, Pere/ABF-6823-2021	Maree, Athanasius F. M./0000-0003-2689-2484				AICHELE P, 1994, P NATL ACAD SCI USA, V91, P444, DOI 10.1073/pnas.91.2.444; AlexanderMiller MA, 1996, P NATL ACAD SCI USA, V93, P4102, DOI 10.1073/pnas.93.9.4102; Amrani A, 2000, NATURE, V406, P739, DOI 10.1038/35021081; Amrani A, 2001, J IMMUNOL, V167, P655, DOI 10.4049/jimmunol.167.2.655; Anderson B, 1999, P NATL ACAD SCI USA, V96, P9311, DOI 10.1073/pnas.96.16.9311; Anderton SM, 1998, EUR J IMMUNOL, V28, P1251, DOI 10.1002/(SICI)1521-4141(199804)28:04<1251::AID-IMMU1251>3.0.CO;2-O; Arif S, 2004, J CLIN INVEST, V113, P451, DOI 10.1172/JCI200419585; Bielekova B, 2000, NAT MED, V6, P1167, DOI 10.1038/80516; DiLorenzo TP, 1998, P NATL ACAD SCI USA, V95, P12538, DOI 10.1073/pnas.95.21.12538; Gross DA, 2004, J CLIN INVEST, V113, P425, DOI 10.1172/JCI200419418; Kappos L, 2000, NAT MED, V6, P1176, DOI 10.1038/80525; KARIN N, 1994, J EXP MED, V180, P2227, DOI 10.1084/jem.180.6.2227; Liblau RS, 2002, IMMUNITY, V17, P1, DOI 10.1016/S1074-7613(02)00338-2; Lieberman SM, 2003, P NATL ACAD SCI USA, V100, P8384, DOI 10.1073/pnas.0932778100; Lieberman SM, 2003, TISSUE ANTIGENS, V62, P359, DOI 10.1034/j.1399-0039.2003.00152.x; LIU GY, 1995, INT IMMUNOL, V7, P1255, DOI 10.1093/intimm/7.8.1255; Martin CC, 2001, J BIOL CHEM, V276, P25197, DOI 10.1074/jbc.M101549200; McKown KM, 1999, ARTHRITIS RHEUM, V42, P1204, DOI 10.1002/1529-0131(199906)42:6<1204::AID-ANR17>3.0.CO;2-U; Metzler B, 2000, IMMUNOL INVEST, V29, P61, DOI 10.3109/08820130009105145; METZLER B, 1993, INT IMMUNOL, V5, P1159, DOI 10.1093/intimm/5.9.1159; NICHOLSON LB, 1995, IMMUNITY, V3, P397, DOI 10.1016/1074-7613(95)90169-8; Perez-Diez A, 2002, J IMMUNOL, V168, P338, DOI 10.4049/jimmunol.168.1.338; Pociot F, 2002, GENES IMMUN, V3, P235, DOI 10.1038/sj.gene.6363875; Pozzilli P, 2000, DIABETOLOGIA, V43, P1000, DOI 10.1007/s001250051482; SANTAMARIA P, 1995, J IMMUNOL, V154, P2494; Santamaria P, 2001, CURR OPIN IMMUNOL, V13, P663, DOI 10.1016/S0952-7915(01)00276-X; Skyler JS, 2002, NEW ENGL J MED, V346, P1685; Toes REM, 1996, P NATL ACAD SCI USA, V93, P7855, DOI 10.1073/pnas.93.15.7855; TRENTHAM DE, 1993, SCIENCE, V261, P1727, DOI 10.1126/science.8378772; Trudeau JD, 2003, J CLIN INVEST, V111, P217, DOI 10.1172/JCI200316409; Verdaguer J, 1997, J EXP MED, V186, P1663, DOI 10.1084/jem.186.10.1663; Verdaguer J, 1996, J IMMUNOL, V157, P4726; WEINER HL, 1993, SCIENCE, V259, P1321, DOI 10.1126/science.7680493; Wong FS, 1999, NAT MED, V5, P1026, DOI 10.1038/12465; WRAITH DC, 1989, CELL, V59, P247, DOI 10.1016/0092-8674(89)90287-0; Zeh HJ, 1999, J IMMUNOL, V162, P989	36	116	122	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2005	11	6					645	652		10.1038/nm1250	http://dx.doi.org/10.1038/nm1250			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	932YD	15908957				2022-12-25	WOS:000229589800031
J	Schirenbeck, A; Bretschneider, T; Arasada, R; Schleicher, M; Faix, J				Schirenbeck, A; Bretschneider, T; Arasada, R; Schleicher, M; Faix, J			The Diaphanous-related formin dDia2 is required for the formation and maintenance of filopodia	NATURE CELL BIOLOGY			English	Article							DICTYOSTELIUM-DISCOIDEUM; CAPPING PROTEIN; ACTIN-BINDING; CELL MOTILITY; CLEAVAGE FURROW; CYTOKINESIS; DOMAIN; PROFILIN; FAMILY; YEAST	Formins have important roles in the nucleation of actin and the formation of linear actin filaments, but their role in filopodium formation has remained elusive. Dictyostelium discoideum Diaphanous-related formin dDia2 is enriched at the tips of filopodia and interacts with profilin II and Rac1. An FH1FH2 fragment of dDia2 nucleated actin polymerization and removed capping protein from capped filament ends. Genetic studies showed that dDia2 is important for cell migration as well as the formation, elongation and maintenance of filopodia. Here we provide evidence that dDia2 specifically controls filopodial dynamics by regulating actin turnover at the barbed ends of actin filaments.	Univ Munich, A Butenandt Inst Zellbiol, D-80336 Munich, Germany; Max Planck Inst Biochem, AG Zelldynamik, D-82152 Martinsried, Germany	University of Munich; Max Planck Society	Faix, J (corresponding author), Hannover Med Sch, Inst Biophys Chem, D-30623 Hannover, Germany.	faix@bpc.mh-hannover.de	Bretschneider, Till/D-4667-2011	Bretschneider, Till/0000-0002-5317-603X				Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; Dai JW, 1999, BIOPHYS J, V77, P3363, DOI 10.1016/S0006-3495(99)77168-7; Dumontier M, 2000, J CELL SCI, V113, P2253; EICHINGER L, 1992, BIOCHEMISTRY-US, V31, P4779, DOI 10.1021/bi00135a006; Eichinger L, 2005, NATURE, V435, P43, DOI 10.1038/nature03481; Evangelista M, 2003, J CELL SCI, V116, P2603, DOI 10.1242/jcs.00611; Evangelista M, 2002, NAT CELL BIOL, V4, P32, DOI 10.1038/ncb718; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Faix J, 1996, FEBS LETT, V394, P251, DOI 10.1016/0014-5793(96)00963-5; Faix J, 1998, J CELL SCI, V111, P3059; Faix J, 2001, EMBO J, V20, P3705, DOI 10.1093/emboj/20.14.3705; Han YH, 2002, J BIOL CHEM, V277, P49877, DOI 10.1074/jbc.M209107200; HARTMANN H, 1989, J BIOL CHEM, V264, P12639; HAUGWITZ M, 1994, CELL, V79, P303, DOI 10.1016/0092-8674(94)90199-6; HUG C, 1995, CELL, V81, P591, DOI 10.1016/0092-8674(95)90080-2; Kitayama C, 2003, J CELL SCI, V116, P711, DOI 10.1242/jcs.00265; Kovar DR, 2003, J CELL BIOL, V161, P875, DOI 10.1083/jcb.200211078; Kovar DR, 2004, P NATL ACAD SCI USA, V101, P14725, DOI 10.1073/pnas.0405902101; Lebrand C, 2004, NEURON, V42, P37, DOI 10.1016/S0896-6273(04)00108-4; Pellegrin S, 2005, CURR BIOL, V15, P129, DOI 10.1016/j.cub.2005.01.011; Peng J, 2003, CURR BIOL, V13, P534, DOI 10.1016/S0960-9822(03)00170-2; Petersen J, 1998, J CELL BIOL, V141, P1217, DOI 10.1083/jcb.141.5.1217; Rivero F, 2001, NUCLEIC ACIDS RES, V29, P1068, DOI 10.1093/nar/29.5.1068; Romero S, 2004, CELL, V119, P419, DOI 10.1016/j.cell.2004.09.039; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; Shimada A, 2004, MOL CELL, V13, P511, DOI 10.1016/S1097-2765(04)00059-0; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; SUTOH K, 1993, PLASMID, V30, P150, DOI 10.1006/plas.1993.1042; Svitkina TM, 2003, J CELL BIOL, V160, P409, DOI 10.1083/jcb.200210174; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Weber I, 1999, EMBO J, V18, P586, DOI 10.1093/emboj/18.3.586; Xu YW, 2004, CELL, V116, P711, DOI 10.1016/S0092-8674(04)00210-7; Zigmond SH, 2004, CURR OPIN CELL BIOL, V16, P99, DOI 10.1016/j.ceb.2003.10.019	35	195	201	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2005	7	6					619	U24		10.1038/ncb1266	http://dx.doi.org/10.1038/ncb1266			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	932OD	15908944				2022-12-25	WOS:000229562100016
J	Tseng, YH; Butte, AJ; Kokkotou, E; Yechoor, VK; Taniguchi, CM; Kriauciunas, KM; Cypess, AM; Niinobe, M; Yoshikawa, K; Patti, ME; Kahn, CR				Tseng, YH; Butte, AJ; Kokkotou, E; Yechoor, VK; Taniguchi, CM; Kriauciunas, KM; Cypess, AM; Niinobe, M; Yoshikawa, K; Patti, ME; Kahn, CR			Prediction of preadipocyte differentiation by gene expression reveals role of insulin receptor substrates and necdin	NATURE CELL BIOLOGY			English	Article							PRADER-WILLI-SYNDROME; ADIPOCYTE DIFFERENTIATION; MATRIX METALLOPROTEINASES; ADIPOSE-TISSUE; ADIPOGENESIS; ACTIVATION; INHIBITION; PROTEIN; RESISTANCE; INTERACTS	The insulin/IGF-1 (insulin-like growth factor 1) signalling pathway promotes adipocyte differentiation via complex signalling networks. Here, using microarray analysis of brown preadipocytes that are derived from wild-type and insulin receptor substrate (Irs) knockout animals that exhibit progressively impaired differentiation, we define 374 genes/expressed-sequence tags whose expression in preadipocytes correlates with the ultimate ability of the cells to differentiate. Many of these genes, including preadipocyte factor-1 (Pref-1) and multiple members of the Wnt signalling pathway, are related to early adipogenic events. Necdin is also markedly increased in Irs knockout cells that cannot differentiate, and knockdown of necdin restores brown adipogenesis with downregulation of Pref-1 and Wnt10a expression. Insulin receptor substrate proteins regulate a necdin-E2F4 interaction that represses peroxisome-proliferator-activated receptor gamma (PPAR gamma) transcription via a cyclic AMP response element binding protein (CREB)-dependent pathway. Together these define a key signalling network that is involved in brown preadipocyte determination.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Informat Program, Childrens Hosp, Boston, MA 02215 USA; Osaka Univ, Inst Prot Res, Div Regulat Macromol Funct, Suita, Osaka 5650871, Japan	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Boston Children's Hospital; Harvard Medical School; Osaka University	Kahn, CR (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA.	c.ronald.kahn@joslin.harvard.edu	Yechoor, Vijay/AAX-3244-2021; Tseng, Yu-Hua/AAE-6471-2021; Kahn, Ronald/AAY-2435-2021	Tseng, Yu-Hua/0000-0003-2053-9559; Kahn, Ronald/0000-0002-7583-9228; Taniguchi, Cullen/0000-0002-8052-3316	NIDDK NIH HHS [DK63696, DK07260, DK101183, DK33201, R01 DK033201, DK60837, P30 DK036836] Funding Source: Medline; NLM NIH HHS [K22 LM008261-01A1, K22 LM008261] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033201, R01DK060837, F32DK101183, P30DK036836, T32DK007260] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [K22LM008261] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Asahara H, 2001, MOL CELL BIOL, V21, P7892, DOI 10.1128/MCB.21.23.7892-7900.2001; BARTHOLOMEW DJ, 1959, BIOMETRIKA, V46, P36; Boeuf S, 2001, PHYSIOL GENOMICS, V7, P15, DOI 10.1152/physiolgenomics.00048.2001; Brunelli S, 2004, CIRC RES, V94, P1571, DOI 10.1161/01.RES.0000132747.12860.10; Chavey C, 2003, J BIOL CHEM, V278, P11888, DOI 10.1074/jbc.M209196200; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Cowherd RM, 1999, SEMIN CELL DEV BIOL, V10, P3, DOI 10.1006/scdb.1998.0276; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Escalante-Alcalde D, 2003, DEVELOPMENT, V130, P4623, DOI 10.1242/dev.00635; Fajas L, 2002, DEV CELL, V3, P39, DOI 10.1016/S1534-5807(02)00190-9; Fasshauer M, 2001, MOL CELL BIOL, V21, P319, DOI 10.1128/MCB.21.1.319-329.2001; Goldstone AP, 2004, TRENDS ENDOCRIN MET, V15, P12, DOI 10.1016/j.tem.2003.11.003; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Gregoire FM, 2001, EXP BIOL MED, V226, P997, DOI 10.1177/153537020122601106; Ideker T, 2000, J COMPUT BIOL, V7, P805, DOI 10.1089/10665270050514945; Jansson PA, 2003, FASEB J, V17, P1434, DOI 10.1096/fj.02-1132com; Kang S, 2005, MOL CELL BIOL, V25, P1272, DOI 10.1128/MCB.25.4.1272-1282.2005; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Klemm DJ, 2001, J BIOL CHEM, V276, P28430, DOI 10.1074/jbc.M103382200; Kobayashi M, 2002, J BIOL CHEM, V277, P42128, DOI 10.1074/jbc.M205024200; Koutnikova H, 2001, ANN MED, V33, P556, DOI 10.3109/07853890108995966; Kuwajima T, 2004, J BIOL CHEM, V279, P40484, DOI 10.1074/jbc.M404143200; Landsberg RL, 2003, P NATL ACAD SCI USA, V100, P2456, DOI 10.1073/pnas.0138064100; Laustsen PG, 2002, GENE DEV, V16, P3213, DOI 10.1101/gad.1034802; Levene H., 1960, CONTRIBUTIONS PROBAB, P278, DOI DOI 10.1137/1003016; MacDougald OA, 2002, TRENDS ENDOCRIN MET, V13, P5, DOI 10.1016/S1043-2760(01)00517-3; Maquoi E, 2002, DIABETES, V51, P1093, DOI 10.2337/diabetes.51.4.1093; Martelli F, 1999, P NATL ACAD SCI USA, V96, P2858, DOI 10.1073/pnas.96.6.2858; Mata J, 2000, CELL, V101, P511, DOI 10.1016/S0092-8674(00)80861-2; Pan W., 2002, GENOME BIOL, V3; PRESS WH, 1993, NUMERICAL RECIPES C; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rangwala SM, 2000, ANNU REV NUTR, V20, P535, DOI 10.1146/annurev.nutr.20.1.535; Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008-1020.2000; Rosen ED, 2000, GENE DEV, V14, P1293; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Schiller PC, 2001, J BIOL CHEM, V276, P14133, DOI 10.1074/jbc.M011055200; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; SPIEGELMAN BM, 1982, CELL, V29, P53, DOI 10.1016/0092-8674(82)90089-7; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Taniura H, 1998, J BIOL CHEM, V273, P720, DOI 10.1074/jbc.273.2.720; Tong Q, 2000, SCIENCE, V290, P134, DOI 10.1126/science.290.5489.134; Tseng YH, 2002, J BIOL CHEM, V277, P31601, DOI 10.1074/jbc.M202932200; Tseng YH, 2004, MOL CELL BIOL, V24, P1918, DOI 10.1128/MCB.24.5.1918-1929.2004; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; WEINER FR, 1989, BIOCHEMISTRY-US, V28, P4094, DOI 10.1021/bi00435a070; Yang T, 1998, NAT GENET, V19, P25, DOI 10.1038/ng0598-25; Yi TG, 2001, EXP MOL MED, V33, P269, DOI 10.1038/emm.2001.44	50	172	182	3	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2005	7	6					601	U22		10.1038/ncb1259	http://dx.doi.org/10.1038/ncb1259			14	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	932OD	15895078				2022-12-25	WOS:000229562100014
J	Denver, DR; Morris, K; Streelman, JT; Kim, SK; Lynch, M; Thomas, WK				Denver, DR; Morris, K; Streelman, JT; Kim, SK; Lynch, M; Thomas, WK			The transcriptional consequences of mutation and natural selection in Caenorhabditis elegans	NATURE GENETICS			English	Article							GENE-EXPRESSION PROFILES; EVOLUTION; GENOME; BIOLOGY; MODEL; DNA	The evolutionary importance of gene-expression divergence is unclear: some studies suggest that it is an important mechanism for evolution by natural selection(1,2), whereas others claim that most between-species regulatory changes are neutral or nearly neutral(3). We examined global transcriptional divergence patterns in a set of Caenorhabditis elegans mutation-accumulation lines and natural isolate lines to provide insights into the evolutionary importance of transcriptional variation and to discriminate between the forces of mutation and natural selection in shaping the evolution of gene expression. We detected the effects of selection on transcriptional divergence patterns and characterized them with respect to coexpressed gene sets, chromosomal clustering of expression changes and functional gene categories. We directly compared observed transcriptional variation patterns in the mutation-accumulation and natural isolate lines to a neutral model of transcriptome evolution to show that strong stabilizing selection dominates the evolution of transcriptional change for thousands of C. elegans expressed sequences.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Univ New Hampshire, Hubbard Ctr Genome Studies, Durham, NH 03824 USA; Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA; Stanford Univ, Med Ctr, Dept Dev Biol, Stanford, CA 94305 USA	Indiana University System; Indiana University Bloomington; University System Of New Hampshire; University of New Hampshire; University System of Georgia; Georgia Institute of Technology; Stanford University	Denver, DR (corresponding author), Massey Univ, Allan Wilson Ctr Mol Ecol & Evolut, Auckland, New Zealand.	d.denver@massey.ac.nz						Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; BARNES TM, 1995, GENETICS, V141, P159; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Charlesworth B, 2002, CURR BIOL, V12, pR716, DOI 10.1016/S0960-9822(02)01244-7; Cui XQ, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-210; Denver DR, 2003, MOL BIOL EVOL, V20, P393, DOI 10.1093/molbev/msg044; Denver DR, 2004, NATURE, V430, P679, DOI 10.1038/nature02697; Enard W, 2002, SCIENCE, V296, P340, DOI 10.1126/science.1068996; FABIAN TJ, 1994, J GERONTOL BIOL SC B, V49, P145; Graustein A, 2002, GENETICS, V161, P99; Harris TW, 2004, NUCLEIC ACIDS RES, V32, pD411, DOI 10.1093/nar/gkh066; HILL WG, 1966, GENET RES, V8, P269, DOI 10.1017/S0016672300010156; Hsieh WP, 2003, GENETICS, V165, P747; Jiang M, 2001, P NATL ACAD SCI USA, V98, P218, DOI 10.1073/pnas.011520898; Kerr M K, 2001, Biostatistics, V2, P183, DOI 10.1093/biostatistics/2.2.183; Khaitovich P, 2004, PLOS BIOL, V2, P682, DOI 10.1371/journal.pbio.0020132; Kim SK, 2001, SCIENCE, V293, P2087, DOI 10.1126/science.1061603; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; Koch R, 2000, GENOME RES, V10, P1690, DOI 10.1101/gr.GR-1471R; Lercher MJ, 2003, GENOME RES, V13, P238, DOI 10.1101/gr.553803; Lynch M, 2003, SCIENCE, V302, P1401, DOI 10.1126/science.1089370; LYNCH M, 1986, EVOLUTION, V40, P915, DOI 10.1111/j.1558-5646.1986.tb00561.x; Oleksiak MF, 2002, NAT GENET, V32, P261, DOI 10.1038/ng983; Roy PJ, 2002, NATURE, V418, P975, DOI 10.1038/nature01012; Vassilieva LL, 2000, EVOLUTION, V54, P1234, DOI 10.1111/j.0014-3820.2000.tb00557.x; Wittkopp PJ, 2004, NATURE, V430, P85, DOI 10.1038/nature02698; Wray GA, 2003, MOL BIOL EVOL, V20, P1377, DOI 10.1093/molbev/msg140	27	205	205	0	35	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2005	37	5					544	548		10.1038/ng1554	http://dx.doi.org/10.1038/ng1554			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	922TU	15852004				2022-12-25	WOS:000228862300026
J	Jadeja, S; Smyth, I; Pitera, JE; Taylor, MS; van Haelst, M; Bentley, E; McGregor, L; Hopkins, J; Chalepakis, G; Philip, N; Aytes, AP; Watt, FM; Darling, SM; Jackson, I; Woolf, AS; Scambler, PJ				Jadeja, S; Smyth, I; Pitera, JE; Taylor, MS; van Haelst, M; Bentley, E; McGregor, L; Hopkins, J; Chalepakis, G; Philip, N; Aytes, AP; Watt, FM; Darling, SM; Jackson, I; Woolf, AS; Scambler, PJ			Identification of a new gene mutated in Fraser syndrome and mouse myelencephalic blebs	NATURE GENETICS			English	Article							CRYPTOPHTHALMOS; PHENOTYPE; ADHESION; MOLECULE; CADHERIN; PROTEIN; DOMAIN; MICE	Fraser syndrome is a recessive, multisystem disorder presenting with cryptophthalmos, syndactyly and renal defects(1,2) and associated with loss-of-function mutations of the extracellular matrix protein FRAS1. Fras1 mutant mice have a blebbed phenotype characterized by intrauterine epithelial fragility generating serous and, later, hemorrhagic blisters. The myelencephalic blebs ( my) strain has a similar phenotype. We mapped my to Frem2, a gene related to Fras1 and Frem1, and showed that a Frem2 gene-trap mutation was allelic to my. Expression of Frem2 in adult kidneys correlated with cyst formation in my homozygotes, indicating that the gene is required for maintaining the differentiated state of renal epithelia. Two individuals with Fraser syndrome were homozygous with respect to the same missense mutation of FREM2, confirming genetic heterogeneity. This is the only missense mutation reported in any blebbing mutant or individual with Fraser syndrome, suggesting that calcium binding in the CALX beta-cadherin motif is important for normal functioning of FREM2.	UCL, Mol Med Unit, Inst Child Hlth, London WC1N 1EH, England; CR UK London Res Inst, London WC2A 3PX, England; UCL, Nephrourol Unit, Inst Child Hlth, London WC1N 1EH, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England; Univ Crete, Dept Biol, Iraklion 71409, Greece; Hosp Enfants Timone, Marseille, France; Hosp Infantil La Fe, Valencia, Spain; Western Gen Hosp, MRC Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of London; University College London; University of London; University College London; University of Oxford; Wellcome Centre for Human Genetics; University of Crete; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; University of Edinburgh	Scambler, PJ (corresponding author), UCL, Mol Med Unit, Inst Child Hlth, London WC1N 1EH, England.	p.scambler@ich.ucl.ac.uk	Scambler, Peter J/C-4998-2008; Woolf, Adrian S./AAZ-1075-2020; Scambler, Peter/AAZ-6026-2020; Watt, Fiona/AHB-0226-2022; Taylor, Martin S/C-3825-2009; Philip, Nicole/I-2881-2016	Scambler, Peter J/0000-0002-1487-4628; Woolf, Adrian S./0000-0001-5541-1358; Scambler, Peter/0000-0002-1487-4628; Watt, Fiona/0000-0001-9151-5154; Taylor, Martin S/0000-0001-7656-330X; Jackson, Ian/0000-0001-6526-0688; Perez-Aytes, Antonio/0000-0003-3401-6943; Smyth, Ian/0000-0002-1727-7829				Darling S, 1994, Clin Dysmorphol, V3, P91; FRASER GR, 1962, ANN HUM GENET, V25, P387, DOI 10.1111/j.1469-1809.1962.tb01774.x; Hodor PG, 2000, DEV BIOL, V222, P181, DOI 10.1006/dbio.2000.9696; Little CC, 1923, AM J ROENTGENOL RADI, V10, P975; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; McGregor L, 2003, NAT GENET, V34, P203, DOI 10.1038/ng1142; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Philipson KD, 2002, ANN NY ACAD SCI, V976, P1; Poschl E, 2004, DEVELOPMENT, V131, P1619, DOI 10.1242/dev.01037; Slavotinek AM, 2002, J MED GENET, V39, P623, DOI 10.1136/jmg.39.9.623; Smyth I, 2004, P NATL ACAD SCI USA, V101, P13560, DOI 10.1073/pnas.0402760101; Takamiya K, 2004, NAT GENET, V36, P172, DOI 10.1038/ng1292; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Vrontou S, 2003, NAT GENET, V34, P209, DOI 10.1038/ng1168; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75	15	122	127	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2005	37	5					520	525		10.1038/ng1549	http://dx.doi.org/10.1038/ng1549			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	922TU	15838507				2022-12-25	WOS:000228862300022
J	van Bokhoven, H; Celli, J; van Reeuwijk, J; Rinne, T; Glaudemans, B; van Beusekom, E; Rieu, P; Newbury-Ecob, RA; Chiang, C; Brunner, HG				van Bokhoven, H; Celli, J; van Reeuwijk, J; Rinne, T; Glaudemans, B; van Beusekom, E; Rieu, P; Newbury-Ecob, RA; Chiang, C; Brunner, HG			MYCN haploinsufficiency is associated with reduced brain size and intestinal atresias in Feingold syndrome	NATURE GENETICS			English	Article							N-MYC; SONIC HEDGEHOG; ESOPHAGEAL ATRESIA; PROLIFERATION; PRECURSORS; DNA	Feingold syndrome is characterized by variable combinations of esophageal and duodenal atresias, microcephaly, learning disability, syndactyly and cardiac defect. We show here that heterozygous mutations in the gene MYCN are present in Feingold syndrome. All mutations are predicted to disrupt both the full-length protein and a new shortened MYCN isoform, suggesting that multiple aspects of early embryogenesis and postnatal brain growth in humans are tightly regulated by MYCN dosage.	Radboud Univ Nijmegen Med Ctr, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen Med Ctr, Dept Pediat Surg, NL-6500 HB Nijmegen, Netherlands; Royal United Hosp, Genet Ctr, Bath BA1 3NG, Avon, England; Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN USA	Radboud University Nijmegen; Radboud University Nijmegen; Vanderbilt University	van Bokhoven, H (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Human Genet, Box 9101, NL-6500 HB Nijmegen, Netherlands.	H.vanBokhoven@antrg.umcn.nl	Rinne, Tuula/B-6339-2018; van Reeuwijk, Jeroen/P-8665-2015; van Bokhoven, Hans/D-8764-2012; Bokhoven, J.H.L.M. van van/H-8015-2014; van Beusekom, Ellen/AAF-2687-2019; Brunner, Han/C-9928-2013	van Reeuwijk, Jeroen/0000-0002-0658-4399; Bokhoven, J.H.L.M. van van/0000-0002-2153-9254; 				Celli J, 2000, AM J HUM GENET, V66, P436, DOI 10.1086/302779; Celli J, 2003, AM J MED GENET A, V122A, P294, DOI 10.1002/ajmg.a.20471; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; HIRVONEN H, 1990, ONCOGENE, V5, P1787; Jopling CL, 2001, ONCOGENE, V20, P2664, DOI 10.1038/sj.onc.1204404; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Knoepfler PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202; Litingtung Y, 1998, NAT GENET, V20, P58, DOI 10.1038/1717; Merei JM, 2002, PEDIATR SURG INT, V18, P319, DOI 10.1007/s00383-002-0751-1; MOENS CB, 1992, GENE DEV, V6, P691, DOI 10.1101/gad.6.5.691; Nair SK, 2003, CELL, V112, P193, DOI 10.1016/S0092-8674(02)01284-9; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; Torfs CP, 1995, TERATOLOGY, V52, P220, DOI 10.1002/tera.1420520408	15	109	113	0	6	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2005	37	5					465	467		10.1038/ng1546	http://dx.doi.org/10.1038/ng1546			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	922TU	15821734				2022-12-25	WOS:000228862300013
J	Dubois, T; Paleotti, O; Mironov, AA; Fraisier, V; Stradal, TEB; De Matteis, MA; Franco, M; Chavrier, P				Dubois, T; Paleotti, O; Mironov, AA; Fraisier, V; Stradal, TEB; De Matteis, MA; Franco, M; Chavrier, P			Golgi-localized GAP for Cdc42 functions downstream of ARF1 to control Arp2/3 complex and F-actin dynamics	NATURE CELL BIOLOGY			English	Article							ENDOPLASMIC-RETICULUM; BREFELDIN-A; PROTEINS; RHO; TRANSPORT; CYTOSKELETON; RECRUITMENT; RESIDUES; GTPASES	The small GTP-binding ADP-ribosylation factor 1 (ARF1) acts as a master regulator of Golgi structure and function through the recruitment and activation of various downstream effectors. It has been proposed that members of the Rho family of small GTPases also control Golgi function in coordination with ARF1, possibly through the regulation of Arp2/3 complex and actin polymerization on Golgi membranes. Here, we identify ARHGAP10 - a novel Rho GTPase-activating protein (Rho-GAP) that is recruited to Golgi membranes through binding to GTP-ARF1. We show that ARHGAP10 functions preferentially as a GAP for Cdc42 and regulates the Arp2/3 complex and F-actin dynamics at the Golgi through the control of Cdc42 activity. Our results establish a role for ARHGAP10 in Golgi structure and function at the crossroads between ARF1 and Cdc42 signalling pathways.	Inst Curie, CNRS, UMR144, Membrane & Cytoskeleton Dynam Grp, F-75248 Paris, France; CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, F-06560 Valbonne, France; Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Santa Maria Imbaro, CH, Italy; Inst Curie, CNRS, UMR144, F-75248 Paris, France; German Res Ctr Biotechnol GBF, Dept Cell Biol, D-38124 Braunschweig, Germany	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Helmholtz Association; Helmholtz-Center for Infection Research	Chavrier, P (corresponding author), Inst Curie, CNRS, UMR144, Membrane & Cytoskeleton Dynam Grp, F-75248 Paris, France.	philippe.chavrier@curie.fr	De Matteis, Maria Antonietta/AHE-5161-2022; CHAVRIER, Philippe/AAG-2645-2020; CHAVRIER, Philippe/B-4707-2010; FRANCO, michel/AAA-9735-2021; Franco, Michel/ABH-4993-2020; Dubois, Thierry/D-2852-2017	De Matteis, Maria Antonietta/0000-0003-0053-3061; CHAVRIER, Philippe/0000-0002-7351-733X; CHAVRIER, Philippe/0000-0002-7351-733X; Franco, Michel/0000-0003-1853-8661; Stradal, Theresia/0000-0002-0352-9474; Mironov, Aleksandr/0000-0002-1497-328X; Dubois, Thierry/0000-0003-4739-6164	Telethon [GP0203Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; Basseres DS, 2002, BIOCHEM BIOPH RES CO, V294, P579; Bonifacino JS, 2004, NAT REV MOL CELL BIO, V5, P23, DOI 10.1038/nrm1279; Camera P, 2003, NAT CELL BIOL, V5, P1071, DOI 10.1038/ncb1064; Carreno S, 2004, J CELL BIOL, V165, P781, DOI 10.1083/jcb.200403120; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Chen JL, 2004, FEBS LETT, V566, P281, DOI 10.1016/j.febslet.2004.04.061; DASCHER C, 1994, J BIOL CHEM, V269, P1437; De Matteis MA, 2000, J CELL SCI, V113, P2331; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Fucini RV, 2002, MOL BIOL CELL, V13, P621, DOI 10.1091/mbc.01-11-0547; Fucini RV, 2000, J BIOL CHEM, V275, P18824, DOI 10.1074/jbc.M000024200; Kikuno R, 2004, NUCLEIC ACIDS RES, V32, pD502, DOI 10.1093/nar/gkh035; Luna A, 2002, MOL BIOL CELL, V13, P866, DOI 10.1091/mbc.01-12-0579; Macia E, 2001, J BIOL CHEM, V276, P24925, DOI 10.1074/jbc.M103284200; Matas OB, 2004, TRAFFIC, V5, P838, DOI 10.1111/j.1600-0854.2004.00225.x; Miura K, 2002, MOL CELL, V9, P109, DOI 10.1016/S1097-2765(02)00428-8; Musch A, 2001, EMBO J, V20, P2171, DOI 10.1093/emboj/20.9.2171; Nie ZZ, 2003, CURR OPIN CELL BIOL, V15, P396, DOI 10.1016/S0955-0674(03)00071-1; Niebuhr K, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P398; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Olazabal IM, 2002, CURR BIOL, V12, P1413, DOI 10.1016/S0960-9822(02)01069-2; Percival JM, 2004, MOL BIOL CELL, V15, P268, DOI 10.1091/mbc.e03-03-0176; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Prigent M, 2003, J CELL BIOL, V163, P1111, DOI 10.1083/jcb.200305029; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; Schafer DA, 2000, TRAFFIC, V1, P892; Sibarita JB, 2002, 2002 IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING, PROCEEDINGS, P769; Stamnes M, 2002, CURR OPIN CELL BIOL, V14, P428, DOI 10.1016/S0955-0674(02)00349-6; TEAL SB, 1994, J BIOL CHEM, V269, P3135; Valderrama F, 2001, TRAFFIC, V2, P717, DOI 10.1034/j.1600-0854.2001.21006.x; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289	33	135	139	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2005	7	4					353	U9		10.1038/ncb1244	http://dx.doi.org/10.1038/ncb1244			14	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	912KA	15793564				2022-12-25	WOS:000228075500011
J	Schubert, C				Schubert, C			HIV unbound	NATURE MEDICINE			English	News Item								A new study cracks the structure of unbound gp120. The structure of a core region of the molecule with a few loops hacked off shows that receptor binding induces a massive change in protein shape. The refolding mechanism of gp120 alsomay create vulnerabilities, leaving many empty cavities in the structure. Researchers found that one such cavity serves as the binding site for a recently discovered class of viral-entry inhibitors.										Chen B, 2005, NATURE, V433, P834, DOI 10.1038/nature03327	1	0	0	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2005	11	4					385	385		10.1038/nm0405-385	http://dx.doi.org/10.1038/nm0405-385			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15812519				2022-12-25	WOS:000228180500024
J	Valentonyte, R; Hampe, J; Huse, K; Rosenstiel, P; Albrecht, M; Stenzel, A; Nagy, M; Gaede, KI; Franke, A; Haesler, R; Koch, A; Lengauer, T; Seegert, D; Reiling, N; Ehlers, S; Schwinger, E; Platzer, M; Krawczak, M; Muller-Quernheim, J; Schurmann, M; Schreiber, S				Valentonyte, R; Hampe, J; Huse, K; Rosenstiel, P; Albrecht, M; Stenzel, A; Nagy, M; Gaede, KI; Franke, A; Haesler, R; Koch, A; Lengauer, T; Seegert, D; Reiling, N; Ehlers, S; Schwinger, E; Platzer, M; Krawczak, M; Muller-Quernheim, J; Schurmann, M; Schreiber, S			Sarcoidosis is associated with a truncating splice site mutation in BTNL2	NATURE GENETICS			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; EPITHELIAL-CELLS; ALLELIC ASSOCIATION; CRYSTAL-STRUCTURE; DUTCH PATIENTS; TNF-ALPHA; GENE; SUSCEPTIBILITY; DISEASE; MARKER	Sarcoidosis is a polygenic immune disorder with predominant manifestation in the lung. Genome-wide linkage analysis previously indicated that the extended major histocompatibility locus on chromosome 6p was linked to susceptibility to sarcoidosis. Here, we carried out a systematic three-stage SNP scan of 16.4 Mb on chromosome 6p21 in as many as 947 independent cases of familial and sporadic sarcoidosis and found that a 15-kb segment of the gene butyrophilin-like 2 (BTNL2) was associated with the disease. The primary disease-associated variant (rs2076530; P-TDT = 3 x 10(-6), Pcase-control = 1.1 x 10(-8); replication P-TDT = 0.0018, Pcase-control = 1.8 x 10(-6)) represents a risk factor that is independent of variation in HLA-DRB1. BTNL2 is a member of the immunoglobulin superfamily and has been implicated as a costimulatory molecule involved in T-cell activation on the basis of its homology to B7-1. The G --> A transition constituting rs2076530 leads to the use of a cryptic splice site located 4 bp upstream of the affected wild-type donor site. Transcripts of the risk-associated allele have a premature stop in the spliced mRNA. The resulting protein lacks the C-terminal IgC domain and transmembrane helix, thereby disrupting the membrane localization of the protein, as shown in experiments using green fluorescent protein and V5 fusion proteins.	Univ Kiel, Univ Klinikum Schleswig Holstein, Inst Clin Mol Biol, D-24105 Kiel, Germany; Univ Kiel, Univ Klinikum Schleswig Holstein, Kiel Ctr German Natl Genotyping Platform, D-24105 Kiel, Germany; Inst Mol Biotechnol, D-07745 Jena, Germany; Max Planck Inst Informat, D-66123 Saarbrucken, Germany; Charite Univ Hosp, Inst Forens Med, D-10115 Berlin, Germany; Res Ctr Borstel, D-23845 Borstel, Germany; Univ Freiburg, Dept Pneumol, D-79106 Freiburg, Germany; Conaris Res Inst AG, D-24118 Kiel, Germany; Univ Lubeck, Inst Human Genet, D-23538 Lubeck, Germany; Univ Kiel, Univ Klinikum Schleswig Holstein, Inst Med Stat & Informat, D-24105 Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; Max Planck Society; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Forschungszentrum Borstel; University of Freiburg; University of Lubeck; University of Kiel; Schleswig Holstein University Hospital	Hampe, J (corresponding author), Univ Kiel, Univ Klinikum Schleswig Holstein, Inst Clin Mol Biol, Campus Kiel,Schittenhelmstr 12, D-24105 Kiel, Germany.	j.hampe@mucosa.de	Hampe, Jochen/A-2555-2010; Häsler, Robert/A-4908-2009; Franke, Andre/B-2151-2010; Seegert, Dirk/B-8826-2011; Krawczak, Michael/A-8964-2010; Müller-Quernheim, Joachim/H-1983-2011; Reiling, Norbert/D-6796-2013; Albrecht, Mario/B-6694-2008; Ehlers, Stefan/B-4075-2010; Rosenstiel, Philip/A-5137-2009	Hampe, Jochen/0000-0002-2421-6127; Häsler, Robert/0000-0003-4174-8229; Franke, Andre/0000-0003-1530-5811; Krawczak, Michael/0000-0003-2603-1502; Reiling, Norbert/0000-0001-6673-4291; Albrecht, Mario/0000-0002-3103-9624; Rosenstiel, Philip/0000-0002-9692-8828; Huse, Klaus/0000-0003-3854-1884				Abdallah A, 2003, GENES IMMUN, V4, P450, DOI 10.1038/sj.gene.6364001; Agadjanyan MG, 2003, J IMMUNOL, V171, P4311, DOI 10.4049/jimmunol.171.8.4311; Albrecht M, 2003, FEBS LETT, V538, P173, DOI 10.1016/S0014-5793(03)00161-3; Bajorath J, 2001, J MOL GRAPH MODEL, V19, P619; Borriello F, 1997, IMMUNITY, V6, P303, DOI 10.1016/S1074-7613(00)80333-7; Clayton D, 1999, AM J HUM GENET, V65, P1161, DOI 10.1086/302566; Collins AV, 2002, IMMUNITY, V17, P201, DOI 10.1016/S1074-7613(02)00362-X; Costabel U, 1999, EUR RESPIR J, V14, P735, DOI 10.1034/j.1399-3003.1999.14d02.x; Foley PJ, 2001, AM J RESP CELL MOL, V25, P272, DOI 10.1165/ajrcmb.25.3.4261; Grutters JC, 2002, AM J RESP CRIT CARE, V165, P1119, DOI 10.1164/ajrccm.165.8.200110-0320; Hampe J, 2004, BIOTECHNIQUES, V36, P148, DOI 10.2144/04361DD01; Hampe J, 2001, BIOINFORMATICS, V17, P654, DOI 10.1093/bioinformatics/17.7.654; Hampe J, 2002, P NATL ACAD SCI USA, V99, P321, DOI 10.1073/pnas.261567999; Hoebe K, 2003, NAT IMMUNOL, V4, P1223, DOI 10.1038/ni1010; Hunninghake GW, 1999, AM J RESP CRIT CARE, V160, P736; HUNNINGHAKE GW, 1979, AM J PATHOL, V97, P149; Ikemizu S, 2000, IMMUNITY, V12, P51, DOI 10.1016/S1074-7613(00)80158-2; KRAWCZAK M, 1992, HUM GENET, V90, P41; KRAWCZAK M, 1988, HUM GENET, V80, P78, DOI 10.1007/BF00451461; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Legouis R, 2003, EMBO REP, V4, P1096, DOI 10.1038/sj.embor.7400006; Long MY, 1999, MOL BIOL EVOL, V16, P1528, DOI 10.1093/oxfordjournals.molbev.a026065; Morton NE, 1998, P NATL ACAD SCI USA, V95, P11389, DOI 10.1073/pnas.95.19.11389; Newman LS, 1997, NEW ENGL J MED, V336, P1224, DOI 10.1056/NEJM199704243361706; Reiling N, 2001, J IMMUNOL, V167, P3339, DOI 10.4049/jimmunol.167.6.3339; Rhodes DA, 2001, GENOMICS, V71, P351, DOI 10.1006/geno.2000.6406; Rosenstiel P, 2003, GASTROENTEROLOGY, V124, P1001, DOI 10.1053/gast.2003.50157; Rossman MD, 2003, AM J HUM GENET, V73, P720, DOI 10.1086/378097; Rybicki BA, 2003, AM J RESP CRIT CARE, V167, P444, DOI 10.1164/rccm.2112060; Rybicki BA, 2001, AM J RESP CRIT CARE, V164, P2085, DOI 10.1164/ajrccm.164.11.2106001; Sato H, 2002, AM J RESP CELL MOL, V27, P406, DOI 10.1165/rcmb.4782; Schurmann M, 2001, AM J RESP CRIT CARE, V164, P840, DOI 10.1164/ajrccm.164.5.2007056; Schwartz JCD, 2001, NATURE, V410, P604, DOI 10.1038/35069112; Sharpe AH, 2002, NAT REV IMMUNOL, V2, P116, DOI 10.1038/nri727; Stammers M, 2000, IMMUNOGENETICS, V51, P373, DOI 10.1007/s002510050633; Stamper CC, 2001, NATURE, V410, P608, DOI 10.1038/35069118; Stenzel A, 2004, HUM GENET, V114, P377, DOI 10.1007/s00439-003-1075-5; Ueda H, 2003, NATURE, V423, P506, DOI 10.1038/nature01621; Walunas TL, 1996, J EXP MED, V183, P2541, DOI 10.1084/jem.183.6.2541; Zhang XW, 2003, P NATL ACAD SCI USA, V100, P2586, DOI 10.1073/pnas.252771499; Ziegenhagen MW, 2003, J INTERN MED, V253, P18, DOI 10.1046/j.1365-2796.2003.01074.x; Zissel G, 2000, J INVEST MED, V48, P66	42	346	362	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2005	37	4					357	364		10.1038/ng1519	http://dx.doi.org/10.1038/ng1519			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	911XL	15735647				2022-12-25	WOS:000228040000018
J	Peters, BA; Diaz, LA; Polyak, K; Meszler, L; Romans, K; Guinan, EC; Antin, JH; Myerson, D; Hamilton, SR; Vogelstein, B; Kinzler, KW; Lengauer, C				Peters, BA; Diaz, LA; Polyak, K; Meszler, L; Romans, K; Guinan, EC; Antin, JH; Myerson, D; Hamilton, SR; Vogelstein, B; Kinzler, KW; Lengauer, C			Contribution of bone marrow-derived endothelial cells to human tumor vasculature	NATURE MEDICINE			English	Article							PROGENITOR CELLS; ANGIOGENESIS; GROWTH; HEPATOCYTES; FUSION	It has been shown that bone marrow-derived stem cells can form a major fraction of the tumor endothelium in mouse tumors. To determine the role of such cells in human tumor angiogenesis, we studied six individuals who developed cancers after bone marrow transplantation with donor cells derived from individuals of the opposite sex. By performing fluorescence in situ hybridization (FISH) with sex chromosome-specific probes in conjunction with fluorescent antibody staining, we found that such stem cells indeed contributed to tumor endothelium, but at low levels, averaging only 4.9% of the total. These results illustrate substantial differences between human tumors and many mouse models with respect to angiogenesis and have important implications for the translation of experimental antiangiogenic therapies to the clinic.	Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21231 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Washington, Sch Med, Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Div Pathol & Lab Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Hematopathol, Div Pathol & Lab Med, Houston, TX 77030 USA	Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Lengauer, C (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, 1650 Orleans St, Baltimore, MD 21231 USA.	lengauer@jhmi.edu	Diaz, Luis A/A-6018-2008	Myerson, David/0000-0002-2628-940X; Peters, Brock/0000-0002-5137-3902; Diaz, Luis/0000-0002-7079-8914	NCI NIH HHS [CA57345] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057345, R37CA057345] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Davidoff AM, 2001, CLIN CANCER RES, V7, P2870; De Palma M, 2003, HUM GENE THER, V14, P1193, DOI 10.1089/104303403322168028; Hilbe W, 2004, J CLIN PATHOL, V57, P965, DOI 10.1136/jcp.2004.016444; Jiang SG, 2004, P NATL ACAD SCI USA, V101, P16891, DOI 10.1073/pnas.0404398101; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Man YG, 2003, PATHOL RES PRACT, V199, P815, DOI 10.1078/0344-0338-00501; Natori T, 2002, BIOCHEM BIOPH RES CO, V297, P1058, DOI 10.1016/S0006-291X(02)02335-5; Reyes M, 2002, J CLIN INVEST, V109, P337, DOI 10.1172/JCI200214327; Ruzinova MB, 2003, CANCER CELL, V4, P277, DOI 10.1016/S1535-6108(03)00240-X; SCHLEGELBERGER YZ, 2000, METHOS MOL BIOL, P379; Sikder H, 2003, CANCER CELL, V4, P291, DOI 10.1016/S1535-6108(03)00245-9; Stoll BR, 2003, BLOOD, V102, P2555, DOI 10.1182/blood-2003-02-0365; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531	15	402	445	1	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					261	262		10.1038/nm1200	http://dx.doi.org/10.1038/nm1200			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15723071				2022-12-25	WOS:000227541300019
J	Belyantseva, IA; Boger, ET; Naz, S; Frolenkov, GI; Sellers, JR; Ahmed, ZM; Griffith, AJ; Friedman, TB				Belyantseva, IA; Boger, ET; Naz, S; Frolenkov, GI; Sellers, JR; Ahmed, ZM; Griffith, AJ; Friedman, TB			Myosin-XVa is required for tip localization of whirlin and differential elongation of hair-cell stereocilia	NATURE CELL BIOLOGY			English	Article							ACTIN-FILAMENTS; UNCONVENTIONAL MYOSIN; MOLECULAR TREADMILL; DEAFNESS DFNB3; BIRD COCHLEA; BUNDLES; MOUSE; ORGANIZATION; CYTOSKELETON; MICROVILLI	Stereocilia are microvilli-derived mechanosensory organelles that are arranged in rows of graded heights on the apical surface of inner-ear hair cells(1). The 'staircase'-like architecture of stereocilia bundles is necessary to detect sound and head movement, and is achieved through differential elongation of the actin core of each stereocilium to a predetermined length(2,3). Abnormally short stereocilia bundles that have a diminished staircase are characteristic of the shaker 2 (Myo15a(sh2)) and whirler (Whrn(wi)) strains of deaf mice(4-6). We show that myosin-XVa is a motor protein that, in vivo, interacts with the third PDZ domain of whirlin through its carboxy-terminal PDZ-ligand. Myosin-XVa then delivers whirlin to the tips of stereocilia. Moreover, if green fluorescent protein (GFP)-Myo15a is transfected into hair cells of Myo15a(sh2) mice, the wild-type pattern of hair bundles is restored by recruitment of endogenous whirlin to the tips of stereocilia. The interaction of myosin-XVa and whirlin is therefore a key event in hair-bundle morphogenesis.	Natl Inst Deafness & Other Commun Disorders, Sect Human Genet, NIH, Rockville, MD 20850 USA; Univ Maryland, Dept Biol, College Pk, MD 20742 USA; Natl Inst Deafness & Other Commun Disorders, Sect Gene Struct & Funct, NIH, Rockville, MD 20850 USA; NHLBI, Lab Mol Physiol, Bethesda, MD 20890 USA; Natl Inst Deafness & Other Commun Disorders, Hearing Sect, NIH, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); University System of Maryland; University of Maryland College Park; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Friedman, TB (corresponding author), Natl Inst Deafness & Other Commun Disorders, Sect Human Genet, NIH, Rockville, MD 20850 USA.	friedman@nidcd.nih.gov	Naz, Sadaf/C-3911-2019	Naz, Sadaf/0000-0002-1912-0235; Frolenkov, Gregory/0000-0002-9810-5024	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL004232, Z01HL004232] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000048, ZIADC000060, ZIADC000039, Z01DC000039, Z01DC000048, Z01DC000060] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Anderson DW, 2000, HUM MOL GENET, V9, P1729, DOI 10.1093/hmg/9.12.1729; Bartles JR, 2000, CURR OPIN CELL BIOL, V12, P72, DOI 10.1016/S0955-0674(99)00059-9; Belyantseva IA, 2003, P NATL ACAD SCI USA, V100, P13958, DOI 10.1073/pnas.2334417100; Berg JS, 2002, NAT CELL BIOL, V4, P246, DOI 10.1038/ncb762; DeRosier DJ, 2000, J CELL BIOL, V148, P1; EDDS KT, 1977, J CELL BIOL, V73, P479, DOI 10.1083/jcb.73.2.479; Frolenkov GI, 2004, NAT REV GENET, V5, P489, DOI 10.1038/nrg1377; Gorelik J, 2003, P NATL ACAD SCI USA, V100, P5819, DOI 10.1073/pnas.1030502100; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; Holme RH, 2002, J COMP NEUROL, V450, P94, DOI 10.1002/cne.10301; KALTENBACH JA, 1994, J COMP NEUROL, V350, P187, DOI 10.1002/cne.903500204; Kambara T, 1999, J BIOL CHEM, V274, P16400, DOI 10.1074/jbc.274.23.16400; Liang Y, 1999, GENOMICS, V61, P243, DOI 10.1006/geno.1999.5976; Mallavarapu A, 1999, J CELL BIOL, V146, P1097, DOI 10.1083/jcb.146.5.1097; Mburu P, 2003, NAT GENET, V34, P421, DOI 10.1038/ng1208; Probst FJ, 1998, SCIENCE, V280, P1444, DOI 10.1126/science.280.5368.1444; Rzadzinska AK, 2004, J CELL BIOL, V164, P887, DOI 10.1083/jcb.200310055; Schneider ME, 2002, NATURE, V418, P837, DOI 10.1038/418837a; Sekerkova G, 2004, J NEUROSCI, V24, P5445, DOI 10.1523/JNEUROSCI.1279-04.2004; SELVE N, 1986, J MOL BIOL, V187, P627, DOI 10.1016/0022-2836(86)90341-4; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Shimada T, 1997, BIOCHEMISTRY-US, V36, P14037, DOI 10.1021/bi971837i; TILNEY LG, 1988, J CELL BIOL, V106, P355, DOI 10.1083/jcb.106.2.355; TILNEY LG, 1986, DEV BIOL, V116, P100, DOI 10.1016/0012-1606(86)90047-3; TILNEY LG, 1992, ANNU REV CELL BIOL, V8, P257, DOI 10.1146/annurev.cb.08.110192.001353; TILNEY LG, 1981, J CELL BIOL, V90, P485, DOI 10.1083/jcb.90.2.485; TILNEY LG, 1986, HEARING RES, V22, P55, DOI 10.1016/0378-5955(86)90077-8; Tokuo H, 2004, BIOCHEM BIOPH RES CO, V319, P214, DOI 10.1016/j.bbrc.2004.04.167; Wang AH, 1998, SCIENCE, V280, P1447, DOI 10.1126/science.280.5368.1447; Zine A, 1996, BRAIN RES, V721, P49, DOI 10.1016/0006-8993(96)00147-3	30	250	262	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2005	7	2					148	U60		10.1038/ncb1219	http://dx.doi.org/10.1038/ncb1219			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	893LC	15654330				2022-12-25	WOS:000226719500011
J	Poot, RA; Bozhenok, L; van den Berg, DLC; Steffensen, S; Ferreira, F; Grimaldi, M; Gilbert, N; Ferreira, J; Varga-Weisz, PD				Poot, RA; Bozhenok, L; van den Berg, DLC; Steffensen, S; Ferreira, F; Grimaldi, M; Gilbert, N; Ferreira, J; Varga-Weisz, PD			The Williams syndrome transcription factor interacts with PCNA to target chromatin remodelling by ISWI to replication foci	NATURE CELL BIOLOGY			English	Article							DNA-REPLICATION; EPIGENETIC INHERITANCE; MAMMALIAN NUCLEI; HUMAN-CELLS; COMPLEX; HETEROCHROMATIN; RECRUITMENT; VARIEGATION; PROTEINS; HISTONES	Chromatin states have to be faithfully duplicated during DNA replication to maintain cell identity. It is unclear whether or how ATP-dependent chromatin-remodelling factors are involved in this process. Here we provide evidence that the Williams syndrome transcription factor (WSTF) is targeted to replication foci through direct interaction with the DNA clamp PCNA, an important coordinator of DNA and chromatin replication. WSTF, in turn, recruits imitation switch (ISWI)-type nucleosome-remodelling factor SNF2H to replication sites. These findings reveal a novel recruitment mechanism for ATP-dependent chromatin-remodelling factors that is fundamentally different from the previously documented targeting by sequence-specific transcriptional regulators. RNA-interference-mediated depletion of WSTF or SNF2H causes a compaction of newly replicated chromatin and increases the amount of heterochromatin markers, including HP1beta. This increase in the amount of HP1beta protein is mediated by progression through S phase and is not the result of an increase in HP1 mRNA levels. We propose that the WSTF - ISWI complex has a role in the maintenance of chromatin structures during DNA replication.	Fac Med, Inst Mol Med, P-1649028 Lisbon, Portugal; Fac Vet Med, CIISA, P-1300477 Lisbon, Portugal; MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Marie Curie Res Inst, Surrey RH8 0TL, England	Universidade de Lisboa; Universidade de Lisboa; University of Edinburgh	Varga-Weisz, PD (corresponding author), Imperial Coll Sch Med, MRC, Ctr Clin Sci, London W12 0NN, England.	patrick.varga-weisz@bbsrc.ac.uk	Ferreira, Fernando Costa/D-8096-2018	Ferreira, Fernando Costa/0000-0001-5765-576X; Varga-Weisz, Patrick/0000-0001-7409-8686; van den Berg, Debbie L.C./0000-0001-6026-8808				Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; Ayyanathan K, 2003, GENE DEV, V17, P1855, DOI 10.1101/gad.1102803; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Bochar DA, 2000, P NATL ACAD SCI USA, V97, P1038, DOI 10.1073/pnas.97.3.1038; Bozhenok L, 2004, METHOD ENZYMOL, V377, P376; Bozhenok L, 2002, EMBO J, V21, P2231, DOI 10.1093/emboj/21.9.2231; Collins N, 2002, NAT GENET, V32, P627, DOI 10.1038/ng1046; CUSICK ME, 1983, BIOCHEMISTRY-US, V22, P3873, DOI 10.1021/bi00285a024; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dirscherl SS, 2004, BIOCHEM CELL BIOL, V82, P482, DOI 10.1139/O04-044; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Francke U, 1999, HUM MOL GENET, V8, P1947, DOI 10.1093/hmg/8.10.1947; Gelbart ME, 2001, MOL CELL BIOL, V21, P2098, DOI 10.1128/MCB.21.6.2098-2106.2001; Grewal SIS, 2002, CURR OPIN GENET DEV, V12, P178, DOI 10.1016/S0959-437X(02)00284-8; GRIGORYEV SA, 1992, EXP CELL RES, V198, P268, DOI 10.1016/0014-4827(92)90379-M; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HENDERSON DS, 1994, EMBO J, V13, P1450, DOI 10.1002/j.1460-2075.1994.tb06399.x; Iida T, 2004, MOL CELL BIOL, V24, P217, DOI 10.1128/MCB.24.1.217-227.2004; Istomina NE, 2003, MOL CELL BIOL, V23, P6455, DOI 10.1128/MCB.23.18.6455-6468.2003; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7; Krude T, 1999, EXP CELL RES, V247, P148, DOI 10.1006/excr.1998.4342; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Martini E, 1998, J CELL BIOL, V143, P563, DOI 10.1083/jcb.143.3.563; McNairn AJ, 2003, BIOESSAYS, V25, P647, DOI 10.1002/bies.10305; Minc E, 2000, CYTOGENET CELL GENET, V90, P279, DOI 10.1159/000056789; Poot RA, 2000, EMBO J, V19, P3377, DOI 10.1093/emboj/19.13.3377; Ridgway P, 2000, J CELL SCI, V113, P2647; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Sporbert A, 2002, MOL CELL, V10, P1355, DOI 10.1016/S1097-2765(02)00729-3; Staynov DZ, 1998, J MOL BIOL, V279, P59, DOI 10.1006/jmbi.1998.1777; Taddei A, 1999, J CELL BIOL, V147, P1153, DOI 10.1083/jcb.147.6.1153; Zhang ZG, 2000, NATURE, V408, P221, DOI 10.1038/35041601; Zheleva DI, 2000, BIOCHEMISTRY-US, V39, P7388, DOI 10.1021/bi992498r	35	145	150	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2004	6	12					1236	1244		10.1038/ncb1196	http://dx.doi.org/10.1038/ncb1196			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	875WQ	15543136				2022-12-25	WOS:000225453300017
J	Bamforth, SD; Braganca, J; Farthing, CR; Schneider, JE; Broadbent, C; Michell, AC; Clarke, K; Neubauer, S; Norris, D; Brown, NA; Anderson, RH; Bhattacharya, S				Bamforth, SD; Braganca, J; Farthing, CR; Schneider, JE; Broadbent, C; Michell, AC; Clarke, K; Neubauer, S; Norris, D; Brown, NA; Anderson, RH; Bhattacharya, S			Cited2 controls left-right patterning and heart development through a Nodal-Pitx2c pathway	NATURE GENETICS			English	Article							LEFT-RIGHT ASYMMETRY; RUBINSTEIN-TAYBI SYNDROME; LEFT-RIGHT AXIS; CARDIAC-MALFORMATIONS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; LATERAL PLATE; PITX2; COACTIVATOR; MORPHOGENESIS	Malformations of the septum, outflow tract and aortic arch are the most common congenital cardiovascular defects and occur in mice lacking Cited2, a transcriptional coactivator of TFAP2. Here we show that Cited2(-/-) mice also develop laterality defects, including right isomerism, abnormal cardiac looping and hyposplenia, which are suppressed on a mixed genetic background. Cited2(-/-) mice lack expression of the Nodal target genes Pitx2c, Nodal and Ebaf in the left lateral plate mesoderm, where they are required for establishing laterality and cardiovascular development. CITED2 and TFAP2 were detected at the Pitx2c promoter in embryonic hearts, and they activate Pitx2c transcription in transient transfection assays. We propose that an abnormal Nodal-Pitx2c pathway represents a unifying mechanism for the cardiovascular malformations observed in Cited2(-/-) mice, and that such malformations may be the sole manifestation of a laterality defect.	Univ Oxford, Dept Cardiovasc Med, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Oxford, Dept Physiol, Oxford OX1 3QU, England; MRC, Mammalian Genet Unit, Harwell OX11 0RD, Berks, England; Univ London St Georges Hosp, Sch Med, London SW17 0RE, England; UCL, Cardiac Unit, Inst Child Hlth, London WC1N 1EH, England	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; St Georges University London; University of London; University College London	Bhattacharya, S (corresponding author), Univ Oxford, Dept Cardiovasc Med, Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.	shoumo.bhattacharya@well.ox.ac.uk	Neubauer, Stefan/B-8448-2011; Braganca, Jose/F-4410-2012; Bamforth, Simon David/I-1277-2019; Bhattacharya, Shoumo/F-4127-2010	Braganca, Jose/0000-0001-9566-400X; Bamforth, Simon David/0000-0002-5666-4485; Bhattacharya, Shoumo/0000-0002-5571-0478	British Heart Foundation [PS/02/002/14893] Funding Source: Medline	British Heart Foundation(British Heart Foundation)		Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; Bamforth SD, 2001, NAT GENET, V29, P469, DOI 10.1038/ng768; Barbera JPM, 2002, HUM MOL GENET, V11, P283, DOI 10.1093/hmg/11.3.283; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Braganca J, 2003, J BIOL CHEM, V278, P16021, DOI 10.1074/jbc.M208144200; Brennan J, 2002, GENE DEV, V16, P2339, DOI 10.1101/gad.1016202; Brewer S, 2002, MECH DEVELOP, V110, P139, DOI 10.1016/S0925-4773(01)00579-2; Brown N, 1999, HEART DEV, P447; Bruneau BG, 2002, CIRC RES, V90, P509, DOI 10.1161/01.RES.0000013072.51957.B7; CALRK EB, 2001, MOSS ADAMS HEART DIS, P64; Dunwoodie SL, 1998, MECH DEVELOP, V72, P27, DOI 10.1016/S0925-4773(98)00011-2; Freedman SJ, 2003, NAT STRUCT BIOL, V10, P504, DOI 10.1038/nsb936; Gage PJ, 1999, DEVELOPMENT, V126, P4643; Gaio U, 1999, CURR BIOL, V9, P1339, DOI 10.1016/S0960-9822(00)80059-7; Glenn DJ, 1999, J BIOL CHEM, V274, P36159, DOI 10.1074/jbc.274.51.36159; Goodman RH, 2000, GENE DEV, V14, P1553; Hamada H, 2002, NAT REV GENET, V3, P103, DOI 10.1038/nrg732; KAUFMAN M, 1999, ANATOMICAL BASIS MOU, P33; KENT GC, 2001, COMP ANATOMY VERTEBR, P314; Kitamura K, 1999, DEVELOPMENT, V126, P5749; Kranc KR, 2003, MOL CELL BIOL, V23, P7658, DOI 10.1128/MCB.23.21.7658-7666.2003; Lin CR, 1999, NATURE, V401, P279, DOI 10.1038/45803; Liu CY, 2002, DEVELOPMENT, V129, P5081; Liu CY, 2001, DEVELOPMENT, V128, P2039; Lu MF, 1999, NATURE, V401, P276, DOI 10.1038/45797; Meno C, 2001, DEV CELL, V1, P127, DOI 10.1016/S1534-5807(01)00006-5; Norris DP, 2002, DEVELOPMENT, V129, P3455; Pena P, 1999, MOL ENDOCRINOL, V13, P1402, DOI 10.1210/me.13.8.1402; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; Saijoh Y, 2003, DEV BIOL, V256, P160, DOI 10.1016/S0012-1606(02)00121-5; Saijoh Y, 2000, MOL CELL, V5, P35, DOI 10.1016/S1097-2765(00)80401-3; Satoda M, 2000, NAT GENET, V25, P42, DOI 10.1038/75578; Schneider JE, 2003, J MOL CELL CARDIOL, V35, P217, DOI 10.1016/S0022-2828(02)00291-2; Shen MM, 1997, DEVELOPMENT, V124, P429; Shiratori H, 2001, MOL CELL, V7, P137, DOI 10.1016/S1097-2765(01)00162-9; STEVENS CA, 1995, AM J MED GENET, V59, P346, DOI 10.1002/ajmg.1320590313; Sun HB, 1998, P NATL ACAD SCI USA, V95, P13555, DOI 10.1073/pnas.95.23.13555; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; Thomas T, 1998, DEV BIOL, V196, P228, DOI 10.1006/dbio.1998.8849; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Weninger WJ, 2002, NAT GENET, V30, P59, DOI 10.1038/ng785; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; Yamamoto M, 2003, DEVELOPMENT, V130, P1795, DOI 10.1242/dev.00408; Yan YT, 1999, GENE DEV, V13, P2527, DOI 10.1101/gad.13.19.2527; Yin Z, 2002, P NATL ACAD SCI USA, V99, P10488, DOI 10.1073/pnas.162371799	48	161	171	1	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2004	36	11					1189	1196		10.1038/ng1446	http://dx.doi.org/10.1038/ng1446			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	867HI	15475956	Bronze			2022-12-25	WOS:000224832800022
J	Fernandes, KJL; McKenzie, IA; Mill, P; Smith, KM; Akhavan, M; Barnabe-Heider, F; Biernaskie, J; Junek, A; Kobayashi, NR; Toma, JG; Kaplan, DR; Labosky, PA; Rafuse, V; Hui, CC; Miller, FD				Fernandes, KJL; McKenzie, IA; Mill, P; Smith, KM; Akhavan, M; Barnabe-Heider, F; Biernaskie, J; Junek, A; Kobayashi, NR; Toma, JG; Kaplan, DR; Labosky, PA; Rafuse, V; Hui, CC; Miller, FD			A dermal niche for multipotent adult skin-derived precursor cells	NATURE CELL BIOLOGY			English	Article							HAIR FOLLICLE DEVELOPMENT; MAMMALIAN NEURAL CREST; STEM-CELLS; GENE-EXPRESSION; SONIC HEDGEHOG; MERKEL CELLS; MOUSE; MORPHOGENESIS; MARROW; MICE	A fundamental question in stem cell research is whether cultured multipotent adult stem cells represent endogenous multipotent precursor cells. Here we address this question, focusing on SKPs, a cultured adult stem cell from the dermis that generates both neural and mesodermal progeny. We show that SKPs derive from endogenous adult dermal precursors that exhibit properties similar to embryonic neural-crest stem cells. We demonstrate that these endogenous SKPs can first be isolated from skin during embryogenesis and that they persist into adulthood, with a niche in the papillae of hair and whisker follicles. Furthermore, lineage analysis indicates that both hair and whisker follicle dermal papillae contain neural-crest-derived cells, and that SKPs from the whisker pad are of neural-crest origin. We propose that SKPs represent an endogenous embryonic precursor cell that arises in peripheral tissues such as skin during development and maintains multipotency into adulthood.	Univ Toronto, Hosp Sick Children, Res Inst, Dept Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Res Inst, Dept Canc Res, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med & Mol Genet, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5G 1X8, Canada; McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Dalhousie Univ, Dept Anat & Neurobiol, Halifax, NS B3H 1X5, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; McGill University; University of Pennsylvania; Dalhousie University	Miller, FD (corresponding author), Univ Toronto, Hosp Sick Children, Res Inst, Dept Dev Biol, Toronto, ON M5G 1X8, Canada.	fredam@sickkids.ca	Mill, Pleasantine/AAE-4718-2019	Smith, Kristen/0000-0003-0960-0937; Mill, Pleasantine/0000-0001-5218-134X; Labosky, Patricia/0000-0001-5880-2194				Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Asakura A, 2003, TRENDS CARDIOVAS MED, V13, P123, DOI 10.1016/S1050-1738(03)00024-0; Barnabe-Heider F, 2003, J NEUROSCI, V23, P5149; Botchkareva NV, 1999, DEV BIOL, V216, P135, DOI 10.1006/dbio.1999.9464; Britsch S, 2001, GENE DEV, V15, P66, DOI 10.1101/gad.186601; Cheung M, 2003, DEVELOPMENT, V130, P5681, DOI 10.1242/dev.00808; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Clement-Jones M, 2000, HUM MOL GENET, V9, P695, DOI 10.1093/hmg/9.5.695; Conway SJ, 1997, DEVELOPMENT, V124, P505; DUCROS DL, 1995, J INVEST DERMATOL, V105, P426, DOI 10.1111/1523-1747.ep12321131; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; Ito CY, 2003, BLOOD, V101, P517, DOI 10.1182/blood-2002-06-1918; Jahoda CAB, 2003, EXP DERMATOL, V12, P849, DOI 10.1111/j.0906-6705.2003.00161.x; Jensen PJ, 2000, J INVEST DERMATOL, V114, P917, DOI 10.1046/j.1523-1747.2000.00945.x; Jiang XB, 2000, DEVELOPMENT, V127, P1607; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Joannides A, 2004, LANCET, V364, P172, DOI 10.1016/S0140-6736(04)16630-0; Joshi CV, 2002, CURR OPIN CELL BIOL, V14, P749, DOI 10.1016/S0955-0674(02)00392-7; Kishimoto J, 1999, P NATL ACAD SCI USA, V96, P7336, DOI 10.1073/pnas.96.13.7336; Lako M, 2002, J CELL SCI, V115, P3967, DOI 10.1242/jcs.00060; Le Douarin N.M., 1982, NEURAL CREST; LEDOUARIN NM, 1993, J NEUROBIOL, V24, P146, DOI 10.1002/neu.480240203; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; Liu YP, 2003, J INVEST DERMATOL, V121, P963, DOI 10.1046/j.1523-1747.2003.12600.x; Mill P, 2003, GENE DEV, V17, P282, DOI 10.1101/gad.1038103; Miura M, 2003, P NATL ACAD SCI USA, V100, P5807, DOI 10.1073/pnas.0937635100; Mo R, 1997, DEVELOPMENT, V124, P113; Moll I, 1996, J INVEST DERMATOL, V106, P281, DOI 10.1111/1523-1747.ep12340714; MONUKI ES, 1989, NEURON, V3, P783, DOI 10.1016/0896-6273(89)90247-X; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Nishimura EK, 2002, NATURE, V416, P854, DOI 10.1038/416854a; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; Panteleyev AA, 1997, J INVEST DERMATOL, V108, P324, DOI 10.1111/1523-1747.ep12286476; Paus R, 1999, J INVEST DERMATOL, V113, P523, DOI 10.1046/j.1523-1747.1999.00740.x; Peters EMJ, 2002, J COMP NEUROL, V448, P28, DOI 10.1002/cne.10212; Reddy S, 2001, MECH DEVELOP, V107, P69, DOI 10.1016/S0925-4773(01)00452-X; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; SMITH DE, 1992, DEVELOPMENT, V116, P1033; Soo K, 2002, DEV BIOL, V247, P251, DOI 10.1006/dbio.2002.0699; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; Szeder V, 2003, DEV BIOL, V253, P258, DOI 10.1016/S0012-1606(02)00015-5; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Toma JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/ncb0901-778; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; White PM, 1999, DEVELOPMENT, V126, P4351	47	573	622	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2004	6	11					1082	U16		10.1038/ncb1181	http://dx.doi.org/10.1038/ncb1181			17	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	867BI	15517002				2022-12-25	WOS:000224816700013
J	Zhou, BHP; Deng, J; Xia, WY; Xu, JH; Li, YM; Gunduz, M; Hung, MC				Zhou, BHP; Deng, J; Xia, WY; Xu, JH; Li, YM; Gunduz, M; Hung, MC			Dual regulation of Snail by GSK-3 beta-mediated phosphorylation in control of epithelial-mesenchymal transition	NATURE CELL BIOLOGY			English	Article							E-CADHERIN EXPRESSION; GLYCOGEN-SYNTHASE KINASE-3; TRANSCRIPTION FACTOR SNAIL; NF-KAPPA-B; BREAST-CANCER; TUMOR-CELLS; PROGRESSION; CARCINOMA; REPRESSION; PATHWAY	The phenotypic changes of increased motility and invasiveness of cancer cells are reminiscent of the epithelial-mesenchymal transition (EMT) that occurs during embryonic development. Snail, a zinc-finger transcription factor, triggers this process by repressing E-cadherin expression; however, the mechanisms that regulate Snail remain elusive. Here we find that Snail is highly unstable, with a short half-life about 25 min. We show that GSK-3beta binds to and phosphorylates Snail at two consensus motifs to dually regulate the function of this protein. Phosphorylation of the first motif regulates its beta-Trcp-mediated ubiquitination, whereas phosphorylation of the second motif controls its subcellular localization. A variant of Snail (Snail-6SA), which abolishes these phosphorylations, is much more stable and resides exclusively in the nucleus to induce EMT. Furthermore, inhibition of GSK-3beta results in the upregulation of Snail and downregulation of E-cadherin in vivo. Thus, Snail and GSK-3beta together function as a molecular switch for many signalling pathways that lead to EMT.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Breast Canc Basic Res Program, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Breast Canc Basic Res Program, 1515 Holcombe Blvd, Houston, TX 77030 USA.	mhung@mdanderson.org	高, 雨莉/HGU-8187-2022; Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NATIONAL CANCER INSTITUTE [P01CA099031, P50CA083639, R01CA058880, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA10193, CA16672, CA58880, CA83639, CA99031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; Bijur GN, 2003, NEUROREPORT, V14, P2415, DOI 10.1097/00001756-200312190-00025; Birchmeier W, 1991, CURR OPIN CELL BIOL, V3, P832, DOI 10.1016/0955-0674(91)90057-6; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Camp RL, 1999, CANCER, V86, P2259, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2259::AID-CNCR13>3.0.CO;2-2; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535-6108(02)00154-X; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Dominguez D, 2003, MOL CELL BIOL, V23, P5078, DOI 10.1128/MCB.23.14.5078-5089.2003; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Giroldi LA, 1997, BIOCHEM BIOPH RES CO, V241, P453, DOI 10.1006/bbrc.1997.7831; Grille SJ, 2003, CANCER RES, V63, P2172; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Gunduz M, 2000, CANCER RES, V60, P3143; Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336; Harwood AJ, 2001, CELL, V105, P821, DOI 10.1016/S0092-8674(01)00412-3; Ji XD, 1997, CELL GROWTH DIFFER, V8, P773; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kim K, 2000, MOL BIOL CELL, V11, P3509, DOI 10.1091/mbc.11.10.3509; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Sugimachi K, 2003, CLIN CANCER RES, V9, P2657; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Xia WY, 2004, CLIN CANCER RES, V10, P3815, DOI 10.1158/1078-0432.CCR-03-0527; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	42	1266	1312	2	76	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2004	6	10					931	+		10.1038/ncb1173	http://dx.doi.org/10.1038/ncb1173			15	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	859FY	15448698				2022-12-25	WOS:000224250000008
J	Austin, CP; Battey, JF; Bradley, A; Bucan, M; Capecchi, M; Collins, FS; Dove, WF; Duyk, G; Dymecki, S; Eppig, JT; Grieder, FB; Heintz, N; Hicks, G; Insel, TR; Joyner, A; Koller, BH; Lloyd, KCK; Magnuson, T; Moore, MW; Nagy, A; Pollock, JD; Roses, AD; Sands, AT; Seed, B; Skarnes, WC; Snoddy, J; Soriano, P; Stewart, DJ; Stewart, F; Stillman, B; Varmus, H; Varticovski, L; Verma, IM; Vogt, TF; von Melchner, H; Witkowski, J; Woychik, RP; Wurst, W; Yancopoulos, GD; Young, SG; Zambrowicz, B				Austin, CP; Battey, JF; Bradley, A; Bucan, M; Capecchi, M; Collins, FS; Dove, WF; Duyk, G; Dymecki, S; Eppig, JT; Grieder, FB; Heintz, N; Hicks, G; Insel, TR; Joyner, A; Koller, BH; Lloyd, KCK; Magnuson, T; Moore, MW; Nagy, A; Pollock, JD; Roses, AD; Sands, AT; Seed, B; Skarnes, WC; Snoddy, J; Soriano, P; Stewart, DJ; Stewart, F; Stillman, B; Varmus, H; Varticovski, L; Verma, IM; Vogt, TF; von Melchner, H; Witkowski, J; Woychik, RP; Wurst, W; Yancopoulos, GD; Young, SG; Zambrowicz, B		Comprehensive Knockout Mouse Proje	The knockout mouse project	NATURE GENETICS			English	Article							EMBRYONIC STEM-CELLS; GENE-TRAP MUTAGENESIS; GENOME; MICE; SEQUENCE; IDENTIFICATION; DEFICIENCY; PHENOTYPE; INSIGHTS; RESOURCE	Mouse knockout technology provides a powerful means of elucidating gene function in vivo, and a publicly available genome-wide collection of mouse knockouts would be significantly enabling for biomedical discovery. To date, published knockouts exist for only about 10% of mouse genes. Furthermore, many of these are limited in utility because they have not been made or phenotyped in standardized ways, and many are not freely available to researchers. It is time to harness new technologies and efficiencies of production to mount a high-throughput international effort to produce and phenotype knockouts for all mouse genes, and place these resources into the public domain.	NHGRI, NIH, Bethesda, MD 20892 USA; Natl Inst Deafness & Other Commun Disorders, NIH, Bethesda, MD 20892 USA; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; Univ Penn, Dept Genet, Philadelphia, PA 19104 USA; Univ Utah, Eccles Inst Human Genet, Salt Lake City, UT 85112 USA; Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA; TPG Ventures, San Francisco, CA 94104 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Jackson Lab, Bar Harbor, ME 04609 USA; NIH, Natl Ctr Res Resources, Bethesda, MD 20817 USA; Rockefeller Univ, Mol Biol Lab, New York, NY 10021 USA; Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada; NIMH, Bethesda, MD 20892 USA; Skirball Inst Biomol Med, New York, NY 10016 USA; Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA; Univ Calif Davis, Sch Vet Med, Davis, CA 95616 USA; Deltagen, Redwood City, CA 94063 USA; Univ Toronto, Samuel Lumenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Natl Inst Drug Abuse, Bethesda, MD 20892 USA; GlaxoSmithKline Inc, Res Triangle Pk, NC 27709 USA; Lexicon Genet, The Woodlands, TX 77381 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Oak Ridge Natl Lab, Univ Tennessee ORNL Grad Sch Genome Sci & Technol, Oak Ridge, TN 37831 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Cold Spring Harbor Lab, Banbury Ctr, Cold Spring Harbor, NY 11724 USA; Univ Technol, Bioz, MPI CBG, D-1307 Dresden, Germany; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; NCI, NIH, Bethesda, MD 20892 USA; Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA; Merck Res Labs, West Point, PA 19486 USA; Goethe Univ Frankfurt, Sch Med, Lab Mol Hematol, D-60590 Frankfurt, Germany; Jackson Lab, Bar Harbor, ME 04609 USA; Max Planck Inst Psychiat, GSF Res Ctr, Inst Dev Genet, D-85764 Munich, Germany; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; Univ Calif San Francisco, Gladstone Fdn Cardiovasc Dis, San Francisco, CA 94143 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Wellcome Trust Sanger Institute; University of Pennsylvania; Utah System of Higher Education; University of Utah; University of Wisconsin System; University of Wisconsin Madison; Harvard University; Harvard Medical School; Jackson Laboratory; National Institutes of Health (NIH) - USA; Rockefeller University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California Davis; University of Toronto; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); GlaxoSmithKline; Lexicon Pharmaceuticals; Harvard University; Massachusetts General Hospital; United States Department of Energy (DOE); Oak Ridge National Laboratory; Fred Hutchinson Cancer Center; Cold Spring Harbor Laboratory; Max Planck Society; Technische Universitat Dresden; Memorial Sloan Kettering Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Salk Institute; Merck & Company; Goethe University Frankfurt; Jackson Laboratory; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Max Planck Society; Regeneron; University of California System; University of California San Francisco; The J David Gladstone Institutes	Austin, CP (corresponding author), NHGRI, NIH, Bldg 31,Room 4B09,31 Ctr Dr, Bethesda, MD 20892 USA.	austinc@mail.nih.gov	Soriano, Philippe M/E-5797-2015; Witkowski, Jan/FHJ-8549-2022; Stewart, A. Francis/E-7789-2010; Nagy, Andras/G-6465-2013; Pollock, Jonathan D/B-1554-2009; Woychik, Richard P/C-8345-2019	Soriano, Philippe M/0000-0002-0427-926X; Nagy, Andras/0000-0003-4311-0413; Woychik, Richard P/0000-0001-8196-1732; Hicks, Geoffrey/0000-0003-4688-2312; Bradley, Allan/0000-0002-2349-8839; Stillman, Bruce/0000-0002-9453-4091; Young, Stephen/0000-0001-7270-3176; Witkowski, Jan/0000-0002-8159-2874; Wurst, Wolfgang/0000-0003-4422-7410; Varticovski, Lyuba/0000-0002-5105-9008	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS003004] Funding Source: NIH RePORTER; Wellcome Trust [077188] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Wellcome Trust(Wellcome TrustEuropean Commission)		BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; Chen RZ, 2001, NAT GENET, V27, P327, DOI 10.1038/85906; Chen WSV, 2004, NAT GENET, V36, P304, DOI 10.1038/ng1306; Clark J., 2000, PATENT POOLS SOLUTIO; D'Orleans-Juste P, 2003, CURR OPIN PHARMACOL, V3, P181, DOI 10.1016/S1471-4892(03)00017-1; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; Eggan K, 2002, NAT BIOTECHNOL, V20, P455, DOI 10.1038/nbt0502-455; Goldstein JL, 2001, NAT MED, V7, P1079, DOI 10.1038/nm1001-1079; Hansen J, 2003, P NATL ACAD SCI USA, V100, P9918, DOI 10.1073/pnas.1633296100; Horton WA, 2003, LANCET, V362, P560, DOI 10.1016/S0140-6736(03)14119-0; Kunath T, 2003, NAT BIOTECHNOL, V21, P559, DOI 10.1038/nbt813; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Nadeau JH, 2001, SCIENCE, V291, P1251, DOI 10.1126/science.1058244; Seong E, 2004, TRENDS GENET, V20, P59, DOI 10.1016/j.tig.2003.12.006; Skarnes WC, 2004, NAT GENET, V36, P543, DOI 10.1038/ng0604-543; Stanford WL, 2001, NAT REV GENET, V2, P756, DOI 10.1038/35093548; Stryke D, 2003, NUCLEIC ACIDS RES, V31, P278, DOI 10.1093/nar/gkg064; Valenzuela DM, 2003, NAT BIOTECHNOL, V21, P652, DOI 10.1038/nbt822; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wallace DC, 2001, AM J MED GENET, V106, P71, DOI 10.1002/ajmg.1393; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Wiles MV, 2000, NAT GENET, V24, P13, DOI 10.1038/71622; Zambrowicz BP, 2003, P NATL ACAD SCI USA, V100, P14109, DOI 10.1073/pnas.2336103100; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	25	440	480	0	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2004	36	9					921	924		10.1038/ng0904-921	http://dx.doi.org/10.1038/ng0904-921			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	851AY	15340423	Green Accepted			2022-12-25	WOS:000223658100005
J	Dolznig, H; Grebien, F; Sauer, T; Beug, H; Mullner, EW				Dolznig, H; Grebien, F; Sauer, T; Beug, H; Mullner, EW			Evidence for a size-sensing mechanism in animal cells	NATURE CELL BIOLOGY			English	Article							GROWTH-FACTOR-I; SACCHAROMYCES-CEREVISIAE; ERYTHROPOIETIN RECEPTOR; ERYTHROID PROGENITORS; MOUSE FIBROBLASTS; S6 KINASE; C-KIT; YEAST; DIVISION; VITRO	Continuously proliferating cells exactly double their mass during each cell cycle. Here we have addressed the controversial question of if and how cell size is sensed and regulated(1-4). We used erythroblasts that proliferate under the control of a constitutively active oncogene (v-ErbB)(5) or under the control of physiological cytokines ( stem cell factor, erythropoietin and v-ErbB inhibitor(6)). The oncogene-driven cells proliferated 1.7 times faster and showed a 1.5-fold increase in cell volume. The two phenotypes could be converted into each other 24 h after altering growth factor signalling. The large cells had a higher rate of protein synthesis, together with a shortened G1 phase. Additional experiments with chicken erythroblasts and mouse fibroblasts, synchronized by centrifugal elutriation, provided further evidence that vertebrate cells can respond to cell size alterations ( induced either through different growth factor signalling or DNA synthesis inhibitors) by compensatory shortening of the subsequent G1 phase. Taken together, these data suggest that an active size threshold mechanism exists in G1, which induces adjustment of cell-cycle length in the next cycle, thus ensuring maintenance of a proper balance between growth and proliferation rates in vertebrates.	Max F Perutz Labs, Vienna Bioctr, Inst Med Biochem, Div Mol Biol, A-1030 Vienna, Austria; Inst Mol Pathol, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Mullner, EW (corresponding author), Max F Perutz Labs, Vienna Bioctr, Inst Med Biochem, Div Mol Biol, Dr Bohr Gasse 7-9, A-1030 Vienna, Austria.	ernst.muellner@univie.ac.at	Grebien, Florian/H-9234-2019; Dolznig, Helmut/L-7005-2015	Grebien, Florian/0000-0003-4289-2281; Dolznig, Helmut/0000-0002-6063-3585				Bartucci M, 2001, CANCER RES, V61, P6747; Beug H, 1996, BBA-REV CANCER, V1288, pM35, DOI 10.1016/S0304-419X(96)00032-7; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Conlon Ian, 2003, J Biol, V2, P7, DOI 10.1186/1475-4924-2-7; Conlon IJ, 2001, NAT CELL BIOL, V3, P918, DOI 10.1038/ncb1001-918; FANTES P, 1977, EXP CELL RES, V107, P377, DOI 10.1016/0014-4827(77)90359-7; FREED KA, 1989, J MOL ENDOCRINOL, V3, P183, DOI 10.1677/jme.0.0030183; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Futcher B, 1996, YEAST, V12, P1635; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; Jorgensen P, 2002, SCIENCE, V297, P395, DOI 10.1126/science.1070850; KILLANDER D, 1965, EXP CELL RES, V40, P12, DOI 10.1016/0014-4827(65)90285-5; KILLANDER D, 1965, EXP CELL RES, V38, P272, DOI 10.1016/0014-4827(65)90403-9; Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387; Mikulits W, 1997, DNA CELL BIOL, V16, P849, DOI 10.1089/dna.1997.16.849; Mitchison JM, 2003, INT REV CYTOL, V226, P165, DOI 10.1016/S0074-7696(03)01004-0; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Polymenis M, 1997, GENE DEV, V11, P2522, DOI 10.1101/gad.11.19.2522; Rupes I, 2002, TRENDS GENET, V18, P479, DOI 10.1016/S0168-9525(02)02745-2; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Saucedo LJ, 2002, CURR OPIN GENET DEV, V12, P565, DOI 10.1016/S0959-437X(02)00341-6; SCHMIDT EE, 1995, J CELL BIOL, V128, P467, DOI 10.1083/jcb.128.4.467; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; STEINLEIN P, 1994, GROWTH FACTORS, V10, P1, DOI 10.3109/08977199409019599; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; von Lindern M, 2001, ONCOGENE, V20, P3651, DOI 10.1038/sj.onc.1204494; Wessely O, 1999, BIOL CHEM, V380, P187, DOI 10.1515/BC.1999.027; Zhang J, 2002, CURR BIOL, V12, P1992, DOI 10.1016/S0960-9822(02)01305-2	29	117	118	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2004	6	9					899	U95		10.1038/ncb1166	http://dx.doi.org/10.1038/ncb1166			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	852IZ	15322555				2022-12-25	WOS:000223750300020
J	Thiel, KA				Thiel, KA			Goodbye Columbus! New NRDOs forego discovery	NATURE BIOTECHNOLOGY			English	Article							THALIDOMIDE											SAMPAIO EP, 1991, J EXP MED, V173, P699, DOI 10.1084/jem.173.3.699; Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102	2	7	7	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2004	22	9					1087	1092		10.1038/nbt0904-1087	http://dx.doi.org/10.1038/nbt0904-1087			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	850ZR	15340473				2022-12-25	WOS:000223653400022
J	Verges, M; Luton, F; Gruber, C; Tiemann, F; Reinders, LG; Huang, L; Burlingame, AL; Haft, CR; Mostov, KE				Verges, M; Luton, F; Gruber, C; Tiemann, F; Reinders, LG; Huang, L; Burlingame, AL; Haft, CR; Mostov, KE			The mammalian retromer regulates transcytosis of the polymeric immunoglobulin receptor	NATURE CELL BIOLOGY			English	Article							POLARIZED EPITHELIAL-CELLS; GOLGI RETROGRADE TRANSPORT; SORTING NEXINS; IG RECEPTOR; YEAST; IDENTIFICATION; PROTEIN; RETRIEVAL; DOMAINS; VPS35P	Epithelial cells have separate apical and basolateral plasma membrane domains with distinct compositions. After delivery to one surface, proteins can be endocytosed and then recycled, degraded or transcytosed to the opposite surface. Proper sorting into the transcytotic pathway is essential for maintaining polarity, as most proteins are endocytosed many times during their lifespan(1). The polymeric immunoglobulin receptor (pIgR) transcytoses polymeric IgA (pIgA) from the basolateral to the apical surface of epithelial cells and hepatocytes(2,3). However, the molecular machinery that controls polarized sorting of pIgR-pIgA and other receptors is only partially understood. The retromer is a multimeric protein complex, originally described in yeast, which mediates intracellular sorting of Vps10p, a receptor that transports vacuolar enzymes(4). The yeast retromer contains two sub-complexes. One includes the Vps5p and Vps17p subunits, which provide mechanical force for vesicle budding(5,6). The other is the Vps35p-Vps29p-Vps26p subcomplex, which provides cargo specificity(7). The mammalian retromer binds to the mannose 6-phosphate receptor, which sorts lysosomal enzymes from the trans-Golgi network to the lysosomal pathway(8,9). Here, we show a function for the mammalian Vps35-Vps29-Vps26 retromer subcomplex in promoting pIgR-pIgA transcytosis.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Atugen AG, D-13125 Berlin, Germany; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; NIDDKD, Div Endocrinol Diabet & Metab Dis, NIH, Bethesda, MD 20892 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Mostov, KE (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.	mostov@itsa.ucsf.edu	Huang, Lan/C-3618-2011; Verges, Marcel/L-5784-2014; Luton, Frederic/N-7673-2017	Verges, Marcel/0000-0002-2606-223X; mostov, keith/0000-0002-8123-6247	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK 26743] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschuler Y, 1999, J CELL BIOL, V147, P7, DOI 10.1083/jcb.147.1.7; Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; Arighi CN, 2004, J CELL BIOL, V165, P123, DOI 10.1083/jcb.200312055; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; BELCHER JD, 1987, P NATL ACAD SCI USA, V84, P6785, DOI 10.1073/pnas.84.19.6785; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; Burda P, 2002, J CELL SCI, V115, P3889, DOI 10.1242/jcs.00090; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Giffroy D, 1998, INT IMMUNOL, V10, P347, DOI 10.1093/intimm/10.3.347; Haft CR, 2000, MOL BIOL CELL, V11, P4105, DOI 10.1091/mbc.11.12.4105; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hoekstra D, 2004, J CELL SCI, V117, P2183, DOI 10.1242/jcs.01217; Huang L, 1999, MOL BIOCHEM PARASIT, V102, P211, DOI 10.1016/S0166-6851(99)00096-1; Jou TS, 2000, MOL BIOL CELL, V11, P287, DOI 10.1091/mbc.11.1.287; Luton F, 1998, MOL BIOL CELL, V9, P1787, DOI 10.1091/mbc.9.7.1787; Mostov K, 2003, NAT CELL BIOL, V5, P287, DOI 10.1038/ncb0403-287; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; Nothwehr SF, 2000, J CELL BIOL, V151, P297, DOI 10.1083/jcb.151.2.297; Nothwehr SF, 1999, MOL BIOL CELL, V10, P875, DOI 10.1091/mbc.10.4.875; Pelham HRB, 2002, CURR OPIN CELL BIOL, V14, P454, DOI 10.1016/S0955-0674(02)00352-6; Reddy JV, 2001, MOL BIOL CELL, V12, P3242, DOI 10.1091/mbc.12.10.3242; Rojas R, 2002, NAT REV MOL CELL BIO, V3, P944, DOI 10.1038/nrm972; Seaman MNJ, 1998, J CELL BIOL, V142, P665, DOI 10.1083/jcb.142.3.665; Seaman MNJ, 2004, J CELL BIOL, V165, P111, DOI 10.1083/jcb.200312034; Seaman MNJ, 2002, MOL BIOL CELL, V13, P2826, DOI 10.1091/mbc.02-05-0064; SONG WX, 1994, P NATL ACAD SCI USA, V91, P163, DOI 10.1073/pnas.91.1.163; Sternberger M, 2002, ANTISENSE NUCLEIC A, V12, P131, DOI 10.1089/108729002760220734; Verges M, 1999, P NATL ACAD SCI USA, V96, P10146, DOI 10.1073/pnas.96.18.10146; Wang YJ, 2002, MOL BIOL CELL, V13, P1965, DOI 10.1091/mbc.E01-11-0131; Worby CA, 2002, NAT REV MOL CELL BIO, V3, P919, DOI 10.1038/nrm974	33	123	128	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2004	6	8					763	769		10.1038/ncb1153	http://dx.doi.org/10.1038/ncb1153			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	842YA	15247922				2022-12-25	WOS:000223039400015
J	Cheslock, PS; Kemp, BJ; Boumil, RM; Dawson, DS				Cheslock, PS; Kemp, BJ; Boumil, RM; Dawson, DS			The roles of MAD1, MAD2 and MAD3 in meiotic progression and the segregation of nonexchange chromosomes	NATURE GENETICS			English	Article							SPINDLE ASSEMBLY CHECKPOINT; MOUSE OOCYTES; BUDDING YEAST; SACCHAROMYCES-CEREVISIAE; MEIOSIS-I; RECOMBINATION; ANEUPLOIDY; BUBR1; MICE; AGE	Errors in meiotic chromosome segregation are the leading cause of spontaneous abortions and birth defects(1). In humans, chromosomes that fail to experience crossovers ( or exchanges) are error- prone, more likely than exchange chromosomes to mis- segregate in meiosis. We used a yeast model to investigate the mechanisms that partition nonexchange chromosomes. These studies showed that the spindle checkpoint genes MAD1, MAD2 and MAD3 have different roles. We identified a new meiotic role for MAD3; though dispensable for the segregation of exchange chromosomes, it is essential for the segregation of nonexchange chromosomes. This function of Mad3p could also be carried out by human BubR1. MAD1 and MAD2 act in a surveillance mechanism that mediates a metaphase delay in response to nonexchange chromosomes, whereas MAD3 acts as a crucial meiotic timer, mediating a prophase delay in every meiosis. These findings suggest plausible models for the basis of errant meiotic segregation in humans.	Tufts Univ, Sch Med, Sackler Sch Biomed Sci, Genet Program, Boston, MA 02111 USA; Tufts Univ, Sch Med, Sackler Sch Biomed Sci, Program Mol Microbiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA	Tufts University; Tufts University; Tufts University	Dawson, DS (corresponding author), Tufts Univ, Sch Med, Sackler Sch Biomed Sci, Genet Program, 136 Harrison Ave, Boston, MA 02111 USA.	dean.dawson@tufts.edu						Baker DJ, 2004, NAT GENET, V36, P744, DOI 10.1038/ng1382; Baudat F, 2000, MOL CELL, V6, P989, DOI 10.1016/S1097-2765(00)00098-8; Boumil RM, 2003, MOL GENET GENOMICS, V268, P750, DOI 10.1007/s00438-002-0796-9; Brunet S, 1999, J CELL BIOL, V146, P1, DOI 10.1083/jcb.146.1.1; Burke D., 2000, METHODS YEAST GENETI; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Gillett ES, 2004, J CELL BIOL, V164, P535, DOI 10.1083/jcb.200308100; Haase SB, 2002, CELL CYCLE, V1, P132, DOI 10.4161/cc.1.2.114; Hassold T, 2001, NAT REV GENET, V2, P280, DOI 10.1038/35066065; Hodges CA, 2002, HUM REPROD, V17, P1171, DOI 10.1093/humrep/17.5.1171; Homer HA, 2005, GENE DEV, V19, P202, DOI 10.1101/gad.328105; Hunt PA, 2002, SCIENCE, V296, P2181, DOI 10.1126/science.1071907; KABACK DB, 1992, SCIENCE, V256, P228, DOI 10.1126/science.1566070; Kemp B, 2004, GENE DEV, V18, P1946, DOI 10.1101/gad.1227304; Kong A, 2004, NAT GENET, V36, P1203, DOI 10.1038/ng1445; Lamb NE, 1996, NAT GENET, V14, P400, DOI 10.1038/ng1296-400; Lew DJ, 2003, ANNU REV GENET, V37, P251, DOI 10.1146/annurev.genet.37.042203.120656; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Meraldi P, 2004, DEV CELL, V7, P45, DOI 10.1016/j.devcel.2004.06.006; NICKLAS RB, 1969, J CELL BIOL, V43, P40, DOI 10.1083/jcb.43.1.40; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; NICOLAS A, 1989, NATURE, V338, P35, DOI 10.1038/338035a0; Shonn MA, 2000, SCIENCE, V289, P300, DOI 10.1126/science.289.5477.300; Shonn MA, 2003, CURR BIOL, V13, P1979, DOI 10.1016/j.cub.2003.10.057; Steuerwald N, 2001, MOL HUM REPROD, V7, P49, DOI 10.1093/molehr/7.1.49; Volarcik K, 1998, HUM REPROD, V13, P154, DOI 10.1093/humrep/13.1.154; Wassmann K, 2003, CURR BIOL, V13, P1596, DOI 10.1016/j.cub.2003.08.052; Wells WAE, 1996, J CELL BIOL, V133, P75, DOI 10.1083/jcb.133.1.75; Zhang D, 2005, BIOL REPROD, V72, P58, DOI 10.1095/biolreprod.104.032987	30	50	52	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2005	37	7					756	760		10.1038/ng1588	http://dx.doi.org/10.1038/ng1588			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	941EA	15951820				2022-12-25	WOS:000230196400024
J	Liu, JD; Valencia-Sanchez, MA; Hannon, GJ; Parker, R				Liu, JD; Valencia-Sanchez, MA; Hannon, GJ; Parker, R			MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies	NATURE CELL BIOLOGY			English	Letter							C-ELEGANS; PROCESSING BODIES; CYTOPLASMIC FOCI; INTERFERENCE; DECAY; PROTEINS; ARABIDOPSIS; COMPLEX; LIN-14; CELLS	Small RNAs, including small interfering RNAs ( siRNAs) and microRNAs ( miRNAs) can silence target genes through several different effector mechanisms(1). Whereas siRNA- directed mRNA cleavage is increasingly understood, the mechanisms by which miRNAs repress protein synthesis are obscure. Recent studies have revealed the existence of specific cytoplasmic foci, referred to herein as processing bodies ( P- bodies), which contain untranslated mRNAs and can serve as sites of mRNA degradation(2-7). Here we demonstrate that Argonaute proteins - the signature components of the RNA interference ( RNAi) effector complex, RISC - localize to mammalian P- bodies. Moreover, reporter mRNAs that are targeted for translational repression by endogenous or exogenous miRNAs become concentrated in P- bodies in a miRNA- dependent manner. These results provide a link between miRNA function and mammalian P- bodies and suggest that translation repression by RISC delivers mRNAs to P- bodies, either as a cause or as a consequence of inhibiting protein synthesis.	Cold Spring Harbor Lab, Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA; Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Univ Arizona, Howard Hughes Med Inst, Tucson, AZ 85721 USA	Cold Spring Harbor Laboratory; University of Arizona; Howard Hughes Medical Institute; University of Arizona	Hannon, GJ (corresponding author), Cold Spring Harbor Lab, Watson Sch Biol Sci, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	hannon@cshl.org; rrparker@u.arizona.edu	Hannon, Gregory/AAB-3568-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM045443] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM045443] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Andrei MA, 2005, RNA, V11, P717, DOI 10.1261/rna.2340405; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Cougot N, 2004, J CELL BIOL, V165, P31, DOI 10.1083/jcb.200309008; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Eystathioy T, 2003, RNA, V9, P1171, DOI 10.1261/rna.5810203; Gazzani S, 2004, SCIENCE, V306, P1046, DOI 10.1126/science.1101092; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Ingelfinger D, 2002, RNA, V8, P1489, DOI 10.1017/S1355838202021726; Janicki SM, 2004, CELL, V116, P683, DOI 10.1016/S0092-8674(04)00171-0; Jing Q, 2005, CELL, V120, P623, DOI 10.1016/j.cell.2004.12.038; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Lykke-Andersen J, 2002, MOL CELL BIOL, V22, P8114, DOI 10.1128/MCB.22.23.8114-8121.2002; Ma JB, 2004, NATURE, V429, P318, DOI 10.1038/nature02519; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Newbury S, 2004, RNA, V10, P59, DOI 10.1261/rna.2195504; Orban TI, 2005, RNA, V11, P459, DOI 10.1261/rna.7231505; SEN GL, NATURE CELL BIOL, V7, P633; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; Souret FF, 2004, MOL CELL, V15, P173, DOI 10.1016/j.molcel.2004.06.006; Teixeira D, 2005, RNA, V11, P371, DOI 10.1261/rna.7258505; Tharun S, 2000, NATURE, V404, P515, DOI 10.1038/35006676; van Dijk E, 2002, EMBO J, V21, P6915, DOI 10.1093/emboj/cdf678; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4	30	898	961	3	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2005	7	7					719	U118		10.1038/ncb1274	http://dx.doi.org/10.1038/ncb1274			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	941BX	15937477	Green Accepted			2022-12-25	WOS:000230190800017
J	Seki, S; Kawaguchi, Y; Chiba, K; Mikami, Y; Kizawa, H; Oya, T; Mio, F; Mori, M; Miyamoto, Y; Masuda, I; Tsunoda, T; Kamata, M; Kubo, T; Toyama, Y; Kimura, T; Nakamura, Y; Ikegawa, S				Seki, S; Kawaguchi, Y; Chiba, K; Mikami, Y; Kizawa, H; Oya, T; Mio, F; Mori, M; Miyamoto, Y; Masuda, I; Tsunoda, T; Kamata, M; Kubo, T; Toyama, Y; Kimura, T; Nakamura, Y; Ikegawa, S			A functional SNP in CILP, encoding cartilage intermediate layer protein, is associated with susceptibility to lumbar disc disease	NATURE GENETICS			English	Article							CHONDROCYTE DIFFERENTIATION; II RECEPTOR; DEGENERATION; EXPRESSION; POLYMORPHISM; MUTATIONS; TISSUE	Lumbar disc disease (LDD) is caused by degeneration of intervertebral discs of the lumbar spine. One of the most common musculoskeletal disorders(1), LDD has strong genetic determinants(2-4). Using a case-control association study, we identified a functional SNP ( 1184T --> C, resulting in the amino acid substitution I395T) in CILP, which encodes the cartilage intermediate layer protein, that acts as a modulator of LDD susceptibility. CILP was expressed abundantly in intervertebral discs, and its expression increased as disc degeneration progressed. CILP colocalized with TGF-beta 1 in clustering chondrocytes and their territorial matrices in intervertebral discs. CILP inhibited TGF-beta 1-mediated induction of cartilage matrix genes through direct interaction with TGF-beta 1 and inhibition of TGF-beta 1 signaling. The susceptibility-associated 1184C allele showed increased binding and inhibition of TGF-beta 1. Therefore, we conclude that the extracellular matrix protein CILP regulates TGF-beta signaling and that this regulation has a crucial role in the etiology and pathogenesis of LDD. Our study also adds to the list of connective tissue diseases that are associated with TGF-beta.	Inst Phys & Chem Res, SNP Res Ctr, Lab Bone & Joint Dis, Minato Ku, Tokyo 1088639, Japan; Toyama Med & Pharmaceut Univ, Fac Med, Dept Orthopaed Surg, Toyama 9300194, Japan; Keio Univ, Sch Med, Dept Orthopaed Surg, Shinjuku Ku, Tokyo 1608582, Japan; Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Orthopaed, Kamigyo Ku, Kyoto 6028566, Japan; Toyama Med & Pharmaceut Univ, Fac Med, Dept Pathol 2, Toyama 9300194, Japan; Med Coll Wisconsin, Dept Med, Div Rheumatol, Milwaukee, WI 53226 USA; RIKEN, SNP Res Ctr, Lab Med Informat, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; RIKEN, SNP Res Ctr, Lab Genotyping, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan	RIKEN; University of Toyama; Keio University; Kyoto Prefectural University of Medicine; University of Toyama; Medical College of Wisconsin; RIKEN; RIKEN	Ikegawa, S (corresponding author), Inst Phys & Chem Res, SNP Res Ctr, Lab Bone & Joint Dis, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	sikegawa@ims.u-tokyo.ac.jp	Toyama, Yoshiaki/K-5743-2013; Tsunoda, Tatsuhiko/K-2061-2014; Ikegawa, Shiro/N-6895-2015	Tsunoda, Tatsuhiko/0000-0002-5439-7918; Ikegawa, Shiro/0000-0003-0316-2147				Andersson GBJ, 1999, LANCET, V354, P581, DOI 10.1016/S0140-6736(99)01312-4; Annunen S, 1999, SCIENCE, V285, P409, DOI 10.1126/science.285.5426.409; Baffi MO, 2004, DEV BIOL, V276, P124, DOI 10.1016/j.ydbio.2004.08.027; BATTIE MC, 1995, J BONE JOINT SURG AM, V77A, P1662, DOI 10.2106/00004623-199511000-00004; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; Chen J, 2004, MATRIX BIOL, V22, P573, DOI 10.1016/j.matbio.2003.11.008; Chiba K, 1997, SPINE, V22, P2885, DOI 10.1097/00007632-199712150-00011; Freedman ML, 2004, NAT GENET, V36, P388, DOI 10.1038/ng1333; Isaka Y, 1996, NAT MED, V2, P418, DOI 10.1038/nm0496-418; Johnson K, 2003, ARTHRITIS RHEUM-US, V48, P1302, DOI 10.1002/art.10927; Kawaguchi Y, 1999, SPINE, V24, P2456, DOI 10.1097/00007632-199912010-00006; Kimura T, 1996, INT ORTHOP, V20, P177, DOI 10.1007/s002640050058; Kinoshita A, 2000, NAT GENET, V26, P19, DOI 10.1038/79128; Kizawa H, 2005, NAT GENET, V37, P138, DOI 10.1038/ng1496; Lorenzo P, 1998, J BIOL CHEM, V273, P23469, DOI 10.1074/jbc.273.36.23469; MASUDA I, 1995, J CLIN INVEST, V95, P699, DOI 10.1172/JCI117716; Matsui H, 1998, SPINE, V23, P1029, DOI 10.1097/00007632-199805010-00013; Mizuguchi T, 2004, NAT GENET, V36, P855, DOI 10.1038/ng1392; Neptune ER, 2003, NAT GENET, V33, P407, DOI 10.1038/ng1116; Pattison ST, 2001, CELL BIOL INT, V25, P679, DOI 10.1006/cbir.2000.0718; SAAL JA, 1989, SPINE, V14, P431, DOI 10.1097/00007632-198904000-00018; Sambrook PN, 1999, ARTHRITIS RHEUM-US, V42, P366, DOI 10.1002/1529-0131(199902)42:2<366::AID-ANR20>3.0.CO;2-6; SCHNEIDERMAN G, 1987, SPINE, V12, P276, DOI 10.1097/00007632-198704000-00016; Serra R, 1997, J CELL BIOL, V139, P541, DOI 10.1083/jcb.139.2.541; Tolonen J, 2001, EUR SPINE J, V10, P172, DOI 10.1007/s005860000213; Watanabe H, 1997, P NATL ACAD SCI USA, V94, P6943, DOI 10.1073/pnas.94.13.6943; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; Yang X, 2001, J CELL BIOL, V153, P35, DOI 10.1083/jcb.153.1.35; Young GD, 2004, J BIOL CHEM, V279, P47633, DOI 10.1074/jbc.M404918200	29	165	187	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2005	37	6					607	612		10.1038/ng1557	http://dx.doi.org/10.1038/ng1557			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	931OT	15864306				2022-12-25	WOS:000229495300014
J	Stephens, P; Edkins, S; Davies, H; Greenman, C; Cox, C; Hunter, C; Bignell, G; Teague, J; Smith, R; Stevens, C; O'Meara, S; Parker, A; Tarpey, P; Avis, T; Barthorpe, A; Brackenbury, L; Buck, G; Butler, A; Clements, J; Cole, J; Dicks, E; Edwards, K; Forbes, S; Gorton, M; Gray, K; Halliday, K; Harrison, R; Hills, K; Hinton, J; Jones, D; Kosmidou, V; Laman, R; Lugg, R; Menzies, A; Perry, J; Petty, R; Raine, K; Shepherd, R; Small, A; Solomon, H; Stephens, Y; Tofts, C; Varian, J; Webb, A; West, S; Widaa, S; Yates, A; Brasseur, F; Cooper, CS; Flanagan, AM; Green, A; Knowles, M; Leung, SY; Looijenga, LHJ; Malkowicz, B; Pierotti, MA; Teh, B; Yuen, ST; Nicholson, AG; Lakhani, S; Easton, DF; Weber, BL; Stratton, MR; Futreal, PA; Wooster, R				Stephens, P; Edkins, S; Davies, H; Greenman, C; Cox, C; Hunter, C; Bignell, G; Teague, J; Smith, R; Stevens, C; O'Meara, S; Parker, A; Tarpey, P; Avis, T; Barthorpe, A; Brackenbury, L; Buck, G; Butler, A; Clements, J; Cole, J; Dicks, E; Edwards, K; Forbes, S; Gorton, M; Gray, K; Halliday, K; Harrison, R; Hills, K; Hinton, J; Jones, D; Kosmidou, V; Laman, R; Lugg, R; Menzies, A; Perry, J; Petty, R; Raine, K; Shepherd, R; Small, A; Solomon, H; Stephens, Y; Tofts, C; Varian, J; Webb, A; West, S; Widaa, S; Yates, A; Brasseur, F; Cooper, CS; Flanagan, AM; Green, A; Knowles, M; Leung, SY; Looijenga, LHJ; Malkowicz, B; Pierotti, MA; Teh, B; Yuen, ST; Nicholson, AG; Lakhani, S; Easton, DF; Weber, BL; Stratton, MR; Futreal, PA; Wooster, R			A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; GENOME	We examined the coding sequence of 518 protein kinases, similar to 1.3 Mb of DNA per sample, in 25 breast cancers. In many tumors, we detected no somatic mutations. But a few had numerous somatic mutations with distinctive patterns indicative of either a mutator phenotype or a past exposure.	Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; Ludwig Inst Canc Res, B-1200 Brussels, Belgium; Inst Canc Res, Sutton SM2 5NG, Surrey, England; UCL, Inst Orthopaed, Stanmore, Middx, England; Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge CB2 2XY, England; St James Univ Hosp, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England; Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Erasmus Univ, Josephine Nefkens Inst, NL-3015 GE Rotterdam, Netherlands; Univ Penn, Div Urol, Philadelphia, PA 19104 USA; Nazl Tumori & FIRC Inst Mol Oncol, Milan, Italy; Van Andel Res Inst, Canc Genet Lab, Grand Rapids, MI 49503 USA; Royal Brompton Hosp, London SW3 6NP, England; Inst Canc Res, Chester Beatty Labs, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; Strangeways Res Labs, Canc Res UK Genet Epidemiol Grp, Cambridge CB1 4RN, England; Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA	Wellcome Trust Sanger Institute; Ludwig Institute for Cancer Research; University of London; Institute of Cancer Research - UK; University of London; University College London; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cancer Research UK; Saint James's University Hospital; University of Leeds; University of Hong Kong; Erasmus University Rotterdam; Erasmus MC; University of Pennsylvania; Fondazione IRCCS Istituto Nazionale Tumori Milan; Van Andel Institute; Royal Brompton Hospital; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Cancer Research UK; University of Pennsylvania	Stratton, MR (corresponding author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Cambridge CB10 1SA, England.	mrs@sanger.ac.uk	Leung, Suet Yi/C-4340-2009; Lakhani, Sunil R/I-1970-2018; Yuen, Siu/K-6311-2014; Looijenga, Leendert/B-8145-2019; Pierotti, Marco Alessandro/AAC-4728-2022; Leung, Suet Yi/T-9620-2019	Lakhani, Sunil R/0000-0003-4067-2760; Looijenga, Leendert/0000-0002-8146-1911; Pierotti, Marco Alessandro/0000-0002-7431-8332; Teh, Bin Tean/0000-0003-1514-1124; Laman, Ross/0000-0003-0545-0521; Knowles, Margaret/0000-0002-9363-8657; Buck, Gemma/0000-0001-5289-1050; Hunter, Christopher/0000-0002-1335-0881; Flanagan, Adrienne/0000-0002-2832-1303; Raine, Keiran/0000-0002-5634-1539; Leung, Suet Yi/0000-0001-8614-4619; Edkins, Sarah/0000-0003-0717-1972; Green, Anthony/0000-0002-9795-0218; Avis, Tim/0000-0001-6120-5729; Gray, Kristian/0000-0002-7035-7107; Yates, Andrew/0000-0002-8886-4772				Huang ME, 2003, P NATL ACAD SCI USA, V100, P11529, DOI 10.1073/pnas.2035018100; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Persons DL, 1997, MODERN PATHOL, V10, P720; Wagner E, 2002, J CELL SCI, V115, P3033; Wang TL, 2002, P NATL ACAD SCI USA, V99, P3076, DOI 10.1073/pnas.261714699; Xiao W, 1999, MUTAT RES-FUND MOL M, V431, P155, DOI 10.1016/S0027-5107(99)00203-1	7	273	299	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2005	37	6					590	592		10.1038/ng1571	http://dx.doi.org/10.1038/ng1571			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	931OT	15908952				2022-12-25	WOS:000229495300011
J	Miklos, GLG				Miklos, GLG			The Human Cancer Genome Project - one more misstep in the war on cancer	NATURE BIOTECHNOLOGY			English	Editorial Material							COLORECTAL-CANCER; GENE-EXPRESSION; CHROMOSOME REASSORTMENTS; MULTIDRUG-RESISTANCE; PRIMARY TUMOR; STEM-CELLS; ANEUPLOIDY; PROGRESSION; MUTATIONS; THERAPY		Secure Genet Pty Ltd, Sydney, NSW 2106, Australia		Miklos, GLG (corresponding author), Secure Genet Pty Ltd, 19 Bungan Head Rd, Sydney, NSW 2106, Australia.	gmiklos@securegenetics.com						Akagi T, 2003, P NATL ACAD SCI USA, V100, P13567, DOI 10.1073/pnas.1834876100; Al-Hajj M, 2004, CURR OPIN GENET DEV, V14, P43, DOI 10.1016/j.gde.2003.11.007; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Auer G, 2004, CELL ONCOL, V26, P171; Barbier M, 2001, NATURE, V413, P796, DOI 10.1038/35101660; Bendell JC, 2003, CANCER-AM CANCER SOC, V97, P2972, DOI 10.1002/cncr.11436; Dick JE, 2003, P NATL ACAD SCI USA, V100, P3547, DOI 10.1073/pnas.0830967100; Duesberg P, 2004, CELL CYCLE, V3, P823; Duesberg P, 2001, P NATL ACAD SCI USA, V98, P11283, DOI 10.1073/pnas.201398998; Duesberg P, 2000, P NATL ACAD SCI USA, V97, P14295, DOI 10.1073/pnas.97.26.14295; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Fidler IJ, 2003, NAT GENET, V34, P23, DOI 10.1038/ng0503-23a; Folkman J, 2004, NATURE, V427, P787, DOI 10.1038/427787a; Fonseca R, 2003, BLOOD, V102, P2562, DOI 10.1182/blood-2003-02-0493; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Harris H, 2004, NATURE, V427, P201, DOI 10.1038/427201a; Hofmann WK, 2002, LANCET, V359, P481, DOI 10.1016/S0140-6736(02)07678-X; Hunter K, 2003, NAT GENET, V34, P23, DOI 10.1038/ng0503-23b; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Klein CA, 2004, CELL CYCLE, V3, P29; Klein CA, 2003, ADV CANCER RES, V89, P35, DOI 10.1016/S0065-230X(03)01002-9; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; Leaf C, 2004, FORTUNE, V149, P76; Marx J, 2004, SCIENCE, V304, P658; Masters JRW, 2000, NATURE, V404, P921, DOI 10.1038/35010139; Mohsin SK, 2005, J CLIN ONCOL, V23, P2460, DOI 10.1200/JCO.2005.00.661; Ozcelik C, 2002, P NATL ACAD SCI USA, V99, P8880, DOI 10.1073/pnas.122249299; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; POLLACK A, 2005, NY TIMES        0328, pA1; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Ramaswamy S, 2003, NAT GENET, V34, P25, DOI 10.1038/ng0503-25a; Rush LJ, 2001, BLOOD, V97, P3226, DOI 10.1182/blood.V97.10.3226; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Schmidt-Kittler O, 2003, P NATL ACAD SCI USA, V100, P7737, DOI 10.1073/pnas.1331931100; Sonnenschein C, 2000, MOL CARCINOGEN, V29, P205, DOI 10.1002/1098-2744(200012)29:4<205::AID-MC1002>3.0.CO;2-W; Tortola S, 2001, J CLIN ONCOL, V19, P2837, DOI 10.1200/JCO.2001.19.11.2837; Vasselli JR, 2003, P NATL ACAD SCI USA, V100, P6958, DOI 10.1073/pnas.1131754100; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087	39	39	48	0	4	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2005	23	5					535	537		10.1038/nbt0505-535	http://dx.doi.org/10.1038/nbt0505-535			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	923XS	15877064				2022-12-25	WOS:000228943500015
J	Simons, M; Gloy, J; Ganner, A; Bullerkotte, A; Bashkurov, M; Kronig, C; Schermer, B; Benzing, T; Cabello, OA; Jenny, A; Mlodzik, M; Polok, B; Driever, W; Obara, T; Walz, G				Simons, M; Gloy, J; Ganner, A; Bullerkotte, A; Bashkurov, M; Kronig, C; Schermer, B; Benzing, T; Cabello, OA; Jenny, A; Mlodzik, M; Polok, B; Driever, W; Obara, T; Walz, G			Inversin, the gene product mutated in nephronophthisis type II, functions as a molecular switch between Wnt signaling pathways	NATURE GENETICS			English	Article							POLYCYSTIC KIDNEY-DISEASE; BETA-CATENIN; PRIMARY CILIUM; COMPLEX; CADHERIN; INV	Cystic renal diseases are caused by mutations of proteins that share a unique subcellular localization: the primary cilium of tubular epithelial cells(1). Mutations of the ciliary protein inversin cause nephronophthisis type II, an autosomal recessive cystic kidney disease characterized by extensive renal cysts, situs inversus and renal failure(2). Here we report that inversin acts as a molecular switch between different Wnt signaling cascades. Inversin inhibits the canonical Wnt pathway by targeting cytoplasmic dishevelled (Dsh or Dvl1) for degradation; concomitantly, it is required for convergent extension movements in gastrulating Xenopus laevis embryos and elongation of animal cap explants, both regulated by noncanonical Wnt signaling. In zebrafish, the structurally related switch molecule diversin ameliorates renal cysts caused by the depletion of inversin, implying that an inhibition of canonical Wnt signaling is required for normal renal development. Fluid flow increases inversin levels in ciliated tubular epithelial cells and seems to regulate this crucial switch between Wnt signaling pathways during renal development.	Univ Hosp Freiburg, Div Renal, D-79106 Freiburg, Germany; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; CUNY Mt Sinai Sch Med, Brookdale Dept Mol Cell & Dev Biol, New York, NY 10029 USA; Univ Freiburg, Dept Biol, D-79104 Freiburg, Germany; Case Western Reserve Univ, Dept Med, Cleveland, OH 44109 USA	University of Freiburg; Baylor College of Medicine; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Freiburg; Case Western Reserve University	Walz, G (corresponding author), Univ Hosp Freiburg, Div Renal, Hugstetter Str 55, D-79106 Freiburg, Germany.	gerd.walz@uniklinik-freiburg.de	Schermer, Bernhard/E-9972-2014; Benzing, Thomas/X-5476-2019; Simons, Matias/I-2038-2017	Schermer, Bernhard/0000-0002-5194-9000; Simons, Matias/0000-0003-3959-6350; Driever, Wolfgang/0000-0002-9551-9141	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK069604, R01DK078209] Funding Source: NIH RePORTER; NIDDK NIH HHS [R21 DK069604, R01 DK078209] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Das G, 2004, DEVELOPMENT, V131, P4467, DOI 10.1242/dev.01317; Feiguin F, 2001, DEV CELL, V1, P93, DOI 10.1016/S1534-5807(01)00010-7; FRIEDBERG V, 1955, GYNAECOLOGIA, V140, P34, DOI 10.1159/000308054; Guo N, 2004, P NATL ACAD SCI USA, V101, P9277, DOI 10.1073/pnas.0402802101; Imai Y, 2001, DEVELOPMENT, V128, P2407; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Leung TC, 2003, DEV DYNAM, V228, P424, DOI 10.1002/dvdy.10408; Liu W, 2003, AM J PHYSIOL-RENAL, V285, pF998, DOI 10.1152/ajprenal.00067.2003; Majumdar A, 2003, DEVELOPMENT, V130, P3175, DOI 10.1242/dev.00520; Mochizuki T, 1998, NATURE, V395, P177, DOI 10.1038/26006; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Morgan D, 1998, NAT GENET, V20, P149, DOI 10.1038/2450; Morgan D, 2002, HUM MOL GENET, V11, P3345, DOI 10.1093/hmg/11.26.3345; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nurnberger J, 2002, MOL BIOL CELL, V13, P3096, DOI 10.1091/mbc.E02-04-0195; Otto EA, 2003, NAT GENET, V34, P413, DOI 10.1038/ng1217; Perantoni AO, 2003, SEMIN CELL DEV BIOL, V14, P201, DOI 10.1016/S1084-9521(03)00022-3; Praetorius HA, 2001, J MEMBRANE BIOL, V184, P71, DOI 10.1007/s00232-001-0075-4; Qian CN, 2005, J BIOL CHEM, V280, P3938, DOI 10.1074/jbc.M410697200; Saadi-Kheddouci S, 2001, ONCOGENE, V20, P5972, DOI 10.1038/sj.onc.1204825; Schneider S, 1996, MECH DEVELOP, V57, P191, DOI 10.1016/0925-4773(96)00546-1; Schwarz-Romond T, 2002, GENE DEV, V16, P2073, DOI 10.1101/gad.230402; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Watnick T, 2003, NAT GENET, V34, P355, DOI 10.1038/ng0803-355; Wharton KA, 2003, DEV BIOL, V253, P1, DOI 10.1006/dbio.2002.0869; Zachariae W, 2004, MOL CELL, V13, P2, DOI 10.1016/S1097-2765(03)00530-6	28	565	588	0	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2005	37	5					537	543		10.1038/ng1552	http://dx.doi.org/10.1038/ng1552			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	922TU	15852005	Green Accepted			2022-12-25	WOS:000228862300025
J	Marchini, J; Donnelly, P; Cardon, LR				Marchini, J; Donnelly, P; Cardon, LR			Genome-wide strategies for detecting multiple loci that influence complex diseases	NATURE GENETICS			English	Article							GENETIC ASSOCIATION; QUANTITATIVE TRAIT; SUSCEPTIBILITY; EPISTASIS; MODELS; POLYMORPHISM; METABOLISM; SNPS	After nearly 10 years of intense academic and commercial research effort, large genome-wide association studies for common complex diseases are now imminent. Although these conditions involve a complex relationship between genotype and phenotype, including interactions between unlinked loci(1), the prevailing strategies for analysis of such studies focus on the locus-by-locus paradigm. Here we consider analytical methods that explicitly look for statistical interactions between loci. We show first that they are computationally feasible, even for studies of hundreds of thousands of loci, and second that even with a conservative correction for multiple testing, they can be more powerful than traditional analyses under a range of models for interlocus interactions. We also show that plausible variations across populations in allele frequencies among interacting loci can markedly affect the power to detect their marginal effects, which may account in part for the well-known difficulties in replicating association results. These results suggest that searching for interactions among genetic loci can be fruitfully incorporated into analysis strategies for genome-wide association studies.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Oxford, Dept Stat, Oxford OX1 3TG, England	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford	Cardon, LR (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.	lon.cardon@well.ox.ac.uk	Marchini, Jonathan/ABE-9024-2020	Marchini, Jonathan/0000-0003-0610-8322; Donnelly, Peter/0000-0001-9495-3408				Carlson CS, 2004, NATURE, V429, P446, DOI 10.1038/nature02623; Carlson CS, 2001, CURR OPIN CHEM BIOL, V5, P78, DOI 10.1016/S1367-5931(00)00171-X; CLAYTON D, 2001, HDB STAT GENETICS, P519; Culverhouse R, 2002, AM J HUM GENET, V70, P461, DOI 10.1086/338759; Hoh J, 2003, NAT REV GENET, V4, P701, DOI 10.1038/nrg1155; Hoh J, 2000, ANN HUM GENET, V64, P413, DOI 10.1046/j.1469-1809.2000.6450413.x; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; Kempthorne O, 1957, INTRO GENETIC STAT; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; Mackay TFC, 2001, NAT REV GENET, V2, P11, DOI 10.1038/35047544; Marchini J, 2004, NAT GENET, V36, P512, DOI 10.1038/ng1337; Moore JH, 2003, HUM HERED, V56, P73, DOI 10.1159/000073735; Moore JH, 2004, JAMA-J AM MED ASSOC, V291, P1642, DOI 10.1001/jama.291.13.1642; Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047; Phillips PC, 1998, GENETICS, V149, P1167; Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718; ROSES A, 2003, NAT GENET S2, V33, P217; Routman EJ, 1997, EVOLUTION, V51, P1654, DOI 10.1111/j.1558-5646.1997.tb01488.x; Schlesselman JJ, 1982, CASE CONTROL STUDIES; Segre D, 2005, NAT GENET, V37, P77, DOI 10.1038/ng1489; Sham P, 2002, NAT REV GENET, V3, P862, DOI 10.1038/nrg930; SHAM PC, 1997, STAT HUMAN GENETICS; SING CF, 1985, AM J HUM GENET, V37, P268; Templeton A. R., 2000, EPISTASIS EVOLUTIONA, P41; Thomas DC, 2004, STAT METHODS GENETIC; Tiwari HK, 1997, GENET EPIDEMIOL, V14, P1131, DOI 10.1002/(SICI)1098-2272(1997)14:6<1131::AID-GEPI95>3.3.CO;2-7; Williams SM, 2004, BIOESSAYS, V26, P170, DOI 10.1002/bies.10401; Zerba KE, 2000, HUM GENET, V107, P466, DOI 10.1007/s004390000394; Zondervan KT, 2004, NAT REV GENET, V5, P89, DOI 10.1038/nrg1270	29	683	709	0	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2005	37	4					413	417		10.1038/ng1537	http://dx.doi.org/10.1038/ng1537			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	911XL	15793588				2022-12-25	WOS:000228040000025
J	Tong, MH; Jiang, H; Liu, P; Lawson, JA; Brass, LF; Song, WC				Tong, MH; Jiang, H; Liu, P; Lawson, JA; Brass, LF; Song, WC			Spontaneous fetal loss caused by placental thrombosis in estrogen sulfotransferase-deficient mice	NATURE MEDICINE			English	Article							HORMONE REPLACEMENT THERAPY; HUMAN PLATELETS CONTAIN; UTERINE TISSUE FACTOR; STEROID SULFOTRANSFERASES; CRYSTALLOGRAPHIC ANALYSIS; SUBSTRATE-SPECIFICITY; ORAL-CONTRACEPTIVES; EPITHELIAL-CELLS; RECEPTOR-BETA; EXPRESSION	Estrogen sulfotransferase (EST, encoded by SULT1E1) catalyzes the sulfoconjugation and inactivation of estrogens. Despite decades of biochemical study and the recognition that high levels of estrogen sulfates circulate in the blood of pregnant and nonpregnant women, the physiological role of estrogen sulfation remains poorly understood. Here we show that ablation of the mouse Sult1e1 gene caused placental thrombosis and spontaneous fetal loss. This phenotype was associated with elevated free estrogen levels systemically and in the amniotic fluid, increased tissue factor expression in the placenta and heightened platelet sensitivity to agonist-induced activation ex vivo. Treatment of pregnant Sult1e1-null mice with either an anticoagulant or antiestrogen prevented the fetal loss phenotype. Our results thus identify Est as a critical estrogen modulator in the placenta and suggest a link between estrogen excess and thrombotic fetal loss. These findings may have implications for understanding and treating human pregnancy failure and intrauterine growth retardation.	Univ Penn, Sch Med, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania	Song, WC (corresponding author), Univ Penn, Sch Med, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA.	song@spirit.gcrc.upenn.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD042767] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045181, P01HL040387] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45181, HL-40387] Funding Source: Medline; NICHD NIH HHS [HD-42767] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adamson SL, 2002, DEV BIOL, V250, P358, DOI 10.1006/dbio.2002.0773; Backlin BM, 1998, APMIS, V106, P785, DOI 10.1111/j.1699-0463.1998.tb00225.x; Buchner Virginia, 2002, Rev Environ Health, V17, P249; Constancia M, 2002, NATURE, V417, P945, DOI 10.1038/nature00819; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; Falany JL, 1996, CANCER RES, V56, P1551; Falany JL, 1997, ONCOL RES, V9, P589; Franklin GC, 1996, PLACENTA, V17, P3, DOI 10.1016/S0143-4004(05)80638-1; Georgiades P, 2001, P NATL ACAD SCI USA, V98, P4522, DOI 10.1073/pnas.081540898; HARTZELL S, 1989, MOL CELL BIOL, V9, P2567, DOI 10.1128/MCB.9.6.2567; HENRIKSON KP, 1992, ENDOCRINOLOGY, V130, P2669, DOI 10.1210/en.130.5.2669; HOBKIRK R, 1983, BIOCHEM J, V216, P451, DOI 10.1042/bj2160451; HOBKIRK R, 1985, CAN J BIOCHEM CELL B, V63, P1127, DOI 10.1139/o85-141; Jayachandran M, 2003, PLATELETS, V14, P75, DOI 10.1080/0953710031000080562; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kakuta Y, 1998, BIOCHEM PHARMACOL, V55, P313, DOI 10.1016/S0006-2952(97)00465-6; Kester MHA, 2000, ENDOCRINOLOGY, V141, P1897, DOI 10.1210/en.141.5.1897; Khetawat G, 2000, BLOOD, V95, P2289, DOI 10.1182/blood.V95.7.2289.007k03_2289_2296; Koh KK, 1999, THROMB HAEMOSTASIS, V82, P626, DOI 10.1055/s-0037-1615889; LUTZ B, 1994, DEVELOPMENT, V120, P25, DOI 10.1242/dev.120.1.25; Mahendroo MS, 1997, MOL ENDOCRINOL, V11, P917, DOI 10.1210/me.11.7.917; Miozzo M, 2002, BIOL NEONATE, V81, P217, DOI 10.1159/000056752; MOORE SS, 1988, AUST J BIOL SCI, V41, P333; Moro L, 2005, BLOOD, V105, P115, DOI 10.1182/blood-2003-11-3840; Nealen ML, 2001, CIRC RES, V88, P438; OATES JA, 1988, NEW ENGL J MED, V319, P689, DOI 10.1056/NEJM198809153191106; Poulter NR, 1997, LANCET, V349, P1202, DOI 10.1016/S0140-6736(97)02358-1; Qian YM, 1998, J PHARMACOL EXP THER, V286, P555; Qian YM, 2001, ENDOCRINOLOGY, V142, P5342, DOI 10.1210/en.142.12.5342; Qian YM, 1999, J STEROID BIOCHEM, V71, P123, DOI 10.1016/S0960-0760(99)00131-4; QUIRK SM, 1995, ENDOCRINE, V3, P177, DOI 10.1007/BF02990070; Rocca B, 2000, NAT MED, V6, P219, DOI 10.1038/72334; Rosendaal FR, 2002, ARTERIOSCL THROM VAS, V22, P201, DOI 10.1161/hq0202.102318; Safe SH, 2000, ENVIRON HEALTH PERSP, V108, P487, DOI 10.2307/3454608; SCARABIN PY, 1995, THROMB HAEMOSTASIS, V74, P928; Shevtsov S, 2003, ENVIRON HEALTH PERSP, V111, P884, DOI 10.1289/ehp.6056; Song WC, 1997, ENDOCRINOLOGY, V138, P5006, DOI 10.1210/en.138.11.5006; SONG WC, 1995, ENDOCRINOLOGY, V136, P2477, DOI 10.1210/en.136.6.2477; Stanley EL, 2001, J CLIN ENDOCR METAB, V86, P5944, DOI 10.1210/jc.86.12.5944; STONE R, 1994, SCIENCE, V265, P308, DOI 10.1126/science.8023147; Strott CA, 1996, ENDOCR REV, V17, P670, DOI 10.1210/er.17.6.670; Suzuki T, 2003, CANCER RES, V63, P2762; Tong MH, 2002, ENDOCRINOLOGY, V143, P3144, DOI 10.1210/en.143.8.3144; TSENG L, 1985, J STEROID BIOCHEM, V22, P611, DOI 10.1016/0022-4731(85)90213-4	44	81	84	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					153	159		10.1038/nm1184	http://dx.doi.org/10.1038/nm1184			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15685171				2022-12-25	WOS:000226797300022
J	Gaston, SM; Soares, MA; Siddiqui, MM; Vu, D; Lee, JM; Goldner, DL; Brice, MJ; Shih, JC; Upton, MP; Perides, G; Baptista, J; Lavin, PT; Bloch, BN; Genega, EM; Rubin, MA; Lenkinski, RE				Gaston, SM; Soares, MA; Siddiqui, MM; Vu, D; Lee, JM; Goldner, DL; Brice, MJ; Shih, JC; Upton, MP; Perides, G; Baptista, J; Lavin, PT; Bloch, BN; Genega, EM; Rubin, MA; Lenkinski, RE			Tissue-print and print-phoresis as platform technologies for the molecular analysis of human surgical specimens: mapping tumor invasion of the prostate capsule	NATURE MEDICINE			English	Article							GENE-EXPRESSION ANALYSIS; CANCER; PROTEOMICS; BIOMARKER; COLLAGEN; MARKERS	Molecular profiling of human biopsies and surgical specimens is frequently complicated by their inherent biological heterogeneity and by the need to conserve tissue for clinical diagnosis. We have developed a set of novel 'tissue print' and 'print-phoresis' technologies to facilitate tissue and tumor-marker profiling under these circumstances. Tissue printing transfers cells and extracellular matrix components from a tissue surface onto nitrocellulose membranes, generating a two-dimensional anatomical image on which molecular markers can be visualized by specific protein and RNA- and DNA-detection techniques. Print-phoresis is a complementary new electrophoresis method in which thin strips from the print are subjected to polyacrylamide gel electrophoresis, providing a straightforward interface between the tissue-print image and gel-based proteomic techniques. Here we have utilized these technologies to identify and characterize markers of tumor invasion of the prostate capsule, an event generally not apparent to the naked eye that may result in tumor at the surgical margins ('positive margins'). We have also shown that tissue-print technologies can provide a general platform for the generation of marker maps that can be superimposed directly onto histopathological and radiological images, permitting molecular identification and classification of individual malignant lesions.	Beth Israel Deaconess Med Ctr, Dept Surg, Div Urol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Tufts Univ New England Med Ctr, Dept Surg, Boston, MA 02111 USA; Averion Biostat, Framingham, MA 01701 USA; Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Tufts Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital	Gaston, SM (corresponding author), Beth Israel Deaconess Med Ctr, Dept Surg, Div Urol, 330 Brookline Ave, Boston, MA 02215 USA.	sgaston@bidmc.harvard.edu	Siddiqui, Mohummad/V-1196-2019; Gaston, Sandra/AAN-4088-2021; Soares, Miguel P/G-4188-2011; Lenkinski, Robert/F-9045-2014	Goldner, Dana/0000-0002-1514-9735; Siddiqui, Mohummad/0000-0002-4484-6820; Rubin, Mark/0000-0002-8321-9950; Lenkinski, Robert/0000-0001-7371-5048; Bloch, B Nicolas/0000-0001-8040-159X	NATIONAL CANCER INSTITUTE [R21CA086365, R33CA086365] Funding Source: NIH RePORTER; NCI NIH HHS [CA86365] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banyard J, 2003, J BIOL CHEM, V278, P20989, DOI 10.1074/jbc.M210616200; Burns-Cox N, 2001, J UROLOGY, V166, P1698, DOI 10.1016/S0022-5347(05)65656-X; Cairns RA, 2003, CURR MOL MED, V3, P659, DOI 10.2174/1566524033479447; Celis JE, 2003, CANCER CELL, V3, P9, DOI 10.1016/S1535-6108(02)00242-8; Chan TY, 2001, J UROLOGY, V166, P2181, DOI 10.1016/S0022-5347(05)65530-9; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Emmert-Buck MR, 2000, J MOL DIAGN, V2, P60, DOI 10.1016/S1525-1578(10)60617-4; Ernst T, 2002, AM J PATHOL, V160, P2169, DOI 10.1016/S0002-9440(10)61165-0; Friedberg MH, 1998, CANCER, V82, P923, DOI 10.1002/(SICI)1097-0142(19980301)82:5<923::AID-CNCR18>3.0.CO;2-2; Hornebeck W, 2002, SEMIN CANCER BIOL, V12, P231, DOI 10.1016/S1044-579X(02)00026-3; Issaq HJ, 2002, BIOCHEM BIOPH RES CO, V292, P587, DOI 10.1006/bbrc.2002.6678; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; KLEINMAN HK, 1998, CURRENT PROTOCOLS CE; Kuniyasu H, 2000, CLIN CANCER RES, V6, P2295; LaTulippe E, 2002, CANCER RES, V62, P4499; Lichtinghagen R, 2003, ANTICANCER RES, V23, P2617; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; Luo J, 2001, CANCER RES, V61, P4683; MURPHY G, 1995, METHOD ENZYMOL, V248, P470; NAGLE RB, 1995, AM J PATHOL, V146, P1498; Ortega N, 2002, J CELL SCI, V115, P4201, DOI 10.1242/jcs.00106; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; Rubin MA, 2002, JAMA-J AM MED ASSOC, V287, P1662, DOI 10.1001/jama.287.13.1662; SCOPES RK, 2002, CURRENT PROTOCOLS MO; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Tuxhorn JA, 2002, CLIN CANCER RES, V8, P2912; VARNER JE, 1994, FASEB J, V8, P378, DOI 10.1096/fasebj.8.6.8168688; Welsh JB, 2001, CANCER RES, V61, P5974; Wise AM, 2002, UROLOGY, V60, P264, DOI 10.1016/S0090-4295(02)01728-4; YOUNG RH, 2000, ATLAS TUMOR PATHOL, P4	30	22	24	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2005	11	1					95	101		10.1038/nm1169	http://dx.doi.org/10.1038/nm1169			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	884ZJ	15619629				2022-12-25	WOS:000226124900039
J	Watson, P; Forster, R; Palmer, KJ; Pepperkok, R; Stephens, DJ				Watson, P; Forster, R; Palmer, KJ; Pepperkok, R; Stephens, DJ			Coupling of ER exit to microtubules through direct interaction of COPII with dynactin	NATURE CELL BIOLOGY			English	Article							TO-GOLGI TRANSPORT; ENDOPLASMIC-RETICULUM; CYTOPLASMIC DYNEIN; LIVING CELLS; IN-VIVO; COMPLEX; SITES; COAT; P150(GLUED); PROTEINS	Transport of proteins from the endoplasmic reticulum ( ER) to the Golgi is mediated by the sequential action of two coat complexes: COPII concentrates cargo for secretion at ER export sites, then COPI is subsequently recruited to nascent carriers and retrieves recycling proteins back to the ER. These carriers then move towards the Golgi along microtubules, driven by the dynein/dynactin complexes. Here we show that the Sec23p component of the COPII complex directly interacts with the dynactin complex through the carboxy-terminal cargo-binding domain of p150(Glued). Functional assays, including measurements of the rate of recycling of COPII on the ER membrane and quantitative analyses of secretion, indicate that this interaction underlies functional coupling of ER export to microtubules. Together, our data suggest a mechanism by which membranes of the early secretory pathway can be linked to motors and microtubules for subsequent organization and movement to the Golgi apparatus.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England; European Mol Biol Lab, Cell Biol & Biophys Programme, D-69117 Heidelberg, Germany	University of Bristol; European Molecular Biology Laboratory (EMBL)	Pepperkok, R (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.	pepperko@embl-heidelberg.de; david.stephens@bristol.ac.uk	Watson, Peter/A-4477-2010	Watson, Peter/0000-0003-0250-7852; Pepperkok, Rainer/0000-0002-9762-3583; Stephens, David/0000-0001-5297-3240	Wellcome Trust [071233] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allan BB, 2000, SCIENCE, V289, P444, DOI 10.1126/science.289.5478.444; Antonny B, 2001, NAT CELL BIOL, V3, P531, DOI 10.1038/35078500; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; Aridor M, 2001, J CELL BIOL, V152, P213, DOI 10.1083/jcb.152.1.213; Askham JM, 2002, MOL BIOL CELL, V13, P3627, DOI 10.1091/mbc.E02-01-0061; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Barlowe C, 2002, CURR OPIN CELL BIOL, V14, P417, DOI 10.1016/S0955-0674(02)00348-4; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Carvalho P, 2003, TRENDS CELL BIOL, V13, P229, DOI 10.1016/S0962-8924(03)00074-6; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Hammond AT, 2000, MOL BIOL CELL, V11, P3013, DOI 10.1091/mbc.11.9.3013; Holleran EA, 1996, J CELL BIOL, V135, P1815, DOI 10.1083/jcb.135.6.1815; Kamal A, 2002, CURR OPIN CELL BIOL, V14, P63, DOI 10.1016/S0955-0674(01)00295-2; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; Lowe M, 1996, J BIOL CHEM, V271, P30725, DOI 10.1074/jbc.271.48.30725; Miller EA, 2003, CELL, V114, P497, DOI 10.1016/S0092-8674(03)00609-3; MIZUNO M, 1994, J CELL SCI, V107, P1321; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; ORCI L, 1991, P NATL ACAD SCI USA, V88, P8611, DOI 10.1073/pnas.88.19.8611; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Quintyne NJ, 1999, J CELL BIOL, V147, P321, DOI 10.1083/jcb.147.2.321; Ralston E, 2001, J NEUROSCI, V21, P875, DOI 10.1523/JNEUROSCI.21-03-00875.2001; SARASTE J, 1991, J CELL SCI, V100, P415; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; Shima DT, 1999, CURR BIOL, V9, P821, DOI 10.1016/S0960-9822(99)80365-0; Stephens DJ, 2000, J CELL SCI, V113, P2177; Stephens DJ, 2003, EMBO REP, V4, P210, DOI 10.1038/sj.embor.embor736; Tang BL, 2000, J BIOL CHEM, V275, P13597, DOI 10.1074/jbc.275.18.13597; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; Vaughan KT, 1999, J CELL SCI, V112, P1437; Vaughan PS, 2002, J CELL BIOL, V158, P305, DOI 10.1083/jcb.200201029; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634	33	137	139	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2005	7	1					48	+		10.1038/ncb1206	http://dx.doi.org/10.1038/ncb1206			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	884UZ	15580264	Green Accepted			2022-12-25	WOS:000226113500014
J	Chirino, AJ; Mire-Sluis, A				Chirino, AJ; Mire-Sluis, A			Characterizing biological products and assessing comparability following manufacturing changes	NATURE BIOTECHNOLOGY			English	Article							RECOMBINANT MONOCLONAL-ANTIBODY; LASER-SCANNING CYTOMETRY; CAPILLARY-ELECTROPHORESIS; ANALYTICAL ULTRACENTRIFUGATION; FACTOR-VIII; NEUTRALIZING ANTIBODIES; CHARGE HETEROGENEITY; COVALENT ATTACHMENT; POLYETHYLENE-GLYCOL; MULTIPLE-SCLEROSIS	Changes in production methods of a biological product may necessitate an assessment of comparability to ensure that these manufacturing changes have not affected the safety, identity, purity, or efficacy of the product. Depending on the nature of the protein or the change, this assessment consists of a hierarchy of sequential tests in analytical testing, preclinical animal studies and clinical studies. Differences in analytical test results between pre- and post-change products may require functional testing to establish the biological or clinical significance of the observed difference. An underlying principle of comparability is that under certain conditions, protein products may be considered comparable on the basis of analytical testing results alone. However, the ability to compare biological materials is solely dependent on the tests used, since no single analytical method is able to compare every aspect of protein structure or function. The advantages and disadvantages of any given method depends on the protein property being characterized.	Xencor Inc, Monrovia, CA 91016 USA; Ctr Drug Evaluat & Res, Off Pharmaceut Sci, Rockville, MD 20852 USA	US Food & Drug Administration (FDA)	Chirino, AJ (corresponding author), Xencor Inc, 111 W Lemon Ave, Monrovia, CA 91016 USA.	art@xencor.com						ABUCHOWSKI A, 1977, J BIOL CHEM, V252, P3582; AVANZI GC, 1990, J CELL PHYSIOL, V145, P458, DOI 10.1002/jcp.1041450310; Bailon P, 2001, BIOCONJUGATE CHEM, V12, P195, DOI 10.1021/bc000082g; BARBOSA MDF, 2003, 90 M AM SOC IMM AM S; Bertolotto A, 2002, J NEUROL NEUROSUR PS, V73, P148, DOI 10.1136/jnnp.73.2.148; Bertolotto A, 2000, IMMUNOPHARMACOLOGY, V48, P95, DOI 10.1016/S0162-3109(00)00182-X; Besman MJ, 1997, PHARM RES-DORDR, V14, P1092, DOI 10.1023/A:1012169832299; Bohidar HB, 1998, BIOPOLYMERS, V45, P1; Boyd PN, 1995, MOL IMMUNOL, V32, P1311, DOI 10.1016/0161-5890(95)00118-2; Braun A, 1997, PHARMACEUT RES, V14, P1472, DOI 10.1023/A:1012193326789; BURRONE OR, 1985, EMBO J, V4, P2855, DOI 10.1002/j.1460-2075.1985.tb04014.x; Casadevall N, 2002, NEW ENGL J MED, V346, P469, DOI 10.1056/NEJMoa011931; Chackerian B, 2002, J IMMUNOL, V169, P6120, DOI 10.4049/jimmunol.169.11.6120; Chapman AP, 2002, ADV DRUG DELIVER REV, V54, P531, DOI 10.1016/S0169-409X(02)00026-1; Chen FTA, 1998, GLYCOBIOLOGY, V8, P1045, DOI 10.1093/glycob/8.11.1045; Chirino AJ, 2004, DRUG DISCOV TODAY, V9, P82, DOI 10.1016/S1359-6446(03)02953-2; CLELAND JL, 1993, CRIT REV THER DRUG, V10, P307; Clore GM, 1998, CURR OPIN CHEM BIOL, V2, P564, DOI 10.1016/S1367-5931(98)80084-7; Colyer C, 2000, CELL BIOCHEM BIOPHYS, V33, P323, DOI 10.1385/CBB:33:3:323; Cook EB, 2001, J IMMUNOL METHODS, V254, P109, DOI 10.1016/S0022-1759(01)00407-0; Delmas C, 1997, GLYCOBIOLOGY, V7, P811, DOI 10.1093/glycob/7.6.811; Garcia FL, 2000, P NATL ACAD SCI USA, V97, P8334, DOI 10.1073/pnas.97.15.8334; Gitlin G, 1996, PHARMACEUT RES, V13, P762, DOI 10.1023/A:1016059902645; Grace MJ, 1999, AM J PATHOL, V155, P1869, DOI 10.1016/S0002-9440(10)65506-X; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; HARRIS RJ, 1995, J CHROMATOGR A, V705, P129, DOI 10.1016/0021-9673(94)01255-D; Harris RJ, 2001, J CHROMATOGR B, V752, P233, DOI 10.1016/S0378-4347(00)00548-X; HARRIS RJ, 1993, BIO-TECHNOL, V11, P1293; Harvey DJ, 2003, INT J MASS SPECTROM, V226, P1, DOI 10.1016/S1387-3806(02)00968-5; Hu S, 2002, ANAL CHEM, V74, P2833, DOI 10.1021/ac0202379; Idusogie EE, 2000, J IMMUNOL, V164, P4178, DOI 10.4049/jimmunol.164.8.4178; Jacobsen NE, 1996, CARBOHYD RES, V280, P1, DOI 10.1016/0008-6215(95)00278-2; Jefferis R, 2001, BIOPHARM-APPL T BIO, V14, P19; Johnson IS, 2003, NAT REV DRUG DISCOV, V2, P747, DOI 10.1038/nrd1179; Johnson LR, 1999, AM J PHYSIOL-CELL PH, V276, pC419, DOI 10.1152/ajpcell.1999.276.2.C419; Josic D, 1999, VOX SANG, V77, P90, DOI 10.1159/000056726; KATRE NV, 1990, J IMMUNOL, V144, P209; Kelly SM, 2000, CURR PROTEIN PEPT SC, V1, P349, DOI 10.2174/1389203003381315; Koren E., 2002, Current Pharmaceutical Biotechnology, V3, P349, DOI 10.2174/1389201023378175; Krishnamurthy Rajesh, 2002, Current Pharmaceutical Biotechnology, V3, P361, DOI 10.2174/1389201023378229; Lam XM, 1997, J PHARM SCI, V86, P1250, DOI 10.1021/js970143s; Laue TM, 1999, ANNU REV BIOPH BIOM, V28, P75, DOI 10.1146/annurev.biophys.28.1.75; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; LEE TT, 1992, J CHROMATOGR, V595, P319, DOI 10.1016/0021-9673(92)85174-R; Li JZ, 2001, BLOOD, V98, P3241, DOI 10.1182/blood.V98.12.3241; Lin YW, 2003, J CHROMATOGR B, V793, P37, DOI 10.1016/S1570-0232(03)00363-5; LU W, 1994, NATURE, V368, P269, DOI 10.1038/368269a0; LUCAS C, 1990, AIDS RES HUM RETROV, V6, P357, DOI 10.1089/aid.1990.6.357; Luo P, 2002, PROTEIN SCI, V11, P1218, DOI 10.1110/ps.4580102; Ma S, 2001, CHROMATOGRAPHIA, V53, pS75; Ma S, 1999, ANAL CHEM, V71, P5185, DOI 10.1021/ac990376z; Macdougall IC, 2002, NEPHROL DIAL TRANSPL, V17, P66, DOI 10.1093/ndt/17.suppl_5.66; McHeyzer-Williams M, 2003, MICROBES INFECT, V5, P205, DOI 10.1016/S1286-4579(03)00012-1; MEAGER A, 1989, J IMMUNOL METHODS, V116, P1, DOI 10.1016/0022-1759(89)90306-2; Miller LL, 1999, BLOOD, V93, P3250, DOI 10.1182/blood.V93.10.3250.410k35_3250_3258; Mire-Sluis AR, 2004, J IMMUNOL METHODS, V289, P1, DOI 10.1016/j.jim.2004.06.002; Moorhouse KG, 1997, J PHARMACEUT BIOMED, V16, P593, DOI 10.1016/S0731-7085(97)00178-7; Musco ML, 1998, CYTOMETRY, V33, P290, DOI 10.1002/(SICI)1097-0320(19981101)33:3<290::AID-CYTO2>3.0.CO;2-L; OKAMOTO M, 1991, ARCH BIOCHEM BIOPHYS, V286, P562, DOI 10.1016/0003-9861(91)90080-3; PARANANDI MV, 1994, J BIOL CHEM, V269, P243; Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480; Raju TS, 2000, GLYCOBIOLOGY, V10, P477, DOI 10.1093/glycob/10.5.477; Reid GE, 2002, J MASS SPECTROM, V37, P663, DOI 10.1002/jms.346; Remmele RL, 1998, PHARMACEUT RES, V15, P200; RENLUND S, 1990, J CHROMATOGR, V512, P325, DOI 10.1016/S0021-9673(01)89499-1; Rich RL, 2000, CURR OPIN BIOTECH, V11, P54, DOI 10.1016/S0958-1669(99)00054-3; Rudd PM, 1997, CURR OPIN BIOTECH, V8, P488, DOI 10.1016/S0958-1669(97)80073-0; Ryff JC, 1997, J INTERF CYTOK RES, V17, pS29; Sadick MD, 1999, J PHARMACEUT BIOMED, V19, P883, DOI 10.1016/S0731-7085(98)00144-7; Schellekens H, 2002, NAT REV DRUG DISCOV, V1, P457, DOI 10.1038/nrd818; Schmelzer AE, 2002, BIOTECHNOL PROGR, V18, P346, DOI 10.1021/bp010187d; Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6; Schultes BC, 2003, J IMMUNOL METHODS, V279, P1, DOI 10.1016/S0022-1759(03)00253-9; Shields RL, 2002, J BIOL CHEM, V277, P26733, DOI 10.1074/jbc.M202069200; Shinkawa T, 2003, J BIOL CHEM, V278, P3466, DOI 10.1074/jbc.M210665200; Soukharev S, 2002, BLOOD CELL MOL DIS, V28, P234, DOI 10.1006/bcmd.2002.0508; Spiro A, 2000, APPL ENVIRON MICROB, V66, P4258, DOI 10.1128/AEM.66.10.4258-4265.2000; STOCKERT RJ, 1995, PHYSIOL REV, V75, P591, DOI 10.1152/physrev.1995.75.3.591; Swanson SJ, 2004, NEPHRON CLIN PRACT, V96, P88, DOI 10.1159/000076746; Takacs MA, 1999, J INTERF CYTOK RES, V19, P781, DOI 10.1089/107999099313631; VANDENHA.CJ, 1970, J BIOL CHEM, V245, P4397; Varley PG, 1997, EUR BIOPHYS J BIOPHY, V25, P437, DOI 10.1007/s002490050058; Wadhwa M, 2003, J IMMUNOL METHODS, V278, P1, DOI 10.1016/S0022-1759(03)00206-0; Wadhwa M, 1999, CLIN CANCER RES, V5, P1353; WATSON E, 1994, GLYCOBIOLOGY, V4, P227, DOI 10.1093/glycob/4.2.227; Wierda D, 2001, TOXICOLOGY, V158, P71, DOI 10.1016/S0300-483X(00)00410-8; Wright A, 1998, J IMMUNOL, V160, P3393; Wright A, 2000, GLYCOBIOLOGY, V10, P1347, DOI 10.1093/glycob/10.12.1347; Wright A, 1997, TRENDS BIOTECHNOL, V15, P26, DOI 10.1016/S0167-7799(96)10062-7; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S; Zhang W, 2002, PHARM RES-DORDR, V19, P1223, DOI 10.1023/A:1019814713428	91	280	301	1	45	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2004	22	11					1383	1391		10.1038/nbt1030	http://dx.doi.org/10.1038/nbt1030			9	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	869CL	15529163				2022-12-25	WOS:000224960600028
J	Deak, F; Schoch, S; Liu, XR; Sudhof, TC; Kavalali, ET				Deak, F; Schoch, S; Liu, XR; Sudhof, TC; Kavalali, ET			Synaptobrevin is essential for fast synaptic-vesicle endocytosis	NATURE CELL BIOLOGY			English	Article							FROG NEUROMUSCULAR-JUNCTION; READILY RELEASABLE POOL; HIPPOCAMPAL SYNAPSES; CAENORHABDITIS-ELEGANS; SYNAPTOTAGMIN-I; NERVE-TERMINALS; MEMBRANE-FUSION; SINGLE; EXOCYTOSIS; SNARES	Synaptobrevin-2 (VAMP-2), the major SNARE protein of synaptic vesicles, is required for fast calcium-triggered synaptic-vesicle exocytosis. Here we show that synaptobrevin-2 is also essential for fast synaptic-vesicle endocytosis. We demonstrate that after depletion of the readily releasable vesicle pool, replenishment of the pool is delayed by knockout of synaptobrevin. This delay was not from a loss of vesicles, because the total number of pre-synaptic vesicles, docked vesicles and actively recycling vesicles was unaffected. However, altered shape and size of the vesicles in synaptobrevin-deficient synapses suggests a defect in endocytosis. Consistent with such a defect, the stimulus-dependent endocytosis of horseradish peroxidase and fluorescent FM1-43 were delayed, indicating that fast vesicle endocytosis may normally be nucleated by a SNARE-dependent coat. Thus, synaptobrevin is essential for two fast synapse-specific membrane trafficking reactions: fast exocytosis for neurotransmitter release and fast endocytosis that mediates rapid reuse of synaptic vesicles.	Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75390 USA.	thomas.sudhof@utsouthwestern.edu; ege.kavalali@utsouthwestern.edu	Schoch, Susanne/F-7741-2012; Deak, Ferenc/AAE-4324-2019		NIMH NIH HHS [MH066198] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH066198] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aravanis AM, 2003, NATURE, V423, P643, DOI 10.1038/nature01686; Betz WJ, 1996, CURR OPIN NEUROBIOL, V6, P365, DOI 10.1016/S0959-4388(96)80121-8; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; GALLI T, 2001, SCI STKE, V88, pRE1; Gandhi SP, 2003, NATURE, V423, P607, DOI 10.1038/nature01677; Gurunathan S, 2000, MOL BIOL CELL, V11, P3629, DOI 10.1091/mbc.11.10.3629; Harata N, 2001, TRENDS NEUROSCI, V24, P637, DOI 10.1016/S0166-2236(00)02030-0; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; Klingauf J, 1998, NATURE, V394, P581, DOI 10.1038/29079; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Murthy VN, 2003, ANNU REV NEUROSCI, V26, P701, DOI 10.1146/annurev.neuro.26.041002.131445; Nonet ML, 1999, MOL BIOL CELL, V10, P2343, DOI 10.1091/mbc.10.7.2343; Poskanzer KE, 2003, NATURE, V426, P559, DOI 10.1038/nature02184; Pyle JL, 2000, NEURON, V28, P221, DOI 10.1016/S0896-6273(00)00098-2; Richards DA, 2000, NEURON, V27, P551, DOI 10.1016/S0896-6273(00)00065-9; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; Sankaranarayanan S, 2001, NAT NEUROSCI, V4, P129, DOI 10.1038/83949; Sara Y, 2002, J NEUROSCI, V22, P1608, DOI 10.1523/JNEUROSCI.22-05-01608.2002; Schoch S, 2001, SCIENCE, V294, P1117, DOI 10.1126/science.1064335; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; Stevens CF, 2000, P NATL ACAD SCI USA, V97, P12828, DOI 10.1073/pnas.230438697; Sun JY, 2002, NATURE, V417, P555, DOI 10.1038/417555a; Virmani T, 2003, EMBO J, V22, P5347, DOI 10.1093/emboj/cdg514; von Poser C, 2000, J BIOL CHEM, V275, P30916, DOI 10.1074/jbc.M005559200; Washbourne P, 2002, NAT NEUROSCI, V5, P19, DOI 10.1038/nn783; Wu LG, 1996, NEURON, V17, P769, DOI 10.1016/S0896-6273(00)80208-1; Zhang B, 1998, NEURON, V21, P1465, DOI 10.1016/S0896-6273(00)80664-9; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	30	182	186	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2004	6	11					1102	U21		10.1038/ncb1185	http://dx.doi.org/10.1038/ncb1185			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	867BI	15475946				2022-12-25	WOS:000224816700015
J	Grinberg, I; Northrup, H; Ardinger, H; Prasad, C; Dobyns, WB; Millen, KJ				Grinberg, I; Northrup, H; Ardinger, H; Prasad, C; Dobyns, WB; Millen, KJ			Heterozygous deletion of the linked genes ZIC1 and ZIC4 is involved in Dandy-Walker malformation	NATURE GENETICS			English	Article							CEREBELLAR DEVELOPMENT; CLASSIFICATION	Dandy-Walker malformation (DWM; OMIM #220200) is a common but poorly understood congenital cerebellar malformation in humans. Through physical mapping of 3q2 interstitial deletions in several individuals with DWM, we defined the first critical region associated with DWM, encompassing two adjacent Zinc finger in cerebellum genes, ZIC1 and ZIC4. Mice with a heterozygous deletion of these two linked genes have a phenotype that closely resembles DWM, providing a mouse model for this malformation.	Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; Univ Texas, Sch Med, Dept Pediat Med Genet, Houston, TX USA; Univ Kansas, Dept Pediat, Kansas City, KS USA; London Hlth Sci Ctr, Dept Pediat, London, ON, Canada; London Hlth Sci Ctr, Med Genet Program SW Ontario, London, ON, Canada; Univ Chicago, Dept Neurol, Chicago, IL 60637 USA; Univ Chicago, Dept Pediat, Chicago, IL 60637 USA	University of Chicago; University of Texas System; University of Kansas; London Health Sciences Centre; London Health Sciences Centre; University of Chicago; University of Chicago	Millen, KJ (corresponding author), Univ Chicago, Dept Human Genet, Room 319 CLSC,920 E 58th St, Chicago, IL 60637 USA.	kmillen@genetics.bsd.uchicago.edu	Dobyns, William/AAI-2768-2020; Dobyns, William Brian/ABC-6525-2021	Dobyns, William/0000-0002-7681-2844; Millen, Kathleen/0000-0001-9978-675X				Anikster Y, 2001, NAT GENET, V28, P376, DOI 10.1038/ng576; Aruga J, 2002, J NEUROSCI, V22, P218, DOI 10.1523/JNEUROSCI.22-01-00218.2002; Aruga J, 1998, J NEUROSCI, V18, P284; Aruga J, 2002, DEV BIOL, V244, P329, DOI 10.1006/dbio.2002.0598; Aruga J, 1996, GENE, V172, P291, DOI 10.1016/0378-1119(96)00111-4; Chen XM, 1997, AM J PHYSIOL-RENAL, V272, pF299, DOI 10.1152/ajprenal.1997.272.3.F299; CHITAYAT D, 1994, AM J MED GENET, V52, P406, DOI 10.1002/ajmg.1320520404; Crisponi L, 2001, NAT GENET, V27, P159, DOI 10.1038/84781; Ebert PJ, 2003, DEVELOPMENT, V130, P1949, DOI 10.1242/dev.00419; MARIA BL, 1987, PEDIATR NEUROSCI, V13, P45, DOI 10.1159/000120300; MURRAY JC, 1985, CLIN GENET, V28, P272; Parisi MA, 2003, MOL GENET METAB, V80, P36, DOI 10.1016/j.ymgme.2003.08.010; Patel S, 2002, AM J NEURORADIOL, V23, P1074; Shim H, 2003, J NUTR, V133, p1527S, DOI 10.1093/jn/133.5.1527S; Sudha T, 2001, CLIN DYSMORPHOL, V10, P193, DOI 10.1097/00019605-200107000-00008	15	156	163	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2004	36	10					1053	1055		10.1038/ng1420	http://dx.doi.org/10.1038/ng1420			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	857YN	15338008	Bronze			2022-12-25	WOS:000224156500010
J	Dove, A				Dove, A			Redesigner drugs	NATURE BIOTECHNOLOGY			English	Article								Drug development is a risky business, and the final product can have serious, sometimes deadly flaws. But by focusing on fixing those flaws, companies are catapulting themselves to profitability.										CUNDY KC, 2004, J PHARM EXP THE 0624; Sundaram M, 2003, P NATL ACAD SCI USA, V100, P651, DOI 10.1073/pnas.252643299; Umana P, 1999, NAT BIOTECHNOL, V17, P176, DOI 10.1038/6179; *US FDA, 1992, FDAS POL STAT DEV NE; *US FDA, 2002, PREV DRUG INT FOC DR	5	2	2	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2004	22	8					953	957		10.1038/nbt0804-953	http://dx.doi.org/10.1038/nbt0804-953			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	842YB	15286643				2022-12-25	WOS:000223039500015
J	Delattre, M; Leidel, S; Wani, K; Baumer, K; Bamat, J; Schnabel, H; Feichtinger, R; Schnabel, R; Gonczy, P				Delattre, M; Leidel, S; Wani, K; Baumer, K; Bamat, J; Schnabel, H; Feichtinger, R; Schnabel, R; Gonczy, P			Centriolar SAS-5 is required for centrosome duplication in C-elegans	NATURE CELL BIOLOGY			English	Article							SPINDLE POLE BODY; CAENORHABDITIS-ELEGANS; MICROTUBULE ORGANIZATION; EPSILON-TUBULIN; HALF-BRIDGE; CELL-CYCLE; PROTEIN; COMPONENT; EMBRYO; MUTATIONS	Centrosomes, the major microtubule-organizing centres (MTOCs) of animal cells, are comprised of a pair of centrioles surrounded by pericentriolar material (PCM). Early in the cell cycle, there is a single centrosome, which duplicates during S-phase to direct bipolar spindle assembly during mitosis(1). Although crucial for proper cell division, the mechanisms that govern centrosome duplication are not fully understood. Here, we identify the Caenorhabditis elegans gene sas-5 as essential for daughter-centriole formation. SAS-5 is a coiled-coil protein that localizes primarily to centrioles. Fluorescence recovery after photobleaching (FRAP) experiments with green fluorescent protein (GFP) fused to SAS-5 (GFP-SAS-5) demonstrated that the protein shuttles between centrioles and the cytoplasm throughout the cell cycle. Analysis of mutant alleles revealed that the presence of SAS-5 at centrioles is crucial for daughter-centriole formation and that ZYG-1, a kinase that is also essential for this process(2), controls the distribution of SAS-5 to centrioles. Furthermore, partial RNA-interference (RNAi)-mediated inactivation experiments suggest that both sas-5 and zyg-1 are dose-dependent regulators of centrosome duplication.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; Tech Univ Carolo Wilhelmina Braunschweig, Inst Genet, D-38106 Braunschweig, Germany	Swiss Institute Experimental Cancer Research; Braunschweig University of Technology	Gonczy, P (corresponding author), Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland.	pierre.gonczy@isrec.unil.ch	Delattre, Marie/AAJ-1491-2020; Leidel, Sebastian/K-9507-2019; Delattre, Marie/CAG-5526-2022; Wani, Khursheed/AAH-9203-2021	Delattre, Marie/0000-0003-1640-0300; Leidel, Sebastian/0000-0002-0523-6325; Delattre, Marie/0000-0003-1640-0300; Gonczy, Pierre/0000-0002-6305-6883				Albertson DG, 1993, CHROMOSOME RES, V1, P15, DOI 10.1007/BF00710603; Bellanger JM, 2003, CURR BIOL, V13, P1488, DOI 10.1016/S0960-9822(03)00582-7; Chang P, 2003, NAT CELL BIOL, V5, P71, DOI 10.1038/ncb900; Chretien D, 1997, J STRUCT BIOL, V120, P117, DOI 10.1006/jsbi.1997.3928; Dutcher SK, 2002, MOL BIOL CELL, V13, P3859, DOI 10.1091/mbc.E02-04-0205; Gonczy P, 1999, J CELL BIOL, V144, P927, DOI 10.1083/jcb.144.5.927; Gonczy P, 2001, DEV CELL, V1, P363, DOI 10.1016/S1534-5807(01)00046-6; Hannak E, 2002, J CELL BIOL, V157, P591, DOI 10.1083/jcb.200202047; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Kemp CA, 2004, DEV CELL, V6, P511, DOI 10.1016/S1534-5807(04)00066-8; Kilmartin JV, 2003, J CELL BIOL, V162, P1211, DOI 10.1083/jcb.200307064; Kirkham M, 2003, CELL, V112, P575, DOI 10.1016/S0092-8674(03)00117-X; KURIYAMA R, 1981, J CELL BIOL, V91, P814, DOI 10.1083/jcb.91.3.814; Leidel S, 2003, DEV CELL, V4, P431, DOI 10.1016/S1534-5807(03)00062-5; Mathies LD, 2003, DEVELOPMENT, V130, P2881, DOI 10.1242/DEV.00483; Matthews LR, 1998, J CELL BIOL, V141, P1159, DOI 10.1083/jcb.141.5.1159; NELSON GA, 1978, DEV BIOL, V66, P386, DOI 10.1016/0012-1606(78)90247-6; O'Connell KF, 2001, CELL, V105, P547, DOI 10.1016/S0092-8674(01)00338-5; PAINTRAND M, 1992, J STRUCT BIOL, V108, P107, DOI 10.1016/1047-8477(92)90011-X; Paoletti A, 2003, MOL BIOL CELL, V14, P2793, DOI 10.1091/mbc.E02-10-0661; Pelletier L, 2004, CURR BIOL, V14, P863, DOI 10.1016/j.cub.2004.04.012; Piano F, 2000, CURR BIOL, V10, P1619, DOI 10.1016/S0960-9822(00)00869-1; Praitis V, 2001, GENETICS, V157, P1217; Reese KJ, 2000, MOL CELL, V6, P445, DOI 10.1016/S1097-2765(00)00043-5; Salisbury JL, 2002, CURR BIOL, V12, P1287, DOI 10.1016/S0960-9822(02)01019-9; SPANG A, 1993, J CELL BIOL, V123, P405, DOI 10.1083/jcb.123.2.405; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; WOLF N, 1978, J ULTRA MOL STRUCT R, V63, P155, DOI 10.1016/S0022-5320(78)80071-9; WOOD WB, 1980, DEV BIOL, V74, P446, DOI 10.1016/0012-1606(80)90445-5; Wright AJ, 2003, MOL BIOL CELL, V14, P4512, DOI 10.1091/mbc.E03-01-0017	30	121	126	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2004	6	7					656	664		10.1038/ncb1146	http://dx.doi.org/10.1038/ncb1146			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	834TX	15232593				2022-12-25	WOS:000222434900021
J	Eddy, SR				Eddy, SR			What is dynamic programming?	NATURE BIOTECHNOLOGY			English	Article									Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63108 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63108 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)	Eddy, SR (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, 4444 Forest Pk Blvd,Box 8510, St Louis, MO 63108 USA.	eddy@genetics.wustl.edu		Eddy, Sean/0000-0001-6676-4706				Bellman RE, 1984, EYE HURRICANE AUTOBI	1	69	75	3	39	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2004	22	7					909	910		10.1038/nbt0704-909	http://dx.doi.org/10.1038/nbt0704-909			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	836CO	15229554				2022-12-25	WOS:000222533000038
J	Rhodes, DR; Kalyana-Sundaram, S; Mahavisno, V; Barrette, TR; Ghosh, D; Chinnaiyan, AM				Rhodes, DR; Kalyana-Sundaram, S; Mahavisno, V; Barrette, TR; Ghosh, D; Chinnaiyan, AM			Mining for regulatory programs in the cancer transcriptome	NATURE GENETICS			English	Article							NEOPLASTIC TRANSFORMATION; MAMMALIAN EMBRYO; STEM-CELLS; N-MYC; C-MYC; GENE; EXPRESSION; PATTERNS; PROGRESSION; ACTIVATION	DNA microarrays have been widely applied to cancer transcriptome analysis. The Oncomine database contains a large collection of such data, as well as hundreds of derived gene-expression signatures. We studied the regulatory mechanisms responsible for gene deregulation in these cancer signatures by searching for the coordinate regulation of genes with common transcription factor binding sites. We found that genes with binding sites for the archetypal cancer transcription factor, E2F, were disproportionately overexpressed in a wide variety of cancers, whereas genes with binding sites for other transcription factors, such as Myc-Max, c-Rel and ATF, were disproportionately overexpressed in specific cancer types. These results suggest that alterations in pathways activating these transcription factors may be responsible for the observed gene deregulation and cancer pathogenesis.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Bioinformat Program, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biostat, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Chinnaiyan, AM (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.	arul@umich.edu	Kalyana-Sundaram, Shanker/F-6860-2012	Ghosh, Debashis/0000-0001-6618-1316; Kalyana-Sundaram, Shanker/0000-0002-7309-3848				Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Caamano J, 2002, CLIN MICROBIOL REV, V15, P414, DOI 10.1128/CMR.15.3.414-429.2002; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Chae HD, 2004, ONCOGENE, V23, P4084, DOI 10.1038/sj.onc.1207482; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Elkon R, 2003, GENOME RES, V13, P773, DOI 10.1101/gr.947203; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Houldsworth J, 2004, BLOOD, V103, P1862, DOI 10.1182/blood-2003-04-1359; Jean D, 2001, CRIT REV IMMUNOL, V21, P275; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; Keenan SM, 2004, J BIOL CHEM, V279, P5387, DOI 10.1074/jbc.M310383200; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; La Thangue NB, 2003, NAT CELL BIOL, V5, P587, DOI 10.1038/ncb0703-587; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Lossos IS, 2002, P NATL ACAD SCI USA, V99, P8886, DOI 10.1073/pnas.132253599; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; Muller M J, 2001, Obes Rev, V2, P15; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166-2236(98)01343-5; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434; SETH A, 1990, ONCOGENE, V5, P1761; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	36	138	148	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2005	37	6					579	583		10.1038/ng1578	http://dx.doi.org/10.1038/ng1578			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	931OT	15920519				2022-12-25	WOS:000229495300008
J	Rugg-Gunn, PJ; Ferguson-Smith, AC; Pedersen, RA				Rugg-Gunn, PJ; Ferguson-Smith, AC; Pedersen, RA			Epigenetic status of human embryonic stem cells	NATURE GENETICS			English	Article							IMPRINTED GENES; MOUSE EMBRYOS; EXPRESSION; CULTURE; H19; METHYLATION	We examined the allele-specific expression of six imprinted genes and the methylation profiles of three imprinting control regions to assess the epigenetic status of human embryonic stem cells. We identified generally monoallelic gene expression and normal methylation patterns. During prolonged passage, one cell line became biallelic with respect to H19, but without loss of the gametic methylation imprint. These data argue for a substantial degree of epigenetic stability in human embryonic stem cells.	Univ Cambridge, Dept Surg, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England	University of Cambridge; University of Cambridge	Rugg-Gunn, PJ (corresponding author), Univ Cambridge, Dept Surg, Cambridge Inst Med Res, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	pjr36@cam.ac.uk	Ferguson-Smith, Anne C/G-7534-2011	Ferguson-Smith, Anne/0000-0002-7608-5894; Rugg-Gunn, Peter/0000-0002-9601-5949	Medical Research Council [G0800784, G0100501] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Dean W, 1998, DEVELOPMENT, V125, P2273; Doherty AS, 2000, BIOL REPROD, V62, P1526, DOI 10.1095/biolreprod62.6.1526; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; GLENN CC, 1993, HUM MOL GENET, V2, P2001, DOI 10.1093/hmg/2.12.2001; Henderson JK, 2002, STEM CELLS, V20, P329, DOI 10.1634/stemcells.20-4-329; Humpherys D, 2001, SCIENCE, V293, P95, DOI 10.1126/science.1061402; Khosla S, 2001, BIOL REPROD, V64, P918, DOI 10.1095/biolreprod64.3.918; Lee MP, 1999, HUM MOL GENET, V8, P683, DOI 10.1093/hmg/8.4.683; Maher ER, 2003, HUM REPROD, V18, P2508, DOI 10.1093/humrep/deg486; Mann MRW, 2004, DEVELOPMENT, V131, P3727, DOI 10.1242/dev.01241; Onyango P, 2002, P NATL ACAD SCI USA, V99, P10599, DOI 10.1073/pnas.152327599; Sasaki H, 1995, DEVELOPMENT, V121, P4195; Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Young LE, 2001, NAT GENET, V27, P153, DOI 10.1038/84769	15	131	136	0	2	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2005	37	6					585	587		10.1038/ng1556	http://dx.doi.org/10.1038/ng1556			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	931OT	15864307				2022-12-25	WOS:000229495300009
J	Adams, DJ; Dermitzakis, ET; Cox, T; Smith, J; Davies, R; Banerjee, R; Bonfield, J; Mullikin, JC; Chung, YJ; Rogers, J; Bradley, A				Adams, DJ; Dermitzakis, ET; Cox, T; Smith, J; Davies, R; Banerjee, R; Bonfield, J; Mullikin, JC; Chung, YJ; Rogers, J; Bradley, A			Complex haplotypes, copy number polymorphisms and coding variation in two recently divergent mouse strains	NATURE GENETICS			English	Article							INBRED STRAINS; GENOME; MICE; EVOLUTION; MUTATIONS; DISCOVERY; GENES	Inbred mouse strains provide the foundation for mouse genetics. By selecting for phenotypic features of interest, inbreeding drives genomic evolution and eliminates individual variation, while fixing certain sets of alleles that are responsible for the trait characteristics of the strain. Mouse strains 129Sv (129S5) and C57BL/6J, two of the most widely used inbred lines, diverged from common ancestors within the last century(1-5), yet very little is known about the genomic differences between them. By comparative genomic hybridization and sequence analysis of 129S5 short insert libraries, we identified substantial structural variation, a complex fine-scale haplotype pattern with a continuous distribution of diversity blocks, and extensive nucleotide variation, including nonsynonymous coding SNPs and stop codons. Collectively, these genomic changes denote the level and direction of allele fixation that has occurred during inbreeding and provide a basis for defining what makes these mouse strains unique.	Wellcome Trust Sanger Inst, Hinxton CB10 1SA, Cambs, England; Univ Geneva, Sch Med, Dept Genet Med & Dev, CH-1211 Geneva, Switzerland; NHGRI, Bethesda, MD 20892 USA	Wellcome Trust Sanger Institute; University of Geneva; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Bradley, A (corresponding author), Wellcome Trust Sanger Inst, Hinxton CB10 1SA, Cambs, England.	abradley@sanger.ac.uk	Dermitzakis, Emmanouil/B-7687-2013	Davies, Robert/0000-0002-9983-1378; Bonfield, James/0000-0002-6447-4112; Smith, James/0000-0002-0445-8305; Bradley, Allan/0000-0002-2349-8839; Adams, David/0000-0001-9490-0306	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG200330, ZIAHG200330] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Adams DJ, 2004, NAT GENET, V36, P867, DOI 10.1038/ng1388; AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; ATTMAN PLK, 1979, INBRED GENETICALLY D, P1; ATWEH GF, 1985, NUCLEIC ACIDS RES, V13, P777, DOI 10.1093/nar/13.3.777; Auerbach W, 2000, BIOTECHNIQUES, V29, P1024, DOI 10.2144/00295st04; Beck JA, 2000, NAT GENET, V24, P23, DOI 10.1038/71641; Bernardi G, 2000, GENE, V259, P31, DOI 10.1016/S0378-1119(00)00441-8; Birney E, 2004, GENOME RES, V14, P925, DOI 10.1101/gr.1860604; BONHOMME F, 1987, BIOL J LINN SOC, V30, P51, DOI 10.1111/j.1095-8312.1987.tb00288.x; Chung YJ, 2004, GENOME RES, V14, P188, DOI 10.1101/gr.1878804; Dermitzakis ET, 2001, MOL BIOL EVOL, V18, P557, DOI 10.1093/oxfordjournals.molbev.a003835; Eichler EE, 2003, SCIENCE, V301, P793, DOI 10.1126/science.1086132; Force A, 1999, GENETICS, V151, P1531; Frazer KA, 2004, GENOME RES, V14, P1493, DOI 10.1101/gr.2627804; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Li JZ, 2004, NAT GENET, V36, P952, DOI 10.1038/ng1417; Lindblad-Toh K, 2000, NAT GENET, V24, P381, DOI 10.1038/74215; Ning ZM, 2001, GENOME RES, V11, P1725, DOI 10.1101/gr.194201; Silver L. M., 1995, MOUSE GENETICS; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; STEVENS LC, 1973, J NATL CANCER I, V50, P235, DOI 10.1093/jnci/50.1.235; Van der Weyden L, 2002, PHYSIOL GENOMICS, V11, P133, DOI 10.1152/physiolgenomics.00074.2002; Wade CM, 2002, NATURE, V420, P574, DOI 10.1038/nature01252; Wiltshire T, 2003, P NATL ACAD SCI USA, V100, P3380, DOI 10.1073/pnas.0130101100; Yalcin B, 2004, P NATL ACAD SCI USA, V101, P9734, DOI 10.1073/pnas.0401189101; Zeniou M, 2004, NUCLEIC ACIDS RES, V32, P1214, DOI 10.1093/nar/gkh272; Zheng BH, 1999, NUCLEIC ACIDS RES, V27, P2354, DOI 10.1093/nar/27.11.2354	28	56	58	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2005	37	5					532	536		10.1038/ng1551	http://dx.doi.org/10.1038/ng1551			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	922TU	15852006				2022-12-25	WOS:000228862300024
J	Becam, IE; Tanentzapf, G; Lepesant, JA; Brown, NH; Huynh, JR				Becam, IE; Tanentzapf, G; Lepesant, JA; Brown, NH; Huynh, JR			Integrin-independent repression of cadherin transcription by talin during axis formation in Drosophila	NATURE CELL BIOLOGY			English	Article							ADHESION; PROTEIN; MORPHOGENESIS; POLARITY; SITE	The Drosophila melanogaster anterior - posterior axis becomes polarized early during oogenesis by the posterior localization of the oocyte within the egg chamber. The invariant position of the oocyte is thought to be driven by an upregulation of the adhesion molecule DE-cadherin in the oocyte and the posterior somatic follicle cells, providing the first in vivo example of cell sorting that is specified by quantitative differences in cell - cell adhesion(1,2). However, it has remained unclear how DE-cadherin levels are regulated. Here, we show that talin, known for its role in linking integrins to the actin cytoskeleton, has the unexpected function of specifically inhibiting DE-cadherin transcription. Follicle cells that are mutant for talin show a strikingly high level of DE-cadherin, due to elevated transcription of DE-cadherin. We demonstrate that this deregulation of DE-cadherin is sufficient to attract the oocyte to lateral and anterior positions. Surprisingly, this function of talin is independent of integrins. These results uncover a new role for talin in regulating cadherin-mediated cell adhesion.	Univ Paris 06, CNRS, Inst Jacques Monod, F-75251 Paris, France; Univ Paris 07, CNRS, Inst Jacques Monod, F-75251 Paris, France; Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Anat, Cambridge CB2 1QR, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; University of Cambridge; University of Cambridge	Huynh, JR (corresponding author), Univ Paris 06, CNRS, Inst Jacques Monod, 2 Pl Jussieu, F-75251 Paris, France.	huynh@ijm.jussieu.fr	Tanentzapf, Guy/C-8864-2012	Tanentzapf, Guy/0000-0002-2443-233X; HUYNH, Jean-Rene/0000-0002-4078-399X; Brown, Nicholas/0000-0002-8958-7017				Avizienyte E, 2002, NAT CELL BIOL, V4, P632, DOI 10.1038/ncb829; Balda MS, 2003, TRENDS CELL BIOL, V13, P310, DOI 10.1016/S0962-8924(03)00105-3; Bateman J, 2001, CURR BIOL, V11, P1317, DOI 10.1016/S0960-9822(01)00420-1; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; Bokel C, 2002, DEV CELL, V3, P311, DOI 10.1016/S1534-5807(02)00265-4; Brown NH, 2002, DEV CELL, V3, P569, DOI 10.1016/S1534-5807(02)00290-3; BUNCH TA, 1992, GENETICS, V132, P519; CHOU TB, 1992, GENETICS, V131, P643; Cram EJ, 2004, TRENDS CELL BIOL, V14, P55, DOI 10.1016/j.tcb.2003.12.009; Cram EJ, 2003, J CELL SCI, V116, P3871, DOI 10.1242/jcs.00705; Devenport D, 2004, DEVELOPMENT, V131, P5405, DOI 10.1242/dev.01427; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; Godt D, 1998, NATURE, V395, P387, DOI 10.1038/26493; Gonzalez-Reyes A, 1998, DEVELOPMENT, V125, P3635; GONZALEZREYES A, 1994, SCIENCE, V266, P639, DOI 10.1126/science.7939717; Gottardi CJ, 2001, CURR BIOL, V11, pR792, DOI 10.1016/S0960-9822(01)00473-0; Huynh JR, 2004, CURR BIOL, V14, pR438, DOI 10.1016/j.cub.2004.05.040; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Li MA, 2003, NAT CELL BIOL, V5, P994, DOI 10.1038/ncb1058; Luschnig S, 2000, MOL CELL, V5, P231, DOI 10.1016/S1097-2765(00)80419-0; Nayal A, 2004, CURR OPIN CELL BIOL, V16, P94, DOI 10.1016/j.ceb.2003.11.007; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; Oda H, 2001, J CELL SCI, V114, P493; Pacquelet A, 2003, J CELL BIOL, V160, P313, DOI 10.1083/jcb.200207160; Pignoni F, 1997, DEVELOPMENT, V124, P271; Prout M, 1997, GENETICS, V146, P275; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; STEINBERG MS, 1994, P NATL ACAD SCI USA, V91, P206, DOI 10.1073/pnas.91.1.206; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; Tepass U, 2002, CURR OPIN GENET DEV, V12, P572, DOI 10.1016/S0959-437X(02)00342-8; Tepass U, 1996, GENE DEV, V10, P672, DOI 10.1101/gad.10.6.672; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Wodarz A, 2000, J CELL BIOL, V150, P1361, DOI 10.1083/jcb.150.6.1361	33	55	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2005	7	5					510	516		10.1038/ncb1253	http://dx.doi.org/10.1038/ncb1253			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	926LA	15852002	Green Submitted			2022-12-25	WOS:000229123500018
J	Kochi, Y; Yamada, R; Suzuki, A; Harley, JB; Shirasawa, S; Sawada, T; Bae, SC; Tokuhiro, S; Chang, XT; Sekine, A; Takahashi, A; Tsunoda, T; Ohnishi, Y; Kaufman, KM; Kang, CSP; Kang, CW; Otsubo, S; Yumura, W; Mimori, A; Koike, T; Nakamura, Y; Sasazuki, T; Yamamoto, K				Kochi, Y; Yamada, R; Suzuki, A; Harley, JB; Shirasawa, S; Sawada, T; Bae, SC; Tokuhiro, S; Chang, XT; Sekine, A; Takahashi, A; Tsunoda, T; Ohnishi, Y; Kaufman, KM; Kang, CSP; Kang, CW; Otsubo, S; Yumura, W; Mimori, A; Koike, T; Nakamura, Y; Sasazuki, T; Yamamoto, K			A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities	NATURE GENETICS			English	Article							REVISED CRITERIA; SUSCEPTIBILITY; GENE; POLYMORPHISMS; FAMILY; IDENTIFICATION; POPULATION; PSORIASIS; LOCI; CLASSIFICATION	Rheumatoid arthritis is a common autoimmune disease with a complex genetic etiology. Here we identify a SNP in the promoter region of FCRL3, a member of the Fc receptor-like family, that is associated with susceptibility to rheumatoid arthritis ( odds ratio = 2.15, P = 0.00000085). This polymorphism alters the binding affinity of nuclear factor-kappa B and regulates FCRL3 expression. We observed high FCRL3 expression on B cells and augmented autoantibody production in individuals with the disease-susceptible genotype. We also found associations between the SNP and susceptibility to autoimmune thyroid disease and systemic lupus erythematosus. FCRL3 may therefore have a pivotal role in autoimmunity.	RIKEN, SNP Res Ctr, Lab Rheumat Dis, Yokohama, Kanagawa 2300045, Japan; Univ Tokyo, Grad Sch Med, Dept Allergy & Rheumatol, Tokyo 1130033, Japan; Univ Oklahoma, Oklahoma City, OK 73104 USA; US Dept Vet Affairs, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA; Int Med Ctr Japan, Tokyo 1628655, Japan; Hanyang Univ, Hosp Rheumat Dis, Div Rheumatol, Dept Internal Med, Seoul 133792, South Korea; RIKEN, SNP Res Ctr, Lab SNP Anal, Yokohama, Kanagawa 2300045, Japan; RIKEN, SNP Res Ctr, Lab Genotyping, Yokohama, Kanagawa 2300045, Japan; RIKEN, SNP Res Ctr, Lab Med Informat, Yokohama, Kanagawa 2300045, Japan; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab, Tokyo 1088639, Japan; Tokyo Womens Med Univ, Kidney Ctr, Dept Med, Tokyo 1628666, Japan; Hokkaido Univ, Sch Med, Dept Med 2, Sapporo, Hokkaido 0608638, Japan; RIKEN, SNP Res Ctr, Res Grp Personalized Med, Yokohama, Kanagawa 2300045, Japan	RIKEN; University of Tokyo; University of Oklahoma System; University of Oklahoma Health Sciences Center; US Department of Veterans Affairs; Oklahoma Medical Research Foundation; National Center for Global Health & Medicine - Japan; Hanyang University; RIKEN; RIKEN; RIKEN; Korea Advanced Institute of Science & Technology (KAIST); University of Tokyo; Tokyo Women's Medical University; Hokkaido University; RIKEN	Yamada, R (corresponding author), RIKEN, SNP Res Ctr, Lab Rheumat Dis, Yokohama, Kanagawa 2300045, Japan.	ryamada@src.riken.go.jp	Kang, Changwon/C-1938-2011; Yamamoto, Kazuhiko/N-5096-2015; Tsunoda, Tatsuhiko/K-2061-2014; Suzuki, Akari/N-5389-2015; Kochi, Yuta/P-4487-2018; Sawed, Tetsuji/GRX-6582-2022	Kang, Changwon/0000-0002-0867-6385; Tsunoda, Tatsuhiko/0000-0002-5439-7918; Yamada, Ryo/0000-0002-1587-630X; Bae, Sang-Cheol/0000-0003-4658-1093	NCRR NIH HHS [P20 RR020143] Funding Source: Medline; NIAID NIH HHS [R01 AI024717] Funding Source: Medline; NIAMS NIH HHS [P01 AR049084, R01 AR042460] Funding Source: Medline; NIDCR NIH HHS [R01 DE015223] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024717] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042460, P01AR049084] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015223] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aikawa Y, 2002, INFLAMM RES, V51, P188, DOI 10.1007/PL00000291; ALARCON GS, 1990, ARTHRITIS RHEUM, V33, P1156; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Barton A, 2004, ARTHRITIS RHEUM, V50, P1117, DOI 10.1002/art.20169; Becker KG, 1998, P NATL ACAD SCI USA, V95, P9979, DOI 10.1073/pnas.95.17.9979; Begovich AB, 2004, AM J HUM GENET, V75, P330, DOI 10.1086/422827; Bowcock AM, 2004, HUM MOL GENET, V13, pR43, DOI 10.1093/hmg/ddh094; Capon F, 2001, J INVEST DERMATOL, V116, P728, DOI 10.1046/j.1523-1747.2001.01311.x; Capon F, 1999, AM J HUM GENET, V65, P1798, DOI 10.1086/302653; Cordell HJ, 2002, AM J HUM GENET, V70, P124, DOI 10.1086/338007; Dai KZ, 2001, GENES IMMUN, V2, P263, DOI 10.1038/sj.gene.6363774; Davis RS, 2001, P NATL ACAD SCI USA, V98, P9772, DOI 10.1073/pnas.171308498; Davis RS, 2002, IMMUNOL REV, V190, P123, DOI 10.1034/j.1600-065X.2002.19009.x; DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003; Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534; Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661; Gray D, 1997, Semin Immunol, V9, P249, DOI 10.1006/smim.1997.0077; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; Hatzivassiliou G, 2001, IMMUNITY, V14, P277, DOI 10.1016/S1074-7613(01)00109-1; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; Hoshinoso M, 1999, J BIOL CHEM, V274, P17837, DOI 10.1074/jbc.274.25.17837; Jirholt J, 1998, EUR J IMMUNOL, V28, P3321, DOI 10.1002/(SICI)1521-4141(199810)28:10<3321::AID-IMMU3321>3.0.CO;2-M; Jorgensen RA, 2004, PLANT CELL, V16, P787, DOI 10.1105/tpc.160490; Kaijzel EL, 2001, GENES IMMUN, V2, P135, DOI 10.1038/sj.gene.6363747; Kochi Y, 2004, ARTHRITIS RHEUM, V50, P63, DOI 10.1002/art.11366; Kyogoku C, 2002, ARTHRITIS RHEUM, V46, P1242, DOI 10.1002/art.10257; Marrack P, 2001, NAT MED, V7, P899, DOI 10.1038/90935; Miller I, 2002, BLOOD, V99, P2662, DOI 10.1182/blood.V99.8.2662; Newton JL, 2004, GENES IMMUN, V5, P151, DOI 10.1038/sj.gene.6364045; Nieto A, 2000, ARTHRITIS RHEUM, V43, P735, DOI 10.1002/1529-0131(200004)43:4<735::AID-ANR3>3.0.CO;2-Q; Podolin PL, 1997, J IMMUNOL, V159, P1835; Pritchard JK, 1999, AM J HUM GENET, V65, P220, DOI 10.1086/302449; Pritchard JK, 2000, GENETICS, V155, P945; Radstake TRDJ, 2003, J RHEUMATOL, V30, P926; Rantapaa-Dahlqvist S, 2003, ARTHRITIS RHEUM, V48, P2741, DOI 10.1002/art.11223; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; Sebastiani P, 2003, P NATL ACAD SCI USA, V100, P9900, DOI 10.1073/pnas.1633613100; Seldin MF, 1999, ARTHRITIS RHEUM, V42, P1071, DOI 10.1002/1529-0131(199906)42:6<1071::AID-ANR1>3.0.CO;2-8; SUNDVALL M, 1995, NAT GENET, V10, P313, DOI 10.1038/ng0795-313; Suzuki A, 2003, NAT GENET, V34, P395, DOI 10.1038/ng1206; Suzuki K, 2003, SCAND J RHEUMATOL, V32, P197, DOI 10.1080/03009740310003677; Takemura S, 2001, J IMMUNOL, V167, P1072, DOI 10.4049/jimmunol.167.2.1072; Teuscher C, 1997, J IMMUNOL, V159, P4930; Tokuhiro S, 2003, NAT GENET, V35, P341, DOI 10.1038/ng1267; Tsao BP, 2003, TRENDS IMMUNOL, V24, P595, DOI 10.1016/j.it.2003.09.006; Tsunoda T, 2004, HUM MOL GENET, V13, P1623, DOI 10.1093/hmg/ddh177; Ueda H, 2003, NATURE, V423, P506, DOI 10.1038/nature01621; van Eijk M, 2001, TRENDS IMMUNOL, V22, P677, DOI 10.1016/S1471-4906(01)02086-5; Weyand CM, 2003, ANN NY ACAD SCI, V987, P140, DOI 10.1111/j.1749-6632.2003.tb06042.x; Xu MJ, 2002, BIOCHEM BIOPH RES CO, V293, P1037, DOI 10.1016/S0006-291X(02)00332-7	50	287	314	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2005	37	5					478	485		10.1038/ng1540	http://dx.doi.org/10.1038/ng1540			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	922TU	15838509	Green Accepted			2022-12-25	WOS:000228862300016
J	Vega, H; Waisfisz, Q; Gordillo, M; Sakai, N; Yanagihara, I; Yamada, M; van Gosliga, D; Kayserili, H; Xu, CZ; Ozono, K; Jabs, EW; Inui, K; Joenje, H				Vega, H; Waisfisz, Q; Gordillo, M; Sakai, N; Yanagihara, I; Yamada, M; van Gosliga, D; Kayserili, H; Xu, CZ; Ozono, K; Jabs, EW; Inui, K; Joenje, H			Roberts syndrome is caused by mutations in ESCO2, a human homolog of yeast ECO1 that is essential for the establishment of sister chromatid cohesion	NATURE GENETICS			English	Article							SYNDROME FIBROBLASTS; DNA-REPLICATION; ACETYLTRANSFERASE; ABNORMALITIES	Roberts syndrome is an autosomal recessive disorder characterized by craniofacial anomalies, tetraphocomelia and loss of cohesion at heterochromatic regions of centromeres and the Y chromosome. We identified mutations in a new human gene, ESCO2, associated with Roberts syndrome in 15 kindreds. The ESCO2 protein product is a member of a conserved protein family that is required for the establishment of sister chromatid cohesion during S phase and has putative acetyltransferase activity.	Univ Nacl Colombia, Inst Genet, Bogota, Colombia; Osaka Univ, Grad Sch Med, Dept Dev Med Pediat D5, Suita, Osaka 5650871, Japan; Vrije Univ Amsterdam Med Ctr, Dept Clin Genet, NL-1081 BT Amsterdam, Netherlands; Johns Hopkins Univ, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA; Osaka Med Ctr Maternal & Child Hlth, Dept Dev Infect Dis, Res Inst, Osaka 5941101, Japan; Istanbul Univ, Istanbul Fac Med, Dept Med Genet, TR-34390 Istanbul, Turkey	Universidad Nacional de Colombia; Osaka University; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Johns Hopkins University; Istanbul University	Vega, H (corresponding author), Univ Nacl Colombia, Inst Genet, Ciudad Univ, Bogota, Colombia.	hhvegaf@unal.edu.co; ejabs1@jhem.jhmi.edu		Jabs, Ethylin/0000-0001-8983-5466; Waisfisz, Quinten/0000-0002-7384-9182	Telethon [GTF04002] Funding Source: Medline	Telethon(Fondazione Telethon)		Bellows AM, 2003, NUCLEIC ACIDS RES, V31, P6334, DOI 10.1093/nar/gkg811; BURNS MA, 1989, MUTAT RES, V216, P243, DOI 10.1016/0165-1161(89)90049-6; GERMAN J, 1979, CLIN GENET, V16, P441; Gimenez-Abian JF, 2004, CURR BIOL, V14, P1187, DOI 10.1016/j.cub.2004.06.052; Hoque MT, 2002, J BIOL CHEM, V277, P42306, DOI 10.1074/jbc.M206836200; Ivanov D, 2002, CURR BIOL, V12, P323, DOI 10.1016/S0960-9822(02)00681-4; JABS EW, 1991, CHROMOSOMA, V100, P251, DOI 10.1007/BF00344159; Petronczki M, 2003, CELL, V112, P423, DOI 10.1016/S0092-8674(03)00083-7; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; Tanaka K, 2000, MOL CELL BIOL, V20, P3459, DOI 10.1128/MCB.20.10.3459-3469.2000; TOMKINS D, 1979, AM J MED GENET, V4, P17, DOI 10.1002/ajmg.1320040104; TOMKINS DJ, 1984, AM J HUM GENET, V36, P1332; VANDENBERG DJ, 1993, AM J MED GENET, V47, P1104, DOI 10.1002/ajmg.1320470735; Williams BC, 2003, CURR BIOL, V13, P2025, DOI 10.1016/j.cub.2003.11.018	15	271	285	2	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2005	37	5					468	470		10.1038/ng1548	http://dx.doi.org/10.1038/ng1548			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	922TU	15821733				2022-12-25	WOS:000228862300014
J	Clemens, J; Jodar, L				Clemens, J; Jodar, L			Introducing new vaccines into developing countries: obstacles, opportunities and complexities	NATURE MEDICINE			English	Editorial Material							TRANSLATIONAL RESEARCH; IMMUNIZATION; VACCINATION; FUTURE; INFECTION; EFFICACY; CHILDREN; TRIAL	Infectious diseases are thought to account for nearly 25% of all deaths worldwide, and extract a disproportionate toll in developing countries(1). Moreover, infectious diseases are now appreciated to be major causes of the poverty and economic underdevelopment that characterize the world's poorest countries(2). Development and deployment of new vaccines to prevent infectious diseases in developing countries have therefore become high priorities in the global health agenda.	Intl Vaccine Inst, Seoul, South Korea		Clemens, J (corresponding author), Intl Vaccine Inst, Seoul, South Korea.	jclemens@ivi.int						Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1; [Anonymous], 2002, B WORLD HEALTH ORGAN, V80, P167; Batson A, 2003, VACCINE BOOK, P345; Clemens J, 1996, JAMA-J AM MED ASSOC, V275, P390, DOI 10.1001/jama.275.5.390; Clemens JD, 2004, J HEALTH POPUL NUTR, V22, P223; Clements CJ, 2004, VACCINE, V22, P2822, DOI 10.1016/j.vaccine.2004.01.002; DeRoeck D, 2003, VACCINE, V22, P121, DOI 10.1016/S0264-410X(03)00533-4; Esparza J, 2003, CURR MOL MED, V3, P183, DOI 10.2174/1566524033479825; Glass RI, 2004, LANCET, V363, P1547, DOI 10.1016/S0140-6736(04)16155-2; GOTUZZO E, 1993, INFECT IMMUN, V61, P3994, DOI 10.1128/IAI.61.9.3994-3997.1993; HANLON P, 1987, LANCET, V1, P1342; Hardon A, 2005, SOC SCI MED, V60, P345, DOI 10.1016/j.socscimed.2004.05.008; JOHN TJ, 1972, AM J EPIDEMIOL, V96, P263, DOI 10.1093/oxfordjournals.aje.a121457; Levine OS, 2004, J HEALTH POPUL NUTR, V22, P268; Mahoney R, 2004, J HEALTH POPUL NUTR, V22, P331; Mahoney RT, 1999, VACCINE, V17, P646, DOI 10.1016/S0264-410X(98)00246-1; Martin JF, 2003, VACCINE, V21, P587, DOI 10.1016/S0264-410X(02)00564-9; Milstien J, 2004, B WORLD HEALTH ORGAN, V82, P128; *NIH NAT I ALL INF, 2002, JORD REP 20 ANN ACC, P261; Salisbury DM, 1998, PEDIATR INFECT DIS J, V17, pS93, DOI 10.1097/00006454-199809001-00002; Taira AV, 2004, EMERG INFECT DIS, V10, P1915, DOI 10.3201/eid1011.040222; Webber D, 2001, B WORLD HEALTH ORGAN, V79, P735; WHO, 2003, WORLD HLTH REP; Widdus R, 2001, B WORLD HEALTH ORGAN, V79, P713	24	44	45	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2005	11	4		S			S12	S15		10.1038/nm1225	http://dx.doi.org/10.1038/nm1225			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	915VO	15812482				2022-12-25	WOS:000228339600005
J	Scaffidi, P; Misteli, T				Scaffidi, P; Misteli, T			(R)eversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome	NATURE MEDICINE			English	Article							A-TYPE LAMINS; ANTISENSE OLIGOMERS; MORPHOLINO; MUTATIONS; MISREGULATION; DEFECTS	Hutchinson-Gilford progeria syndrome (HGPS) is a childhood premature aging disease caused by a spontaneous point mutation in lamin A ( encoded by LMNA), one of the major architectural elements of the mammalian cell nucleus(1-4). The HGPS mutation activates an aberrant cryptic splice site in LMNA pre-mRNA, leading to synthesis of a truncated lamin A protein and concomitant reduction in wild-type lamin A(3,4). Fibroblasts from individuals with HGPS have severe morphological abnormalities in nuclear envelope structure. Here we show that the cellular disease phenotype is reversible in cells from individuals with HGPS. Introduction of wild-type lamin A protein does not rescue the cellular disease symptoms. The mutant LMNA mRNA and lamin A protein can be efficiently eliminated by correction of the aberrant splicing event using a modified oligonucleotide targeted to the activated cryptic splice site. Upon splicing correction, HGPS fibroblasts assume normal nuclear morphology, the aberrant nuclear distribution and cellular levels of lamina-associated proteins are rescued, defects in heterochromatin-specific histone modifications are corrected and proper expression of several misregulated genes is reestablished. Our results establish proof of principle for the correction of the premature aging phenotype in individuals with HGPS.	NCI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Misteli, T (corresponding author), NCI, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	mistelit@mail.nih.gov	Scaffidi, Paola/GRS-9019-2022	Scaffidi, Paola/0000-0002-3642-4193	NCI NIH HHS [Z01 BC010309-07] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010309, ZIABC010309] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Csoka AB, 2004, AGING CELL, V3, P235, DOI 10.1111/j.1474-9728.2004.00105.x; Csoka AB, 2004, J MED GENET, V41, P304, DOI 10.1136/jmg.2003.015651; De Sandre-Giovannoli A, 2003, SCIENCE, V300, P2055, DOI 10.1126/science.1084125; DEBUSK FL, 1972, J PEDIATR-US, V80, P697, DOI 10.1016/S0022-3476(72)80229-4; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; Garcia-Blanco MA, 2004, NAT BIOTECHNOL, V22, P535, DOI 10.1038/nbt964; Gebski BL, 2003, HUM MOL GENET, V12, P1801, DOI 10.1093/hmg/ddg196; Giles RV, 1999, ANTISENSE NUCLEIC A, V9, P213, DOI 10.1089/oli.1.1999.9.213; Goldman RD, 2004, P NATL ACAD SCI USA, V101, P8963, DOI 10.1073/pnas.0402943101; Holt I, 2003, J CELL SCI, V116, P3027, DOI 10.1242/jcs.00599; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnson BR, 2004, P NATL ACAD SCI USA, V101, P9677, DOI 10.1073/pnas.0403250101; LIN F, 1993, J BIOL CHEM, V268, P16321; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Moulton HM, 2004, BIOCONJUGATE CHEM, V15, P290, DOI 10.1021/bc034221g; Mounkes LC, 2003, NATURE, V423, P298, DOI 10.1038/nature01631; Sazani P, 2003, J CLIN INVEST, V112, P481, DOI 10.1172/JCI200319547; Summerton J, 1999, BBA-GENE STRUCT EXPR, V1489, P141, DOI 10.1016/S0167-4781(99)00150-5; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P63, DOI 10.1089/oli.1.1997.7.63; Uitto Jouni, 2002, Trends in Endocrinology and Metabolism, V13, P140, DOI 10.1016/S1043-2760(02)00595-7; Vaughan OA, 2001, J CELL SCI, V114, P2577; Ye QA, 1997, J BIOL CHEM, V272, P14983, DOI 10.1074/jbc.272.23.14983	22	420	445	3	45	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2005	11	4					440	445		10.1038/nm1204	http://dx.doi.org/10.1038/nm1204			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15750600	Green Accepted			2022-12-25	WOS:000228180500037
J	Schubert, C				Schubert, C			Oxygen sensor damages DNA	NATURE MEDICINE			English	News Item								Cancer cells often overexpress HIF 1-alpha (hypoxia inducible factor 1-alpha),a transcription factor that regulates responses to low oxygen and inhibits a complex of proteins that repair DNA, MutS-alpha. MutS-alpha consists of two proteins, MSH2 and MSH6. Expression studies have hinted that in sporadic colon cancer, HIF 1-alpha overexpression was associated with the loss of MSH2 expression.										Koshiji M, 2005, MOL CELL, V17, P793, DOI 10.1016/j.molcel.2005.02.015	1	0	0	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2005	11	4					385	385						1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15812519				2022-12-25	WOS:000228180500026
J	Taverne, D				Taverne, D			The new fundamentalism	NATURE BIOTECHNOLOGY			English	Editorial Material							GM CROPS; PLANTS					dicktaverne@hotmail.com						*5 YEAR FREEZ CAMP, WHY 5 YEAR FREEZ; [Anonymous], 2004, US GEN MOD CROPS DEV; Bates SL, 2005, NAT BIOTECHNOL, V23, P57, DOI 10.1038/nbt1056; CONWAY G, 2005, IN PRESS GMOS ECOLOG; CRICHTON M, 2003, COMMUNICATION   0915; Giddings G, 2000, NAT BIOTECHNOL, V18, P1151, DOI 10.1038/81132; *INT SERV ACQ AGR, 2005, GLOB STAT BIOT CROPS; Losey JE, 1999, NATURE, V399, P214, DOI 10.1038/20338; Lucca P, 2002, J AM COLL NUTR, V21, p184S, DOI 10.1080/07315724.2002.10719264; Ma JKC, 2003, NAT REV GENET, V4, P794, DOI 10.1038/nrg1177; Peterson RKD, 2004, TRENDS BIOTECHNOL, V22, P64, DOI 10.1016/j.tibtech.2003.11.007; Potrykus I, 2001, PLANT PHYSIOL, V125, P1157, DOI 10.1104/pp.125.3.1157; Shelton AM, 2001, PLANT J, V27, P483, DOI 10.1046/j.1365-313X.2001.01118.x; Trewavas AJ, 2001, EMBO REP, V2, P455, DOI 10.1093/embo-reports/kve123; Zhang HX, 2001, NAT BIOTECHNOL, V19, P765, DOI 10.1038/90824; [No title captured]	16	9	9	0	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2005	23	4					415	416		10.1038/nbt0405-415	http://dx.doi.org/10.1038/nbt0405-415			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	914AR	15815661				2022-12-25	WOS:000228197300013
J	Zhang, R; Khoo, MSC; Wu, YJ; Yang, YB; Grueter, CE; Ni, GM; Price, EE; Thiel, W; Guatimosim, S; Song, LS; Madu, EC; Shah, AN; Vishnivetskaya, TA; Atkinson, JB; Gurevich, VV; Salama, G; Lederer, WJ; Colbran, RJ; Anderson, ME				Zhang, R; Khoo, MSC; Wu, YJ; Yang, YB; Grueter, CE; Ni, GM; Price, EE; Thiel, W; Guatimosim, S; Song, LS; Madu, EC; Shah, AN; Vishnivetskaya, TA; Atkinson, JB; Gurevich, VV; Salama, G; Lederer, WJ; Colbran, RJ; Anderson, ME			Calmodulin kinase II inhibition protects against structural heart disease	NATURE MEDICINE			English	Article							CARDIAC RYANODINE RECEPTOR; VENTRICULAR MYOCYTES; SER(16) PHOSPHORYLATION; DILATED CARDIOMYOPATHY; DEPENDENT FACILITATION; CALCIUM-CHANNELS; ANGIOTENSIN-II; CA2+ CURRENT; EXCITATION; FAILURE	beta-Adrenergic receptor (beta AR) stimulation increases cytosolic Ca2+ to physiologically augment cardiac contraction, whereas excessive beta AR activation causes adverse cardiac remodeling, including myocardial hypertrophy, dilation and dysfunction, in individuals with myocardial infarction. The Ca2+-calmodulin-dependent protein kinase II ( CaMKII) is a recently identified downstream element of the beta AR-initiated signaling cascade that is linked to pathological myocardial remodeling and to regulation of key proteins involved in cardiac excitation-contraction coupling. We developed a genetic mouse model of cardiac CaMKII inhibition to test the role of CaMKII in beta AR signaling in vivo. Here we show CaMKII inhibition substantially prevented maladaptive remodeling from excessive beta AR stimulation and myocardial infarction, and induced balanced changes in excitation-contraction coupling that preserved baseline and beta AR-stimulated physiological increases in cardiac function. These findings mark CaMKII as a determinant of clinically important heart disease phenotypes, and suggest CaMKII inhibition can be a highly selective approach for targeting adverse myocardial remodeling linked to beta AR signaling.	Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, Baltimore, MD 21021 USA; Univ Fed Minas Gerais, Dept Physiol & Biophys, BR-31270901 Belo Horizonte, MG, Brazil; Univ Pittsburgh, Sch Med, Dept Cell Biol, Pittsburgh, PA 15261 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; University System of Maryland; University of Maryland Baltimore; Universidade Federal de Minas Gerais; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Vanderbilt University	Anderson, ME (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, 2220 Pierce Ave, Nashville, TN 37232 USA.	mark.anderson@vanderbilt.edu	Salama, Guy/GWQ-9862-2022; Guatimosim, Silvia/AAN-7441-2021; Vishnivetskaya, Tatiana/A-4488-2008; Song, Long-Sheng/D-5899-2012; Gurevich, Vsevolod/A-3236-2008; Colbran, Roger/AAU-7708-2021; Lederer, William/B-1285-2010	Guatimosim, Silvia/0000-0001-8386-3722; Vishnivetskaya, Tatiana/0000-0002-0660-023X; Gurevich, Vsevolod/0000-0002-3950-5351; Colbran, Roger/0000-0001-7401-8244; MADU, ERNEST/0000-0001-5739-2816; Grueter, Chad/0000-0001-8950-742X; Song, Long-Sheng/0000-0002-6035-8106; Thiel, William/0000-0002-2372-2925	NEI NIH HHS [EY11500] Funding Source: Medline; NHLBI NIH HHS [HL070250, HL046681, HL70709, HL70511, HL67849, HL25675, HL36974] Funding Source: Medline; NIGMS NIH HHS [GM63097] Funding Source: Medline; NIMH NIH HHS [MH63232] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046681, R01HL070250, R01HL025675, R01HL070511, P01HL067849, R01HL036974, P01HL070709, R37HL036974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063097] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alseikhan BA, 2002, P NATL ACAD SCI USA, V99, P17185, DOI 10.1073/pnas.262372999; ANDERSON ME, 1994, CIRC RES, V75, P854, DOI 10.1161/01.RES.75.5.854; Bauman AL, 2002, NAT CELL BIOL, V4, pE203, DOI 10.1038/ncb0802-e203; Benedict CR, 1996, CIRCULATION, V94, P690, DOI 10.1161/01.CIR.94.4.690; Benitah JP, 1999, CIRC RES, V85, P1139; BENJAMIN IJ, 1989, CIRC RES, V65, P657, DOI 10.1161/01.RES.65.3.657; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; BRAUN AP, 1995, J PHYSIOL-LONDON, V488, P37, DOI 10.1113/jphysiol.1995.sp020944; Cannon WB, 1911, AM J PHYSIOL, V28, P64, DOI 10.1152/ajplegacy.1911.28.1.64; CHAO SH, 1984, MOL PHARMACOL, V26, P75; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; Choi BR, 1998, AM J PHYSIOL-HEART C, V274, pH829, DOI 10.1152/ajpheart.1998.274.3.H829; Chu GX, 2000, J BIOL CHEM, V275, P38938, DOI 10.1074/jbc.M004079200; Chu L, 2003, CIRC RES, V92, P1024, DOI 10.1161/01.RES.0000070595.10196.CF; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Currie S, 2004, BIOCHEM J, V377, P357, DOI 10.1042/BJ20031043; Doughty RN, 1997, J AM COLL CARDIOL, V29, P1060, DOI 10.1016/S0735-1097(97)00012-0; DRAGO GA, 1994, J BIOL CHEM, V269, P25073; Dzhura I, 2000, NAT CELL BIOL, V2, P173, DOI 10.1038/35004052; FABIATO A, 1975, J PHYSIOL-LONDON, V249, P469, DOI 10.1113/jphysiol.1975.sp011026; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gomez AM, 1997, SCIENCE, V276, P800, DOI 10.1126/science.276.5313.800; GWATHMEY JK, 1987, CIRC RES, V61, P70, DOI 10.1161/01.RES.61.1.70; HADLEY RW, 1991, J GEN PHYSIOL, V98, P265, DOI 10.1085/jgp.98.2.265; Hagemann D, 2000, J BIOL CHEM, V275, P22532, DOI 10.1074/jbc.C000253200; Hjalmarson A, 1999, LANCET, V353, P2001; Hoch B, 1999, CIRC RES, V84, P713, DOI 10.1161/01.RES.84.6.713; Huang WY, 2000, NAT MED, V6, P482, DOI 10.1038/74914; Hudmon A, 2002, BIOCHEM J, V364, P593, DOI 10.1042/BJ20020228; Ichihara S, 2002, CIRCULATION, V106, P2244, DOI 10.1161/01.CIR.0000033826.52681.37; Jessup M, 2003, NEW ENGL J MED, V348, P2007, DOI 10.1056/NEJMra021498; Kudej RK, 1997, J MOL CELL CARDIOL, V29, P2735, DOI 10.1006/jmcc.1997.0508; Maier LS, 2003, CIRC RES, V92, P904, DOI 10.1161/01.RES.0000069685.20258.F1; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Muth JN, 2001, CIRCULATION, V103, P140; Pan L, 2003, J BIOL CHEM, V278, P11623, DOI 10.1074/jbc.M209532200; Patberg KW, 2003, CIRC RES, V93, P472, DOI 10.1161/01.RES.0000088785.24381.2F; Ramirez MT, 1997, J BIOL CHEM, V272, P31203, DOI 10.1074/jbc.272.49.31203; Rodriguez P, 2003, J BIOL CHEM, V278, P38593, DOI 10.1074/jbc.C301180200; Rottman JN, 2003, J AM SOC ECHOCARDIOG, V16, P1150, DOI 10.1067/S0894-7317(03)00471-1; Sah R, 2001, J PHYSIOL-LONDON, V533, P201, DOI 10.1111/j.1469-7793.2001.0201b.x; Vinogradova TM, 2000, CIRC RES, V87, P760, DOI 10.1161/01.RES.87.9.760; Wehrens XHT, 2004, CIRC RES, V94, pE61, DOI 10.1161/01.RES.0000125626.33738.E2; Wu YJ, 2002, CIRCULATION, V106, P1288, DOI 10.1161/01.CIR.0000027583.73268.E7; Wu YJ, 2001, P NATL ACAD SCI USA, V98, P2877, DOI 10.1073/pnas.051449198; XIAO RP, 1994, P NATL ACAD SCI USA, V91, P9659, DOI 10.1073/pnas.91.20.9659; YUAN WL, 1994, AM J PHYSIOL, V267, pH982, DOI 10.1152/ajpheart.1994.267.3.H982; YUE DT, 1990, P NATL ACAD SCI USA, V87, P753, DOI 10.1073/pnas.87.2.753; Zhang T, 2003, CIRC RES, V92, P912, DOI 10.1161/01.RES.0000069686.31472.C5; Zhu WZ, 2003, J CLIN INVEST, V111, P617, DOI 10.1172/JCI200316326	50	445	471	0	36	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2005	11	4					409	417		10.1038/nm1215	http://dx.doi.org/10.1038/nm1215			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15793582				2022-12-25	WOS:000228180500032
J	Harada, M; Qin, YJ; Takano, H; Minamino, T; Zou, YZ; Toko, H; Ohtsuka, M; Matsuura, K; Sano, M; Nishi, J; Iwanaga, K; Akazawa, H; Kunieda, T; Zhu, WD; Hasegawa, H; Kunisada, K; Nagai, T; Nakaya, H; Yamauchi-Takihara, K; Komuro, I				Harada, M; Qin, YJ; Takano, H; Minamino, T; Zou, YZ; Toko, H; Ohtsuka, M; Matsuura, K; Sano, M; Nishi, J; Iwanaga, K; Akazawa, H; Kunieda, T; Zhu, WD; Hasegawa, H; Kunisada, K; Nagai, T; Nakaya, H; Yamauchi-Takihara, K; Komuro, I			G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes	NATURE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM-CELLS; ISCHEMIC-MYOCARDIUM; SIGNAL TRANSDUCER; ANNEXIN-V; REGENERATION; PROTEINS; SURVIVAL; RECEPTOR; NEOVASCULARIZATION	Granulocyte colony-stimulating factor (G-CSF) was reported to induce myocardial regeneration by promoting mobilization of bone marrow stem cells to the injured heart after myocardial infarction, but the precise mechanisms of the beneficial effects of G-CSF are not fully understood. Here we show that G-CSF acts directly on cardiomyocytes and promotes their survival after myocardial infarction. G-CSF receptor was expressed on cardiomyocytes and G-CSF activated the Jak/Stat pathway in cardiomyocytes. The G-CSF treatment did not affect initial infarct size at 3 d but improved cardiac function as early as 1 week after myocardial infarction. Moreover, the beneficial effects of G-CSF on cardiac function were reduced by delayed start of the treatment. G-CSF induced antiapoptotic proteins and inhibited apoptotic death of cardiomyocytes in the infarcted hearts. G-CSF also reduced apoptosis of endothelial cells and increased vascularization in the infarcted hearts, further protecting against ischemic injury. All these effects of G-CSF on infarcted hearts were abolished by overexpression of a dominant-negative mutant Stat3 protein in cardiomyocytes. These results suggest that G-CSF promotes survival of cardiac myocytes and prevents left ventricular remodeling after myocardial infarction through the functional communication between cardiomyocytes and noncardiomyocytes.	Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, Chiba 2608670, Japan; Osaka Univ, Sch Med, Dept Mol Med, Suita, Osaka 5650871, Japan; Chiba Univ, Grad Sch Med, Dept Pharmacol, Chuo Ku, Chiba 2608670, Japan	Chiba University; Osaka University; Chiba University	Komuro, I (corresponding author), Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	komuro-tky@umin.ac.jp	Minamino, Tohru/P-8145-2018	Minamino, Tohru/0000-0003-1627-6151; Akazawa, Hiroshi/0000-0002-3574-9607				Aarts LHJ, 2004, BLOOD, V103, P571, DOI 10.1182/blood-2003-07-2250; Adachia Y, 2004, J MOL CELL CARDIOL, V36, P707, DOI 10.1016/j.yjmcc.2004.03.005; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Avalos BR, 1996, BLOOD, V88, P761, DOI 10.1182/blood.V88.3.761.bloodjournal883761; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; BERLINER N, 1995, BLOOD, V85, P799, DOI 10.1182/blood.V85.3.799.bloodjournal853799; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; DEMETRI GD, 1991, BLOOD, V78, P2791; Dumont EAWJ, 2000, CIRCULATION, V102, P1564, DOI 10.1161/01.CIR.102.13.1564; El-Adawi H, 2003, CARDIOVASC RES, V57, P129, DOI 10.1016/S0008-6363(02)00614-4; Funamoto M, 2000, J BIOL CHEM, V275, P10561, DOI 10.1074/jbc.275.14.10561; Ikeda K, 2000, LIFE SCI, V67, P2991, DOI 10.1016/S0024-3205(00)00879-1; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Kawada H, 2004, BLOOD, V104, P3581, DOI 10.1182/blood-2004-04-1488; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Matsuura K, 2004, J BIOL CHEM, V279, P11384, DOI 10.1074/jbc.M310822200; Minatoguchi S, 2004, CIRCULATION, V109, P2572, DOI 10.1161/01.CIR.0000129770.93985.3E; Moon C, 2003, P NATL ACAD SCI USA, V100, P11612, DOI 10.1073/pnas.1930406100; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Norol F, 2003, BLOOD, V102, P4361, DOI 10.1182/blood-2003-03-0685; Ohtsuka M, 2004, FASEB J, V18, P851, DOI 10.1096/fj.03-0637fje; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Parsa CJ, 2003, J CLIN INVEST, V112, P999, DOI 10.1172/JCI200318200; Smithgall TE, 2000, ONCOGENE, V19, P2612, DOI 10.1038/sj.onc.1203477; van Heerde WL, 2000, CARDIOVASC RES, V45, P549, DOI 10.1016/S0008-6363(99)00396-X; Zou YZ, 2003, CIRCULATION, V108, P748, DOI 10.1161/01.CIR.0000081773.76337.44; Zou YZ, 1999, J BIOL CHEM, V274, P9760, DOI 10.1074/jbc.274.14.9760	29	452	483	0	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					305	311		10.1038/nm1199	http://dx.doi.org/10.1038/nm1199			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15723072				2022-12-25	WOS:000227541300026
J	Jonker, JW; Merino, G; Musters, S; van Herwaarden, AE; Bolscher, E; Wagenaar, E; Mesman, E; Dale, TC; Schinkel, AH				Jonker, JW; Merino, G; Musters, S; van Herwaarden, AE; Bolscher, E; Wagenaar, E; Mesman, E; Dale, TC; Schinkel, AH			The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk	NATURE MEDICINE			English	Article							DIETARY CARCINOGEN; FOOD MUTAGEN; TRANSPORT; CELLS; CIMETIDINE; EXPOSURE; HIV-1; RATS	Contamination of milk with drugs, pesticides and other xenotoxins can pose a major health risk to breast-fed infants and dairy consumers. Here we show that the multidrug transporter BCRP (encoded by ABCG2) is strongly induced in the mammary gland of mice, cows and humans during lactation and that it is responsible for the active secretion of clinically and toxicologically important substrates such as the dietary carcinogen PhIP, the anticancer drug topotecan and the antiulcerative cimetidine into mouse milk.	Netherlands Canc Inst, Div Expt Therapy, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Expt Anim Pathol, NL-1066 CX Amsterdam, Netherlands; Univ Wales Coll Cardiff, Sch Biosci, Cardiff CF10 3US, S Glam, Wales	Netherlands Cancer Institute; Netherlands Cancer Institute; Cardiff University	Schinkel, AH (corresponding author), Netherlands Canc Inst, Div Expt Therapy, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	a.schinkel@nki.nl	Dale, Trevor C/D-3749-2009; Herwaarden, A.E./L-4369-2015; Jonker, Johan W./ABE-6853-2020; Merino, Gracia/H-8811-2015	Dale, Trevor C/0000-0002-4880-9963; Jonker, Johan W./0000-0002-3919-5437; Merino, Gracia/0000-0002-7620-3475				Alcorn J, 2002, ANTIMICROB AGENTS CH, V46, P1831, DOI 10.1128/AAC.46.6.1831-1836.2002; ANDERSON PO, 1991, CLIN PHARMACY, V10, P594; Boelaert JR, 2001, AIDS, V15, P2205, DOI 10.1097/00002030-200111090-00024; Chen ZS, 2003, CANCER RES, V63, P4048; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; JAGERSTAD IM, 1994, CARCINOGENESIS, V15, P2479, DOI 10.1093/carcin/15.11.2479; Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599; Martin FL, 2000, CARCINOGENESIS, V21, P799, DOI 10.1093/carcin/21.4.799; McNamara PJ, 1996, J PHARMACOL EXP THER, V277, P1615; Paulsen JE, 1999, CARCINOGENESIS, V20, P1277, DOI 10.1093/carcin/20.7.1277; Pavek P, 2005, J PHARMACOL EXP THER, V312, P144, DOI 10.1124/jpet.104.073916; Shennan DB, 2000, PHYSIOL REV, V80, P925, DOI 10.1152/physrev.2000.80.3.925; Suzuki M, 2003, J BIOL CHEM, V278, P22644, DOI 10.1074/jbc.M212399200; van Herwaarden AE, 2003, CANCER RES, V63, P6447; Wang X, 2003, MOL PHARMACOL, V63, P65, DOI 10.1124/mol.63.1.65	15	326	336	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					127	129		10.1038/nm1186	http://dx.doi.org/10.1038/nm1186			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15685169				2022-12-25	WOS:000226797300018
J	Amendola, M; Venneri, MA; Biffi, A; Vigna, E; Naldini, L				Amendola, M; Venneri, MA; Biffi, A; Vigna, E; Naldini, L			Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters	NATURE BIOTECHNOLOGY			English	Article							HEMATOPOIETIC STEM-CELLS; HUMAN GENOME; TRANSCRIPTIONAL ACTIVITY; RETROVIRAL VECTOR; EXPRESSION; TRANSLATION; SEQUENCES; SITES; TRANSPLANTATION; TRANSMISSION	Transferring multiple genes into the same cell allows for the combination of genetic correction, marking, selection and conditional elimination of transduced cells or the reconstitution of multisubunit components and synergistic pathways. However, this cannot be reliably accomplished by current gene transfer technologies. Based on the finding that some cellular promoters intrinsically promote divergent transcription, we have developed synthetic bidirectional promoters that mediate coordinate transcription of two mRNAs in a ubiquitous or a tissue-specific manner. Lentiviral vectors incorporating the new promoters enabled efficient dual gene transfer in several tissues in vivo after direct delivery or transgenesis, and in a human gene therapy model. Because divergent gene pairs, likely transcribed from shared promoters, are common in the genome, the synthetic promoters that we developed may mimic a well-represented feature of transcription. Vectors incorporating these promoters should increase the power of gene function studies and expand the reach and safety of gene therapy.	San Raffaele Telethon Inst Gene Therapy HSR TIGET, I-20132 Milan, Italy; Vita Salute San Raffaele Univ, San Raffaele Sci Inst, I-20132 Milan, Italy; Univ Turin, Sch Med, Inst Canc Res & Treatment, I-10060 Turin, Italy	Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Turin	Naldini, L (corresponding author), San Raffaele Telethon Inst Gene Therapy HSR TIGET, Via Olgettina 58, I-20132 Milan, Italy.	naldini.luigi@hsr.it	Biffi, Alessandra/AAA-8890-2019; Naldini, Luigi/E-9083-2012; amendola, mario/I-1728-2017	amendola, mario/0000-0002-1188-8856; NALDINI, Luigi/0000-0002-7835-527X; Vigna, Elisa/0000-0001-9787-5732; VENNERI, MARY ANNA/0000-0002-0687-8135	Telethon [TGT03D01, TGT06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		Adachi N, 2002, CELL, V109, P807, DOI 10.1016/S0092-8674(02)00758-4; Ailles L, 2002, MOL THER, V6, P615, DOI 10.1006/mthe.2002.0720; BARON U, 1995, NUCLEIC ACIDS RES, V23, P3605, DOI 10.1093/nar/23.17.3605; Biffi A, 2004, J CLIN INVEST, V113, P1118, DOI 10.1172/JCI200419205; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; Cavalieri S, 2003, BLOOD, V102, P497, DOI 10.1182/blood-2003-01-0297; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; de Felipe P, 2004, TRAFFIC, V5, P616, DOI 10.1111/j.1398-9219.2004.00205.x; De Palma M, 2003, NAT MED, V9, P789, DOI 10.1038/nm871; EMERMAN M, 1986, MOL CELL BIOL, V6, P792, DOI 10.1128/MCB.6.3.792; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Furler S, 2001, GENE THER, V8, P864, DOI 10.1038/sj.gt.3301469; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Hennecke M, 2001, NUCLEIC ACIDS RES, V29, P3327, DOI 10.1093/nar/29.16.3327; JOHNSON P, 1990, GENE, V88, P207, DOI 10.1016/0378-1119(90)90033-N; Kay MA, 2001, NAT MED, V7, P33, DOI 10.1038/83324; Klump H, 2001, GENE THER, V8, P811, DOI 10.1038/sj.gt.3301447; Kozak M, 2003, GENE, V318, P1, DOI 10.1016/S0378-1119(03)00774-1; LAVIA P, 1987, EMBO J, V6, P2773, DOI 10.1002/j.1460-2075.1987.tb02572.x; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Martinez-Salas E, 1999, CURR OPIN BIOTECH, V10, P458, DOI 10.1016/S0958-1669(99)00010-5; MILLER AD, 2000, RETROVIRUSES, P437; Mizuguchi H, 2000, MOL THER, V1, P376, DOI 10.1006/mthe.2000.0050; Qiao J, 2002, HUM GENE THER, V13, P881, DOI 10.1089/10430340252899046; Scacheri PC, 2001, GENESIS, V30, P259, DOI 10.1002/gene.1072; Sokolic RA, 1996, BLOOD, V87, P42, DOI 10.1182/blood.V87.1.42.bloodjournal87142; Szymczak AL, 2004, NAT BIOTECHNOL, V22, P589, DOI 10.1038/nbt957; Takai D, 2004, MOL BIOL EVOL, V21, P463, DOI 10.1093/molbev/msh040; Taveau M, 2004, GENOMICS, V84, P592, DOI 10.1016/j.ygeno.2004.04.011; Trinklein ND, 2004, GENOME RES, V14, P62, DOI 10.1101/gr.1982804; Unsinger J, 2001, MOL THER, V4, P484, DOI 10.1006/mthe.2001.0480; Xie MT, 2001, NAT BIOTECHNOL, V19, P677, DOI 10.1038/90296	32	247	279	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2005	23	1					108	116		10.1038/nbt1049	http://dx.doi.org/10.1038/nbt1049			9	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	885ZK	15619618				2022-12-25	WOS:000226195700037
J	Bitko, V; Musiyenko, A; Shulyayeva, O; Barik, S				Bitko, V; Musiyenko, A; Shulyayeva, O; Barik, S			Inhibition of respiratory viruses by nasally administered siRNA	NATURE MEDICINE			English	Article							SYNCYTIAL VIRUS; RNA INTERFERENCE; F-PROTEIN; GENE-EXPRESSION; INFECTED MICE; DISEASE; TYPE-3; FUSION; MODEL; ACTIN	Respiratory syncytial virus (RSV) and parainfluenza virus (PIV) are two respiratory pathogens of paramount medical significance that exert high mortality. At present, there is no reliable vaccine or antiviral drug against either virus. Using an RNA interference (RNAi) approach, we show that individual as well as joint infection by RSV and PIV can be specifically prevented and inhibited by short interfering RNAs (siRNAs), instilled intranasally in the mouse, with or without transfection reagents. The degree of protection matched the antiviral activity of the siRNA in cell culture, allowing an avenue for quick screening of an efficacious siRNA. When targeting both viruses in a joint infection, excess of one siRNA moderated the inhibitory effect of the other, suggesting competition for the RNAi machinery. Our results suggest that, if properly designed, low dosages of inhaled siRNA might offer a fast, potent and easily administrable antiviral regimen against respiratory viral diseases in humans.	Univ S Alabama, Coll Med, Dept Biochem & Mol Biol, Mobile, AL 36688 USA	University of South Alabama	Barik, S (corresponding author), Univ S Alabama, Coll Med, Dept Biochem & Mol Biol, MSB 2370,307 Univ Blvd, Mobile, AL 36688 USA.	sbarik@jaguar1.usouthal.edu			NATIONAL EYE INSTITUTE [R01EY013826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI049682] Funding Source: NIH RePORTER; NEI NIH HHS [EY013826] Funding Source: Medline; NIAID NIH HHS [AI049682] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barik S, 2004, VIRUS RES, V102, P27, DOI 10.1016/j.virusres.2004.01.012; Bernhard W, 2001, AM J RESP CELL MOL, V25, P725, DOI 10.1165/ajrcmb.25.6.4616; Bitko V, 2001, BMC Microbiol, V1, P34, DOI 10.1186/1471-2180-1-34; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Burke E, 2000, J VIROL, V74, P669, DOI 10.1128/JVI.74.2.669-675.2000; Burke E, 1998, VIROLOGY, V252, P137, DOI 10.1006/viro.1998.9471; Coiras MT, 2004, J MED VIROL, V72, P484, DOI 10.1002/jmv.20008; Das AT, 2004, J VIROL, V78, P2601, DOI 10.1128/JVI.78.5.2601-2605.2004; Durbin AP, 2000, VACCINE, V18, P2462, DOI 10.1016/S0264-410X(99)00575-7; Durbin JE, 2002, J IMMUNOL, V168, P2944, DOI 10.4049/jimmunol.168.6.2944; Easton AJ, 2004, CLIN MICROBIOL REV, V17, P390, DOI 10.1128/CMR.17.2.390-412.2004; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ge Q, 2004, P NATL ACAD SCI USA, V101, P8676, DOI 10.1073/pnas.0402486101; GRAHAM BS, 1988, J MED VIROL, V26, P153, DOI 10.1002/jmv.1890260207; Gupta S, 1998, J VIROL, V72, P2655, DOI 10.1128/JVI.72.4.2655-2662.1998; Haeberle HA, 2001, J VIROL, V75, P878, DOI 10.1128/JVI.75.2.878-890.2001; Haller AA, 2003, J GEN VIROL, V84, P2153, DOI 10.1099/vir.0.19079-0; Haynes LM, 2003, J VIROL, V77, P9831, DOI 10.1128/JVI.77.18.9831-9844.2003; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Khvorova A, 2003, CELL, V115, P505, DOI 10.1016/S0092-8674(03)00893-6; Kim DH, 2004, NAT BIOTECHNOL, V22, P321, DOI 10.1038/nbt940; Maggon K, 2004, REV MED VIROL, V14, P149, DOI 10.1002/rmv.423; McCaffrey AP, 2003, NAT BIOTECHNOL, V21, P639, DOI 10.1038/nbt824; Morton CJ, 2003, VIROLOGY, V311, P275, DOI 10.1016/S0042-6822(03)00115-6; Novina CD, 2004, NATURE, V430, P161, DOI 10.1038/430161a; Openshaw PJM, 2002, RESPIR RES, V3, DOI 10.1186/rr184; Peebles RS, 2003, VIRAL IMMUNOL, V16, P25, DOI 10.1089/088282403763635429; Persengiev SP, 2004, RNA, V10, P12, DOI 10.1261/rna5160904; Polack FP, 2002, J EXP MED, V196, P859, DOI 10.1084/jem.20020781; Ramaswamy M, 2004, AM J RESP CELL MOL, V30, P893, DOI 10.1165/rcmb.2003-0410OC; Razinkov V, 2002, ANTIVIR RES, V55, P189, DOI 10.1016/S0166-3542(02)00050-5; Reinhart BJ, 2002, GENE DEV, V16, P1616, DOI 10.1101/gad.1004402; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Schlender J, 2000, J VIROL, V74, P8234, DOI 10.1128/JVI.74.18.8234-8242.2000; Schmidt AC, 2001, J VIROL, V75, P4594, DOI 10.1128/JVI.75.10.4594-4603.2001; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Sullender WM, 2000, CLIN MICROBIOL REV, V13, P1, DOI 10.1128/CMR.13.1.1-15.2000; Tompkins SM, 2004, P NATL ACAD SCI USA, V101, P8682, DOI 10.1073/pnas.0402630101; UEBA O, 1978, ACTA MED OKAYAMA, V32, P265; van Schaik SM, 1998, J INFECT DIS, V177, P269, DOI 10.1086/514208; VOLOVITZ B, 1988, PEDIATR RES, V24, P504, DOI 10.1203/00006450-198810000-00018; Welliver RC, 2003, J INFECT DIS, V187, P1773, DOI 10.1086/375277	45	562	704	2	56	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2005	11	1					50	55		10.1038/nm1164	http://dx.doi.org/10.1038/nm1164			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	884ZJ	15619632				2022-12-25	WOS:000226124900032
J	Croce, A; Cassata, G; Disanza, A; Gagliani, MC; Tacchetti, C; Malabarba, MG; Carlier, MF; Scita, G; Baumeister, R; Di Fiore, PP				Croce, A; Cassata, G; Disanza, A; Gagliani, MC; Tacchetti, C; Malabarba, MG; Carlier, MF; Scita, G; Baumeister, R; Di Fiore, PP			A novel actin barbed-end-capping activity in EPS-8 regulates apical morphogenesis in intestinal cells of Caenorhabditis elegans	NATURE CELL BIOLOGY			English	Article							ORGANIZATION; ACTIVATION; BUNDLES; COMPLEX; FAMILY; SOS-1; EPS15; RAC	Redundant gene function frequently hampers investigations of the physiological roles of mammalian proteins. This is the case for Eps8, a receptor tyrosine kinase ( RTK) substrate(1) that participates in the activation of the Rac-specific guanine nucleotide-exchange function of Sos1 ( refs 2 - 5), thereby regulating actin remodelling by RTKs. EPS8-knockout mice, however, exhibit no evident phenotype(2), owing to the redundant function of three other EPS8-related genes(6). Here we show that in the nematode Caenorhabditis elegans, only one orthologue of the EPS8 gene exists, which gives rise to two alternatively spliced isoforms, EPS-8A and EPS-8B, differing at their carboxyl termini. In the nematode, eps-8 is essential for embryonic development. Furthermore, EPS-8A, but not EPS-8B, is specifically required for proper apical morphogenesis in the intestinal cells. This latter phenotype could be precisely correlated with a previously unknown actin barbed-end-capping activity, which is present in the C terminus of the EPS-8A isoform. Therefore, nematode genetics allowed not only the unmasking of distinct EPS-8-linked phenotypes, but also the definition of a novel function for this molecule in actin dynamics.	IFOM Inst FIRC Oncol Mol, I-20139 Milan, Italy; ISt europeo Oncol, Dept Expt Oncol, I-20141 Milan, Italy; LMU, ABI Mol Neurogenet, D-80336 Munich, Germany; Univ Genoa, Dept Expt Med, Anat Sect, I-16132 Genoa, Italy; CNRS, Dynam Cytosquelette Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; Bioll Bioinformat & Mol Genet, D-79104 Freiburg, Germany; Univ Milan, Dipartimento Med Chirurg & Odontooatria, I-20122 Milan, Italy	IFOM - FIRC Institute of Molecular Oncology; IRCCS European Institute of Oncology (IEO); University of Munich; University of Genoa; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Milan	Di Fiore, PP (corresponding author), IFOM Inst FIRC Oncol Mol, Via Adamello 16, I-20139 Milan, Italy.	pierpaolo.difiore@ifom-ieo-campus.it	Di Fiore, Pier Paolo/K-2130-2012; Malabarba, Maria Grazia/L-4805-2015; Scita, Giorgio/J-9670-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950; Malabarba, Maria Grazia/0000-0002-9457-2047; Scita, Giorgio/0000-0001-7984-1889; TACCHETTI, CARLO/0000-0003-4602-000X; gagliani, maria cristina/0000-0002-2902-2719; Disanza, Andrea/0000-0001-5101-2907				Anderson P, 1995, METHOD CELL BIOL, V48, P31; Bartles JR, 2000, CURR OPIN CELL BIOL, V12, P72, DOI 10.1016/S0955-0674(99)00059-9; Confalonieri S, 2000, J CELL BIOL, V150, P905, DOI 10.1083/jcb.150.4.905; DeRosier DJ, 2000, J CELL BIOL, V148, P1; Disanza A, 2004, NAT CELL BIOL, V6, P1180, DOI 10.1038/ncb1199; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; Ferrary E, 1999, J CELL BIOL, V146, P819, DOI 10.1083/jcb.146.4.819; Gremm D, 2000, EUR J BIOCHEM, V267, P4339, DOI 10.1046/j.1432-1327.2000.01463.x; Innocenti M, 2003, J CELL BIOL, V160, P17, DOI 10.1083/jcb.200206079; Innocenti M, 2002, J CELL BIOL, V156, P125, DOI 10.1083/jcb.200108035; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; Nehrke K, 2003, J BIOL CHEM, V278, P44657, DOI 10.1074/jbc.M307351200; Offenhauser N, 2004, MOL BIOL CELL, V15, P91, DOI 10.1091/mbc.E03-06-0427; Pantaloni D, 2000, NAT CELL BIOL, V2, P385, DOI 10.1038/35017011; Salcini AE, 2001, NAT CELL BIOL, V3, P755, DOI 10.1038/35087075; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Scita G, 2001, J CELL BIOL, V154, P1031, DOI 10.1083/jcb.200103146; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Tocchetti A, 2003, GENOMICS, V81, P234, DOI 10.1016/S0888-7543(03)00002-8	20	82	83	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2004	6	12					1173	1179		10.1038/ncb1198	http://dx.doi.org/10.1038/ncb1198			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	875WQ	15558032				2022-12-25	WOS:000225453300009
J	Hiller, M; Huse, K; Szafranski, K; Jahn, N; Hampe, J; Schreiber, S; Backofen, R; Platzer, M				Hiller, M; Huse, K; Szafranski, K; Jahn, N; Hampe, J; Schreiber, S; Backofen, R; Platzer, M			Widespread occurrence of alternative splicing at NAGNAG acceptors contributes to proteome plasticity	NATURE GENETICS			English	Article							MESSENGER-RNA; VARIANTS; IMPACT	Splice acceptors with the genomic NAGNAG motif may cause NAG insertion-deletions in transcripts, occur in 30% of human genes and are functional in at least 5% of human genes. We found five significant biases indicating that their distribution is nonrandom and that they are evolutionarily conserved and tissue-specific. Because of their subtle effects on mRNA and protein structures, these splice acceptors are often overlooked or underestimated, but they may have a great impact on biology and disease.	Inst Mol Biotechnol, D-07745 Jena, Germany; Univ Jena, Chair Bioinformat, Inst Comp Sci, D-07743 Jena, Germany; Univ Kiel, Inst Clin Mol Biol, D-24105 Kiel, Germany	Friedrich Schiller University of Jena; University of Kiel	Platzer, M (corresponding author), Inst Mol Biotechnol, Beutenbergstr 11, D-07745 Jena, Germany.	mplatzer@imb-jena.de	Hampe, Jochen/A-2555-2010	Hampe, Jochen/0000-0002-2421-6127; Backofen, Rolf/0000-0001-8231-3323; Huse, Klaus/0000-0003-3854-1884				Chen SY, 2000, P NATL ACAD SCI USA, V97, P593, DOI 10.1073/pnas.97.2.593; CONDORELLI G, 1994, J BIOL CHEM, V269, P8510; Ferranti P, 1999, J PROTEIN CHEM, V18, P595, DOI 10.1023/A:1020659518748; Garcia-Blanco MA, 2004, NAT BIOTECHNOL, V22, P535, DOI 10.1038/nbt964; Karinch AM, 1997, BIOCHEM J, V321, P39, DOI 10.1042/bj3210039; Li L, 2001, PLANT MOL BIOL, V46, P409, DOI 10.1023/A:1010645330275; Long MY, 1999, MOL BIOL EVOL, V16, P1528, DOI 10.1093/oxfordjournals.molbev.a026065; Ma BY, 2003, P NATL ACAD SCI USA, V100, P5772, DOI 10.1073/pnas.1030237100; Neves G, 2004, NAT GENET, V36, P240, DOI 10.1038/ng1299; Resch A, 2004, J PROTEOME RES, V3, P76, DOI 10.1021/pr034064v; ROGINA B, 1995, BIOCHEM MOL BIOL INT, V35, P825; Stamm S, 2000, DNA CELL BIOL, V19, P739, DOI 10.1089/104454900750058107; Sugnet C W, 2004, Pac Symp Biocomput, P66; Zavolan M, 2003, GENOME RES, V13, P1290, DOI 10.1101/gr.1017303; Zhang HB, 1996, RNA, V2, P380	15	149	152	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2004	36	12					1255	1257		10.1038/ng1469	http://dx.doi.org/10.1038/ng1469			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	874MI	15516930				2022-12-25	WOS:000225354100011
J	Kuroda, TS; Fukuda, M				Kuroda, TS; Fukuda, M			Rab27A-binding protein Slp2-a is required for peripheral melanosome distribution and elongated cell shape in melanocytes	NATURE CELL BIOLOGY			English	Article							MYOSIN-VA; BINDING DOMAIN; FUNCTIONAL DIVERSITY; ASHEN MICE; RAB27A; TRANSPORT; ORGANELLE; MELANOPHILIN; SLAC2-A/MELANOPHILIN; LYMPHOCYTES	The synaptotagmin-like protein (Slp) family is implicated in regulating Rab27A-mediated membrane transport(1-3), but how it might do this is unknown. Here we report that Slp2-a, a previously uncharacterized Rab27A-binding protein in melanocytes, controls melanosome distribution in the cell periphery and regulates the morphology of melanocytes. Slp2-a is the most abundantly expressed of the Slp- and Slac2-family proteins in melanocytes and colocalizes with Rab27A on melanosomes. Knockdown of endogenous Slp2-a protein by small-interfering RNAs (siRNAs) markedly reduced the number of melanosomes in the cell periphery of mouse melanocytes ('peripheral dilution'). Expression of siRNA-resistant Slp2-a (Slp2-a(SR)) rescued the peripheral dilution of melanosomes induced by Slp2-a siRNAs, but Slp2-a(SR) mutants, which failed to interact with either phospholipids or Rab27A, did not. Loss of Slp2-a protein also induced a change in melanocyte morphology, from their normal elongated shape to a more rounded shape, which depended on the phospholipid-binding activity of Slp2-a, but not on its Rab27A-binding activity. By contrast, knockdown of Slac2-a ( also called melanophilin), another Rab27A-binding protein in melanocytes(4,5), caused perinuclear aggregation of melanosomes alone without altering cell shape. These results reveal the differential and sequential roles of Rab27A-binding proteins in melanosome transport in melanocytes.	RIKEN, Inst Phys & Chem Res, Fukuda Initiat Res Unit, Wako, Saitama 3510198, Japan	RIKEN	Fukuda, M (corresponding author), RIKEN, Inst Phys & Chem Res, Fukuda Initiat Res Unit, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853; Kuroda, Taruho/0000-0001-6693-4496				Bahadoran P, 2001, J CELL BIOL, V152, P843, DOI 10.1083/jcb.152.4.843; Barral DC, 2004, PIGM CELL RES, V17, P111, DOI 10.1111/j.1600-0749.2004.00138.x; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Feldmann J, 2003, CELL, V115, P461, DOI 10.1016/S0092-8674(03)00855-9; Fukuda M, 2004, BIOCHEM J, V380, P875, DOI 10.1042/BJ20040096; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; FUKUDA M, IN PRESS J BIOCH; Haddad EK, 2001, J CELL BIOL, V152, P835, DOI 10.1083/jcb.152.4.835; Hammer JA, 2002, CURR OPIN CELL BIOL, V14, P69, DOI 10.1016/S0955-0674(01)00296-4; Hume AN, 2002, TRAFFIC, V3, P193, DOI 10.1034/j.1600-0854.2002.030305.x; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; Imai A, 2004, J CELL SCI, V117, P1945, DOI 10.1242/jcs.01048; Kuroda TS, 2003, MOL CELL BIOL, V23, P5245, DOI 10.1128/MCB.23.15.5245-5255.2003; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; Menasche G, 2003, J CLIN INVEST, V112, P450, DOI 10.1172/JCI200318264; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Nascimento AA, 2003, ANNU REV CELL DEV BI, V19, P469, DOI 10.1146/annurev.cellbio.19.111401.092937; Provance DW, 2002, TRAFFIC, V3, P124, DOI 10.1034/j.1600-0854.2002.030205.x; Raposo G, 2001, J CELL BIOL, V152, P809, DOI 10.1083/jcb.152.4.809; Shirakawa R, 2004, J BIOL CHEM, V279, P10730, DOI 10.1074/jbc.M309426200; Stinchcombe JC, 2001, J CELL BIOL, V152, P825, DOI 10.1083/jcb.152.4.825; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; Trambas CM, 2003, NAT IMMUNOL, V4, P399, DOI 10.1038/ni0503-399; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Wu XF, 2002, MOL BIOL CELL, V13, P1735, DOI 10.1091/mbc.01-12-0595; Wu XF, 1998, J CELL BIOL, V143, P1899, DOI 10.1083/jcb.143.7.1899; Wu XF, 2001, J CELL SCI, V114, P1091; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760	30	120	126	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2004	6	12					1195	1203		10.1038/ncb1197	http://dx.doi.org/10.1038/ncb1197			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	875WQ	15543135				2022-12-25	WOS:000225453300012
J	Jacinto, E; Loewith, R; Schmidt, A; Lin, S; Ruegg, MA; Hall, A; Hall, MN				Jacinto, E; Loewith, R; Schmidt, A; Lin, S; Ruegg, MA; Hall, A; Hall, MN			Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive	NATURE CELL BIOLOGY			English	Article							CELL-GROWTH; TARGET; RAPTOR; INHIBITION; NUTRIENT; ADHESION; CDC42; MTOR; ACTIVATION; MECHANISM	The target of rapamycin ( TOR) is a highly conserved protein kinase and a central controller of cell growth. In budding yeast, TOR is found in structurally and functionally distinct protein complexes: TORC1 and TORC2. A mammalian counterpart of TORC1 (mTORC1) has been described, but it is not known whether TORC2 is conserved in mammals. Here, we report that a mammalian counterpart of TORC2 (mTORC2) also exists. mTORC2 contains mTOR, mLST8 and mAVO3, but not raptor. Like yeast TORC2, mTORC2 is rapamycin insensitive and seems to function upstream of Rho GTPases to regulate the actin cytoskeleton. mTORC2 is not upstream of the mTORC1 effector S6K. Thus, two distinct TOR complexes constitute a primordial signalling network conserved in eukaryotic evolution to control the fundamental process of cell growth.	Univ Basel, Biozentrum, CH-4056 Basel, Switzerland; UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England	University of Basel; University of London; University College London	Hall, MN (corresponding author), Univ Basel, Biozentrum, Klingelbergstr 70, CH-4056 Basel, Switzerland.	m.hall@unibas.ch	Loewith, Robbie J/S-6289-2016; Ruegg, Markus/X-7256-2019	Loewith, Robbie J/0000-0002-2482-603X; Ruegg, Markus/0000-0002-4974-9384; Jacinto, Estela/0000-0001-7118-1759; Hall, Michael N/0000-0002-2998-0757; Lin, Shuo/0000-0003-2317-0339				Astrinidis A, 2002, ONCOGENE, V21, P8470, DOI 10.1038/sj.onc.1205962; Azim AC, 2000, METHOD ENZYMOL, V325, P257; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fang YM, 2003, CURR BIOL, V13, P2037, DOI 10.1016/j.cub.2003.11.021; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gingras AC, 2003, CURR TOP MICROBIOL, V279, P169; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; HARRIS TE, 2003, SCI STKE, V15, P1; Hubberstey A, 1996, J CELL BIOCHEM, V61, P459, DOI 10.1002/(SICI)1097-4644(19960601)61:3<459::AID-JCB13>3.0.CO;2-E; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Oshiro N, 2004, GENES CELLS, V9, P359, DOI 10.1111/j.1356-9597.2004.00727.x; Peterson RT, 2000, J BIOL CHEM, V275, P7416, DOI 10.1074/jbc.275.10.7416; RIDLEY AJ, 1995, METHOD ENZYMOL, V256, P306; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Sarkaria JN, 1999, CANCER RES, V59, P4375; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Wedaman KP, 2003, MOL BIOL CELL, V14, P1204, DOI 10.1091/mbc.E02-09-0609; Xia Y, 2003, J BIOL CHEM, V278, P13143, DOI 10.1074/jbc.M208500200	30	1604	1671	4	131	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2004	6	11					1122	U30		10.1038/ncb1183	http://dx.doi.org/10.1038/ncb1183			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	867BI	15467718				2022-12-25	WOS:000224816700018
J	Kulaga, HM; Leitch, CC; Eichers, ER; Badano, JL; Lesemann, A; Hoskins, BE; Lupski, JR; Beales, PL; Reed, RR; Katsanis, N				Kulaga, HM; Leitch, CC; Eichers, ER; Badano, JL; Lesemann, A; Hoskins, BE; Lupski, JR; Beales, PL; Reed, RR; Katsanis, N			Loss of BBS proteins causes anosmia in humans and defects in olfactory cilia structure and function in the mouse	NATURE GENETICS			English	Article							BARDET-BIEDL-SYNDROME; HUMAN OBESITY SYNDROME; INTRAFLAGELLAR TRANSPORT; ADENYLYL-CYCLASE; DISEASE GENE; IDENTIFICATION; MUTATIONS; HOMOLOG; CLONING	Defects in cilia are associated with several human disorders, including Kartagener syndrome(1), polycystic kidney disease(2,3), nephronophthisis(4) and hydrocephalus(5). We proposed that the pleiotropic phenotype of Bardet-Biedl syndrome (BBS), which encompasses retinal degeneration, truncal obesity, renal and limb malformations and developmental delay, is due to dysfunction of basal bodies and cilia(6,7). Here we show that individuals with BBS have partial or complete anosmia. To test whether this phenotype is caused by ciliary defects of olfactory sensory neurons, we examined mice with deletions of Bbs1 or Bbs4. Loss of function of either BBS protein affected the olfactory, but not the respiratory, epithelium, causing severe reduction of the ciliated border, disorganization of the dendritic microtubule network and trapping of olfactory ciliary proteins in dendrites and cell bodies. Our data indicate that BBS proteins have a role in the microtubule organization of mammalian ciliated cells and that anosmia might be a useful determinant of other pleiotropic disorders with a suspected ciliary involvement.	Johns Hopkins Univ, Inst Med Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; UCL, Inst Child Hlth, Mol Med Unit, London WC1 1EH, England; Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21287 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Baylor College of Medicine; University of London; University College London; Baylor College of Medicine; Baylor College of Medicine; Johns Hopkins University; Johns Hopkins Medicine	Katsanis, N (corresponding author), Johns Hopkins Univ, Inst Med Genet, 533 Broadway St Bldg,733 N Broadway, Baltimore, MD 21205 USA.	katsanis@jhmi.edu	Katsanis, Nicholas/E-1837-2012; Beales, Philip L/C-7367-2009; Reed, Russell/HGU-0528-2022	Katsanis, Nicholas/0000-0002-2480-0171; Badano, Jose/0000-0002-0706-8652				AFZELIUS B A, 1976, Science (Washington D C), V193, P317; Ansley SJ, 2003, NATURE, V425, P628, DOI 10.1038/nature02030; Badano JL, 2003, HUM MOL GENET, V12, P1651, DOI 10.1093/hmg/ddg188; Badano JL, 2003, AM J HUM GENET, V72, P650, DOI 10.1086/368204; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; Beales PL, 1999, J MED GENET, V36, P437; Beales PL, 2003, AM J HUM GENET, V72, P1187, DOI 10.1086/375178; Chen JC, 1998, J CLIN INVEST, V102, P1077, DOI 10.1172/JCI4786; Doty RL, 1996, LARYNGOSCOPE, V106, P353, DOI 10.1097/00005537-199603000-00021; Gervais FG, 2002, NAT CELL BIOL, V4, P95, DOI 10.1038/ncb735; Goldstein BJ, 2003, JARO-J ASSOC RES OTO, V4, P74, DOI 10.1007/s10162-002-2039-5; GRAZIADEI PPC, 1978, OLFACTORY SYSTEM MOD, P131; Haycraft CJ, 2003, EXP CELL RES, V284, P251, DOI 10.1016/S0014-4827(02)00089-7; Katsanis N, 2001, SCIENCE, V293, P2256, DOI 10.1126/science.1063525; Katsanis N, 2000, NAT GENET, V26, P67, DOI 10.1038/79201; Kim JC, 2004, NAT GENET, V36, P462, DOI 10.1038/ng1352; Li JB, 2004, CELL, V117, P541, DOI 10.1016/S0092-8674(04)00450-7; Menco Bert P. M., 1994, Seminars in Cell Biology, V5, P11, DOI 10.1006/scel.1994.1003; Moore AB, 1999, J CLIN EXP NEUROPSYC, V21, P341, DOI 10.1076/jcen.21.3.341.918; Mykytyn K, 2002, NAT GENET, V31, P435, DOI 10.1038/ng935; Mykytyn K, 2001, NAT GENET, V28, P188, DOI 10.1038/88925; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Nishimura DY, 2001, HUM MOL GENET, V10, P865, DOI 10.1093/hmg/10.8.865; Otto EA, 2003, NAT GENET, V34, P413, DOI 10.1038/ng1217; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; RUGARLI EI, 1993, NAT GENET, V4, P19, DOI 10.1038/ng0593-19; Signor D, 2000, Essays Biochem, V35, P89; Slavotinek AM, 2000, NAT GENET, V26, P15, DOI 10.1038/79116; Wong ST, 2000, NEURON, V27, P487, DOI 10.1016/S0896-6273(00)00060-X	30	255	262	1	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2004	36	9					994	998		10.1038/ng1418	http://dx.doi.org/10.1038/ng1418			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	851AY	15322545	Bronze			2022-12-25	WOS:000223658100027
J	Mandal, L; Banerjee, U; Hartenstein, V				Mandal, L; Banerjee, U; Hartenstein, V			Evidence for a fruit fly hemangioblast and similarities between lymph-gland hematopoiesis in fruit fly and mammal aorta-gonadal-mesonephros mesoderm	NATURE GENETICS			English	Article							DROSOPHILA EMBRYO; ENDOTHELIAL-CELLS; HEART DEVELOPMENT; REGION; GENES; DIFFERENTIATION; SPECIFICATION; VERTEBRATES; INDUCTION; PANNIER	The Drosophila melanogaster lymph gland is a hematopoietic organ(1) and, together with prospective vascular cells (cardioblasts) and excretory cells (pericardial nephrocytes), arises from the cardiogenic mesoderm. Clonal analysis provided evidence for a hemangioblast(2,3) that can give rise to two daughter cells: one that differentiates into heart or aorta and another that differentiates into blood. In addition, the GATA factor gene pannier (pnr) and the homeobox gene tinman (tin), which are controlled by the convergence of Decapentaplegic (Dpp), fibroblast growth factor (FGF), Wingless (Wg) and Notch signaling, are required for the development of all cardiogenic mesoderm, including the lymph gland. Here we show that an essential genetic switch that differentiates between the blood or nephrocyte and vascular lineages involves the Notch pathway. Further specification occurs through specific expression of the GATA factor Serpent (Srp) in the lymph-gland primordium. Our findings suggest that there is a close parallel between the molecular mechanisms functioning in the D. melanogaster cardiogenic mesoderm and those functioning in the mammalian aorta-gonadal-mesonephros mesoderm(4).	Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Banerjee, U (corresponding author), Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA.	banerjee@mbi.ucla.edu; volkerh@mcdb.ucla.edu		MANDAL, LOLITIKA/0000-0002-7711-6090				Alvarez AD, 2003, DEVELOPMENT, V130, P3015, DOI 10.1242/dev.00488; Beiman M, 1996, GENE DEV, V10, P2993, DOI 10.1101/gad.10.23.2993; Chartier A, 2002, DEVELOPMENT, V129, P3241; Choi K, 1998, DEVELOPMENT, V125, P725; CROSSLEY AC, 1972, TISSUE CELL, V4, P529, DOI 10.1016/S0040-8166(72)80029-6; Ema M, 2003, GENE DEV, V17, P380, DOI 10.1101/gad.1049803; Evans CJ, 2003, DEV CELL, V5, P673, DOI 10.1016/S1534-5807(03)00335-6; Fehling HJ, 2003, DEVELOPMENT, V130, P4217, DOI 10.1242/dev.00589; Fossett N, 2001, DIFFERENTIATION, V69, P83, DOI 10.1046/j.1432-0436.2001.690202.x; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; HARTENSTEIN AY, 1992, DEVELOPMENT, V116, P1203; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; Klinedinst SL, 2003, DEVELOPMENT, V130, P3027, DOI 10.1242/dev.00517; Kumano K, 2003, IMMUNITY, V18, P699, DOI 10.1016/S1074-7613(03)00117-1; Lawson ND, 2001, DEVELOPMENT, V128, P3675; Lebestky T, 2000, SCIENCE, V288, P146, DOI 10.1126/science.288.5463.146; Lo PCH, 2002, DEV BIOL, V251, P307, DOI 10.1006/dbio.2002.0839; Marshall CJ, 2000, BLOOD, V96, P1591, DOI 10.1182/blood.V96.4.1591.h8001591_1591_1593; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; MURRAY PDF, 1932, P R SOC LOND, V11, P497; Nishikawa M, 2001, ANN NY ACAD SCI, V938, P109; Orelio C, 2003, BLOOD, V101, P2246, DOI 10.1182/blood-2002-07-2260; Rehorn KP, 1996, DEVELOPMENT, V122, P4023; Schroeder T, 2003, P NATL ACAD SCI USA, V100, P4018, DOI 10.1073/pnas.0438008100; TEPASS U, 1994, DEVELOPMENT, V120, P1829; Ward EJ, 2000, DEVELOPMENT, V127, P4959; WU XS, 1995, DEV BIOL, V169, P619, DOI 10.1006/dbio.1995.1174; Yin ZZ, 1997, DEVELOPMENT, V124, P4971	28	158	164	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2004	36	9					1019	1023		10.1038/ng1404	http://dx.doi.org/10.1038/ng1404			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	851AY	15286786	Bronze			2022-12-25	WOS:000223658100032
J	Seaberg, RM; Smukler, SR; Kieffer, TJ; Enikolopov, G; Asghar, Z; Wheeler, MB; Korbutt, G; van der Kooy, D				Seaberg, RM; Smukler, SR; Kieffer, TJ; Enikolopov, G; Asghar, Z; Wheeler, MB; Korbutt, G; van der Kooy, D			Clonal identification of multipotent precursors from adult mouse pancreas that generate neural and pancreatic lineages	NATURE BIOTECHNOLOGY			English	Article							HEMATOPOIETIC STEM-CELLS; NESTIN-POSITIVE PRECURSORS; PROGENITOR CELLS; BETA-CELLS; TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS; EXPRESSING CELLS; NERVOUS-SYSTEM; EX-VIVO; MICE	The clonal isolation of putative adult pancreatic precursors has been an elusive goal of researchers seeking to develop cell replacement strategies for diabetes. We report the clonal identification of multipotent precursor cells from the adult mouse pancreas. The application of a serum-free, colony-forming assay to pancreatic cells enabled the identification of precursors from pancreatic islet and ductal populations. These cells proliferate in vitro to form clonal colonies that coexpress neural and pancreatic precursor markers. Upon differentiation, individual clonal colonies produce distinct populations of neurons and glial cells, pancreatic endocrine beta-, alpha- and delta-cells, and pancreatic exocrine and stellate cells. Moreover, the newly generated b- like cells demonstrate glucose-dependent Ca2+ responsiveness and insulin release. Pancreas colonies do not express markers of embryonic stem cells, nor genes suggestive of mesodermal or neural crest origins. These cells represent a previously unidentified adult intrinsic pancreatic precursor population and are a promising candidate for cell-based therapeutic strategies.	Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Univ British Columbia, Dept Physiol, Vancouver, BC V6T 1Z3, Canada; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Alberta, Dept Surg, Edmonton, AB T6G 2N8, Canada; Univ Alberta, Dept Physiol, Edmonton, AB T6G 2N8, Canada	University of Toronto; University of British Columbia; Cold Spring Harbor Laboratory; University of Toronto; University of Alberta; University of Alberta	Seaberg, RM (corresponding author), Univ Toronto, Dept Med Genet & Microbiol, 100 Coll St, Toronto, ON M5S 1A8, Canada.	raewyn.seaberg@utoronto.ca	Enikolopov, Grigori N/B-7771-2009; Enikolopov, Grigori/P-5731-2019	Enikolopov, Grigori N/0000-0001-8178-8917; Enikolopov, Grigori/0000-0001-8178-8917; Wheeler, Michael B./0000-0002-7480-7267; Asghar Shyr, Zeenat/0000-0001-8710-9938				Abraham EJ, 2002, ENDOCRINOLOGY, V143, P3152, DOI 10.1210/en.143.8.3152; AHREN B, 1990, PROG BRAIN RES, V84, P209; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Aybar MJ, 2003, DEVELOPMENT, V130, P483, DOI 10.1242/dev.00238; Benveniste P, 2003, NAT IMMUNOL, V4, P708, DOI 10.1038/ni940; Bylund M, 2003, NAT NEUROSCI, V6, P1162, DOI 10.1038/nn1131; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Delacour A, 2004, MECH DEVELOP, V121, P3, DOI 10.1016/j.mod.2003.11.004; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; EFTIMIE R, 1991, P NATL ACAD SCI USA, V88, P1349, DOI 10.1073/pnas.88.4.1349; Esni F, 2004, MECH DEVELOP, V121, P15, DOI 10.1016/j.mod.2003.08.010; Garcia-Ocana A, 2001, DIABETES, V50, P2752, DOI 10.2337/diabetes.50.12.2752; GOTOH M, 1985, TRANSPLANTATION, V40, P437, DOI 10.1097/00007890-198510000-00018; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; GUZ Y, 1995, DEVELOPMENT, V121, P11; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; Honore SM, 2003, DEV BIOL, V260, P79, DOI 10.1016/S0012-1606(03)00247-1; Humphrey RK, 2003, DIABETES, V52, P2519, DOI 10.2337/diabetes.52.10.2519; Hunziker E, 2000, BIOCHEM BIOPH RES CO, V271, P116, DOI 10.1006/bbrc.2000.2611; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kang GX, 2003, J BIOL CHEM, V278, P8279, DOI 10.1074/jbc.M211682200; Klein T, 2003, J HISTOCHEM CYTOCHEM, V51, P697, DOI 10.1177/002215540305100601; Krizik MR, 1999, J ENDOCRINOL, V163, P523, DOI 10.1677/joe.0.1630523; Lardon J, 2002, HISTOCHEM CELL BIOL, V117, P535, DOI 10.1007/s00418-002-0412-4; Lechner A, 2003, AM J PHYSIOL-ENDOC M, V284, pE259, DOI 10.1152/ajpendo.00393.2002; Lee HY, 2004, SCIENCE, V303, P1020, DOI 10.1126/science.1091611; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Li HW, 2003, NAT MED, V9, P1293, DOI 10.1038/nm925; Liu Y, 2003, TRENDS NEUROSCI, V26, P410, DOI 10.1016/S0166-2236(03)00201-7; Lumelsky N, 2001, SCIENCE, V292, P1389, DOI 10.1126/science.1058866; MacDonald PE, 2002, DIABETES, V51, pS434, DOI 10.2337/diabetes.51.2007.S434; MCKENZIE I, 2003, ABSTR SOC NEUROSCI, V28, P9; Mignone JL, 2004, J COMP NEUROL, V469, P311, DOI 10.1002/cne.10964; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Morshead CM, 2003, EUR J NEUROSCI, V18, P76, DOI 10.1046/j.1460-9568.2003.02727.x; Morshead CM, 2002, NAT MED, V8, P268, DOI 10.1038/nm0302-268; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Persson-Sjogren S, 2001, HISTOCHEM J, V33, P373, DOI 10.1023/A:1012439510709; Peterson DA, 1997, SCIENCE, V277, P837, DOI 10.1126/science.277.5327.837; Piper K, 2002, DIABETOLOGIA, V45, P1045, DOI 10.1007/s00125-002-0864-z; Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092-8674(03)00437-9; Rajagopal J, 2003, SCIENCE, V299, P363; Ramiya VK, 2000, NAT MED, V6, P278; Roe MW, 1996, J BIOL CHEM, V271, P32241, DOI 10.1074/jbc.271.50.32241; Sawamoto K, 2001, J NEUROSCI, V21, P3895, DOI 10.1523/JNEUROSCI.21-11-03895.2001; Scharfmann R, 1997, HORM METAB RES, V29, P294, DOI 10.1055/s-2007-979038; Seaberg RM, 2003, TRENDS NEUROSCI, V26, P125, DOI 10.1016/S0166-2236(03)00031-6; Seaberg RM, 2002, J NEUROSCI, V22, P1784, DOI 10.1523/JNEUROSCI.22-05-01784.2002; Selander L, 2002, MECH DEVELOP, V113, P189, DOI 10.1016/S0925-4773(02)00023-0; Sipione S, 2004, DIABETOLOGIA, V47, P499, DOI 10.1007/s00125-004-1349-z; Smukler SR, 2002, DIABETES, V51, P3450, DOI 10.2337/diabetes.51.12.3450; Sommer L, 1996, MOL CELL NEUROSCI, V8, P221, DOI 10.1006/mcne.1996.0060; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; STOETZEL C, 1995, MECH DEVELOP, V51, P251, DOI 10.1016/0925-4773(95)00369-X; Street CN, 2004, J ENDOCRINOL, V180, P213, DOI 10.1677/joe.0.1800213; Toma JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/ncb0901-778; Treutelaar MK, 2003, DIABETES, V52, P2503, DOI 10.2337/diabetes.52.10.2503; Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; Weiss S, 1996, TRENDS NEUROSCI, V19, P387, DOI 10.1016/S0166-2236(96)10035-7; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Welsh M, 2004, BIOCHEM J, V382, P261, DOI 10.1042/BJ20040285; Zhang YQ, 2003, DIABETES-METAB RES, V19, P363, DOI 10.1002/dmrr.406; Zulewski H, 2001, DIABETES, V50, P521, DOI 10.2337/diabetes.50.3.521	68	410	493	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2004	22	9					1115	1124		10.1038/nbt1004	http://dx.doi.org/10.1038/nbt1004			10	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	850ZR	15322557				2022-12-25	WOS:000223653400030
J	Mizuguchi, T; Collod-Beroud, G; Akiyama, T; Abifadel, M; Harada, N; Morisaki, T; Allard, D; Varret, M; Claustres, M; Morisaki, H; Ihara, M; Kinoshita, A; Yoshiura, K; Junien, C; Kajii, T; Jondeau, G; Ohta, T; Kishino, T; Furukawa, Y; Nakamura, Y; Niikawa, N; Boileau, C; Matsumoto, N				Mizuguchi, T; Collod-Beroud, G; Akiyama, T; Abifadel, M; Harada, N; Morisaki, T; Allard, D; Varret, M; Claustres, M; Morisaki, H; Ihara, M; Kinoshita, A; Yoshiura, K; Junien, C; Kajii, T; Jondeau, G; Ohta, T; Kishino, T; Furukawa, Y; Nakamura, Y; Niikawa, N; Boileau, C; Matsumoto, N			Heterozygous TGFBR2 mutations in Marfan syndrome	NATURE GENETICS			English	Article							II RECEPTOR GENE; BETA ACTIVATION; MICROSATELLITE INSTABILITY; COLON-CANCER; INACTIVATION; LOCUS	Marfan syndrome is an extracellular matrix disorder with cardinal manifestations in the eye, skeleton and cardiovascular systems associated with defects in the gene encoding fibrillin (FBN1) at 15q21.1 (ref. 1). A second type of the disorder ( Marfan syndrome type 2; OMIM 154705) is associated with a second locus, MFS2, at 3p25-p24.2 in a large French family (family MS1)(2). Identification of a 3p24.1 chromosomal breakpoint disrupting the gene encoding TGF-beta receptor 2 (TGFBR2) in a Japanese individual with Marfan syndrome led us to consider TGFBR2 as the gene underlying association with Marfan syndrome at the MSF2 locus. The mutation 1524G --> A in TGFBR2 ( causing the synonymous amino acid substitution Q508Q) resulted in abnormal splicing and segregated with MFS2 in family MS1. We identified three other missense mutations in four unrelated probands, which led to loss of function of TGF-beta signaling activity on extracellular matrix formation. These results show that heterozygous mutations in TGFBR2, a putative tumor-suppressor gene implicated in several malignancies, are also associated with inherited connective-tissue disorders.	Nagasaki Univ, Grad Sch Biomed Sci, Dept Human Genet, Nagasaki 852, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi, Japan; Inst Univ Rech Clin, Genet Mol Lab, Montpellier, France; Univ Paris 05, INSERM, U383, Hop Necker Enfants Malad, Paris, France; Natl Okayama Med Ctr, Div Pediat Surg, Okayama, Japan; Kyushu Med Sci Nagasaki Lab, Nagasaki, Japan; Natl Cardiovasc Ctr, Res Inst, Dept Biosci, Suita, Osaka 565, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Radiat Biophys, Nagasaki 852, Japan; Hop Ambroise Pare, Lab Biochim Hormonol & Genet Mol, Boulogne, France; Hop Ambroise Pare, Serv Cardiol, Boulogne, France; Nagasaki Univ, Ctr Frontier Life Sci, Div Funct Gen, Nagasaki 852, Japan; Hlth Sci Univ Hokkaido, Ishikari, Hokkaido 06102, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Tokyo, Japan; Yokohama City Univ, Grad Sch Med, Dept Human Genet, Yokohama, Kanagawa 232, Japan	Nagasaki University; Japan Science & Technology Agency (JST); Universite de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; National Cerebral & Cardiovascular Center - Japan; Nagasaki University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Nagasaki University; Health Sciences University of Hokkaido; University of Tokyo; Yokohama City University	Boileau, C (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Human Genet, Nagasaki 852, Japan.	boileau@necker.fr; naomat@yokohama-cu.ac.jp	COLLOD-BEROUD, Gwenaëlle/A-8342-2008; VARRET, Mathilde/C-2279-2016; Abifadel, Marianne/ABH-5370-2020; boileau, catherine/M-4482-2017	COLLOD-BEROUD, Gwenaëlle/0000-0003-4098-6161; VARRET, Mathilde/0000-0001-9261-1551; boileau, catherine/0000-0002-0371-7539; ABIFADEL, Marianne/0000-0001-7645-8323; ALLARD, Delphine/0000-0001-7534-8982				Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; BOILEAU C, 1993, AM J HUM GENET, V53, P46; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; COLLOD G, 1994, NAT GENET, V8, P264, DOI 10.1038/ng1194-264; Collod-Beroud G, 2002, EUR J HUM GENET, V10, P673, DOI 10.1038/sj.ejhg.5200876; Collod-Beroud G, 2003, HUM MUTAT, V22, P199, DOI 10.1002/humu.10249; DePaepe A, 1996, AM J MED GENET, V62, P417, DOI 10.1002/(SICI)1096-8628(19960424)62:4<417::AID-AJMG15>3.3.CO;2-S; Grady WM, 1999, CANCER RES, V59, P320; Grady WM, 2002, ANNU REV GENOM HUM G, V3, P101, DOI 10.1146/annurev.genom.3.022502.103043; Hasham SN, 2003, CIRCULATION, V107, P3184, DOI 10.1161/01.CIR.0000078634.33124.95; Kaartinen V, 2003, NAT GENET, V33, P331, DOI 10.1038/ng0303-331; Kinoshita A, 2000, NAT GENET, V26, P19, DOI 10.1038/79128; Kissin EY, 2002, ARTHRITIS RHEUM, V46, P3000, DOI 10.1002/art.10621; Lu SL, 1999, BIOCHEM BIOPH RES CO, V259, P385, DOI 10.1006/bbrc.1999.0788; Lu SL, 1998, NAT GENET, V19, P17, DOI 10.1038/ng0598-17; Lucke CD, 2001, CANCER RES, V61, P482; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Matsukawa R, 2001, HUM MUTAT, V17, DOI 10.1002/1098-1004(2001)17:1<71::AID-HUMU9>3.0.CO;2-0; Neptune ER, 2003, NAT GENET, V33, P407, DOI 10.1038/ng1116; PARSONS R, 1995, CANCER RES, V55, P5548; ROMAN MJ, 1989, AM J CARDIOL, V64, P507, DOI 10.1016/0002-9149(89)90430-X; Tanaka S, 2000, BRIT J CANCER, V82, P1557	22	456	483	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2004	36	8					855	860		10.1038/ng1392	http://dx.doi.org/10.1038/ng1392			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	842AG	15235604	Green Accepted			2022-12-25	WOS:000222974000018
J	Davies, W; Isles, A; Smith, R; Karunadasa, D; Burrmann, D; Humby, T; Ojarikre, O; Biggin, C; Skuse, D; Burgoyne, P; Wilkinson, L				Davies, W; Isles, A; Smith, R; Karunadasa, D; Burrmann, D; Humby, T; Ojarikre, O; Biggin, C; Skuse, D; Burgoyne, P; Wilkinson, L			Xlr3b is a new imprinted candidate for X-linked parent-of-origin effects on cognitive function in mice	NATURE GENETICS			English	Article							TURNERS-SYNDROME; CHROMOSOME; MOUSE; SEQUENCE; GENOME; AUTISM; GENES; BRAIN; SCHIZOPHRENIA; REGIONS	Imprinted genes show differential expression between maternal and paternal alleles as a consequence of epigenetic modification that can result in 'parent-of-origin' effects on phenotypic traits(1). There is increasing evidence from mouse and human studies that imprinted genes may influence behavior and cognitive functioning(2). Previous work in girls with Turner syndrome (45,XO) has suggested that there are X-linked parent-of-origin effects on brain development(3) and cognitive functioning(4), although the interpretation of these data in terms of imprinted gene effects has been questioned(5). We used a 39,XO mouse model to examine the influence of the parental origin of the X chromosome on cognitive behaviors and expression of X-linked genes in brain. Our findings confirm the existence of X-linked imprinted effects on cognitive processes and identify a new maternally expressed imprinted gene candidate on the X chromosome, Xlr3b, which may be of importance in mediating the behavioral effects.	Babraham Inst, Lab Cognit & Behav Neurosci, Cambridge CB2 4AT, England; Babraham Inst, Lab Dev Genet & Imprinting, Cambridge CB2 4AT, England; Natl Inst Med Res, MRC, Div Dev Genet, London NW7 1AA, England; Inst Child Hlth, Behav Sci Unit, London WC1N 1EH, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; MRC National Institute for Medical Research; University of London; University College London	Wilkinson, L (corresponding author), Babraham Inst, Lab Cognit & Behav Neurosci, Babraham Res Campus, Cambridge CB2 4AT, England.	lawrence.wilkinson@bbsrc.ac.uk	Davies, William/A-8006-2009; Humby, Trevor/A-1698-2010	Davies, William/0000-0002-7714-2440; Isles, Anthony/0000-0002-7587-5712; HUMBY, trevor/0000-0002-1840-1799	MRC [MC_U117532009] Funding Source: UKRI; Medical Research Council [MC_U117532009] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BERGSAGEL PL, 1994, GENE, V150, P345, DOI 10.1016/0378-1119(94)90450-2; Burgoyne PS, 2000, CYTOGENET CELL GENET, V91, P57, DOI 10.1159/000056819; Bussey TJ, 1997, BEHAV NEUROSCI, V111, P920, DOI 10.1037/0735-7044.111.5.920; Crider A, 1997, SCHIZOPHRENIA BULL, V23, P63, DOI 10.1093/schbul/23.1.63; EVANS EP, 1975, NATURE, V256, P40, DOI 10.1038/256040a0; Ford CE, 1966, TISSUE GRAFTING RADI, P197; Haig D, 2000, ANNU REV ECOL SYST, V31, P9, DOI 10.1146/annurev.ecolsys.31.1.9; Heard E, 1997, ANNU REV GENET, V31, P571, DOI 10.1146/annurev.genet.31.1.571; Henn W, 1997, NATURE, V390, P569, DOI 10.1038/37514; Hill EL, 2003, PHILOS T R SOC B, V358, P281, DOI 10.1098/rstb.2002.1209; Ishikawa H, 2003, BIOL REPROD, V69, P483, DOI 10.1095/biolreprod.102.012641; Isles AR, 2000, TRENDS COGN SCI, V4, P309, DOI 10.1016/S1364-6613(00)01504-7; Jamieson RV, 1998, DEV BIOL, V201, P13, DOI 10.1006/dbio.1998.8972; Ke XY, 2002, MAMM GENOME, V13, P639, DOI 10.1007/s00335-002-3038-x; Kesler SR, 2003, BIOL PSYCHIAT, V54, P636, DOI 10.1016/S0006-3223(03)00289-0; Lercher MJ, 2003, GENETICS, V165, P1629; Levin ML, 1996, GENOME RES, V6, P465, DOI 10.1101/gr.6.6.465; Lockhart DJ, 2001, NAT REV NEUROSCI, V2, P63, DOI 10.1038/35049070; Mallon AM, 2000, GENOME RES, V10, P758, DOI 10.1101/gr.10.6.758; Martinez-Garay I, 2002, GENOMICS, V80, P259, DOI 10.1006/geno.2002.6834; Milunsky J, 1999, CLIN GENET, V55, P455, DOI 10.1034/j.1399-0004.1999.550610.x; Murray TK, 1999, BEHAV BRAIN RES, V99, P103, DOI 10.1016/S0166-4328(98)00077-1; Nery S, 2002, NAT NEUROSCI, V5, P1279, DOI 10.1038/nn971; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Schoenbaum G, 2003, LEARN MEMORY, V10, P129, DOI 10.1101/lm.55203; Skuse DH, 2000, PEDIATR RES, V47, P9, DOI 10.1203/00006450-200001000-00006; Skuse DH, 1997, NATURE, V387, P705, DOI 10.1038/42706; Thomas NS, 1999, HUM GENET, V104, P43, DOI 10.1007/s004390050908; THORNHILL AR, 1993, DEVELOPMENT, V118, P171; Zechner U, 2001, TRENDS GENET, V17, P697, DOI 10.1016/S0168-9525(01)02446-5	30	159	161	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2005	37	6					625	629		10.1038/ng1577	http://dx.doi.org/10.1038/ng1577			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	931OT	15908950				2022-12-25	WOS:000229495300017
J	Ezratty, EJ; Partridge, MA; Gundersen, GG				Ezratty, EJ; Partridge, MA; Gundersen, GG			Microtubule-induced focal adhesion disassembly is mediated by dynamin and focal adhesion kinase	NATURE CELL BIOLOGY			English	Article							BINDING PROTEIN RHO; CELL-MIGRATION; LYSOPHOSPHATIDIC ACID; SIGNAL-TRANSDUCTION; REGULATES RHO; INTEGRIN; FIBROBLASTS; FAK; PHOSPHORYLATION; STABILIZATION	Imaging studies implicate microtubule targeting of focal adhesions in focal adhesion disassembly, although the molecular mechanism is unknown. Here, we develop a model system of focal adhesion disassembly based on the finding that microtubule regrowth after nocodazole washout induces disassembly of focal adhesions, and that this disassembly occurs independently of Rho and Rac, but depends on focal adhesion kinase (FAK) and dynamin. During disassembly, dynamin interacts with FAK and colocalizes with focal adhesions. Inhibition of dynamin prevents migration of cells with a focal adhesion phenotype. Our results show that focal adhesion disassembly involves microtubules, dynamin and FAK, and is not simply the reversal of focal adhesion formation.	Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Columbia Univ, Dept Pathol, New York, NY 10032 USA	Columbia University; Columbia University	Gundersen, GG (corresponding author), Columbia Univ, Dept Anat & Cell Biol, 630 W 168th St,BB 1217, New York, NY 10032 USA.	ggg1@columbia.edu			NIGMS NIH HHS [GM68595] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068595] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; CHAN PY, 1994, J BIOL CHEM, V269, P20567; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Cook TA, 1998, J CELL BIOL, V141, P175, DOI 10.1083/jcb.141.1.175; Dujardin DL, 2003, J CELL BIOL, V163, P1205, DOI 10.1083/jcb.200310097; Franco SJ, 2004, NAT CELL BIOL, V6, P977, DOI 10.1038/ncb1175; GUNDERSEN GG, 1994, J CELL SCI, V107, P645; GUNDERSEN GG, 1984, CELL, V38, P779, DOI 10.1016/0092-8674(84)90273-3; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; Hauck CR, 2002, IUBMB LIFE, V53, P115, DOI 10.1080/15216540211470; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Kaverina I, 1999, J CELL BIOL, V146, P1033, DOI 10.1083/jcb.146.5.1033; KHARBANDA S, 1995, P NATL ACAD SCI USA, V92, P6132, DOI 10.1073/pnas.92.13.6132; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kranenburg O, 1999, BIOCHEM J, V339, P11, DOI 10.1042/0264-6021:3390011; Kreitzer G, 2000, NAT CELL BIOL, V2, P125, DOI 10.1038/35000081; Krylyshkina O, 2003, J CELL BIOL, V161, P853, DOI 10.1083/jcb.200301102; Krylyshkina O, 2002, J CELL BIOL, V156, P349, DOI 10.1083/jcb.200105051; Liu BP, 1998, CELL ADHES COMMUN, V5, P249, DOI 10.3109/15419069809040295; Maddox AS, 2003, J CELL BIOL, V160, P255, DOI 10.1083/jcb.200207130; Mikhailov A, 1998, CELL MOTIL CYTOSKEL, V41, P325, DOI 10.1002/(SICI)1097-0169(1998)41:4<325::AID-CM5>3.0.CO;2-D; Ochoa GC, 2000, J CELL BIOL, V150, P377, DOI 10.1083/jcb.150.2.377; Orth JD, 2003, CURR OPIN CELL BIOL, V15, P31, DOI 10.1016/S0955-0674(02)00010-8; Ory S, 2002, EUR J CELL BIOL, V81, P351, DOI 10.1078/0171-9335-00255; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Palazzo AF, 2004, SCIENCE, V303, P836, DOI 10.1126/science.1091325; Pierini LM, 2000, BLOOD, V95, P2471; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; REGEN CM, 1992, J CELL BIOL, V119, P1347, DOI 10.1083/jcb.119.5.1347; Ren XD, 2000, J CELL SCI, V113, P3673; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; Schafer DA, 2004, TRAFFIC, V5, P463, DOI 10.1111/j.1600-0854.2004.00199.x; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlunck G, 2004, MOL BIOL CELL, V15, P256, DOI 10.1091/mbc.E03-01-0019; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; Sieg DJ, 1999, J CELL SCI, V112, P2677; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Small JV, 2002, NAT REV MOL CELL BIO, V3, P957, DOI 10.1038/nrm971; Smilenov LB, 1999, SCIENCE, V286, P1172, DOI 10.1126/science.286.5442.1172; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094	50	458	468	2	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2005	7	6					581	U15		10.1038/ncb1262	http://dx.doi.org/10.1038/ncb1262			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	932OD	15895076				2022-12-25	WOS:000229562100012
J	Stech, J; Garn, H; Wegmann, M; Wagner, R; Klenk, HD				Stech, J; Garn, H; Wegmann, M; Wagner, R; Klenk, HD			A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin	NATURE MEDICINE			English	Article							FUSION PEPTIDE MUTANTS; A-VIRUS; PROTEOLYTIC CLEAVAGE; INACTIVATED VIRUS; ANTIBODY-RESPONSE; ACTIVATION; MICE; PATHOGENICITY; PROTECTION; INFECTION	A promising approach to reduce the impact of influenza is the use of an attenuated, live virus as a vaccine. Using reverse genetics, we generated a mutant of strain A/WSN/33 with a modified cleavage site within its hemagglutinin, which depends on proteolytic activation by elastase. Unlike the wildtype, which requires trypsin, this mutant is strictly dependent on elastase. Both viruses grow equally well in cell culture. In contrast to the lethal wild-type virus, the mutant is entirely attenuated in mice. At a dose of 10(5) plaque-forming units, it induced complete protection against lethal challenge. This approach allows the conversion of any epidemic strain into a genetically homologous attenuated virus.	Klinikum Philipps Univ Marburg, Inst Virol, D-35011 Marburg, Germany; Klinikum Philipps Univ Marburg, Inst Klin Chem & Mol Diagnost, Biomed Forschungszentrum, D-35033 Marburg, Germany; Paul Ehrlich Inst, Bundesamt Sera & Impfstoffe, D-63225 Langen, Germany	Philipps University Marburg; Philipps University Marburg; Paul Ehrlich Institute	Stech, J (corresponding author), Klinikum Philipps Univ Marburg, Inst Virol, Postfach 2360, D-35011 Marburg, Germany.	stech@med.uni-marburg.de		Garn, Holger/0000-0002-5178-4023; Stech, Juergen/0000-0002-3187-702X; Wegmann, Michael/0000-0002-1658-1554				BELSHE RB, 1992, J INFECT DIS, V165, P727, DOI 10.1093/infdis/165.4.727; Beyer WEP, 2002, VACCINE, V20, P1340, DOI 10.1016/S0264-410X(01)00471-6; BOSCH FX, 1981, VIROLOGY, V113, P725, DOI 10.1016/0042-6822(81)90201-4; Cross KJ, 2001, EMBO J, V20, P4432, DOI 10.1093/emboj/20.16.4432; GARTEN W, 1981, VIROLOGY, V115, P361, DOI 10.1016/0042-6822(81)90117-3; GOTOH B, 1990, EMBO J, V9, P4189, DOI 10.1002/j.1460-2075.1990.tb07643.x; GRUBER WC, 1998, TXB INFLUENZA, P435; GUNTHER I, 1993, VIRUS RES, V27, P147, DOI 10.1016/0168-1702(93)90078-2; Hoffmann E, 2000, P NATL ACAD SCI USA, V97, P6108, DOI 10.1073/pnas.100133697; HUANG RTC, 1980, VIROLOGY, V104, P294, DOI 10.1016/0042-6822(80)90334-7; Jin H, 2003, VIROLOGY, V306, P18, DOI 10.1016/S0042-6822(02)00035-1; KAWAOKA Y, 1990, VIROLOGY, V179, P759, DOI 10.1016/0042-6822(90)90143-F; KENDAL AP, 1982, CONCEPTS PROCEDURE B, V17, P17; KLENK HD, 1975, VIROLOGY, V68, P426, DOI 10.1016/0042-6822(75)90284-6; LAZAROWITZ SG, 1975, VIROLOGY, V68, P440, DOI 10.1016/0042-6822(75)90285-8; LAZAROWITZ SG, 1973, VIROLOGY, V56, P172, DOI 10.1016/0042-6822(73)90296-1; MAASSAB HF, 1967, NATURE, V213, P612, DOI 10.1038/213612a0; MAEDA T, 1980, FEBS LETT, V122, P283, DOI 10.1016/0014-5793(80)80457-1; Mecham RP, 1997, J BIOL CHEM, V272, P18071, DOI 10.1074/jbc.272.29.18071; MURPHY BR, 1979, INFECT IMMUN, V23, P253, DOI 10.1128/IAI.23.2.253-259.1979; Neumann G, 1999, P NATL ACAD SCI USA, V96, P9345, DOI 10.1073/pnas.96.16.9345; O'Neill E, 2000, J GEN VIROL, V81, P2689, DOI 10.1099/0022-1317-81-11-2689; ORLICH M, 1995, J GEN VIROL, V76, P625, DOI 10.1099/0022-1317-76-3-625; Qiao H, 1999, MOL BIOL CELL, V10, P2759, DOI 10.1091/mbc.10.8.2759; Ribeiro RM, 1998, AIDS, V12, P461, DOI 10.1097/00002030-199805000-00006; RUSSELL SM, 1979, NATURE, V280, P147, DOI 10.1038/280147a0; SCHEIBLAUER H, 1995, ARCH VIROL, V140, P341, DOI 10.1007/BF01309867; SCHERLE PA, 1988, P NATL ACAD SCI USA, V85, P4446, DOI 10.1073/pnas.85.12.4446; SCHOLTISSEK C, 1979, VIROLOGY, V95, P492, DOI 10.1016/0042-6822(79)90503-8; Stech J, 1999, J VIROL, V73, P1878, DOI 10.1128/JVI.73.3.1878-1884.1999; STEINHAUER DA, 1995, J VIROL, V69, P6643, DOI 10.1128/JVI.69.11.6643-6651.1995; Suarez DL, 1998, J VIROL, V72, P6678, DOI 10.1128/JVI.72.8.6678-6688.1998; Takada A, 2003, VACCINE, V21, P3212, DOI 10.1016/S0264-410X(03)00234-2; TAKADA A, 1994, J VET MED SCI, V56, P633, DOI 10.1292/jvms.56.633; WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992; WEBSTER RG, 1980, EUR J IMMUNOL, V10, P396, DOI 10.1002/eji.1830100515; WHITE J, 1981, J CELL BIOL, V89, P674, DOI 10.1083/jcb.89.3.674; WRIGHT PF, 1975, J PEDIATR-US, V87, P1109, DOI 10.1016/S0022-3476(75)80123-5; YAMNIKOVA SS, 1993, VIROLOGY, V197, P558, DOI 10.1006/viro.1993.1629	39	64	97	0	5	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2005	11	6					683	689		10.1038/nm1256	http://dx.doi.org/10.1038/nm1256			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	932YD	15924146	Bronze			2022-12-25	WOS:000229589800037
J	Thomson, JM; Gaucher, EA; Burgan, MF; De Kee, DW; Li, T; Aris, JP; Benner, SA				Thomson, JM; Gaucher, EA; Burgan, MF; De Kee, DW; Li, T; Aris, JP; Benner, SA			Resurrecting ancestral alcohol dehydrogenases from yeast	NATURE GENETICS			English	Article							GENOME	Modern yeast living in fleshy fruits rapidly convert sugars into bulk ethanol through pyruvate. Pyruvate loses carbon dioxide to produce acetaldehyde, which is reduced by alcohol dehydrogenase 1 (Adh1) to ethanol, which accumulates. Yeast later consumes the accumulated ethanol, exploiting Adh2, an Adh1 homolog differing by 24 ( of 348) amino acids. As many microorganisms cannot grow in ethanol, accumulated ethanol may help yeast defend resources in the fruit(1). We report here the resurrection of the last common ancestor(2) of Adh1 and Adh2, called Adh(A). The kinetic behavior of Adh(A) suggests that the ancestor was optimized to make ( not consume) ethanol. This is consistent with the hypothesis that before the Adh1-Adh2 duplication, yeast did not accumulate ethanol for later consumption but rather used Adh(A) to recycle NADH generated in the glycolytic pathway. Silent nucleotide dating suggests that the Adh1-Adh2 duplication occurred near the time of duplication of several other proteins involved in the accumulation of ethanol, possibly in the Cretaceous age when fleshy fruits arose. These results help to connect the chemical behavior of these enzymes through systems analysis to a time of global ecosystem change, a small but useful step towards a planetary systems biology.	Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Fdn Appl Mol Evolut, Gainesville, FL 32601 USA; Univ Florida, Dept Chem, Gainesville, FL 32611 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Benner, SA (corresponding author), Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA.	benner@chem.ufl.edu	Gaucher, Eric/I-7313-2013	Aris, John/0000-0002-6475-064X; Green, Michelle/0000-0002-6055-4342	NATIONAL INSTITUTE ON AGING [R21AG023719] Funding Source: NIH RePORTER; NIA NIH HHS [R21 AG023719-02] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ashburner M, 1998, BIOESSAYS, V20, P949, DOI 10.1002/(SICI)1521-1878(199811)20:11&lt;949::AID-BIES10&gt;3.0.CO;2-0; Barrett PM, 2001, BIOL REV, V76, P411, DOI 10.1017/S1464793101005735; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Benner SA, 2003, ADV ENZYME REGUL, V43, P271, DOI 10.1016/S0065-2571(02)00024-9; Benner SA, 2002, SCIENCE, V296, P864, DOI 10.1126/science.1069863; BERBEE ML, 1993, CAN J BOT, V71, P1114, DOI 10.1139/b93-131; Boulton R.B., 1996, PRINCIPLES PRACTICES, P139; Bozzi A, 1997, BBA-PROTEIN STRUCT M, V1339, P133, DOI 10.1016/S0167-4838(96)00225-7; COLLINSON ME, 1991, PHILOS T ROY SOC B, V333, P197, DOI 10.1098/rstb.1991.0068; ELLINGTON AD, 1987, J THEOR BIOL, V127, P491, DOI 10.1016/S0022-5193(87)80145-5; Fernandez-Espinar MT, 2003, YEAST, V20, P1213, DOI 10.1002/yea.1034; Fersht AR., 1977, ENZYME STRUCTURE MEC; Fleet G.H., 1993, WINE MICROBIOLOGY BI; GANZHORN AJ, 1987, J BIOL CHEM, V262, P3754; Kellis M, 2004, NATURE, V428, P617, DOI 10.1038/nature02424; KREITMAN M, 1995, ANNU REV ECOL SYST, V26, P403, DOI 10.1146/annurev.es.26.110195.002155; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; McGovern PE, 2004, P NATL ACAD SCI USA, V101, P17593, DOI 10.1073/pnas.0407921102; Pretorius IS, 2000, YEAST, V16, P675, DOI 10.1002/1097-0061(20000615)16:8<675::AID-YEA585>3.0.CO;2-B; SCHAAFF I, 1989, YEAST, V5, P285, DOI 10.1002/yea.320050408; SEGAL IH, 1975, ENZYME KINETICS; Stryer L., 1988, BIOCHEMISTRY-US; Sun G, 2002, SCIENCE, V296, P899, DOI 10.1126/science.1069439; SWOFFORD DL, 2001, PHYLOGENETIC ANAL US; THOMSON JM, 2002, THESIS U FLORIDA GAI; Thornton JW, 2004, NAT REV GENET, V5, P366, DOI 10.1038/nrg1324; WEINHOLD EG, 1991, P NATL ACAD SCI USA, V88, P8420, DOI 10.1073/pnas.88.19.8420; WILLS C, 1976, NATURE, V261, P26, DOI 10.1038/261026a0; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555	30	222	232	2	112	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2005	37	6					630	635		10.1038/ng1553	http://dx.doi.org/10.1038/ng1553			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	931OT	15864308	Green Accepted			2022-12-25	WOS:000229495300018
J	Brittain, SM; Ficarro, SB; Brock, A; Peters, EC				Brittain, SM; Ficarro, SB; Brock, A; Peters, EC			Enrichment and analysis of peptide subsets using fluorous affinity tags and mass spectrometry	NATURE BIOTECHNOLOGY			English	Article							REVERSE-PHASE SILICA; SEPARATION; PHOSPHOPEPTIDES; PURIFICATION; PROTEINS; STRATEGY; PHOSPHORYLATION; PHOSPHOPROTEOME; IDENTIFICATION; DERIVATIZATION	Although mass spectrometry has become a powerful tool for the functional analysis of biological systems, complete proteome characterization cannot yet be achieved. Instead, the sheer complexity of living organisms demands fractionation of cellular extracts to enable more targeted analyses. Here, we introduce the concept of 'fluorous proteomics, ' whereby specific peptide subsets from samples of biological origin are tagged with perfluorinated moieties and subsequently enriched by solid-phase extraction over a fluorous-functionalized stationary phase. This approach is extremely selective, yet can readily be tailored to enrich different subsets of peptides. Additionally, this methodology overcomes many of the limitations of traditional bioaffinity-based enrichment strategies, while enabling new affinity enrichment schemes impossible to implement with bioaffinity reagents. The potential of this methodology is demonstrated by the facile enrichment of peptides bearing particular side-chain functionalities or post-translational modifications from tryptic digests of individual proteins as well as whole cell lysates.	Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA	Novartis	Peters, EC (corresponding author), Novartis Res Fdn, Genom Inst, 10675 John Jay Hopkins Dr, San Diego, CA 92121 USA.	peters@gnf.org	Peters, Eric/W-2739-2019					BYFORD MF, 1991, BIOCHEM J, V280, P261, DOI 10.1042/bj2800261; Campbell DA, 2003, CURR OPIN CHEM BIOL, V7, P296, DOI 10.1016/S1367-5931(03)00029-2; Chen XH, 1999, ANAL BIOCHEM, V273, P192, DOI 10.1006/abio.1999.4243; Curran D, 2001, GREEN CHEM, V3, pG3, DOI 10.1039/b100266j; Curran DP, 2001, SYNLETT, P1488; Curran DP, 1999, J AM CHEM SOC, V121, P9069, DOI 10.1021/ja991496r; de Visser PC, 2003, TETRAHEDRON LETT, V44, P9013, DOI 10.1016/j.tetlet.2003.09.220; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hale JE, 2000, ANAL BIOCHEM, V287, P110, DOI 10.1006/abio.2000.4834; HORVATH IT, 1994, SCIENCE, V266, P72, DOI 10.1126/science.266.5182.72; Kainz S, 1998, SYNTHESIS-STUTTGART, P1425; Khidekel N, 2004, P NATL ACAD SCI USA, V101, P13132, DOI 10.1073/pnas.0403471101; Luo ZY, 2001, SCIENCE, V291, P1766, DOI 10.1126/science.1057567; McLachlin DT, 2003, ANAL CHEM, V75, P6826, DOI 10.1021/ac034989u; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; Miura T, 2003, ANGEW CHEM INT EDIT, V42, P2047, DOI 10.1002/anie.200250531; Nakamura Y, 2000, TETRAHEDRON LETT, V41, P57, DOI 10.1016/S0040-4039(99)01999-1; Nilsson CL, 2003, ANAL CHEM, V75, p348A, DOI 10.1021/ac031373w; Oda Y, 2001, NAT BIOTECHNOL, V19, P379, DOI 10.1038/86783; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Peters EC, 2001, RAPID COMMUN MASS SP, V15, P2387, DOI 10.1002/rcm.517.abs; Posewitz MC, 1999, ANAL CHEM, V71, P2883, DOI 10.1021/ac981409y; Salomon AR, 2003, P NATL ACAD SCI USA, V100, P443, DOI 10.1073/pnas.2436191100; Shen M, 2003, MOL CELL PROTEOMICS, V2, P315, DOI 10.1074/mcp.M300028-MCP200; Steen H, 2002, J AM SOC MASS SPECTR, V13, P996, DOI 10.1016/S1044-0305(02)00415-4; Trester-Zedlitz M, 2003, J AM CHEM SOC, V125, P2416, DOI 10.1021/ja026917a; Wells L, 2002, MOL CELL PROTEOMICS, V1, P791, DOI 10.1074/mcp.M200048-MCP200; Zhang H, 2003, NAT BIOTECHNOL, V21, P660, DOI 10.1038/nbt827; Zhou HL, 2001, NAT BIOTECHNOL, V19, P375, DOI 10.1038/86777	30	158	163	1	57	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2005	23	4					463	468		10.1038/nbt1076	http://dx.doi.org/10.1038/nbt1076			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	914AR	15768030				2022-12-25	WOS:000228197300030
J	Ingouff, M; Gerald, JNF; Guerin, C; Robert, H; Sorensen, MB; Van Damme, D; Geelen, D; Blanchoin, L; Berger, F				Ingouff, M; Gerald, JNF; Guerin, C; Robert, H; Sorensen, MB; Van Damme, D; Geelen, D; Blanchoin, L; Berger, F			Plant formin AtFH5 is an evolutionarily conserved actin nucleator involved in cytokinesis	NATURE CELL BIOLOGY			English	Article							ARABIDOPSIS-THALIANA; CELL PLATE; SEED DEVELOPMENT; ENDOSPERM; PROTEIN; TRANSFORMATION; ORGANIZATION; CYTOSKELETON; INTERPHASE; FILAMENTS	Formins are actin-organizing proteins that are involved in cytokinesis and cell polarity(1). In the plant Arabidopsis thaliana, there are more than 20 formin homologues, all of which have unknown roles(2). In this study, we characterize specific cellular and molecular functions of the Arabidopsis formin AtFH5. Despite the low identity of AtFH5 to yeast and mammalian formins, the AtFH5 protein interacts with the barbed end of actin filaments and nucleates actin-filament polymerization in vitro, as is the case in yeast and mammals. In vivo, the AtFH5-GFP fusion protein localizes to the cell plate, a plant-specific membranous component that is assembled at the plane of cell division. Consistent with these data, loss of function of atfh5 compromises cytokinesis in the seed endosperm. Furthermore, endogenous AtFH5 transcripts accumulate in the posterior pole of the endosperm and loss of function of atfh5 perturbs proper morphogenesis of the endosperm posterior pole. Although cytokinesis in animals, yeast and plants occurs through morphologically distinct mechanisms, our study finds that formin recruitment to sites of actin assembly is a common feature of cell division among eukaryotes.	Ecole Normale Super Lyon, Inst Federat Rech 128, UMR 5667, EMBO YIP Team, F-69364 Lyon, France; Univ Grenoble 1, CNRS, CEA, Physiol Cellulaire Vegetale Lab, F-38054 Grenoble, France; Ghent Univ VIB, Dept Plant Syst Biol, B-9052 Ghent, Belgium	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Ecole Normale Superieure de Lyon (ENS de LYON); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Flanders Institute for Biotechnology (VIB); Ghent University	Berger, F (corresponding author), Natl Univ Singapore, Temasek Lifesci Lab, 1 Res Link, Singapore 117604, Singapore.	laurent.blanchoin@cea.fr; fred@tll.org.sg	Berger, Frédéric/B-6947-2009; Ingouff, Mathieu/F-7373-2016; van damme, daniel/ABA-1397-2020; Sørensen, Mikael Blom/B-4183-2012; van damme, daniel/F-6139-2014; robert, helene/I-3130-2012	van damme, daniel/0000-0002-9385-4851; van damme, daniel/0000-0002-9385-4851; robert, helene/0000-0002-6610-836X; INGOUFF, Mathieu/0000-0002-6106-4564; Berger, Frederic/0000-0002-3609-8260				Berger F, 2003, CURR OPIN PLANT BIOL, V6, P42, DOI 10.1016/S1369526602000043; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; Boisnard-Lorig C, 2001, PLANT CELL, V13, P495, DOI 10.1105/tpc.13.3.495; Brown RC, 1999, SEX PLANT REPROD, V12, P32, DOI 10.1007/s004970050169; Cheung AY, 2004, PLANT CELL, V16, P257, DOI 10.1105/tpc.016550; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Deeks MJ, 2003, CURR OPIN PLANT BIOL, V6, P561, DOI 10.1016/j.pbi.2003.09.013; Deeks MJ, 2002, TRENDS PLANT SCI, V7, P492, DOI 10.1016/S1360-1385(02)02341-5; Endle MC, 1998, EUR J CELL BIOL, V77, P10, DOI 10.1016/S0171-9335(98)80097-6; Evangelista M, 2003, J CELL SCI, V116, P2603, DOI 10.1242/jcs.00611; Evangelista M, 2002, NAT CELL BIOL, V4, P32, DOI 10.1038/ncb718; Gu XJ, 1997, PLANT CELL, V9, P157, DOI 10.1105/tpc.9.2.157; Guitton AE, 2004, DEVELOPMENT, V131, P2971, DOI 10.1242/dev.01168; Hellens RP, 2000, PLANT MOL BIOL, V42, P819, DOI 10.1023/A:1006496308160; Huang SJ, 2003, J BIOL CHEM, V278, P44832, DOI 10.1074/jbc.M306670200; Huang SR, 1997, PLANT MOL BIOL, V33, P125, DOI 10.1023/A:1005741514764; JACKSON D, 1992, MOL PLANT PATHOL, V1, P163; Karimi M, 2002, TRENDS PLANT SCI, V7, P193, DOI 10.1016/S1360-1385(02)02251-3; Ketelaar T, 2004, PLANT PHYSIOL, V136, P3990, DOI 10.1104/pp.104.050799; Kovar DR, 2003, J CELL BIOL, V161, P875, DOI 10.1083/jcb.200211078; Mayer U, 2002, CURR OPIN PLANT BIOL, V5, P494, DOI 10.1016/S1369-5266(02)00302-3; Nguyen H, 2001, INT J PLANT SCI, V162, P1, DOI 10.1086/317898; PALEVITZ BA, 1974, CHROMOSOMA, V46, P327, DOI 10.1007/BF00284885; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; Robinson DN, 2004, CURR OPIN CELL BIOL, V16, P182, DOI 10.1016/j.ceb.2004.02.002; SCHMIT AC, 1987, J CELL BIOL, V105, P2157, DOI 10.1083/jcb.105.5.2157; Shimada A, 2004, MOL CELL, V13, P511, DOI 10.1016/S1097-2765(04)00059-0; Sorensen MB, 2002, DEVELOPMENT, V129, P5567, DOI 10.1242/dev.00152; Sorensen MB, 2001, CURR BIOL, V11, P277, DOI 10.1016/S0960-9822(01)00072-0; Staehlin LA, 1996, CELL, V84, P821, DOI 10.1016/S0092-8674(00)81060-0; Valster AH, 1997, PLANT CELL, V9, P1815; Verma DPS, 2001, ANNU REV PLANT PHYS, V52, P751, DOI 10.1146/annurev.arplant.52.1.751; Xu YW, 2004, CELL, V116, P711, DOI 10.1016/S0092-8674(04)00210-7; ZIGMOND SH, 2004, CURR OPIN CELL BIOL, V16, P1	34	130	140	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2005	7	4					374	U34		10.1038/ncb1238	http://dx.doi.org/10.1038/ncb1238			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	912KA	15765105				2022-12-25	WOS:000228075500013
J	Sheridan, C				Sheridan, C			Tysabri raises alarm bells on drug class	NATURE BIOTECHNOLOGY			English	News Item								Tysabri, a first-in-class IgG4 monoclonal antibody, had prompted multibillion dollar revenue forecasts on the strength of its potential as a treatment for Multiple Sclerosis and other autoimmune disorders. Although the financial implications of Elan's and Biogen Idec's shock withdrawal of the drug from the market, were immediate and dramatic, the wider consequences remain unclear. Meanwhile, ripples from the withdrawal are spreading to other companies that are developing drugs in the same class, some of which have had to interrupt clinical trials as a precautionary measure.											0	10	11	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2005	23	4					397	398		10.1038/nbt0405-397	http://dx.doi.org/10.1038/nbt0405-397			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	914AR	15815649				2022-12-25	WOS:000228197300002
J	Helgason, A; Yngvadottir, B; Hrafnkelsson, B; Gulcher, J; Stefansson, K				Helgason, A; Yngvadottir, B; Hrafnkelsson, B; Gulcher, J; Stefansson, K			An Icelandic example of the impact of population structure on association studies	NATURE GENETICS			English	Article							GENETIC ASSOCIATION; GAELIC ANCESTRY; CONFERS RISK; DIFFERENTIATION; STRATIFICATION; STROKE; MTDNA; DRIFT	The impact of population structure on association studies undertaken to identify genetic variants underlying common human diseases is an issue of growing interest(1-4). Spurious associations of alleles with disease phenotypes may be obtained or true associations overlooked when allele frequencies differ notably among subpopulations that are not represented equally among cases and controls. Population structure influences even carefully designed studies and can affect the validity of association results(1,2). Most study designs address this problem by sampling cases and controls from groups that share the same nationality or self-reported ethnic background, with the implicit assumption that no substructure exists within such groups. We examined population structure in the Icelandic gene pool using extensive genealogical and genetic data. Our results indicate that sampling strategies need to take account of substructure even in a relatively homogenous(5) genetic isolate(6). This will probably be even more important in larger populations.	deCODE Genet, IS-101 Reykjavik, Iceland; Univ Iceland, IS-101 Reykjavik, Iceland	University of Iceland	Helgason, A (corresponding author), deCODE Genet, Sturlugata 8, IS-101 Reykjavik, Iceland.	agnar@decode.is	Stefansson, Kari/AAE-7187-2019; Peng, Bo/A-6920-2009; Helgason, Agnar/K-1522-2015	Peng, Bo/0000-0001-8225-2284; Helgason, Agnar/0000-0002-8545-3767				Ardlie KG, 2002, AM J HUM GENET, V71, P304, DOI 10.1086/341719; BARBUJANI G, 1991, AM J HUM GENET, V48, P398; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; CAVALLISFORZA LL, 1967, AM J HUM GENET, V19, P233, DOI 10.2307/2406616; CLAYTON D, 2001, HDB STAT GENETICS, P519; Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x; EXCOFFIER L, 1992, GENETICS, V131, P491; Excoffier L, 2001, HDB STAT GENETICS, P271; FALSETTI AB, 1993, ANN HUM BIOL, V20, P215, DOI 10.1080/03014469300002652; Freedman ML, 2004, NAT GENET, V36, P388, DOI 10.1038/ng1333; Gretarsdottir S, 2003, NAT GENET, V35, P131, DOI 10.1038/ng1245; Helgadottir A, 2004, NAT GENET, V36, P233, DOI 10.1038/ng1311; Helgason A, 2000, AM J HUM GENET, V67, P697, DOI 10.1086/303046; Helgason A, 2003, ANN HUM GENET, V67, P281, DOI 10.1046/j.1469-1809.2003.00046.x; Helgason A, 2003, AM J HUM GENET, V72, P1370, DOI 10.1086/375453; Helgason A, 2001, AM J HUM GENET, V68, P723, DOI 10.1086/318785; JORDE LB, 1982, HUM HERED, V32, P1, DOI 10.1159/000153251; JORDE LB, 1980, CURRENT DEV ANTHR GE, V1, P133; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Kong A, 2004, NAT GENET, V36, P1203, DOI 10.1038/ng1445; Marchini J, 2004, NAT GENET, V36, P512, DOI 10.1038/ng1337; Nicholson G, 2002, J ROY STAT SOC B, V64, P695, DOI 10.1111/1467-9868.00357; Raymond M, 1995, EVOLUTION, V49, P1280, DOI 10.1111/j.1558-5646.1995.tb04456.x; Reich DE, 2001, GENET EPIDEMIOL, V20, P4, DOI 10.1002/1098-2272(200101)20:1<4::AID-GEPI2>3.0.CO;2-T; Steffensen J., 1975, MENNING MEINSEMDIR R; TILLS D, 1982, ANN HUM BIOL, V9, P507, DOI 10.1080/03014468200006041; TILLS D, 1977, HUM HERED, V27, P153, DOI 10.1159/000152865; WILLIAMS JT, 1993, HUM BIOL, V65, P167; WORKMAN PL, 1976, AM J PHYS ANTHROPOL, V44, P341, DOI 10.1002/ajpa.1330440216; Ziv E, 2003, PHARMACOGENOMICS, V4, P431, DOI 10.1517/phgs.4.4.431.22758	30	205	208	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2005	37	1					90	95		10.1038/ng1492	http://dx.doi.org/10.1038/ng1492			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	883FX	15608637				2022-12-25	WOS:000225997500026
J	McClain, MT; Heinlen, LD; Dennis, GJ; Roebuck, J; Harley, JB; James, JA				McClain, MT; Heinlen, LD; Dennis, GJ; Roebuck, J; Harley, JB; James, JA			Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry	NATURE MEDICINE			English	Article							EPSTEIN-BARR-VIRUS; B-CELL EPITOPES; AUTOANTIBODIES; ERYTHEMATOSUS; ANTIBODIES; INFECTION; RESPONSES; PEPTIDES; INDUCE; RO60	The origins of autoimmunity in systemic lupus erythematosus (SLE) are thought to involve both genetic and environmental factors. To identify environmental agents that could potentially incite autoimmunity, we have traced the autoantibody response in human SLE back in time, prior to clinical disease onset, and identified the initial autoantigenic epitope for some lupus patients positive for antibodies to 60 kDa Ro. This initial epitope directly cross-reacts with a peptide from the latent viral protein Epstein-Barr virus nuclear antigen-1 (EBNA-1). Animals immunized with either the first epitope of 60 kDa Ro or the cross-reactive EBNA-1 epitope progressively develop autoantibodies binding multiple epitopes of Ro and spliceosomal autoantigens. They eventually acquire clinical symptoms of lupus such as leukopenia, thrombocytopenia and renal dysfunction. These data support the hypothesis that some humoral autoimmunity in human lupus arises through molecular mimicry between EBNA-1 and lupus autoantigens and provide further evidence to suspect an etiologic role for Epstein-Barr virus in SLE.	Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK 73104 USA; Dept Vet Affairs Med Ctr, Oklahoma City, OK 73104 USA; Walter Reed Army Med Ctr, Dept Rheumatol, Washington, DC 20307 USA; NIAMSD, Bethesda, MD 20892 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	James, JA (corresponding author), Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA.	jamesj@omrf.ouhsc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR014467, P20RR015577, P20RR020143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R41AI054117, T32AI007633, R01AI024717, R01AI047575, R37AI024717, R21AI053747, R01AI031584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR048940, R03AR045084, R29AR045451, R01AR042460, P50AR045231, R01AR045451, R01AR048045] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015223] Funding Source: NIH RePORTER; NCRR NIH HHS [RR20143, RR14467, RR15577] Funding Source: Medline; NIAID NIH HHS [AI53747, T32 AI007633, AI54117, AI31584, AI24717, AI47575] Funding Source: Medline; NIAMS NIH HHS [AR48045, AR48940, AR45451, AR45084, AR45231, AR42460] Funding Source: Medline; NIDCR NIH HHS [DE015223] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Arbuckle MR, 1999, SCAND J IMMUNOL, V50, P447; Arbuckle MR, 2003, NEW ENGL J MED, V349, P1526, DOI 10.1056/NEJMoa021933; Ascherio A, 2001, JAMA-J AM MED ASSOC, V286, P3083, DOI 10.1001/jama.286.24.3083; DALE JB, 1985, J EXP MED, V162, P583, DOI 10.1084/jem.162.2.583; Deshmukh US, 2000, J IMMUNOL, V164, P6655, DOI 10.4049/jimmunol.164.12.6655; Deshmukh US, 1999, J EXP MED, V189, P531, DOI 10.1084/jem.189.3.531; Goodnow CC, 1996, P NATL ACAD SCI USA, V93, P2264, DOI 10.1073/pnas.93.6.2264; Harley JB, 1998, IMMUNOLOGIST, V6, P79; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; HUANG SC, 1997, J CLIN IMMUNOL, V156, P4059; James JA, 1997, J CLIN INVEST, V100, P3019, DOI 10.1172/JCI119856; JAMES JA, 1992, J IMMUNOL, V148, P2074; James JA, 2001, ARTHRITIS RHEUM-US, V44, P1122, DOI 10.1002/1529-0131(200105)44:5<1122::AID-ANR193>3.0.CO;2-D; JAMES JA, 1997, ANN NY ACAD SCI, V5, P124; Kang I, 2004, J IMMUNOL, V172, P1287, DOI 10.4049/jimmunol.172.2.1287; Kirvan CA, 2003, NAT MED, V9, P914, DOI 10.1038/nm892; Kong PL, 2003, ANN NY ACAD SCI, V987, P60, DOI 10.1111/j.1749-6632.2003.tb06033.x; Levin MC, 2002, NAT MED, V8, P509, DOI 10.1038/nm0502-509; McClain MT, 2004, P NATL ACAD SCI USA, V101, P3551, DOI 10.1073/pnas.0306267101; McClain MT, 2003, J MED VIROL, V70, P253, DOI 10.1002/jmv.10385; McClain MT, 2002, SCAND J IMMUNOL, V56, P399, DOI 10.1046/j.1365-3083.2002.01141.x; McClain MT, 2002, J IMMUNOL, V168, P2054, DOI 10.4049/jimmunol.168.4.2054; McClain MT, 2001, FRONT BIOSCI-LANDMRK, V6, pE137, DOI 10.2741/McClain; Olsen JK, 2001, J CLIN INVEST, V108, P311; Riemekasten G, 1998, J CLIN INVEST, V102, P754, DOI 10.1172/JCI2749; Routsias JG, 1998, SCAND J IMMUNOL, V47, P280; SABBATINI A, 1993, EUR J IMMUNOL, V23, P1146, DOI 10.1002/eji.1830230525; Scofield AN, 2001, LUPUS, V10, P547, DOI 10.1191/096120301701549679; Thompson MP, 2004, CLIN CANCER RES, V10, P803, DOI 10.1158/1078-0432.CCR-0670-3; VAUGHAN JH, 1995, J CLIN INVEST, V95, P1316, DOI 10.1172/JCI117782	30	296	307	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2005	11	1					85	89		10.1038/nm1167	http://dx.doi.org/10.1038/nm1167			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	884ZJ	15619631				2022-12-25	WOS:000226124900037
J	Sano, S; Chan, KS; Carbajal, S; Clifford, J; Peavey, M; Kiguchi, K; Itami, S; Nickoloff, BJ; DiGiovanni, J				Sano, S; Chan, KS; Carbajal, S; Clifford, J; Peavey, M; Kiguchi, K; Itami, S; Nickoloff, BJ; DiGiovanni, J			Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model	NATURE MEDICINE			English	Article							RECOMBINANT GAMMA-INTERFERON; BONE-MARROW TRANSPLANTATION; GROWTH-FACTOR RECEPTOR; CELL-GROWTH; TRANSCRIPTION FACTOR; PLAQUE PSORIASIS; HAIR FOLLICLE; SKIN; EXPRESSION; INHIBITION	Here we report that epidermal keratinocytes in psoriatic lesions are characterized by activated Stat3. Transgenic mice with keratinocytes expressing a constitutively active Stat3 (K5.Stat3C mice) develop a skin phenotype either spontaneously, or in response to wounding, that closely resembles psoriasis. Keratinocytes from K5. Stat3C mice show upregulation of several molecules linked to the pathogenesis of psoriasis. In addition, the development of psoriatic lesions in K5. Stat3C mice requires cooperation between Stat3 activation in keratinocytes and activated T cells. Finally, abrogation of Stat3 function by a decoy oligonucleotide inhibits the onset and reverses established psoriatic lesions in K5. Stat3C mice. Thus, targeting Stat3 may be potentially therapeutic in the treatment of psoriasis.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, Smithville, TX 78957 USA; Louisiana State Univ, Sch Med, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Feist Weiller Canc Ctr, Shreveport, LA 71130 USA; Osaka Univ, Grad Sch, Dept Dermatol, Suita, Osaka 5650871, Japan; Loyola Univ, Cardinal Bernardin Canc Ctr, Dept Pathol, Maywood, IL 60153 USA; Loyola Univ, Cardinal Bernardin Canc Ctr, Dept Microbiol & Immunol, Maywood, IL 60153 USA	University of Texas System; UTMD Anderson Cancer Center; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Osaka University; Loyola University Chicago; Loyola University Chicago	DiGiovanni, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, 1808 Pk Rd 1C,POB 389, Smithville, TX 78957 USA.	ssano@mdanderson.org; jdigiovanni@sprd1.mdacc.tmc.edu			NATIONAL CANCER INSTITUTE [R01CA076520, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784, U01ES011047] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA76520] Funding Source: Medline; NIAMS NIH HHS [AR40065] Funding Source: Medline; NIEHS NIH HHS [U01ES11047, ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAKER BS, 1988, SCAND J IMMUNOL, V28, P735, DOI 10.1111/j.1365-3083.1988.tb01507.x; Blumberg H, 2001, CELL, V104, P9, DOI 10.1016/S0092-8674(01)00187-8; Bos JD, 1999, IMMUNOL TODAY, V20, P40, DOI 10.1016/S0167-5699(98)01381-4; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; CALDENHOVEN E, 1995, J BIOL CHEM, V270, P25778, DOI 10.1074/jbc.270.43.25778; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Chan KS, 2004, CANCER RES, V64, P2382, DOI 10.1158/0008-5472.CAN-03-3197; Christophers E, 1996, INT ARCH ALLERGY IMM, V110, P199, DOI 10.1159/000237288; Cook PW, 1997, J CLIN INVEST, V100, P2286, DOI 10.1172/JCI119766; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; EEDY DJ, 1990, BRIT MED J, V300, P908, DOI 10.1136/bmj.300.6729.908; GARDEMBASPAIN M, 1990, ARCH DERMATOL, V126, P1523, DOI 10.1001/archderm.1990.01670350139033; Ghadially R, 1996, J INVEST DERMATOL, V107, P558, DOI 10.1111/1523-1747.ep12582813; Gilhar A, 1997, J INVEST DERMATOL, V109, P283, DOI 10.1111/1523-1747.ep12335758; Gottlieb AB, 2002, CLIN IMMUNOL, V105, P105, DOI 10.1006/clim.2002.5289; GRIFFITHS CEM, 1989, J AM ACAD DERMATOL, V20, P617, DOI 10.1016/S0190-9622(89)70073-6; HERTLE MD, 1992, J CLIN INVEST, V89, P1892, DOI 10.1172/JCI115794; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Koo J, 1997, Adv Dermatol, V12, P47; Krueger JG, 2002, J AM ACAD DERMATOL, V46, P1, DOI 10.1067/mjd.2002.120568; Lebwohl M, 2003, NEW ENGL J MED, V349, P2004, DOI 10.1056/NEJMoa030002; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Leong PL, 2003, P NATL ACAD SCI USA, V100, P4138, DOI 10.1073/pnas.0534764100; LEUNG DYM, 1995, J CLIN INVEST, V96, P2106, DOI 10.1172/JCI118263; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lew W, 2004, TRENDS IMMUNOL, V25, P295, DOI 10.1016/j.it.2004.03.006; LEWIS HM, 1993, BRIT J DERMATOL, V129, P514, DOI 10.1111/j.1365-2133.1993.tb00477.x; Li AG, 2004, EMBO J, V23, P1770, DOI 10.1038/sj.emboj.7600183; McKenzie RC, 2003, EXP DERMATOL, V12, P337, DOI 10.1034/j.1600-0625.2003.00100.x; MILLER RAW, 1982, INT J DERMATOL, V21, P192, DOI 10.1111/j.1365-4362.1982.tb02070.x; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; NICKOLOFF BJ, 1989, BRIT J DERMATOL, V121, P161, DOI 10.1111/j.1365-2133.1989.tb01795.x; Nickoloff BJ, 1999, AM J PATHOL, V155, P145, DOI 10.1016/S0002-9440(10)65109-7; Ortonne JP, 1996, BRIT J DERMATOL, V135, P1, DOI 10.1111/j.1365-2133.1996.tb15660.x; Piepkorn M, 1998, J INVEST DERMATOL, V111, P715, DOI 10.1046/j.1523-1747.1998.00390.x; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; Sano S, 2001, J INVEST DERM SYMP P, V6, P43, DOI 10.1046/j.0022-202x.2001.00004.x; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Sato T, 1997, BLOOD, V90, P4749, DOI 10.1182/blood.V90.12.4749.4749_4749_4758; Schon MP, 1999, J INVEST DERMATOL, V112, P405, DOI 10.1046/j.1523-1747.1999.00538.x; Takeda J, 2000, J DERMATOL SCI, V23, P147, DOI 10.1016/S0923-1811(00)00082-7; THEWES M, 1991, ARCH DERMATOL RES, V283, P465, DOI 10.1007/BF00371784; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; VALDIMARSSON H, 1995, IMMUNOL TODAY, V16, P145, DOI 10.1016/0167-5699(95)80132-4; WroneSmith T, 1996, J CLIN INVEST, V98, P1878, DOI 10.1172/JCI118989; Xia YP, 2003, BLOOD, V102, P161, DOI 10.1182/blood-2002-12-3793	46	538	596	3	48	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2005	11	1					43	49		10.1038/nm1162	http://dx.doi.org/10.1038/nm1162			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	884ZJ	15592573				2022-12-25	WOS:000226124900031
J	Spanagel, R; Pendyala, G; Abarca, C; Zghoul, T; Sanchis-Segura, C; Magnone, MC; Lascorz, J; Depner, M; Holzberg, D; Soyka, M; Schreiber, S; Matsuda, F; Lathrop, M; Schumann, G; Albrecht, U				Spanagel, R; Pendyala, G; Abarca, C; Zghoul, T; Sanchis-Segura, C; Magnone, MC; Lascorz, J; Depner, M; Holzberg, D; Soyka, M; Schreiber, S; Matsuda, F; Lathrop, M; Schumann, G; Albrecht, U			The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption	NATURE MEDICINE			English	Article							AMINO-ACIDS; COCAINE SENSITIZATION; CIRCADIAN GENES; ACAMPROSATE; ETHANOL; DEPENDENCE; DOPAMINE; EXPRESSION; REWARD; NEUROBIOLOGY	Period (Per) genes are involved in regulation of the circadian clock and are thought to modulate several brain functions. We demonstrate that Per2(Brdm1) mutant mice, which have a deletion in the PAS domain of the Per2 protein, show alterations in the glutamatergic system. Lowered expression of the glutamate transporter Eaat1 is observed in these animals, leading to reduced uptake of glutamate by astrocytes. As a consequence, glutamate levels increase in the extracellular space of Per2(Brdm1) mutant mouse brains. This is accompanied by increased alcohol intake in these animals. In humans, variations of the PER2 gene are associated with regulation of alcohol consumption. Acamprosate, a drug used to prevent craving and relapse in alcoholic patients is thought to act by dampening a hyper-glutamatergic state. This drug reduced augmented glutamate levels and normalized increased alcohol consumption in Per2(Brdm1) mutant mice. Collectively, these data establish glutamate as a link between dysfunction of the circadian clock gene Per2 and enhanced alcohol intake.	Cent Inst Mental Hlth, Dept Psychopharmacol, D-68159 Mannheim, Germany; Cent Inst Mental Hlth, Dept Psychiat, D-68159 Mannheim, Germany; Univ Fribourg, Dept Med, Div Biochem, CH-1700 Fribourg, Switzerland; Free Univ Brussels, Dept Pharmaceut Chem, B-1090 Brussels, Belgium; Max Planck Inst Expt Endocrinol, D-30625 Hannover, Germany; Univ Munich, Dept Psychiat & Psychotherapy, D-80336 Munich, Germany; Univ Kiel, Inst Clin Mol Biol, UKSH Kiel, D-24098 Kiel, Germany; Ctr Natl Genotypage, F-91057 Evry, France	Central Institute of Mental Health; Central Institute of Mental Health; University of Fribourg; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Max Planck Society; University of Munich; University of Kiel; Schleswig Holstein University Hospital; CEA; UDICE-French Research Universities; Universite Paris Saclay	Spanagel, R (corresponding author), Cent Inst Mental Hlth, Dept Psychopharmacol, J5, D-68159 Mannheim, Germany.	spanagel@zi-mannheim.de; urs.albrecht@unifr.ch	Sanchis-Segura, Carla/C-5222-2012; Albrecht, Urs/A-9831-2011; Matsuda, Fumihiko/B-9893-2009; Schumann, Gunter/H-1013-2013; Jansen, Heiko T./A-5770-2008; s, c/Y-9655-2019	Sanchis-Segura, Carla/0000-0002-6951-5972; Albrecht, Urs/0000-0002-0663-8676; Jansen, Heiko T./0000-0003-0178-396X; s, c/0000-0002-6951-5972				Abarca C, 2002, P NATL ACAD SCI USA, V99, P9026, DOI 10.1073/pnas.142039099; Albrecht U, 2001, J BIOL RHYTHM, V16, P100, DOI 10.1177/074873001129001791; Albrecht U, 2002, J APPL PHYSIOL, V92, P1348, DOI 10.1152/japplphysiol.00759.2001; Andretic R, 1999, SCIENCE, V285, P1066, DOI 10.1126/science.285.5430.1066; ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775; Aronica E, 2003, EUR J NEUROSCI, V17, P2106, DOI 10.1046/j.1460-9568.2003.02657.x; BUCHOLZ KK, 1994, J STUD ALCOHOL, V55, P149, DOI 10.15288/jsa.1994.55.149; Buijs RM, 2001, NAT REV NEUROSCI, V2, P521, DOI 10.1038/35081582; Cano-Cebrian MJ, 2003, N-S ARCH PHARMACOL, V368, P324, DOI 10.1007/s00210-003-0795-3; Dahchour A, 2000, PROG NEUROBIOL, V60, P343, DOI 10.1016/S0301-0082(99)00031-3; Dahchour A, 2003, ALCOHOL CLIN EXP RES, V27, P465, DOI 10.1097/01.ALC.0000056617.68874.18; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Ebling FJP, 1996, PROG NEUROBIOL, V50, P109, DOI 10.1016/S0301-0082(96)00032-9; Hastings MH, 2003, NAT REV NEUROSCI, V4, P649, DOI 10.1038/nrn1177; Heinz A, 2003, PHARMACOPSYCHIATRY, V36, pS255; Jelic P, 1998, PSYCHOPHARMACOLOGY, V138, P143, DOI 10.1007/s002130050656; King DP, 2000, ANNU REV NEUROSCI, V23, P713, DOI 10.1146/annurev.neuro.23.1.713; Koob GF, 2002, ALCOHOL CLIN EXP RES, V26, P586, DOI 10.1111/j.1530-0277.2002.tb02578.x; Krystal JH, 2003, PHARMACOL THERAPEUT, V99, P79, DOI 10.1016/S0163-7258(03)00054-8; Le AD, 2002, PHARMACOL THERAPEUT, V94, P137, DOI 10.1016/S0163-7258(02)00200-0; LITTLETON J, 1995, ADDICTION, V90, P1179, DOI 10.1046/j.1360-0443.1995.90911793.x; LIU Y, IN PRESS NEUROPSYCHO; Mann K, 2004, ALCOHOL CLIN EXP RES, V28, P51, DOI 10.1097/01.ALC.0000108656.81563.05; Masubuchi S, 2000, EUR J NEUROSCI, V12, P4206, DOI 10.1046/j.1460-9568.2000.01313.x; Matsumoto H, 2002, ADDICT BIOL, V7, P5, DOI 10.1080/135562101200100553; McQuade JA, 2003, ADDICT BIOL, V8, P295, DOI 10.1080/13556210310001602202; Nikaido T, 2001, MOL PHARMACOL, V59, P894, DOI 10.1124/mol.59.4.894; Pulvirenti L, 2001, REV NEUROSCIENCE, V12, P141; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Rogers H Lynn, 2002, AAOHN J, V50, P449; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Salamone JD, 2003, J PHARMACOL EXP THER, V305, P1, DOI 10.1124/jpet.102.035063; Sass H, 1996, ARCH GEN PSYCHIAT, V53, P673; Schreiber R, 2000, Med Sci Monit, V6, P649; Schumann G, 2003, BIOL PSYCHIAT, V54, P1422, DOI 10.1016/S0006-3223(03)00635-8; Siggins GR, 2003, ANN NY ACAD SCI, V1003, P196, DOI 10.1196/annals.1300.012; SMOLDERS I, 1995, J NEUROSCI METH, V57, P47, DOI 10.1016/0165-0270(94)00124-Y; Spanagel R, 2002, J NEUROSCI, V22, P8676; Spanagel R, 1997, TRENDS PHARMACOL SCI, V18, P54, DOI 10.1016/S0165-6147(97)89800-8; Spanagel R, 1999, TRENDS NEUROSCI, V22, P521, DOI 10.1016/S0166-2236(99)01447-2; SPANAGEL R, 2002, IONOTROPIC GLUTAMATE, P1; Trinkoff AM, 1998, AM J IND MED, V34, P266, DOI 10.1002/(SICI)1097-0274(199809)34:3<266::AID-AJIM9>3.3.CO;2-#; Tsai GC, 1998, ANNU REV MED, V49, P173; Weiss F, 2002, J NEUROSCI, V22, P3332; Yan L, 2002, EUR J NEUROSCI, V16, P1531, DOI 10.1046/j.1460-9568.2002.02224.x; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576; Yuferov V, 2003, SYNAPSE, V48, P157, DOI 10.1002/syn.10198; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118	48	440	448	4	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2005	11	1					35	42		10.1038/nm1163	http://dx.doi.org/10.1038/nm1163			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	884ZJ	15608650	Green Submitted			2022-12-25	WOS:000226124900030
J	Yu, WQ; Ginjala, V; Pant, V; Chernukhin, I; Whitehead, J; Docquier, F; Farrar, D; Tavoosidana, G; Mukhopadhyay, R; Kanduri, C; Oshimura, M; Feinberg, AP; Lobanenkov, V; Klenova, E; Ohlsson, R				Yu, WQ; Ginjala, V; Pant, V; Chernukhin, I; Whitehead, J; Docquier, F; Farrar, D; Tavoosidana, G; Mukhopadhyay, R; Kanduri, C; Oshimura, M; Feinberg, AP; Lobanenkov, V; Klenova, E; Ohlsson, R			Poly(ADP-ribosyl)ation regulates CTCF-dependent chromatin insulation	NATURE GENETICS			English	Article							IMPRINTING CONTROL REGION; METHYLATION-FREE DOMAINS; PROTEIN CTCF; GENE; H19; EXPRESSION; TRANSCRIPTION; BINDING; PARP; ASSOCIATION	Chromatin insulators demarcate expression domains by blocking the cis effects of enhancers or silencers in a position-dependent manner(1,2). We show that the chromatin insulator protein CTCF carries a post-translational modification: poly(ADP-ribosyl)ation. Chromatin immunoprecipitation analysis showed that a poly(ADP-ribosyl)ation mark, which exclusively segregates with the maternal allele of the insulator domain in the H19 imprinting control region, requires the bases that are essential for interaction with CTCF3. Chromatin immunoprecipitation-on-chip analysis documented that the link between CTCF and poly(ADP-ribosyl)ation extended to more than 140 mouse CTCF target sites. An insulator trap assay showed that the insulator function of most of these CTCF target sites is sensitive to 3-aminobenzamide, an inhibitor of poly(ADP-ribose) polymerase activity. We suggest that poly(ADP-ribosyl)ation imparts chromatin insulator properties to CTCF at both imprinted and nonimprinted loci, which has implications for the regulation of expression domains and their demise in pathological lesions.	Uppsala Univ, Evolut Biol Ctr, Dept Genet & Dev, S-75236 Uppsala, Sweden; Univ Essex, Dept Biol Sci, Colchester CO4 3SQ, Essex, England; Tottori Univ, Dept Mol & Cellular Biol, Tottori, Japan; Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21205 USA; NIAID, Mol PAthol Sect, Immunopathol Lab, NIH, Bethesda, MD 20892 USA	Uppsala University; University of Essex; Tottori University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Ohlsson, R (corresponding author), Uppsala Univ, Evolut Biol Ctr, Dept Genet & Dev, Norbyvagen 18A, S-75236 Uppsala, Sweden.	Rolf.Ohlsson@ebc.uu.se	Tavoosidana, Gholamreza/AAV-3893-2020; Lobanenkov, Victor V./AGQ-8903-2022; Ginjala, Vasudeva/E-5869-2019; Lobanenkov, Victor/ABD-5710-2021; Whitehead, Joanne/A-8597-2008; Feinberg, Andrew/AAY-7666-2020	Tavoosidana, Gholamreza/0000-0002-1079-7434; Whitehead, Joanne/0000-0002-9602-2081; Feinberg, Andrew/0000-0002-8364-1991; Pant, Vinod/0000-0002-3286-1804; Kanduri, Chandrasekhar/0000-0001-6271-9078; Lobanenkov, Victor/0000-0001-6665-3635	NATIONAL CANCER INSTITUTE [R37CA054358, R01CA054358] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000860] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA054358, R37 CA054358, R37 CA054358-14] Funding Source: Medline; Worldwide Cancer Research [99-0514] Funding Source: Medline; Breast Cancer Now [2000:137] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Worldwide Cancer Research; Breast Cancer Now		Allen MD, 2003, J MOL BIOL, V330, P503, DOI 10.1016/S0022-2836(03)00473-X; Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; Chernukhin IV, 2000, J BIOL CHEM, V275, P29915, DOI 10.1074/jbc.M001538200; CONSTANZI C, 1998, NATURE, V393, P599; Davidovic L, 2001, EXP CELL RES, V268, P7, DOI 10.1006/excr.2001.5263; Dean W, 1998, DEVELOPMENT, V125, P2273; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; Holmgren C, 2001, CURR BIOL, V11, P1128, DOI 10.1016/S0960-9822(01)00314-1; Horike S, 2000, HUM MOL GENET, V9, P2075, DOI 10.1093/hmg/9.14.2075; Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960-9822(00)00597-2; Kanduri C, 2000, CURR BIOL, V10, P449, DOI 10.1016/S0960-9822(00)00442-5; Kanduri C, 2002, CANCER RES, V62, P4545; Kanduri C, 2002, J BIOL CHEM, V277, P18106, DOI 10.1074/jbc.M200031200; Kanduri M, 2002, MOL CELL BIOL, V22, P3339, DOI 10.1128/MCB.22.10.3339-3344.2002; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Li YM, 1998, J BIOL CHEM, V273, P28247, DOI 10.1074/jbc.273.43.28247; Lynch Catherine A, 2002, Mol Cancer, V1, P2, DOI 10.1186/1476-4598-1-2; MIRANDA EA, 1995, BIOCHEM BIOPH RES CO, V212, P317, DOI 10.1006/bbrc.1995.1972; Mukhopadhyay R, 2004, GENOME RES, V14, P1594, DOI 10.1101/gr.2408304; OHLSSON R, 1989, EMBO J, V8, P1993, DOI 10.1002/j.1460-2075.1989.tb03606.x; Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6; Pant V, 2003, GENE DEV, V17, P586, DOI 10.1101/gad.254903; Quitschke WW, 2000, NUCLEIC ACIDS RES, V28, P3370, DOI 10.1093/nar/28.17.3370; Sallmann FR, 2000, J BIOL CHEM, V275, P15504, DOI 10.1074/jbc.275.20.15504; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Tulin A, 2002, GENE DEV, V16, P2108, DOI 10.1101/gad.1003902; YUSUFZAI T, 2001, MOL CELL, V13, P291; Ziegler M, 2001, BIOESSAYS, V23, P543, DOI 10.1002/bies.1074	30	206	212	1	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2004	36	10					1105	1110		10.1038/ng1426	http://dx.doi.org/10.1038/ng1426			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	857YN	15361875	Bronze			2022-12-25	WOS:000224156500020
J	Zaph, C; Uzonna, J; Beverley, SM; Scott, P				Zaph, C; Uzonna, J; Beverley, SM; Scott, P			Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites	NATURE MEDICINE			English	Article							LYMPHOCYTES IN-VIVO; PROTECTIVE IMMUNITY; EFFECTOR; VACCINE; INFECTION; ANTIGEN; SUBSETS; IMMUNOLOGY; GENERATION; INDUCTION	Infection with Leishmania major induces a protective immune response and long-term resistance to reinfection, which is thought to depend upon persistent parasites. Here we demonstrate that although effector CD4(+) T cells are lost in the absence of parasites, central memory CD4(+) T cells are maintained. Upon secondary infection, these central memory T cells become tissue-homing effector T cells and mediate protection. Thus, immunity to L. major is mediated by at least two distinct populations of CD4(+) T cells: short-lived pathogen-dependent effector cells and long-lived pathogen-independent central memory cells. These data suggest that central memory T cells should be the targets for nonlive vaccines against infectious diseases requiring cell-mediated immunity.	Univ Penn, Dept Pathobiol, Philadelphia, PA 19104 USA; Washington Univ, Dept Mol Microbiol, St Louis, MO 63110 USA	University of Pennsylvania; Washington University (WUSTL)	Scott, P (corresponding author), Univ Penn, Dept Pathobiol, 3800 Spruce St, Philadelphia, PA 19104 USA.	pscott@vet.upenn.edu		Zaph, Colby/0000-0002-9889-9848; Beverley, Stephen/0000-0001-5319-0811	NIAID NIH HHS [AI35914] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035914, R21AI035914] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AFONSO LCC, 1994, SCIENCE, V263, P235, DOI 10.1126/science.7904381; Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; BRADLEY LM, 1994, J EXP MED, V180, P2401, DOI 10.1084/jem.180.6.2401; Brodskyn C, 2000, CLIN EXP IMMUNOL, V119, P299, DOI 10.1046/j.1365-2249.2000.01122.x; Bunce C, 1997, J EXP MED, V185, P767, DOI 10.1084/jem.185.4.767; Desjeux P, 1996, CLIN DERMATOL, V14, P417, DOI 10.1016/0738-081X(96)00057-0; Desrosiers RC, 2004, NAT MED, V10, P221, DOI 10.1038/nm0304-221; Doyle AM, 2001, J EXP MED, V194, P893, DOI 10.1084/jem.194.7.893; Flynn JL, 2004, TUBERCULOSIS, V84, P93, DOI 10.1016/j.tube.2003.08.010; Garcia S, 1999, IMMUNITY, V11, P163, DOI 10.1016/S1074-7613(00)80091-6; Gicheru MM, 2001, INFECT IMMUN, V69, P245, DOI 10.1128/IAI.69.1.245-251.2001; Gray D, 2002, NAT REV IMMUNOL, V2, P60, DOI 10.1038/nri706; Gurunathan S, 1998, NAT MED, V4, P1409, DOI 10.1038/4000; Gurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927; Harbertson J, 2002, J IMMUNOL, V168, P1095, DOI 10.4049/jimmunol.168.3.1095; Iezzi G, 2001, J EXP MED, V193, P987, DOI 10.1084/jem.193.8.987; JUNG TM, 1988, J IMMUNOL, V141, P4110; Kaech SM, 2002, CELL, V111, P837, DOI 10.1016/S0092-8674(02)01139-X; Lanzavecchia A, 2002, NAT REV IMMUNOL, V2, P982, DOI 10.1038/nri959; London CA, 1999, J IMMUNOL, V162, P766; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867; Mocci S, 1997, J IMMUNOL, V158, P1559; MOCCI S, 1995, J IMMUNOL, V154, P3779; Murali-Krishna K, 1999, SCIENCE, V286, P1377, DOI 10.1126/science.286.5443.1377; PICKER LJ, 1990, J IMMUNOL, V145, P3247; REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055; Reinhardt RL, 2001, NATURE, V410, P101, DOI 10.1038/35065111; Rhee EG, 2002, J EXP MED, V195, P1565, DOI 10.1084/jem.20020147; Roman E, 2002, J EXP MED, V196, P957, DOI 10.1084/jem.20021052; Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; SCOTT P, 1987, J IMMUNOL, V139, P221; Seder RA, 2003, NAT IMMUNOL, V4, P835, DOI 10.1038/ni969; Swain SL, 1999, SCIENCE, V286, P1381, DOI 10.1126/science.286.5443.1381; TITUS RG, 1995, P NATL ACAD SCI USA, V92, P10267, DOI 10.1073/pnas.92.22.10267; Uzonna JE, 2001, J IMMUNOL, V167, P6967, DOI 10.4049/jimmunol.167.12.6967; Wang XW, 2001, J EXP MED, V194, P1069, DOI 10.1084/jem.194.8.1069; Wherry EJ, 2003, NAT IMMUNOL, V4, P225, DOI 10.1038/ni889; Zaph C, 2003, J IMMUNOL, V171, P4726, DOI 10.4049/jimmunol.171.9.4726; Zinkernagel RM, 2003, ANNU REV IMMUNOL, V21, P515, DOI 10.1146/annurev.immunol.21.120601.141045	41	263	275	1	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2004	10	10					1104	1110		10.1038/nm1108	http://dx.doi.org/10.1038/nm1108			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15448686				2022-12-25	WOS:000224245800041
J	Daniels, GA; Sanchez-Perez, L; Diaz, RM; Kottke, T; Thompson, J; Lai, MY; Gough, M; Karim, M; Bushell, A; Chong, H; Melcher, A; Harrington, K; Vile, RG				Daniels, GA; Sanchez-Perez, L; Diaz, RM; Kottke, T; Thompson, J; Lai, MY; Gough, M; Karim, M; Bushell, A; Chong, H; Melcher, A; Harrington, K; Vile, RG			A simple method to cure established tumors by inflammatory killing of normal cells	NATURE BIOTECHNOLOGY			English	Article							T-CELLS; ANTIGEN-4 BLOCKADE; CANCER REGRESSION; MELANOMA VACCINE; AUTOIMMUNITY; GENE; TYROSINASE; EXPRESSION; TOLERANCE; HSP70	We describe a simple technology used to cure an established metastatic disease. Intradermal injection of plasmid DNA encoding a transcriptionally targeted cytotoxic gene, along with hsp70, not only promoted tissue-specific, inflammatory killing of normal melanocytes, but also induced a CD8(+) T-cell-dependent, antigen-specific response in mice that eradicated systemically established B16 tumors. This CD8(+) T cell response was subsequently suppressed in vivo within a few days. The data demonstrate that deliberate destruction of normal tissue can be exploited to generate immunity against a malignant disease originating from that tissue. This approach obviates the need to identify tumor antigens and does not require complex isolation of tumor cells or their derivatives. In addition, it provides a model system for studying the mechanisms underlying the etiology and control of autoimmune diseases. Finally, despite targeting normal tissue, therapy could be separated from development of overt autoimmune symptoms, suggesting that the strategy may be valuable against tumors derived from both non-essential and essential tissue types.	Mayo Clin & Mayo Fdn, Program Mol Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Surg, Oxford OX3 9DU, England; Univ London St Georges Hosp, Sch Med, Dept Pathol, London SW17 0RE, England; St James Hosp, CRUK Oncol Unit, Leeds LS9 7TF, W Yorkshire, England; Inst Canc Res, Chester Beatty Labs, London SW3 6JB, England	Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Oxford; St Georges University London; Saint James's University Hospital; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Vile, RG (corresponding author), Mayo Clin & Mayo Fdn, Program Mol Med, Rochester, MN 55905 USA.	vile.richard@mayo.edu	Gough, Michael/AAY-3419-2020; Lai, Maoyi/I-5946-2013	Gough, Michael/0000-0002-5575-0074; Lai, Maoyi/0000-0001-5648-7717; Harrington, Kevin/0000-0002-6014-348X; Melcher, Alan/0000-0002-2042-3380	NATIONAL CANCER INSTITUTE [P50CA091956, R01CA094180] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA94180, P50CA91956] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexeev V, 2000, PIGM CELL RES, V13, P72, DOI 10.1034/j.1600-0749.2000.130205.x; Alexeev V, 1998, NAT BIOTECHNOL, V16, P1343, DOI 10.1038/4322; Alexeev V, 2000, NAT BIOTECHNOL, V18, P43, DOI 10.1038/71901; Altman DG, 1991, PRACTICAL STAT MED R, P365; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Bonnotte B, 2003, CANCER RES, V63, P2145; Bronte V, 2000, CANCER RES, V60, P253; Christoph T, 2000, BRIT J DERMATOL, V142, P862, DOI 10.1046/j.1365-2133.2000.03464.x; COLIGAN JE, 1998, CURRENT PROTOCOLS IM, V1; Diaz RM, 1998, J VIROL, V72, P789, DOI 10.1128/JVI.72.1.789-795.1998; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Dyall R, 1998, J EXP MED, V188, P1553, DOI 10.1084/jem.188.9.1553; Engelhard VH, 2002, IMMUNOL REV, V188, P136, DOI 10.1034/j.1600-065X.2002.18812.x; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; GANSS R, 1994, EMBO J, V13, P3083, DOI 10.1002/j.1460-2075.1994.tb06607.x; Gough MJ, 2001, CANCER RES, V61, P7240; HARA I, 1995, INT J CANCER, V61, P253, DOI 10.1002/ijc.2910610219; Hodi FS, 2003, P NATL ACAD SCI USA, V100, P4712, DOI 10.1073/pnas.0830997100; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; KEMP EH, 2001, EXPERT REV MOL MED, P1; Konstantopoulos K, 2003, BRIT J CANCER, V88, P981, DOI 10.1038/sj.bjc.6600834; Kursar M, 2002, J EXP MED, V196, P1585, DOI 10.1084/jem.20011347; Linardakis E, 2002, CANCER RES, V62, P5495; Liu K, 2002, J EXP MED, V196, P1091, DOI 10.1084/jem.20021215; MacAry PA, 2004, IMMUNITY, V20, P95, DOI 10.1016/S1074-7613(03)00357-1; Melcher A, 1999, J MOL MED-JMM, V77, P824, DOI 10.1007/s001099900066; Melcher A, 1998, NAT MED, V4, P581, DOI 10.1038/nm0598-581; Millar DG, 2003, NAT MED, V9, P1469, DOI 10.1038/nm962; Mougneau E, 2002, J EXP MED, V196, P1013, DOI 10.1084/jem.20021636; Musette P, 1999, J IMMUNOL, V162, P1789; Onizuka S, 1999, CANCER RES, V59, P3128; Overwijk WW, 2003, J EXP MED, V198, P569, DOI 10.1084/jem.20030590; Pardoll DM, 2002, NAT REV IMMUNOL, V2, P227, DOI 10.1038/nri774; Pardoll DM, 1999, P NATL ACAD SCI USA, V96, P5340, DOI 10.1073/pnas.96.10.5340; PARMIANI G, 1993, IMMUNOL TODAY, V14, P536, DOI 10.1016/0167-5699(93)90183-L; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100; Restifo NP, 2000, CURR OPIN IMMUNOL, V12, P597, DOI 10.1016/S0952-7915(00)00148-5; Saito N, 2002, P NATL ACAD SCI USA, V99, P13120, DOI 10.1073/pnas.192453799; Srivastava Pramod K, 2003, Cancer Immun, V3, P4; Todryk S, 1999, J IMMUNOL, V163, P1398; VALVERDE P, 1992, FEBS LETT, V304, P114, DOI 10.1016/0014-5793(92)80600-L; van Elsas A, 2001, J EXP MED, V194, P481, DOI 10.1084/jem.194.4.481; VILE RG, 1993, CANCER RES, V53, P962; VILE RG, 1993, CANCER RES, V53, P3860; Walker LSK, 2002, NAT REV IMMUNOL, V2, P11, DOI 10.1038/nri701	47	83	98	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2004	22	9					1125	1132		10.1038/nbt1007	http://dx.doi.org/10.1038/nbt1007			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	850ZR	15300260				2022-12-25	WOS:000223653400031
J	Nielsen, KM; Townsend, JP				Nielsen, KM; Townsend, JP			Monitoring and modeling horizontal gene transfer	NATURE BIOTECHNOLOGY			English	Article							TRANSGENIC PLANT DNA; RESISTANCE GENES; ACINETOBACTER SP; SOIL BACTERIA; TRANSFORMATION; EXTRACTION; BIAS	Monitoring efforts have failed to identify horizontal gene transfer (HGT) events occurring from transgenic plants into bacterial communities in soil or intestinal environments. The lack of such observations is frequently cited in biosafety literature and by regulatory risk assessment. Our analysis of the sensitivity of current monitoring efforts shows that studies to date have examined potential HGT events occurring in less than 2 g of sample material, when combined. Moreover, a population genetic model predicts that rare bacterial transformants acquiring transgenes require years of growth to out-compete wild-type bacteria. Time of sampling is therefore crucial to the useful implementation of monitoring. A population genetic approach is advocated for elucidating the necessary sample sizes and times of sampling for monitoring HGT into large bacterial populations. Major changes in current monitoring approaches are needed, including explicit consideration of the population size of exposed bacteria, the bacterial generation time, the strength of selection acting on the transgene-carrying bacteria, and the sample size necessary to verify or falsify the HGT hypotheses tested.	Univ Tromso, Fac Med, Dept Pharm, N-9037 Tromso, Norway; Norwegian Inst Gene Ecol, N-9294 Tromso, Norway; Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA	UiT The Arctic University of Tromso; University of California System; University of California Berkeley	Nielsen, KM (corresponding author), Univ Tromso, Fac Med, Dept Pharm, N-9037 Tromso, Norway.	knielsen@farmasi.uit.no	Townsend, Jeffrey/H-2747-2019; Nielsen, Kaare Magne/G-8107-2018	Townsend, Jeffrey/0000-0002-9890-3907; Nielsen, Kaare Magne/0000-0002-7217-2114				Badosa E, 2004, FEMS MICROBIOL ECOL, V48, P169, DOI 10.1016/j.femsec.2004.01.005; Ceccherini MT, 2003, APPL ENVIRON MICROB, V69, P673, DOI 10.1128/AEM.69.1.673-678.2003; Conner AJ, 2003, PLANT J, V33, P19, DOI 10.1046/j.0960-7412.2002.001607.x; de Vries J, 2001, FEMS MICROBIOL LETT, V195, P211, DOI 10.1111/j.1574-6968.2001.tb10523.x; Elena SF, 1998, GENETICA, V102-3, P349, DOI 10.1023/A:1017031008316; European Food Safety Authority, 2004, EFSA J, V48, P1; Frostegard A, 1999, APPL ENVIRON MICROB, V65, P5409; Gebhard F, 1999, FEMS MICROBIOL ECOL, V28, P261, DOI 10.1016/S0168-6496(98)00115-9; Gebhard F, 1998, APPL ENVIRON MICROB, V64, P1550; Hartl D.L., 1997, PRINCIPLES POPULATIO, V3rd ed.; HENSCHKE RB, 1990, BIOL FERT SOILS, V9, P257, DOI 10.1007/BF00336236; Kay E, 2002, APPL ENVIRON MICROB, V68, P3345, DOI 10.1128/AEM.68.7.3345-3351.2002; Ma JKC, 2003, NAT REV GENET, V4, P794, DOI 10.1038/nrg1177; Martin-Laurent F, 2001, APPL ENVIRON MICROB, V67, P2354, DOI 10.1128/AEM.67.5.2354-2359.2001; Netherwood T, 2004, NAT BIOTECHNOL, V22, P204, DOI 10.1038/nbt934; Nielsen KM, 1998, FEMS MICROBIOL REV, V22, P79, DOI 10.1111/j.1574-6976.1998.tb00362.x; Nielsen KM, 2000, APPL ENVIRON MICROB, V66, P1237, DOI 10.1128/AEM.66.3.1237-1242.2000; NIELSEN KM, 2003, COLLECTION BIOSAFETY, V1, P96; Ochman H, 2000, NATURE, V405, P299, DOI 10.1038/35012500; Paget E, 1998, EUR J SOIL BIOL, V34, P81, DOI 10.1016/S1164-5563(99)90005-5; Remold SK, 2004, NAT GENET, V36, P423, DOI 10.1038/ng1324; SHAW KJ, 1993, MICROBIOL REV, V57, P138, DOI 10.1128/MMBR.57.1.138-163.1993; Smith JM, 2000, BIOESSAYS, V22, P1115, DOI 10.1002/1521-1878(200012)22:12&lt;1115::AID-BIES9&gt;3.0.CO;2-R	23	71	90	2	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2004	22	9					1110	1114		10.1038/nbt1006	http://dx.doi.org/10.1038/nbt1006			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	850ZR	15340481				2022-12-25	WOS:000223653400029
J	Suzuki, M; Igarashi, R; Sekiya, M; Utsugi, T; Morishita, S; Yukawa, M; Ohya, Y				Suzuki, M; Igarashi, R; Sekiya, M; Utsugi, T; Morishita, S; Yukawa, M; Ohya, Y			Dynactin is involved in a checkpoint to monitor cell wall synthesis in Saccharomyces cerevisiae	NATURE CELL BIOLOGY			English	Article							SPINDLE POLE BODY; PROTEIN; MORPHOGENESIS; TRANSCRIPTION; ENCODES; BINDING; GENES; MICROTUBULES; CYTOKINESIS; ORIENTATION	Checkpoint controls ensure the completion of cell cycle events with high fidelity in the correct order. Here we show the existence of a novel checkpoint that ensures coupling of cell wall synthesis and mitosis. In response to a defect in cell wall synthesis, S. cerevisiae cells arrest the cell-cycle before spindle pole body separation. This arrest results from the regulation of the M-phase cyclin Clb2p at the transcriptional level through the transcription factor Fkh2p. Components of the dynactin complex are required to achieve the G2 arrest whilst keeping cells highly viable. Thus, the dynactin complex has a function in a checkpoint that monitors cell wall synthesis.	Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Chiba 2778562, Japan; Univ Tokyo, Grad Sch Frontier Sci, Dept Computat Biol, Chiba 2778562, Japan; Japan Sci & Technol Corp, Inst Bioinformat & Res Dev, Chiyoda Ku, Tokyo 1028666, Japan	University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST)	Ohya, Y (corresponding author), Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Chiba 2778562, Japan.	ohya@k.u-tokyo.ac.jp		Morishita, Shinichi/0000-0002-6201-8885				Adames NR, 2000, J CELL BIOL, V149, P863, DOI 10.1083/jcb.149.4.863; AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; Breeden LL, 2000, CURR BIOL, V10, pR586, DOI 10.1016/S0960-9822(00)00634-5; BROWN JL, 1993, J BACTERIOL, V175, P6908, DOI 10.1128/jb.175.21.6908-6915.1993; CABIB E, 1982, ANNU REV BIOCHEM, V51, P763, DOI 10.1146/annurev.bi.51.070182.003555; CID VJ, 1995, MICROBIOL REV, V59, P345, DOI 10.1128/MMBR.59.3.345-386.1995; Donaldson AD, 1996, J CELL BIOL, V132, P887, DOI 10.1083/jcb.132.5.887; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Farkasovsky M, 2001, J CELL BIOL, V152, P251, DOI 10.1083/jcb.152.2.251; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; Gardner RD, 2000, TRENDS CELL BIOL, V10, P154, DOI 10.1016/S0962-8924(00)01727-X; Geiser JR, 1997, MOL BIOL CELL, V8, P1035, DOI 10.1091/mbc.8.6.1035; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Haase SB, 2001, NAT CELL BIOL, V3, P38, DOI 10.1038/35050543; Harrison JC, 2001, NAT CELL BIOL, V3, P417, DOI 10.1038/35070104; Harvey SL, 2003, CURR BIOL, V13, P264, DOI 10.1016/S0960-9822(03)00049-6; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Ishihara S, 2001, MOL GENET GENOMICS, V265, P585; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Kahana JA, 1998, MOL BIOL CELL, V9, P1741, DOI 10.1091/mbc.9.7.1741; Lee WL, 2003, J CELL BIOL, V160, P355, DOI 10.1083/jcb.200209022; LEW DJ, 1995, J CELL BIOL, V129, P739, DOI 10.1083/jcb.129.3.739; Lew DJ, 1997, MOL CELLULAR BIOL YE, P607; Lim HH, 1996, MOL CELL BIOL, V16, P6385; Liu JH, 2000, J CELL SCI, V113, P1223; Madden K, 1997, SCIENCE, V275, P1781, DOI 10.1126/science.275.5307.1781; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; MCMILLAN JN, 1994, J CELL BIOL, V125, P143, DOI 10.1083/jcb.125.1.143; McMillan JN, 1998, J CELL BIOL, V142, P1487, DOI 10.1083/jcb.142.6.1487; Mondesert G, 1996, J CELL BIOL, V132, P137, DOI 10.1083/jcb.132.1.137; Muhua L, 1998, NATURE, V393, P487, DOI 10.1038/31014; MUHUA L, 1994, CELL, V78, P669, DOI 10.1016/0092-8674(94)90531-2; Ohtani Miwaka, 2004, J Bioinform Comput Biol, V1, P695, DOI 10.1142/S0219720004000363; Orlean P., 1997, MOL CELLULAR BIOL YE, P229; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; ROUT MP, 1990, J CELL BIOL, V111, P1913, DOI 10.1083/jcb.111.5.1913; SAWISTOWSKASCHRODER ET, 1984, FEBS LETT, V173, P134, DOI 10.1016/0014-5793(84)81032-7; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; Sekiya-Kawasaki M, 2002, GENETICS, V162, P663; SIKORSKI RS, 1989, GENETICS, V122, P19; Simon I, 2001, CELL, V106, P697, DOI 10.1016/S0092-8674(01)00494-9; SUN GH, 1992, J CELL BIOL, V119, P1625, DOI 10.1083/jcb.119.6.1625; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Vaughan PS, 2002, J CELL BIOL, V158, P305, DOI 10.1083/jcb.200201029; Watanabe Y, 1997, MOL CELL BIOL, V17, P2615, DOI 10.1128/MCB.17.5.2615	50	39	42	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2004	6	9					861	871		10.1038/ncb1162	http://dx.doi.org/10.1038/ncb1162			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	852IZ	15311283				2022-12-25	WOS:000223750300016
J	Adams, DJ; Biggs, PJ; Cox, T; Davies, R; van der Weyden, L; Jonkers, J; Smith, J; Plumb, B; Taylor, R; Nishijima, I; Yu, YJ; Rogers, J; Bradley, A				Adams, DJ; Biggs, PJ; Cox, T; Davies, R; van der Weyden, L; Jonkers, J; Smith, J; Plumb, B; Taylor, R; Nishijima, I; Yu, YJ; Rogers, J; Bradley, A			Mutagenic insertion and chromosome engineering resource (MICER)	NATURE GENETICS			English	Article							EMBRYONIC STEM-CELLS; MOUSE GENOME; HOMOLOGOUS RECOMBINATION; REARRANGEMENTS; ALLELES; LINE	Embryonic stem cell technology revolutionized biology by providing a means to assess mammalian gene function in vivo. Although it is now routine to generate mice from embryonic stem cells, one of the principal methods used to create mutations, gene targeting, is a cumbersome process. Here we describe the indexing of 93,960 ready-made insertional targeting vectors from two libraries. 5,925 of these vectors can be used directly to inactivate genes with an average targeting efficiency of 28%. Combinations of vectors from the two libraries can be used to disrupt both alleles of a gene or engineer larger genomic changes such as deletions, duplications, translocations or inversions. These indexed vectors constitute a public resource ( Mutagenic Insertion and Chromosome Engineering Resource; MICER) for high-throughput, targeted manipulation of the mouse genome.	Wellcome Trust Sanger Inst, Hinxton CB10 1SA, Cambs, England; Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Wellcome Trust Sanger Institute; Netherlands Cancer Institute; Baylor College of Medicine	Bradley, A (corresponding author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Hinxton CB10 1SA, Cambs, England.	abradley@sanger.ac.uk	Biggs, Patrick Jon/H-3355-2014; Jonkers, Jos/AAG-3246-2019; van der Weyden, Louise/AAV-5711-2021	Biggs, Patrick Jon/0000-0002-0285-4101; Jonkers, Jos/0000-0002-9264-9792; van der Weyden, Louise/0000-0002-0645-1879; Smith, James/0000-0002-0445-8305; Adams, David/0000-0001-9490-0306; Davies, Robert/0000-0002-9983-1378; Bradley, Allan/0000-0002-2349-8839				Birney E, 2004, NUCLEIC ACIDS RES, V32, pD468, DOI 10.1093/nar/gkh038; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; Bult CJ, 2004, NUCLEIC ACIDS RES, V32, pD476, DOI 10.1093/nar/gkh125; Collins FS, 2003, NATURE, V422, P835, DOI 10.1038/nature01626; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519; HASTY P, 1994, MOL CELL BIOL, V14, P8385, DOI 10.1128/MCB.14.12.8385; Klysik J, 2004, GENOMICS, V83, P303, DOI 10.1016/j.ygeno.2003.08.011; Kucera GT, 1996, DEV BIOL, V173, P162, DOI 10.1006/dbio.1996.0014; Liu PT, 2003, GENOME RES, V13, P476, DOI 10.1101/gr.749203; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Ning ZM, 2001, GENOME RES, V11, P1725, DOI 10.1101/gr.194201; Nishijima I, 2003, GENESIS, V36, P142, DOI 10.1002/gene.10207; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; Skarnes WC, 2004, NAT GENET, V36, P543, DOI 10.1038/ng0604-543; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; SMITHIES O, 1985, NATURE, V317, P230, DOI 10.1038/317230a0; Testa G, 2003, NAT BIOTECHNOL, V21, P443, DOI 10.1038/nbt804; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Walz K, 2003, MOL CELL BIOL, V23, P3646, DOI 10.1128/MCB.23.10.3646-3655.2003; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; YOKOYAMA T, 1990, NUCLEIC ACIDS RES, V18, P7293, DOI 10.1093/nar/18.24.7293; Yu YJ, 2001, NAT REV GENET, V2, P780, DOI 10.1038/35093564; Zheng BH, 2002, CANCER BIOL THER, V1, P433, DOI 10.4161/cbt.1.4.24; Zheng BH, 1999, NUCLEIC ACIDS RES, V27, P2354, DOI 10.1093/nar/27.11.2354	26	106	126	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2004	36	8					867	871		10.1038/ng1388	http://dx.doi.org/10.1038/ng1388			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	842AG	15235602				2022-12-25	WOS:000222974000020
J	Plagge, A; Gordon, E; Dean, W; Boiani, R; Cinti, S; Peters, J; Kelsey, G				Plagge, A; Gordon, E; Dean, W; Boiani, R; Cinti, S; Peters, J; Kelsey, G			The imprinted signaling protein XL alpha s is required for postnatal adaptation to feeding	NATURE GENETICS			English	Article							ADIPOSE-TISSUE; GENE; GNAS; IDENTIFICATION; TRANSCRIPTS; G-ALPHA(S); RESISTANCE; EXPRESSION; MUTATIONS; LOCUS	Genomic imprinting, by which maternal and paternal alleles of some genes have different levels of activity, has profound effects on growth and development of the mammalian fetus. The action of imprinted genes after birth, in particular while the infant is dependent on maternal provision of nutrients, is far less well understood. We disrupted a paternally expressed transcript at the Gnas locus, Gnasxl, which encodes the unusual Gsalpha isoform XLalphas. Mice with mutations in Gnasxl have poor postnatal growth and survival and a spectrum of phenotypic effects that indicate that XLas controls a number of key postnatal physiological adaptations, including suckling, blood glucose and energy homeostasis. Increased cAMP levels in brown adipose tissue of Gnasxl mutants and phenotypic comparison with Gnas mutants suggest that XLas can antagonize Gsalpha-dependent signaling pathways. The opposing effects of maternally and paternally expressed products of the Gnas locus provide tangible molecular support for the parental-conflict hypothesis of imprinting.	Babraham Inst, Lab Dev Genet & Imprinting, Cambridge CB2 4AT, England; Multitech Univ MArche, Fac Med, I-60020 Ancona, Italy; MRC, Mammalian Genet Unit, Didcot OX11 0RD, Oxon, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; MRC Harwell	Kelsey, G (corresponding author), Babraham Inst, Lab Dev Genet & Imprinting, Cambridge CB2 4AT, England.	gavin.kelsey@bbsrc.ac.uk	Plagge, Antonius/AAH-3877-2019	Plagge, Antonius/0000-0001-6592-1343; Dean, Wendy/0000-0001-9441-5044; CINTI, Saverio/0000-0003-0362-5017; Kelsey, Gavin/0000-0002-9762-5634				Ahren B, 2000, DIABETOLOGIA, V43, P393, DOI 10.1007/s001250051322; Bartness TJ, 1998, AM J PHYSIOL-REG I, V275, pR1399, DOI 10.1152/ajpregu.1998.275.5.R1399; Bastepe M, 2002, MOL ENDOCRINOL, V16, P1912, DOI 10.1210/me.2002-0054; Berridge CW, 2003, BRAIN RES REV, V42, P33, DOI 10.1016/S0165-0173(03)00143-7; BLASS EM, 1980, SCIENCE, V210, P15, DOI 10.1126/science.6997992; Bunting M, 1999, GENE DEV, V13, P1524, DOI 10.1101/gad.13.12.1524; Cattanach BM, 2000, HUM MOL GENET, V9, P2263, DOI 10.1093/oxfordjournals.hmg.a018917; CATTANACH BM, 1985, NATURE, V315, P496, DOI 10.1038/315496a0; Collins S, 2001, RECENT PROG HORM RES, V56, P309, DOI 10.1210/rp.56.1.309; Coombes C, 2003, MOL CELL BIOL, V23, P5475, DOI 10.1128/MCB.23.16.5475-5488.2003; CRAWFORD JA, 1993, J BIOL CHEM, V268, P9879; DAVIES SJ, 1993, J MED GENET, V30, P101, DOI 10.1136/jmg.30.2.101; de la Casa-Esperon E, 2003, ANNU REV GENET, V37, P349, DOI 10.1146/annurev.genet.37.110801.143741; Fay RA, 1997, BRAIN RES REV, V25, P276, DOI 10.1016/S0165-0173(97)00027-1; Freson K, 2003, HUM MOL GENET, V12, P1121, DOI 10.1093/hmg/ddg130; Germain-Lee EL, 2002, BIOCHEM BIOPH RES CO, V296, P67, DOI 10.1016/S0006-291X(02)00833-1; Hayward BE, 1998, P NATL ACAD SCI USA, V95, P15475, DOI 10.1073/pnas.95.26.15475; Hayward BE, 2001, J CLIN INVEST, V107, pR31, DOI 10.1172/JCI11887; Hayward BE, 1998, P NATL ACAD SCI USA, V95, P10038, DOI 10.1073/pnas.95.17.10038; HENNING SJ, 1981, AM J PHYSIOL, V241, pG199, DOI 10.1152/ajpgi.1981.241.3.G199; Hurst L. D., 1997, GENOMIC IMPRINTING, P211; Ischia R, 1997, J BIOL CHEM, V272, P11657; Itier JM, 1998, NATURE, V393, P125, DOI 10.1038/30120; KEHLENBACH RH, 1994, NATURE, V372, P804; Kelsey G, 1999, GENOMICS, V62, P129, DOI 10.1006/geno.1999.6022; Klemke M, 2000, J BIOL CHEM, V275, P33633, DOI 10.1074/jbc.M006594200; Klemke M, 2001, EMBO J, V20, P3849, DOI 10.1093/emboj/20.14.3849; Li T, 2000, GENOMICS, V69, P295, DOI 10.1006/geno.2000.6337; Lund JP, 1998, CURR OPIN NEUROBIOL, V8, P718, DOI 10.1016/S0959-4388(98)80113-X; Mantovani G, 2002, J CLIN ENDOCR METAB, V87, P4736, DOI 10.1210/jc.2002-020183; MOORE T, 1991, TRENDS GENET, V7, P45, DOI 10.1016/0168-9525(91)90230-N; Pasolli HA, 2000, J BIOL CHEM, V275, P33622, DOI 10.1074/jbc.M001335200; Peters J, 1999, P NATL ACAD SCI USA, V96, P3830, DOI 10.1073/pnas.96.7.3830; Sawczuk A, 2001, CRIT REV ORAL BIOL M, V12, P18, DOI 10.1177/10454411010120010101; Skinner JA, 2002, GENOMICS, V80, P373, DOI 10.1006/geno.2002.6842; Storck T, 1996, NUCLEIC ACIDS RES, V24, P4594, DOI 10.1093/nar/24.22.4594; Sutcliffe JG, 2002, NAT REV NEUROSCI, V3, P339, DOI 10.1038/nrn808; Tycko B, 2002, J CELL PHYSIOL, V192, P245, DOI 10.1002/jcp.10129; VOLLMER RR, 1997, AM J PHYSIOL-REG I, V273, pR1758; Voss AK, 1997, EXP CELL RES, V230, P45, DOI 10.1006/excr.1996.3418; Weinstein LS, 2001, ENDOCR REV, V22, P675, DOI 10.1210/er.22.5.675; Wilkins JF, 2003, NAT REV GENET, V4, P359, DOI 10.1038/nrg1062; Williamson CM, 1998, GENET RES, V72, P255, DOI 10.1017/S0016672398003528; Yang T, 1998, NAT GENET, V19, P25, DOI 10.1038/ng0598-25; YOUNG JB, 1982, J CLIN INVEST, V69, P1061, DOI 10.1172/JCI110541; Yu SH, 2000, J CLIN INVEST, V105, P615, DOI 10.1172/JCI8437; Yu SH, 1998, P NATL ACAD SCI USA, V95, P8715, DOI 10.1073/pnas.95.15.8715; Yu SH, 2001, J BIOL CHEM, V276, P19994, DOI 10.1074/jbc.M010313200; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757; Zhou ZH, 2003, NAT GENET, V35, P49, DOI 10.1038/ng1225	50	198	205	5	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2004	36	8					818	826		10.1038/ng1397	http://dx.doi.org/10.1038/ng1397			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	842AG	15273686				2022-12-25	WOS:000222974000013
J	Rajagopalan, S; Deitinghoff, L; Davis, D; Conrad, S; Skutella, T; Chedotal, A; Mueller, BK; Strittmatter, SM				Rajagopalan, S; Deitinghoff, L; Davis, D; Conrad, S; Skutella, T; Chedotal, A; Mueller, BK; Strittmatter, SM			Neogenin mediates the action of repulsive guidance molecule	NATURE CELL BIOLOGY			English	Article							COLORECTAL-CANCER; RETINAL AXONS; NETRIN RECEPTORS; DCC; MOUSE; CELLS; MEMBRANES; INVITRO; DOMAINS; BINDING	Repulsive guidance molecule (RGM) is a recently identified protein implicated in both axonal guidance and neural tube closure(1,2). The avoidance of chick RGM in the posterior optic tectum by growing temporal, but not nasal, retinal ganglion cell axons is thought to contribute to visual map formation. In contrast to ephrins, semaphorins, netrins and slits(3,4), no receptor mechanism for RGM action has been defined. Here, an expression cloning strategy identified neogenin as a binding site for RGM, with a sub-nanomolar affinity. Consistent with selective axonal responsiveness to RGM, neogenin is expressed in a gradient across the chick retina. Neogenin is known to be one of several netrin-binding proteins(5) but only neogenin interacts with RGM. The avoidance of RGM by temporal retinal axons is blocked by the anti-neogenin antibody and the soluble neogenin ectodomain. Dorsal root ganglion axons are unresponsive to RGM but are converted to a responsive state by neogenin expression. Thus, neogenin functions as an RGM receptor.	Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; Abbott GmbH & Co KG, D-67061 Ludwigshafen, Germany; Inst Anat, Dept Expt Embryol, Tissue Engn Div, D-72074 Tubingen, Germany; Univ Paris 06, CNRS, UMR 7102, F-75005 Paris, France	Yale University; ABBOTT GMBH & CO. KG; Eberhard Karls University of Tubingen; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Strittmatter, SM (corresponding author), Yale Univ, Sch Med, Dept Neurol, 333 Cedar St, New Haven, CT 06510 USA.	stephen.strittmatter@yale.edu	Chedotal, Alain/F-2750-2017; Strittmatter, Stephen/F-5739-2011	Chedotal, Alain/0000-0001-7577-3794; Strittmatter, Stephen/0000-0001-8188-3092				Brinks H, 2004, J NEUROSCI, V24, P3862, DOI 10.1523/JNEUROSCI.5296-03.2004; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; Feldheim DA, 2000, NEURON, V25, P563, DOI 10.1016/S0896-6273(00)81060-0; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Gad JM, 2000, EXP EYE RES, V70, P711, DOI 10.1006/exer.2000.0823; Geisbrecht BV, 2003, J BIOL CHEM, V278, P32561, DOI 10.1074/jbc.M302943200; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Hornberger MR, 1999, NEURON, V22, P731, DOI 10.1016/S0896-6273(00)80732-1; Keeling SL, 1997, ONCOGENE, V15, P691, DOI 10.1038/sj.onc.1201225; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Liu BP, 2002, SCIENCE, V297, P1190, DOI 10.1126/science.1073031; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Monnier PP, 2002, NATURE, V419, P392, DOI 10.1038/nature01041; Muller BK, 1996, CURR BIOL, V6, P1497, DOI 10.1016/S0960-9822(96)00754-3; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; Niederkofler V, 2004, J NEUROSCI, V24, P808, DOI 10.1523/JNEUROSCI.4610-03.2004; SHEPPARD AM, 1991, NEUROSCI LETT, V123, P87, DOI 10.1016/0304-3940(91)90164-O; SHEPPARD AM, 1988, DEV BRAIN RES, V43, P49, DOI 10.1016/0165-3806(88)90152-6; Srinivasan K, 2003, DEV CELL, V4, P371, DOI 10.1016/S1534-5807(03)00054-6; Stein E, 2001, SCIENCE, V291, P1976, DOI 10.1126/science.1059391; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; VIELMETTER J, 1990, EXP BRAIN RES, V81, P283; WALTER J, 1987, DEVELOPMENT, V101, P685; WALTER J, 1987, DEVELOPMENT, V101, P909; Wang H, 1999, J NEUROSCI, V19, P4938; Yu TW, 2001, NAT NEUROSCI, V4, P1169, DOI 10.1038/nn748	27	218	236	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2004	6	8					756	762		10.1038/ncb1156	http://dx.doi.org/10.1038/ncb1156			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	842YA	15258590				2022-12-25	WOS:000223039400014
J	Howard, JK; Cave, BJ; Oksanen, LJ; Tzameli, I; Bjorbaek, C; Flier, JS				Howard, JK; Cave, BJ; Oksanen, LJ; Tzameli, I; Bjorbaek, C; Flier, JS			Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3	NATURE MEDICINE			English	Article							HYPOTHALAMIC NEURONS; INSULIN SENSITIVITY; BODY-WEIGHT; IN-VIVO; RESISTANCE; RECEPTOR; IDENTIFICATION; CHANNELS	Leptin is an adipocyte-derived hormone that regulates energy balance and neuroendocrine function primarily by acting on specific hypothalamic pathways(1,2). Resistance to the weight reducing effects of leptin is a feature of most cases of human and rodent obesity(1,2), yet the molecular basis of leptin resistance is poorly understood. We have previously identified suppressor of cytokine signaling-3 (Socs3) as a leptin-induced negative regulator of leptin receptor signaling and potential mediator of leptin resistance(3-5). However, due to the non-viability of mice with targeted disruption of Socs3 (ref. 6), the importance of Socs3 in leptin action in vivo was unclear. To determine the functional significance of Socs3 in energy balance in vivo we undertook studies in mice with heterozygous Socs3 deficiency (Socs3(+/-)). We report here that Socs3(+/-) mice display greater leptin sensitivity than wild-type control mice: Socs3(+/-) mice show both enhanced weight loss and increased hypothalamic leptin receptor signaling in response to exogenous leptin administration. Furthermore, Socs3(+/-) mice are significantly protected against the development of diet-induced obesity and associated metabolic complications. The level of Socs3 expression is thus a critical determinant of leptin sensitivity and obesity susceptibility in vivo and this molecule is a potential target for therapeutic intervention.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Endocrinol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Flier, JS (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Endocrinol, Boston, MA 02215 USA.	jflier@bidmc.harvard.edu	Bjorbaek, Christian/S-4727-2019; Flier, jeffrey/AAG-6223-2019	Howard, Jane/0000-0003-2754-8300				Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Bjorbaek C, 2000, J BIOL CHEM, V275, P40649, DOI 10.1074/jbc.M007577200; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; El-Haschimi K, 2000, J CLIN INVEST, V105, P1827, DOI 10.1172/JCI9842; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Eyckerman S, 2000, FEBS LETT, V486, P33, DOI 10.1016/S0014-5793(00)02205-5; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; Heymsfield SB, 1999, JAMA-J AM MED ASSOC, V282, P1568, DOI 10.1001/jama.282.16.1568; Kim YB, 2000, ENDOCRINOLOGY, V141, P2328, DOI 10.1210/en.141.7.2328; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Lin S, 2000, INT J OBESITY, V24, P639, DOI 10.1038/sj.ijo.0801209; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; SALMON DMW, 1985, INT J OBESITY, V9, P443; Scarpace PJ, 2002, ENDOCRINOLOGY, V143, P3026, DOI 10.1210/en.143.8.3026; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; SHI H, IN PRESS J BIOL CHEM; Spanswick D, 1997, NATURE, V390, P521, DOI 10.1038/37379; Spanswick D, 2000, NAT NEUROSCI, V3, P757, DOI 10.1038/77660; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Wang ZW, 2000, BIOCHEM BIOPH RES CO, V277, P20, DOI 10.1006/bbrc.2000.3615; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X	29	362	387	7	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7					734	738		10.1038/nm1072	http://dx.doi.org/10.1038/nm1072			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	835DM	15220914				2022-12-25	WOS:000222460400028
